← Back to topics

Design Principles For Antibody Drug Conjugates Adc

demo

1. Documents

2720

1434 papers 865 patents 421 theses

Full text available

Paper Recent advances in bispecific antibody-drug conjugates for breast cancer therapy

Xuan Ji; Yalong Yang; Cong Ma et al. · 2026 · Cancer Chemotherapy and Pharmacology · DOI

Full title: Recent advances in bispecific antibody-drug conjugates for breast cancer therapy

Authors: Xuan Ji; Yalong Yang; Cong Ma; Wenqin Huang; Senyang Guo; Lingzi Wang; Hongmei Zheng; Xinhong Wu

Year: 2026

Venue: Cancer Chemotherapy and Pharmacology

DOI: https://doi.org/10.1007/s00280-025-04863-9

Paper Evaluating post-T-DXd treatment strategies in HER2-positive metastatic breast cancer

Sophia Zelizer; Grace Gallagher; Mithat Gonen et al. · 2025 · Breast Cancer Research and Treatment · DOI

Full title: Evaluating post-T-DXd treatment strategies in HER2-positive metastatic breast cancer

Authors: Sophia Zelizer; Grace Gallagher; Mithat Gonen; Chau T. Dang; S. Modi; S. Chandarlapaty; Joshua Z. Drago

Year: 2025

Venue: Breast Cancer Research and Treatment

DOI: https://doi.org/10.1007/s10549-025-07853-w

Paper Current Status: Site-Specific Antibody Drug Conjugates.

Schumacher, Dominik; Hackenberger, Christian P R; Leonhardt, Heinrich et al. · 2016 · Journal of clinical immunology · DOI

Full title: Current Status: Site-Specific Antibody Drug Conjugates.

Authors: Schumacher, Dominik; Hackenberger, Christian P R; Leonhardt, Heinrich; Helma, Jonas

Year: 2016

Venue: Journal of clinical immunology

DOI: https://doi.org/10.1007/s10875-016-0265-6

Paper Antibody-Drug Conjugates.

Li Peng; Xiaoyuan Chen · 2015 · Bioconjugate chemistry · DOI

Full title: Antibody-Drug Conjugates.

Authors: Li Peng; Xiaoyuan Chen

Year: 2015

Venue: Bioconjugate chemistry

DOI: https://doi.org/10.1021/acs.bioconjchem.5b00515

Paper An Elusive Case of Mycosis Fungoides: Case Report and Review of the Literature

V. Pallazola; G. Deib; S. Abha et al. · 2019 · Journal of general internal medicine · DOI

Full title: An Elusive Case of Mycosis Fungoides: Case Report and Review of the Literature

Authors: V. Pallazola; G. Deib; S. Abha; R. Geha; Kimiyoshi Kobayashi

Year: 2019

Venue: Journal of general internal medicine

DOI: https://doi.org/10.1007/s11606-019-05231-z

Paper Mechanisms of Resistance to Antibody-Drug Conjugates

Rita Khoury; K. Saleh; N. Khalife et al. · 2023 · International Journal of Molecular Sciences · DOI

Full title: Mechanisms of Resistance to Antibody-Drug Conjugates

Authors: Rita Khoury; K. Saleh; N. Khalife; M. Saleh; C. Chahine; Rebecca Ibrahim; A. Lecesne

Year: 2023

Venue: International Journal of Molecular Sciences

DOI: https://doi.org/10.3390/ijms24119674

Paper Antibody–Drug Conjugates for the Treatment of Renal Cancer: A Scoping Review on Current Evidence and Clinical Perspectives

S. Sganga; S. Riondino; G. M. Iannantuono et al. · 2023 · Journal of Personalized Medicine · DOI

Full title: Antibody–Drug Conjugates for the Treatment of Renal Cancer: A Scoping Review on Current Evidence and Clinical Perspectives

Authors: S. Sganga; S. Riondino; G. M. Iannantuono; R. Rosenfeld; M. Roselli; F. Torino

Year: 2023

Venue: Journal of Personalized Medicine

DOI: https://doi.org/10.3390/jpm13091339

Paper State-of-the-Art Native Mass Spectrometry and Ion Mobility Methods to Monitor Homogeneous Site-Specific Antibody-Drug Conjugates Synthesis

Evolène Deslignière; Anthony Ehkirch; Bastiaan L. Duivelshof et al. · 2021 · Pharmaceuticals · DOI

Full title: State-of-the-Art Native Mass Spectrometry and Ion Mobility Methods to Monitor Homogeneous Site-Specific Antibody-Drug Conjugates Synthesis

Authors: Evolène Deslignière; Anthony Ehkirch; Bastiaan L. Duivelshof; Hanna Toftevall; Jonathan Sjögren; D. Guillarme; V. D’Atri; A. Beck; Oscar Hernandez-Alba; S. Cianférani

Year: 2021

Venue: Pharmaceuticals

DOI: https://doi.org/10.3390/ph14060498

Paper Development of Photoremovable Linkers as a Novel Strategy to Improve the Pharmacokinetics of Drug Conjugates and Their Potential Application in Antibody-Drug Conjugates for Cancer Therapy.

Johan, Audrey Nathania; Li, Yi · 2022 · Pharmaceuticals (Basel, Switzerland) · DOI

Full title: Development of Photoremovable Linkers as a Novel Strategy to Improve the Pharmacokinetics of Drug Conjugates and Their Potential Application in Antibody-Drug Conjugates for Cancer Therapy.

Authors: Johan, Audrey Nathania; Li, Yi

Year: 2022

Venue: Pharmaceuticals (Basel, Switzerland)

DOI: https://doi.org/10.3390/ph15060655

Paper Antibody–Drug Conjugates (ADCs) and Their Journey to Autoimmune Disease Immunotherapy

A. Justiz-Vaillant · 2025 · IOCAB 2025 · DOI

Full title: Antibody–Drug Conjugates (ADCs) and Their Journey to Autoimmune Disease Immunotherapy

Authors: A. Justiz-Vaillant

Year: 2025

Venue: IOCAB 2025

DOI: https://doi.org/10.3390/msf2025040002

Paper Experimental HER2-Targeted Therapy Using ADAPT6-ABD-mcDM1 in Mice Bearing SKOV3 Ovarian Cancer Xenografts: Efficacy and Selection of Companion Imaging Counterpart

J. Garousi; Tianqi Xu; Yongsheng Liu et al. · 2022 · Pharmaceutics · DOI

Full title: Experimental HER2-Targeted Therapy Using ADAPT6-ABD-mcDM1 in Mice Bearing SKOV3 Ovarian Cancer Xenografts: Efficacy and Selection of Companion Imaging Counterpart

Authors: J. Garousi; Tianqi Xu; Yongsheng Liu; O. Vorontsova; S. Hober; A. Orlova; V. Tolmachev; T. Gräslund; A. Vorobyeva

Year: 2022

Venue: Pharmaceutics

DOI: https://doi.org/10.3390/pharmaceutics14081612

Paper Trastuzumab: More than a Guide in HER2-Positive Cancer Nanomedicine

Celia Nieto; Milena A. Vega; E. M. Martín del Valle · 2020 · Nanomaterials · DOI

Full title: Trastuzumab: More than a Guide in HER2-Positive Cancer Nanomedicine

Authors: Celia Nieto; Milena A. Vega; E. M. Martín del Valle

Year: 2020

Venue: Nanomaterials

DOI: https://doi.org/10.3390/nano10091674

Paper Design, Synthesis, and Evaluation of Camptothecin-Based Antibody–Drug Conjugates with High Hydrophilicity and Structural Stability

Tingyu Xiong; Jiyu Jin; Dongliang Liu et al. · 2025 · Molecules · DOI

Full title: Design, Synthesis, and Evaluation of Camptothecin-Based Antibody–Drug Conjugates with High Hydrophilicity and Structural Stability

Authors: Tingyu Xiong; Jiyu Jin; Dongliang Liu; Chen Jin

Year: 2025

Venue: Molecules

DOI: https://doi.org/10.3390/molecules30071398

Paper Pharmacokinetics and Pharmacodynamics of Antibody-Drug Conjugates Administered via Subcutaneous and Intratumoral Routes.

Chang, Hsuan-Ping; Le, Huyen Khanh; Shah, Dhaval K · 2023 · Pharmaceutics · DOI

Full title: Pharmacokinetics and Pharmacodynamics of Antibody-Drug Conjugates Administered via Subcutaneous and Intratumoral Routes.

Authors: Chang, Hsuan-Ping; Le, Huyen Khanh; Shah, Dhaval K

Year: 2023

Venue: Pharmaceutics

DOI: https://doi.org/10.3390/pharmaceutics15041132

Paper Advances in Targeted Therapy of Breast Cancer with Antibody-Drug Conjugate

Md Abdus Subhan; V. Torchilin · 2023 · Pharmaceutics · DOI

Full title: Advances in Targeted Therapy of Breast Cancer with Antibody-Drug Conjugate

Authors: Md Abdus Subhan; V. Torchilin

Year: 2023

Venue: Pharmaceutics

DOI: https://doi.org/10.3390/pharmaceutics15041242

Paper Linkers: An Assurance for Controlled Delivery of Antibody-Drug Conjugate.

Sheyi, Rotimi; de la Torre, Beatriz G; Albericio, Fernando · 2022 · Pharmaceutics · DOI

Full title: Linkers: An Assurance for Controlled Delivery of Antibody-Drug Conjugate.

Authors: Sheyi, Rotimi; de la Torre, Beatriz G; Albericio, Fernando

Year: 2022

Venue: Pharmaceutics

DOI: https://doi.org/10.3390/pharmaceutics14020396

Paper Antibody-Drug Conjugates for Cancer Therapy: Chemistry to Clinical Implications.

Dan, Nirnoy; Setua, Saini; Kashyap, Vivek K et al. · 2018 · Pharmaceuticals (Basel, Switzerland) · DOI

Full title: Antibody-Drug Conjugates for Cancer Therapy: Chemistry to Clinical Implications.

Authors: Dan, Nirnoy; Setua, Saini; Kashyap, Vivek K; Khan, Sheema; Jaggi, Meena; Yallapu, Murali M; Chauhan, Subhash C

Year: 2018

Venue: Pharmaceuticals (Basel, Switzerland)

DOI: https://doi.org/10.3390/ph11020032

Paper EV20/NMS-P945, a Novel Thienoindole Based Antibody-Drug Conjugate Targeting HER-3 for Solid Tumors

E. Capone; R. Lattanzio; F. Gasparri et al. · 2021 · Pharmaceutics · DOI

Full title: EV20/NMS-P945, a Novel Thienoindole Based Antibody-Drug Conjugate Targeting HER-3 for Solid Tumors

Authors: E. Capone; R. Lattanzio; F. Gasparri; P. Orsini; C. Rossi; Valentina Iacobelli; V. de Laurenzi; P. Natali; B. Valsasina; S. Iacobelli; G. Sala

Year: 2021

Venue: Pharmaceutics

DOI: https://doi.org/10.3390/pharmaceutics13040483

Paper Understanding the Toxicity Profile of Approved ADCs

Pablo Ballestín; Alfonso López de Sá; Cristina Díaz-Tejeiro et al. · 2025 · Pharmaceutics · DOI

Full title: Understanding the Toxicity Profile of Approved ADCs

Authors: Pablo Ballestín; Alfonso López de Sá; Cristina Díaz-Tejeiro; Lucía Paniagua-Herranz; Adrián Sanvicente; I. López-Cade; P. Pérez-Segura; C. Alonso-Moreno; Cristina Nieto-Jiménez; Alberto Ocaña

Year: 2025

Venue: Pharmaceutics

DOI: https://doi.org/10.3390/pharmaceutics17020258

Paper Structural Characterization of Linker Shielding in ADC Site-Specific Conjugates.

Jaime-Garza, Maru; Waight, Andrew; Hudlikar, Manish et al. · 2025 · Pharmaceutics · DOI

Full title: Structural Characterization of Linker Shielding in ADC Site-Specific Conjugates.

Authors: Jaime-Garza, Maru; Waight, Andrew; Hudlikar, Manish; Eddins, Michael J; Rasti, Elnaz S; Zaragoza, Jan Paulo T; Fayadat-Dilman, Laurence; Chrencik, Jill E; Gabelli, Sandra B; Chen, Yun-Ting; Noland, Cameron L

Year: 2025

Venue: Pharmaceutics

DOI: https://doi.org/10.3390/pharmaceutics17121568

Paper Implementation of Systematic Bioanalysis of Antibody–Drug Conjugates for Preclinical Pharmacokinetic Study of Ado-Trastuzumab Emtansine (T-DM1) in Rats

Eun-Jeong Jeon; Junfeng Han; Youjin Seo et al. · 2023 · Pharmaceutics · DOI

Full title: Implementation of Systematic Bioanalysis of Antibody–Drug Conjugates for Preclinical Pharmacokinetic Study of Ado-Trastuzumab Emtansine (T-DM1) in Rats

Authors: Eun-Jeong Jeon; Junfeng Han; Youjin Seo; E. Koh; Kang Han; K. Hwang; Kyung-Jin Jung

Year: 2023

Venue: Pharmaceutics

DOI: https://doi.org/10.3390/pharmaceutics15030756

Paper Towards Aptamer-Targeted Drug Delivery to Brain Tumors: The Synthesis of Ramified Conjugates of an EGFR-Specific Aptamer with MMAE on a Cathepsin B-Cleavable Linker

V. Brylev; E. V. Ryabukhina; Ekaterina V. Nazarova et al. · 2024 · Pharmaceutics · DOI

Full title: Towards Aptamer-Targeted Drug Delivery to Brain Tumors: The Synthesis of Ramified Conjugates of an EGFR-Specific Aptamer with MMAE on a Cathepsin B-Cleavable Linker

Authors: V. Brylev; E. V. Ryabukhina; Ekaterina V. Nazarova; N. Samoylenkova; E. L. Gulyak; K. A. Sapozhnikova; F. Dzarieva; Alexey V. Ustinov; I. Pronin; D. Usachev; A. Kopylov; Andrey V Golovin; G. Pavlova; D. Ryazantsev; V. Korshun

Year: 2024

Venue: Pharmaceutics

DOI: https://doi.org/10.3390/pharmaceutics16111434

Paper PK/PD of Positively Charged ADC in Mice

Hsuan-Ping Chang; Huyen Khanh Le; Shufang Liu et al. · 2025 · Pharmaceutics · DOI

Full title: PK/PD of Positively Charged ADC in Mice

Authors: Hsuan-Ping Chang; Huyen Khanh Le; Shufang Liu; Dhaval K. Shah

Year: 2025

Venue: Pharmaceutics

DOI: https://doi.org/10.3390/pharmaceutics17030377

Paper CXCR4-targeted theranostics in non-Hodgkin lymphoma: Present evidence and future directions

Marcus Yoakam; Uma A. Obalapuram; Kameron Hahn et al. · 2026 · Advances in Radiotherapy & Nuclear Medicine · DOI

Full title: CXCR4-targeted theranostics in non-Hodgkin lymphoma: Present evidence and future directions

Authors: Marcus Yoakam; Uma A. Obalapuram; Kameron Hahn; Samir Dalia

Year: 2026

Venue: Advances in Radiotherapy & Nuclear Medicine

DOI: https://doi.org/10.36922/arnm025480061

Paper Novel Anti-Trop2 Nanobodies Disrupt Receptor Dimerization and Inhibit Tumor Cell Growth

Junwen Deng; Zhongmin Geng; Linli Luan et al. · 2024 · Pharmaceutics · DOI

Full title: Novel Anti-Trop2 Nanobodies Disrupt Receptor Dimerization and Inhibit Tumor Cell Growth

Authors: Junwen Deng; Zhongmin Geng; Linli Luan; Dingwen Jiang; Jian Lu; Hanzhong Zhang; Bingguan Chen; Xin-long Liu; Dongming Xing

Year: 2024

Venue: Pharmaceutics

DOI: https://doi.org/10.3390/pharmaceutics16101255

Paper Revolutionizing cancer therapy: Monoclonal antibodies in radiosensitization

Abolfazl Bemidinezhad; Yasaman Abolhassani; Mojgan Noroozi-Karimabad et al. · 2025 · BioImpacts · DOI

Full title: Revolutionizing cancer therapy: Monoclonal antibodies in radiosensitization

Authors: Abolfazl Bemidinezhad; Yasaman Abolhassani; Mojgan Noroozi-Karimabad; Arman Abroumand Gholami; Abbas Alalikhan; Ramin Roshani; Mohammad Parsa-kondelaji; Fatemeh Gheybi

Year: 2025

Venue: BioImpacts

DOI: https://doi.org/10.34172/bi.30996

Paper Assessments of the In Vitro and In Vivo Linker Stability and Catabolic Fate for the Ortho Hydroxy-Protected Aryl Sulfate Linker by Immuno-Affinity Capture Liquid Chromatography Quadrupole Time-of-Flight Mass Spectrometric Assay

Byeong Ill Lee; Seo-jin Park; Yuri Park et al. · 2021 · Pharmaceutics · DOI

Full title: Assessments of the In Vitro and In Vivo Linker Stability and Catabolic Fate for the Ortho Hydroxy-Protected Aryl Sulfate Linker by Immuno-Affinity Capture Liquid Chromatography Quadrupole Time-of-Flight Mass Spectrometric Assay

Authors: Byeong Ill Lee; Seo-jin Park; Yuri Park; Seok-Ho Shin; Jang-mi Choi; Min-jae Park; Jeong-hyeon Lim; S. Kim; Hyangsook Lee; Y. Shin

Year: 2021

Venue: Pharmaceutics

DOI: https://doi.org/10.3390/pharmaceutics13010125

Paper Advancing antibody-drug conjugates in gynecological malignancies: myth or reality?

M. Nerone; M. D. Grande; C. Sessa et al. · 2022 · Exploration of Targeted Anti-tumor Therapy · DOI

Full title: Advancing antibody-drug conjugates in gynecological malignancies: myth or reality?

Authors: M. Nerone; M. D. Grande; C. Sessa; I. Colombo

Year: 2022

Venue: Exploration of Targeted Anti-tumor Therapy

DOI: https://doi.org/10.37349/etat.2022.00077

Paper Antibody-drug conjugate therapies in multiple myeloma—what’s next on the horizon?

Monique A. Hartley-Brown; P. Richardson · 2022 · Exploration of Targeted Anti-tumor Therapy · DOI

Full title: Antibody-drug conjugate therapies in multiple myeloma—what’s next on the horizon?

Authors: Monique A. Hartley-Brown; P. Richardson

Year: 2022

Venue: Exploration of Targeted Anti-tumor Therapy

DOI: https://doi.org/10.37349/etat.2022.00067

Paper Physical characteristics comparison between maytansinoid-based and auristatin-based antibody-drug conjugates

Tomohiro Fujii; C. Reiling; Colette F. Quinn et al. · 2021 · Exploration of Targeted Anti-tumor Therapy · DOI

Full title: Physical characteristics comparison between maytansinoid-based and auristatin-based antibody-drug conjugates

Authors: Tomohiro Fujii; C. Reiling; Colette F. Quinn; Michal Kliman; B. Mendelsohn; Yutaka Matsuda

Year: 2021

Venue: Exploration of Targeted Anti-tumor Therapy

DOI: https://doi.org/10.37349/etat.2021.00064

Paper Precision medicine and beyond: Evolving roles of targeted therapy, immunotherapy, and artificial intelligence in oncology

Linwei Li; Anika Doppalapudi; Jennifer Escamilla et al. · 2025 · INNOSC Theranostics and Pharmacological Sciences · DOI

Full title: Precision medicine and beyond: Evolving roles of targeted therapy, immunotherapy, and artificial intelligence in oncology

Authors: Linwei Li; Anika Doppalapudi; Jennifer Escamilla; Annu Karithara; Christine Pham; Angel Phillip; Anjali Binoy; Sriya Gullapalli; Lois Baldado; Arjun Bellamkonda; Daniela Gonzalez; Amin Ibrahim; Daniela Ramos; David Sta. Maria; Kaitlyn Ybanez; Hugo Zamarron; Shizue Mito

Year: 2025

Venue: INNOSC Theranostics and Pharmacological Sciences

DOI: https://doi.org/10.36922/itps025140018

Paper Comparative analysis of the efficacy and safety of antibody-drug conjugates, radionuclide-drug conjugates and their combination targeting claudin 18.2 in gastric cancer treatment

Huan Du; Xiaofei Hao; B. Lin et al. · 2025 · Oncology Report · DOI

Full title: Comparative analysis of the efficacy and safety of antibody-drug conjugates, radionuclide-drug conjugates and their combination targeting claudin 18.2 in gastric cancer treatment

Authors: Huan Du; Xiaofei Hao; B. Lin; Yu Zhang; Luo Rui; Jing Wang; Mingming Tang; Decai Wang; Yihan Zhu; Jie Li; Tang-Zhi Dai; Yuchuan Yang; Xia Yang; Xiaobo Du

Year: 2025

Venue: Oncology Report

DOI: https://doi.org/10.3892/or.2025.9009

Paper Trastuzumab Emtansine: Antibody-drug Conjugate in Treatment of Human Epidermal Growth Factor Receptor-2-Positive Metastatic Breast Cancer

A. Gogia; J. Nigade; C. Desai et al. · 2018 · Indian Journal of Medical and Paediatric Oncology · DOI

Full title: Trastuzumab Emtansine: Antibody-drug Conjugate in Treatment of Human Epidermal Growth Factor Receptor-2-Positive Metastatic Breast Cancer

Authors: A. Gogia; J. Nigade; C. Desai; B. Govind; C. Deshmukh; Binay Swarup

Year: 2018

Venue: Indian Journal of Medical and Paediatric Oncology

DOI: https://doi.org/10.4103/ijmpo.ijmpo_53_17

Paper Advances in adoptive cell therapies in small cell lung cancer

Eljie Isaak Bragasin; Justin Cheng; Lauren Ford et al. · 2025 · Exploration of Targeted Anti-tumor Therapy · DOI

Full title: Advances in adoptive cell therapies in small cell lung cancer

Authors: Eljie Isaak Bragasin; Justin Cheng; Lauren Ford; Darin Poei; Sana Ali; R. Hsu

Year: 2025

Venue: Exploration of Targeted Anti-tumor Therapy

DOI: https://doi.org/10.37349/etat.2025.1002302

Paper Preparation and evaluation of the PD0721‑DOX antibody‑drug conjugate targeting EGFRvIII to inhibit glioblastoma

Minmin Hu; Hong Liu; Yubing Zhang et al. · 2024 · Experimental and Therapeutic Medicine · DOI

Full title: Preparation and evaluation of the PD0721‑DOX antibody‑drug conjugate targeting EGFRvIII to inhibit glioblastoma

Authors: Minmin Hu; Hong Liu; Yubing Zhang; Dingyan Lu; Lin Zheng; Yonglin Wang; Shuaishuai Chen; Ting Liu

Year: 2024

Venue: Experimental and Therapeutic Medicine

DOI: https://doi.org/10.3892/etm.2024.12542

Paper Targeting HER2: a decade of progress in breast and gastric cancer therapy

Zahraa Alkhafaje; Attaa S. Dawood; Hiba G. Hussain et al. · 2025 · Pharmacia · DOI

Full title: Targeting HER2: a decade of progress in breast and gastric cancer therapy

Authors: Zahraa Alkhafaje; Attaa S. Dawood; Hiba G. Hussain; Raghad Layth Fadhil; Huda A. Rasheed; Hussein A. Dawood; Bassam A. Al-Zubaidi; Mostafa Adnan Abdalrahman; Amjad I. Oraibi; Hiba Ezzat Hameed; Ferial Majed; H. A. Al-hussaniy

Year: 2025

Venue: Pharmacia

DOI: https://doi.org/10.3897/pharmacia.72.e148259

Paper Perioperative systemic therapy in muscle invasive bladder cancer: Current standard method, biomarkers and emerging strategies

Kyung Hwan Kim; H. Lee; H. Ha et al. · 2023 · Investigative and Clinical Urology · DOI

Full title: Perioperative systemic therapy in muscle invasive bladder cancer: Current standard method, biomarkers and emerging strategies

Authors: Kyung Hwan Kim; H. Lee; H. Ha; H. Seo

Year: 2023

Venue: Investigative and Clinical Urology

DOI: https://doi.org/10.4111/icu.20230006

Paper Treatment of metastatic bladder cancer according to clinical considerations: a narrative review

Sung Goo Yoon; Seokho Kang · 2025 · Journal of Korean Medical Association · DOI

Full title: Treatment of metastatic bladder cancer according to clinical considerations: a narrative review

Authors: Sung Goo Yoon; Seokho Kang

Year: 2025

Venue: Journal of Korean Medical Association

DOI: https://doi.org/10.5124/jkma.25.0047

Paper Exo-Cleavable Linkers: Enhancing Stability and Therapeutic Efficacy in Antibody-Drug Conjugates

Tomohiro Watanabe; Tomohiro Fujii; Yutaka Matsuda · 2024 · Journal of Synthetic Organic Chemistry, Japan · DOI

Full title: Exo-Cleavable Linkers: Enhancing Stability and Therapeutic Efficacy in Antibody-Drug Conjugates

Authors: Tomohiro Watanabe; Tomohiro Fujii; Yutaka Matsuda

Year: 2024

Venue: Journal of Synthetic Organic Chemistry, Japan

DOI: https://doi.org/10.5059/yukigoseikyokaishi.82.1117

Paper Navigating Solid Tumor Heterogeneity: The Promise and Challenges of Antibody-Drug Conjugates

Ashley A. Duhon; Karen McLean · 2025 · Cancer heterogeneity and plasticity · DOI

Full title: Navigating Solid Tumor Heterogeneity: The Promise and Challenges of Antibody-Drug Conjugates

Authors: Ashley A. Duhon; Karen McLean

Year: 2025

Venue: Cancer heterogeneity and plasticity

DOI: https://doi.org/10.47248/chp2502040017

Paper Targeted Therapeutics for Cancer Treatment: A Review of Kinase Inhibitors, Angiogenesis Inhibitors, and Other Molecularly targeted Agents

M. Abah; M. Oladosu; Nkwocha John Nnaemeka et al. · 2025 · Biotechnology Frontiers · DOI

Full title: Targeted Therapeutics for Cancer Treatment: A Review of Kinase Inhibitors, Angiogenesis Inhibitors, and Other Molecularly targeted Agents

Authors: M. Abah; M. Oladosu; Nkwocha John Nnaemeka; Ochuele Dominic Agida

Year: 2025

Venue: Biotechnology Frontiers

DOI: https://doi.org/10.51470/bf.2025.5.1.09

Paper Trastuzumab-deruxtecan in breast cancer treatment: Balancing the triad of efficacy, safety and accessibility.

Victor Guan Hui Lee; J. Lim · 2025 · Annals of the Academy of Medicine, Singapore · DOI

Full title: Trastuzumab-deruxtecan in breast cancer treatment: Balancing the triad of efficacy, safety and accessibility.

Authors: Victor Guan Hui Lee; J. Lim

Year: 2025

Venue: Annals of the Academy of Medicine, Singapore

DOI: https://doi.org/10.47102/annals-acadmedsg.2025229

Paper Current trends in the treatment of gastrointestinal cancer: clinical applications of precision medicine and approaches by primary care and multidisciplinary teams

M. Lee · 2025 · Journal of Korean Medical Association · DOI

Full title: Current trends in the treatment of gastrointestinal cancer: clinical applications of precision medicine and approaches by primary care and multidisciplinary teams

Authors: M. Lee

Year: 2025

Venue: Journal of Korean Medical Association

DOI: https://doi.org/10.5124/jkma.25.0110

Paper Constrained Peptides in Drug Discovery and Development

D. R. Cary; Masaki Ohuchi; P. Reid et al. · 2017 · DOI

Full title: Constrained Peptides in Drug Discovery and Development

Authors: D. R. Cary; Masaki Ohuchi; P. Reid; K. Masuya

Year: 2017

DOI: https://doi.org/10.5059/yukigoseikyokaishi.75.1171

Paper Analysis Of Research Status of Antibody-Drug Conjugate in The Treatment of Colorectal Cancer

Shaoting Luo · 2024 · Highlights in Science Engineering and Technology · DOI

Full title: Analysis Of Research Status of Antibody-Drug Conjugate in The Treatment of Colorectal Cancer

Authors: Shaoting Luo

Year: 2024

Venue: Highlights in Science Engineering and Technology

DOI: https://doi.org/10.54097/xmck6m47

Paper Research on precision treatment of pancreatic cancer targeted by antibody-drug conjugates.

Xinyue Liu; Weishuai Liu; Chao Wu et al. · 2025 · BioScience Trends · DOI

Full title: Research on precision treatment of pancreatic cancer targeted by antibody-drug conjugates.

Authors: Xinyue Liu; Weishuai Liu; Chao Wu; Yudong Yuan; Antao Chang; Jihui Hao

Year: 2025

Venue: BioScience Trends

DOI: https://doi.org/10.5582/bst.2025.01271

Paper Unique Toxicities of Novel Myeloma Therapies: Focus on Belantamab Mafodotin, Talquetamab, and Selinexor

Jesse Shustik · 2025 · Canadian Hematology Today · DOI

Full title: Unique Toxicities of Novel Myeloma Therapies: Focus on Belantamab Mafodotin, Talquetamab, and Selinexor

Authors: Jesse Shustik

Year: 2025

Venue: Canadian Hematology Today

DOI: https://doi.org/10.58931/cht.2025.4379

Paper Linker Chemistry for Tumor Microenvironment-Responsive Payload Release in ADCs

Yuhe Wang · 2025 · Academic Journal of Science and Technology · DOI

Full title: Linker Chemistry for Tumor Microenvironment-Responsive Payload Release in ADCs

Authors: Yuhe Wang

Year: 2025

Venue: Academic Journal of Science and Technology

DOI: https://doi.org/10.54097/qq36d868

Paper Research Progress on Antibody-Drug Conjugates Therapy for Non-Small Cell Lung Cancer (NSCLC)

Han Li · 2025 · Theoretical and Natural Science · DOI

Full title: Research Progress on Antibody-Drug Conjugates Therapy for Non-Small Cell Lung Cancer (NSCLC)

Authors: Han Li

Year: 2025

Venue: Theoretical and Natural Science

DOI: https://doi.org/10.54254/2753-8818/2025.au23397

Paper The application and development of antibody drug conjugates in cancer therapy

Hengkang He; Enxin Li; Sifei Sheng · 2023 · Theoretical and Natural Science · DOI

Full title: The application and development of antibody drug conjugates in cancer therapy

Authors: Hengkang He; Enxin Li; Sifei Sheng

Year: 2023

Venue: Theoretical and Natural Science

DOI: https://doi.org/10.54254/2753-8818/20/20230797

Paper Targeted Liposomal Nanomedicines: Advancing Precision Therapeutics for HER-2 Positive and Triple-Negative Breast Cancer

Ujjwal Chaudhary; A. Parashar; L. Tyagi et al. · 2025 · International Journal of Newgen Research in Pharmacy & Healthcare · DOI

Full title: Targeted Liposomal Nanomedicines: Advancing Precision Therapeutics for HER-2 Positive and Triple-Negative Breast Cancer

Authors: Ujjwal Chaudhary; A. Parashar; L. Tyagi; Vandana Arora Sethi

Year: 2025

Venue: International Journal of Newgen Research in Pharmacy & Healthcare

DOI: https://doi.org/10.61554/ijnrph.v3i2.2025.214

Paper Targeted Nanoparticles: an Innovative Modality in the Treatment of Cancer

Hyung-Gyoo Kang; Bryon Upton; Ryan W. Holly et al. · 2025 · bioRxiv · DOI

Full title: Targeted Nanoparticles: an Innovative Modality in the Treatment of Cancer

Authors: Hyung-Gyoo Kang; Bryon Upton; Ryan W. Holly; Racheal Upton; Sheetal A. Mitra; Jean-Hugues Parmentier; Ann F. Mohrbacher; Yong-Mi Kim; Timothy J. Triche; Jon O. Nagy

Year: 2025

Venue: bioRxiv

DOI: https://doi.org/10.64898/2025.12.01.691687

Paper Research Status And Development Trend Of Monoclonal Antibodies For Non-Small Cell Lung Cancer

Minghui Gao · 2025 · Transactions on Materials, Biotechnology and Life Sciences · DOI

Full title: Research Status And Development Trend Of Monoclonal Antibodies For Non-Small Cell Lung Cancer

Authors: Minghui Gao

Year: 2025

Venue: Transactions on Materials, Biotechnology and Life Sciences

DOI: https://doi.org/10.62051/hg0b7s02

Paper Antibody-Drug Conjugates in Solid Tumors: Mechanisms, Clinical Advances, and Emerging Resistance Patterns

Hassan A. Abdou; Shadi Awny · 2026 · ASIDE Oncology · DOI

Full title: Antibody-Drug Conjugates in Solid Tumors: Mechanisms, Clinical Advances, and Emerging Resistance Patterns

Authors: Hassan A. Abdou; Shadi Awny

Year: 2026

Venue: ASIDE Oncology

DOI: https://doi.org/10.71079/aside.onc.012026464

Paper A strategically designed homogeneous antibody-drug conjugate improves safety and therapeutic index in renal cell carcinoma.

Thurakkal, Liya; Velayutham, Krishna; Sarkar, Binayak et al. · 2026 · bioRxiv : the preprint server for biology · DOI

Full title: A strategically designed homogeneous antibody-drug conjugate improves safety and therapeutic index in renal cell carcinoma.

Authors: Thurakkal, Liya; Velayutham, Krishna; Sarkar, Binayak; Kalyan, Akshaya; Sengupta, Shiladitya; Saha, Tanmoy

Year: 2026

Venue: bioRxiv : the preprint server for biology

DOI: https://doi.org/10.64898/2026.01.12.699160

Paper Recent Progress in Targeted Drug Delivery Systems for Cancer Treatment

Ghadah Ali Al-Oudah; Noor Thamer Mahmood; Dhelal Fouad Mohammed · 2025 · Journal of Biomedicine and Biochemistry · DOI

Full title: Recent Progress in Targeted Drug Delivery Systems for Cancer Treatment

Authors: Ghadah Ali Al-Oudah; Noor Thamer Mahmood; Dhelal Fouad Mohammed

Year: 2025

Venue: Journal of Biomedicine and Biochemistry

DOI: https://doi.org/10.57238/jbb.2025.7432.1141

Paper Advances In The Application Of Click Chemistry In The Research Of Targeted Therapeutic Drugs

Yue Zhang · 2025 · Transactions on Materials, Biotechnology and Life Sciences · DOI

Full title: Advances In The Application Of Click Chemistry In The Research Of Targeted Therapeutic Drugs

Authors: Yue Zhang

Year: 2025

Venue: Transactions on Materials, Biotechnology and Life Sciences

DOI: https://doi.org/10.62051/y0yezt68

Paper Orthogonally targeted tumor radiosensitization using cell penetrating peptide-ATM inhibitor conjugates to stimulate anti-tumor immune responses

Kanika Dhawan; Mike M Allevato; Jacqueline Lesperance et al. · 2026 · bioRxiv · DOI

Full title: Orthogonally targeted tumor radiosensitization using cell penetrating peptide-ATM inhibitor conjugates to stimulate anti-tumor immune responses

Authors: Kanika Dhawan; Mike M Allevato; Jacqueline Lesperance; M. F. Camargo; Marcus M Cheng; Mahsa Mortaja; Bamdad Zareh; Dina V. Hingorani; Stephen R. Adams; J. Gutkind; Sunil J. Advani

Year: 2026

Venue: bioRxiv

DOI: https://doi.org/10.64898/2026.01.09.698736

Paper A novel anti-DR5 antibody-drug conjugate possesses a high-potential therapeutic efficacy for leukemia and solid tumors

Shuyong Zhang; Chao Zheng; Wan Zhu et al. · 2019 · Theranostics · DOI

Full title: A novel anti-DR5 antibody-drug conjugate possesses a high-potential therapeutic efficacy for leukemia and solid tumors

Authors: Shuyong Zhang; Chao Zheng; Wan Zhu; P. Xiong; Dongdong Zhou; Changjiang Huang; D. Zheng

Year: 2019

Venue: Theranostics

DOI: https://doi.org/10.7150/thno.33598

Paper Activated platelets in the tumor microenvironment for targeting of antibody-drug conjugates to tumors and metastases

M. Yap; James D. McFadyen; James D. McFadyen et al. · 2019 · Theranostics · DOI

Full title: Activated platelets in the tumor microenvironment for targeting of antibody-drug conjugates to tumors and metastases

Authors: M. Yap; James D. McFadyen; James D. McFadyen; Xiaowei Wang; M. Ziegler; Yung-Chih Chen; A. Willcox; A. Willcox; C. Nowell; Andrew M. Scott; Andrew M. Scott; E. Sloan; P. M. Hogarth; P. M. Hogarth; P. M. Hogarth; G. Pietersz; K. Peter

Year: 2019

Venue: Theranostics

DOI: https://doi.org/10.7150/thno.29146

Paper B7-H3 in Brain Malignancies: Immunology and Immunotherapy

Xiaopeng Guo; Mengqi Chang; Yu Wang et al. · 2023 · International Journal on Biological Sciences · DOI

Full title: B7-H3 in Brain Malignancies: Immunology and Immunotherapy

Authors: Xiaopeng Guo; Mengqi Chang; Yu Wang; B. Xing; Wenbin Ma

Year: 2023

Venue: International Journal on Biological Sciences

DOI: https://doi.org/10.7150/ijbs.85813

Paper Untangling Triple-Negative Breast Cancer Molecular Peculiarity and Chemo-Resistance: Trailing Towards Marker-Based Targeted Therapies

Bushra Kanwal · 2021 · Cureus · DOI

Full title: Untangling Triple-Negative Breast Cancer Molecular Peculiarity and Chemo-Resistance: Trailing Towards Marker-Based Targeted Therapies

Authors: Bushra Kanwal

Year: 2021

Venue: Cureus

DOI: https://doi.org/10.7759/cureus.16636

Paper Prostate-specific Membrane Antigen Based Antibody-drug Conjugates for Metastatic Castration-resistance Prostate Cancer

M. O. Niaz; Michael M C Sun; M. Ramirez-Fort et al. · 2020 · Cureus · DOI

Full title: Prostate-specific Membrane Antigen Based Antibody-drug Conjugates for Metastatic Castration-resistance Prostate Cancer

Authors: M. O. Niaz; Michael M C Sun; M. Ramirez-Fort; M. Niaz

Year: 2020

Venue: Cureus

DOI: https://doi.org/10.7759/cureus.7147

Paper Immunotherapy in hematologic malignancies: achievements, challenges and future prospects

Lu Tang; Zhongpei Huang; H. Mei et al. · 2023 · Signal Transduction and Targeted Therapy · DOI

Full title: Immunotherapy in hematologic malignancies: achievements, challenges and future prospects

Authors: Lu Tang; Zhongpei Huang; H. Mei; Yu Hu

Year: 2023

Venue: Signal Transduction and Targeted Therapy

DOI: https://doi.org/10.1038/s41392-023-01521-5

Paper The evolving landscape of antibody-drug conjugates (ADCs) for treatment of prostate cancer

Claire Lin; Matthew J. Hadfield; Ariana Santopietro et al. · 2025 · npj Precision Oncology · DOI

Full title: The evolving landscape of antibody-drug conjugates (ADCs) for treatment of prostate cancer

Authors: Claire Lin; Matthew J. Hadfield; Ariana Santopietro; G. Lagos; Liang Cheng; Wafik S. El-Deiry; Rahul Aggarwal; Anthony E Mega; E. Hyams; B. Carneiro

Year: 2025

Venue: npj Precision Oncology

DOI: https://doi.org/10.1038/s41698-025-01131-0

Paper Stereoselective design of amino acid bioconjugates: targeting strategies and physicochemical optimization

Soma Mandal; ab Rajat; Choudhary † ab et al. · 2025 · RSC Medicinal Chemistry · DOI

Full title: Stereoselective design of amino acid bioconjugates: targeting strategies and physicochemical optimization

Authors: Soma Mandal; ab Rajat; Choudhary † ab; Badireenath Konkimalla

Year: 2025

Venue: RSC Medicinal Chemistry

DOI: https://doi.org/10.1039/d5md00760g

Paper Development of therapeutic antibodies for the treatment of diseases

Zeng Wang; Guoqing Wang; Huaqing Lu et al. · 2022 · Molecular Biomedicine · DOI

Full title: Development of therapeutic antibodies for the treatment of diseases

Authors: Zeng Wang; Guoqing Wang; Huaqing Lu; Hongjian Li; Mei Tang; A. Tong

Year: 2022

Venue: Molecular Biomedicine

DOI: https://doi.org/10.1186/s43556-022-00100-4

Paper Antibody-drug conjugates in cancer therapy: current landscape, challenges, and future directions.

Chen, Bonan; Zheng, Xiaohong; Wu, Jialin et al. · 2025 · Molecular cancer · DOI

Full title: Antibody-drug conjugates in cancer therapy: current landscape, challenges, and future directions.

Authors: Chen, Bonan; Zheng, Xiaohong; Wu, Jialin; Chen, Guoming; Yu, Jun; Xu, Yi; Wu, William K K; Tse, Gary M K; To, Ka Fai; Kang, Wei

Year: 2025

Venue: Molecular cancer

DOI: https://doi.org/10.1186/s12943-025-02489-2

Paper Oligospecific Human Antibodies with Therapeutic Potential Derived from Immunized Chickens

Jan P. Bogen · 2021 · Frontiers in Immunology · DOI

Full title: Oligospecific Human Antibodies with Therapeutic Potential Derived from Immunized Chickens

Authors: Jan P. Bogen

Year: 2021

Venue: Frontiers in Immunology

DOI: https://doi.org/10.26083/tuprints-00019360

Paper Importance and Considerations of Antibody Engineering in Antibody-Drug Conjugates Development from a Clinical Pharmacologist's Perspective.

Lucas, Andrew T; Moody, Amber; Schorzman, Allison N et al. · 2021 · Antibodies (Basel, Switzerland) · DOI

Full title: Importance and Considerations of Antibody Engineering in Antibody-Drug Conjugates Development from a Clinical Pharmacologist's Perspective.

Authors: Lucas, Andrew T; Moody, Amber; Schorzman, Allison N; Zamboni, William C

Year: 2021

Venue: Antibodies (Basel, Switzerland)

DOI: https://doi.org/10.3390/antib10030030

Paper Antibody-Drug Conjugates in Breast Cancer: Navigating Innovations, Overcoming Resistance, and Shaping Future Therapies.

Sabit, Hussein; Abbas, Salma; El-Safoury, Moataz T et al. · 2025 · Biomedicines · DOI

Full title: Antibody-Drug Conjugates in Breast Cancer: Navigating Innovations, Overcoming Resistance, and Shaping Future Therapies.

Authors: Sabit, Hussein; Abbas, Salma; El-Safoury, Moataz T; Madkour, Engy M; Mahmoud, Sahar; Abdel-Ghany, Shaimaa; Albrahim, Yasser; Al-Dhuayan, Ibtesam S; Rashwan, Sanaa; El-Hashash, Ahmed; Arneth, Borros

Year: 2025

Venue: Biomedicines

DOI: https://doi.org/10.3390/biomedicines13092227

Paper Actively Targeted Nanomedicines in Breast Cancer: From Pre-Clinal Investigation to Clinic

A. Fraguas-Sánchez; Irene Lozza; A. Torres-Suárez · 2022 · Cancers · DOI

Full title: Actively Targeted Nanomedicines in Breast Cancer: From Pre-Clinal Investigation to Clinic

Authors: A. Fraguas-Sánchez; Irene Lozza; A. Torres-Suárez

Year: 2022

Venue: Cancers

DOI: https://doi.org/10.3390/cancers14051198

Paper Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability.

Nguyen, Toan D; Bordeau, Brandon M; Balthasar, Joseph P · 2023 · Cancers · DOI

Full title: Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability.

Authors: Nguyen, Toan D; Bordeau, Brandon M; Balthasar, Joseph P

Year: 2023

Venue: Cancers

DOI: https://doi.org/10.3390/cancers15030713

Paper The Immunotherapy of Acute Myeloid Leukemia: A Clinical Point of View

F. Mosna · 2024 · Cancers · DOI

Full title: The Immunotherapy of Acute Myeloid Leukemia: A Clinical Point of View

Authors: F. Mosna

Year: 2024

Venue: Cancers

DOI: https://doi.org/10.3390/cancers16132359

Paper Single-Domain Antibodies as Antibody–Drug Conjugates: From Promise to Practice—A Systematic Review

Víctor Manuel Medina Pérez; Marta Baselga; A. J. Schuhmacher · 2024 · Cancers · DOI

Full title: Single-Domain Antibodies as Antibody–Drug Conjugates: From Promise to Practice—A Systematic Review

Authors: Víctor Manuel Medina Pérez; Marta Baselga; A. J. Schuhmacher

Year: 2024

Venue: Cancers

DOI: https://doi.org/10.3390/cancers16152681

Paper How Far Have We Developed Antibody–Drug Conjugate for the Treatment of Cancer?

Yu Jun Lim; Pei Sze Clarissa Lau; Shi Xuan Low et al. · 2023 · Drugs and Drug Candidates · DOI

Full title: How Far Have We Developed Antibody–Drug Conjugate for the Treatment of Cancer?

Authors: Yu Jun Lim; Pei Sze Clarissa Lau; Shi Xuan Low; Shong Li Ng; Min Yee Ong; Huey Ming Pang; Z. Lee; H. Yow; S. Hamzah; Renukha Sellappans; J. Foo

Year: 2023

Venue: Drugs and Drug Candidates

DOI: https://doi.org/10.3390/ddc2020020

Paper Antibody Drug Conjugates for Cancer Therapy

P. Polakis · 2016 · Pharmacological Reviews · DOI

Full title: Antibody Drug Conjugates for Cancer Therapy

Authors: P. Polakis

Year: 2016

Venue: Pharmacological Reviews

DOI: https://doi.org/10.1124/pr.114.009373

Paper Antibody Drug Conjugates for Cancer Therapy: From Metallodrugs to Nature-Inspired Payloads

Giovanni Tonon; F. Rizzolio; F. Visentin et al. · 2024 · International Journal of Molecular Sciences · DOI

Full title: Antibody Drug Conjugates for Cancer Therapy: From Metallodrugs to Nature-Inspired Payloads

Authors: Giovanni Tonon; F. Rizzolio; F. Visentin; T. Scattolin

Year: 2024

Venue: International Journal of Molecular Sciences

DOI: https://doi.org/10.3390/ijms25168651

Paper Functional Peptide-Based Biomaterials for Pharmaceutical Application: Sequences, Mechanisms, and Optimization Strategies

Dedong Yu; Nari Han; Hyejeong Son et al. · 2026 · Journal of Functional Biomaterials · DOI

Full title: Functional Peptide-Based Biomaterials for Pharmaceutical Application: Sequences, Mechanisms, and Optimization Strategies

Authors: Dedong Yu; Nari Han; Hyejeong Son; Sun Jo Kim; S. Kweon

Year: 2026

Venue: Journal of Functional Biomaterials

DOI: https://doi.org/10.3390/jfb17010037

Paper Impact of Endocytosis Mechanisms for the Receptors Targeted by the Currently Approved Antibody-Drug Conjugates (ADCs)—A Necessity for Future ADC Research and Development

Manar Hammood; A. Craig; Jeffrey V. Leyton · 2021 · Pharmaceuticals · DOI

Full title: Impact of Endocytosis Mechanisms for the Receptors Targeted by the Currently Approved Antibody-Drug Conjugates (ADCs)—A Necessity for Future ADC Research and Development

Authors: Manar Hammood; A. Craig; Jeffrey V. Leyton

Year: 2021

Venue: Pharmaceuticals

DOI: https://doi.org/10.3390/ph14070674

Paper Exploring Experimental and In Silico Approaches for Antibody–Drug Conjugates in Oncology Therapies

V. M. de Almeida; M. Soares; O. Santos-Filho · 2025 · Pharmaceuticals · DOI

Full title: Exploring Experimental and In Silico Approaches for Antibody–Drug Conjugates in Oncology Therapies

Authors: V. M. de Almeida; M. Soares; O. Santos-Filho

Year: 2025

Venue: Pharmaceuticals

DOI: https://doi.org/10.3390/ph18081198

Paper Strategic and Chemical Advances in Antibody-Drug Conjugates.

Alradwan, Ibrahim A; Alnefaie, Meshal K; Al Fayez, Nojoud et al. · 2025 · Pharmaceutics · DOI

Full title: Strategic and Chemical Advances in Antibody-Drug Conjugates.

Authors: Alradwan, Ibrahim A; Alnefaie, Meshal K; Al Fayez, Nojoud; Aodah, Alhassan H; Majrashi, Majed A; Alturki, Meshael; Fallatah, Mohannad M; Almughem, Fahad A; Tawfik, Essam A; Alshehri, Abdullah A

Year: 2025

Venue: Pharmaceutics

DOI: https://doi.org/10.3390/pharmaceutics17091164

Paper Immunoconjugates as an Efficient Platform for Drug Delivery: A Resurgence of Natural Products in Targeted Antitumor Therapy

Rositsa Mihaylova; D. Momekova; Viktoria Elincheva et al. · 2024 · Pharmaceuticals · DOI

Full title: Immunoconjugates as an Efficient Platform for Drug Delivery: A Resurgence of Natural Products in Targeted Antitumor Therapy

Authors: Rositsa Mihaylova; D. Momekova; Viktoria Elincheva; Georgi Momekov

Year: 2024

Venue: Pharmaceuticals

DOI: https://doi.org/10.3390/ph17121701

Paper A Review on the Stability Challenges of Advanced Biologic Therapeutics

Sruthi Sarvepalli; Shashank Reddy Pasika; Vartika Verma et al. · 2025 · Pharmaceutics · DOI

Full title: A Review on the Stability Challenges of Advanced Biologic Therapeutics

Authors: Sruthi Sarvepalli; Shashank Reddy Pasika; Vartika Verma; Anusha Thumma; Sandeep Bolla; Pavan Kumar Nukala; Arun Butreddy; Pradeep Kumar Bolla

Year: 2025

Venue: Pharmaceutics

DOI: https://doi.org/10.3390/pharmaceutics17050550

Paper A Narrative Review of Current Advances and Future Changes Regarding Bladder Cancer Treatment

Dominik Godlewski; Sara Czech; Jakub Szpara et al. · 2025 · Uro · DOI

Full title: A Narrative Review of Current Advances and Future Changes Regarding Bladder Cancer Treatment

Authors: Dominik Godlewski; Sara Czech; Jakub Szpara; D. Bartusik-Aebisher; D. Aebisher

Year: 2025

Venue: Uro

DOI: https://doi.org/10.3390/uro5020011

Paper Strategic Combinations of Antibody–Drug Conjugates from 2023 to 2025: From Dual Therapies to Innovative ADC-Based Regimens

Heewon Jang; Ji-Eun Chang · 2025 · Pharmaceutics · DOI

Full title: Strategic Combinations of Antibody–Drug Conjugates from 2023 to 2025: From Dual Therapies to Innovative ADC-Based Regimens

Authors: Heewon Jang; Ji-Eun Chang

Year: 2025

Venue: Pharmaceutics

DOI: https://doi.org/10.3390/pharmaceutics17121581

Paper ASCO 2025: key highlights in endometrial cancer

I. Tsibulak · 2026 · memo - Magazine of European Medical Oncology · DOI

Full title: ASCO 2025: key highlights in endometrial cancer

Authors: I. Tsibulak

Year: 2026

Venue: memo - Magazine of European Medical Oncology

DOI: https://doi.org/10.1007/s12254-025-01096-7

Paper Adverse events of antibody–drug conjugates on the ocular surface in cancer therapy

Sandra Domínguez-Llamas; M. Caro-Magdaleno; B. Mataix-Albert et al. · 2023 · Clinical and Translational Oncology · DOI

Full title: Adverse events of antibody–drug conjugates on the ocular surface in cancer therapy

Authors: Sandra Domínguez-Llamas; M. Caro-Magdaleno; B. Mataix-Albert; Javier Avilés-Prieto; Isabel Romero-Barranca; E. Rodríguez-de-la-Rúa

Year: 2023

Venue: Clinical and Translational Oncology

DOI: https://doi.org/10.1007/s12094-023-03261-y

Paper Recent Developments in ADC Technology: Preclinical Studies Signal Future Clinical Trends

Penelope M. Drake; David Rabuka · 2017 · BioDrugs · DOI

Full title: Recent Developments in ADC Technology: Preclinical Studies Signal Future Clinical Trends

Authors: Penelope M. Drake; David Rabuka

Year: 2017

Venue: BioDrugs

DOI: https://doi.org/10.1007/s40259-017-0254-1

Paper Antibody–drug conjugates for breast cancer: a bibliometric study and clinical trial analysis

Mengjie Xing; Zhiyi Li; Yuwan Cui et al. · 2024 · Discover Oncology · DOI

Full title: Antibody–drug conjugates for breast cancer: a bibliometric study and clinical trial analysis

Authors: Mengjie Xing; Zhiyi Li; Yuwan Cui; Minghua He; Yang Xing; Lei Yang; Ziling Liu; Linzhi Luo; Hong Wang; Rui Guo

Year: 2024

Venue: Discover Oncology

DOI: https://doi.org/10.1007/s12672-024-01192-w

Paper Subcutaneous Administration of Antibody-drug Conjugates

Aiman A Yaseen; Mohammad Asikur Rahman; L. N. Tumey · 2026 · Current Pharmacology Reports · DOI

Full title: Subcutaneous Administration of Antibody-drug Conjugates

Authors: Aiman A Yaseen; Mohammad Asikur Rahman; L. N. Tumey

Year: 2026

Venue: Current Pharmacology Reports

DOI: https://doi.org/10.1007/s40495-026-00442-5

Paper Antibody–drug conjugates treatment of small cell lung cancer: advances in clinical research

Y. Meng; Xuerui Wang; Jie Yang et al. · 2024 · Discover Oncology · DOI

Full title: Antibody–drug conjugates treatment of small cell lung cancer: advances in clinical research

Authors: Y. Meng; Xuerui Wang; Jie Yang; Meiying Zhu; Minghui Yu; Long-Yan Li; Yangyueying Liang; F. Kong

Year: 2024

Venue: Discover Oncology

DOI: https://doi.org/10.1007/s12672-024-01171-1

Paper Development of FAP-targeted theranostics discovered by next-generation sequencing-augmented mining of a novel immunized VNAR library

Gihan S. Gunaratne; Joseph P. Gallant; Kendahl L. Ott et al. · 2025 · bioRxiv · DOI

Full title: Development of FAP-targeted theranostics discovered by next-generation sequencing-augmented mining of a novel immunized VNAR library

Authors: Gihan S. Gunaratne; Joseph P. Gallant; Kendahl L. Ott; Payson L. Broome; Sasha Celada; Jayden L. West; J. Mixdorf; E. Aluicio‐Sarduy; Jonathan W. Engle; Eszter Boros; Labros Meimetis; Joshua M. Lang; Shuang G. Zhao; Reinier Hernandez; D. Kosoff; A.M. LeBeau

Year: 2025

Venue: bioRxiv

DOI: https://doi.org/10.1101/2025.01.13.632555

Paper Dual Site-Specific Chemoenzymatic Antibody Fragment Conjugation Using CRISPR-Based Hybridoma Engineering

Camille M. Le Gall; Johan M. S. van der Schoot; Iván Ramos-Tomillero et al. · 2020 · bioRxiv · DOI

Full title: Dual Site-Specific Chemoenzymatic Antibody Fragment Conjugation Using CRISPR-Based Hybridoma Engineering

Authors: Camille M. Le Gall; Johan M. S. van der Schoot; Iván Ramos-Tomillero; M. Khalily; F. V. van Dalen; Zacharias Wijfjes; Liyan Smeding; Duco van Dalen; Anna Cammarata; Kimberly M. Bonger; C. Figdor; F. Scheeren; M. Verdoes

Year: 2020

Venue: bioRxiv

DOI: https://doi.org/10.1101/2020.12.08.415182

Paper NECTIN-4 PET FOR OPTIMIZING ENFORTUMAB VEDOTIN DOSE-RESPONSE IN UROTHELIAL CARCINOMA

Akhilesh Mishra; A. K. Sharma; Kuldeep Gupta et al. · 2024 · bioRxiv · DOI

Full title: NECTIN-4 PET FOR OPTIMIZING ENFORTUMAB VEDOTIN DOSE-RESPONSE IN UROTHELIAL CARCINOMA

Authors: Akhilesh Mishra; A. K. Sharma; Kuldeep Gupta; Dhanush R. Banka; Burles A Johnson; Jeannie Hoffman-Censits; Peng Huang; D. McConkey; S. Nimmagadda

Year: 2024

Venue: bioRxiv

DOI: https://doi.org/10.1101/2024.12.25.630315

Paper An antibody-drug conjugate targeting GPR56 demonstrates efficacy in preclinical models of colorectal cancer

J. Jacob; Liezl E. Francisco; Treena Chatterjee et al. · 2022 · bioRxiv · DOI

Full title: An antibody-drug conjugate targeting GPR56 demonstrates efficacy in preclinical models of colorectal cancer

Authors: J. Jacob; Liezl E. Francisco; Treena Chatterjee; Zhengdong Liang; Shraddha Subramanian; Qingyun J. Liu; Julie Rowe; Kendra S. Carmon

Year: 2022

Venue: bioRxiv

DOI: https://doi.org/10.1101/2022.08.11.503187

Paper In Vivo Biorthogonal Antibody Click for Dual Targeting and Augmented Efficacy in Cancer Treatment

S. S. Panikar; Na-Keysha Berry; Shayla Shmuel et al. · 2023 · bioRxiv · DOI

Full title: In Vivo Biorthogonal Antibody Click for Dual Targeting and Augmented Efficacy in Cancer Treatment

Authors: S. S. Panikar; Na-Keysha Berry; Shayla Shmuel; Nai Keltee; Patrícia M R Pereira

Year: 2023

Venue: bioRxiv

DOI: https://doi.org/10.1101/2023.09.05.556426

Paper Engineering antibody–drug conjugates targeting an adhesion GPCR, CD97

T. Hattori; Michelle Wang; Alexis D Corrado et al. · 2025 · bioRxiv · DOI

Full title: Engineering antibody–drug conjugates targeting an adhesion GPCR, CD97

Authors: T. Hattori; Michelle Wang; Alexis D Corrado; Suzanne Gross; Michelle Fang; I. Bang; Nainita Roy; Iryna Berezniuk; Hayley Donaldson; Karenna J. Groff; Niklas Ravn-Boess; A. Koide; Dimitris G. Placantonakis; Christopher Y Park; Shohei Koide

Year: 2025

Venue: bioRxiv

DOI: https://doi.org/10.1101/2025.08.24.671942

Paper Epitope Expression Persists in Circulating Tumor Cells as Breast Cancers Acquire Resistance to Antibody Drug Conjugates

Avanish Mishra; R. Abelman; Quinn Cunneely et al. · 2025 · bioRxiv · DOI

Full title: Epitope Expression Persists in Circulating Tumor Cells as Breast Cancers Acquire Resistance to Antibody Drug Conjugates

Authors: Avanish Mishra; R. Abelman; Quinn Cunneely; Victor Putaturo; Akansha Deshpande; Remy Bell; Elizabeth M. Seider; K. Xu; M. Shan; Justin Kelly; Shih-Bo Huang; Kaustav A. Gopinathan; Kruthika Kikkeri; Jon F Edd; John R. Walsh; Charles S. Dai; Leif W. Ellisen; David T. Ting; Linda T. Nieman; Mehmet Toner; Aditya Bardia; D. Haber; S. Maheswaran

Year: 2025

Venue: bioRxiv

DOI: https://doi.org/10.1101/2025.04.02.646822

Paper Tandem-Cleavage Linkers Improve the In Vivo Stability and Tolerability of Antibody-Drug Conjugates.

Chuprakov, Stepan; Ogunkoya, Ayodele O; Barfield, Robyn M et al. · 2021 · Bioconjugate chemistry · DOI

Full title: Tandem-Cleavage Linkers Improve the In Vivo Stability and Tolerability of Antibody-Drug Conjugates.

Authors: Chuprakov, Stepan; Ogunkoya, Ayodele O; Barfield, Robyn M; Bauzon, Maxine; Hickle, Colin; Kim, Yun Cheol; Yeo, Dominick; Zhang, Fangjiu; Rabuka, David; Drake, Penelope M

Year: 2021

Venue: Bioconjugate chemistry

DOI: https://doi.org/10.1021/acs.bioconjchem.1c00029

Paper Low-density lipoprotein receptor-targeting chimeras for membrane protein degradation and enhanced drug delivery

Fangzhu Zhao; Yan Wu; K. Schaefer et al. · 2025 · bioRxiv · DOI

Full title: Low-density lipoprotein receptor-targeting chimeras for membrane protein degradation and enhanced drug delivery

Authors: Fangzhu Zhao; Yan Wu; K. Schaefer; Yun Zhang; Kun Miao; Zi Yao; Snehal D Ganjave; Kaan Kumru; Trenton M. Peters-Clarke; Alex Inague; James A. Olzmann; K. Leung; James A. Wells

Year: 2025

Venue: bioRxiv

DOI: https://doi.org/10.1101/2025.06.06.658366

Paper CD20 expression regulates CD37 levels in B-cell lymphoma – implications for immunotherapies

M. Bobrowicz; Aleksandra Kusowska; Marta Krawczyk et al. · 2023 · bioRxiv · DOI

Full title: CD20 expression regulates CD37 levels in B-cell lymphoma – implications for immunotherapies

Authors: M. Bobrowicz; Aleksandra Kusowska; Marta Krawczyk; A. Ślusarczyk; J. Barankiewicz; Joanna Domagala; Matylda Kubacz; Michal Šmída; Lenka Dostálová; Katsiaryna Marhelava; K. Fidyt; C. Forcados; M. Pepek; Iwona Baranowska; A. Szumera-Ciećkiewicz; E. Inderberg; S. Wälchli; Agnieszka Graczyk-Jarzynka; C. Gehlert; M. Peipp; M. Firczuk; M. Prochorec-Sobieszek; M. Winiarska

Year: 2023

Venue: bioRxiv

DOI: https://doi.org/10.1101/2023.12.06.570441

Paper TUB-010, a novel anti-CD30 antibody-drug conjugate based on Tub-tag technology, widens the therapeutic window by reducing toxicity while maintaining high efficacy

M. Gerlach; Saskia Schmitt; Philipp Cyprys et al. · 2025 · bioRxiv · DOI

Full title: TUB-010, a novel anti-CD30 antibody-drug conjugate based on Tub-tag technology, widens the therapeutic window by reducing toxicity while maintaining high efficacy

Authors: M. Gerlach; Saskia Schmitt; Philipp Cyprys; Marc‐André Kasper; I. Mai; Magdalena Klanova; Andreas Maiser; Heinrich Leonhardt; Christian P. R. Hackenberger; Guenter R. Fingerle-Rowson; Annette M Vogl; Dominik Schumacher; Jonas Helma

Year: 2025

Venue: bioRxiv

DOI: https://doi.org/10.1101/2025.01.15.633119

Paper Biodistribution-Driven Discovery Identifies a Glycosidase-Cleavable Linker to Reprogram Radiotheranostics.

Lee, Woonghee; Doda, Sai Reddy; Baidoo, Kwamena E et al. · 2025 · bioRxiv : the preprint server for biology · DOI

Full title: Biodistribution-Driven Discovery Identifies a Glycosidase-Cleavable Linker to Reprogram Radiotheranostics.

Authors: Lee, Woonghee; Doda, Sai Reddy; Baidoo, Kwamena E; Nambiar, Divya; Chung, Joon-Yong; Adler, Stephen; Edmondson, Elijah; Ueda, Yuki; Omiya, Satoshi; Li, Xiaoyi; Makala, Hima; Sheehan-Klenk, Julia; Fayn, Stanley; Weiss, Orit Jacobson; Lindberg, Eric; Beck, Jessica A; LeBlanc, Amy K; Lin, Frank I; Choyke, Peter L; Swenson, Rolf; Schnermann, Martin J; Escorcia, Freddy E

Year: 2025

Venue: bioRxiv : the preprint server for biology

DOI: https://doi.org/10.1101/2025.09.11.675134

Paper Systematic identification of regulators of antibody-drug conjugate toxicity using CRISPR-Cas9 screens

C. K. Tsui; Robyn M. Barfield; Curt R. Fischer et al. · 2019 · bioRxiv · DOI

Full title: Systematic identification of regulators of antibody-drug conjugate toxicity using CRISPR-Cas9 screens

Authors: C. K. Tsui; Robyn M. Barfield; Curt R. Fischer; D. Morgens; Amy Li; Benjamin A. H. Smith; Carolyn R. Bertozzi; Carolyn R. Bertozzi; David Rabuka; M. Bassik

Year: 2019

Venue: bioRxiv

DOI: https://doi.org/10.1101/557454

Paper FOLR1-targeted Actinium-225-based Alpha-particle Therapy Eliminates Ovarian Cancer

Neetu Singh; Esther Need; Ayden Berndt et al. · 2025 · bioRxiv · DOI

Full title: FOLR1-targeted Actinium-225-based Alpha-particle Therapy Eliminates Ovarian Cancer

Authors: Neetu Singh; Esther Need; Ayden Berndt; Matthew Goff; Lydia J Wilson; F. Mourtada; Feng Guo; Tara Mastren; T. Al-Hilal; Anil K Sood; Amit Maity; Scott C Miller; Satoshi Minoshima; Shreya Goel; Sixiang Shi

Year: 2025

Venue: bioRxiv

DOI: https://doi.org/10.1101/2025.10.27.684721

Paper Co-administered antibody improves penetration of antibody–dye conjugate into human cancers with implications for antibody–drug conjugates

G. Lu; N. Nishio; N. S. van den Berg et al. · 2020 · Nature Communications · DOI

Full title: Co-administered antibody improves penetration of antibody–dye conjugate into human cancers with implications for antibody–drug conjugates

Authors: G. Lu; N. Nishio; N. S. van den Berg; B. Martin; Shayan Fakurnejad; S. van Keulen; A. Colevas; Greg M. Thurber; E. Rosenthal

Year: 2020

Venue: Nature Communications

DOI: https://doi.org/10.1038/s41467-020-19498-y

Paper Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd)

Li-Chung Tsao; John S Wang; Xingru Ma et al. · 2025 · Nature Communications · DOI

Full title: Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd)

Authors: Li-Chung Tsao; John S Wang; Xingru Ma; Sirajbir Sodhi; Joey V. Ragusa; Bushangqing Liu; Jason McBane; Tao Wang; Junping Wei; Congxiao Liu; Xiao Yang; Gangjun Lei; Ivan Spasojevic; Ping Fan; T. Trotter; Michael Morse; H. Lyerly; Z. Hartman

Year: 2025

Venue: Nature Communications

DOI: https://doi.org/10.1038/s41467-025-58266-8

Paper Glutamic acid–valine–citrulline linkers ensure stability and efficacy of antibody–drug conjugates in mice

Y. Anami; Chisato M. Yamazaki; Wei Xiong et al. · 2018 · Nature Communications · DOI

Full title: Glutamic acid–valine–citrulline linkers ensure stability and efficacy of antibody–drug conjugates in mice

Authors: Y. Anami; Chisato M. Yamazaki; Wei Xiong; X. Gui; Ningyan Zhang; Z. An; K. Tsuchikama

Year: 2018

Venue: Nature Communications

DOI: https://doi.org/10.1038/s41467-018-04982-3

Paper Construction of paclitaxel-based antibody–drug conjugates with a PEGylated linker to achieve superior therapeutic index

T. Shao; Tianzhi Chen; Yuning Chen et al. · 2020 · Signal Transduction and Targeted Therapy · DOI

Full title: Construction of paclitaxel-based antibody–drug conjugates with a PEGylated linker to achieve superior therapeutic index

Authors: T. Shao; Tianzhi Chen; Yuning Chen; Xiaoyue Liu; Yi-Li Chen; Qi Wang; Tong Zhu; Maojun Guo; Hui Li; D. Ju; Chunhe Wang

Year: 2020

Venue: Signal Transduction and Targeted Therapy

DOI: https://doi.org/10.1038/s41392-020-00247-y

Paper The multifaceted roles of GSDME-mediated pyroptosis in cancer: therapeutic strategies and persisting obstacles

Yixiang Hu; Ya Liu; Lijuan Zong et al. · 2023 · Cell Death and Disease · DOI

Full title: The multifaceted roles of GSDME-mediated pyroptosis in cancer: therapeutic strategies and persisting obstacles

Authors: Yixiang Hu; Ya Liu; Lijuan Zong; Wenyou Zhang; Renzhu Liu; Qichang Xing; Zheng Liu; Qingzi Yan; Wencan Li; Haibo Lei; Xiang Liu

Year: 2023

Venue: Cell Death and Disease

DOI: https://doi.org/10.1038/s41419-023-06382-y

Paper Subtyping-based platform guides precision medicine for heavily pretreated metastatic triple-negative breast cancer: The FUTURE phase II umbrella clinical trial

Y. Liu; Xiuzhi Zhu; Yi Xiao et al. · 2023 · Cell Research · DOI

Full title: Subtyping-based platform guides precision medicine for heavily pretreated metastatic triple-negative breast cancer: The FUTURE phase II umbrella clinical trial

Authors: Y. Liu; Xiuzhi Zhu; Yi Xiao; Songyang Wu; W. Zuo; Q. Yu; A. Cao; Junjie Li; Keda Yu; Guangrong Liu; Jiong Wu; T. Sun; J. Cui; Zheng Lv; Huiping Li; Xiao-yu Zhu; Yizhou Jiang; Zhonghua Wang; Z. Shao

Year: 2023

Venue: Cell Research

DOI: https://doi.org/10.1038/s41422-023-00795-2

Paper Exploring the therapeutic use and outcome of antibody-drug conjugates in ovarian cancer treatment

Revu V L Narayana; Romi Gupta · 2025 · Oncogene · DOI

Full title: Exploring the therapeutic use and outcome of antibody-drug conjugates in ovarian cancer treatment

Authors: Revu V L Narayana; Romi Gupta

Year: 2025

Venue: Oncogene

DOI: https://doi.org/10.1038/s41388-025-03448-3

Paper Delivery of a BET protein degrader via a CEACAM6-targeted antibody–drug conjugate inhibits tumour growth in pancreatic cancer models

Youya Nakazawa; Masayuki Miyano; Shuntaro Tsukamoto et al. · 2024 · Nature Communications · DOI

Full title: Delivery of a BET protein degrader via a CEACAM6-targeted antibody–drug conjugate inhibits tumour growth in pancreatic cancer models

Authors: Youya Nakazawa; Masayuki Miyano; Shuntaro Tsukamoto; Hiroyuki Kogai; Akihiko Yamamoto; Kentaro Iso; Satoshi Inoue; Yoshinobu Yamane; Yuki Yabe; Hirotatsu Umihara; Junichi Taguchi; Tsuyoshi Akagi; Atsumi Yamaguchi; Minaho Koga; Kohta Toshimitsu; Toshifumi Hirayama; Yohei Mukai; Akihito Machinaga

Year: 2024

Venue: Nature Communications

DOI: https://doi.org/10.1038/s41467-024-46167-1

Paper Identification of a hotspot on PD-L1 for pH-dependent binding by monoclonal antibodies for tumor therapy

Hongchuan Liu; Xiaoshan Bi; Yuehua Zhou et al. · 2020 · Signal Transduction and Targeted Therapy · DOI

Full title: Identification of a hotspot on PD-L1 for pH-dependent binding by monoclonal antibodies for tumor therapy

Authors: Hongchuan Liu; Xiaoshan Bi; Yuehua Zhou; R. Shi; S. Yao; J. Qi; H. Feng; Meiqing Feng; Jinghua Yan; Shuguang Tan

Year: 2020

Venue: Signal Transduction and Targeted Therapy

DOI: https://doi.org/10.1038/s41392-020-00254-z

Paper Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance — Source link

Chisato M. Yamazaki; A. Yamaguchi; Y. Anami et al. · 2020 · Nature Communications · DOI

Full title: Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance — Source link

Authors: Chisato M. Yamazaki; A. Yamaguchi; Y. Anami; Wei Xiong; Y. Otani; 6. Jangsoon; Lee; N. Ueno; Ningyan Zhang; Z. An; K. Tsuchikama

Year: 2020

Venue: Nature Communications

DOI: https://doi.org/10.1038/s41467-021-23793-7

Paper Site-specific ligase-dependent conjugation with ring-opening linker improves safety and stability of HER2-targeting ADCs

Lei Huang; Gang Qin; C. Gong et al. · 2025 · Nature Communications · DOI

Full title: Site-specific ligase-dependent conjugation with ring-opening linker improves safety and stability of HER2-targeting ADCs

Authors: Lei Huang; Gang Qin; C. Gong; Yajun Sun; Hui Yang; Cao Lv; Chong Liu; Lu Jiang; Jinduo Yuan; Mingyu Hu; Xinju Gao; Jun Yang; Xuesong Li; Yu Si; Paul Song; Yan Shi; Lili Shi; Bo Yang; Biyun Wang

Year: 2025

Venue: Nature Communications

DOI: https://doi.org/10.1038/s41467-025-64675-6

Paper Novel treatment approaches utilizing antibody-drug conjugates in breast cancer

A. Davis; Jennifer Hesse; Patrícia M R Pereira et al. · 2025 · npj Breast Cancer · DOI

Full title: Novel treatment approaches utilizing antibody-drug conjugates in breast cancer

Authors: A. Davis; Jennifer Hesse; Patrícia M R Pereira; Cynthia X. Ma

Year: 2025

Venue: npj Breast Cancer

DOI: https://doi.org/10.1038/s41523-025-00743-w

Paper Treatment strategies for breast cancer brain metastases

C. Bailleux; Lauriane Eberst; T. Bachelot · 2020 · British Journal of Cancer · DOI

Full title: Treatment strategies for breast cancer brain metastases

Authors: C. Bailleux; Lauriane Eberst; T. Bachelot

Year: 2020

Venue: British Journal of Cancer

DOI: https://doi.org/10.1038/s41416-020-01175-y

Paper Expanding the payload scope in antibody-drug conjugates by delivery of hydroxy-containing drugs through self-immolative phosphoramidates

Philipp Ochtrop; Anil P. Jagtap; Jan G. Felber et al. · 2026 · Nature Communications · DOI

Full title: Expanding the payload scope in antibody-drug conjugates by delivery of hydroxy-containing drugs through self-immolative phosphoramidates

Authors: Philipp Ochtrop; Anil P. Jagtap; Jan G. Felber; Simon Vogt; Sarah Herterich; I. Mai; Philipp Cyprys; Saskia Schmitt; Sarah Payer; Annabel Kitowski; Swetlana Wunder; Paul Machui; Julia Brandmeier; Natascia Leonardi; Elizaveta Poliak; Christian P. R. Hackenberger; Olivier Marcq; Dominik Schumacher; Jonas Helma; Annette M Vogl; Marc‐André Kasper

Year: 2026

Venue: Nature Communications

DOI: https://doi.org/10.1038/s41467-026-68605-y

Paper Tumor cell-directed STING agonist antibody-drug conjugates induce type III interferons and anti-tumor innate immune responses

Naniye Malli Cetinbas; Travis Monnell; Jahna Soomer-James et al. · 2024 · Nature Communications · DOI

Full title: Tumor cell-directed STING agonist antibody-drug conjugates induce type III interferons and anti-tumor innate immune responses

Authors: Naniye Malli Cetinbas; Travis Monnell; Jahna Soomer-James; P. Shaw; Kelly Lancaster; Kalli C. Catcott; Melissa Dolan; Rebecca Mosher; C. Routhier; Chen-Ni Chin; D. Toader; Jeremy R Duvall; R. Bukhalid; T. Lowinger; M. Damelin

Year: 2024

Venue: Nature Communications

DOI: https://doi.org/10.1038/s41467-024-49932-4

Paper Precemtabart tocentecan, an anti-CEACAM5 antibody–drug conjugate, in metastatic colorectal cancer: a phase 1 trial

S. Kopetz; Valentina Boni; Ken Kato et al. · 2025 · Nature Medicine · DOI

Full title: Precemtabart tocentecan, an anti-CEACAM5 antibody–drug conjugate, in metastatic colorectal cancer: a phase 1 trial

Authors: S. Kopetz; Valentina Boni; Ken Kato; K. Raghav; M. Vieito; A. Pallis; C. Habermehl; Abdul Siddiqui; Perrine Courlet; W. Sloot; Sabine Raab-Westphal; Felix Hart; I. Rodriguez-Rivera

Year: 2025

Venue: Nature Medicine

DOI: https://doi.org/10.1038/s41591-025-03843-z

Paper CLDN18.2–targeting antibody–drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: a phase 1 trial

Jia Liu; Jianwei Yang; Yuping Sun et al. · 2025 · Nature Medicine · DOI

Full title: CLDN18.2–targeting antibody–drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: a phase 1 trial

Authors: Jia Liu; Jianwei Yang; Yuping Sun; J. Gong; Jinbo Yue; Yueyin Pan; Meili Sun; Rongfeng Song; Xiuying Xiao; Andrea Tazbirkova; Jian Ruan; Zhen-Yin Liu; Zimin Liu; Zhihua Li; Lili Sheng; Yanru Qin; Jieer Ying; Xianjun Yu; Jian Zhang; Yiping Mou; Chuangxin Lu; Ping Chen; Suyi Li; Jie Li; Xiujuan Qu; Ting Deng; Juan Du; Aiping Zhou; Enxiao Li; Xianglin Yuan; Xinjun Liang; Weiming Yu; Michelle Morris; Yang Luo; Xin Zhao; Yingmei Guo; Hui Zhou; L. Shen

Year: 2025

Venue: Nature Medicine

DOI: https://doi.org/10.1038/s41591-025-03783-8

Paper Emerging systemic therapy options beyond CDK4/6 inhibitors for hormone receptor-positive HER2-negative advanced breast cancer.

Ma, Jun; Chan, Jack Junjie; Toh, Ching Han et al. · 2023 · NPJ breast cancer · DOI

Full title: Emerging systemic therapy options beyond CDK4/6 inhibitors for hormone receptor-positive HER2-negative advanced breast cancer.

Authors: Ma, Jun; Chan, Jack Junjie; Toh, Ching Han; Yap, Yoon-Sim

Year: 2023

Venue: NPJ breast cancer

DOI: https://doi.org/10.1038/s41523-023-00578-3

Paper RF1 attenuation enables efficient non-natural amino acid incorporation for production of homogeneous antibody drug conjugates

Gang Yin; Heather T Stephenson; Junhao Yang et al. · 2017 · Scientific Reports · DOI

Full title: RF1 attenuation enables efficient non-natural amino acid incorporation for production of homogeneous antibody drug conjugates

Authors: Gang Yin; Heather T Stephenson; Junhao Yang; Xiaofan Li; S. Armstrong; Tyler H Heibeck; Cuong Tran; Mary Rose Masikat; Sihong Zhou; R. Stafford; A. Yam; John Lee; Alexander R. Steiner; A. Gill; K. Penta; S. Pollitt; R. Baliga; C. J. Murray; C. Thanos; L. Mcevoy; A. Sato; T. Hallam

Year: 2017

Venue: Scientific Reports

DOI: https://doi.org/10.1038/s41598-017-03192-z

Paper Antibody–drug conjugates in breast cancer: mechanisms of resistance and future therapeutic perspectives

Irene Valle; T. Grinda; Lorenzo Antonuzzo et al. · 2025 · npj Breast Cancer · DOI

Full title: Antibody–drug conjugates in breast cancer: mechanisms of resistance and future therapeutic perspectives

Authors: Irene Valle; T. Grinda; Lorenzo Antonuzzo; B. Pistilli

Year: 2025

Venue: npj Breast Cancer

DOI: https://doi.org/10.1038/s41523-025-00829-5

Paper Conservation of oncofetal antigens on human embryonic stem cells enables discovery of monoclonal antibodies against cancer

H. Tan; C. Yong; B. Tan et al. · 2018 · Scientific Reports · DOI

Full title: Conservation of oncofetal antigens on human embryonic stem cells enables discovery of monoclonal antibodies against cancer

Authors: H. Tan; C. Yong; B. Tan; Wey Jia Fong; J. Padmanabhan; A. Chin; Vanessa M. Y. Ding; Ally Lau; Lu Zheng; X. Bi; Yuansheng Yang; A. Choo

Year: 2018

Venue: Scientific Reports

DOI: https://doi.org/10.1038/s41598-018-30070-z

Paper Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic Cancer

Guoyun Zhu; D. Foletti; Xiaohui Liu et al. · 2019 · Scientific Reports · DOI

Full title: Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic Cancer

Authors: Guoyun Zhu; D. Foletti; Xiaohui Liu; Sheng Ding; Jody Melton Witt; Adela Hasa-Moreno; M. Rickert; Charles Holz; L. Aschenbrenner; Amy H. Yang; E. Kraynov; W. Evering; Leslie Obert; Chenyu Lee; T. Sai; Tina Mistry; Kevin C. Lindquist; Thomas J. Van Blarcom; P. Strop; J. Chaparro-Riggers; Shu-Hui Liu

Year: 2019

Venue: Scientific Reports

DOI: https://doi.org/10.1038/s41598-019-44874-0

Paper Internalization of CD239 highly expressed in breast cancer cells: a potential antigen for antibody-drug conjugates

Y. Kikkawa; Yurie Enomoto-Okawa; Aiko Fujiyama et al. · 2018 · Scientific Reports · DOI

Full title: Internalization of CD239 highly expressed in breast cancer cells: a potential antigen for antibody-drug conjugates

Authors: Y. Kikkawa; Yurie Enomoto-Okawa; Aiko Fujiyama; Takeshi Fukuhara; Nozomi Harashima; Yumika Sugawara; Y. Negishi; Fumihiko Katagiri; K. Hozumi; M. Nomizu; Yuji Ito

Year: 2018

Venue: Scientific Reports

DOI: https://doi.org/10.1038/s41598-018-24961-4

Paper Novel method for screening functional antibody with comprehensive analysis of its immunoliposome

S. Hamamichi; Takeshi Fukuhara; I. Umeda et al. · 2021 · Scientific Reports · DOI

Full title: Novel method for screening functional antibody with comprehensive analysis of its immunoliposome

Authors: S. Hamamichi; Takeshi Fukuhara; I. Umeda; H. Fujii; N. Hattori

Year: 2021

Venue: Scientific Reports

DOI: https://doi.org/10.1038/s41598-021-84043-w

Paper Placenta-specific1 (PLAC1) is a potential target for antibody-drug conjugate-based prostate cancer immunotherapy

Mohammad Reza Nejadmoghaddam; A. Zarnani; R. Ghahremanzadeh et al. · 2017 · Scientific Reports · DOI

Full title: Placenta-specific1 (PLAC1) is a potential target for antibody-drug conjugate-based prostate cancer immunotherapy

Authors: Mohammad Reza Nejadmoghaddam; A. Zarnani; R. Ghahremanzadeh; R. Ghods; Jafar Mahmoudian; M. Yousefi; M. Nazari; M. Ghahremani; M. Abolhasani; A. Anissian; M. Mahmoudi; R. Dinarvand

Year: 2017

Venue: Scientific Reports

DOI: https://doi.org/10.1038/s41598-017-13682-9

Paper On the use of DNA as a linker in antibody-drug conjugates: synthesis, stability and in vitro potency

I. Dovgan; Anthony Ehkirch; Victor Lehot et al. · 2020 · Scientific Reports · DOI

Full title: On the use of DNA as a linker in antibody-drug conjugates: synthesis, stability and in vitro potency

Authors: I. Dovgan; Anthony Ehkirch; Victor Lehot; I. Kuhn; Oleksandr Koniev; S. Kolodych; Alexandre Hentz; M. Ripoll; S. Ursuegui; M. Nothisen; S. Cianférani; A. Wagner

Year: 2020

Venue: Scientific Reports

DOI: https://doi.org/10.1038/s41598-020-64518-y

Paper Preclinical evaluation of a novel antibody–drug conjugate OBI-992 for Cancer therapy

Ting-Yu Chang; Chun-Jung Lin; Shih-Ni Wen et al. · 2025 · Scientific Reports · DOI

Full title: Preclinical evaluation of a novel antibody–drug conjugate OBI-992 for Cancer therapy

Authors: Ting-Yu Chang; Chun-Jung Lin; Shih-Ni Wen; Yi-Chen Wu; Cheng-Yen Wei; Jye-Yu Huang; Yu-Hsuan Tsao; Yu-Jung Chen; Wei-Chien Tang; Yuen-Chin Wu; Wei-Han Lee; Teng-Yi Huang; Tzer-Min Kuo; Wan-Fen Li; Ming-Tain Lai

Year: 2025

Venue: Scientific Reports

DOI: https://doi.org/10.1038/s41598-025-92697-z

Paper Rapid conjugation of antibodies to toxins to select candidates for the development of anticancer Antibody-Drug Conjugates (ADCs)

Ricarda M Hoffmann; S. Mele; A. Cheung et al. · 2020 · Scientific Reports · DOI

Full title: Rapid conjugation of antibodies to toxins to select candidates for the development of anticancer Antibody-Drug Conjugates (ADCs)

Authors: Ricarda M Hoffmann; S. Mele; A. Cheung; Daniel Larcombe-Young; Gintare Bucaite; Eirini Sachouli; Iva Zlatareva; Hassan O. J. Morad; Rebecca Marlow; J. McDonnell; M. Figini; K. Lacy; A. Tutt; J. Spicer; D. Thurston; S. Karagiannis; S. Crescioli

Year: 2020

Venue: Scientific Reports

DOI: https://doi.org/10.1038/s41598-020-65860-x

Paper Immune-checkpoint targeting drug conjugates: a novel class of promising therapeutic agents for cancer treatment

S. Marchesi; Arianna Marinello; Paolo Ambrosini et al. · 2025 · npj Precision Oncology · DOI

Full title: Immune-checkpoint targeting drug conjugates: a novel class of promising therapeutic agents for cancer treatment

Authors: S. Marchesi; Arianna Marinello; Paolo Ambrosini; Chiara Cavalli; G. Lo Russo; M. Occhipinti

Year: 2025

Venue: npj Precision Oncology

DOI: https://doi.org/10.1038/s41698-025-01011-7

Paper Linker-GPT: design of Antibody-drug conjugates linkers with molecular generators and reinforcement learning

An Su; Yanlin Luo; Chengwei Zhang et al. · 2025 · Scientific Reports · DOI

Full title: Linker-GPT: design of Antibody-drug conjugates linkers with molecular generators and reinforcement learning

Authors: An Su; Yanlin Luo; Chengwei Zhang; Hongliang Duan

Year: 2025

Venue: Scientific Reports

DOI: https://doi.org/10.1038/s41598-025-05555-3

Paper Antibody–drug nanoparticle induces synergistic treatment efficacies in HER2 positive breast cancer cells

Muhammad Raisul Abedin; Kaitlyne Powers; Rachel Aiardo et al. · 2021 · Scientific Reports · DOI

Full title: Antibody–drug nanoparticle induces synergistic treatment efficacies in HER2 positive breast cancer cells

Authors: Muhammad Raisul Abedin; Kaitlyne Powers; Rachel Aiardo; Dibbya Barua; Sutapa Barua

Year: 2021

Venue: Scientific Reports

DOI: https://doi.org/10.1038/s41598-021-86762-6

Paper Ortho-functionalized pyridinyl-tetrazines break the inverse correlation between click reactivity and cleavage yields in click-to-release chemistry

Ron M. Versteegen; R. Rossin; I. Filot et al. · 2024 · Communications Chemistry · DOI

Full title: Ortho-functionalized pyridinyl-tetrazines break the inverse correlation between click reactivity and cleavage yields in click-to-release chemistry

Authors: Ron M. Versteegen; R. Rossin; I. Filot; F. Hoeben; Arthur H. A. M. van Onzen; Henk M. Janssen; M. S. Robillard

Year: 2024

Venue: Communications Chemistry

DOI: https://doi.org/10.1038/s42004-024-01392-z

Paper Antibody-drug conjugates in lung cancer: dawn of a new era?

N. Coleman; T. Yap; J. Heymach et al. · 2023 · npj Precision Oncology · DOI

Full title: Antibody-drug conjugates in lung cancer: dawn of a new era?

Authors: N. Coleman; T. Yap; J. Heymach; F. Meric-Bernstam; X. Le

Year: 2023

Venue: npj Precision Oncology

DOI: https://doi.org/10.1038/s41698-022-00338-9

Paper Leveraging artificial intelligence in antibody-drug conjugate development: from target identification to clinical translation in oncology

Ye Lu; Weijun Huang; Yuxuan Li et al. · 2025 · npj Precision Oncology · DOI

Full title: Leveraging artificial intelligence in antibody-drug conjugate development: from target identification to clinical translation in oncology

Authors: Ye Lu; Weijun Huang; Yuxuan Li; Yanzhi Xu; Qing Wei; Chulin Sha; Peng Guo

Year: 2025

Venue: npj Precision Oncology

DOI: https://doi.org/10.1038/s41698-025-01159-2

Paper Through every lens: assessing the impact of chemical modifications on antibody-conjugates using in vivo imaging

V. V. S. R. Edupuganti; Freddy E. Escorcia; M. Schnermann · 2025 · npj Imaging · DOI

Full title: Through every lens: assessing the impact of chemical modifications on antibody-conjugates using in vivo imaging

Authors: V. V. S. R. Edupuganti; Freddy E. Escorcia; M. Schnermann

Year: 2025

Venue: npj Imaging

DOI: https://doi.org/10.1038/s44303-025-00109-8

Paper A new TROP2-targeting antibody-drug conjugate shows potent antitumor efficacy in breast and lung cancers

Dan-dan Zhou; Xiao-Tian Zhai; Lan-Wen Zhang et al. · 2024 · npj Precision Oncology · DOI

Full title: A new TROP2-targeting antibody-drug conjugate shows potent antitumor efficacy in breast and lung cancers

Authors: Dan-dan Zhou; Xiao-Tian Zhai; Lan-Wen Zhang; Zi-hui Xie; Ying Wang; Yong-su Zhen; Rui-juan Gao; Qing-Fang Miao

Year: 2024

Venue: npj Precision Oncology

DOI: https://doi.org/10.1038/s41698-024-00584-z

Paper Development of potent antibody drug conjugates against ICAM1+ cancer cells in preclinical models of cholangiocarcinoma

B. Zhu; Xinyan Wang; T. Shimura et al. · 2023 · npj Precision Oncology · DOI

Full title: Development of potent antibody drug conjugates against ICAM1+ cancer cells in preclinical models of cholangiocarcinoma

Authors: B. Zhu; Xinyan Wang; T. Shimura; Andrew C Huang; Nana Kong; Yujie Dai; Jianmin Fang; Peng Guo; Jieer Ying

Year: 2023

Venue: npj Precision Oncology

DOI: https://doi.org/10.1038/s41698-023-00447-z

Paper - **DOI:** 10.1038/srep30835 - **Authors:** I. Dovgan, S. Kolodych, Oleksandr Koniev, A. Wagner - **Year:** 2016 - **Journal:** Scientific Reports

I. Dovgan; S. Kolodych; Oleksandr Koniev et al. · 2016 · Scientific Reports · DOI

Full title: - **DOI:** 10.1038/srep30835 - **Authors:** I. Dovgan, S. Kolodych, Oleksandr Koniev, A. Wagner - **Year:** 2016 - **Journal:** Scientific Reports

Authors: I. Dovgan; S. Kolodych; Oleksandr Koniev; A. Wagner

Year: 2016

Venue: Scientific Reports

DOI: https://doi.org/10.1038/srep30835

Paper The characterization of variable new antigen receptors targeting FAP isolated from a novel immunized library

Gihan S. Gunaratne; Joseph P. Gallant; Kendahl L. Ott et al. · 2025 · Communications Biology · DOI

Full title: The characterization of variable new antigen receptors targeting FAP isolated from a novel immunized library

Year: 2025

Venue: Communications Biology

DOI: https://doi.org/10.1038/s42003-025-08610-x

Paper Development of a facile antibody–drug conjugate platform for increased stability and homogeneity† †Electronic supplementary information (ESI) available: Synthetic schemes and characterization data, experimental procedures, Fig. S1 and S2. See DOI: 10.1039/c6sc05149a Click here for additional data fi

Nimish Gupta; Johny Kancharla; Shelly Kaushik et al. · 2016 · Chemical Science · DOI

Full title: Development of a facile antibody–drug conjugate platform for increased stability and homogeneity† †Electronic supplementary information (ESI) available: Synthetic schemes and characterization data, experimental procedures, Fig. S1 and S2. See DOI: 10.1039/c6sc05149a Click here for additional data fi

Authors: Nimish Gupta; Johny Kancharla; Shelly Kaushik; Aasif Ansari; Samad Hossain; R. Goyal; M. Pandey; Jwala Sivaccumar; Sazid Hussain; Arindam Sarkar; Aniruddha Sengupta; S. Mandal; Monideepa Roy; Shiladitya Sengupta

Year: 2016

Venue: Chemical Science

DOI: https://doi.org/10.1039/c6sc05149a

Paper Towards a glutathione-cleavable azobenzene linker for antibody-drug conjugates.

M. Kapun; Roshan Patel; Mahri Park et al. · 2025 · Chemical Communications · DOI

Full title: Towards a glutathione-cleavable azobenzene linker for antibody-drug conjugates.

Authors: M. Kapun; Roshan Patel; Mahri Park; F. J. Pérez‐Areales; Kristina Kostadinova; Thomas Wharton; Jason S. Carroll; David R. Spring

Year: 2025

Venue: Chemical Communications

DOI: https://doi.org/10.1039/d5cc05824d

Paper Diazido macrocyclic sulfates as a platform for the synthesis of sequence-defined polymers for antibody drug conjugates

N. L. Forsythe; Mikayla F. Tan; H. Maynard · 2022 · Chemical Science · DOI

Full title: Diazido macrocyclic sulfates as a platform for the synthesis of sequence-defined polymers for antibody drug conjugates

Authors: N. L. Forsythe; Mikayla F. Tan; H. Maynard

Year: 2022

Venue: Chemical Science

DOI: https://doi.org/10.1039/d1sc06242e

Paper Rapid and robust cysteine bioconjugation with vinylheteroarenes

H. Seki; Stephen J. Walsh; Jonathan D Bargh et al. · 2021 · Chemical Science · DOI

Full title: Rapid and robust cysteine bioconjugation with vinylheteroarenes

Authors: H. Seki; Stephen J. Walsh; Jonathan D Bargh; J. Parker; J. Carroll; D. Spring

Year: 2021

Venue: Chemical Science

DOI: https://doi.org/10.1039/d1sc02722k

Paper All-in-one disulfide bridging enables the generation of antibody conjugates with modular cargo loading

Friederike M Dannheim; Stephen J. Walsh; Carolina T Orozco et al. · 2022 · Chemical Science · DOI

Full title: All-in-one disulfide bridging enables the generation of antibody conjugates with modular cargo loading

Authors: Friederike M Dannheim; Stephen J. Walsh; Carolina T Orozco; A. Hansen; Jonathan D Bargh; S. Jackson; N. Bond; J. Parker; J. Carroll; D. Spring

Year: 2022

Venue: Chemical Science

DOI: https://doi.org/10.1039/d2sc02198f

Paper Compact hydrophilic electrophiles enable highly efficacious high DAR ADCs with excellent in vivo PK profile

P. Ochtrop; Jahaziel Jahzerah; Paul Machui et al. · 2023 · Chemical Science · DOI

Full title: Compact hydrophilic electrophiles enable highly efficacious high DAR ADCs with excellent in vivo PK profile

Authors: P. Ochtrop; Jahaziel Jahzerah; Paul Machui; I. Mai; D. Schumacher; J. Helma; Marc‐André Kasper; C. Hackenberger

Year: 2023

Venue: Chemical Science

DOI: https://doi.org/10.1039/d2sc05678j

Paper Sulfatase-cleavable linkers for antibody-drug conjugates†

Jonathan D Bargh; Stephen J. Walsh; Albert Isidro-Llobet et al. · 2020 · Chemical Science · DOI

Full title: Sulfatase-cleavable linkers for antibody-drug conjugates†

Authors: Jonathan D Bargh; Stephen J. Walsh; Albert Isidro-Llobet; Soleilmane Omarjee; J. Carroll; D. Spring

Year: 2020

Venue: Chemical Science

DOI: https://doi.org/10.1039/c9sc06410a

Paper Technical, preclinical, and clinical developments of Fc-glycan-specific antibody-drug conjugates.

Yang, Qiang; Liu, Yunpeng · 2025 · RSC medicinal chemistry · DOI

Full title: Technical, preclinical, and clinical developments of Fc-glycan-specific antibody-drug conjugates.

Authors: Yang, Qiang; Liu, Yunpeng

Year: 2025

Venue: RSC medicinal chemistry

DOI: https://doi.org/10.1039/d4md00637b

Paper Steric and stereoscopic disulfide construction for cross-linkage via N-dithiophthalimides†‡

Wen-Chao Gao; Jun Tian; Y. Shang et al. · 2020 · Chemical Science · DOI

Full title: Steric and stereoscopic disulfide construction for cross-linkage via N-dithiophthalimides†‡

Authors: Wen-Chao Gao; Jun Tian; Y. Shang; Xuefeng Jiang

Year: 2020

Venue: Chemical Science

DOI: https://doi.org/10.1039/d0sc01060j

Paper A biparatopic HER2-targeting ADC constructed via site-specific glycan conjugation exhibits superior stability, safety, and efficacy

Q. Xue; Jianjian Peng; Wenying Dai et al. · 2025 · RSC Chemical Biology · DOI

Full title: A biparatopic HER2-targeting ADC constructed via site-specific glycan conjugation exhibits superior stability, safety, and efficacy

Authors: Q. Xue; Jianjian Peng; Wenying Dai; Qingsong Wu; Jinbiao Jiao; Yudi Hu; W. Sha; Yang Yang; Wenhao Yu; Siyang Liu; Ting Xu; Jie P. Li

Year: 2025

Venue: RSC Chemical Biology

DOI: https://doi.org/10.1039/d5cb00096c

Paper Generating a Bispecific Antibody Drug Conjugate Targeting PRLR and HER2 with Improving the Internalization

Huifang Zong; Baohong Zhang; Jianjia Zhu · 2022 · Pharmaceutical Fronts · DOI

Full title: Generating a Bispecific Antibody Drug Conjugate Targeting PRLR and HER2 with Improving the Internalization

Authors: Huifang Zong; Baohong Zhang; Jianjia Zhu

Year: 2022

Venue: Pharmaceutical Fronts

DOI: https://doi.org/10.1055/s-0042-1749334

Paper Functional native disulfide bridging enables delivery of a potent, stable and targeted antibody-drug conjugate (ADC).

João P. M. Nunes; M. Morais; V. Vassileva et al. · 2015 · Chemical Communications · DOI

Full title: Functional native disulfide bridging enables delivery of a potent, stable and targeted antibody-drug conjugate (ADC).

Authors: João P. M. Nunes; M. Morais; V. Vassileva; E. Robinson; V. Rajkumar; Mark E. B. Smith; R. Pedley; S. Caddick; J. R. Baker; V. Chudasama

Year: 2015

Venue: Chemical Communications

DOI: https://doi.org/10.1039/c5cc03557k

Paper A novel antibody–drug conjugate targeting SAIL for the treatment of hematologic malignancies

S. Kim; Jan-Willem Theunissen; J. Balibalos et al. · 2015 · Blood Cancer Journal · DOI

Full title: A novel antibody–drug conjugate targeting SAIL for the treatment of hematologic malignancies

Authors: S. Kim; Jan-Willem Theunissen; J. Balibalos; Sindy Liao-Chan; M. C. Babcock; T. Wong; B. Cairns; D. Gonzalez; E. V. D. Horst; M. Perez; Z. Levashova; L. Chinn; J. A. D'alessio; Flory Mr; A. Bermudez; D. Y. Jackson; E. Ha; J. Monteon; Maureen Fitch Bruhns; Guoqing Chen; T. Migone

Year: 2015

Venue: Blood Cancer Journal

DOI: https://doi.org/10.1038/bcj.2015.39

Paper From prodrug to pro-prodrug: hypoxia-sensitive antibody–drug conjugates

Yanming Wang; Dian Xiao; Jiaguo Li et al. · 2022 · Signal Transduction and Targeted Therapy · DOI

Full title: From prodrug to pro-prodrug: hypoxia-sensitive antibody–drug conjugates

Authors: Yanming Wang; Dian Xiao; Jiaguo Li; Shiyong Fan; Fei Xie; Wu Zhong; Xinbo Zhou; Song Li

Year: 2022

Venue: Signal Transduction and Targeted Therapy

DOI: https://doi.org/10.1038/s41392-021-00833-8

Paper Quantitative systems pharmacology modeling of HER2-positive metastatic breast cancer for translational efficacy evaluation and combination assessment across therapeutic modalities

Ya-ting Zhou; Jia-Hui Chu; Shu-han Zhao et al. · 2024 · Acta Pharmacologica Sinica · DOI

Full title: Quantitative systems pharmacology modeling of HER2-positive metastatic breast cancer for translational efficacy evaluation and combination assessment across therapeutic modalities

Authors: Ya-ting Zhou; Jia-Hui Chu; Shu-han Zhao; Geli Li; Zi-yi Fu; Sujie Zhang; Xue-Hu Gao; Wen Ma; Kai Shen; Yuan Gao; Wei Li; Yongmei Yin; Chen Zhao

Year: 2024

Venue: Acta Pharmacologica Sinica

DOI: https://doi.org/10.1038/s41401-024-01232-9

Paper Milatuzumab-Doxorubicin Antibody-Drug Conjugate IMMU-110

· 2020 · Definitions · DOI

Full title: Milatuzumab-Doxorubicin Antibody-Drug Conjugate IMMU-110

Year: 2020

Venue: Definitions

DOI: https://doi.org/10.32388/szq78x

Paper Naked antibodies and antibody-drug conjugates: targeted therapy for childhood acute lymphoblastic leukemia

Erica Brivio; Francisco Bautista; C. Zwaan · 2024 · Haematologica · DOI

Full title: Naked antibodies and antibody-drug conjugates: targeted therapy for childhood acute lymphoblastic leukemia

Authors: Erica Brivio; Francisco Bautista; C. Zwaan

Year: 2024

Venue: Haematologica

DOI: https://doi.org/10.3324/haematol.2023.283815

Paper Anti-LAMP1 Antibody-drug Conjugate SAR428926

· 2020 · Definitions · DOI

Full title: Anti-LAMP1 Antibody-drug Conjugate SAR428926

Year: 2020

Venue: Definitions

DOI: https://doi.org/10.32388/qrdzap

Paper Antibody-drug Conjugate ABBV-155

· 2020 · Definitions · DOI

Full title: Antibody-drug Conjugate ABBV-155

Year: 2020

Venue: Definitions

DOI: https://doi.org/10.32388/hvqe5n

Paper Antibody-Drug Conjugate DFRF4539A

· 2020 · Definitions · DOI

Full title: Antibody-Drug Conjugate DFRF4539A

Year: 2020

Venue: Definitions

DOI: https://doi.org/10.32388/yr3mn4

Paper Soluble B-cell maturation antigen in lacrimal fluid as a potential biomarker and mediator of keratopathy in multiple myeloma

U. Munawar; J. Theuersbacher; M. Steinhardt et al. · 2024 · Haematologica · DOI

Full title: Soluble B-cell maturation antigen in lacrimal fluid as a potential biomarker and mediator of keratopathy in multiple myeloma

Authors: U. Munawar; J. Theuersbacher; M. Steinhardt; Xiang Zhou; Seungbin Han; S. Nerreter; C. Vogt; Shilpa Kurian; Thorsten Keller; Ann-Kathrin Regensburger; E. Teufel; J. Mersi; M. Bittrich; Franziska Seifert; M. S. Haider; L. Rasche; Jost Hillenkamp; H. Einsele; D. Kampik; K. M. Kortüm; J. Waldschmidt; A. Regensburger

Year: 2024

Venue: Haematologica

DOI: https://doi.org/10.3324/haematol.2024.285205

Paper Antibody-drug Conjugate SC-003

· 2020 · Definitions · DOI

Full title: Antibody-drug Conjugate SC-003

Year: 2020

Venue: Definitions

DOI: https://doi.org/10.32388/zyby9z

Paper Discovery research and translation science of trastuzumab deruxtecan, from non-clinical study to clinical trial

T. Nakada · 2021 · Translational and Regulatory Sciences · DOI

Full title: Discovery research and translation science of trastuzumab deruxtecan, from non-clinical study to clinical trial

Authors: T. Nakada

Year: 2021

Venue: Translational and Regulatory Sciences

DOI: https://doi.org/10.33611/trs.2021-010

Paper The Role of Immunotherapy in Non-transplant Eligible Multiple Myeloma

A. Bobin; Hélène Gardeney; Florence Sabirou et al. · 2020 · Frontiers in Oncology · DOI

Full title: The Role of Immunotherapy in Non-transplant Eligible Multiple Myeloma

Authors: A. Bobin; Hélène Gardeney; Florence Sabirou; Cécile Gruchet; A. Lévy; Laly Nsiala; Laura Cailly; C. Tomowiak; J. Torregrosa; S. Guidez; X. Leleu

Year: 2020

Venue: Frontiers in Oncology

DOI: https://doi.org/10.3389/fonc.2020.00676

Paper Conditional activation of an anti-IgM antibody-drug conjugate for precise B cell lymphoma targeting

K. Schoenfeld; Julia Harwardt; Jan Habermann et al. · 2023 · Frontiers in Immunology · DOI

Full title: Conditional activation of an anti-IgM antibody-drug conjugate for precise B cell lymphoma targeting

Authors: K. Schoenfeld; Julia Harwardt; Jan Habermann; Adrian Elter; H. Kolmar

Year: 2023

Venue: Frontiers in Immunology

DOI: https://doi.org/10.3389/fimmu.2023.1258700

Paper Anti-lipolysis-stimulated lipoprotein receptor antibody-drug conjugate to treat triple-negative breast cancer

Zhuoxin Zhou; Davis Ballard; Tanvi Varadkar et al. · 2025 · Frontiers in Oncology · DOI

Full title: Anti-lipolysis-stimulated lipoprotein receptor antibody-drug conjugate to treat triple-negative breast cancer

Authors: Zhuoxin Zhou; Davis Ballard; Tanvi Varadkar; Jiashuai Zhang; Zhantao Du; Ashley George; Aaron Krabacher; Rachel Yengo; Lufang Zhou; X. Liu

Year: 2025

Venue: Frontiers in Oncology

DOI: https://doi.org/10.3389/fonc.2025.1663743

Paper Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy

B. Nazha; C. Inal; T. Owonikoko · 2020 · Frontiers in Oncology · DOI

Full title: Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy

Authors: B. Nazha; C. Inal; T. Owonikoko

Year: 2020

Venue: Frontiers in Oncology

DOI: https://doi.org/10.3389/fonc.2020.01000

Paper Antibody-drug conjugates: the paradigm shifts in the targeted cancer therapy.

Aggarwal, Devesh; Yang, Jie; Salam, Md Abdus et al. · 2023 · Frontiers in immunology · DOI

Full title: Antibody-drug conjugates: the paradigm shifts in the targeted cancer therapy.

Authors: Aggarwal, Devesh; Yang, Jie; Salam, Md Abdus; Sengupta, Sagnik; Al-Amin, Md Yusuf; Mustafa, Saad; Khan, Mohammad Aasif; Huang, Xun; Pawar, Jogendra Singh

Year: 2023

Venue: Frontiers in immunology

DOI: https://doi.org/10.3389/fimmu.2023.1203073

Paper Novel Antibody Drug Conjugates Targeting Tumor-Associated Receptor Tyrosine Kinase ROR2 by Functional Screening of Fully Human Antibody Libraries Using Transpo-mAb Display on Progenitor B Cells

I. Hellmann; L. Waldmeier; Marie-Christine Bannwarth-Escher et al. · 2018 · Frontiers in Immunology · DOI

Full title: Novel Antibody Drug Conjugates Targeting Tumor-Associated Receptor Tyrosine Kinase ROR2 by Functional Screening of Fully Human Antibody Libraries Using Transpo-mAb Display on Progenitor B Cells

Authors: I. Hellmann; L. Waldmeier; Marie-Christine Bannwarth-Escher; Kseniya Maslova; Fabian I. Wolter; U. Grawunder; R. Beerli

Year: 2018

Venue: Frontiers in Immunology

DOI: https://doi.org/10.3389/fimmu.2018.02490

Paper Antibody-drug conjugates as game changers in bladder cancer: current progress and future directions

Fei Zhang; Sheng Li · 2025 · Frontiers in Immunology · DOI

Full title: Antibody-drug conjugates as game changers in bladder cancer: current progress and future directions

Authors: Fei Zhang; Sheng Li

Year: 2025

Venue: Frontiers in Immunology

DOI: https://doi.org/10.3389/fimmu.2025.1591191

Paper A Unique Human Immunoglobulin Heavy Chain Variable Domain-Only CD33 CAR for the Treatment of Acute Myeloid Leukemia

D. Schneider; Y. Xiong; Peirong Hu et al. · 2018 · Frontiers in Oncology · DOI

Full title: A Unique Human Immunoglobulin Heavy Chain Variable Domain-Only CD33 CAR for the Treatment of Acute Myeloid Leukemia

Authors: D. Schneider; Y. Xiong; Peirong Hu; Darong Wu; Wei-zao Chen; T. Ying; Zhongyu Zhu; D. Dimitrov; B. Dropulić; R. Orentas

Year: 2018

Venue: Frontiers in Oncology

DOI: https://doi.org/10.3389/fonc.2018.00539

Paper Lysosomal P-gp-MDR1 Confers Drug Resistance of Brentuximab Vedotin and Its Cytotoxic Payload Monomethyl Auristatin E in Tumor Cells

Liu-Kreyche Peggy; Hong Shen; A. Marino et al. · 2019 · Frontiers in Pharmacology · DOI

Full title: Lysosomal P-gp-MDR1 Confers Drug Resistance of Brentuximab Vedotin and Its Cytotoxic Payload Monomethyl Auristatin E in Tumor Cells

Authors: Liu-Kreyche Peggy; Hong Shen; A. Marino; R. Iyer; W. Humphreys; Yurong Lai

Year: 2019

Venue: Frontiers in Pharmacology

DOI: https://doi.org/10.3389/fphar.2019.00749

Paper Brentuximab vedotin use in pediatric anaplastic large cell lymphoma

J. Agrusa; Emily R. Egress; E. Lowe · 2023 · Frontiers in Immunology · DOI

Full title: Brentuximab vedotin use in pediatric anaplastic large cell lymphoma

Authors: J. Agrusa; Emily R. Egress; E. Lowe

Year: 2023

Venue: Frontiers in Immunology

DOI: https://doi.org/10.3389/fimmu.2023.1203471

Paper Antibody-drug conjugates targeting HER2 for the treatment of urothelial carcinoma: potential therapies for HER2-positive urothelial carcinoma

Chia-Hsien Shih; Yu-Hua Lin; Hao-Lun Luo et al. · 2024 · Frontiers in Pharmacology · DOI

Full title: Antibody-drug conjugates targeting HER2 for the treatment of urothelial carcinoma: potential therapies for HER2-positive urothelial carcinoma

Authors: Chia-Hsien Shih; Yu-Hua Lin; Hao-Lun Luo; Wen-Wei Sung

Year: 2024

Venue: Frontiers in Pharmacology

DOI: https://doi.org/10.3389/fphar.2024.1326296

Paper The potential of antibody-drug conjugates in immunotherapy for non-small cell lung cancer: current progress and future

Hongyu Lin; Xinyu Ma; Xinhai Zhu et al. · 2025 · Frontiers in Oncology · DOI

Full title: The potential of antibody-drug conjugates in immunotherapy for non-small cell lung cancer: current progress and future

Authors: Hongyu Lin; Xinyu Ma; Xinhai Zhu; Linru Zhong

Year: 2025

Venue: Frontiers in Oncology

DOI: https://doi.org/10.3389/fonc.2025.1630056

Paper Insights and therapeutic advances in pancreatic cancer: the role of electron microscopy in decoding the tumor microenvironment

Hong Dai; Xingxuan Chen; Jiawen Yang et al. · 2024 · Frontiers in Cell and Developmental Biology · DOI

Full title: Insights and therapeutic advances in pancreatic cancer: the role of electron microscopy in decoding the tumor microenvironment

Authors: Hong Dai; Xingxuan Chen; Jiawen Yang; Yuying Wang; R. Loiola; Aiping Lu; K. Cheung

Year: 2024

Venue: Frontiers in Cell and Developmental Biology

DOI: https://doi.org/10.3389/fcell.2024.1460544

Paper Preclinical profiles of SKB264, a novel anti-TROP2 antibody conjugated to topoisomerase inhibitor, demonstrated promising antitumor efficacy compared to IMMU-132

Yezhe Cheng; Xiaoxi Yuan; Qiang Tian et al. · 2022 · Frontiers in Oncology · DOI

Full title: Preclinical profiles of SKB264, a novel anti-TROP2 antibody conjugated to topoisomerase inhibitor, demonstrated promising antitumor efficacy compared to IMMU-132

Authors: Yezhe Cheng; Xiaoxi Yuan; Qiang Tian; Xiuying Huang; Yang Chen; Yuzhi Pu; Huaicheng Long; Mingyu Xu; Yafei Ji; Jia Xie; Yuping Tan; Xi Zhao; Hongmei Song

Year: 2022

Venue: Frontiers in Oncology

DOI: https://doi.org/10.3389/fonc.2022.951589

Paper Antibody-drug conjugate: a newly developed biological missile for tumor treatment.

Tang, Zhuoran; Xie, Yanchun; Zeng, Yanping · 2025 · Frontiers in oncology · DOI

Full title: Antibody-drug conjugate: a newly developed biological missile for tumor treatment.

Authors: Tang, Zhuoran; Xie, Yanchun; Zeng, Yanping

Year: 2025

Venue: Frontiers in oncology

DOI: https://doi.org/10.3389/fonc.2025.1688057

Paper The development and evaluation of a tublysine-based antibody-drug conjugate with enhanced tumor therapeutic efficacy

Huihui Guo; Hongsheng Xie; Yuanyuan Huang et al. · 2025 · Frontiers in Pharmacology · DOI

Full title: The development and evaluation of a tublysine-based antibody-drug conjugate with enhanced tumor therapeutic efficacy

Authors: Huihui Guo; Hongsheng Xie; Yuanyuan Huang; Junxiang Jia; Xiangfei Kong; Qingliang Yang; Shun Gai; Wenjun Li; Lu Bai; Lingli Zhang; Xiaoxiao Chen; Zhicang Ye; Hangbo Ye; Linyao Zhao; Yifang Xu; Yong Du; Xiuzhen Zhang; Miaomiao Chen; Xiaomai Zhou; R. Zhao

Year: 2025

Venue: Frontiers in Pharmacology

DOI: https://doi.org/10.3389/fphar.2025.1532104

Paper Elucidating Novel Targets for Ovarian Cancer Antibody–Drug Conjugate Development: Integrating In Silico Prediction and Surface Plasmon Resonance to Identify Targets with Enhanced Antibody Internalization Capacity

E. Onyido; David James; Jezabel Garcia-Parra et al. · 2023 · Antibodies · DOI

Full title: Elucidating Novel Targets for Ovarian Cancer Antibody–Drug Conjugate Development: Integrating In Silico Prediction and Surface Plasmon Resonance to Identify Targets with Enhanced Antibody Internalization Capacity

Authors: E. Onyido; David James; Jezabel Garcia-Parra; John Sinfield; Anna Moberg; Zoe Coombes; Jenny Worthington; Nicole Williams; Lewis W. Francis; R. S. Conlan; D. Gonzalez

Year: 2023

Venue: Antibodies

DOI: https://doi.org/10.3390/antib12040065

Paper Linker Design Impacts Antibody-Drug Conjugate Pharmacokinetics and Efficacy via Modulating the Stability and Payload Release Efficiency

Dian Su; Donglu Zhang · 2021 · Frontiers in Pharmacology · DOI

Full title: Linker Design Impacts Antibody-Drug Conjugate Pharmacokinetics and Efficacy via Modulating the Stability and Payload Release Efficiency

Authors: Dian Su; Donglu Zhang

Year: 2021

Venue: Frontiers in Pharmacology

DOI: https://doi.org/10.3389/fphar.2021.687926

Paper Hydrophilic Auristatin Glycoside Payload Enables Improved Antibody-Drug Conjugate Efficacy and Biocompatibility

T. Satomaa; Henna Pynnönen; A. Vilkman et al. · 2018 · Antibodies · DOI

Full title: Hydrophilic Auristatin Glycoside Payload Enables Improved Antibody-Drug Conjugate Efficacy and Biocompatibility

Authors: T. Satomaa; Henna Pynnönen; A. Vilkman; Titta Kotiranta; Virve Pitkänen; A. Heiskanen; B. Herpers; L. Price; J. Helin; J. Saarinen

Year: 2018

Venue: Antibodies

DOI: https://doi.org/10.3390/antib7020015

Paper Factors Affecting the Pharmacology of Antibody–Drug Conjugates

A. Lucas; Lauren S. L. Price; Allison N. Schorzman et al. · 2018 · Antibodies · DOI

Full title: Factors Affecting the Pharmacology of Antibody–Drug Conjugates

Authors: A. Lucas; Lauren S. L. Price; Allison N. Schorzman; Mallory Storrie; J. Piscitelli; Juan Razo; W. Zamboni

Year: 2018

Venue: Antibodies

DOI: https://doi.org/10.3390/antib7010010

Paper Updates on Antibody Drug Conjugates and Bispecific T-Cell Engagers in SCLC

Kinsley Wang; Kyle Taing; R. Hsu · 2026 · Antibodies · DOI

Full title: Updates on Antibody Drug Conjugates and Bispecific T-Cell Engagers in SCLC

Authors: Kinsley Wang; Kyle Taing; R. Hsu

Year: 2026

Venue: Antibodies

DOI: https://doi.org/10.3390/antib15010004

Paper A Purification Strategy Utilizing Hydrophobic Interaction Chromatography to Obtain Homogeneous Species from a Site-Specific Antibody Drug Conjugate Produced by AJICAP™ First Generation.

Matsuda, Yutaka; Leung, Monica; Okuzumi, Tatsuya et al. · 2020 · Antibodies (Basel, Switzerland) · DOI

Full title: A Purification Strategy Utilizing Hydrophobic Interaction Chromatography to Obtain Homogeneous Species from a Site-Specific Antibody Drug Conjugate Produced by AJICAP™ First Generation.

Authors: Matsuda, Yutaka; Leung, Monica; Okuzumi, Tatsuya; Mendelsohn, Brian

Year: 2020

Venue: Antibodies (Basel, Switzerland)

DOI: https://doi.org/10.3390/antib9020016

Paper A RAGE-Targeted Antibody-Drug Conjugate: Surface Plasmon Resonance as a Platform for Accelerating Effective ADC Design and Development

Gareth D Healey; Å. Frostell; T. Fagge et al. · 2019 · Antibodies · DOI

Full title: A RAGE-Targeted Antibody-Drug Conjugate: Surface Plasmon Resonance as a Platform for Accelerating Effective ADC Design and Development

Authors: Gareth D Healey; Å. Frostell; T. Fagge; D. Gonzalez; R. S. Conlan

Year: 2019

Venue: Antibodies

DOI: https://doi.org/10.3390/antib8010007

Paper Navigating hepatotoxicity of antibody-drug conjugates: from mechanistic insights to clinical and postmarketing evidence

Yinuo Dong; Yang Zhi; Xiaoyun Li et al. · 2025 · Frontiers in Pharmacology · DOI

Full title: Navigating hepatotoxicity of antibody-drug conjugates: from mechanistic insights to clinical and postmarketing evidence

Authors: Yinuo Dong; Yang Zhi; Xiaoyun Li; Mingyang Ma; Minyan Ye; Sha Huang; Jieting Tang; Wei Zhong; X. Lei; Yimin Mao

Year: 2025

Venue: Frontiers in Pharmacology

DOI: https://doi.org/10.3389/fphar.2025.1694436

Paper Evaluation of Two Chemoenzymatic Glycan Remodeling Approaches to Generate Site-Specific Antibody–Drug Conjugates

Qiang Yang; He Chen; Chong Ou et al. · 2023 · Antibodies · DOI

Full title: Evaluation of Two Chemoenzymatic Glycan Remodeling Approaches to Generate Site-Specific Antibody–Drug Conjugates

Authors: Qiang Yang; He Chen; Chong Ou; Zhihao Zheng; Xiao Zhang; Yunpeng Liu; Guanghui Zong; Lai-Xi Wang

Year: 2023

Venue: Antibodies

DOI: https://doi.org/10.3390/antib12040071

Paper A Polar Sulfamide Spacer Significantly Enhances the Manufacturability, Stability, and Therapeutic Index of Antibody-Drug Conjugates.

Verkade, Jorge M M; Wijdeven, Marloes A; Van Geel, Remon et al. · 2018 · Antibodies (Basel, Switzerland) · DOI

Full title: A Polar Sulfamide Spacer Significantly Enhances the Manufacturability, Stability, and Therapeutic Index of Antibody-Drug Conjugates.

Authors: Verkade, Jorge M M; Wijdeven, Marloes A; Van Geel, Remon; Janssen, Brian M G; Van Berkel, Sander S; Van Delft, Floris L

Year: 2018

Venue: Antibodies (Basel, Switzerland)

DOI: https://doi.org/10.3390/antib7010012

Paper Peptide–Drug Conjugates as Next-Generation Therapeutics: Exploring the Potential and Clinical Progress

Krishna Jadhav; Ashwin Abhang; Eknath Kole et al. · 2025 · Bioengineering · DOI

Full title: Peptide–Drug Conjugates as Next-Generation Therapeutics: Exploring the Potential and Clinical Progress

Authors: Krishna Jadhav; Ashwin Abhang; Eknath Kole; Dipak Gadade; Apurva Dusane; Aditya Iyer; Ankur Sharma; S. Rout; A. Gholap; Jitendra B. Naik; R. Verma; Satish Rojekar

Year: 2025

Venue: Bioengineering

DOI: https://doi.org/10.3390/bioengineering12050481

Paper Quantification for Antibody-Conjugated Drug in Trastuzumab Emtansine and Application to In Vitro Linker Stability and In Vivo Pharmacokinetic Study in Rat Using an Immuno-Affinity Capture Liquid Chromatography-Mass Spectrometric Method

Seo-jin Park; Byeong Ill Lee; Min-Ho Park et al. · 2021 · Applied Sciences · DOI

Full title: Quantification for Antibody-Conjugated Drug in Trastuzumab Emtansine and Application to In Vitro Linker Stability and In Vivo Pharmacokinetic Study in Rat Using an Immuno-Affinity Capture Liquid Chromatography-Mass Spectrometric Method

Authors: Seo-jin Park; Byeong Ill Lee; Min-Ho Park; Jang-mi Choi; Yuri Park; Min-jae Park; Jeong-hyeon Lim; Ji-Young Lee; Sangsoo Hwang; Jeongmin Lee; Young G. Shin

Year: 2021

Venue: Applied Sciences

DOI: https://doi.org/10.3390/app11209437

Paper Multiplex LC-MS/MS Assays for Clinical Bioanalysis of MEDI4276, an Antibody-Drug Conjugate of Tubulysin Analogue Attached via Cleavable Linker to a Biparatopic Humanized Antibody against HER-2

Morse Faria; Marlking Peay; B. Lam et al. · 2019 · Antibodies · DOI

Full title: Multiplex LC-MS/MS Assays for Clinical Bioanalysis of MEDI4276, an Antibody-Drug Conjugate of Tubulysin Analogue Attached via Cleavable Linker to a Biparatopic Humanized Antibody against HER-2

Authors: Morse Faria; Marlking Peay; B. Lam; Eric Ma; Moucun Yuan; Michael P Waldron; W. Mylott; M. Liang; A. Rosenbaum

Year: 2019

Venue: Antibodies

DOI: https://doi.org/10.3390/antib8010011

Paper Antibody Drug Conjugates as Cancer Therapeutics

P. Trail · 2013 · DOI

Full title: Antibody Drug Conjugates as Cancer Therapeutics

Authors: P. Trail

Year: 2013

DOI: https://doi.org/10.3390/antib2010113

Paper Pyrrolobenzodiazepine Antibody-Drug Conjugates Designed for Stable Thiol Conjugation

R. Christie; A. Tiberghien; Qun Du et al. · 2017 · Antibodies · DOI

Full title: Pyrrolobenzodiazepine Antibody-Drug Conjugates Designed for Stable Thiol Conjugation

Authors: R. Christie; A. Tiberghien; Qun Du; Binyam Z Bezabeh; R. Fleming; Amanda Shannon; S. Mao; S. Breen; Jing Zhang; Haihong Zhong; Jay Harper; Herren Wu; P. Howard; Changshou Gao

Year: 2017

Venue: Antibodies

DOI: https://doi.org/10.3390/antib6040020

Paper Immunoconjugates for Osteosarcoma Therapy: Preclinical Experiences and Future Perspectives

D. Mercatelli; M. Bortolotti; A. Bazzocchi et al. · 2018 · Biomedicines · DOI

Full title: Immunoconjugates for Osteosarcoma Therapy: Preclinical Experiences and Future Perspectives

Authors: D. Mercatelli; M. Bortolotti; A. Bazzocchi; A. Bolognesi; L. Polito

Year: 2018

Venue: Biomedicines

DOI: https://doi.org/10.3390/biomedicines6010019

Paper Advances and Limitations of Antibody Drug Conjugates for Cancer

Candice Maria Mckertish; Veysel Kayser · 2021 · Biomedicines · DOI

Full title: Advances and Limitations of Antibody Drug Conjugates for Cancer

Authors: Candice Maria Mckertish; Veysel Kayser

Year: 2021

Venue: Biomedicines

DOI: https://doi.org/10.3390/biomedicines9080872

Paper Updates in the Development of ImmunoRNases for the Selective Killing of Tumor Cells

S. Jordaan; O. Akinrinmade; T. Nachreiner et al. · 2018 · Biomedicines · DOI

Full title: Updates in the Development of ImmunoRNases for the Selective Killing of Tumor Cells

Authors: S. Jordaan; O. Akinrinmade; T. Nachreiner; Christian Cremer; K. Naran; S. Chetty; S. Barth

Year: 2018

Venue: Biomedicines

DOI: https://doi.org/10.3390/biomedicines6010028

Paper Antibody-Drug Conjugates for the Treatment of Breast Cancer.

Corti, Chiara; Giugliano, Federica; Nicolò, Eleonora et al. · 2021 · Cancers · DOI

Full title: Antibody-Drug Conjugates for the Treatment of Breast Cancer.

Authors: Corti, Chiara; Giugliano, Federica; Nicolò, Eleonora; Ascione, Liliana; Curigliano, Giuseppe

Year: 2021

Venue: Cancers

DOI: https://doi.org/10.3390/cancers13122898

Paper Novel Silyl Ether-Based Acid-Cleavable Antibody-MMAE Conjugates with Appropriate Stability and Efficacy

Yanming Wang; Shiyong Fan; Dian Xiao et al. · 2019 · Cancers · DOI

Full title: Novel Silyl Ether-Based Acid-Cleavable Antibody-MMAE Conjugates with Appropriate Stability and Efficacy

Authors: Yanming Wang; Shiyong Fan; Dian Xiao; Fei Xie; Wei Li; Wu Zhong; Xinbo Zhou

Year: 2019

Venue: Cancers

DOI: https://doi.org/10.3390/cancers11070957

Paper Rapid Evaluation of Antibody Fragment Endocytosis for Antibody Fragment–Drug Conjugates

Eunhee Kim; Jieun K. Jeong; Junghyeon Lee et al. · 2020 · Biomolecules · DOI

Full title: Rapid Evaluation of Antibody Fragment Endocytosis for Antibody Fragment–Drug Conjugates

Authors: Eunhee Kim; Jieun K. Jeong; Junghyeon Lee; H. Jung; Minho Kim; Yi Zhao; E. Yi; Kristine M Kim

Year: 2020

Venue: Biomolecules

DOI: https://doi.org/10.3390/biom10060955

Paper Unlocking New Horizons: Antibody–Drug Conjugates in Small Cell Lung Cancer

Jiayu Liu; Yan Cui; Dongying Liao et al. · 2025 · Biology · DOI

Full title: Unlocking New Horizons: Antibody–Drug Conjugates in Small Cell Lung Cancer

Authors: Jiayu Liu; Yan Cui; Dongying Liao; Mingwei Sima; Moxuan Han; Wanhao Li; Yan Bi; Donghui Yue

Year: 2025

Venue: Biology

DOI: https://doi.org/10.3390/biology14121677

Paper Acquired Resistance to Antibody-Drug Conjugates

D. Collins; B. Bossenmaier; Gwendlyn Kollmorgen et al. · 2019 · Cancers · DOI

Full title: Acquired Resistance to Antibody-Drug Conjugates

Authors: D. Collins; B. Bossenmaier; Gwendlyn Kollmorgen; G. Niederfellner

Year: 2019

Venue: Cancers

DOI: https://doi.org/10.3390/cancers11030394

Paper Lysosomal-Cleavable Peptide Linkers in Antibody–Drug Conjugates

S. Balamkundu; Chuan-Fa Liu · 2023 · Biomedicines · DOI

Full title: Lysosomal-Cleavable Peptide Linkers in Antibody–Drug Conjugates

Authors: S. Balamkundu; Chuan-Fa Liu

Year: 2023

Venue: Biomedicines

DOI: https://doi.org/10.3390/biomedicines11113080

Paper Antibody-Drug Conjugates: A Promising Novel Therapy for the Treatment of Ovarian Cancer

A. Manzano; A. Ocaña · 2020 · Cancers · DOI

Full title: Antibody-Drug Conjugates: A Promising Novel Therapy for the Treatment of Ovarian Cancer

Authors: A. Manzano; A. Ocaña

Year: 2020

Venue: Cancers

DOI: https://doi.org/10.3390/cancers12082223

Paper The Landscape of Nucleic-Acid-Based Aptamers for Treatment of Hematologic Malignancies: Challenges and Future Directions

Siwan Wang; Xing Yan; Chang Yang et al. · 2022 · Bioengineering · DOI

Full title: The Landscape of Nucleic-Acid-Based Aptamers for Treatment of Hematologic Malignancies: Challenges and Future Directions

Authors: Siwan Wang; Xing Yan; Chang Yang; Hua Naranmandura

Year: 2022

Venue: Bioengineering

DOI: https://doi.org/10.3390/bioengineering9110635

Paper Antibody-Drug Conjugate Using Ionized Cys-Linker-MMAE as the Potent Payload Shows Optimal Therapeutic Safety

Yanming Wang; Lianqi Liu; Shiyong Fan et al. · 2020 · Cancers · DOI

Full title: Antibody-Drug Conjugate Using Ionized Cys-Linker-MMAE as the Potent Payload Shows Optimal Therapeutic Safety

Authors: Yanming Wang; Lianqi Liu; Shiyong Fan; Dian Xiao; Fei Xie; Wei Li; Wu Zhong; Xinbo Zhou

Year: 2020

Venue: Cancers

DOI: https://doi.org/10.3390/cancers12030744

Paper Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma: Results of the Compassionate Use or the Expanded Access Program in Spain

J. de la Rubia; R. Alonso; María Esther Clavero et al. · 2023 · Cancers · DOI

Full title: Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma: Results of the Compassionate Use or the Expanded Access Program in Spain

Authors: J. de la Rubia; R. Alonso; María Esther Clavero; Elham Askari; Alfonso García; C. Antón; M. Fernández; F. Escalante; A. García; R. Ríos-Tamayo; V. Conesa; María Arancha Bermúdez; Beatriz Merchán; Alberto Velasco; M. Blanchard; A. Sampol; Eukene Gainza; Prisma Montserrat Hernández; A. Alegre

Year: 2023

Venue: Cancers

DOI: https://doi.org/10.3390/cancers15112964

Paper Antibody–Drug Conjugates: The Dynamic Evolution from Conventional to Next-Generation Constructs

Virginia Metrangolo; L. Engelholm · 2024 · Cancers · DOI

Full title: Antibody–Drug Conjugates: The Dynamic Evolution from Conventional to Next-Generation Constructs

Authors: Virginia Metrangolo; L. Engelholm

Year: 2024

Venue: Cancers

DOI: https://doi.org/10.3390/cancers16020447

Paper EGFR-Targeted Antibody-Drug Conjugate to Different Aminobisphosphonates: Direct and Indirect Antitumor Effects on Colorectal Carcinoma Cells.

Pisheh, Leila; Matis, Serena; Taglieri, Martina et al. · 2024 · Cancers · DOI

Full title: EGFR-Targeted Antibody-Drug Conjugate to Different Aminobisphosphonates: Direct and Indirect Antitumor Effects on Colorectal Carcinoma Cells.

Authors: Pisheh, Leila; Matis, Serena; Taglieri, Martina; Di Gregorio, Linda; Benelli, Roberto; Poggi, Alessandro

Year: 2024

Venue: Cancers

DOI: https://doi.org/10.3390/cancers16071256

Paper Unlocking New Horizons in Small-Cell Lung Cancer Treatment: The Onset of Antibody-Drug Conjugates.

Belluomini, Lorenzo; Sposito, Marco; Avancini, Alice et al. · 2023 · Cancers · DOI

Full title: Unlocking New Horizons in Small-Cell Lung Cancer Treatment: The Onset of Antibody-Drug Conjugates.

Authors: Belluomini, Lorenzo; Sposito, Marco; Avancini, Alice; Insolda, Jessica; Milella, Michele; Rossi, Antonio; Pilotto, Sara

Year: 2023

Venue: Cancers

DOI: https://doi.org/10.3390/cancers15225368

Paper Camptothein-Based Anti-Cancer Therapies and Strategies to Improve Their Therapeutic Index.

Gong, Jue; Zhang, Wenqiu; Balthasar, Joseph P · 2025 · Cancers · DOI

Full title: Camptothein-Based Anti-Cancer Therapies and Strategies to Improve Their Therapeutic Index.

Authors: Gong, Jue; Zhang, Wenqiu; Balthasar, Joseph P

Year: 2025

Venue: Cancers

DOI: https://doi.org/10.3390/cancers17061032

Paper Precision Medicine to Treat Urothelial Carcinoma—The Way Forward

Carvy Floyd Luceno; Won Jin Jeon; Ravand Samaeekia et al. · 2023 · Cancers · DOI

Full title: Precision Medicine to Treat Urothelial Carcinoma—The Way Forward

Authors: Carvy Floyd Luceno; Won Jin Jeon; Ravand Samaeekia; John Shin; G. Sonpavde

Year: 2023

Venue: Cancers

DOI: https://doi.org/10.3390/cancers15113024

Paper Next-Generation HER2-Targeted Antibody–Drug Conjugates in Breast Cancer

B. Zimmerman; F. Esteva · 2024 · Cancers · DOI

Full title: Next-Generation HER2-Targeted Antibody–Drug Conjugates in Breast Cancer

Authors: B. Zimmerman; F. Esteva

Year: 2024

Venue: Cancers

DOI: https://doi.org/10.3390/cancers16040800

Paper Opportunities and Challenges in Antibody–Drug Conjugates for Cancer Therapy: A New Era for Cancer Treatment

Idil Buyukgolcigezli; A. Tenekeci; İ. H. Şahin · 2025 · Cancers · DOI

Full title: Opportunities and Challenges in Antibody–Drug Conjugates for Cancer Therapy: A New Era for Cancer Treatment

Authors: Idil Buyukgolcigezli; A. Tenekeci; İ. H. Şahin

Year: 2025

Venue: Cancers

DOI: https://doi.org/10.3390/cancers17060958

Paper 'Targeting' Improved Outcomes with Antibody-Drug Conjugates in Non-Small Cell Lung Cancer-An Updated Review.

Verma, Saurav; Breadner, Daniel; Raphael, Jacques · 2023 · Current oncology (Toronto, Ont.) · DOI

Full title: 'Targeting' Improved Outcomes with Antibody-Drug Conjugates in Non-Small Cell Lung Cancer-An Updated Review.

Authors: Verma, Saurav; Breadner, Daniel; Raphael, Jacques

Year: 2023

Venue: Current oncology (Toronto, Ont.)

DOI: https://doi.org/10.3390/curroncol30040330

Paper Systemic Therapy for HER2-Positive Metastatic Breast Cancer: Current and Future Trends

Kreina Sharela Vega Cano; David Humberto Marmolejo Castañeda; S. Escrivá-de-Romaní et al. · 2022 · Cancers · DOI

Full title: Systemic Therapy for HER2-Positive Metastatic Breast Cancer: Current and Future Trends

Authors: Kreina Sharela Vega Cano; David Humberto Marmolejo Castañeda; S. Escrivá-de-Romaní; C. Saura

Year: 2022

Venue: Cancers

DOI: https://doi.org/10.3390/cancers15010051

Paper Therapeutic Antibodies in Hematology: Advances in Malignant and Non-Malignant Disorders

Hiroshi Yasui; M. Idogawa; Tadao Ishida et al. · 2025 · Cells · DOI

Full title: Therapeutic Antibodies in Hematology: Advances in Malignant and Non-Malignant Disorders

Authors: Hiroshi Yasui; M. Idogawa; Tadao Ishida; Kohzoh Imai

Year: 2025

Venue: Cells

DOI: https://doi.org/10.3390/cells15010046

Paper Anti-GD3 Antibody-drug Conjugate PF-06688992

· 2020 · Definitions · DOI

Full title: Anti-GD3 Antibody-drug Conjugate PF-06688992

Year: 2020

Venue: Definitions

DOI: https://doi.org/10.32388/j0hps1

Paper Antibody-Drug Conjugates in Urothelial Cancer: From Scientific Rationale to Clinical Development

W. Kwon; Seo-Yeon Lee; Tae Jeong et al. · 2024 · Cancers · DOI

Full title: Antibody-Drug Conjugates in Urothelial Cancer: From Scientific Rationale to Clinical Development

Authors: W. Kwon; Seo-Yeon Lee; Tae Jeong; Hyeon Kim; Min-Kyung Lee

Year: 2024

Venue: Cancers

DOI: https://doi.org/10.3390/cancers16132420

Paper Antibody–Drug Conjugates: A Start of a New Era in Gynecological Cancers

Samir Fasih; Stephen Welch; A. E. Lohmann · 2024 · Current Oncology · DOI

Full title: Antibody–Drug Conjugates: A Start of a New Era in Gynecological Cancers

Authors: Samir Fasih; Stephen Welch; A. E. Lohmann

Year: 2024

Venue: Current Oncology

DOI: https://doi.org/10.3390/curroncol31110522

Paper HER2 in Non-Small Cell Lung Cancer: A Review of Emerging Therapies

N. Uy; C. Merkhofer; C. Baik · 2022 · Cancers · DOI

Full title: HER2 in Non-Small Cell Lung Cancer: A Review of Emerging Therapies

Authors: N. Uy; C. Merkhofer; C. Baik

Year: 2022

Venue: Cancers

DOI: https://doi.org/10.3390/cancers14174155

Paper PEG Linker Improves Antitumor Efficacy and Safety of Affibody-Based Drug Conjugates

Qiyu Li; Wenjing Li; Keyuan Xu et al. · 2021 · International Journal of Molecular Sciences · DOI

Full title: PEG Linker Improves Antitumor Efficacy and Safety of Affibody-Based Drug Conjugates

Authors: Qiyu Li; Wenjing Li; Keyuan Xu; Yutong Xing; Haobo Shi; Zhe Jing; Shuang Li; Zhangyong Hong

Year: 2021

Venue: International Journal of Molecular Sciences

DOI: https://doi.org/10.3390/ijms22041540

Paper Novel Systemic Treatment Modalities Including Immunotherapy and Molecular Targeted Therapy for Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma

Soma Ghosh; P. Shah; F. Johnson · 2022 · International Journal of Molecular Sciences · DOI

Full title: Novel Systemic Treatment Modalities Including Immunotherapy and Molecular Targeted Therapy for Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma

Authors: Soma Ghosh; P. Shah; F. Johnson

Year: 2022

Venue: International Journal of Molecular Sciences

DOI: https://doi.org/10.3390/ijms23147889

Paper Development and Properties of Valine-Alanine based Antibody-Drug Conjugates with Monomethyl Auristatin E as the Potent Payload

Yanming Wang; Shiyong Fan; Wu Zhong et al. · 2017 · International Journal of Molecular Sciences · DOI

Full title: Development and Properties of Valine-Alanine based Antibody-Drug Conjugates with Monomethyl Auristatin E as the Potent Payload

Authors: Yanming Wang; Shiyong Fan; Wu Zhong; Xinbo Zhou; Song Li

Year: 2017

Venue: International Journal of Molecular Sciences

DOI: https://doi.org/10.3390/ijms18091860

Paper A Versatile Chemo-Enzymatic Conjugation Approach Yields Homogeneous and Highly Potent Antibody-Drug Conjugates

Ying Xu; Shijie Jin; Wenbin Zhao et al. · 2017 · International Journal of Molecular Sciences · DOI

Full title: A Versatile Chemo-Enzymatic Conjugation Approach Yields Homogeneous and Highly Potent Antibody-Drug Conjugates

Authors: Ying Xu; Shijie Jin; Wenbin Zhao; Wenhui Liu; Ding Ding; Jie Zhou; Shuqing Chen

Year: 2017

Venue: International Journal of Molecular Sciences

DOI: https://doi.org/10.3390/ijms18112284

Paper Peptide Drug Conjugates and Their Role in Cancer Therapy

Ethan Heh; J. Allen; Fabiola Ramirez et al. · 2023 · International Journal of Molecular Sciences · DOI

Full title: Peptide Drug Conjugates and Their Role in Cancer Therapy

Authors: Ethan Heh; J. Allen; Fabiola Ramirez; Daniel Lovasz; Lorena Fernandez; Tanis Hogg; Hannah R. Riva; Nathan Holland; Jessica Chacon

Year: 2023

Venue: International Journal of Molecular Sciences

DOI: https://doi.org/10.3390/ijms24010829

Paper Theranostic Small-Molecule Prodrug Conjugates for Targeted Delivery and Controlled Release of Toll-like Receptor 7 Agonists

Sashi Debnath; G. Hao; B. Guan et al. · 2022 · International Journal of Molecular Sciences · DOI

Full title: Theranostic Small-Molecule Prodrug Conjugates for Targeted Delivery and Controlled Release of Toll-like Receptor 7 Agonists

Authors: Sashi Debnath; G. Hao; B. Guan; Pawan Thapa; Justin Hao; H. Hammers; Xiankai Sun

Year: 2022

Venue: International Journal of Molecular Sciences

DOI: https://doi.org/10.3390/ijms23137160

Paper Understanding the Preclinical Efficacy of Antibody–Drug Conjugates

Cristina Díaz-Tejeiro; Alfonso López de Sá; Elisa Poyatos-Racionero et al. · 2024 · International Journal of Molecular Sciences · DOI

Full title: Understanding the Preclinical Efficacy of Antibody–Drug Conjugates

Authors: Cristina Díaz-Tejeiro; Alfonso López de Sá; Elisa Poyatos-Racionero; Pablo Ballestín; Jorge Bartolomé; Emiliano Calvo; Víctor Moreno; Francisco Moris; P. Pérez-Segura; Balázs Győrffy; A. Pandiella; Alberto Ocaña

Year: 2024

Venue: International Journal of Molecular Sciences

DOI: https://doi.org/10.3390/ijms252312875

Paper Linkers Having a Crucial Role in Antibody–Drug Conjugates

Jun Lu; Feng Jiang; Aiping Lu et al. · 2016 · International Journal of Molecular Sciences · DOI

Full title: Linkers Having a Crucial Role in Antibody–Drug Conjugates

Authors: Jun Lu; Feng Jiang; Aiping Lu; Ge Zhang

Year: 2016

Venue: International Journal of Molecular Sciences

DOI: https://doi.org/10.3390/ijms17040561

Paper A Newly Developed Anti-L1CAM Monoclonal Antibody Targets Small Cell Lung Carcinoma Cells

Miki Yamaguchi; S. Hirai; M. Idogawa et al. · 2024 · International Journal of Molecular Sciences · DOI

Full title: A Newly Developed Anti-L1CAM Monoclonal Antibody Targets Small Cell Lung Carcinoma Cells

Authors: Miki Yamaguchi; S. Hirai; M. Idogawa; Toshiyuki Sumi; Hiroaki Uchida; Yuji Sakuma

Year: 2024

Venue: International Journal of Molecular Sciences

DOI: https://doi.org/10.3390/ijms25168748

Paper Advances and Challenges in Structural Studies of Bioactive Peptide-Anthracycline Conjugates: A Mass Spectrometric Insight

Eszter Fehérvári; Katalin Uray; Gitta Schlosser · 2025 · International Journal of Molecular Sciences · DOI

Full title: Advances and Challenges in Structural Studies of Bioactive Peptide-Anthracycline Conjugates: A Mass Spectrometric Insight

Authors: Eszter Fehérvári; Katalin Uray; Gitta Schlosser

Year: 2025

Venue: International Journal of Molecular Sciences

DOI: https://doi.org/10.3390/ijms26104896

Paper Theranostics for Triple-Negative Breast Cancer

Hyeryeon Choi; Kwang-Hyeok Kim · 2023 · Diagnostics · DOI

Full title: Theranostics for Triple-Negative Breast Cancer

Authors: Hyeryeon Choi; Kwang-Hyeok Kim

Year: 2023

Venue: Diagnostics

DOI: https://doi.org/10.3390/diagnostics13020272

Paper New Senolysis Approach via Antibody–Drug Conjugate Targeting of the Senescent Cell Marker Apolipoprotein D for Skin Rejuvenation

Kento Takaya; T. Asou; Kazuo Kishi · 2023 · International Journal of Molecular Sciences · DOI

Full title: New Senolysis Approach via Antibody–Drug Conjugate Targeting of the Senescent Cell Marker Apolipoprotein D for Skin Rejuvenation

Authors: Kento Takaya; T. Asou; Kazuo Kishi

Year: 2023

Venue: International Journal of Molecular Sciences

DOI: https://doi.org/10.3390/ijms24065857

Paper Toxicity Profiles of Antibody-Drug Conjugates: Synthesis and Graphical Insights to Optimize Patient-Centered Treatment Strategies for HER2-Negative Metastatic Breast Cancer.

Collineau, Bérénice; Gonçalves, Anthony; Domon, Marie et al. · 2025 · Cancers · DOI

Full title: Toxicity Profiles of Antibody-Drug Conjugates: Synthesis and Graphical Insights to Optimize Patient-Centered Treatment Strategies for HER2-Negative Metastatic Breast Cancer.

Authors: Collineau, Bérénice; Gonçalves, Anthony; Domon, Marie; Bruyat, Damien; Bertucci, François; de Nonneville, Alexandre

Year: 2025

Venue: Cancers

DOI: https://doi.org/10.3390/cancers17142307

Paper CD74-Targeting Antibody–Drug Conjugate Enhances Immunosuppression of Glucocorticoid in Systemic Lupus Erythematosus

Qizhen Du; Shengtao Yao; Yuying Huang et al. · 2025 · International Journal of Molecular Sciences · DOI

Full title: CD74-Targeting Antibody–Drug Conjugate Enhances Immunosuppression of Glucocorticoid in Systemic Lupus Erythematosus

Authors: Qizhen Du; Shengtao Yao; Yuying Huang; Jia Zhang; Wangmo Sonam; Xiao Lu; Jichao Yang; Shipeng Cheng; Ran Wang; Jiefang Xu; Liyan Ma; Yu Liu; Guanghao Wu; Jing Zhang; Xuelei Wang; Wei Lu; Z. Ling; C. Yi; Bing Sun

Year: 2025

Venue: International Journal of Molecular Sciences

DOI: https://doi.org/10.3390/ijms262311761

Paper Antibody-Drug Conjugates and Targeted Treatment Strategies for Hepatocellular Carcinoma: A Drug-Delivery Perspective

D. Dahlgren; H. Lennernäs · 2020 · Molecules · DOI

Full title: Antibody-Drug Conjugates and Targeted Treatment Strategies for Hepatocellular Carcinoma: A Drug-Delivery Perspective

Authors: D. Dahlgren; H. Lennernäs

Year: 2020

Venue: Molecules

DOI: https://doi.org/10.3390/molecules25122861

Paper Generation and Characterization of SORT1-Targeted Antibody–Drug Conjugate for the Treatment of SORT1-Positive Breast Tumor

Weiliang Zhuang; Wei Zhang; Liping Xie et al. · 2023 · International Journal of Molecular Sciences · DOI

Full title: Generation and Characterization of SORT1-Targeted Antibody–Drug Conjugate for the Treatment of SORT1-Positive Breast Tumor

Authors: Weiliang Zhuang; Wei Zhang; Liping Xie; Lei Wang; Yuan Li; Ziyu Wang; Ao Zhang; Haitao Qiu; Jun Feng; Baohong Zhang; Youjia Hu

Year: 2023

Venue: International Journal of Molecular Sciences

DOI: https://doi.org/10.3390/ijms242417631

Paper Leveraging Synergy: A Review of the Therapeutic Potential of SN-38 and Immune Checkpoint Blockade in Breast and Prostate Cancer Treatment

Tayo A. Adekiya; Simeon K. Adesina · 2025 · Journal of Personalized Medicine · DOI

Full title: Leveraging Synergy: A Review of the Therapeutic Potential of SN-38 and Immune Checkpoint Blockade in Breast and Prostate Cancer Treatment

Authors: Tayo A. Adekiya; Simeon K. Adesina

Year: 2025

Venue: Journal of Personalized Medicine

DOI: https://doi.org/10.3390/jpm15110512

Paper Unlocking the Complexity of Antibody-Drug Conjugates: A Cutting-Edge LC-HRMS Approach to Refine Drug-to-Antibody Ratio Measurements with Highly Reactive Payloads

Andrea Di Ianni; Kyra J. Cowan; Federico Riccardi Sirtori et al. · 2025 · International Journal of Molecular Sciences · DOI

Full title: Unlocking the Complexity of Antibody-Drug Conjugates: A Cutting-Edge LC-HRMS Approach to Refine Drug-to-Antibody Ratio Measurements with Highly Reactive Payloads

Authors: Andrea Di Ianni; Kyra J. Cowan; Federico Riccardi Sirtori; Luca Barbero

Year: 2025

Venue: International Journal of Molecular Sciences

DOI: https://doi.org/10.3390/ijms26073080

Paper Antibody–Drug Conjugates Powered by Deruxtecan: Innovations and Challenges in Oncology

J. Jang; Donghwan Kim; Na Kyeong Lee et al. · 2025 · International Journal of Molecular Sciences · DOI

Full title: Antibody–Drug Conjugates Powered by Deruxtecan: Innovations and Challenges in Oncology

Authors: J. Jang; Donghwan Kim; Na Kyeong Lee; Eunok Im; Nam Deuk Kim

Year: 2025

Venue: International Journal of Molecular Sciences

DOI: https://doi.org/10.3390/ijms26136523

Paper Quantification of an Antibody-Conjugated Drug in Fat Plasma by an Affinity Capture LC-MS/MS Method for a Novel Prenyl Transferase-Mediated Site-Specific Antibody–Drug Conjugate

Byeong Ill Lee; Min-Ho Park; Jin-Ju Byeon et al. · 2020 · Molecules · DOI

Full title: Quantification of an Antibody-Conjugated Drug in Fat Plasma by an Affinity Capture LC-MS/MS Method for a Novel Prenyl Transferase-Mediated Site-Specific Antibody–Drug Conjugate

Authors: Byeong Ill Lee; Min-Ho Park; Jin-Ju Byeon; Seok-Ho Shin; Jang-mi Choi; Yuri Park; Yun-Hee Park; Jeiwook Chae; Young G. Shin

Year: 2020

Venue: Molecules

DOI: https://doi.org/10.3390/molecules25071515

Paper Cyanobacterial Peptides in Anticancer Therapy: A Comprehensive Review of Mechanisms, Clinical Advances, and Biotechnological Innovation.

Lee, Heayyean; Nihan, Khuld; Kwon, Yale Ryan · 2025 · Marine drugs · DOI

Full title: Cyanobacterial Peptides in Anticancer Therapy: A Comprehensive Review of Mechanisms, Clinical Advances, and Biotechnological Innovation.

Authors: Lee, Heayyean; Nihan, Khuld; Kwon, Yale Ryan

Year: 2025

Venue: Marine drugs

DOI: https://doi.org/10.3390/md23060233

Paper Peptide-Drug Conjugates: A New Hope for Cancer Management

Vivek P. Chavda; Hetvi K. Solanki; Majid Davidson et al. · 2022 · Molecules · DOI

Full title: Peptide-Drug Conjugates: A New Hope for Cancer Management

Authors: Vivek P. Chavda; Hetvi K. Solanki; Majid Davidson; V. Apostolopoulos; J. Bojarska

Year: 2022

Venue: Molecules

DOI: https://doi.org/10.3390/molecules27217232

Paper Antibody–Drug Conjugates in Hematological Malignancies: Current Landscape and Future Perspectives

M. C. Montalbano; Matilde Micillo; Silvia Deaglio et al. · 2026 · International Journal of Molecular Sciences · DOI

Full title: Antibody–Drug Conjugates in Hematological Malignancies: Current Landscape and Future Perspectives

Authors: M. C. Montalbano; Matilde Micillo; Silvia Deaglio; T. Vaisitti

Year: 2026

Venue: International Journal of Molecular Sciences

DOI: https://doi.org/10.3390/ijms27021025

Paper Melanotransferrin as a Potential Target for the Selective Killing of Melanoma and Triple-Negative Breast Cancer Cells In Vitro Using Novel SNAP-Tag-Based Antibody–AURIF Conjugate

Suzanne Hippolite Magagoum; G. Siwe; F. A. Biteghe et al. · 2025 · Onco · DOI

Full title: Melanotransferrin as a Potential Target for the Selective Killing of Melanoma and Triple-Negative Breast Cancer Cells In Vitro Using Novel SNAP-Tag-Based Antibody–AURIF Conjugate

Authors: Suzanne Hippolite Magagoum; G. Siwe; F. A. Biteghe; A. M. Huysamen; Dirk Lang; Roger Hunter; Stefan Barth

Year: 2025

Venue: Onco

DOI: https://doi.org/10.3390/onco6010001

Paper Antibody–Drug Conjugates—A Tutorial Review

Stephanie Baah; Mark Laws; K. Rahman · 2021 · Molecules · DOI

Full title: Antibody–Drug Conjugates—A Tutorial Review

Authors: Stephanie Baah; Mark Laws; K. Rahman

Year: 2021

Venue: Molecules

DOI: https://doi.org/10.3390/molecules26102943

Paper IL1RAP is an immunotherapeutic target for normal karyotype triple-mutated acute myeloid leukemia

Arnaud Métois; Marie-Ève Bordeleau; L. Théret et al. · 2025 · Biomarker Research · DOI

Full title: IL1RAP is an immunotherapeutic target for normal karyotype triple-mutated acute myeloid leukemia

Authors: Arnaud Métois; Marie-Ève Bordeleau; L. Théret; Azadeh Hajmirza; Ossama Moujaber; Jean-François Spinella; J. Chagraoui; N. Mayotte; I. Boivin; E. Audemard; L. Aubert; V. Lisi; B. Khakipoor; A. Farah; É. Bonneil; Alma Robert; Julie Lippens; Anna N. Moraitis; François Béliveau; Albert Feghaly; G. Boucher; Richard Marcotte; Patrick Gendron; Pierre Thibault; Sébastien Lemieux; Guillaume Richard-Carpentier; Vincent-Philippe Lavallée; J. Hébert; Philippe P. Roux; Guy Sauvageau

Year: 2025

Venue: Biomarker Research

DOI: https://doi.org/10.1186/s40364-025-00769-z

Paper Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions.

Ferraro, Emanuela; Drago, Joshua Z; Modi, Shanu · 2021 · Breast cancer research : BCR · DOI

Full title: Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions.

Authors: Ferraro, Emanuela; Drago, Joshua Z; Modi, Shanu

Year: 2021

Venue: Breast cancer research : BCR

DOI: https://doi.org/10.1186/s13058-021-01459-y

Paper Antibody Drug Conjugates: Application of Quantitative Pharmacology in Modality Design and Target Selection.

Sadekar, S; Figueroa, I; Tabrizi, M · 2015 · The AAPS journal · DOI

Full title: Antibody Drug Conjugates: Application of Quantitative Pharmacology in Modality Design and Target Selection.

Authors: Sadekar, S; Figueroa, I; Tabrizi, M

Year: 2015

Venue: The AAPS journal

DOI: https://doi.org/10.1208/s12248-015-9766-0

Paper [Novel Chemical Linkers for Next-generation Antibody-drug Conjugates(ADCs)].

K. Tsuchikama · 2019 · Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan · DOI

Full title: [Novel Chemical Linkers for Next-generation Antibody-drug Conjugates(ADCs)].

Authors: K. Tsuchikama

Year: 2019

Venue: Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan

DOI: https://doi.org/10.1248/yakushi.18-00169-3

Paper Joint Disposition Properties and Comprehensive Pharmacokinetic Characterization of Antibody-Drug Conjugates.

Liao, Kai H; Williams, Jason H; Palani, Santhosh et al. · 2022 · The AAPS journal · DOI

Full title: Joint Disposition Properties and Comprehensive Pharmacokinetic Characterization of Antibody-Drug Conjugates.

Authors: Liao, Kai H; Williams, Jason H; Palani, Santhosh; Yin, Donghua; Meng, Xu

Year: 2022

Venue: The AAPS journal

DOI: https://doi.org/10.1208/s12248-022-00717-x

Paper Therapeutic Potential and Challenges of Targeting Receptor Tyrosine Kinase ROR1 with Monoclonal Antibodies in B-Cell Malignancies

Jiahui Yang; S. Baskar; K. Kwong et al. · 2011 · PLoS ONE · DOI

Full title: Therapeutic Potential and Challenges of Targeting Receptor Tyrosine Kinase ROR1 with Monoclonal Antibodies in B-Cell Malignancies

Authors: Jiahui Yang; S. Baskar; K. Kwong; Michael G. Kennedy; A. Wiestner; C. Rader

Year: 2011

Venue: PLoS ONE

DOI: https://doi.org/10.1371/journal.pone.0021018

Paper Dasatinib Pharmacokinetics and Advanced Nanocarrier Strategies: from Systemic Limitations to Targeted Success

Mahesha Keerikkadu; Pragathi Devanand Bangera; Vamshi Krishna Tippavajhala et al. · 2025 · AAPS PharmSciTech · DOI

Full title: Dasatinib Pharmacokinetics and Advanced Nanocarrier Strategies: from Systemic Limitations to Targeted Success

Authors: Mahesha Keerikkadu; Pragathi Devanand Bangera; Vamshi Krishna Tippavajhala; Mahalaxmi Rathnanand

Year: 2025

Venue: AAPS PharmSciTech

DOI: https://doi.org/10.1208/s12249-025-03130-7

Paper Site-Dependent Degradation of a Non-Cleavable Auristatin-Based Linker-Payload in Rodent Plasma and Its Effect on ADC Efficacy.

Dorywalska, Magdalena; Strop, Pavel; Melton-Witt, Jody A et al. · 2015 · PloS one · DOI

Full title: Site-Dependent Degradation of a Non-Cleavable Auristatin-Based Linker-Payload in Rodent Plasma and Its Effect on ADC Efficacy.

Authors: Dorywalska, Magdalena; Strop, Pavel; Melton-Witt, Jody A; Hasa-Moreno, Adela; Farias, Santiago E; Galindo Casas, Meritxell; Delaria, Kathy; Lui, Victor; Poulsen, Kris; Sutton, Janette; Bolton, Gary; Zhou, Dahui; Moine, Ludivine; Dushin, Russell; Tran, Thomas-Toan; Liu, Shu-Hui; Rickert, Mathias; Foletti, Davide; Shelton, David L; Pons, Jaume; Rajpal, Arvind

Year: 2015

Venue: PloS one

DOI: https://doi.org/10.1371/journal.pone.0132282

Paper A monomethyl auristatin E-conjugated antibody to guanylyl cyclase C is cytotoxic to target-expressing cells in vitro and in vivo

M. Gallery; Julie Zhang; D. Bradley et al. · 2018 · PLoS ONE · DOI

Full title: A monomethyl auristatin E-conjugated antibody to guanylyl cyclase C is cytotoxic to target-expressing cells in vitro and in vivo

Authors: M. Gallery; Julie Zhang; D. Bradley; P. Brauer; D. Cvet; Jose Estevam; H. Danaee; E. Greenfield; Ping Li; M. Manfredi; H. Loke; C. Rabino; B. Stringer; Mark Williamson; T. Wyant; Johnny J. Yang; Qing Zhu; A. Abu-Yousif; O. P. Veiby

Year: 2018

Venue: PLoS ONE

DOI: https://doi.org/10.1371/journal.pone.0191046

Paper NAV-001, a high-efficacy antibody-drug conjugate targeting mesothelin with improved delivery of a potent payload by counteracting MUC16/CA125 inhibitory effects

N. Nicolaides; J. Kline; L. Grasso · 2023 · PLoS ONE · DOI

Full title: NAV-001, a high-efficacy antibody-drug conjugate targeting mesothelin with improved delivery of a potent payload by counteracting MUC16/CA125 inhibitory effects

Authors: N. Nicolaides; J. Kline; L. Grasso

Year: 2023

Venue: PLoS ONE

DOI: https://doi.org/10.1371/journal.pone.0285161

Paper Bioprocess development of antibody-drug conjugate production for cancer treatment

Jianfa Ou; Yingnan Si; K. Goh et al. · 2018 · PLoS ONE · DOI

Full title: Bioprocess development of antibody-drug conjugate production for cancer treatment

Authors: Jianfa Ou; Yingnan Si; K. Goh; Norio Yasui; Yichen Guo; Jiajia Song; Lizhong Wang; R. Jaskula-Sztul; Jinda Fan; Lufang Zhou; Runhua Liu; X. Liu

Year: 2018

Venue: PLoS ONE

DOI: https://doi.org/10.1371/journal.pone.0206246

Paper In Vitro and In Vivo Evaluation of Cysteine and Site Specific Conjugated Herceptin Antibody-Drug Conjugates

D. Jackson; J. Atkinson; Claudia I. Guevara et al. · 2014 · PLoS ONE · DOI

Full title: In Vitro and In Vivo Evaluation of Cysteine and Site Specific Conjugated Herceptin Antibody-Drug Conjugates

Authors: D. Jackson; J. Atkinson; Claudia I. Guevara; Chunying Zhang; V. Kéry; S. Moon; C. Virata; Penghua Yang; C. Lowe; J. Pinkstaff; H. Cho; Nick A Knudsen; Anthony Manibusan; Feng Tian; Ying Sun; Yingchun Lu; Aaron Sellers; X. Jia; I. Joseph; B. Anand; K. Morrison; D. Pereira; D. Stover

Year: 2014

Venue: PLoS ONE

DOI: https://doi.org/10.1371/journal.pone.0083865

Paper Quantitative Assessment of Antibody Internalization with Novel Monoclonal Antibodies against Alexa Fluorophores

Sindy Liao-Chan; B. Daine-Matsuoka; N. Heald et al. · 2015 · PLoS ONE · DOI

Full title: Quantitative Assessment of Antibody Internalization with Novel Monoclonal Antibodies against Alexa Fluorophores

Authors: Sindy Liao-Chan; B. Daine-Matsuoka; N. Heald; T. Wong; Tracey Lin; Allen G Cai; Michelle Lai; J. A. D'alessio; Jan-Willem Theunissen

Year: 2015

Venue: PLoS ONE

DOI: https://doi.org/10.1371/journal.pone.0124708

Paper The Latest Research and Development into the Antibody-Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy.

Nakada, Takashi; Sugihara, Kiyoshi; Jikoh, Takahiro et al. · 2019 · Chemical & pharmaceutical bulletin · DOI

Full title: The Latest Research and Development into the Antibody-Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy.

Authors: Nakada, Takashi; Sugihara, Kiyoshi; Jikoh, Takahiro; Abe, Yuki; Agatsuma, Toshinori

Year: 2019

Venue: Chemical & pharmaceutical bulletin

DOI: https://doi.org/10.1248/cpb.c18-00744

Paper Development and Evaluation of a Fluorescent Antibody-Drug Conjugate for Molecular Imaging and Targeted Therapy of Pancreatic Cancer

Steve Knutson; Erum K Raja; Ryan D. Bomgarden et al. · 2016 · PLoS ONE · DOI

Full title: Development and Evaluation of a Fluorescent Antibody-Drug Conjugate for Molecular Imaging and Targeted Therapy of Pancreatic Cancer

Authors: Steve Knutson; Erum K Raja; Ryan D. Bomgarden; M. Nlend; Aoshuang Chen; R. Kalyanasundaram; S. Desai

Year: 2016

Venue: PLoS ONE

DOI: https://doi.org/10.1371/journal.pone.0157762

Paper SHR-A1811, a novel anti-HER2 antibody–drug conjugate with optimal drug-to-antibody ratio, efficient tumor killing potency, and favorable safety profiles

Ting Zhang; Jianyan Xu; Junzhao Yin et al. · 2025 · PLoS ONE · DOI

Full title: SHR-A1811, a novel anti-HER2 antibody–drug conjugate with optimal drug-to-antibody ratio, efficient tumor killing potency, and favorable safety profiles

Authors: Ting Zhang; Jianyan Xu; Junzhao Yin; Yun Gao; Hanwen Zheng; Beibei Fu; Jiakang Sun; Zhibin Xu; Shiwei Tu; Yuchang Mao; Weiyun Wen; Bolei Qu; Lingfeng You; Zhendong Xue; Xing Sun; Dan Cao; Jun Feng; Min Hu; Feng He

Year: 2025

Venue: PLoS ONE

DOI: https://doi.org/10.1371/journal.pone.0326691

Paper Tumor antigen glycosaminoglycan modification regulates antibody-drug conjugate delivery and cytotoxicity

H. Christianson; J. Menard; Vineesh Indira Chandran et al. · 2017 · OncoTarget · DOI

Full title: Tumor antigen glycosaminoglycan modification regulates antibody-drug conjugate delivery and cytotoxicity

Authors: H. Christianson; J. Menard; Vineesh Indira Chandran; E. Bourseau-Guilmain; D. Shevela; Jon Lidfeldt; A. Månsson; S. Pastoreková; J. Messinger; M. Belting

Year: 2017

Venue: OncoTarget

DOI: https://doi.org/10.18632/oncotarget.16921

Paper Engineering a high-affinity humanized anti-CD24 antibody to target hepatocellular carcinoma by a novel CDR grafting design

Fumou Sun; Tong Wang; Jiahao Jiang et al. · 2017 · OncoTarget · DOI

Full title: Engineering a high-affinity humanized anti-CD24 antibody to target hepatocellular carcinoma by a novel CDR grafting design

Authors: Fumou Sun; Tong Wang; Jiahao Jiang; Yang Wang; Zhaoxiong Ma; Zhaoting Li; Yue Han; Mingzhu Pan; Jialing Cai; Min Wang; Juan Zhang

Year: 2017

Venue: OncoTarget

DOI: https://doi.org/10.18632/oncotarget.17228

Paper Functional relevance of in vivo half antibody exchange of an IgG4 therapeutic antibody-drug conjugate

P. Herbener; K. Schönfeld; M. König et al. · 2018 · PLoS ONE · DOI

Full title: Functional relevance of in vivo half antibody exchange of an IgG4 therapeutic antibody-drug conjugate

Authors: P. Herbener; K. Schönfeld; M. König; M. Germer; Jude M. Przyborski; Katrin Bernöster; J. Schüttrumpf

Year: 2018

Venue: PLoS ONE

DOI: https://doi.org/10.1371/journal.pone.0195823

Paper Reducing target binding affinity improves the therapeutic index of anti-MET antibody-drug conjugate in tumor bearing animals.

Datta-Mannan, Amita; Choi, Hiuwan; Jin, Zhaoyan et al. · 2024 · PloS one · DOI

Full title: Reducing target binding affinity improves the therapeutic index of anti-MET antibody-drug conjugate in tumor bearing animals.

Authors: Datta-Mannan, Amita; Choi, Hiuwan; Jin, Zhaoyan; Liu, Ling; Lu, Jirong; Stokell, David J; Murphy, Anthony T; Dunn, Kenneth W; Martinez, Michelle M; Feng, Yiqing

Year: 2024

Venue: PloS one

DOI: https://doi.org/10.1371/journal.pone.0293703

Paper Antibody-drug conjugates in breast cancer: overcoming resistance and boosting immune response

Hannah L Chang; Blake Schwettmann; Heather L. McArthur et al. · 2023 · Journal of Clinical Investigation · DOI

Full title: Antibody-drug conjugates in breast cancer: overcoming resistance and boosting immune response

Authors: Hannah L Chang; Blake Schwettmann; Heather L. McArthur; Isaac S. Chan

Year: 2023

Venue: Journal of Clinical Investigation

DOI: https://doi.org/10.1172/jci172156

Paper First-generation and preclinical evaluation of an EphA5-targeted antibody-drug conjugate in solid tumors

F. Staquicini; F. Tang; Vanessa de Oliveira et al. · 2025 · Journal of Clinical Investigation · DOI

Full title: First-generation and preclinical evaluation of an EphA5-targeted antibody-drug conjugate in solid tumors

Authors: F. Staquicini; F. Tang; Vanessa de Oliveira; Sun-Young Kim; Ethan R. Chen; Christopher Markosian; Daniela I. Staquicini; Yongjian Wu; J. K. Parsons; Kirstin F. Barnhart; Stephen C. Alley; Isan Chen; W. Arap; R. Pasqualini

Year: 2025

Venue: Journal of Clinical Investigation

DOI: https://doi.org/10.1172/jci188492

Paper Targeting CD46 for both adenocarcinoma and neuroendocrine prostate cancer.

Yang Su; Yue Liu; Christopher Behrens et al. · 2018 · JCI Insight · DOI

Full title: Targeting CD46 for both adenocarcinoma and neuroendocrine prostate cancer.

Authors: Yang Su; Yue Liu; Christopher Behrens; S. Bidlingmaier; Nam-Kyung Lee; R. Aggarwal; Daniel W. Sherbenou; A. Burlingame; B. Hann; J. Simko; Gayatri Premasekharan; P. Paris; M. Shuman; Youngho Seo; E. Small; B. Liu

Year: 2018

Venue: JCI Insight

DOI: https://doi.org/10.1172/jci.insight.121497

Paper Engineered scPDL1-DM1 drug conjugate with improved in vitro analysis to target PD-L1 positive cancer cells and intracellular trafficking studies in cancer therapy

M. Kalim; Shenghao Wang; Keying Liang et al. · 2020 · Genetics and Molecular Biology · DOI

Full title: Engineered scPDL1-DM1 drug conjugate with improved in vitro analysis to target PD-L1 positive cancer cells and intracellular trafficking studies in cancer therapy

Authors: M. Kalim; Shenghao Wang; Keying Liang; Muhammad Saleem Iqbal Khan; Jinbiao Zhan

Year: 2020

Venue: Genetics and Molecular Biology

DOI: https://doi.org/10.1590/1678-4685-gmb-2018-0391

Paper Tissue biodistribution and tumor targeting of near-infrared labelled anti-CD38 antibody-drug conjugate in preclinical multiple myeloma

Nicholas Cho; Sooah Ko; M. Shokeen · 2021 · OncoTarget · DOI

Full title: Tissue biodistribution and tumor targeting of near-infrared labelled anti-CD38 antibody-drug conjugate in preclinical multiple myeloma

Authors: Nicholas Cho; Sooah Ko; M. Shokeen

Year: 2021

Venue: OncoTarget

DOI: https://doi.org/10.18632/oncotarget.28074

Paper Targeting CD74 in multiple myeloma with the novel, site-specific antibody-drug conjugate STRO-001

C. Abrahams; Xiaofan Li; M. Embry et al. · 2018 · OncoTarget · DOI

Full title: Targeting CD74 in multiple myeloma with the novel, site-specific antibody-drug conjugate STRO-001

Authors: C. Abrahams; Xiaofan Li; M. Embry; Abigail S. Yu; Stellanie Krimm; S. Krueger; Nancy Greenland; K. Wen; C. Jones; V. Dealmeida; W. Solis; S. Matheny; T. Kline; A. Yam; R. Stafford; Arun P. Wiita; T. Hallam; M. Lupher; A. Molina

Year: 2018

Venue: OncoTarget

DOI: https://doi.org/10.18632/oncotarget.26491

Paper Evaluation of a novel human IgG1 anti-claudin3 antibody that specifically recognizes its aberrantly localized antigen in ovarian cancer cells and that is suitable for selective drug delivery

C. Romani; E. Cocco; E. Bignotti et al. · 2015 · OncoTarget · DOI

Full title: Evaluation of a novel human IgG1 anti-claudin3 antibody that specifically recognizes its aberrantly localized antigen in ovarian cancer cells and that is suitable for selective drug delivery

Authors: C. Romani; E. Cocco; E. Bignotti; D. Moratto; A. Bugatti; P. Todeschini; E. Bandiera; R. Tassi; L. Zanotti; S. Pecorelli; E. Sartori; F. Odicino; A. de Marco; Alessandro Davide Santin; A. Ravaggi; S. Mitola

Year: 2015

Venue: OncoTarget

DOI: https://doi.org/10.18632/oncotarget.5315

Paper Evaluation of SAS1B as a target for antibody-drug conjugate therapy in the treatment of pancreatic cancer

Kiley A. Knapp; Eusebio S. Pires; S. Adair et al. · 2018 · OncoTarget · DOI

Full title: Evaluation of SAS1B as a target for antibody-drug conjugate therapy in the treatment of pancreatic cancer

Authors: Kiley A. Knapp; Eusebio S. Pires; S. Adair; A. Mandal; A. Mills; W. Olson; C. Slingluff; J. Parsons; T. Bauer; T. Bullock; J. Herr

Year: 2018

Venue: OncoTarget

DOI: https://doi.org/10.18632/oncotarget.23944

Paper Preclinical evaluation of a GFRA1 targeted antibody-drug conjugate in breast cancer

E. Bosco; R. Christie; R. Carrasco et al. · 2018 · OncoTarget · DOI

Full title: Preclinical evaluation of a GFRA1 targeted antibody-drug conjugate in breast cancer

Authors: E. Bosco; R. Christie; R. Carrasco; Darrin Sabol; J. Zha; Karma Dacosta; L. Brown; Maureen A. Kennedy; John H Meekin; S. Phipps; J. Ayriss; Qun Du; Binyam Z Bezabeh; P. Chowdhury; S. Breen; Cui Chen; Molly Reed; M. Hinrichs; Haihong Zhong; Zhan Xiao; R. Dixit; R. Herbst; D. Tice

Year: 2018

Venue: OncoTarget

DOI: https://doi.org/10.18632/oncotarget.25160

Paper Evaluation of Factors Influencing Antibody Reduction for Development of Antibody Drug Conjugates.

Abdollahpour-Alitappeh, Meghdad; Lotfinia, Majid; Razavi-Vakhshourpour, Sepand et al. · 2017 · Iranian biomedical journal · DOI

Full title: Evaluation of Factors Influencing Antibody Reduction for Development of Antibody Drug Conjugates.

Authors: Abdollahpour-Alitappeh, Meghdad; Lotfinia, Majid; Razavi-Vakhshourpour, Sepand; Jahandideh, Saeed; Najminejad, Hamid; Sineh Sepehr, Koushan; Moazami, Reza; Shams, Elnaz; Habibi-Anbouhi, Mahdi; Abolhassani, Mohsen

Year: 2017

Venue: Iranian biomedical journal

DOI: https://doi.org/10.18869/acadpub.ibj.21.4.270

Paper Targeted human cytolytic fusion proteins at the cutting edge: harnessing the apoptosis-inducing properties of human enzymes for the selective elimination of tumor cells

Neelakshi Mungra; S. Jordaan; Precious Hlongwane et al. · 2019 · OncoTarget · DOI

Full title: Targeted human cytolytic fusion proteins at the cutting edge: harnessing the apoptosis-inducing properties of human enzymes for the selective elimination of tumor cells

Authors: Neelakshi Mungra; S. Jordaan; Precious Hlongwane; K. Naran; S. Chetty; S. Barth

Year: 2019

Venue: OncoTarget

DOI: https://doi.org/10.18632/oncotarget.26618

Paper Mechanisms of resistance to antibody-drug conjugates in cancer therapy: molecular basis and therapeutic strategies

Yue Hao; Zhengbo Song · 2025 · Cancer Drug Resistance · DOI

Full title: Mechanisms of resistance to antibody-drug conjugates in cancer therapy: molecular basis and therapeutic strategies

Authors: Yue Hao; Zhengbo Song

Year: 2025

Venue: Cancer Drug Resistance

DOI: https://doi.org/10.20517/cdr.2025.148

Paper Assessment of near-infrared fluorophores to study the biodistribution and tumor targeting of an IL13 receptor α2 antibody by fluorescence molecular tomography

Parul Gupta; J. Wentland; M. Leal et al. · 2017 · OncoTarget · DOI

Full title: Assessment of near-infrared fluorophores to study the biodistribution and tumor targeting of an IL13 receptor α2 antibody by fluorescence molecular tomography

Authors: Parul Gupta; J. Wentland; M. Leal; D. Ma; Rachel Roach; Antonio Esparza; Lindsay King; M. Spilker; C. Bagi; C. Winkelmann; A. Giddabasappa

Year: 2017

Venue: OncoTarget

DOI: https://doi.org/10.18632/oncotarget.19569

Paper Biodistribution and efficacy of an anti-TENB2 antibody-drug conjugate in a patient-derived model of prostate cancer

C. Boswell; D. B. Yadav; E. E. Mundo et al. · 2019 · OncoTarget · DOI

Full title: Biodistribution and efficacy of an anti-TENB2 antibody-drug conjugate in a patient-derived model of prostate cancer

Authors: C. Boswell; D. B. Yadav; E. E. Mundo; Shang‐Fan Yu; J. Lacap; Aimee Fourie-O'Donohue; K. Kozak; G. Ferl; Crystal Zhang; Jason Ho; S. Ulufatu; L. Khawli; L. Khawli; Kedan Lin

Year: 2019

Venue: OncoTarget

DOI: https://doi.org/10.18632/oncotarget.27263

Paper Multimodal, PSMA-Targeted, PAMAM Dendrimer-Drug Conjugates for Treatment of Prostate Cancer: Preclinical Evaluation

Wojciech G Lesniak; Srikanth Boinapally; Gabriela Lofland et al. · 2024 · International Journal of Nanomedicine · DOI

Full title: Multimodal, PSMA-Targeted, PAMAM Dendrimer-Drug Conjugates for Treatment of Prostate Cancer: Preclinical Evaluation

Authors: Wojciech G Lesniak; Srikanth Boinapally; Gabriela Lofland; Zirui Jiang; C. Foss; Babak Behman Azad; Anna Jablonska; Mauro Garcia; Maria Brzezinski; Martin G. Pomper

Year: 2024

Venue: International Journal of Nanomedicine

DOI: https://doi.org/10.2147/ijn.s454128

Paper Targeted therapy for Hodgkin lymphoma and systemic anaplastic large cell lymphoma: focus on brentuximab vedotin

Xueyan Chen; L. Soma; J. Fromm · 2013 · OncoTargets and Therapy · DOI

Full title: Targeted therapy for Hodgkin lymphoma and systemic anaplastic large cell lymphoma: focus on brentuximab vedotin

Authors: Xueyan Chen; L. Soma; J. Fromm

Year: 2013

Venue: OncoTargets and Therapy

DOI: https://doi.org/10.2147/ott.s39107

Paper Antibody-drug conjugates in breast cancer treatment: resistance mechanisms and the role of therapeutic sequencing

Émilie Audrey Larose; Xinying Hua; Silin Yu et al. · 2025 · Cancer Drug Resistance · DOI

Full title: Antibody-drug conjugates in breast cancer treatment: resistance mechanisms and the role of therapeutic sequencing

Authors: Émilie Audrey Larose; Xinying Hua; Silin Yu; Amritha Thulaseedharan Pillai; Zongbi Yi; Haijun Yu

Year: 2025

Venue: Cancer Drug Resistance

DOI: https://doi.org/10.20517/cdr.2024.180

Paper Serum HER2 Level Predicts Therapeutic Efficacy and Prognosis in Advanced Breast Cancer Patients [Letter]

Febie Syahruddin; Prihantono; Mirna Muis · 2024 · Breast Cancer · DOI

Full title: Serum HER2 Level Predicts Therapeutic Efficacy and Prognosis in Advanced Breast Cancer Patients [Letter]

Authors: Febie Syahruddin; Prihantono; Mirna Muis

Year: 2024

Venue: Breast Cancer

DOI: https://doi.org/10.2147/bctt.s472589

Paper Belantamab Mafodotin for the Treatment of Multiple Myeloma: An Overview of the Clinical Efficacy and Safety

M. Offidani; L. Corvatta; S. Morè et al. · 2021 · Drug Design, Development and Therapy · DOI

Full title: Belantamab Mafodotin for the Treatment of Multiple Myeloma: An Overview of the Clinical Efficacy and Safety

Authors: M. Offidani; L. Corvatta; S. Morè; A. Olivieri

Year: 2021

Venue: Drug Design, Development and Therapy

DOI: https://doi.org/10.2147/dddt.s267404

Paper An Innovative Site-Specific Anti-HER2 Antibody-Drug Conjugate with High Homogeneity and Improved Therapeutic Index

Xiwu Hui; Can Yuan; Weirong Cao et al. · 2022 · OncoTargets and Therapy · DOI

Full title: An Innovative Site-Specific Anti-HER2 Antibody-Drug Conjugate with High Homogeneity and Improved Therapeutic Index

Authors: Xiwu Hui; Can Yuan; Weirong Cao; Wenli Ge; Di Zhang; Mo Dan; Qian Zhao; Boning Liu; Bing Yao

Year: 2022

Venue: OncoTargets and Therapy

DOI: https://doi.org/10.2147/ott.s357326

Paper Targeting CD 19 in B-cell lymphoma : emerging role of SAR 3419

A. Raufi; A. Ebrahim; A. Al-Katib · 2013 · Cancer Management and Research · DOI

Full title: Targeting CD 19 in B-cell lymphoma : emerging role of SAR 3419

Authors: A. Raufi; A. Ebrahim; A. Al-Katib

Year: 2013

Venue: Cancer Management and Research

DOI: https://doi.org/10.2147/cmar.s45957

Paper Current Protein Conjugation Strategies and Pioneering Anti-Cancer Applications.

Mckertish, Candice Maria; Kayser, Veysel · 2023 · Discovery medicine · DOI

Full title: Current Protein Conjugation Strategies and Pioneering Anti-Cancer Applications.

Authors: Mckertish, Candice Maria; Kayser, Veysel

Year: 2023

Venue: Discovery medicine

DOI: https://doi.org/10.24976/Discov.Med.202335178.67

Paper Antibody-drug conjugate review in breast cancer: A targeted approach

Veenoo Agarwal; Manoj Umeshchandra Mahajan; Randeep Singh · 2024 · International Journal of Molecular and Immuno Oncology · DOI

Full title: Antibody-drug conjugate review in breast cancer: A targeted approach

Authors: Veenoo Agarwal; Manoj Umeshchandra Mahajan; Randeep Singh

Year: 2024

Venue: International Journal of Molecular and Immuno Oncology

DOI: https://doi.org/10.25259/ijmio_30_2024

Paper Anti-ROR1 ADC VLS-101

· 2020 · Definitions · DOI

Full title: Anti-ROR1 ADC VLS-101

Year: 2020

Venue: Definitions

DOI: https://doi.org/10.32388/5pw8s1

Paper Anti-CD37 Antibody-Drug Conjugate IMGN529

· 2020 · Definitions · DOI

Full title: Anti-CD37 Antibody-Drug Conjugate IMGN529

Year: 2020

Venue: Definitions

DOI: https://doi.org/10.32388/3f9y5f

Paper Preparation and evaluation of injectable dosage form for Pemetrexed-monoclonal antibody conjugate

Faten Q. Ibraheem; Nidhal K. Maraie; Basma Talib Al-Sudani · 2025 · Iraqi Journal of Pharmaceutical Sciences · DOI

Full title: Preparation and evaluation of injectable dosage form for Pemetrexed-monoclonal antibody conjugate

Authors: Faten Q. Ibraheem; Nidhal K. Maraie; Basma Talib Al-Sudani

Year: 2025

Venue: Iraqi Journal of Pharmaceutical Sciences

DOI: https://doi.org/10.31351/vol34iss3pp100-110

Paper Anti-c-Met Antibody-drug Conjugate HTI-1066

· 2020 · Definitions · DOI

Full title: Anti-c-Met Antibody-drug Conjugate HTI-1066

Year: 2020

Venue: Definitions

DOI: https://doi.org/10.32388/2onqv7

Paper Anti-B7H3 Antibody-drug Conjugate MGC018

· 2020 · Definitions · DOI

Full title: Anti-B7H3 Antibody-drug Conjugate MGC018

Year: 2020

Venue: Definitions

DOI: https://doi.org/10.32388/0dmqn6

Paper Anti-mesothelin Antibody-drug Conjugate BMS-986148

· 2020 · Definitions · DOI

Full title: Anti-mesothelin Antibody-drug Conjugate BMS-986148

Year: 2020

Venue: Definitions

DOI: https://doi.org/10.32388/5lejez

Paper Polatuzumab Vedotin

Polatuzumab Vedotin · 2020 · Definitions · DOI

Full title: Polatuzumab Vedotin

Authors: Polatuzumab Vedotin

Year: 2020

Venue: Definitions

DOI: https://doi.org/10.32388/0mx9q1

Paper Anti-HER2 ADC DS-8201a

· 2020 · Definitions · DOI

Full title: Anti-HER2 ADC DS-8201a

Year: 2020

Venue: Definitions

DOI: https://doi.org/10.32388/1c11sc

Paper Anti-Ly6E Antibody-Drug Conjugate RG 7841

· 2020 · Definitions · DOI

Full title: Anti-Ly6E Antibody-Drug Conjugate RG 7841

Year: 2020

Venue: Definitions

DOI: https://doi.org/10.32388/956a5x

Paper Antibody-drug Conjugate SC-006

· 2020 · Definitions · DOI

Full title: Antibody-drug Conjugate SC-006

Year: 2020

Venue: Definitions

DOI: https://doi.org/10.32388/1iio6o

Paper Anti-c-Met Antibody-drug Conjugate TR1801

· 2020 · Definitions · DOI

Full title: Anti-c-Met Antibody-drug Conjugate TR1801

Year: 2020

Venue: Definitions

DOI: https://doi.org/10.32388/atw92w

Paper Antibody-drug Conjugate MEDI7247

· 2020 · Definitions · DOI

Full title: Antibody-drug Conjugate MEDI7247

Year: 2020

Venue: Definitions

DOI: https://doi.org/10.32388/8akbp0

Paper Telisotuzumab Vedotin

Telisotuzumab Vedotin · 2020 · Definitions · DOI

Full title: Telisotuzumab Vedotin

Authors: Telisotuzumab Vedotin

Year: 2020

Venue: Definitions

DOI: https://doi.org/10.32388/f1gne4

Paper Antibody-drug Conjugate ABBV-085

· 2020 · Definitions · DOI

Full title: Antibody-drug Conjugate ABBV-085

Year: 2020

Venue: Definitions

DOI: https://doi.org/10.32388/bs5fak

Paper Anti-HER2 Antibody-drug Conjugate ARX788

· 2020 · Definitions · DOI

Full title: Anti-HER2 Antibody-drug Conjugate ARX788

Year: 2020

Venue: Definitions

DOI: https://doi.org/10.32388/h0ytu2

Paper Anti-mesothelin/MMAE Antibody-Drug Conjugate DMOT4039A

· 2020 · Definitions · DOI

Full title: Anti-mesothelin/MMAE Antibody-Drug Conjugate DMOT4039A

Year: 2020

Venue: Definitions

DOI: https://doi.org/10.32388/8v5j4d

Paper Anti-FLT3 Antibody-drug Conjugate AGS62P1

· 2020 · Definitions · DOI

Full title: Anti-FLT3 Antibody-drug Conjugate AGS62P1

Year: 2020

Venue: Definitions

DOI: https://doi.org/10.32388/ae2wyi

Paper Anti-CD123 ADC IMGN632

· 2020 · Definitions · DOI

Full title: Anti-CD123 ADC IMGN632

Year: 2020

Venue: Definitions

DOI: https://doi.org/10.32388/gzfaib

Paper Anti-BCMA/PBD ADC MEDI2228

· 2020 · Definitions · DOI

Full title: Anti-BCMA/PBD ADC MEDI2228

Year: 2020

Venue: Definitions

DOI: https://doi.org/10.32388/cd2qq3

Paper Loncastuximab Tesirine

Loncastuximab Tesirine · 2020 · Definitions · DOI

Full title: Loncastuximab Tesirine

Authors: Loncastuximab Tesirine

Year: 2020

Venue: Definitions

DOI: https://doi.org/10.32388/hg0n0d

Paper Antibody-drug Conjugate ABBV-176

· 2020 · Definitions · DOI

Full title: Antibody-drug Conjugate ABBV-176

Year: 2020

Venue: Definitions

DOI: https://doi.org/10.32388/e1xwyq

Paper Anti-CD33 Antibody-drug Conjugate IMGN779

· 2020 · Definitions · DOI

Full title: Anti-CD33 Antibody-drug Conjugate IMGN779

Year: 2020

Venue: Definitions

DOI: https://doi.org/10.32388/c3jmqs

Paper Vandortuzumab Vedotin

Vandortuzumab Vedotin · 2020 · Definitions · DOI

Full title: Vandortuzumab Vedotin

Authors: Vandortuzumab Vedotin

Year: 2020

Venue: Definitions

DOI: https://doi.org/10.32388/ee1zh1

Paper Anti-CD37 MMAE Antibody-drug Conjugate AGS67E

· 2020 · Definitions · DOI

Full title: Anti-CD37 MMAE Antibody-drug Conjugate AGS67E

Year: 2020

Venue: Definitions

DOI: https://doi.org/10.32388/6np2fw

Paper Anti-HER2-vc0101 ADC PF-06804103

· 2020 · Definitions · DOI

Full title: Anti-HER2-vc0101 ADC PF-06804103

Year: 2020

Venue: Definitions

DOI: https://doi.org/10.32388/b4zjry

Paper Anti-HER2 Bispecific Antibody-drug Conjugate ZW49

· 2020 · Definitions · DOI

Full title: Anti-HER2 Bispecific Antibody-drug Conjugate ZW49

Year: 2020

Venue: Definitions

DOI: https://doi.org/10.32388/i3iq0u

Paper Antibody-drug Conjugate SC-004

· 2020 · Definitions · DOI

Full title: Antibody-drug Conjugate SC-004

Year: 2020

Venue: Definitions

DOI: https://doi.org/10.32388/mq5o2b

Paper Lifastuzumab Vedotin

Lifastuzumab Vedotin · 2020 · Definitions · DOI

Full title: Lifastuzumab Vedotin

Authors: Lifastuzumab Vedotin

Year: 2020

Venue: Definitions

DOI: https://doi.org/10.32388/imseaj

Paper Anti-BCMA Antibody-drug Conjugate AMG 224

· 2020 · Definitions · DOI

Full title: Anti-BCMA Antibody-drug Conjugate AMG 224

Year: 2020

Venue: Definitions

DOI: https://doi.org/10.32388/op46i6

Paper Antibody-drug Conjugate SC-005

· 2020 · Definitions · DOI

Full title: Antibody-drug Conjugate SC-005

Year: 2020

Venue: Definitions

DOI: https://doi.org/10.32388/qc1fxk

Paper Anti-HER2 Antibody-drug Conjugate RC48

· 2020 · Definitions · DOI

Full title: Anti-HER2 Antibody-drug Conjugate RC48

Year: 2020

Venue: Definitions

DOI: https://doi.org/10.32388/uss50u

Paper Anti-PTK7/Auristatin-0101 Antibody-drug Conjugate PF-06647020

· 2020 · Definitions · DOI

Full title: Anti-PTK7/Auristatin-0101 Antibody-drug Conjugate PF-06647020

Year: 2020

Venue: Definitions

DOI: https://doi.org/10.32388/wn41c5

Paper Anti-HER2 Antibody-drug Conjugate A166

· 2020 · Definitions · DOI

Full title: Anti-HER2 Antibody-drug Conjugate A166

Year: 2020

Venue: Definitions

DOI: https://doi.org/10.32388/jqjnth

Paper Antibody-drug Conjugate ADC XMT-1536

· 2020 · Definitions · DOI

Full title: Antibody-drug Conjugate ADC XMT-1536

Year: 2020

Venue: Definitions

DOI: https://doi.org/10.32388/qcbnb8

Paper Anti-CD123-Pyrrolobenzodiazepine Dimer Antibody Drug Conjugate SGN-CD123A

· 2020 · Definitions · DOI

Full title: Anti-CD123-Pyrrolobenzodiazepine Dimer Antibody Drug Conjugate SGN-CD123A

Year: 2020

Venue: Definitions

DOI: https://doi.org/10.32388/j6ii5b

Paper Anti-CD71/vcMMAE Probody-drug Conjugate CX-2029

· 2020 · Definitions · DOI

Full title: Anti-CD71/vcMMAE Probody-drug Conjugate CX-2029

Year: 2020

Venue: Definitions

DOI: https://doi.org/10.32388/r6csm6

Paper Anti-BCMA Antibody-drug Conjugate GSK2857916

· 2020 · Definitions · DOI

Full title: Anti-BCMA Antibody-drug Conjugate GSK2857916

Year: 2020

Venue: Definitions

DOI: https://doi.org/10.32388/ses2rp

Paper Anti-CD19 Antibody-drug Conjugate SGN-CD19B

· 2020 · Definitions · DOI

Full title: Anti-CD19 Antibody-drug Conjugate SGN-CD19B

Year: 2020

Venue: Definitions

DOI: https://doi.org/10.32388/r3y88p

Paper Sacituzumab Govitecan

Sacituzumab Govitecan · 2020 · Definitions · DOI

Full title: Sacituzumab Govitecan

Authors: Sacituzumab Govitecan

Year: 2020

Venue: Definitions

DOI: https://doi.org/10.32388/u85je1

Paper Emerging trends in synthesis, characterization, and mechanism of action of antibody-drug and antibody-nanoparticle conjugates.

Dixit, Tanu; Aswini, Annamraju; Nikam, Harshal et al. · 2025 · Discover nano · DOI

Full title: Emerging trends in synthesis, characterization, and mechanism of action of antibody-drug and antibody-nanoparticle conjugates.

Authors: Dixit, Tanu; Aswini, Annamraju; Nikam, Harshal; Vaidya, Anuradha; Ravindran, Selvan

Year: 2025

Venue: Discover nano

DOI: https://doi.org/10.1186/s11671-025-04303-w

Paper ITC-6102RO, a novel B7-H3 antibody-drug conjugate, exhibits potent therapeutic effects against B7-H3 expressing solid tumors

S. Shin; E. Ju; J. Park et al. · 2023 · Cancer Cell International · DOI

Full title: ITC-6102RO, a novel B7-H3 antibody-drug conjugate, exhibits potent therapeutic effects against B7-H3 expressing solid tumors

Authors: S. Shin; E. Ju; J. Park; E. Ko; M. Kwon; H. Lee; G. Son; Yun‐Yong Park; Yeon Joo Kim; S. Song; Sangkwang Lee; Beom-Seok Seo; Jin-A Song; Sangbin Lim; Doohwan Jung; Sunyoung Kim; Hyangsook Lee; S. Park; Seong-Yun Jeong; E. Choi

Year: 2023

Venue: Cancer Cell International

DOI: https://doi.org/10.1186/s12935-023-02991-x

Paper Developing an antibody drug encapsulation nanoagent targeting HER2 for cancer treatment

Linrong Li; Ru Yao; Yan Liu et al. · 2026 · Journal of Translational Medicine · DOI

Full title: Developing an antibody drug encapsulation nanoagent targeting HER2 for cancer treatment

Authors: Linrong Li; Ru Yao; Yan Liu; Nelyda Gonzalez Almeyda; Qiang Sun; Faqing Huang; Leslie Wang; Kinsley Wang; James Turkson; L. Medina-Kauwe; Armando E Giuliano; Changjun Yu; Xiaojiang Cui

Year: 2026

Venue: Journal of Translational Medicine

DOI: https://doi.org/10.1186/s12967-025-07450-x

Paper The cytotoxic conjugate of highly internalizing tetravalent antibody for targeting FGFR1-overproducing cancer cells

Marta Poźniak; Natalia Porębska; M. Krzyścik et al. · 2021 · Molecular Medicine · DOI

Full title: The cytotoxic conjugate of highly internalizing tetravalent antibody for targeting FGFR1-overproducing cancer cells

Authors: Marta Poźniak; Natalia Porębska; M. Krzyścik; Aleksandra Sokołowska-Wędzina; K. Jastrzębski; Martyna Sochacka; Jakub Szymczyk; M. Zakrzewska; J. Otlewski; Łukasz Opaliński

Year: 2021

Venue: Molecular Medicine

DOI: https://doi.org/10.1186/s10020-021-00306-2

Paper CD13 as a new tumor target for antibody-drug conjugates: validation with the conjugate MI130110

J. Domı́nguez; G. Perez-Chacon; M. Guillén et al. · 2020 · Journal of Hematology & Oncology · DOI

Full title: CD13 as a new tumor target for antibody-drug conjugates: validation with the conjugate MI130110

Authors: J. Domı́nguez; G. Perez-Chacon; M. Guillén; M. Muñoz-Alonso; B. Somovilla-Crespo; Danay Cibrian; Barbara Acosta-Iborra; M. Adrados; C. Muñoz‐Calleja; C. Cuevas; F. Sánchez‐Madrid; P. Avilés; J. Zapata

Year: 2020

Venue: Journal of Hematology & Oncology

DOI: https://doi.org/10.1186/s13045-020-00865-7

Paper TROP2-directed nanobody-drug conjugate elicited potent antitumor effect in pancreatic cancer

Cailing Xu; Min Zhu; Qian Wang et al. · 2023 · Journal of Nanobiotechnology · DOI

Full title: TROP2-directed nanobody-drug conjugate elicited potent antitumor effect in pancreatic cancer

Authors: Cailing Xu; Min Zhu; Qian Wang; Jiajun Cui; Yuping Huang; Xiting Huang; Jing Huang; J. Gai; Guanghui Li; P. Qiao; Xian Zeng; Dianwen Ju; Y. Wan; Xuyao Zhang

Year: 2023

Venue: Journal of Nanobiotechnology

DOI: https://doi.org/10.1186/s12951-023-02183-9

Paper Decoding of the surfaceome and endocytome in primary glioblastoma cells identifies potential target antigens in the hypoxic tumor niche

K. G. de Oliveira; A. Bång-Rudenstam; Sarah Beyer et al. · 2024 · Acta Neuropathologica Communications · DOI

Full title: Decoding of the surfaceome and endocytome in primary glioblastoma cells identifies potential target antigens in the hypoxic tumor niche

Authors: K. G. de Oliveira; A. Bång-Rudenstam; Sarah Beyer; A. Boukredine; H. Talbot; V. Governa; Maria C Johansson; A. Månsson; K. Forsberg-Nilsson; J. Bengzon; Johan Malmström; C. Welinder; M. Belting

Year: 2024

Venue: Acta Neuropathologica Communications

DOI: https://doi.org/10.1186/s40478-024-01740-z

Paper Treatment-related adverse events of antibody drug-conjugates in clinical trials.

Tan, Harold Nathan; Morcillo, Marta Ascanio; Lopez, Juanita et al. · 2025 · Journal of hematology & oncology · DOI

Full title: Treatment-related adverse events of antibody drug-conjugates in clinical trials.

Authors: Tan, Harold Nathan; Morcillo, Marta Ascanio; Lopez, Juanita; Minchom, Anna; Sharp, Adam; Paschalis, Alec; Silva-Fortes, Georgina; Raobaikady, Bindu; Banerji, Udai

Year: 2025

Venue: Journal of hematology & oncology

DOI: https://doi.org/10.1186/s13045-025-01720-3

Paper CD46 targeted 212Pb alpha particle radioimmunotherapy for prostate cancer treatment

Jun Li; Tao Huang; Jun Hua et al. · 2023 · bioRxiv · DOI

Full title: CD46 targeted 212Pb alpha particle radioimmunotherapy for prostate cancer treatment

Authors: Jun Li; Tao Huang; Jun Hua; Qiong Wang; Yang Su; Pin-Li Chen; S. Bidlingmaier; Allan Li; Zhongqiu Xie; A. Bidkar; S. Shen; Weibin Shi; Youngho Seo; R. Flavell; D. Gioeli; R. Dreicer; Hui Li; Bin Liu; Jiang He

Year: 2023

Venue: bioRxiv

DOI: https://doi.org/10.1186/s13046-023-02636-x

Paper Learn from antibody–drug conjugates: consideration in the future construction of peptide-drug conjugates for cancer therapy

Mo Wu; Wei Huang; Nan Yang et al. · 2022 · Experimental Hematology & Oncology · DOI

Full title: Learn from antibody–drug conjugates: consideration in the future construction of peptide-drug conjugates for cancer therapy

Authors: Mo Wu; Wei Huang; Nan Yang; Yanyong Liu

Year: 2022

Venue: Experimental Hematology & Oncology

DOI: https://doi.org/10.1186/s40164-022-00347-1

Paper Clinical trial update on bispecific antibodies, antibody-drug conjugates, and antibody-containing regimens for acute lymphoblastic leukemia

Delong Liu; Juanjuan Zhao; Yongping Song et al. · 2019 · Journal of Hematology & Oncology · DOI

Full title: Clinical trial update on bispecific antibodies, antibody-drug conjugates, and antibody-containing regimens for acute lymphoblastic leukemia

Authors: Delong Liu; Juanjuan Zhao; Yongping Song; Xiao-feng Luo; Ting Yang

Year: 2019

Venue: Journal of Hematology & Oncology

DOI: https://doi.org/10.1186/s13045-019-0703-z

Paper DLL3: an emerging target in small cell lung cancer

D. Owen; M. Giffin; J. Bailis et al. · 2019 · Journal of Hematology & Oncology · DOI

Full title: DLL3: an emerging target in small cell lung cancer

Authors: D. Owen; M. Giffin; J. Bailis; M. Smit; D. Carbone; K. He

Year: 2019

Venue: Journal of Hematology & Oncology

DOI: https://doi.org/10.1186/s13045-019-0745-2

Paper A novel anti-CD22 scFv–apoptin fusion protein induces apoptosis in malignant B-cells

S. Agha Amiri; S. Shahhosseini; N. Zarei et al. · 2017 · AMB Express · DOI

Full title: A novel anti-CD22 scFv–apoptin fusion protein induces apoptosis in malignant B-cells

Authors: S. Agha Amiri; S. Shahhosseini; N. Zarei; Dorsa Khorasanizadeh; Elahe Aminollahi; Faegheh Rezaie; M. Zargari; M. Azizi; V. Khalaj

Year: 2017

Venue: AMB Express

DOI: https://doi.org/10.1186/s13568-017-0410-5

Paper A bifunctional molecule-based strategy for the development of theranostic antibody-drug conjugate

Dian Xiao; Lei Zhao; Fei Xie et al. · 2021 · Theranostics · DOI

Full title: A bifunctional molecule-based strategy for the development of theranostic antibody-drug conjugate

Authors: Dian Xiao; Lei Zhao; Fei Xie; Shiyong Fan; Lianqi Liu; Wei Li; Ruiyuan Cao; Song Li; Wu Zhong; Xinbo Zhou

Year: 2021

Venue: Theranostics

DOI: https://doi.org/10.7150/thno.51232

Paper Safety and Efficacy of Anti-B-cell Maturation Antigen (Anti-BCMA) Bispecific Antibodies for Relapsed/Refractory Multiple Myeloma: A Systematic Review of Clinical Trials

Asad Ali Khan; Mansoor Rahman; Inshal Jawed et al. · 2025 · Cureus · DOI

Full title: Safety and Efficacy of Anti-B-cell Maturation Antigen (Anti-BCMA) Bispecific Antibodies for Relapsed/Refractory Multiple Myeloma: A Systematic Review of Clinical Trials

Authors: Asad Ali Khan; Mansoor Rahman; Inshal Jawed; Muhammad Sajjad; Muhammad Musa Khan

Year: 2025

Venue: Cureus

DOI: https://doi.org/10.7759/cureus.98368

Paper Optimal design, anti-tumour efficacy and tolerability of anti-CXCR4 antibody drug conjugates.

Costa, Maria José; Kudaravalli, Jyothirmayee; Ma, Jing-Tyan et al. · 2019 · Scientific reports · DOI

Full title: Optimal design, anti-tumour efficacy and tolerability of anti-CXCR4 antibody drug conjugates.

Authors: Costa, Maria José; Kudaravalli, Jyothirmayee; Ma, Jing-Tyan; Ho, Wei-Hsien; Delaria, Kathy; Holz, Charles; Stauffer, Angela; Chunyk, Allison Given; Zong, Qing; Blasi, Eileen; Buetow, Bernard; Tran, Thomas-Toan; Lindquist, Kevin; Dorywalska, Magdalena; Rajpal, Arvind; Shelton, David L; Strop, Pavel; Liu, Shu-Hui

Year: 2019

Venue: Scientific reports

DOI: https://doi.org/10.1038/s41598-019-38745-x

Paper Targeting the ITGA3B1 Complex with A Novel Antibody-Drug Conjugate for Metastatic Bladder Cancer

H. Jung; Junghyeon Lee; Eunhee G Kim et al. · 2025 · bioRxiv · DOI

Full title: Targeting the ITGA3B1 Complex with A Novel Antibody-Drug Conjugate for Metastatic Bladder Cancer

Authors: H. Jung; Junghyeon Lee; Eunhee G Kim; Jinsung Ahn; Michael C. Haffner; Peter S. Nelson; Kwang Pyo Kim; John K. Lee; Eugene C. Yi; Kristine M. Kim

Year: 2025

Venue: bioRxiv

DOI: https://doi.org/10.1101/2025.04.06.647354

Paper Customized Protein Nanoreactors for Affibody-Directed Activation of 5-Fluorcytosin in HER2-Positive Cells

Mariia Zmyslia; Martin Holzer; C. Jessen-Trefzer · 2025 · bioRxiv · DOI

Full title: Customized Protein Nanoreactors for Affibody-Directed Activation of 5-Fluorcytosin in HER2-Positive Cells

Authors: Mariia Zmyslia; Martin Holzer; C. Jessen-Trefzer

Year: 2025

Venue: bioRxiv

DOI: https://doi.org/10.1101/2025.09.11.675605

Paper Targeting the human MUC1-C oncoprotein with an antibody-drug conjugate.

G. Panchamoorthy; Caining Jin; D. Raina et al. · 2018 · JCI Insight · DOI

Full title: Targeting the human MUC1-C oncoprotein with an antibody-drug conjugate.

Authors: G. Panchamoorthy; Caining Jin; D. Raina; A. Bharti; Masaaki Yamamoto; Dennis Adeebge; Qing Zhao; R. Bronson; Shirley Jiang; Linjing Li; Yozo Suzuki; Ashujit Tagde; P. Ghoroghchian; Kwok-kin Wong; S. Kharbanda; D. Kufe

Year: 2018

Venue: JCI Insight

DOI: https://doi.org/10.1172/jci.insight.99880

Paper Improving the Therapeutic Selectivity of Trastuzumab Deruxtecan Using 8C2 Fab Fragments.

Gong, Jue; Bordeau, Brandon M; Balthasar, Joseph P · 2025 · The AAPS journal · DOI

Full title: Improving the Therapeutic Selectivity of Trastuzumab Deruxtecan Using 8C2 Fab Fragments.

Authors: Gong, Jue; Bordeau, Brandon M; Balthasar, Joseph P

Year: 2025

Venue: The AAPS journal

DOI: https://doi.org/10.1208/s12248-025-01087-w

Thesis Exploring novel peptide-based natural products as a payload for the generation of antibody and peptide-assisted targeted cancer therapy

Kavianinia, Iman · 2024 · Universidade de São Paulo – USP Digital Library · DOI

Full title: Exploring novel peptide-based natural products as a payload for the generation of antibody and peptide-assisted targeted cancer therapy

Authors: Kavianinia, Iman

Year: 2024

Venue: Universidade de São Paulo – USP Digital Library

DOI: https://eps2024.com/wp-content/uploads/2024/08/EPS_PROGRAMME-18.pdf

Thesis SYNTHESIS OF PEPTIDOMIMETIC LIGANDS TARGETING CELL-SURFACE RECEPTORS INVOLVED IN TUMOR ANGIOGENESIS

S. Zanella · 2017 · Università degli Studi di Milano (AIR) · DOI

Full title: SYNTHESIS OF PEPTIDOMIMETIC LIGANDS TARGETING CELL-SURFACE RECEPTORS INVOLVED IN TUMOR ANGIOGENESIS

Authors: S. Zanella

Year: 2017

Venue: Università degli Studi di Milano (AIR)

DOI: http://hdl.handle.net/2434/473075

Thesis SYNTHESIS AND BIOLOGICAL EVALUATION OF POTENT INTEGRIN LIGANDS CONTAINING A DIKETOPIPERAZINE SCAFFOLD, AND OF THEIR CONJUGATES WITH CYTOTOXIC AGENTS

R. Colombo · 2013 · Università degli Studi di Milano (AIR) · DOI

Full title: SYNTHESIS AND BIOLOGICAL EVALUATION OF POTENT INTEGRIN LIGANDS CONTAINING A DIKETOPIPERAZINE SCAFFOLD, AND OF THEIR CONJUGATES WITH CYTOTOXIC AGENTS

Authors: R. Colombo

Year: 2013

Venue: Università degli Studi di Milano (AIR)

DOI: http://hdl.handle.net/2434/214953

Thesis TARGETED DNA DAMAGE BOOST WITH LONCASTUXIMAB TESIRINE IN COMBINATION WITH PARP INHIBITORS IN DIFFUSE LARGE B-CELL LYMPHOMA

FUSANI, STEFANIA · 2023 · Università degli Studi di Milano (AIR) · DOI

Full title: TARGETED DNA DAMAGE BOOST WITH LONCASTUXIMAB TESIRINE IN COMBINATION WITH PARP INHIBITORS IN DIFFUSE LARGE B-CELL LYMPHOMA

Authors: FUSANI, STEFANIA

Year: 2023

Venue: Università degli Studi di Milano (AIR)

DOI: https://hdl.handle.net/2434/1015888

Thesis TUMOR TARGETING VIA INTEGRIN LIGANDS: SYNTHESIS AND BIOLOGICAL EVALUATION OF RGD PEPTIDOMIMETIC-DRUG CONJUGATES

A. DAL CORSO · 2015 · Università degli Studi di Milano (AIR) · DOI

Full title: TUMOR TARGETING VIA INTEGRIN LIGANDS: SYNTHESIS AND BIOLOGICAL EVALUATION OF RGD PEPTIDOMIMETIC-DRUG CONJUGATES

Authors: A. DAL CORSO

Year: 2015

Venue: Università degli Studi di Milano (AIR)

DOI: http://hdl.handle.net/2434/331100

Thesis HOOKING TRAIL-R2 TO ¿EDUCATE¿ IMMUNE SYSTEM TO RECOGNIZE CANCER CELLS

A. Satta · 2015 · Università degli Studi di Milano (AIR) · DOI

Full title: HOOKING TRAIL-R2 TO ¿EDUCATE¿ IMMUNE SYSTEM TO RECOGNIZE CANCER CELLS

Authors: A. Satta

Year: 2015

Venue: Università degli Studi di Milano (AIR)

DOI: http://hdl.handle.net/2434/333177

Thesis SYNTHESIS AND BIOLOGICAL EVALUATION OF POTENT INTEGRIN LIGANDS CONTAINING A DIKETOPIPERAZINE SCAFFOLD, AND OF THEIR DUAL-ACTION CONJUGATES

M. Mingozzi · 2014 · Università degli Studi di Milano (AIR) · DOI

Full title: SYNTHESIS AND BIOLOGICAL EVALUATION OF POTENT INTEGRIN LIGANDS CONTAINING A DIKETOPIPERAZINE SCAFFOLD, AND OF THEIR DUAL-ACTION CONJUGATES

Authors: M. Mingozzi

Year: 2014

Venue: Università degli Studi di Milano (AIR)

DOI: http://hdl.handle.net/2434/229387

Thesis DEVELOPMENT OF NOVEL STRATEGIES TO ENHANCE THE AFFINITY OF CYCLIC PEPTIDE LIGANDS FOR INTEGRIN RECEPTORS

SACCO, GIOVANNI · 2022 · Università degli Studi di Milano (AIR) · DOI

Full title: DEVELOPMENT OF NOVEL STRATEGIES TO ENHANCE THE AFFINITY OF CYCLIC PEPTIDE LIGANDS FOR INTEGRIN RECEPTORS

Authors: SACCO, GIOVANNI

Year: 2022

Venue: Università degli Studi di Milano (AIR)

DOI: http://hdl.handle.net/2434/919134

Thesis SYNTHESIS OF INTEGRIN-TARGETING PRO-DRUGS FOR THE SELECTIVE RELEASE OF ANTI-TUMOR AGENTS

LOPEZ RIVAS, PAULA · 2018 · Università degli Studi di Milano (AIR) · DOI

Full title: SYNTHESIS OF INTEGRIN-TARGETING PRO-DRUGS FOR THE SELECTIVE RELEASE OF ANTI-TUMOR AGENTS

Authors: LOPEZ RIVAS, PAULA

Year: 2018

Venue: Università degli Studi di Milano (AIR)

DOI: http://hdl.handle.net/2434/584099

Thesis SYNTHESIS OF RGD PEPTIDOMIMETIC-DRUG CONJUGATES FOR THE TUMOR-TARGETED DELIVERY OF CYTOTOXIC AGENTS

RAPOSO MOREIRA DIAS, ANDRE FILIPE · 2018 · Università degli Studi di Milano (AIR) · DOI

Full title: SYNTHESIS OF RGD PEPTIDOMIMETIC-DRUG CONJUGATES FOR THE TUMOR-TARGETED DELIVERY OF CYTOTOXIC AGENTS

Authors: RAPOSO MOREIRA DIAS, ANDRE FILIPE

Year: 2018

Venue: Università degli Studi di Milano (AIR)

DOI: http://hdl.handle.net/2434/583313

Thesis Development of inhibitors of the prostate specific membrane antigen (PSMA) for imaging and endoradiotherapy

Dos Santos, José Carlos · 2024 · Heidelberg University · DOI

Full title: Development of inhibitors of the prostate specific membrane antigen (PSMA) for imaging and endoradiotherapy

Authors: Dos Santos, José Carlos

Year: 2024

Venue: Heidelberg University

DOI: https://archiv.ub.uni-heidelberg.de/volltextserver/27617/1/Development%20of%20inhibitors%20of%20the%20prostate%20specific%20membrane%20antigen%20%28PSMA%29%20for%20imaging%20and%20endoradiotherapy.pdf

Thesis SYNTHESIS OF NEW RGD PEPTIDOMIMETIC-DRUG CONJUGATES TARGETING ΑVΒ3 INTEGRIN

PINA, ARIANNA · 2019 · Università degli Studi di Milano (AIR) · DOI

Full title: SYNTHESIS OF NEW RGD PEPTIDOMIMETIC-DRUG CONJUGATES TARGETING ΑVΒ3 INTEGRIN

Authors: PINA, ARIANNA

Year: 2019

Venue: Università degli Studi di Milano (AIR)

DOI: http://hdl.handle.net/2434/606167

Thesis Chemically self-assembled antibody nanorings: a multifaceted approach to anti-cancer therapeutics using techniques including drug delivery, bispecific targeting, and T cell surface modification.

Gabrielse, Kari A. · 2013 · University of Minnesota - Digital Conservancy · DOI

Full title: Chemically self-assembled antibody nanorings: a multifaceted approach to anti-cancer therapeutics using techniques including drug delivery, bispecific targeting, and T cell surface modification.

Authors: Gabrielse, Kari A.

Year: 2013

Venue: University of Minnesota - Digital Conservancy

DOI: http://purl.umn.edu/158163

Thesis IDENTIFICATION AND CHARACTERIZATION OF MONOCLONAL ANTIBODY 14C5 - A potential agent for radioimmunodetection and -therapy

Burvenich, Ingrid · 2007 · Ghent University (Universiteit Gent) · DOI

Full title: IDENTIFICATION AND CHARACTERIZATION OF MONOCLONAL ANTIBODY 14C5 - A potential agent for radioimmunodetection and -therapy

Authors: Burvenich, Ingrid

Year: 2007

Venue: Ghent University (Universiteit Gent)

DOI: https://biblio.ugent.be/publication/470887

Thesis Intracellular Delivery of Cancer-Targeting Antibody-Drug Conjugates

Berguig, Geoffrey Yehuda · 2013 · University of Washington - ResearchWorks · DOI

Full title: Intracellular Delivery of Cancer-Targeting Antibody-Drug Conjugates

Authors: Berguig, Geoffrey Yehuda

Year: 2013

Venue: University of Washington - ResearchWorks

DOI: http://hdl.handle.net/1773/24174

Thesis Development and characterization of CD133 positive cancer stem cell targeted toxins for use in carcinoma therapy

Waldron, Nate N. · 2013 · University of Minnesota - Digital Conservancy · DOI

Full title: Development and characterization of CD133 positive cancer stem cell targeted toxins for use in carcinoma therapy

Authors: Waldron, Nate N.

Year: 2013

Venue: University of Minnesota - Digital Conservancy

DOI: http://purl.umn.edu/154974

Thesis Development of Novel Reagents for the Selective Enrichment of Vascular Accessible Proteins and the Identification of Disease-Specific Biomarkers

Hanke, Sabrina Annette · 2015 · Heidelberg University · DOI

Full title: Development of Novel Reagents for the Selective Enrichment of Vascular Accessible Proteins and the Identification of Disease-Specific Biomarkers

Authors: Hanke, Sabrina Annette

Year: 2015

Venue: Heidelberg University

DOI: https://archiv.ub.uni-heidelberg.de/volltextserver/19620/1/Doktorarbeit_Hanke.pdf

Thesis Design, Synthesis, and Application of a Rapidly Diversifiable Trioxacarcin Pharmacophore in Antibody-Drug Conjugates

Anesini, Jason E · 2023 · Harvard University - DASH · DOI

Full title: Design, Synthesis, and Application of a Rapidly Diversifiable Trioxacarcin Pharmacophore in Antibody-Drug Conjugates

Authors: Anesini, Jason E

Year: 2023

Venue: Harvard University - DASH

DOI: https://nrs.harvard.edu/URN-3:HUL.INSTREPOS:37375457

Thesis Site-specific labeling of affinity molecules for in vitro and in vivo studies

Perols, Anna · 2014 · KTH Royal Institute of Technology · DOI

Full title: Site-specific labeling of affinity molecules for in vitro and in vivo studies

Authors: Perols, Anna

Year: 2014

Venue: KTH Royal Institute of Technology

DOI: http://urn.kb.se/resolve?urn=urn:nbn:se:kth:diva-152349

Thesis Tumor targeted delivery of cytotoxic payloads using affibody molecules and ABD-derived affinity proteins

Liu, Hao · 2018 · KTH Royal Institute of Technology · DOI

Full title: Tumor targeted delivery of cytotoxic payloads using affibody molecules and ABD-derived affinity proteins

Authors: Liu, Hao

Year: 2018

Venue: KTH Royal Institute of Technology

DOI: http://urn.kb.se/resolve?urn=urn:nbn:se:kth:diva-228015

Thesis Affibody-mediated targeting of HER-family receptors for cancer imaging and therapy

Dahlsson Leitao, Charles · 2022 · KTH Royal Institute of Technology · DOI

Full title: Affibody-mediated targeting of HER-family receptors for cancer imaging and therapy

Authors: Dahlsson Leitao, Charles

Year: 2022

Venue: KTH Royal Institute of Technology

DOI: http://urn.kb.se/resolve?urn=urn:nbn:se:kth:diva-309574

Thesis PNA and affinity protein tools for selective tumor targeting of radiopharmaceuticals

Tano, Hanna · 2022 · KTH Royal Institute of Technology · DOI

Full title: PNA and affinity protein tools for selective tumor targeting of radiopharmaceuticals

Authors: Tano, Hanna

Year: 2022

Venue: KTH Royal Institute of Technology

DOI: http://urn.kb.se/resolve?urn=urn:nbn:se:kth:diva-317137

Thesis Targeting HER2-expressing tumors with potent drug conjugates and fusion toxins based on scaffold proteins

Ding, Haozhong · 2022 · KTH Royal Institute of Technology · DOI

Full title: Targeting HER2-expressing tumors with potent drug conjugates and fusion toxins based on scaffold proteins

Authors: Ding, Haozhong

Year: 2022

Venue: KTH Royal Institute of Technology

DOI: http://urn.kb.se/resolve?urn=urn:nbn:se:kth:diva-316518

Thesis Development and evaluation of analytical techniques for antibodies and antibody-drug conjugates : From verification of conjugation to stability testing

Källsten, Malin · 2020 · Uppsala University · DOI

Full title: Development and evaluation of analytical techniques for antibodies and antibody-drug conjugates : From verification of conjugation to stability testing

Authors: Källsten, Malin

Year: 2020

Venue: Uppsala University

DOI: http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-403473

Thesis Preclinical Development of New Alkylating Oligopeptides for Cancer Therapy

Gullbo, Joachim · 2003 · Uppsala University · DOI

Full title: Preclinical Development of New Alkylating Oligopeptides for Cancer Therapy

Authors: Gullbo, Joachim

Year: 2003

Venue: Uppsala University

DOI: http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-3785

Thesis Investigations of chemical and enzymatic functionalization of affinity proteins

Myrhammar, Anders · 2020 · KTH Royal Institute of Technology · DOI

Full title: Investigations of chemical and enzymatic functionalization of affinity proteins

Authors: Myrhammar, Anders

Year: 2020

Venue: KTH Royal Institute of Technology

DOI: http://urn.kb.se/resolve?urn=urn:nbn:se:kth:diva-279052

Thesis Pharmacometric Models for Antibody Drug Conjugates and Taxanes in HER2+ and HER2- Breast Cancer

Bender, Brendan · 2016 · Uppsala University · DOI

Full title: Pharmacometric Models for Antibody Drug Conjugates and Taxanes in HER2+ and HER2- Breast Cancer

Authors: Bender, Brendan

Year: 2016

Venue: Uppsala University

DOI: http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-292617

Thesis Engineering of alternative scaffold derived drug conjugates and fusion-toxins for targeted cancer therapy

Yin, Wen · 2022 · KTH Royal Institute of Technology · DOI

Full title: Engineering of alternative scaffold derived drug conjugates and fusion-toxins for targeted cancer therapy

Authors: Yin, Wen

Year: 2022

Venue: KTH Royal Institute of Technology

DOI: http://urn.kb.se/resolve?urn=urn:nbn:se:kth:diva-308526

Thesis A Chemical Approach Toward the Therapeutic Optimization of Cytotoxic Bioconjugates

Hartmann, Rafael · 2021 · Uppsala University · DOI

Full title: A Chemical Approach Toward the Therapeutic Optimization of Cytotoxic Bioconjugates

Authors: Hartmann, Rafael

Year: 2021

Venue: Uppsala University

DOI: http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-451298

Thesis Bioconjugation of antibodies and affinity proteins for the development of novel diagnostic and therapeutic tools

Nagy, Abel · 2024 · KTH Royal Institute of Technology · DOI

Full title: Bioconjugation of antibodies and affinity proteins for the development of novel diagnostic and therapeutic tools

Authors: Nagy, Abel

Year: 2024

Venue: KTH Royal Institute of Technology

DOI: http://urn.kb.se/resolve?urn=urn:nbn:se:kth:diva-351396

Thesis Targeting Human Epidermal Growth Factor Receptors with Drug Conjugates Based on Affibody Molecules

Zhang, Jie · 2023 · KTH Royal Institute of Technology · DOI

Full title: Targeting Human Epidermal Growth Factor Receptors with Drug Conjugates Based on Affibody Molecules

Authors: Zhang, Jie

Year: 2023

Venue: KTH Royal Institute of Technology

DOI: http://urn.kb.se/resolve?urn=urn:nbn:se:kth:diva-334736

Thesis Mechanism-based pharmacometric models to improve the development and use of anticancer therapies

Ibrahim, Eman I. K. · 2025 · Uppsala University · DOI

Full title: Mechanism-based pharmacometric models to improve the development and use of anticancer therapies

Authors: Ibrahim, Eman I. K.

Year: 2025

Venue: Uppsala University

DOI: http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-565557

Thesis Scaffold Protein-based Theranostics of HER2-overexpressing Ovarian Cancer: Imaging-guided Therapy

Xu, Tianqi · 2024 · Uppsala University · DOI

Full title: Scaffold Protein-based Theranostics of HER2-overexpressing Ovarian Cancer: Imaging-guided Therapy

Authors: Xu, Tianqi

Year: 2024

Venue: Uppsala University

DOI: http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-539484

Thesis Next generation CD40 targeting immunotherapy : Development of antibody-based personalized cancer treatment

Laurén, Ida · 2025 · Uppsala University · DOI

Full title: Next generation CD40 targeting immunotherapy : Development of antibody-based personalized cancer treatment

Authors: Laurén, Ida

Year: 2025

Venue: Uppsala University

DOI: http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-554023

Thesis Clustering-Induced, Clathrin-Mediated Endocytosis (CIC-ME) for Cancer Therapy

Heukers, R. · 2014 · Utrecht University · DOI

Full title: Clustering-Induced, Clathrin-Mediated Endocytosis (CIC-ME) for Cancer Therapy

Authors: Heukers, R.

Year: 2014

Venue: Utrecht University

DOI: https://dspace.library.uu.nl/handle/1874/287846

Thesis Functionalized nanobodies for cancer therapy

van Vught, R.W.M. · 2014 · Utrecht University · DOI

Full title: Functionalized nanobodies for cancer therapy

Authors: van Vught, R.W.M.

Year: 2014

Venue: Utrecht University

DOI: https://dspace.library.uu.nl/handle/1874/307928

Thesis Stimuli-responsive biodegradable polymeric micelles for targeted cancer therapy

Talelli, M.A. · 2011 · Utrecht University · DOI

Full title: Stimuli-responsive biodegradable polymeric micelles for targeted cancer therapy

Authors: Talelli, M.A.

Year: 2011

Venue: Utrecht University

DOI: https://dspace.library.uu.nl/handle/1874/209205

Thesis Development of HER2-targeted nanobodies for molecular optical imaging and therapy of breast cancer

Kijanka, M.M. · 2014 · Utrecht University · DOI

Full title: Development of HER2-targeted nanobodies for molecular optical imaging and therapy of breast cancer

Authors: Kijanka, M.M.

Year: 2014

Venue: Utrecht University

DOI: https://dspace.library.uu.nl/handle/1874/298483

Thesis Pharmaceutical development and clinical application of radiolabeled rituximab

Tran, T.H.L. · 2009 · Utrecht University · DOI

Full title: Pharmaceutical development and clinical application of radiolabeled rituximab

Authors: Tran, T.H.L.

Year: 2009

Venue: Utrecht University

DOI: https://dspace.library.uu.nl/handle/1874/36948

Thesis What NIR photodynamic activation offers molecular targeted nanomedicines: Perspectives into the conundrum of tumor specificity and selectivity

Bhandari, Chanda; Guirguis, Mina; Savan, N Anna et al. · 2021 · Utrecht University · DOI

Full title: What NIR photodynamic activation offers molecular targeted nanomedicines: Perspectives into the conundrum of tumor specificity and selectivity

Authors: Bhandari, Chanda; Guirguis, Mina; Savan, N Anna; Shrivastava, Navadeep; Oliveira, Sabrina; Hasan, Tayyaba; Obaid, Girgis

Year: 2021

Venue: Utrecht University

DOI: https://dspace.library.uu.nl/handle/1874/411946

Thesis Drug conjugates and polymeric micelles for targeted delivery of kinase inhibitors

SHI, HAILI · 2019 · Utrecht University · DOI

Full title: Drug conjugates and polymeric micelles for targeted delivery of kinase inhibitors

Authors: SHI, HAILI

Year: 2019

Venue: Utrecht University

DOI: https://dspace.library.uu.nl/handle/1874/386194

Thesis Innovative cleavable and bioorthogonal conjugation chemistries for application in core-crosslinked polymeric micelles and bioconjugates

Timmers, Mattijs · 2023 · Utrecht University · DOI

Full title: Innovative cleavable and bioorthogonal conjugation chemistries for application in core-crosslinked polymeric micelles and bioconjugates

Authors: Timmers, Mattijs

Year: 2023

Venue: Utrecht University

DOI: https://dspace.library.uu.nl/handle/1874/433434

Thesis Quantitative analysis of cellular processing of Antibody-Drug Conjugates

Maass, Katie F · 2016 · Massachusetts Institute of Technology (MIT) · DOI

Full title: Quantitative analysis of cellular processing of Antibody-Drug Conjugates

Authors: Maass, Katie F

Year: 2016

Venue: Massachusetts Institute of Technology (MIT)

DOI: http://hdl.handle.net/1721.1/103185

Thesis Layer-by-Layer Nanoparticles for Targeted Delivery and Treatment of Ovarian Cancer

Kong, Stephanie Mabel · 2022 · Massachusetts Institute of Technology (MIT) · DOI

Full title: Layer-by-Layer Nanoparticles for Targeted Delivery and Treatment of Ovarian Cancer

Authors: Kong, Stephanie Mabel

Year: 2022

Venue: Massachusetts Institute of Technology (MIT)

DOI: https://hdl.handle.net/1721.1/139996

Thesis Engineering kinetics of immunotherapies and vaccines

Bhagchandani, Sachin Haresh · 2024 · Massachusetts Institute of Technology (MIT) · DOI

Full title: Engineering kinetics of immunotherapies and vaccines

Authors: Bhagchandani, Sachin Haresh

Year: 2024

Venue: Massachusetts Institute of Technology (MIT)

DOI: https://hdl.handle.net/1721.1/154366

Thesis Design and Synthesis of Stimuli-Responsive Polymers with Programmable Cleavability

Zafar, Hadiqa · 2024 · Massachusetts Institute of Technology (MIT) · DOI

Full title: Design and Synthesis of Stimuli-Responsive Polymers with Programmable Cleavability

Authors: Zafar, Hadiqa

Year: 2024

Venue: Massachusetts Institute of Technology (MIT)

DOI: https://hdl.handle.net/1721.1/157070

Thesis Novel genotoxins that target estrogen receptor- and androgen receptor- positive cancers : identification of DNA adducts, pharmacokinetics, and mechanism

Hillier, Shawn M. (Shawn Matthew) · 2006 · Massachusetts Institute of Technology (MIT) · DOI

Full title: Novel genotoxins that target estrogen receptor- and androgen receptor- positive cancers : identification of DNA adducts, pharmacokinetics, and mechanism

Authors: Hillier, Shawn M. (Shawn Matthew)

Year: 2006

Venue: Massachusetts Institute of Technology (MIT)

DOI: http://hdl.handle.net/1721.1/32480

Thesis Antibody engineering for cancer therapy

Yeung, Yik Andy · 2006 · Massachusetts Institute of Technology (MIT) · DOI

Full title: Antibody engineering for cancer therapy

Authors: Yeung, Yik Andy

Year: 2006

Venue: Massachusetts Institute of Technology (MIT)

DOI: http://hdl.handle.net/1721.1/32325

Thesis Rational Approaches to Improving Selectivity in Drug Design

Huggins, David J.; Sherman, Woody; Tidor, Bruce · 2012 · Massachusetts Institute of Technology (MIT) · DOI

Full title: Rational Approaches to Improving Selectivity in Drug Design

Authors: Huggins, David J.; Sherman, Woody; Tidor, Bruce

Year: 2012

Venue: Massachusetts Institute of Technology (MIT)

DOI: http://hdl.handle.net/1721.1/73545

Thesis Improved mehtods and reagents for pretargeted radioimmunotherapy of cancer

Zajic, Stefan C · 2007 · Massachusetts Institute of Technology (MIT) · DOI

Full title: Improved mehtods and reagents for pretargeted radioimmunotherapy of cancer

Authors: Zajic, Stefan C

Year: 2007

Venue: Massachusetts Institute of Technology (MIT)

DOI: http://hdl.handle.net/1721.1/38971

Thesis The generation and characterisation of anti-glycan monoclonal antibodies

Chua, Jia Xin · 2017 · University of Nottingham · DOI

Full title: The generation and characterisation of anti-glycan monoclonal antibodies

Authors: Chua, Jia Xin

Year: 2017

Venue: University of Nottingham

DOI: https://eprints.nottingham.ac.uk/34932/1/chua%20PHD%20thesis%20%2812.7.16%29.pdf

Thesis Selective targeting of WNT receptor FZD7 in human pluripotent stem cells and ovarian cancer

Do, Myan · 2021 · University of California, San Diego (UCSD) · DOI

Full title: Selective targeting of WNT receptor FZD7 in human pluripotent stem cells and ovarian cancer

Authors: Do, Myan

Year: 2021

Venue: University of California, San Diego (UCSD)

DOI: https://escholarship.org/uc/item/43h0n4x3

Thesis Preclinical activity of the antibody-drug conjugate denintuzumab mafodotin (SGN-CD19A) against pediatric acute lymphoblastic leukemia xenografts

Jones, L; McCalmont, H; Evans, K et al. · 2019 · UNSW Sydney · DOI

Full title: Preclinical activity of the antibody-drug conjugate denintuzumab mafodotin (SGN-CD19A) against pediatric acute lymphoblastic leukemia xenografts

Authors: Jones, L; McCalmont, H; Evans, K; Mayoh, C ; https://orcid.org/0000-0002-6398-3046; Kurmasheva, RT; Billups, CA; Houghton, PJ; Smith, MA; Lock, RB ; https://orcid.org/0000-0002-3436-9071

Year: 2019

Venue: UNSW Sydney

DOI: http://hdl.handle.net/1959.4/unsworks_57907

Thesis Site-Selective Modification of Proteins with Oxetanes

Boutureira, O; Martínez-Sáez, N; Brindle, KM et al. · 2017 · University of Cambridge · DOI

Full title: Site-Selective Modification of Proteins with Oxetanes

Authors: Boutureira, O; Martínez-Sáez, N; Brindle, KM; Neves, AA; Corzana, F; Lopes Bernardes, GJ

Year: 2017

Venue: University of Cambridge

DOI: https://www.repository.cam.ac.uk/handle/1810/264048

Thesis The CD123 antibody–drug conjugate pivekimab sunirine exerts profound activity in preclinical models of pediatric acute lymphoblastic leukemia

Watts, B; Smith, CM; Evans, K et al. · 2025 · UNSW Sydney · DOI

Full title: The CD123 antibody–drug conjugate pivekimab sunirine exerts profound activity in preclinical models of pediatric acute lymphoblastic leukemia

Authors: Watts, B; Smith, CM; Evans, K; Gifford, AJ ; https://orcid.org/0000-0002-4092-2347; Mohamed, SMA ; https://orcid.org/0000-0001-9948-7979; Erickson, SW; Earley, EJ; Neuhauser, S; Stearns, TM; Philip, VM; Chuang, JH; Zweidler-McKay, PA; Lakshmikanthan, S; Jocoy, EL; Bult, CJ; Teicher, BA; Smith, MA; Lock, RB ; https://orcid.org/0000-0002-3436-9071

Year: 2025

Venue: UNSW Sydney

DOI: http://hdl.handle.net/1959.4/103944

Thesis Synthesis and Biological Evaluation of Homogeneous Thiol-Linked NHC*-Au-Albumin and -Trastuzumab Bioconjugates.

Matos, Maria J; Labão-Almeida, Carlos; Sayers, Claire et al. · 2018 · University of Cambridge · DOI

Full title: Synthesis and Biological Evaluation of Homogeneous Thiol-Linked NHC*-Au-Albumin and -Trastuzumab Bioconjugates.

Authors: Matos, Maria J; Labão-Almeida, Carlos; Sayers, Claire; Dada, Oyinlola; Tacke, Matthias; Bernardes, Gonçalo JL

Year: 2018

Venue: University of Cambridge

DOI: https://www.repository.cam.ac.uk/handle/1810/279328

Thesis A general approach for the site-selective modification of native proteins, enabling the generation of stable and functional antibody-drug conjugates.

Walsh, Stephen J; Omarjee, Soleilmane; Galloway, Warren RJD et al. · 2018 · University of Cambridge · DOI

Full title: A general approach for the site-selective modification of native proteins, enabling the generation of stable and functional antibody-drug conjugates.

Authors: Walsh, Stephen J; Omarjee, Soleilmane; Galloway, Warren RJD; Kwan, Terence T-L; Sore, Hannah F; Parker, Jeremy S; Hyvönen, Marko; Carroll, Jason S; Spring, David R

Year: 2018

Venue: University of Cambridge

DOI: https://www.repository.cam.ac.uk/handle/1810/287080

Thesis A fully human anti-IL-7Rα antibody promotes antitumor activity against T-cell acute lymphoblastic leukemia.

Akkapeddi, Padma; Fragoso, Rita; Hixon, Julie A et al. · 2019 · University of Cambridge · DOI

Full title: A fully human anti-IL-7Rα antibody promotes antitumor activity against T-cell acute lymphoblastic leukemia.

Authors: Akkapeddi, Padma; Fragoso, Rita; Hixon, Julie A; Ramalho, Ana Sofia; Oliveira, Mariana L; Carvalho, Tânia; Gloger, Andreas; Matasci, Mattia; Corzana, Francisco; Durum, Scott K; Neri, Dario; Bernardes, Gonçalo JL; Barata, João T

Year: 2019

Venue: University of Cambridge

DOI: https://www.repository.cam.ac.uk/handle/1810/290686

Thesis Single Mutation on Trastuzumab Modulates the Stability of Antibody-Drug Conjugates Built Using Acetal-Based Linkers and Thiol-Maleimide Chemistry.

Ferhati, Xhenti; Jiménez-Moreno, Ester; Hoyt, Emily A et al. · 2022 · University of Cambridge · DOI

Full title: Single Mutation on Trastuzumab Modulates the Stability of Antibody-Drug Conjugates Built Using Acetal-Based Linkers and Thiol-Maleimide Chemistry.

Authors: Ferhati, Xhenti; Jiménez-Moreno, Ester; Hoyt, Emily A; Salluce, Giulia; Cabeza-Cabrerizo, Mar; Navo, Claudio D; Compañón, Ismael; Akkapeddi, Padma; Matos, Maria J; Salaverri, Noelia; Garrido, Pablo; Martínez, Alfredo; Laserna, Víctor; Murray, Thomas V; Jiménez-Osés, Gonzalo; Ravn, Peter; Lopes Bernardes, Goncalo; Corzana, Francisco

Year: 2022

Venue: University of Cambridge

DOI: https://www.repository.cam.ac.uk/handle/1810/334784

Thesis Sulfatase-cleavable linkers for antibody-drug conjugates.

Bargh, Jonathan D; Walsh, Stephen J; Isidro-Llobet, Albert et al. · 2021 · University of Cambridge · DOI

Full title: Sulfatase-cleavable linkers for antibody-drug conjugates.

Authors: Bargh, Jonathan D; Walsh, Stephen J; Isidro-Llobet, Albert; Omarjee, Soleilmane; Carroll, Jason S; Spring, David R

Year: 2021

Venue: University of Cambridge

DOI: https://www.repository.cam.ac.uk/handle/1810/325434

Thesis In Vivo Pretargeting Based on Cysteine-Selective Antibody Modification with IEDDA Bioorthogonal Handles for Click Chemistry.

Ferreira, Vera FC; Oliveira, Bruno L; D'Onofrio, Alice et al. · 2020 · University of Cambridge · DOI

Full title: In Vivo Pretargeting Based on Cysteine-Selective Antibody Modification with IEDDA Bioorthogonal Handles for Click Chemistry.

Authors: Ferreira, Vera FC; Oliveira, Bruno L; D'Onofrio, Alice; Farinha, Carlos M; Gano, Lurdes; Paulo, António; Bernardes, Gonçalo JL; Mendes, Filipa

Year: 2020

Venue: University of Cambridge

DOI: https://www.repository.cam.ac.uk/handle/1810/314771

Thesis Controlled masking and targeted release of redox-cycling ortho-quinones via a C-C bond-cleaving 1,6-elimination.

Dunsmore, Lavinia; Navo, Claudio D; Becher, Julie et al. · 2022 · University of Cambridge · DOI

Full title: Controlled masking and targeted release of redox-cycling ortho-quinones via a C-C bond-cleaving 1,6-elimination.

Authors: Dunsmore, Lavinia; Navo, Claudio D; Becher, Julie; de Montes, Enrique Gil; Guerreiro, Ana; Hoyt, Emily; Brown, Libby; Zelenay, Viviane; Mikutis, Sigitas; Cooper, Jonathan; Barbieri, Isaia; Lawrinowitz, Stefanie; Siouve, Elise; Martin, Esther; Ruivo, Pedro R; Rodrigues, Tiago; da Cruz, Filipa P; Werz, Oliver; Vassiliou, George; Ravn, Peter; Jiménez-Osés, Gonzalo; Bernardes, Gonçalo JL

Year: 2022

Venue: University of Cambridge

DOI: https://www.repository.cam.ac.uk/handle/1810/339672

Thesis All-in-one disulfide bridging enables the generation of antibody conjugates with modular cargo loading.

Dannheim, Friederike M; Walsh, Stephen J; Orozco, Carolina T et al. · 2022 · University of Cambridge · DOI

Full title: All-in-one disulfide bridging enables the generation of antibody conjugates with modular cargo loading.

Authors: Dannheim, Friederike M; Walsh, Stephen J; Orozco, Carolina T; Hansen, Anders Højgaard; Bargh, Jonathan D; Jackson, Sophie E; Bond, Nicholas J; Parker, Jeremy S; Carroll, Jason S; Spring, David R

Year: 2022

Venue: University of Cambridge

DOI: https://www.repository.cam.ac.uk/handle/1810/341118

Thesis Mechanistic insights into the rational design of masked antibodies.

Orozco, Carolina T; Bersellini, Manuela; Irving, Lorraine M et al. · 2022 · University of Cambridge · DOI

Full title: Mechanistic insights into the rational design of masked antibodies.

Authors: Orozco, Carolina T; Bersellini, Manuela; Irving, Lorraine M; Howard, Wesley W; Hargreaves, David; Devine, Paul WA; Siouve, Elise; Browne, Gareth J; Bond, Nicholas J; Phillips, Jonathan J; Ravn, Peter; Jackson, Sophie E

Year: 2022

Venue: University of Cambridge

DOI: https://www.repository.cam.ac.uk/handle/1810/339932

Thesis Peroxide-cleavable linkers for antibody–drug conjugates †

Ashman, Nicola; Bargh, Jonathan D.; Walsh, Stephen J. et al. · 2023 · University of Cambridge · DOI

Full title: Peroxide-cleavable linkers for antibody–drug conjugates †

Authors: Ashman, Nicola; Bargh, Jonathan D.; Walsh, Stephen J.; Greenwood, Ryan D.; Tiberghien, Arnaud; Carroll, Jason S.; Spring, David R.; resid: K-2283-2016

Year: 2023

Venue: University of Cambridge

DOI: https://www.repository.cam.ac.uk/handle/1810/345781

Thesis Rapid and robust cysteine bioconjugation with vinylheteroarenes.

Seki, Hikaru; Walsh, Stephen J; Bargh, Jonathan D et al. · 2021 · University of Cambridge · DOI

Full title: Rapid and robust cysteine bioconjugation with vinylheteroarenes.

Authors: Seki, Hikaru; Walsh, Stephen J; Bargh, Jonathan D; Parker, Jeremy S; Carroll, Jason; Spring, David R

Year: 2021

Venue: University of Cambridge

DOI: https://www.repository.cam.ac.uk/handle/1810/327136

Thesis Cathepsin B Processing Is Required for the In Vivo Efficacy of Albumin-Drug Conjugates.

Bernardim, Barbara; Conde, João; Hakala, Tuuli et al. · 2024 · University of Cambridge · DOI

Full title: Cathepsin B Processing Is Required for the In Vivo Efficacy of Albumin-Drug Conjugates.

Authors: Bernardim, Barbara; Conde, João; Hakala, Tuuli; Becher, Julie B; Canzano, Mary; Vasco, Aldrin V; Knowles, Tuomas PJ; Cameron, Jason; Bernardes, Gonçalo JL

Year: 2024

Venue: University of Cambridge

DOI: https://www.repository.cam.ac.uk/handle/1810/364915

Thesis Is HER2-Low a New Clinical Entity or Merely a Biomarker for an Antibody Drug Conjugate?

Ko, Heidi; Previs, Rebecca A; Strickland, Kyle C et al. · 2024 · University of Cambridge · DOI

Full title: Is HER2-Low a New Clinical Entity or Merely a Biomarker for an Antibody Drug Conjugate?

Authors: Ko, Heidi; Previs, Rebecca A; Strickland, Kyle C; Klein, Jonathan; Caveney, Brian; Chiruzzi, Chiara; Eisenberg, Marcia; Severson, Eric A; Ramkissoon, Shakti; Saini, Kamal S

Year: 2024

Venue: University of Cambridge

DOI: https://www.repository.cam.ac.uk/handle/1810/364928

Thesis Expeditious Total Synthesis of Hemiasterlin through a Convergent Multicomponent Strategy and Its Use in Targeted Cancer Therapeutics

Charoenpattarapreeda, Jiraborrirak; Walsh, Stephen J; Carroll, Jason S et al. · 2020 · University of Cambridge · DOI

Full title: Expeditious Total Synthesis of Hemiasterlin through a Convergent Multicomponent Strategy and Its Use in Targeted Cancer Therapeutics

Authors: Charoenpattarapreeda, Jiraborrirak; Walsh, Stephen J; Carroll, Jason S; Spring, David R

Year: 2020

Venue: University of Cambridge

DOI: https://www.repository.cam.ac.uk/handle/1810/313569

Thesis Tuneable thiol exchange linkers for traceless drug release applications in prodrugs and ADCs †

Walther, Raoul; Park, Mahri; Ashman, Nicola et al. · 2024 · University of Cambridge · DOI

Full title: Tuneable thiol exchange linkers for traceless drug release applications in prodrugs and ADCs †

Authors: Walther, Raoul; Park, Mahri; Ashman, Nicola; Welch, Martin; Carroll, Jason S.; resid: K-2283-2016

Year: 2024

Venue: University of Cambridge

DOI: https://www.repository.cam.ac.uk/handle/1810/369847

Thesis A Platform for SpyCatcher Conjugation to Native Antibodies

Krajčovičová, Soňa; Wharton, Thomas; Driscoll, Claudia L et al. · 2025 · University of Cambridge · DOI

Full title: A Platform for SpyCatcher Conjugation to Native Antibodies

Authors: Krajčovičová, Soňa; Wharton, Thomas; Driscoll, Claudia L; King, Thomas A; Howarth, Mark R; Spring, David R

Year: 2025

Venue: University of Cambridge

DOI: https://www.repository.cam.ac.uk/handle/1810/384028

Thesis Divinylpyrimidine reagents generate antibody-drug conjugates with excellent in vivo efficacy and tolerability.

Walsh, Stephen J; Omarjee, Soleilmane; Dannheim, Friederike M et al. · 2023 · University of Cambridge · DOI

Full title: Divinylpyrimidine reagents generate antibody-drug conjugates with excellent in vivo efficacy and tolerability.

Authors: Walsh, Stephen J; Omarjee, Soleilmane; Dannheim, Friederike M; Couturier, Dominique-Laurent; Bexheti, Dorentina; Mendil, Lee; Cronshaw, Gemma; Fewster, Toby; Gregg, Charlotte; Brodie, Cara; Miller, Jodi L; Houghton, Richard; Carroll, Jason S; Spring, David R

Year: 2023

Venue: University of Cambridge

DOI: https://www.repository.cam.ac.uk/handle/1810/350669

Thesis Advances in the Release of Amide-Containing Molecules.

Wharton, Thomas; Spring, David R · 2025 · University of Cambridge · DOI

Full title: Advances in the Release of Amide-Containing Molecules.

Authors: Wharton, Thomas; Spring, David R

Year: 2025

Venue: University of Cambridge

DOI: https://www.repository.cam.ac.uk/handle/1810/379353

Thesis Disulfide re-bridging reagents for single-payload antibody-drug conjugates.

King, Thomas A; Walsh, Stephen J; Kapun, Mia et al. · 2023 · University of Cambridge · DOI

Full title: Disulfide re-bridging reagents for single-payload antibody-drug conjugates.

Authors: King, Thomas A; Walsh, Stephen J; Kapun, Mia; Wharton, Thomas; Krajcovicova, Sona; Glossop, Melanie S; Spring, David R

Year: 2023

Venue: University of Cambridge

DOI: https://www.repository.cam.ac.uk/handle/1810/355297

Thesis [2.2.1]Heterobicyclic Bromovinyl Sulfones for Thiol-Triggered Strategies in Linker Chemistry: Aza- vs Oxa-Norbornadienic Systems.

Carranza, Marina; Carmona, Ana T; Maya, Celia et al. · 2025 · University of Cambridge · DOI

Full title: [2.2.1]Heterobicyclic Bromovinyl Sulfones for Thiol-Triggered Strategies in Linker Chemistry: Aza- vs Oxa-Norbornadienic Systems.

Authors: Carranza, Marina; Carmona, Ana T; Maya, Celia; Gil de Montes, Enrique; Vasco, Aldrin V; Bernardes, Gonçalo JL; Moreno-Vargas, Antonio J

Year: 2025

Venue: University of Cambridge

DOI: https://www.repository.cam.ac.uk/handle/1810/390595

Thesis Insights from the bottom-up development of LGR5-targeting immunotherapeutics.

Mueller, Nico; de la Roche, Marc Andrew; de la Roche, Maike · 2025 · University of Cambridge · DOI

Full title: Insights from the bottom-up development of LGR5-targeting immunotherapeutics.

Authors: Mueller, Nico; de la Roche, Marc Andrew; de la Roche, Maike

Year: 2025

Venue: University of Cambridge

DOI: https://www.repository.cam.ac.uk/handle/1810/381716

Thesis Recent advances and perspectives in cancer drug design

Andricopulo, Adriano Defini · 2018 · Universidade de São Paulo – USP Digital Library · DOI

Full title: Recent advances and perspectives in cancer drug design

Authors: Andricopulo, Adriano Defini

Year: 2018

Venue: Universidade de São Paulo – USP Digital Library

DOI: https://doi.org/10.1590/0001-3765201820170823

Thesis Bridging Metals and Peptides: Introducing selectivity to transition metal complexes towards targeted cancer therapy

Truong, Dianna · 2021 · University of Auckland · DOI

Full title: Bridging Metals and Peptides: Introducing selectivity to transition metal complexes towards targeted cancer therapy

Authors: Truong, Dianna

Year: 2021

Venue: University of Auckland

DOI: https://hdl.handle.net/2292/57835

Thesis Conjugation Strategies of the Anticancer Ruthenium Complex Plecstatin-1 to Tumour-targeting Peptides using Cleavable and Non-cleavable Linkers

Kumar, Saawan · 2024 · University of Auckland · DOI

Full title: Conjugation Strategies of the Anticancer Ruthenium Complex Plecstatin-1 to Tumour-targeting Peptides using Cleavable and Non-cleavable Linkers

Authors: Kumar, Saawan

Year: 2024

Venue: University of Auckland

DOI: https://hdl.handle.net/2292/67465

Thesis Novel approaches for targeting the FGFR pathway in cancer to improve the therapeutic index

Ortega, Raquel · 2025 · University of Auckland · DOI

Full title: Novel approaches for targeting the FGFR pathway in cancer to improve the therapeutic index

Authors: Ortega, Raquel

Year: 2025

Venue: University of Auckland

DOI: https://hdl.handle.net/2292/73558

Thesis Novel Cleavable Linkers for Antibody-Drug Conjugate Targeted Cancer Therapy

Tong, Juliana T.W. · 2024 · University of Auckland · DOI

Full title: Novel Cleavable Linkers for Antibody-Drug Conjugate Targeted Cancer Therapy

Authors: Tong, Juliana T.W.

Year: 2024

Venue: University of Auckland

DOI: https://hdl.handle.net/2292/67548

Thesis Evaluation of nitroCBI prodrugs in models of pancreatic cancer and development of novel nitroCBI based ADCs

van Leeuwen, Wouter Franciscus · 2021 · University of Auckland · DOI

Full title: Evaluation of nitroCBI prodrugs in models of pancreatic cancer and development of novel nitroCBI based ADCs

Authors: van Leeuwen, Wouter Franciscus

Year: 2021

Venue: University of Auckland

DOI: https://hdl.handle.net/2292/56696

Thesis Exploiting Tumor-intrinsic Cues to Engineer Interleukin-12 for Cancer Immunotherapy

Mansurov, Aslan · 2021 · University of Chicago - Knowledge@UChicago · DOI

Full title: Exploiting Tumor-intrinsic Cues to Engineer Interleukin-12 for Cancer Immunotherapy

Authors: Mansurov, Aslan

Year: 2021

Venue: University of Chicago - Knowledge@UChicago

DOI: https://knowledge.uchicago.edu/record/3480/files/Mansurov_uchicago_0330D_16002.pdf

Thesis Development of acid-cleavable polymeric nano/microparticles for the delivery of therapeutics

Chan, Yannie Ka Yan · 2007 · UNSW Sydney · DOI

Full title: Development of acid-cleavable polymeric nano/microparticles for the delivery of therapeutics

Authors: Chan, Yannie Ka Yan

Year: 2007

Venue: UNSW Sydney

DOI: http://hdl.handle.net/1959.4/40442

Thesis Multivalent Polymer-peptide Therapeutics by Combinatorial Design

Li, Zihao; https://orcid.org/0000-0002-1723-5047 · 2022 · UNSW Sydney · DOI

Full title: Multivalent Polymer-peptide Therapeutics by Combinatorial Design

Authors: Li, Zihao ; https://orcid.org/0000-0002-1723-5047

Year: 2022

Venue: UNSW Sydney

DOI: http://hdl.handle.net/1959.4/100471

Thesis Design of antibody-polymer conjugates for immunotherapy: the influence of polymer structure on the antibody's activity.

Melodia, Daniele · 2022 · UNSW Sydney · DOI

Full title: Design of antibody-polymer conjugates for immunotherapy: the influence of polymer structure on the antibody's activity.

Authors: Melodia, Daniele

Year: 2022

Venue: UNSW Sydney

DOI: http://hdl.handle.net/1959.4/100630

Thesis Modular nanoparticle drug delivery systems for treating multiple types of cancer

Chang, David · 2020 · UNSW Sydney · DOI

Full title: Modular nanoparticle drug delivery systems for treating multiple types of cancer

Authors: Chang, David

Year: 2020

Venue: UNSW Sydney

DOI: http://hdl.handle.net/1959.4/69713

Thesis Cell-targeting peptides for selective drug delivery to tumour cells

Tjandra, Kristel · 2018 · UNSW Sydney · DOI

Full title: Cell-targeting peptides for selective drug delivery to tumour cells

Authors: Tjandra, Kristel

Year: 2018

Venue: UNSW Sydney

DOI: http://hdl.handle.net/1959.4/61937

Thesis The Development of Divinyl-Heteroaryl Linkers for the Synthesis of Stable and Functional Antibody-Drug Conjugates

Walsh, Stephen · 2019 · University of Cambridge · DOI

Full title: The Development of Divinyl-Heteroaryl Linkers for the Synthesis of Stable and Functional Antibody-Drug Conjugates

Authors: Walsh, Stephen

Year: 2019

Venue: University of Cambridge

DOI: https://www.repository.cam.ac.uk/handle/1810/297916

Thesis The Potential of Cellulose Nanocrystals in the Detection and Treatment of Cancer

Colacino, Katelyn · 2015 · Virginia Tech - VTechWorks · DOI

Full title: The Potential of Cellulose Nanocrystals in the Detection and Treatment of Cancer

Authors: Colacino, Katelyn

Year: 2015

Venue: Virginia Tech - VTechWorks

DOI: http://hdl.handle.net/10919/51212

Thesis Metal Mediated Mechanisms of Drug Release

Stenton, Benjamin James · 2018 · University of Cambridge · DOI

Full title: Metal Mediated Mechanisms of Drug Release

Authors: Stenton, Benjamin James

Year: 2018

Venue: University of Cambridge

DOI: https://www.repository.cam.ac.uk/handle/1810/284402

Thesis Designed analogues of the aplyronines for use in antibody-drug conjugates

Porter, Rachel Jayne · 2019 · University of Cambridge · DOI

Full title: Designed analogues of the aplyronines for use in antibody-drug conjugates

Authors: Porter, Rachel Jayne

Year: 2019

Venue: University of Cambridge

DOI: https://www.repository.cam.ac.uk/handle/1810/298168

Thesis Exploration of novel linker scaffolds enabling the simultaneous rebridging of disulfide bonds for the synthesis of antibody-drug conjugates

King, Thomas · 2023 · University of Cambridge · DOI

Full title: Exploration of novel linker scaffolds enabling the simultaneous rebridging of disulfide bonds for the synthesis of antibody-drug conjugates

Authors: King, Thomas

Year: 2023

Venue: University of Cambridge

DOI: https://www.repository.cam.ac.uk/handle/1810/355950

Thesis One-Carbon Bridge Stapling for use in Peptide-Drug Conjugates

Cooper, Bethany · 2022 · University of Cambridge · DOI

Full title: One-Carbon Bridge Stapling for use in Peptide-Drug Conjugates

Authors: Cooper, Bethany

Year: 2022

Venue: University of Cambridge

DOI: https://www.repository.cam.ac.uk/handle/1810/343871

Thesis The Development of a Tumour-Responsive Format for Antibody Conjugates

Counsell, Andrew · 2024 · University of Cambridge · DOI

Full title: The Development of a Tumour-Responsive Format for Antibody Conjugates

Authors: Counsell, Andrew

Year: 2024

Venue: University of Cambridge

DOI: https://www.repository.cam.ac.uk/handle/1810/362896

Thesis Single-Payload Bioconjugation to Native Antibodies And A General Method for the Self-Immolative Release of Amide-Containing Molecules

Wharton, Thomas · 2025 · University of Cambridge · DOI

Full title: Single-Payload Bioconjugation to Native Antibodies And A General Method for the Self-Immolative Release of Amide-Containing Molecules

Authors: Wharton, Thomas

Year: 2025

Venue: University of Cambridge

DOI: https://www.repository.cam.ac.uk/handle/1810/378310

Thesis T cell-redirecting therapies in hematological malignancies: Current developments and novel strategies for improved targeting.

Anderson, Georgina SF; Chapman, Michael A · 2025 · University of Cambridge · DOI

Full title: T cell-redirecting therapies in hematological malignancies: Current developments and novel strategies for improved targeting.

Authors: Anderson, Georgina SF; Chapman, Michael A

Year: 2025

Venue: University of Cambridge

DOI: https://www.repository.cam.ac.uk/handle/1810/378647

Thesis Engineering all-in-one protein-based nanoparticles for targeted cancer therapies

Sánchez García, Laura · 2019 · Universitat Autònoma de Barcelona (TDX) · DOI

Full title: Engineering all-in-one protein-based nanoparticles for targeted cancer therapies

Authors: Sánchez García, Laura

Year: 2019

Venue: Universitat Autònoma de Barcelona (TDX)

DOI: http://hdl.handle.net/10803/667195

Thesis Development of antibody-based antitumor therapies based on Trastuzumab: antibody-drug conjugates, immunocytokines and fragment conjugates

Miret Minard, Joan · 2020 · Universitat Autònoma de Barcelona (TDX) · DOI

Full title: Development of antibody-based antitumor therapies based on Trastuzumab: antibody-drug conjugates, immunocytokines and fragment conjugates

Authors: Miret Minard, Joan

Year: 2020

Venue: Universitat Autònoma de Barcelona (TDX)

DOI: http://hdl.handle.net/10803/669342

Thesis Exploring the Dysregulation of Iron Metabolism in Cancer: Leveraging Fenton Chemistry for Selective Drug Delivery

Spangler, Benjamin · 2015 · University of California, San Francisco (UCSF) · DOI

Full title: Exploring the Dysregulation of Iron Metabolism in Cancer: Leveraging Fenton Chemistry for Selective Drug Delivery

Authors: Spangler, Benjamin

Year: 2015

Venue: University of California, San Francisco (UCSF)

DOI: https://escholarship.org/uc/item/0tr3v78n

Thesis Passerini multicomponent reaction: a versatile synthesis of nanomedicines for triple negative breast cancer treatment

Travanut, Alessandra · 2021 · University of Nottingham · DOI

Full title: Passerini multicomponent reaction: a versatile synthesis of nanomedicines for triple negative breast cancer treatment

Authors: Travanut, Alessandra

Year: 2021

Venue: University of Nottingham

DOI: https://eprints.nottingham.ac.uk/64610/1/AT%20Corrected%20Thesis%20Feb%2021.pdf

Thesis Development of novel bispecific antibody modalities for targeted degradation and anti-viral therapeutic applications

Pance, Katarina · 2021 · University of California, San Francisco (UCSF) · DOI

Full title: Development of novel bispecific antibody modalities for targeted degradation and anti-viral therapeutic applications

Authors: Pance, Katarina

Year: 2021

Venue: University of California, San Francisco (UCSF)

DOI: https://escholarship.org/uc/item/2130p0m7

Thesis DNA Programmed Assembly of Proteins: Applications in Antibody Engineering and Epidermal Growth Factor Receptor Signaling

Liang, Samantha Isabel · 2016 · University of California, San Francisco (UCSF) · DOI

Full title: DNA Programmed Assembly of Proteins: Applications in Antibody Engineering and Epidermal Growth Factor Receptor Signaling

Authors: Liang, Samantha Isabel

Year: 2016

Venue: University of California, San Francisco (UCSF)

DOI: https://escholarship.org/uc/item/3w5002f1

Thesis Developing Covalent Biologics through Genetic Code Expansion for Cancer Therapeutics

Klauser, Paul Chuang · 2023 · University of California, San Francisco (UCSF) · DOI

Full title: Developing Covalent Biologics through Genetic Code Expansion for Cancer Therapeutics

Authors: Klauser, Paul Chuang

Year: 2023

Venue: University of California, San Francisco (UCSF)

DOI: https://escholarship.org/uc/item/4h4104s0

Thesis Utilizing bio-conjugation and protein engineering to develop enhanced cancer therapeutics, viral diagnostics, and biochemical tools

Elledge, Susanna Kuroda · 2022 · University of California, San Francisco (UCSF) · DOI

Full title: Utilizing bio-conjugation and protein engineering to develop enhanced cancer therapeutics, viral diagnostics, and biochemical tools

Authors: Elledge, Susanna Kuroda

Year: 2022

Venue: University of California, San Francisco (UCSF)

DOI: https://escholarship.org/uc/item/6f066638

Thesis Development of novel folate receptor (FR)-targeted indenoisoquinoline drug delivery systems (DDSs) using acid sensitive N-Ethoxybenzylimidazole (NEBI) crosslinkers for anti-cancer therapy /

Cao, Yuchen Z. · 2014 · University of California, San Diego (UCSD) · DOI

Full title: Development of novel folate receptor (FR)-targeted indenoisoquinoline drug delivery systems (DDSs) using acid sensitive N-Ethoxybenzylimidazole (NEBI) crosslinkers for anti-cancer therapy /

Authors: Cao, Yuchen Z.

Year: 2014

Venue: University of California, San Diego (UCSD)

DOI: https://escholarship.org/uc/item/0vs1n74d

Thesis Delivery of RNAi Therapeutics: Building Multifunctional RNAi Triggers for Extra-Hepatic Targeting and Endosomal Escape

Springer, Aaron David · 2019 · University of California, San Diego (UCSD) · DOI

Full title: Delivery of RNAi Therapeutics: Building Multifunctional RNAi Triggers for Extra-Hepatic Targeting and Endosomal Escape

Authors: Springer, Aaron David

Year: 2019

Venue: University of California, San Diego (UCSD)

DOI: https://escholarship.org/uc/item/2fr5b3tj

Thesis Development of acid-sensitive N-ethoxybenzylimidazoles for use as linkers in drug delivery systems

Luong, Alice · 2011 · University of California, San Diego (UCSD) · DOI

Full title: Development of acid-sensitive N-ethoxybenzylimidazoles for use as linkers in drug delivery systems

Authors: Luong, Alice

Year: 2011

Venue: University of California, San Diego (UCSD)

DOI: https://escholarship.org/uc/item/6th9r5v5

Thesis Expanding the Antibody Toolbox

Cotton, Adam David · 2021 · University of California, San Francisco (UCSF) · DOI

Full title: Expanding the Antibody Toolbox

Authors: Cotton, Adam David

Year: 2021

Venue: University of California, San Francisco (UCSF)

DOI: https://escholarship.org/uc/item/52s0h9h3

Thesis Investigation of the Enhancement of Drug Synergy by Co-Delivery in Targeted Liposomes

Riviere, Kareen · 2009 · University of California, San Francisco (UCSF) · DOI

Full title: Investigation of the Enhancement of Drug Synergy by Co-Delivery in Targeted Liposomes

Authors: Riviere, Kareen

Year: 2009

Venue: University of California, San Francisco (UCSF)

DOI: https://escholarship.org/uc/item/8753p1pf

Thesis Development of Antibody-RNA Conjugates for Targets Beyond the Liver

Medina, Carlos · 2021 · University of California, San Diego (UCSD) · DOI

Full title: Development of Antibody-RNA Conjugates for Targets Beyond the Liver

Authors: Medina, Carlos

Year: 2021

Venue: University of California, San Diego (UCSD)

DOI: https://escholarship.org/uc/item/6sw099fd

Thesis Targeted Drug Delivery via Exploitation of the Tumor Microenvironment

Callmann, Cassandra Elizabeth · 2018 · University of California, San Diego (UCSD) · DOI

Full title: Targeted Drug Delivery via Exploitation of the Tumor Microenvironment

Authors: Callmann, Cassandra Elizabeth

Year: 2018

Venue: University of California, San Diego (UCSD)

DOI: https://escholarship.org/uc/item/8cj741hm

Thesis Protease-Gated Programmable Fusogenic Nano-Encapsulations for Spatially Selective Targeted Delivery

Mathur, Vineet Keshav · 2025 · University of California, San Francisco (UCSF) · DOI

Full title: Protease-Gated Programmable Fusogenic Nano-Encapsulations for Spatially Selective Targeted Delivery

Authors: Mathur, Vineet Keshav

Year: 2025

Venue: University of California, San Francisco (UCSF)

DOI: https://escholarship.org/uc/item/7cs7291d

Thesis Receptor-Mediated Targeting to Enhance Therapeutic Efficacy of Chemotherapeutic Agents

Shah, Kush · 2014 · OhioLINK Electronic Theses and Dissertations · DOI

Full title: Receptor-Mediated Targeting to Enhance Therapeutic Efficacy of Chemotherapeutic Agents

Authors: Shah, Kush

Year: 2014

Venue: OhioLINK Electronic Theses and Dissertations

DOI: http://rave.ohiolink.edu/etdc/view?acc_num=akron1390926627

Thesis Approaches to prostate cancer imaging and therapy: the use of pharmacokinetics, metabolism and biodistribution to identify new drugs

Yang, Jun · 2005 · OhioLINK Electronic Theses and Dissertations · DOI

Full title: Approaches to prostate cancer imaging and therapy: the use of pharmacokinetics, metabolism and biodistribution to identify new drugs

Authors: Yang, Jun

Year: 2005

Venue: OhioLINK Electronic Theses and Dissertations

DOI: http://rave.ohiolink.edu/etdc/view?acc_num=osu1133362520

Thesis Activatable cell penetrating peptides and their use in clinical contrast agent and therapeutic development

Aguilera, Todd Anthony · 2009 · University of California, San Diego (UCSD) · DOI

Full title: Activatable cell penetrating peptides and their use in clinical contrast agent and therapeutic development

Authors: Aguilera, Todd Anthony

Year: 2009

Venue: University of California, San Diego (UCSD)

DOI: https://escholarship.org/uc/item/9871p905

Thesis The pharmacokinetics of adriamycin and side chain elimination and the pharmacokinetics of cytembena following oral administration /

Chow, Wing Sun · 1980 · OhioLINK Electronic Theses and Dissertations · DOI

Full title: The pharmacokinetics of adriamycin and side chain elimination and the pharmacokinetics of cytembena following oral administration /

Authors: Chow, Wing Sun

Year: 1980

Venue: OhioLINK Electronic Theses and Dissertations

DOI: http://rave.ohiolink.edu/etdc/view?acc_num=osu1487094144435427

Thesis An integrated system for tumor detection and target drug therapy of colorectal cancers with a humanized tumor targeting antibody, HuCC49ÄCH2

Fang, Lanyan · 2007 · OhioLINK Electronic Theses and Dissertations · DOI

Full title: An integrated system for tumor detection and target drug therapy of colorectal cancers with a humanized tumor targeting antibody, HuCC49ÄCH2

Authors: Fang, Lanyan

Year: 2007

Venue: OhioLINK Electronic Theses and Dissertations

DOI: http://rave.ohiolink.edu/etdc/view?acc_num=osu1173905544

Thesis Novel payloads for immunotoxin-based treatment of neuroblastoma

Rust, Aleksander · 2016 · White Rose eTheses (Leeds, Sheffield, York) · DOI

Full title: Novel payloads for immunotoxin-based treatment of neuroblastoma

Authors: Rust, Aleksander

Year: 2016

Venue: White Rose eTheses (Leeds, Sheffield, York)

DOI: https://etheses.whiterose.ac.uk/id/eprint/16990/1/Aleksander_Rust_120252613_Thesis.pdf

Thesis Synthesis of Agents Targeting Cancer Cells While Reducing MDR Liability

El-Dakdouki, Mohammad H. · 2009 · OhioLINK Electronic Theses and Dissertations · DOI

Full title: Synthesis of Agents Targeting Cancer Cells While Reducing MDR Liability

Authors: El-Dakdouki, Mohammad H.

Year: 2009

Venue: OhioLINK Electronic Theses and Dissertations

DOI: http://rave.ohiolink.edu/etdc/view?acc_num=toledo1259679671

Thesis Targeted delivery of anti-cancer drugs by MS2 virus-like particles

Yan, Ruiyang · 2015 · White Rose eTheses (Leeds, Sheffield, York) · DOI

Full title: Targeted delivery of anti-cancer drugs by MS2 virus-like particles

Authors: Yan, Ruiyang

Year: 2015

Venue: White Rose eTheses (Leeds, Sheffield, York)

DOI: https://etheses.whiterose.ac.uk/id/eprint/8989/1/PhD%20Thesis%20%20Yan%20R%202015.pdf

Thesis Design, Synthesis and Biological Evaluation of New Molecules to Selectively Target Specific Cancers

Premnauth, Gurdat · 2020 · OhioLINK Electronic Theses and Dissertations · DOI

Full title: Design, Synthesis and Biological Evaluation of New Molecules to Selectively Target Specific Cancers

Authors: Premnauth, Gurdat

Year: 2020

Venue: OhioLINK Electronic Theses and Dissertations

DOI: http://rave.ohiolink.edu/etdc/view?acc_num=ucin1613744938434214

Thesis Development of Doxorubicin Prodrugs for Targeted and Responsive Cancer Therapy

Jafari, Mina · 2022 · OhioLINK Electronic Theses and Dissertations · DOI

Full title: Development of Doxorubicin Prodrugs for Targeted and Responsive Cancer Therapy

Authors: Jafari, Mina

Year: 2022

Venue: OhioLINK Electronic Theses and Dissertations

DOI: http://rave.ohiolink.edu/etdc/view?acc_num=ucin1668635232339841

Thesis The targeted delivery of G3 peptide drug conjugates in prostate cancer

Martinez Andrade, Gisela · 2023 · White Rose eTheses (Leeds, Sheffield, York) · DOI

Full title: The targeted delivery of G3 peptide drug conjugates in prostate cancer

Authors: Martinez Andrade, Gisela

Year: 2023

Venue: White Rose eTheses (Leeds, Sheffield, York)

DOI: https://etheses.whiterose.ac.uk/id/eprint/33963/1/Gisela%20Martinez-Andrade%20Thesis%20PhD.pdf

Thesis Characterisation of HER2 binding Affimer drug conjugates in 2D and 3D cell culture

Roberts, Sophie Elizabeth · 2020 · White Rose eTheses (Leeds, Sheffield, York) · DOI

Full title: Characterisation of HER2 binding Affimer drug conjugates in 2D and 3D cell culture

Authors: Roberts, Sophie Elizabeth

Year: 2020

Venue: White Rose eTheses (Leeds, Sheffield, York)

DOI: https://etheses.whiterose.ac.uk/id/eprint/27897/1/Corrected%20Thesis.pdf

Thesis INVESTIGATION OF LIGAND SIZE ON TARGETED PLGA NANOPARTICLES FOR HER2 BREAST CANCER: TRASTUZUMAB AND ITS ScFv ANTI-HER2 ANTIBODY

Zagzoog, Ayat H 1990- · 2018 · University of Saskatchewan - HARVEST · DOI

Full title: INVESTIGATION OF LIGAND SIZE ON TARGETED PLGA NANOPARTICLES FOR HER2 BREAST CANCER: TRASTUZUMAB AND ITS ScFv ANTI-HER2 ANTIBODY

Authors: Zagzoog, Ayat H 1990-

Year: 2018

Venue: University of Saskatchewan - HARVEST

DOI: http://hdl.handle.net/10388/8622

Thesis Development and preclinical evaluation of theranostic agents targeting muc16/ca125 and nectin-4 expression in breast, ovarian and pancreatic cancers

Babeker, Hanan · 2023 · University of Saskatchewan - HARVEST · DOI

Full title: Development and preclinical evaluation of theranostic agents targeting muc16/ca125 and nectin-4 expression in breast, ovarian and pancreatic cancers

Authors: Babeker, Hanan

Year: 2023

Venue: University of Saskatchewan - HARVEST

DOI: https://hdl.handle.net/10388/15068

Thesis Developing protein conjugation techniques to enhance cell delivery of therapeutic enzymes

Hart, R J · 2017 · White Rose eTheses (Leeds, Sheffield, York) · DOI

Full title: Developing protein conjugation techniques to enhance cell delivery of therapeutic enzymes

Authors: Hart, R J

Year: 2017

Venue: White Rose eTheses (Leeds, Sheffield, York)

DOI: https://etheses.whiterose.ac.uk/id/eprint/18996/1/Rose%20Hart%20final%20thesis.pdf

Thesis Drug-conjugated biopolymers as osteosarcoma and rheumatoid arthritis therapeutics

Perkins, Ethan Dickson · 2020 · White Rose eTheses (Leeds, Sheffield, York) · DOI

Full title: Drug-conjugated biopolymers as osteosarcoma and rheumatoid arthritis therapeutics

Authors: Perkins, Ethan Dickson

Year: 2020

Venue: White Rose eTheses (Leeds, Sheffield, York)

DOI: https://etheses.whiterose.ac.uk/id/eprint/28785/1/Perkins_ED_Dentistry_PhD_2020.pdf

Thesis Příprava anti-CD20 vazebné domény a její konjugace na polymerní nosič

Cibiková, Tereza · 2024 · Charles University Prague (Univerzita Karlova) · DOI

Full title: Příprava anti-CD20 vazebné domény a její konjugace na polymerní nosič

Authors: Cibiková, Tereza

Year: 2024

Venue: Charles University Prague (Univerzita Karlova)

DOI: http://hdl.handle.net/20.500.11956/190552

Thesis Development and Evaluation of Novel Anti-HER2 Theranostics Against HER2-Positive Breast Cancer

Pougoue Ketchemen, Jessica · 2024 · University of Saskatchewan - HARVEST · DOI

Full title: Development and Evaluation of Novel Anti-HER2 Theranostics Against HER2-Positive Breast Cancer

Authors: Pougoue Ketchemen, Jessica

Year: 2024

Venue: University of Saskatchewan - HARVEST

DOI: https://hdl.handle.net/10388/16064

Thesis Development of targeted radioimmunotherapy for osteosarcoma using a comparative oncology approach

Prabaharan, Chandra Bose · 2024 · University of Saskatchewan - HARVEST · DOI

Full title: Development of targeted radioimmunotherapy for osteosarcoma using a comparative oncology approach

Authors: Prabaharan, Chandra Bose

Year: 2024

Venue: University of Saskatchewan - HARVEST

DOI: https://hdl.handle.net/10388/15501

Thesis Surface Functionalization of Nanocarriers with Anti-EGFR Ligands for Cancer Active Targeting

Spada, Alessandra; Gerber-Lemaire, Sandrine · 2025 · École polytechnique fédérale de Lausanne (EPFL) · DOI

Full title: Surface Functionalization of Nanocarriers with Anti-EGFR Ligands for Cancer Active Targeting

Authors: Spada, Alessandra; Gerber-Lemaire, Sandrine

Year: 2025

Venue: École polytechnique fédérale de Lausanne (EPFL)

DOI: https://infoscience.epfl.ch/handle/20.500.14299/247110

Thesis Syntéza, charakterizace a studium vlastností funkčních konjugátů protilátek

Stránská, Andrea · 2024 · Charles University Prague (Univerzita Karlova) · DOI

Full title: Syntéza, charakterizace a studium vlastností funkčních konjugátů protilátek

Authors: Stránská, Andrea

Year: 2024

Venue: Charles University Prague (Univerzita Karlova)

DOI: http://hdl.handle.net/20.500.11956/190586

Thesis Použití imunomodulace pro potenciaci chemoterapie polymerními cytostatiky

Chmelová, Helena · 2017 · Charles University Prague (Univerzita Karlova) · DOI

Full title: Použití imunomodulace pro potenciaci chemoterapie polymerními cytostatiky

Authors: Chmelová, Helena

Year: 2017

Venue: Charles University Prague (Univerzita Karlova)

DOI: http://hdl.handle.net/20.500.11956/24851

Thesis Development of cysteine cathepsin inhibitors combined with cell type-specific delivery for the treatment of B-cell lymphoma and solid tumors

Petruzzella, Aaron Simone · 2024 · École polytechnique fédérale de Lausanne (EPFL) · DOI

Full title: Development of cysteine cathepsin inhibitors combined with cell type-specific delivery for the treatment of B-cell lymphoma and solid tumors

Authors: Petruzzella, Aaron Simone

Year: 2024

Venue: École polytechnique fédérale de Lausanne (EPFL)

DOI: https://infoscience.epfl.ch/handle/20.500.14299/207552

Thesis Dendrimer-Mediated Targeted Immunotherapies for the Treatment of Glioblastoma

Liaw, Kevin · 2020 · Johns Hopkins University · DOI

Full title: Dendrimer-Mediated Targeted Immunotherapies for the Treatment of Glioblastoma

Authors: Liaw, Kevin

Year: 2020

Venue: Johns Hopkins University

DOI: http://jhir.library.jhu.edu/handle/1774.2/62520

Thesis ALPHA-PARTICLE NANOTHERAPEUTICS AGAINST METASTATIC AND/OR CHEMORESISTANT TRIPLE NEGATIVE BREAST CANCER

Prasad, Aprameya Ganesh · 2022 · Johns Hopkins University · DOI

Full title: ALPHA-PARTICLE NANOTHERAPEUTICS AGAINST METASTATIC AND/OR CHEMORESISTANT TRIPLE NEGATIVE BREAST CANCER

Authors: Prasad, Aprameya Ganesh

Year: 2022

Venue: Johns Hopkins University

DOI: http://jhir.library.jhu.edu/handle/1774.2/67067

Thesis Mechanistic Studies of the Transcription Inhibitor Triptolide and its Selective Targeting to Cancer Cells under Hypoxia

Datan, Emmanuel · 2020 · Johns Hopkins University · DOI

Full title: Mechanistic Studies of the Transcription Inhibitor Triptolide and its Selective Targeting to Cancer Cells under Hypoxia

Authors: Datan, Emmanuel

Year: 2020

Venue: Johns Hopkins University

DOI: http://jhir.library.jhu.edu/handle/1774.2/62440

Thesis Computational Systems Pharmacology of Antibody-Drug Conjugates

Lam, Inez · 2025 · Johns Hopkins University · DOI

Full title: Computational Systems Pharmacology of Antibody-Drug Conjugates

Authors: Lam, Inez

Year: 2025

Venue: Johns Hopkins University

DOI: https://jscholarship.library.jhu.edu/handle/1774.2/70242

Thesis uSPIO-based Nanocarrier for Pretargeted, PET-MR Image-Guided Delivery

Si, Ge · 2023 · Johns Hopkins University · DOI

Full title: uSPIO-based Nanocarrier for Pretargeted, PET-MR Image-Guided Delivery

Authors: Si, Ge

Year: 2023

Venue: Johns Hopkins University

DOI: http://jhir.library.jhu.edu/handle/1774.2/68934

Thesis Antibody⇓drug conjugates for cancer therapy

Hafeez, U; Parakh, S; Gan, HK et al. · 2020 · University of Melbourne · DOI

Full title: Antibody⇓drug conjugates for cancer therapy

Authors: Hafeez, U; Parakh, S; Gan, HK; Scott, AM

Year: 2020

Venue: University of Melbourne

DOI: https://hdl.handle.net/11343/251739

Thesis Synthese und Charakterisierung eines synthetischen Antikörpers

Brehs, Manuel · 2015 · Technical University of Munich · DOI

Full title: Synthese und Charakterisierung eines synthetischen Antikörpers

Authors: Brehs, Manuel

Year: 2015

Venue: Technical University of Munich

DOI: https://mediatum.ub.tum.de/1096320

Thesis Synthesis and biological properties of cytotoxic lectin conjugates

Ma, Long · 2007 · University of Liverpool · DOI

Full title: Synthesis and biological properties of cytotoxic lectin conjugates

Authors: Ma, Long

Year: 2007

Venue: University of Liverpool

DOI: https://livrepository.liverpool.ac.uk/3186170/1/33081293.pdf

Thesis Targeting cancer therapy: using protease cleavage sequences to develop more selective and effective cancer treatments

Basel, Matthew T. · 2012 · Kansas State University - K-REx · DOI

Full title: Targeting cancer therapy: using protease cleavage sequences to develop more selective and effective cancer treatments

Authors: Basel, Matthew T.

Year: 2012

Venue: Kansas State University - K-REx

DOI: http://hdl.handle.net/2097/14087

Thesis Radioimmunotherapy of Metastatic Disease - Studies of Alpha- and Beta-particle-Emitting Radionuclides in a Preclinical Model

Eriksson, Sophie · 2013 · Lund University (LUP) · DOI

Full title: Radioimmunotherapy of Metastatic Disease - Studies of Alpha- and Beta-particle-Emitting Radionuclides in a Preclinical Model

Authors: Eriksson, Sophie

Year: 2013

Venue: Lund University (LUP)

DOI: https://lup.lub.lu.se/record/3732513

Thesis Structural modifications of PSMA ligands to optimize their pharmacokinetics

Schmidt, Alexander · 2018 · Technical University of Munich (TUM) · DOI

Full title: Structural modifications of PSMA ligands to optimize their pharmacokinetics

Authors: Schmidt, Alexander

Year: 2018

Venue: Technical University of Munich (TUM)

DOI: https://mediatum.ub.tum.de/1375257

Thesis In vitro Untersuchungen des zytotoxischen Effekts der alpha-emittierenden Nuklide 213Bi, 149Tb und 225Ac gekoppelt an monoklonale Antikörper und Bewertung der physikalischen und biologischen Eigenschaften der Nuklide und Antikörper

Miederer, Matthias · 2005 · Technical University of Munich · DOI

Full title: In vitro Untersuchungen des zytotoxischen Effekts der alpha-emittierenden Nuklide 213Bi, 149Tb und 225Ac gekoppelt an monoklonale Antikörper und Bewertung der physikalischen und biologischen Eigenschaften der Nuklide und Antikörper

Authors: Miederer, Matthias

Year: 2005

Venue: Technical University of Munich

DOI: https://mediatum.ub.tum.de/602174

Thesis Rational design of targeted drug delivery devices for enhancing therapeutic potential of anticancer agents through bioorthogonal reactions

Hudlikar, Manish Satish · 2025 · University of Georgia - UGA Open Scholar · DOI

Full title: Rational design of targeted drug delivery devices for enhancing therapeutic potential of anticancer agents through bioorthogonal reactions

Authors: Hudlikar, Manish Satish

Year: 2025

Venue: University of Georgia - UGA Open Scholar

DOI: https://openscholar.uga.edu/record/26848/files/hudlikar_manish_s_201712_phd.pdf

Thesis Development of SNAP-tag based fusion proteins as novel auristatin F-containing immunoconjugates and photoimmunotheranostics in the detection and treatment of triple-negative breast cancer

Mungra, Neelakshi · 2022 · University of Cape Town · DOI

Full title: Development of SNAP-tag based fusion proteins as novel auristatin F-containing immunoconjugates and photoimmunotheranostics in the detection and treatment of triple-negative breast cancer

Authors: Mungra, Neelakshi

Year: 2022

Venue: University of Cape Town

DOI: http://hdl.handle.net/11427/36825

Thesis Rational Design of Responsive Prodrug-based Nanomedicines for Antitumor Therapy

Nagel, Gregor · 2019 · Freie Universität Berlin (Refubium) · DOI

Full title: Rational Design of Responsive Prodrug-based Nanomedicines for Antitumor Therapy

Authors: Nagel, Gregor

Year: 2019

Venue: Freie Universität Berlin (Refubium)

DOI: https://refubium.fu-berlin.de/handle/fub188/26054

Thesis Efficacy of dianthin-based targeted toxins in a pancreatic carcinoma xenograft model

Bhargava, Cheenu · 2017 · Freie Universität Berlin (Refubium) · DOI

Full title: Efficacy of dianthin-based targeted toxins in a pancreatic carcinoma xenograft model

Authors: Bhargava, Cheenu

Year: 2017

Venue: Freie Universität Berlin (Refubium)

DOI: https://refubium.fu-berlin.de/handle/fub188/1854

Thesis Design and generation of antibody-drug conjugates using non-canonical amino acids

Rakotoarinoro, Nathanaël · 2023 · Freie Universität Berlin (Refubium) · DOI

Full title: Design and generation of antibody-drug conjugates using non-canonical amino acids

Authors: Rakotoarinoro, Nathanaël

Year: 2023

Venue: Freie Universität Berlin (Refubium)

DOI: https://refubium.fu-berlin.de/handle/fub188/42224

Thesis Kombinationstherapie von Anti-Tumor-Toxinen und Reinsaponinen am Maus- Tumormodell

Mallinckrodt, Benedicta-Leonie von · 2015 · Freie Universität Berlin (Refubium) · DOI

Full title: Kombinationstherapie von Anti-Tumor-Toxinen und Reinsaponinen am Maus- Tumormodell

Authors: Mallinckrodt, Benedicta-Leonie von

Year: 2015

Venue: Freie Universität Berlin (Refubium)

DOI: https://refubium.fu-berlin.de/handle/fub188/13069

Thesis Charakterisierung zielgerichteter Fusionsproteine und Etablierung eines murinen Kolonkarzinom-Modells für die Antibody-directed Enzyme Prodrug Therapy

Schellmann, Nicole · 2013 · Freie Universität Berlin (Refubium) · DOI

Full title: Charakterisierung zielgerichteter Fusionsproteine und Etablierung eines murinen Kolonkarzinom-Modells für die Antibody-directed Enzyme Prodrug Therapy

Authors: Schellmann, Nicole

Year: 2013

Venue: Freie Universität Berlin (Refubium)

DOI: https://refubium.fu-berlin.de/handle/fub188/6628

Thesis Elucidating the potential of IgA antibodies for cancer immunotherapy

Hart, Felix Andreas Wolfgang · 2016 · Freie Universität Berlin (Refubium) · DOI

Full title: Elucidating the potential of IgA antibodies for cancer immunotherapy

Authors: Hart, Felix Andreas Wolfgang

Year: 2016

Venue: Freie Universität Berlin (Refubium)

DOI: https://refubium.fu-berlin.de/handle/fub188/401

Thesis Development of a platform technology for enhanced endo/lysosomal escape of targeted toxins by structurally specific oleanane saponins

Gilabert-Oriol, Roger · 2014 · Freie Universität Berlin (Refubium) · DOI

Full title: Development of a platform technology for enhanced endo/lysosomal escape of targeted toxins by structurally specific oleanane saponins

Authors: Gilabert-Oriol, Roger

Year: 2014

Venue: Freie Universität Berlin (Refubium)

DOI: https://refubium.fu-berlin.de/handle/fub188/3421

Thesis Mechanismen der zielgerichteten antitumoralen Wirksamkeit von Dianthin-Panitumumab-Konjugaten in Kombination mit dem glykosylierten Triterpenoid SO1861

Trautner, Alexandra · 2021 · Freie Universität Berlin (Refubium) · DOI

Full title: Mechanismen der zielgerichteten antitumoralen Wirksamkeit von Dianthin-Panitumumab-Konjugaten in Kombination mit dem glykosylierten Triterpenoid SO1861

Authors: Trautner, Alexandra

Year: 2021

Venue: Freie Universität Berlin (Refubium)

DOI: https://refubium.fu-berlin.de/handle/fub188/28851

Thesis Protein Phosphatase Inhibition and Cellular Uptake of Semi-Synthetic Microcystin Derivatives - Investigation of Microcystins as Leads for Drug Development

Sallandt, Laura Louisa · 2024 · Freie Universität Berlin (Refubium) · DOI

Full title: Protein Phosphatase Inhibition and Cellular Uptake of Semi-Synthetic Microcystin Derivatives - Investigation of Microcystins as Leads for Drug Development

Authors: Sallandt, Laura Louisa

Year: 2024

Venue: Freie Universität Berlin (Refubium)

DOI: https://refubium.fu-berlin.de/handle/fub188/47124

Thesis Expanding the Anti-cancer Toolbox with Glycan- and Thiol-binding Nanobodies

Goerdeler, Felix · 2022 · Freie Universität Berlin (Refubium) · DOI

Full title: Expanding the Anti-cancer Toolbox with Glycan- and Thiol-binding Nanobodies

Authors: Goerdeler, Felix

Year: 2022

Venue: Freie Universität Berlin (Refubium)

DOI: https://refubium.fu-berlin.de/handle/fub188/37209

Thesis Membrane lytic peptide-based molecular therapeutic for targeted anticancer treatment

Zhong, Jieying · 2012 · Hong Kong University of Science and Technology (HKUST) · DOI

Full title: Membrane lytic peptide-based molecular therapeutic for targeted anticancer treatment

Authors: Zhong, Jieying

Year: 2012

Venue: Hong Kong University of Science and Technology (HKUST)

DOI: http://repository.hkust.edu.hk/ir/Record/1783.1-7637

Thesis Investigation of bystander effects of hypoxia-activated prodrugs using three dimensional cell cultures

Hong, Cho · 2019 · University of Auckland · DOI

Full title: Investigation of bystander effects of hypoxia-activated prodrugs using three dimensional cell cultures

Authors: Hong, Cho

Year: 2019

Venue: University of Auckland

DOI: https://hdl.handle.net/2292/45172

Thesis Identification of determinants of sensitivity to duocarmycin analogues: A class of potent anti-cancer drugs

Ghamri, Nour · 2021 · University of Auckland · DOI

Full title: Identification of determinants of sensitivity to duocarmycin analogues: A class of potent anti-cancer drugs

Authors: Ghamri, Nour

Year: 2021

Venue: University of Auckland

DOI: https://hdl.handle.net/2292/56941

Thesis Design of BET Inhibitor Bottlebrush Prodrugs with Superior Efficacy and Devoid of Systemic Toxicities

· 2022 · Massachusetts Institute of Technology (MIT) · DOI

Full title: Design of BET Inhibitor Bottlebrush Prodrugs with Superior Efficacy and Devoid of Systemic Toxicities

Year: 2022

Venue: Massachusetts Institute of Technology (MIT)

DOI: https://hdl.handle.net/1721.1/141089

Thesis De novo design of a two-step approach targeting Claudin-6 for enhanced drug delivery to solid tumors

Yan, Jiayao; Zhong, Liqing; Chen, Xiaotong et al. · 2025 · Massachusetts Institute of Technology (MIT) · DOI

Full title: De novo design of a two-step approach targeting Claudin-6 for enhanced drug delivery to solid tumors

Authors: Yan, Jiayao; Zhong, Liqing; Chen, Xiaotong; Li, Lin; Liu, Fangcen; Lei, Lei; An, Mengchao; Wei, Xiao; Wang, Ying; Chen, Tianran; Guo, Jingyi; Shao, Jie; Yu, Xiaoxiao; Zhao, Yingjie; Li, Rutian; Liu, Qin

Year: 2025

Venue: Massachusetts Institute of Technology (MIT)

DOI: https://hdl.handle.net/1721.1/164016

Thesis Engineering of Targeted Nanoparticles for Cancer Therapy Using Internalizing Aptamers Isolated by Cell-Uptake Selection

Xiao, Zeyu; Levy-Nissenbaum, Etgar; Alexis, Frank et al. · 2013 · Massachusetts Institute of Technology (MIT) · DOI

Full title: Engineering of Targeted Nanoparticles for Cancer Therapy Using Internalizing Aptamers Isolated by Cell-Uptake Selection

Authors: Xiao, Zeyu; Levy-Nissenbaum, Etgar; Alexis, Frank; Luptak, Andrej; Teply, Benjamin A.; Chan, Juliana Maria; Shi, Jinjun; Digga, Elise; Cheng, Judy; Langer, Robert; Farokhzad, Omid C.

Year: 2013

Venue: Massachusetts Institute of Technology (MIT)

DOI: http://hdl.handle.net/1721.1/79109

Thesis Targeting of drugs and nanoparticles to tumors

Ruoslahti, Erkki; Sailor, Michael J.; Bhatia, Sangeeta N. · 2010 · Massachusetts Institute of Technology (MIT) · DOI

Full title: Targeting of drugs and nanoparticles to tumors

Authors: Ruoslahti, Erkki; Sailor, Michael J.; Bhatia, Sangeeta N.

Year: 2010

Venue: Massachusetts Institute of Technology (MIT)

DOI: http://hdl.handle.net/1721.1/58699

Thesis Targeted Stimuli-Responsive Dextran Conjugates for Doxorubicin Delivery to Hepatocytes

Zaman, Noreen T.; Tan, Fred E.; Joshi, Shilpa M. et al. · 2005 · Massachusetts Institute of Technology (MIT) · DOI

Full title: Targeted Stimuli-Responsive Dextran Conjugates for Doxorubicin Delivery to Hepatocytes

Authors: Zaman, Noreen T.; Tan, Fred E.; Joshi, Shilpa M.; Ying, Jackie Y.

Year: 2005

Venue: Massachusetts Institute of Technology (MIT)

DOI: http://hdl.handle.net/1721.1/30394

Thesis A Systems Approach for Tumor Pharmacokinetics

Thurber, Greg Michael; Weissleder, Ralph · 2012 · Massachusetts Institute of Technology (MIT) · DOI

Full title: A Systems Approach for Tumor Pharmacokinetics

Authors: Thurber, Greg Michael; Weissleder, Ralph

Year: 2012

Venue: Massachusetts Institute of Technology (MIT)

DOI: http://hdl.handle.net/1721.1/70475

Thesis Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy

Kolishetti, Nagesh; Dhar, Shanta; Valencia, Pedro Miguel et al. · 2013 · Massachusetts Institute of Technology (MIT) · DOI

Full title: Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy

Authors: Kolishetti, Nagesh; Dhar, Shanta; Valencia, Pedro Miguel; Lin, Lucy Q.; Karnik, Rohit; Lippard, Stephen J.; Langer, Robert; Farokhzad, Omid C.

Year: 2013

Venue: Massachusetts Institute of Technology (MIT)

DOI: http://hdl.handle.net/1721.1/78881

Thesis Sortase-mediated modification of αDEC205 affords optimization of antigen presentation and immunization against a set of viral epitopes

Ploegh, Hidde; Swee, Lee Kim; Guimaraes, Carla P. et al. · 2013 · Massachusetts Institute of Technology (MIT) · DOI

Full title: Sortase-mediated modification of αDEC205 affords optimization of antigen presentation and immunization against a set of viral epitopes

Authors: Ploegh, Hidde; Swee, Lee Kim; Guimaraes, Carla P.; Sehrawat, Sharvan; Spooner, Eric; Barrasa, M. Inmaculada

Year: 2013

Venue: Massachusetts Institute of Technology (MIT)

DOI: http://hdl.handle.net/1721.1/79815

Thesis Synergistic Antitumor Activity from Two-Stage Delivery of Targeted Toxins and Endosome-Disrupting Nanoparticles

Su, Xingfang; Yang, Nicole Jie Yeon; Wittrup, Karl Dane et al. · 2013 · Massachusetts Institute of Technology (MIT) · DOI

Full title: Synergistic Antitumor Activity from Two-Stage Delivery of Targeted Toxins and Endosome-Disrupting Nanoparticles

Authors: Su, Xingfang; Yang, Nicole Jie Yeon; Wittrup, Karl Dane; Irvine, Darrell J

Year: 2013

Venue: Massachusetts Institute of Technology (MIT)

DOI: http://hdl.handle.net/1721.1/79767

Thesis Selective treatment and monitoring of disseminated cancer micrometastases in vivo using dual-function, activatable immunoconjugates

Spring, Bryan Q.; Abu-Yousif, Adnan O.; Palanisami, Akilan et al. · 2014 · Massachusetts Institute of Technology (MIT) · DOI

Full title: Selective treatment and monitoring of disseminated cancer micrometastases in vivo using dual-function, activatable immunoconjugates

Authors: Spring, Bryan Q.; Abu-Yousif, Adnan O.; Palanisami, Akilan; Rizvi, Imran; Zheng, Xiang; Mai, Zhiming; Anbil, Sriram; Sears, R. Bryan; Mensah, Lawrence B.; Goldschmidt, Ruth; Erdem, S. Sibel; Oliva, Esther; Hasan, Tayyaba

Year: 2014

Venue: Massachusetts Institute of Technology (MIT)

DOI: http://hdl.handle.net/1721.1/90355

Thesis Antigen specificity can be irrelevant to immunocytokine efficacy and biodistribution

Tzeng, Alice; Navaratna, Tejas; Kwan, Byron Hua et al. · 2015 · Massachusetts Institute of Technology (MIT) · DOI

Full title: Antigen specificity can be irrelevant to immunocytokine efficacy and biodistribution

Authors: Tzeng, Alice; Navaratna, Tejas; Kwan, Byron Hua; Opel, Cary Francis; Wittrup, Karl Dane

Year: 2015

Venue: Massachusetts Institute of Technology (MIT)

DOI: http://hdl.handle.net/1721.1/98398

Thesis Combination antibody treatment down-regulates epidermal growth factor receptor by inhibiting endosomal recycling

Spangler, Jamie Berta; Neil, Jason Robert; Abramovitch, Sivan et al. · 2011 · Massachusetts Institute of Technology (MIT) · DOI

Full title: Combination antibody treatment down-regulates epidermal growth factor receptor by inhibiting endosomal recycling

Authors: Spangler, Jamie Berta; Neil, Jason Robert; Abramovitch, Sivan; Yarden, Yosef; White, Forest M.; Lauffenburger, Douglas A.; Wittrup, Karl Dane

Year: 2011

Venue: Massachusetts Institute of Technology (MIT)

DOI: http://hdl.handle.net/1721.1/66709

Thesis Triepitopic Antibody Fusions Inhibit Cetuximab-Resistant BRAF and KRAS Mutant Tumors via EGFR Signal Repression

Manzari, Mandana T.; Rosalia, Elizabeth K.; Chen, Tiffany Fen-yi et al. · 2014 · Massachusetts Institute of Technology (MIT) · DOI

Full title: Triepitopic Antibody Fusions Inhibit Cetuximab-Resistant BRAF and KRAS Mutant Tumors via EGFR Signal Repression

Authors: Manzari, Mandana T.; Rosalia, Elizabeth K.; Chen, Tiffany Fen-yi; Wittrup, Karl Dane; Spangler, Jamie Berta

Year: 2014

Venue: Massachusetts Institute of Technology (MIT)

DOI: http://hdl.handle.net/1721.1/91646

Thesis Sensitizing Protective Tumor Microenvironments to Antibody-Mediated Therapy

Pallasch, Christian; Leskov, Ilya B.; Vorholt, Daniela et al. · 2015 · Massachusetts Institute of Technology (MIT) · DOI

Full title: Sensitizing Protective Tumor Microenvironments to Antibody-Mediated Therapy

Authors: Pallasch, Christian; Leskov, Ilya B.; Vorholt, Daniela; Drake, Adam; Bent, Eric H.; Schwamb, Janine; Iliopoulou, Bettina P.; Kutsch, Nadine; van Rooijen, Nico; Frenzel, Lukas P.; Wendtner, Clemens M.; Heukamp, Lukas; Kreuzer, Karl Anton; Hallek, Michael; Chen, Jianzhu; Braun, Christian Joerg; Soto Feliciano, Yadira Marie; Hemann, Michael

Year: 2015

Venue: Massachusetts Institute of Technology (MIT)

DOI: http://hdl.handle.net/1721.1/96265

Thesis Effect of Small-Molecule-Binding Affinity on Tumor Uptake In Vivo: A Systematic Study Using a Pretargeted Bispecific Antibody

Rhoden, John J.; Ruiz-Yi, Benjamin; Wittrup, Karl Dane et al. · 2014 · Massachusetts Institute of Technology (MIT) · DOI

Full title: Effect of Small-Molecule-Binding Affinity on Tumor Uptake In Vivo: A Systematic Study Using a Pretargeted Bispecific Antibody

Authors: Rhoden, John J.; Ruiz-Yi, Benjamin; Wittrup, Karl Dane; Frangioni, John V.; Orcutt, Kelly Davis

Year: 2014

Venue: Massachusetts Institute of Technology (MIT)

DOI: http://hdl.handle.net/1721.1/91642

Thesis Targeted Nanoparticle Drugs with Immunotherapy Against Bladder and Breast Cancer

Abou-Adas, Sara · 2024 · University of California, Davis · DOI

Full title: Targeted Nanoparticle Drugs with Immunotherapy Against Bladder and Breast Cancer

Authors: Abou-Adas, Sara

Year: 2024

Venue: University of California, Davis

DOI: https://escholarship.org/uc/item/0wc2s6q3

Thesis Production and Analysis of Re-engineered Fusion Protein to Target Receptors on Cancer Stem Cells

Tikle, Sanika · 2022 · University of California, San Diego (UCSD) · DOI

Full title: Production and Analysis of Re-engineered Fusion Protein to Target Receptors on Cancer Stem Cells

Authors: Tikle, Sanika

Year: 2022

Venue: University of California, San Diego (UCSD)

DOI: https://escholarship.org/uc/item/5wb2f55v

Thesis Evaluating the Efficacy of Combination CD46-Targeted 225Ac Radioimmunotherapy and Antibody-Drug Conjugate Therapy in Multiple Myeloma

Mayne, Ellis · 2024 · University of California, San Francisco (UCSF) · DOI

Full title: Evaluating the Efficacy of Combination CD46-Targeted 225Ac Radioimmunotherapy and Antibody-Drug Conjugate Therapy in Multiple Myeloma

Authors: Mayne, Ellis

Year: 2024

Venue: University of California, San Francisco (UCSF)

DOI: https://escholarship.org/uc/item/7vr404c8

Thesis PSMA-1-Doxorubicin Conjugates for Targeted Therapy of Prostate Cancer

Walker, Natalie · 2019 · OhioLINK Electronic Theses and Dissertations · DOI

Full title: PSMA-1-Doxorubicin Conjugates for Targeted Therapy of Prostate Cancer

Authors: Walker, Natalie

Year: 2019

Venue: OhioLINK Electronic Theses and Dissertations

DOI: http://rave.ohiolink.edu/etdc/view?acc_num=case1554496393458066

Thesis Exploring Composition of Peptide Loops to Enhance Biophysical Properties of Antibody Fragments for Cancer Therapeutics

Han, Jeong Min · 2020 · OhioLINK Electronic Theses and Dissertations · DOI

Full title: Exploring Composition of Peptide Loops to Enhance Biophysical Properties of Antibody Fragments for Cancer Therapeutics

Authors: Han, Jeong Min

Year: 2020

Venue: OhioLINK Electronic Theses and Dissertations

DOI: http://rave.ohiolink.edu/etdc/view?acc_num=osu1598278801134316

Thesis Synthesis and Investigation of Clickable and Cleavable Linkers for Drug Delivery

Bogen, William C. · 2016 · OhioLINK Electronic Theses and Dissertations · DOI

Full title: Synthesis and Investigation of Clickable and Cleavable Linkers for Drug Delivery

Authors: Bogen, William C.

Year: 2016

Venue: OhioLINK Electronic Theses and Dissertations

DOI: http://rave.ohiolink.edu/etdc/view?acc_num=ucin1471347221

Thesis Design and Characterization of Antibody-Conjugated T-Cells and Mimetic Nanovesicles for Cancer Therapy

Medina Salguero, Andres X · 2023 · University of Saskatchewan - HARVEST · DOI

Full title: Design and Characterization of Antibody-Conjugated T-Cells and Mimetic Nanovesicles for Cancer Therapy

Authors: Medina Salguero, Andres X

Year: 2023

Venue: University of Saskatchewan - HARVEST

DOI: https://hdl.handle.net/10388/15314

Thesis Příprava a charakterizace terapeutické protilátky Farletuzumab - Thiomab E154C S378C

Mochánová, Michaela · 2023 · Charles University Prague (Univerzita Karlova) · DOI

Full title: Příprava a charakterizace terapeutické protilátky Farletuzumab - Thiomab E154C S378C

Authors: Mochánová, Michaela

Year: 2023

Venue: Charles University Prague (Univerzita Karlova)

DOI: http://hdl.handle.net/20.500.11956/181559

Thesis Příprava polymerního terapeutika cílícího na CD20 pozitivní B lymfomy a NK buňky

Hejl, Maxmilián · 2023 · Charles University Prague (Univerzita Karlova) · DOI

Full title: Příprava polymerního terapeutika cílícího na CD20 pozitivní B lymfomy a NK buňky

Authors: Hejl, Maxmilián

Year: 2023

Venue: Charles University Prague (Univerzita Karlova)

DOI: http://hdl.handle.net/20.500.11956/185124

Thesis Polymerní terapeutika pro imunoonkoterapii

Kashmel, Pavel · 2022 · Charles University Prague (Univerzita Karlova) · DOI

Full title: Polymerní terapeutika pro imunoonkoterapii

Authors: Kashmel, Pavel

Year: 2022

Venue: Charles University Prague (Univerzita Karlova)

DOI: http://hdl.handle.net/20.500.11956/175217

Thesis Nanoléčiva pro léčbu nádorů slinivky břišní

Bulková, Alžběta · 2025 · Charles University Prague (Univerzita Karlova) · DOI

Full title: Nanoléčiva pro léčbu nádorů slinivky břišní

Authors: Bulková, Alžběta

Year: 2025

Venue: Charles University Prague (Univerzita Karlova)

DOI: http://hdl.handle.net/20.500.11956/204058

Thesis Rational Design of Chemically Controlled Antibodies and Protein Therapeutics

Marchand, Anthony; Bonati, Lucia; Shui, Sailan et al. · 2023 · École polytechnique fédérale de Lausanne (EPFL) · DOI

Full title: Rational Design of Chemically Controlled Antibodies and Protein Therapeutics

Authors: Marchand, Anthony; Bonati, Lucia; Shui, Sailan; Scheller, Leo; Gainza Cirauqui, Pablo; Rosset, Stéphane; Georgeon, Sandrine; Tang, Li; Correia, Bruno

Year: 2023

Venue: École polytechnique fédérale de Lausanne (EPFL)

DOI: https://infoscience.epfl.ch/handle/20.500.14299/198280

Thesis Protease-activation using anti-idiotypic masks enables tumor specificity of a folate receptor 1-T cell bispecific antibody

Geiger, Martina; Stubenrauch, Kay-Gunnar; Sam, Johannes et al. · 2020 · École polytechnique fédérale de Lausanne (EPFL) · DOI

Full title: Protease-activation using anti-idiotypic masks enables tumor specificity of a folate receptor 1-T cell bispecific antibody

Authors: Geiger, Martina; Stubenrauch, Kay-Gunnar; Sam, Johannes; Richter, Wolfgang F.; Jordan, Gregor; Eckmann, Jan; Hage, Carina; Nicolini, Valeria; Freimoser-Grundschober, Anne; Ritter, Mirko; Lauer, Matthias E.; Stahlberg, Henning; Ringler, Philippe; Patel, Jigar; Sullivan, Eric; Grau-Richards, Sandra; Endres, Stefan; Kobold, Sebastian; Umaña, Pablo; Brünker, Peter; Klein, Christian

Year: 2020

Venue: École polytechnique fédérale de Lausanne (EPFL)

DOI: https://infoscience.epfl.ch/handle/20.500.14299/171106

Thesis Switchable immune modulator for tumor-specific activation of anticancer immunity

Zhao, Yu; Xie, Yu-Qing; Van Herck, Simon et al. · 2021 · École polytechnique fédérale de Lausanne (EPFL) · DOI

Full title: Switchable immune modulator for tumor-specific activation of anticancer immunity

Authors: Zhao, Yu; Xie, Yu-Qing; Van Herck, Simon; Nassiri, Sina; Gao, Min; Guo, Yugang; Tang, Li

Year: 2021

Venue: École polytechnique fédérale de Lausanne (EPFL)

DOI: https://infoscience.epfl.ch/handle/20.500.14299/181693

Thesis IMPROVING NEXT-GENERATION THERAPEUTIC DELIVERY SYSTEMS THROUGH ALLOSTERIC EXCHANGE AND SELECTIVE GLYCOSYLATION

Rosas, Jonah · 2019 · Johns Hopkins University · DOI

Full title: IMPROVING NEXT-GENERATION THERAPEUTIC DELIVERY SYSTEMS THROUGH ALLOSTERIC EXCHANGE AND SELECTIVE GLYCOSYLATION

Authors: Rosas, Jonah

Year: 2019

Venue: Johns Hopkins University

DOI: http://jhir.library.jhu.edu/handle/1774.2/61733

Thesis Activated platelets in the tumor microenvironment for targeting of antibody-drug conjugates to tumors and metastases

Yap, ML; McFadyen, JD; Wang, X et al. · 2020 · University of Melbourne · DOI

Full title: Activated platelets in the tumor microenvironment for targeting of antibody-drug conjugates to tumors and metastases

Authors: Yap, ML; McFadyen, JD; Wang, X; Ziegler, M; Chen, YC; Willcox, A; Nowell, CJ; Scott, AM; Sloan, EK; Hogarth, MP; Pietersz, GA; Peter, K

Year: 2020

Venue: University of Melbourne

DOI: https://hdl.handle.net/11343/253772

Thesis Engineering anti-Lewis-Y hu3S193 antibodies with improved therapeutic ratio for radioimmunotherapy of epithelial cancers

Burvenich, IJG; Lee, FT; O’Keefe, GJ et al. · 2021 · University of Melbourne · DOI

Full title: Engineering anti-Lewis-Y hu3S193 antibodies with improved therapeutic ratio for radioimmunotherapy of epithelial cancers

Authors: Burvenich, IJG; Lee, FT; O’Keefe, GJ; Makris, D; Cao, D; Gong, S; Rigopoulos, A; Allan, LC; Brechbiel, MW; Liu, Z; Ramsland, PA; Scott, AM

Year: 2021

Venue: University of Melbourne

DOI: https://hdl.handle.net/11343/262194

Thesis Precision medicine and targeted therapy : Turning the tables on cancer

Mortensen, Anja · 2018 · Uppsala University · DOI

Full title: Precision medicine and targeted therapy : Turning the tables on cancer

Authors: Mortensen, Anja

Year: 2018

Venue: Uppsala University

DOI: http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-342030

Thesis l-Tyrosine Confers Residualizing Properties to a d-Amino Acid-Rich Residualizing Peptide for Radioiodination of Internalizing Antibodies

Lee, FT; Burvenich, IJG; Guo, N et al. · 2021 · University of Melbourne · DOI

Full title: l-Tyrosine Confers Residualizing Properties to a d-Amino Acid-Rich Residualizing Peptide for Radioiodination of Internalizing Antibodies

Authors: Lee, FT; Burvenich, IJG; Guo, N; Kocovski, P; Tochon-Danguy, H; Ackermann, U; O’Keefe, GJ; Gong, S; Rigopoulos, A; Liu, Z; Gan, HK; Scott, AM

Year: 2021

Venue: University of Melbourne

DOI: https://hdl.handle.net/11343/260406

Thesis First clinical study of a pegylated diabody 124I-labeled PEG-AVP0458 in patients with tumor-associated glycoprotein 72 positive cancers

Scott, AM; Akhurst, T; Lee, FT et al. · 2020 · University of Melbourne · DOI

Full title: First clinical study of a pegylated diabody 124I-labeled PEG-AVP0458 in patients with tumor-associated glycoprotein 72 positive cancers

Authors: Scott, AM; Akhurst, T; Lee, FT; Ciprotti, M; Davis, ID; Weickhardt, AJ; Gan, HK; Hicks, RJ; Lee, ST; Kocovski, P; Guo, N; Oh, M; Mileshkin, L; Williams, S; Murphy, D; Pathmaraj, K; O’Keefe, GJ; Gong, SJ; Pedersen, JS; Scott, FE; Wheatcroft, MP; Hudson, PJ

Year: 2020

Venue: University of Melbourne

DOI: https://hdl.handle.net/11343/252937

Thesis Template-Assisted Antibody Assembly: A Versatile Approach for Engineering Functional Antibody Nanoparticles

Hu, Y; Li, J; Ju, Y et al. · 2022 · University of Melbourne · DOI

Full title: Template-Assisted Antibody Assembly: A Versatile Approach for Engineering Functional Antibody Nanoparticles

Authors: Hu, Y; Li, J; Ju, Y; Houston, ZH; Fletcher, NL; De Rose, R; Fernandes, S; Hagemeyer, CE; Alt, K; Thurecht, KJ; Cortez-Jugo, C; Caruso, F

Year: 2022

Venue: University of Melbourne

DOI: https://hdl.handle.net/11343/302043

Thesis Harnessing Cu-64/Cu-67 for a theranostic approach to pretargeted radioimmunotherapy

Keinanen, O; Fung, K; Brennan, JM et al. · 2020 · University of Melbourne · DOI

Full title: Harnessing Cu-64/Cu-67 for a theranostic approach to pretargeted radioimmunotherapy

Authors: Keinanen, O; Fung, K; Brennan, JM; Zia, N; Harris, M; van Dam, E; Biggin, C; Hedt, A; Stoner, J; Donnelly, PS; Lewis, JS; Zeglis, BM

Year: 2020

Venue: University of Melbourne

DOI: https://hdl.handle.net/11343/252244

Thesis Radiolabeled Antibodies for Cancer Imaging and Therapy

Parakh, S; Lee, ST; Gan, HK et al. · 2022 · University of Melbourne · DOI

Full title: Radiolabeled Antibodies for Cancer Imaging and Therapy

Authors: Parakh, S; Lee, ST; Gan, HK; Scott, AM

Year: 2022

Venue: University of Melbourne

DOI: https://hdl.handle.net/11343/307131

Thesis Antibody-drug conjugates: beyond current approvals and potential future strategies

Menon, S; Parakh, S; Scott, AM et al. · 2022 · University of Melbourne · DOI

Full title: Antibody-drug conjugates: beyond current approvals and potential future strategies

Authors: Menon, S; Parakh, S; Scott, AM; Gan, HK

Year: 2022

Venue: University of Melbourne

DOI: https://hdl.handle.net/11343/308767

Thesis Antibody Drug Conjugates in Glioblastoma – Is There a Future for Them?

Parakh, S; Nicolazzo, J; Scott, AM et al. · 2022 · University of Melbourne · DOI

Full title: Antibody Drug Conjugates in Glioblastoma – Is There a Future for Them?

Authors: Parakh, S; Nicolazzo, J; Scott, AM; Gan, HK

Year: 2022

Venue: University of Melbourne

DOI: https://hdl.handle.net/11343/305444

Thesis Tumor volumes as a predictor of response to the anti-EGFR antibody drug conjugate depatuxizumab mafadotin

Gan, HK; Parakh, S; Lassman, AB et al. · 2022 · University of Melbourne · DOI

Full title: Tumor volumes as a predictor of response to the anti-EGFR antibody drug conjugate depatuxizumab mafadotin

Authors: Gan, HK; Parakh, S; Lassman, AB; Seow, A; Lau, E; Lee, ST; Ameratunga, M; Perchyonok, Y; Cao, D; Burvenich, IJG; O'keefe, GJ; Rigopoulos, A; Gomez, E; Maag, D; Scott, AM

Year: 2022

Venue: University of Melbourne

DOI: https://hdl.handle.net/11343/296955

Thesis Bifunctional Aptamer-Doxorubicin Conjugate Crosses the Blood-Brain Barrier and Selectively Delivers Its Payload to EpCAM-Positive Tumor Cells

Macdonald, J; Denoyer, D; Henri, J et al. · 2022 · University of Melbourne · DOI

Full title: Bifunctional Aptamer-Doxorubicin Conjugate Crosses the Blood-Brain Barrier and Selectively Delivers Its Payload to EpCAM-Positive Tumor Cells

Authors: Macdonald, J; Denoyer, D; Henri, J; Jamieson, A; Burvenich, IJG; Pouliot, N; Shigdar, S

Year: 2022

Venue: University of Melbourne

DOI: https://hdl.handle.net/11343/304410

Thesis The in vitro and in vivo anti-tumour activity of N-AcMEL-(Fab′)2 conjugates

Smyth, MJ; Pietersz, GA; McKenzie, IFC · 2021 · University of Melbourne · DOI

Full title: The in vitro and in vivo anti-tumour activity of N-AcMEL-(Fab′)2 conjugates

Authors: Smyth, MJ; Pietersz, GA; McKenzie, IFC

Year: 2021

Venue: University of Melbourne

DOI: https://hdl.handle.net/11343/269476

Thesis Engineering of bispecific affinity proteins with high affinity for ERBB2 and adaptable binding to albumin

Nilvebrant, J; Åstrand, M; Georgieva-Kotseva, M et al. · 2021 · University of Melbourne · DOI

Full title: Engineering of bispecific affinity proteins with high affinity for ERBB2 and adaptable binding to albumin

Authors: Nilvebrant, J; Åstrand, M; Georgieva-Kotseva, M; Björnmalm, M; Löfblom, J; Hober, S

Year: 2021

Venue: University of Melbourne

DOI: https://hdl.handle.net/11343/260014

Thesis Targeting and efficacy of novel mab806-antibody-drug conjugates in malignant mesothelioma

Chia, PL; Parakh, S; Tsao, MS et al. · 2021 · University of Melbourne · DOI

Full title: Targeting and efficacy of novel mab806-antibody-drug conjugates in malignant mesothelioma

Authors: Chia, PL; Parakh, S; Tsao, MS; Pham, NA; Gan, HK; Cao, D; Burvenich, IJG; Rigopoulos, A; Reilly, EB; John, T; Scott, AM

Year: 2021

Venue: University of Melbourne

DOI: https://hdl.handle.net/11343/271967

Thesis Tumor targeted alpha particle therapy with an actinium-225 labelled antibody for carbonic anhydrase IX

Morgan, KA; Wichmann, CW; Osellame, LD et al. · 2024 · University of Melbourne · DOI

Full title: Tumor targeted alpha particle therapy with an actinium-225 labelled antibody for carbonic anhydrase IX

Authors: Morgan, KA; Wichmann, CW; Osellame, LD; Cao, Z; Guo, N; Scott, AM; Donnelly, PS

Year: 2024

Venue: University of Melbourne

DOI: https://hdl.handle.net/11343/350949

Thesis HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy

Yu, HA; Goto, Y; Hayashi, H et al. · 2023 · University of Melbourne · DOI

Full title: HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy

Authors: Yu, HA; Goto, Y; Hayashi, H; Felip, E; Chih-Hsin Yang, J; Reck, M; Yoh, K; Lee, S-H; Paz-Ares, L; Besse, B; Bironzo, P; Kim, D-W; Johnson, ML; Wu, Y-L; John, T; Kao, S; Kozuki, T; Massarelli, E; Patel, J; Smit, E; Reckamp, KL; Dong, Q; Shrestha, P; Fan, P-D; Patel, P; Sporchia, A; Sternberg, DW; Sellami, D; Jaenne, PA

Year: 2023

Venue: University of Melbourne

DOI: https://hdl.handle.net/11343/337233

Thesis Preferential Antibody and Drug Conjugate Targeting of the ADAM10 Metalloprotease in Tumours

Yan, H; Vail, ME; Hii, L et al. · 2022 · University of Melbourne · DOI

Full title: Preferential Antibody and Drug Conjugate Targeting of the ADAM10 Metalloprotease in Tumours

Authors: Yan, H; Vail, ME; Hii, L; Guo, N; McMurrick, PJ; Oliva, K; Wilkins, S; Saha, N; Nikolov, DB; Lee, FT; Scott, AM; Janes, PW

Year: 2022

Venue: University of Melbourne

DOI: https://hdl.handle.net/11343/316890

Thesis Patient-Specific Nanoparticle Targeting in Human Leukemia Blood

Ju, Y; Li, S; Tan, AEQ et al. · 2024 · University of Melbourne · DOI

Full title: Patient-Specific Nanoparticle Targeting in Human Leukemia Blood

Authors: Ju, Y; Li, S; Tan, AEQ; Pilkington, EH; Brannon, PT; Plebanski, M; Cui, J; Caruso, F; Thurecht, KJ; Tam, C; Kent, SJ

Year: 2024

Venue: University of Melbourne

DOI: https://hdl.handle.net/11343/353155

Thesis The antibody–drug conjugate targeting ROR1, NBE-002, is active in high-grade serous ovarian cancer preclinical models

Liu, D; Vandenberg, CJ; Sini, P et al. · 2025 · University of Melbourne · DOI

Full title: The antibody–drug conjugate targeting ROR1, NBE-002, is active in high-grade serous ovarian cancer preclinical models

Authors: Liu, D; Vandenberg, CJ; Sini, P; Waldmeier, L; Baumgartinger, R; Pisarsky, L; Petroczi, G; Ratnayake, G; Scott, CL; Ford, CE

Year: 2025

Venue: University of Melbourne

DOI: https://hdl.handle.net/11343/360653

Thesis α-Radioimmunotherapy with 213 Bi-anti-CD38 immunoconjugates is effective in a mouse model of human multiple myeloma

Teiluf, Katharina; Seidl, Christof; Blechert, Birgit et al. · 2014 · Technical University of Munich (TUM) · DOI

Full title: α-Radioimmunotherapy with 213 Bi-anti-CD38 immunoconjugates is effective in a mouse model of human multiple myeloma

Authors: Teiluf, Katharina;Seidl, Christof;Blechert, Birgit;Gaertner, Florian C.;Gilbertz, Klaus-Peter;Fernandez, Vanesa;Bassermann, Florian;Endell, Jan;Boxhammer, Rainer;Leclair, Stephane;Vallon, Mario;Aichler, Michaela;Feuchtinger, Annette;Bruchertseifer, Frank;Morgenstern, Alfred;Essler, Markus

Year: 2014

Venue: Technical University of Munich (TUM)

DOI: https://mediatum.ub.tum.de/1514919

Thesis Differential internalization of hu14.18-IL2 immunocytokine by NK and tumor cell: impact on conjugation, cytotoxicity, and targeting

Reisfeld, RA; Gillies, SD; Rakhmilevich, AL et al. · 2011 · University of Wisconsin-Madison · DOI

Full title: Differential internalization of hu14.18-IL2 immunocytokine by NK and tumor cell: impact on conjugation, cytotoxicity, and targeting

Authors: Reisfeld, RA; Gillies, SD; Rakhmilevich, AL; Yamane, B; Hank, JA; Gubbels, JA; Patankar, MS; Buhtoiarov, TN; Gan, J; Buhtoiarov, IN; Neal, ZC; Sondel, PM

Year: 2011

Venue: University of Wisconsin-Madison

DOI: http://digital.library.wisc.edu/1793/54211

Thesis Rabbit derived VL single-domains as promising scaffolds to generate antibody-drug conjugates

André, Ana S. (University of Lisbon / Associate Laboratory for Animal and Veterinary Sciences); Aires-da-Silva, Frederico (University of Lisbon / Associate Laboratory for Animal and Veterinary Sciences); Braz, Berta São (University of Lisbon / Associate Laboratory for Animal and Veterinary Sciences) et al. · 2023 · University of Veterinary Medicine Vienna (Vetmeduni Vienna) · DOI

Full title: Rabbit derived VL single-domains as promising scaffolds to generate antibody-drug conjugates

Authors: André, Ana S. (University of Lisbon / Associate Laboratory for Animal and Veterinary Sciences); Aires-da-Silva, Frederico (University of Lisbon / Associate Laboratory for Animal and Veterinary Sciences); Braz, Berta São (University of Lisbon / Associate Laboratory for Animal and Veterinary Sciences); Carrapiço, Belmira (University of Lisbon / Associate Laboratory for Animal and Veterinary Sciences); Vicente, Gonçalo (Universidade de Lisboa); Oliveira, Soraia (Technophage SA); Neves, Vera (Universidade de Lisboa); Cavaco, Marco (Universidade de Lisboa); António, João P M (Universidade de Lisboa); Carvalho, Joana Inês (University of Lisbon); Bule, Pedro (University of Lisbon / Associate Laboratory for Animal and Veterinary Sciences); Nogueira, Sara (University of Lisbon / Associate Laboratory for Animal and Veterinary Sciences); Tavares, Luís (University of Lisbon / Associate Laboratory for Animal and Veterinary Sciences); Aguiar, Sandra (University of Lisbon / Associate Laboratory for Animal and Veterinary Sciences); Dias, Joana N. R. (University of Lisbon / Associate Laboratory for Animal and Veterinary Sciences); Gil, Solange (University of Lisbon / Associate Laboratory for Animal and Veterinary Sciences); Gois, Pedro M. P. (Universidade de Lisboa); Goncalves, Joao (Universidade de Lisboa); Castanho, Miguel (Universidade de Lisboa); Correia, João D. G. (Universidade de Lisboa); Gano, Lurdes (Universidade de Lisboa); Rütgen, Barbara (University of Veterinary Medicine Vienna)

Year: 2023

Venue: University of Veterinary Medicine Vienna (Vetmeduni Vienna)

DOI: https://phaidra.vetmeduni.ac.at/o:2223

Thesis Recombinant Fusion proteins for Antibody-Directed-Enzyme-Prodrug-Therapy (ADEPT) in colon cancer

Coelho, Vânia · 2008 · Freie Universität Berlin (Refubium) · DOI

Full title: Recombinant Fusion proteins for Antibody-Directed-Enzyme-Prodrug-Therapy (ADEPT) in colon cancer

Authors: Coelho, Vânia

Year: 2008

Venue: Freie Universität Berlin (Refubium)

DOI: https://refubium.fu-berlin.de/handle/fub188/2880

Thesis Pró-fármaco ativado por enzima, uma estratégia promissora na quimioterapia

Blau, Lorena [UNESP]; Menegon, Renato Farina [UNESP]; Chin, Chung Man [UNESP] · 2014 · Universidade Estadual Paulista (UNESP) · DOI

Full title: Pró-fármaco ativado por enzima, uma estratégia promissora na quimioterapia

Authors: Blau, Lorena [UNESP]; Menegon, Renato Farina [UNESP]; Chin, Chung Man [UNESP]

Year: 2014

Venue: Universidade Estadual Paulista (UNESP)

DOI: http://dx.doi.org/10.1590/S0100-40422006000600028

Thesis Chagasin-based Carriers Designed for the Cancer-targeted Release of Proteases

Jai, Jyotsna · 2025 · Hong Kong University of Science and Technology (HKUST) · DOI

Full title: Chagasin-based Carriers Designed for the Cancer-targeted Release of Proteases

Authors: Jai, Jyotsna

Year: 2025

Venue: Hong Kong University of Science and Technology (HKUST)

DOI: http://repository.hkust.edu.hk/ir/Record/1783.1-152509

Thesis Peptide therapeutics: unveiling the potential against cancer - a journey through 1989

Almusaimi, Othman · 2024 · Imperial College London · DOI

Full title: Peptide therapeutics: unveiling the potential against cancer - a journey through 1989

Authors: Almusaimi, Othman

Year: 2024

Venue: Imperial College London

DOI: https://www.mdpi.com/2072-6694/16/5/1032

Thesis ANTIBODY-DRUG CONJUGATES FOR THE TREATMENT OF BREAST CANCER.

TARANTINO, PAOLO · 2024 · Università degli Studi di Milano (AIR) · DOI

Full title: ANTIBODY-DRUG CONJUGATES FOR THE TREATMENT OF BREAST CANCER.

Authors: TARANTINO, PAOLO

Year: 2024

Venue: Università degli Studi di Milano (AIR)

DOI: https://hdl.handle.net/2434/1119775

Thesis Development of a RET activity gene signature and a RET antibody-drug conjugate

Vinoo, Saasha · 2025 · University of Minnesota - Digital Conservancy · DOI

Full title: Development of a RET activity gene signature and a RET antibody-drug conjugate

Authors: Vinoo, Saasha

Year: 2025

Venue: University of Minnesota - Digital Conservancy

DOI: https://hdl.handle.net/11299/275842

Thesis A Complete Pipeline for the Discovery and Development of Haptenizing Chimeras at Scale

Dhaliwal, Rohil · 2025 · Harvard University - DASH · DOI

Full title: A Complete Pipeline for the Discovery and Development of Haptenizing Chimeras at Scale

Authors: Dhaliwal, Rohil

Year: 2025

Venue: Harvard University - DASH

DOI: https://dash.harvard.edu/handle/1/42719542

Thesis Radiolabeled HER-2 Binding Affibody Molecules for Tumor Targeting : Preclinical Studies

Steffen, Ann-Charlott · 2006 · Uppsala University · DOI

Full title: Radiolabeled HER-2 Binding Affibody Molecules for Tumor Targeting : Preclinical Studies

Authors: Steffen, Ann-Charlott

Year: 2006

Venue: Uppsala University

DOI: http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-6678

Thesis Indirect Radiohalogenation of Targeting Proteins : Labelling Chemistry and Biological Characterisation

Orlova, Anna · 2003 · Uppsala University · DOI

Full title: Indirect Radiohalogenation of Targeting Proteins : Labelling Chemistry and Biological Characterisation

Authors: Orlova, Anna

Year: 2003

Venue: Uppsala University

DOI: http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-3349

Thesis Targeted Therapy of Colorectal Cancer : Preclinical Evaluation of a Radiolabelled Antibody

Almqvist, Ylva · 2008 · Uppsala University · DOI

Full title: Targeted Therapy of Colorectal Cancer : Preclinical Evaluation of a Radiolabelled Antibody

Authors: Almqvist, Ylva

Year: 2008

Venue: Uppsala University

DOI: http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-8657

Thesis Antibody Mediated Radionuclide Targeting of HER-2 for Cancer Diagnostics and Therapy : Preclinical Studies

Persson, Mikael · 2006 · Uppsala University · DOI

Full title: Antibody Mediated Radionuclide Targeting of HER-2 for Cancer Diagnostics and Therapy : Preclinical Studies

Authors: Persson, Mikael

Year: 2006

Venue: Uppsala University

DOI: http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-6798

Thesis Tandem Native Mass-Spectrometry on Antibody-Drug Conjugates and Submillion da Antibody-Antigen Protein Assemblies on an Orbitrap EMR Equipped with a High-Mass Quadrupole Mass Selector

Dyachenko, Andrey; Wang, Guanbo; Belov, Mike et al. · 2015 · Utrecht University · DOI

Full title: Tandem Native Mass-Spectrometry on Antibody-Drug Conjugates and Submillion da Antibody-Antigen Protein Assemblies on an Orbitrap EMR Equipped with a High-Mass Quadrupole Mass Selector

Authors: Dyachenko, Andrey; Wang, Guanbo; Belov, Mike; Makarov, Alexander; De Jong, Rob N.; Van Den Bremer, Ewald T J; Parren, Paul W H I; Heck, Albert J R

Year: 2015

Venue: Utrecht University

DOI: https://dspace.library.uu.nl/handle/1874/320054

Thesis Nanobody-based cancer therapy of solid tumors

Kijanka, Marta; Dorresteijn, Bram; Oliveira, Sabrina et al. · 2015 · Utrecht University · DOI

Full title: Nanobody-based cancer therapy of solid tumors

Authors: Kijanka, Marta; Dorresteijn, Bram; Oliveira, Sabrina; van Bergen en Henegouwen, Paul M P

Year: 2015

Venue: Utrecht University

DOI: https://dspace.library.uu.nl/handle/1874/330269

Thesis Lysine conjugation properties in human IgGs studied by integrating high-resolution native mass spectrometry and bottom-up proteomics

Gautier, Violette; Boumeester, Anja J.; Lössl, Philip et al. · 2015 · Utrecht University · DOI

Full title: Lysine conjugation properties in human IgGs studied by integrating high-resolution native mass spectrometry and bottom-up proteomics

Authors: Gautier, Violette; Boumeester, Anja J.; Lössl, Philip; Heck, Albert J R

Year: 2015

Venue: Utrecht University

DOI: https://dspace.library.uu.nl/handle/1874/320061

Thesis High turnover of Tissue Factor enables efficient intracellular delivery of antibody-drug conjugates

de Goeij, Bart Ecg; Satijn, David; Freitag, Claudia M et al. · 2015 · Utrecht University · DOI

Full title: High turnover of Tissue Factor enables efficient intracellular delivery of antibody-drug conjugates

Authors: de Goeij, Bart Ecg; Satijn, David; Freitag, Claudia M; Wubbolts, Richard; Bleeker, Wim K; Khasanov, Alisher; Zhu, Tong; Chen, Gary; Miao, David; van Berkel, Patrick Hc; Parren, Paul W H I

Year: 2015

Venue: Utrecht University

DOI: https://dspace.library.uu.nl/handle/1874/330565

Thesis EGFR targeted nanobody-photosensitizer conjugates for photodynamic therapy in a pre-clinical model of head and neck cancer

van Driel, Pieter B A A; Boonstra, Martin C; Slooter, Maxime D et al. · 2016 · Utrecht University · DOI

Full title: EGFR targeted nanobody-photosensitizer conjugates for photodynamic therapy in a pre-clinical model of head and neck cancer

Authors: van Driel, Pieter B A A; Boonstra, Martin C; Slooter, Maxime D; Heukers, Raimond; Stammes, Marieke A; Snoeks, Thomas J A; de Bruijn, Henriette S; van Diest, Paul J; Vahrmeijer, Alexander L; van Bergen En Henegouwen, Paul M P; van de Velde, Cornelis J H; Löwik, Clemens W G M; Robinson, Dominic J; Oliveira, Sabrina

Year: 2016

Venue: Utrecht University

DOI: https://dspace.library.uu.nl/handle/1874/343679

Thesis Efficient payload delivery by a bispecific antibody-drug conjugate targeting HER2 and CD63

de Goeij, Bart Ecg; Vink, Tom; Ten Napel, Hendrik et al. · 2016 · Utrecht University · DOI

Full title: Efficient payload delivery by a bispecific antibody-drug conjugate targeting HER2 and CD63

Authors: de Goeij, Bart Ecg; Vink, Tom; Ten Napel, Hendrik; Breij, Esther Cw; Satijn, David; Wubbolts, Richard; Miao, David; Parren, Paul Whi

Year: 2016

Venue: Utrecht University

DOI: https://dspace.library.uu.nl/handle/1874/346781

Thesis Controlled Multi-functionalization Facilitates Targeted Delivery of Nanoparticles to Cancer Cells

Hudlikar, Manish S; Li, Xiuru; Gagarinov, Ivan A et al. · 2016 · Utrecht University · DOI

Full title: Controlled Multi-functionalization Facilitates Targeted Delivery of Nanoparticles to Cancer Cells

Authors: Hudlikar, Manish S; Li, Xiuru; Gagarinov, Ivan A; Kolishetti, Nagesh; Wolfert, Margreet A; Boons, Geert-Jan

Year: 2016

Venue: Utrecht University

DOI: https://dspace.library.uu.nl/handle/1874/368245

Thesis Complete regression of xenograft tumors upon targeted delivery of paclitaxel via ∏ - ∏ stacking stabilized polymeric micelles

Shi, Yang; Van Der Meel, Roy; Theek, Benjamin et al. · 2015 · Utrecht University · DOI

Full title: Complete regression of xenograft tumors upon targeted delivery of paclitaxel via ∏ - ∏ stacking stabilized polymeric micelles

Authors: Shi, Yang; Van Der Meel, Roy; Theek, Benjamin; Oude Blenke, Erik; Pieters, Ebel H E; Fens, Marcel H A M; Ehling, Josef; Schiffelers, Raymond M.; Storm, Gert; Van Nostrum, Cornelus F.; Lammers, Twan; Hennink, Wim E.

Year: 2015

Venue: Utrecht University

DOI: https://dspace.library.uu.nl/handle/1874/314667

Thesis Strategies to target drugs to gliomas and CNS metastases of solid tumors

Milojkovic Kerklaan, B.; van Tellingen, O.; Huitema, A. D R et al. · 2016 · Utrecht University · DOI

Full title: Strategies to target drugs to gliomas and CNS metastases of solid tumors

Authors: Milojkovic Kerklaan, B.; van Tellingen, O.; Huitema, A. D R; Beijnen, J. H.; Boogerd, W.; Schellens, J. H M; Brandsma, D.

Year: 2016

Venue: Utrecht University

DOI: https://dspace.library.uu.nl/handle/1874/345903

Thesis Cancer nanomedicines: oversold or underappreciated?

van der Meel, Roy; Lammers, Twan; Hennink, Wim E. · 2017 · Utrecht University · DOI

Full title: Cancer nanomedicines: oversold or underappreciated?

Authors: van der Meel, Roy; Lammers, Twan; Hennink, Wim E.

Year: 2017

Venue: Utrecht University

DOI: https://dspace.library.uu.nl/handle/1874/348233

Thesis Folate decorated polymeric micelles for targeted delivery of the kinase inhibitor dactolisib to cancer cells

Shi, Haili; van Steenbergen, Mies J.; Lou, Bo et al. · 2020 · Utrecht University · DOI

Full title: Folate decorated polymeric micelles for targeted delivery of the kinase inhibitor dactolisib to cancer cells

Authors: Shi, Haili; van Steenbergen, Mies J.; Lou, Bo; Liu, Yanna; Hennink, Wim E.; Kok, Robbert J.

Year: 2020

Venue: Utrecht University

DOI: https://dspace.library.uu.nl/handle/1874/408808

Thesis Anti-GD2 Immunoliposomes for Targeted Delivery of the Survivin Inhibitor Sepantronium Bromide (YM155) to Neuroblastoma Tumor Cells

Gholizadeh, Shima; Dolman, Emmy M.; Wieriks, Rebecca et al. · 2018 · Utrecht University · DOI

Full title: Anti-GD2 Immunoliposomes for Targeted Delivery of the Survivin Inhibitor Sepantronium Bromide (YM155) to Neuroblastoma Tumor Cells

Authors: Gholizadeh, Shima; Dolman, Emmy M.; Wieriks, Rebecca; Sparidans, Rolf W.; Hennink, Wim E.; Kok, Robbert J.

Year: 2018

Venue: Utrecht University

DOI: https://dspace.library.uu.nl/handle/1874/369779

Thesis Antibody or Antibody Fragments: Implications for Molecular Imaging and Targeted Therapy of Solid Tumors

Xenaki, Katerina T; Oliveira, Sabrina; van Bergen En Henegouwen, Paul M P · 2017 · Utrecht University · DOI

Full title: Antibody or Antibody Fragments: Implications for Molecular Imaging and Targeted Therapy of Solid Tumors

Authors: Xenaki, Katerina T; Oliveira, Sabrina; van Bergen En Henegouwen, Paul M P

Year: 2017

Venue: Utrecht University

DOI: https://dspace.library.uu.nl/handle/1874/359772

Thesis Selective Cytotoxicity to HER2 Positive Breast Cancer Cells by Saporin-Loaded Nanobody-Targeted Polymeric Nanoparticles in Combination With Photochemical Internalization

Martinez Jothar, Lucia; Beztsinna, Nataliia; van Nostrum, Cornelus F et al. · 2019 · Utrecht University · DOI

Full title: Selective Cytotoxicity to HER2 Positive Breast Cancer Cells by Saporin-Loaded Nanobody-Targeted Polymeric Nanoparticles in Combination With Photochemical Internalization

Authors: Martinez Jothar, Lucia; Beztsinna, Nataliia; van Nostrum, Cornelus F; Hennink, Wim E; Oliveira, Sabrina

Year: 2019

Venue: Utrecht University

DOI: https://dspace.library.uu.nl/handle/1874/379619

Thesis In Vitro Assessment of Binding Affinity, Selectivity, Uptake, Intracellular Degradation, and Toxicity of Nanobody-Photosensitizer Conjugates

Beltrán Hernández, Irati; De Groof, Timo W M; Heukers, Raimond et al. · 2022 · Utrecht University · DOI

Full title: In Vitro Assessment of Binding Affinity, Selectivity, Uptake, Intracellular Degradation, and Toxicity of Nanobody-Photosensitizer Conjugates

Authors: Beltrán Hernández, Irati; De Groof, Timo W M; Heukers, Raimond; Oliveira, Sabrina

Year: 2022

Venue: Utrecht University

DOI: https://dspace.library.uu.nl/handle/1874/422262

Thesis Nanobody-targeted photodynamic therapy induces significant tumor regression of trastuzumab-resistant HER2-positive breast cancer, after a single treatment session

Deken, Marion M; Kijanka, Marta M; Beltrán Hernández, Irati et al. · 2020 · Utrecht University · DOI

Full title: Nanobody-targeted photodynamic therapy induces significant tumor regression of trastuzumab-resistant HER2-positive breast cancer, after a single treatment session

Authors: Deken, Marion M; Kijanka, Marta M; Beltrán Hernández, Irati; Slooter, Maxime D; de Bruijn, Henriette S; van Diest, Paul J; van Bergen En Henegouwen, Paul M P; Lowik, Clemens W G M; Robinson, Dominic J; Vahrmeijer, Alexander L; Oliveira, Sabrina

Year: 2020

Venue: Utrecht University

DOI: https://dspace.library.uu.nl/handle/1874/396707

Thesis VHH-Photosensitizer Conjugates for Targeted Photodynamic Therapy of Met-Overexpressing Tumor Cells

Heukers, Raimond; Mashayekhi, Vida; Ramirez-Escudero, Mercedes et al. · 2019 · Utrecht University · DOI

Full title: VHH-Photosensitizer Conjugates for Targeted Photodynamic Therapy of Met-Overexpressing Tumor Cells

Authors: Heukers, Raimond; Mashayekhi, Vida; Ramirez-Escudero, Mercedes; de Haard, Hans; Verrips, Theo; van Bergen en Henegouwen, Paul.; Oliveira, Sabrina

Year: 2019

Venue: Utrecht University

DOI: https://dspace.library.uu.nl/handle/1874/384399

Thesis Single Domain Antibodies as Carriers for Intracellular Drug Delivery: A Proof of Principle Study

Pronk, Sebas D.; Schooten, Erik; Heinen, Jurgen et al. · 2021 · Utrecht University · DOI

Full title: Single Domain Antibodies as Carriers for Intracellular Drug Delivery: A Proof of Principle Study

Authors: Pronk, Sebas D.; Schooten, Erik; Heinen, Jurgen; Helfrich, Esra; Oliveira, Sabrina; Henegouwen, Paul M. P. van Bergen en

Year: 2021

Venue: Utrecht University

DOI: https://dspace.library.uu.nl/handle/1874/412539

Thesis A New Class of Tunable Acid-Sensitive Linkers for Native Drug Release Based on the Trityl Protecting Group

Timmers, Matt; Weterings, Jimmy; Van Geijn, Michiel et al. · 2022 · Utrecht University · DOI

Full title: A New Class of Tunable Acid-Sensitive Linkers for Native Drug Release Based on the Trityl Protecting Group

Authors: Timmers, Matt; Weterings, Jimmy; Van Geijn, Michiel; Bell, Roel; Lenting, Peter E.; Rijcken, Cristianne J.F.; Vermonden, Tina; Hennink, Wim E.; Liskamp, Rob M.J.

Year: 2022

Venue: Utrecht University

DOI: https://dspace.library.uu.nl/handle/1874/424173

Thesis Homogeneous tumor targeting with a single dose of HER2-targeted albumin-binding domain-fused nanobody-drug conjugates results in long-lasting tumor remission in mice

Xenaki, Katerina T; Dorrestijn, Bram; Muns, Joey A et al. · 2021 · Utrecht University · DOI

Full title: Homogeneous tumor targeting with a single dose of HER2-targeted albumin-binding domain-fused nanobody-drug conjugates results in long-lasting tumor remission in mice

Authors: Xenaki, Katerina T; Dorrestijn, Bram; Muns, Joey A; Adamzek, Kevin; Doulkeridou, Sofia; Houthoff, HendrikJan; Oliveira, Sabrina; van Bergen En Henegouwen, Paul Mp

Year: 2021

Venue: Utrecht University

DOI: https://dspace.library.uu.nl/handle/1874/411979

Thesis Repurposing the Pentameric B-Subunit of Shiga Toxin for Gb3-Targeted Immunotherapy of Colorectal Cancer by Rhamnose Conjugation

Liu, Zhicheng; Li, Xia; Lu, Zhongkai et al. · 2022 · Utrecht University · DOI

Full title: Repurposing the Pentameric B-Subunit of Shiga Toxin for Gb3-Targeted Immunotherapy of Colorectal Cancer by Rhamnose Conjugation

Authors: Liu, Zhicheng; Li, Xia; Lu, Zhongkai; Qin, Xinfang; Hong, Haofei; Zhou, Zhifang; Pieters, Roland J.; Shi, Jie; Wu, Zhimeng

Year: 2022

Venue: Utrecht University

DOI: https://dspace.library.uu.nl/handle/1874/426399

Thesis Versatile Click Linker Enabling Native Peptide Release from Nanocarriers upon Redox Trigger

Hebels, Erik R.; Dietl, Stefanie; Timmers, Matt et al. · 2023 · Utrecht University · DOI

Full title: Versatile Click Linker Enabling Native Peptide Release from Nanocarriers upon Redox Trigger

Authors: Hebels, Erik R.; Dietl, Stefanie; Timmers, Matt; Hak, Jaimie; van den Dikkenberg, Antionette; Rijcken, Cristianne J.F.; Hennink, Wim E.; Liskamp, Rob M.J.; Vermonden, Tina

Year: 2023

Venue: Utrecht University

DOI: https://dspace.library.uu.nl/handle/1874/437857

Thesis Penetration of Nanobody-Dextran Polymer Conjugates through Tumor Spheroids

Bitsch, Peter; Baum, Eva S.; Beltrán Hernández, Irati et al. · 2023 · Utrecht University · DOI

Full title: Penetration of Nanobody-Dextran Polymer Conjugates through Tumor Spheroids

Authors: Bitsch, Peter; Baum, Eva S.; Beltrán Hernández, Irati; Bitsch, Sebastian; Harwood, Jakob; Oliveira, Sabrina; Kolmar, Harald

Year: 2023

Venue: Utrecht University

DOI: https://dspace.library.uu.nl/handle/1874/434542

Thesis The physiological interactome of TCR-like antibody therapeutics in human tissues

Marrer-Berger, Estelle; Nicastri, Annalisa; Augustin, Angelique et al. · 2024 · Utrecht University · DOI

Full title: The physiological interactome of TCR-like antibody therapeutics in human tissues

Authors: Marrer-Berger, Estelle; Nicastri, Annalisa; Augustin, Angelique; Kramar, Vesna; Liao, Hanqing; Hanisch, Lydia Jasmin; Carpy, Alejandro; Weinzierl, Tina; Durr, Evelyne; Schaub, Nathalie; Nudischer, Ramona; Ortiz-Franyuti, Daniela; Breous-Nystrom, Ekaterina; Stucki, Janick; Hobi, Nina; Raggi, Giulia; Cabon, Lauriane; Lezan, Emmanuelle; Umaña, Pablo; Woodhouse, Isaac; Bujotzek, Alexander; Klein, Christian; Ternette, Nicola

Year: 2024

Venue: Utrecht University

DOI: https://dspace.library.uu.nl/handle/1874/438495

Thesis Nanobody-fotosensibilisatorconjugaten voor gerichte fotodynamische therapie

Heukers, Raimond; Van Bergen en Henegouwen, Paul M P; Oliveira, Sabrina · 2015 · Utrecht University · DOI

Full title: Nanobody-fotosensibilisatorconjugaten voor gerichte fotodynamische therapie

Authors: Heukers, Raimond; Van Bergen en Henegouwen, Paul M P; Oliveira, Sabrina

Year: 2015

Venue: Utrecht University

DOI: https://dspace.library.uu.nl/handle/1874/428489

Thesis Antibody-Drug Conjugates to Treat Bacterial Biofilms via Targeting and Extracellular Drug Release

Tvilum, Anne; Johansen, Mikkel I; Glud, Laerke N et al. · 2023 · Utrecht University · DOI

Full title: Antibody-Drug Conjugates to Treat Bacterial Biofilms via Targeting and Extracellular Drug Release

Authors: Tvilum, Anne; Johansen, Mikkel I; Glud, Laerke N; Ivarsen, Diana M; Khamas, Amanda B; Carmali, Sheiliza; Mhatre, Snehit Satish; Søgaard, Ane B; Faddy, Emma; de Vor, Lisanne; Rooijakkers, Suzan H M; Østergaard, Lars; Jørgensen, Nis P; Meyer, Rikke L; Zelikin, Alexander N

Year: 2023

Venue: Utrecht University

DOI: https://dspace.library.uu.nl/handle/1874/450688

Thesis The relevance of tumor target expression levels on IgA-mediated cytotoxicity in cancer immunotherapy

Chan, Chilam; Cabanes, Núria Casalé; Jansen, J H Marco et al. · 2024 · Utrecht University · DOI

Full title: The relevance of tumor target expression levels on IgA-mediated cytotoxicity in cancer immunotherapy

Authors: Chan, Chilam; Cabanes, Núria Casalé; Jansen, J H Marco; Guillaume, Joël; Nederend, Maaike; Passchier, Elsemieke M; Gómez-Mellado, Valentina E; Peipp, Matthias; Boes, Marianne; van Tetering, Geert; Leusen, Jeanette H W

Year: 2024

Venue: Utrecht University

DOI: https://dspace.library.uu.nl/handle/1874/456522

Thesis Population Pharmacokinetics of Inotuzumab Ozogamicin in Pediatric Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia: Results of Study ITCC-059

Wu, Jen Hao; Pennesi, Edoardo; Bautista, Francisco et al. · 2024 · Utrecht University · DOI

Full title: Population Pharmacokinetics of Inotuzumab Ozogamicin in Pediatric Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia: Results of Study ITCC-059

Authors: Wu, Jen Hao; Pennesi, Edoardo; Bautista, Francisco; Garrett, May; Fukuhara, Kei; Brivio, Erica; Ammerlaan, Anneke C.J.; Locatelli, Franco; van der Sluis, Inge M.; Rossig, Claudia; Chen-Santel, Christiane; Bielorai, Bella; Petit, Arnaud; Starý, Jan; Díaz-de-Heredia, Cristina; Rives, Susana; O’Marcaigh, Aengus; Rizzari, Carmelo; Engstler, Gernot; Nysom, Karsten; Rubio-San-Simón, Alba; Bruno, Benedicte; Bertrand, Yves; Brethon, Benoît; Rialland, Fanny; Plat, Geneviève; Dirksen, Uta; Sramkova, Lucie; Zwaan, C. Michel; Huitema, Alwin D.R.

Year: 2024

Venue: Utrecht University

DOI: https://dspace.library.uu.nl/handle/1874/454801

Thesis Fc gamma receptor is not required for in vivo processing of radio- and drug-conjugates of the dead tumor cell-targeting monoclonal antibody, APOMAB (R)

Staudacher, Alexander H; Liapis, Vasilios; Wittwer, Nicole L et al. · 2022 · Utrecht University · DOI

Full title: Fc gamma receptor is not required for in vivo processing of radio- and drug-conjugates of the dead tumor cell-targeting monoclonal antibody, APOMAB (R)

Authors: Staudacher, Alexander H; Liapis, Vasilios; Wittwer, Nicole L; Tieu, William; Lam, Hiu Chun; Leusen, Jeanette; Brown, Michael P

Year: 2022

Venue: Utrecht University

DOI: https://dspace.library.uu.nl/handle/1874/446334

Thesis Practical Theoretic Guidance for the Design of Tumor-Targeting Agents

Thurber, Greg M.; Schmidt, Michael M.; Rhoden, John J. et al. · 2016 · Massachusetts Institute of Technology (MIT) · DOI

Full title: Practical Theoretic Guidance for the Design of Tumor-Targeting Agents

Authors: Thurber, Greg M.; Schmidt, Michael M.; Rhoden, John J.; Wittrup, Karl Dane

Year: 2016

Venue: Massachusetts Institute of Technology (MIT)

DOI: http://hdl.handle.net/1721.1/101376

Thesis Engineering of anticancer human immunoglobulin A equipped with albumin for enhanced plasma half-life

Mester, Simone; Chan, Chilam; Lustig, Marta et al. · 2025 · Utrecht University · DOI

Full title: Engineering of anticancer human immunoglobulin A equipped with albumin for enhanced plasma half-life

Authors: Mester, Simone; Chan, Chilam; Lustig, Marta; Foss, Stian; Jansen, J H Marco; Leangen Herigstad, Marie; Evers, Mitchell; Nilsen, Jeannette; Reiding, Karli R; A Damen, J Mirjam; Burger, Renate; Grevys, Algirdas; Dalhus, Bjørn; Valerius, Thomas; Sandlie, Inger; Leusen, Jeanette H W; Andersen, Jan Terje

Year: 2025

Venue: Utrecht University

DOI: https://dspace.library.uu.nl/handle/1874/460851

Thesis Salt Effect Accelerates Site-Selective Cysteine Bioconjugation

Dai, Peng; Zhang, Chi; Welborn, Matthew Gregory et al. · 2018 · Massachusetts Institute of Technology (MIT) · DOI

Full title: Salt Effect Accelerates Site-Selective Cysteine Bioconjugation

Authors: Dai, Peng; Zhang, Chi; Welborn, Matthew Gregory; Shepherd, James J; Zhu, Tianyu; Van Voorhis, Troy; Pentelute, Bradley L.

Year: 2018

Venue: Massachusetts Institute of Technology (MIT)

DOI: http://hdl.handle.net/1721.1/113664

Thesis Nanoparticle conjugates of a highly potent toxin enhance safety and circumvent platinum resistance in ovarian cancer

Lauffer, Sam; Matulonis, Ursula; Pepin, David et al. · 2018 · Massachusetts Institute of Technology (MIT) · DOI

Full title: Nanoparticle conjugates of a highly potent toxin enhance safety and circumvent platinum resistance in ovarian cancer

Authors: Lauffer, Sam; Matulonis, Ursula; Pepin, David; Birrer, Michael J.; Qi, Ruogu; Wang, Yongheng; Bruno, Peter Michael; Xiao, Haihua; Yu, Yingjie; Li, Ting; Chen, Qixian; Kang, Xiang; Song, Haiqin; Yang, Xi; Huang, Xing; Detappe, Alexandre; Hemann, Michael; Ghoroghchian, Paiman Peter; Wei, Wei, S.M. Massachusetts Institute of Technology. Department of Civil and Environmental Engineering

Year: 2018

Venue: Massachusetts Institute of Technology (MIT)

DOI: http://hdl.handle.net/1721.1/113634

Thesis Development and therapeutic evaluation of 5D3(CC-MLN8237)3.2 antibody-theranostic conjugates for PSMA-positive prostate cancer therapy

Liatsou, Ioanna; Assefa, Betelhem; Liyanage, Wathsala et al. · 2024 · Utrecht University · DOI

Full title: Development and therapeutic evaluation of 5D3(CC-MLN8237)3.2 antibody-theranostic conjugates for PSMA-positive prostate cancer therapy

Authors: Liatsou, Ioanna; Assefa, Betelhem; Liyanage, Wathsala; Surasinghe, Sharmane; Nováková, Zora; Bařinka, Cyril; Gabrielson, Kathleen; Raman, Venu; Artemov, Dmitri; Hapuarachchige, Sudath

Year: 2024

Venue: Utrecht University

DOI: https://dspace.library.uu.nl/handle/1874/455381

Thesis Breaking the selectivity-uptake trade-off of photoimmunoconjugates with nanoliposomal irinotecan for synergistic multi-tier cancer targeting

Liang, Barry J; Pigula, Michael; Baglo, Yan et al. · 2020 · Massachusetts Institute of Technology (MIT) · DOI

Full title: Breaking the selectivity-uptake trade-off of photoimmunoconjugates with nanoliposomal irinotecan for synergistic multi-tier cancer targeting

Authors: Liang, Barry J; Pigula, Michael; Baglo, Yan; Najafali, Daniel; Hasan, Tayyaba; Huang, Huang-Chiao

Year: 2020

Venue: Massachusetts Institute of Technology (MIT)

DOI: https://hdl.handle.net/1721.1/126246

Thesis Determination of Cellular Processing Rates for a Trastuzumab-Maytansinoid Antibody-Drug Conjugate (ADC) Highlights Key Parameters for ADC Design

Kulkarni, Chethana; Betts, Alison M.; Wittrup, Karl Dane et al. · 2016 · Massachusetts Institute of Technology (MIT) · DOI

Full title: Determination of Cellular Processing Rates for a Trastuzumab-Maytansinoid Antibody-Drug Conjugate (ADC) Highlights Key Parameters for ADC Design

Authors: Kulkarni, Chethana; Betts, Alison M.; Wittrup, Karl Dane; Maass, Katie F

Year: 2016

Venue: Massachusetts Institute of Technology (MIT)

DOI: http://hdl.handle.net/1721.1/103801

Thesis Enzyme-Mediated Modification of Single-Domain Antibodies for Imaging Modalities with Different Characteristics

Rashidian, Mohammad; Wang, Lu; Edens, Jerre G. et al. · 2017 · Massachusetts Institute of Technology (MIT) · DOI

Full title: Enzyme-Mediated Modification of Single-Domain Antibodies for Imaging Modalities with Different Characteristics

Authors: Rashidian, Mohammad; Wang, Lu; Edens, Jerre G.; Jacobsen, Johanne T.; Hossain, Intekhab; Wang, Qifan; Victora, Gabriel D.; Vasdev, Neil; Liang, Steven H.; Ploegh, Hidde

Year: 2017

Venue: Massachusetts Institute of Technology (MIT)

DOI: http://hdl.handle.net/1721.1/107992

Thesis Antibody-Mediated Neutralization of Perfringolysin O for Intracellular Protein Delivery

Yang, Nicole Jie Yeon; Sklaviadis, Demetra; Wittrup, Karl Dane et al. · 2016 · Massachusetts Institute of Technology (MIT) · DOI

Full title: Antibody-Mediated Neutralization of Perfringolysin O for Intracellular Protein Delivery

Authors: Yang, Nicole Jie Yeon; Sklaviadis, Demetra; Wittrup, Karl Dane; Gui, Dan Yi; Vander Heiden, Matthew G.; Liu, David V.

Year: 2016

Venue: Massachusetts Institute of Technology (MIT)

DOI: http://hdl.handle.net/1721.1/105826

Thesis π-Clamp-mediated cysteine conjugation

Zhang, Chi; Welborn, Matthew Gregory; Zhu, Tianyu et al. · 2017 · Massachusetts Institute of Technology (MIT) · DOI

Full title: π-Clamp-mediated cysteine conjugation

Authors: Zhang, Chi; Welborn, Matthew Gregory; Zhu, Tianyu; Yang, Nicole Jie Yeon; Santos, Michael; Van Voorhis, Troy; Pentelute, Bradley L.

Year: 2017

Venue: Massachusetts Institute of Technology (MIT)

DOI: http://hdl.handle.net/1721.1/109381

Thesis Theranostic pretargeted radioimmunotherapy of colorectal cancer xenografts in mice using picomolar affinity [superscript 86]Y- or [superscipt 177]Lu-DOTA-Bn binding scFv C825/GPA33 IgG bispecific immunoconjugates

Xu, Hong; Guo, Hong-fen; Lee, Sang-gyu et al. · 2016 · Massachusetts Institute of Technology (MIT) · DOI

Full title: Theranostic pretargeted radioimmunotherapy of colorectal cancer xenografts in mice using picomolar affinity [superscript 86]Y- or [superscipt 177]Lu-DOTA-Bn binding scFv C825/GPA33 IgG bispecific immunoconjugates

Authors: Xu, Hong; Guo, Hong-fen; Lee, Sang-gyu; Punzalan, Blesida; Chalasani, Sandhya; Jungbluth, Achim; O’Donoghue, Joseph; Cheal, Sarah M.; Fung, Edward K.; Zanzonico, Pat B.; Carrasquillo, Jorge A.; Smith-Jones, Peter M.; Cheung, Nai-Kong V.; Larson, Steven M.; Wittrup, Karl Dane

Year: 2016

Venue: Massachusetts Institute of Technology (MIT)

DOI: http://hdl.handle.net/1721.1/104432

Thesis Comparative Analysis of Bispecific Antibody and Streptavidin-Targeted Radioimmunotherapy for B-cell Cancers

Green, Damian J.; Frayo, Shani L.; Lin, Yukang et al. · 2020 · Massachusetts Institute of Technology (MIT) · DOI

Full title: Comparative Analysis of Bispecific Antibody and Streptavidin-Targeted Radioimmunotherapy for B-cell Cancers

Authors: Green, Damian J.; Frayo, Shani L.; Lin, Yukang; Hamlin, Donald K.; Fisher, Darrell R.; Frost, Sofia H.L.; Kenoyer, Aimee L.; Hylarides, Mark D.; Gopal, Ajay K.; Gooley, Theodore A.; Orozco, Johnnie J.; Till, Brian G.; O'Steen, Shyril; Orcutt, Kelly Davis; Wilbur, D. Scott; Wittrup, Karl Dane; Press, Oliver W.

Year: 2020

Venue: Massachusetts Institute of Technology (MIT)

DOI: https://hdl.handle.net/1721.1/125642

Thesis Site-Specific Antibody Functionalization Using Tetrazine–Styrene Cycloaddition

Mix, Kalie; Raines, Ronald T · 2020 · Massachusetts Institute of Technology (MIT) · DOI

Full title: Site-Specific Antibody Functionalization Using Tetrazine–Styrene Cycloaddition

Authors: Mix, Kalie; Raines, Ronald T

Year: 2020

Venue: Massachusetts Institute of Technology (MIT)

DOI: https://hdl.handle.net/1721.1/125600

Thesis One-Step Enzymatic Modification of the Cell Surface Redirects Cellular Cytotoxicity and Parasite Tropism

Swee, Lee Kim; Lourido, Sebastian; Bell, George W et al. · 2021 · Massachusetts Institute of Technology (MIT) · DOI

Full title: One-Step Enzymatic Modification of the Cell Surface Redirects Cellular Cytotoxicity and Parasite Tropism

Authors: Swee, Lee Kim; Lourido, Sebastian; Bell, George W; Ingram, Jessica R; Ploegh, Hidde L

Year: 2021

Venue: Massachusetts Institute of Technology (MIT)

DOI: https://hdl.handle.net/1721.1/134576

Thesis A Tumor-Homing Peptide Platform Enhances Drug Solubility, Improves Blood–Brain Barrier Permeability and Targets Glioblastoma

Cho, Choi-Fong; Farquhar, Charlotte E.; Fadzen, Colin M. et al. · 2022 · Massachusetts Institute of Technology (MIT) · DOI

Full title: A Tumor-Homing Peptide Platform Enhances Drug Solubility, Improves Blood–Brain Barrier Permeability and Targets Glioblastoma

Authors: Cho, Choi-Fong; Farquhar, Charlotte E.; Fadzen, Colin M.; Scott, Benjamin; Zhuang, Pei; von Spreckelsen, Niklas; Loas, Andrei; Hartrampf, Nina; Pentelute, Bradley L.; Lawler, Sean E.

Year: 2022

Venue: Massachusetts Institute of Technology (MIT)

DOI: https://hdl.handle.net/1721.1/142518

Thesis A mechanistic compartmental model for total antibody uptake in tumors

Thurber, Greg M; Dane Wittrup, K · 2021 · Massachusetts Institute of Technology (MIT) · DOI

Full title: A mechanistic compartmental model for total antibody uptake in tumors

Authors: Thurber, Greg M; Dane Wittrup, K

Year: 2021

Venue: Massachusetts Institute of Technology (MIT)

DOI: https://hdl.handle.net/1721.1/134471

Thesis IgG-Engineered Protective Antigen for Cytosolic Delivery of Proteins into Cancer Cells

Lu, Zeyu; Truex, Nicholas L; Melo, Mariane B et al. · 2021 · Massachusetts Institute of Technology (MIT) · DOI

Full title: IgG-Engineered Protective Antigen for Cytosolic Delivery of Proteins into Cancer Cells

Authors: Lu, Zeyu; Truex, Nicholas L; Melo, Mariane B; Cheng, Yiran; Li, Na; Irvine, Darrell J; Pentelute, Bradley L

Year: 2021

Venue: Massachusetts Institute of Technology (MIT)

DOI: https://hdl.handle.net/1721.1/133532

Thesis Sensitization of tumor cells for T cell mediated eradication through targeted delivery of virus-derived immunogenic peptide epitopes

Sefrin, Julian Peter · 2017 · Heidelberg University · DOI

Full title: Sensitization of tumor cells for T cell mediated eradication through targeted delivery of virus-derived immunogenic peptide epitopes

Authors: Sefrin, Julian Peter

Year: 2017

Venue: Heidelberg University

DOI: https://archiv.ub.uni-heidelberg.de/volltextserver/22809/1/Dissertation_JulianSefrin_2017.pdf

Thesis Synthesis and evaluation of radiolabeled peptide multimers for tumor targeting

Yim, C.B. · 2011 · Utrecht University · DOI

Full title: Synthesis and evaluation of radiolabeled peptide multimers for tumor targeting

Authors: Yim, C.B.

Year: 2011

Venue: Utrecht University

DOI: https://dspace.library.uu.nl/handle/1874/199335

Thesis Targeted Cytolysins Synergistically Potentiate Cytoplasmic Delivery of Gelonin Immunotoxin

Wittrup, K. D.; Pirie, Christopher M.; Liu, David V. et al. · 2016 · Massachusetts Institute of Technology (MIT) · DOI

Full title: Targeted Cytolysins Synergistically Potentiate Cytoplasmic Delivery of Gelonin Immunotoxin

Authors: Wittrup, K. D.; Pirie, Christopher M.; Liu, David V.; Wittrup, Karl Dane

Year: 2016

Venue: Massachusetts Institute of Technology (MIT)

DOI: http://hdl.handle.net/1721.1/101380

Patent us-10314921-b2

· 2019

Full title: us-10314921-b2

Year: 2019

Patent us-10314922-b2

· 2019

Full title: us-10314922-b2

Year: 2019

Patent us-10322192-b2

· 2019

Full title: us-10322192-b2

Year: 2019

Patent us-10442836-b2

· 2019

Full title: us-10442836-b2

Year: 2019

Patent us-10435432-b2

· 2019

Full title: us-10435432-b2

Year: 2019

Patent us-10407743-b2

· 2019

Full title: us-10407743-b2

Year: 2019

Patent us-10617670-b2

· 2020

Full title: us-10617670-b2

Year: 2020

Patent us-10494423-b2

· 2019

Full title: us-10494423-b2

Year: 2019

Patent us-10414826-b2

· 2019

Full title: us-10414826-b2

Year: 2019

Patent us-10537645-b2

· 2020

Full title: us-10537645-b2

Year: 2020

Patent us-10550190-b2

· 2020

Full title: us-10550190-b2

Year: 2020

Patent us-10618935-b2

· 2020

Full title: us-10618935-b2

Year: 2020

Patent us-10610602-b2

· 2020

Full title: us-10610602-b2

Year: 2020

Patent us-10548986-b2

· 2020

Full title: us-10548986-b2

Year: 2020

Patent us-10617764-b2

· 2020

Full title: us-10617764-b2

Year: 2020

Patent us-10639373-b2

· 2020

Full title: us-10639373-b2

Year: 2020

Patent us-10722591-b2

· 2020

Full title: us-10722591-b2

Year: 2020

Patent us-10723727-b2

· 2020

Full title: us-10723727-b2

Year: 2020

Patent us-10633453-b2

· 2020

Full title: us-10633453-b2

Year: 2020

Patent us-10729740-b2

· 2020

Full title: us-10729740-b2

Year: 2020

Patent us-10632196-b2

· 2020

Full title: us-10632196-b2

Year: 2020

Patent us-10633448-b2

· 2020

Full title: us-10633448-b2

Year: 2020

Patent us-10787480-b2

· 2020

Full title: us-10787480-b2

Year: 2020

Patent us-10780179-b2

· 2020

Full title: us-10780179-b2

Year: 2020

Patent us-10752673-b2

· 2020

Full title: us-10752673-b2

Year: 2020

Patent us-10864279-b2

· 2020

Full title: us-10864279-b2

Year: 2020

Patent us-10842881-b2

· 2020

Full title: us-10842881-b2

Year: 2020

Patent us-10960082-b2

· 2021

Full title: us-10960082-b2

Year: 2021

Patent us-10808039-b2

· 2020

Full title: us-10808039-b2

Year: 2020

Patent us-10913770-b2

· 2021

Full title: us-10913770-b2

Year: 2021

Patent us-10835617-b2

· 2020

Full title: us-10835617-b2

Year: 2020

Patent us-10836821-b2

· 2020

Full title: us-10836821-b2

Year: 2020

Patent us-10967068-b2

· 2021

Full title: us-10967068-b2

Year: 2021

Patent us-10987430-b2

· 2021

Full title: us-10987430-b2

Year: 2021

Patent us-10792372-b2

· 2020

Full title: us-10792372-b2

Year: 2020

Patent us-10994019-b2

· 2021

Full title: us-10994019-b2

Year: 2021

Patent us-10912841-b2

· 2021

Full title: us-10912841-b2

Year: 2021

Patent us-11104968-b2

· 2021

Full title: us-11104968-b2

Year: 2021

Patent us-10994021-b1

· 2021

Full title: us-10994021-b1

Year: 2021

Patent us-11135306-b2

· 2021

Full title: us-11135306-b2

Year: 2021

Patent us-11135308-b2

· 2021

Full title: us-11135308-b2

Year: 2021

Patent us-11090390-b2

· 2021

Full title: us-11090390-b2

Year: 2021

Patent us-11090322-b2

· 2021

Full title: us-11090322-b2

Year: 2021

Patent us-11028126-b2

· 2021

Full title: us-11028126-b2

Year: 2021

Patent us-11046759-b2

· 2021

Full title: us-11046759-b2

Year: 2021

Patent us-11149059-b2

· 2021

Full title: us-11149059-b2

Year: 2021

Patent us-11136633-b2

· 2021

Full title: us-11136633-b2

Year: 2021

Patent us-11135307-b2

· 2021

Full title: us-11135307-b2

Year: 2021

Patent us-11141490-b2

· 2021

Full title: us-11141490-b2

Year: 2021

Patent us-11229711-b2

· 2022

Full title: us-11229711-b2

Year: 2022

Patent us-11236131-b2

· 2022

Full title: us-11236131-b2

Year: 2022

Patent us-11167040-b2

· 2021

Full title: us-11167040-b2

Year: 2021

Patent us-11224663-b2

· 2022

Full title: us-11224663-b2

Year: 2022

Patent us-11311626-b2

· 2022

Full title: us-11311626-b2

Year: 2022

Patent us-11185594-b2

· 2021

Full title: us-11185594-b2

Year: 2021

Patent us-11193117-b2

· 2021

Full title: us-11193117-b2

Year: 2021

Patent us-11186642-b2

· 2021

Full title: us-11186642-b2

Year: 2021

Patent us-11278627-b2

· 2022

Full title: us-11278627-b2

Year: 2022

Patent us-11235065-b2

· 2022

Full title: us-11235065-b2

Year: 2022

Patent us-11325888-b2

· 2022

Full title: us-11325888-b2

Year: 2022

Patent us-11219693-b2

· 2022

Full title: us-11219693-b2

Year: 2022

Patent us-11352348-b2

· 2022

Full title: us-11352348-b2

Year: 2022

Patent us-11413353-b2

· 2022

Full title: us-11413353-b2

Year: 2022

Patent us-11458120-b2

· 2022

Full title: us-11458120-b2

Year: 2022

Patent us-11472875-b1

· 2022

Full title: us-11472875-b1

Year: 2022

Patent us-11311622-b2

· 2022

Full title: us-11311622-b2

Year: 2022

Patent us-11370838-b2

· 2022

Full title: us-11370838-b2

Year: 2022

Patent us-11242407-b2

· 2022

Full title: us-11242407-b2

Year: 2022

Patent us-11419944-b2

· 2022

Full title: us-11419944-b2

Year: 2022

Patent us-11517625-b2

· 2022

Full title: us-11517625-b2

Year: 2022

Patent us-11564989-b2

· 2023

Full title: us-11564989-b2

Year: 2023

Patent us-11478553-b2

· 2022

Full title: us-11478553-b2

Year: 2022

Patent us-11446292-b2

· 2022

Full title: us-11446292-b2

Year: 2022

Patent us-11547762-b2

· 2023

Full title: us-11547762-b2

Year: 2023

Patent us-11510994-b2

· 2022

Full title: us-11510994-b2

Year: 2022

Patent us-11602525-b2

· 2023

Full title: us-11602525-b2

Year: 2023

Patent us-11400157-b2

· 2022

Full title: us-11400157-b2

Year: 2022

Patent us-11548943-b2

· 2023

Full title: us-11548943-b2

Year: 2023

Patent us-11591295-b2

· 2023

Full title: us-11591295-b2

Year: 2023

Patent us-11596693-b2

· 2023

Full title: us-11596693-b2

Year: 2023

Patent us-11584800-b2

· 2023

Full title: us-11584800-b2

Year: 2023

Patent us-11607460-b2

· 2023

Full title: us-11607460-b2

Year: 2023

Patent us-11541128-b2

· 2023

Full title: us-11541128-b2

Year: 2023

Patent us-11613588-b2

· 2023

Full title: us-11613588-b2

Year: 2023

Patent us-11628225-b2

· 2023

Full title: us-11628225-b2

Year: 2023

Patent us-11690919-b2

· 2023

Full title: us-11690919-b2

Year: 2023

Patent us-11548944-b2

· 2023

Full title: us-11548944-b2

Year: 2023

Patent us-11446388-b2

· 2022

Full title: us-11446388-b2

Year: 2022

Patent us-11623965-b2

· 2023

Full title: us-11623965-b2

Year: 2023

Patent us-11666657-b2

· 2023

Full title: us-11666657-b2

Year: 2023

Patent us-11692043-b2

· 2023

Full title: us-11692043-b2

Year: 2023

Patent us-11662348-b2

· 2023

Full title: us-11662348-b2

Year: 2023

Patent us-11661457-b2

· 2023

Full title: us-11661457-b2

Year: 2023

Patent us-11744900-b2

· 2023

Full title: us-11744900-b2

Year: 2023

Patent us-11814410-b2

· 2023

Full title: us-11814410-b2

Year: 2023

Patent us-11696958-b2

· 2023

Full title: us-11696958-b2

Year: 2023

Patent us-11702473-b2

· 2023

Full title: us-11702473-b2

Year: 2023

Patent us-11786605-b2

· 2023

Full title: us-11786605-b2

Year: 2023

Patent us-11833214-b2

· 2023

Full title: us-11833214-b2

Year: 2023

Patent us-11753431-b2

· 2023

Full title: us-11753431-b2

Year: 2023

Patent us-11752215-b2

· 2023

Full title: us-11752215-b2

Year: 2023

Patent us-11786606-b2

· 2023

Full title: us-11786606-b2

Year: 2023

Patent us-11884746-b2

· 2024

Full title: us-11884746-b2

Year: 2024

Patent us-11857565-b2

· 2024

Full title: us-11857565-b2

Year: 2024

Patent us-11964025-b2

· 2024

Full title: us-11964025-b2

Year: 2024

Patent us-11918656-b2

· 2024

Full title: us-11918656-b2

Year: 2024

Patent us-11827686-b2

· 2023

Full title: us-11827686-b2

Year: 2023

Patent us-11951175-b2

· 2024

Full title: us-11951175-b2

Year: 2024

Patent us-11945807-b2

· 2024

Full title: us-11945807-b2

Year: 2024

Patent us-11951173-b2

· 2024

Full title: us-11951173-b2

Year: 2024

Patent us-12187745-b2

· 2025

Full title: us-12187745-b2

Year: 2025

Patent us-11987622-b2

· 2024

Full title: us-11987622-b2

Year: 2024

Patent us-12049505-b2

· 2024

Full title: us-12049505-b2

Year: 2024

Patent us-12018081-b1

· 2024

Full title: us-12018081-b1

Year: 2024

Patent us-12090210-b2

· 2024

Full title: us-12090210-b2

Year: 2024

Patent us-12036286-b2

· 2024

Full title: us-12036286-b2

Year: 2024

Patent us-12172986-b2

· 2024

Full title: us-12172986-b2

Year: 2024

Patent us-12090211-b2

· 2024

Full title: us-12090211-b2

Year: 2024

Patent us-12144864-b2

· 2024

Full title: us-12144864-b2

Year: 2024

Patent us-11980668-b2

· 2024

Full title: us-11980668-b2

Year: 2024

Patent us-12115227-b2

· 2024

Full title: us-12115227-b2

Year: 2024

Patent us-12115226-b2

· 2024

Full title: us-12115226-b2

Year: 2024

Patent us-12162942-b2

· 2024

Full title: us-12162942-b2

Year: 2024

Patent us-12195552-b2

· 2025

Full title: us-12195552-b2

Year: 2025

Patent us-12180552-b2

· 2024

Full title: us-12180552-b2

Year: 2024

Patent us-12178881-b2

· 2024

Full title: us-12178881-b2

Year: 2024

Patent us-12357701-b2

· 2025

Full title: us-12357701-b2

Year: 2025

Patent us-12280120-b2

· 2025

Full title: us-12280120-b2

Year: 2025

Patent us-12257340-b2

· 2025

Full title: us-12257340-b2

Year: 2025

Patent us-12269793-b2

· 2025

Full title: us-12269793-b2

Year: 2025

Patent us-12220604-b2

· 2025

Full title: us-12220604-b2

Year: 2025

Patent us-12187810-b2

· 2025

Full title: us-12187810-b2

Year: 2025

Patent us-12281174-b2

· 2025

Full title: us-12281174-b2

Year: 2025

Patent us-12214049-b2

· 2025

Full title: us-12214049-b2

Year: 2025

Patent us-12350345-b2

· 2025

Full title: us-12350345-b2

Year: 2025

Patent us-12268752-b2

· 2025

Full title: us-12268752-b2

Year: 2025

Patent us-12345711-b2

· 2025

Full title: us-12345711-b2

Year: 2025

Patent us-12358999-b2

· 2025

Full title: us-12358999-b2

Year: 2025

Patent us-12377143-b2

· 2025

Full title: us-12377143-b2

Year: 2025

Patent us-12428450-b2

· 2025

Full title: us-12428450-b2

Year: 2025

Patent us-12324841-b2

· 2025

Full title: us-12324841-b2

Year: 2025

Patent us-12440573-b2

· 2025

Full title: us-12440573-b2

Year: 2025

Patent us-12428494-b2

· 2025

Full title: us-12428494-b2

Year: 2025

Patent us-2003035804-a1

· 2003

Full title: us-2003035804-a1

Year: 2003

Patent us-12358998-b2

· 2025

Full title: us-12358998-b2

Year: 2025

Patent us-2003130189-a1

· 2003

Full title: us-2003130189-a1

Year: 2003

Patent us-12390471-b2

· 2025

Full title: us-12390471-b2

Year: 2025

Patent us-2004006049-a1

· 2004

Full title: us-2004006049-a1

Year: 2004

Patent us-12440570-b2

· 2025

Full title: us-12440570-b2

Year: 2025

Patent us-2003216298-a1

· 2003

Full title: us-2003216298-a1

Year: 2003

Patent us-2003096743-a1

· 2003

Full title: us-2003096743-a1

Year: 2003

Patent us-2005233948-a1

· 2005

Full title: us-2005233948-a1

Year: 2005

Patent us-2004192900-a1

· 2004

Full title: us-2004192900-a1

Year: 2004

Patent us-2003199519-a1

· 2003

Full title: us-2003199519-a1

Year: 2003

Patent us-2004109867-a1

· 2004

Full title: us-2004109867-a1

Year: 2004

Patent us-2005202561-a1

· 2005

Full title: us-2005202561-a1

Year: 2005

Patent us-2005069551-a1

· 2005

Full title: us-2005069551-a1

Year: 2005

Patent us-2005214310-a1

· 2005

Full title: us-2005214310-a1

Year: 2005

Patent us-2005054607-a1

· 2005

Full title: us-2005054607-a1

Year: 2005

Patent us-2008248052-a1

· 2008

Full title: us-2008248052-a1

Year: 2008

Patent us-2005255042-a1

· 2005

Full title: us-2005255042-a1

Year: 2005

Patent us-2005233943-a1

· 2005

Full title: us-2005233943-a1

Year: 2005

Patent us-2006009462-a1

· 2006

Full title: us-2006009462-a1

Year: 2006

Patent us-2006002942-a1

· 2006

Full title: us-2006002942-a1

Year: 2006

Patent us-2007135346-a1

· 2007

Full title: us-2007135346-a1

Year: 2007

Patent us-2004082764-a1

· 2004

Full title: us-2004082764-a1

Year: 2004

Patent us-2008267865-a1

· 2008

Full title: us-2008267865-a1

Year: 2008

Patent us-5338542-a

· 1994

Full title: us-5338542-a

Year: 1994

Patent us-5416064-a

· 1995

Full title: us-5416064-a

Year: 1995

Patent us-4880935-a

· 1989

Full title: us-4880935-a

Year: 1989

Patent us-5144012-a

· 1992

Full title: us-5144012-a

Year: 1992

Patent us-2025325690-a1

· 2025

Full title: us-2025325690-a1

Year: 2025

Patent us-5252713-a

· 1993

Full title: us-5252713-a

Year: 1993

Patent us-2025296912-a1

· 2025

Full title: us-2025296912-a1

Year: 2025

Patent us-5017693-a

· 1991

Full title: us-5017693-a

Year: 1991

Patent us-5141648-a

· 1992

Full title: us-5141648-a

Year: 1992

Patent us-5643573-a

· 1997

Full title: us-5643573-a

Year: 1997

Patent us-5306809-a

· 1994

Full title: us-5306809-a

Year: 1994

Patent us-5475092-a

· 1995

Full title: us-5475092-a

Year: 1995

Patent us-5563250-a

· 1996

Full title: us-5563250-a

Year: 1996

Patent us-5208020-a

· 1993

Full title: us-5208020-a

Year: 1993

Patent us-5665358-a

· 1997

Full title: us-5665358-a

Year: 1997

Patent us-5585499-a

· 1996

Full title: us-5585499-a

Year: 1996

Patent us-6441163-b1

· 2002

Full title: us-6441163-b1

Year: 2002

Patent us-5556623-a

· 1996

Full title: us-5556623-a

Year: 1996

Patent us-6368598-b1

· 2002

Full title: us-6368598-b1

Year: 2002

Patent us-5716990-a

· 1998

Full title: us-5716990-a

Year: 1998

Patent us-6552007-b2

· 2003

Full title: us-6552007-b2

Year: 2003

Patent us-7049316-b2

· 2006

Full title: us-7049316-b2

Year: 2006

Patent us-6756397-b2

· 2004

Full title: us-6756397-b2

Year: 2004

Patent us-7388026-b2

· 2008

Full title: us-7388026-b2

Year: 2008

Patent us-7091186-b2

· 2006

Full title: us-7091186-b2

Year: 2006

Patent us-7252993-b2

· 2007

Full title: us-7252993-b2

Year: 2007

Patent us-7135547-b2

· 2006

Full title: us-7135547-b2

Year: 2006

Patent us-6649587-b1

· 2003

Full title: us-6649587-b1

Year: 2003

Patent us-7232805-b2

· 2007

Full title: us-7232805-b2

Year: 2007

Patent us-7279502-b2

· 2007

Full title: us-7279502-b2

Year: 2007

Patent us-6759509-b1

· 2004

Full title: us-6759509-b1

Year: 2004

Patent us-7745394-b2

· 2010

Full title: us-7745394-b2

Year: 2010

Patent us-7553816-b2

· 2009

Full title: us-7553816-b2

Year: 2009

Patent us-7718601-b2

· 2010

Full title: us-7718601-b2

Year: 2010

Patent us-7655661-b2

· 2010

Full title: us-7655661-b2

Year: 2010

Patent us-7964567-b2

· 2011

Full title: us-7964567-b2

Year: 2011

Patent us-7638127-b2

· 2009

Full title: us-7638127-b2

Year: 2009

Patent us-7655660-b2

· 2010

Full title: us-7655660-b2

Year: 2010

Patent us-8313731-b2

· 2012

Full title: us-8313731-b2

Year: 2012

Patent us-8273787-b2

· 2012

Full title: us-8273787-b2

Year: 2012

Patent us-7964566-b2

· 2011

Full title: us-7964566-b2

Year: 2011

Patent us-7829531-b2

· 2010

Full title: us-7829531-b2

Year: 2010

Patent us-7906545-b2

· 2011

Full title: us-7906545-b2

Year: 2011

Patent us-7981400-b2

· 2011

Full title: us-7981400-b2

Year: 2011

Patent us-8557780-b2

· 2013

Full title: us-8557780-b2

Year: 2013

Patent us-8722629-b2

· 2014

Full title: us-8722629-b2

Year: 2014

Patent us-7994135-b2

· 2011

Full title: us-7994135-b2

Year: 2011

Patent us-8465724-b2

· 2013

Full title: us-8465724-b2

Year: 2013

Patent us-8153768-b2

· 2012

Full title: us-8153768-b2

Year: 2012

Patent us-8314060-b2

· 2012

Full title: us-8314060-b2

Year: 2012

Patent us-8703714-b2

· 2014

Full title: us-8703714-b2

Year: 2014

Patent us-8895702-b2

· 2014

Full title: us-8895702-b2

Year: 2014

Patent us-8835611-b2

· 2014

Full title: us-8835611-b2

Year: 2014

Patent us-8808679-b2

· 2014

Full title: us-8808679-b2

Year: 2014

Patent us-9242012-b2

· 2016

Full title: us-9242012-b2

Year: 2016

Patent us-8747857-b2

· 2014

Full title: us-8747857-b2

Year: 2014

Patent us-9351986-b2

· 2016

Full title: us-9351986-b2

Year: 2016

Patent us-9044468-b2

· 2015

Full title: us-9044468-b2

Year: 2015

Patent us-9408923-b2

· 2016

Full title: us-9408923-b2

Year: 2016

Patent us-8795673-b2

· 2014

Full title: us-8795673-b2

Year: 2014

Patent us-9089614-b2

· 2015

Full title: us-9089614-b2

Year: 2015

Patent us-9150649-b2

· 2015

Full title: us-9150649-b2

Year: 2015

Patent us-9375488-b2

· 2016

Full title: us-9375488-b2

Year: 2016

Patent us-9254339-b2

· 2016

Full title: us-9254339-b2

Year: 2016

Patent us-9428543-b2

· 2016

Full title: us-9428543-b2

Year: 2016

Patent us-9193791-b2

· 2015

Full title: us-9193791-b2

Year: 2015

Patent us-9522194-b2

· 2016

Full title: us-9522194-b2

Year: 2016

Patent us-9617326-b2

· 2017

Full title: us-9617326-b2

Year: 2017

Patent us-9579317-b2

· 2017

Full title: us-9579317-b2

Year: 2017

Patent us-9669106-b2

· 2017

Full title: us-9669106-b2

Year: 2017

Patent us-2018133340-a1

· 2018

Full title: us-2018133340-a1

Year: 2018

Patent us-2018125972-a1

· 2018

Full title: us-2018125972-a1

Year: 2018

Patent us-2018125988-a1

· 2018

Full title: us-2018125988-a1

Year: 2018

Patent us-2018085478-a1

· 2018

Full title: us-2018085478-a1

Year: 2018

Patent us-2018147295-a1

· 2018

Full title: us-2018147295-a1

Year: 2018

Patent us-2018228915-a1

· 2018

Full title: us-2018228915-a1

Year: 2018

Patent us-2018169262-a1

· 2018

Full title: us-2018169262-a1

Year: 2018

Patent us-2018193478-a1

· 2018

Full title: us-2018193478-a1

Year: 2018

Patent us-2018228769-a1

· 2018

Full title: us-2018228769-a1

Year: 2018

Patent us-2018177889-a1

· 2018

Full title: us-2018177889-a1

Year: 2018

Patent us-2018273581-a1

· 2018

Full title: us-2018273581-a1

Year: 2018

Patent us-2018243428-a1

· 2018

Full title: us-2018243428-a1

Year: 2018

Patent us-2018355025-a1

· 2018

Full title: us-2018355025-a1

Year: 2018

Patent us-2018326062-a1

· 2018

Full title: us-2018326062-a1

Year: 2018

Patent us-2018264131-a1

· 2018

Full title: us-2018264131-a1

Year: 2018

Patent us-2018296694-a1

· 2018

Full title: us-2018296694-a1

Year: 2018

Patent us-2018311375-a1

· 2018

Full title: us-2018311375-a1

Year: 2018

Patent us-2018339058-a1

· 2018

Full title: us-2018339058-a1

Year: 2018

Patent us-2018344864-a1

· 2018

Full title: us-2018344864-a1

Year: 2018

Patent us-2018362519-a1

· 2018

Full title: us-2018362519-a1

Year: 2018

Patent us-2019054102-a1

· 2019

Full title: us-2019054102-a1

Year: 2019

Patent us-2019135864-a1

· 2019

Full title: us-2019135864-a1

Year: 2019

Patent us-2019015519-a1

· 2019

Full title: us-2019015519-a1

Year: 2019

Patent us-2019030180-a1

· 2019

Full title: us-2019030180-a1

Year: 2019

Patent us-2019184029-a1

· 2019

Full title: us-2019184029-a1

Year: 2019

Patent us-2019144559-a1

· 2019

Full title: us-2019144559-a1

Year: 2019

Patent us-2019055321-a1

· 2019

Full title: us-2019055321-a1

Year: 2019

Patent us-2019134213-a1

· 2019

Full title: us-2019134213-a1

Year: 2019

Patent us-2019083637-a1

· 2019

Full title: us-2019083637-a1

Year: 2019

Patent us-2019030179-a1

· 2019

Full title: us-2019030179-a1

Year: 2019

Patent us-2019201544-a1

· 2019

Full title: us-2019201544-a1

Year: 2019

Patent us-2019248887-a1

· 2019

Full title: us-2019248887-a1

Year: 2019

Patent us-2019077752-a1

· 2019

Full title: us-2019077752-a1

Year: 2019

Patent us-2019151464-a1

· 2019

Full title: us-2019151464-a1

Year: 2019

Patent us-2019194315-a1

· 2019

Full title: us-2019194315-a1

Year: 2019

Patent us-2019262467-a1

· 2019

Full title: us-2019262467-a1

Year: 2019

Patent us-2019151462-a1

· 2019

Full title: us-2019151462-a1

Year: 2019

Patent us-2019209704-a1

· 2019

Full title: us-2019209704-a1

Year: 2019

Patent us-2019270828-a1

· 2019

Full title: us-2019270828-a1

Year: 2019

Patent us-2019241652-a9

· 2019

Full title: us-2019241652-a9

Year: 2019

Patent us-2019321482-a1

· 2019

Full title: us-2019321482-a1

Year: 2019

Patent us-2019269788-a1

· 2019

Full title: us-2019269788-a1

Year: 2019

Patent us-2019284283-a1

· 2019

Full title: us-2019284283-a1

Year: 2019

Patent us-2019262417-a1

· 2019

Full title: us-2019262417-a1

Year: 2019

Patent us-2019328895-a1

· 2019

Full title: us-2019328895-a1

Year: 2019

Patent us-2019203192-a1

· 2019

Full title: us-2019203192-a1

Year: 2019

Patent us-2019381183-a1

· 2019

Full title: us-2019381183-a1

Year: 2019

Patent us-2019365914-a1

· 2019

Full title: us-2019365914-a1

Year: 2019

Patent us-2019375837-a1

· 2019

Full title: us-2019375837-a1

Year: 2019

Patent us-2019367999-a1

· 2019

Full title: us-2019367999-a1

Year: 2019

Patent us-2019358202-a1

· 2019

Full title: us-2019358202-a1

Year: 2019

Patent us-2019368000-a1

· 2019

Full title: us-2019368000-a1

Year: 2019

Patent us-2019358340-a1

· 2019

Full title: us-2019358340-a1

Year: 2019

Patent us-2019328899-a1

· 2019

Full title: us-2019328899-a1

Year: 2019

Patent us-2019388555-a1

· 2019

Full title: us-2019388555-a1

Year: 2019

Patent us-2019388553-a1

· 2019

Full title: us-2019388553-a1

Year: 2019

Patent us-2019382441-a1

· 2019

Full title: us-2019382441-a1

Year: 2019

Patent us-2019338045-a1

· 2019

Full title: us-2019338045-a1

Year: 2019

Patent us-2020016276-a1

· 2020

Full title: us-2020016276-a1

Year: 2020

Patent us-2020054764-a1

· 2020

Full title: us-2020054764-a1

Year: 2020

Patent us-2020003778-a1

· 2020

Full title: us-2020003778-a1

Year: 2020

Patent us-2020108152-a1

· 2020

Full title: us-2020108152-a1

Year: 2020

Patent us-2020129639-a1

· 2020

Full title: us-2020129639-a1

Year: 2020

Patent us-2019381185-a1

· 2019

Full title: us-2019381185-a1

Year: 2019

Patent us-2020116727-a1

· 2020

Full title: us-2020116727-a1

Year: 2020

Patent us-2020069814-a1

· 2020

Full title: us-2020069814-a1

Year: 2020

Patent us-2020254111-a1

· 2020

Full title: us-2020254111-a1

Year: 2020

Patent us-2020255543-a1

· 2020

Full title: us-2020255543-a1

Year: 2020

Patent us-2020069815-a1

· 2020

Full title: us-2020069815-a1

Year: 2020

Patent us-2020147231-a1

· 2020

Full title: us-2020147231-a1

Year: 2020

Patent us-2020157240-a1

· 2020

Full title: us-2020157240-a1

Year: 2020

Patent us-2020270352-a1

· 2020

Full title: us-2020270352-a1

Year: 2020

Patent us-2020276331-a1

· 2020

Full title: us-2020276331-a1

Year: 2020

Patent us-2020172484-a1

· 2020

Full title: us-2020172484-a1

Year: 2020

Patent us-2020330604-a1

· 2020

Full title: us-2020330604-a1

Year: 2020

Patent us-2020338206-a1

· 2020

Full title: us-2020338206-a1

Year: 2020

Patent us-2020282072-a1

· 2020

Full title: us-2020282072-a1

Year: 2020

Patent us-2007160573-a1

· 2007

Full title: us-2007160573-a1

Year: 2007

Patent us-2006008475-a1

· 2006

Full title: us-2006008475-a1

Year: 2006

Patent us-2008260685-a1

· 2008

Full title: us-2008260685-a1

Year: 2008

Patent us-2007160617-a1

· 2007

Full title: us-2007160617-a1

Year: 2007

Patent us-2009155289-a1

· 2009

Full title: us-2009155289-a1

Year: 2009

Patent us-2009275664-a1

· 2009

Full title: us-2009275664-a1

Year: 2009

Patent us-2009105461-a1

· 2009

Full title: us-2009105461-a1

Year: 2009

Patent us-2010129314-a1

· 2010

Full title: us-2010129314-a1

Year: 2010

Patent us-2009281158-a1

· 2009

Full title: us-2009281158-a1

Year: 2009

Patent us-2009220529-a1

· 2009

Full title: us-2009220529-a1

Year: 2009

Patent us-2010168019-a1

· 2010

Full title: us-2010168019-a1

Year: 2010

Patent us-2010215670-a1

· 2010

Full title: us-2010215670-a1

Year: 2010

Patent us-2010329992-a1

· 2010

Full title: us-2010329992-a1

Year: 2010

Patent us-2011178279-a1

· 2011

Full title: us-2011178279-a1

Year: 2011

Patent us-2010022615-a1

· 2010

Full title: us-2010022615-a1

Year: 2010

Patent us-2011229476-a1

· 2011

Full title: us-2011229476-a1

Year: 2011

Patent us-2011250216-a1

· 2011

Full title: us-2011250216-a1

Year: 2011

Patent us-2011243914-a1

· 2011

Full title: us-2011243914-a1

Year: 2011

Patent us-2011008373-a1

· 2011

Full title: us-2011008373-a1

Year: 2011

Patent us-2011064657-a1

· 2011

Full title: us-2011064657-a1

Year: 2011

Patent us-2011152252-a1

· 2011

Full title: us-2011152252-a1

Year: 2011

Patent us-2012121615-a1

· 2012

Full title: us-2012121615-a1

Year: 2012

Patent us-2011160147-a1

· 2011

Full title: us-2011160147-a1

Year: 2011

Patent us-2012226026-a1

· 2012

Full title: us-2012226026-a1

Year: 2012

Patent us-2012253021-a1

· 2012

Full title: us-2012253021-a1

Year: 2012

Patent us-2013060010-a1

· 2013

Full title: us-2013060010-a1

Year: 2013

Patent us-2012213804-a1

· 2012

Full title: us-2012213804-a1

Year: 2012

Patent us-2014004081-a1

· 2014

Full title: us-2014004081-a1

Year: 2014

Patent us-2013150558-a1

· 2013

Full title: us-2013150558-a1

Year: 2013

Patent us-2013184435-a1

· 2013

Full title: us-2013184435-a1

Year: 2013

Patent us-2013309192-a1

· 2013

Full title: us-2013309192-a1

Year: 2013

Patent us-2014235835-a1

· 2014

Full title: us-2014235835-a1

Year: 2014

Patent us-2014058064-a1

· 2014

Full title: us-2014058064-a1

Year: 2014

Patent us-2014193437-a1

· 2014

Full title: us-2014193437-a1

Year: 2014

Patent us-2014309406-a1

· 2014

Full title: us-2014309406-a1

Year: 2014

Patent us-2015044238-a1

· 2015

Full title: us-2015044238-a1

Year: 2015

Patent us-2014322234-a1

· 2014

Full title: us-2014322234-a1

Year: 2014

Patent us-2014286968-a1

· 2014

Full title: us-2014286968-a1

Year: 2014

Patent us-2015064130-a1

· 2015

Full title: us-2015064130-a1

Year: 2015

Patent us-2015218217-a1

· 2015

Full title: us-2015218217-a1

Year: 2015

Patent us-2015105540-a1

· 2015

Full title: us-2015105540-a1

Year: 2015

Patent us-2015165067-a1

· 2015

Full title: us-2015165067-a1

Year: 2015

Patent us-2015079114-a1

· 2015

Full title: us-2015079114-a1

Year: 2015

Patent us-2015140022-a1

· 2015

Full title: us-2015140022-a1

Year: 2015

Patent us-2024148883-a1

· 2024

Full title: us-2024148883-a1

Year: 2024

Patent us-2024156976-a1

· 2024

Full title: us-2024156976-a1

Year: 2024

Patent us-2024131176-a1

· 2024

Full title: us-2024131176-a1

Year: 2024

Patent us-2024132595-a1

· 2024

Full title: us-2024132595-a1

Year: 2024

Patent us-2024150478-a1

· 2024

Full title: us-2024150478-a1

Year: 2024

Patent us-2024131180-a1

· 2024

Full title: us-2024131180-a1

Year: 2024

Patent us-2024182537-a1

· 2024

Full title: us-2024182537-a1

Year: 2024

Patent us-2024156978-a1

· 2024

Full title: us-2024156978-a1

Year: 2024

Patent us-2024197907-a1

· 2024

Full title: us-2024197907-a1

Year: 2024

Patent us-2024165251-a1

· 2024

Full title: us-2024165251-a1

Year: 2024

Patent us-2024216521-a1

· 2024

Full title: us-2024216521-a1

Year: 2024

Patent us-2024216420-a1

· 2024

Full title: us-2024216420-a1

Year: 2024

Patent us-2024238431-a1

· 2024

Full title: us-2024238431-a1

Year: 2024

Patent us-2024293569-a1

· 2024

Full title: us-2024293569-a1

Year: 2024

Patent us-2024207427-a1

· 2024

Full title: us-2024207427-a1

Year: 2024

Patent us-2024218037-a1

· 2024

Full title: us-2024218037-a1

Year: 2024

Patent us-2024245801-a1

· 2024

Full title: us-2024245801-a1

Year: 2024

Patent us-2024197900-a1

· 2024

Full title: us-2024197900-a1

Year: 2024

Patent us-2024269305-a1

· 2024

Full title: us-2024269305-a1

Year: 2024

Patent us-2024335557-a1

· 2024

Full title: us-2024335557-a1

Year: 2024

Patent us-2024293570-a1

· 2024

Full title: us-2024293570-a1

Year: 2024

Patent us-2024261424-a1

· 2024

Full title: us-2024261424-a1

Year: 2024

Patent us-2024238440-a1

· 2024

Full title: us-2024238440-a1

Year: 2024

Patent us-2024342303-a1

· 2024

Full title: us-2024342303-a1

Year: 2024

Patent us-2024335570-a1

· 2024

Full title: us-2024335570-a1

Year: 2024

Patent us-2024335552-a1

· 2024

Full title: us-2024335552-a1

Year: 2024

Patent us-2024327538-a1

· 2024

Full title: us-2024327538-a1

Year: 2024

Patent us-2024366779-a1

· 2024

Full title: us-2024366779-a1

Year: 2024

Patent us-2024382611-a1

· 2024

Full title: us-2024382611-a1

Year: 2024

Patent us-2024360108-a1

· 2024

Full title: us-2024360108-a1

Year: 2024

Patent us-2024342304-a1

· 2024

Full title: us-2024342304-a1

Year: 2024

Patent us-2024400696-a1

· 2024

Full title: us-2024400696-a1

Year: 2024

Patent us-2024398971-a1

· 2024

Full title: us-2024398971-a1

Year: 2024

Patent us-2024400614-a1

· 2024

Full title: us-2024400614-a1

Year: 2024

Patent us-2025018052-a1

· 2025

Full title: us-2025018052-a1

Year: 2025

Patent us-2024398972-a1

· 2024

Full title: us-2024398972-a1

Year: 2024

Patent us-2024417437-a1

· 2024

Full title: us-2024417437-a1

Year: 2024

Patent us-2024423973-a1

· 2024

Full title: us-2024423973-a1

Year: 2024

Patent us-2025018051-a1

· 2025

Full title: us-2025018051-a1

Year: 2025

Patent us-2025064966-a1

· 2025

Full title: us-2025064966-a1

Year: 2025

Patent us-2025049938-a1

· 2025

Full title: us-2025049938-a1

Year: 2025

Patent us-2025049937-a1

· 2025

Full title: us-2025049937-a1

Year: 2025

Patent us-2025064953-a1

· 2025

Full title: us-2025064953-a1

Year: 2025

Patent us-2025082768-a1

· 2025

Full title: us-2025082768-a1

Year: 2025

Patent us-2025011470-a1

· 2025

Full title: us-2025011470-a1

Year: 2025

Patent us-2025059296-a1

· 2025

Full title: us-2025059296-a1

Year: 2025

Patent us-2025064965-a1

· 2025

Full title: us-2025064965-a1

Year: 2025

Patent us-2025115677-a1

· 2025

Full title: us-2025115677-a1

Year: 2025

Patent us-2025135017-a1

· 2025

Full title: us-2025135017-a1

Year: 2025

Patent us-2025195680-a1

· 2025

Full title: us-2025195680-a1

Year: 2025

Patent us-2025090875-a9

· 2025

Full title: us-2025090875-a9

Year: 2025

Patent us-2025108123-a1

· 2025

Full title: us-2025108123-a1

Year: 2025

Patent us-2025115679-a1

· 2025

Full title: us-2025115679-a1

Year: 2025

Patent us-2025121075-a1

· 2025

Full title: us-2025121075-a1

Year: 2025

Patent us-2025145731-a1

· 2025

Full title: us-2025145731-a1

Year: 2025

Patent us-2025161506-a1

· 2025

Full title: us-2025161506-a1

Year: 2025

Patent us-2025152723-a1

· 2025

Full title: us-2025152723-a1

Year: 2025

Patent us-2025188172-a1

· 2025

Full title: us-2025188172-a1

Year: 2025

Patent us-2025179117-a1

· 2025

Full title: us-2025179117-a1

Year: 2025

Patent us-2025195675-a1

· 2025

Full title: us-2025195675-a1

Year: 2025

Patent us-2025213712-a1

· 2025

Full title: us-2025213712-a1

Year: 2025

Patent us-2025195683-a1

· 2025

Full title: us-2025195683-a1

Year: 2025

Patent us-2025222128-a1

· 2025

Full title: us-2025222128-a1

Year: 2025

Patent us-2025136717-a1

· 2025

Full title: us-2025136717-a1

Year: 2025

Patent us-2025188184-a1

· 2025

Full title: us-2025188184-a1

Year: 2025

Patent us-2025257146-a1

· 2025

Full title: us-2025257146-a1

Year: 2025

Patent us-2025262312-a1

· 2025

Full title: us-2025262312-a1

Year: 2025

Patent us-2025205349-a1

· 2025

Full title: us-2025205349-a1

Year: 2025

Patent us-2025235547-a1

· 2025

Full title: us-2025235547-a1

Year: 2025

Patent us-2025249111-a1

· 2025

Full title: us-2025249111-a1

Year: 2025

Patent us-2025223302-a1

· 2025

Full title: us-2025223302-a1

Year: 2025

Patent us-2025242044-a1

· 2025

Full title: us-2025242044-a1

Year: 2025

Patent us-2025249113-a1

· 2025

Full title: us-2025249113-a1

Year: 2025

Patent us-2025249112-a1

· 2025

Full title: us-2025249112-a1

Year: 2025

Patent us-2025262307-a1

· 2025

Full title: us-2025262307-a1

Year: 2025

Patent us-2025276075-a1

· 2025

Full title: us-2025276075-a1

Year: 2025

Patent us-2025277060-a1

· 2025

Full title: us-2025277060-a1

Year: 2025

Patent us-2025270314-a1

· 2025

Full title: us-2025270314-a1

Year: 2025

Patent us-2025276077-a1

· 2025

Full title: us-2025276077-a1

Year: 2025

Patent us-5094849-a

· 1992

Full title: us-5094849-a

Year: 1992

Patent us-2020291135-a1

· 2020

Full title: us-2020291135-a1

Year: 2020

Patent us-2020164077-a1

· 2020

Full title: us-2020164077-a1

Year: 2020

Patent us-2020353032-a1

· 2020

Full title: us-2020353032-a1

Year: 2020

Patent us-2020347149-a1

· 2020

Full title: us-2020347149-a1

Year: 2020

Patent us-2020297865-a1

· 2020

Full title: us-2020297865-a1

Year: 2020

Patent us-2020297859-a1

· 2020

Full title: us-2020297859-a1

Year: 2020

Patent us-2020377602-a1

· 2020

Full title: us-2020377602-a1

Year: 2020

Patent us-2020297860-a1

· 2020

Full title: us-2020297860-a1

Year: 2020

Patent us-2020361988-a1

· 2020

Full title: us-2020361988-a1

Year: 2020

Patent us-2020306243-a1

· 2020

Full title: us-2020306243-a1

Year: 2020

Patent us-2021030889-a1

· 2021

Full title: us-2021030889-a1

Year: 2021

Patent us-2021017274-a1

· 2021

Full title: us-2021017274-a1

Year: 2021

Patent us-2020405874-a1

· 2020

Full title: us-2020405874-a1

Year: 2020

Patent us-2021008099-a1

· 2021

Full title: us-2021008099-a1

Year: 2021

Patent us-2020407457-a1

· 2020

Full title: us-2020407457-a1

Year: 2020

Patent us-2021101888-a1

· 2021

Full title: us-2021101888-a1

Year: 2021

Patent us-2021002343-a1

· 2021

Full title: us-2021002343-a1

Year: 2021

Patent us-2020399365-a1

· 2020

Full title: us-2020399365-a1

Year: 2020

Patent us-2020392108-a1

· 2020

Full title: us-2020392108-a1

Year: 2020

Patent us-2021138077-a1

· 2021

Full title: us-2021138077-a1

Year: 2021

Patent us-2021038738-a1

· 2021

Full title: us-2021038738-a1

Year: 2021

Patent us-2021205464-a1

· 2021

Full title: us-2021205464-a1

Year: 2021

Patent us-2021177985-a1

· 2021

Full title: us-2021177985-a1

Year: 2021

Patent us-2021030887-a1

· 2021

Full title: us-2021030887-a1

Year: 2021

Patent us-2021113710-a1

· 2021

Full title: us-2021113710-a1

Year: 2021

Patent us-2021113707-a1

· 2021

Full title: us-2021113707-a1

Year: 2021

Patent us-2021023094-a1

· 2021

Full title: us-2021023094-a1

Year: 2021

Patent us-2021154321-a1

· 2021

Full title: us-2021154321-a1

Year: 2021

Patent us-2021138083-a1

· 2021

Full title: us-2021138083-a1

Year: 2021

Patent us-2021260208-a1

· 2021

Full title: us-2021260208-a1

Year: 2021

Patent us-2021139549-a1

· 2021

Full title: us-2021139549-a1

Year: 2021

Patent us-2021238303-a1

· 2021

Full title: us-2021238303-a1

Year: 2021

Patent us-2021205463-a1

· 2021

Full title: us-2021205463-a1

Year: 2021

Patent us-2021155583-a1

· 2021

Full title: us-2021155583-a1

Year: 2021

Patent us-2021220477-a1

· 2021

Full title: us-2021220477-a1

Year: 2021

Patent us-2021283269-a1

· 2021

Full title: us-2021283269-a1

Year: 2021

Patent us-2021162058-a1

· 2021

Full title: us-2021162058-a1

Year: 2021

Patent us-2021290775-a1

· 2021

Full title: us-2021290775-a1

Year: 2021

Patent us-2021252160-a1

· 2021

Full title: us-2021252160-a1

Year: 2021

Patent us-2021299269-a1

· 2021

Full title: us-2021299269-a1

Year: 2021

Patent us-2021261505-a1

· 2021

Full title: us-2021261505-a1

Year: 2021

Patent us-2021228728-a1

· 2021

Full title: us-2021228728-a1

Year: 2021

Patent us-2021299270-a1

· 2021

Full title: us-2021299270-a1

Year: 2021

Patent us-2021290777-a1

· 2021

Full title: us-2021290777-a1

Year: 2021

Patent us-2021322401-a1

· 2021

Full title: us-2021322401-a1

Year: 2021

Patent us-2021300972-a1

· 2021

Full title: us-2021300972-a1

Year: 2021

Patent us-2021330802-a1

· 2021

Full title: us-2021330802-a1

Year: 2021

Patent us-2021324031-a1

· 2021

Full title: us-2021324031-a1

Year: 2021

Patent us-2021301015-a1

· 2021

Full title: us-2021301015-a1

Year: 2021

Patent us-2021347886-a1

· 2021

Full title: us-2021347886-a1

Year: 2021

Patent us-2021346510-a1

· 2021

Full title: us-2021346510-a1

Year: 2021

Patent us-2021355208-a1

· 2021

Full title: us-2021355208-a1

Year: 2021

Patent us-2021393789-a1

· 2021

Full title: us-2021393789-a1

Year: 2021

Patent us-2021386867-a1

· 2021

Full title: us-2021386867-a1

Year: 2021

Patent us-2021388017-a1

· 2021

Full title: us-2021388017-a1

Year: 2021

Patent us-2021369855-a1

· 2021

Full title: us-2021369855-a1

Year: 2021

Patent us-2022031859-a1

· 2022

Full title: us-2022031859-a1

Year: 2022

Patent us-2022031858-a1

· 2022

Full title: us-2022031858-a1

Year: 2022

Patent us-2021388115-a1

· 2021

Full title: us-2021388115-a1

Year: 2021

Patent us-2021393795-a1

· 2021

Full title: us-2021393795-a1

Year: 2021

Patent us-2021393790-a1

· 2021

Full title: us-2021393790-a1

Year: 2021

Patent us-2021393792-a1

· 2021

Full title: us-2021393792-a1

Year: 2021

Patent us-2022040321-a1

· 2022

Full title: us-2022040321-a1

Year: 2022

Patent us-2022040320-a1

· 2022

Full title: us-2022040320-a1

Year: 2022

Patent us-2022105195-a1

· 2022

Full title: us-2022105195-a1

Year: 2022

Patent us-2022023433-a1

· 2022

Full title: us-2022023433-a1

Year: 2022

Patent us-2022088191-a1

· 2022

Full title: us-2022088191-a1

Year: 2022

Patent us-2022073637-a1

· 2022

Full title: us-2022073637-a1

Year: 2022

Patent us-2022072137-a1

· 2022

Full title: us-2022072137-a1

Year: 2022

Patent us-2022062436-a1

· 2022

Full title: us-2022062436-a1

Year: 2022

Patent us-2022096652-a1

· 2022

Full title: us-2022096652-a1

Year: 2022

Patent us-2022119549-a1

· 2022

Full title: us-2022119549-a1

Year: 2022

Patent us-2022054649-a1

· 2022

Full title: us-2022054649-a1

Year: 2022

Patent us-2022111067-a1

· 2022

Full title: us-2022111067-a1

Year: 2022

Patent us-2022105197-a1

· 2022

Full title: us-2022105197-a1

Year: 2022

Patent us-2022133899-a1

· 2022

Full title: us-2022133899-a1

Year: 2022

Patent us-2022153869-a1

· 2022

Full title: us-2022153869-a1

Year: 2022

Patent us-2022175950-a1

· 2022

Full title: us-2022175950-a1

Year: 2022

Patent us-2022118104-a1

· 2022

Full title: us-2022118104-a1

Year: 2022

Patent us-2022143196-a1

· 2022

Full title: us-2022143196-a1

Year: 2022

Patent us-2022241423-a1

· 2022

Full title: us-2022241423-a1

Year: 2022

Patent us-2022218837-a1

· 2022

Full title: us-2022218837-a1

Year: 2022

Patent us-2021346508-a1

· 2021

Full title: us-2021346508-a1

Year: 2021

Patent us-2022226490-a1

· 2022

Full title: us-2022226490-a1

Year: 2022

Patent us-2022168436-a1

· 2022

Full title: us-2022168436-a1

Year: 2022

Patent us-2015087810-a1

· 2015

Full title: us-2015087810-a1

Year: 2015

Patent us-2015359903-a1

· 2015

Full title: us-2015359903-a1

Year: 2015

Patent us-2015352222-a1

· 2015

Full title: us-2015352222-a1

Year: 2015

Patent us-2016045616-a1

· 2016

Full title: us-2016045616-a1

Year: 2016

Patent us-2015343083-a1

· 2015

Full title: us-2015343083-a1

Year: 2015

Patent us-2016015830-a1

· 2016

Full title: us-2016015830-a1

Year: 2016

Patent us-2015307587-a1

· 2015

Full title: us-2015307587-a1

Year: 2015

Patent us-2015297748-a1

· 2015

Full title: us-2015297748-a1

Year: 2015

Patent us-2016114052-a1

· 2016

Full title: us-2016114052-a1

Year: 2016

Patent us-2016129128-a1

· 2016

Full title: us-2016129128-a1

Year: 2016

Patent us-2016144042-a1

· 2016

Full title: us-2016144042-a1

Year: 2016

Patent us-2016022829-a1

· 2016

Full title: us-2016022829-a1

Year: 2016

Patent us-2016106856-a1

· 2016

Full title: us-2016106856-a1

Year: 2016

Patent us-2016015832-a1

· 2016

Full title: us-2016015832-a1

Year: 2016

Patent us-2016130359-a1

· 2016

Full title: us-2016130359-a1

Year: 2016

Patent us-2016152711-a1

· 2016

Full title: us-2016152711-a1

Year: 2016

Patent us-2016051695-a1

· 2016

Full title: us-2016051695-a1

Year: 2016

Patent us-2016263244-a1

· 2016

Full title: us-2016263244-a1

Year: 2016

Patent us-2016220696-a1

· 2016

Full title: us-2016220696-a1

Year: 2016

Patent us-2016185875-a1

· 2016

Full title: us-2016185875-a1

Year: 2016

Patent us-2016289324-a1

· 2016

Full title: us-2016289324-a1

Year: 2016

Patent us-2016297890-a1

· 2016

Full title: us-2016297890-a1

Year: 2016

Patent us-2017035892-a1

· 2017

Full title: us-2017035892-a1

Year: 2017

Patent us-2016311853-a1

· 2016

Full title: us-2016311853-a1

Year: 2016

Patent us-2016303252-a1

· 2016

Full title: us-2016303252-a1

Year: 2016

Patent us-2017035894-a1

· 2017

Full title: us-2017035894-a1

Year: 2017

Patent us-2017037080-a1

· 2017

Full title: us-2017037080-a1

Year: 2017

Patent us-2017028080-a1

· 2017

Full title: us-2017028080-a1

Year: 2017

Patent us-2017043032-a1

· 2017

Full title: us-2017043032-a1

Year: 2017

Patent us-2017080102-a1

· 2017

Full title: us-2017080102-a1

Year: 2017

Patent us-2017043033-a1

· 2017

Full title: us-2017043033-a1

Year: 2017

Patent us-2017043031-a1

· 2017

Full title: us-2017043031-a1

Year: 2017

Patent us-2017182181-a1

· 2017

Full title: us-2017182181-a1

Year: 2017

Patent us-2017080103-a1

· 2017

Full title: us-2017080103-a1

Year: 2017

Patent us-2017119902-a1

· 2017

Full title: us-2017119902-a1

Year: 2017

Patent us-2017088621-a1

· 2017

Full title: us-2017088621-a1

Year: 2017

Patent us-2017088614-a1

· 2017

Full title: us-2017088614-a1

Year: 2017

Patent us-2017218074-a1

· 2017

Full title: us-2017218074-a1

Year: 2017

Patent us-2017112943-a1

· 2017

Full title: us-2017112943-a1

Year: 2017

Patent us-2017252458-a1

· 2017

Full title: us-2017252458-a1

Year: 2017

Patent us-2017232023-a1

· 2017

Full title: us-2017232023-a1

Year: 2017

Patent us-2017204139-a1

· 2017

Full title: us-2017204139-a1

Year: 2017

Patent us-2017210825-a1

· 2017

Full title: us-2017210825-a1

Year: 2017

Patent us-2017267727-a1

· 2017

Full title: us-2017267727-a1

Year: 2017

Patent us-2017319709-a1

· 2017

Full title: us-2017319709-a1

Year: 2017

Patent us-2017281787-a1

· 2017

Full title: us-2017281787-a1

Year: 2017

Patent us-2018055944-a1

· 2018

Full title: us-2018055944-a1

Year: 2018

Patent us-2017224835-a1

· 2017

Full title: us-2017224835-a1

Year: 2017

Patent us-2017326233-a1

· 2017

Full title: us-2017326233-a1

Year: 2017

Patent us-2018078654-a1

· 2018

Full title: us-2018078654-a1

Year: 2018

Patent us-2018028658-a1

· 2018

Full title: us-2018028658-a1

Year: 2018

Patent us-2017355750-a1

· 2017

Full title: us-2017355750-a1

Year: 2017

Patent us-2018125994-a1

· 2018

Full title: us-2018125994-a1

Year: 2018

Patent us-2018117172-a1

· 2018

Full title: us-2018117172-a1

Year: 2018

Patent us-2018078656-a1

· 2018

Full title: us-2018078656-a1

Year: 2018

Patent us-2022220222-a1

· 2022

Full title: us-2022220222-a1

Year: 2022

Patent us-2022211861-a1

· 2022

Full title: us-2022211861-a1

Year: 2022

Patent us-2022233708-a1

· 2022

Full title: us-2022233708-a1

Year: 2022

Patent us-2022249686-a1

· 2022

Full title: us-2022249686-a1

Year: 2022

Patent us-2022306716-a1

· 2022

Full title: us-2022306716-a1

Year: 2022

Patent us-2022257766-a1

· 2022

Full title: us-2022257766-a1

Year: 2022

Patent us-2022249594-a1

· 2022

Full title: us-2022249594-a1

Year: 2022

Patent us-2022211863-a1

· 2022

Full title: us-2022211863-a1

Year: 2022

Patent us-2022378929-a1

· 2022

Full title: us-2022378929-a1

Year: 2022

Patent us-2022281852-a1

· 2022

Full title: us-2022281852-a1

Year: 2022

Patent us-2022249681-a1

· 2022

Full title: us-2022249681-a1

Year: 2022

Patent us-2022265848-a1

· 2022

Full title: us-2022265848-a1

Year: 2022

Patent us-2022281936-a1

· 2022

Full title: us-2022281936-a1

Year: 2022

Patent us-2023001001-a1

· 2023

Full title: us-2023001001-a1

Year: 2023

Patent us-2022387615-a1

· 2022

Full title: us-2022387615-a1

Year: 2022

Patent us-2022362397-a1

· 2022

Full title: us-2022362397-a1

Year: 2022

Patent us-2022380453-a9

· 2022

Full title: us-2022380453-a9

Year: 2022

Patent us-2022372141-a1

· 2022

Full title: us-2022372141-a1

Year: 2022

Patent us-2022324975-a1

· 2022

Full title: us-2022324975-a1

Year: 2022

Patent us-2022380352-a1

· 2022

Full title: us-2022380352-a1

Year: 2022

Patent us-2023010108-a1

· 2023

Full title: us-2023010108-a1

Year: 2023

Patent us-2023025327-a1

· 2023

Full title: us-2023025327-a1

Year: 2023

Patent us-2022411470-a1

· 2022

Full title: us-2022411470-a1

Year: 2022

Patent us-2023013963-a1

· 2023

Full title: us-2023013963-a1

Year: 2023

Patent us-2023021500-a1

· 2023

Full title: us-2023021500-a1

Year: 2023

Patent us-2023022596-a1

· 2023

Full title: us-2023022596-a1

Year: 2023

Patent us-2023021301-a9

· 2023

Full title: us-2023021301-a9

Year: 2023

Patent us-2022401557-a1

· 2022

Full title: us-2022401557-a1

Year: 2022

Patent us-2023071763-a1

· 2023

Full title: us-2023071763-a1

Year: 2023

Patent us-2023061858-a1

· 2023

Full title: us-2023061858-a1

Year: 2023

Patent us-2023027495-a1

· 2023

Full title: us-2023027495-a1

Year: 2023

Patent us-2023057350-a1

· 2023

Full title: us-2023057350-a1

Year: 2023

Patent us-2023072822-a1

· 2023

Full title: us-2023072822-a1

Year: 2023

Patent us-2023035308-a1

· 2023

Full title: us-2023035308-a1

Year: 2023

Patent us-2023066474-a1

· 2023

Full title: us-2023066474-a1

Year: 2023

Patent us-2023146646-a1

· 2023

Full title: us-2023146646-a1

Year: 2023

Patent us-2023043447-a1

· 2023

Full title: us-2023043447-a1

Year: 2023

Patent us-2023091653-a1

· 2023

Full title: us-2023091653-a1

Year: 2023

Patent us-2023084099-a1

· 2023

Full title: us-2023084099-a1

Year: 2023

Patent us-2023085485-a1

· 2023

Full title: us-2023085485-a1

Year: 2023

Patent us-2023069722-a1

· 2023

Full title: us-2023069722-a1

Year: 2023

Patent us-2023071019-a1

· 2023

Full title: us-2023071019-a1

Year: 2023

Patent us-2023081720-a1

· 2023

Full title: us-2023081720-a1

Year: 2023

Patent us-2023158169-a1

· 2023

Full title: us-2023158169-a1

Year: 2023

Patent us-2023092679-a1

· 2023

Full title: us-2023092679-a1

Year: 2023

Patent us-2023212113-a1

· 2023

Full title: us-2023212113-a1

Year: 2023

Patent us-2023218778-a1

· 2023

Full title: us-2023218778-a1

Year: 2023

Patent us-2023109312-a1

· 2023

Full title: us-2023109312-a1

Year: 2023

Patent us-2023241072-a1

· 2023

Full title: us-2023241072-a1

Year: 2023

Patent us-2023277679-a1

· 2023

Full title: us-2023277679-a1

Year: 2023

Patent us-2023212181-a1

· 2023

Full title: us-2023212181-a1

Year: 2023

Patent us-2023277676-a1

· 2023

Full title: us-2023277676-a1

Year: 2023

Patent us-2023190939-a1

· 2023

Full title: us-2023190939-a1

Year: 2023

Patent us-2023241243-a1

· 2023

Full title: us-2023241243-a1

Year: 2023

Patent us-2023111996-a1

· 2023

Full title: us-2023111996-a1

Year: 2023

Patent us-2023212283-a1

· 2023

Full title: us-2023212283-a1

Year: 2023

Patent us-2023201366-a1

· 2023

Full title: us-2023201366-a1

Year: 2023

Patent us-2023256114-a1

· 2023

Full title: us-2023256114-a1

Year: 2023

Patent us-2023233700-a1

· 2023

Full title: us-2023233700-a1

Year: 2023

Patent us-2023310557-a1

· 2023

Full title: us-2023310557-a1

Year: 2023

Patent us-2023338572-a1

· 2023

Full title: us-2023338572-a1

Year: 2023

Patent us-2023279151-a1

· 2023

Full title: us-2023279151-a1

Year: 2023

Patent us-2023270874-a1

· 2023

Full title: us-2023270874-a1

Year: 2023

Patent us-2023372518-a1

· 2023

Full title: us-2023372518-a1

Year: 2023

Patent us-2023338570-a1

· 2023

Full title: us-2023338570-a1

Year: 2023

Patent us-2023277682-a1

· 2023

Full title: us-2023277682-a1

Year: 2023

Patent us-2023310629-a1

· 2023

Full title: us-2023310629-a1

Year: 2023

Patent us-2023321265-a1

· 2023

Full title: us-2023321265-a1

Year: 2023

Patent us-2023310624-a1

· 2023

Full title: us-2023310624-a1

Year: 2023

Patent us-2023406877-a1

· 2023

Full title: us-2023406877-a1

Year: 2023

Patent us-2023381330-a1

· 2023

Full title: us-2023381330-a1

Year: 2023

Patent us-2023390413-a1

· 2023

Full title: us-2023390413-a1

Year: 2023

Patent us-2023405129-a1

· 2023

Full title: us-2023405129-a1

Year: 2023

Patent us-2024082409-a1

· 2024

Full title: us-2024082409-a1

Year: 2024

Patent us-2024000960-a1

· 2024

Full title: us-2024000960-a1

Year: 2024

Patent us-2023414775-a1

· 2023

Full title: us-2023414775-a1

Year: 2023

Patent us-2023405141-a1

· 2023

Full title: us-2023405141-a1

Year: 2023

Patent us-2024058468-a1

· 2024

Full title: us-2024058468-a1

Year: 2024

Patent us-2023398228-a1

· 2023

Full title: us-2023398228-a1

Year: 2023

Patent us-2024075160-a1

· 2024

Full title: us-2024075160-a1

Year: 2024

Patent us-2024033372-a1

· 2024

Full title: us-2024033372-a1

Year: 2024

Patent us-2024026030-a1

· 2024

Full title: us-2024026030-a1

Year: 2024

Patent us-2024148887-a1

· 2024

Full title: us-2024148887-a1

Year: 2024

Patent us-2024009319-a1

· 2024

Full title: us-2024009319-a1

Year: 2024

Patent us-2024108744-a1

· 2024

Full title: us-2024108744-a1

Year: 2024

Patent us-2024084022-a1

· 2024

Full title: us-2024084022-a1

Year: 2024

Patent us-2024091375-a1

· 2024

Full title: us-2024091375-a1

Year: 2024

Patent us-2024150402-a1

· 2024

Full title: us-2024150402-a1

Year: 2024

Patent us-2024148895-a1

· 2024

Full title: us-2024148895-a1

Year: 2024

Patent us-9849192-b2

· 2017

Full title: us-9849192-b2

Year: 2017

Patent us-9562073-b2

· 2017

Full title: us-9562073-b2

Year: 2017

Patent us-9738726-b2

· 2017

Full title: us-9738726-b2

Year: 2017

Patent us-9914748-b2

· 2018

Full title: us-9914748-b2

Year: 2018

Patent us-9988420-b2

· 2018

Full title: us-9988420-b2

Year: 2018

Patent us-9884122-b2

· 2018

Full title: us-9884122-b2

Year: 2018

Patent us-9872904-b2

· 2018

Full title: us-9872904-b2

Year: 2018

Patent us-9624309-b2

· 2017

Full title: us-9624309-b2

Year: 2017

Patent us-9943609-b2

· 2018

Full title: us-9943609-b2

Year: 2018

Patent us-9943610-b2

· 2018

Full title: us-9943610-b2

Year: 2018

Patent us-9982018-b2

· 2018

Full title: us-9982018-b2

Year: 2018

Patent us-10058613-b2

· 2018

Full title: us-10058613-b2

Year: 2018

Patent us-10183997-b2

· 2019

Full title: us-10183997-b2

Year: 2019

Patent us-10118965-b2

· 2018

Full title: us-10118965-b2

Year: 2018

Patent us-10226535-b2

· 2019

Full title: us-10226535-b2

Year: 2019

Patent us-10039845-b2

· 2018

Full title: us-10039845-b2

Year: 2018

Patent us-10201615-b2

· 2019

Full title: us-10201615-b2

Year: 2019

Patent us-10138272-b2

· 2018

Full title: us-10138272-b2

Year: 2018

Patent us-10227417-b2

· 2019

Full title: us-10227417-b2

Year: 2019

Patent us-10280229-b2

· 2019

Full title: us-10280229-b2

Year: 2019

Patent us-10195289-b2

· 2019

Full title: us-10195289-b2

Year: 2019

Patent us-10149913-b2

· 2018

Full title: us-10149913-b2

Year: 2018

Patent us-10265413-b2

· 2019

Full title: us-10265413-b2

Year: 2019

Patent us-10392421-b2

· 2019

Full title: us-10392421-b2

Year: 2019

Patent us-10357571-b2

· 2019

Full title: us-10357571-b2

Year: 2019

Patent us-10307488-b2

· 2019

Full title: us-10307488-b2

Year: 2019

Patent us-10287321-b2

· 2019

Full title: us-10287321-b2

Year: 2019

Patent us-10376597-b2

· 2019

Full title: us-10376597-b2

Year: 2019

Patent us-10533058-b2

· 2020

Full title: us-10533058-b2

Year: 2020

Patent us-10544215-b2

· 2020

Full title: us-10544215-b2

Year: 2020

Patent us-11008398-b2

· 2021

Full title: us-11008398-b2

Year: 2021

Patent us-11173213-b2

· 2021

Full title: us-11173213-b2

Year: 2021

Patent us-2015314008-a1

· 2015

Full title: us-2015314008-a1

Year: 2015

Patent us-2018147292-a1

· 2018

Full title: us-2018147292-a1

Year: 2018

Patent us-2021260210-a1

· 2021

Full title: us-2021260210-a1

Year: 2021

Patent us-2021386865-a1

· 2021

Full title: us-2021386865-a1

Year: 2021

Patent us-2024424129-a1

· 2024

Full title: us-2024424129-a1

Year: 2024

Metadata only

Paper Combining antibody conjugates with cytotoxic and immune-stimulating payloads maximizes anti-cancer activity.

Tiexin Wang; Dong Jun Koo; Peter M. Tessier et al. · 2026 · Molecular Oncology · DOI

Full title: Combining antibody conjugates with cytotoxic and immune-stimulating payloads maximizes anti-cancer activity.

Authors: Tiexin Wang; Dong Jun Koo; Peter M. Tessier; Greg M. Thurber

Year: 2026

Venue: Molecular Oncology

DOI: https://doi.org/10.1002/1878-0261.70198

Paper Immune therapies in the treatment of multiple myeloma

C. Brugnara · 2023 · American journal of hematology/oncology · DOI

Full title: Immune therapies in the treatment of multiple myeloma

Authors: C. Brugnara

Year: 2023

Venue: American journal of hematology/oncology

DOI: https://doi.org/10.1002/ajh.26843

Paper Targeting of DDR1 with antibody‐drug conjugates has antitumor effects in a mouse model of colon carcinoma

Yiran Tao; Rui-xue Wang; Qinhuai Lai et al. · 2019 · Molecular Oncology · DOI

Full title: Targeting of DDR1 with antibody‐drug conjugates has antitumor effects in a mouse model of colon carcinoma

Authors: Yiran Tao; Rui-xue Wang; Qinhuai Lai; Mengdan Wu; Yuxi Wang; Xiaohua Jiang; Lishi Zeng; Shijie Zhou; Zhongping Li; Tinghan Yang; Yuqin Yao; Yangping Wu; Lin Yu; Yuyin Fu; Weirong Lai; Yujia Peng; Ying Lu; Zhixiong Zhang; Cuiyu Guo; Guangbing Zhang; L. Gou; Jinliang Yang

Year: 2019

Venue: Molecular Oncology

DOI: https://doi.org/10.1002/1878-0261.12520

Paper An Anti‐CD147 Antibody−Drug Conjugate Mehozumab‐DM1 is Efficacious Against Hepatocellular Carcinoma in Cynomolgus Monkey

Wan Huang; Liping Zhong; Ying Shi et al. · 2025 · Advancement of science · DOI

Full title: An Anti‐CD147 Antibody−Drug Conjugate Mehozumab‐DM1 is Efficacious Against Hepatocellular Carcinoma in Cynomolgus Monkey

Authors: Wan Huang; Liping Zhong; Ying Shi; Qingzhi Ma; Xiang-Min Yang; Hongmei Zhang; Jing Zhang; Ling Wang; Kun Wang; Jingzhuo Li; Jie Zou; Xu Yang; Liu Yang; Qingmei Zeng; Lin Jing; Zhi-Nan Chen; Yongxiang Zhao

Year: 2025

Venue: Advancement of science

DOI: https://doi.org/10.1002/advs.202410438

Paper Antibody-drug conjugates: an emerging concept in cancer therapy.

Chari, Ravi V J; Miller, Michael L; Widdison, Wayne C · 2014 · Angewandte Chemie (International ed. in English) · DOI

Full title: Antibody-drug conjugates: an emerging concept in cancer therapy.

Authors: Chari, Ravi V J; Miller, Michael L; Widdison, Wayne C

Year: 2014

Venue: Angewandte Chemie (International ed. in English)

DOI: https://doi.org/10.1002/anie.201307628

Paper A Serum‐Stable Antimicrobial Peptide‐Based Delivery Platform for Selective Treatment of Nontargetable and Chemoresistant Tumors

Tianxing Liu; Lingyu Ke; Ruize Sun et al. · 2025 · Advancement of science · DOI

Full title: A Serum‐Stable Antimicrobial Peptide‐Based Delivery Platform for Selective Treatment of Nontargetable and Chemoresistant Tumors

Authors: Tianxing Liu; Lingyu Ke; Ruize Sun; Xiaoling Chen; Mei Zhou; Olaf R P Bininda-Emond; Chengbang Ma; Yangyang Jiang; Tao Wang; Chris Shaw; Lei Wang; Tianbao Chen; Alideertu Dong

Year: 2025

Venue: Advancement of science

DOI: https://doi.org/10.1002/advs.202504710

Paper Interstitial Lung Disease Induced by Anti-ERBB2 Antibody-Drug Conjugates: A Review.

Tarantino, Paolo; Modi, Shanu; Tolaney, Sara M et al. · 2021 · JAMA oncology · DOI

Full title: Interstitial Lung Disease Induced by Anti-ERBB2 Antibody-Drug Conjugates: A Review.

Authors: Tarantino, Paolo; Modi, Shanu; Tolaney, Sara M; Cortés, Javier; Hamilton, Erika P; Kim, Sung-Bae; Toi, Masazaku; Andrè, Fabrice; Curigliano, Giuseppe

Year: 2021

Venue: JAMA oncology

DOI: https://doi.org/10.1001/jamaoncol.2021.3595

Paper Engineered Ultrasmall Nanoparticle Drug-Immune Conjugates with "Hit and Run" Tumor Delivery to Eradicate Gastric Cancer.

Zhang, Li; Aragon-Sanabria, Virginia; Aditya, Anusha et al. · 2023 · Advanced therapeutics · DOI

Full title: Engineered Ultrasmall Nanoparticle Drug-Immune Conjugates with "Hit and Run" Tumor Delivery to Eradicate Gastric Cancer.

Authors: Zhang, Li; Aragon-Sanabria, Virginia; Aditya, Anusha; Marelli, Marcello; Cao, Tianye; Chen, Feng; Yoo, Barney; Ma, Kai; Zhuang, Li; Cailleau, Thais; Masterson, Luke; Turker, Melik Z; Lee, Rachel; DeLeon, Gabriel; Monette, Sebastien; Colombo, Raffaele; Christie, Ronald J; Zanzonico, Pat; Wiesner, Ulrich; Subramony, J Anand; Bradbury, Michelle S

Year: 2023

Venue: Advanced therapeutics

DOI: https://doi.org/10.1002/adtp.202370009

Paper TR1801‐ADC: a highly potent cMet antibody–drug conjugate with high activity in patient‐derived xenograft models of solid tumors

Marco Gymnopoulos; O. Betancourt; V. Blot et al. · 2019 · Molecular Oncology · DOI

Full title: TR1801‐ADC: a highly potent cMet antibody–drug conjugate with high activity in patient‐derived xenograft models of solid tumors

Authors: Marco Gymnopoulos; O. Betancourt; V. Blot; R. Fujita; Diana Galvan; Vincent Lieuw; S. Nguyen; J. Snedden; Christine Stewart; J. Villicana; J. Wojciak; Eley Wong; Raúl Pardo; Neki Patel; François D'Hooge; B. Vijayakrishnan; Conor S Barry; J. Hartley; P. Howard; R. Newman; Julia Coronella

Year: 2019

Venue: Molecular Oncology

DOI: https://doi.org/10.1002/1878-0261.12600

Paper Novel Quaternary Ammonium Salt‐Linked STING Agonist Antibody‐Drug Conjugate: Synergistic Activation of Tumor Immunity with Mitigated Off‐Target Toxicity

Yu Long; Borui Tang; Fei Xie et al. · 2025 · Advancement of science · DOI

Full title: Novel Quaternary Ammonium Salt‐Linked STING Agonist Antibody‐Drug Conjugate: Synergistic Activation of Tumor Immunity with Mitigated Off‐Target Toxicity

Authors: Yu Long; Borui Tang; Fei Xie; Lianqi Liu; Yang Zhou; Jingwen Dong; Jianfeng Wang; Cuicui Sun; Yuting Wang; Ruoqi Li; Na Zhang; Liping Li; Longlong Luo; Junhai Xiao; Wu Zhong; Dian Xiao; Hongbin Deng; Xinbo Zhou

Year: 2025

Venue: Advancement of science

DOI: https://doi.org/10.1002/advs.202502270

Paper Investigating the Nonclinical ADME and PK/PD of an Antibody–Drug Conjugate: A Case Study of Ado‐Trastuzumab Emtansine (T‐DM1)

J. Tibbitts · 2015 · DOI

Full title: Investigating the Nonclinical ADME and PK/PD of an Antibody–Drug Conjugate: A Case Study of Ado‐Trastuzumab Emtansine (T‐DM1)

Authors: J. Tibbitts

Year: 2015

DOI: https://doi.org/10.1002/9780470571224.pse561

Paper Shifting the paradigm in personalized cancer care through next‐generation therapeutics and computational pathology

J. Reis-Filho; Maurizio Scaltriti; A. Kapil et al. · 2024 · Molecular Oncology · DOI

Full title: Shifting the paradigm in personalized cancer care through next‐generation therapeutics and computational pathology

Authors: J. Reis-Filho; Maurizio Scaltriti; A. Kapil; H. Sade; Susan Galbraith

Year: 2024

Venue: Molecular Oncology

DOI: https://doi.org/10.1002/1878-0261.13724

Paper Interactions of Antibody Drug Conjugate Anti-Tubulin and Topoisomerase I Inhibitor Payloads with Radiotherapy to Potentiate Immunotherapy.

Lesperance, Jacqueline; Yung, Bryan S; Allevato, Michael M et al. · 2025 · Advanced science (Weinheim, Baden-Wurttemberg, Germany) · DOI

Full title: Interactions of Antibody Drug Conjugate Anti-Tubulin and Topoisomerase I Inhibitor Payloads with Radiotherapy to Potentiate Immunotherapy.

Authors: Lesperance, Jacqueline; Yung, Bryan S; Allevato, Michael M; Cheng, Marcus M; Camargo, Maria F; Saddawi-Konefka, Robert; Dhawan, Kanika; Sharma, Ashwyn K; Mortaja, Mahsa; Bice, Sophie; Scanderbeg, Daniel J; Alvarado, Diego; Mayadev, Jyoti; Eskander, Ramez N; Adams, Stephen R; Cosper, Pippa F; Gutkind, J Silvio; Advani, Sunil J

Year: 2025

Venue: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

DOI: https://doi.org/10.1002/advs.202506552

Paper Therapeutic Targeting of Osteosarcoma and Lung Metastases in Preclinical Models Using a CD24 Antibody‐Drug Conjugate

P. Guo; Yuxuan Li; Jing Huang et al. · 2025 · Advances in Therapy · DOI

Full title: Therapeutic Targeting of Osteosarcoma and Lung Metastases in Preclinical Models Using a CD24 Antibody‐Drug Conjugate

Authors: P. Guo; Yuxuan Li; Jing Huang; Liming Jin; Xing Liu; Dawei He; Marsha A. Moses

Year: 2025

Venue: Advances in Therapy

DOI: https://doi.org/10.1002/adtp.202400423

Paper Pharmacokinetic characterization of BMS‐936561, an anti‐CD70 antibody‐drug conjugate, in preclinical animal species and prediction of its pharmacokinetics in humans

Haiqing Wang; V. Rangan; Mei-Chen Sung et al. · 2016 · Biopharmaceutics & drug disposition · DOI

Full title: Pharmacokinetic characterization of BMS‐936561, an anti‐CD70 antibody‐drug conjugate, in preclinical animal species and prediction of its pharmacokinetics in humans

Authors: Haiqing Wang; V. Rangan; Mei-Chen Sung; D. Passmore; T. Kempe; Xiaoli Wang; L. Thevanayagam; C. Pan; Chetana Rao; M. Srinivasan; Qian Zhang; S. Gangwar; S. Deshpande; P. Cardarelli; P. Marathe; Zheng Yang

Year: 2016

Venue: Biopharmaceutics & drug disposition

DOI: https://doi.org/10.1002/bdd.1953

Paper Azobenzene-based Linker Strategy for Selective Activation of Antibody-Drug Conjugates.

Dian Xiao; Lianqi Liu; Fei Xie et al. · 2024 · Angewandte Chemie · DOI

Full title: Azobenzene-based Linker Strategy for Selective Activation of Antibody-Drug Conjugates.

Authors: Dian Xiao; Lianqi Liu; Fei Xie; Jingwen Dong; Yanming Wang; Xin Xu; Wu Zhong; Hongbin Deng; Xinbo Zhou; Song Li

Year: 2024

Venue: Angewandte Chemie

DOI: https://doi.org/10.1002/anie.202310318

Paper A Novel FGFR3‐Targeting Antibody‐Drug Conjugate Induces Tumor Cell Apoptosis through the cGAS–STING Pathway in Bladder Cancer

Shu Cui; Xiongfei Luo; Guangrui Fan et al. · 2025 · Advancement of science · DOI

Full title: A Novel FGFR3‐Targeting Antibody‐Drug Conjugate Induces Tumor Cell Apoptosis through the cGAS–STING Pathway in Bladder Cancer

Authors: Shu Cui; Xiongfei Luo; Guangrui Fan; Jingqi Jiang; Yingru Wang; Enguang Yang; Jinpeng Ma; Ze Zhang; Yuhan Wang; Juan Wang; Dengtuo Wang; Hanzhang Wang; Liang Cheng; Junqiang Tian; Zhilong Dong; Yingqian Liu; Zhiping Wang

Year: 2025

Venue: Advancement of science

DOI: https://doi.org/10.1002/advs.202509933

Paper A HER2‐targeted Antibody‐Drug Conjugate, RC48‐ADC, Exerted Promising Antitumor Efficacy and Safety with Intravesical Instillation in Preclinical Models of Bladder Cancer

Xuwei Hong; Xu Chen; Hongjin Wang et al. · 2023 · Advancement of science · DOI

Full title: A HER2‐targeted Antibody‐Drug Conjugate, RC48‐ADC, Exerted Promising Antitumor Efficacy and Safety with Intravesical Instillation in Preclinical Models of Bladder Cancer

Authors: Xuwei Hong; Xu Chen; Hongjin Wang; Qingchun Xu; Kanghua Xiao; Yuanfeng Zhang; Ze-pai Chi; Yeqing Liu; Guang-Yao Liu; Hong Li; Jianmin Fang; Tianxin Lin; Yonghai Zhang

Year: 2023

Venue: Advancement of science

DOI: https://doi.org/10.1002/advs.202302377

Paper A Traceless Site-Specific Conjugation on Native Antibodies Enables Efficient One-Step Payload Assembly.

Zeng, Yue; Shi, Wei; Dong, Qian et al. · 2022 · Angewandte Chemie (International ed. in English) · DOI

Full title: A Traceless Site-Specific Conjugation on Native Antibodies Enables Efficient One-Step Payload Assembly.

Authors: Zeng, Yue; Shi, Wei; Dong, Qian; Li, Wanzhen; Zhang, Jianxin; Ren, Xuelian; Tang, Caihong; Liu, Bo; Song, Yuanli; Wu, Yali; Diao, Xingxing; Zhou, Hu; Huang, He; Tang, Feng; Huang, Wei

Year: 2022

Venue: Angewandte Chemie (International ed. in English)

DOI: https://doi.org/10.1002/anie.202204132

Paper Advanced Antibody-Drug Conjugates Design: Innovation in Linker Chemistry and Site-Specific Conjugation Technologies.

Matsuda, Yutaka; Chang, Jenny R; Mendelsohn, Brian A · 2025 · Chembiochem : a European journal of chemical biology · DOI

Full title: Advanced Antibody-Drug Conjugates Design: Innovation in Linker Chemistry and Site-Specific Conjugation Technologies.

Authors: Matsuda, Yutaka; Chang, Jenny R; Mendelsohn, Brian A

Year: 2025

Venue: Chembiochem : a European journal of chemical biology

DOI: https://doi.org/10.1002/cbic.202500305

Paper Ethynylphosphonamidates for the Rapid and Cysteine‐Selective Generation of Efficacious Antibody–Drug Conjugates

Marc‐André Kasper; A. Stengl; P. Ochtrop et al. · 2019 · Angewandte Chemie · DOI

Full title: Ethynylphosphonamidates for the Rapid and Cysteine‐Selective Generation of Efficacious Antibody–Drug Conjugates

Authors: Marc‐André Kasper; A. Stengl; P. Ochtrop; M. Gerlach; Tina Stoschek; D. Schumacher; J. Helma; Martin Penkert; E. Krause; H. Leonhardt; C. Hackenberger

Year: 2019

Venue: Angewandte Chemie

DOI: https://doi.org/10.1002/anie.201904193

Paper Epigenetic Reprogramming Potentiates ICAM1 Antibody Drug Conjugates in Preclinical Models of Melanoma

Peng Zhang; Changjuan Tao; Ye Lu et al. · 2024 · Advancement of science · DOI

Full title: Epigenetic Reprogramming Potentiates ICAM1 Antibody Drug Conjugates in Preclinical Models of Melanoma

Authors: Peng Zhang; Changjuan Tao; Ye Lu; Peijing Li; Xing Wang; Yujie Dai; Yun Xi; T. Shimura; Xinfang Li; Jianmin Fang; Liu Yang; Dawei He; Peng Guo

Year: 2024

Venue: Advancement of science

DOI: https://doi.org/10.1002/advs.202400203

Paper Analyzing protein conjugation reactions for antibody‐drug conjugate synthesis using polarized excitation emission matrix spectroscopy

A. L. de Faria e Silva; Alan G. Ryder · 2022 · Biotechnology and Bioengineering · DOI

Full title: Analyzing protein conjugation reactions for antibody‐drug conjugate synthesis using polarized excitation emission matrix spectroscopy

Authors: A. L. de Faria e Silva; Alan G. Ryder

Year: 2022

Venue: Biotechnology and Bioengineering

DOI: https://doi.org/10.1002/bit.28229

Paper The Methylene Alkoxy Carbamate Self-Immolative Unit: Utilization for the Targeted Delivery of Alcohol-Containing Payloads with Antibody-Drug Conjugates.

Robert V. Kolakowski; Karl T. Haelsig; Kim K. Emmerton et al. · 2016 · Angewandte Chemie · DOI

Full title: The Methylene Alkoxy Carbamate Self-Immolative Unit: Utilization for the Targeted Delivery of Alcohol-Containing Payloads with Antibody-Drug Conjugates.

Authors: Robert V. Kolakowski; Karl T. Haelsig; Kim K. Emmerton; C. Leiske; J. Miyamoto; Julia H Cochran; R. Lyon; P. Senter; S. Jeffrey

Year: 2016

Venue: Angewandte Chemie

DOI: https://doi.org/10.1002/anie.201601506

Paper N‐Hydroxysuccinimide‐Modified Ethynylphosphonamidates Enable the Synthesis of Configurationally Defined Protein Conjugates

Marc‐André Kasper; M. Gerlach; Anselm F. L. Schneider et al. · 2020 · ChemBioChem · DOI

Full title: N‐Hydroxysuccinimide‐Modified Ethynylphosphonamidates Enable the Synthesis of Configurationally Defined Protein Conjugates

Authors: Marc‐André Kasper; M. Gerlach; Anselm F. L. Schneider; Christiane Groneberg; P. Ochtrop; Stefanie Boldt; D. Schumacher; J. Helma; H. Leonhardt; M. Christmann; C. Hackenberger

Year: 2020

Venue: ChemBioChem

DOI: https://doi.org/10.1002/cbic.201900587

Paper Benzyl Ammonium Carbamates Undergo Two‐Step Linker Cleavage and Improve the Properties of Antibody Conjugates

Xiaoyi Li; Nimit L. Patel; J. Kalen et al. · 2024 · Angewandte Chemie · DOI

Full title: Benzyl Ammonium Carbamates Undergo Two‐Step Linker Cleavage and Improve the Properties of Antibody Conjugates

Authors: Xiaoyi Li; Nimit L. Patel; J. Kalen; M. Schnermann

Year: 2024

Venue: Angewandte Chemie

DOI: https://doi.org/10.1002/anie.202417651

Paper Efforts toward the Total Synthesis of Tubulysins: New Hopes for a More Effective Targeted Drug Delivery to Tumors

D. Neri; G. Fossati; M. Zanda · 2006 · ChemMedChem · DOI

Full title: Efforts toward the Total Synthesis of Tubulysins: New Hopes for a More Effective Targeted Drug Delivery to Tumors

Authors: D. Neri; G. Fossati; M. Zanda

Year: 2006

Venue: ChemMedChem

DOI: https://doi.org/10.1002/cmdc.200500043

Paper Improving Antibody‐Tubulysin Conjugates through Linker Chemistry and Site‐Specific Conjugation

Joseph Z. Hamilton; Thomas A Pires; Jamie A. Mitchell et al. · 2020 · ChemMedChem · DOI

Full title: Improving Antibody‐Tubulysin Conjugates through Linker Chemistry and Site‐Specific Conjugation

Authors: Joseph Z. Hamilton; Thomas A Pires; Jamie A. Mitchell; Julia H Cochran; Kim K. Emmerton; Margo Zaval; I. Stone; Martha E. Anderson; Steven Jin; A. Waight; R. Lyon; P. Senter; S. Jeffrey; P. Burke

Year: 2020

Venue: ChemMedChem

DOI: https://doi.org/10.1002/cmdc.202000889

Paper Advancements in Targeted Therapies for Colorectal Cancer: Innovative Drug Formulation and Delivery Strategies

Ali Ahmadizad Firouzjaei; Samira Mohammadi-Yeganeh · 2025 · Archiv der Pharmazie · DOI

Full title: Advancements in Targeted Therapies for Colorectal Cancer: Innovative Drug Formulation and Delivery Strategies

Authors: Ali Ahmadizad Firouzjaei; Samira Mohammadi-Yeganeh

Year: 2025

Venue: Archiv der Pharmazie

DOI: https://doi.org/10.1002/ardp.202400969

Paper Toxicity-reducing potential of extracorporeal affinity adsorption treatment in combination with the auristatin-conjugated monoclonal antibody BR96 in a syngeneic rat tumor model.

Nilsson, Rune; Mårtensson, Linda; Eriksson, Sophie E et al. · 2010 · Cancer · DOI

Full title: Toxicity-reducing potential of extracorporeal affinity adsorption treatment in combination with the auristatin-conjugated monoclonal antibody BR96 in a syngeneic rat tumor model.

Authors: Nilsson, Rune; Mårtensson, Linda; Eriksson, Sophie E; Sjögren, Hans-Olov; Tennvall, Jan

Year: 2010

Venue: Cancer

DOI: https://doi.org/10.1002/cncr.24790

Paper Strategies to Reduce the On-Target Platelet Toxicity of Bcl-xL Inhibitors: PROTACs, SNIPERs and Prodrug-Based Approaches.

Negi, Arvind; Voisin-Chiret, Anne Sophie · 2022 · Chembiochem : a European journal of chemical biology · DOI

Full title: Strategies to Reduce the On-Target Platelet Toxicity of Bcl-xL Inhibitors: PROTACs, SNIPERs and Prodrug-Based Approaches.

Authors: Negi, Arvind; Voisin-Chiret, Anne Sophie

Year: 2022

Venue: Chembiochem : a European journal of chemical biology

DOI: https://doi.org/10.1002/cbic.202100689

Paper Optimal treatment of early stage HER2‐positive breast cancer

S. Pernas; R. Barroso-Sousa; S. Tolaney · 2018 · Cancer · DOI

Full title: Optimal treatment of early stage HER2‐positive breast cancer

Authors: S. Pernas; R. Barroso-Sousa; S. Tolaney

Year: 2018

Venue: Cancer

DOI: https://doi.org/10.1002/cncr.31657

Paper Assembly of pH-Responsive Antibody-Drug-Inspired Conjugates.

Marco Raabe; A. Heck; Siska Führer et al. · 2021 · Macromolecular Bioscience · DOI

Full title: Assembly of pH-Responsive Antibody-Drug-Inspired Conjugates.

Authors: Marco Raabe; A. Heck; Siska Führer; Dominik Schauenburg; Michaela Pieszka; Tao Wang; M. M. Zegota; L. Nuhn; D. Ng; S. Kuan; T. Weil

Year: 2021

Venue: Macromolecular Bioscience

DOI: https://doi.org/10.1002/mabi.202100299

Paper Linker Design for the Antibody Drug Conjugates: A Comprehensive Review

Yaxin Lei; Minglei Zheng; Peng Chen et al. · 2025 · ChemMedChem · DOI

Full title: Linker Design for the Antibody Drug Conjugates: A Comprehensive Review

Authors: Yaxin Lei; Minglei Zheng; Peng Chen; Chen Seng Ng; Teck Peng Loh; Huitao Liu

Year: 2025

Venue: ChemMedChem

DOI: https://doi.org/10.1002/cmdc.202500262

Paper Anti‐EGFR antibody‐drug conjugate for triple‐negative breast cancer therapy

Yingnan Si; Yuanxin Xu; Jiashiung Guan et al. · 2020 · Engineering in Life Sciences · DOI

Full title: Anti‐EGFR antibody‐drug conjugate for triple‐negative breast cancer therapy

Authors: Yingnan Si; Yuanxin Xu; Jiashiung Guan; Kai Chen; Seulhee Kim; E. Yang; Lufang Zhou; X. Liu

Year: 2020

Venue: Engineering in Life Sciences

DOI: https://doi.org/10.1002/elsc.202000027

Paper A Novel Concept for Cleavable Linkers Applicable to Conjugation Chemistry – Design, Synthesis and Characterization

Utpal Majumder; Xiaojie Zhu; Daniel Custar et al. · 2024 · ChemBioChem · DOI

Full title: A Novel Concept for Cleavable Linkers Applicable to Conjugation Chemistry – Design, Synthesis and Characterization

Authors: Utpal Majumder; Xiaojie Zhu; Daniel Custar; Danyang Li; Hui Fang; Sharon McGonigle; Earl Albone; Xin Cheng; Weidong Lai; Amy Siu; Karen Bresciano; Andrew Hart; Maarten Postema

Year: 2024

Venue: ChemBioChem

DOI: https://doi.org/10.1002/cbic.202400826

Paper Quantitative collision‐induced unfolding differentiates model antibody–drug conjugates

Yuwei Tian; Jennifer L. Lippens; Chawita Netirojjanakul et al. · 2018 · Protein Science · DOI

Full title: Quantitative collision‐induced unfolding differentiates model antibody–drug conjugates

Authors: Yuwei Tian; Jennifer L. Lippens; Chawita Netirojjanakul; Iain D G Campuzano; B. Ruotolo

Year: 2018

Venue: Protein Science

DOI: https://doi.org/10.1002/pro.3560

Paper Dextramabs: A Novel Format of Antibody‐Drug Conjugates Featuring a Multivalent Polysaccharide Scaffold

Hendrik Schneider; Lukas Deweid; T. Pirzer et al. · 2019 · ChemistryOpen · DOI

Full title: Dextramabs: A Novel Format of Antibody‐Drug Conjugates Featuring a Multivalent Polysaccharide Scaffold

Authors: Hendrik Schneider; Lukas Deweid; T. Pirzer; Desislava Yanakieva; Simon Englert; Bastian Becker; O. Avrutina; H. Kolmar

Year: 2019

Venue: ChemistryOpen

DOI: https://doi.org/10.1002/open.201900066

Paper Measurement of Trogocytosis: Quantitative Analyses Validated with Rigorous Controls

Ronald P. Taylor; M. Lindorfer · 2023 · Current Protocols · DOI

Full title: Measurement of Trogocytosis: Quantitative Analyses Validated with Rigorous Controls

Authors: Ronald P. Taylor; M. Lindorfer

Year: 2023

Venue: Current Protocols

DOI: https://doi.org/10.1002/cpz1.897

Paper Probing the Internalization and Efficacy of Antibody-Drug Conjugate via Site-Specific Fc-Glycan Labelling of a Homogeneous Antibody Targeting SSEA-4 Bearing Tumors.

Shivatare, Vidya S; Huang, Han-Wen; Tseng, Tzu-Hao et al. · 2023 · Israel journal of chemistry · DOI

Full title: Probing the Internalization and Efficacy of Antibody-Drug Conjugate via Site-Specific Fc-Glycan Labelling of a Homogeneous Antibody Targeting SSEA-4 Bearing Tumors.

Authors: Shivatare, Vidya S; Huang, Han-Wen; Tseng, Tzu-Hao; Chuang, Po-Kai; Zeng, Yi-Fang; Wong, Chi-Huey

Year: 2023

Venue: Israel journal of chemistry

DOI: https://doi.org/10.1002/ijch.202300042

Paper Antibody Drug Conjugate Formation Using 2-14C-Iminothiolane: A Radiochemical Analysis of Sequential Lysine Conjugation, Uncloaking of a Phantom Drug-to-Antibody Ratio, and Stability of the ADC.

Michael Wallace; Michael J Smith; John A Brailsford et al. · 2025 · Journal of labelled compounds & radiopharmaceuticals · DOI

Full title: Antibody Drug Conjugate Formation Using 2-14C-Iminothiolane: A Radiochemical Analysis of Sequential Lysine Conjugation, Uncloaking of a Phantom Drug-to-Antibody Ratio, and Stability of the ADC.

Authors: Michael Wallace; Michael J Smith; John A Brailsford; Difei Qiu; Alban J Allentoff; Annie Tam; Selin Aytar; Michael Hay; Sharon Gong; Samuel Bonacorsi

Year: 2025

Venue: Journal of labelled compounds & radiopharmaceuticals

DOI: https://doi.org/10.1002/jlcr.70002

Paper Neoadjuvant Strategies for Triple Negative Breast Cancer: Current Evidence and Future Perspectives

Zhenjun Huang; Qing Peng; L. Mao et al. · 2025 · MedComm – Future Medicine · DOI

Full title: Neoadjuvant Strategies for Triple Negative Breast Cancer: Current Evidence and Future Perspectives

Authors: Zhenjun Huang; Qing Peng; L. Mao; Wenhao Ouyang; Yunjing Xiong; Yujie Tan; Haizhu Chen; Zebang Zhang; Tang Li; Yuanjia Hu; Ying Wang; Wei Zhang; Herui Yao; Yunfang Yu

Year: 2025

Venue: MedComm – Future Medicine

DOI: https://doi.org/10.1002/mef2.70013

Paper Non‐internalizing antibody–drug conjugates display potent anti‐cancer activity upon proteolytic release of monomethyl auristatin E in the subendothelial extracellular matrix

Rémy Gébleux; Marco Stringhini; R. Casanova et al. · 2017 · International Journal of Cancer · DOI

Full title: Non‐internalizing antibody–drug conjugates display potent anti‐cancer activity upon proteolytic release of monomethyl auristatin E in the subendothelial extracellular matrix

Authors: Rémy Gébleux; Marco Stringhini; R. Casanova; A. Soltermann; D. Neri

Year: 2017

Venue: International Journal of Cancer

DOI: https://doi.org/10.1002/ijc.30569

Paper Targeted therapies in bladder cancer: signaling pathways, applications, and challenges

Mei Peng; Xuetong Chu; Yan Peng et al. · 2023 · MedComm · DOI

Full title: Targeted therapies in bladder cancer: signaling pathways, applications, and challenges

Authors: Mei Peng; Xuetong Chu; Yan Peng; Duo Li; Zhirong Zhang; Weifan Wang; Xiaochen Zhou; D. Xiao; Xiaoping Yang

Year: 2023

Venue: MedComm

DOI: https://doi.org/10.1002/mco2.455

Paper In Silico Structural Analysis of Human β‐Glucuronidase for Antibody–Drug Conjugates Optimization

Giorgia Canini; S. Saporiti; Crescenzo Coppa et al. · 2025 · Proteins: Structure, Function, and Bioinformatics · DOI

Full title: In Silico Structural Analysis of Human β‐Glucuronidase for Antibody–Drug Conjugates Optimization

Authors: Giorgia Canini; S. Saporiti; Crescenzo Coppa; Mara Rossi; Fabio Centola; Alessandro Arcovito

Year: 2025

Venue: Proteins: Structure, Function, and Bioinformatics

DOI: https://doi.org/10.1002/prot.70077

Paper Linker Technology and Impact of Linker Design on ADC Properties

V. Goldmacher; Rajeeva Singh; T. Chittenden et al. · 2013 · DOI

Full title: Linker Technology and Impact of Linker Design on ADC Properties

Authors: V. Goldmacher; Rajeeva Singh; T. Chittenden; Y. Kovtun

Year: 2013

DOI: https://doi.org/10.1007/978-1-4614-5456-4_7

Paper Intact quantitation of cysteine-conjugated antibody-drug conjugates using native mass spectrometry.

Yihan Li; Yuting Wang; Vikram M Shenoy et al. · 2024 · Rapid Communications in Mass Spectrometry · DOI

Full title: Intact quantitation of cysteine-conjugated antibody-drug conjugates using native mass spectrometry.

Authors: Yihan Li; Yuting Wang; Vikram M Shenoy; Shuai Niu; Gary J Jenkins; Hetal Sarvaiya

Year: 2024

Venue: Rapid Communications in Mass Spectrometry

DOI: https://doi.org/10.1002/rcm.9774

Paper The Impact of Conjugation Mode and Site on Tubulysin Antibody‐Drug‐Conjugate Efficacy and Stability

Sayumi Yamazoe; Qinqin Cheng; Srikanth Kotapati et al. · 2025 · ChemistryOpen · DOI

Full title: The Impact of Conjugation Mode and Site on Tubulysin Antibody‐Drug‐Conjugate Efficacy and Stability

Authors: Sayumi Yamazoe; Qinqin Cheng; Srikanth Kotapati; V. Rangan; Mei-Chen Sung; Madhura Deshpande; Aarti Jashnani; Cong Qiang; Michael J Smith; Chin Pan; Gavin Dollinger; A. Rajpal; P. Strop; Chetana Rao

Year: 2025

Venue: ChemistryOpen

DOI: https://doi.org/10.1002/open.202400522

Paper Phase 1 study of PSMA ADC, an antibody‐drug conjugate targeting prostate‐specific membrane antigen, in chemotherapy‐refractory prostate cancer

D. Petrylak; P. Kantoff; N. Vogelzang et al. · 2019 · The Prostate · DOI

Full title: Phase 1 study of PSMA ADC, an antibody‐drug conjugate targeting prostate‐specific membrane antigen, in chemotherapy‐refractory prostate cancer

Authors: D. Petrylak; P. Kantoff; N. Vogelzang; A. Mega; M. Fleming; J. Stephenson; R. Frank; N. Shore; R. Dreicer; E. McClay; W. Berry; Manish Agarwal; V. DiPippo; Y. Rotshteyn; N. Stambler; W. Olson; S. Morris; R. Israel

Year: 2019

Venue: The Prostate

DOI: https://doi.org/10.1002/pros.23765

Paper Site-Specific Conjugation to Cys-Engineered THIOMAB™ Antibodies.

Adhikari, Pragya; Zacharias, Neelie; Ohri, Rachana et al. · 2020 · Methods in molecular biology (Clifton, N.J.) · DOI

Full title: Site-Specific Conjugation to Cys-Engineered THIOMAB™ Antibodies.

Authors: Adhikari, Pragya; Zacharias, Neelie; Ohri, Rachana; Sadowsky, Jack

Year: 2020

Venue: Methods in molecular biology (Clifton, N.J.)

DOI: https://doi.org/10.1007/978-1-4939-9929-3_4

Paper Peptide-Drug Conjugates: A New Hope for Cancer.

Armstrong, Amy; Coburn, Fleur; Nsereko, Yanyamba et al. · 2025 · Journal of peptide science : an official publication of the European Peptide Society · DOI

Full title: Peptide-Drug Conjugates: A New Hope for Cancer.

Authors: Armstrong, Amy; Coburn, Fleur; Nsereko, Yanyamba; Al Musaimi, Othman

Year: 2025

Venue: Journal of peptide science : an official publication of the European Peptide Society

DOI: https://doi.org/10.1002/psc.70040

Paper Utilizing Solid-Phase to Enable High-Throughput, Site-Specific Conjugation and Dual-Labeled Antibody and Fab Conjugates.

Puthenveetil, Sujiet · 2020 · Methods in molecular biology (Clifton, N.J.) · DOI

Full title: Utilizing Solid-Phase to Enable High-Throughput, Site-Specific Conjugation and Dual-Labeled Antibody and Fab Conjugates.

Authors: Puthenveetil, Sujiet

Year: 2020

Venue: Methods in molecular biology (Clifton, N.J.)

DOI: https://doi.org/10.1007/978-1-4939-9929-3_7

Paper Antibody-drug conjugates in gastric cancer: clinical advances and resistance mechanisms.

Wenke Li; Mo Cheng; Hongyan Han et al. · 2026 · Gastric Cancer · DOI

Full title: Antibody-drug conjugates in gastric cancer: clinical advances and resistance mechanisms.

Authors: Wenke Li; Mo Cheng; Hongyan Han; Menghui Xu; Yiqiao Luo; Feng Bi; Ming Liu

Year: 2026

Venue: Gastric Cancer

DOI: https://doi.org/10.1007/s10120-025-01703-w

Paper Proposed mechanism of off-target toxicity for antibody-drug conjugates driven by mannose receptor uptake.

Gorovits, Boris; Krinos-Fiorotti, Corinna · 2013 · Cancer immunology, immunotherapy : CII · DOI

Full title: Proposed mechanism of off-target toxicity for antibody-drug conjugates driven by mannose receptor uptake.

Authors: Gorovits, Boris; Krinos-Fiorotti, Corinna

Year: 2013

Venue: Cancer immunology, immunotherapy : CII

DOI: https://doi.org/10.1007/s00262-012-1369-3

Paper Pharmacokinetic considerations for antibody drug conjugates.

Lin, Kedan; Tibbitts, Jay · 2012 · Pharmaceutical research · DOI

Full title: Pharmacokinetic considerations for antibody drug conjugates.

Authors: Lin, Kedan; Tibbitts, Jay

Year: 2012

Venue: Pharmaceutical research

DOI: https://doi.org/10.1007/s11095-012-0800-y

Paper Evaluation of Targets for Maytansinoid ADC Therapy Using a Novel Radiochemical Assay

Katharine C. Lai; J. Deckert; Y. Setiady et al. · 2015 · Pharmaceutical Research · DOI

Full title: Evaluation of Targets for Maytansinoid ADC Therapy Using a Novel Radiochemical Assay

Authors: Katharine C. Lai; J. Deckert; Y. Setiady; Prerak Shah; Lintao Wang; R. Chari; J. Lambert

Year: 2015

Venue: Pharmaceutical Research

DOI: https://doi.org/10.1007/s11095-015-1633-2

Paper Site-Specific Bioconjugation Using SMARTag® Technology: A Practical and Effective Chemoenzymatic Approach to Generate Antibody-Drug Conjugates.

Liu, Junjie; Barfield, Robyn M; Rabuka, David · 2019 · Methods in molecular biology (Clifton, N.J.) · DOI

Full title: Site-Specific Bioconjugation Using SMARTag® Technology: A Practical and Effective Chemoenzymatic Approach to Generate Antibody-Drug Conjugates.

Authors: Liu, Junjie; Barfield, Robyn M; Rabuka, David

Year: 2019

Venue: Methods in molecular biology (Clifton, N.J.)

DOI: https://doi.org/10.1007/978-1-4939-9654-4_10

Paper Targeting HER2-positive cancer with dolastatin 15 derivatives conjugated to trastuzumab, novel antibody–drug conjugates

D. Gianolio; C. Rouleau; William Bauta et al. · 2012 · Cancer Chemotherapy and Pharmacology · DOI

Full title: Targeting HER2-positive cancer with dolastatin 15 derivatives conjugated to trastuzumab, novel antibody–drug conjugates

Authors: D. Gianolio; C. Rouleau; William Bauta; D. Lovett; W. Cantrell; Antonio Iii Recio; Paul Wolstenholme-Hogg; Michelle Busch; Peng Pan; J. E. Stefano; H. M. Kramer; James Goebel; Roy D. Krumbholz; Stephanie Roth; S. Schmid; B. Teicher

Year: 2012

Venue: Cancer Chemotherapy and Pharmacology

DOI: https://doi.org/10.1007/s00280-012-1925-8

Paper Method development of a novel PK assay for antibody-conjugated drug measurement of ADCs using peptide-linker drug analyte

Suk-Joon Hyung; Dongwei Li; Neelima Koppada et al. · 2019 · Analytical and Bioanalytical Chemistry · DOI

Full title: Method development of a novel PK assay for antibody-conjugated drug measurement of ADCs using peptide-linker drug analyte

Authors: Suk-Joon Hyung; Dongwei Li; Neelima Koppada; S. Kaur; Ola M. Saad

Year: 2019

Venue: Analytical and Bioanalytical Chemistry

DOI: https://doi.org/10.1007/s00216-019-01701-9

Paper Evolving Strategies for Target Selection for Antibody-Drug Conjugates.

Damelin, Marc; Zhong, Wenyan; Myers, Jeremy et al. · 2015 · Pharmaceutical research · DOI

Full title: Evolving Strategies for Target Selection for Antibody-Drug Conjugates.

Authors: Damelin, Marc; Zhong, Wenyan; Myers, Jeremy; Sapra, Puja

Year: 2015

Venue: Pharmaceutical research

DOI: https://doi.org/10.1007/s11095-015-1624-3

Paper Selecting an optimal antibody for antibody-drug conjugate therapy: internalization and intracellular localization.

Jay Harper; S. Mao; P. Strout et al. · 2013 · Methods in molecular biology · DOI

Full title: Selecting an optimal antibody for antibody-drug conjugate therapy: internalization and intracellular localization.

Authors: Jay Harper; S. Mao; P. Strout; A. Kamal

Year: 2013

Venue: Methods in molecular biology

DOI: https://doi.org/10.1007/978-1-62703-541-5_3

Paper Bench-to-Bedside Perspectives on Ocular Toxicity of Antibody-Drug Conjugates: Toxicology, Clinical Management and Molecule Optimization.

Jialing Zhang; Weiyu Li; Meng Li et al. · 2026 · Pharmaceutical Research · DOI

Full title: Bench-to-Bedside Perspectives on Ocular Toxicity of Antibody-Drug Conjugates: Toxicology, Clinical Management and Molecule Optimization.

Authors: Jialing Zhang; Weiyu Li; Meng Li; Gang Wu; Yongbo Ni; Jialiang Du; Gangling Xu; Maoqin Duan; Yalan Yang; Xiaojuan Yu; Chunbo Cui; Chun-yu Liu; Chuan-fei Yu; Lan Wang

Year: 2026

Venue: Pharmaceutical Research

DOI: https://doi.org/10.1007/s11095-025-03953-w

Paper Characteristics and utilization of the three BCMA-targeted therapies in multiple myeloma.

Keichiro Mihara; Takahiko Miyama · 2025 · International journal of hematology · DOI

Full title: Characteristics and utilization of the three BCMA-targeted therapies in multiple myeloma.

Authors: Keichiro Mihara; Takahiko Miyama

Year: 2025

Venue: International journal of hematology

DOI: https://doi.org/10.1007/s12185-025-04128-4

Paper Research progress of CD22-targeting antibody-drug conjugates

Hao Niu · 2017 · DOI

Full title: Research progress of CD22-targeting antibody-drug conjugates

Authors: Hao Niu

Year: 2017

DOI: https://doi.org/10.3760/cma.j.issn.1673-4211.2017.06.007

Paper Research progress of antibody-drug conjugate targeting B cell maturation antigen in treatment of relapsed/refractory multiple myeloma

Yao Chao; Yanping Ma · 2019 · DOI

Full title: Research progress of antibody-drug conjugate targeting B cell maturation antigen in treatment of relapsed/refractory multiple myeloma

Authors: Yao Chao; Yanping Ma

Year: 2019

DOI: https://doi.org/10.3760/cma.j.issn.1673-419x.2019.05.013

Paper Antibody-Drug Conjugates (ADCs) for Breast Cancer Therapeutic Landscape: Concept and Mechanisms of Action.

Paz-Manrique, Roberto; Pinto, Joseph A; Gomez Moreno, Henry L · 2026 · Hematology/oncology and stem cell therapy · DOI

Full title: Antibody-Drug Conjugates (ADCs) for Breast Cancer Therapeutic Landscape: Concept and Mechanisms of Action.

Authors: Paz-Manrique, Roberto; Pinto, Joseph A; Gomez Moreno, Henry L

Year: 2026

Venue: Hematology/oncology and stem cell therapy

DOI: https://doi.org/10.4103/hemoncstem.HEMONCSTEM-D-24-00042

Paper Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction

Benjamí Oller‐Salvia · 2018 · Journal of Visualized Experiments · DOI

Full title: Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction

Authors: Benjamí Oller‐Salvia

Year: 2018

Venue: Journal of Visualized Experiments

DOI: https://doi.org/10.3791/58066

Paper Pharmacodynamics, Pharmacokinetics, and Tolerability of a B-Cell Specific Antibody-Targeted Chemotherapeutic Agent, Anti-CD79b-MCC-DM1, in Cynomolgus Monkeys (41.12)

Marna B. Williams; Dongwei Li; R. Fuji et al. · 2009 · Journal of Immunology · DOI

Full title: Pharmacodynamics, Pharmacokinetics, and Tolerability of a B-Cell Specific Antibody-Targeted Chemotherapeutic Agent, Anti-CD79b-MCC-DM1, in Cynomolgus Monkeys (41.12)

Authors: Marna B. Williams; Dongwei Li; R. Fuji; F. Fuh; S. Prabhu; B. Zheng; Kristi Elkins; Shang‐Fan Yu; Josefa Chuh; Christine Tan; J. Hongo; H. Raab; Judy C. Young; S. Ross; K. Kozak; D. Eaton; S. Spencer; K. A. Poon; P. Fielder; J. Tibbitts; K. Berry; W. Manning; V. Ramakrishnan; A. Ebens; A. Polson

Year: 2009

Venue: Journal of Immunology

DOI: https://doi.org/10.4049/jimmunol.182.supp.41.12

Paper Antibody–Drug Conjugates: Bridging Science and Therapeutics

Kakoli Patnaik; Rajul Lodha; Meenakshi et al. · 2025 · Amrita Journal of Medicine · DOI

Full title: Antibody–Drug Conjugates: Bridging Science and Therapeutics

Authors: Kakoli Patnaik; Rajul Lodha; Meenakshi; Nitin Sharma

Year: 2025

Venue: Amrita Journal of Medicine

DOI: https://doi.org/10.4103/amjm.amjm_39_25

Paper A personal perspective of the development and validation of a phase-specific antibody-drug conjugate cytotoxicity potency assay.

Robert Wilson · 2013 · Bioanalysis · DOI

Full title: A personal perspective of the development and validation of a phase-specific antibody-drug conjugate cytotoxicity potency assay.

Authors: Robert Wilson

Year: 2013

Venue: Bioanalysis

DOI: https://doi.org/10.4155/bio.13.67

Paper Antibody drug-conjugates targeting the tumor vasculature

H. Gerber; P. Senter; I. Grewal · 2009 · mAbs · DOI

Full title: Antibody drug-conjugates targeting the tumor vasculature

Authors: H. Gerber; P. Senter; I. Grewal

Year: 2009

Venue: mAbs

DOI: https://doi.org/10.4161/mabs.1.3.8515

Paper TCR-like antibody duocarmycin conjugates promote cytotoxicity of tumor cells expressing low peptide/HLA targets

Christian E Herrera; D. Lowe; Camille K Bivens et al. · 2017 · Journal of Immunology · DOI

Full title: TCR-like antibody duocarmycin conjugates promote cytotoxicity of tumor cells expressing low peptide/HLA targets

Authors: Christian E Herrera; D. Lowe; Camille K Bivens; Alexis S. Mobley; Amanda L McCormick; Timea Wichner; Manoj K Sabnani; L. Wood; J. Weidanz

Year: 2017

Venue: Journal of Immunology

DOI: https://doi.org/10.4049/jimmunol.198.supp.120.4

Paper Impact of linker and conjugation chemistry on antigen binding, Fc receptor binding and thermal stability of model antibody-drug conjugates

M. Acchione; Hyewon Kwon; C. Jochheim et al. · 2012 · mAbs · DOI

Full title: Impact of linker and conjugation chemistry on antigen binding, Fc receptor binding and thermal stability of model antibody-drug conjugates

Authors: M. Acchione; Hyewon Kwon; C. Jochheim; W. Atkins

Year: 2012

Venue: mAbs

DOI: https://doi.org/10.4161/mabs.19449

Paper Analytical methods for physicochemical characterization of antibody drug conjugates

Aditya A Wakankar; Yan Chen; Yatin R. Gokarn et al. · 2011 · mAbs · DOI

Full title: Analytical methods for physicochemical characterization of antibody drug conjugates

Authors: Aditya A Wakankar; Yan Chen; Yatin R. Gokarn; F. Jacobson

Year: 2011

Venue: mAbs

DOI: https://doi.org/10.4161/mabs.3.2.14960

Paper Antibody-Drug Conjugates For the Treatment of Hematological Malignancy

Sudhir A. Shah · 2018 · Atlas of Genetics and Cytogenetics in Oncology and Haematology · DOI

Full title: Antibody-Drug Conjugates For the Treatment of Hematological Malignancy

Authors: Sudhir A. Shah

Year: 2018

Venue: Atlas of Genetics and Cytogenetics in Oncology and Haematology

DOI: https://doi.org/10.4267/2042/68883

Paper The biology of MDR1-P-glycoprotein (MDR1-Pgp) in designing functional antibody drug conjugates (ADCs): the experience of gemtuzumab ozogamicin.

M. Cianfriglia · 2013 · Annali dell'Istituto Superiore di Sanità · DOI

Full title: The biology of MDR1-P-glycoprotein (MDR1-Pgp) in designing functional antibody drug conjugates (ADCs): the experience of gemtuzumab ozogamicin.

Authors: M. Cianfriglia

Year: 2013

Venue: Annali dell'Istituto Superiore di Sanità

DOI: https://doi.org/10.4415/ann_13_02_07

Paper Site-specific antibody drug conjugates for cancer therapy

S. Panowski; S. Bhakta; H. Raab et al. · 2013 · mAbs · DOI

Full title: Site-specific antibody drug conjugates for cancer therapy

Authors: S. Panowski; S. Bhakta; H. Raab; P. Polakis; Jagath R Junutula

Year: 2013

Venue: mAbs

DOI: https://doi.org/10.4161/mabs.27022

Paper Antibody-drug conjugates: using monoclonal antibodies for delivery of cytotoxic payloads to cancer cells.

V. Goldmacher; Y. Kovtun · 2011 · Therapeutic delivery · DOI

Full title: Antibody-drug conjugates: using monoclonal antibodies for delivery of cytotoxic payloads to cancer cells.

Authors: V. Goldmacher; Y. Kovtun

Year: 2011

Venue: Therapeutic delivery

DOI: https://doi.org/10.4155/tde.10.98

Paper Chemical strategies for linker design in antibody-drug conjugates : Enhancing stability and efficacy

Mohd Junaid Anju Bala · 2023 · Biochemical and Cellular Archives · DOI

Full title: Chemical strategies for linker design in antibody-drug conjugates : Enhancing stability and efficacy

Authors: Mohd Junaid Anju Bala

Year: 2023

Venue: Biochemical and Cellular Archives

DOI: https://doi.org/10.51470/bca.2023.23.2.1179

Paper Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates

M. Ritchie; Lioudmila Tchistiakova; Nathan Scott · 2013 · mAbs · DOI

Full title: Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates

Authors: M. Ritchie; Lioudmila Tchistiakova; Nathan Scott

Year: 2013

Venue: mAbs

DOI: https://doi.org/10.4161/mabs.22854

Paper Antibody Therapeutics in Oncology

Erik D. Wold; Vaughn V. Smider; Brunhilde H. Felding · 2016 · Immunotherapy · DOI

Full title: Antibody Therapeutics in Oncology

Authors: Erik D. Wold; Vaughn V. Smider; Brunhilde H. Felding

Year: 2016

Venue: Immunotherapy

DOI: https://doi.org/10.4172/2471-9552.1000108

Paper The novel EpCAM-targeting monoclonal antibody 3–17I linked to saporin is highly cytotoxic after photochemical internalization in breast, pancreas and colon cancer cell lines

Kaja Lund; Monica Bostad; E. Skarpen et al. · 2014 · mAbs · DOI

Full title: The novel EpCAM-targeting monoclonal antibody 3–17I linked to saporin is highly cytotoxic after photochemical internalization in breast, pancreas and colon cancer cell lines

Authors: Kaja Lund; Monica Bostad; E. Skarpen; M. Braunagel; S. Kiprijanov; S. Krauss; A. Duncan; A. Høgset; P. Selbo

Year: 2014

Venue: mAbs

DOI: https://doi.org/10.4161/mabs.28207

Paper Targeting MDR1-P-glycoprotein (MDR1-Pgp) in immunochemotherapy of acute myeloid leukemia (AML).

M. Cianfriglia · 2013 · Annali dell'Istituto Superiore di Sanità · DOI

Full title: Targeting MDR1-P-glycoprotein (MDR1-Pgp) in immunochemotherapy of acute myeloid leukemia (AML).

Authors: M. Cianfriglia

Year: 2013

Venue: Annali dell'Istituto Superiore di Sanità

DOI: https://doi.org/10.4415/ann_13_02_11

Paper Methods for site-specific drug conjugation to antibodies.

Behrens, Christopher R; Liu, Bin · 2014 · mAbs · DOI

Full title: Methods for site-specific drug conjugation to antibodies.

Authors: Behrens, Christopher R; Liu, Bin

Year: 2014

Venue: mAbs

DOI: https://doi.org/10.4161/mabs.26632

Paper [Oncology. Antibody-drug conjugates : a challenging innovation].

Rita S Brito; Timothée Olivier; A. Wolfer · 2025 · Revue medicale suisse · DOI

Full title: [Oncology. Antibody-drug conjugates : a challenging innovation].

Authors: Rita S Brito; Timothée Olivier; A. Wolfer

Year: 2025

Venue: Revue medicale suisse

DOI: https://doi.org/10.53738/revmed.2025.21.902.142

Paper A new perspective in the research of antibody drug conjugate

Qiao Li; Mingxia Jiang; Bing-he Xu · 2023 · The Innovation Medicine · DOI

Full title: A new perspective in the research of antibody drug conjugate

Authors: Qiao Li; Mingxia Jiang; Bing-he Xu

Year: 2023

Venue: The Innovation Medicine

DOI: https://doi.org/10.59717/j.xinn-med.2023.100018

Paper Click chemistry in drug development recent trends and application

Nikhil Nikhil; Anchal Guleria; U. S. M. Rao et al. · 2025 · Research Journal of Pharmacy and Technology · DOI

Full title: Click chemistry in drug development recent trends and application

Authors: Nikhil Nikhil; Anchal Guleria; U. S. M. Rao; Lee Wan Zhen; Suganya Mahadeva Rao; Kalandar Ameer; Venketash Kumar Krishnamoorthy; Thanapakiam Ganeson; Kamini Vijeepallam; M. B. Sundaram; V. Selvaraj

Year: 2025

Venue: Research Journal of Pharmacy and Technology

DOI: https://doi.org/10.52711/0974-360x.2025.00345

Paper Therapeutic Applications and Target Strategies of Antibody-Drug Conjugates in Ovarian Cancer

Qiming Liu; Runji Zhou; Taiqi He et al. · 2025 · Iranian journal of pharmaceutical research · DOI

Full title: Therapeutic Applications and Target Strategies of Antibody-Drug Conjugates in Ovarian Cancer

Authors: Qiming Liu; Runji Zhou; Taiqi He; Yonghong Zhao; Mei Yang

Year: 2025

Venue: Iranian journal of pharmaceutical research

DOI: https://doi.org/10.5812/ijpr-165383

Paper Emerging Therapeutic Options in Acute Lymphoblastic Leukemia

P. Brown · 2020 · The Journal of the National Comprehensive Cancer Network · DOI

Full title: Emerging Therapeutic Options in Acute Lymphoblastic Leukemia

Authors: P. Brown

Year: 2020

Venue: The Journal of the National Comprehensive Cancer Network

DOI: https://doi.org/10.6004/jnccn.2020.5038

Paper Antibody–drug conjugates in B-cell lymphomas: current evidence and future directions

Alexandros Angelopoulos · 2026 · MediShorts · DOI

Full title: Antibody–drug conjugates in B-cell lymphomas: current evidence and future directions

Authors: Alexandros Angelopoulos

Year: 2026

Venue: MediShorts

DOI: https://doi.org/10.70145/mesh0004

Paper Antibody-Drug Conjugates, the Combination of Large and Small Therapeutic Molecules

B. Kratochvíl; E. Benešová · 2023 · Chemické listy (Print) · DOI

Full title: Antibody-Drug Conjugates, the Combination of Large and Small Therapeutic Molecules

Authors: B. Kratochvíl; E. Benešová

Year: 2023

Venue: Chemické listy (Print)

DOI: https://doi.org/10.54779/chl20230319

Paper HER2-targeted ADC DX126-262 combined with chemotherapy demonstrates superior antitumor efficacy in HER2-positive gastric cancer.

X. Cai; Min Cao; Qingliang Yang et al. · 2024 · American Journal of Cancer Research · DOI

Full title: HER2-targeted ADC DX126-262 combined with chemotherapy demonstrates superior antitumor efficacy in HER2-positive gastric cancer.

Authors: X. Cai; Min Cao; Qingliang Yang; Xiazhen Yu; Xin-Hua Feng; R. Zhao

Year: 2024

Venue: American Journal of Cancer Research

DOI: https://doi.org/10.62347/qcdr9612

Paper Factors Influencing the Adoption of Antibody-Drug Conjugates in Oncology: A Statistical Study

Sabrina Rahman; Sana Rashid; Mehwish et al. · 2024 · Indus Journal of Bioscience Research · DOI

Full title: Factors Influencing the Adoption of Antibody-Drug Conjugates in Oncology: A Statistical Study

Authors: Sabrina Rahman; Sana Rashid; Mehwish; Ubaida Hussain; Zafar Ahmad Khan; Asma Ul Hosna Patowary; Atif Munir

Year: 2024

Venue: Indus Journal of Bioscience Research

DOI: https://doi.org/10.70749/ijbr.v2i02.287

Paper Towards A Computational QSP Platform To Support Antibody Drug Conjugate Design In Cancer

C. Couty; T. Galland; Brian Topp et al. · Proceedings of the American Conference of Pharmacometrics 2024 · DOI

Full title: Towards A Computational QSP Platform To Support Antibody Drug Conjugate Design In Cancer

Authors: C. Couty; T. Galland; Brian Topp; Jim Bosley; Simon Arsène; Lara Bruezière

Venue: Proceedings of the American Conference of Pharmacometrics 2024

DOI: https://doi.org/10.70534/mhfs8825

Paper A quantitative systems pharmacology model framework for combined clinical efficacy and hematological toxicity predictions for antibody drug conjugates

Bhairav Paleja; Raunak Dutta; Swagatika Sahoo et al. · Proceedings of the American Conference of Pharmacometrics 2024 · DOI

Full title: A quantitative systems pharmacology model framework for combined clinical efficacy and hematological toxicity predictions for antibody drug conjugates

Authors: Bhairav Paleja; Raunak Dutta; Swagatika Sahoo; Rukmini Kumar

Venue: Proceedings of the American Conference of Pharmacometrics 2024

DOI: https://doi.org/10.70534/yhwh3587

Paper A phase I study of the antibody drug conjugate ASG-5ME, an SLC44A4-targeting antibody carrying auristatin E, in metastatic castration-resistant prostate cancer.

McHugh, Deaglan; Eisenberger, Mario; Heath, Elisabeth I et al. · 2019 · Investigational new drugs · DOI

Full title: A phase I study of the antibody drug conjugate ASG-5ME, an SLC44A4-targeting antibody carrying auristatin E, in metastatic castration-resistant prostate cancer.

Authors: McHugh, Deaglan; Eisenberger, Mario; Heath, Elisabeth I; Bruce, Justine; Danila, Daniel C; Rathkopf, Dana E; Feldman, Jarett; Slovin, Susan F; Anand, Banmeet; Chu, Rong; Lackey, Jacqueline; Reyno, Leonard; Antonarakis, Emmanuel S; Morris, Michael J

Year: 2019

Venue: Investigational new drugs

DOI: https://doi.org/10.1007/s10637-019-00731-5

Paper Antibody-Drug Conjugates for Melanoma and Other Skin Malignancies

Rachel E Goodman; Douglas B. Johnson · 2022 · Current Treatment Options in Oncology · DOI

Full title: Antibody-Drug Conjugates for Melanoma and Other Skin Malignancies

Authors: Rachel E Goodman; Douglas B. Johnson

Year: 2022

Venue: Current Treatment Options in Oncology

DOI: https://doi.org/10.1007/s11864-022-01018-3

Paper Antibody-drug conjugates in cancer therapy: innovations, challenges, and future directions.

Kumari, Shivangi; Raj, Sonam; Babu, M Arockia et al. · 2024 · Archives of pharmacal research · DOI

Full title: Antibody-drug conjugates in cancer therapy: innovations, challenges, and future directions.

Authors: Kumari, Shivangi; Raj, Sonam; Babu, M Arockia; Bhatti, Gurjit Kaur; Bhatti, Jasvinder Singh

Year: 2024

Venue: Archives of pharmacal research

DOI: https://doi.org/10.1007/s12272-023-01479-6

Paper Antibody-drug conjugate as targeted therapeutics against hepatocellular carcinoma: preclinical studies and clinical relevance.

Murali, M; Kumar, A R; Nair, B et al. · 2022 · Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · DOI

Full title: Antibody-drug conjugate as targeted therapeutics against hepatocellular carcinoma: preclinical studies and clinical relevance.

Authors: Murali, M; Kumar, A R; Nair, B; Pavithran, K; Devan, A R; Pradeep, G K; Nath, L R

Year: 2022

Venue: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

DOI: https://doi.org/10.1007/s12094-021-02707-5

Paper Antibody drug conjugates as targeted cancer therapy: past development, present challenges and future opportunities.

Maiti, Ritwik; Patel, Bhumika; Patel, Nrupesh et al. · 2023 · Archives of pharmacal research · DOI

Full title: Antibody drug conjugates as targeted cancer therapy: past development, present challenges and future opportunities.

Authors: Maiti, Ritwik; Patel, Bhumika; Patel, Nrupesh; Patel, Mehul; Patel, Alkesh; Dhanesha, Nirav

Year: 2023

Venue: Archives of pharmacal research

DOI: https://doi.org/10.1007/s12272-023-01447-0

Paper CD30 and CD30-Targeted Therapies in Hodgkin Lymphoma and Other B cell Lymphomas

Geetika Bhatt; K. Maddocks; Beth Christian · 2016 · Current Hematologic Malignancy Reports · DOI

Full title: CD30 and CD30-Targeted Therapies in Hodgkin Lymphoma and Other B cell Lymphomas

Authors: Geetika Bhatt; K. Maddocks; Beth Christian

Year: 2016

Venue: Current Hematologic Malignancy Reports

DOI: https://doi.org/10.1007/s11899-016-0345-y

Paper Conditionally Activatable Antibody Platforms: Mechanisms, Modalities, and Clinical Translation Potential.

Kim, Namyeong; Kwon, Inchan · 2026 · BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · DOI

Full title: Conditionally Activatable Antibody Platforms: Mechanisms, Modalities, and Clinical Translation Potential.

Authors: Kim, Namyeong; Kwon, Inchan

Year: 2026

Venue: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy

DOI: https://doi.org/10.1007/s40259-025-00752-y

Paper Targeting HER2+ Breast Cancer Brain Metastases: A Review of Brain-Directed HER2-Directed Therapies

Lauren Chiec; P. Kumthekar · 2022 · CNS Drugs · DOI

Full title: Targeting HER2+ Breast Cancer Brain Metastases: A Review of Brain-Directed HER2-Directed Therapies

Authors: Lauren Chiec; P. Kumthekar

Year: 2022

Venue: CNS Drugs

DOI: https://doi.org/10.1007/s40263-021-00894-x

Paper Future potential targets of antibody-drug conjugates in breast cancer.

Corti, Chiara; Boscolo Bielo, Luca; Schianca, Ambra Carnevale et al. · 2023 · Breast (Edinburgh, Scotland) · DOI

Full title: Future potential targets of antibody-drug conjugates in breast cancer.

Authors: Corti, Chiara; Boscolo Bielo, Luca; Schianca, Ambra Carnevale; Salimbeni, Beatrice Taurelli; Criscitiello, Carmen; Curigliano, Giuseppe

Year: 2023

Venue: Breast (Edinburgh, Scotland)

DOI: https://doi.org/10.1016/j.breast.2023.03.007

Paper Multivalent protein-drug conjugates - An emerging strategy for the upgraded precision and efficiency of drug delivery to cancer cells.

Porębska, Natalia; Ciura, Krzysztof; Chorążewska, Aleksandra et al. · 2023 · Biotechnology advances · DOI

Full title: Multivalent protein-drug conjugates - An emerging strategy for the upgraded precision and efficiency of drug delivery to cancer cells.

Authors: Porębska, Natalia; Ciura, Krzysztof; Chorążewska, Aleksandra; Zakrzewska, Małgorzata; Otlewski, Jacek; Opaliński, Łukasz

Year: 2023

Venue: Biotechnology advances

DOI: https://doi.org/10.1016/j.biotechadv.2023.108213

Paper [Treatment-related adverse events associated with antibody drug conjugate in breast cancer].

Collineau, Bérénice; Gonçalves, Anthony; Bertucci, François et al. · 2024 · Bulletin du cancer · DOI

Full title: [Treatment-related adverse events associated with antibody drug conjugate in breast cancer].

Authors: Collineau, Bérénice; Gonçalves, Anthony; Bertucci, François; de Nonneville, Alexandre

Year: 2024

Venue: Bulletin du cancer

DOI: https://doi.org/10.1016/j.bulcan.2024.04.004

Paper Integrated strategy for biotransformation of antibody-drug conjugates and multidimensional interpretation via high-resolution mass spectrometry.

Li, Ziyi; Zhang, Jingxian; Wu, Yue et al. · 2025 · Drug metabolism and disposition: the biological fate of chemicals · DOI

Full title: Integrated strategy for biotransformation of antibody-drug conjugates and multidimensional interpretation via high-resolution mass spectrometry.

Authors: Li, Ziyi; Zhang, Jingxian; Wu, Yue; Wang, Fan; Cai, Tingting

Year: 2025

Venue: Drug metabolism and disposition: the biological fate of chemicals

DOI: https://doi.org/10.1016/j.dmd.2025.100081

Paper Sortagged anti-EGFR immunoliposomes exhibit increased cytotoxicity on target cells.

Wöll, Steffen; Dickgiesser, Stephan; Rasche, Nicolas et al. · 2019 · European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · DOI

Full title: Sortagged anti-EGFR immunoliposomes exhibit increased cytotoxicity on target cells.

Authors: Wöll, Steffen; Dickgiesser, Stephan; Rasche, Nicolas; Schiller, Stefan; Scherließ, Regina

Year: 2019

Venue: European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V

DOI: https://doi.org/10.1016/j.ejpb.2019.01.020

Paper A new construct of antibody-drug conjugates for treatment of B-cell non-Hodgkin's lymphomas.

Zhang, Libin; Fang, Yixin; Kopeček, Jindřich et al. · 2017 · European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences · DOI

Full title: A new construct of antibody-drug conjugates for treatment of B-cell non-Hodgkin's lymphomas.

Authors: Zhang, Libin; Fang, Yixin; Kopeček, Jindřich; Yang, Jiyuan

Year: 2017

Venue: European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences

DOI: https://doi.org/10.1016/j.ejps.2017.02.034

Paper Bispecific antibody drug conjugates: Making 1+1>2.

Gu, Yilin; Wang, Zhijia; Wang, Yuxi · 2024 · Acta pharmaceutica Sinica. B · DOI

Full title: Bispecific antibody drug conjugates: Making 1+1>2.

Authors: Gu, Yilin; Wang, Zhijia; Wang, Yuxi

Year: 2024

Venue: Acta pharmaceutica Sinica. B

DOI: https://doi.org/10.1016/j.apsb.2024.01.009

Paper Albubody: an engineered scFv variant platform for site-specific drug conjugation and enhanced tumor efficacy.

Kwon, Na Hyun; Lee, Jae Hun; Kim, Yeongchae et al. · 2025 · Journal of controlled release : official journal of the Controlled Release Society · DOI

Full title: Albubody: an engineered scFv variant platform for site-specific drug conjugation and enhanced tumor efficacy.

Authors: Kwon, Na Hyun; Lee, Jae Hun; Kim, Yeongchae; Hahn, Young S; Kwon, Inchan

Year: 2025

Venue: Journal of controlled release : official journal of the Controlled Release Society

DOI: https://doi.org/10.1016/j.jconrel.2025.114165

Paper Monoclonal antibody-based therapies in cancer: advances and challenges.

Sapra, Puja; Shor, Boris · 2013 · Pharmacology & therapeutics · DOI

Full title: Monoclonal antibody-based therapies in cancer: advances and challenges.

Authors: Sapra, Puja; Shor, Boris

Year: 2013

Venue: Pharmacology & therapeutics

DOI: https://doi.org/10.1016/j.pharmthera.2013.03.004

Paper Antibody-drug conjugate [ADC] treatment of leukaemia.

Hassan, Hassan Tawhid · 2023 · Leukemia research · DOI

Full title: Antibody-drug conjugate [ADC] treatment of leukaemia.

Authors: Hassan, Hassan Tawhid

Year: 2023

Venue: Leukemia research

DOI: https://doi.org/10.1016/j.leukres.2023.107078

Paper The journey of antibody-drug conjugates for revolutionizing cancer therapy: A review.

Akram, Fatima; Ali, Amna Murrawat; Akhtar, Muhammad Tayyab et al. · 2025 · Bioorganic & medicinal chemistry · DOI

Full title: The journey of antibody-drug conjugates for revolutionizing cancer therapy: A review.

Authors: Akram, Fatima; Ali, Amna Murrawat; Akhtar, Muhammad Tayyab; Fatima, Taseer; Shabbir, Ifrah; Ul Haq, Ikram

Year: 2025

Venue: Bioorganic & medicinal chemistry

DOI: https://doi.org/10.1016/j.bmc.2024.118010

Paper Design of cathepsin-sensitive linkers for tumor-selective bioconjugate drug delivery.

Giri, Anil; Shin, Yulim; Ha, Jin et al. · 2025 · Journal of controlled release : official journal of the Controlled Release Society · DOI

Full title: Design of cathepsin-sensitive linkers for tumor-selective bioconjugate drug delivery.

Authors: Giri, Anil; Shin, Yulim; Ha, Jin; Chae, Siyeon; Shrestha, Prabhat; Pham, Khang-Yen; Kwon, Taeg Kyu; Park, Jong Ho; Jeong, Jee-Heon; Lee, Na Kyeong; Yook, Simmyung

Year: 2025

Venue: Journal of controlled release : official journal of the Controlled Release Society

DOI: https://doi.org/10.1016/j.jconrel.2025.114197

Paper Preclinical safety profile of trastuzumab emtansine (T-DM1): mechanism of action of its cytotoxic component retained with improved tolerability.

Poon, Kirsten Achilles; Flagella, Kelly; Beyer, Joseph et al. · 2013 · Toxicology and applied pharmacology · DOI

Full title: Preclinical safety profile of trastuzumab emtansine (T-DM1): mechanism of action of its cytotoxic component retained with improved tolerability.

Authors: Poon, Kirsten Achilles; Flagella, Kelly; Beyer, Joseph; Tibbitts, Jay; Kaur, Surinder; Saad, Ola; Yi, Joo-Hee; Girish, Sandhya; Dybdal, Noel; Reynolds, Theresa

Year: 2013

Venue: Toxicology and applied pharmacology

DOI: https://doi.org/10.1016/j.taap.2013.09.003

Paper Drug deconjugation-assisted peptide mapping by LC-MS/MS to identify conjugation sites and quantify site occupancy for antibody-drug conjugates.

Wang, Tongdan; Huang, Zi-Ao; Zhou, Moyin et al. · 2024 · Journal of pharmaceutical and biomedical analysis · DOI

Full title: Drug deconjugation-assisted peptide mapping by LC-MS/MS to identify conjugation sites and quantify site occupancy for antibody-drug conjugates.

Authors: Wang, Tongdan; Huang, Zi-Ao; Zhou, Moyin; Wang, Ruxin; Li, Yufei; Guo, Longyun; Cao, Xiaolin; Huang, Jincui

Year: 2024

Venue: Journal of pharmaceutical and biomedical analysis

DOI: https://doi.org/10.1016/j.jpba.2024.116098

Paper Antibody-drug conjugates: Current challenges and innovative solutions for precision cancer therapy.

Zhou, Xingyu; Han, Yanjie; Fang, Yuan et al. · 2025 · Med (New York, N.Y.) · DOI

Full title: Antibody-drug conjugates: Current challenges and innovative solutions for precision cancer therapy.

Authors: Zhou, Xingyu; Han, Yanjie; Fang, Yuan; Ma, Peiwen; Zhou, Jiawei; Jiang, Yale; Xing, Shujun; Tang, Qiyu; Hou, Yiru; Wang, Shuhang; Li, Ning

Year: 2025

Venue: Med (New York, N.Y.)

DOI: https://doi.org/10.1016/j.medj.2025.100849

Paper Chromatographic analysis of site-specific antibody-drug conjugates produced by AJICAP first-generation technology using a recombinant FcγIIIa receptor-ligand affinity column.

Matsuda, Yutaka; Chakrabarti, Atis; Takahashi, Kazutoshi et al. · 2021 · Journal of chromatography. B, Analytical technologies in the biomedical and life sciences · DOI

Full title: Chromatographic analysis of site-specific antibody-drug conjugates produced by AJICAP first-generation technology using a recombinant FcγIIIa receptor-ligand affinity column.

Authors: Matsuda, Yutaka; Chakrabarti, Atis; Takahashi, Kazutoshi; Yamada, Kei; Nakata, Kunio; Okuzumi, Tatsuya; Mendelsohn, Brian A

Year: 2021

Venue: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences

DOI: https://doi.org/10.1016/j.jchromb.2021.122753

Paper Considerations for the nonclinical safety evaluation of antibody drug conjugates for oncology.

Roberts, Stanley A; Andrews, Paul A; Blanset, Diann et al. · 2013 · Regulatory toxicology and pharmacology : RTP · DOI

Full title: Considerations for the nonclinical safety evaluation of antibody drug conjugates for oncology.

Authors: Roberts, Stanley A; Andrews, Paul A; Blanset, Diann; Flagella, Kelly M; Gorovits, Boris; Lynch, Carmel M; Martin, Pauline L; Kramer-Stickland, Kimberly; Thibault, Stephane; Warner, Garvin

Year: 2013

Venue: Regulatory toxicology and pharmacology : RTP

DOI: https://doi.org/10.1016/j.yrtph.2013.08.017

Paper Therapeutic Roles of Antibody Drug Conjugates (ADCs) in Relapsed/Refractory Lymphomas.

Hashmi, Hamza; Darwin, Alicia; Nishihori, Taiga · 2023 · Hematology/oncology and stem cell therapy · DOI

Full title: Therapeutic Roles of Antibody Drug Conjugates (ADCs) in Relapsed/Refractory Lymphomas.

Authors: Hashmi, Hamza; Darwin, Alicia; Nishihori, Taiga

Year: 2023

Venue: Hematology/oncology and stem cell therapy

DOI: https://doi.org/10.1016/j.hemonc.2021.07.002

Paper Antibody-drug conjugate directed against the guanylyl cyclase antigen for the treatment of gastrointestinal malignancies.

Almhanna, Khaldoun; Prithviraj, Gopi K; Veiby, Petter et al. · 2017 · Pharmacology & therapeutics · DOI

Full title: Antibody-drug conjugate directed against the guanylyl cyclase antigen for the treatment of gastrointestinal malignancies.

Authors: Almhanna, Khaldoun; Prithviraj, Gopi K; Veiby, Petter; Kalebic, Thea

Year: 2017

Venue: Pharmacology & therapeutics

DOI: https://doi.org/10.1016/j.pharmthera.2016.10.007

Paper Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates.

Mahalingaiah, Prathap Kumar; Ciurlionis, Rita; Durbin, Kenneth R et al. · 2019 · Pharmacology & therapeutics · DOI

Full title: Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates.

Authors: Mahalingaiah, Prathap Kumar; Ciurlionis, Rita; Durbin, Kenneth R; Yeager, Ronnie L; Philip, Binu K; Bawa, Bhupinder; Mantena, Srinivasa R; Enright, Brian P; Liguori, Michael J; Van Vleet, Terry R

Year: 2019

Venue: Pharmacology & therapeutics

DOI: https://doi.org/10.1016/j.pharmthera.2019.04.008

Paper Clinical perspective: Antibody-drug conjugates for the treatment of HER2-positive breast cancer.

Najminejad, Zohreh; Dehghani, Fatemeh; Mirzaei, Yousef et al. · 2023 · Molecular therapy : the journal of the American Society of Gene Therapy · DOI

Full title: Clinical perspective: Antibody-drug conjugates for the treatment of HER2-positive breast cancer.

Authors: Najminejad, Zohreh; Dehghani, Fatemeh; Mirzaei, Yousef; Mer, Ali Hussein; Saghi, Seyyed Amirreza; Abdolvahab, Mohadeseh Haji; Bagheri, Nader; Meyfour, Anna; Jafari, Ameneh; Jahandideh, Saeed; Gharibi, Tohid; Amirkhani, Zahra; Delam, Hamed; Mashatan, Noushin; Shahsavarani, Hosein; Abdollahpour-Alitappeh, Meghdad

Year: 2023

Venue: Molecular therapy : the journal of the American Society of Gene Therapy

DOI: https://doi.org/10.1016/j.ymthe.2023.03.019

Paper Conjugation Site Influences Antibody-Conjugated Drug PK Assays: Case Studies for Disulfide-Linked, Self-Immolating Next-Generation Antibody Drug Conjugates.

M. V. Lee; S. Kaur; Ola M. Saad · 2020 · Analytical Chemistry · DOI

Full title: Conjugation Site Influences Antibody-Conjugated Drug PK Assays: Case Studies for Disulfide-Linked, Self-Immolating Next-Generation Antibody Drug Conjugates.

Authors: M. V. Lee; S. Kaur; Ola M. Saad

Year: 2020

Venue: Analytical Chemistry

DOI: https://doi.org/10.1021/acs.analchem.0c00773

Paper Multiple protease-activated probody-drug conjugates for treating CD147-positive ovarian cancer with limited toxicity.

Wang, Bo; Zhang, Qiangzhe; Yang, Yuqing et al. · 2026 · Pharmacological research · DOI

Full title: Multiple protease-activated probody-drug conjugates for treating CD147-positive ovarian cancer with limited toxicity.

Authors: Wang, Bo; Zhang, Qiangzhe; Yang, Yuqing; Wang, Chenhui; Deng, Guiyu; Chen, Ying; Xu, Zichang; Chen, Zhinan; Zhou, Chuanzheng; Zhang, Sihe

Year: 2026

Venue: Pharmacological research

DOI: https://doi.org/10.1016/j.phrs.2026.108120

Paper Site-Specific Quantitation of Drug Conjugations on Antibody-Drug Conjugates (ADCs) Using a Protease-Assisted Drug Deconjugation and Linker-like Labeling (PADDLL) Method.

Xiangkun Yang; Haeri Seol; Wei Lin et al. · 2021 · Analytical Chemistry · DOI

Full title: Site-Specific Quantitation of Drug Conjugations on Antibody-Drug Conjugates (ADCs) Using a Protease-Assisted Drug Deconjugation and Linker-like Labeling (PADDLL) Method.

Authors: Xiangkun Yang; Haeri Seol; Wei Lin; Xiaobin Xu; Biao Shen; Haibo Qiu; Ning Li

Year: 2021

Venue: Analytical Chemistry

DOI: https://doi.org/10.1021/acs.analchem.1c01619

Paper Bottom-Up Protein Analysis Workflow for Simultaneous Characterization of Payloads, Disulfide Bonds, and Free Thiols in Antibody-Drug Conjugates.

Keting Zhou; Yu Xia · 2025 · Analytical Chemistry · DOI

Full title: Bottom-Up Protein Analysis Workflow for Simultaneous Characterization of Payloads, Disulfide Bonds, and Free Thiols in Antibody-Drug Conjugates.

Authors: Keting Zhou; Yu Xia

Year: 2025

Venue: Analytical Chemistry

DOI: https://doi.org/10.1021/acs.analchem.5c05683

Paper CMC Regulatory Considerations for Antibody-Drug Conjugates.

Bechtold-Peters, Karoline; Ruggiero, Andrea; Vriezen, Nienke et al. · 2023 · Journal of pharmaceutical sciences · DOI

Full title: CMC Regulatory Considerations for Antibody-Drug Conjugates.

Authors: Bechtold-Peters, Karoline; Ruggiero, Andrea; Vriezen, Nienke; Ihle, Nathan; Klein, Armin; Morgan, Charles; Schweizer, Daniel; Liu, Dengfeng; Jacobson, Fred; Buecheler, Jakob; Panek, Mark; Duggan, Naomi; Malyala, Padma; Dupraz, Philippe; Desai, Priyanka; Niu, Shufang; Feng, Yiqing; Wang, Xiangyang

Year: 2023

Venue: Journal of pharmaceutical sciences

DOI: https://doi.org/10.1016/j.xphs.2023.09.007

Paper TUB-010, a novel antibody drug conjugate with reduced nonspecific toxicity profile based on Tub-tag technology widens the therapeutic window of targeting CD30

M. Gerlach; S. Schmitt; P. Cyprys et al. · 2022 · European Journal of Cancer · DOI

Full title: TUB-010, a novel antibody drug conjugate with reduced nonspecific toxicity profile based on Tub-tag technology widens the therapeutic window of targeting CD30

Authors: M. Gerlach; S. Schmitt; P. Cyprys; Marc‐André Kasper; I. Mai; M. Vermeer; SM Horwitz; G. Fingerle-Rowson; A. Vogl; D. Schumacher; J. Helma-Smets

Year: 2022

Venue: European Journal of Cancer

DOI: https://doi.org/10.1016/s0959-8049(22)00604-9

Paper In vivo safety testing of Antibody Drug Conjugates.

Pretto, Francesca; FitzGerald, Rex E · 2021 · Regulatory toxicology and pharmacology : RTP · DOI

Full title: In vivo safety testing of Antibody Drug Conjugates.

Authors: Pretto, Francesca; FitzGerald, Rex E

Year: 2021

Venue: Regulatory toxicology and pharmacology : RTP

DOI: https://doi.org/10.1016/j.yrtph.2021.104890

Paper Can we do better with Mylotarg? Model-based assessment of opportunities to improve therapeutic index.

Stoddard, Madison; Yuan, Lin; Cooper, Jodi et al. · 2024 · Toxicology and applied pharmacology · DOI

Full title: Can we do better with Mylotarg? Model-based assessment of opportunities to improve therapeutic index.

Authors: Stoddard, Madison; Yuan, Lin; Cooper, Jodi; Carcillo Neumar, Christine; Hibner, Barbara; Gardner, Humphrey; Chakravarty, Arijit

Year: 2024

Venue: Toxicology and applied pharmacology

DOI: https://doi.org/10.1016/j.taap.2024.117034

Paper Reducing the antigen-independent toxicity of antibody-drug conjugates by minimizing their non-specific clearance through PEGylation.

Simmons, Jessica K; Burke, Patrick J; Cochran, Julia H et al. · 2020 · Toxicology and applied pharmacology · DOI

Full title: Reducing the antigen-independent toxicity of antibody-drug conjugates by minimizing their non-specific clearance through PEGylation.

Authors: Simmons, Jessica K; Burke, Patrick J; Cochran, Julia H; Pittman, Paul G; Lyon, Robert P

Year: 2020

Venue: Toxicology and applied pharmacology

DOI: https://doi.org/10.1016/j.taap.2020.114932

Paper Tandem-Cleavage Linkers Improve the In Vivo Stability and Tolerability of Antibody-Drug Conjugates.

Chuprakov, Stepan; Ogunkoya, Ayodele O; Barfield, Robyn M et al. · 2021 · Bioconjugate chemistry · DOI

Full title: Tandem-Cleavage Linkers Improve the In Vivo Stability and Tolerability of Antibody-Drug Conjugates.

Authors: Chuprakov, Stepan; Ogunkoya, Ayodele O; Barfield, Robyn M; Bauzon, Maxine; Hickle, Colin; Kim, Yun Cheol; Yeo, Dominick; Zhang, Fangjiu; Rabuka, David; Drake, Penelope M

Year: 2021

Venue: Bioconjugate chemistry

DOI: https://doi.org/10.1021/acs.bioconjchem.1c00029

Paper A Two-Step Immunocapture LC/MS/MS Assay for Plasma Stability and Payload Migration Assessment of Cysteine-Maleimide-Based Antibody Drug Conjugates.

Linlin Dong; C. Li; C. Locuson et al. · 2018 · Analytical Chemistry · DOI

Full title: A Two-Step Immunocapture LC/MS/MS Assay for Plasma Stability and Payload Migration Assessment of Cysteine-Maleimide-Based Antibody Drug Conjugates.

Authors: Linlin Dong; C. Li; C. Locuson; Susan Chen; M. Qian

Year: 2018

Venue: Analytical Chemistry

DOI: https://doi.org/10.1021/acs.analchem.8b00694

Paper Characterization of Positional Isomers of Interchain Cysteine Linked Antibody-Drug Conjugates by High-Resolution Mass Spectrometry.

Ke Li; Z. Lin; Honglan Shi et al. · 2019 · Analytical Chemistry · DOI

Full title: Characterization of Positional Isomers of Interchain Cysteine Linked Antibody-Drug Conjugates by High-Resolution Mass Spectrometry.

Authors: Ke Li; Z. Lin; Honglan Shi; Yinfa Ma

Year: 2019

Venue: Analytical Chemistry

DOI: https://doi.org/10.1021/acs.analchem.9b01808

Paper Digestion-Free Middle-Down Mass Spectrometry Method for Absolute Quantification of Conjugated Payload from Antibody-Drug Conjugates

Jiaqi Yuan; Hui Yin Tan; Yue Huang et al. · 2024 · Analytical Chemistry · DOI

Full title: Digestion-Free Middle-Down Mass Spectrometry Method for Absolute Quantification of Conjugated Payload from Antibody-Drug Conjugates

Authors: Jiaqi Yuan; Hui Yin Tan; Yue Huang; A. Rosenbaum

Year: 2024

Venue: Analytical Chemistry

DOI: https://doi.org/10.1021/acs.analchem.4c03383

Paper Cysteine-Based Coupling: Challenges and Solutions.

J. You; Juan Zhang; Jun Wang et al. · 2021 · Bioconjugate chemistry · DOI

Full title: Cysteine-Based Coupling: Challenges and Solutions.

Authors: J. You; Juan Zhang; Jun Wang; Mingzhi Jin

Year: 2021

Venue: Bioconjugate chemistry

DOI: https://doi.org/10.1021/acs.bioconjchem.1c00213

Paper Stable Isotope Dilution LC-HRMS Assay To Determine Free SN-38, Total SN-38, and SN-38G in a Tumor Xenograft Model after Intravenous Administration of Antibody-Drug Conjugate (Sacituzumab Govitecan).

Pandey, Renu; Gruslova, Aleksandra; Chiou, Jennifer et al. · 2020 · Analytical chemistry · DOI

Full title: Stable Isotope Dilution LC-HRMS Assay To Determine Free SN-38, Total SN-38, and SN-38G in a Tumor Xenograft Model after Intravenous Administration of Antibody-Drug Conjugate (Sacituzumab Govitecan).

Authors: Pandey, Renu; Gruslova, Aleksandra; Chiou, Jennifer; Brenner, Andrew J; Tiziani, Stefano

Year: 2020

Venue: Analytical chemistry

DOI: https://doi.org/10.1021/acs.analchem.9b04419

Paper A Universal Affinity Capture LC-MS Assay for Evaluation of Biotransformation of Site-Specific Antibody Drug Conjugates in Preclinical Studies.

Srikanth Kotapati; D. Passmore; Sayumi Yamazoe et al. · 2019 · Analytical Chemistry · DOI

Full title: A Universal Affinity Capture LC-MS Assay for Evaluation of Biotransformation of Site-Specific Antibody Drug Conjugates in Preclinical Studies.

Authors: Srikanth Kotapati; D. Passmore; Sayumi Yamazoe; Rajesh Kishore Kumar Sanku; Qiang Cong; Yam B. Poudel; N. Chowdari; S. Gangwar; Chetana Rao; V. Rangan; P. Cardarelli; S. Deshpande; P. Strop; G. Dollinger; A. Rajpal

Year: 2019

Venue: Analytical Chemistry

DOI: https://doi.org/10.1021/acs.analchem.9b04572

Paper Extensive Biotransformation Profiling of AZD8205, an Anti-B7-H4 Antibody-Drug Conjugate, Elucidates Pathways Underlying Its Stability In Vivo

Yue Huang; Hui Yin Tan; Jiaqi Yuan et al. · 2024 · Analytical Chemistry · DOI

Full title: Extensive Biotransformation Profiling of AZD8205, an Anti-B7-H4 Antibody-Drug Conjugate, Elucidates Pathways Underlying Its Stability In Vivo

Authors: Yue Huang; Hui Yin Tan; Jiaqi Yuan; Ruipeng Mu; Junyan Yang; Kathryn Ball; B. Vijayakrishnan; Luke Masterson; Krista Kinneer; N. Luheshi; Meina Liang; A. Rosenbaum

Year: 2024

Venue: Analytical Chemistry

DOI: https://doi.org/10.1021/acs.analchem.4c02309

Paper A Platform for the Generation of Site-Specific Antibody-Drug Conjugates That Allows for Selective Reduction of Engineered Cysteines.

Coumans, Ruud G E; Ariaans, Gerry J A; Spijker, Henri J et al. · 2020 · Bioconjugate chemistry · DOI

Full title: A Platform for the Generation of Site-Specific Antibody-Drug Conjugates That Allows for Selective Reduction of Engineered Cysteines.

Authors: Coumans, Ruud G E; Ariaans, Gerry J A; Spijker, Henri J; Renart Verkerk, Pascal; Beusker, Patrick H; Kokke, Bas P A; Schouten, Jan; Blomenröhr, Marion; van der Lee, Miranda M C; Groothuis, Patrick G; Ubink, Ruud; Dokter, Wim H A; Timmers, C Marco

Year: 2020

Venue: Bioconjugate chemistry

DOI: https://doi.org/10.1021/acs.bioconjchem.0c00337

Paper Where Did the Linker-Payload Go? A Quantitative Investigation on the Destination of the Released Linker-Payload from an Antibody-Drug Conjugate with a Maleimide Linker in Plasma.

Cong Wei; Guodong Zhang; T. Clark et al. · 2016 · Analytical Chemistry · DOI

Full title: Where Did the Linker-Payload Go? A Quantitative Investigation on the Destination of the Released Linker-Payload from an Antibody-Drug Conjugate with a Maleimide Linker in Plasma.

Authors: Cong Wei; Guodong Zhang; T. Clark; F. Barletta; L. N. Tumey; Brian Rago; S. Hansel; Xiaogang Han

Year: 2016

Venue: Analytical Chemistry

DOI: https://doi.org/10.1021/acs.analchem.6b00976

Paper A Novel Family of Acid-Cleavable Linker Based on Cyclic Acetal Motifs for the Production of Antibody-Drug Conjugates with High Potency and Selectivity.

Tony Rady; Lorenzo Turelli; M. Nothisen et al. · 2022 · Bioconjugate chemistry · DOI

Full title: A Novel Family of Acid-Cleavable Linker Based on Cyclic Acetal Motifs for the Production of Antibody-Drug Conjugates with High Potency and Selectivity.

Authors: Tony Rady; Lorenzo Turelli; M. Nothisen; Elisabetta Tobaldi; Stéphane Erb; Fabien Thoreau; Oscar Hernandez-Alba; S. Cianférani; F. Daubeuf; Alain Wagner; Guilhem Chaubet

Year: 2022

Venue: Bioconjugate chemistry

DOI: https://doi.org/10.1021/acs.bioconjchem.2c00314

Paper Site-specific conjugation of native antibodies using engineered microbial transglutaminases.

Stephan Dickgiesser; M. Rieker; Dirk Mueller-Pompalla et al. · 2020 · Bioconjugate chemistry · DOI

Full title: Site-specific conjugation of native antibodies using engineered microbial transglutaminases.

Authors: Stephan Dickgiesser; M. Rieker; Dirk Mueller-Pompalla; C. Schroeter; Jason Tonillo; S. Warszawski; Sabine Raab-Westphal; S. Kühn; T. Knehans; Doreen Könning; J. Dotterweich; U. Betz; J. Anderl; S. Hecht; Nicolas Rasche

Year: 2020

Venue: Bioconjugate chemistry

DOI: https://doi.org/10.1021/acs.bioconjchem.0c00061

Paper AJICAP Second Generation: Improved Chemical Site-Specific Conjugation Technology for Antibody-Drug Conjugate Production.

Fujii, Tomohiro; Matsuda, Yutaka; Seki, Takuya et al. · 2023 · Bioconjugate chemistry · DOI

Full title: AJICAP Second Generation: Improved Chemical Site-Specific Conjugation Technology for Antibody-Drug Conjugate Production.

Authors: Fujii, Tomohiro; Matsuda, Yutaka; Seki, Takuya; Shikida, Natsuki; Iwai, Yusuke; Ooba, Yuri; Takahashi, Kazutoshi; Isokawa, Muneki; Kawaguchi, Sayaka; Hatada, Noriko; Watanabe, Tomohiro; Takasugi, Rika; Nakayama, Akira; Shimbo, Kazutaka; Mendelsohn, Brian A; Okuzumi, Tatsuya; Yamada, Kei

Year: 2023

Venue: Bioconjugate chemistry

DOI: https://doi.org/10.1021/acs.bioconjchem.3c00040

Paper Therapeutic Potential of MF-TTZ-MMAE, a Site-Specifically Conjugated Antibody-Drug Conjugate, for the Treatment of HER2-Overexpressing Breast Cancer.

Ludovic Juen; C. Baltus; Camille Gély et al. · 2022 · Bioconjugate chemistry · DOI

Full title: Therapeutic Potential of MF-TTZ-MMAE, a Site-Specifically Conjugated Antibody-Drug Conjugate, for the Treatment of HER2-Overexpressing Breast Cancer.

Authors: Ludovic Juen; C. Baltus; Camille Gély; Thibault Kervarrec; Ofelia Feuillâtre; A. Desgranges; M. Viaud-Massuard; Camille Martin

Year: 2022

Venue: Bioconjugate chemistry

DOI: https://doi.org/10.1021/acs.bioconjchem.2c00015

Paper Innovative Bioconjugation Technology for Antibody-Drug Conjugates: Proof of Concept in a CD30-Positive Lymphoma Mouse Model.

Ludovic Juen; C. Baltus; Camille Gély et al. · 2021 · Bioconjugate chemistry · DOI

Full title: Innovative Bioconjugation Technology for Antibody-Drug Conjugates: Proof of Concept in a CD30-Positive Lymphoma Mouse Model.

Authors: Ludovic Juen; C. Baltus; Camille Gély; Ofelia Feuillâtre; A. Desgranges; M. Viaud-Massuard; Camille Martin

Year: 2021

Venue: Bioconjugate chemistry

DOI: https://doi.org/10.1021/acs.bioconjchem.1c00058

Paper Synthesis and Biological Evaluation of a Carbamate-Containing Tubulysin Antibody Drug Conjugate.

Heng Cheng; Qiang Cong; D. Dervin et al. · 2020 · Bioconjugate chemistry · DOI

Full title: Synthesis and Biological Evaluation of a Carbamate-Containing Tubulysin Antibody Drug Conjugate.

Authors: Heng Cheng; Qiang Cong; D. Dervin; A. Stevens; K. Vemuri; M. Huber; J. Juliano; Severino Cuison; Janette Sung; D. Passmore; Coling Chong; Meghan Greenbaum; E. Kwok; Jerry Jiang; C. Pan; C. Rao-Naik; V. Rangan; T. Kempe; A. Tatum; S. Deshpande; P. Cardarelli; Gregory Vite; S. Gangwar

Year: 2020

Venue: Bioconjugate chemistry

DOI: https://doi.org/10.1021/acs.bioconjchem.0c00429

Paper Specific Inhibition of Tumor Growth by T Cell Receptor-Drug Conjugates Targeting Intracellular Cancer-Testis Antigen NY-ESO-1/LAGE-1.

Chixiao Qiu; Xuefei Bai; Ying Shen et al. · 2020 · Bioconjugate chemistry · DOI

Full title: Specific Inhibition of Tumor Growth by T Cell Receptor-Drug Conjugates Targeting Intracellular Cancer-Testis Antigen NY-ESO-1/LAGE-1.

Authors: Chixiao Qiu; Xuefei Bai; Ying Shen; Zhan Zhou; L. Pan; Ying-chun Xu; Wenbin Zhao; Shuqing Chen

Year: 2020

Venue: Bioconjugate chemistry

DOI: https://doi.org/10.1021/acs.bioconjchem.0c00548

Paper Enzyme-Agnostic Lysosomal Screen Identifies New Legumain-Cleavable ADC Linkers.

Jared T. Miller; Caitlin Vitro; S. Fang et al. · 2021 · Bioconjugate chemistry · DOI

Full title: Enzyme-Agnostic Lysosomal Screen Identifies New Legumain-Cleavable ADC Linkers.

Authors: Jared T. Miller; Caitlin Vitro; S. Fang; Samantha R. Benjamin; L. N. Tumey

Year: 2021

Venue: Bioconjugate chemistry

DOI: https://doi.org/10.1021/acs.bioconjchem.1c00124

Paper Generation and Biological Evaluation of Fc Antigen Binding Fragment-Drug Conjugates as a Novel Antibody-Based Format for Targeted Drug Delivery.

S. Jäger; T. Wagner; Nicolas Rasche et al. · 2021 · Bioconjugate chemistry · DOI

Full title: Generation and Biological Evaluation of Fc Antigen Binding Fragment-Drug Conjugates as a Novel Antibody-Based Format for Targeted Drug Delivery.

Authors: S. Jäger; T. Wagner; Nicolas Rasche; H. Kolmar; S. Hecht; C. Schröter

Year: 2021

Venue: Bioconjugate chemistry

DOI: https://doi.org/10.1021/acs.bioconjchem.1c00240

Paper Targeted Drug Delivery by MMAE Farnesyl-Bioconjugated Multivalent Chemically Self-Assembled Nanorings Induces Potent Receptor-Dependent Immunogenic Cell Death.

Yiao Wang; Ozgun Kilic; Lakmal Rozumalski et al. · 2024 · Bioconjugate chemistry · DOI

Full title: Targeted Drug Delivery by MMAE Farnesyl-Bioconjugated Multivalent Chemically Self-Assembled Nanorings Induces Potent Receptor-Dependent Immunogenic Cell Death.

Authors: Yiao Wang; Ozgun Kilic; Lakmal Rozumalski; M. Distefano; C. Wagner

Year: 2024

Venue: Bioconjugate chemistry

DOI: https://doi.org/10.1021/acs.bioconjchem.4c00004

Paper Synthesis and Evaluation of Three Azide-Modified Disaccharide Oxazolines as Enzyme Substrates for Single-Step Fc Glycan-Mediated Antibody-Drug Conjugation.

Zhang, Xiao; Ou, Chong; Liu, Huiying et al. · 2022 · Bioconjugate chemistry · DOI

Full title: Synthesis and Evaluation of Three Azide-Modified Disaccharide Oxazolines as Enzyme Substrates for Single-Step Fc Glycan-Mediated Antibody-Drug Conjugation.

Authors: Zhang, Xiao; Ou, Chong; Liu, Huiying; Wang, Lai-Xi

Year: 2022

Venue: Bioconjugate chemistry

DOI: https://doi.org/10.1021/acs.bioconjchem.2c00142

Paper One-Pot Conversion of Free Sialoglycans to Functionalized Glycan Oxazolines and Efficient Synthesis of Homogeneous Antibody-Drug Conjugates through Site-Specific Chemoenzymatic Glycan Remodeling.

Ou, Chong; Li, Chao; Zhang, Roushu et al. · 2021 · Bioconjugate chemistry · DOI

Full title: One-Pot Conversion of Free Sialoglycans to Functionalized Glycan Oxazolines and Efficient Synthesis of Homogeneous Antibody-Drug Conjugates through Site-Specific Chemoenzymatic Glycan Remodeling.

Authors: Ou, Chong; Li, Chao; Zhang, Roushu; Yang, Qiang; Zong, Guanghui; Dai, Yuanwei; Francis, Rebecca L; Bournazos, Stylianos; Ravetch, Jeffrey V; Wang, Lai-Xi

Year: 2021

Venue: Bioconjugate chemistry

DOI: https://doi.org/10.1021/acs.bioconjchem.1c00314

Paper PEGylation of Dipeptide Linker Improves Therapeutic Index and Pharmacokinetics of Antibody-Drug Conjugates.

Long, Jing; Shao, Ting; Wang, Yongmei et al. · 2025 · Bioconjugate chemistry · DOI

Full title: PEGylation of Dipeptide Linker Improves Therapeutic Index and Pharmacokinetics of Antibody-Drug Conjugates.

Authors: Long, Jing; Shao, Ting; Wang, Yongmei; Chen, Tianzhi; Chen, Yuning; Chen, Yi-Li; Wang, Qi; Yu, Xiong; Yu, Jinghua; He, Kaifeng; Lin, Han-Bin; Diao, Xingxing; Wang, Guifeng; Wang, Chunhe

Year: 2025

Venue: Bioconjugate chemistry

DOI: https://doi.org/10.1021/acs.bioconjchem.4c00392

Paper Generation and Characterization of Iduronidase-Cleavable ADCs.

Sebastian Jäger; Doreen Könning; Nicolas Rasche et al. · 2023 · Bioconjugate chemistry · DOI

Full title: Generation and Characterization of Iduronidase-Cleavable ADCs.

Authors: Sebastian Jäger; Doreen Könning; Nicolas Rasche; Felix Hart; Janike Sensbach; Carina Krug; Sabine Raab-Westphal; Konstantin Richter; Carlo Unverzagt; S. Hecht; Jan Anderl; Christian Schröter

Year: 2023

Venue: Bioconjugate chemistry

DOI: https://doi.org/10.1021/acs.bioconjchem.3c00363

Paper Evaluation of Cellular Targeting by Fab' vs Full-Length Antibodies in Antibody-Nanoparticle Conjugates (ANCs) Using CD4 T-cells.

Khushboo Singh; Mine Canakci; Pintu Kanjilal et al. · 2022 · Bioconjugate chemistry · DOI

Full title: Evaluation of Cellular Targeting by Fab' vs Full-Length Antibodies in Antibody-Nanoparticle Conjugates (ANCs) Using CD4 T-cells.

Authors: Khushboo Singh; Mine Canakci; Pintu Kanjilal; Natalie A. Williams; S. Shanthalingam; Barbara A. Osborne; S. Thayumanavan

Year: 2022

Venue: Bioconjugate chemistry

DOI: https://doi.org/10.1021/acs.bioconjchem.2c00024

Paper Late-Stage Desulfurization Enables Rapid and Efficient Solid-Phase Synthesis of Cathepsin-Cleavable Linkers for Antibody-Drug Conjugates.

Marzieh Ahangarpour; M. Brimble; I. Kavianinia · 2024 · Bioconjugate chemistry · DOI

Full title: Late-Stage Desulfurization Enables Rapid and Efficient Solid-Phase Synthesis of Cathepsin-Cleavable Linkers for Antibody-Drug Conjugates.

Authors: Marzieh Ahangarpour; M. Brimble; I. Kavianinia

Year: 2024

Venue: Bioconjugate chemistry

DOI: https://doi.org/10.1021/acs.bioconjchem.4c00199

Paper The Evolving Landscape of Antibody–Drug Conjugates: In Depth Analysis of Recent Research Progress

Janet M Sasso; Rumiana Tenchov; Robert E. Bird et al. · 2023 · Bioconjugate chemistry · DOI

Full title: The Evolving Landscape of Antibody–Drug Conjugates: In Depth Analysis of Recent Research Progress

Authors: Janet M Sasso; Rumiana Tenchov; Robert E. Bird; Kavita A. Iyer; Krittika Ralhan; Yacidzohara Rodriguez; Q. Zhou

Year: 2023

Venue: Bioconjugate chemistry

DOI: https://doi.org/10.1021/acs.bioconjchem.3c00374

Paper A Novel NAMPT Inhibitor-Based Antibody–Drug Conjugate Payload Class for Cancer Therapy

N. Böhnke; M. Berger; N. Griebenow et al. · 2022 · Bioconjugate chemistry · DOI

Full title: A Novel NAMPT Inhibitor-Based Antibody–Drug Conjugate Payload Class for Cancer Therapy

Authors: N. Böhnke; M. Berger; N. Griebenow; A. Rottmann; Michael Erkelenz; S. Hammer; Sandra Berndt; Judith Günther; A. Wengner; B. Stelte-Ludwig; C. Mahlert; Simone Greven; L. Dietz; H. Jörißen; Naomi Barak; U. Bömer; R. Hillig; U. Eberspaecher; J. Weiske; A. Giese; D. Mumberg; C. Nising; H. Weinmann; A. Sommer

Year: 2022

Venue: Bioconjugate chemistry

DOI: https://doi.org/10.1021/acs.bioconjchem.2c00178

Paper Impact of Drug Conjugation on Thermal and Metabolic Stabilities of Aglycosylated and N-Glycosylated Antibodies

Sayumi Yamazoe; Srikanth Kotapati; J. Hogan et al. · 2022 · Bioconjugate chemistry · DOI

Full title: Impact of Drug Conjugation on Thermal and Metabolic Stabilities of Aglycosylated and N-Glycosylated Antibodies

Authors: Sayumi Yamazoe; Srikanth Kotapati; J. Hogan; S. West; Xiaodi A Deng; S. Diong; J. Arbanas; Thien-Anh Nguyen; Aarti Jashnani; Diksha Gupta; A. Rajpal; G. Dollinger; P. Strop

Year: 2022

Venue: Bioconjugate chemistry

DOI: https://doi.org/10.1021/acs.bioconjchem.1c00572

Paper One-Pot Assembly of Dual-Site-Specific Antibody-Drug Conjugates via Glycan Remodeling and Affinity-Directed Traceless Conjugation.

Caihong Tang; Yue Zeng; Jianxing Zhang et al. · 2023 · Bioconjugate chemistry · DOI

Full title: One-Pot Assembly of Dual-Site-Specific Antibody-Drug Conjugates via Glycan Remodeling and Affinity-Directed Traceless Conjugation.

Authors: Caihong Tang; Yue Zeng; Jianxing Zhang; Xing Zheng; Feng Tang; X. Yao; Zhong-Xing Jiang; Weiwei Shi; Wei Huang

Year: 2023

Venue: Bioconjugate chemistry

DOI: https://doi.org/10.1021/acs.bioconjchem.3c00048

Paper Selective Reduction of Cysteine Mutant Antibodies for Site-Specific Antibody-Drug Conjugates.

Liao, Xiaoli; Haight, Anthony; Welch, Dennie et al. · 2023 · Bioconjugate chemistry · DOI

Full title: Selective Reduction of Cysteine Mutant Antibodies for Site-Specific Antibody-Drug Conjugates.

Authors: Liao, Xiaoli; Haight, Anthony; Welch, Dennie; Han, Linjie

Year: 2023

Venue: Bioconjugate chemistry

DOI: https://doi.org/10.1021/acs.bioconjchem.3c00425

Paper Characterization and Higher-Order Structure Assessment of an Interchain Cysteine-Based ADC: Impact of Drug Loading and Distribution on the Mechanism of Aggregation.

Jian-xin Guo; Sandeep Kumar; Mark Chipley et al. · 2016 · Bioconjugate chemistry · DOI

Full title: Characterization and Higher-Order Structure Assessment of an Interchain Cysteine-Based ADC: Impact of Drug Loading and Distribution on the Mechanism of Aggregation.

Authors: Jian-xin Guo; Sandeep Kumar; Mark Chipley; O. Marcq; Devansh Gupta; Zhaowei Jin; D. Tomar; Cecily Swabowski; Jacquelynn Smith; Jason A. Starkey; S. Singh

Year: 2016

Venue: Bioconjugate chemistry

DOI: https://doi.org/10.1021/acs.bioconjchem.5b00603

Paper Linker and Conjugation Site Synergy in Antibody-Drug Conjugates: Impacts on Biological Activity.

Aoyama, Michihiko; Tada, Minoru; Yokoo, Hidetomo et al. · 2024 · Bioconjugate chemistry · DOI

Full title: Linker and Conjugation Site Synergy in Antibody-Drug Conjugates: Impacts on Biological Activity.

Authors: Aoyama, Michihiko; Tada, Minoru; Yokoo, Hidetomo; Ito, Takahito; Misawa, Takashi; Demizu, Yosuke; Ishii-Watabe, Akiko

Year: 2024

Venue: Bioconjugate chemistry

DOI: https://doi.org/10.1021/acs.bioconjchem.4c00348

Paper Use of Coiled-Coil Affinity Peptides to Manufacture Antibody Conjugates

S. F. Baniahmad; A. Burlacu; L. Delafosse et al. · 2025 · Bioconjugate chemistry · DOI

Full title: Use of Coiled-Coil Affinity Peptides to Manufacture Antibody Conjugates

Authors: S. F. Baniahmad; A. Burlacu; L. Delafosse; Mauro Acchione; Miriam Simmons; Binbing Ling; Umar Iqbal; Maria J Moreno; G. De Crescenzo; Yves Durocher

Year: 2025

Venue: Bioconjugate chemistry

DOI: https://doi.org/10.1021/acs.bioconjchem.5c00178

Paper A Genetically Encoded Photocaged Cysteine for Facile Site-Specific Introduction of Conjugation-Ready Thiol Residues in Antibodies.

Arianna O. Osgood; S. J. S. Roy; David Koo et al. · 2024 · Bioconjugate chemistry · DOI

Full title: A Genetically Encoded Photocaged Cysteine for Facile Site-Specific Introduction of Conjugation-Ready Thiol Residues in Antibodies.

Authors: Arianna O. Osgood; S. J. S. Roy; David Koo; Renpeng Gu; Abhishek Chatterjee

Year: 2024

Venue: Bioconjugate chemistry

DOI: https://doi.org/10.1021/acs.bioconjchem.3c00513

Paper Delivery of Monomethyl Auristatin F to the Tumor Microenvironment with Noninternalizing Fibroblast Activation Protein-Cleavable Small Molecule-Drug Conjugates Elicits Potent In Vivo Anticancer Activity.

M. Bocci; Lucrezia Principi; Ettore Gilardoni et al. · 2024 · Bioconjugate chemistry · DOI

Full title: Delivery of Monomethyl Auristatin F to the Tumor Microenvironment with Noninternalizing Fibroblast Activation Protein-Cleavable Small Molecule-Drug Conjugates Elicits Potent In Vivo Anticancer Activity.

Authors: M. Bocci; Lucrezia Principi; Ettore Gilardoni; D. Neri; S. Cazzamalli; A. Galbiati

Year: 2024

Venue: Bioconjugate chemistry

DOI: https://doi.org/10.1021/acs.bioconjchem.4c00503

Paper Understanding How the Stability of the Thiol-Maleimide Linkage Impacts the Pharmacokinetics of Lysine-Linked Antibody-Maytansinoid Conjugates.

Jose F. Ponte; Xiuxia Sun; Nicholas C. Yoder et al. · 2016 · Bioconjugate chemistry · DOI

Full title: Understanding How the Stability of the Thiol-Maleimide Linkage Impacts the Pharmacokinetics of Lysine-Linked Antibody-Maytansinoid Conjugates.

Authors: Jose F. Ponte; Xiuxia Sun; Nicholas C. Yoder; N. Fishkin; Rassol Laleau; Jennifer A. Coccia; Leanne Lanieri; Megan Bogalhas; Lintao Wang; Sharon D. Wilhelm; Wayne C. Widdison; J. Pinkas; T. Keating; R. Chari; H. Erickson; J. Lambert

Year: 2016

Venue: Bioconjugate chemistry

DOI: https://doi.org/10.1021/acs.bioconjchem.6b00117

Paper Antibody-Drug Conjugates for Tumor Targeting-Novel Conjugation Chemistries and the Promise of non-IgG Binding Proteins.

H. Merten; Fabian Brandl; A. Plückthun et al. · 2015 · Bioconjugate chemistry · DOI

Full title: Antibody-Drug Conjugates for Tumor Targeting-Novel Conjugation Chemistries and the Promise of non-IgG Binding Proteins.

Authors: H. Merten; Fabian Brandl; A. Plückthun; U. Zangemeister‐Wittke

Year: 2015

Venue: Bioconjugate chemistry

DOI: https://doi.org/10.1021/acs.bioconjchem.5b00260

Paper Elucidating Critical Factors of Internalization and Drug Release of Antibody-Drug Conjugates (ADCs) Using Kinetic Parameters Evaluated by a Novel Tool Named TORCH.

Stanley Sweeney-Lasch; Marie Quillmann; Jens Hannewald et al. · 2025 · Bioconjugate chemistry · DOI

Full title: Elucidating Critical Factors of Internalization and Drug Release of Antibody-Drug Conjugates (ADCs) Using Kinetic Parameters Evaluated by a Novel Tool Named TORCH.

Authors: Stanley Sweeney-Lasch; Marie Quillmann; Jens Hannewald; Stephan Dickgiesser; Nicolas Rasche; Min Shan; Carl Deutsch; S. Hecht; Jan Anderl; Harald Kolmar; Birgit Piater

Year: 2025

Venue: Bioconjugate chemistry

DOI: https://doi.org/10.1021/acs.bioconjchem.4c00579

Paper Mechanistic Characterization of the Potency of THIOMAB Antibody-Drug Conjugates Targeting Staphylococcus aureus and ETbR-Expressing Tumor Cells Using Quantitative LC-MS/MS Analysis of Intracellular Drug Accumulation.

Hernandez-Barry, Hilda; Dela Cruz-Chuh, Josefa; Kajihara, Kimberly K et al. · 2025 · Bioconjugate chemistry · DOI

Full title: Mechanistic Characterization of the Potency of THIOMAB Antibody-Drug Conjugates Targeting Staphylococcus aureus and ETbR-Expressing Tumor Cells Using Quantitative LC-MS/MS Analysis of Intracellular Drug Accumulation.

Authors: Hernandez-Barry, Hilda; Dela Cruz-Chuh, Josefa; Kajihara, Kimberly K; Asundi, Jyoti; Vandlen, Richard; Zhang, Donglu; Hazenbos, Wouter L W; Pillow, Thomas; Liu, Yichin; Wu, Cong; Kozak, Katherine R; Loyet, Kelly M

Year: 2025

Venue: Bioconjugate chemistry

DOI: https://doi.org/10.1021/acs.bioconjchem.4c00533

Paper One-Step Conjugation Method for Site-Specific Antibody-Drug Conjugates through Reactive Cysteine-Engineered Antibodies.

Daisuke Shinmi; E. Taguchi; Junko Iwano et al. · 2016 · Bioconjugate chemistry · DOI

Full title: One-Step Conjugation Method for Site-Specific Antibody-Drug Conjugates through Reactive Cysteine-Engineered Antibodies.

Authors: Daisuke Shinmi; E. Taguchi; Junko Iwano; Tsuyoshi Yamaguchi; K. Masuda; J. Enokizono; Y. Shiraishi

Year: 2016

Venue: Bioconjugate chemistry

DOI: https://doi.org/10.1021/acs.bioconjchem.6b00133

Paper Genetically Encoded Azide Containing Amino Acid in Mammalian Cells Enables Site-Specific Antibody-Drug Conjugates Using Click Cycloaddition Chemistry.

VanBrunt, Michael P; Shanebeck, Kurt; Caldwell, Zachary et al. · 2015 · Bioconjugate chemistry · DOI

Full title: Genetically Encoded Azide Containing Amino Acid in Mammalian Cells Enables Site-Specific Antibody-Drug Conjugates Using Click Cycloaddition Chemistry.

Authors: VanBrunt, Michael P; Shanebeck, Kurt; Caldwell, Zachary; Johnson, Jeffrey; Thompson, Pamela; Martin, Thomas; Dong, Huifang; Li, Gary; Xu, Hengyu; D'Hooge, Francois; Masterson, Luke; Bariola, Pauline; Tiberghien, Arnaud; Ezeadi, Ebele; Williams, David G; Hartley, John A; Howard, Philip W; Grabstein, Kenneth H; Bowen, Michael A; Marelli, Marcello

Year: 2015

Venue: Bioconjugate chemistry

DOI: https://doi.org/10.1021/acs.bioconjchem.5b00359

Paper Chemoenzymatic Conjugation of Toxic Payloads to the Globally Conserved N-Glycan of Native mAbs Provides Homogeneous and Highly Efficacious Antibody-Drug Conjugates.

van Geel, Remon; Wijdeven, Marloes A; Heesbeen, Ryan et al. · 2015 · Bioconjugate chemistry · DOI

Full title: Chemoenzymatic Conjugation of Toxic Payloads to the Globally Conserved N-Glycan of Native mAbs Provides Homogeneous and Highly Efficacious Antibody-Drug Conjugates.

Authors: van Geel, Remon; Wijdeven, Marloes A; Heesbeen, Ryan; Verkade, Jorge M M; Wasiel, Anna A; van Berkel, Sander S; van Delft, Floris L

Year: 2015

Venue: Bioconjugate chemistry

DOI: https://doi.org/10.1021/acs.bioconjchem.5b00224

Paper Second-Generation Tunable pH-Sensitive Phosphoramidate-Based Linkers for Controlled Release.

C. J. Choy; Corinne R Ley; Austen L. Davis et al. · 2016 · Bioconjugate chemistry · DOI

Full title: Second-Generation Tunable pH-Sensitive Phosphoramidate-Based Linkers for Controlled Release.

Authors: C. J. Choy; Corinne R Ley; Austen L. Davis; Brian S. Backer; Jonathan J. Geruntho; B. Clowers; C. Berkman

Year: 2016

Venue: Bioconjugate chemistry

DOI: https://doi.org/10.1021/acs.bioconjchem.6b00422

Paper Protease-Cleavable Linkers Modulate the Anticancer Activity of Noninternalizing Antibody-Drug Conjugates.

Alberto Dal Corso; S. Cazzamalli; Rémy Gébleux et al. · 2017 · Bioconjugate chemistry · DOI

Full title: Protease-Cleavable Linkers Modulate the Anticancer Activity of Noninternalizing Antibody-Drug Conjugates.

Authors: Alberto Dal Corso; S. Cazzamalli; Rémy Gébleux; Martin Mattarella; D. Neri

Year: 2017

Venue: Bioconjugate chemistry

DOI: https://doi.org/10.1021/acs.bioconjchem.7b00304

Paper Abstract 2641: ZW191, a novel FRa-targeting antibody drug conjugate bearing a topoisomerase 1 inhibitor payload

Samuel O. Lawn; Andrea Hernández Rojas; R. Colombo et al. · 2023 · Cancer Research · DOI

Full title: Abstract 2641: ZW191, a novel FRa-targeting antibody drug conjugate bearing a topoisomerase 1 inhibitor payload

Authors: Samuel O. Lawn; Andrea Hernández Rojas; R. Colombo; Dayananda Siddappa; Jodi Wong; Kaylee J Wu; Vincent Fung; Dunja Urosev; Luying Yang; J. Rich; Stuart D Barnscher

Year: 2023

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2023-2641

Paper Abstract LB522: Fibroblast activation protein triggers the release of drug payload from non-internalizing small molecule-drug conjugates in solid tumors

Aureliano Zana; A. Galbiati; Ettore Gilardoni et al. · 2022 · Cancer Research · DOI

Full title: Abstract LB522: Fibroblast activation protein triggers the release of drug payload from non-internalizing small molecule-drug conjugates in solid tumors

Authors: Aureliano Zana; A. Galbiati; Ettore Gilardoni; J. Millul; Theo Sturm; R. Stucchi; M. Bocci; Abdullah Elsayed; Lisa Nadal; Martina Cirillo; D. Neri; S. Cazzamalli

Year: 2022

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2022-lb522

Paper Abstract 1541: NextGen conditionally active biologic (CAB) anti-Nectin-4-ADC with improved stability and safety

G. Frey; Jing Wang; Kyrie Johnson et al. · 2023 · Cancer Research · DOI

Full title: Abstract 1541: NextGen conditionally active biologic (CAB) anti-Nectin-4-ADC with improved stability and safety

Authors: G. Frey; Jing Wang; Kyrie Johnson; Haizhen Liu; C. Wheeler; Charles Xing; A. P. Cugnetti; P. McNeeley; Solmarie Joyner; Cathy Y. Chang; W. J. Boyle; J. Short

Year: 2023

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2023-1541

Paper Abstract 1544: MBK-103, a potent novel conjugation platform-based antibody-drug conjugate, changing therapeutic options in folate receptor alpha positive cancer patients

W. Viricel; L. Conilh; Edouard Leroy et al. · 2023 · Cancer Research · DOI

Full title: Abstract 1544: MBK-103, a potent novel conjugation platform-based antibody-drug conjugate, changing therapeutic options in folate receptor alpha positive cancer patients

Authors: W. Viricel; L. Conilh; Edouard Leroy; Jean-Guillaume Lafay; F. Brune; L. Sadílková; C. Dumontet

Year: 2023

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2023-1544

Paper Abstract 1876: NAV-001, a high-efficacy antibody-drug conjugate targeting mesothelin with improved delivery of potent payload by counteracting MUC16/CA125 effects

L. Grasso; J. Kline; N. Nicolaides · 2023 · Cancer Research · DOI

Full title: Abstract 1876: NAV-001, a high-efficacy antibody-drug conjugate targeting mesothelin with improved delivery of potent payload by counteracting MUC16/CA125 effects

Authors: L. Grasso; J. Kline; N. Nicolaides

Year: 2023

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2023-1876

Paper Abstract 1542: Generation of an antibody-drug conjugate-optimized TLR 7/8 agonist payload

K. Wang; Chris Neumann; A. Epp et al. · 2023 · Cancer Research · DOI

Full title: Abstract 1542: Generation of an antibody-drug conjugate-optimized TLR 7/8 agonist payload

Authors: K. Wang; Chris Neumann; A. Epp; Weiping Zeng; T. Griffith; David Ferguson; S. Gardai; Alyson J. Smith

Year: 2023

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2023-1542

Paper Abstract 1530: Gastric cancerantibody fragment drug-conjugates (FDCs): Applying a successful concept to solid tumours

M. Deonarain; G. Yahioglu; I. Stamati et al. · 2023 · Cancer Research · DOI

Full title: Abstract 1530: Gastric cancerantibody fragment drug-conjugates (FDCs): Applying a successful concept to solid tumours

Authors: M. Deonarain; G. Yahioglu; I. Stamati; S. Diez-Posada; B. Edwards; A. Pomowski; I. Perez-Castro; Sam Ness; Laura Bouché; Jeaniffer E. Yap; H. Desmond; Lowri Davies; Malcolm Ngiam; Quinn Xue

Year: 2023

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2023-1530

Paper Abstract 2634: AMB302/GR1017, an antibody-drug conjugate (ADC) with topoisomerase 1 inhibitor shows therapeutic potency in orthotopic glioblastoma PDX and bladder cancer models with FGFR3-TACC3 fusion

· 2023 · Cancer Research · DOI

Full title: Abstract 2634: AMB302/GR1017, an antibody-drug conjugate (ADC) with topoisomerase 1 inhibitor shows therapeutic potency in orthotopic glioblastoma PDX and bladder cancer models with FGFR3-TACC3 fusion

Year: 2023

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2023-2634

Paper Abstract 2640: An innovative site-specific dual-payload antibody drug conjugate (dpADC) combining a novel Topo1 inhibitor and an immune agonist delivers a strong immunogenic cell death (ICD) and antitumor response in vitro and in vivo

Meijun Xiong; Beibei Fan; Xinju Gao et al. · 2023 · Cancer Research · DOI

Full title: Abstract 2640: An innovative site-specific dual-payload antibody drug conjugate (dpADC) combining a novel Topo1 inhibitor and an immune agonist delivers a strong immunogenic cell death (ICD) and antitumor response in vitro and in vivo

Authors: Meijun Xiong; Beibei Fan; Xinju Gao; Yajun Sun; Cao Lv; Yu Si; Xiao Liu; Lili Shi; P. H. Song; Gang Qin

Year: 2023

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2023-2640

Paper Abstract 1879: A novel dual CAB nectin-4 x CD3 bispecific antibody targeting solid tumors

· 2023 · Cancer Research · DOI

Full title: Abstract 1879: A novel dual CAB nectin-4 x CD3 bispecific antibody targeting solid tumors

Year: 2023

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2023-1879

Paper Abstract 2660: HMBD-501 - a novel Fc engineered, exatecan-based next generation HER3 targeting antibody drug conjugate shows robust efficacy and tolerability in pre-clinical solid tumor models

S. A. K. Rasheed; D. Thakkar; Shalini Paliwal et al. · 2023 · Cancer Research · DOI

Full title: Abstract 2660: HMBD-501 - a novel Fc engineered, exatecan-based next generation HER3 targeting antibody drug conjugate shows robust efficacy and tolerability in pre-clinical solid tumor models

Authors: S. A. K. Rasheed; D. Thakkar; Shalini Paliwal; W. J. Chin; A. Bansal; Benjamin J. Ayers; Cherchenko Ng; B. Hanson; P. Ingram; Jerome D Boyd-Kirkup

Year: 2023

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2023-2660

Paper - **DOI:** 10.1158/1538-7445.am2023-2012 - **Authors:** Ludovic Juen, A. Collier, A. Tolcher, Myriam M. Ouberai - **Year:** 2023 - **Journal:** Cancer Research

Ludovic Juen; A. Collier; A. Tolcher et al. · 2023 · Cancer Research · DOI

Full title: - **DOI:** 10.1158/1538-7445.am2023-2012 - **Authors:** Ludovic Juen, A. Collier, A. Tolcher, Myriam M. Ouberai - **Year:** 2023 - **Journal:** Cancer Research

Authors: Ludovic Juen; A. Collier; A. Tolcher; Myriam M. Ouberai

Year: 2023

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2023-2012

Paper Abstract 2013: Oxidized anthracycline payloads induce anti-tumor immunogenic cell-death and show linker-dependent tolerability when delivered as ADCs

Joseph Z. Hamilton; K. Klussman; Rebecca Mahzereh et al. · 2023 · Cancer Research · DOI

Full title: Abstract 2013: Oxidized anthracycline payloads induce anti-tumor immunogenic cell-death and show linker-dependent tolerability when delivered as ADCs

Authors: Joseph Z. Hamilton; K. Klussman; Rebecca Mahzereh; J. Simmons; Michelle Ulrich; S. Gardai; P. Senter; P. Burke

Year: 2023

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2023-2013

Paper Abstract 2648: In vivo efficacy and preclinical safety profile of NN3201, an anti-cKIT antibody-drug conjugate, for treating SCLC and AML

Han-Jik Ko; Sung Tae Kim; Jin Gu Cho et al. · 2023 · Cancer Research · DOI

Full title: Abstract 2648: In vivo efficacy and preclinical safety profile of NN3201, an anti-cKIT antibody-drug conjugate, for treating SCLC and AML

Authors: Han-Jik Ko; Sung Tae Kim; Jin Gu Cho; Jin-Ock Kim; Jung Tae Lee; Sang Gyu Park

Year: 2023

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2023-2648

Paper Abstract 2793: Preclinical pharmacokinetics in cynomolgus monkeys and first in human dose prediction of DB-1303, a HER2-targeting antibody-drug conjugate

Rong Shi; Shengchao Lin; Yu Zhang et al. · 2023 · Cancer Research · DOI

Full title: Abstract 2793: Preclinical pharmacokinetics in cynomolgus monkeys and first in human dose prediction of DB-1303, a HER2-targeting antibody-drug conjugate

Authors: Rong Shi; Shengchao Lin; Yu Zhang; Bing Li; Haiqing Hua; Yang Qiu

Year: 2023

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2023-2793

Paper Abstract 3253: CD30 is a marker of activated effector regulatory T cells in solid tumors providing clinical rationale for the combination of brentuximab vedotin and PD-1 inhibitors

Ryan A Heiser; Bryan M. Grogan; Reice James et al. · 2023 · Cancer Research · DOI

Full title: Abstract 3253: CD30 is a marker of activated effector regulatory T cells in solid tumors providing clinical rationale for the combination of brentuximab vedotin and PD-1 inhibitors

Authors: Ryan A Heiser; Bryan M. Grogan; Reice James; Michelle Ulrich; J. Berndt; Brian P. O'Connor; S. Gardai; Hailing Lu; Scott M. Knowles

Year: 2023

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2023-3253

Paper Abstract 2967: Preclinical development of a B7-H3-targeting ADC with a novel DNA topoisomerase I inhibitor for solid tumors

Chenggang Li; Jun Yao; Chen Qu et al. · 2023 · Cancer Research · DOI

Full title: Abstract 2967: Preclinical development of a B7-H3-targeting ADC with a novel DNA topoisomerase I inhibitor for solid tumors

Authors: Chenggang Li; Jun Yao; Chen Qu; Bing Li; Yu Zhang; Rong Shi; Yang Qiu; Haiqing Hua

Year: 2023

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2023-2967

Paper Abstract 2944: Trastuzumab-deruxtecan (T-Dxd) induces superior macrophage/DC activation, antigen-presentation and anti-tumor adaptive immune responses, which can be augmented by CD47/SIRPA blockade

Li-Chung Tsao; Z. Hartman · 2023 · Cancer Research · DOI

Full title: Abstract 2944: Trastuzumab-deruxtecan (T-Dxd) induces superior macrophage/DC activation, antigen-presentation and anti-tumor adaptive immune responses, which can be augmented by CD47/SIRPA blockade

Authors: Li-Chung Tsao; Z. Hartman

Year: 2023

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2023-2944

Paper Abstract 2638: Preclinical development of ADCT-212, a PSMA-targeted antibody-drug conjugate employing the pyrrolobenzodiazepine dimer SG2000 for PSMA-expressing cancers

F. Zammarchi; K. Havenith; L. de Haan et al. · 2023 · Cancer Research · DOI

Full title: Abstract 2638: Preclinical development of ADCT-212, a PSMA-targeted antibody-drug conjugate employing the pyrrolobenzodiazepine dimer SG2000 for PSMA-expressing cancers

Authors: F. Zammarchi; K. Havenith; L. de Haan; I. Kirby; N. Janghra; Veronica S. Gil; P. Alves; Kristina Zaitseva; Meghann Kerr; Ben Leatherdale; Afroze Patel; Marie Thoelke; Shiran Huang; J. Hartley; P. V. van Berkel

Year: 2023

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2023-2638

Paper Abstract 2978: YH013, a novel EGFR x MET bispecific antibody-drug conjugate, exhibits potent antitumor efficacy

Yanfei Han; Chengzhang Shang; Zhuo Li et al. · 2023 · Cancer Research · DOI

Full title: Abstract 2978: YH013, a novel EGFR x MET bispecific antibody-drug conjugate, exhibits potent antitumor efficacy

Authors: Yanfei Han; Chengzhang Shang; Zhuo Li; Zhenyan Han; J. Li; Zixu Cui; G. An; Wanjun Hao; Yujie Liu; Hao Li; Baihong Liu; Ellen Zhang; Qingcong Lin; Yi Yang; Yuelei Shen

Year: 2023

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2023-2978

Paper Abstract 3997: Preclinical characterization of ARX517, a next-generation anti-PSMA antibody drug conjugate for the treatment of metastatic castration-resistant prostate cancer

Lillian K Skidmore; David Mills; Ji Young Kim et al. · 2023 · Cancer Research · DOI

Full title: Abstract 3997: Preclinical characterization of ARX517, a next-generation anti-PSMA antibody drug conjugate for the treatment of metastatic castration-resistant prostate cancer

Authors: Lillian K Skidmore; David Mills; Ji Young Kim; P. Shastri; Nick A Knudsen; J. Steen; Jay D Nelson; Ying J Buechler; Feng Tian; S. Zhang

Year: 2023

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2023-3997

Paper Abstract 438: Antibody drug conjugate using a novel anti-CDCP1 antibody with low hematopoietic stem-cell binding and rapid internalization showed high efficacy for solid cancer

Shu-ichi Hashimoto; Shiori Miyamoyo; A. Takaiwa et al. · 2023 · Cancer Research · DOI

Full title: Abstract 438: Antibody drug conjugate using a novel anti-CDCP1 antibody with low hematopoietic stem-cell binding and rapid internalization showed high efficacy for solid cancer

Authors: Shu-ichi Hashimoto; Shiori Miyamoyo; A. Takaiwa; Koji Nakamura; Yukihito Tsukumo; Y. Yamashita

Year: 2023

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2023-438

Paper Abstract 4891: Ifinatamab deruxtecan (I-DXd), a novel B7-H3-targeting antibody-drug conjugate, demonstrates efficient payload delivery into tumor through target-dependent internalization

L. Katsumata; Tsuneo Deguchi; J. Hasegawa et al. · 2023 · Cancer Research · DOI

Full title: Abstract 4891: Ifinatamab deruxtecan (I-DXd), a novel B7-H3-targeting antibody-drug conjugate, demonstrates efficient payload delivery into tumor through target-dependent internalization

Authors: L. Katsumata; Tsuneo Deguchi; J. Hasegawa; M. Yamato; Y. Nishiya; Akiko Watanabe; T. Honda; Megumi Minami; N. Kasanuki; T. Maejima; Sumie Muramatsu; M. Herrmann; Nina Schulte; Gernot Polier; Xuya Wang; T. Yoshida; Nanae Izumi; Xiaozhong Qian; T. Agatsuma; K. Nakamaru

Year: 2023

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2023-4891

Paper Abstract 456: Raptamer-drug conjugates as molecularly targeted cancer therapeutics

Stephanie P. Vega; D. Chatterjee; A. Varadhachary et al. · 2023 · Cancer Research · DOI

Full title: Abstract 456: Raptamer-drug conjugates as molecularly targeted cancer therapeutics

Authors: Stephanie P. Vega; D. Chatterjee; A. Varadhachary; M. Ritchie; Michael L. Heffernan; D. Ciznadija

Year: 2023

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2023-456

Paper Abstract 4890: A novel topoisomerase I inhibitor antibody-drug conjugate targeting CEACAM5 has potent anti-tumor activity in colorectal cancer models

Y. Baudat; Haley D Neff-LaFord; C. Nicolazzi et al. · 2023 · Cancer Research · DOI

Full title: Abstract 4890: A novel topoisomerase I inhibitor antibody-drug conjugate targeting CEACAM5 has potent anti-tumor activity in colorectal cancer models

Authors: Y. Baudat; Haley D Neff-LaFord; C. Nicolazzi; David J. Meyer; J. Sigurjonsson; Ryan Lyski; V. Fantin; Marie-Priscille Brun; Marie-Lise Chiron; Stéphanie Decary

Year: 2023

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2023-4890

Paper Abstract 2977: A first-in-class anti-HER2/TROP2 bispecific antibody-drug conjugate (YH012) exhibits potent anti-tumor efficacy

Chengzhang Shang; Gao An; Yuming Guo et al. · 2023 · Cancer Research · DOI

Full title: Abstract 2977: A first-in-class anti-HER2/TROP2 bispecific antibody-drug conjugate (YH012) exhibits potent anti-tumor efficacy

Authors: Chengzhang Shang; Gao An; Yuming Guo; Ellen Zhang; Qingcong Lin; Yi Yang

Year: 2023

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2023-2977

Paper Abstract 584: Doppel, an exosome mediated biomarker specific to tumor endothelial cells

Byoung-Ae Kim; Ha Kyeong Lee; Y. Byun et al. · 2023 · Cancer Research · DOI

Full title: Abstract 584: Doppel, an exosome mediated biomarker specific to tumor endothelial cells

Authors: Byoung-Ae Kim; Ha Kyeong Lee; Y. Byun; S. Hwang; S. Y. Kim

Year: 2023

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2023-584

Paper Abstract 6300: Therapeutic potential of EO-3021/SYSA1801, a Claudin18.2 antibody-drug conjugate, for the treatment of CLDN18.2-expressing cancers

Mo Dan; Xiwu Hui; Yancui Wang et al. · 2023 · Cancer Research · DOI

Full title: Abstract 6300: Therapeutic potential of EO-3021/SYSA1801, a Claudin18.2 antibody-drug conjugate, for the treatment of CLDN18.2-expressing cancers

Authors: Mo Dan; Xiwu Hui; Yancui Wang; Can Yuan; T. O'hare; V. Jansen; S. Leland; Yang Zhang; D. Dornan; Xiaoyan Wang

Year: 2023

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2023-6300

Paper Abstract 6311: ABBV-400: An ADC delivering a novel topoisomerase 1 inhibitor to c-Met-positive solid tumors

R. Reilly; Cheng Ji; Ryan P. Matuszak et al. · 2023 · Cancer Research · DOI

Full title: Abstract 6311: ABBV-400: An ADC delivering a novel topoisomerase 1 inhibitor to c-Met-positive solid tumors

Authors: R. Reilly; Cheng Ji; Ryan P. Matuszak; Mark G. Anderson; L. Tucker; N. Klunder; Adelyn L. Lazo; E. Boghaert; Marybeth Pysz; A. D’Souza; Laura M. Kreckler; M. Bruncko; Brittney J. Mills; Matthew Ravn; George Doherty; K. Freise; A. Phillips

Year: 2023

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2023-6311

Paper Abstract 6297: Rationale for the development of a differentiated Trop2 ADC

S. Mitra; William Monteith; M. Do et al. · 2023 · Cancer Research · DOI

Full title: Abstract 6297: Rationale for the development of a differentiated Trop2 ADC

Authors: S. Mitra; William Monteith; M. Do; Greg Tuffy; Scott Savage; Jeffrey C. Kang; Mastewal Abuhay; Teodora Losic; S. Ghone; W. Haskins; V. Jammalamadaka; Sanjeev Satyal

Year: 2023

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2023-6297

Paper Abstract 596: Development and assessment of a novel tumor microenvironment activable linker (TMALIN) ADC platform for solid tumor treatments

Jiaqiang Cai; Shuai Song; Qing Zong et al. · 2023 · Cancer Research · DOI

Full title: Abstract 596: Development and assessment of a novel tumor microenvironment activable linker (TMALIN) ADC platform for solid tumor treatments

Authors: Jiaqiang Cai; Shuai Song; Qing Zong; Qigang Liu; Jian Xu

Year: 2023

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2023-596

Paper Abstract 6304: Preclinical development of a next generation antibody drug conjugate (ADC) targeting B7-H3 for treatment of solid tumors

Jian Xu; Qing Zong; Wei Wang et al. · 2023 · Cancer Research · DOI

Full title: Abstract 6304: Preclinical development of a next generation antibody drug conjugate (ADC) targeting B7-H3 for treatment of solid tumors

Authors: Jian Xu; Qing Zong; Wei Wang; Qigang Liu; Sasha Stann; Jiaqiang Cai

Year: 2023

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2023-6304

Paper Abstract 4019: Preclinical activity of ELVN-002: A potent, selective, and irreversible HER2 and pan-HER2 mutant small molecule inhibitor for the treatment of HER2 driven malignancies

M. Aujay; A. Broad; S. Gross et al. · 2023 · Cancer Research · DOI

Full title: Abstract 4019: Preclinical activity of ELVN-002: A potent, selective, and irreversible HER2 and pan-HER2 mutant small molecule inhibitor for the treatment of HER2 driven malignancies

Authors: M. Aujay; A. Broad; S. Gross; Liqun Ren; J. Lyssikatos; Samuel Kintz; Qi Wang; Helen Collins

Year: 2023

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2023-4019

Paper Abstract 595: Targeting metabolic vulnerability in brain-metastatic HER2+ breast cancer

H. Serhan; Liwei Bao; Xu Cheng et al. · 2023 · Cancer Research · DOI

Full title: Abstract 595: Targeting metabolic vulnerability in brain-metastatic HER2+ breast cancer

Authors: H. Serhan; Liwei Bao; Xu Cheng; S. Merajver; A. Morikawa; Nathan M. Merrill

Year: 2023

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2023-595

Paper Abstract 6308: Preclinical development of ABBV-319: a CD19-targeting glucocorticoid receptor modulator (GRM) agonist antibody-drug conjugate (ADC) for the treatment of B-cell malignancies

C. Chang; E. Emberley; A. D’Souza et al. · 2023 · Cancer Research · DOI

Full title: Abstract 6308: Preclinical development of ABBV-319: a CD19-targeting glucocorticoid receptor modulator (GRM) agonist antibody-drug conjugate (ADC) for the treatment of B-cell malignancies

Authors: C. Chang; E. Emberley; A. D’Souza; Wei Zhao; C. Cosgrove; Axel Hernandez Jr; Anatol Oleksijew; P. Ellis; L. Rodriguez; G. Bukofzer; David Peetz; Wissam Assaily; R. Mali; W. Liu; Danqing Xu; Gregory K. Potts; Shaun M. McLoughlin; Kimberley McCarthy; Zhaomei Zhang; J. Campbell; Isabella Sturdevant; Gloria Zhang; T. Curran; Jon D. Williams; E. Boghaert; M. Bruncko; C. C. Marvin; A. Hobson; Michael McPherson; Tamar Uziel; Marybeth Pysz; Xi Zhao; A. Bankovich; K. Freise; S. Morgan-Lappe; J. Purcell

Year: 2023

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2023-6308

Paper Abstract 825: Targeted nanospheres for the treatment of cancer

Hyung-Gyoo Kang; Bryon Upton; P. Scott et al. · 2023 · Cancer Research · DOI

Full title: Abstract 825: Targeted nanospheres for the treatment of cancer

Authors: Hyung-Gyoo Kang; Bryon Upton; P. Scott; Mark Lewis; J. Nagy; T. Triche

Year: 2023

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2023-825

Paper Abstract 6296: Preclinical study of a novel anti-CLEC12A antibody-drug conjugate with a glucuronide-protected pyrrolobenzodiazepine payload

Jinwon Jung; Ju-hyang Kim; Bora Lee et al. · 2023 · Cancer Research · DOI

Full title: Abstract 6296: Preclinical study of a novel anti-CLEC12A antibody-drug conjugate with a glucuronide-protected pyrrolobenzodiazepine payload

Authors: Jinwon Jung; Ju-hyang Kim; Bora Lee; Jung A Kwon; Suyoung Lee; B. Yoo; Minji Ko; Ilhwan Ryu; D. Yeom; Kyoungjae Lee; Jae-Hyeun Eom; Hanbyul Lee; Jinhyung Ahn; Eunsil Sung; W. You; S. H. Lee; Myeong Joo Kim; K. Kwon; Hyun Joo Bae; Yun-Hee Park; Ho Young Song; Chul-Woong Chung

Year: 2023

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2023-6296

Paper Abstract 6325: A novel EGFR x MUC1 bispecific antibody-drug conjugate, BSA01, targets MUC1 transmembrane cleavage products and improves tumor selectivity

Yifu Zhang; Chenzhang Shang; Anqi Wang et al. · 2023 · Cancer Research · DOI

Full title: Abstract 6325: A novel EGFR x MUC1 bispecific antibody-drug conjugate, BSA01, targets MUC1 transmembrane cleavage products and improves tumor selectivity

Authors: Yifu Zhang; Chenzhang Shang; Anqi Wang; Jia Zhang; Yuji Liu; Hao Li; Xiaopeng Li; G. An; Li Hui; F. An; Yezhou Yang

Year: 2023

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2023-6325

Paper Abstract LB209: An ADC composed of daratumumab and lenalidomide is extremely powerful in killing multiple myeloma cells

Yueh-Hsiang Yu; Ming-yu Hsieh; P. Wu et al. · 2023 · Cancer Research · DOI

Full title: Abstract LB209: An ADC composed of daratumumab and lenalidomide is extremely powerful in killing multiple myeloma cells

Authors: Yueh-Hsiang Yu; Ming-yu Hsieh; P. Wu; Hui-Ju Lee; P. Lin; C. Lim; H. Chu; T. Chang

Year: 2023

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2023-lb209

Paper Abstract LB216: Discovery of BCG033, a novel anti-PTK7 x TROP2 bispecific antibody-drug conjugate with promising efficacy against triple-negative breast cancer

Sufei Yao; Chengzhang Shang; G. An et al. · 2023 · Cancer Research · DOI

Full title: Abstract LB216: Discovery of BCG033, a novel anti-PTK7 x TROP2 bispecific antibody-drug conjugate with promising efficacy against triple-negative breast cancer

Authors: Sufei Yao; Chengzhang Shang; G. An; Ellen Zhang; Qingcong Lin; Yi Yang

Year: 2023

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2023-lb216

Paper Abstract LB213: Identification of DM004, a first-in-class anti-5T4/MET bispecific antibody-drug conjugate

Zhenyan Han; Chengzhang Shang; Wenjuan Dai et al. · 2023 · Cancer Research · DOI

Full title: Abstract LB213: Identification of DM004, a first-in-class anti-5T4/MET bispecific antibody-drug conjugate

Authors: Zhenyan Han; Chengzhang Shang; Wenjuan Dai; G. An; Ellen Zhang; Qingcong Lin; Yi Yang

Year: 2023

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2023-lb213

Paper Abstract 6318: Preclinical characterization of ARX305, a next-generation anti-CD70 antibody drug conjugate for the treatment of CD70-expressing cancers

Lillian K Skidmore; Jingjing Zhu; David Mills et al. · 2023 · Cancer Research · DOI

Full title: Abstract 6318: Preclinical characterization of ARX305, a next-generation anti-CD70 antibody drug conjugate for the treatment of CD70-expressing cancers

Authors: Lillian K Skidmore; Jingjing Zhu; David Mills; Ting Jin; Suqin Li; K. Tatsukawa; Nick A Knudsen; Liying Gong; Jay D Nelson; Kari Cox; Amha G. Hewet; Jianing Wang; Timothy N. Buss; Feng Tian; Gang Xia; S. Zhang

Year: 2023

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2023-6318

Paper Abstract 1885: Developing a biparatopic anti-ROR1 antibody drug conjugate BR111 for hematological and solid tumor treatment

Xiaobei Zhao; Jie Zhu; Zhen-Hua Wu et al. · 2024 · Cancer Research · DOI

Full title: Abstract 1885: Developing a biparatopic anti-ROR1 antibody drug conjugate BR111 for hematological and solid tumor treatment

Authors: Xiaobei Zhao; Jie Zhu; Zhen-Hua Wu; Yiqun Li; Jing Li; Yaqiong Zhou; Lei Nie; Haibin Wang; Gang Chen

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-1885

Paper Abstract CT121: ARX517, an anti-PSMA ADC targeting mCRPC resistant or refractory to standard therapies: A phase 1 dose escalation and dose expansion study (ARX517-2011, NCT04662580)

John Paul Shen; Richard Pachynski; L. Nordquist et al. · 2023 · Cancer Research · DOI

Full title: Abstract CT121: ARX517, an anti-PSMA ADC targeting mCRPC resistant or refractory to standard therapies: A phase 1 dose escalation and dose expansion study (ARX517-2011, NCT04662580)

Authors: John Paul Shen; Richard Pachynski; L. Nordquist; N. Adra; M. Bilen; R. Aggarwal; Z. Reichert; M. Schweizer; Dong Xu; Manan Patel; Jin Zhang; W. Shi; D. L'Heureux; S. Tagawa

Year: 2023

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2023-ct121

Paper Abstract LB215: A first-in-class anti-TROP2/EGFR bispecific antibody-drug conjugate, DM001, exhibits potent anti-tumor efficacy

Zhuolin Li; Chengzhang Shang; Xuewa Guan et al. · 2023 · Cancer Research · DOI

Full title: Abstract LB215: A first-in-class anti-TROP2/EGFR bispecific antibody-drug conjugate, DM001, exhibits potent anti-tumor efficacy

Authors: Zhuolin Li; Chengzhang Shang; Xuewa Guan; G. An; Yuming Guo; Ellen Zhang; Qingcong Lin; Yi Yang

Year: 2023

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2023-lb215

Paper Abstract 1858: Discovery of AT86474, a highly efficacious anti-ROR1 ADC utilizing a proprietary payload

Ban Xiong Tan; Xi Yun Zhang; You Xue Wu et al. · 2024 · Cancer Research · DOI

Full title: Abstract 1858: Discovery of AT86474, a highly efficacious anti-ROR1 ADC utilizing a proprietary payload

Authors: Ban Xiong Tan; Xi Yun Zhang; You Xue Wu; Yin Wen Cheng; Shao Jun Liu; Ping Du; Chen Zhong; Bin Zou

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-1858

Paper Abstract 1882: DXC024, a novel anti-TROP2/EGFR bispecific antibody and tubulysin conjugate, for targeted treatment of highly TROP2- or EGFR-expressing tumors

Jingjing Zhu; Junxiang Jia; Huihui Guo et al. · 2024 · Cancer Research · DOI

Full title: Abstract 1882: DXC024, a novel anti-TROP2/EGFR bispecific antibody and tubulysin conjugate, for targeted treatment of highly TROP2- or EGFR-expressing tumors

Authors: Jingjing Zhu; Junxiang Jia; Huihui Guo; Xiangfei Kong; Yong Du; Zhicang Ye; Lingli Zhang; Yongxiang Chen; Lu Bai; Yunxia Zheng; Wei Zheng; Jun Zheng; Juan Wang; Wenjun Li; Yuanyuan Huang; Zhongliang Fan; Mengmeng Liu; Binbin Chen; Meng Dai; Fang Du; Miaomiao Chen; Zhixiang Guo; Qingliang Yang; R. Zhao

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-1882

Paper Abstract 1890: HMA800067, a novel CD38-targeting antibody-drug conjugate (ADC), demonstrated superior anti-tumor activity to daratumumab in preclinical B-cell malignancies models

Yan Xu; Junqing Liang; Shuwen Jiang et al. · 2024 · Cancer Research · DOI

Full title: Abstract 1890: HMA800067, a novel CD38-targeting antibody-drug conjugate (ADC), demonstrated superior anti-tumor activity to daratumumab in preclinical B-cell malignancies models

Authors: Yan Xu; Junqing Liang; Shuwen Jiang; Haibin Yang; Hui Zhang; Fangfang Mao; Jiahuan Zhu; Jianlin He; Na Yang; Jian Wang; Weihan Zhang; Yongxin Ren; W. Su

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-1890

Paper Abstract 1869: The AI-powered KisoSeek™ platform identifies functional anti-TROP2 heavy-chain antibodies with potent anti-cancer activity

Sophie E. Cousineau; Amit Subedi; Richard Wargachuk et al. · 2024 · Cancer Research · DOI

Full title: Abstract 1869: The AI-powered KisoSeek™ platform identifies functional anti-TROP2 heavy-chain antibodies with potent anti-cancer activity

Authors: Sophie E. Cousineau; Amit Subedi; Richard Wargachuk; Juliana The; Xiaowei Wang; Wenyang Hou; Amogh Nair; Wansu Qiu; Alex Zhou; Tiffany Cheng; Morteza Babaie; Benyamin Gojogh; Marinieve Montero; H. Zahreddine; E. Undzys; Lucy Lai; Gordon Ngan; Luis A. Da Cruz; David Young

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-1869

Paper Abstract 1909: Advancing a novel tubulin-inhibitor ADC technology: The Adcentrx auristatin platform offers enhanced efficacy and safety profiles compared to vedotin technology

Dong Jun Lee; Sabine Rottmann; Anna Y. Wang et al. · 2024 · Cancer Research · DOI

Full title: Abstract 1909: Advancing a novel tubulin-inhibitor ADC technology: The Adcentrx auristatin platform offers enhanced efficacy and safety profiles compared to vedotin technology

Authors: Dong Jun Lee; Sabine Rottmann; Anna Y. Wang; Peter P. Challita; Andrew M. Hau; Wes Sisson; Mario M. Kuo; Kris Zhang; Monica Leung; Alexis Mahloch; Erin Nye; Paul Datta; Sam Janssen; Felipe Acosta; Oscar Betancourt; Maria Shahmoradgoli; Alexander Chu-Kung; Maojun Guo; P. Challita-Eid; Hui Li

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-1909

Paper Abstract 1812: Development of novel topoisomerase 1 inhibitor PBX-7 payload-based ADC including tandem cleavable linker system

Younghwa Chun; Areum Go; Hyun Yong Cho et al. · 2024 · Cancer Research · DOI

Full title: Abstract 1812: Development of novel topoisomerase 1 inhibitor PBX-7 payload-based ADC including tandem cleavable linker system

Authors: Younghwa Chun; Areum Go; Hyun Yong Cho; Byeong Sung Lee; Seunggun Shin; JaeHyeon Lee; Sohui Kweon; Hyemin Han; Suhyun Park; Doo Young Jung

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-1812

Paper Abstract 1902: ADRX-0706 Nectin-4 antibody-drug conjugate PK/PD characterization elucidates its widened therapeutic window

Maria Shahmoradgoli; Andrew M. Hau; Dong Jun Lee et al. · 2024 · Cancer Research · DOI

Full title: Abstract 1902: ADRX-0706 Nectin-4 antibody-drug conjugate PK/PD characterization elucidates its widened therapeutic window

Authors: Maria Shahmoradgoli; Andrew M. Hau; Dong Jun Lee; Anna Y. Wang; Peter P. Challita; Oscar Betancourt; Wes Sisson; Mario M. Kuo; Kris Zhang; Albert Goldson; Sam Janssen; Paul Datta; Felipe Acosta; Alexander Chu-Kung; Hui Li; P. Challita-Eid; Sabine Rottmann

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-1902

Paper Abstract 1904: Preclinical development of MGC026, a glycan-linked, exatecan-based antibody-drug conjugate (ADC) targeting B7-H3 for solid cancer

Juniper A Scribner; Jennifer G Brown; T. Son et al. · 2024 · Cancer Research · DOI

Full title: Abstract 1904: Preclinical development of MGC026, a glycan-linked, exatecan-based antibody-drug conjugate (ADC) targeting B7-H3 for solid cancer

Authors: Juniper A Scribner; Jennifer G Brown; T. Son; Linda Jin; Carroll McKenzie; Viktoriya Nam; Curtis Bush; Dienis Quinonez; J. Tamura; S. Gorlatov; Hua Li; Shelley Butler; E. Bonvini; Deryk Loo

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-1904

Paper Abstract 1871: Discovery and characterization of NXV01c, an EGFR × cMET bispecific nanobody drug conjugate with potent anti-tumor activity

Ran Wu; Puwei Yuan; Yang Xie et al. · 2024 · Cancer Research · DOI

Full title: Abstract 1871: Discovery and characterization of NXV01c, an EGFR × cMET bispecific nanobody drug conjugate with potent anti-tumor activity

Authors: Ran Wu; Puwei Yuan; Yang Xie; Jianxiu Guo; Fei Zhang; Fan Liu; Taylor B. Guo

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-1871

Paper Abstract 1896: Therapeutic potential of TORL-4-500, an antibody-drug conjugate directed against delta like non-canonical notch ligand 1 (DLK1)

M. Mcdermott; Neil A. O’Brien; Ming Lu et al. · 2024 · Cancer Research · DOI

Full title: Abstract 1896: Therapeutic potential of TORL-4-500, an antibody-drug conjugate directed against delta like non-canonical notch ligand 1 (DLK1)

Authors: M. Mcdermott; Neil A. O’Brien; Ming Lu; Jun Zhang; K. Gong; Benjamin Hoffstrom; Tong Luo; Min Liang; W. Jia; Kevin Chau; Leonard Presta; John A. Glaspy; D. Slamon

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-1896

Paper Abstract 1872: A next generation treatment for Nectin-4 positive cancers - Preclinical characterization of LY4052031, an anti-Nectin-4 antibody, conjugated to a novel camptothecin payload

Divya Sagar; Mohan Srinivasan; K. Lindquist et al. · 2024 · Cancer Research · DOI

Full title: Abstract 1872: A next generation treatment for Nectin-4 positive cancers - Preclinical characterization of LY4052031, an anti-Nectin-4 antibody, conjugated to a novel camptothecin payload

Authors: Divya Sagar; Mohan Srinivasan; K. Lindquist; Qianxu Guo; Wailin Wong; Maria B. Lebron; Rose Marie Sattler; Jieyu Zhou; Whitney Helms; Jeffrey Boyles; Petra Verdino; Xuan Zhao; Yvonne Mak; Joshua I. Park; R. Holmgaard; Kyla Driscoll; O. Duramad; Kristin Bedard

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-1872

Paper Abstract 1893: OBI-992, a novel TROP2 targeting antibody-drug conjugate, displayed excellent antitumor efficacy in various animal models

Wan-Fen Li; Ming-Feng Chiang; Hao-Cheng Weng et al. · 2024 · Cancer Research · DOI

Full title: Abstract 1893: OBI-992, a novel TROP2 targeting antibody-drug conjugate, displayed excellent antitumor efficacy in various animal models

Authors: Wan-Fen Li; Ming-Feng Chiang; Hao-Cheng Weng; Jhih-Jie Yang; Hsin-Shan Wu; Chun-Jung Lin; Ping-Tzu Chiu; Ming-Tain Lai

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-1893

Paper Abstract 2377: HER2-ADC efficacy is rooted in its induction of immunogenic cell death with FcGR activation and a systemic bystander effect

Li-Chung Tsao; Xingru Ma; John S Wang et al. · 2024 · Cancer Research · DOI

Full title: Abstract 2377: HER2-ADC efficacy is rooted in its induction of immunogenic cell death with FcGR activation and a systemic bystander effect

Authors: Li-Chung Tsao; Xingru Ma; John S Wang; T. Trotter; Tao Wang; Junping Wei; Gangjun Lei; Jason McBane; Ping Fan; Ivan Spasojevic; Z. Hartman

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-2377

Paper Abstract 1862: ZW191 - a FRα-targeting antibody drug conjugate with strong preclinical activity across multiple FRα-expressing indications

S. Lawn; Andrea Hernández Rojas; Raffaele Colombo et al. · 2024 · Cancer Research · DOI

Full title: Abstract 1862: ZW191 - a FRα-targeting antibody drug conjugate with strong preclinical activity across multiple FRα-expressing indications

Authors: S. Lawn; Andrea Hernández Rojas; Raffaele Colombo; Jodi Wong; Kaylee J Wu; Vincent Fung; M. Lasalle; Mark E Petersen; L. Degefie; A. Sagoe-Wagner; Dunja Urosev; Luying Yang; Ambroise Wu; Catrina Kim; Amos Chua; Kurt Stahl; Geoffrey C. Winters; John C. Fann; Jamie R Rich; Stuart D Barnscher

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-1862

Paper Abstract 1898: LNCB74 is a potent and safe next-generation antibody-drug-conjugate utilizing a cancer selective linker for the treatment of B7-H4 expressing cancers

Daniel P Fitzgerald; D. N. Doan; Riley B. Peacock et al. · 2024 · Cancer Research · DOI

Full title: Abstract 1898: LNCB74 is a potent and safe next-generation antibody-drug-conjugate utilizing a cancer selective linker for the treatment of B7-H4 expressing cancers

Authors: Daniel P Fitzgerald; D. N. Doan; Riley B. Peacock; Shannon M Kahan; S. Lomash; Stephen Slocum; K. Jung; Hwanhee Oh; Ingrid Meza; Yanira Manzanarez; Shanmugam Selvam; D. Flies; Chul-Woong Chung; Sol Langermann

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-1898

Paper Abstract 1919: Activity and affinity tuning next-generation immunotoxins for targeted therapy

Huazhu Liang; Greg L. Beilhartz; Shi Bo Cao et al. · 2024 · Cancer Research · DOI

Full title: Abstract 1919: Activity and affinity tuning next-generation immunotoxins for targeted therapy

Authors: Huazhu Liang; Greg L. Beilhartz; Shi Bo Cao; Roman A. Melnyk

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-1919

Paper Abstract 2052: Screening novel format antibodies to design bispecific ADCs that address target heterogeneity

Stuart D Barnscher; Dunja Urosev; Kevin Yin et al. · 2024 · Cancer Research · DOI

Full title: Abstract 2052: Screening novel format antibodies to design bispecific ADCs that address target heterogeneity

Authors: Stuart D Barnscher; Dunja Urosev; Kevin Yin; Andrea Hernández Rojas; S. Lawn; Vincent Fung; Jodi Wong; A. Sagoe-Wagner; L. Degefie; Ali Livernois; Catrina Kim; Paul A. Moore; Jamie R Rich

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-2052

Paper Abstract 2118: SGN-CEACAM5C/SAR445953, a novel topoisomerase I inhibitor antibody-drug conjugate targeting CEACAM5, has potent anti-tumor activity in CRC, PDAC, GC and lung cancer tumor models

Y. Baudat; C. Nicolazzi; J. Sigurjonsson et al. · 2024 · Cancer Research · DOI

Full title: Abstract 2118: SGN-CEACAM5C/SAR445953, a novel topoisomerase I inhibitor antibody-drug conjugate targeting CEACAM5, has potent anti-tumor activity in CRC, PDAC, GC and lung cancer tumor models

Authors: Y. Baudat; C. Nicolazzi; J. Sigurjonsson; Céline Amara; Astrid Clarke; Ryan Lyski; David J. Meyer; Valeria R. Fantin; Marie-Lise Chiron; Stéphanie Decary

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-2118

Paper Abstract 2360: ADV101, a first-in-class IL-1RAP ADC demonstrates significant anti-tumor activity in solid tumor models

Richard C. A. Sainson; Laura Demolis; Edouard De Dreuzy et al. · 2024 · Cancer Research · DOI

Full title: Abstract 2360: ADV101, a first-in-class IL-1RAP ADC demonstrates significant anti-tumor activity in solid tumor models

Authors: Richard C. A. Sainson; Laura Demolis; Edouard De Dreuzy; Olivier Favre-Bulle; Alexis Collette; Lucas Bourhis; Soha Reda El Sayed; Delphine Genin; Clementine Primus; L. Bouquet; Ksenija Pavletic; Christophe Ferrand; M. Deschamps; Stephane Lameynardie; Erik Rutjens; Jens Hasskarl

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-2360

Paper Abstract 2614: GlycoConnect™ ADC toolbox expansion with high DAR technology

Lianne Lelieveldt; Elias Post; Marie Nassiet et al. · 2024 · Cancer Research · DOI

Full title: Abstract 2614: GlycoConnect™ ADC toolbox expansion with high DAR technology

Authors: Lianne Lelieveldt; Elias Post; Marie Nassiet; Veronique Hendriks; Mick Verhagen; R. van Geel; Sander van Berkel; Floris van Delft

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-2614

Paper Abstract 1894: Preclinical development of YL205, a novel NaPi2b-targeting antibody-drug conjugate (ADC) with novel topoisomerase I inhibitor-based linker-payload for treatment of solid tumors

Liang Xiao; Wei Lian; Qigang Liu et al. · 2024 · Cancer Research · DOI

Full title: Abstract 1894: Preclinical development of YL205, a novel NaPi2b-targeting antibody-drug conjugate (ADC) with novel topoisomerase I inhibitor-based linker-payload for treatment of solid tumors

Authors: Liang Xiao; Wei Lian; Qigang Liu; Qing Zong; Shuai Song; Sasha Stann; Jiaqiang Cai; Tongtong Xue

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-1894

Paper Abstract 2056: Click chemistry enabled selective activation of highly cytotoxic MMAE payload at tumors using TROP2 targeting agent

G. Coricor; J. McFarland; S. Srinivasan et al. · 2024 · Cancer Research · DOI

Full title: Abstract 2056: Click chemistry enabled selective activation of highly cytotoxic MMAE payload at tumors using TROP2 targeting agent

Authors: G. Coricor; J. McFarland; S. Srinivasan; S. Wagner; Tri-Hung Nguyen; J. Oneto

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-2056

Paper Abstract 2620: BCG016, a first-in-class bispecific antibody-drug conjugate targeting 5T4 and MUC1, demonstrates potent preclinical anti-tumor activity

Zhenyan Han; Chengzhang Shang; Yifu Zhang et al. · 2024 · Cancer Research · DOI

Full title: Abstract 2620: BCG016, a first-in-class bispecific antibody-drug conjugate targeting 5T4 and MUC1, demonstrates potent preclinical anti-tumor activity

Authors: Zhenyan Han; Chengzhang Shang; Yifu Zhang; G. An; Chaoshe Guo; W. An; Yi Yang

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-2620

Paper Abstract 2601: Potent antitumor activity of anti-HER2 antibody-topoisomerase I inhibitor conjugate based on self-immolative dendritic dimeric-linker

Yulia Liubomirski; G. Tiram; A. Scomparin et al. · 2024 · Cancer Research · DOI

Full title: Abstract 2601: Potent antitumor activity of anti-HER2 antibody-topoisomerase I inhibitor conjugate based on self-immolative dendritic dimeric-linker

Authors: Yulia Liubomirski; G. Tiram; A. Scomparin; Samer Gnaim; Sayantan Das; Sachin Gholap; Liang Ge; E. Yeini; Omri Shelef; Arie Zauberman; Nir Berger; Doron Kalimi; Mira Toister-Achituv; Christian Schröter; Stephan Dickgiesser; Jason Tonillo; Min Shan; Carl Deutsch; Stanley Sweeney-Lasch; D. Shabat; R. Satchi‐Fainaro

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-2601

Paper Abstract 2616: BCG033, a novel bispecific antibody-drug conjugate targeting PTK7 and TROP2, demonstrates preclinical efficacy against triple-negative breast cancer and other solid tumor xenografts

Sufei Yao; Chengzhang Shang; G. An et al. · 2024 · Cancer Research · DOI

Full title: Abstract 2616: BCG033, a novel bispecific antibody-drug conjugate targeting PTK7 and TROP2, demonstrates preclinical efficacy against triple-negative breast cancer and other solid tumor xenografts

Authors: Sufei Yao; Chengzhang Shang; G. An; Chaoshe Guo; W. F. an; Yi Yang

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-2616

Paper Abstract 2617: BCG022, a novel HER3 × MET bispecific antibody-drug conjugate (bsADC), demonstrates promising anti-tumor efficacy

Zhuolin Li; Chengzhang Shang; Zhenyan Han et al. · 2024 · Cancer Research · DOI

Full title: Abstract 2617: BCG022, a novel HER3 × MET bispecific antibody-drug conjugate (bsADC), demonstrates promising anti-tumor efficacy

Authors: Zhuolin Li; Chengzhang Shang; Zhenyan Han; G. An; Chaoshe Guo; W. An; Yi Yang

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-2617

Paper Abstract 2615: Preclinical development of a next generation antibody drug conjugate (ADC) targeting cMET for treatment of solid tumors

Liang Xiao; Wei Lian; Shuai Song et al. · 2024 · Cancer Research · DOI

Full title: Abstract 2615: Preclinical development of a next generation antibody drug conjugate (ADC) targeting cMET for treatment of solid tumors

Authors: Liang Xiao; Wei Lian; Shuai Song; Qigang Liu; Qing Zong; Sasha Stann; Jiaqiang Cai; Tongtong Xue

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-2615

Paper Abstract 3135: BSI-730, a bispecific antibody targeting HER2 and PD-L1 for the development of a first-in-class bispecific ADC

Xiaoyao Hao; Hongyan Li; Xiaodong F. Liu et al. · 2024 · Cancer Research · DOI

Full title: Abstract 3135: BSI-730, a bispecific antibody targeting HER2 and PD-L1 for the development of a first-in-class bispecific ADC

Authors: Xiaoyao Hao; Hongyan Li; Xiaodong F. Liu; Jinyu Liu; Wenwen Dai; Ying Pan; Hui-Han Hu; Jun Li; Shukai Xia; Qun Lyu; Hugh M. Davis; Mingjiu Chen; Zeyu Peng

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-3135

Paper Abstract 2621: Preclinical Efficacy of DM002, a bispecific HER3 × MUC1 antibody-drug conjugate with a novel DNA topoisomerase I inhibitor, in solid tumor models

Yifu Zhang; Chengzhang Shang; Nannan Wang et al. · 2024 · Cancer Research · DOI

Full title: Abstract 2621: Preclinical Efficacy of DM002, a bispecific HER3 × MUC1 antibody-drug conjugate with a novel DNA topoisomerase I inhibitor, in solid tumor models

Authors: Yifu Zhang; Chengzhang Shang; Nannan Wang; G. An; Chaoshe Guo; W. An; Yi Yang

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-2621

Paper Abstract 2591: Nonclinical ocular toxicity of a maytansinoid payload-antibody drug conjugate: Ocular tissue distribution, lesion pathogenesis, and mitigation

Ali Warbington; Olga Ab; S. Lakshmikanthan et al. · 2024 · Cancer Research · DOI

Full title: Abstract 2591: Nonclinical ocular toxicity of a maytansinoid payload-antibody drug conjugate: Ocular tissue distribution, lesion pathogenesis, and mitigation

Authors: Ali Warbington; Olga Ab; S. Lakshmikanthan; Shana Dalton; Paul Miller; Edward Stevens; P. Zweidler-McKay; Grace Lytle

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-2591

Paper Abstract 2623: Enabling 5T4 for targeted cancer therapy: TUB-030, a novel ADC built with ethynylphosphonamidate conjugation chemistry, shows long-lasting anti-tumor activity via Topoisomerase-I inhibition with an optimized therapeutic index

Saskia Schmitt; I. Mai; Paul Machui et al. · 2024 · Cancer Research · DOI

Full title: Abstract 2623: Enabling 5T4 for targeted cancer therapy: TUB-030, a novel ADC built with ethynylphosphonamidate conjugation chemistry, shows long-lasting anti-tumor activity via Topoisomerase-I inhibition with an optimized therapeutic index

Authors: Saskia Schmitt; I. Mai; Paul Machui; Sarah Herterich; Danila Hauswald; Philipp Ochtrop; Philipp Cyprys; Izabela Kozlowska; Annabel Kitowski; M. Gerlach; Olivier Marcq; Pamela A Trail; Dominik Schumacher; Marc‐André Kasper; Günter R Fingerle-Rowson; Björn Hock; J. Helma-Smets; Annette M Vogl

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-2623

Paper Abstract 3131: Novel CDH17-targeting antibody-drug conjugate exhibits anti-tumor efficacy in preclinical models of gastrointestinal cancers

Po Yee Wong; Lin He; Kronos Chow et al. · 2024 · Cancer Research · DOI

Full title: Abstract 3131: Novel CDH17-targeting antibody-drug conjugate exhibits anti-tumor efficacy in preclinical models of gastrointestinal cancers

Authors: Po Yee Wong; Lin He; Kronos Chow; Kwan Wa Wong; Chui Yee O; D. Wong; J. M. Luk; Pui-Chi Lo; K. F. Wong

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-3131

Paper Abstract 3123: Preclinical characterization of AMB302/GQ1011, a first-in-class FGFR3 antibody-drug conjugate (ADC) with topoisomerase 1 inhibitor against diverse FGFR3 overexpression or alteration

Byeongkwi Min; Sunghyun Lee; Wonsik Jung et al. · 2024 · Cancer Research · DOI

Full title: Abstract 3123: Preclinical characterization of AMB302/GQ1011, a first-in-class FGFR3 antibody-drug conjugate (ADC) with topoisomerase 1 inhibitor against diverse FGFR3 overexpression or alteration

Authors: Byeongkwi Min; Sunghyun Lee; Wonsik Jung; Lina Wang; Yajun Sun; Hyejin Kim; N. Her; Paul Song; Gang Qin; Do-Hyun Nam

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-3123

Paper Abstract 2619: A novel EGFR × HER3-targeting bispecific antibody drug-conjugate, BCG019, demonstrates robust anti-tumor efficacy in preclinical evaluation

Zhuolin Li; Chengzhang Shang; G. An et al. · 2024 · Cancer Research · DOI

Full title: Abstract 2619: A novel EGFR × HER3-targeting bispecific antibody drug-conjugate, BCG019, demonstrates robust anti-tumor efficacy in preclinical evaluation

Authors: Zhuolin Li; Chengzhang Shang; G. An; Chaoshe Guo; W. An; Yi Yang

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-2619

Paper Abstract 3184: Development of an innovative bifunctional CPL976-MMAE conjugate based on a bispecific anti-PD-L1/ant-AXL antibody with a dual mechanism of action

Krysztof Lacek; Anna Jabłońska; Olga Abramczyk et al. · 2024 · Cancer Research · DOI

Full title: Abstract 3184: Development of an innovative bifunctional CPL976-MMAE conjugate based on a bispecific anti-PD-L1/ant-AXL antibody with a dual mechanism of action

Authors: Krysztof Lacek; Anna Jabłońska; Olga Abramczyk; Martyna Janowska; Filip Mitula; Aleksandra Sowińska; Agnieszka Bojko-Matuszek; Tomasz Kornatowski; Damian Kołakowski; Magdalena Bojko; M. Skupińska; Wiktor Pyra; Michał Górka; J. Hucz-Kalitowska; Emilia Mróz; Małgorzata Choroś; Jerzy Pieczykoland; Maciej Wieczorek; Delfina Popiel

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-3184

Paper Abstract 3133: A novel bispecific antibody-drug conjugate targeting HER2 and Trop-2 displays potent antitumor activity in a variety of tumor models with promising preclinical characteristics

Haihong (Helen) Zhong; Yan Xiong; Han Huang et al. · 2024 · Cancer Research · DOI

Full title: Abstract 3133: A novel bispecific antibody-drug conjugate targeting HER2 and Trop-2 displays potent antitumor activity in a variety of tumor models with promising preclinical characteristics

Authors: Haihong (Helen) Zhong; Yan Xiong; Han Huang; Yuming Pan; Na Wang; Bin Sun; Shen Liu; Wei Yuan; Dingguo Liu; Jan Fang; Haifeng Bao

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-3133

Paper Abstract 2618: BCG017, a bispecific ADC targeting PTK7 and EGFR exhibits anti-tumor efficacy in PDX models

Sufei Yao; Chengzhang Shang; Zhuolin Li et al. · 2024 · Cancer Research · DOI

Full title: Abstract 2618: BCG017, a bispecific ADC targeting PTK7 and EGFR exhibits anti-tumor efficacy in PDX models

Authors: Sufei Yao; Chengzhang Shang; Zhuolin Li; G. An; Chaoshe Guo; W. An; Yi Yang

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-2618

Paper Abstract 3149: Development of a novel site-specific ADC glycan platform with potential for improved in vivo efficacy and stability of the ADC in animal studies

Teng-Yi Huang; Yin-Cheng Hsieh; Ka-Shu Fung et al. · 2024 · Cancer Research · DOI

Full title: Abstract 3149: Development of a novel site-specific ADC glycan platform with potential for improved in vivo efficacy and stability of the ADC in animal studies

Authors: Teng-Yi Huang; Yin-Cheng Hsieh; Ka-Shu Fung; Yu-Chao Huang; Chi-Sheng Shia; Ming-Feng Chiang; Nan-Hsuan Wang; Wan-Fen Li; Ming-Tain Lai

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-3149

Paper Abstract 3136: Towards development of a novel biparatopic trop2-ADC

Yinan Wu; Brittany Jiang; Julliet Rivera et al. · 2024 · Cancer Research · DOI

Full title: Abstract 3136: Towards development of a novel biparatopic trop2-ADC

Authors: Yinan Wu; Brittany Jiang; Julliet Rivera; Fang Wang; Jing Zhou; Lin Liu; Silvia Hudson; Will Draper; Jennifer Li; Xiaoshan Min; Hang Chen; Zhulun Wang

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-3136

Paper - **DOI:** 10.1158/1538-7445.am2024-3370 - **Authors:** L. Piggott, E. Imedio, Francesco Staehli - **Year:** 2024 - **Journal:** Cancer Research

L. Piggott; E. Imedio; Francesco Staehli · 2024 · Cancer Research · DOI

Full title: - **DOI:** 10.1158/1538-7445.am2024-3370 - **Authors:** L. Piggott, E. Imedio, Francesco Staehli - **Year:** 2024 - **Journal:** Cancer Research

Authors: L. Piggott; E. Imedio; Francesco Staehli

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-3370

Paper Abstract 3124: MRG006A, a novel glypican-3-targeting antibody-drug conjugate, demonstrated potent anti-tumor activity and good safety profile in preclinical studies

Yanchun Wang; Hongfeng Li; Hao Shen et al. · 2024 · Cancer Research · DOI

Full title: Abstract 3124: MRG006A, a novel glypican-3-targeting antibody-drug conjugate, demonstrated potent anti-tumor activity and good safety profile in preclinical studies

Authors: Yanchun Wang; Hongfeng Li; Hao Shen; Wenchao Liu; Shoujia Liu; Kequan Yin; Haili Xu; Xueyuan Cui; Wei Li; Wei Liu; Xiangyu Wu; Liu Yang; Tian Ma; Zhongrun Zhao; Jun Wang; Feifei Cui; Lei Fang; Minmin Qin; Chaohong Hu

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-3124

Paper Abstract 3125: TCX-101, a novel antibody-drug conjugate targeting a tumor-associated carbohydrate antigen for the treatment of solid tumors

Fausto G. Gomes; F. Muraca; Gustavo M. Schmidt Garcia Moreira et al. · 2024 · Cancer Research · DOI

Full title: Abstract 3125: TCX-101, a novel antibody-drug conjugate targeting a tumor-associated carbohydrate antigen for the treatment of solid tumors

Authors: Fausto G. Gomes; F. Muraca; Gustavo M. Schmidt Garcia Moreira; Kathrin Rösch; Maria Bräutigam; P. Sondermann; Matthias Ocker

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-3125

Paper Abstract 3212: Development of a Trop2/CD3 bispecific antibody with modulated Trop2 binding affinity as a novel immunotherapy for advanced gastrointestinal cancer treatment

Chui Yee O; Po Yee Wong; Kronos Chow et al. · 2024 · Cancer Research · DOI

Full title: Abstract 3212: Development of a Trop2/CD3 bispecific antibody with modulated Trop2 binding affinity as a novel immunotherapy for advanced gastrointestinal cancer treatment

Authors: Chui Yee O; Po Yee Wong; Kronos Chow; Kwan Wa Wong; D. Wong; J. M. Luk; K. F. Wong

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-3212

Paper Abstract 4702: MediLink’s TMALIN ADC linker technology: Tumor microenvironment specific extracellular and intracellular double cleavage mechanism for better efficacy and expanded target space

Tongtong Xue; Liang Xiao; Qigang Liu et al. · 2024 · Cancer Research · DOI

Full title: Abstract 4702: MediLink’s TMALIN ADC linker technology: Tumor microenvironment specific extracellular and intracellular double cleavage mechanism for better efficacy and expanded target space

Authors: Tongtong Xue; Liang Xiao; Qigang Liu; Shuai Song; Ailin Shan; Xiaozhou Zhang; Sasha Stann; Jiaqiang Cai

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-4702

Paper Abstract 4077: T cell targeting with PD-1-selective immune cell engagers based on GlycoConnect™ (GC™-ICEs) show excellent efficacy and tolerability

R. van Geel; Mick Verhagen; Elias Post et al. · 2024 · Cancer Research · DOI

Full title: Abstract 4077: T cell targeting with PD-1-selective immune cell engagers based on GlycoConnect™ (GC™-ICEs) show excellent efficacy and tolerability

Authors: R. van Geel; Mick Verhagen; Elias Post; Willem Vugs; Sorraya Popal; Sander van Berkel; Floris van Delft

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-4077

Paper Abstract 5820: An antibody drug conjugate platform based on novel camptothecin payloads with branch hydrophilic linkers and site-specific conjugation

Yuanyuan Huang; Hangbo Ye; Qingliang Yang et al. · 2024 · Cancer Research · DOI

Full title: Abstract 5820: An antibody drug conjugate platform based on novel camptothecin payloads with branch hydrophilic linkers and site-specific conjugation

Authors: Yuanyuan Huang; Hangbo Ye; Qingliang Yang; Lingli Zhang; Huihui Guo; Xiaolei Liu; Wenjun Li; Lu Bai; Junxiang Jia; Juan Wang; Xiangfei Kong; Jun Zheng; Yifang Xu; Gengxiang Zhao; Linyao Zhao; Xiang Cai; Ziyu Zhao; Hui Xia; Xia Zhou; You Zhou; R. Zhao

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-5820

Paper Abstract 3148: ABBV-706 is a novel SEZ6-targeted topoisomerase 1 inhibitor ADC for SCLC and other neuroendocrine cancers

Emily J. Faivre; Marybeth Pysz; Eoghainín Ó hAinmhire et al. · 2024 · Cancer Research · DOI

Full title: Abstract 3148: ABBV-706 is a novel SEZ6-targeted topoisomerase 1 inhibitor ADC for SCLC and other neuroendocrine cancers

Authors: Emily J. Faivre; Marybeth Pysz; Eoghainín Ó hAinmhire; Laura Kreckler; Kelly Doyle; Aloma L D'Souza; Zhiyong Ding; Trusha Sondkar; Dolonchampa Maji; Fan Zhao; Andrew Phillips

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-3148

Paper Abstract 479: Enhanced payload delivery for acute myeloid leukemia treatment through CD37-targeting DNA nanobots

Nicholas J Vantangoli; Patrick Halley; Jeffrey R. Spitzner et al. · 2024 · Cancer Research · DOI

Full title: Abstract 479: Enhanced payload delivery for acute myeloid leukemia treatment through CD37-targeting DNA nanobots

Authors: Nicholas J Vantangoli; Patrick Halley; Jeffrey R. Spitzner; John C. Byrd; Karilyn T. Larkin; Carlos E. Castro; Christopher R. Lucas

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-479

Paper Abstract 3210: Raptamer-drug conjugates as molecularly targeted cancer therapeutics

Stephanie P. Vega; Nancy E. Ward; U. Saini et al. · 2024 · Cancer Research · DOI

Full title: Abstract 3210: Raptamer-drug conjugates as molecularly targeted cancer therapeutics

Authors: Stephanie P. Vega; Nancy E. Ward; U. Saini; Leniher Castan-Chibas; Garima Kaushik; D. Ciznadija; Dev Chatterjee; Michael J. Heffernan; A. Varadhachary; Michael Ritchie

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-3210

Paper Abstract 3108: Antibody labeling reagents to rapidly screen for the binding and internalization of therapeutic antibodies

Ryan W. Holly · 2024 · Cancer Research · DOI

Full title: Abstract 3108: Antibody labeling reagents to rapidly screen for the binding and internalization of therapeutic antibodies

Authors: Ryan W. Holly

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-3108

Paper Abstract 4700: Induced phenotype targeted ADC by using caspase enzymatic cleavable peptide linker to overcome tumor heterogeneity

Ha Kyeong Lee; B. Kim; H. Chang et al. · 2024 · Cancer Research · DOI

Full title: Abstract 4700: Induced phenotype targeted ADC by using caspase enzymatic cleavable peptide linker to overcome tumor heterogeneity

Authors: Ha Kyeong Lee; B. Kim; H. Chang; Sang Yoon Kim; Y. Byun

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-4700

Paper Abstract 5908: Angiosarcoma growth inhibition by targeting Doppel, a specific endothelial marker, with an antibody drug conjugate

B. Kim; Ha Kyeong Lee; Y. Byun et al. · 2024 · Cancer Research · DOI

Full title: Abstract 5908: Angiosarcoma growth inhibition by targeting Doppel, a specific endothelial marker, with an antibody drug conjugate

Authors: B. Kim; Ha Kyeong Lee; Y. Byun; Yoon Gun Ko; Sang Yoon Kim

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-5908

Paper Abstract 5896: Platform approach to develop antibodies specifically recognizing cancer-associated glycoforms

Patrik Kehler; Johanna Gellert; Lisa Kalfhues et al. · 2024 · Cancer Research · DOI

Full title: Abstract 5896: Platform approach to develop antibodies specifically recognizing cancer-associated glycoforms

Authors: Patrik Kehler; Johanna Gellert; Lisa Kalfhues; Sophie Marinoff; Manon Weis; Andreas Franz; Naomi Kast; Stephanie Gurka; Marianne Morche; Evelyn Hartung; T. Lischke; Sarah Mayer-Hain; A. Danielczyk

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-5896

Paper A comparison of the activity, lysosomal stability, and efficacy of legumain-cleavable and cathepsin-cleavable ADC linkers

Meghan E. Gray; Karina M Zielinski; Fanny Xu et al. · 2024 · Xenobiotica; the fate of foreign compounds in biological systems · DOI

Full title: A comparison of the activity, lysosomal stability, and efficacy of legumain-cleavable and cathepsin-cleavable ADC linkers

Authors: Meghan E. Gray; Karina M Zielinski; Fanny Xu; Kayla K. Elder; Steven J McKay; Victor T Ojo; Samantha R. Benjamin; Aiman A Yaseen; Tracy A. Brooks; L. N. Tumey

Year: 2024

Venue: Xenobiotica; the fate of foreign compounds in biological systems

DOI: https://doi.org/10.1080/00498254.2024.2352051

Paper Antibody drug conjugates under investigation in phase I and phase II clinical trials for gastrointestinal cancer

A. Leal; A. Krishnamurthy; L. Head et al. · 2018 · Expert Opinion on Investigational Drugs · DOI

Full title: Antibody drug conjugates under investigation in phase I and phase II clinical trials for gastrointestinal cancer

Authors: A. Leal; A. Krishnamurthy; L. Head; W. Messersmith

Year: 2018

Venue: Expert Opinion on Investigational Drugs

DOI: https://doi.org/10.1080/13543784.2018.1541085

Paper Blinatumomab for the treatment of acute lymphoblastic leukemia in a real-world setting: clinical vignettes

Shilpa Paul; E. Jabbour; Dan E. Nichols et al. · 2024 · Leukemia and Lymphoma · DOI

Full title: Blinatumomab for the treatment of acute lymphoblastic leukemia in a real-world setting: clinical vignettes

Authors: Shilpa Paul; E. Jabbour; Dan E. Nichols; N. Short; Hagop Kantarjian

Year: 2024

Venue: Leukemia and Lymphoma

DOI: https://doi.org/10.1080/10428194.2024.2426052

Paper Synthesis and evaluation of highly releasable and structurally stable antibody-SN-38-conjugates

Lianqi Liu; Fei Xie; Dian Xiao et al. · 2021 · Drug Delivery · DOI

Full title: Synthesis and evaluation of highly releasable and structurally stable antibody-SN-38-conjugates

Authors: Lianqi Liu; Fei Xie; Dian Xiao; Xin Xu; Zheng Su; Yanming Wang; Shiyong Fan; Xinbo Zhou; Song Li

Year: 2021

Venue: Drug Delivery

DOI: https://doi.org/10.1080/10717544.2021.2008053

Paper Salvage systemic therapy for metastatic urothelial carcinoma: an unmet clinical need

K. Montazeri; G. Sonpavde · 2020 · Expert Review of Anticancer Therapy · DOI

Full title: Salvage systemic therapy for metastatic urothelial carcinoma: an unmet clinical need

Authors: K. Montazeri; G. Sonpavde

Year: 2020

Venue: Expert Review of Anticancer Therapy

DOI: https://doi.org/10.1080/14737140.2021.1855981

Paper Development of applicable thiol-linked antibody-drug conjugates with improved stability and therapeutic index.

Wang, Yanming; Xie, Fei; Liu, Lianqi et al. · 2022 · Drug delivery · DOI

Full title: Development of applicable thiol-linked antibody-drug conjugates with improved stability and therapeutic index.

Authors: Wang, Yanming; Xie, Fei; Liu, Lianqi; Xu, Xin; Fan, Shiyong; Zhong, Wu; Zhou, Xinbo

Year: 2022

Venue: Drug delivery

DOI: https://doi.org/10.1080/10717544.2022.2039807

Paper Sacituzumab govitecan for hormone receptor–positive HER2-negative advanced breast cancer

L. Garrigós; Daniela Camacho; J. Peréz-García et al. · 2024 · Expert Review of Anticancer Therapy · DOI

Full title: Sacituzumab govitecan for hormone receptor–positive HER2-negative advanced breast cancer

Authors: L. Garrigós; Daniela Camacho; J. Peréz-García; A. Llombart-Cussac; Javier Cortés; G. Antonarelli

Year: 2024

Venue: Expert Review of Anticancer Therapy

DOI: https://doi.org/10.1080/14737140.2024.2392775

Paper Sacituzumab govitecan, a novel, third-generation, antibody-drug conjugate (ADC) for cancer therapy

D. Goldenberg; R. Sharkey · 2020 · Expert Opinion on Biological Therapy · DOI

Full title: Sacituzumab govitecan, a novel, third-generation, antibody-drug conjugate (ADC) for cancer therapy

Authors: D. Goldenberg; R. Sharkey

Year: 2020

Venue: Expert Opinion on Biological Therapy

DOI: https://doi.org/10.1080/14712598.2020.1757067

Paper Targeting claudin 18.2 in gastric cancer: a review of emerging biologic agents.

Kazumasa Yamamoto; I. Nakayama; K. Shitara · 2026 · Expert Opinion on Biological Therapy · DOI

Full title: Targeting claudin 18.2 in gastric cancer: a review of emerging biologic agents.

Authors: Kazumasa Yamamoto; I. Nakayama; K. Shitara

Year: 2026

Venue: Expert Opinion on Biological Therapy

DOI: https://doi.org/10.1080/14712598.2026.2617271

Paper The safety of current and emerging therapies for multiple myeloma.

Nadeem, Omar; Anderson, Kenneth C · 2020 · Expert opinion on drug safety · DOI

Full title: The safety of current and emerging therapies for multiple myeloma.

Authors: Nadeem, Omar; Anderson, Kenneth C

Year: 2020

Venue: Expert opinion on drug safety

DOI: https://doi.org/10.1080/14740338.2020.1733968

Paper Evaluation of sacituzumab govitecan for advanced/metastatic non-small cell lung cancer

Irfan Cicin; Berivan Karatekin; Esra Güzelaltuncekic et al. · 2025 · Expert Review of Anticancer Therapy · DOI

Full title: Evaluation of sacituzumab govitecan for advanced/metastatic non-small cell lung cancer

Authors: Irfan Cicin; Berivan Karatekin; Esra Güzelaltuncekic; I. Kolbas

Year: 2025

Venue: Expert Review of Anticancer Therapy

DOI: https://doi.org/10.1080/14737140.2025.2515989

Paper Investigating osimertinib plus chemotherapy in EGFR-mutated advanced non-small cell lung cancer

A. Spagnuolo; C. Gridelli · 2025 · Expert Opinion on Pharmacotherapy · DOI

Full title: Investigating osimertinib plus chemotherapy in EGFR-mutated advanced non-small cell lung cancer

Authors: A. Spagnuolo; C. Gridelli

Year: 2025

Venue: Expert Opinion on Pharmacotherapy

DOI: https://doi.org/10.1080/14656566.2025.2464903

Paper Biological therapy in elderly patients with acute myeloid leukemia

Giulia Ciotti; G. Marconi; A. Sperotto et al. · 2023 · Expert Opinion on Biological Therapy · DOI

Full title: Biological therapy in elderly patients with acute myeloid leukemia

Authors: Giulia Ciotti; G. Marconi; A. Sperotto; M. B. Giannini; M. Gottardi; G. Martinelli

Year: 2023

Venue: Expert Opinion on Biological Therapy

DOI: https://doi.org/10.1080/14712598.2023.2174015

Paper Investigational antibody-drug conjugates in clinical trials for the treatment of breast cancer

A. Okines; L. Ulrich · 2021 · Expert Opinion on Investigational Drugs · DOI

Full title: Investigational antibody-drug conjugates in clinical trials for the treatment of breast cancer

Authors: A. Okines; L. Ulrich

Year: 2021

Venue: Expert Opinion on Investigational Drugs

DOI: https://doi.org/10.1080/13543784.2021.1940950

Paper Zelenectide pevedotin (BT-8009): a bicyclic peptide toxin conjugate targeting nectin-4 for the treatment of bladder cancer

A. Cigliola; Valentina Tateo; Ravasi Michela et al. · 2025 · Expert Opinion on Investigational Drugs · DOI

Full title: Zelenectide pevedotin (BT-8009): a bicyclic peptide toxin conjugate targeting nectin-4 for the treatment of bladder cancer

Authors: A. Cigliola; Valentina Tateo; Ravasi Michela; Giorgia Di Maria; Serena Manzo; Brigida Anna Mercinelli; Chiara Maiorano; A. Necchi

Year: 2025

Venue: Expert Opinion on Investigational Drugs

DOI: https://doi.org/10.1080/13543784.2025.2510669

Paper An overview of the preclinical discovery and development of trastuzumab deruxtecan: a novel gastric cancer therapeutic

J. Kalmuk; Dan Rinder; C. Heltzel et al. · 2022 · Expert Opinion on Drug Discovery · DOI

Full title: An overview of the preclinical discovery and development of trastuzumab deruxtecan: a novel gastric cancer therapeutic

Authors: J. Kalmuk; Dan Rinder; C. Heltzel; A. Lockhart

Year: 2022

Venue: Expert Opinion on Drug Discovery

DOI: https://doi.org/10.1080/17460441.2022.2050692

Paper What are the challenges involved in the strategies for future antibody-drug conjugate discovery and development for oncology?

Begum, Sajeli Ahil; Kamal, Ahmed · 2023 · Expert opinion on drug discovery · DOI

Full title: What are the challenges involved in the strategies for future antibody-drug conjugate discovery and development for oncology?

Authors: Begum, Sajeli Ahil; Kamal, Ahmed

Year: 2023

Venue: Expert opinion on drug discovery

DOI: https://doi.org/10.1080/17460441.2023.2203910

Paper Cardiac toxicity of HER-2 targeting antibody-drug conjugates: overview and clinicalimplications.

Ziad Zalaquett; Maria Catherine Rita Hachem; Ahmad Assi et al. · 2024 · Future Oncology · DOI

Full title: Cardiac toxicity of HER-2 targeting antibody-drug conjugates: overview and clinicalimplications.

Authors: Ziad Zalaquett; Maria Catherine Rita Hachem; Ahmad Assi; Rami Mohanna; Mohamad Farhat; Charbel Noujaim; H. Kourie

Year: 2024

Venue: Future Oncology

DOI: https://doi.org/10.1080/14796694.2024.2407756

Paper An enzymatic deconjugation method for the analysis of small molecule active drugs on antibody-drug conjugates

Yi Li; Christine Gu; J. Gruenhagen et al. · 2016 · mAbs · DOI

Full title: An enzymatic deconjugation method for the analysis of small molecule active drugs on antibody-drug conjugates

Authors: Yi Li; Christine Gu; J. Gruenhagen; P. Yehl; Nik P. Chetwyn; Colin D. Medley

Year: 2016

Venue: mAbs

DOI: https://doi.org/10.1080/19420862.2016.1151590

Paper Future directions for antibody-drug conjugates in urothelial cancer.

Elisa D'Agostino; Marta Pirola; Vanessa Callegari et al. · 2025 · Expert Review of Anticancer Therapy · DOI

Full title: Future directions for antibody-drug conjugates in urothelial cancer.

Authors: Elisa D'Agostino; Marta Pirola; Vanessa Callegari; Elena Tonni; Cyrielle Tchawa; Rossana Matranga; O. Ponzoni; Marco Oltrecolli; C. Piombino; S. Pipitone; C. Baldessari; Francesca Bacchelli; Massimo Dominici; Roberto Sabbatini; Maria Giuseppa Vitale

Year: 2025

Venue: Expert Review of Anticancer Therapy

DOI: https://doi.org/10.1080/14737140.2025.2592735

Paper CD33-D2 isoform characterization for advancement of its therapeutic potential.

Vivek M Shastri; S. S. Madabushi; Susanta K. Hui et al. · 2025 · Immunotherapy · DOI

Full title: CD33-D2 isoform characterization for advancement of its therapeutic potential.

Authors: Vivek M Shastri; S. S. Madabushi; Susanta K. Hui; J. Lamba

Year: 2025

Venue: Immunotherapy

DOI: https://doi.org/10.1080/1750743x.2025.2493038

Paper Targeting CD123 in BPDCN: an emerging field

Adam J. DiPippo; N. Wilson; N. Pemmaraju · 2021 · Expert Review of Hematology · DOI

Full title: Targeting CD123 in BPDCN: an emerging field

Authors: Adam J. DiPippo; N. Wilson; N. Pemmaraju

Year: 2021

Venue: Expert Review of Hematology

DOI: https://doi.org/10.1080/17474086.2021.1988848

Paper The potential of antibody-drug conjugates for effective therapy in diffuse large B-cell lymphoma

Gulrayz Ahmed; M. Hamadani; Taha Al-Juhaishi · 2025 · Expert Opinion on Biological Therapy · DOI

Full title: The potential of antibody-drug conjugates for effective therapy in diffuse large B-cell lymphoma

Authors: Gulrayz Ahmed; M. Hamadani; Taha Al-Juhaishi

Year: 2025

Venue: Expert Opinion on Biological Therapy

DOI: https://doi.org/10.1080/14712598.2025.2453524

Paper Advances in click chemistry for drug discovery and development

Jiaojiao Dai; Xiaojia Xue; Xiangyi Jiang et al. · 2025 · Expert Opinion on Drug Discovery · DOI

Full title: Advances in click chemistry for drug discovery and development

Authors: Jiaojiao Dai; Xiaojia Xue; Xiangyi Jiang; Xinyong Liu; Peng Zhan

Year: 2025

Venue: Expert Opinion on Drug Discovery

DOI: https://doi.org/10.1080/17460441.2025.2552146

Paper Safety considerations with targeted therapy drugs for B-cell non-Hodgkin lymphoma

S. Makita; Rika Hosoba; K. Tobinai · 2020 · Expert Opinion on Drug Safety · DOI

Full title: Safety considerations with targeted therapy drugs for B-cell non-Hodgkin lymphoma

Authors: S. Makita; Rika Hosoba; K. Tobinai

Year: 2020

Venue: Expert Opinion on Drug Safety

DOI: https://doi.org/10.1080/14740338.2020.1802424

Paper Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates.

Donaghy, Heather · 2016 · mAbs · DOI

Full title: Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates.

Authors: Donaghy, Heather

Year: 2016

Venue: mAbs

DOI: https://doi.org/10.1080/19420862.2016.1156829

Paper Novel anti-Sialyl-Tn monoclonal antibodies and antibody-drug conjugates demonstrate tumor specificity and anti-tumor activity

Jillian Prendergast; Ana Paula Galvão da Silva; D. Eavarone et al. · 2017 · mAbs · DOI

Full title: Novel anti-Sialyl-Tn monoclonal antibodies and antibody-drug conjugates demonstrate tumor specificity and anti-tumor activity

Authors: Jillian Prendergast; Ana Paula Galvão da Silva; D. Eavarone; Darius Ghaderi; Mai Zhang; Dane Brady; J. Wicks; Julie DeSander; Jeff Behrens; B. Rueda

Year: 2017

Venue: mAbs

DOI: https://doi.org/10.1080/19420862.2017.1290752

Paper Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: A case study of anti-TROP-2 sacituzumab govitecan

D. Goldenberg; R. Sharkey · 2019 · mAbs · DOI

Full title: Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: A case study of anti-TROP-2 sacituzumab govitecan

Authors: D. Goldenberg; R. Sharkey

Year: 2019

Venue: mAbs

DOI: https://doi.org/10.1080/19420862.2019.1632115

Paper Investigating protein–excipient interactions of a multivalent VHH therapeutic protein using NMR spectroscopy

Jainik P. Panchal; Bradley T. Falk; Valentyn Antochshuk et al. · 2022 · mAbs · DOI

Full title: Investigating protein–excipient interactions of a multivalent VHH therapeutic protein using NMR spectroscopy

Authors: Jainik P. Panchal; Bradley T. Falk; Valentyn Antochshuk; M. Mccoy

Year: 2022

Venue: mAbs

DOI: https://doi.org/10.1080/19420862.2022.2124902

Paper Antibody-drug conjugates with HER2-targeting antibodies from synthetic antibody libraries are highly potent against HER2-positive human gastric tumor in xenograft models

W. Kuo; H. Hsu; Chun-Yi Wu et al. · 2018 · mAbs · DOI

Full title: Antibody-drug conjugates with HER2-targeting antibodies from synthetic antibody libraries are highly potent against HER2-positive human gastric tumor in xenograft models

Authors: W. Kuo; H. Hsu; Chun-Yi Wu; Hong-Sen Chen; Y. Chou; Yueh-Liang Tsou; Hung-Pin Peng; J. Jian; Chung-Ming Yu; Yi-Kai Chiu; I. Chen; Chao-Ping Tung; M. Hsiao; Chia-Lung Lin; Y. Wang; A. H. Wang; A. Yang

Year: 2018

Venue: mAbs

DOI: https://doi.org/10.1080/19420862.2018.1541370

Paper Improved translation of stability for conjugated antibodies using an in vitro whole blood assay

Aimee Fourie-O'Donohue; Phillip Y Chu; Josefa dela Cruz Chuh et al. · 2020 · mAbs · DOI

Full title: Improved translation of stability for conjugated antibodies using an in vitro whole blood assay

Authors: Aimee Fourie-O'Donohue; Phillip Y Chu; Josefa dela Cruz Chuh; Robert Tchelepi; S. Tsai; J. C. Tran; William S. Sawyer; Dian Su; Carl Ng; Keyang Xu; Shang‐Fan Yu; Thomas H. Pillow; J. Sadowsky; P. Dragovich; Yichin Liu; K. Kozak

Year: 2020

Venue: mAbs

DOI: https://doi.org/10.1080/19420862.2020.1715705

Paper Engineering humanized antibody framework sequences for optimal site-specific conjugation of cytotoxins.

Spidel, Jared L; Albone, Earl F; Cheng, Xin et al. · 2017 · mAbs · DOI

Full title: Engineering humanized antibody framework sequences for optimal site-specific conjugation of cytotoxins.

Authors: Spidel, Jared L; Albone, Earl F; Cheng, Xin; Vaessen, Benjamin; Jacob, Sara; Milinichik, Andrew Z; Verdi, Arielle; Kline, J Bradford; Grasso, Luigi

Year: 2017

Venue: mAbs

DOI: https://doi.org/10.1080/19420862.2017.1330734

Paper Preclinical pharmacokinetics and pharmacodynamics of DCLL9718A: An antibody-drug conjugate for the treatment of acute myeloid leukemia

D. Leipold; I. Figueroa; Shabkhaiz Masih et al. · 2018 · mAbs · DOI

Full title: Preclinical pharmacokinetics and pharmacodynamics of DCLL9718A: An antibody-drug conjugate for the treatment of acute myeloid leukemia

Authors: D. Leipold; I. Figueroa; Shabkhaiz Masih; Brandon Latifi; Victor Yip; Ben-Quan Shen; Randall Dere; M. Carrasco-Triguero; M. V. Lee; Ola M Saad; Luna Liu; Jintang He; Dian Su; Keyang Xu; Brian R. Vuillemenot; Steven T. Laing; M. Schutten; K. Kozak; B. Zheng; A. Polson; Amrita V. Kamath

Year: 2018

Venue: mAbs

DOI: https://doi.org/10.1080/19420862.2018.1517565

Paper Impact of linker-drug on ion exchange chromatography separation of antibody-drug conjugates

Zhaorui Zhang; Shiyue Zhou; Linjie Han et al. · 2019 · mAbs · DOI

Full title: Impact of linker-drug on ion exchange chromatography separation of antibody-drug conjugates

Authors: Zhaorui Zhang; Shiyue Zhou; Linjie Han; Qunying Zhang; Wayne A. Pritts

Year: 2019

Venue: mAbs

DOI: https://doi.org/10.1080/19420862.2019.1628589

Paper Discovery of a novel highly specific, fully human PSCA antibody and its application as an antibody-drug conjugate in prostate cancer

Xiaojie Chu; Seungmin Shin; Du-San Baek et al. · 2024 · mAbs · DOI

Full title: Discovery of a novel highly specific, fully human PSCA antibody and its application as an antibody-drug conjugate in prostate cancer

Authors: Xiaojie Chu; Seungmin Shin; Du-San Baek; Liyong Zhang; Alex Conard; Megan Shi; Ye-Jin Kim; Cynthia Adams; Margaret G. Hines; Xianglei Liu; Chuan Chen; Zehua Sun; D. Jelev; John W. Mellors; Dimiter S. Dimitrov; Wei Li

Year: 2024

Venue: mAbs

DOI: https://doi.org/10.1080/19420862.2024.2387240

Paper Effective antitumor therapy based on a novel antibody-drug conjugate targeting the Tn carbohydrate antigen

C. Sedlik; A. Heitzmann; S. Viel et al. · 2016 · Oncoimmunology · DOI

Full title: Effective antitumor therapy based on a novel antibody-drug conjugate targeting the Tn carbohydrate antigen

Authors: C. Sedlik; A. Heitzmann; S. Viel; R. Ait Sarkouh; Cornélie Batisse; Frédéric Schmidt; Philippe De La Rochere; Nathalie Amzallag; E. Osinaga; P. Oppezzo; O. Pritsch; X. Sastre-Garau; P. Hubert; S. Amigorena; E. Piaggio

Year: 2016

Venue: Oncoimmunology

DOI: https://doi.org/10.1080/2162402x.2016.1171434

Paper A glyco-engineering approach for site-specific conjugation to Fab glycans.

Jaramillo, Maria L; Sulea, Traian; Durocher, Yves et al. · 2023 · mAbs · DOI

Full title: A glyco-engineering approach for site-specific conjugation to Fab glycans.

Authors: Jaramillo, Maria L; Sulea, Traian; Durocher, Yves; Acchione, Mauro; Schur, Melissa J; Robotham, Anna; Kelly, John F; Goneau, Marie-France; Robert, Alma; Cepero-Donates, Yuneivy; Gilbert, Michel

Year: 2023

Venue: mAbs

DOI: https://doi.org/10.1080/19420862.2022.2149057

Paper Targeting cancer with antibody-drug conjugates: Promises and challenges.

Dean, Alexis Q; Luo, Shen; Twomey, Julianne D et al. · 2021 · mAbs · DOI

Full title: Targeting cancer with antibody-drug conjugates: Promises and challenges.

Authors: Dean, Alexis Q; Luo, Shen; Twomey, Julianne D; Zhang, Baolin

Year: 2021

Venue: mAbs

DOI: https://doi.org/10.1080/19420862.2021.1951427

Paper Full-length recombinant antibodies from Escherichia coli: production, characterization, effector function (Fc) engineering, and clinical evaluation

Md. Harunur Rashid · 2022 · mAbs · DOI

Full title: Full-length recombinant antibodies from Escherichia coli: production, characterization, effector function (Fc) engineering, and clinical evaluation

Authors: Md. Harunur Rashid

Year: 2022

Venue: mAbs

DOI: https://doi.org/10.1080/19420862.2022.2111748

Paper 3C conjugates: a highly sensitive platform for antibody internalization assessment in ADC development

Changyan Chen; Yutian Zhang; Yadan Wu et al. · 2025 · mAbs · DOI

Full title: 3C conjugates: a highly sensitive platform for antibody internalization assessment in ADC development

Authors: Changyan Chen; Yutian Zhang; Yadan Wu; Shuhui Luan; Xi Jiao; Jingli Liao; Shuai Wang; Yayuan Fu

Year: 2025

Venue: mAbs

DOI: https://doi.org/10.1080/19420862.2025.2577161

Paper Engineering hydrophobicity and manufacturability for optimized biparatopic antibody–drug conjugates targeting c-MET

Andreas Evers; Simon Krah; Deniz Demir et al. · 2024 · mAbs · DOI

Full title: Engineering hydrophobicity and manufacturability for optimized biparatopic antibody–drug conjugates targeting c-MET

Authors: Andreas Evers; Simon Krah; Deniz Demir; Ramona Gaa; Desislava Elter; Christian Schroeter; Stefan Zielonka; Nicolas Rasche; J. Dotterweich; Christine Knuehl; Achim Doerner

Year: 2024

Venue: mAbs

DOI: https://doi.org/10.1080/19420862.2024.2302386

Paper A bispecific antibody–drug conjugate targeting CD7 and CD33 shows anti-tumor activity and improved tumor selectivity in an aggressive subtype of acute myeloid leukemia

Hollie B. S. Griffiths; Nyle Jones; Mattia Vitale et al. · 2025 · mAbs · DOI

Full title: A bispecific antibody–drug conjugate targeting CD7 and CD33 shows anti-tumor activity and improved tumor selectivity in an aggressive subtype of acute myeloid leukemia

Authors: Hollie B. S. Griffiths; Nyle Jones; Mattia Vitale; Nikhil Faulkner; Edward W. Masters; Naomi L. A. Nabi-Aldridge; Meera Mistry; Chloe Patterson; Adrian Blanco-Gomez; Emmanuel Griessinger; Oliver Schon; Tiffany J. Daniels-Thorn

Year: 2025

Venue: mAbs

DOI: https://doi.org/10.1080/19420862.2025.2551205

Paper The physiological limits of bispecific monoclonal antibody tissue targeting specificity.

Sepp, Armin; Stader, Felix; Derbalah, Abdallah et al. · 2025 · mAbs · DOI

Full title: The physiological limits of bispecific monoclonal antibody tissue targeting specificity.

Authors: Sepp, Armin; Stader, Felix; Derbalah, Abdallah; Liu, Cong; Zyla, Adriana; Gardner, Iain; Jamei, Masoud

Year: 2025

Venue: mAbs

DOI: https://doi.org/10.1080/19420862.2025.2492236

Paper CD20 expression regulates CD37 levels in B-cell lymphoma – implications for immunotherapies

M. Bobrowicz; Aleksandra Kusowska; Marta Krawczyk et al. · 2023 · bioRxiv · DOI

Full title: CD20 expression regulates CD37 levels in B-cell lymphoma – implications for immunotherapies

Year: 2023

Venue: bioRxiv

DOI: https://doi.org/10.1101/2023.12.06.570441

Paper Perspectives on the development of antibody-drug conjugates targeting ROR1 for hematological and solid cancers

Haiyong Peng · 2021 · Antibody Therapeutics · DOI

Full title: Perspectives on the development of antibody-drug conjugates targeting ROR1 for hematological and solid cancers

Authors: Haiyong Peng

Year: 2021

Venue: Antibody Therapeutics

DOI: https://doi.org/10.1093/abt/tbab023

Paper Research hotspots and frontier analysis of the novel immune checkpoint Nectin-4

Yu Qiao; Wanyu Zhao; Yusen Gou et al. · 2025 · Human Vaccines & Immunotherapeutics · DOI

Full title: Research hotspots and frontier analysis of the novel immune checkpoint Nectin-4

Authors: Yu Qiao; Wanyu Zhao; Yusen Gou; Yuwei Li; Fang Su; Rui Wang; Jiejun Wang; Haibo Zhang; Lei Sun; Feng Qian; Zishu Wang

Year: 2025

Venue: Human Vaccines & Immunotherapeutics

DOI: https://doi.org/10.1080/21645515.2025.2504776

Paper Overview of antibody-drug conjugates nonclinical and clinical toxicities and related contributing factors.

Yumei Cheng; Jing Lu; Chonghao Zhang et al. · 2025 · Antibody Therapeutics · DOI

Full title: Overview of antibody-drug conjugates nonclinical and clinical toxicities and related contributing factors.

Authors: Yumei Cheng; Jing Lu; Chonghao Zhang; Weiyuan Yan; Panpan Zhu; Qiuping Qin; Likun Gong

Year: 2025

Venue: Antibody Therapeutics

DOI: https://doi.org/10.1093/abt/tbaf004

Paper Novel development strategies and challenges for anti-Her2 antibody-drug conjugates

Xinling Zhang; Andrew C Huang; Fahai Chen et al. · 2022 · Antibody Therapeutics · DOI

Full title: Novel development strategies and challenges for anti-Her2 antibody-drug conjugates

Authors: Xinling Zhang; Andrew C Huang; Fahai Chen; Hu Chen; Lele Li; Nana Kong; W. Luo; Jian-min Fang

Year: 2022

Venue: Antibody Therapeutics

DOI: https://doi.org/10.1093/abt/tbac001

Paper Preclinical development of mecbotamab vedotin (BA3011), a novel, AXL-specific conditional active biologic antibody–drug conjugate

H. Chang; Jing Wang; Haizhen Liu et al. · 2025 · Antibody Therapeutics · DOI

Full title: Preclinical development of mecbotamab vedotin (BA3011), a novel, AXL-specific conditional active biologic antibody–drug conjugate

Authors: H. Chang; Jing Wang; Haizhen Liu; Charles Xing; Jian Chen; G. Frey; William J Boyle; Jay M Short

Year: 2025

Venue: Antibody Therapeutics

DOI: https://doi.org/10.1093/abt/tbaf006

Paper Antibody-Drug Conjugates in breast cancer.

Yinxing Zhu; Yaqi Song; Xilei Zhou et al. · 2025 · Carcinogenesis · DOI

Full title: Antibody-Drug Conjugates in breast cancer.

Authors: Yinxing Zhu; Yaqi Song; Xilei Zhou; Wenwen Zhang; Honglei Luo

Year: 2025

Venue: Carcinogenesis

DOI: https://doi.org/10.1093/carcin/bgae082

Paper Strategies to mitigate the on- and off-target toxicities of recombinant immunotoxins: an antibody engineering perspective.

Li, Mengyu; Mei, Sen; Yang, Yi et al. · 2022 · Antibody therapeutics · DOI

Full title: Strategies to mitigate the on- and off-target toxicities of recombinant immunotoxins: an antibody engineering perspective.

Authors: Li, Mengyu; Mei, Sen; Yang, Yi; Shen, Yuelei; Chen, Lei

Year: 2022

Venue: Antibody therapeutics

DOI: https://doi.org/10.1093/abt/tbac014

Paper Design, optimization, production and activity testing of recombinant immunotoxins expressed in plants and plant cells for the treatment of monocytic leukemia

M. Knödler; Katharina Frank; Lucy Kerpen et al. · 2023 · Bioengineered · DOI

Full title: Design, optimization, production and activity testing of recombinant immunotoxins expressed in plants and plant cells for the treatment of monocytic leukemia

Authors: M. Knödler; Katharina Frank; Lucy Kerpen; J. Buyel

Year: 2023

Venue: Bioengineered

DOI: https://doi.org/10.1080/21655979.2023.2244235

Paper New and emerging pharmacotherapies for management of multiple myeloma.

D. Moore; Carolyn J Oxencis; Brandon R. Shank · 2022 · American Journal of Health-System Pharmacy · DOI

Full title: New and emerging pharmacotherapies for management of multiple myeloma.

Authors: D. Moore; Carolyn J Oxencis; Brandon R. Shank

Year: 2022

Venue: American Journal of Health-System Pharmacy

DOI: https://doi.org/10.1093/ajhp/zxac091

Paper Tumour stroma targeting and modulation by OMTX705 ADC, a novel and potent immunotherapeutic treatment of solid tumours

M. Fabre; C. Ferrer; S. Domínguez-Hormaetxe et al. · 2019 · Annals of Oncology · DOI

Full title: Tumour stroma targeting and modulation by OMTX705 ADC, a novel and potent immunotherapeutic treatment of solid tumours

Authors: M. Fabre; C. Ferrer; S. Domínguez-Hormaetxe; R. Kontermann; K. Pfizenmaier; O. Seifer; M. Vivanco; S. Lee; P. López-Casas; M. Abbas; W. Richter; L. Simon; M. Hidalgo

Year: 2019

Venue: Annals of Oncology

DOI: https://doi.org/10.1093/annonc/mdz253.026

Paper Novel fluorogenic indicators of antibody and biologic trafficking and lysosomal catabolism 2670

Ryan W. Holly; Chris Langsdorf · 2025 · Journal of Immunology · DOI

Full title: Novel fluorogenic indicators of antibody and biologic trafficking and lysosomal catabolism 2670

Authors: Ryan W. Holly; Chris Langsdorf

Year: 2025

Venue: Journal of Immunology

DOI: https://doi.org/10.1093/jimmun/vkaf283.561

Paper Simple and Rapid LC-MS/MS Methods for Quantifying Catabolites of Antibody-Drug Conjugates with SMCC Linker.

Li Li; Chanrui Wang; Yijue Wu et al. · 2021 · Journal of Chromatographic Science · DOI

Full title: Simple and Rapid LC-MS/MS Methods for Quantifying Catabolites of Antibody-Drug Conjugates with SMCC Linker.

Authors: Li Li; Chanrui Wang; Yijue Wu; Lihou Dong; Fang Chen; K. Dong; Haifeng Song

Year: 2021

Venue: Journal of Chromatographic Science

DOI: https://doi.org/10.1093/chromsci/bmaa122

Paper Radioimmunotherapy combined with antibody-drug conjugate-induced radiosensitization leads to long-term remission in mycosis fungoides.

M. Oymanns; K. Elsayad; M. Daum-Marzian et al. · 2025 · British Journal of Dermatology · DOI

Full title: Radioimmunotherapy combined with antibody-drug conjugate-induced radiosensitization leads to long-term remission in mycosis fungoides.

Authors: M. Oymanns; K. Elsayad; M. Daum-Marzian; R. Abu-Dawud; M. Motiei; David R Steinke; Kathrin A. Brücksken; H.T. Eich; Burkhard Greve; Chalid Assaf

Year: 2025

Venue: British Journal of Dermatology

DOI: https://doi.org/10.1093/bjd/ljaf521

Paper Targeting Universal CAR T cells via antibody-drug conjugates adaptors 4830

E. Ruffo; Avani Parikh; G. Falcone et al. · 2025 · Journal of Immunology · DOI

Full title: Targeting Universal CAR T cells via antibody-drug conjugates adaptors 4830

Authors: E. Ruffo; Avani Parikh; G. Falcone; Yan Ma; A. Deiters; Jason Jakob Lomueller

Year: 2025

Venue: Journal of Immunology

DOI: https://doi.org/10.1093/jimmun/vkaf283.2447

Paper Antibody-Drug Conjugate-Based Therapeutics: State of the Science.

M. Birrer; K. Moore; I. Betella et al. · 2019 · Journal of the National Cancer Institute · DOI

Full title: Antibody-Drug Conjugate-Based Therapeutics: State of the Science.

Authors: M. Birrer; K. Moore; I. Betella; R. Bates

Year: 2019

Venue: Journal of the National Cancer Institute

DOI: https://doi.org/10.1093/jnci/djz035

Paper Preclinical in vitro and in vivo evidence for CD74-targeting as effective treatment strategy for cutaneous T cell lymphomas.

Mariantonia Costanza; Catello Giordano; Ann-Christin von Brünneck et al. · 2025 · British Journal of Dermatology · DOI

Full title: Preclinical in vitro and in vivo evidence for CD74-targeting as effective treatment strategy for cutaneous T cell lymphomas.

Authors: Mariantonia Costanza; Catello Giordano; Ann-Christin von Brünneck; Jing Zhao; Ahmad Makky; Katharina Vinh; I. Montes-Mojarro; Florian Reisinger; Stephan Forchhammer; A. Witalisz-Siepracka; S. Edtmayer; D. Stoiber; Gang Yin; David Horst; Anja Fischer; Reiner Siebert; Jan P. Nicolay; Menghong Yin; Martin Janz; F. Fend; Jürgen C. Becker; C. M. Schürch; L. Kenner; Chalid Assaf; Olaf Merkel; S. Mathas

Year: 2025

Venue: British Journal of Dermatology

DOI: https://doi.org/10.1093/bjd/ljaf001

Paper A disruptive clickable antibody design for the generation of antibody-drug conjugates.

Nathanaël Rakotoarinoro; Yan F K Dyck; Simon K Krebs et al. · 2023 · Antibody Therapeutics · DOI

Full title: A disruptive clickable antibody design for the generation of antibody-drug conjugates.

Authors: Nathanaël Rakotoarinoro; Yan F K Dyck; Simon K Krebs; Miriam-Kousso Assi; M. K. Parr; Marlitt Stech

Year: 2023

Venue: Antibody Therapeutics

DOI: https://doi.org/10.1093/abt/tbad023

Paper Antibody drugs conjugates in non–small cell lung cancer: current status and challenges

Arjun Syal; May-Lucie Meyer; Kenneth Angelino et al. · 2025 · The Oncologist · DOI

Full title: Antibody drugs conjugates in non–small cell lung cancer: current status and challenges

Authors: Arjun Syal; May-Lucie Meyer; Kenneth Angelino; Noah Osei; Jorge E. Gomez; T. Sen; F. Hirsch

Year: 2025

Venue: The Oncologist

DOI: https://doi.org/10.1093/oncolo/oyaf331

Paper - **DOI:** 10.1093/neuonc/noz175.177 - **Authors:** C. Achenbach, V. Blot, W. Weiss, M. Weller - **Year:** 2019 - **Journal:** Neuro-Oncology

C. Achenbach; V. Blot; W. Weiss et al. · 2019 · Neuro-Oncology · DOI

Full title: - **DOI:** 10.1093/neuonc/noz175.177 - **Authors:** C. Achenbach, V. Blot, W. Weiss, M. Weller - **Year:** 2019 - **Journal:** Neuro-Oncology

Authors: C. Achenbach; V. Blot; W. Weiss; M. Weller

Year: 2019

Venue: Neuro-Oncology

DOI: https://doi.org/10.1093/neuonc/noz175.177

Paper P06.02.B DECODING THE DIVERSE SURFACEOME LANDSCAPE IN MALIGNANT BRAIN TUMORS IDENTIFIES TARGET CANDIDATES FOR PERSONALIZED IMMUNOTHERAPY

A. Boukredine; K. Gonçalves de Oliveira; H. Talbot et al. · 2024 · Neuro-Oncology · DOI

Full title: P06.02.B DECODING THE DIVERSE SURFACEOME LANDSCAPE IN MALIGNANT BRAIN TUMORS IDENTIFIES TARGET CANDIDATES FOR PERSONALIZED IMMUNOTHERAPY

Authors: A. Boukredine; K. Gonçalves de Oliveira; H. Talbot; V. Governa; A. Bång-Rudenstam; K. Forsberg-Nilsson; J. Bengzon; J. Malmström; C. Welinder; M. Belting

Year: 2024

Venue: Neuro-Oncology

DOI: https://doi.org/10.1093/neuonc/noae144.139

Paper P-1165. Development of Novel CD4+ Cell Targeting Antibody-Drug Conjugates for HIV Treatment

Chin-Ming Chang; Jason mao; Gina C L Wen · 2026 · Open Forum Infectious Diseases · DOI

Full title: P-1165. Development of Novel CD4+ Cell Targeting Antibody-Drug Conjugates for HIV Treatment

Authors: Chin-Ming Chang; Jason mao; Gina C L Wen

Year: 2026

Venue: Open Forum Infectious Diseases

DOI: https://doi.org/10.1093/ofid/ofaf695.1358

Paper ADCNet: a unified framework for predicting the activity of antibody-drug conjugates

Liye Chen; Biaoshun Li; Yihao Chen et al. · 2024 · Briefings Bioinform. · DOI

Full title: ADCNet: a unified framework for predicting the activity of antibody-drug conjugates

Authors: Liye Chen; Biaoshun Li; Yihao Chen; Mujie Lin; Shipeng Zhang; Chenxin Li; Yu Pang; Ling Wang

Year: 2024

Venue: Briefings Bioinform.

DOI: https://doi.org/10.1093/bib/bbaf228

Paper The Icarian flight of antibody-drug conjugates: target selection amidst complexity and tackling adverse impacts

Han Liu; Hongye Zeng; Xiaojing Qin et al. · 2025 · Protein & Cell · DOI

Full title: The Icarian flight of antibody-drug conjugates: target selection amidst complexity and tackling adverse impacts

Authors: Han Liu; Hongye Zeng; Xiaojing Qin; Wenjing Ning; Lin Xu; Shiting Yang; Xue Liu; Wenxin Luo; N. Xia

Year: 2025

Venue: Protein & Cell

DOI: https://doi.org/10.1093/procel/pwaf002

Paper Tumor-selective, antigen-independent delivery of a pH sensitive peptide-topoisomerase inhibitor conjugate suppresses tumor growth without systemic toxicity.

Gayle, Sophia; Aiello, Robert; Leelatian, Nalin et al. · 2021 · NAR cancer · DOI

Full title: Tumor-selective, antigen-independent delivery of a pH sensitive peptide-topoisomerase inhibitor conjugate suppresses tumor growth without systemic toxicity.

Authors: Gayle, Sophia; Aiello, Robert; Leelatian, Nalin; Beckta, Jason M; Bechtold, Jane; Bourassa, Patricia; Csengery, Johanna; Maguire, Robert J; Marshall, Dan; Sundaram, Ranjini K; Van Doorn, Jinny; Jones, Kelli; Moore, Hunter; Lopresti-Morrow, Lori; Paradis, Timothy; Tylaska, Laurie; Zhang, Qing; Visca, Hannah; Reshetnyak, Yana K; Andreev, Oleg A; Engelman, Donald M; Glazer, Peter M; Bindra, Ranjit S; Paralkar, Vishwas M

Year: 2021

Venue: NAR cancer

DOI: https://doi.org/10.1093/narcan/zcab021

Paper Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment.

McDonagh, Charlotte F; Turcott, Eileen; Westendorf, Lori et al. · 2006 · Protein engineering, design & selection : PEDS · DOI

Full title: Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment.

Authors: McDonagh, Charlotte F; Turcott, Eileen; Westendorf, Lori; Webster, Jennifer B; Alley, Stephen C; Kim, Kristine; Andreyka, Jamie; Stone, Ivan; Hamblett, Kevin J; Francisco, Joseph A; Carter, Paul

Year: 2006

Venue: Protein engineering, design & selection : PEDS

DOI: https://doi.org/10.1093/protein/gzl013

Paper Antibody-drug conjugates in breast cancer: the chemotherapy of the future?

E. Nicolò; P. Zagami; G. Curigliano · 2020 · Current Opinion in Oncology · DOI

Full title: Antibody-drug conjugates in breast cancer: the chemotherapy of the future?

Authors: E. Nicolò; P. Zagami; G. Curigliano

Year: 2020

Venue: Current Opinion in Oncology

DOI: https://doi.org/10.1097/cco.0000000000000656

Paper Innovative design concepts in tumor-targeting peptide-drug conjugates: Insights into emerging applications

Ruirong Tan; Zhenya Yang; Jun Xie et al. · 2025 · Chinese Medical Journal · DOI

Full title: Innovative design concepts in tumor-targeting peptide-drug conjugates: Insights into emerging applications

Authors: Ruirong Tan; Zhenya Yang; Jun Xie; Zijun Wu; Shanshan Guo; Li Li; Zhujun Yin; Hua Hua; Miao Liu; Rui Li

Year: 2025

Venue: Chinese Medical Journal

DOI: https://doi.org/10.1097/cm9.0000000000003438

Paper The target invites a foe: antibody-drug conjugates in gynecologic oncology.

Campos, Maira P; Konecny, Gottfried E · 2018 · Current opinion in obstetrics & gynecology · DOI

Full title: The target invites a foe: antibody-drug conjugates in gynecologic oncology.

Authors: Campos, Maira P; Konecny, Gottfried E

Year: 2018

Venue: Current opinion in obstetrics & gynecology

DOI: https://doi.org/10.1097/GCO.0000000000000432

Paper The Role of Radiolabeled Monoclonal Antibodies in Cancer Imaging and ADC Treatment.

Lucia Martiniova; Rafal Zieliński; Mai Lin et al. · 2022 · Cancer Journal · DOI

Full title: The Role of Radiolabeled Monoclonal Antibodies in Cancer Imaging and ADC Treatment.

Authors: Lucia Martiniova; Rafal Zieliński; Mai Lin; L. Depalatis; G. Ravizzini

Year: 2022

Venue: Cancer Journal

DOI: https://doi.org/10.1097/ppo.0000000000000625

Paper Antibody-drug conjugates in lung cancer: current landscape and future perspectives.

Xinru Chen; Caicun Zhou · 2025 · Current Opinion in Oncology · DOI

Full title: Antibody-drug conjugates in lung cancer: current landscape and future perspectives.

Authors: Xinru Chen; Caicun Zhou

Year: 2025

Venue: Current Opinion in Oncology

DOI: https://doi.org/10.1097/cco.0000000000001200

Paper Highlights of 2024. Broadening anti‐cancer immunotherapy modalities with antibody–drug conjugates: emerging insights from clinical studies

Jiya Jose; John D. Hooper; Fernando Souza-Fonseca-Guimarães · 2025 · Immunology and Cell Biology · DOI

Full title: Highlights of 2024. Broadening anti‐cancer immunotherapy modalities with antibody–drug conjugates: emerging insights from clinical studies

Authors: Jiya Jose; John D. Hooper; Fernando Souza-Fonseca-Guimarães

Year: 2025

Venue: Immunology and Cell Biology

DOI: https://doi.org/10.1111/imcb.70017

Paper The initial management of multiple myeloma in the era of novel agents: 2021 and beyond

Omar Nadeem; P. Richardson · 2021 · British Journal of Haematology · DOI

Full title: The initial management of multiple myeloma in the era of novel agents: 2021 and beyond

Authors: Omar Nadeem; P. Richardson

Year: 2021

Venue: British Journal of Haematology

DOI: https://doi.org/10.1111/bjh.17407

Paper Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma

L. Lee; D. Bounds; J. Paterson et al. · 2016 · British Journal of Haematology · DOI

Full title: Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma

Authors: L. Lee; D. Bounds; J. Paterson; Gaelle Herledan; K. Sully; L. Seestaller-Wehr; W. Fieles; J. Tunstead; Lee Mccahon; F. Germaschewski; P. Mayes; J. Craigen; M. Rodríguez-Justo; K. Yong

Year: 2016

Venue: British Journal of Haematology

DOI: https://doi.org/10.1111/bjh.14145

Paper Targeting the Membrane-Proximal C2-Set Domain of CD33 for Improved CD33-Directed Immunotherapy

C. Godwin; G. S. Laszlo; S. Fiorenza et al. · 2021 · Leukemia · DOI

Full title: Targeting the Membrane-Proximal C2-Set Domain of CD33 for Improved CD33-Directed Immunotherapy

Authors: C. Godwin; G. S. Laszlo; S. Fiorenza; Eliotte E. Garling; T. Phi; Olivia M. Bates; C. Correnti; B. Hoffstrom; Margaret C. Lunn; Olivier Humbert; H. Kiem; C. Turtle; R. Walter

Year: 2021

Venue: Leukemia

DOI: https://doi.org/10.1038/s41375-021-01160-1

Paper HER3 upregulation reduces DS-8201 sensitivity in HER2-positive tumor cells by ATR/CHK1/FoxO1 signaling cascade

Wen-Jing Li; Kai-Ge Kang; Yu-xiang Zhang et al. · 2025 · Acta Pharmacologica Sinica · DOI

Full title: HER3 upregulation reduces DS-8201 sensitivity in HER2-positive tumor cells by ATR/CHK1/FoxO1 signaling cascade

Authors: Wen-Jing Li; Kai-Ge Kang; Yu-xiang Zhang; Xin-Xin Zhao; Xi Zhu; Jiao Tang; Yongpeng Li; Hao-Yu Fu; Qing Yao; Lei Wang; Li-guang Lou

Year: 2025

Venue: Acta Pharmacologica Sinica

DOI: https://doi.org/10.1038/s41401-025-01647-y

Paper Cancer therapy with antibodies.

Paul, Suman; Konig, Maximilian F; Pardoll, Drew M et al. · 2024 · Nature reviews. Cancer · DOI

Full title: Cancer therapy with antibodies.

Authors: Paul, Suman; Konig, Maximilian F; Pardoll, Drew M; Bettegowda, Chetan; Papadopoulos, Nickolas; Wright, Katharine M; Gabelli, Sandra B; Ho, Mitchell; van Elsas, Andrea; Zhou, Shibin

Year: 2024

Venue: Nature reviews. Cancer

DOI: https://doi.org/10.1038/s41568-024-00690-x

Paper Tissue penetration to optimize PSMA ADCs

Annette Fenner · 2020 · Nature reviews. Urology · DOI

Full title: Tissue penetration to optimize PSMA ADCs

Authors: Annette Fenner

Year: 2020

Venue: Nature reviews. Urology

DOI: https://doi.org/10.1038/s41585-020-0291-2

Paper Unlocking the potential of antibody-drug conjugates for cancer therapy.

Drago, Joshua Z; Modi, Shanu; Chandarlapaty, Sarat · 2021 · Nature reviews. Clinical oncology · DOI

Full title: Unlocking the potential of antibody-drug conjugates for cancer therapy.

Authors: Drago, Joshua Z; Modi, Shanu; Chandarlapaty, Sarat

Year: 2021

Venue: Nature reviews. Clinical oncology

DOI: https://doi.org/10.1038/s41571-021-00470-8

Paper The clinical development of antibody–drug conjugates — lessons from leukaemia

E. Jabbour; Shilpa Paul; H. Kantarjian · 2021 · Nature Reviews Clinical Oncology · DOI

Full title: The clinical development of antibody–drug conjugates — lessons from leukaemia

Authors: E. Jabbour; Shilpa Paul; H. Kantarjian

Year: 2021

Venue: Nature Reviews Clinical Oncology

DOI: https://doi.org/10.1038/s41571-021-00484-2

Paper CHAPTER 5. Maytansinoid Payloads for Antibody–Drug Conjugates (ADCs)

Wayne C. Widdison · 2019 · Cytotoxic Payloads for Antibody–Drug Conjugates · DOI

Full title: CHAPTER 5. Maytansinoid Payloads for Antibody–Drug Conjugates (ADCs)

Authors: Wayne C. Widdison

Year: 2019

Venue: Cytotoxic Payloads for Antibody–Drug Conjugates

DOI: https://doi.org/10.1039/9781788012898-00100

Paper CHAPTER 20. Protein Toxins as Antibody–Drug Conjugate (ADC) Payloads

K. Gehlsen · 2019 · Cytotoxic Payloads for Antibody–Drug Conjugates · DOI

Full title: CHAPTER 20. Protein Toxins as Antibody–Drug Conjugate (ADC) Payloads

Authors: K. Gehlsen

Year: 2019

Venue: Cytotoxic Payloads for Antibody–Drug Conjugates

DOI: https://doi.org/10.1039/9781788012898-00427

Paper CHAPTER 2. Design Factors Important for Antibody–Drug Conjugate (ADC) Payloads

J. Lambert · 2019 · Cytotoxic Payloads for Antibody–Drug Conjugates · DOI

Full title: CHAPTER 2. Design Factors Important for Antibody–Drug Conjugate (ADC) Payloads

Authors: J. Lambert

Year: 2019

Venue: Cytotoxic Payloads for Antibody–Drug Conjugates

DOI: https://doi.org/10.1039/9781788012898-00031

Paper A preliminary study for the development of cleavable linkers using activatable fluorescent probes targeting leucine aminopeptidase.

Julie Kang; Seul-Ki Mun; Eu-Jin Choi et al. · 2022 · In Analysis · DOI

Full title: A preliminary study for the development of cleavable linkers using activatable fluorescent probes targeting leucine aminopeptidase.

Authors: Julie Kang; Seul-Ki Mun; Eu-Jin Choi; Jong-Jin Kim; S. Yee; Dong-Jo Chang

Year: 2022

Venue: In Analysis

DOI: https://doi.org/10.1039/d2an01145j

Paper New linker structures applied in glycosite-specific antibody drug conjugates

Faridoon Faridoon; Weiwei Shi; Ken Qin et al. · 2019 · Organic Chemistry Frontiers · DOI

Full title: New linker structures applied in glycosite-specific antibody drug conjugates

Authors: Faridoon Faridoon; Weiwei Shi; Ken Qin; Yubo Tang; Mingjie Li; Dongliang Guan; Xiaobo Tian; Bofeng Jiang; Jinhua Dong; Feng Tang; Wei Huang

Year: 2019

Venue: Organic Chemistry Frontiers

DOI: https://doi.org/10.1039/c9qo00646j

Paper Linker substitution influences succinimide ring hydrolysis equilibrium impacting the stability of attachment to antibody-drug conjugates.

Lu Wang; A. Hobson; Paulin L Salomon et al. · 2024 · RSC Medicinal Chemistry · DOI

Full title: Linker substitution influences succinimide ring hydrolysis equilibrium impacting the stability of attachment to antibody-drug conjugates.

Authors: Lu Wang; A. Hobson; Paulin L Salomon; J. Fitzgibbons; Jianwen Xu; Sean McCarthy; Kan Wu; Ying Jia; Axel Hernandez; Xiang Li; Zhou Xu; Zhong-Xu Wang; Yajie Yu; Junxian Li; Lin Tao

Year: 2024

Venue: RSC Medicinal Chemistry

DOI: https://doi.org/10.1039/d3md00569k

Paper CHAPTER 18. Tubulysins as Antibody–Drug Conjugate (ADC) Payloads

J. Parker · 2019 · Cytotoxic Payloads for Antibody–Drug Conjugates · DOI

Full title: CHAPTER 18. Tubulysins as Antibody–Drug Conjugate (ADC) Payloads

Authors: J. Parker

Year: 2019

Venue: Cytotoxic Payloads for Antibody–Drug Conjugates

DOI: https://doi.org/10.1039/9781788012898-00380

Paper An MMAE-loaded PDL1 active targeting nanomedicine for the precision treatment of colon cancer.

Zhenqian Zhang; Honglei Zhang; Linjie Cui et al. · 2023 · Biomaterials Science · DOI

Full title: An MMAE-loaded PDL1 active targeting nanomedicine for the precision treatment of colon cancer.

Authors: Zhenqian Zhang; Honglei Zhang; Linjie Cui; Xiaoshuang Wang; Di Wang; Zhi-Lin Liu; Xuefei Zhang; Zhaohui Tang

Year: 2023

Venue: Biomaterials Science

DOI: https://doi.org/10.1039/d3bm00664f

Paper Targeted delivery of alcohol-containing payloads with antibody-drug conjugates.

Katja E Grier; A. Hansen; Christina Haxvig et al. · 2023 · Chemical Communications · DOI

Full title: Targeted delivery of alcohol-containing payloads with antibody-drug conjugates.

Authors: Katja E Grier; A. Hansen; Christina Haxvig; Xin Li; Oliver Krigslund; Niels Behrendt; L. Engelholm; Fabio Rossi; B. Sousa; Grant Harradence; N. Camper; Katrine M Qvortrup

Year: 2023

Venue: Chemical Communications

DOI: https://doi.org/10.1039/d3cc01596c

Paper Harnessing acylhydrazone-oxime exchange reaction to achieve diverse synthesis of glycosite-specific antibody-drug conjugates.

Fei Xia; Zhi Liu; Jiaying Hang et al. · 2025 · Organic and biomolecular chemistry · DOI

Full title: Harnessing acylhydrazone-oxime exchange reaction to achieve diverse synthesis of glycosite-specific antibody-drug conjugates.

Authors: Fei Xia; Zhi Liu; Jiaying Hang; Hao Xu; Yuting Xiao; Shuyue Niu; Ji Qin; Songyue Lou; Bo Liu; Feng Tang; Wei Huang; Yang Yang; Weiwei Shi

Year: 2025

Venue: Organic and biomolecular chemistry

DOI: https://doi.org/10.1039/d4ob01826e

Paper Chemical evolution of antibody-drug conjugates focused on linker design and conjugation strategies in hematology.

Park, Seungbin; Gone, Geetanjali B; Ahn, Dohee et al. · 2025 · Seminars in hematology · DOI

Full title: Chemical evolution of antibody-drug conjugates focused on linker design and conjugation strategies in hematology.

Authors: Park, Seungbin; Gone, Geetanjali B; Ahn, Dohee; Chung, Sang J

Year: 2025

Venue: Seminars in hematology

DOI: https://doi.org/10.1053/j.seminhematol.2025.11.004

Paper The medicinal chemistry evolution of antibody-drug conjugates.

A. Hobson · 2024 · RSC Medicinal Chemistry · DOI

Full title: The medicinal chemistry evolution of antibody-drug conjugates.

Authors: A. Hobson

Year: 2024

Venue: RSC Medicinal Chemistry

DOI: https://doi.org/10.1039/d3md00674c

Paper Antibody-drug conjugates as novel anti-cancer chemotherapeutics.

Peters, Christina; Brown, Stuart · 2015 · Bioscience reports · DOI

Full title: Antibody-drug conjugates as novel anti-cancer chemotherapeutics.

Authors: Peters, Christina; Brown, Stuart

Year: 2015

Venue: Bioscience reports

DOI: https://doi.org/10.1042/BSR20150089

Paper Discovery of a microbial transglutaminase enabling highly site-specific labeling of proteins

W. Steffen; F. Ko; Jigar Patel et al. · 2017 · Journal of Biological Chemistry · DOI

Full title: Discovery of a microbial transglutaminase enabling highly site-specific labeling of proteins

Authors: W. Steffen; F. Ko; Jigar Patel; V. Lyamichev; T. Albert; J. Benz; M. Rudolph; F. Bergmann; Thomas Streidl; Peter Kratzsch; Mara Boenitz-Dulat; Tobias Oelschlaegel; Michael Schraeml

Year: 2017

Venue: Journal of Biological Chemistry

DOI: https://doi.org/10.1074/jbc.m117.797811

Paper Emerging conjugation strategies and protein engineering technologies aim to improve ADCs in the fight against cancer

Eric J Moore; Megan Rice; Gourgopal Roy et al. · 2024 · Xenobiotica; the fate of foreign compounds in biological systems · DOI

Full title: Emerging conjugation strategies and protein engineering technologies aim to improve ADCs in the fight against cancer

Authors: Eric J Moore; Megan Rice; Gourgopal Roy; Wenting Zhang; M. Marelli

Year: 2024

Venue: Xenobiotica; the fate of foreign compounds in biological systems

DOI: https://doi.org/10.1080/00498254.2024.2339993

Paper BCMA biology and therapeutic targeting in multiple myeloma: From ligand signaling to antigen escape.

Ebru Sezer; Seungyoun Lee; Junho Chung · 2025 · Seminars in hematology (Print) · DOI

Full title: BCMA biology and therapeutic targeting in multiple myeloma: From ligand signaling to antigen escape.

Authors: Ebru Sezer; Seungyoun Lee; Junho Chung

Year: 2025

Venue: Seminars in hematology (Print)

DOI: https://doi.org/10.1053/j.seminhematol.2025.12.004

Paper ADME and DMPK considerations for the discovery and development of antibody drug conjugates (ADCs)

Kevin Beaumont; A. Pike; Michael Davies et al. · 2022 · Xenobiotica; the fate of foreign compounds in biological systems · DOI

Full title: ADME and DMPK considerations for the discovery and development of antibody drug conjugates (ADCs)

Authors: Kevin Beaumont; A. Pike; Michael Davies; Adriana Savoca; Christina Vasalou; Steffi Harlfinger; D. Ramsden; Douglas Ferguson; Niresh Hariparsad; Owen Jones; D. Mcginnity

Year: 2022

Venue: Xenobiotica; the fate of foreign compounds in biological systems

DOI: https://doi.org/10.1080/00498254.2022.2141667

Paper Preface for special issue: "Emerging strategies, technologies, and approaches for the next generation ADCs".

Walles, Markus; Xu, Keyang · 2024 · Xenobiotica; the fate of foreign compounds in biological systems · DOI

Full title: Preface for special issue: "Emerging strategies, technologies, and approaches for the next generation ADCs".

Authors: Walles, Markus; Xu, Keyang

Year: 2024

Venue: Xenobiotica; the fate of foreign compounds in biological systems

DOI: https://doi.org/10.1080/00498254.2024.2386407

Paper Exploring the surfaceome of Ewing sarcoma identifies a new and unique therapeutic target

J. Town; H. Pais; Sally M. Harrison et al. · 2016 · Proceedings of the National Academy of Sciences of the United States of America · DOI

Full title: Exploring the surfaceome of Ewing sarcoma identifies a new and unique therapeutic target

Authors: J. Town; H. Pais; Sally M. Harrison; Lucy F. Stead; C. Bataille; Wilawan Bunjobpol; Jing Zhang; T. Rabbitts

Year: 2016

Venue: Proceedings of the National Academy of Sciences of the United States of America

DOI: https://doi.org/10.1073/pnas.1521251113

Paper Approaches to improve the translation of safety, pharmacokinetics and therapeutic index of ADCs.

Huang, Qihong; Ravindra Pilvankar, Minu; Dixit, Rakesh et al. · 2024 · Xenobiotica; the fate of foreign compounds in biological systems · DOI

Full title: Approaches to improve the translation of safety, pharmacokinetics and therapeutic index of ADCs.

Authors: Huang, Qihong; Ravindra Pilvankar, Minu; Dixit, Rakesh; Yu, Hongbin

Year: 2024

Venue: Xenobiotica; the fate of foreign compounds in biological systems

DOI: https://doi.org/10.1080/00498254.2024.2352600

Paper Lysosomal Trafficking and Cysteine Protease Metabolism Confer Target-specific Cytotoxicity by Peptide-linked Anti-CD30-Auristatin Conjugates*

M. Sutherland; R. Sanderson; K. Gordon et al. · 2006 · Journal of Biological Chemistry · DOI

Full title: Lysosomal Trafficking and Cysteine Protease Metabolism Confer Target-specific Cytotoxicity by Peptide-linked Anti-CD30-Auristatin Conjugates*

Authors: M. Sutherland; R. Sanderson; K. Gordon; J. Andreyka; C. Cerveny; Changpu Yu; T. Lewis; Damon L. Meyer; R. Zabinski; S. Doronina; P. Senter; C. Law; A. Wahl

Year: 2006

Venue: Journal of Biological Chemistry

DOI: https://doi.org/10.1074/jbc.m510026200

Paper Nutritional Strategies in Oncology: A Narrative Review of Advances in Folate-Targeted Therapeutic Approaches for Cancer Treatment

Pouya Saraei; Morteza Ghasemi; Athar Talebi et al. · 2025 · Nutrition and Cancer · DOI

Full title: Nutritional Strategies in Oncology: A Narrative Review of Advances in Folate-Targeted Therapeutic Approaches for Cancer Treatment

Authors: Pouya Saraei; Morteza Ghasemi; Athar Talebi; Arefe Vafaeinezhad; Jamileh Saberzadeh

Year: 2025

Venue: Nutrition and Cancer

DOI: https://doi.org/10.1080/01635581.2025.2497096

Paper Translational PK/PD framework for antibody-drug conjugates to inform drug discovery and development.

Liao, Michael Z; Leipold, Douglas D; Chen, Shang-Chiung et al. · 2024 · Xenobiotica; the fate of foreign compounds in biological systems · DOI

Full title: Translational PK/PD framework for antibody-drug conjugates to inform drug discovery and development.

Authors: Liao, Michael Z; Leipold, Douglas D; Chen, Shang-Chiung; Li, Zao; Kamath, Amrita V; Li, Chunze

Year: 2024

Venue: Xenobiotica; the fate of foreign compounds in biological systems

DOI: https://doi.org/10.1080/00498254.2024.2351044

Paper High-content Analysis of Antibody Phage-display Library Selection Outputs Identifies Tumor Selective Macropinocytosis-dependent Rapidly Internalizing Antibodies*

Kevin D. Ha; S. Bidlingmaier; Yafeng Zhang et al. · 2014 · Molecular & Cellular Proteomics · DOI

Full title: High-content Analysis of Antibody Phage-display Library Selection Outputs Identifies Tumor Selective Macropinocytosis-dependent Rapidly Internalizing Antibodies*

Authors: Kevin D. Ha; S. Bidlingmaier; Yafeng Zhang; Yang Su; B. Liu

Year: 2014

Venue: Molecular & Cellular Proteomics

DOI: https://doi.org/10.1074/mcp.m114.039768

Paper BCMA-directed therapy, new treatments in the myeloma toolbox, and how to use them

M. Rees; Shaji K. Kumar · 2023 · Leukemia and Lymphoma · DOI

Full title: BCMA-directed therapy, new treatments in the myeloma toolbox, and how to use them

Authors: M. Rees; Shaji K. Kumar

Year: 2023

Venue: Leukemia and Lymphoma

DOI: https://doi.org/10.1080/10428194.2023.2284088

Paper Metabolism of bioconjugate therapeutics: why, when, and how?

Hanlan Liu; Jayaprakasam Bolleddula; A. Nichols et al. · 2020 · Drug metabolism reviews (Softcover ed.) · DOI

Full title: Metabolism of bioconjugate therapeutics: why, when, and how?

Authors: Hanlan Liu; Jayaprakasam Bolleddula; A. Nichols; Lei Tang; Zhiyang Zhao; C. Prakash

Year: 2020

Venue: Drug metabolism reviews (Softcover ed.)

DOI: https://doi.org/10.1080/03602532.2020.1716784

Paper Beyond cytotoxic potency: disposition features required to design ADC payload.

Sun, Hao; Wienkers, Larry C; Lee, Anthony · 2024 · Xenobiotica; the fate of foreign compounds in biological systems · DOI

Full title: Beyond cytotoxic potency: disposition features required to design ADC payload.

Authors: Sun, Hao; Wienkers, Larry C; Lee, Anthony

Year: 2024

Venue: Xenobiotica; the fate of foreign compounds in biological systems

DOI: https://doi.org/10.1080/00498254.2024.2381139

Paper Precision navigation through the labyrinth: overcoming EGFR resistance in non-Small cell lung cancer

Junhui Wang; Jian Wang; Jianxin Chen · 2025 · Annals medicus · DOI

Full title: Precision navigation through the labyrinth: overcoming EGFR resistance in non-Small cell lung cancer

Authors: Junhui Wang; Jian Wang; Jianxin Chen

Year: 2025

Venue: Annals medicus

DOI: https://doi.org/10.1080/07853890.2025.2574526

Paper Inotuzumab ozogamicin is deliverable in relapsed ALL patients with end-stage renal disease on hemodialysis

Idoroenyi Amanam; Dat Ngo; V. Pullarkat et al. · 2022 · Leukemia and Lymphoma · DOI

Full title: Inotuzumab ozogamicin is deliverable in relapsed ALL patients with end-stage renal disease on hemodialysis

Authors: Idoroenyi Amanam; Dat Ngo; V. Pullarkat; Ibrahim Aldoss

Year: 2022

Venue: Leukemia and Lymphoma

DOI: https://doi.org/10.1080/10428194.2022.2113529

Paper Antibody-drug conjugates in breast cancer: From therapeutic and immune activation mechanisms to resistance prevention

Nik Mohd Asri Nik Amirah Auni; Norhanani Mohd Redzwan; Maya Mazuwin Yahya et al. · 2025 · International Reviews of Immunology · DOI

Full title: Antibody-drug conjugates in breast cancer: From therapeutic and immune activation mechanisms to resistance prevention

Authors: Nik Mohd Asri Nik Amirah Auni; Norhanani Mohd Redzwan; Maya Mazuwin Yahya; K. Wong

Year: 2025

Venue: International Reviews of Immunology

DOI: https://doi.org/10.1080/08830185.2025.2545364

Paper Antibody-drug conjugates targeting DDR1 as a novel strategy for treatment of breast cancer

Yiran Tao; Ying Lu; Ting Xue et al. · 2024 · Journal of drug targeting (Print) · DOI

Full title: Antibody-drug conjugates targeting DDR1 as a novel strategy for treatment of breast cancer

Authors: Yiran Tao; Ying Lu; Ting Xue; Qinhuai Lai; Hengrui Song; Xiaofeng Chen; Cuiyu Guo; Jinliang Yang; Yuxi Wang

Year: 2024

Venue: Journal of drug targeting (Print)

DOI: https://doi.org/10.1080/1061186x.2024.2386621

Paper Polatuzumab vedotin: an investigational anti-CD79b antibody drug conjugate for the treatment of diffuse large B-cell lymphoma.

Bourbon, Estelle; Salles, Gilles · 2020 · Expert opinion on investigational drugs · DOI

Full title: Polatuzumab vedotin: an investigational anti-CD79b antibody drug conjugate for the treatment of diffuse large B-cell lymphoma.

Authors: Bourbon, Estelle; Salles, Gilles

Year: 2020

Venue: Expert opinion on investigational drugs

DOI: https://doi.org/10.1080/13543784.2020.1800638

Paper Emerging HER2-directed therapeutic agents for gastric cancer in early phase clinical trials

H. Lote; I. Chau · 2022 · Expert Opinion on Investigational Drugs · DOI

Full title: Emerging HER2-directed therapeutic agents for gastric cancer in early phase clinical trials

Authors: H. Lote; I. Chau

Year: 2022

Venue: Expert Opinion on Investigational Drugs

DOI: https://doi.org/10.1080/13543784.2022.2030311

Paper Phenotypic discovery and therapeutic evaluation of an ITGA3B1-targeting antibody-drug conjugate for bladder cancer

Junghyeon Lee; H. Jung; Eunhee G Kim et al. · 2026 · Science Advances · DOI

Full title: Phenotypic discovery and therapeutic evaluation of an ITGA3B1-targeting antibody-drug conjugate for bladder cancer

Authors: Junghyeon Lee; H. Jung; Eunhee G Kim; Jinsung Ahn; Michael C. Haffner; Peter S. Nelson; Kwang Pyo Kim; John K. Lee; Eugene C. Yi; Kristine M. Kim

Year: 2026

Venue: Science Advances

DOI: https://doi.org/10.1126/sciadv.ady0041

Paper Carfilzomib Is Not an Appropriate Payload of Antibody-Drug Conjugates Due to Rapid Inactivation by Lysosomal Enzymes

Yong Ma; Josefa dela Cruz-Chuh; S. C. Khojasteh et al. · 2019 · Drug Metabolism And Disposition · DOI

Full title: Carfilzomib Is Not an Appropriate Payload of Antibody-Drug Conjugates Due to Rapid Inactivation by Lysosomal Enzymes

Authors: Yong Ma; Josefa dela Cruz-Chuh; S. C. Khojasteh; P. Dragovich; Thomas H. Pillow; Donglu Zhang

Year: 2019

Venue: Drug Metabolism And Disposition

DOI: https://doi.org/10.1124/dmd.119.086595

Paper Evaluation of Quantitative Relationship Between Target Expression and Antibody-Drug Conjugate Exposure Inside Cancer Cells

Sharad K Sharma; Zhe Li; David Bussing et al. · 2020 · Drug Metabolism And Disposition · DOI

Full title: Evaluation of Quantitative Relationship Between Target Expression and Antibody-Drug Conjugate Exposure Inside Cancer Cells

Authors: Sharad K Sharma; Zhe Li; David Bussing; D. Shah

Year: 2020

Venue: Drug Metabolism And Disposition

DOI: https://doi.org/10.1124/dmd.119.089276

Paper Biotechnology at the Frontline of Cancer Treatment and Therapeutic Innovation

R. Salvi; Suresh Kumar Sharma; Babli Shama et al. · 2025 · 2025 IEEE 5th International Conference on ICT in Business Industry & Government (ICTBIG) · DOI

Full title: Biotechnology at the Frontline of Cancer Treatment and Therapeutic Innovation

Authors: R. Salvi; Suresh Kumar Sharma; Babli Shama; S. Kale; Aayushi Bansal

Year: 2025

Venue: 2025 IEEE 5th International Conference on ICT in Business Industry & Government (ICTBIG)

DOI: https://doi.org/10.1109/ictbig68706.2025.11323745

Paper Preclinical Characterization of Catabolic Pathways and Metabolism of ABBV-011, a Novel Calicheamicin-Based SEZ6-Targeting Antibody-Drug Conjugate

Daniel Ladror; Christine Gu; Vince Tong et al. · 2023 · Drug Metabolism And Disposition · DOI

Full title: Preclinical Characterization of Catabolic Pathways and Metabolism of ABBV-011, a Novel Calicheamicin-Based SEZ6-Targeting Antibody-Drug Conjugate

Authors: Daniel Ladror; Christine Gu; Vince Tong; Alexander Schammel; Julia Gavrilyuk; Anthony Haight; H. Sarvaiya

Year: 2023

Venue: Drug Metabolism And Disposition

DOI: https://doi.org/10.1124/dmd.123.001516

Paper An antibody-drug conjugate directed to the ALK receptor demonstrates efficacy in preclinical models of neuroblastoma

R. Sano; K. Krytska; C. Larmour et al. · 2019 · Science Translational Medicine · DOI

Full title: An antibody-drug conjugate directed to the ALK receptor demonstrates efficacy in preclinical models of neuroblastoma

Authors: R. Sano; K. Krytska; C. Larmour; Pichai Raman; D. Martinez; G. Ligon; J. Lillquist; U. Cucchi; P. Orsini; S. Rizzi; B. Pawel; Diego Alvarado; Y. Mossé

Year: 2019

Venue: Science Translational Medicine

DOI: https://doi.org/10.1126/scitranslmed.aau9732

Paper An array of 60,000 antibodies for proteome-scale antibody generation and target discovery

Zhaohui Wang; Yang Li; B. Hou et al. · 2019 · Science Advances · DOI

Full title: An array of 60,000 antibodies for proteome-scale antibody generation and target discovery

Authors: Zhaohui Wang; Yang Li; B. Hou; Mira I. Pronobis; Yuemeng Wang; Mingqiao Wang; G. Cheng; Zhe Zhang; Weining Weng; Yiqiang Wang; Yanfang Tang; Xuefan Xu; Rong Pan; Fei Lin; Nan Wang; Ziqing Chen; Shiwei Wang; Luyan Z. Ma; Yangrui Li; Dongliang Huang; Li Jiang; Zhiqiang Wang; Wenfang Zeng; Ying Zhang; Xuemei Du; Ying Lin; Zhiqing Li; Q. Xia; Jing Geng; H. Dai; Chen Wang; Yuan Yu; Xiaodong Zhao; Zheng Yuan; Jian Yan; B. Ren; Q. Nie; Xiquan Zhang; Kun Wang; Fulin Chen; Qin Zhang; Yuxian Zhu; K. Poss; S. Tao; Xun Meng

Year: 2019

Venue: Science Advances

DOI: https://doi.org/10.1126/sciadv.aax2271

Paper Detection and Characterization of In Vitro Payload-Containing Catabolites of Noncleavable Antibody-Drug Conjugates by High-Resolution Mass Spectrometry and Multiple Data Mining Tools

Tingting Cai; Liqi Shi; Huihui Guo et al. · 2023 · Drug Metabolism And Disposition · DOI

Full title: Detection and Characterization of In Vitro Payload-Containing Catabolites of Noncleavable Antibody-Drug Conjugates by High-Resolution Mass Spectrometry and Multiple Data Mining Tools

Authors: Tingting Cai; Liqi Shi; Huihui Guo; Ruixing Li; Weiqun Cao; Liang Shen; M. Zhu; Yi Tao

Year: 2023

Venue: Drug Metabolism And Disposition

DOI: https://doi.org/10.1124/dmd.122.001135

Paper Exposure-Efficacy Analysis of Antibody-Drug Conjugates Delivering an Excessive Level of Payload to Tissues

Donglu Zhang; P. Dragovich; Shang‐Fan Yu et al. · 2019 · Drug Metabolism And Disposition · DOI

Full title: Exposure-Efficacy Analysis of Antibody-Drug Conjugates Delivering an Excessive Level of Payload to Tissues

Authors: Donglu Zhang; P. Dragovich; Shang‐Fan Yu; Yong Ma; Thomas H. Pillow; J. Sadowsky; Dian Su; Wei Wang; A. Polson; S. C. Khojasteh; C. Hop

Year: 2019

Venue: Drug Metabolism And Disposition

DOI: https://doi.org/10.1124/dmd.119.087023

Paper 842 A novel agonistic anti-CD40 targeting strategy with an affinity peptide binding feature for antigen cargo functionality: improving peptide stability and T cell proliferation

I. Olsson; M. Eltahir; S. Mangsbo · 2020 · DOI

Full title: 842 A novel agonistic anti-CD40 targeting strategy with an affinity peptide binding feature for antigen cargo functionality: improving peptide stability and T cell proliferation

Authors: I. Olsson; M. Eltahir; S. Mangsbo

Year: 2020

DOI: https://doi.org/10.1136/jitc-2020-sitc2020.0842

Paper Tumor-specific activation of an EGFR-targeting probody enhances therapeutic index.

Desnoyers, Luc R; Vasiljeva, Olga; Richardson, Jennifer H et al. · 2013 · Science translational medicine · DOI

Full title: Tumor-specific activation of an EGFR-targeting probody enhances therapeutic index.

Authors: Desnoyers, Luc R; Vasiljeva, Olga; Richardson, Jennifer H; Yang, Annie; Menendez, Elizabeth E M; Liang, Tony W; Wong, Chihunt; Bessette, Paul H; Kamath, Kathy; Moore, Stephen J; Sagert, Jason G; Hostetter, Daniel R; Han, Fei; Gee, Jason; Flandez, Jeanne; Markham, Kate; Nguyen, Margaret; Krimm, Michael; Wong, Kenneth R; Liu, Shouchun; Daugherty, Patrick S; West, James W; Lowman, Henry B

Year: 2013

Venue: Science translational medicine

DOI: https://doi.org/10.1126/scitranslmed.3006682

Paper 1184 SYN101, a first in class, immune cell targeted TGF-beta inhibitor therapy, selectively blocks immune suppression and drives tumor clearance in vitro and in vivo

D. Thomas-Karyat; R. Lutz; Douglas B. Burtrum · 2022 · Regular and Young Investigator Award Abstracts · DOI

Full title: 1184 SYN101, a first in class, immune cell targeted TGF-beta inhibitor therapy, selectively blocks immune suppression and drives tumor clearance in vitro and in vivo

Authors: D. Thomas-Karyat; R. Lutz; Douglas B. Burtrum

Year: 2022

Venue: Regular and Young Investigator Award Abstracts

DOI: https://doi.org/10.1136/jitc-2022-sitc2022.1184

Paper 620 Tumor cell-intrinsic STING pathway is activated in the presence of cues from immune cells and contributes to the anti-tumor activity of tumor cell-targeted STING agonist antibody-drug conjugates

N. Cetinbas; Travis Monnell; Winnie Lee et al. · 2020 · Journal for ImmunoTherapy of Cancer · DOI

Full title: 620 Tumor cell-intrinsic STING pathway is activated in the presence of cues from immune cells and contributes to the anti-tumor activity of tumor cell-targeted STING agonist antibody-drug conjugates

Authors: N. Cetinbas; Travis Monnell; Winnie Lee; Kalli C. Catcott; C. Chin; P. Shaw; K. Slocum; Liuliang Qin; Kenneth Avocetien; Keith W Bentley; S. Clardy; Brian Jones; Eugene W Kelleher; Joshua D Thomas; R. Mosher; D. Toader; Jeremy R. Duvall; R. Bukhalid; M. Damelin; T. Lowinger

Year: 2020

Venue: Journal for ImmunoTherapy of Cancer

DOI: https://doi.org/10.1136/jitc-2020-sitc2020.0620

Paper Precision Medicine in Rheumatic Diseases: Unlocking the Potential of Antibody-Drug Conjugates

Zhiwen Huang; Z. Braunstein; Jun Chen et al. · 2024 · Pharmacological Reviews · DOI

Full title: Precision Medicine in Rheumatic Diseases: Unlocking the Potential of Antibody-Drug Conjugates

Authors: Zhiwen Huang; Z. Braunstein; Jun Chen; Yingying Wei; Xiaoquan Rao; Lingli Dong; Jixin Zhong

Year: 2024

Venue: Pharmacological Reviews

DOI: https://doi.org/10.1124/pharmrev.123.001084

Paper Optimization of Adcitmer, a Monomethyl-Auristatin E bearing antibody-drug conjugate for the treatment of CD56-expressing cancers

Aurélie Drouin; Laurine Durand; C. Esnault et al. · 2025 · Journal for ImmunoTherapy of Cancer · DOI

Full title: Optimization of Adcitmer, a Monomethyl-Auristatin E bearing antibody-drug conjugate for the treatment of CD56-expressing cancers

Authors: Aurélie Drouin; Laurine Durand; C. Esnault; P. Gaboriaud; Valérie Leblond; Shawk Karim; Morgane Fouché; Christine Dhommée; C. Baltus; Fanny Boursin; Nicolas Aubrey; R. Houben; D. Schrama; Serge Guyétant; A. Desgranges; M. Viaud-Massuard; Valérie Gouilleux-Gruart; M. Samimi; Thibault Kervarrec; Antoine Touzé

Year: 2025

Venue: Journal for ImmunoTherapy of Cancer

DOI: https://doi.org/10.1136/jitc-2024-010897

Paper 854 SGN-B7H4V, a novel, investigational vedotin antibody-drug conjugate directed to the T cell checkpoint ligand B7-H4, shows promising activity in preclinical models

E. Gray; A. Epp; Michelle Ulrich et al. · 2021 · Journal for ImmunoTherapy of Cancer · DOI

Full title: 854 SGN-B7H4V, a novel, investigational vedotin antibody-drug conjugate directed to the T cell checkpoint ligand B7-H4, shows promising activity in preclinical models

Authors: E. Gray; A. Epp; Michelle Ulrich; Disha Sahetya; Kelly Hensley; Julie Hahn; S. Allred; Jane Haass; Katie M Snead; Sasha Y. Lucas; J. Gosink; R. Boyce; E. Trueblood; P. Treuting; C. Frantz; Alyson J. Smith; Jason P. Schrum; N. Nazarenko; S. Gardai

Year: 2021

Venue: Journal for ImmunoTherapy of Cancer

DOI: https://doi.org/10.1136/jitc-2021-sitc2021.854

Paper The clinical landscape of antibody-drug conjugates in endometrial cancer

G. Fucà; Ilaria Sabatucci; Mariachiara Paderno et al. · 2024 · International Journal of Gynecological Cancer · DOI

Full title: The clinical landscape of antibody-drug conjugates in endometrial cancer

Authors: G. Fucà; Ilaria Sabatucci; Mariachiara Paderno; Domenica Lorusso

Year: 2024

Venue: International Journal of Gynecological Cancer

DOI: https://doi.org/10.1136/ijgc-2024-005607

Paper Antibody-maytansinoid conjugates designed to bypass multidrug resistance.

Kovtun, Yelena V; Audette, Charlene A; Mayo, Michele F et al. · 2010 · Cancer research · DOI

Full title: Antibody-maytansinoid conjugates designed to bypass multidrug resistance.

Authors: Kovtun, Yelena V; Audette, Charlene A; Mayo, Michele F; Jones, Gregory E; Doherty, Heather; Maloney, Erin K; Erickson, Hans K; Sun, Xiuxia; Wilhelm, Sharon; Ab, Olga; Lai, Katharine C; Widdison, Wayne C; Kellogg, Brenda; Johnson, Holly; Pinkas, Jan; Lutz, Robert J; Singh, Rajeeva; Goldmacher, Victor S; Chari, Ravi V J

Year: 2010

Venue: Cancer research

DOI: https://doi.org/10.1158/0008-5472.CAN-09-3546

Paper Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates.

C. Law; K. Gordon; B. Toki et al. · 2006 · Cancer Research · DOI

Full title: Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates.

Authors: C. Law; K. Gordon; B. Toki; A. Yamane; Michelle A Hering; C. Cerveny; J. Petroziello; M. Ryan; Leia M. Smith; R. Simon; G. Sauter; E. Oflazoglu; S. Doronina; Damon L. Meyer; J. A. Francisco; P. Carter; P. Senter; J. Copland; C. Wood; A. Wahl

Year: 2006

Venue: Cancer Research

DOI: https://doi.org/10.1158/0008-5472.can-05-2883

Paper 1188 Antibody substrate oligonucleotide conjugates (ASOCs): a new class of immunotherapeutic agents to inhibit metastasis of tumor cells and block checkpoint inhibition

B. Packard; A. Komoriya · 2022 · Regular and Young Investigator Award Abstracts · DOI

Full title: 1188 Antibody substrate oligonucleotide conjugates (ASOCs): a new class of immunotherapeutic agents to inhibit metastasis of tumor cells and block checkpoint inhibition

Authors: B. Packard; A. Komoriya

Year: 2022

Venue: Regular and Young Investigator Award Abstracts

DOI: https://doi.org/10.1136/jitc-2022-sitc2022.1188

Paper 618 Vedotin ADCs induce ER stress and elicit hallmarks of ICD across multiple cancer indications

K. Klussman; Elena-Marie Tenn; Shaylin Higgins et al. · 2020 · DOI

Full title: 618 Vedotin ADCs induce ER stress and elicit hallmarks of ICD across multiple cancer indications

Authors: K. Klussman; Elena-Marie Tenn; Shaylin Higgins; Rebecca Mazahreh; Katie M Snead; Joseph Z. Hamilton; Bryan M. Grogan; J. Sigurjonsson; Anthony T. Cao; S. Gardai; Bernard A. Liu

Year: 2020

DOI: https://doi.org/10.1136/jitc-2020-sitc2020.0618

Paper Armed antibodies targeting the mucin repeats of the ovarian cancer antigen, MUC16, are highly efficacious in animal tumor models.

Youjun Chen; Suzanna Clark; T. Wong et al. · 2007 · Cancer Research · DOI

Full title: Armed antibodies targeting the mucin repeats of the ovarian cancer antigen, MUC16, are highly efficacious in animal tumor models.

Authors: Youjun Chen; Suzanna Clark; T. Wong; Yongmei Chen; Yvonne Chen; M. Dennis; Elizabeth Luis; Fiona Zhong; S. Bheddah; H. Koeppen; Alvin Gogineni; S. Ross; P. Polakis; W. Mallet

Year: 2007

Venue: Cancer Research

DOI: https://doi.org/10.1158/0008-5472.can-06-4512

Paper Predictive Platforms of Bond Cleavage and Drug Release Kinetics for Macromolecule-Drug Conjugates.

Ghosal, Souvik; Walker, Javon E; Alabi, Christopher A · 2021 · Annual review of chemical and biomolecular engineering · DOI

Full title: Predictive Platforms of Bond Cleavage and Drug Release Kinetics for Macromolecule-Drug Conjugates.

Authors: Ghosal, Souvik; Walker, Javon E; Alabi, Christopher A

Year: 2021

Venue: Annual review of chemical and biomolecular engineering

DOI: https://doi.org/10.1146/annurev-chembioeng-091720-030636

Paper SLC46A3 Is Required to Transport Catabolites of Noncleavable Antibody Maytansine Conjugates from the Lysosome to the Cytoplasm.

Kevin J. Hamblett; A. Jacob; Jesse L. Gurgel et al. · 2015 · Cancer Research · DOI

Full title: SLC46A3 Is Required to Transport Catabolites of Noncleavable Antibody Maytansine Conjugates from the Lysosome to the Cytoplasm.

Authors: Kevin J. Hamblett; A. Jacob; Jesse L. Gurgel; Mark E. Tometsko; Brooke M. Rock; Sonal Patel; R. Milburn; S. Siu; S. Ragan; D. Rock; Christopher J. Borths; J. O'neill; Wesley S. Chang; M. Weidner; M. Bio; K. Quon; W. Fanslow

Year: 2015

Venue: Cancer Research

DOI: https://doi.org/10.1158/0008-5472.can-15-1610

Paper Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection.

A. Polson; Jill Calemine-Fenaux; Pamela Chan et al. · 2009 · Cancer Research · DOI

Full title: Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection.

Authors: A. Polson; Jill Calemine-Fenaux; Pamela Chan; Wesley S. Chang; E. Christensen; Suzanna Clark; F. D. de Sauvage; D. Eaton; Kristi Elkins; J. M. Elliott; G. Frantz; R. Fuji; A. Gray; Kristin Harden; G. Ingle; Noelyn M. Kljavin; H. Koeppen; C. Nelson; S. Prabhu; H. Raab; S. Ross; Dionysos Slaga; J. Stephan; S. Scales; S. Spencer; R. Vandlen; Bernd J. Wranik; Shang‐Fan Yu; B. Zheng; A. Ebens

Year: 2009

Venue: Cancer Research

DOI: https://doi.org/10.1158/0008-5472.can-08-2250

Paper Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma

Yuncheng Bei; Jian He; Xuhui Dong et al. · 2023 · Cancer Research · DOI

Full title: Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma

Authors: Yuncheng Bei; Jian He; Xuhui Dong; Yuxin Wang; Sijie Wang; Wan Guo; Chengjie Cai; Zhiye Xu; Jia Wei; Baorui Liu; N. Zhang; Pingping Shen

Year: 2023

Venue: Cancer Research

DOI: https://doi.org/10.1158/0008-5472.can-23-0510

Paper A Novel Platinum(II)-Based Bifunctional ADC Linker Benchmarked Using 89Zr-Desferal and Auristatin F-Conjugated Trastuzumab.

N. Sijbrandi; E. Merkul; J. Muns et al. · 2017 · Cancer Research · DOI

Full title: A Novel Platinum(II)-Based Bifunctional ADC Linker Benchmarked Using 89Zr-Desferal and Auristatin F-Conjugated Trastuzumab.

Authors: N. Sijbrandi; E. Merkul; J. Muns; Dennis C. J. Waalboer; K. Adamzek; M. Bolijn; V. Montserrat; G. Somsen; R. Haselberg; P. Steverink; H. Houthoff; G. V. van Dongen

Year: 2017

Venue: Cancer Research

DOI: https://doi.org/10.1158/0008-5472.can-16-1900

Paper Antibody-Mediated Endocytosis of Polysialic Acid Enables Intracellular Delivery and Cytotoxicity of a Glycan-Directed Antibody-Drug Conjugate.

E. C. Cox; Dana N. Thornlow; Michael A. Jones et al. · 2019 · Cancer Research · DOI

Full title: Antibody-Mediated Endocytosis of Polysialic Acid Enables Intracellular Delivery and Cytotoxicity of a Glycan-Directed Antibody-Drug Conjugate.

Authors: E. C. Cox; Dana N. Thornlow; Michael A. Jones; J. L. Fuller; Judith H. Merritt; M. Paszek; C. Alabi; M. DeLisa

Year: 2019

Venue: Cancer Research

DOI: https://doi.org/10.1158/0008-5472.can-18-3119

Paper Curative properties of noninternalizing antibody-drug conjugates based on maytansinoids.

Elena Perrino; M. Steiner; N. Krall et al. · 2014 · Cancer Research · DOI

Full title: Curative properties of noninternalizing antibody-drug conjugates based on maytansinoids.

Authors: Elena Perrino; M. Steiner; N. Krall; G. Bernardes; Francesca Pretto; Giulio Casi; D. Neri

Year: 2014

Venue: Cancer Research

DOI: https://doi.org/10.1158/0008-5472.can-13-2990

Paper Osteosarcoma: Lessons Learned and Future Avenues

A. Puri; N. Jaffe; H. Gelderblom · 2013 · Sarcoma · DOI

Full title: Osteosarcoma: Lessons Learned and Future Avenues

Authors: A. Puri; N. Jaffe; H. Gelderblom

Year: 2013

Venue: Sarcoma

DOI: https://doi.org/10.1155/2013/641687

Paper Where does ISAC (immune-stimulating antibody conjugates) go from here?

Chen Fu · 2025 · Journal for ImmunoTherapy of Cancer · DOI

Full title: Where does ISAC (immune-stimulating antibody conjugates) go from here?

Authors: Chen Fu

Year: 2025

Venue: Journal for ImmunoTherapy of Cancer

DOI: https://doi.org/10.1136/jitc-2025-012500

Paper Antibody-Drug Conjugates: Future Directions in Clinical and Translational Strategies to Improve the Therapeutic Index.

Coats, Steven; Williams, Marna; Kebble, Benjamin et al. · 2019 · Clinical cancer research : an official journal of the American Association for Cancer Research · DOI

Full title: Antibody-Drug Conjugates: Future Directions in Clinical and Translational Strategies to Improve the Therapeutic Index.

Authors: Coats, Steven; Williams, Marna; Kebble, Benjamin; Dixit, Rakesh; Tseng, Leo; Yao, Nai-Shun; Tice, David A; Soria, Jean-Charles

Year: 2019

Venue: Clinical cancer research : an official journal of the American Association for Cancer Research

DOI: https://doi.org/10.1158/1078-0432.CCR-19-0272

Paper Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate.

Hamblett, Kevin J; Senter, Peter D; Chace, Dana F et al. · 2004 · Clinical cancer research : an official journal of the American Association for Cancer Research · DOI

Full title: Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate.

Authors: Hamblett, Kevin J; Senter, Peter D; Chace, Dana F; Sun, Michael M C; Lenox, Joel; Cerveny, Charles G; Kissler, Kim M; Bernhardt, Starr X; Kopcha, Anastasia K; Zabinski, Roger F; Meyer, Damon L; Francisco, Joseph A

Year: 2004

Venue: Clinical cancer research : an official journal of the American Association for Cancer Research

DOI: https://doi.org/10.1158/1078-0432.CCR-04-0789

Paper AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma

F. Doñate; A. Raitano; K. Morrison et al. · 2015 · Clinical Cancer Research · DOI

Full title: AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma

Authors: F. Doñate; A. Raitano; K. Morrison; Z. An; L. Capo; Héctor Aviña; S. Karki; K. Morrison; P. Yang; J. Ou; Ryuichi Moriya; Y. Shostak; Faisal Malik; R. Nadell; Wendy Liu; Daulet Satpayev; J. Atkinson; I. Joseph; D. Pereira; P. Challita-Eid; D. Stover

Year: 2015

Venue: Clinical Cancer Research

DOI: https://doi.org/10.1158/1078-0432.ccr-15-1542

Paper The Dawn of the Antibody-Drug Conjugates Era: How T-DM1 Reinvented the Future of Chemotherapy for Solid Tumors.

P. Tarantino; S. Tolaney · 2022 · Cancer Research · DOI

Full title: The Dawn of the Antibody-Drug Conjugates Era: How T-DM1 Reinvented the Future of Chemotherapy for Solid Tumors.

Authors: P. Tarantino; S. Tolaney

Year: 2022

Venue: Cancer Research

DOI: https://doi.org/10.1158/0008-5472.can-22-2324

Paper Increased Tumor Penetration of Single-Domain Antibody Drug Conjugates Improves In Vivo Efficacy in Prostate Cancer Models.

I. Nessler; Eshita Khera; S. Vance et al. · 2020 · Cancer Research · DOI

Full title: Increased Tumor Penetration of Single-Domain Antibody Drug Conjugates Improves In Vivo Efficacy in Prostate Cancer Models.

Authors: I. Nessler; Eshita Khera; S. Vance; Anna Kopp; Qifeng Qiu; T. Keating; A. Abu-Yousif; T. Sandal; J. Legg; Lorraine H Thompson; Normann Goodwin; Greg M. Thurber

Year: 2020

Venue: Cancer Research

DOI: https://doi.org/10.1158/0008-5472.can-19-2295

Paper Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer.

Junutula, Jagath R; Flagella, Kelly M; Graham, Richard A et al. · 2010 · Clinical cancer research : an official journal of the American Association for Cancer Research · DOI

Full title: Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer.

Authors: Junutula, Jagath R; Flagella, Kelly M; Graham, Richard A; Parsons, Kathryn L; Ha, Edward; Raab, Helga; Bhakta, Sunil; Nguyen, Trung; Dugger, Debra L; Li, Guangmin; Mai, Elaine; Lewis Phillips, Gail D; Hiraragi, Hajime; Fuji, Reina N; Tibbitts, Jay; Vandlen, Richard; Spencer, Susan D; Scheller, Richard H; Polakis, Paul; Sliwkowski, Mark X

Year: 2010

Venue: Clinical cancer research : an official journal of the American Association for Cancer Research

DOI: https://doi.org/10.1158/1078-0432.CCR-10-0987

Paper Fractionated Dosing Improves Preclinical Therapeutic Index of Pyrrolobenzodiazepine-Containing Antibody Drug Conjugates.

Hinrichs, Mary Jane Masson; Ryan, Pauline M; Zheng, Bo et al. · 2017 · Clinical cancer research : an official journal of the American Association for Cancer Research · DOI

Full title: Fractionated Dosing Improves Preclinical Therapeutic Index of Pyrrolobenzodiazepine-Containing Antibody Drug Conjugates.

Authors: Hinrichs, Mary Jane Masson; Ryan, Pauline M; Zheng, Bo; Afif-Rider, Shameen; Yu, Xiang Qing; Gunsior, Michele; Zhong, Haihong; Harper, Jay; Bezabeh, Binyam; Vashisht, Kapil; Rebelatto, Marlon; Reed, Molly; Ryan, Patricia C; Breen, Shannon; Patel, Neki; Chen, Cui; Masterson, Luke; Tiberghien, Arnaud; Howard, Phillip W; Dimasi, Nazzareno; Dixit, Rakesh

Year: 2017

Venue: Clinical cancer research : an official journal of the American Association for Cancer Research

DOI: https://doi.org/10.1158/1078-0432.CCR-17-0219

Paper A Cell Surface-Binding Antibody Atlas Nominates a MUC18-Directed Antibody-Drug Conjugate for Targeting Melanoma.

Shi, Jing; Jiao, Tao; Guo, Qian et al. · 2023 · Cancer research · DOI

Full title: A Cell Surface-Binding Antibody Atlas Nominates a MUC18-Directed Antibody-Drug Conjugate for Targeting Melanoma.

Authors: Shi, Jing; Jiao, Tao; Guo, Qian; Weng, Weining; Ma, Linjie; Zhang, Qing; Wang, Lijun; Zhang, Jianjian; Chen, Caiwei; Huang, Yaling; Wang, Mingqiao; Pan, Rong; Tang, Yanfang; Hu, Wenhao; Meng, Tao; Liu, Shu-Hui; Guo, Jun; Kong, Yan; Meng, Xun

Year: 2023

Venue: Cancer research

DOI: https://doi.org/10.1158/0008-5472.CAN-23-1356

Paper Potent Anticarcinoma Activity of the Humanized Anti-CD70 Antibody h1F6 Conjugated to the Tubulin Inhibitor Auristatin via an Uncleavable Linker

E. Oflazoglu; I. Stone; K. Gordon et al. · 2008 · Clinical Cancer Research · DOI

Full title: Potent Anticarcinoma Activity of the Humanized Anti-CD70 Antibody h1F6 Conjugated to the Tubulin Inhibitor Auristatin via an Uncleavable Linker

Authors: E. Oflazoglu; I. Stone; K. Gordon; C. Wood; E. Repasky; I. Grewal; C. Law; H. Gerber

Year: 2008

Venue: Clinical Cancer Research

DOI: https://doi.org/10.1158/1078-0432.ccr-08-0916

Paper A Phase I Study of DLYE5953A, an Anti-LY6E Antibody Covalently Linked to Monomethyl Auristatin E, in Patients with Refractory Solid Tumors

S. Tolaney; K. Do; J. Eder et al. · 2020 · Clinical Cancer Research · DOI

Full title: A Phase I Study of DLYE5953A, an Anti-LY6E Antibody Covalently Linked to Monomethyl Auristatin E, in Patients with Refractory Solid Tumors

Authors: S. Tolaney; K. Do; J. Eder; P. LoRusso; C. Weekes; S. Chandarlapaty; Ching-Wei Chang; Shang-Chiung Chen; Denise Nazzal; E. Schuth; F. Brunstein; M. Carrasco-Triguero; W. Darbonne; J. Giltnane; W. Flanagan; S. Commerford; A. Ungewickell; G. Shapiro; S. Modi

Year: 2020

Venue: Clinical Cancer Research

DOI: https://doi.org/10.1158/1078-0432.ccr-20-1067

Paper An Antibody–Drug Conjugate Directed against Lymphocyte Antigen 6 Complex, Locus E (LY6E) Provides Robust Tumor Killing in a Wide Range of Solid Tumor Malignancies

Jyoti Asundi; Lisa M. Crocker; Jarrod R. Tremayne et al. · 2015 · Clinical Cancer Research · DOI

Full title: An Antibody–Drug Conjugate Directed against Lymphocyte Antigen 6 Complex, Locus E (LY6E) Provides Robust Tumor Killing in a Wide Range of Solid Tumor Malignancies

Authors: Jyoti Asundi; Lisa M. Crocker; Jarrod R. Tremayne; P. Chang; C. Sakanaka; Josh Tanguay; S. Spencer; Sreedevi Chalasani; Elizabeth Luis; Karen E Gascoigne; Rupal H Desai; R. Raja; Brad A. Friedman; Peter M. Haverty; P. Polakis; R. Firestein

Year: 2015

Venue: Clinical Cancer Research

DOI: https://doi.org/10.1158/1078-0432.ccr-15-0156

Paper Bystander Effects, Pharmacokinetics, and Linker-Payload Stability of EGFR-Targeting Antibody-Drug Conjugates Losatuxizumab Vedotin and Depatux-M in Glioblastoma Models

Sonia Jain; Jessica I Griffith; K. Porath et al. · 2024 · Clinical Cancer Research · DOI

Full title: Bystander Effects, Pharmacokinetics, and Linker-Payload Stability of EGFR-Targeting Antibody-Drug Conjugates Losatuxizumab Vedotin and Depatux-M in Glioblastoma Models

Authors: Sonia Jain; Jessica I Griffith; K. Porath; Sneha Rathi; Jiayan Le; Tugce Pasa; Paul A. Decker; Shiv K. Gupta; Zeng Hu; B. Carlson; K. Bakken; Danielle M. Burgenske; Thomas M Feldsien; D. Lefebvre; R. Vaubel; Jeanette E. Eckel-Passow; Edward B Reilly; W. Elmquist; J. Sarkaria

Year: 2024

Venue: Clinical Cancer Research

DOI: https://doi.org/10.1158/1078-0432.ccr-24-0426

Paper Development of Highly Optimized Antibody-Drug Conjugates against CD33 and CD123 for Acute Myeloid Leukemia.

Han, Yoon-Chi; Kahler, Jennifer; Piché-Nicholas, Nicole et al. · 2021 · Clinical cancer research : an official journal of the American Association for Cancer Research · DOI

Full title: Development of Highly Optimized Antibody-Drug Conjugates against CD33 and CD123 for Acute Myeloid Leukemia.

Authors: Han, Yoon-Chi; Kahler, Jennifer; Piché-Nicholas, Nicole; Hu, Wenyue; Thibault, Stephane; Jiang, Fan; Leal, Mauricio; Katragadda, Madan; Maderna, Andreas; Dushin, Russell; Prashad, Nadira; Charati, Manoj B; Clark, Tracey; Tumey, L Nathan; Tan, Xingzhi; Giannakou, Andreas; Rosfjord, Edward; Gerber, Hans-Peter; Tchistiakova, Lioudmila; Loganzo, Frank; O'Donnell, Christopher J; Sapra, Puja

Year: 2021

Venue: Clinical cancer research : an official journal of the American Association for Cancer Research

DOI: https://doi.org/10.1158/1078-0432.CCR-20-2149

Paper Anti-CD79B Antibody-Drug Conjugate DCDS0780A in Patients with B-Cell Non-Hodgkin Lymphoma: Phase 1 Dose-Escalation Study.

Herrera, Alex F; Patel, Manish R; Burke, John M et al. · 2022 · Clinical cancer research : an official journal of the American Association for Cancer Research · DOI

Full title: Anti-CD79B Antibody-Drug Conjugate DCDS0780A in Patients with B-Cell Non-Hodgkin Lymphoma: Phase 1 Dose-Escalation Study.

Authors: Herrera, Alex F; Patel, Manish R; Burke, John M; Advani, Ranjana; Cheson, Bruce D; Sharman, Jeff P; Penuel, Elicia; Polson, Andrew G; Liao, Chen Di; Li, Chunze; Schuth, Eva; Vaze, Anjali; Samineni, Divya; Elstrom, Rebecca; Cooper, James; Diefenbach, Catherine

Year: 2022

Venue: Clinical cancer research : an official journal of the American Association for Cancer Research

DOI: https://doi.org/10.1158/1078-0432.CCR-21-3261

Paper Design and Preclinical Evaluation of a Novel B7-H4-Directed Antibody-Drug Conjugate, AZD8205, Alone and in Combination with the PARP1-Selective Inhibitor AZD5305.

Krista Kinneer; P. Wortmann; Z. Cooper et al. · 2022 · Clinical Cancer Research · DOI

Full title: Design and Preclinical Evaluation of a Novel B7-H4-Directed Antibody-Drug Conjugate, AZD8205, Alone and in Combination with the PARP1-Selective Inhibitor AZD5305.

Authors: Krista Kinneer; P. Wortmann; Z. Cooper; Niall J Dickinson; Luke A Masterson; Thais Cailleau; I. Hutchinson; B. Vijayakrishnan; Mary McFarlane; Kathryn Ball; M. Davies; A. Lewis; Yue Huang; A. Rosenbaum; Jiaqi Yuan; Jon Chesebrough; J. Anderton; N. Monks; S. Novick; Jixin Wang; N. Dimasi; R. Christie; Darrin Sabol; F. Tosto; Y. Wallez; Elisabetta Leo; M. Albertella; A. Staniszewska; D. Tice; P. Howard; N. Luheshi; P. Sapra

Year: 2022

Venue: Clinical Cancer Research

DOI: https://doi.org/10.1158/1078-0432.ccr-22-2630

Paper Targeting a Radiosensitizing Antibody–Drug Conjugate to a Radiation-Inducible Antigen

Calvin D. Lewis; A. Singh; F. Hsu et al. · 2021 · Clinical Cancer Research · DOI

Full title: Targeting a Radiosensitizing Antibody–Drug Conjugate to a Radiation-Inducible Antigen

Authors: Calvin D. Lewis; A. Singh; F. Hsu; D. Thotala; D. Hallahan; V. Kapoor

Year: 2021

Venue: Clinical Cancer Research

DOI: https://doi.org/10.1158/1078-0432.ccr-20-1725

Paper A Novel HER3-Targeting Antibody–Drug Conjugate, U3-1402, Exhibits Potent Therapeutic Efficacy through the Delivery of Cytotoxic Payload by Efficient Internalization

Y. Hashimoto; K. Koyama; Y. Kamai et al. · 2019 · Clinical Cancer Research · DOI

Full title: A Novel HER3-Targeting Antibody–Drug Conjugate, U3-1402, Exhibits Potent Therapeutic Efficacy through the Delivery of Cytotoxic Payload by Efficient Internalization

Authors: Y. Hashimoto; K. Koyama; Y. Kamai; Kenji Hirotani; Y. Ogitani; Akiko Zembutsu; Manabu Abe; Y. Kaneda; N. Maeda; Y. Shiose; Takuma Iguchi; Tomomichi Ishizaka; Tsuyoshi Karibe; I. Hayakawa; K. Morita; T. Nakada; T. Nomura; K. Wakita; T. Kagari; Yuki Abe; M. Murakami; Suguru Ueno; T. Agatsuma

Year: 2019

Venue: Clinical Cancer Research

DOI: https://doi.org/10.1158/1078-0432.ccr-19-1745

Paper Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors

M. McDermott; Neil A. O’Brien; Benjamin Hoffstrom et al. · 2023 · Clinical Cancer Research · DOI

Full title: Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors

Authors: M. McDermott; Neil A. O’Brien; Benjamin Hoffstrom; Ke Gong; Ming Lu; Jun Zhang; Tong Luo; M. Liang; W. Jia; Jenny Hong; Kevin Chau; Simon Davenport; Bin Xie; M. Press; R. Panayiotou; Abram Handly-Santana; J. Brugge; L. Presta; J. Glaspy; D. Slamon

Year: 2023

Venue: Clinical Cancer Research

DOI: https://doi.org/10.1158/1078-0432.ccr-22-2981

Paper Antibody-Drug Conjugates: Advancing from magic bullet to biological missile.

A. Veneziani; Suku Sneha; Amit M Oza · 2024 · Clinical Cancer Research · DOI

Full title: Antibody-Drug Conjugates: Advancing from magic bullet to biological missile.

Authors: A. Veneziani; Suku Sneha; Amit M Oza

Year: 2024

Venue: Clinical Cancer Research

DOI: https://doi.org/10.1158/1078-0432.ccr-23-3414

Paper Payload Diversification Overcomes Resistance and Guides Sequential Antibody-Drug Conjugate Therapy in Breast Cancer.

D. R. Rampa; Minji Seo; Nanae Ogata et al. · 2026 · Clinical Cancer Research · DOI

Full title: Payload Diversification Overcomes Resistance and Guides Sequential Antibody-Drug Conjugate Therapy in Breast Cancer.

Authors: D. R. Rampa; Minji Seo; Nanae Ogata; Zhaoxuan Yang; Nithya Sridhar; Fujii Takeo; Chalothorn Wannaphut; Jennifer A. Maynard; K. Tsuchikama; G. Sledge; Naoto T. Ueno; Jangsoon Lee

Year: 2026

Venue: Clinical Cancer Research

DOI: https://doi.org/10.1158/1078-0432.ccr-25-3321

Paper Preclinical validation of anti-TMEFF2-auristatin E-conjugated antibodies in the treatment of prostate cancer.

D. Afar; V. Bhaskar; E. Ibsen et al. · 2004 · Molecular Cancer Therapeutics · DOI

Full title: Preclinical validation of anti-TMEFF2-auristatin E-conjugated antibodies in the treatment of prostate cancer.

Authors: D. Afar; V. Bhaskar; E. Ibsen; D. Breinberg; S. Henshall; J. Kench; M. Drobnjak; R. Powers; M. Wong; F. Evangelista; C. O'Hara; D. Powers; R. Dubridge; I. Caras; Ruth Winter; T. Anderson; N. Solvason; P. Stricker; C. Cordon-Cardo; H. Scher; J. Grygiel; R. Sutherland; R. Murray; V. Ramakrishnan; D. Law

Year: 2004

Venue: Molecular Cancer Therapeutics

DOI: https://doi.org/10.1158/1535-7163.921.3.8

Paper Long-term tumor regression induced by an antibody-drug conjugate that targets 5T4, an oncofetal antigen expressed on tumor-initiating cells.

Sapra, Puja; Damelin, Marc; Dijoseph, John et al. · 2013 · Molecular cancer therapeutics · DOI

Full title: Long-term tumor regression induced by an antibody-drug conjugate that targets 5T4, an oncofetal antigen expressed on tumor-initiating cells.

Authors: Sapra, Puja; Damelin, Marc; Dijoseph, John; Marquette, Kimberly; Geles, Kenneth G; Golas, Jonathon; Dougher, Maureen; Narayanan, Bitha; Giannakou, Andreas; Khandke, Kiran; Dushin, Russell; Ernstoff, Elana; Lucas, Judy; Leal, Mauricio; Hu, George; O'Donnell, Christopher J; Tchistiakova, Lioudmila; Abraham, Robert T; Gerber, Hans-Peter

Year: 2013

Venue: Molecular cancer therapeutics

DOI: https://doi.org/10.1158/1535-7163.MCT-12-0603

Paper Sequencing of Anti-CD19 Therapies in the Management of Diffuse Large B-Cell Lymphoma

Joseph Lownik; Jonathan Boiarsky; R. Birhiray et al. · 2024 · Clinical Cancer Research · DOI

Full title: Sequencing of Anti-CD19 Therapies in the Management of Diffuse Large B-Cell Lymphoma

Authors: Joseph Lownik; Jonathan Boiarsky; R. Birhiray; A. Merchant; M. Mead

Year: 2024

Venue: Clinical Cancer Research

DOI: https://doi.org/10.1158/1078-0432.ccr-23-1962

Paper Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer

A. Bardia; Sheng Sun; Nayana Thimmiah et al. · 2024 · Clinical Cancer Research · DOI

Full title: Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer

Authors: A. Bardia; Sheng Sun; Nayana Thimmiah; James T Coates; Bogang Wu; R. Abelman; Laura M. Spring; B. Moy; P.K. Ryan; Mark N Melkonyan; Ann H. Partridge; D. Juric; Jeffrey M Peppercorn; H. Parsons; Seth A. Wander; V. Attaya; Brenda Lormil; M. Shellock; Aiko Nagayama; V. Bossuyt; S. Isakoff; S. Tolaney; L. Ellisen

Year: 2024

Venue: Clinical Cancer Research

DOI: https://doi.org/10.1158/1078-0432.ccr-24-0428

Paper RN927C, a Site-Specific Trop-2 Antibody–Drug Conjugate (ADC) with Enhanced Stability, Is Highly Efficacious in Preclinical Solid Tumor Models

P. Strop; Thomas-Toan Tran; M. Dorywalska et al. · 2016 · Molecular Cancer Therapeutics · DOI

Full title: RN927C, a Site-Specific Trop-2 Antibody–Drug Conjugate (ADC) with Enhanced Stability, Is Highly Efficacious in Preclinical Solid Tumor Models

Authors: P. Strop; Thomas-Toan Tran; M. Dorywalska; K. Delaria; R. Dushin; O. K. Wong; W. Ho; Dahui Zhou; Aidong Wu; E. Kraynov; L. Aschenbrenner; Bora Han; C. J. O’Donnell; J. Pons; A. Rajpal; D. Shelton; Shu-Hui Liu

Year: 2016

Venue: Molecular Cancer Therapeutics

DOI: https://doi.org/10.1158/1535-7163.mct-16-0431

Paper Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index.

McDonagh, Charlotte F; Kim, Kristine M; Turcott, Eileen et al. · 2008 · Molecular cancer therapeutics · DOI

Full title: Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index.

Authors: McDonagh, Charlotte F; Kim, Kristine M; Turcott, Eileen; Brown, Lindsay L; Westendorf, Lori; Feist, Tiffany; Sussman, Django; Stone, Ivan; Anderson, Martha; Miyamoto, Jamie; Lyon, Robert; Alley, Stephen C; Gerber, Hans-Peter; Carter, Paul J

Year: 2008

Venue: Molecular cancer therapeutics

DOI: https://doi.org/10.1158/1535-7163.MCT-08-0295

Paper Epratuzumab–SN-38: A New Antibody–Drug Conjugate for the Therapy of Hematologic Malignancies

R. Sharkey; S. Govindan; Thomas M Cardillo et al. · 2011 · Molecular Cancer Therapeutics · DOI

Full title: Epratuzumab–SN-38: A New Antibody–Drug Conjugate for the Therapy of Hematologic Malignancies

Authors: R. Sharkey; S. Govindan; Thomas M Cardillo; D. Goldenberg

Year: 2011

Venue: Molecular Cancer Therapeutics

DOI: https://doi.org/10.1158/1535-7163.mct-11-0632

Paper Synergistic treatment of prostate cancer and multiple myeloma using CD46-targeted radioimmunotherapy-antibody drug conjugates.

A. Bidkar; S. Bidlingmaier; Anju Wadhwa et al. · 2026 · Clinical Cancer Research · DOI

Full title: Synergistic treatment of prostate cancer and multiple myeloma using CD46-targeted radioimmunotherapy-antibody drug conjugates.

Authors: A. Bidkar; S. Bidlingmaier; Anju Wadhwa; Ellis Mayne; Athira Raveendran; Shubhankar A. Naik; Cheng Xue; Megha Basak; K. Bobba; B. Patiño-Escobar; Nancy Greenland; Juan Antonio Camara Serrano; V. Steri; Jonathan Chou; Arun P. Wiita; Jiang He; David M Wilson; Rahul R Aggarwal; H. VanBrocklin; Youngho Seo; Bin Liu; R. Flavell

Year: 2026

Venue: Clinical Cancer Research

DOI: https://doi.org/10.1158/1078-0432.ccr-25-4110

Paper In Vitro and In Vivo Responses of Advanced Prostate Tumors to PSMA ADC, an Auristatin-Conjugated Antibody to Prostate-Specific Membrane Antigen

Xinning Wang; D. Ma; W. Olson et al. · 2011 · Molecular Cancer Therapeutics · DOI

Full title: In Vitro and In Vivo Responses of Advanced Prostate Tumors to PSMA ADC, an Auristatin-Conjugated Antibody to Prostate-Specific Membrane Antigen

Authors: Xinning Wang; D. Ma; W. Olson; W. Heston

Year: 2011

Venue: Molecular Cancer Therapeutics

DOI: https://doi.org/10.1158/1535-7163.mct-11-0191

Paper The Mode of Action and Clinical Outcomes of Sacituzumab Govitecan in Solid Tumors

S. Tolaney; Thomas M Cardillo; Chih-Chien Chou et al. · 2025 · Clinical Cancer Research · DOI

Full title: The Mode of Action and Clinical Outcomes of Sacituzumab Govitecan in Solid Tumors

Authors: S. Tolaney; Thomas M Cardillo; Chih-Chien Chou; Carrie Dornan; Mary Faris

Year: 2025

Venue: Clinical Cancer Research

DOI: https://doi.org/10.1158/1078-0432.ccr-24-1525

Paper Anetumab Ravtansine: A Novel Mesothelin-Targeting Antibody–Drug Conjugate Cures Tumors with Heterogeneous Target Expression Favored by Bystander Effect

S. Golfier; C. Kopitz; A. Kahnert et al. · 2014 · Molecular Cancer Therapeutics · DOI

Full title: Anetumab Ravtansine: A Novel Mesothelin-Targeting Antibody–Drug Conjugate Cures Tumors with Heterogeneous Target Expression Favored by Bystander Effect

Authors: S. Golfier; C. Kopitz; A. Kahnert; I. Heisler; Christoph A Schatz; B. Stelte-Ludwig; Anke Mayer-Bartschmid; Kerstin Unterschemmann; Sandra Bruder; Lars Linden; A. Harrenga; P. Hauff; F. Scholle; B. Müller-Tiemann; B. Kreft; K. Ziegelbauer

Year: 2014

Venue: Molecular Cancer Therapeutics

DOI: https://doi.org/10.1158/1535-7163.mct-13-0926

Paper Preclinical Profile of the HER2-Targeting ADC SYD983/SYD985: Introduction of a New Duocarmycin-Based Linker-Drug Platform

Wim H A Dokter; R. Ubink; M. V. D. Van der Lee et al. · 2014 · Molecular Cancer Therapeutics · DOI

Full title: Preclinical Profile of the HER2-Targeting ADC SYD983/SYD985: Introduction of a New Duocarmycin-Based Linker-Drug Platform

Authors: Wim H A Dokter; R. Ubink; M. V. D. Van der Lee; Monique A J Van der Vleuten; T. V. van Achterberg; D. Jacobs; Eline M. Loosveld; D. J. van den Dobbelsteen; D. Egging; E. Mattaar; P. Groothuis; P. Beusker; Ruud G. E. Coumans; R. Elgersma; W. Menge; J. Joosten; H. Spijker; T. Huijbregts; Vincent de Groot; M. Eppink; G. de Roo; G. Verheijden; M. Timmers

Year: 2014

Venue: Molecular Cancer Therapeutics

DOI: https://doi.org/10.1158/1535-7163.mct-14-0040-t

Paper MEN1309/OBT076, a First-In-Class Antibody–Drug Conjugate Targeting CD205 in Solid Tumors

G. Merlino; Alessio Fiascarelli; M. Bigioni et al. · 2019 · Molecular Cancer Therapeutics · DOI

Full title: MEN1309/OBT076, a First-In-Class Antibody–Drug Conjugate Targeting CD205 in Solid Tumors

Authors: G. Merlino; Alessio Fiascarelli; M. Bigioni; A. Bressan; Corrado Carrisi; D. Bellarosa; Massimiliano Salerno; R. Bugianesi; Rosanna Manno; C. B. Bernadó Morales; J. Arribas; R. Dusek; J. Ackroyd; P. H. Pham; Rahel Awdew; D. Aud; M. Trang; C. Lynch; J. Terrett; Keith E. Wilson; C. Rohlff; S. Manzini; A. Pellacani; M. Binaschi

Year: 2019

Venue: Molecular Cancer Therapeutics

DOI: https://doi.org/10.1158/1535-7163.mct-18-0624

Paper Milatuzumab–SN-38 Conjugates for the Treatment of CD74+ Cancers

S. Govindan; Thomas M Cardillo; R. Sharkey et al. · 2013 · Molecular Cancer Therapeutics · DOI

Full title: Milatuzumab–SN-38 Conjugates for the Treatment of CD74+ Cancers

Authors: S. Govindan; Thomas M Cardillo; R. Sharkey; F. Tat; D. Gold; D. Goldenberg

Year: 2013

Venue: Molecular Cancer Therapeutics

DOI: https://doi.org/10.1158/1535-7163.mct-12-1170

Paper Preclinical Evaluation of MEDI0641, a Pyrrolobenzodiazepine-Conjugated Antibody-Drug Conjugate Targeting 5T4.

Harper, Jay; Lloyd, Christopher; Dimasi, Nazzareno et al. · 2017 · Molecular cancer therapeutics · DOI

Full title: Preclinical Evaluation of MEDI0641, a Pyrrolobenzodiazepine-Conjugated Antibody-Drug Conjugate Targeting 5T4.

Authors: Harper, Jay; Lloyd, Christopher; Dimasi, Nazzareno; Toader, Dorin; Marwood, Rose; Lewis, Leeanne; Bannister, David; Jovanovic, Jelena; Fleming, Ryan; D'Hooge, Francois; Mao, Shenlan; Marrero, Allison M; Korade, Martin; Strout, Patrick; Xu, Linda; Chen, Cui; Wetzel, Leslie; Breen, Shannon; van Vlerken-Ysla, Lilian; Jalla, Sanjoo; Rebelatto, Marlon; Zhong, Haihong; Hurt, Elaine M; Hinrichs, Mary Jane; Huang, Keven; Howard, Philip W; Tice, David A; Hollingsworth, Robert E; Herbst, Ronald; Kamal, Adeela

Year: 2017

Venue: Molecular cancer therapeutics

DOI: https://doi.org/10.1158/1535-7163.MCT-16-0825

Paper Molecular Basis of Valine-Citrulline-PABC Linker Instability in Site-Specific ADCs and Its Mitigation by Linker Design

M. Dorywalska; R. Dushin; L. Moine et al. · 2016 · Molecular Cancer Therapeutics · DOI

Full title: Molecular Basis of Valine-Citrulline-PABC Linker Instability in Site-Specific ADCs and Its Mitigation by Linker Design

Authors: M. Dorywalska; R. Dushin; L. Moine; Santiago E Farias; Dahui Zhou; T. Navaratnam; Victor Lui; Adela Hasa-Moreno; M. Casas; Thomas-Toan Tran; K. Delaria; Shu-Hui Liu; D. Foletti; C. J. O’Donnell; J. Pons; D. Shelton; A. Rajpal; P. Strop

Year: 2016

Venue: Molecular Cancer Therapeutics

DOI: https://doi.org/10.1158/1535-7163.mct-15-1004

Paper First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody–Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors

M. Maitland; J. Sachdev; Manish R. Sharma et al. · 2021 · Clinical Cancer Research · DOI

Full title: First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody–Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors

Authors: M. Maitland; J. Sachdev; Manish R. Sharma; V. Moreno; V. Boni; S. Kummar; E. Stringer-Reasor; N. Lakhani; Allison Moreau; D. Xuan; Ray Li; E. Powell; Amy Jackson-Fisher; M. Bowers; S. Alekar; Xiaohua Xin; A. Tolcher; E. Calvo

Year: 2021

Venue: Clinical Cancer Research

DOI: https://doi.org/10.1158/1078-0432.ccr-20-3757

Paper ABT-414, an Antibody–Drug Conjugate Targeting a Tumor-Selective EGFR Epitope

A. Phillips; E. Boghaert; Kedar S Vaidya et al. · 2016 · Molecular Cancer Therapeutics · DOI

Full title: ABT-414, an Antibody–Drug Conjugate Targeting a Tumor-Selective EGFR Epitope

Authors: A. Phillips; E. Boghaert; Kedar S Vaidya; M. Mitten; Suzanne Norvell; H. D. Falls; P. Devries; Dong Cheng; J. Meulbroek; F. G. Buchanan; Laura M. Mckay; N. Goodwin; E. Reilly

Year: 2016

Venue: Molecular Cancer Therapeutics

DOI: https://doi.org/10.1158/1535-7163.mct-15-0901

Paper Highly Potent, Anthracycline-based Antibody–Drug Conjugates Generated by Enzymatic, Site-specific Conjugation

Nikolas Stefan; Rémy Gébleux; L. Waldmeier et al. · 2017 · Molecular Cancer Therapeutics · DOI

Full title: Highly Potent, Anthracycline-based Antibody–Drug Conjugates Generated by Enzymatic, Site-specific Conjugation

Authors: Nikolas Stefan; Rémy Gébleux; L. Waldmeier; T. Hell; M. Escher; Fabian I. Wolter; U. Grawunder; R. Beerli

Year: 2017

Venue: Molecular Cancer Therapeutics

DOI: https://doi.org/10.1158/1535-7163.mct-16-0688

Paper APOMAB Antibody–Drug Conjugates Targeting Dead Tumor Cells are Effective In Vivo

A. H. Staudacher; Yanrui Li; Vasilios Liapis et al. · 2018 · Molecular Cancer Therapeutics · DOI

Full title: APOMAB Antibody–Drug Conjugates Targeting Dead Tumor Cells are Effective In Vivo

Authors: A. H. Staudacher; Yanrui Li; Vasilios Liapis; J. Hou; David Y. Chin; O. Dolezal; T. Adams; P. V. van Berkel; M. Brown

Year: 2018

Venue: Molecular Cancer Therapeutics

DOI: https://doi.org/10.1158/1535-7163.mct-18-0842

Paper An Anti-GDNF Family Receptor Alpha 1 (GFRA1) Antibody–Drug Conjugate for the Treatment of Hormone Receptor–Positive Breast Cancer

S. Bhakta; Lisa M. Crocker; Yvonne Chen et al. · 2017 · Molecular Cancer Therapeutics · DOI

Full title: An Anti-GDNF Family Receptor Alpha 1 (GFRA1) Antibody–Drug Conjugate for the Treatment of Hormone Receptor–Positive Breast Cancer

Authors: S. Bhakta; Lisa M. Crocker; Yvonne Chen; Meredith Hazen; M. Schutten; Dongwei Li; C. Kuijl; Rachana Ohri; Fiona Zhong; K. A. Poon; M. Go; Eric Cheng; Robert Piskol; R. Firestein; Aimee Fourie-O'Donohue; K. Kozak; H. Raab; J. Hongo; D. Sampath; M. Dennis; R. Scheller; P. Polakis; Jagath R Junutula

Year: 2017

Venue: Molecular Cancer Therapeutics

DOI: https://doi.org/10.1158/1535-7163.mct-17-0813

Paper Manipulation of Cell-Type Selective Antibody Internalization by a Guide-Effector Bispecific Design

Nam-Kyung Lee; Yang Su; S. Bidlingmaier et al. · 2019 · Molecular Cancer Therapeutics · DOI

Full title: Manipulation of Cell-Type Selective Antibody Internalization by a Guide-Effector Bispecific Design

Authors: Nam-Kyung Lee; Yang Su; S. Bidlingmaier; B. Liu

Year: 2019

Venue: Molecular Cancer Therapeutics

DOI: https://doi.org/10.1158/1535-7163.mct-18-1313

Paper Antitumor Activity of MEDI3726 (ADCT-401), a Pyrrolobenzodiazepine Antibody–Drug Conjugate Targeting PSMA, in Preclinical Models of Prostate Cancer

S. Cho; F. Zammarchi; David G. Williams et al. · 2018 · Molecular Cancer Therapeutics · DOI

Full title: Antitumor Activity of MEDI3726 (ADCT-401), a Pyrrolobenzodiazepine Antibody–Drug Conjugate Targeting PSMA, in Preclinical Models of Prostate Cancer

Authors: S. Cho; F. Zammarchi; David G. Williams; C. Havenith; N. Monks; P. Tyrer; François D'Hooge; R. Fleming; K. Vashisht; N. Dimasi; F. Bertelli; Simon Corbett; Lauren Adams; H. Reinert; Sandamali Dissanayake; Charles E. Britten; Wanda King; Karma Dacosta; R. Tammali; Kevin P. Schifferli; P. Strout; Martin Korade; Mary Jane Masson Hinrichs; S. Chivers; E. Corey; He Liu; Sae Kim; N. Bander; P. Howard; J. Hartley; S. Coats; D. Tice; R. Herbst; P. V. van Berkel

Year: 2018

Venue: Molecular Cancer Therapeutics

DOI: https://doi.org/10.1158/1535-7163.mct-17-0982

Paper Preclinical Characterization of an Antibody–Drug Conjugate Targeting CS-1 and the Identification of Uncharacterized Populations of CS-1–Positive Cells

Ruoyan Chen; Saravanan Rajan; Michael G. Overstreet et al. · 2020 · Molecular Cancer Therapeutics · DOI

Full title: Preclinical Characterization of an Antibody–Drug Conjugate Targeting CS-1 and the Identification of Uncharacterized Populations of CS-1–Positive Cells

Authors: Ruoyan Chen; Saravanan Rajan; Michael G. Overstreet; E. Hurt; Suneetha B. Thomas; Vanessa M. Muniz-Medina; Christopher Ward; A. Sadowska; R. Fleming; Subramanya Karanth; S. Breen; B. Zheng; Yuling Wu; W. Iverson; S. Novick; T. O’Day; Dipesha P Shah; N. Dimasi; A. Tiberghien; J. Osbourn; Jill Walker

Year: 2020

Venue: Molecular Cancer Therapeutics

DOI: https://doi.org/10.1158/1535-7163.mct-19-0482

Paper A DNA-Interacting Payload Designed to Eliminate Cross-Linking Improves the Therapeutic Index of Antibody-Drug Conjugates (ADCs).

Miller, Michael L; Shizuka, Manami; Wilhelm, Alan et al. · 2018 · Molecular cancer therapeutics · DOI

Full title: A DNA-Interacting Payload Designed to Eliminate Cross-Linking Improves the Therapeutic Index of Antibody-Drug Conjugates (ADCs).

Authors: Miller, Michael L; Shizuka, Manami; Wilhelm, Alan; Salomon, Paulin; Reid, Emily E; Lanieri, Leanne; Sikka, Surina; Maloney, Erin K; Harvey, Lauren; Qiu, Qifeng; Archer, Katie E; Bai, Chen; Vitharana, Dilrukshi; Harris, Luke; Singh, Rajeeva; Ponte, Jose F; Yoder, Nicholas C; Kovtun, Yelena; Lai, Katharine C; Ab, Olga; Pinkas, Jan; Keating, Thomas A; Chari, Ravi V J

Year: 2018

Venue: Molecular cancer therapeutics

DOI: https://doi.org/10.1158/1535-7163.MCT-17-0940

Paper Preclinical Activity of the Novel Anti-Prolactin Receptor (PRLR) Antibody–Drug Conjugate REGN2878-DM1 in PRLR-Positive Breast Cancers

Marcus P. Kelly; Carlos Hickey; S. Makonnen et al. · 2017 · Molecular Cancer Therapeutics · DOI

Full title: Preclinical Activity of the Novel Anti-Prolactin Receptor (PRLR) Antibody–Drug Conjugate REGN2878-DM1 in PRLR-Positive Breast Cancers

Authors: Marcus P. Kelly; Carlos Hickey; S. Makonnen; Sandra Coetzee; Sumreen Jalal; Yu Wang; F. Delfino; Jing Shan; Terra Potocky; I. Chatterjee; J. Andreev; A. Kunz; Christopher D'Souza; Jason T Giurleo; T. Nittoli; P. Trail; G. Thurston; J. Kirshner

Year: 2017

Venue: Molecular Cancer Therapeutics

DOI: https://doi.org/10.1158/1535-7163.mct-16-0839

Paper Efficacy, Tolerability, and Pharmacokinetic Studies of Antibody-Drug Conjugates Containing a Low-Potency Pyrrolobenzodiazepine Dimer.

Gregson, Stephen J; Pugh, Kathryn; Patel, Neki et al. · 2022 · Molecular cancer therapeutics · DOI

Full title: Efficacy, Tolerability, and Pharmacokinetic Studies of Antibody-Drug Conjugates Containing a Low-Potency Pyrrolobenzodiazepine Dimer.

Authors: Gregson, Stephen J; Pugh, Kathryn; Patel, Neki; Afif-Rider, Shameen; Vijayakrishnan, Balakumar; Santos, Kathleen; Riedl, Jitka; Hutchinson, Ian; Kang, Gyoung-Dong; Chooi, K Phin; Beard, Rhiannon; Adams, Lauren; Barry, Conor S; Ball, Kathryn; Masterson, Luke A; McFarlane, Mary; Hartley, John A; Howard, Philip W

Year: 2022

Venue: Molecular cancer therapeutics

DOI: https://doi.org/10.1158/1535-7163.MCT-22-0145

Paper Anti-Extra Domain B Splice Variant of Fibronectin Antibody–Drug Conjugate Eliminates Tumors with Enhanced Efficacy When Combined with Checkpoint Blockade

A. Hooper; Kimberly Marquette; Chao-Pei Betty Chang et al. · 2022 · Molecular Cancer Therapeutics · DOI

Full title: Anti-Extra Domain B Splice Variant of Fibronectin Antibody–Drug Conjugate Eliminates Tumors with Enhanced Efficacy When Combined with Checkpoint Blockade

Authors: A. Hooper; Kimberly Marquette; Chao-Pei Betty Chang; J. Golas; Sadhana Jain; M. Lam; M. Guffroy; M. Leal; Hadi Falahatpisheh; Divya Mathur; Ting Chen; K. Kelleher; K. Khandke; Elwira Muszynska; F. Loganzo; E. Rosfjord; J. Lucas; Zhengyan Kan; C. Subramanyam; C. O'Donnell; D. Neri; H. Gerber; C. May; P. Sapra

Year: 2022

Venue: Molecular Cancer Therapeutics

DOI: https://doi.org/10.1158/1535-7163.mct-22-0099

Paper Payload-Binding Fab Fragments Increase the Therapeutic Index of MMAE Antibody-Drug Conjugates.

Bordeau, Brandon M; Nguyen, Toan Duc; Polli, Joseph Ryan et al. · 2023 · Molecular cancer therapeutics · DOI

Full title: Payload-Binding Fab Fragments Increase the Therapeutic Index of MMAE Antibody-Drug Conjugates.

Authors: Bordeau, Brandon M; Nguyen, Toan Duc; Polli, Joseph Ryan; Chen, Ping; Balthasar, Joseph P

Year: 2023

Venue: Molecular cancer therapeutics

DOI: https://doi.org/10.1158/1535-7163.MCT-22-0440

Paper Antibody–Drug Conjugate Efficacy in Neuroblastoma: Role of Payload, Resistance Mechanisms, Target Density, and Antibody Internalization

Samantha N Buongervino; M. Lane; Emily Garrigan et al. · 2021 · Molecular Cancer Therapeutics · DOI

Full title: Antibody–Drug Conjugate Efficacy in Neuroblastoma: Role of Payload, Resistance Mechanisms, Target Density, and Antibody Internalization

Authors: Samantha N Buongervino; M. Lane; Emily Garrigan; D. Zhelev; D. Dimitrov; K. Bosse

Year: 2021

Venue: Molecular Cancer Therapeutics

DOI: https://doi.org/10.1158/1535-7163.mct-20-1034

Paper Antibody–Drug Conjugate Sacituzumab Govitecan Drives Efficient Tissue Penetration and Rapid Intracellular Drug Release

Anna Kopp; S. Hofsess; Thomas M Cardillo et al. · 2022 · Molecular Cancer Therapeutics · DOI

Full title: Antibody–Drug Conjugate Sacituzumab Govitecan Drives Efficient Tissue Penetration and Rapid Intracellular Drug Release

Authors: Anna Kopp; S. Hofsess; Thomas M Cardillo; S. Govindan; J. Donnell; Greg M. Thurber

Year: 2022

Venue: Molecular Cancer Therapeutics

DOI: https://doi.org/10.1158/1535-7163.mct-22-0375

Paper ARX788, a Site-specific Anti-HER2 Antibody–Drug Conjugate, Demonstrates Potent and Selective Activity in HER2-low and T-DM1–resistant Breast and Gastric Cancers

Lillian K Skidmore; S. Sakamuri; Nick A Knudsen et al. · 2020 · Molecular Cancer Therapeutics · DOI

Full title: ARX788, a Site-specific Anti-HER2 Antibody–Drug Conjugate, Demonstrates Potent and Selective Activity in HER2-low and T-DM1–resistant Breast and Gastric Cancers

Authors: Lillian K Skidmore; S. Sakamuri; Nick A Knudsen; Amha G. Hewet; S. Milutinovic; Wisam Barkho; S. Biroc; J. Kirtley; R. Marsden; Kristine Storey; Ianina Lopez; Wayne Yu; Shiao-Yan Fang; S. Yao; Yi Gu; Feng Tian

Year: 2020

Venue: Molecular Cancer Therapeutics

DOI: https://doi.org/10.1158/1535-7163.mct-19-1004

Paper Calicheamicin Antibody-Drug Conjugates with Improved Properties.

Vollmar, Breanna S; Frantz, Chris; Schutten, Melissa M et al. · 2021 · Molecular cancer therapeutics · DOI

Full title: Calicheamicin Antibody-Drug Conjugates with Improved Properties.

Authors: Vollmar, Breanna S; Frantz, Chris; Schutten, Melissa M; Zhong, Fiona; Del Rosario, Geoffrey; Go, Mary Ann T; Yu, Shang-Fan; Leipold, Douglas D; Kamath, Amrita V; Ng, Carl; Xu, Keyang; Dela Cruz-Chuh, Josefa; Kozak, Katherine R; Chen, Jinhua; Xu, Zijin; Wai, John; Adhikari, Pragya; Erickson, Hans K; Dragovich, Peter S; Polson, Andrew G; Pillow, Thomas H

Year: 2021

Venue: Molecular cancer therapeutics

DOI: https://doi.org/10.1158/1535-7163.MCT-20-0035

Paper Anti-Glypican-1 Antibody–drug Conjugate as Potential Therapy Against Tumor Cells and Tumor Vasculature for Glypican-1–Positive Cholangiocarcinoma

Keiichiro Yokota; S. Serada; Shigehiro Tsujii et al. · 2021 · Molecular Cancer Therapeutics · DOI

Full title: Anti-Glypican-1 Antibody–drug Conjugate as Potential Therapy Against Tumor Cells and Tumor Vasculature for Glypican-1–Positive Cholangiocarcinoma

Authors: Keiichiro Yokota; S. Serada; Shigehiro Tsujii; Keisuke Toya; Tsuyoshi Takahashi; T. Matsunaga; M. Fujimoto; S. Uemura; T. Namikawa; I. Murakami; Shogo Kobayashi; H. Eguchi; Y. Doki; K. Hanazaki; T. Naka

Year: 2021

Venue: Molecular Cancer Therapeutics

DOI: https://doi.org/10.1158/1535-7163.mct-21-0015

Paper Comparison of Pyrrolobenzodiazepine Dimer Bis-imine versus Mono-imine: DNA Interstrand Cross-linking, Cytotoxicity, Antibody-Drug Conjugate Efficacy and Toxicity.

Tiberghien, Arnaud C; Vijayakrishnan, Balakumar; Esfandiari, Arman et al. · 2023 · Molecular cancer therapeutics · DOI

Full title: Comparison of Pyrrolobenzodiazepine Dimer Bis-imine versus Mono-imine: DNA Interstrand Cross-linking, Cytotoxicity, Antibody-Drug Conjugate Efficacy and Toxicity.

Authors: Tiberghien, Arnaud C; Vijayakrishnan, Balakumar; Esfandiari, Arman; Ahmed, Mahammad; Pardo, Raul; Bingham, John; Adams, Lauren; Santos, Kathleen; Kang, Gyoung-Dong; Pugh, Kathryn M; Afif-Rider, Shameen; Vashisht, Kapil; Haque, Kemal; Tammali, Ravinder; Rosfjord, Edward; Savoca, Adriana; Hartley, John A; Howard, Philip W

Year: 2023

Venue: Molecular cancer therapeutics

DOI: https://doi.org/10.1158/1535-7163.MCT-21-0693

Paper Development of Novel Antibody–Camptothecin Conjugates

Ryan Lyski; Lauren Bou; Uland Y. Lau et al. · 2020 · Molecular Cancer Therapeutics · DOI

Full title: Development of Novel Antibody–Camptothecin Conjugates

Authors: Ryan Lyski; Lauren Bou; Uland Y. Lau; David W Meyer; Julia H Cochran; N. Okeley; Kim K. Emmerton; Francisco Zapata; J. Simmons; E. Trueblood; David Ortiz; Margo Zaval; Katie M Snead; Steven Jin; Lauren Farr; M. Ryan; P. Senter; S. Jeffrey

Year: 2020

Venue: Molecular Cancer Therapeutics

DOI: https://doi.org/10.1158/1535-7163.mct-20-0526

Paper Preclinical Development of ADCT-601, a Novel Pyrrolobenzodiazepine Dimer-based Antibody–drug Conjugate Targeting AXL-expressing Cancers

F. Zammarchi; K. Havenith; S. Chivers et al. · 2022 · Molecular Cancer Therapeutics · DOI

Full title: Preclinical Development of ADCT-601, a Novel Pyrrolobenzodiazepine Dimer-based Antibody–drug Conjugate Targeting AXL-expressing Cancers

Authors: F. Zammarchi; K. Havenith; S. Chivers; Paul W. Hogg; F. Bertelli; P. Tyrer; N. Janghra; H. Reinert; J. Hartley; P. V. van Berkel

Year: 2022

Venue: Molecular Cancer Therapeutics

DOI: https://doi.org/10.1158/1535-7163.mct-21-0715

Paper PF-06804103, A Site-specific Anti-HER2 Antibody-Drug Conjugate for the Treatment of HER2-expressing Breast, Gastric, and Lung Cancers.

Graziani, Edmund I; Sung, Matthew; Ma, Dangshe et al. · 2020 · Molecular cancer therapeutics · DOI

Full title: PF-06804103, A Site-specific Anti-HER2 Antibody-Drug Conjugate for the Treatment of HER2-expressing Breast, Gastric, and Lung Cancers.

Authors: Graziani, Edmund I; Sung, Matthew; Ma, Dangshe; Narayanan, Bitha; Marquette, Kimberly; Puthenveetil, Sujiet; Tumey, L Nathan; Bikker, Jack; Casavant, Jeffrey; Bennett, Eric M; Charati, Manoj B; Golas, Jonathon; Hosselet, Christine; Rohde, Cynthia M; Hu, George; Guffroy, Magali; Falahatpisheh, Hadi; Finkelstein, Martin; Clark, Tracey; Barletta, Frank; Tchistiakova, Lioudmila; Lucas, Judy; Rosfjord, Edward; Loganzo, Frank; O'Donnell, Christopher J; Gerber, Hans-Peter; Sapra, Puja

Year: 2020

Venue: Molecular cancer therapeutics

DOI: https://doi.org/10.1158/1535-7163.MCT-20-0237

Paper ASN004, A 5T4-targeting scFv-Fc Antibody–Drug Conjugate with High Drug-to-Antibody Ratio, Induces Complete and Durable Tumor Regressions in Preclinical Models

R. Smith; D. Zammit; N. Damle et al. · 2021 · Molecular Cancer Therapeutics · DOI

Full title: ASN004, A 5T4-targeting scFv-Fc Antibody–Drug Conjugate with High Drug-to-Antibody Ratio, Induces Complete and Durable Tumor Regressions in Preclinical Models

Authors: R. Smith; D. Zammit; N. Damle; H. Usansky; Sanjeeva P. Reddy; Jun-hsiang Lin; M. Mistry; N. Rao; L. Denis; Sandeep Gupta

Year: 2021

Venue: Molecular Cancer Therapeutics

DOI: https://doi.org/10.1158/1535-7163.mct-20-0565

Paper Targeted Delivery of TLR7 Agonists to the Tumor Microenvironment Enhances Tumor Immunity via Activation of Tumor-Resident Myeloid Cells

Emanuela Sega; Srikanth Kotapati; Yam B. Poudel et al. · 2025 · Bioconjugate chemistry · DOI

Full title: Targeted Delivery of TLR7 Agonists to the Tumor Microenvironment Enhances Tumor Immunity via Activation of Tumor-Resident Myeloid Cells

Authors: Emanuela Sega; Srikanth Kotapati; Yam B. Poudel; Qinqin Cheng; Keerthi Sadanala; Bridget Schneider; Eugene P Chekler; Chetana Rao; Sanjeev Gangwar; Tim Sproul; Deborah Law; Miranda Broz; P. Strop; Sayumi Yamazoe

Year: 2025

Venue: Bioconjugate chemistry

DOI: https://doi.org/10.1021/acs.bioconjchem.4c00534

Paper Effects of Drug-Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody-Maytansinoid Conjugates.

Sun, Xiuxia; Ponte, Jose F; Yoder, Nicholas C et al. · 2017 · Bioconjugate chemistry · DOI

Full title: Effects of Drug-Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody-Maytansinoid Conjugates.

Authors: Sun, Xiuxia; Ponte, Jose F; Yoder, Nicholas C; Laleau, Rassol; Coccia, Jennifer; Lanieri, Leanne; Qiu, Qifeng; Wu, Rui; Hong, Erica; Bogalhas, Megan; Wang, Lintao; Dong, Ling; Setiady, Yulius; Maloney, Erin K; Ab, Olga; Zhang, Xiaoyan; Pinkas, Jan; Keating, Thomas A; Chari, Ravi; Erickson, Hans K; Lambert, John M

Year: 2017

Venue: Bioconjugate chemistry

DOI: https://doi.org/10.1021/acs.bioconjchem.7b00062

Paper Design of a Small-Molecule Drug Conjugate for Prostate Cancer Targeted Theranostics.

Amit Kumar; T. Mastren; Bin Wang et al. · 2016 · Bioconjugate chemistry · DOI

Full title: Design of a Small-Molecule Drug Conjugate for Prostate Cancer Targeted Theranostics.

Authors: Amit Kumar; T. Mastren; Bin Wang; J. Hsieh; G. Hao; Xiankai Sun

Year: 2016

Venue: Bioconjugate chemistry

DOI: https://doi.org/10.1021/acs.bioconjchem.6b00222

Paper High-Throughput Cysteine Scanning To Identify Stable Antibody Conjugation Sites for Maleimide- and Disulfide-Based Linkers.

Rachana Ohri; S. Bhakta; Aimee Fourie-O'Donohue et al. · 2018 · Bioconjugate chemistry · DOI

Full title: High-Throughput Cysteine Scanning To Identify Stable Antibody Conjugation Sites for Maleimide- and Disulfide-Based Linkers.

Authors: Rachana Ohri; S. Bhakta; Aimee Fourie-O'Donohue; Josefa dela Cruz-Chuh; S. Tsai; Ryan Cook; Binqing Wei; Carl Ng; Athena W Wong; A. B. Bos; Farzam Farahi; Jiten Bhakta; Thomas H. Pillow; H. Raab; R. Vandlen; P. Polakis; Yichin Liu; H. Erickson; Jagath R Junutula; K. Kozak

Year: 2018

Venue: Bioconjugate chemistry

DOI: https://doi.org/10.1021/acs.bioconjchem.7b00791

Paper Modulating Thiol p Ka Promotes Disulfide Formation at Physiological pH: An Elegant Strategy To Design Disulfide Cross-Linked Hyaluronic Acid Hydrogels.

Daniel Bermejo-Velasco; Alice Azémar; Oommen P. Oommen et al. · 2019 · Biomacromolecules · DOI

Full title: Modulating Thiol p Ka Promotes Disulfide Formation at Physiological pH: An Elegant Strategy To Design Disulfide Cross-Linked Hyaluronic Acid Hydrogels.

Authors: Daniel Bermejo-Velasco; Alice Azémar; Oommen P. Oommen; J. Hilborn; O. Varghese

Year: 2019

Venue: Biomacromolecules

DOI: https://doi.org/10.1021/acs.biomac.8b01830

Paper Tuning the Diels-Alder Reaction for Bioconjugation to Maleimide Drug-Linkers.

Andre H St Amant; D. Lemen; Stelios Florinas et al. · 2018 · Bioconjugate chemistry · DOI

Full title: Tuning the Diels-Alder Reaction for Bioconjugation to Maleimide Drug-Linkers.

Authors: Andre H St Amant; D. Lemen; Stelios Florinas; S. Mao; Christine Fazenbaker; Haihong Zhong; Herren Wu; Changshou Gao; R. Christie; Javier Read de Alaniz

Year: 2018

Venue: Bioconjugate chemistry

DOI: https://doi.org/10.1021/acs.bioconjchem.8b00320

Paper Natural Product Bis-Intercalator Depsipeptides as a New Class of Payloads for Antibody-Drug Conjugates.

A. Ratnayake; Li-Ping Chang; L. N. Tumey et al. · 2018 · Bioconjugate chemistry · DOI

Full title: Natural Product Bis-Intercalator Depsipeptides as a New Class of Payloads for Antibody-Drug Conjugates.

Authors: A. Ratnayake; Li-Ping Chang; L. N. Tumey; F. Loganzo; Joseph A. Chemler; M. Wagenaar; S. Musto; Fengping Li; J. Janso; T. Eric Ballard; Brian Rago; Greg L Steele; W. Ding; Xidong Feng; C. Hosselet; Vlad Buklan; J. Lucas; F. Koehn; Christopher J. O’Donnell; Edmund I. Graziani

Year: 2018

Venue: Bioconjugate chemistry

DOI: https://doi.org/10.1021/acs.bioconjchem.8b00843

Paper Novel Phosphate Modified Cathepsin B Linkers: Improving Aqueous Solubility and Enhancing Payload Scope of ADCs.

J. Kern; D. Dooney; Rena Zhang et al. · 2016 · Bioconjugate chemistry · DOI

Full title: Novel Phosphate Modified Cathepsin B Linkers: Improving Aqueous Solubility and Enhancing Payload Scope of ADCs.

Authors: J. Kern; D. Dooney; Rena Zhang; Linda Liang; P. Brandish; M. Cheng; Guo Feng; Andrew Beck; D. Bresson; Juhi Firdos; D. Gately; Nick A Knudsen; Anthony Manibusan; Ying Sun; R. Garbaccio

Year: 2016

Venue: Bioconjugate chemistry

DOI: https://doi.org/10.1021/acs.bioconjchem.6b00337

Paper Identification of a Novel Linker Enabling the Bioconjugation of a Cyclic Dinucleotide for the STING Antibody-Drug Conjugate TAK-500

Hong Myung Lee; Kojo Abdul-Hadi; Vicky A. Appleman et al. · 2025 · Bioconjugate chemistry · DOI

Full title: Identification of a Novel Linker Enabling the Bioconjugation of a Cyclic Dinucleotide for the STING Antibody-Drug Conjugate TAK-500

Authors: Hong Myung Lee; Kojo Abdul-Hadi; Vicky A. Appleman; David Cardin; Linlin Dong; Dylan England; M. Ganno; Rachel E. Gershman; Kenneth Gigstad; Nanda Gulavita; Zhigen Hu; Jian Huang; Shih-Chung Huang; David Lok; Liting Ma; J. Malley; Miho Mizutani; N. Molchanova; Konstantin I Piatkov; Elise Rice; Zhan Shi; S. Vyskocil; Jianing Wang; He Xu; Tianlin Xu; Dong Mei Zhang; Ji Zhang; Adnan O Abu-Yousif

Year: 2025

Venue: Bioconjugate chemistry

DOI: https://doi.org/10.1021/acs.bioconjchem.5c00424

Paper Internalization of Influenza Virus and Cell Surface Proteins Monitored by Site-Specific Conjugation of Protease-Sensitive Probes.

Ross W. Cheloha; Zeyang Li; Djenet Bousbaine et al. · 2019 · ACS Chemical Biology · DOI

Full title: Internalization of Influenza Virus and Cell Surface Proteins Monitored by Site-Specific Conjugation of Protease-Sensitive Probes.

Authors: Ross W. Cheloha; Zeyang Li; Djenet Bousbaine; Andrew W. Woodham; P. Perrin; Jana Volarić; H. Ploegh

Year: 2019

Venue: ACS Chemical Biology

DOI: https://doi.org/10.1021/acschembio.9b00493

Paper Enhancing the Safety and Efficacy of PSMA-Based Small-Molecule Drug Conjugates by Linker Stabilization and Conjugation to Transthyretin Binding Ligand.

T. Amin; Rasha Emara; A. Pal et al. · 2022 · Journal of Medicinal Chemistry · DOI

Full title: Enhancing the Safety and Efficacy of PSMA-Based Small-Molecule Drug Conjugates by Linker Stabilization and Conjugation to Transthyretin Binding Ligand.

Authors: T. Amin; Rasha Emara; A. Pal; Hala Aldawod; G. Jiang; Dengpan Liang; Md Tariqul Haque Tuhin; A. Balgoname; Arjun D Patel; Mamoun M. Alhamadsheh

Year: 2022

Venue: Journal of Medicinal Chemistry

DOI: https://doi.org/10.1021/acs.jmedchem.2c01423

Paper Immolation of p-Aminobenzyl Ether Linker and Payload Potency and Stability Determine the Cell-Killing Activity of Antibody-Drug Conjugates with Phenol-Containing Payloads.

Donglu Zhang; Hoa Le; Josefa dela Cruz-Chuh et al. · 2018 · Bioconjugate chemistry · DOI

Full title: Immolation of p-Aminobenzyl Ether Linker and Payload Potency and Stability Determine the Cell-Killing Activity of Antibody-Drug Conjugates with Phenol-Containing Payloads.

Authors: Donglu Zhang; Hoa Le; Josefa dela Cruz-Chuh; Sudheer Bobba; Jun Guo; Leanna R Staben; Chenghong Zhang; Yong Ma; K. Kozak; Gail D Lewis Phillips; B. Vollmar; J. Sadowsky; R. Vandlen; Binqing Wei; Dian Su; P. Fan; P. Dragovich; S. C. Khojasteh; C. Hop; Thomas H. Pillow

Year: 2018

Venue: Bioconjugate chemistry

DOI: https://doi.org/10.1021/acs.bioconjchem.7b00576

Paper Exo-Cleavable Linkers: Enhanced Stability and Therapeutic Efficacy in Antibody–Drug Conjugates

Tomohiro Watanabe; Naoko Arashida; Tomohiro Fujii et al. · 2024 · Journal of Medicinal Chemistry · DOI

Full title: Exo-Cleavable Linkers: Enhanced Stability and Therapeutic Efficacy in Antibody–Drug Conjugates

Authors: Tomohiro Watanabe; Naoko Arashida; Tomohiro Fujii; Natsuki Shikida; Kenichiro Ito; Kazutaka Shimbo; Takuya Seki; Yusuke Iwai; Ryusuke Hirama; Noriko Hatada; Akira Nakayama; T. Okuzumi; Yutaka Matsuda

Year: 2024

Venue: Journal of Medicinal Chemistry

DOI: https://doi.org/10.1021/acs.jmedchem.4c01251

Paper Development of Anti-CD74 Antibody-Drug Conjugates to Target Glucocorticoids to Immune Cells.

Brandish, Philip E; Palmieri, Anthony; Antonenko, Svetlana et al. · 2018 · Bioconjugate chemistry · DOI

Full title: Development of Anti-CD74 Antibody-Drug Conjugates to Target Glucocorticoids to Immune Cells.

Authors: Brandish, Philip E; Palmieri, Anthony; Antonenko, Svetlana; Beaumont, Maribel; Benso, Lia; Cancilla, Mark; Cheng, Mangeng; Fayadat-Dilman, Laurence; Feng, Guo; Figueroa, Isabel; Firdos, Juhi; Garbaccio, Robert; Garvin-Queen, Laura; Gately, Dennis; Geda, Prasanthi; Haines, Christopher; Hseih, SuChun; Hodges, Douglas; Kern, Jeffrey; Knudsen, Nickolas; Kwasnjuk, Kristen; Liang, Linda; Ma, Huiping; Manibusan, Anthony; Miller, Paul L; Moy, Lily Y; Qu, Yujie; Shah, Sanjiv; Shin, John S; Stivers, Peter; Sun, Ying; Tomazela, Daniela; Woo, Hyun Chong; Zaller, Dennis; Zhang, Shuli; Zhang, Yiwei; Zielstorff, Mark

Year: 2018

Venue: Bioconjugate chemistry

DOI: https://doi.org/10.1021/acs.bioconjchem.8b00312

Paper Recent Advances in Targeted Cancer Therapy: Are PDCs the Next Generation of ADCs?

Zhang, Baochen; Wang, Mo; Sun, Li et al. · 2024 · Journal of medicinal chemistry · DOI

Full title: Recent Advances in Targeted Cancer Therapy: Are PDCs the Next Generation of ADCs?

Authors: Zhang, Baochen; Wang, Mo; Sun, Li; Liu, Jiawei; Yin, Libinghan; Xia, Mingjing; Zhang, Ling; Liu, Xifu; Cheng, Yu

Year: 2024

Venue: Journal of medicinal chemistry

DOI: https://doi.org/10.1021/acs.jmedchem.4c00106

Paper hIMB1636-MMAE, a Novel TROP2-Targeting Antibody-Drug Conjugate Exerting Potent Antitumor Efficacy in Pancreatic Cancer.

Li-Ping Sun; Wei-Qi Bai; Dan-dan Zhou et al. · 2023 · Journal of Medicinal Chemistry · DOI

Full title: hIMB1636-MMAE, a Novel TROP2-Targeting Antibody-Drug Conjugate Exerting Potent Antitumor Efficacy in Pancreatic Cancer.

Authors: Li-Ping Sun; Wei-Qi Bai; Dan-dan Zhou; Xiao-Fan Wu; Lan-Wen Zhang; Along Cui; Zi-hui Xie; Rui-juan Gao; Yong-su Zhen; Zhuo-rong Li; Qing-Fang Miao

Year: 2023

Venue: Journal of Medicinal Chemistry

DOI: https://doi.org/10.1021/acs.jmedchem.3c01210

Paper Site-Specific Conjugation of the Indolinobenzodiazepine DGN549 to Antibodies Affords Antibody-Drug Conjugates with an Improved Therapeutic Index as Compared with Lysine Conjugation.

Bai, Chen; Reid, Emily E; Wilhelm, Alan et al. · 2020 · Bioconjugate chemistry · DOI

Full title: Site-Specific Conjugation of the Indolinobenzodiazepine DGN549 to Antibodies Affords Antibody-Drug Conjugates with an Improved Therapeutic Index as Compared with Lysine Conjugation.

Authors: Bai, Chen; Reid, Emily E; Wilhelm, Alan; Shizuka, Manami; Maloney, Erin K; Laleau, Rassol; Harvey, Lauren; Archer, Katie E; Vitharana, Dilrukshi; Adams, Sharlene; Kovtun, Yelena; Miller, Michael L; Chari, Ravi; Keating, Thomas A; Yoder, Nicholas C

Year: 2020

Venue: Bioconjugate chemistry

DOI: https://doi.org/10.1021/acs.bioconjchem.9b00777

Paper Optimization of Drug-Linker to Enable Long-term Storage of Antibody-Drug Conjugate for Subcutaneous Dosing.

Hobson, Adrian D; Xu, Jianwen; Marvin, Christopher C et al. · 2023 · Journal of medicinal chemistry · DOI

Full title: Optimization of Drug-Linker to Enable Long-term Storage of Antibody-Drug Conjugate for Subcutaneous Dosing.

Authors: Hobson, Adrian D; Xu, Jianwen; Marvin, Christopher C; McPherson, Michael J; Hollmann, Markus; Gattner, Michael; Dzeyk, Kristina; Fettis, Margaret M; Bischoff, Agnieszka K; Wang, Lu; Fitzgibbons, Julia; Wang, Lu; Salomon, Paulin; Hernandez, Axel; Jia, Ying; Sarvaiya, Hetal; Goess, Christian A; Mathieu, Suzanne L; Santora, Ling C

Year: 2023

Venue: Journal of medicinal chemistry

DOI: https://doi.org/10.1021/acs.jmedchem.3c00794

Paper Legumain-Cleavable Top1i Antibody-Drug Conjugates without Self-Immolative Spacers Demonstrate Potent Antitumor Activity.

Victor T Ojo; Nicholas A Bianchi; Michele Yi et al. · 2025 · Journal of Medicinal Chemistry · DOI

Full title: Legumain-Cleavable Top1i Antibody-Drug Conjugates without Self-Immolative Spacers Demonstrate Potent Antitumor Activity.

Authors: Victor T Ojo; Nicholas A Bianchi; Michele Yi; Samuel H Chung; Meghan E. Gray; Mohammad Asikur Rahman; Kayla K. Elder; Tao Zhang; Tracy A Brooks; L. N. Tumey

Year: 2025

Venue: Journal of Medicinal Chemistry

DOI: https://doi.org/10.1021/acs.jmedchem.5c02681

Paper Hiding Payload Inside the IgG Fc Cavity Significantly Enhances the Therapeutic Index of Antibody-Drug Conjugates.

Shi, Wei; Zhang, Jianxin; Liu, Liya et al. · 2023 · Journal of medicinal chemistry · DOI

Full title: Hiding Payload Inside the IgG Fc Cavity Significantly Enhances the Therapeutic Index of Antibody-Drug Conjugates.

Authors: Shi, Wei; Zhang, Jianxin; Liu, Liya; Li, Wanzhen; Liu, Zhi; Ren, Anni; Wang, Jie; Tang, Caihong; Yang, Yang; Xu, Dandan; Huang, Qianqian; Wang, Yongqin; Luo, Caili; Huang, Wei; Tang, Feng

Year: 2023

Venue: Journal of medicinal chemistry

DOI: https://doi.org/10.1021/acs.jmedchem.2c01812

Paper Antibody-Drug Conjugates and Small Molecule-Drug Conjugates: Opportunities and Challenges for the Development of Selective Anticancer Cytotoxic Agents.

Giulio Casi; D. Neri · 2015 · Journal of Medicinal Chemistry · DOI

Full title: Antibody-Drug Conjugates and Small Molecule-Drug Conjugates: Opportunities and Challenges for the Development of Selective Anticancer Cytotoxic Agents.

Authors: Giulio Casi; D. Neri

Year: 2015

Venue: Journal of Medicinal Chemistry

DOI: https://doi.org/10.1021/acs.jmedchem.5b00457

Paper Antibody-Drug Conjugates of NLRP3 Agonists: How Overcoming Lysosomal Accumulation Necessitated Noncanonical Linker Attachments.

Paul S. Riehl; Meng Yao Zhang; Payal Dhar et al. · 2025 · Journal of Medicinal Chemistry · DOI

Full title: Antibody-Drug Conjugates of NLRP3 Agonists: How Overcoming Lysosomal Accumulation Necessitated Noncanonical Linker Attachments.

Authors: Paul S. Riehl; Meng Yao Zhang; Payal Dhar; Zhiying Wang; Jie Pan; Kathleen Mansfield; Walter L Johnson; Qian Zhang; Yvonne Li; Ryan D'Souza; Jun Zhang; Jonathan Olsen; Madhura Deshpande; Srikanth Kotapati; Scott A Hollingsworth; Isha Verma; Yi-Xin Li; Yang Su; Qinqin Cheng; Sayumi Yamazoe; Luca Micci; Miranda Broz; James Janc; Eugene P Chekler; Julian C Lo

Year: 2025

Venue: Journal of Medicinal Chemistry

DOI: https://doi.org/10.1021/acs.jmedchem.5c00596

Paper Design, Synthesis, and Biological Evaluation of Tubulysin Analogues, Linker-Drugs, and Antibody-Drug Conjugates, Insights into Structure-Activity Relationships, and Tubulysin-Tubulin Binding Derived from X-ray Crystallographic Analysis.

K. Nicolaou; Saiyong Pan; K. K. Pulukuri et al. · 2021 · Journal of Organic Chemistry · DOI

Full title: Design, Synthesis, and Biological Evaluation of Tubulysin Analogues, Linker-Drugs, and Antibody-Drug Conjugates, Insights into Structure-Activity Relationships, and Tubulysin-Tubulin Binding Derived from X-ray Crystallographic Analysis.

Authors: K. Nicolaou; Saiyong Pan; K. K. Pulukuri; Qiuji Ye; S. Rigol; Rohan D. Erande; D. Vourloumis; B. Nocek; Stefan Munneke; J. Lyssikatos; Amanda Valdiosera; Christine Gu; B. Lin; Hetal Sarvaiaya; J. Trinidad; Joseph Sandoval; Christina Lee; M. Hammond; M. Aujay; Nicole Taylor; Marybeth Pysz; J. Purcell; J. Gavrilyuk

Year: 2021

Venue: Journal of Organic Chemistry

DOI: https://doi.org/10.1021/acs.joc.0c02755

Paper Discovery of ABBV-154, an anti-TNF Glucocorticoid Receptor Modulator Immunology Antibody-Drug Conjugate (iADC).

A. Hobson; Jianwen Xu; Dennie S. Welch et al. · 2023 · Journal of Medicinal Chemistry · DOI

Full title: Discovery of ABBV-154, an anti-TNF Glucocorticoid Receptor Modulator Immunology Antibody-Drug Conjugate (iADC).

Authors: A. Hobson; Jianwen Xu; Dennie S. Welch; C. C. Marvin; Michael McPherson; Bradley Gates; Xiaoli Liao; Markus Hollmann; Michael J Gattner; Kristina Dzeyk; H. Sarvaiya; Vikram M Shenoy; Margaret M. Fettis; Agnieszka K Bischoff; Lu Wang; Ling C Santora; Lu Wang; J. Fitzgibbons; Paulin L Salomon; Axel Hernandez; Ying Jia; C. Goess; S. Mathieu; S. Bryant; Mary E Larsen; Baoliang Cui; Yu Tian

Year: 2023

Venue: Journal of Medicinal Chemistry

DOI: https://doi.org/10.1021/acs.jmedchem.3c01174

Paper Antibody-Vincristine Conjugates as Potent Anticancer Therapeutic Agents.

Agathe Boos; Julien Most; Héloïse Cahuzac et al. · 2024 · Journal of Medicinal Chemistry · DOI

Full title: Antibody-Vincristine Conjugates as Potent Anticancer Therapeutic Agents.

Authors: Agathe Boos; Julien Most; Héloïse Cahuzac; Louis Moreira da Silva; François Daubeuf; Stéphane Erb; Sarah Cianférani; Oscar Hernandez-Alba; Constantin Semenchenko; I. Dovgan; S. Kolodych; Alexandre Detappe; Françoise Dantzer; Alain Wagner; Maria Zeniou; Guilhem Chaubet

Year: 2024

Venue: Journal of Medicinal Chemistry

DOI: https://doi.org/10.1021/acs.jmedchem.4c02425

Paper Site-Specific Stability Evaluation of Antibody-Drug Conjugate in Serum Using a Validated Liquid Chromatography-Mass Spectrometry Method.

Meiling Qi; Chenyue Zhu; Yi Chen et al. · 2024 · Journal of Proteome Research · DOI

Full title: Site-Specific Stability Evaluation of Antibody-Drug Conjugate in Serum Using a Validated Liquid Chromatography-Mass Spectrometry Method.

Authors: Meiling Qi; Chenyue Zhu; Yi Chen; Chenxi Wang; Xinyuan Ye; Sen Li; Zhongzhe Cheng; Hongliang Jiang; Zhifeng Du

Year: 2024

Venue: Journal of Proteome Research

DOI: https://doi.org/10.1021/acs.jproteome.4c00631

Paper Discovery and Optimization of a STING Agonist Platform for Application in Antibody Drug Conjugates

Jeremy R. Duvall; Joshua D Thomas; R. Bukhalid et al. · 2023 · Journal of Medicinal Chemistry · DOI

Full title: Discovery and Optimization of a STING Agonist Platform for Application in Antibody Drug Conjugates

Authors: Jeremy R. Duvall; Joshua D Thomas; R. Bukhalid; Kalli C. Catcott; Keith W Bentley; S. Collins; Timothy K Eitas; Brian Jones; Eugene W Kelleher; K. Lancaster; M. Protopopova; Soumya S. Ray; Elena Ter-Ovanesyan; Ling Xu; Liping Yang; J. Zurita; M. Damelin; D. Toader; T. Lowinger

Year: 2023

Venue: Journal of Medicinal Chemistry

DOI: https://doi.org/10.1021/acs.jmedchem.3c00907

Paper Evaluation of Double Self-Immolative Linker-Based Antibody-Drug Conjugate FDA022-BB05 with Enhanced Therapeutic Potential.

Zhang, Yifan; Wang, Lei; Cao, Xuemei et al. · 2024 · Journal of medicinal chemistry · DOI

Full title: Evaluation of Double Self-Immolative Linker-Based Antibody-Drug Conjugate FDA022-BB05 with Enhanced Therapeutic Potential.

Authors: Zhang, Yifan; Wang, Lei; Cao, Xuemei; Song, Ruiwen; Yin, Sicheng; Cheng, Zhiyang; Li, Weinan; Shen, Keyu; Zhao, Teng; Xu, Jun; Liu, Shuangxi; Xie, Qian; Wu, Yinghan; Gao, Bei; Guo, Qingsong; Wu, Jingsong; Qiu, Xuefei; Wang, Baoxia; Zhang, Wenbo; Yang, Tong; Lu, Wei; Zhu, Shulei

Year: 2024

Venue: Journal of medicinal chemistry

DOI: https://doi.org/10.1021/acs.jmedchem.4c02243

Paper Recent Advances in Peptide Linkers of Antibody-Drug Conjugates.

Yang, Lu; Ma, Jiahui; Liu, Ben et al. · 2025 · Journal of medicinal chemistry · DOI

Full title: Recent Advances in Peptide Linkers of Antibody-Drug Conjugates.

Authors: Yang, Lu; Ma, Jiahui; Liu, Ben; Li, Yangbing; Ma, Yaping; Chen, Hao; Han, Zhijian

Year: 2025

Venue: Journal of medicinal chemistry

DOI: https://doi.org/10.1021/acs.jmedchem.5c01500

Paper Chemical Modification of Linkers Provides Stable Linker-Payloads for the Generation of Antibody-Drug Conjugates.

Yam B. Poudel; N. Chowdari; Heng Cheng et al. · 2020 · ACS Medicinal Chemistry Letters · DOI

Full title: Chemical Modification of Linkers Provides Stable Linker-Payloads for the Generation of Antibody-Drug Conjugates.

Authors: Yam B. Poudel; N. Chowdari; Heng Cheng; Christiana I. Iwuagwu; D. King; Srikanth Kotapati; D. Passmore; R. Rampulla; A. Mathur; G. Vite; S. Gangwar

Year: 2020

Venue: ACS Medicinal Chemistry Letters

DOI: https://doi.org/10.1021/acsmedchemlett.0c00325

Paper Chemical Site-Specific Conjugation Platform to Improve the Pharmacokinetics and Therapeutic Index of Antibody-Drug Conjugates.

Matsuda, Yutaka; Seki, Takuya; Yamada, Kei et al. · 2021 · Molecular pharmaceutics · DOI

Full title: Chemical Site-Specific Conjugation Platform to Improve the Pharmacokinetics and Therapeutic Index of Antibody-Drug Conjugates.

Authors: Matsuda, Yutaka; Seki, Takuya; Yamada, Kei; Ooba, Yuri; Takahashi, Kazutoshi; Fujii, Tomohiro; Kawaguchi, Sayaka; Narita, Takahiro; Nakayama, Akira; Kitahara, Yoshiro; Mendelsohn, Brian A; Okuzumi, Tatsuya

Year: 2021

Venue: Molecular pharmaceutics

DOI: https://doi.org/10.1021/acs.molpharmaceut.1c00473

Paper Recent Advances in Peptide Linkers for Antibody-Drug Conjugates.

Shaoting Li; Yu Guo; Jinxin Che et al. · 2025 · Journal of Medicinal Chemistry · DOI

Full title: Recent Advances in Peptide Linkers for Antibody-Drug Conjugates.

Authors: Shaoting Li; Yu Guo; Jinxin Che; Haibin Dai; Xiaowu Dong

Year: 2025

Venue: Journal of Medicinal Chemistry

DOI: https://doi.org/10.1021/acs.jmedchem.5c01982

Paper Visualizing Galectin-3 Binding Protein Expression with ImmunoPET

Outi M Keinänen; Samantha M. Sarrett; Samantha Delaney et al. · 2023 · Molecular Pharmaceutics · DOI

Full title: Visualizing Galectin-3 Binding Protein Expression with ImmunoPET

Authors: Outi M Keinänen; Samantha M. Sarrett; Samantha Delaney; Cindy Rodriguez; Eric J. Dayts; E. Capone; Frederic Sauniere; R. Ippoliti; G. Sala; S. Iacobelli; Brian M. Zeglis

Year: 2023

Venue: Molecular Pharmaceutics

DOI: https://doi.org/10.1021/acs.molpharmaceut.3c00241

Paper Small Molecule-Drug Conjugates: An Emerging Drug Design Strategy for Targeted Therapeutics.

Xiaolong Wang; Can Guo; Jikuan Shao et al. · 2025 · Journal of Medicinal Chemistry · DOI

Full title: Small Molecule-Drug Conjugates: An Emerging Drug Design Strategy for Targeted Therapeutics.

Authors: Xiaolong Wang; Can Guo; Jikuan Shao; Xinyu Zou; Shuaishuai Xing; Chunlei Xu; Qun Zhao; Yulan Wu; Chengliang Sun; Yao Chen; Haopeng Sun

Year: 2025

Venue: Journal of Medicinal Chemistry

DOI: https://doi.org/10.1021/acs.jmedchem.5c01861

Paper Effect of Linker Stereochemistry on the Activity of Indolinobenzodiazepine Containing Antibody-Drug Conjugates (ADCs).

Reid, Emily E; Archer, Katie E; Shizuka, Manami et al. · 2019 · ACS medicinal chemistry letters · DOI

Full title: Effect of Linker Stereochemistry on the Activity of Indolinobenzodiazepine Containing Antibody-Drug Conjugates (ADCs).

Authors: Reid, Emily E; Archer, Katie E; Shizuka, Manami; Wilhelm, Alan; Yoder, Nicholas C; Bai, Chen; Fishkin, Nathan E; Harris, Luke; Maloney, Erin K; Salomon, Paulin; Hong, Erica; Wu, Rui; Ab, Olga; Jin, Shan; Lai, Katharine C; Sikka, Surina; Chari, Ravi V J; Miller, Michael L

Year: 2019

Venue: ACS medicinal chemistry letters

DOI: https://doi.org/10.1021/acsmedchemlett.9b00240

Paper Site-Selective Anti-PD-L1 Antibody-MMAE Conjugate for Enhanced NSCLC Therapy.

Se Jeong Kwon; Jinyoung Son; Sang J. Chung · 2025 · ACS Medicinal Chemistry Letters · DOI

Full title: Site-Selective Anti-PD-L1 Antibody-MMAE Conjugate for Enhanced NSCLC Therapy.

Authors: Se Jeong Kwon; Jinyoung Son; Sang J. Chung

Year: 2025

Venue: ACS Medicinal Chemistry Letters

DOI: https://doi.org/10.1021/acsmedchemlett.5c00178

Paper Antibody-Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs.

Behrens, Christopher R; Ha, Edward H; Chinn, Lawrence L et al. · 2015 · Molecular pharmaceutics · DOI

Full title: Antibody-Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs.

Authors: Behrens, Christopher R; Ha, Edward H; Chinn, Lawrence L; Bowers, Simeon; Probst, Gary; Fitch-Bruhns, Maureen; Monteon, Jorge; Valdiosera, Amanda; Bermudez, Abel; Liao-Chan, Sindy; Wong, Tiffany; Melnick, Jonathan; Theunissen, Jan-Willem; Flory, Mark R; Houser, Derrick; Venstrom, Kristy; Levashova, Zoia; Sauer, Paul; Migone, Thi-Sau; van der Horst, Edward H; Halcomb, Randall L; Jackson, David Y

Year: 2015

Venue: Molecular pharmaceutics

DOI: https://doi.org/10.1021/acs.molpharmaceut.5b00432

Paper Development of 5D3-DM1: A Novel Anti-Prostate-Specific Membrane Antigen Antibody-Drug Conjugate for PSMA-Positive Prostate Cancer Therapy.

Colin T Huang; Xin Guo; C. Bařinka et al. · 2020 · Molecular Pharmaceutics · DOI

Full title: Development of 5D3-DM1: A Novel Anti-Prostate-Specific Membrane Antigen Antibody-Drug Conjugate for PSMA-Positive Prostate Cancer Therapy.

Authors: Colin T Huang; Xin Guo; C. Bařinka; Shawn E Lupold; M. Pomper; K. Gabrielson; V. Raman; D. Artemov; S. Hapuarachchige

Year: 2020

Venue: Molecular Pharmaceutics

DOI: https://doi.org/10.1021/acs.molpharmaceut.0c00457

Paper DNA-Model-Based Design and Execution of Some Fused Benzodiazepine Hybrid Payloads for Antibody-Drug Conjugate Modality.

P. Sivaprakasam; I. Mcdonald; Christiana I. Iwuagwu et al. · 2021 · ACS Medicinal Chemistry Letters · DOI

Full title: DNA-Model-Based Design and Execution of Some Fused Benzodiazepine Hybrid Payloads for Antibody-Drug Conjugate Modality.

Authors: P. Sivaprakasam; I. Mcdonald; Christiana I. Iwuagwu; N. Chowdari; K. Peese; D. Langley; Heng Cheng; M. Luzung; Michael A. Schmidt; B. Zheng; Yichen Tan; Patricia Y Cho; S. Rakshit; Thirumalai Lakshminarasimhan; Sivakrishna Guturi; K. Kanagavel; Umamaheswararao Kanusu; Ankita G. Niyogi; Somprabha Sidhar; R. Vaidyanathan; Martin D. Eastgate; Srikanth Kotapati; Madhura Deshpande; C. Pan; P. Cardarelli; Chunshan Xie; Chetana Rao; Patrick G. Holder; G. Sarma; G. Vite; S. Gangwar

Year: 2021

Venue: ACS Medicinal Chemistry Letters

DOI: https://doi.org/10.1021/acsmedchemlett.0c00578

Paper Optimization of Tubulysin Antibody-Drug Conjugates: A Case Study in Addressing ADC Metabolism.

Tumey, L Nathan; Leverett, Carolyn A; Vetelino, Beth et al. · 2016 · ACS medicinal chemistry letters · DOI

Full title: Optimization of Tubulysin Antibody-Drug Conjugates: A Case Study in Addressing ADC Metabolism.

Authors: Tumey, L Nathan; Leverett, Carolyn A; Vetelino, Beth; Li, Fengping; Rago, Brian; Han, Xiaogang; Loganzo, Frank; Musto, Sylvia; Bai, Guoyun; Sukuru, Sai Chetan K; Graziani, Edmund I; Puthenveetil, Sujiet; Casavant, Jeffrey; Ratnayake, Anokha; Marquette, Kimberly; Hudson, Sarah; Doppalapudi, Venkata Ramana; Stock, Joseph; Tchistiakova, Lioudmila; Bessire, Andrew J; Clark, Tracey; Lucas, Judy; Hosselet, Christine; O'Donnell, Christopher J; Subramanyam, Chakrapani

Year: 2016

Venue: ACS medicinal chemistry letters

DOI: https://doi.org/10.1021/acsmedchemlett.6b00195

Paper Altering Antibody-Drug Conjugate Binding to the Neonatal Fc Receptor Impacts Efficacy and Tolerability.

Hamblett, Kevin J; Le, Tiep; Rock, Brooke M et al. · 2016 · Molecular pharmaceutics · DOI

Full title: Altering Antibody-Drug Conjugate Binding to the Neonatal Fc Receptor Impacts Efficacy and Tolerability.

Authors: Hamblett, Kevin J; Le, Tiep; Rock, Brooke M; Rock, Dan A; Siu, Sophia; Huard, Justin N; Conner, Kip P; Milburn, Robert R; O'Neill, Jason W; Tometsko, Mark E; Fanslow, William C

Year: 2016

Venue: Molecular pharmaceutics

DOI: https://doi.org/10.1021/acs.molpharmaceut.6b00153

Paper In Vitro and In Vivo Evaluation of Cysteine Rebridged Trastuzumab-MMAE Antibody Drug Conjugates with Defined Drug-to-Antibody Ratios.

Penny Bryant; M. Pabst; George O. Badescu et al. · 2015 · Molecular Pharmaceutics · DOI

Full title: In Vitro and In Vivo Evaluation of Cysteine Rebridged Trastuzumab-MMAE Antibody Drug Conjugates with Defined Drug-to-Antibody Ratios.

Authors: Penny Bryant; M. Pabst; George O. Badescu; M. Bird; W. McDowell; Estera Jamieson; Julia Swierkosz; Kosma Jurlewicz; R. Tommasi; K. Henseleit; Xiaobo Sheng; N. Camper; Anaïs Manin; K. Kozakowska; K. Peciak; Emmanuelle Laurine; R. Grygorash; Andrew F. Kyle; David Morris; Vimal Parekh; Amrita Abhilash; J. Choi; Jeff Edwards; M. Frigerio; M. Baker; A. Godwin

Year: 2015

Venue: Molecular Pharmaceutics

DOI: https://doi.org/10.1021/acs.molpharmaceut.5b00116

Paper Detailed Structural Elucidation of Antibody-Drug Conjugate Biotransformation Species Using High Resolution Multiple Reaction Monitoring Mass Spectrometry with Orthogonal Dissociation Methods

Junyan Yang; Hui Yin Tan; Jiaqi Yuan et al. · 2024 · ACS Pharmacology & Translational Science · DOI

Full title: Detailed Structural Elucidation of Antibody-Drug Conjugate Biotransformation Species Using High Resolution Multiple Reaction Monitoring Mass Spectrometry with Orthogonal Dissociation Methods

Authors: Junyan Yang; Hui Yin Tan; Jiaqi Yuan; Yue Huang; A. Rosenbaum

Year: 2024

Venue: ACS Pharmacology & Translational Science

DOI: https://doi.org/10.1021/acsptsci.4c00445

Paper Distinctive Low-Resolution Structural Features of Dimers of Antibody Drug Conjugates and Parent Antibody determined by Small-Angle X-Ray Scattering.

Didier Law-Hine; Sergii Rudiuk; Audrey Bonestebe et al. · 2019 · Molecular Pharmaceutics · DOI

Full title: Distinctive Low-Resolution Structural Features of Dimers of Antibody Drug Conjugates and Parent Antibody determined by Small-Angle X-Ray Scattering.

Authors: Didier Law-Hine; Sergii Rudiuk; Audrey Bonestebe; Romain Ienco; S. Huille; C. Tribet

Year: 2019

Venue: Molecular Pharmaceutics

DOI: https://doi.org/10.1021/acs.molpharmaceut.9b00792

Paper Optimizing lysosomal activation of antibody-drug conjugates (ADCs) by incorporation of novel cleavable dipeptide linkers.

Paulin L. Salomon; E. E. Reid; Katie E. Archer et al. · 2019 · Molecular Pharmaceutics · DOI

Full title: Optimizing lysosomal activation of antibody-drug conjugates (ADCs) by incorporation of novel cleavable dipeptide linkers.

Authors: Paulin L. Salomon; E. E. Reid; Katie E. Archer; Luke Harris; E. K. Maloney; Alan J. Wilhelm; Michael L. Miller; R. Chari; T. Keating; Rajeeva Singh

Year: 2019

Venue: Molecular Pharmaceutics

DOI: https://doi.org/10.1021/acs.molpharmaceut.9b00696

Paper Lactone Stabilization is Not a Necessary Feature for Antibody Conjugates of Camptothecins.

Uland Y. Lau; Lauren T Benoit; Nicole Stevens et al. · 2018 · Molecular Pharmaceutics · DOI

Full title: Lactone Stabilization is Not a Necessary Feature for Antibody Conjugates of Camptothecins.

Authors: Uland Y. Lau; Lauren T Benoit; Nicole Stevens; Kim K. Emmerton; Margo Zaval; Julia H Cochran; P. Senter

Year: 2018

Venue: Molecular Pharmaceutics

DOI: https://doi.org/10.1021/acs.molpharmaceut.8b00477

Paper AbClick Pro H: Scavenger-Free, Traceless Lys248 Conjugation Via O-Acyl Hydroxamate Chemistry for Homogeneous Antibody-Drug Conjugates (ADCs).

Jinyoung Son; Jin Woo Seo; Sun Hee Park et al. · 2025 · Organic Letters · DOI

Full title: AbClick Pro H: Scavenger-Free, Traceless Lys248 Conjugation Via O-Acyl Hydroxamate Chemistry for Homogeneous Antibody-Drug Conjugates (ADCs).

Authors: Jinyoung Son; Jin Woo Seo; Sun Hee Park; Hojin Yeom; Nayoung Ko; Young Geun Lee; Jinyoung Kim; Ju Hwan Kim; Seong-Hyun Park; Taedong Han; Sang J. Chung

Year: 2025

Venue: Organic Letters

DOI: https://doi.org/10.1021/acs.orglett.5c04902

Paper Antibody-Drug Conjugates (ADCs) with Indolinobenzodiazepine Dimer (IGN) Payloads: DNA-Binding Mechanism of IGN Catabolites in Target Cancer Cells.

Rajeeva Singh; E. E. Reid; Luke Harris et al. · 2019 · Molecular Pharmaceutics · DOI

Full title: Antibody-Drug Conjugates (ADCs) with Indolinobenzodiazepine Dimer (IGN) Payloads: DNA-Binding Mechanism of IGN Catabolites in Target Cancer Cells.

Authors: Rajeeva Singh; E. E. Reid; Luke Harris; Paulin L. Salomon; Michael L. Miller; R. Chari; T. Keating

Year: 2019

Venue: Molecular Pharmaceutics

DOI: https://doi.org/10.1021/acs.molpharmaceut.9b00675

Paper Biological Evaluation of Cleavable Linkers in Exatecan-Based Antibody–Drug Conjugates: A Comparative Study of DXd and Exo-Linker Platforms

Tomohiro Watanabe; Yusuke Iwai; Natsuki Shikida et al. · 2025 · ACS Omega · DOI

Full title: Biological Evaluation of Cleavable Linkers in Exatecan-Based Antibody–Drug Conjugates: A Comparative Study of DXd and Exo-Linker Platforms

Authors: Tomohiro Watanabe; Yusuke Iwai; Natsuki Shikida; J. Stofleth; Tomohiro Fujii; Takuya Seki; Kazutaka Shimbo; Yutaka Matsuda

Year: 2025

Venue: ACS Omega

DOI: https://doi.org/10.1021/acsomega.5c03755

Paper Thiolation of Q295: Site-Specific Conjugation of Hydrophobic Payloads without the Need for Genetic Engineering.

Samantha R. Benjamin; Courtney P Jackson; S. Fang et al. · 2019 · Molecular Pharmaceutics · DOI

Full title: Thiolation of Q295: Site-Specific Conjugation of Hydrophobic Payloads without the Need for Genetic Engineering.

Authors: Samantha R. Benjamin; Courtney P Jackson; S. Fang; Dane P Carlson; Zhongyuan Guo; L. N. Tumey

Year: 2019

Venue: Molecular Pharmaceutics

DOI: https://doi.org/10.1021/acs.molpharmaceut.9b00323

Paper Development of a Small Molecule Tubulysin B Conjugate for Treatment of Carbonic Anhydrase IX Receptor Expressing Cancers.

Isaac S. Marks; Spencer Gardeen; Sarah J. Kurdziel et al. · 2018 · Molecular Pharmaceutics · DOI

Full title: Development of a Small Molecule Tubulysin B Conjugate for Treatment of Carbonic Anhydrase IX Receptor Expressing Cancers.

Authors: Isaac S. Marks; Spencer Gardeen; Sarah J. Kurdziel; Sonia T. Nicolaou; J. Evan Woods; S. Kularatne; Philip S. Low

Year: 2018

Venue: Molecular Pharmaceutics

DOI: https://doi.org/10.1021/acs.molpharmaceut.8b00139

Paper Study on the Heterogeneity of T-DM1 and the Analysis of the Unconjugated Linker Structure under a Stable Conjugation Process

Guanghao Wu; Yanbo Gao; Datao Liu et al. · 2019 · ACS Omega · DOI

Full title: Study on the Heterogeneity of T-DM1 and the Analysis of the Unconjugated Linker Structure under a Stable Conjugation Process

Authors: Guanghao Wu; Yanbo Gao; Datao Liu; Xiaoding Tan; Lide Hu; Zidan Qiu; Jingyan Liu; Huidan He; Yanjun Liu

Year: 2019

Venue: ACS Omega

DOI: https://doi.org/10.1021/acsomega.9b00430

Paper Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity.

S. Doronina; B. Mendelsohn; Tim D. Bovee et al. · 2006 · Bioconjugate chemistry · DOI

Full title: Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity.

Authors: S. Doronina; B. Mendelsohn; Tim D. Bovee; C. Cerveny; S. Alley; Damon L. Meyer; E. Oflazoglu; B. Toki; R. Sanderson; R. Zabinski; A. Wahl; P. Senter

Year: 2006

Venue: Bioconjugate chemistry

DOI: https://doi.org/10.1021/bc0502917

Paper High-Throughput, Multispecies, Parallelized Plasma Stability Assay for the Determination and Characterization of Antibody–Drug Conjugate Aggregation and Drug Release

Kenneth R. Durbin; M. S. Nottoli; Nathaniel D. Catron et al. · 2017 · ACS Omega · DOI

Full title: High-Throughput, Multispecies, Parallelized Plasma Stability Assay for the Determination and Characterization of Antibody–Drug Conjugate Aggregation and Drug Release

Authors: Kenneth R. Durbin; M. S. Nottoli; Nathaniel D. Catron; Nicole Richwine; Gary J. Jenkins

Year: 2017

Venue: ACS Omega

DOI: https://doi.org/10.1021/acsomega.7b00452

Paper Evaluation of Antibody–Drug Conjugate Performances Using a Novel HPLC–DAD Method for Tumor-Specific Detection of DM4 and S‑Methyl-DM4

Giulio Lovato; M. Perrucci; Ilaria Cela et al. · 2025 · ACS Omega · DOI

Full title: Evaluation of Antibody–Drug Conjugate Performances Using a Novel HPLC–DAD Method for Tumor-Specific Detection of DM4 and S‑Methyl-DM4

Authors: Giulio Lovato; M. Perrucci; Ilaria Cela; A. Lamolinara; Arianna Mercatelli; Vincenzo De Laurenzi; E. Capone; Marcello Locatelli; Gianluca Sala

Year: 2025

Venue: ACS Omega

DOI: https://doi.org/10.1021/acsomega.5c07693

Paper Comparative Enzymatic and Stability Assays Reveal GPLG as an Effective Cathepsin B Cleavable Linker for Tumor-Targeting Drug Conjugates

Giulia Cazzaniga; M. Zambra; Samuele Bongiolo et al. · 2025 · ACS Omega · DOI

Full title: Comparative Enzymatic and Stability Assays Reveal GPLG as an Effective Cathepsin B Cleavable Linker for Tumor-Targeting Drug Conjugates

Authors: Giulia Cazzaniga; M. Zambra; Samuele Bongiolo; Helena Prpić; Elettra Fasola; F. Arrigoni; Umberto Piarulli; Silvia Gazzola

Year: 2025

Venue: ACS Omega

DOI: https://doi.org/10.1021/acsomega.5c05758

Paper Contribution of linker stability to the activities of anticancer immunoconjugates.

S. Alley; Dennis R. Benjamin; S. Jeffrey et al. · 2008 · Bioconjugate chemistry · DOI

Full title: Contribution of linker stability to the activities of anticancer immunoconjugates.

Authors: S. Alley; Dennis R. Benjamin; S. Jeffrey; N. Okeley; Damon L. Meyer; R. Sanderson; P. Senter

Year: 2008

Venue: Bioconjugate chemistry

DOI: https://doi.org/10.1021/bc7004329

Paper Impact of drug conjugation on pharmacokinetics and tissue distribution of anti-STEAP1 antibody-drug conjugates in rats.

C. A. Boswell; E. E. Mundo; Crystal Zhang et al. · 2011 · Bioconjugate chemistry · DOI

Full title: Impact of drug conjugation on pharmacokinetics and tissue distribution of anti-STEAP1 antibody-drug conjugates in rats.

Authors: C. A. Boswell; E. E. Mundo; Crystal Zhang; Daniela Bumbaca; Nicole R. Valle; K. Kozak; Aimee Fourie; Josefa Chuh; Neelima Koppada; Ola M. Saad; Herman Gill; Ben-Quan Shen; B. Rubinfeld; J. Tibbitts; Surinder Kaur; F. Theil; Paul J. Fielder; L. Khawli; Kedan Lin

Year: 2011

Venue: Bioconjugate chemistry

DOI: https://doi.org/10.1021/bc200212a

Paper Secondary mAb--vcMMAE conjugates are highly sensitive reporters of antibody internalization via the lysosome pathway.

K. Klussman; B. Mixan; C. Cerveny et al. · 2004 · Bioconjugate chemistry · DOI

Full title: Secondary mAb--vcMMAE conjugates are highly sensitive reporters of antibody internalization via the lysosome pathway.

Authors: K. Klussman; B. Mixan; C. Cerveny; Damon L. Meyer; P. Senter; A. Wahl

Year: 2004

Venue: Bioconjugate chemistry

DOI: https://doi.org/10.1021/bc049969t

Paper Discovery of Pyrophosphate Diesters as Tunable, Soluble, and Bioorthogonal Linkers for Site-Specific Antibody-Drug Conjugates.

J. Kern; M. Cancilla; D. Dooney et al. · 2016 · Journal of the American Chemical Society · DOI

Full title: Discovery of Pyrophosphate Diesters as Tunable, Soluble, and Bioorthogonal Linkers for Site-Specific Antibody-Drug Conjugates.

Authors: J. Kern; M. Cancilla; D. Dooney; Kristen Kwasnjuk; Rena Zhang; M. Beaumont; I. Figueroa; SuChun Hsieh; Linda Liang; D. Tomazela; Jeffrey Zhang; P. Brandish; A. Palmieri; Peter Stivers; M. Cheng; Guo Feng; Prasanthi Geda; Sanjiv J. Shah; Andrew Beck; D. Bresson; Juhi Firdos; D. Gately; Nick A Knudsen; Anthony Manibusan; P. Schultz; Ying Sun; R. Garbaccio

Year: 2016

Venue: Journal of the American Chemical Society

DOI: https://doi.org/10.1021/jacs.5b12547

Paper Novel peptide linkers for highly potent antibody-auristatin conjugate.

Doronina, Svetlana O; Bovee, Tim D; Meyer, David W et al. · 2008 · Bioconjugate chemistry · DOI

Full title: Novel peptide linkers for highly potent antibody-auristatin conjugate.

Authors: Doronina, Svetlana O; Bovee, Tim D; Meyer, David W; Miyamoto, Jamie B; Anderson, Martha E; Morris-Tilden, Carol A; Senter, Peter D

Year: 2008

Venue: Bioconjugate chemistry

DOI: https://doi.org/10.1021/bc800289a

Paper Improving the Serum Stability of Site-Specific Antibody Conjugates with Sulfone Linkers

James T. Patterson; Shigehiro Asano; Xiuling Li et al. · 2014 · Bioconjugate chemistry · DOI

Full title: Improving the Serum Stability of Site-Specific Antibody Conjugates with Sulfone Linkers

Authors: James T. Patterson; Shigehiro Asano; Xiuling Li; C. Rader; C. Barbas

Year: 2014

Venue: Bioconjugate chemistry

DOI: https://doi.org/10.1021/bc500276m

Paper Production of site-specific antibody-drug conjugates using optimized non-natural amino acids in a cell-free expression system.

Zimmerman, Erik S; Heibeck, Tyler H; Gill, Avinash et al. · 2014 · Bioconjugate chemistry · DOI

Full title: Production of site-specific antibody-drug conjugates using optimized non-natural amino acids in a cell-free expression system.

Authors: Zimmerman, Erik S; Heibeck, Tyler H; Gill, Avinash; Li, Xiaofan; Murray, Christopher J; Madlansacay, Mary Rose; Tran, Cuong; Uter, Nathan T; Yin, Gang; Rivers, Patrick J; Yam, Alice Y; Wang, Willie D; Steiner, Alexander R; Bajad, Sunil U; Penta, Kalyani; Yang, Wenjin; Hallam, Trevor J; Thanos, Christopher D; Sato, Aaron K

Year: 2014

Venue: Bioconjugate chemistry

DOI: https://doi.org/10.1021/bc400490z

Paper Single Mutation on Trastuzumab Modulates the Stability of Antibody–Drug Conjugates Built Using Acetal-Based Linkers and Thiol-Maleimide Chemistry

Xhenti Ferhati; Ester Jiménez-Moreno; E. Hoyt et al. · 2022 · Journal of the American Chemical Society · DOI

Full title: Single Mutation on Trastuzumab Modulates the Stability of Antibody–Drug Conjugates Built Using Acetal-Based Linkers and Thiol-Maleimide Chemistry

Authors: Xhenti Ferhati; Ester Jiménez-Moreno; E. Hoyt; Giulia Salluce; Mar Cabeza-Cabrerizo; Claudio D. Navo; I. Compañón; P. Akkapeddi; M. Matos; Noelia Salaverri; Pablo Garrido; Alfredo Martínez; V. Laserna; Thomas V Murray; Gonzalo Jiménez‐Osés; P. Ravn; G. Bernardes; F. Corzana

Year: 2022

Venue: Journal of the American Chemical Society

DOI: https://doi.org/10.1021/jacs.1c07675

Paper Site-Specific Conjugation of Monomethyl Auristatin E to Anti-CD30 Antibodies Improves Their Pharmacokinetics and Therapeutic Index in Rodent Models.

Lhospice, F; Brégeon, D; Belmant, C et al. · 2015 · Molecular pharmaceutics · DOI

Full title: Site-Specific Conjugation of Monomethyl Auristatin E to Anti-CD30 Antibodies Improves Their Pharmacokinetics and Therapeutic Index in Rodent Models.

Authors: Lhospice, F; Brégeon, D; Belmant, C; Dennler, P; Chiotellis, A; Fischer, E; Gauthier, L; Boëdec, A; Rispaud, H; Savard-Chambard, S; Represa, A; Schneider, N; Paturel, C; Sapet, M; Delcambre, C; Ingoure, S; Viaud, N; Bonnafous, C; Schibli, R; Romagné, F

Year: 2015

Venue: Molecular pharmaceutics

DOI: https://doi.org/10.1021/mp500666j

Paper Design, Synthesis, and Evaluation of Linker-Duocarmycin Payloads: Toward Selection of HER2-Targeting Antibody-Drug Conjugate SYD985.

R. Elgersma; Ruud G. E. Coumans; T. Huijbregts et al. · 2015 · Molecular Pharmaceutics · DOI

Full title: Design, Synthesis, and Evaluation of Linker-Duocarmycin Payloads: Toward Selection of HER2-Targeting Antibody-Drug Conjugate SYD985.

Authors: R. Elgersma; Ruud G. E. Coumans; T. Huijbregts; W. Menge; J. Joosten; H. Spijker; F. M. D. de Groot; M. V. D. Van der Lee; R. Ubink; D. J. van den Dobbelsteen; D. Egging; Wim H A Dokter; G. Verheijden; J. Lemmens; C. Timmers; P. Beusker

Year: 2015

Venue: Molecular Pharmaceutics

DOI: https://doi.org/10.1021/mp500781a

Paper Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index.

Junutula, Jagath R; Raab, Helga; Clark, Suzanna et al. · 2008 · Nature biotechnology · DOI

Full title: Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index.

Authors: Junutula, Jagath R; Raab, Helga; Clark, Suzanna; Bhakta, Sunil; Leipold, Douglas D; Weir, Sylvia; Chen, Yvonne; Simpson, Michelle; Tsai, Siao Ping; Dennis, Mark S; Lu, Yanmei; Meng, Y Gloria; Ng, Carl; Yang, Jihong; Lee, Chien C; Duenas, Eileen; Gorrell, Jeffrey; Katta, Viswanatham; Kim, Amy; McDorman, Kevin; Flagella, Kelly; Venook, Rayna; Ross, Sarajane; Spencer, Susan D; Lee Wong, Wai; Lowman, Henry B; Vandlen, Richard; Sliwkowski, Mark X; Scheller, Richard H; Polakis, Paul; Mallet, William

Year: 2008

Venue: Nature biotechnology

DOI: https://doi.org/10.1038/nbt.1480

Paper Hijacking Extracellular Targeted Protein Degrader–Drug Conjugates for Enhanced Drug Delivery

Fangzhu Zhao; Yan Wu; K. Schaefer et al. · 2025 · Journal of the American Chemical Society · DOI

Full title: Hijacking Extracellular Targeted Protein Degrader–Drug Conjugates for Enhanced Drug Delivery

Authors: Fangzhu Zhao; Yan Wu; K. Schaefer; Yun Zhang; Kun Miao; Zi Yao; Snehal D Ganjave; Kaan Kumru; Trenton M. Peters-Clarke; Alex Inague; James A. Olzmann; K. Leung; James A. Wells

Year: 2025

Venue: Journal of the American Chemical Society

DOI: https://doi.org/10.1021/jacs.5c15047

Paper Targeted Delivery of an Anti-inflammatory PDE4 Inhibitor to Immune Cells via an Antibody-drug Conjugate.

Shan Yu; Aaron D. Pearson; Reyna K V Lim et al. · 2016 · Molecular Therapy · DOI

Full title: Targeted Delivery of an Anti-inflammatory PDE4 Inhibitor to Immune Cells via an Antibody-drug Conjugate.

Authors: Shan Yu; Aaron D. Pearson; Reyna K V Lim; David T. Rodgers; Sijia Li; Holly Parker; M. Weglarz; Eric N. Hampton; Michael J. Bollong; Jiayin Shen; C. Zambaldo; Danling Wang; A. Woods; T. Wright; P. Schultz; Stephanie A. Kazane; T. Young; Matthew S. Tremblay

Year: 2016

Venue: Molecular Therapy

DOI: https://doi.org/10.1038/mt.2016.175

Paper Synthesis and Biological Evaluation of Shishijimicin A-Type Linker-Drugs and Antibody-Drug Conjugates.

K. Nicolaou; Ruofan Li; Qifeng Chen et al. · 2020 · Journal of the American Chemical Society · DOI

Full title: Synthesis and Biological Evaluation of Shishijimicin A-Type Linker-Drugs and Antibody-Drug Conjugates.

Authors: K. Nicolaou; Ruofan Li; Qifeng Chen; Zhaoyong Lu; E. Pitsinos; A. Schammel; B. Lin; Christine Gu; H. Sarvaiya; Robert Tchelepi; Amanda Valdiosera; J. Clubb; Nicole Barbour; V. Sisodiya; Joseph Sandoval; Christina Lee; M. Aujay; J. Gavrilyuk

Year: 2020

Venue: Journal of the American Chemical Society

DOI: https://doi.org/10.1021/jacs.0c06554

Paper Targeted drug delivery through the traceless release of tertiary and heteroaryl amines from antibody-drug conjugates.

Staben, Leanna R; Koenig, Stefan G; Lehar, Sophie M et al. · 2016 · Nature chemistry · DOI

Full title: Targeted drug delivery through the traceless release of tertiary and heteroaryl amines from antibody-drug conjugates.

Authors: Staben, Leanna R; Koenig, Stefan G; Lehar, Sophie M; Vandlen, Richard; Zhang, Donglu; Chuh, Josefa; Yu, Shang-Fan; Ng, Carl; Guo, Jun; Liu, Yanzhou; Fourie-O'Donohue, Aimee; Go, MaryAnn; Linghu, Xin; Segraves, Nathaniel L; Wang, Tao; Chen, Jinhua; Wei, BinQing; Phillips, Gail D Lewis; Xu, Keyang; Kozak, Katherine R; Mariathasan, Sanjeev; Flygare, John A; Pillow, Thomas H

Year: 2016

Venue: Nature chemistry

DOI: https://doi.org/10.1038/nchem.2635

Paper Second Generation Tiancimycin-Based Antibody-Drug Conjugates Enabled by Highly Efficient Semi-synthetic Approach Specifically Targeting B-Cell Malignancies.

Kiefer, Alexander F; Thirugnanasambantham, Pankajavalli; Jin, Yuan et al. · 2025 · JACS Au · DOI

Full title: Second Generation Tiancimycin-Based Antibody-Drug Conjugates Enabled by Highly Efficient Semi-synthetic Approach Specifically Targeting B-Cell Malignancies.

Authors: Kiefer, Alexander F; Thirugnanasambantham, Pankajavalli; Jin, Yuan; Steele, Andrew D; Hwang, Dobeen; Jiang, Yanlong; Adhikari, Ajeeth; Yang, Dong; Chang, Jing; Tafesse, Rakeb; Rader, Christoph; Muthusamy, Natarajan; Shen, Ben

Year: 2025

Venue: JACS Au

DOI: https://doi.org/10.1021/jacsau.5c00353

Paper Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index.

Lyon, Robert P; Bovee, Tim D; Doronina, Svetlana O et al. · 2015 · Nature biotechnology · DOI

Full title: Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index.

Authors: Lyon, Robert P; Bovee, Tim D; Doronina, Svetlana O; Burke, Patrick J; Hunter, Joshua H; Neff-LaFord, Haley D; Jonas, Mechthild; Anderson, Martha E; Setter, Jocelyn R; Senter, Peter D

Year: 2015

Venue: Nature biotechnology

DOI: https://doi.org/10.1038/nbt.3212

Paper Improving the therapeutic index in cancer therapy by using antibody-drug conjugates designed with a moderately cytotoxic drug.

Govindan, Serengulam V; Cardillo, Thomas M; Rossi, Edmund A et al. · 2015 · Molecular pharmaceutics · DOI

Full title: Improving the therapeutic index in cancer therapy by using antibody-drug conjugates designed with a moderately cytotoxic drug.

Authors: Govindan, Serengulam V; Cardillo, Thomas M; Rossi, Edmund A; Trisal, Preeti; McBride, William J; Sharkey, Robert M; Goldenberg, David M

Year: 2015

Venue: Molecular pharmaceutics

DOI: https://doi.org/10.1021/mp5006195

Paper The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma

P. Senter; E. Sievers · 2012 · Nature Biotechnology · DOI

Full title: The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma

Authors: P. Senter; E. Sievers

Year: 2012

Venue: Nature Biotechnology

DOI: https://doi.org/10.1038/nbt.2289

Paper PSMA-Targeting Chimeras for Cell-Type-Specific Degradation of Surface Immune Checkpoint Protein PD-L1

Yuqing Luo; Xiaoxiao Gong; Keren Peng et al. · 2026 · JACS Au · DOI

Full title: PSMA-Targeting Chimeras for Cell-Type-Specific Degradation of Surface Immune Checkpoint Protein PD-L1

Authors: Yuqing Luo; Xiaoxiao Gong; Keren Peng; Yanqing Yang; Meng Chen; Yu Guo; Kang Chen; Jinming Gao; Xing Su; Jinxin Che; Xiaowu Dong; Jiang-Jiang Tang; Xiaolei Zhang; Peng Teng; Ruhong Zhou

Year: 2026

Venue: JACS Au

DOI: https://doi.org/10.1021/jacsau.5c01216

Paper Anti-SSTR2 antibody-drug conjugate for neuroendocrine tumor therapy

Yingnan Si; Seulhee Kim; Jianfa Ou et al. · 2020 · Cancer Gene Therapy · DOI

Full title: Anti-SSTR2 antibody-drug conjugate for neuroendocrine tumor therapy

Authors: Yingnan Si; Seulhee Kim; Jianfa Ou; Yun Lu; Patrick Ernst; Kai Chen; J. Whitt; A. Carter; J. Markert; J. Bibb; Herbert Chen; Lufang Zhou; R. Jaskula-Sztul; X. Liu

Year: 2020

Venue: Cancer Gene Therapy

DOI: https://doi.org/10.1038/s41417-020-0196-5

Paper Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates

R. Lyon; J. Setter; Tim D. Bovee et al. · 2014 · Nature Biotechnology · DOI

Full title: Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates

Authors: R. Lyon; J. Setter; Tim D. Bovee; S. Doronina; J. Hunter; Martha E. Anderson; Cindy Balasubramanian; S. Duniho; C. Leiske; Fu Li; P. Senter

Year: 2014

Venue: Nature Biotechnology

DOI: https://doi.org/10.1038/nbt.2968

Paper Antibody-Drug Conjugates in Head and Neck Cancer

J. W. Kim · 2017 · DOI

Full title: Antibody-Drug Conjugates in Head and Neck Cancer

Authors: J. W. Kim

Year: 2017

DOI: https://doi.org/10.3342/kjorl-hns.2017.00031

Paper Evolving Therapeutic Paradigms in Bladder Cancer: the Impact of Immunotherapy and Antibody-Drug Conjugates

S. M. Ibrahim; Ahmed Attia Ahmed Abdelmoaty; Ahmed Helmy Abdelhaseb · 2025 · annals of urologic oncology · DOI

Full title: Evolving Therapeutic Paradigms in Bladder Cancer: the Impact of Immunotherapy and Antibody-Drug Conjugates

Authors: S. M. Ibrahim; Ahmed Attia Ahmed Abdelmoaty; Ahmed Helmy Abdelhaseb

Year: 2025

Venue: annals of urologic oncology

DOI: https://doi.org/10.32948/auo.2025.09.25

Paper Assembly of pH-Responsive Antibody-Inspired Protein-Drug Conjugates

Marco Raabe; A. Heck; Michaela Pieszka et al. · 2021 · DOI

Full title: Assembly of pH-Responsive Antibody-Inspired Protein-Drug Conjugates

Authors: Marco Raabe; A. Heck; Michaela Pieszka; Tao Wang; M. M. Zegota; L. Nuhn; D. Ng; S. Kuan; T. Weil

Year: 2021

DOI: https://doi.org/10.33774/chemrxiv-2021-5hvgc

Paper Development of Diazaborines as ROS Sensitive Linkers for the Construction of Stimuli-Responsive Antibody Drug Conjugates

Pedro M. P. Gois; J. António; J. Carvalho et al. · 2021 · DOI

Full title: Development of Diazaborines as ROS Sensitive Linkers for the Construction of Stimuli-Responsive Antibody Drug Conjugates

Authors: Pedro M. P. Gois; J. António; J. Carvalho; A. André; J. Dias; Hélio Faustino; Ricardo M R M Lopes; L. Veiros; G. Bernardes; Frederico Silva

Year: 2021

DOI: https://doi.org/10.33774/chemrxiv-2021-qh8zd

Paper Integrating Hematopoietic Stem Cell Transplantation (HSCT) and Targeted Antibody-Drug Conjugates (ADCs) in Leukemia Treatment: Current Landscape, Translational Advances, and Emerging Therapeutic Horizons

Malika Salhi · 2025 · Clinical Reviews & Cases · DOI

Full title: Integrating Hematopoietic Stem Cell Transplantation (HSCT) and Targeted Antibody-Drug Conjugates (ADCs) in Leukemia Treatment: Current Landscape, Translational Advances, and Emerging Therapeutic Horizons

Authors: Malika Salhi

Year: 2025

Venue: Clinical Reviews & Cases

DOI: https://doi.org/10.33425/2689-1069.1064

Paper Picking the optimal target for antibody-drug conjugates.

Rohan Mathur; G. Weiner · 2013 · American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting · DOI

Full title: Picking the optimal target for antibody-drug conjugates.

Authors: Rohan Mathur; G. Weiner

Year: 2013

Venue: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting

DOI: https://doi.org/10.1200/edbook_am.2013.33.e103

Paper Unmet Potential of Antibody-Drug Conjugates: An Evaluation of the Past, Present, and Future of Antibody-Drug Conjugate Development in Advanced Urothelial Carcinoma.

Kevin K. Zarrabi; Abhiraj Saxena; Kent W. Mouw et al. · 2025 · American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting · DOI

Full title: Unmet Potential of Antibody-Drug Conjugates: An Evaluation of the Past, Present, and Future of Antibody-Drug Conjugate Development in Advanced Urothelial Carcinoma.

Authors: Kevin K. Zarrabi; Abhiraj Saxena; Kent W. Mouw; V. Koshkin; Terence W. Friedlander

Year: 2025

Venue: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting

DOI: https://doi.org/10.1200/edbk-25-471924

Paper Therapeutic activity of a new antibody-drug immunoconjugate, IMMU-110, in preclinical studies targeted against multiple myeloma.

R. Stein; G. Griffiths; T. Cardillo et al. · 2004 · Journal of Clinical Oncology · DOI

Full title: Therapeutic activity of a new antibody-drug immunoconjugate, IMMU-110, in preclinical studies targeted against multiple myeloma.

Authors: R. Stein; G. Griffiths; T. Cardillo; R. Blumenthal; I. Horak; D. Goldenberg

Year: 2004

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2004.22.14_suppl.6535

Paper Prostate-specific membrane antigen antibody-drug conjugate (PSMA ADC): A phase I trial in taxane-refractory prostate cancer.

D. Petrylak; P. Kantoff; R. Frank et al. · 2011 · Journal of Clinical Oncology · DOI

Full title: Prostate-specific membrane antigen antibody-drug conjugate (PSMA ADC): A phase I trial in taxane-refractory prostate cancer.

Authors: D. Petrylak; P. Kantoff; R. Frank; N. Shore; Y. Rotshteyn; R. Israel; W. Olson; T. Ramakrishna; S. Morris

Year: 2011

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2011.29.15_suppl.4650

Paper Conceptual Framework for Therapeutic Development Beyond Anti-PD-1/PD-L1 in Urothelial Cancer.

P. Grivas; A. Drakaki; T. Friedlander et al. · 2019 · American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting · DOI

Full title: Conceptual Framework for Therapeutic Development Beyond Anti-PD-1/PD-L1 in Urothelial Cancer.

Authors: P. Grivas; A. Drakaki; T. Friedlander; G. Sonpavde

Year: 2019

Venue: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting

DOI: https://doi.org/10.1200/edbk_237449

Paper A phase I study of trastuzumab-MCC-DM1 (T-DM1), a first-in-class HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+ metastatic breast cancer (BC)

M. Beeram; I. Krop; S. Modi et al. · 2007 · DOI

Full title: A phase I study of trastuzumab-MCC-DM1 (T-DM1), a first-in-class HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+ metastatic breast cancer (BC)

Authors: M. Beeram; I. Krop; S. Modi; A. Tolcher; N. Rabbee; S. Girish; J. Tibbitts; S. Holden; S. Lutzker; H. Burris

Year: 2007

DOI: https://doi.org/10.1200/jco.2007.25.18_suppl.1042

Paper Update on Emerging Therapies for Advanced Colorectal Cancer.

O. Alese; Christina Wu; W. Chapin et al. · 2023 · American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting · DOI

Full title: Update on Emerging Therapies for Advanced Colorectal Cancer.

Authors: O. Alese; Christina Wu; W. Chapin; Mark B. Ulanja; Binbin Zheng-Lin; Millicent Amankwah; J. Eads

Year: 2023

Venue: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting

DOI: https://doi.org/10.1200/edbk_389574

Paper Antibody-Drug Conjugates: Patient and Treatment Selection.

Makawita, Shalini; Meric-Bernstam, Funda · 2020 · American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting · DOI

Full title: Antibody-Drug Conjugates: Patient and Treatment Selection.

Authors: Makawita, Shalini; Meric-Bernstam, Funda

Year: 2020

Venue: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting

DOI: https://doi.org/10.1200/EDBK_280775

Paper Beyond Chemoimmunotherapy in Advanced Non-Small Cell Lung Cancer: New Frontiers, New Challenges.

G. Mountzios; J. Naidoo; Chao Wang et al. · 2024 · American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting · DOI

Full title: Beyond Chemoimmunotherapy in Advanced Non-Small Cell Lung Cancer: New Frontiers, New Challenges.

Authors: G. Mountzios; J. Naidoo; Chao Wang; B. Creelan; Daniel C Trotier; Toby C Campbell; S. Peters

Year: 2024

Venue: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting

DOI: https://doi.org/10.1200/edbk_432526

Paper Phase I/II study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered weekly to patients (pts) with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL).

B. Coiffier; V. Ribrag; J. Dupuis et al. · 2011 · Journal of Clinical Oncology · DOI

Full title: Phase I/II study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered weekly to patients (pts) with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL).

Authors: B. Coiffier; V. Ribrag; J. Dupuis; H. Tilly; C. Haioun; F. Morschhauser; T. Lamy; C. Copie-Bergman; O. Brehar; R. Houot; J. Lambert; R. Morarui-Zamfir

Year: 2011

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2011.29.15_suppl.8017

Paper Antibody drug conjugates against the receptor for advanced glycation end products (RAGE), a novel therapeutic target in endometrial cancer

Gareth D Healey; B. Pan-Castillo; Jezabel Garcia-Parra et al. · 2019 · Journal of Immunotherapy for Cancer · DOI

Full title: Antibody drug conjugates against the receptor for advanced glycation end products (RAGE), a novel therapeutic target in endometrial cancer

Authors: Gareth D Healey; B. Pan-Castillo; Jezabel Garcia-Parra; J. Davies; S. Roberts; E. Jones; K. Dhar; Sarika Nandanan; N. Tofazzal; L. Piggott; R. Clarkson; G. Seaton; Å. Frostell; T. Fagge; C. Mckee; L. Margarit; L. Margarit; R. S. Conlan; D. Gonzalez

Year: 2019

Venue: Journal of Immunotherapy for Cancer

DOI: https://doi.org/10.1186/s40425-019-0765-z

Paper Phase I study of A166 in patients with HER2-expressing locally advanced or metastatic solid tumors.

Xichun Hu; Jian Zhang; Rujiao Liu et al. · 2021 · Journal of Clinical Oncology · DOI

Full title: Phase I study of A166 in patients with HER2-expressing locally advanced or metastatic solid tumors.

Authors: Xichun Hu; Jian Zhang; Rujiao Liu; Shuiping Gao; Y. Qing; Shuli Yi; Ju-Xia Yuan; Hong Chen; Bin Fan; Hao Zheng; Jingyi Wang

Year: 2021

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2021.39.15_suppl.1024

Paper Outcomes in patients (pts) aged ≥65 years in the phase 3 ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC).

K. Kalinsky; Mafalda Oliveira; T. Traina et al. · 2021 · DOI

Full title: Outcomes in patients (pts) aged ≥65 years in the phase 3 ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC).

Authors: K. Kalinsky; Mafalda Oliveira; T. Traina; S. Tolaney; D. Loirat; K. Punie; S. Hurvitz; F. Lynce; E. Hamilton; R. Nanda; L. Hart; P. Richards; Z. Malik; H. Rugo; V. Diéras; A. Bardia; Q. Hong; M. Olivo; L. Itri; S. Loibl

Year: 2021

DOI: https://doi.org/10.1200/jco.2021.39.15_suppl.1011

Paper ARTEMIS-001: Phase 1 study of HS-20093, a B7-H3–targeting antibody-drug conjugate, in patients with advanced solid tumor.

Jie Wang; J. Duan; L. Xing et al. · 2023 · Journal of Clinical Oncology · DOI

Full title: ARTEMIS-001: Phase 1 study of HS-20093, a B7-H3–targeting antibody-drug conjugate, in patients with advanced solid tumor.

Authors: Jie Wang; J. Duan; L. Xing; Yuping Sun; W. Guo; Hong Wang; Jianhua Chen; L. Han; Baogang Liu; Qiming Wang; Ying Hu; Hongying Wei; Chuan-yin Li; Qiqi Huang; Yiwei Dong; Qiong Wu

Year: 2023

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2023.41.16_suppl.3017

Paper Prostate-specific membrane antigen antibody-drug conjugate (PSMA ADC): A phase I trial in taxane-refractory prostate cancer.

D. Petrylak; P. Kantoff; R. Frank et al. · 2011 · Journal of Clinical Oncology · DOI

Full title: Prostate-specific membrane antigen antibody-drug conjugate (PSMA ADC): A phase I trial in taxane-refractory prostate cancer.

Authors: D. Petrylak; P. Kantoff; R. Frank; N. Shore; Y. Rotshteyn; R. Israel; W. Olson; T. Ramakrishna; S. Morris

Year: 2011

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2011.29.15_suppl.4650

Paper MEDI3726, a prostate-specific membrane antigen (PSMA)-targeted antibody-drug conjugate (ADC) in mCRPC after failure of abiraterone or enzalutamide.

J. Bono; M. Fleming; Judy S. Wang et al. · 2020 · DOI

Full title: MEDI3726, a prostate-specific membrane antigen (PSMA)-targeted antibody-drug conjugate (ADC) in mCRPC after failure of abiraterone or enzalutamide.

Authors: J. Bono; M. Fleming; Judy S. Wang; R. Cathomas; Marna B. Williams; J. Bothos; K. Balic; S. Cho; Pablo Martinez; D. Petrylak

Year: 2020

DOI: https://doi.org/10.1200/jco.2020.38.6_suppl.99

Paper Prostate-specific membrane antigen antibody drug conjugate (PSMA ADC): A phase I trial in men with prostate cancer previously treated with taxane.

D. Petrylak; P. Kantoff; A. Mega et al. · 2012 · Journal of Clinical Oncology · DOI

Full title: Prostate-specific membrane antigen antibody drug conjugate (PSMA ADC): A phase I trial in men with prostate cancer previously treated with taxane.

Authors: D. Petrylak; P. Kantoff; A. Mega; R. Dreicer; R. Frank; N. Shore; S. Morris; W. Olson; R. Israel

Year: 2012

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2012.30.5_suppl.107

Paper A single-arm, open-label, phase II study investigating anti-HER2 ADC plus anti-PD-1 antibody in patients with unresectable locally advanced or metastatic BTC with HER2 overexpression.

Xiaofeng Chen; Feng Guo; Xinyi Zhang et al. · 2023 · Journal of Clinical Oncology · DOI

Full title: A single-arm, open-label, phase II study investigating anti-HER2 ADC plus anti-PD-1 antibody in patients with unresectable locally advanced or metastatic BTC with HER2 overexpression.

Authors: Xiaofeng Chen; Feng Guo; Xinyi Zhang; Jinrong Qiu; T. Zheng; H. Qiu; Yitong Tian; Lan-Lan Pan; Jiaguang Zhang; Yizhang Chen; H. Shen; Chao Wang

Year: 2023

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2023.41.4_suppl.tps619

Paper Prostate-specific membrane antigen antibody drug conjugate (PSMA ADC): A phase I trial in metastatic castration-resistant prostate cancer (mCRPC) previously treated with a taxane.

Anthony Mega; D. Petrylak; P. Kantoff et al. · 2013 · Journal of Clinical Oncology · DOI

Full title: Prostate-specific membrane antigen antibody drug conjugate (PSMA ADC): A phase I trial in metastatic castration-resistant prostate cancer (mCRPC) previously treated with a taxane.

Authors: Anthony Mega; D. Petrylak; P. Kantoff; Joe Stephenson; Nicholas J. Vogelzang; R. Dreicer; Neal D. Shore; N. Stambler; J. Carpenito; P. D'Ambrosio; Robert J. Israel

Year: 2013

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2012.30.15_suppl.4662

Paper A phase 1a/b, multi-regional, first-in-human study of CS5001, a novel anti-ROR1 ADC, in patients with advanced solid tumors and lymphomas.

C. Lemech; Richard Zuniga; M. Barve et al. · 2024 · Journal of Clinical Oncology · DOI

Full title: A phase 1a/b, multi-regional, first-in-human study of CS5001, a novel anti-ROR1 ADC, in patients with advanced solid tumors and lymphomas.

Authors: C. Lemech; Richard Zuniga; M. Barve; Yuqin Song; Jian Zhang; K. Zhou; Liling Zhang; L. Shen; Sarwan Bishnoi; H. Cherng; Caicun Zhou; Wenyu Li; Jingru Wang; Xiaoli Zhu; Dan Zhu; Fei Li; Zhenwei Shen; Jason Yang

Year: 2024

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2024.42.16_suppl.3023

Paper A phase 1 trial of claudin 18.2-specific antibody-drug conjugate CMG901 in patients with advanced gastric/gastroesophageal junction cancer.

R. Xu; D. Ruan; D. Zhang et al. · 2023 · Journal of Clinical Oncology · DOI

Full title: A phase 1 trial of claudin 18.2-specific antibody-drug conjugate CMG901 in patients with advanced gastric/gastroesophageal junction cancer.

Authors: R. Xu; D. Ruan; D. Zhang; Fu-rong Liu; S. Luo; Zhixiang Zhuang; Zhenning Wang; Funan Liu; Yan-Qiao Zhang; Jian-Wei Yang; Zhen-dong Chen; Yong-Sheng Wang; Jun-Ye Wang; Xiao-Hua Liang; Xiao-Jie Wu; Yulong Zheng; Jian Liu; Xi Shi; Wei Liu; Bo Chen

Year: 2023

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2023.41.36_suppl.434420

Paper Evaluation of the safety, pharmacokinetics, and efficacy of JSKN003 in patients with advanced solid tumors: A phase I/II clinical study.

Xiaojun Liu; Jian Zhang; L. Shen et al. · 2024 · Journal of Clinical Oncology · DOI

Full title: Evaluation of the safety, pharmacokinetics, and efficacy of JSKN003 in patients with advanced solid tumors: A phase I/II clinical study.

Authors: Xiaojun Liu; Jian Zhang; L. Shen; Jieqiong Liu; Jianjun Huang; Zhixiang Zhuang; Yongmei Yin; Xiang Wang; Xian Wang; Jiong Wu

Year: 2024

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2024.42.16_suppl.3031

Paper Safety and efficacy of DB-1303 in patients with advanced/metastatic solid tumors: A multicenter, open-label, first-in-human, phase 1/2a study.

K. Moore; Dhanusha Sabanathan; Yiqun Du et al. · 2023 · Journal of Clinical Oncology · DOI

Full title: Safety and efficacy of DB-1303 in patients with advanced/metastatic solid tumors: A multicenter, open-label, first-in-human, phase 1/2a study.

Authors: K. Moore; Dhanusha Sabanathan; Yiqun Du; Huaxin Duan; Xiumin Li; Feng Wang; O. Marathe; Hua Yang; V. Makker; W. Growdon; J. Coward; Peng Zhao; Liming Liu; Rong Shi; Shengxue Liu; W. Gu; Yang Qiu; Zhongyuan Zhu; Jian Zhang; E. Hamilton

Year: 2023

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2023.41.16_suppl.3023

Paper Development of novel MUC1-C targeting antibody-drug conjugate for pancreatic cancer treatment.

Rehan Ahmad; G. Panchamoorthy; D. Raina et al. · 2024 · Journal of Clinical Oncology · DOI

Full title: Development of novel MUC1-C targeting antibody-drug conjugate for pancreatic cancer treatment.

Authors: Rehan Ahmad; G. Panchamoorthy; D. Raina; B. Lawney; S. Kharbanda; R. Jasuja

Year: 2024

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2024.42.16_suppl.e15025

Paper TROPION-PanTumor03: Phase 2, multicenter study of datopotamab deruxtecan (Dato-DXd) as monotherapy and in combination with anticancer agents in patients (pts) with advanced/metastatic solid tumors.

Y. Janjigian; A. Oaknin; J. Lang et al. · 2023 · Journal of Clinical Oncology · DOI

Full title: TROPION-PanTumor03: Phase 2, multicenter study of datopotamab deruxtecan (Dato-DXd) as monotherapy and in combination with anticancer agents in patients (pts) with advanced/metastatic solid tumors.

Authors: Y. Janjigian; A. Oaknin; J. Lang; K. Ciombor; I. Ray-Coquard; A. Oza; K. Yonemori; R. Xu; Jimmy L. Zhao; S. Gajavelli; J. Filant; T. Hovey; F. Meric-Bernstam

Year: 2023

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2023.41.16_suppl.tps3153

Paper An engineered Trop2/CD3 bispecific antibody for treatment of gastric, pancreatic, and colorectal cancers.

Diana O; Kronos Chow; D. Iyer et al. · 2023 · Journal of Clinical Oncology · DOI

Full title: An engineered Trop2/CD3 bispecific antibody for treatment of gastric, pancreatic, and colorectal cancers.

Authors: Diana O; Kronos Chow; D. Iyer; Monarca Wong; T. K. Wong; Dennis A. Wong; J. Luk

Year: 2023

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2023.41.16_suppl.e14521

Paper Preclinical antitumor activity of an anti-HER2/Trop-2 bispecific antibody-drug conjugate with a new DNA topoisomerase I inhibitor.

Helen Zhong; Yan Xiong; Han Huang et al. · 2023 · Journal of Clinical Oncology · DOI

Full title: Preclinical antitumor activity of an anti-HER2/Trop-2 bispecific antibody-drug conjugate with a new DNA topoisomerase I inhibitor.

Authors: Helen Zhong; Yan Xiong; Han Huang; Yuming Pan; Lijin Cao; Shen Liu; Na Wang; Bin Sun; Dingguo Liu; W. Yuan; Jan Fang; H. Bao

Year: 2023

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2023.41.16_suppl.e15013

Paper A phase 1/2, first-in-human study of DS-3939a in patients with advanced solid tumors: A new DXd ADC targeting TA-MUC1.

N. Yamamoto; Toshihiko Doi; Manish R Patel et al. · 2024 · Journal of Clinical Oncology · DOI

Full title: A phase 1/2, first-in-human study of DS-3939a in patients with advanced solid tumors: A new DXd ADC targeting TA-MUC1.

Authors: N. Yamamoto; Toshihiko Doi; Manish R Patel; I. Garrido-Laguna; Sutan Wu; Satoshi Nishioka; K. Nakajima; B. Carneiro

Year: 2024

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2024.42.16_suppl.tps3165

Paper JSKN003, a biparatopic HER2-targeting ADC, in heavily pretreated HER2-positive breast cancer: A pooled analysis of early-phase studies.

Yiqun Du; Jian Zhang; Jieqiong Liu et al. · 2025 · Journal of Clinical Oncology · DOI

Full title: JSKN003, a biparatopic HER2-targeting ADC, in heavily pretreated HER2-positive breast cancer: A pooled analysis of early-phase studies.

Authors: Yiqun Du; Jian Zhang; Jieqiong Liu; Wenfeng Li; Qingyuan Zhang; Louisa Lo; Yongmei Yin; Yanxia Zhao; Zhixiang Zhuang; Xinshuai Wang; Xian Wang; Jianjun Huang; Hong Zong; Guixiang Weng; Zhongmin Zhang; Xiaochen Zhang; Jian Ruan; Zhen Li; Xiang Wang; Jiong Wu

Year: 2025

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2025.43.16_suppl.1028

Paper RC48-ADC versus BCG in adjuvant treatment of high-risk non-muscle-invasive bladder cancer with HER2 over-expression: A real-world retrospective study.

Haoyang Liu; Junru Chen; Haolin Liu et al. · 2024 · Journal of Clinical Oncology · DOI

Full title: RC48-ADC versus BCG in adjuvant treatment of high-risk non-muscle-invasive bladder cancer with HER2 over-expression: A real-world retrospective study.

Authors: Haoyang Liu; Junru Chen; Haolin Liu; Qiyu Zhu; Banghua Liao; Zhenhua Liu; P. Shen; H. Zeng

Year: 2024

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2024.42.4_suppl.644

Paper Safety and preliminary efficacy of GQ1001, a next generation HER2-targeting ADC, combined with pyrotinib in pretreated patients with HER2-positive metastatic breast cancer: A phase 1b clinical trial.

Biyun Wang; C. Gong; Leiping Wang et al. · 2024 · Journal of Clinical Oncology · DOI

Full title: Safety and preliminary efficacy of GQ1001, a next generation HER2-targeting ADC, combined with pyrotinib in pretreated patients with HER2-positive metastatic breast cancer: A phase 1b clinical trial.

Authors: Biyun Wang; C. Gong; Leiping Wang; Xichun Hu; Ting Li; Z. Tao; Mingchuan Zhao; Yannan Zhao

Year: 2024

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2024.42.16_suppl.e13020

Paper Phase 1 study of ZV0203, a first in class pertuzumab ADC, in patients with HER2 positive advanced solid tumors.

Zhenwei Miao; Fengjuan Lin; Xi Rao et al. · 2024 · Journal of Clinical Oncology · DOI

Full title: Phase 1 study of ZV0203, a first in class pertuzumab ADC, in patients with HER2 positive advanced solid tumors.

Authors: Zhenwei Miao; Fengjuan Lin; Xi Rao; Yong Huang; Feng Wang; Yao Lu; Xiuying Huang; Yunsheng Huang

Year: 2024

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2024.42.16_suppl.e15004

Paper A phase I study of EO-3021 in adult patients with solid tumors likely to express CLDN18.2.

Meredith S. Pelster; Cesar A Perez; S. Chandana et al. · 2024 · Journal of Clinical Oncology · DOI

Full title: A phase I study of EO-3021 in adult patients with solid tumors likely to express CLDN18.2.

Authors: Meredith S. Pelster; Cesar A Perez; S. Chandana; N. Uboha; Ashwin Swami; Holly McDonald; Jaya Srivastava; M. Barve

Year: 2024

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2024.42.3_suppl.tps429

Paper An open-label, multicenter phase 1 study to characterize safety, tolerability, preliminary antitumor activity, pharmacokinetics, and pharmacodynamics of VIP943 monotherapy in patients with advanced CD123+ hematologic malignancies.

Stephen A Strickland; Emily K. Curran; Omer Hassan Jamy et al. · 2024 · Journal of Clinical Oncology · DOI

Full title: An open-label, multicenter phase 1 study to characterize safety, tolerability, preliminary antitumor activity, pharmacokinetics, and pharmacodynamics of VIP943 monotherapy in patients with advanced CD123+ hematologic malignancies.

Authors: Stephen A Strickland; Emily K. Curran; Omer Hassan Jamy; M. Percival; Amy J. Johnson; Joseph Birkett; Xin Huang; M. Frigault; H. Lerchen; B. Stelte-Ludwig; Tasheda Navarro; Jim Peck; Wyatt Gross; R. Izumi; A. Hamdy; N. Daver

Year: 2024

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2024.42.16_suppl.tps3167

Paper Adverse events of patients treated with antibody-drug conjugates in phase 1 clinical trials at the Royal Marsden Drug Development Unit from 2014 to 2024.

Harold Nathan Tan; Marta Ascanio Morcillo; J. D. de Bono et al. · 2024 · Journal of Clinical Oncology · DOI

Full title: Adverse events of patients treated with antibody-drug conjugates in phase 1 clinical trials at the Royal Marsden Drug Development Unit from 2014 to 2024.

Authors: Harold Nathan Tan; Marta Ascanio Morcillo; J. D. de Bono; Juanita Lopez; A. Minchom; A. Sharp; A. Paschalis; U. Banerji

Year: 2024

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2024.42.16_suppl.e15020

Paper Development of a highly efficacious, first-in-class antibody-drug conjugate against a novel MUC1-C oncoprotein for metastatic colorectal cancer.

D. Raina; G. Panchamoorthy; Rehan Ahmad et al. · 2024 · Journal of Clinical Oncology · DOI

Full title: Development of a highly efficacious, first-in-class antibody-drug conjugate against a novel MUC1-C oncoprotein for metastatic colorectal cancer.

Authors: D. Raina; G. Panchamoorthy; Rehan Ahmad; R. Jasuja; S. Kharbanda

Year: 2024

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2024.42.16_suppl.e15600

Paper A retrospective cohort study to monitor real-world safety in patients with locally advanced or metastatic urothelial carcinoma (LA/mUC) treated with sacituzumab govitecan (SG) in the United States.

M. Parikh; F. Boateng; Susan Eng et al. · 2024 · Journal of Clinical Oncology · DOI

Full title: A retrospective cohort study to monitor real-world safety in patients with locally advanced or metastatic urothelial carcinoma (LA/mUC) treated with sacituzumab govitecan (SG) in the United States.

Authors: M. Parikh; F. Boateng; Susan Eng; M. Sierecki; Fangfei Chen; J. M. Brockman; Youssef Ghazi; Leslie Ng

Year: 2024

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2024.42.4_suppl.608

Paper First-in-human phase 1 dose escalation trial of OMTX705, a novel anti-fibroblast activation protein (FAP) antibody drug conjugate (ADC), in monotherapy and in combination with pembrolizumab in patients with solid tumors.

J. Torres-Jiménez; Ana Paisan; Mariano Ponz-Sarvise et al. · 2025 · Journal of Clinical Oncology · DOI

Full title: First-in-human phase 1 dose escalation trial of OMTX705, a novel anti-fibroblast activation protein (FAP) antibody drug conjugate (ADC), in monotherapy and in combination with pembrolizumab in patients with solid tumors.

Authors: J. Torres-Jiménez; Ana Paisan; Mariano Ponz-Sarvise; B. Bockorny; M. Gil-Martin; Ricardo Cubedo; L. Paz-Ares; Ana Landa-Magdalena; Gerburg Wulf; Paula Sabat; Fabio Franco Perez; M. Fabre; Alvaro González; Patricia González; Isabel Egaña; Susana Roman; Laureano Simón; Ignacio Garcia-Ribas; A. Urruticoechea

Year: 2025

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2025.43.16_suppl.3028

Paper First in human PK analysis of antibody conjugated liposome encapsulating doxorubicin (HF-K1) in advanced cancer patients: Comparison with ADCs.

M. Barve; Shanshan Jin; Xun Wang et al. · 2025 · Journal of Clinical Oncology · DOI

Full title: First in human PK analysis of antibody conjugated liposome encapsulating doxorubicin (HF-K1) in advanced cancer patients: Comparison with ADCs.

Authors: M. Barve; Shanshan Jin; Xun Wang; Hailong Wu; Nayyar T. Syed; Fengwei Xu; Reva Schneider; Ntombizodwa Sayi; Christiana Panciotti; Reza Chalangari; Rachel Won; Yuhong Xu

Year: 2025

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2025.43.16_suppl.e15011

Paper Off-label use of fam-trastuzumab deruxtecan in desmoplastic small round cell tumor.

E. Slotkin; Tamar Y Feinberg; Umesh Bhanot et al. · 2025 · Journal of Clinical Oncology · DOI

Full title: Off-label use of fam-trastuzumab deruxtecan in desmoplastic small round cell tumor.

Authors: E. Slotkin; Tamar Y Feinberg; Umesh Bhanot; Anita Price; Gerald Behr; N. Pandit-Taskar; Narasimhan P. Agaram; C. Antonescu; Meera R. Hameed; K. Linos; Carla Saoud; D. Domenico; E. Papaemmanuil; Filemon S. Dela Cruz; Chelsey M Burke; M. Ortiz; J. L. Glade Bender; Andrew L Kung; Damon R. Reed

Year: 2025

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2025.43.16_suppl.11504

Paper CD79b-targeted antibody-drug conjugate (ADC) SHR-A1912 in combination with rituximab, gemcitabine, and oxaliplatin (R-GemOx) in relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL): Data from a phase 1b/2 study.

Yajun Li; H. Cen; Zengjun Li et al. · 2025 · Journal of Clinical Oncology · DOI

Full title: CD79b-targeted antibody-drug conjugate (ADC) SHR-A1912 in combination with rituximab, gemcitabine, and oxaliplatin (R-GemOx) in relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL): Data from a phase 1b/2 study.

Authors: Yajun Li; H. Cen; Zengjun Li; Yan Zhang; Zhiming Li; Yang Xie; Haisheng Liu; Jie Li; K. Zhou; Meiyun Fang; Xiang Li; Zhengming Jin; S. Tu; Yiming Liu; Dahua Ma; Wenjun Mao; Z. Xiao; Hong Zheng; Yuqin Song

Year: 2025

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2025.43.16_suppl.7013

Paper First-in-human study of JSKN016, a bispecific anti-TROP2/HER3 antibody drug conjugate (ADC): Antitumor activity in patients (pts) with metastatic triple-negative breast cancer (mTNBC) and safety results.

Herui Yao; Jieqiong Liu; Yinduo Zeng et al. · 2025 · Journal of Clinical Oncology · DOI

Full title: First-in-human study of JSKN016, a bispecific anti-TROP2/HER3 antibody drug conjugate (ADC): Antitumor activity in patients (pts) with metastatic triple-negative breast cancer (mTNBC) and safety results.

Authors: Herui Yao; Jieqiong Liu; Yinduo Zeng; Zhangzhou Huang; Jing Wang; Yu Cao; Ying Wang; Wenjing Wu; Ya-Ping Yang; Fengyan Yu; Xiuping Lai; Hong Zong; Dongqing Lv; Junyan Wu; Suiwen Ye; Ting Xu; Zhenjiu Wang; Xiaowen Tang; Ruyi Xu; Erwei Song

Year: 2025

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2025.43.16_suppl.e13138

Paper An open-label phase 1 study to investigate SGNCEACAM5C/SAR445953 in adults with advanced solid tumors (SGNCEA5C-001).

A. Patnaik; Nilofer S. Azad; M. Borad et al. · 2024 · Journal of Clinical Oncology · DOI

Full title: An open-label phase 1 study to investigate SGNCEACAM5C/SAR445953 in adults with advanced solid tumors (SGNCEA5C-001).

Authors: A. Patnaik; Nilofer S. Azad; M. Borad; Andrea J. Bullock; J. Call; S. L. Davis; M. Fakih; Rachel Goodwin; N. Lakhani; Meredith S. Pelster; Cesar A Perez; Pourya Pourhosseini; Tianhua Wang; Brigitte Demers; F. Meric-Bernstam

Year: 2024

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2024.42.16_suppl.tps3160

Paper Preclinical evaluation of the efficacy of anti-PVR antibody-drug conjugates combined with anti-PD-1 therapy for bladder cancer.

S. Fu; Haifeng Wang; Xu Chen et al. · 2025 · Journal of Clinical Oncology · DOI

Full title: Preclinical evaluation of the efficacy of anti-PVR antibody-drug conjugates combined with anti-PD-1 therapy for bladder cancer.

Authors: S. Fu; Haifeng Wang; Xu Chen; Jiansong Wang; Mingxia Ding; Chunming Guo; Hongjin Shi; Jieming Zuo; Junhao Chen

Year: 2025

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2025.43.16_suppl.e16547

Paper A single-center, open-label, single-arm, phase I study with dose expansion cohort of sacituzumab govitecan in combination with cisplatin for patients with platinum sensitive recurrent ovarian and endometrial cancer.

Melanie W Kier; Erin Moshier; S. Blank et al. · 2025 · Journal of Clinical Oncology · DOI

Full title: A single-center, open-label, single-arm, phase I study with dose expansion cohort of sacituzumab govitecan in combination with cisplatin for patients with platinum sensitive recurrent ovarian and endometrial cancer.

Authors: Melanie W Kier; Erin Moshier; S. Blank; M. Hayes; Jamal Rahaman; Konstantin Zakashansky; V. Kolev; K. Zeligs; Samantha Cohen; Caitlin Carr; Ana Acuna-Villaorduna; Theresa Shao; Dmitriy Zamarin; A. Tiersten

Year: 2025

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2025.43.16_suppl.tps5623

Paper A dose escalation and cohort expansion phase I/IIa study of ACR246, an innovative 5T4- antibody drug conjugate (ADC), in patients (pts) with advanced solid tumors.

Panpan Zhang; Yunsheng Huang; Lina Chen et al. · 2025 · Journal of Clinical Oncology · DOI

Full title: A dose escalation and cohort expansion phase I/IIa study of ACR246, an innovative 5T4- antibody drug conjugate (ADC), in patients (pts) with advanced solid tumors.

Authors: Panpan Zhang; Yunsheng Huang; Lina Chen; Feng Wang; Zhenwei Miao

Year: 2025

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2025.43.16_suppl.tps3166

Paper Intravesical sacituzumab tirumotecan in participants with intermediate-risk non–muscle-invasive bladder cancer: The phase 1/2 TroFuse-027 study.

J. Meeks; Roger Li; A. Kamat et al. · 2025 · Journal of Clinical Oncology · DOI

Full title: Intravesical sacituzumab tirumotecan in participants with intermediate-risk non–muscle-invasive bladder cancer: The phase 1/2 TroFuse-027 study.

Authors: J. Meeks; Roger Li; A. Kamat; Girish S. Kulkarni; Noah M Hahn; E. Kapadia; Qing Zhao; H. Dave; Max Kates

Year: 2025

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2025.43.16_suppl.tps4627

Paper Targeting BCMA in relapsed and refractory multiple myeloma: A systematic review and meta-analysis of efficacy and safety of belantamab mafodotin.

Shahzaib Maqbool; Imran Khan; Arham Ihtesham et al. · 2025 · Journal of Clinical Oncology · DOI

Full title: Targeting BCMA in relapsed and refractory multiple myeloma: A systematic review and meta-analysis of efficacy and safety of belantamab mafodotin.

Authors: Shahzaib Maqbool; Imran Khan; Arham Ihtesham; Abdur Rehman; Adil Khan

Year: 2025

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2025.43.16_suppl.e19512

Paper The anti-STEAP1/PSMA ADC, DXC008: Assessment of anti-tumor efficacy, pharmacokinetic, and toxicity properties.

Jiaojiao Yu; Huihui Guo; Junxiang Jia et al. · 2025 · Journal of Clinical Oncology · DOI

Full title: The anti-STEAP1/PSMA ADC, DXC008: Assessment of anti-tumor efficacy, pharmacokinetic, and toxicity properties.

Authors: Jiaojiao Yu; Huihui Guo; Junxiang Jia; Yuanyuan Huang; Yongxiang Chen; You Zhou; Xiangfei Kong; Lingli Zhang; Lu Bai; Yunxia Zheng; Jun Zheng; Wenjun Li; Zhiwei Li; Zhixiang Guo; Miaomiao Chen; Xiaoyan Zhao; Binbin Chen; Meng Dai; Qingliang Yang; R. Zhao

Year: 2025

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2025.43.16_suppl.e17161

Paper The Properties of Cysteine-Conjugated Antibody-Drug Conjugates Are Impacted by the IgG Subclass

A. Datta-Mannan; Hiuwan Choi; D. Stokell et al. · 2018 · AAPS Journal · DOI

Full title: The Properties of Cysteine-Conjugated Antibody-Drug Conjugates Are Impacted by the IgG Subclass

Authors: A. Datta-Mannan; Hiuwan Choi; D. Stokell; Jason X Tang; A. Murphy; Aaron D. Wrobleski; Yiqing Feng

Year: 2018

Venue: AAPS Journal

DOI: https://doi.org/10.1208/s12248-018-0263-0

Paper Ocular toxicity and tolerability of BCMA directed antibody drug conjugate (ADC) therapy in relapsed multiple myeloma (MM).

Matthew Rees; Timothy T. Xu; S. Atallah-Yunes et al. · 2025 · Journal of Clinical Oncology · DOI

Full title: Ocular toxicity and tolerability of BCMA directed antibody drug conjugate (ADC) therapy in relapsed multiple myeloma (MM).

Authors: Matthew Rees; Timothy T. Xu; S. Atallah-Yunes; K. Lim; A. Dispenzieri; M. Gertz; T. Kourelis; Eli Muchtar; Rafael Fonseca; Ricardo D. Parrondo; S. Ailawadhi; P. Bergsagel; W. Gonsalves; D. Dingli; F. Buadi; S. Rajkumar; P. Kapoor; J. Abeykoon; Sanjay V. Patel; Shaji K Kumar

Year: 2025

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2025.43.16_suppl.e19503

Paper A Mechanistic Pharmacokinetic Model Elucidating the Disposition of Trastuzumab Emtansine (T-DM1), an Antibody–Drug Conjugate (ADC) for Treatment of Metastatic Breast Cancer

B. Bender; D. Leipold; Keyang Xu et al. · 2014 · AAPS Journal · DOI

Full title: A Mechanistic Pharmacokinetic Model Elucidating the Disposition of Trastuzumab Emtansine (T-DM1), an Antibody–Drug Conjugate (ADC) for Treatment of Metastatic Breast Cancer

Authors: B. Bender; D. Leipold; Keyang Xu; Ben-Quan Shen; J. Tibbitts; L. Friberg

Year: 2014

Venue: AAPS Journal

DOI: https://doi.org/10.1208/s12248-014-9618-3

Paper NEXUS-01, a phase 1 study of LY4052031, an antibody-drug conjugate targeting Nectin-4 in participants with advanced or metastatic urothelial carcinoma or other solid tumors.

Xin Gao; A. Patnaik; N. Lakhani et al. · 2025 · Journal of Clinical Oncology · DOI

Full title: NEXUS-01, a phase 1 study of LY4052031, an antibody-drug conjugate targeting Nectin-4 in participants with advanced or metastatic urothelial carcinoma or other solid tumors.

Authors: Xin Gao; A. Patnaik; N. Lakhani; J. Call; M. Galsky; Benjamin Garmezy; Alexander Z. Wei; Louise Carter; T. Powles; A. Siefker-Radtke; P. H. O'Donnell; Shigehisa Kitano; D. Castellano; R. Shinde; A.M. Joshua; M. Balbas; Hongmei Han; A.E. Chang; Capucine Baldini; G. Iyer

Year: 2025

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2025.43.5_suppl.tps900

Paper Current Landscape of Antibody-Drug Conjugate Development in Head and Neck Cancer.

J. C. Park; Donghoon Shin · 2024 · JCO Precision Oncology · DOI

Full title: Current Landscape of Antibody-Drug Conjugate Development in Head and Neck Cancer.

Authors: J. C. Park; Donghoon Shin

Year: 2024

Venue: JCO Precision Oncology

DOI: https://doi.org/10.1200/po.24.00179

Paper Phase IB/II study to evaluate safety and preliminary efficacy of the WEE1 inhibitor Debio 0123 in combination with sacituzumab govitecan (SG) in triple-negative or hormone receptor–positive (HR+)/HER2-negative (HER2–) advanced breast cancer (ABC): The WIN-B study.

T. J. Robinson; M. Gion; Isabel Blancas et al. · 2025 · Journal of Clinical Oncology · DOI

Full title: Phase IB/II study to evaluate safety and preliminary efficacy of the WEE1 inhibitor Debio 0123 in combination with sacituzumab govitecan (SG) in triple-negative or hormone receptor–positive (HR+)/HER2-negative (HER2–) advanced breast cancer (ABC): The WIN-B study.

Authors: T. J. Robinson; M. Gion; Isabel Blancas; Meritxell Aguiló; Juliana Carvalho Santos; Sandra Santasusagna; Michela Verbeni; E. Rodrigo Imedio; L. Piggott; José Manuel Pérez García; J. Cortes; A. Llombart-Cussac

Year: 2025

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2025.43.16_suppl.tps3172

Paper Determination of Cellular Processing Rates for a Trastuzumab-Maytansinoid Antibody-Drug Conjugate (ADC) Highlights Key Parameters for ADC Design

K. Maass; C. Kulkarni; A. Betts et al. · 2016 · AAPS Journal · DOI

Full title: Determination of Cellular Processing Rates for a Trastuzumab-Maytansinoid Antibody-Drug Conjugate (ADC) Highlights Key Parameters for ADC Design

Authors: K. Maass; C. Kulkarni; A. Betts; K. Wittrup

Year: 2016

Venue: AAPS Journal

DOI: https://doi.org/10.1208/s12248-016-9892-3

Paper Site Selection: a Case Study in the Identification of Optimal Cysteine Engineered Antibody Drug Conjugates.

Tumey, L Nathan; Li, Fengping; Rago, Brian et al. · 2017 · The AAPS journal · DOI

Full title: Site Selection: a Case Study in the Identification of Optimal Cysteine Engineered Antibody Drug Conjugates.

Authors: Tumey, L Nathan; Li, Fengping; Rago, Brian; Han, Xiaogang; Loganzo, Frank; Musto, Sylvia; Graziani, Edmund I; Puthenveetil, Sujiet; Casavant, Jeffrey; Marquette, Kimberly; Clark, Tracey; Bikker, Jack; Bennett, Eric M; Barletta, Frank; Piche-Nicholas, Nicole; Tam, Amy; O'Donnell, Christopher J; Gerber, Hans Peter; Tchistiakova, Lioudmila

Year: 2017

Venue: The AAPS journal

DOI: https://doi.org/10.1208/s12248-017-0083-7

Paper Antibody-Drug Conjugates in Breast Cancer: Toward a Molecular Perspective Into Clinical Practice.

Roberto Paz-Manrique; Joseph A Pinto; H. G. Gomez Moreno · 2024 · JCO Precision Oncology · DOI

Full title: Antibody-Drug Conjugates in Breast Cancer: Toward a Molecular Perspective Into Clinical Practice.

Authors: Roberto Paz-Manrique; Joseph A Pinto; H. G. Gomez Moreno

Year: 2024

Venue: JCO Precision Oncology

DOI: https://doi.org/10.1200/po.24.00173

Paper Activity of DEM301, a novel anti-DEM-TXX antibody-drug conjugate for the treatment of gastrointestinal tumors.

Sarah E. Carden; Agnieszka Denslow; Carmen Adriaens et al. · 2026 · Journal of Clinical Oncology · DOI

Full title: Activity of DEM301, a novel anti-DEM-TXX antibody-drug conjugate for the treatment of gastrointestinal tumors.

Authors: Sarah E. Carden; Agnieszka Denslow; Carmen Adriaens; Peter Sandy; Sandeep Kumar; Loise Francisco

Year: 2026

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2026.44.2_suppl.159

Paper SAT-304 Targeted Inhibition of Prostate Cancer Cells upon Acrolein-enabled Bioorthogonal Activation of Prodrugs

Bob-Gyu Park; D. Jha; Mohana V S Muppidi et al. · 2025 · Journal of the Endocrine Society · DOI

Full title: SAT-304 Targeted Inhibition of Prostate Cancer Cells upon Acrolein-enabled Bioorthogonal Activation of Prodrugs

Authors: Bob-Gyu Park; D. Jha; Mohana V S Muppidi; Marc Torres; Yaguang Liu; J. C. Zhao; Bandana Chatterjee

Year: 2025

Venue: Journal of the Endocrine Society

DOI: https://doi.org/10.1210/jendso/bvaf149.2447

Paper A phase 1/2 study of JK06, a 5T4 antibody drug conjugate, in patients with unresectable locally advanced or metastatic cancer.

Nuria Kotecki; S. Rottey; B. Delafontaine et al. · 2025 · Journal of Clinical Oncology · DOI

Full title: A phase 1/2 study of JK06, a 5T4 antibody drug conjugate, in patients with unresectable locally advanced or metastatic cancer.

Authors: Nuria Kotecki; S. Rottey; B. Delafontaine; V. Galvao; M. D. de Miguel; Omar Saavedra; Valentina Boni; H. Prenen; Bernd Dekeyser; Judit W. Johnson; Jonathan P. McNally; J. Lindelien; A. Drumheller; Jijun Dong; Samuel Murphy; S. Singhal; N. Pandya

Year: 2025

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2025.43.16_suppl.tps3182

Paper A Systems Pharmacology Model for Drug Delivery to Solid Tumors by Antibody-Drug Conjugates: Implications for Bystander Effects

Jackson K. Burton; D. Bottino; T. Secomb · 2019 · AAPS Journal · DOI

Full title: A Systems Pharmacology Model for Drug Delivery to Solid Tumors by Antibody-Drug Conjugates: Implications for Bystander Effects

Authors: Jackson K. Burton; D. Bottino; T. Secomb

Year: 2019

Venue: AAPS Journal

DOI: https://doi.org/10.1208/s12248-019-0390-2

Paper Selection of Payloads for Antibody–Drug Conjugates Targeting Ubiquitously Expressed Tumor-Associated Antigens: a Case Study

Bing Yao; Xiao Gao; Mo Dan et al. · 2022 · AAPS Journal · DOI

Full title: Selection of Payloads for Antibody–Drug Conjugates Targeting Ubiquitously Expressed Tumor-Associated Antigens: a Case Study

Authors: Bing Yao; Xiao Gao; Mo Dan; Can Yuan; Xixin Hu; Zhao-Gui Sun; Xiwu Hui; Boning Liu; Pingkai Ouyang; Guoguang Chen

Year: 2022

Venue: AAPS Journal

DOI: https://doi.org/10.1208/s12248-022-00720-2

Paper Capturing the Magic Bullet: Pharmacokinetic Principles and Modeling of Antibody-Drug Conjugates.

Zuo, Peiying · 2020 · The AAPS journal · DOI

Full title: Capturing the Magic Bullet: Pharmacokinetic Principles and Modeling of Antibody-Drug Conjugates.

Authors: Zuo, Peiying

Year: 2020

Venue: The AAPS journal

DOI: https://doi.org/10.1208/s12248-020-00475-8

Paper ARB1002, a potential first-in-class CDH17-specific ADC, for treatment of pancreatic and other gastrointestinal cancers.

J. M. Luk; Po Yee Wong; T. K. Wong et al. · 2026 · Journal of Clinical Oncology · DOI

Full title: ARB1002, a potential first-in-class CDH17-specific ADC, for treatment of pancreatic and other gastrointestinal cancers.

Authors: J. M. Luk; Po Yee Wong; T. K. Wong; D. Wong

Year: 2026

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2026.44.2_suppl.736

Paper PK/PD Evaluation of Antibody–Drug Conjugates with Enhanced Immune Effector Functions

Hsuan-Ping Chang; Shufang Liu; Dhaval K. Shah · 2024 · AAPS Journal · DOI

Full title: PK/PD Evaluation of Antibody–Drug Conjugates with Enhanced Immune Effector Functions

Authors: Hsuan-Ping Chang; Shufang Liu; Dhaval K. Shah

Year: 2024

Venue: AAPS Journal

DOI: https://doi.org/10.1208/s12248-024-00998-4

Paper Validation of ADC Platform for Protein Concentration and the Drug-Antibody Ratio (DAR) using Variable Pathlength Technology

Melissa Nixon; Bérengère François · 2023 · ADC Review / Journal of Antibody-drug Conjugates · DOI

Full title: Validation of ADC Platform for Protein Concentration and the Drug-Antibody Ratio (DAR) using Variable Pathlength Technology

Authors: Melissa Nixon; Bérengère François

Year: 2023

Venue: ADC Review / Journal of Antibody-drug Conjugates

DOI: https://doi.org/10.14229/jadc.2023.12.05.001

Paper The role of CD33 as therapeutic target in acute myeloid leukemia

R. Walter · 2014 · Expert opinion on therapeutic targets · DOI

Full title: The role of CD33 as therapeutic target in acute myeloid leukemia

Authors: R. Walter

Year: 2014

Venue: Expert opinion on therapeutic targets

DOI: https://doi.org/10.1517/14728222.2014.909413

Paper Designing immunoconjugates for cancer therapy.

Govindan, Serengulam V; Goldenberg, David M · 2012 · Expert opinion on biological therapy · DOI

Full title: Designing immunoconjugates for cancer therapy.

Authors: Govindan, Serengulam V; Goldenberg, David M

Year: 2012

Venue: Expert opinion on biological therapy

DOI: https://doi.org/10.1517/14712598.2012.685153

Paper Exo-Linker: Positional Reconfiguration Driving Significant Advances in ADC Stability and Efficacy

Tomohiro Watanabe; Tomohiro Fujii; Yutaka Matsuda · 2024 · ADC Review / Journal of Antibody-drug Conjugates · DOI

Full title: Exo-Linker: Positional Reconfiguration Driving Significant Advances in ADC Stability and Efficacy

Authors: Tomohiro Watanabe; Tomohiro Fujii; Yutaka Matsuda

Year: 2024

Venue: ADC Review / Journal of Antibody-drug Conjugates

DOI: https://doi.org/10.14229/jadc.2024.12.30.001.

Paper Abstract 5481: A 3D bioprinted vascularized human tumor-on-a-Chip model for simultaneous evaluation of immunotherapeutic efficacy and safety

Juliana Navarro-Yepes; Queeny Dasgupta; Purboja Purkayastha et al. · 2025 · Cancer Research · DOI

Full title: Abstract 5481: A 3D bioprinted vascularized human tumor-on-a-Chip model for simultaneous evaluation of immunotherapeutic efficacy and safety

Authors: Juliana Navarro-Yepes; Queeny Dasgupta; Purboja Purkayastha; Clara Erice; Carly Truong; Kim Phan; YongDuk Han; Michael Doerfert; C. Mello; Kevin Janson; Alma Antonio; Tracy Lin; Ameya Narkar; Sammy S. Datwani; S. Ng; Taci Pereira

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-5481

Paper Abstract 5452: Novel tryptophan-based antibody-drug conjugate (ADC) targeting EGFR-positive lung cancer demonstrates robust antitumor efficacy by triggering immunogenic cell death

H. Inoue; Kounosuke Oisaki; Hiroshi Tagawa et al. · 2025 · Cancer Research · DOI

Full title: Abstract 5452: Novel tryptophan-based antibody-drug conjugate (ADC) targeting EGFR-positive lung cancer demonstrates robust antitumor efficacy by triggering immunogenic cell death

Authors: H. Inoue; Kounosuke Oisaki; Hiroshi Tagawa; A. Nakao; N. Ebi; Takeshi Mori; Masaki Fujita

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-5452

Paper Abstract 5459: Accelerating the development of biologics: PRISM high throughput screening enables rapid preclinical characterization of antibodies, ADCs and payloads

Jillian N. Eskra; Alvin Kalathungal; Aydin Golabi et al. · 2025 · Cancer Research · DOI

Full title: Abstract 5459: Accelerating the development of biologics: PRISM high throughput screening enables rapid preclinical characterization of antibodies, ADCs and payloads

Authors: Jillian N. Eskra; Alvin Kalathungal; Aydin Golabi; Bailey Porter; Antonella Masciotti; Nashielli Diaz-Gallegos; Anup Jonchhe; Maha Naim; Lia Petronio; Maggie LeMaitre; Jacob Asiedu; Ashish Bino George; Mustafa Kocak; M. Ronan; M. Rees; Jennifer A. Roth

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-5459

Paper Abstract 5476: In vitro real-time evaluation of bystander effects of antibody-drug conjugates

Xiaoyu Zhang; Yun-fei Pu; Tian Wang et al. · 2025 · Cancer Research · DOI

Full title: Abstract 5476: In vitro real-time evaluation of bystander effects of antibody-drug conjugates

Authors: Xiaoyu Zhang; Yun-fei Pu; Tian Wang; Grace Yang; Peifang Ye; Nancy Li

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-5476

Paper Abstract 5675: ThiOBI® platform, a novel hydrophilic linker for irreversible cysteine-selective biomolecular conjugation, demonstrated potent and durable antitumor activities in various animal models

Yu-Chao Huang; Ting-Wei Liu; Chi-Huan Lu et al. · 2025 · Cancer Research · DOI

Full title: Abstract 5675: ThiOBI® platform, a novel hydrophilic linker for irreversible cysteine-selective biomolecular conjugation, demonstrated potent and durable antitumor activities in various animal models

Authors: Yu-Chao Huang; Ting-Wei Liu; Chi-Huan Lu; R. Hsu; Nan-Hsuan Wang; Ya-Chi Chen; Ming-Tain Lai; Teng-Yi Huang

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-5675

Paper Abstract 6736: Preclinical development of ADCT-241, a novel exatecan-based antibody-drug conjugate targeting PSMA for the treatment of prostate cancer

Ben Leatherdale; Beccie Martin; Banusha Rajeenthira et al. · 2025 · Cancer Research · DOI

Full title: Abstract 6736: Preclinical development of ADCT-241, a novel exatecan-based antibody-drug conjugate targeting PSMA for the treatment of prostate cancer

Authors: Ben Leatherdale; Beccie Martin; Banusha Rajeenthira; Cecile Oblette; Lara Montolio; Abigail Kimpalu; Pedro L. Alves; Hafsah Omar; Alison Faid; Elizabeth Horsley; Lina Baxter; Valenti Gomez; Charles E. Britten; L. de Haan; Paul W. Hogg; Chris Pickford; P. V. van Berkel

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-6736

Paper Abstract 5731: BGB-C354, a novel B7H3 ADC with high DAR stability and strong bystander effect, demonstrates robust antitumor activity in preclinical models

Xiao Ding; Charng-Sheng Tsai; Mei-Hsuan Tsai et al. · 2025 · Cancer Research · DOI

Full title: Abstract 5731: BGB-C354, a novel B7H3 ADC with high DAR stability and strong bystander effect, demonstrates robust antitumor activity in preclinical models

Authors: Xiao Ding; Charng-Sheng Tsai; Mei-Hsuan Tsai; Maggie Tang; Liu Xue; Chi Guan; Meiling Tan; Yiren Xiao; Yuanyuan Xie; Kunpeng Lyu; Xiaotong Chen; Wenhao Li; Qi Liu; Yunyun Chen; Jie Pan; Wenjin Yao; Yang Lyu; Kaiying Jia; Chang Song; Weiwei Song; Ce Wang; Fan Wang; Zhitao Wan; Mingming Guo; Beibei Jiang; Xiaomin Song; Wei Jin; Qiansheng Ren; Yu Shen; Zhirong Shen

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-5731

Paper Abstract 5486: Bioluminescent assays for antibody-drug conjugate development: internalization and Fc-mediated functions

Julia K Gilden; Christopher Eggers; Yitong Li et al. · 2025 · Cancer Research · DOI

Full title: Abstract 5486: Bioluminescent assays for antibody-drug conjugate development: internalization and Fc-mediated functions

Authors: Julia K Gilden; Christopher Eggers; Yitong Li; Rod Flemming; Nicholas J. Hess; Gopal Krishnan; F. Fan; B. Binkowski; Marjeta Uhr; M. Cong

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-5486

Paper Abstract 5482: In vitro assays for prediction of ADC hematological toxicities: contribution of antibody, linker, and payload

Yongzhao Huang; Emer Clarke; Graham A E Garnett et al. · 2025 · Cancer Research · DOI

Full title: Abstract 5482: In vitro assays for prediction of ADC hematological toxicities: contribution of antibody, linker, and payload

Authors: Yongzhao Huang; Emer Clarke; Graham A E Garnett; M. Lasalle; Jodi Wong; Ambroise Wu; A. Sagoe-Wagner; Elena Barbosa; Catalina Suarez; Stuart D Barnscher; Jamie R Rich; Raffaele Colombo

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-5482

Paper Abstract 578: ATNM-400 is a novel Actinium-225 antibody radioconjugate with strong efficacy in preclinical models of prostate cancer

Denis Beckford; S. Mukherjee; Debbie Lewis et al. · 2025 · Cancer Research · DOI

Full title: Abstract 578: ATNM-400 is a novel Actinium-225 antibody radioconjugate with strong efficacy in preclinical models of prostate cancer

Authors: Denis Beckford; S. Mukherjee; Debbie Lewis; Jason Li; Dina Yang; Karina Peregrina; Amanda S. Chin; Le-Cun Xu; Monideepa Roy; Adeela Kamal

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-578

Paper Abstract 6072: Engineering and preclinical development of an anti-TROP2/PD-L1 bispecific antibody drug conjugate (ADC) for enhanced anti-tumor efficacy

Chuan Chen; L. Tian; Chenpeng Su et al. · 2025 · Cancer Research · DOI

Full title: Abstract 6072: Engineering and preclinical development of an anti-TROP2/PD-L1 bispecific antibody drug conjugate (ADC) for enhanced anti-tumor efficacy

Authors: Chuan Chen; L. Tian; Chenpeng Su; Dandan Liu; Jiyuan Tian; Yujuan Li; Bing Yang; Yongxin Shan; Xiaoqian Chen; Jian Peng; Zhenping Zhu

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-6072

Paper Current Role of Topoisomerase I Inhibitors for the Treatment of Mesenchymal Malignancies and Their Potential Future Use as Payload of Sarcoma-Specific Antibody-Drug Conjugates.

Schöffski, Patrick; Wang, Chao-Chi; Schöffski, Morris Patrick et al. · 2024 · Oncology research and treatment · DOI

Full title: Current Role of Topoisomerase I Inhibitors for the Treatment of Mesenchymal Malignancies and Their Potential Future Use as Payload of Sarcoma-Specific Antibody-Drug Conjugates.

Authors: Schöffski, Patrick; Wang, Chao-Chi; Schöffski, Morris Patrick; Wozniak, Agnieszka

Year: 2024

Venue: Oncology research and treatment

DOI: https://doi.org/10.1159/000535491

Paper Abstract 5734: Advancing ADC discovery with a highly versatile linker-camptothecin library

Meijun Xiong; Qingsong Wu; Yanchun Li et al. · 2025 · Cancer Research · DOI

Full title: Abstract 5734: Advancing ADC discovery with a highly versatile linker-camptothecin library

Authors: Meijun Xiong; Qingsong Wu; Yanchun Li; Chong Liu; Yajun Sun; Zengyan Mu; Xinju Gao; Yanwen Feng; Haibo He; Paul Song; Gang Qin

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-5734

Paper Abstract 5730: Discovery of a novel antibody-drug conjugate linker-payload with a distinct killing mechanism via prolonged unfolded protein response activation

Rui Liu; Yushi Chi; Yongqiang Shan et al. · 2025 · Cancer Research · DOI

Full title: Abstract 5730: Discovery of a novel antibody-drug conjugate linker-payload with a distinct killing mechanism via prolonged unfolded protein response activation

Authors: Rui Liu; Yushi Chi; Yongqiang Shan; Chenqiang Jia; Yingying Zhang; Xiayan Zhang; Wentao Zhang; Xuemei Tian; Yifan Zhang; Fan Yang; Dongmei Han; Simon Hsu; Jiamin Su; Jijun Yuan; Wan-Jen Yang; Xiaoling Yuan; Zhiyu Ma; Chen Hu

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-5730

Paper Abstract 5733: Design and synthesis of the novel camptothecin analog MF-6 for application into site-specific antibody-drug conjugate

Xiaowei Cen; Hui Xu; Huikai Zhu et al. · 2025 · Cancer Research · DOI

Full title: Abstract 5733: Design and synthesis of the novel camptothecin analog MF-6 for application into site-specific antibody-drug conjugate

Authors: Xiaowei Cen; Hui Xu; Huikai Zhu; Hua Deng; Zhenzhen Wang; Junwei Xu; Xueying Li; Zhiheng Wu; Yiyan Zhang; Yuhang Chen; Xiaolin Chen; Li Chen; Wei Zhou; Hai Wu

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-5733

Paper Abstract 6743: Patient-derived organoids: an in vitro platform for evaluating ADC efficacy, potency, and specificity

Daniele Mori; Claudia Beaurivage; Eider Valle Encinas et al. · 2025 · Cancer Research · DOI

Full title: Abstract 6743: Patient-derived organoids: an in vitro platform for evaluating ADC efficacy, potency, and specificity

Authors: Daniele Mori; Claudia Beaurivage; Eider Valle Encinas; Yara Hendriksen; Anna Schepers; Foteini Gkogkou; Joris Maas; Ka Wai Lai; Mariana Silva; Sumeyra Mucuk; Vineeta Adegbenro; R. Korporaal; Merel Derksen; Sylvia F Boj

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-6743

Paper Abstract 7336: B7-H7 is a novel ADC target for solid tumors and shows potent activity with multiple payload-linker technologies

Emilien Loeuillard; Bijan Etemad-Gilbertson; Susannah L. Hewitt et al. · 2025 · Cancer Research · DOI

Full title: Abstract 7336: B7-H7 is a novel ADC target for solid tumors and shows potent activity with multiple payload-linker technologies

Authors: Emilien Loeuillard; Bijan Etemad-Gilbertson; Susannah L. Hewitt; Jamie Strand; Riale Gilligan; Silvia Ferrati; Tatiana Novobrantseva; Matthew P Rausch

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-7336

Paper Abstract 6748: Comparison of activities and identification of predictive genomic biomarkers of response to trastuzumab and the trastuzumab deruxtecan ADC using the OncoPanel® platform

Luciano Galdieri; Steven M. Garner; Brogan A. Epkins et al. · 2025 · Cancer Research · DOI

Full title: Abstract 6748: Comparison of activities and identification of predictive genomic biomarkers of response to trastuzumab and the trastuzumab deruxtecan ADC using the OncoPanel® platform

Authors: Luciano Galdieri; Steven M. Garner; Brogan A. Epkins; Emily Schultz; Daria Clucas; Kaitlyne Powers; Justin Lipner; Elsa Liu; ChunYao Lee; Alastair J. King

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-6748

Paper Abstract 6081: Bispecific antibody drug conjugates (bsADCs) targeting DLL3 and B7-H3 demonstrated potent anti-tumor activity in preclinical models of small cell lung cancer (SCLC)

Kaiqing Zhang; Liu Yang; Peiran Li et al. · 2025 · Cancer Research · DOI

Full title: Abstract 6081: Bispecific antibody drug conjugates (bsADCs) targeting DLL3 and B7-H3 demonstrated potent anti-tumor activity in preclinical models of small cell lung cancer (SCLC)

Authors: Kaiqing Zhang; Liu Yang; Peiran Li; Yu Qi; Jushi Gai; Luheng Du; G. An; Chengzhang Shang; Yanan Guo; Yi Yang; Frank An

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-6081

Paper Abstract 6742: High-affinity human IgG1 antibody against GUCY2C for ADC development: Identification, characterization, and efficacy

Yunxia Zheng; Xiafen Wu; Junxiang Jia et al. · 2025 · Cancer Research · DOI

Full title: Abstract 6742: High-affinity human IgG1 antibody against GUCY2C for ADC development: Identification, characterization, and efficacy

Authors: Yunxia Zheng; Xiafen Wu; Junxiang Jia; Huihui Guo; Xiangfei Kong; Gengxiang Zhao; Yuanyuan Huang; Hangbo Ye; Xiaolei Liu; Yi Luo; Xiaoqiang Xie; Xia Zhou; Lu Bai; Wenjun Li; Binbin Chen; Qingliang Yang; R. Zhao

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-6742

Paper Abstract 6735: E-cM-Topi, a potent EGFR-cMET bispecific antibody drug conjugate, with superior anti-tumor effect in non-small-cell lung cancer (NSCLC)

Huihui Chen; Le Sun; Bing Hu et al. · 2025 · Cancer Research · DOI

Full title: Abstract 6735: E-cM-Topi, a potent EGFR-cMET bispecific antibody drug conjugate, with superior anti-tumor effect in non-small-cell lung cancer (NSCLC)

Authors: Huihui Chen; Le Sun; Bing Hu; Zhiping Zhao; Ziheng Liu; Guangbao Qiu; Dongmei Bai; Ying Li; Ziwei Ren; Ting Zhang; Xin Ye; Lingfeng You; Zhendong Xue; Yuchang Mao; Huaixin Dang; Shuyu Cai; Jun Feng; Min Hu; Feng He

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-6735

Paper Abstract LB004: Preclinical discovery and characterization of EO-1022, a site-specific glycan-conjugated anti-HER3 vc-MMAE ADC for treating solid tumors

T. O'Hare; Jaya Srivastava; J. Cleveland et al. · 2025 · Cancer Research · DOI

Full title: Abstract LB004: Preclinical discovery and characterization of EO-1022, a site-specific glycan-conjugated anti-HER3 vc-MMAE ADC for treating solid tumors

Authors: T. O'Hare; Jaya Srivastava; J. Cleveland; V. M. Jansen; D. Dornan

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-lb004

Paper Abstract 7463: A linker platform for antibody drug conjugates (ADCs): expanding the therapeutic window

David Yi; Wen Zhang; John Liu et al. · 2025 · Cancer Research · DOI

Full title: Abstract 7463: A linker platform for antibody drug conjugates (ADCs): expanding the therapeutic window

Authors: David Yi; Wen Zhang; John Liu; Suk Lee; Alice Chen

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-7463

Paper Abstract 6851: An integrated preclinical platform for antibody-drug conjugate development

Stefano Cairo; Mara Gilardi; Marianna Zipeto et al. · 2025 · Cancer Research · DOI

Full title: Abstract 6851: An integrated preclinical platform for antibody-drug conjugate development

Authors: Stefano Cairo; Mara Gilardi; Marianna Zipeto; M. Ritchie

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-6851

Paper Abstract 6755: Discovery of the synergistic dual-payload antibody-drug conjugate (CTPH-02) by combination of MMAE and novel payloads

Chang-Sun Lee; Myeong Joo Kim; Da hyun Kim et al. · 2025 · Cancer Research · DOI

Full title: Abstract 6755: Discovery of the synergistic dual-payload antibody-drug conjugate (CTPH-02) by combination of MMAE and novel payloads

Authors: Chang-Sun Lee; Myeong Joo Kim; Da hyun Kim; Soyeon Lim; Jiwoo Lee; Eunseok Choi; Wonbin Ha; Han ah Kim; Jaebeom Park; Seung Chan Kim

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-6755

Paper Abstract P4-14-28: XMT-1522 induces tumor regressions in pre-clinical models representing HER2-positive and HER2 low-expressing breast cancer

D. Bergstrom; N. Bodyak; Pu-Reum Park et al. · 2016 · DOI

Full title: Abstract P4-14-28: XMT-1522 induces tumor regressions in pre-clinical models representing HER2-positive and HER2 low-expressing breast cancer

Authors: D. Bergstrom; N. Bodyak; Pu-Reum Park; A. Yurkovetskiy; M. Devit; M. Yin; Laura L Poling; Joshua D Thomas; D. Gumerov; D. Xiao; Elena Ter-Ovanesyan; Liuliang Qin; Alex Uttard; Alexander Johnson; T. Lowinger

Year: 2016

DOI: https://doi.org/10.1158/1538-7445.sabcs15-p4-14-28

Paper Abstract A004: MEDI3726 (ADCT-401), a novel antibody-drug conjugate targeting PSMA, has potent in vivo antitumor activity in prostate cancer patient-derived xenograft models

S. Cho; F. Zammarchi; N. Monks et al. · 2018 · Poster Presentations - Proffered Abstracts · DOI

Full title: Abstract A004: MEDI3726 (ADCT-401), a novel antibody-drug conjugate targeting PSMA, has potent in vivo antitumor activity in prostate cancer patient-derived xenograft models

Authors: S. Cho; F. Zammarchi; N. Monks; K. Vashisht; R. Tammali; Kevin P. Schifferli; P. Strout; Wanda King; Karma Dacosta; R. Fleming; David G. Williams; K. Havenith; M. Hinrichs; S. Chivers; N. Dimasi; P. Howard; J. Hartley; S. Coats; R. Herbst; P. V. Berkel; D. Tice

Year: 2018

Venue: Poster Presentations - Proffered Abstracts

DOI: https://doi.org/10.1158/1538-7445.prca2017-a004

Paper - **DOI:** 10.1158/1538-7445.am2025-833 - **Authors:** M. Wu, Yao-Tsung Tsai, Chee Voon Yap - **Year:** 2025 - **Journal:** Cancer Research

M. Wu; Yao-Tsung Tsai; Chee Voon Yap · 2025 · Cancer Research · DOI

Full title: - **DOI:** 10.1158/1538-7445.am2025-833 - **Authors:** M. Wu, Yao-Tsung Tsai, Chee Voon Yap - **Year:** 2025 - **Journal:** Cancer Research

Authors: M. Wu; Yao-Tsung Tsai; Chee Voon Yap

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-833

Paper Abstract A024: Insights across indications from the Pediatric Bespoke Therapeutic Development Workshop initiative

Joseph S Baxter; Claudia Montiel Equihua; Jan J Molenaar et al. · 2025 · Cancer Research · DOI

Full title: Abstract A024: Insights across indications from the Pediatric Bespoke Therapeutic Development Workshop initiative

Authors: Joseph S Baxter; Claudia Montiel Equihua; Jan J Molenaar; Sheena Patel; Siwan Oldham; Andrew DJ Pearson; David Jenkinson

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.pediatric25-a024

Paper Abstract B068: In vitro and in vivo efficacy of the antibody-drug-conjugate (ADC) PB-vcMMAE-5 against human ovarian cancer expressing truncated core 2 O-glycans

Kwong Y. Tsang; Massimo Fantini; A. Zaki et al. · 2025 · Cancer Research · DOI

Full title: Abstract B068: In vitro and in vivo efficacy of the antibody-drug-conjugate (ADC) PB-vcMMAE-5 against human ovarian cancer expressing truncated core 2 O-glycans

Authors: Kwong Y. Tsang; Massimo Fantini; A. Zaki; Sharon A Mavroukakis; Christina M. Annunziata; Philip M. Arlen

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.ovarian25-b068

Paper - **DOI:** 10.1158/1538-7445.am2025-lb135 - **Authors:** Yi Yang, Kaiqing Zhang, Kunying Hao, Chengzhang Shang - **Year:** 2025 - **Journal:** Cancer Research

Yi Yang; Kaiqing Zhang; Kunying Hao et al. · 2025 · Cancer Research · DOI

Full title: - **DOI:** 10.1158/1538-7445.am2025-lb135 - **Authors:** Yi Yang, Kaiqing Zhang, Kunying Hao, Chengzhang Shang - **Year:** 2025 - **Journal:** Cancer Research

Authors: Yi Yang; Kaiqing Zhang; Kunying Hao; Chengzhang Shang

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-lb135

Paper Abstract 6832: SYS6041, a next-generation Folate Receptor α-targeted antibody-drug conjugates for the treatment of FRα-expressing malignancies

Jieru Liu; Huan Li; Mo Dan et al. · 2025 · Cancer Research · DOI

Full title: Abstract 6832: SYS6041, a next-generation Folate Receptor α-targeted antibody-drug conjugates for the treatment of FRα-expressing malignancies

Authors: Jieru Liu; Huan Li; Mo Dan; Xiwu Hui; Bing Yao; Yang Zhang; Linlin Xiao; Bin Kang; Can Yuan; Bin Bao; Miaomiao Wei; Chunqing Qu; Yanling Li; Wei Yang

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-6832

Paper Abstract 3000: Impact of trastuzumab coating when prototyping immunoliposomes in breast cancer models: The more the merrier

A. Rodallec; Corentin Franco; S. Robert et al. · 2019 · Experimental and Molecular Therapeutics · DOI

Full title: Abstract 3000: Impact of trastuzumab coating when prototyping immunoliposomes in breast cancer models: The more the merrier

Authors: A. Rodallec; Corentin Franco; S. Robert; G. Sicard; S. Giacometti; A. Savina; F. Bouquet; B. Lacarelle; J. Ciccolini; P. Poncelet; R. Fanciullino

Year: 2019

Venue: Experimental and Molecular Therapeutics

DOI: https://doi.org/10.1158/1538-7445.sabcs18-3000

Paper Abstract A071: Inverse Biomarker Exploring Technology (IBMET) Mathematical Identification of Cancer-Specific Epitopes and Novel Targets (Biomarkers) from Big Data of Single-Domain Antibodies Recognizing Higher Structures

Akihiro Imura; Kazutaka Araki; Tsuyoshi Inoue et al. · 2024 · Cancer Research · DOI

Full title: Abstract A071: Inverse Biomarker Exploring Technology (IBMET) Mathematical Identification of Cancer-Specific Epitopes and Novel Targets (Biomarkers) from Big Data of Single-Domain Antibodies Recognizing Higher Structures

Authors: Akihiro Imura; Kazutaka Araki; Tsuyoshi Inoue; R. Maeda; Hiroyuki Yamazaki

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.pancreatic24-a071

Paper Abstract 1543: Discovery of antibodies for ADC therapy from cancer patients who show durable clinical response to checkpoint inhibitors

Alexander Scholz; Jerald Aurellano; Michael Harbell et al. · 2019 · Immunology · DOI

Full title: Abstract 1543: Discovery of antibodies for ADC therapy from cancer patients who show durable clinical response to checkpoint inhibitors

Authors: Alexander Scholz; Jerald Aurellano; Michael Harbell; Danhui Zhang; Samantha O'Connor; Beatriz Millare; Felix Chu; Sheila Fernandez; C. Czupalla; Iraz T. Aydin; Amy B. Manning-Boğ; Yvonne Leung; K. Williamson; Chantia Carroll; Dongkyoon Kim; Xiaomu Chen; Sean M. Carroll; Ish Dhawan; Ngan Nguyen; S. Thyagarajan; M. Whidden; Gregg Espiritu Santo; Nicole Haaser; G. Cavet; L. Steinman; T. Serafini; W. Volkmuth; J. Benjamin; W. Robinson; N. Greenberg; D. Emerling; J. Defalco

Year: 2019

Venue: Immunology

DOI: https://doi.org/10.1158/1538-7445.sabcs18-1543

Paper Abstract 237: Preclinical evaluation of anti-HER2 Antibody Targeted Amanitin Conjugates (ATACs) on HER2low breast cancer with chromosome 17p deletion

C. Breunig; A. Pálfi; Michael Kulke et al. · 2019 · Experimental and Molecular Therapeutics · DOI

Full title: Abstract 237: Preclinical evaluation of anti-HER2 Antibody Targeted Amanitin Conjugates (ATACs) on HER2low breast cancer with chromosome 17p deletion

Authors: C. Breunig; A. Pálfi; Michael Kulke; C. Lutz; C. Müller; Torsten Hechler; A. Pahl

Year: 2019

Venue: Experimental and Molecular Therapeutics

DOI: https://doi.org/10.1158/1538-7445.sabcs18-237

Paper Abstract OT1-02-02: A global, phase 2 study of ARX788 in patients with HER2-positive metastatic breast cancer whose disease is resistant or refractory to T-DM1, and/or T-DXd, and/or tucatinib-containing regimens

Janice M. Lu; K. Kalinsky; D. Tripathy et al. · 2022 · Cancer Research · DOI

Full title: Abstract OT1-02-02: A global, phase 2 study of ARX788 in patients with HER2-positive metastatic breast cancer whose disease is resistant or refractory to T-DM1, and/or T-DXd, and/or tucatinib-containing regimens

Authors: Janice M. Lu; K. Kalinsky; D. Tripathy; G. Sledge; W. Gradishar; R. O'Regan; J. O’Shaughnessy; S. Modi; Joshua Z. Drago; Haeseong Park; A. McCartney; S. Frentzas; C. Shannon; K. Cuff; R. Eek; Miguel Martín; G. Curigliano; G. Jerusalem; Chiun-Sheng Huang; M. Press; Ma Li; Dong Xu; C. Song; R. Huhn; Jinchun Yan; S. Hurvitz

Year: 2022

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.sabcs21-ot1-02-02

Paper Abstract PD3-06: Safety and efficacy of anti-Trop-2 antibody drug conjugate, sacituzumab govitecan (IMMU-132), in heavily pretreated patients with TNBC

A. Bardia; J. Diamond; I. Mayer et al. · 2016 · DOI

Full title: Abstract PD3-06: Safety and efficacy of anti-Trop-2 antibody drug conjugate, sacituzumab govitecan (IMMU-132), in heavily pretreated patients with TNBC

Authors: A. Bardia; J. Diamond; I. Mayer; A. Starodub; R. Moroose; S. Isakoff; A. Ocean; M. Guarino; J. Berlin; W. Messersmith; Sajev Thomas; J. O’Shaughnessy; K. Kalinsky; M. Maurer; J. Chang; A. Forero; T. Traina; A. Gucalp; F. Wilhelm; W. Wegener; P. Maliakal; R. Sharkey; D. Goldenberg; L. Vahdat

Year: 2016

DOI: https://doi.org/10.1158/1538-7445.sabcs15-pd3-06

Paper Abstract P6-20-16: BAT8003, a potent anti-Trop-2 antibody-drug conjugate, for the treatment of triple negative breast cancer

W. Tang; X. Huang; Z. Ou et al. · 2019 · Poster Session Abstracts · DOI

Full title: Abstract P6-20-16: BAT8003, a potent anti-Trop-2 antibody-drug conjugate, for the treatment of triple negative breast cancer

Authors: W. Tang; X. Huang; Z. Ou; H. Yan; J. Gan; Q. Dong; B. Tan; Y. Yang; Y. Guo; S. Li; B. Thomas; J-C. Yu

Year: 2019

Venue: Poster Session Abstracts

DOI: https://doi.org/10.1158/1538-7445.sabcs18-p6-20-16

Paper Abstract P3-11-06: Pre-clinical assessment of combined ABT-263/Navitoclax and ABT-414 or ABBV-321 treatment for EGFR-expressing TNBC

Jason J. Zoeller; Aleksandr Vagodny; Veerle W. Daniels et al. · 2020 · Poster Session Abstracts · DOI

Full title: Abstract P3-11-06: Pre-clinical assessment of combined ABT-263/Navitoclax and ABT-414 or ABBV-321 treatment for EGFR-expressing TNBC

Authors: Jason J. Zoeller; Aleksandr Vagodny; Veerle W. Daniels; Krishan Taneja; Benjamin Y. Tan; Yoko S Derose; Maihi Fujita; A. Welm; A. Letai; J. Leverson; V. Blot; R. Bronson; D. Dillon; J. Brugge

Year: 2020

Venue: Poster Session Abstracts

DOI: https://doi.org/10.1158/1538-7445.sabcs19-p3-11-06

Paper Abstract P6-17-39: BAT8001, a potent anti-HER2 antibody-drug conjugate with a novel stable linker for the treatment of HER2-positive breast cancer

W. Tang; X. Deng; Z. Ou et al. · 2019 · Poster Session Abstracts · DOI

Full title: Abstract P6-17-39: BAT8001, a potent anti-HER2 antibody-drug conjugate with a novel stable linker for the treatment of HER2-positive breast cancer

Authors: W. Tang; X. Deng; Z. Ou; J. Gan; Q. Dong; B. Tan; L. Lu; B. Chen; C. Bao; S. Li; B. Thomas; J-C. Yu

Year: 2019

Venue: Poster Session Abstracts

DOI: https://doi.org/10.1158/1538-7445.sabcs18-p6-17-39

Paper Abstract P3-08-52: Systemic toxicities of trastuzumab-emtansine predict tumor response in HER2+ metastatic breast cancer

Shou-Ching Tang; C. Capra; Germame Ajebo et al. · 2020 · DOI

Full title: Abstract P3-08-52: Systemic toxicities of trastuzumab-emtansine predict tumor response in HER2+ metastatic breast cancer

Authors: Shou-Ching Tang; C. Capra; Germame Ajebo; S. Mairs; J. Meza‐Junco; William B. Hillegass; B. Craft; Xiaofu Zhu

Year: 2020

DOI: https://doi.org/10.1158/1538-7445.sabcs19-p3-08-52

Paper Abstract C049: Implementing human bone marrow organoids to interrogate microenvironmental influences on the efficacy of blood cancer immunotherapies

Zoë C. Wong; Yuqi Shen; Alexandros Rampotas et al. · 2024 · Cancer Research · DOI

Full title: Abstract C049: Implementing human bone marrow organoids to interrogate microenvironmental influences on the efficacy of blood cancer immunotherapies

Authors: Zoë C. Wong; Yuqi Shen; Alexandros Rampotas; Isaac Gannon; Charlotte K. Brierley; Camelia Benlabiod; Nawshad Hayder; Eleanor Murphy; Aude-Anais Olijnik; C. Roddie; Martin Pule; A. Mead; Abdullah O. Khan; B. Psaila

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.tumbody-c049

Paper - **DOI:** 10.1158/1557-3125.advbc17-a36 - **Authors:** Jeffrey H. Wu, L. Muldoon, E. Neuwelt - **Year:** 2018 - **Journal:** Resistance Mechanisms

Jeffrey H. Wu; L. Muldoon; E. Neuwelt · 2018 · Resistance Mechanisms · DOI

Full title: - **DOI:** 10.1158/1557-3125.advbc17-a36 - **Authors:** Jeffrey H. Wu, L. Muldoon, E. Neuwelt - **Year:** 2018 - **Journal:** Resistance Mechanisms

Authors: Jeffrey H. Wu; L. Muldoon; E. Neuwelt

Year: 2018

Venue: Resistance Mechanisms

DOI: https://doi.org/10.1158/1557-3125.advbc17-a36

Paper Abstract P1-18-36: The safety, tolerability, and pharmacokinetics of BAT8001 in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer: An open-label, dose-up, phase 1 study

Shusen Wang; R. Hong; Liye Wang et al. · 2020 · DOI

Full title: Abstract P1-18-36: The safety, tolerability, and pharmacokinetics of BAT8001 in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer: An open-label, dose-up, phase 1 study

Authors: Shusen Wang; R. Hong; Liye Wang; Fei Xu; W. Xia

Year: 2020

DOI: https://doi.org/10.1158/1538-7445.sabcs19-p1-18-36

Paper Abstract P2-13-25: A phase I dose-escalation study of DHES0815A, a HER2-targeting antibody-drug conjugate with a DNA monoalkylator payload, in patients with HER2-positive breast cancer

I. Krop; E. Hamilton; K. Jung et al. · 2022 · Cancer Research · DOI

Full title: Abstract P2-13-25: A phase I dose-escalation study of DHES0815A, a HER2-targeting antibody-drug conjugate with a DNA monoalkylator payload, in patients with HER2-positive breast cancer

Authors: I. Krop; E. Hamilton; K. Jung; S. Modi; K. Kalinsky; G. Phillips; Rong Shi; S. Monemi; M. Mamounas; Ola M. Saad; V. Choeurng; Renee Commerford; E. Cho; A. Ungewickell; P. LoRusso

Year: 2022

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.sabcs21-p2-13-25

Paper Abstract OT1-03-02: Efficacy and safety of SKB264 for previously treated metastatic triple negative breast cancer in Phase 2 study

Yongmei Yin; Xin-hong Wu; Q. Ouyang et al. · 2023 · Cancer Research · DOI

Full title: Abstract OT1-03-02: Efficacy and safety of SKB264 for previously treated metastatic triple negative breast cancer in Phase 2 study

Authors: Yongmei Yin; Xin-hong Wu; Q. Ouyang; Min Yan; Lihua Song; Yunpeng Liu; Z. Tong; C. Geng; Ying Wang; Guohua Yu; Xiang Wang; Ying Cheng; Weihong Zhao; Qun Li; Y. Diao; Gesha Liu; J. Ge; Jin Li

Year: 2023

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.sabcs22-ot1-03-02

Paper Abstract SP113: The making of an ADC

Pwhi Parren · 2021 · DOI

Full title: Abstract SP113: The making of an ADC

Authors: Pwhi Parren

Year: 2021

DOI: https://doi.org/10.1158/1538-7445.sabcs20-sp113

Paper Abstract P3-07-08: Exposure-adjusted incidence rates (EAIRs) of adverse events (AEs) from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) in HR+/HER2- metastatic breast cancer (MBC)

S. Tolaney; P. Schmid; A. Bardia et al. · 2023 · Cancer Research · DOI

Full title: Abstract P3-07-08: Exposure-adjusted incidence rates (EAIRs) of adverse events (AEs) from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) in HR+/HER2- metastatic breast cancer (MBC)

Authors: S. Tolaney; P. Schmid; A. Bardia; F. Marmé; D. Loirat; Priyanka Sharma; Hao Wang; Olivia Fu; W. Verret; H. Rugo

Year: 2023

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.sabcs22-p3-07-08

Paper Abstract OT1-12-02: Trial in progress: Phase 2, open-label study to evaluate the safety and efficacy of praluzatamab ravtansine in metastatic HER2 non-amplified breast cancer as monotherapy and combination with pacmilimab

K. Miller; L. Emens; S. Tolaney et al. · 2022 · Cancer Research · DOI

Full title: Abstract OT1-12-02: Trial in progress: Phase 2, open-label study to evaluate the safety and efficacy of praluzatamab ravtansine in metastatic HER2 non-amplified breast cancer as monotherapy and combination with pacmilimab

Authors: K. Miller; L. Emens; S. Tolaney; S. Hurvitz; E. Hamilton; V. Paton; A. Hannah; V. Boni

Year: 2022

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.sabcs21-ot1-12-02

Paper Abstract P2-13-33: Preclinical development of DHES0815A: A HER2-directed antibody-drug conjugate comprised of a reduced potency PBD dimer linked to a domain I binding HER2 antibody

G. Phillips; Guangmin Li; Jun Guo et al. · 2022 · Cancer Research · DOI

Full title: Abstract P2-13-33: Preclinical development of DHES0815A: A HER2-directed antibody-drug conjugate comprised of a reduced potency PBD dimer linked to a domain I binding HER2 antibody

Authors: G. Phillips; Guangmin Li; Jun Guo; Shang‐Fan Yu; Genee Y. Lee; Donglu Zhang; P. Dragovich; Thomas H. Pillow; Binqing Wei; M. V. Lee; Ola M. Saad; Shabkhaiz Masih; D. Leipold; Lisa M. Crocker; M. Schutten

Year: 2022

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.sabcs21-p2-13-33

Paper Abstract P4-08-18: Engineered Toxin Bodies Specific for TROP2 Positive Cancers

G. Cornelison; Ileana Pedraza; Kendra C. Garrison et al. · 2023 · Cancer Research · DOI

Full title: Abstract P4-08-18: Engineered Toxin Bodies Specific for TROP2 Positive Cancers

Authors: G. Cornelison; Ileana Pedraza; Kendra C. Garrison; Elizabeth M. Kapeel; Channing C. Pletka; A. Khan; Jessica Momb; Rebecca Martin; Adam Bartos; Joseph Dekker; Jay Zhao; J. Majercak; G. Robinson

Year: 2023

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.sabcs22-p4-08-18

Paper Abstract IA023: Dual-drug ADC platform for effective and safe cancer treatment

K. Tsuchikama · 2024 · Molecular Cancer Therapeutics · DOI

Full title: Abstract IA023: Dual-drug ADC platform for effective and safe cancer treatment

Authors: K. Tsuchikama

Year: 2024

Venue: Molecular Cancer Therapeutics

DOI: https://doi.org/10.1158/1538-8514.cancerchem24-ia023

Paper Abstract P1-07-27: Triple-negative breast cancer with bone marrow involvement and response after use of antibody-drug conjugate (ADC)

Sophia Freitas; Rafael Silva; Thales Silva et al. · 2025 · Clinical Cancer Research · DOI

Full title: Abstract P1-07-27: Triple-negative breast cancer with bone marrow involvement and response after use of antibody-drug conjugate (ADC)

Authors: Sophia Freitas; Rafael Silva; Thales Silva; Bianca Carnevalli; Danillo Souza; Aumilto Junior; João Victor Oliveira

Year: 2025

Venue: Clinical Cancer Research

DOI: https://doi.org/10.1158/1557-3265.sabcs24-p1-07-27

Paper Abstract B013: Folate receptor alpha (FRa) expression and correlation with other molecular alterations in high grade serous endometrial cancer (EC)

Rebecca Porter; Sandy Elias; N. Xiong et al. · 2024 · Clinical Cancer Research · DOI

Full title: Abstract B013: Folate receptor alpha (FRa) expression and correlation with other molecular alterations in high grade serous endometrial cancer (EC)

Authors: Rebecca Porter; Sandy Elias; N. Xiong; Madeline Polak; Kayla Fahey; N. Tayob; Courtney H. Qi; Carina Feeney; Swati Narayan; J. Curtis; Susana M. Campos; C. Krasner; Elizabeth K. Lee; Elizabeth H. Stover; Alexi A. Wright; Joyce Liu; U. Matulonis; P. Konstantinopoulos

Year: 2024

Venue: Clinical Cancer Research

DOI: https://doi.org/10.1158/1557-3265.endo24-b013

Paper Abstract P4-12-17: Pre-clinical data and phase I design for PQ-203: a novel peptide-drug conjugate (PDC) targeting the SORT1 receptor in hormone receptor "Triple" Negative Breast Cancer (TNBC)

Francine Lui; Andrew Zhai; Sungwon Hwang et al. · 2025 · Clinical Cancer Research · DOI

Full title: Abstract P4-12-17: Pre-clinical data and phase I design for PQ-203: a novel peptide-drug conjugate (PDC) targeting the SORT1 receptor in hormone receptor "Triple" Negative Breast Cancer (TNBC)

Authors: Francine Lui; Andrew Zhai; Sungwon Hwang; Mitchell Elliott; Lucas Siow; E. Garmey; D. Cescon; David White

Year: 2025

Venue: Clinical Cancer Research

DOI: https://doi.org/10.1158/1557-3265.sabcs24-p4-12-17

Paper Abstract P6-10-18: Developing novel lysyl oxidase (LOX) inhibitors to overcome chemotherapy resistance in triple negative breast cancer

M. Cetin; Ozge Saatci; Ozge Akbulut et al. · 2023 · Cancer Research · DOI

Full title: Abstract P6-10-18: Developing novel lysyl oxidase (LOX) inhibitors to overcome chemotherapy resistance in triple negative breast cancer

Authors: M. Cetin; Ozge Saatci; Ozge Akbulut; Chad Beneker; A. Rezaeian; M. Chernov; Campbell McInnes; O. Sahin

Year: 2023

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.sabcs22-p6-10-18

Paper - **DOI:** 10.1158/1557-3265.sabcs24-p4-04-39 - **Authors:** E. Giontella, E. Fiorio - **Year:** 2025 - **Journal:** Clinical Cancer Research

E. Giontella; E. Fiorio · 2025 · Clinical Cancer Research · DOI

Full title: - **DOI:** 10.1158/1557-3265.sabcs24-p4-04-39 - **Authors:** E. Giontella, E. Fiorio - **Year:** 2025 - **Journal:** Clinical Cancer Research

Authors: E. Giontella; E. Fiorio

Year: 2025

Venue: Clinical Cancer Research

DOI: https://doi.org/10.1158/1557-3265.sabcs24-p4-04-39

Paper Abstract P2-08-27: ICARUS-BREAST02: Safety, Tolerability, & Anti-tumor Activity of patritumab deruxtecan (HER3-DXd) monotherapy & combinations in patients (pts) with inoperable advanced breast cancer (ABC) following progression on trastuzumab deruxtecan (T-DXd)

B. Pistilli; S. Michiels; Rasha Cheikh-Hussin et al. · 2025 · Clinical Cancer Research · DOI

Full title: Abstract P2-08-27: ICARUS-BREAST02: Safety, Tolerability, & Anti-tumor Activity of patritumab deruxtecan (HER3-DXd) monotherapy & combinations in patients (pts) with inoperable advanced breast cancer (ABC) following progression on trastuzumab deruxtecan (T-DXd)

Authors: B. Pistilli; S. Michiels; Rasha Cheikh-Hussin; M. Lacroix-Triki; Pierre Guyader; L. Tselikas; Souad Cosse; Tiffany Malleck; Jacqueline Deneuve; Ghada Nachabeh; Françoise Farace; M. Oulhen; Patricia Kannouche; Andrea Sporchia; Esther Pang; D. Sternberg; D. Sellami; Noemie Corcos; Fabrice André; F. Mosele; G. Montagnac

Year: 2025

Venue: Clinical Cancer Research

DOI: https://doi.org/10.1158/1557-3265.sabcs24-p2-08-27

Paper Abstract IA022: DYP688, a first-in-class PMEL17-targeted antibody drug conjugate delivering a Gq/11-specific inhibitor for the treatment of metastatic uveal melanoma

Josephzore Wk; Joseph A D'Alessio; P. Yerramilli-Rao et al. · 2024 · Molecular Cancer Therapeutics · DOI

Full title: Abstract IA022: DYP688, a first-in-class PMEL17-targeted antibody drug conjugate delivering a Gq/11-specific inhibitor for the treatment of metastatic uveal melanoma

Authors: Josephzore Wk; Joseph A D'Alessio; P. Yerramilli-Rao; John Blankenship; Kathrin Buntin; Matthew T Burger; Zhuoliang Chen; Young Shin Cho; John Davis; N. Ebel; Jochen Eisfeld; Anne Haberkorn; Dominik Hainzl; Keith Hoffmaster; Matthias Napp; Dominik Pistorius; Vivek Rauniyar; Aimee Reynolds; Vincent Romanet; Christian Schnell; Katherine Seiss; William R. Tschantz; Susanne Wieland-Berghausen; Laurin Wimmer; Kuno Wuersch; Alan Zhang; Eusebio Manchado

Year: 2024

Venue: Molecular Cancer Therapeutics

DOI: https://doi.org/10.1158/1538-8514.cancerchem24-ia022

Paper Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B Cell Lymphoma.

Sean R Corcoran; J. Phelan; Jaewoo Choi et al. · 2024 · Cancer Discovery · DOI

Full title: Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B Cell Lymphoma.

Authors: Sean R Corcoran; J. Phelan; Jaewoo Choi; Galina Shevchenko; Rachel E Fenner; Xin Yu; Sebastian Scheich; Tony Hsiao; Vivian M Morris; Evangelia K. Papachristou; Kamal Kishore; Clive S D'Santos; Yanlong Ji; Stefania Pittaluga; George W. Wright; Henning Urlaub; Kuan-Ting Pan; T. Oellerich; J. Muppidi; Daniel J Hodson; Louis M. Staudt

Year: 2024

Venue: Cancer Discovery

DOI: https://doi.org/10.1158/2159-8290.cd-23-0802

Paper Abstract NT-090: PRECLINICAL ACTIVITY AND SAFETY OF STRO-002, A NOVEL ADC TARGETING FOLATE RECEPTOR ALPHA FOR OVARIAN AND ENDOMETRIAL CANCER

C. Abrahams; Stellanie Krimm; Xiaofan Li et al. · 2019 · DOI

Full title: Abstract NT-090: PRECLINICAL ACTIVITY AND SAFETY OF STRO-002, A NOVEL ADC TARGETING FOLATE RECEPTOR ALPHA FOR OVARIAN AND ENDOMETRIAL CANCER

Authors: C. Abrahams; Stellanie Krimm; Xiaofan Li; Sihong Zhou; J. Hanson; Mary Rose Masikat; Krishna Bajjuri; Tyler H Heibeck; D. Kothari; Abigail S. Yu; R. Henningsen; Cuong Tran; Gang Yin; J. Zawada; Julie S. Hang; Maureen Fitch Bruhns; W. Solis; Alexander R. Steiner; Adam Galan; T. Kline; R. Stafford; A. Yam; V. D. Almeida; M. Lupher; T. Hallam

Year: 2019

DOI: https://doi.org/10.1158/1557-3265.ovcasymp18-nt-090

Paper Abstract P5-05-30: Unlocking the Therapeutic Potential of T DXd Enhertu Mechanisms of Action in HER2 Low Cancers and Immunomodulatory Effects

Li-Chung Tsao; John S Wang; Xingru Ma et al. · 2025 · Clinical Cancer Research · DOI

Full title: Abstract P5-05-30: Unlocking the Therapeutic Potential of T DXd Enhertu Mechanisms of Action in HER2 Low Cancers and Immunomodulatory Effects

Authors: Li-Chung Tsao; John S Wang; Xingru Ma; Sirajbir Sodhi; Joey V. Ragusa; Bushangqing Liu; Jason McBane; Tao Wang; Junping Wei; Congxiao Liu; Xiao Yang; Gangjun Liu; Ivan Spasojevic; Ping Fan; T. Trotter; Michael Morse; H. Lyerly; Z. Hartman

Year: 2025

Venue: Clinical Cancer Research

DOI: https://doi.org/10.1158/1557-3265.sabcs24-p5-05-30

Paper Abstract 538: LC-MS based catabolite identification study of an ADC with DM21-C, a novel maytansinoid linker-payload

J. Lau; Paulin L. Salomon; K. Sinkevicius et al. · 2019 · Clinical research · DOI

Full title: Abstract 538: LC-MS based catabolite identification study of an ADC with DM21-C, a novel maytansinoid linker-payload

Authors: J. Lau; Paulin L. Salomon; K. Sinkevicius; Juliet A. Costoplus; Megan E Fuller; R. Xu; S. Hicks; R. Chari; Wayne C. Widdison; Nicholas C. Yoder; T. Keating

Year: 2019

Venue: Clinical research

DOI: https://doi.org/10.1158/1538-7445.sabcs18-538

Paper Abstract PO-006: ABBV-319: A CD19–targeting glucocorticoid receptor modulator antibody-drug conjugate therapy for B-cell malignancies

C. Chang · 2024 · Blood Cancer Discovery · DOI

Full title: Abstract PO-006: ABBV-319: A CD19–targeting glucocorticoid receptor modulator antibody-drug conjugate therapy for B-cell malignancies

Authors: C. Chang

Year: 2024

Venue: Blood Cancer Discovery

DOI: https://doi.org/10.1158/2643-3249.lymphoma24-po-006

Paper Abstract P5-03-09: Evaluating Post-T-DXd Treatment Strategies in HER2-positive Metastatic Breast Cancer

Sophia Zelizer; Grace Gallagher; E. Ferraro et al. · 2025 · Clinical Cancer Research · DOI

Full title: Abstract P5-03-09: Evaluating Post-T-DXd Treatment Strategies in HER2-positive Metastatic Breast Cancer

Authors: Sophia Zelizer; Grace Gallagher; E. Ferraro; Chau T. Dang; Mithat Gonen; S. Modi; S. Chandarlapaty; Joshua Z. Drago

Year: 2025

Venue: Clinical Cancer Research

DOI: https://doi.org/10.1158/1557-3265.sabcs24-p5-03-09

Paper Abstract A009: Development of monoclonal antibodies targeting truncated O-glycans expressed specifically by cancer cells offers a novel strategy to enhance cancer immunotherapy efficacy

Massimo Fantini; A. Zaki; Sharon A Mavroukakis et al. · 2025 · Cancer immunology research · DOI

Full title: Abstract A009: Development of monoclonal antibodies targeting truncated O-glycans expressed specifically by cancer cells offers a novel strategy to enhance cancer immunotherapy efficacy

Authors: Massimo Fantini; A. Zaki; Sharon A Mavroukakis; Philip M. Arlen; Kwong Y. Tsang

Year: 2025

Venue: Cancer immunology research

DOI: https://doi.org/10.1158/2326-6074.io2025-a009

Paper Abstract P5-05-02: Pharmacokinetic profile and preliminary efficacy of GQ1001, a next generation HER2-targeting ADC, combined with pyrotinib in pretreated patients with HER2-positive metastatic breast cancer: A phase 1b clinical trial

C. Gong; Leiping Wang; Xichun Hu et al. · 2025 · Clinical Cancer Research · DOI

Full title: Abstract P5-05-02: Pharmacokinetic profile and preliminary efficacy of GQ1001, a next generation HER2-targeting ADC, combined with pyrotinib in pretreated patients with HER2-positive metastatic breast cancer: A phase 1b clinical trial

Authors: C. Gong; Leiping Wang; Xichun Hu; Ting Li; Z. Tao; Mingchuan Zhao; Yannan Zhao; Biyun Wang

Year: 2025

Venue: Clinical Cancer Research

DOI: https://doi.org/10.1158/1557-3265.sabcs24-p5-05-02

Paper Abstract IA23: Marker-guided targeted therapy, PARP inhibitors, and novel post-translational modification of PD-L1

M. Hung · 2020 · Oral Presentations - Invited Abstracts · DOI

Full title: Abstract IA23: Marker-guided targeted therapy, PARP inhibitors, and novel post-translational modification of PD-L1

Authors: M. Hung

Year: 2020

Venue: Oral Presentations - Invited Abstracts

DOI: https://doi.org/10.1158/2326-6074.tumimm18-ia23

Paper Abstract PS8-07: Efficacy and Safety of GQ1005, a Promising HER2-ADC, in Patients with Metastatic HER2-Positive Breast Cancer

Biyun Wang; Jian Zhang; Yuping Sun et al. · 2025 · Clinical Cancer Research · DOI

Full title: Abstract PS8-07: Efficacy and Safety of GQ1005, a Promising HER2-ADC, in Patients with Metastatic HER2-Positive Breast Cancer

Authors: Biyun Wang; Jian Zhang; Yuping Sun; Ting Deng; Jing Liu; Bo Yang; Hongwei Yang; Jingfen Wang; Rongbo Lin; Jia Wei; Xian Wang; Q. Cheng; Zhuang Wu; Caicun Zhou

Year: 2025

Venue: Clinical Cancer Research

DOI: https://doi.org/10.1158/1557-3265.sabcs24-ps8-07

Paper Preclinical Evaluation of STI-8811, a Novel Antibody–Drug Conjugate Targeting BCMA for the Treatment of Multiple Myeloma

Aaron D Springer; Rengang Wang; Jiawei Wang et al. · 2024 · Cancer Research Communications · DOI

Full title: Preclinical Evaluation of STI-8811, a Novel Antibody–Drug Conjugate Targeting BCMA for the Treatment of Multiple Myeloma

Authors: Aaron D Springer; Rengang Wang; Jiawei Wang; Qinyi Du; Willie Pi; Austin Q Nguyen; Xiaoqing Li; Alisher Khasanov; Tong Zhu; Zheng Yan; Yufeng Hong; Heyue Zhou; Yanliang Zhang; Lisa Kerwin; Lingna Li; Henry Ji; Hong Zhang

Year: 2024

Venue: Cancer Research Communications

DOI: https://doi.org/10.1158/2767-9764.crc-24-0413

Paper An overview of antibody-drug conjugates in oncological practice.

Theocharopoulos, Charalampos; Lialios, Panagiotis-Petros; Gogas, Helen et al. · 2020 · Therapeutic advances in medical oncology · DOI

Full title: An overview of antibody-drug conjugates in oncological practice.

Authors: Theocharopoulos, Charalampos; Lialios, Panagiotis-Petros; Gogas, Helen; Ziogas, Dimitrios C

Year: 2020

Venue: Therapeutic advances in medical oncology

DOI: https://doi.org/10.1177/1758835920962997

Paper Emerging Role of Antibody Drug Conjugates (ADCs) in Therapeutics: An Appraisal

R. Chakraverty; Tatini Debnath · 2017 · DOI

Full title: Emerging Role of Antibody Drug Conjugates (ADCs) in Therapeutics: An Appraisal

Authors: R. Chakraverty; Tatini Debnath

Year: 2017

DOI: https://doi.org/10.11648/j.ejcbs.20170301.12

Paper A Brief Introduction to Antibody–Drug Conjugates for Toxicologic Pathologists

L. Mecklenburg · 2018 · Toxicologic pathology (Print) · DOI

Full title: A Brief Introduction to Antibody–Drug Conjugates for Toxicologic Pathologists

Authors: L. Mecklenburg

Year: 2018

Venue: Toxicologic pathology (Print)

DOI: https://doi.org/10.1177/0192623318803059

Paper A review of the novel tissue factor antibody–drug conjugate: Tisotumab vedotin

Kevin Luu; Angelyne Chu; B. Chang · 2022 · Journal of Oncology Pharmacy Practice · DOI

Full title: A review of the novel tissue factor antibody–drug conjugate: Tisotumab vedotin

Authors: Kevin Luu; Angelyne Chu; B. Chang

Year: 2022

Venue: Journal of Oncology Pharmacy Practice

DOI: https://doi.org/10.1177/10781552221139775

Paper Cancer therapy with radiolabeled and drug/toxin-conjugated antibodies.

Govindan, Serengulam V; Griffiths, Gary L; Hansen, Hans J et al. · 2005 · Technology in cancer research & treatment · DOI

Full title: Cancer therapy with radiolabeled and drug/toxin-conjugated antibodies.

Authors: Govindan, Serengulam V; Griffiths, Gary L; Hansen, Hans J; Horak, Ivan D; Goldenberg, David M

Year: 2005

Venue: Technology in cancer research & treatment

DOI: https://doi.org/10.1177/153303460500400406

Paper Antibody and Cellular-Based Therapies for Pediatric Acute Lymphoblastic Leukemia: Mechanisms and Prospects

Wei Li; Ya-Ya Zhang; R. Kankala et al. · 2022 · Pharmacology · DOI

Full title: Antibody and Cellular-Based Therapies for Pediatric Acute Lymphoblastic Leukemia: Mechanisms and Prospects

Authors: Wei Li; Ya-Ya Zhang; R. Kankala; Liang Zou; Zhoujiang Chen

Year: 2022

Venue: Pharmacology

DOI: https://doi.org/10.1159/000524040

Paper Exploring the Potential of Antibody-Drug Conjugates in Targeting Non-small Cell Lung Cancer Biomarkers

A. Khadela; Kaivalya Megha; Vraj B Shah et al. · 2024 · Clinical Medicine Insights: Oncology · DOI

Full title: Exploring the Potential of Antibody-Drug Conjugates in Targeting Non-small Cell Lung Cancer Biomarkers

Authors: A. Khadela; Kaivalya Megha; Vraj B Shah; Shruti Soni; A. Shah; Hetvi Mistry; Shelly Bhatt; Manthan Merja

Year: 2024

Venue: Clinical Medicine Insights: Oncology

DOI: https://doi.org/10.1177/11795549241260534

Paper Antibody-drug conjugates: the evolving field of targeted chemotherapy for breast cancer treatment.

Nader-Marta, Guilherme; Molinelli, Chiara; Debien, Véronique et al. · 2023 · Therapeutic advances in medical oncology · DOI

Full title: Antibody-drug conjugates: the evolving field of targeted chemotherapy for breast cancer treatment.

Authors: Nader-Marta, Guilherme; Molinelli, Chiara; Debien, Véronique; Martins-Branco, Diogo; Aftimos, Philippe; de Azambuja, Evandro; Awada, Ahmad

Year: 2023

Venue: Therapeutic advances in medical oncology

DOI: https://doi.org/10.1177/17588359231183679

Paper cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity.

J. A. Francisco; C. Cerveny; Damon L. Meyer et al. · 2003 · Blood · DOI

Full title: cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity.

Authors: J. A. Francisco; C. Cerveny; Damon L. Meyer; B. Mixan; K. Klussman; D. Chace; Starr X Rejniak; K. Gordon; R. DeBlanc; B. Toki; C. Law; S. Doronina; C. Siegall; P. Senter; A. Wahl

Year: 2003

Venue: Blood

DOI: https://doi.org/10.1182/blood-2003-01-0039

Paper A Cell-Based Internalization and Degradation Assay with an Activatable Fluorescence–Quencher Probe as a Tool for Functional Antibody Screening

Yan Li; Peter Corbett Liu; Yang Shen et al. · 2015 · Journal of biomolecular screening · DOI

Full title: A Cell-Based Internalization and Degradation Assay with an Activatable Fluorescence–Quencher Probe as a Tool for Functional Antibody Screening

Authors: Yan Li; Peter Corbett Liu; Yang Shen; M. Snavely; K. Hiraga

Year: 2015

Venue: Journal of biomolecular screening

DOI: https://doi.org/10.1177/1087057115588511

Paper High-Throughput Screening for Internalizing Antibodies by Homogeneous Fluorescence Imaging of a pH-Activated Probe

T. Riedl; Egon van Boxtel; M. Bosch et al. · 2016 · Journal of biomolecular screening · DOI

Full title: High-Throughput Screening for Internalizing Antibodies by Homogeneous Fluorescence Imaging of a pH-Activated Probe

Authors: T. Riedl; Egon van Boxtel; M. Bosch; P. Parren; A. Gerritsen

Year: 2016

Venue: Journal of biomolecular screening

DOI: https://doi.org/10.1177/1087057115613270

Paper HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance

S. Pernas; S. Tolaney · 2019 · Therapeutic Advances in Medical Oncology · DOI

Full title: HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance

Authors: S. Pernas; S. Tolaney

Year: 2019

Venue: Therapeutic Advances in Medical Oncology

DOI: https://doi.org/10.1177/1758835919833519

Paper Antibody-drug conjugates outperform chemotherapy in EGFR-TKI-resistant NSCLC: a Bayesian network meta-analysis

Yueying Chen; Yanjun Du; Juan Ni et al. · 2025 · Therapeutic Advances in Medical Oncology · DOI

Full title: Antibody-drug conjugates outperform chemotherapy in EGFR-TKI-resistant NSCLC: a Bayesian network meta-analysis

Authors: Yueying Chen; Yanjun Du; Juan Ni; Dong Wang; Ping Zhan; Yong Song; Hedong Han; Tangfeng Lv

Year: 2025

Venue: Therapeutic Advances in Medical Oncology

DOI: https://doi.org/10.1177/17588359251405044

Paper Toxicities and management strategies of emerging antibody–drug conjugates in breast cancer

Sora Kang; Sung-Bae Kim · 2025 · Therapeutic Advances in Medical Oncology · DOI

Full title: Toxicities and management strategies of emerging antibody–drug conjugates in breast cancer

Authors: Sora Kang; Sung-Bae Kim

Year: 2025

Venue: Therapeutic Advances in Medical Oncology

DOI: https://doi.org/10.1177/17588359251324889

Paper Emerging formats for next-generation antibody drug conjugates.

Deonarain, Mahendra P; Yahioglu, Gokhan; Stamati, Ioanna et al. · 2015 · Expert opinion on drug discovery · DOI

Full title: Emerging formats for next-generation antibody drug conjugates.

Authors: Deonarain, Mahendra P; Yahioglu, Gokhan; Stamati, Ioanna; Marklew, Jared

Year: 2015

Venue: Expert opinion on drug discovery

DOI: https://doi.org/10.1517/17460441.2015.1025049

Paper Новые перспективы применения препарата Кадсила® при раке молочной железы

Г. А. Дашян; Владимир Семиглазов; П. В. Криворотько et al. · 2015 · DOI

Full title: Новые перспективы применения препарата Кадсила® при раке молочной железы

Authors: Г. А. Дашян; Владимир Семиглазов; П. В. Криворотько; Р. М. Палтуев; Э. Э. Топузов; Т. Ю. Семиглазова; Е. К. Жильцова; Р. В. Донских; Т. Т. Табагуа; В. С. Аполлонова

Year: 2015

DOI: https://doi.org/10.17650/1994-4098-2015-11-4-46-52

Paper [Brentuximab vedotin treatment in patients with relapsed or refractory Hodgkin lymphoma. A Hungarian retrospective study].

Z. Molnár; L. Pinczés; Klára Piukovics et al. · 2017 · Orvosi Hetilap · DOI

Full title: [Brentuximab vedotin treatment in patients with relapsed or refractory Hodgkin lymphoma. A Hungarian retrospective study].

Authors: Z. Molnár; L. Pinczés; Klára Piukovics; I. Istenes; Krisztina Wolf; Zoltán Csukly; Á. Szomor; Árpád Illés; Zsófia Miltényi

Year: 2017

Venue: Orvosi Hetilap

DOI: https://doi.org/10.1556/650.2017.30867

Paper Drugs in development for small cell lung cancer

M. Serzan; S. Farid; Stephen V. Liu · 2020 · Journal of Thoracic Disease · DOI

Full title: Drugs in development for small cell lung cancer

Authors: M. Serzan; S. Farid; Stephen V. Liu

Year: 2020

Venue: Journal of Thoracic Disease

DOI: https://doi.org/10.21037/jtd-2019-sclc-10

Paper Bi-specific immunotherapy for gastrointestinal malignancies

T. Baybutt; A. Snook · 2020 · DOI

Full title: Bi-specific immunotherapy for gastrointestinal malignancies

Authors: T. Baybutt; A. Snook

Year: 2020

DOI: https://doi.org/10.21037/dmr-20-79

Paper Novel immunotherapy in follicular lymphoma: a narrative review

A. Khurana; S. Ansell · 2021 · DOI

Full title: Novel immunotherapy in follicular lymphoma: a narrative review

Authors: A. Khurana; S. Ansell

Year: 2021

DOI: https://doi.org/10.21037/aol-20-48

Paper Sacituzumab govitecan in triple-negative breast cancer

A. de Nonneville; A. Gonçalves; E. Mamessier et al. · 2021 · Annals of Translational Medicine · DOI

Full title: Sacituzumab govitecan in triple-negative breast cancer

Authors: A. de Nonneville; A. Gonçalves; E. Mamessier; F. Bertucci

Year: 2021

Venue: Annals of Translational Medicine

DOI: https://doi.org/10.21037/atm-22-813

Paper EGFR exon 20 insertion mutations and ERBB2 mutations in lung cancer: a narrative review on approved targeted therapies from oral kinase inhibitors to antibody-drug conjugates

Daniel Sentana-Lledo; Emmeline C. Academia; Hollis Viray et al. · 2023 · Translational Lung Cancer Research · DOI

Full title: EGFR exon 20 insertion mutations and ERBB2 mutations in lung cancer: a narrative review on approved targeted therapies from oral kinase inhibitors to antibody-drug conjugates

Authors: Daniel Sentana-Lledo; Emmeline C. Academia; Hollis Viray; Deepa Rangachari; Susumu S. Kobayashi; P. VanderLaan; D. Costa

Year: 2023

Venue: Translational Lung Cancer Research

DOI: https://doi.org/10.21037/tlcr-23-98

Paper Biological Therapy of Hematologic Malignancies: Toward a Chemotherapy- free Era.

Klener, Pavel; Etrych, Tomas; Klener, Pavel · 2019 · Current medicinal chemistry · DOI

Full title: Biological Therapy of Hematologic Malignancies: Toward a Chemotherapy- free Era.

Authors: Klener, Pavel; Etrych, Tomas; Klener, Pavel

Year: 2019

Venue: Current medicinal chemistry

DOI: https://doi.org/10.2174/0929867324666171006144725

Paper Antibody-Drug Conjugates as Novel and Potent Cancer Therapeutics

Veneela Kr Vasigala · 2017 · DOI

Full title: Antibody-Drug Conjugates as Novel and Potent Cancer Therapeutics

Authors: Veneela Kr Vasigala

Year: 2017

DOI: https://doi.org/10.19080/ctoij.2017.06.555698

Paper ADCs, as novel revolutionary weapons for providing a step forward in targeted therapy of malignancies.

Nooshafarin Amani; F. Dorkoosh; H. Mobedi · 2019 · Current Drug Delivery · DOI

Full title: ADCs, as novel revolutionary weapons for providing a step forward in targeted therapy of malignancies.

Authors: Nooshafarin Amani; F. Dorkoosh; H. Mobedi

Year: 2019

Venue: Current Drug Delivery

DOI: https://doi.org/10.2174/1567201816666191121145109

Paper CT109-SN-38, a Novel Antibody-drug Conjugate with Dual Specificity for CEACAM5 and 6, Elicits Potent Killing of Pancreatic Cancer Cells.

Kelly C Arias Cardenas; Clinton W Enos; Mark R Spear et al. · 2024 · Current Cancer Drug Targets · DOI

Full title: CT109-SN-38, a Novel Antibody-drug Conjugate with Dual Specificity for CEACAM5 and 6, Elicits Potent Killing of Pancreatic Cancer Cells.

Authors: Kelly C Arias Cardenas; Clinton W Enos; Mark R Spear; Dana E Austin; R. Almofeez; Stephanie Kortchak; Lauren Pincus; Hua-Bei Guo; Samuel Dolezal; J. M. Pierce; Emma Furth; Cyrille Gineste; Yongjun Kwon; Cohava Gelber

Year: 2024

Venue: Current Cancer Drug Targets

DOI: https://doi.org/10.2174/0115680096260614231115192343

Paper Cancer Stem Cell-targeted Antibody-drug Conjugates for Cancer Immunotherapy.

Khan, Gyas; Hanbashi, Ali; Mawkili, Wedad et al. · 2025 · Current medicinal chemistry · DOI

Full title: Cancer Stem Cell-targeted Antibody-drug Conjugates for Cancer Immunotherapy.

Authors: Khan, Gyas; Hanbashi, Ali; Mawkili, Wedad; Kamli, Faroq; Ali, Md Sajid; Ahmad, Sarfaraz; Khardali, Amani; Alam, Nawazish; Alam, Prawez; Hussain, Md Sadique

Year: 2025

Venue: Current medicinal chemistry

DOI: https://doi.org/10.2174/0109298673393449250818052754

Paper ANTIBODY DRUG CONJUGATES: A LEAP AHEAD IN CANCER TREATMENT

H. Singh; S. Gullaiya; Ishpreet Kaur · 2014 · DOI

Full title: ANTIBODY DRUG CONJUGATES: A LEAP AHEAD IN CANCER TREATMENT

Authors: H. Singh; S. Gullaiya; Ishpreet Kaur

Year: 2014

DOI: https://doi.org/10.22270/jddt.v4i3.832

Paper Advances in the Development of Site-Specific Antibody-Drug Conjugation.

Zhou, Qun; Kim, Jennifer · 2015 · Anti-cancer agents in medicinal chemistry · DOI

Full title: Advances in the Development of Site-Specific Antibody-Drug Conjugation.

Authors: Zhou, Qun; Kim, Jennifer

Year: 2015

Venue: Anti-cancer agents in medicinal chemistry

DOI: https://doi.org/10.2174/1871520615666150302125448

Paper Comprehensive Overview on Antibody Drug Conjugates- A Promising Approach in Cancer Therapy

Lenna Muppa; Shruthi Ravindranathan; S. Sivaram et al. · 2025 · Journal of Drug Delivery and Therapeutics · DOI

Full title: Comprehensive Overview on Antibody Drug Conjugates- A Promising Approach in Cancer Therapy

Authors: Lenna Muppa; Shruthi Ravindranathan; S. Sivaram; Aadhira Jinnah; Achsa Sharon Shibu

Year: 2025

Venue: Journal of Drug Delivery and Therapeutics

DOI: https://doi.org/10.22270/jddt.v15i3.7011

Paper Self-immolative Linkers in Prodrugs and Antibody Drug Conjugates in Cancer Treatment.

V. V. S. R. Edupuganti; J. Tyndall; Allan B. Gamble · 2021 · Recent Patents on Anti-Cancer Drug Discovery · DOI

Full title: Self-immolative Linkers in Prodrugs and Antibody Drug Conjugates in Cancer Treatment.

Authors: V. V. S. R. Edupuganti; J. Tyndall; Allan B. Gamble

Year: 2021

Venue: Recent Patents on Anti-Cancer Drug Discovery

DOI: https://doi.org/10.2174/1574892816666210509001139

Paper Antibody Based Targeted Interventions for the Diagnosis and Treatment of Skin Cancers.

Suresh Madheswaran; Neelakshi Mungra; F. A. Biteghe et al. · 2020 · Anti-Cancer Agents in Medicinal Chemistry · DOI

Full title: Antibody Based Targeted Interventions for the Diagnosis and Treatment of Skin Cancers.

Authors: Suresh Madheswaran; Neelakshi Mungra; F. A. Biteghe; Jean de la Croix Ndong; A. Arowolo; H. Adeola; D. Ramamurthy; K. Naran; N. Khumalo; S. Barth

Year: 2020

Venue: Anti-Cancer Agents in Medicinal Chemistry

DOI: https://doi.org/10.2174/1871520620666200728123006

Paper Antibody-Drug Conjugates: A Review on the Epitome of Targeted Anti- Cancer Therapy.

M. Hasan; Safaet Alam; S. Poddar · 2019 · Current Clinical Pharmacology · DOI

Full title: Antibody-Drug Conjugates: A Review on the Epitome of Targeted Anti- Cancer Therapy.

Authors: M. Hasan; Safaet Alam; S. Poddar

Year: 2019

Venue: Current Clinical Pharmacology

DOI: https://doi.org/10.2174/1574884712666180802095521

Paper Characterising novel Antibody-Drug Conjugate targets for ovarian cancer: Implications for patient stratification and precision medicine

Alice M. Luther · DOI

Full title: Characterising novel Antibody-Drug Conjugate targets for ovarian cancer: Implications for patient stratification and precision medicine

Authors: Alice M. Luther

DOI: https://doi.org/10.23889/suthesis.58415

Paper Antibody-Drug Nanoparticles for Combination Treatment of Breast Cancer Cells

Muhammad Raisul Abedin; Sutapa Barua · 2020 · DOI

Full title: Antibody-Drug Nanoparticles for Combination Treatment of Breast Cancer Cells

Authors: Muhammad Raisul Abedin; Sutapa Barua

Year: 2020

DOI: https://doi.org/10.22541/au.159620880.06235011

Paper More than Toxins-Current Prospects in Designing the Next Generation of Antibody Drug Conjugates.

Jonathan Schwach; Mustafa Abdellatif; A. Stengl · 2022 · Frontiers in Bioscience · DOI

Full title: More than Toxins-Current Prospects in Designing the Next Generation of Antibody Drug Conjugates.

Authors: Jonathan Schwach; Mustafa Abdellatif; A. Stengl

Year: 2022

Venue: Frontiers in Bioscience

DOI: https://doi.org/10.31083/j.fbl2708240

Paper Antibody drug conjugates: Progress, pitfalls, and promises

Anubhab Mukherjee; Ariana K Waters; I. Babic et al. · 2018 · Human Antibodies · DOI

Full title: Antibody drug conjugates: Progress, pitfalls, and promises

Authors: Anubhab Mukherjee; Ariana K Waters; I. Babic; Elmar Nurmemmedov; M. Glassy; S. Kesari; V. Yenugonda

Year: 2018

Venue: Human Antibodies

DOI: https://doi.org/10.3233/hab-180348

Paper Belantamab Mafodotin: Advancing Treatment Paradigms in Relapsed/Refractory Multiple Myeloma

Syed Owais Akhtar; Bibek Gautam; Kuchi Deekshitha et al. · 2024 · Journal of Cancer Science and Clinical Therapeutics · DOI

Full title: Belantamab Mafodotin: Advancing Treatment Paradigms in Relapsed/Refractory Multiple Myeloma

Authors: Syed Owais Akhtar; Bibek Gautam; Kuchi Deekshitha; Adees Wirtan Sarkees Bedros; Fiza Arif; I. Saleem; Laiba Arif; Nadir Akhtar

Year: 2024

Venue: Journal of Cancer Science and Clinical Therapeutics

DOI: https://doi.org/10.26502/jcsct.5079250

Paper Antibody-drug conjugates: a mini-review. The synopsis of two approved medicines.

Papachristos, Apostolos; Pippa, Natassa; Demetzos, Costas et al. · 2016 · Drug delivery · DOI

Full title: Antibody-drug conjugates: a mini-review. The synopsis of two approved medicines.

Authors: Papachristos, Apostolos; Pippa, Natassa; Demetzos, Costas; Sivolapenko, Gregory

Year: 2016

Venue: Drug delivery

DOI: https://doi.org/10.3109/10717544.2014.998323

Paper Bioorthogonal Tetrazine Carbamate Cleavage by Highly Reactive Trans-Cyclooctene.

Arthur H. A. M. van Onzen; Ron M. Versteegen; F. Hoeben et al. · 2019 · Journal of the American Chemical Society · DOI

Full title: Bioorthogonal Tetrazine Carbamate Cleavage by Highly Reactive Trans-Cyclooctene.

Authors: Arthur H. A. M. van Onzen; Ron M. Versteegen; F. Hoeben; I. Filot; R. Rossin; T. Zhu; Jer-Cheng Wu; P. Hudson; H. Janssen; W. ten Hoeve; M. Robillard

Year: 2019

Venue: Journal of the American Chemical Society

DOI: https://doi.org/10.26434/chemrxiv.11383659

Paper TRASTUZUMAB DERUXTECAN: NOVEL ANTIBODY-DRUG CONJUGATE TARGETING HER2 IN PATIENTS WITH GASTRIC ADENOCARCINOMA

Cristiane Tefé-Silva; Beatriz G. Rodrigues; Barbara B. Pascoal et al. · 2023 · Journal of Applied Pharmaceutical Sciences and Research · DOI

Full title: TRASTUZUMAB DERUXTECAN: NOVEL ANTIBODY-DRUG CONJUGATE TARGETING HER2 IN PATIENTS WITH GASTRIC ADENOCARCINOMA

Authors: Cristiane Tefé-Silva; Beatriz G. Rodrigues; Barbara B. Pascoal; Beatriz I. Minante; Bianca C. Vitoreli; Bianca Vieira De Sousa; Isabella S. B Arros; Isadora M. Fortunato; Samara C. De Castro

Year: 2023

Venue: Journal of Applied Pharmaceutical Sciences and Research

DOI: https://doi.org/10.31069/japsr.v5i4.01

Paper Modern developments in germline pharmacogenomics for oncology prescribing

Natalie M Reizine; P. O’Donnell · 2022 · Ca · DOI

Full title: Modern developments in germline pharmacogenomics for oncology prescribing

Authors: Natalie M Reizine; P. O’Donnell

Year: 2022

Venue: Ca

DOI: https://doi.org/10.3322/caac.21722

Paper A Phase I, First-in-Human Study Evaluating the Safety and Preliminary Antileukemia Activity of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Other CD123-Positive Hematologic Malignancies

N. Daver; H. Erba; Nikolaos Papadantonakis et al. · 2018 · Blood · DOI

Full title: A Phase I, First-in-Human Study Evaluating the Safety and Preliminary Antileukemia Activity of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Other CD123-Positive Hematologic Malignancies

Authors: N. Daver; H. Erba; Nikolaos Papadantonakis; D. DeAngelo; E. Wang; M. Konopleva; C. Sloss; K. Culm-Merdek; P. Zweidler-McKay; H. Kantarjian

Year: 2018

Venue: Blood

DOI: https://doi.org/10.1182/blood-2018-99-112955

Paper Pre-Clinical Efficacy of CD123-Targeting Antibody-Drug Conjugate IMGN632 in Blastic Plasmacytoid Dentritic Cell Neoplasm (BPDCN) Models

Qi Zhang; Tianyu Cai; Lina Han et al. · 2018 · Blood · DOI

Full title: Pre-Clinical Efficacy of CD123-Targeting Antibody-Drug Conjugate IMGN632 in Blastic Plasmacytoid Dentritic Cell Neoplasm (BPDCN) Models

Authors: Qi Zhang; Tianyu Cai; Lina Han; Vinitha M Kuruvilla; Sharlene Adams; Sloss M Callum; Karine G. Harutyunyan; A. Lane; Y. Kovtun; N. Daver; N. Pemmaraju; Patrick Zweider McKay; M. Konopleva

Year: 2018

Venue: Blood

DOI: https://doi.org/10.1182/blood-2018-99-116771

Paper CD117-Amanitin Antibody Drug Conjugates Effectively Deplete Human and Non-Human Primate HSCs: Proof of Concept As a Targeted Strategy for Conditioning Patients for Bone Marrow Transplant

B. Pearse; S. McDonough; J. Proctor et al. · 2018 · Blood · DOI

Full title: CD117-Amanitin Antibody Drug Conjugates Effectively Deplete Human and Non-Human Primate HSCs: Proof of Concept As a Targeted Strategy for Conditioning Patients for Bone Marrow Transplant

Authors: B. Pearse; S. McDonough; J. Proctor; Rajiv Panwar; G. Sarma; M. McShea; L. Kien; Junia Dushime; H. Adams; S. Hyzy; M. Brooks; R. Palchaudhuri; Qing Li; Nathan M Kallen; P. Sawant; C. McDonagh; Anthony E. Boitano; M. Cooke

Year: 2018

Venue: Blood

DOI: https://doi.org/10.1182/blood-2018-99-114881

Paper Innovative payloads for ADCs in cancer treatment: moving beyond the selective delivery of chemotherapy

Davide Izzo; L. Ascione; Lorenzo Guidi et al. · 2025 · Therapeutic Advances in Medical Oncology · DOI

Full title: Innovative payloads for ADCs in cancer treatment: moving beyond the selective delivery of chemotherapy

Authors: Davide Izzo; L. Ascione; Lorenzo Guidi; R. Marsicano; Chrysanthi Koukoutzeli; D. Trapani; G. Curigliano

Year: 2025

Venue: Therapeutic Advances in Medical Oncology

DOI: https://doi.org/10.1177/17588359241309461

Paper Advances in Antibody-Drug Conjugate Design: Current Clinical Landscape and Future Innovations.

Gauzy-Lazo, Laurence; Sassoon, Ingrid; Brun, Marie-Priscille · 2020 · SLAS discovery : advancing life sciences R & D · DOI

Full title: Advances in Antibody-Drug Conjugate Design: Current Clinical Landscape and Future Innovations.

Authors: Gauzy-Lazo, Laurence; Sassoon, Ingrid; Brun, Marie-Priscille

Year: 2020

Venue: SLAS discovery : advancing life sciences R & D

DOI: https://doi.org/10.1177/2472555220912955

Paper Comprehensive Transcriptome Profiling of Cryptic CBFA2T3-GLIS2 Fusion-Positive AML Defines Novel Therapeutic Options — a COG and Target Pediatric AML Study

Jenny L. Smith; R. Ries; Marianne T Santaguida et al. · 2018 · Blood · DOI

Full title: Comprehensive Transcriptome Profiling of Cryptic CBFA2T3-GLIS2 Fusion-Positive AML Defines Novel Therapeutic Options — a COG and Target Pediatric AML Study

Authors: Jenny L. Smith; R. Ries; Marianne T Santaguida; C. Gekas; T. Alonzo; R. Gerbing; A. Gamis; R. Aplenc; E. Kolb; Tiffany A. Hylkema; Lisa Eidenschink Brodersen; M. Loken; H. Bolouri; S. Meshinchi

Year: 2018

Venue: Blood

DOI: https://doi.org/10.1182/blood-2018-99-115544

Paper Immunotherapeutic Targeting of Mesothelin in Acute Myeloid Leukemia in Vitro with Anetumab Ravtansine and a Novel Antibody-Drug Conjugate

Allison J. Kaeding; Katherine Tarlock; E. Kolb et al. · 2018 · Blood · DOI

Full title: Immunotherapeutic Targeting of Mesothelin in Acute Myeloid Leukemia in Vitro with Anetumab Ravtansine and a Novel Antibody-Drug Conjugate

Authors: Allison J. Kaeding; Katherine Tarlock; E. Kolb; S. Meshinchi

Year: 2018

Venue: Blood

DOI: https://doi.org/10.1182/blood-2018-99-110845

Paper No free rides: management of toxicities of novel immunotherapies in ALL, including financial.

T. Jain; M. Litzow · 2018 · Hematology. American Society of Hematology. Education Program · DOI

Full title: No free rides: management of toxicities of novel immunotherapies in ALL, including financial.

Authors: T. Jain; M. Litzow

Year: 2018

Venue: Hematology. American Society of Hematology. Education Program

DOI: https://doi.org/10.1182/asheducation-2018.1.25

Paper Myc-Driven, Primary Mouse Lymphoma Expressing Human CD22 Are Highly Infiltrated By Syngeneic Immune Cells and Provide a Unique Model to Test CD22-Targeted Therapies

F. Wagner; C. Brandl; C. Emmerich et al. · 2018 · Blood · DOI

Full title: Myc-Driven, Primary Mouse Lymphoma Expressing Human CD22 Are Highly Infiltrated By Syngeneic Immune Cells and Provide a Unique Model to Test CD22-Targeted Therapies

Authors: F. Wagner; C. Brandl; C. Emmerich; A. Mackensen; L. Nitschke; F. Müller

Year: 2018

Venue: Blood

DOI: https://doi.org/10.1182/blood-2018-99-110284

Paper Maturing Clinical Profile of IMGN779, a Next-Generation CD33-Targeting Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Acute Myeloid Leukemia

J. Cortes; D. DeAngelo; H. Erba et al. · 2018 · Blood · DOI

Full title: Maturing Clinical Profile of IMGN779, a Next-Generation CD33-Targeting Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Authors: J. Cortes; D. DeAngelo; H. Erba; E. Traer; Nikolaos Papadantonakis; C. Arana-Yi; W. Blum; C. Sloss; K. Culm-Merdek; P. Zweidler-McKay; E. Wang

Year: 2018

Venue: Blood

DOI: https://doi.org/10.1182/blood-2018-99-112891

Paper Shared Expression of CD93 and Other Antigens By AML and Endothelial Cells Highlights a Need for Rational Combinatorial Targeting

R. Richards; Feifei Zhao; K. Murphy et al. · 2020 · DOI

Full title: Shared Expression of CD93 and Other Antigens By AML and Endothelial Cells Highlights a Need for Rational Combinatorial Targeting

Authors: R. Richards; Feifei Zhao; K. Murphy; P. Xu; Amy C Fan; E. Sotillo; M. Daugaard; H. Oo; Jie Liu; W. Hong; P. Sorensen; R. Majzner; R. Majeti; C. Mackall

Year: 2020

DOI: https://doi.org/10.1182/blood-2020-133988

Paper Encouraging Clinical Outcomes for Lymphoma Patients Participating in Early Phase Clinical Trials in the Current Era: A Single Institution and a Global Perspective

J. O'Nions; A. Cowley; Hakim-Moulay Dehbi et al. · 2018 · Blood · DOI

Full title: Encouraging Clinical Outcomes for Lymphoma Patients Participating in Early Phase Clinical Trials in the Current Era: A Single Institution and a Global Perspective

Authors: J. O'Nions; A. Cowley; Hakim-Moulay Dehbi; D. El-Sharkawi; S. D’Sa; K. Ardeshna; R. Popat; W. Townsend

Year: 2018

Venue: Blood

DOI: https://doi.org/10.1182/blood-2018-99-118497

Paper ADCT-402, a PBD dimer-containing antibody drug conjugate targeting CD19-expressing malignancies.

F. Zammarchi; Simon Corbett; Lauren Adams et al. · 2018 · Blood · DOI

Full title: ADCT-402, a PBD dimer-containing antibody drug conjugate targeting CD19-expressing malignancies.

Authors: F. Zammarchi; Simon Corbett; Lauren Adams; P. Tyrer; K. Kiakos; N. Janghra; T. Marafioti; Charles E. Britten; C. Havenith; S. Chivers; François D'Hooge; David G. Williams; A. Tiberghien; P. Howard; J. Hartley; P. V. van Berkel

Year: 2018

Venue: Blood

DOI: https://doi.org/10.1182/blood-2017-10-813493

Paper CD45-ADC Plus Janus Kinase (JAK) Inhibitors As Conditioning for MHC-Mismatched Murine Hematopoietic Stem Cell Transplantation Is Associated with Minimal Toxicity and Graft Versus Host Disease

Stephen P. Persaud; M. Cooper; Julie Ritchey et al. · 2019 · Blood · DOI

Full title: CD45-ADC Plus Janus Kinase (JAK) Inhibitors As Conditioning for MHC-Mismatched Murine Hematopoietic Stem Cell Transplantation Is Associated with Minimal Toxicity and Graft Versus Host Disease

Authors: Stephen P. Persaud; M. Cooper; Julie Ritchey; M. Rettig; J. Dipersio

Year: 2019

Venue: Blood

DOI: https://doi.org/10.1182/blood-2019-123519

Paper Discovery and Development of MEDI7247, a Novel Pyrrolobenzodiazepine (PBD)-Based Antibody Drug Conjugate Targeting ASCT2, for Treating Hematological Cancers

N. Pore; Kevin P. Schifferli; N. Monks et al. · 2018 · Blood · DOI

Full title: Discovery and Development of MEDI7247, a Novel Pyrrolobenzodiazepine (PBD)-Based Antibody Drug Conjugate Targeting ASCT2, for Treating Hematological Cancers

Authors: N. Pore; Kevin P. Schifferli; N. Monks; R. Tammali; J BorrokMartin; E. Hurt; M. Flynn; M. Rebelatto; D. Townsley; M. Hinrichs; R. Dixit; S. Coats; R. Herbst; D. Tice

Year: 2018

Venue: Blood

DOI: https://doi.org/10.1182/blood-2018-99-119836

Paper Development of Cirmtuzumab Antibody-Drug Conjugates (ADCs) Targeting Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1)

Yousaf A. Mian; G. Widhopf; Thanh-Trang T. Vo et al. · 2018 · Blood · DOI

Full title: Development of Cirmtuzumab Antibody-Drug Conjugates (ADCs) Targeting Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1)

Authors: Yousaf A. Mian; G. Widhopf; Thanh-Trang T. Vo; Katti A. Jessen; L. Rassenti; T. Kipps

Year: 2018

Venue: Blood

DOI: https://doi.org/10.1182/blood-2018-99-119447

Paper Preclinical Development of an Anti-CD38 Antibody-Drug Conjugate for Treatment of Hematological Malignancies

Lingna Li; Wenyong Tong; M. Lau et al. · 2019 · Blood · DOI

Full title: Preclinical Development of an Anti-CD38 Antibody-Drug Conjugate for Treatment of Hematological Malignancies

Authors: Lingna Li; Wenyong Tong; M. Lau; Katherine Fells; Tong Zhu; Yingqing Sun; Ernest W Kovacs; Alisher Khasanov; Zheng Yan; D. Deng; K. Takeshita; G. Kaufmann; Henry Ji; Hui Li; Hong Zhang

Year: 2019

Venue: Blood

DOI: https://doi.org/10.1182/blood-2019-132062

Paper Tub-010, a Novel Antibody-Drug-Conjugate with Reduced Nonspecific Toxicity Profile Based on Tub-Tag Technology Widens the Therapeutic Window for the Treatment of CD30+ Malignancies

M. Gerlach; S. Schmitt; P. Cyprys et al. · 2022 · European Journal of Cancer · DOI

Full title: Tub-010, a Novel Antibody-Drug-Conjugate with Reduced Nonspecific Toxicity Profile Based on Tub-Tag Technology Widens the Therapeutic Window for the Treatment of CD30+ Malignancies

Authors: M. Gerlach; S. Schmitt; P. Cyprys; Marc‐André Kasper; I. Mai; M. Vermeer; SM Horwitz; G. Fingerle-Rowson; A. Vogl; D. Schumacher; J. Helma-Smets

Year: 2022

Venue: European Journal of Cancer

DOI: https://doi.org/10.1016/s0959-8049(22)00604-9

Paper Preclinical Development of a Bcma Targeting Antibody-Drug Conjugate with Novel Payload for Multiple Myeloma Therapy

A. Hau; Tong Zhu; Rengang Wang et al. · 2019 · Blood · DOI

Full title: Preclinical Development of a Bcma Targeting Antibody-Drug Conjugate with Novel Payload for Multiple Myeloma Therapy

Authors: A. Hau; Tong Zhu; Rengang Wang; M. Lau; Lingna Li; Xiaoqing Li; Yingqing Sun; Ernest W Kovacs; Alisher Khasanov; D. Deng; Zheng Yan; R. Knight; G. Kaufmann; Henry Ji; Hui Li; Hong Zhang

Year: 2019

Venue: Blood

DOI: https://doi.org/10.1182/blood-2019-132080

Paper Clinical Efficacy of Polatuzumab Vedotin in Patients with Relapsed/Refractory Large B-Cell Lymphoma after Standard of Care Axicabtagene Ciloleucel

P. Strati; G. Watson; S. Horowitz et al. · 2020 · DOI

Full title: Clinical Efficacy of Polatuzumab Vedotin in Patients with Relapsed/Refractory Large B-Cell Lymphoma after Standard of Care Axicabtagene Ciloleucel

Authors: P. Strati; G. Watson; S. Horowitz; R. Nair; M. Rodriguez; R. Steiner; L. Fayad; J. Westin; S. Neelapu

Year: 2020

DOI: https://doi.org/10.1182/blood-2020-135835

Paper A Phase 1, Open-Label, Dose-Escalation Study of the Safety and Efficacy of Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients with Relapsed or Refractory Multiple Myeloma

R. Chakraborty; Ying Yan; M. Royal · 2021 · Blood · DOI

Full title: A Phase 1, Open-Label, Dose-Escalation Study of the Safety and Efficacy of Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients with Relapsed or Refractory Multiple Myeloma

Authors: R. Chakraborty; Ying Yan; M. Royal

Year: 2021

Venue: Blood

DOI: https://doi.org/10.1182/blood-2021-150783

Paper Novel Single Agents Are Equivalent to Conventional Chemotherapy Inpatients with Relapsed and Refractory Mature T-Cell Lymphomas: A Meta-Analysis

Nazila Shafagati; Robert N Stuver; Leora Boussi et al. · 2021 · Blood · DOI

Full title: Novel Single Agents Are Equivalent to Conventional Chemotherapy Inpatients with Relapsed and Refractory Mature T-Cell Lymphomas: A Meta-Analysis

Authors: Nazila Shafagati; Robert N Stuver; Leora Boussi; Min Jung Koh; Allison Park; P. Bain; F. Foss; Changyu Shen; Salvia Jain

Year: 2021

Venue: Blood

DOI: https://doi.org/10.1182/blood-2021-150315

Paper Debio 1562M, a Next Generation Antibody Drug Conjugate (ADC) Targeting CD37 for AML and MDS Treatment

Lisa Ivanschitz; Josée Hue-Perron; Léo Marx et al. · 2023 · Blood · DOI

Full title: Debio 1562M, a Next Generation Antibody Drug Conjugate (ADC) Targeting CD37 for AML and MDS Treatment

Authors: Lisa Ivanschitz; Josée Hue-Perron; Léo Marx; Marie-Claude Roubaudi-Fraschini; Caroline Peet; Nathalie Bellocq; Riccardo Colombo; Karilyn T. Larkin; Esthela Artiga

Year: 2023

Venue: Blood

DOI: https://doi.org/10.1182/blood-2023-180767

Paper Splicing Polymorphism rs12459419 Modulates Antibody-Bound Internalization of CD33 Isoforms

Vivek M Shastri; Mohammed O Gbadamosi; J. Lamba · 2023 · Blood · DOI

Full title: Splicing Polymorphism rs12459419 Modulates Antibody-Bound Internalization of CD33 Isoforms

Authors: Vivek M Shastri; Mohammed O Gbadamosi; J. Lamba

Year: 2023

Venue: Blood

DOI: https://doi.org/10.1182/blood-2023-186889

Paper VLS-101, a ROR1-Targeting Antibody-Drug Conjugate, Demonstrates a Predictable Safety Profile and Clinical Efficacy in Patients with Heavily Pretreated Mantle Cell Lymphoma and Diffuse Large B-Cell Lymphoma

Michael L. Wang; J. Barrientos; R. Furman et al. · 2020 · DOI

Full title: VLS-101, a ROR1-Targeting Antibody-Drug Conjugate, Demonstrates a Predictable Safety Profile and Clinical Efficacy in Patients with Heavily Pretreated Mantle Cell Lymphoma and Diffuse Large B-Cell Lymphoma

Authors: Michael L. Wang; J. Barrientos; R. Furman; M. Mei; P. Barr; M. Choi; S. Vos; A. Kallam; K. Patel; S. Rule; Kate Flanders; Katti A. Jessen; P. Riebling; P. Graham; L. King; Elizabeth M. Schmidt; B. Lannutti; D. Johnson; L. Miller; S. Spurgeon

Year: 2020

DOI: https://doi.org/10.1182/blood-2020-136373

Paper Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

N. Daver; P. Montesinos; D. DeAngelo et al. · 2019 · Blood · DOI

Full title: Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Authors: N. Daver; P. Montesinos; D. DeAngelo; E. Wang; Nikolaos Papadantonakis; E. Deconinck; H. Erba; N. Pemmaraju; A. Lane; D. Rizzieri; K. Sweet; G. Martinelli; C. Tarella; E. Todisco; M. Konopleva; C. Sloss; K. Culm-Merdek; P. Zweidler-McKay; H. Kantarjian

Year: 2019

Venue: Blood

DOI: https://doi.org/10.1182/blood-2019-128648

Paper A Novel Fc-Optimized Antibody Drug Conjugate Targeting CD7 As a Therapeutic Strategy in T-Cell Acute Lymphoblastic Leukemia

C. Gehlert; D. Schewe; Katja Klausz et al. · 2023 · Blood · DOI

Full title: A Novel Fc-Optimized Antibody Drug Conjugate Targeting CD7 As a Therapeutic Strategy in T-Cell Acute Lymphoblastic Leukemia

Authors: C. Gehlert; D. Schewe; Katja Klausz; S. Krohn; D. Winterberg; F. Vogiatzi; Ammelie Svea Boje; A. Lux; F. Nimmerjahn; R. Scherließ; Andreas Humpe; M. Schrappe; G. Cario; T. Valerius; Lars Fransecky; Monika Brüggemann; C. Baldus; M. Gramatzki; L. Lenk; Christian Kellner; M. Peipp

Year: 2023

Venue: Blood

DOI: https://doi.org/10.1182/blood-2023-185875

Paper SGN-CD30C, an Investigational CD30-Directed Camptothecin Antibody-Drug Conjugate (ADC), Shows Strong Anti Tumor Activity and Superior Tolerability in Preclinical Studies

M. Ryan; Ryan Lyski; Lauren Bou et al. · 2020 · DOI

Full title: SGN-CD30C, an Investigational CD30-Directed Camptothecin Antibody-Drug Conjugate (ADC), Shows Strong Anti Tumor Activity and Superior Tolerability in Preclinical Studies

Authors: M. Ryan; Ryan Lyski; Lauren Bou; Ryan A Heiser; Bryan M. Grogan; David J. Meyer; Steven Jin; J. Simmons; M. Conerly; P. Senter; S. Jeffrey

Year: 2020

DOI: https://doi.org/10.1182/blood-2020-136577

Paper Phase 1, First-in-Human Study of MEDI2228, a BCMA-Targeted ADC in Patients with Relapsed/Refractory Multiple Myeloma

Shaji K. Kumar; M. Migkou; M. Bhutani et al. · 2020 · Blood · DOI

Full title: Phase 1, First-in-Human Study of MEDI2228, a BCMA-Targeted ADC in Patients with Relapsed/Refractory Multiple Myeloma

Authors: Shaji K. Kumar; M. Migkou; M. Bhutani; A. Spencer; S. Ailawadhi; A. Kalff; F. Walcott; N. Pore; D. Gibson; Fujun Wang; Lily I. Cheng; Ioannis Kagiampakis; Marna B. Williams; Krista Kinneer; Yu Jiang; J. Zonder; J. Larsen; S. Sirdesai; A. Yee; M. Dimopoulos

Year: 2020

Venue: Blood

DOI: https://doi.org/10.1182/blood-2020-136375

Paper Development of Next Generation Antibody-Polymer-Drug Conjugates for Treatment of Multiple Myeloma

Jiahui Li; M. T. Gambles; Shannuo Li et al. · 2023 · Blood · DOI

Full title: Development of Next Generation Antibody-Polymer-Drug Conjugates for Treatment of Multiple Myeloma

Authors: Jiahui Li; M. T. Gambles; Shannuo Li; Jindřich Kopeček; D. Sborov; Jiyuan Yang

Year: 2023

Venue: Blood

DOI: https://doi.org/10.1182/blood-2023-186661

Paper Preliminary Results of a Phase 1, First-in-Human Study of INA03, an Anti-CD71 Antibody-Drug Conjugate in Patients with Relapsed or Refractory (R/R) Acute Leukemias

S. Garciaz; P. Bories; J. Boher et al. · 2023 · Blood · DOI

Full title: Preliminary Results of a Phase 1, First-in-Human Study of INA03, an Anti-CD71 Antibody-Drug Conjugate in Patients with Relapsed or Refractory (R/R) Acute Leukemias

Authors: S. Garciaz; P. Bories; J. Boher; M. Hospital; C. Récher; C. Saillard; Y. Hicheri; Coralie Belanger; Renato C Monteiro; Olivier Hermine; Pierre Launay; N. Vey

Year: 2023

Venue: Blood

DOI: https://doi.org/10.1182/blood-2023-185717

Paper Single Cell Multi-Omic Correlation of Single Nucleotide Variants, Copy Number Variation and Surface Epitopes for Clonal Profiling of Myeloma

Adam Sciambi; Cedric Dos Santos; Yang Li et al. · 2023 · Blood · DOI

Full title: Single Cell Multi-Omic Correlation of Single Nucleotide Variants, Copy Number Variation and Surface Epitopes for Clonal Profiling of Myeloma

Authors: Adam Sciambi; Cedric Dos Santos; Yang Li; Joanne Nguyen; Priyam Priyam; Vivek Chopra; Habib Hamidi; M. Nixon; Yann Nouet; Todd E. Druley; Hervé Avet-Loiseau

Year: 2023

Venue: Blood

DOI: https://doi.org/10.1182/blood-2023-189518

Paper Hdp-101, an Anti-BCMA Antibody-Drug Conjugate with a Novel Payload Amanitin in Patients with Relapsed Multiple Myeloma, Initial Findings of the First in Human Study

M. Raab; J. Kaufman; S. Richard et al. · 2023 · Blood · DOI

Full title: Hdp-101, an Anti-BCMA Antibody-Drug Conjugate with a Novel Payload Amanitin in Patients with Relapsed Multiple Myeloma, Initial Findings of the First in Human Study

Authors: M. Raab; J. Kaufman; S. Richard; S. Grosicki; István Takács; A. Strassz; Andreas Pahl; Thorsten Michael; Anette Last; Hajnalka Szabóki; Garrit Jentsch; O. Schönborn-Kellenberger; R. Orlowski

Year: 2023

Venue: Blood

DOI: https://doi.org/10.1182/blood-2023-182480

Paper Macropinocytosis As a Means of Selectively Targeting RAS-Mutant Multiple Myeloma

Nathan Beals; Craig Ramirez; Andy Hauser et al. · 2023 · Blood · DOI

Full title: Macropinocytosis As a Means of Selectively Targeting RAS-Mutant Multiple Myeloma

Authors: Nathan Beals; Craig Ramirez; Andy Hauser; F. E. Davies; D. Bar-Sagi; G. Morgan

Year: 2023

Venue: Blood

DOI: https://doi.org/10.1182/blood-2023-186114

Paper BVX001, a Bispecific ADC Targeting CD7-Positive AML with Favorable Toxicity Profile, Exhibits Significant Efficacy in Primary Patient Samples and PDX-Models

Mattia Vitale; Hollie B. S. Griffiths; Nyle Jones et al. · 2024 · Blood · DOI

Full title: BVX001, a Bispecific ADC Targeting CD7-Positive AML with Favorable Toxicity Profile, Exhibits Significant Efficacy in Primary Patient Samples and PDX-Models

Authors: Mattia Vitale; Hollie B. S. Griffiths; Nyle Jones; Meera Mistry; Jack Sangster; Chloe Patterson; Samuel E O'Halloran; Adrian Blanco-Gomez; Oliver Schon; Tiffany Thorn (nee Daniels)

Year: 2024

Venue: Blood

DOI: https://doi.org/10.1182/blood-2024-198370

Paper Development of an Antibody-Drug Conjugate Targeting CADM1 in Adult T-Cell Leukemia/Lymphoma

Aki Tanabe; Yoshiaki Takahashi; A. Yui et al. · 2024 · Blood · DOI

Full title: Development of an Antibody-Drug Conjugate Targeting CADM1 in Adult T-Cell Leukemia/Lymphoma

Authors: Aki Tanabe; Yoshiaki Takahashi; A. Yui; Makoto Nakakido; Tomohiro Nasu; Mami Uemura; K. Tezuka; K. Uchimaru; A. Utsunomiya; T. Matano; T. Mizukami; Toshiki Watanabe; Kouhei Tsumoto; K. Nakano

Year: 2024

Venue: Blood

DOI: https://doi.org/10.1182/blood-2024-198569

Paper CLEC2A Is a Novel AML-Restricted Immunotherapeutic Target Enriched in KMT2A-Rearranged Acute Myeloid Leukemia

Danielle C Kirkey; Leila Robinson; D. Janssens et al. · 2023 · Blood · DOI

Full title: CLEC2A Is a Novel AML-Restricted Immunotherapeutic Target Enriched in KMT2A-Rearranged Acute Myeloid Leukemia

Authors: Danielle C Kirkey; Leila Robinson; D. Janssens; Margaret G. Hines; Tiffany A. Hylkema; Makia K Manselle; R. Ries; Jack H. Peplinski; Logan K. Wallace; Dominik J. Otto; Katherine Tarlock; S. Henikoff; Wei Li; S. Meshinchi

Year: 2023

Venue: Blood

DOI: https://doi.org/10.1182/blood-2023-188439

Paper Potent Activity of Duocarmyin- and Mmaf-Conjugated FLT3-Directed Antibody-Drug Conjugates Towards Acute Myeloid Leukemia Stem Cells in Vitro and In Vivo

Marina Able; Marc‐André Kasper; B. Vick et al. · 2024 · Blood · DOI

Full title: Potent Activity of Duocarmyin- and Mmaf-Conjugated FLT3-Directed Antibody-Drug Conjugates Towards Acute Myeloid Leukemia Stem Cells in Vitro and In Vivo

Authors: Marina Able; Marc‐André Kasper; B. Vick; Jonathan Schwach; Xiang Gao; Saskia Schmitt; B. Tizazu; Amrei Fischer; Sarah Künzl; Marit Leilich; I. Mai; Philipp Ochtrop; A. Stengl; Mark A. R. de Geus; Michael von Bergwelt-Baildon; Dominik Schumacher; Jonas Helma; Katharina S. S. Götze; I. Jeremias; Michaela Feuring; Karsten Spiekermann

Year: 2024

Venue: Blood

DOI: https://doi.org/10.1182/blood-2024-206832

Paper Preclinical Development of a Novel Humanized and Fc-Engineered Antibody-Drug Conjugate for the Therapy of T-Cell Acute Lymphoblastic Leukemia

S. Krohn; C. Gehlert; D. Winterberg et al. · 2024 · Blood · DOI

Full title: Preclinical Development of a Novel Humanized and Fc-Engineered Antibody-Drug Conjugate for the Therapy of T-Cell Acute Lymphoblastic Leukemia

Authors: S. Krohn; C. Gehlert; D. Winterberg; Alexander Jochimsen; Ammelie Svea Boje; Natalie Baum; C. Baldus; Monika Brüggemann; Gunnar Cario; M. Schrappe; L. Lenk; M. Gramatzki; Katja Klausz; Christian Kellner; M. Peipp

Year: 2024

Venue: Blood

DOI: https://doi.org/10.1182/blood-2024-207737

Paper A Novel Antibody-Drug Conjugate Targeting the CD179a Component of the Surrogate Light Chain for the Treatment of B-Cell Acute Lymphoblastic Leukemia/Lymphoma

Peter M. Gordon; Robin Williams; Jason Ostergaard et al. · 2024 · Blood · DOI

Full title: A Novel Antibody-Drug Conjugate Targeting the CD179a Component of the Surrogate Light Chain for the Treatment of B-Cell Acute Lymphoblastic Leukemia/Lymphoma

Authors: Peter M. Gordon; Robin Williams; Jason Ostergaard; Joseph M. Muretta; Bridget S. Wilson; Luke Lambert; Timothy P. Singleton; S. Tasian; S. Winter

Year: 2024

Venue: Blood

DOI: https://doi.org/10.1182/blood-2024-199853

Paper AZD4512: A novel CD22-directed antibody-drug conjugate for the treatment of b-cell malignancies

Huiying Han; Morgann Klink; Kalyani Daita et al. · 2025 · Blood · DOI

Full title: AZD4512: A novel CD22-directed antibody-drug conjugate for the treatment of b-cell malignancies

Authors: Huiying Han; Morgann Klink; Kalyani Daita; Rebecca Filippi; Marcello Marelli; Jin Niu; Ryan Fleming; Andrea Christmas; Steve Arbitman; Francesca Casano; Shraddha Kale; Mark Hutchinson; Qun Du; Reena Varkey; Karyn Folliot; Chandrika Kannadka; Harini Shandilya; Jaqueline Picache; Stefanie Meyer; Rebecca Sargeant; Nicolas Damond; John H Meekin; Christina Vasalou; Jennifer Wheeler; Thomas Linke; Ekaterina Jahn; Connor Hall; B. Vijayakrishnan; Maximillian Lee; Ali Saleh; Kimberly M. Cook; Benedicte Recolin; Jay Harper; John Bullen; Krista Kinneer; E. Rosfjord; Arthur Shaffer; Elaine Hurt; Ken Wood; P. Sapra

Year: 2025

Venue: Blood

DOI: https://doi.org/10.1182/blood-2025-3296

Paper Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed/refractory B-cell acute lymphoblastic leukemia.

N. Jain; W. Stock; A. Zeidan et al. · 2020 · Blood Advances · DOI

Full title: Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed/refractory B-cell acute lymphoblastic leukemia.

Authors: N. Jain; W. Stock; A. Zeidan; E. Atallah; J. Mccloskey; L. Heffner; B. Tomlinson; B. Bhatnagar; J. Feingold; D. Ungar; G. Chao; Xiaoyan Zhang; Y. Qin; K. Havenith; H. Kantarjian; M. Wieduwilt

Year: 2020

Venue: Blood Advances

DOI: https://doi.org/10.1182/bloodadvances.2019000767

Paper Leveraging novel CD38 targeted antibody-drug-conjugates for the treatment of multiple myeloma

Amanda Duplan; Conn Mallett; Yead S. M. Jewel et al. · 2025 · Blood · DOI

Full title: Leveraging novel CD38 targeted antibody-drug-conjugates for the treatment of multiple myeloma

Authors: Amanda Duplan; Conn Mallett; Yead S. M. Jewel; Miso Park; Preeti Sharma; Asaul Gonzalez; Kevin Ly; Hyeran Choi; Bea Parcutela; Carmina Ladra; Amrita Y Krishnan; Flavia Pichiorri; John C. Williams

Year: 2025

Venue: Blood

DOI: https://doi.org/10.1182/blood-2025-2161

Paper Antibody Drug Conjugates with a Novel Translation Inhibitor Payload Demonstrate Cytotoxicity and Tumor Growth Reduction in Multiple Myeloma Models

Tara L. Chapman-Arvedson · 2024 · Blood · DOI

Full title: Antibody Drug Conjugates with a Novel Translation Inhibitor Payload Demonstrate Cytotoxicity and Tumor Growth Reduction in Multiple Myeloma Models

Authors: Tara L. Chapman-Arvedson

Year: 2024

Venue: Blood

DOI: https://doi.org/10.1182/blood-2024-212081

Paper Identifying and overcoming mechanisms of resistance to a VpreB1-directed antibody-drug conjugate in the treatment of B-cell acute lymphoblastic leukemia

Robin Williams; Xiaohong Wang; Jason Ostergaard et al. · 2025 · Blood · DOI

Full title: Identifying and overcoming mechanisms of resistance to a VpreB1-directed antibody-drug conjugate in the treatment of B-cell acute lymphoblastic leukemia

Authors: Robin Williams; Xiaohong Wang; Jason Ostergaard; Joseph M. Muretta; Sarah Tasian; Stuart Winter; Peter M. Gordon

Year: 2025

Venue: Blood

DOI: https://doi.org/10.1182/blood-2025-5115

Paper Discovery of first-in-class calr-targeted precision ADCs delivering a CDK9degrader payload for the treatment of calr-mutated MPNs

Norman Fultang; Ashley M. Schwab; Sharayu Chandratre et al. · 2025 · Blood · DOI

Full title: Discovery of first-in-class calr-targeted precision ADCs delivering a CDK9degrader payload for the treatment of calr-mutated MPNs

Authors: Norman Fultang; Ashley M. Schwab; Sharayu Chandratre; Jake Karwoski; G. Davis; Ian Johnson; Neha Bhagwat; Yue Zou; Arpita Mondal; Max Foroutan; R. Holmes; Chun Chen; C. Basch; A. Buesking; Sang Hyun Lee; Diane Heiser; Andrew Combs; P. Scherle

Year: 2025

Venue: Blood

DOI: https://doi.org/10.1182/blood-2025-72

Paper Identification of Interstitial Loss of Heterozygosity (LOH) Regions Flanking CD33 Locus in AML Patients

Vivek M Shastri; Francisco Marchi; MR Loken et al. · 2024 · Blood · DOI

Full title: Identification of Interstitial Loss of Heterozygosity (LOH) Regions Flanking CD33 Locus in AML Patients

Authors: Vivek M Shastri; Francisco Marchi; MR Loken; J. Lamba

Year: 2024

Venue: Blood

DOI: https://doi.org/10.1182/blood-2024-211258

Paper BT062, An Antibody-Drug Conjugate Directed Against CD138, Shows Clinical Activity In a Phase I Study In Patients with Relapsed or Relapsed/Refractory Multiple Myeloma

S. Jagannath; A. Chanan-Khan; L. Heffner et al. · 2010 · DOI

Full title: BT062, An Antibody-Drug Conjugate Directed Against CD138, Shows Clinical Activity In a Phase I Study In Patients with Relapsed or Relapsed/Refractory Multiple Myeloma

Authors: S. Jagannath; A. Chanan-Khan; L. Heffner; D. Avigan; R. Lutz; C. Uherek; F. Osterroth; Markus Ruehle; Thomas Q. Haeder; G. Niemann; A. Wartenberg-Demand; N. Munshi; K. Anderson

Year: 2010

DOI: https://doi.org/10.1182/blood.v116.21.3060.3060

Paper A novel and highly effective truncated BCMA safety switch for adoptive cell therapy

Jingwei Liu; Sridevi Patchva; Yongfu Tang et al. · 2025 · Blood · DOI

Full title: A novel and highly effective truncated BCMA safety switch for adoptive cell therapy

Authors: Jingwei Liu; Sridevi Patchva; Yongfu Tang; Chun-Yen Lin; F. Chu; Jingjing Cao; Xiaoyun Cheng; Neeraj Y Saini; Federico Mario Aletti; Jinsheng Weng; Cuong Le; S. Neelapu

Year: 2025

Venue: Blood

DOI: https://doi.org/10.1182/blood-2025-7620

Paper Clinical efficacy and safety of polatuzumab vedotin, rituximab, and zanubrutinib (POLA-Z-R) therapy in treatment of super-elderly patients with DLBCL: A real-world retrospective study

Rong Xie; Qiang He; Linna Xie et al. · 2025 · Blood · DOI

Full title: Clinical efficacy and safety of polatuzumab vedotin, rituximab, and zanubrutinib (POLA-Z-R) therapy in treatment of super-elderly patients with DLBCL: A real-world retrospective study

Authors: Rong Xie; Qiang He; Linna Xie; Lili Feng; Qi Kong; Kuntong Liu; Ziqing Ma; Yuhong Ba; Zonghong Li; Qian Wu; Tan Sang; Y. L. Wang; Ji Ma

Year: 2025

Venue: Blood

DOI: https://doi.org/10.1182/blood-2025-7221

Paper Targeting CD300f to enhance hematopoietic stem cell transplantation in acute myeloid leukemia.

Edward Abadir; P. Silveira; R. Gasiorowski et al. · 2020 · Blood Advances · DOI

Full title: Targeting CD300f to enhance hematopoietic stem cell transplantation in acute myeloid leukemia.

Authors: Edward Abadir; P. Silveira; R. Gasiorowski; M. Ramesh; Adelina Romano; Ahmed H. Mekkawy; T. Lo; K. Kabani; Sarah Sutherland; G. Pietersz; P. Ho; C. Bryant; S. Larsen; G. Clark

Year: 2020

Venue: Blood Advances

DOI: https://doi.org/10.1182/bloodadvances.2019001289

Paper Application of Inotuzumab Ozogamicin in Children with B-ALL

Zuofei Chi; Bin Zhang; Liangchun Hao · 2024 · Blood · DOI

Full title: Application of Inotuzumab Ozogamicin in Children with B-ALL

Authors: Zuofei Chi; Bin Zhang; Liangchun Hao

Year: 2024

Venue: Blood

DOI: https://doi.org/10.1182/blood-2024-210200

Paper SGN-CD33A: A Novel CD33-Directed Antibody-Drug Conjugate, Utilizing Pyrrolobenzodiazepine Dimers, Demonstrates Preclinical Antitumor Activity Against Multi-Drug Resistant Human AML

M. Sutherland; R. Walter; S. Jeffrey et al. · 2012 · DOI

Full title: SGN-CD33A: A Novel CD33-Directed Antibody-Drug Conjugate, Utilizing Pyrrolobenzodiazepine Dimers, Demonstrates Preclinical Antitumor Activity Against Multi-Drug Resistant Human AML

Authors: M. Sutherland; R. Walter; S. Jeffrey; P. Burke; Changpu Yu; Kimberly H. Harrington; I. Stone; M. Ryan; D. Sussman; Weiping Zeng; Dennis R. Benjamin; I. Bernstein; P. Senter; J. Drachman; J. McEarchern

Year: 2012

DOI: https://doi.org/10.1182/blood.v120.21.3589.3589

Paper Efficacy of an Anti-CD22 Antibody-Monomethyl Auristatin E Conjugate in a Preclinical Xenograft Model of Precursor B Cell Acute Lymphoblastic Leukemia

S. Yoshida; Emily Tuscano; Connie P. M. Duong et al. · 2014 · DOI

Full title: Efficacy of an Anti-CD22 Antibody-Monomethyl Auristatin E Conjugate in a Preclinical Xenograft Model of Precursor B Cell Acute Lymphoblastic Leukemia

Authors: S. Yoshida; Emily Tuscano; Connie P. M. Duong; J. Tuscano; N. Satake

Year: 2014

DOI: https://doi.org/10.1182/blood.v124.21.971.971

Paper Trials in progress - A phase I study of loncastuximab tesirine and rituximab following stereotactic radiosurgery in patients with primary and secondary central nervous system lymphomas (SOLAR)

N. Epperla; Alli Bock; Yizhe Xu et al. · 2025 · Blood · DOI

Full title: Trials in progress - A phase I study of loncastuximab tesirine and rituximab following stereotactic radiosurgery in patients with primary and secondary central nervous system lymphomas (SOLAR)

Authors: N. Epperla; Alli Bock; Yizhe Xu; Boyu Hu; L. Fitzgerald; H. Shah; Kelsey Baron; D. Ermann; Joe Mendez; Lindsay M Burt; D.M. Cannon; Amit Maity; J. Palmer; I. Alnahhas; Thomas A. Ollila

Year: 2025

Venue: Blood

DOI: https://doi.org/10.1182/blood-2025-8241

Paper Pharmacodynamics, Pharmacokinetics, and Tolerability of a B-Cell Specific Antibody-Targeted Chemotherapeutic Agent, Anti-CD79b-MCC-DM1, in Cynomolgus Monkeys (41.12)

Marna B. Williams; Dongwei Li; R. Fuji et al. · 2009 · Journal of Immunology · DOI

Full title: Pharmacodynamics, Pharmacokinetics, and Tolerability of a B-Cell Specific Antibody-Targeted Chemotherapeutic Agent, Anti-CD79b-MCC-DM1, in Cynomolgus Monkeys (41.12)

Year: 2009

Venue: Journal of Immunology

DOI: https://doi.org/10.4049/jimmunol.182.supp.41.12

Paper Mechanistic and Pharmacodynamic Studies of Adct-301, a Pyrrolobenzodiazepine (PBD) Dimer-Containing Antibody Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies

M. Flynn; P. V. Berkel; F. Zammarchi et al. · 2015 · DOI

Full title: Mechanistic and Pharmacodynamic Studies of Adct-301, a Pyrrolobenzodiazepine (PBD) Dimer-Containing Antibody Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies

Authors: M. Flynn; P. V. Berkel; F. Zammarchi; P. Tyrer; A. Akarca; N. Janghra; Vishvesh Shende; J. Linares; T. Marafioti; David G. Williams; P. Howard; J. Hartley

Year: 2015

DOI: https://doi.org/10.1182/blood.v126.23.1559.1559

Paper Efficacy and safety of pola-ICE, with or without rituximab in relapsed/refractory diffuse large B-cell lymphoma: A real-world multicenter study

Huiqiang Huang; Xuan-Ye Zhang; Jicheng Hong et al. · 2025 · Blood · DOI

Full title: Efficacy and safety of pola-ICE, with or without rituximab in relapsed/refractory diffuse large B-cell lymphoma: A real-world multicenter study

Authors: Huiqiang Huang; Xuan-Ye Zhang; Jicheng Hong; G. Yan; Peng Liu; Kai Hu; Jingping Pi; Rui Liu; Haoqing Chen; Jialing Zhuang

Year: 2025

Venue: Blood

DOI: https://doi.org/10.1182/blood-2025-7208

Paper First in Human Study with GSK2857916, an Antibody Drug Conjugated to Microtubule-Disrupting Agent Directed Against B-Cell Maturation Antigen (BCMA) in Patients with Relapsed/Refractory Multiple Myeloma (MM): Results from Study BMA117159 Part 1 Dose Escalation

A. Cohen; R. Popat; S. Trudel et al. · 2016 · DOI

Full title: First in Human Study with GSK2857916, an Antibody Drug Conjugated to Microtubule-Disrupting Agent Directed Against B-Cell Maturation Antigen (BCMA) in Patients with Relapsed/Refractory Multiple Myeloma (MM): Results from Study BMA117159 Part 1 Dose Escalation

Authors: A. Cohen; R. Popat; S. Trudel; P. Richardson; E. Libby; N. Lendvai; L. Anderson; H. Sutherland; S. Dewall; C. Ellis; Zangdong He; J. Mazumdar; Catherine Wang; J. Opalinska; P. Voorhees

Year: 2016

DOI: https://doi.org/10.1182/blood.v128.22.1148.1148

Paper High Frequency of CD74 Expression in B-Cell Non-Hodgkin's Lymphoma (NHL) and Targeting with SΤRO-001, a Novel Anti-CD74 Antibody Drug Conjugate (ADC) with Potent I n Vitro Cytotoxicty and In Vivo Anti-Tumor Activity

Abigail S. Yu; C. Abrahams; M. Embry et al. · 2017 · DOI

Full title: High Frequency of CD74 Expression in B-Cell Non-Hodgkin's Lymphoma (NHL) and Targeting with SΤRO-001, a Novel Anti-CD74 Antibody Drug Conjugate (ADC) with Potent I n Vitro Cytotoxicty and In Vivo Anti-Tumor Activity

Authors: Abigail S. Yu; C. Abrahams; M. Embry; Xiaofan Li; Shuchun Zhao; R. Henningsen; V. Dealmeida; S. Matheny; T. Kline; A. Yam; R. Stafford; Y. Natkunam; T. Hallam; M. Lupher; A. Molina

Year: 2017

DOI: https://doi.org/10.1182/blood.v130.suppl_1.573.573

Paper Deep and Durable Responses in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (MM) Treated with Monotherapy GSK2857916, an Antibody Drug Conjugate Against B-Cell Maturation Antigen (BCMA): Preliminary Results from Part 2 of Study BMA117159

S. Trudel; N. Lendvai; R. Popat et al. · 2017 · DOI

Full title: Deep and Durable Responses in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (MM) Treated with Monotherapy GSK2857916, an Antibody Drug Conjugate Against B-Cell Maturation Antigen (BCMA): Preliminary Results from Part 2 of Study BMA117159

Authors: S. Trudel; N. Lendvai; R. Popat; P. Voorhees; B. Reeves; E. Libby; P. Richardson; L. Anderson; H. Sutherland; K. Yong; A. Hoos; M. Gorczyca; S. Lahiri; Zangdong He; R. Jewell; J. Opalinska; A. Cohen

Year: 2017

DOI: https://doi.org/10.1182/blood.v130.suppl_1.741.741

Paper Myeloma: next generation immunotherapy.

A. Cohen · 2019 · Hematology. American Society of Hematology. Education Program · DOI

Full title: Myeloma: next generation immunotherapy.

Authors: A. Cohen

Year: 2019

Venue: Hematology. American Society of Hematology. Education Program

DOI: https://doi.org/10.1182/hematology.2019000068

Paper Bispecifics, trispecifics, and other novel immune treatments in myeloma.

G. Lancman; J. Richter; A. Chari · 2020 · Hematology. American Society of Hematology. Education Program · DOI

Full title: Bispecifics, trispecifics, and other novel immune treatments in myeloma.

Authors: G. Lancman; J. Richter; A. Chari

Year: 2020

Venue: Hematology. American Society of Hematology. Education Program

DOI: https://doi.org/10.1182/hematology.2020000110

Paper CD74 Is Expressed in Relapsed and Refractory Multiple Myeloma and Can be Targeted with a Novel Anti-CD74 Antibody Drug Conjugate, SΤRO-001

M. Embry; Xiaofan Li; Abigail S. Yu et al. · 2017 · DOI

Full title: CD74 Is Expressed in Relapsed and Refractory Multiple Myeloma and Can be Targeted with a Novel Anti-CD74 Antibody Drug Conjugate, SΤRO-001

Authors: M. Embry; Xiaofan Li; Abigail S. Yu; C. Abrahams; Nancy Greenland; K. Wen; C. Jones; V. Dealmeida; Stellanie Krimm; S. Krueger; S. Matheny; T. Kline; A. Yam; R. Stafford; Arun P. Wiita; T. Hallam; M. Lupher; A. Molina

Year: 2017

DOI: https://doi.org/10.1182/blood.v130.suppl_1.4420.4420

Paper Abstract 6314: Novel granzyme B-based fusion constructs targeting FRα on liquid and solid tumors

Ana Alvarez-Cienfuegos; L. Cheung; K. Mohamedali et al. · 2023 · Cancer Research · DOI

Full title: Abstract 6314: Novel granzyme B-based fusion constructs targeting FRα on liquid and solid tumors

Authors: Ana Alvarez-Cienfuegos; L. Cheung; K. Mohamedali; Natalia Baran; M. Konopleva; M. Rosenblum

Year: 2023

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2023-6314

Paper Datopotamab Deruxtecan, a Novel TROP2-directed Antibody–drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells

D. Okajima; Satoru Yasuda; T. Maejima et al. · 2021 · Molecular Cancer Therapeutics · DOI

Full title: Datopotamab Deruxtecan, a Novel TROP2-directed Antibody–drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells

Authors: D. Okajima; Satoru Yasuda; T. Maejima; Tsuyoshi Karibe; Ken Sakurai; T. Aida; Tadashi Toki; J. Yamaguchi; Michiko Kitamura; Reiko Kamei; Tomomichi Fujitani; T. Honda; T. Shibutani; Sumie Muramatsu; T. Nakada; R. Goto; S. Takahashi; M. Yamaguchi; H. Hamada; Yutaka Noguchi; M. Murakami; Yuki Abe; T. Agatsuma

Year: 2021

Venue: Molecular Cancer Therapeutics

DOI: https://doi.org/10.1158/1535-7163.mct-21-0206

Paper PCA062, a P-cadherin Targeting Antibody–Drug Conjugate, Displays Potent Antitumor Activity Against P-cadherin–expressing Malignancies

Q. Sheng; J. A. D'alessio; D. Menezes et al. · 2021 · Molecular Cancer Therapeutics · DOI

Full title: PCA062, a P-cadherin Targeting Antibody–Drug Conjugate, Displays Potent Antitumor Activity Against P-cadherin–expressing Malignancies

Authors: Q. Sheng; J. A. D'alessio; D. Menezes; Christopher Karim; Yan Tang; Angela Tam; Suzanna Clark; C. Ying; Anu V. Connor; K. Mansfield; J. Rondeau; M. Ghoddusi; F. Geyer; J. Gu; M. Mclaughlin; R. Newcombe; GiNell Elliot; W. Tschantz; S. Lehmann; C. Fanton; K. Miller; T. Huber; K. Rendahl; U. Jeffry; N. Pryer; E. Lees; P. Kwon; J. Abraham; J. Damiano; T. Abrams

Year: 2021

Venue: Molecular Cancer Therapeutics

DOI: https://doi.org/10.1158/1535-7163.mct-20-0708

Paper Use of Payload Binding Selectivity Enhancers to Improve Therapeutic Index of Maytansinoid-Antibody-Drug Conjugates.

Nguyen, Toan D; Bordeau, Brandon M; Balthasar, Joseph P · 2023 · Molecular cancer therapeutics · DOI

Full title: Use of Payload Binding Selectivity Enhancers to Improve Therapeutic Index of Maytansinoid-Antibody-Drug Conjugates.

Authors: Nguyen, Toan D; Bordeau, Brandon M; Balthasar, Joseph P

Year: 2023

Venue: Molecular cancer therapeutics

DOI: https://doi.org/10.1158/1535-7163.MCT-22-0804

Paper Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody-Drug Conjugate for the Treatment of Cancer.

Toader, Dorin; Fessler, Shawn P; Collins, Scott D et al. · 2023 · Molecular cancer therapeutics · DOI

Full title: Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody-Drug Conjugate for the Treatment of Cancer.

Authors: Toader, Dorin; Fessler, Shawn P; Collins, Scott D; Conlon, Patrick R; Bollu, Reddy; Catcott, Kalli C; Chin, Chen-Ni; Dirksen, Anouk; Du, Bingfan; Duvall, Jeremy R; Higgins, Stacy; Kozytska, Mariya V; Bellovoda, Kamela; Faircloth, Chelsey; Lee, David; Li, Fu; Qin, Liuliang; Routhier, Caitlin; Shaw, Pamela; Stevenson, Cheri A; Wang, Jason; Wongthida, Phonphimon; Ter-Ovanesyan, Elena; Ditty, Elizabeth; Bradley, Stephen P; Xu, Ling; Yin, Mao; Yurkovetskiy, Alexandr V; Mosher, Rebecca; Damelin, Marc; Lowinger, Timothy B

Year: 2023

Venue: Molecular cancer therapeutics

DOI: https://doi.org/10.1158/1535-7163.MCT-22-0786

Paper Improving Intracellular Delivery of an Antibody-Drug Conjugate Targeting Carcinoembryonic Antigen Increases Efficacy at Clinically Relevant Doses In Vivo.

I. Nessler; B. Rubahamya; Anna Kopp et al. · 2023 · Molecular Cancer Therapeutics · DOI

Full title: Improving Intracellular Delivery of an Antibody-Drug Conjugate Targeting Carcinoembryonic Antigen Increases Efficacy at Clinically Relevant Doses In Vivo.

Authors: I. Nessler; B. Rubahamya; Anna Kopp; S. Hofsess; Thomas M Cardillo; Nalini Sathyanarayan; J. Donnell; S. Govindan; Greg M. Thurber

Year: 2023

Venue: Molecular Cancer Therapeutics

DOI: https://doi.org/10.1158/1535-7163.mct-23-0437

Paper An Enzymatically Cleavable Tripeptide Linker for Maximizing the Therapeutic Index of Antibody-Drug Conjugates.

Ha, Summer Y Y; Anami, Yasuaki; Yamazaki, Chisato M et al. · 2022 · Molecular cancer therapeutics · DOI

Full title: An Enzymatically Cleavable Tripeptide Linker for Maximizing the Therapeutic Index of Antibody-Drug Conjugates.

Authors: Ha, Summer Y Y; Anami, Yasuaki; Yamazaki, Chisato M; Xiong, Wei; Haase, Candice M; Olson, Scott D; Lee, Jangsoon; Ueno, Naoto T; Zhang, Ningyan; An, Zhiqiang; Tsuchikama, Kyoji

Year: 2022

Venue: Molecular cancer therapeutics

DOI: https://doi.org/10.1158/1535-7163.MCT-22-0362

Paper MYTX-011: A pH-Dependent Anti-c-MET Antibody-Drug Conjugate Designed for Enhanced Payload Delivery to c-MET-Expressing Tumor Cells.

Gera, Nimish; Fitzgerald, Kyle M; Ramesh, Vijay et al. · 2024 · Molecular cancer therapeutics · DOI

Full title: MYTX-011: A pH-Dependent Anti-c-MET Antibody-Drug Conjugate Designed for Enhanced Payload Delivery to c-MET-Expressing Tumor Cells.

Authors: Gera, Nimish; Fitzgerald, Kyle M; Ramesh, Vijay; Patel, Purvi; Kanojia, Deepak; Colombo, Federico; Kien, Lena; Aoyama, Simon; Xu, Lihui; Jean, Jussekia; Deshpande, Amit M; Comb, William C; Chittenden, Thomas; Fiske, Brian P

Year: 2024

Venue: Molecular cancer therapeutics

DOI: https://doi.org/10.1158/1535-7163.MCT-23-0784

Paper MTX-13, a Novel PTK7-Directed Antibody-Drug Conjugate with Widened Therapeutic Index Shows Sustained Tumor Regressions for a Broader Spectrum of PTK7-Positive Tumors.

Kong, Chao; Pu, Junyi; Zhao, Qianqian et al. · 2023 · Molecular cancer therapeutics · DOI

Full title: MTX-13, a Novel PTK7-Directed Antibody-Drug Conjugate with Widened Therapeutic Index Shows Sustained Tumor Regressions for a Broader Spectrum of PTK7-Positive Tumors.

Authors: Kong, Chao; Pu, Junyi; Zhao, Qianqian; Weng, Weining; Ma, Linjie; Qian, Yu; Hu, Wenhao; Meng, Xun; Meng, Tao

Year: 2023

Venue: Molecular cancer therapeutics

DOI: https://doi.org/10.1158/1535-7163.MCT-23-0164

Paper Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E–based Antibody–Drug Conjugate for Treatment of Nectin-4–expressing Cancers

Wei Zhou; P. Fang; Dongan Yu et al. · 2023 · Molecular Cancer Therapeutics · DOI

Full title: Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E–based Antibody–Drug Conjugate for Treatment of Nectin-4–expressing Cancers

Authors: Wei Zhou; P. Fang; Dongan Yu; Hongyuan Ren; M. You; Long Yin; Fei Mei; Huikai Zhu; Zhenzhen Wang; Hui Xu; Yuxia Cao; Xiaowei Sun; Xiaohong Xu; Jianjun Bi; Jin Wang; Lanping Ma; Xin Wang; Lin Chen; Yongliang Zhang; Xiaowei Cen; Xi Zhu; L. Lou; Datao Liu; Xiaoding Tan; Jinliang Yang; T. Meng; Jingkang Shen

Year: 2023

Venue: Molecular Cancer Therapeutics

DOI: https://doi.org/10.1158/1535-7163.mct-22-0743

Paper SGN-CD228A Is an Investigational CD228-Directed Antibody–Drug Conjugate with Potent Antitumor Activity across a Wide Spectrum of Preclinical Solid Tumor Models

Rebecca Mazahreh; Marsha L Mason; J. Gosink et al. · 2023 · Molecular Cancer Therapeutics · DOI

Full title: SGN-CD228A Is an Investigational CD228-Directed Antibody–Drug Conjugate with Potent Antitumor Activity across a Wide Spectrum of Preclinical Solid Tumor Models

Authors: Rebecca Mazahreh; Marsha L Mason; J. Gosink; Devra Olson; Robert Thurman; Christopher Hale; Lori Westendorf; Thomas A Pires; Christopher I Leiske; Markus Carlson; L. Nguyen; Julia H Cochran; N. Okeley; Roma Yumul; Steven Jin; I. Stone; Disha Sahetya; A. Nesterova; S. Allred; Kelly Hensley; Rachael Hu; Robert Lawrence; T. Lewis; S. Sandall

Year: 2023

Venue: Molecular Cancer Therapeutics

DOI: https://doi.org/10.1158/1535-7163.mct-22-0401

Paper Trastuzumab-MMAU Antibody-Auristatin Conjugates: Valine-Glucoserine Linker with Stabilized Maleimide Conjugation Improves In Vivo Efficacy and Tolerability.

Shalom D Goldberg; T. Satomaa; Olulanu Aina et al. · 2024 · Molecular Cancer Therapeutics · DOI

Full title: Trastuzumab-MMAU Antibody-Auristatin Conjugates: Valine-Glucoserine Linker with Stabilized Maleimide Conjugation Improves In Vivo Efficacy and Tolerability.

Authors: Shalom D Goldberg; T. Satomaa; Olulanu Aina; O. Aitio; Krista Burke; Vadim Dudkin; Brian Geist; O. Irrechukwu; Anna-Liisa Hänninen; A. Heiskanen; J. Helin; Jukka O Hiltunen; Jacqueline Kinyamu-Akunda; Donna M Klein; Neeraj Kohli; Titta Kotiranta; Tuula Lähteenmäki; Ritva Niemelä; Virve Pitkänen; Henna Pynnönen; William Rittase; Kristen Wiley; Junguo Zhou; J. Saarinen

Year: 2024

Venue: Molecular Cancer Therapeutics

DOI: https://doi.org/10.1158/1535-7163.mct-23-0591

Paper A Novel Dual-Payload ADC Platform Integrating Exatecan and Triptolide to Enhance Antitumor Efficacy and Overcome Resistance.

Pengfei Ren; Menglong Guan; Jiao Tang et al. · 2025 · Molecular Cancer Therapeutics · DOI

Full title: A Novel Dual-Payload ADC Platform Integrating Exatecan and Triptolide to Enhance Antitumor Efficacy and Overcome Resistance.

Authors: Pengfei Ren; Menglong Guan; Jiao Tang; Shijun Yin; Lu Qi; Ju Yue; Zhengping Li; Xinzou Fan; Gang Lei; Teng Zuo; Jiao Chen; Yanhua Xu; Xiao Ke; Yonghao Zhao

Year: 2025

Venue: Molecular Cancer Therapeutics

DOI: https://doi.org/10.1158/1535-7163.mct-25-0271

Paper Novel Amanitin-Based Antibody–Drug Conjugates Targeting TROP2 for the Treatment of Pancreatic Cancer

Eleni Papacharisi; Alexandra Braun; Marija Vranic et al. · 2024 · Molecular Cancer Therapeutics · DOI

Full title: Novel Amanitin-Based Antibody–Drug Conjugates Targeting TROP2 for the Treatment of Pancreatic Cancer

Authors: Eleni Papacharisi; Alexandra Braun; Marija Vranic; Andreas Pahl; Torsten Hechler

Year: 2024

Venue: Molecular Cancer Therapeutics

DOI: https://doi.org/10.1158/1535-7163.mct-24-0266

Paper Development of antibody-drug conjugates targeting L1CAM to treat metastatic cancer.

J. Park; Carson Kenum; Lan He et al. · 2026 · Molecular Cancer Therapeutics · DOI

Full title: Development of antibody-drug conjugates targeting L1CAM to treat metastatic cancer.

Authors: J. Park; Carson Kenum; Lan He; Abdul G Khan; Mary Ann Pohl; Thomas E White; S. Kodangattil; C. Rudin; Paul J Balderes; Ivo C. Lorenz; J. Massagué; K. Ganesh

Year: 2026

Venue: Molecular Cancer Therapeutics

DOI: https://doi.org/10.1158/1535-7163.mct-25-1184

Paper Preclinical Pharmacokinetic, Pharmacodynamic, and Safety Profile of OBI-992: A Novel TROP2-Targeted Antibody–Drug Conjugate

Chi-Sheng Shia; Shih-Ni Wen; R. Hsu et al. · 2025 · Molecular Cancer Therapeutics · DOI

Full title: Preclinical Pharmacokinetic, Pharmacodynamic, and Safety Profile of OBI-992: A Novel TROP2-Targeted Antibody–Drug Conjugate

Authors: Chi-Sheng Shia; Shih-Ni Wen; R. Hsu; Jyy-Shiuan Tu; Hui-Wen Chang; Hao-Cheng Weng; Jhih-Jie Yang; Ming-Feng Chiang; Yu-Hsuan Tsao; Chi-Huan Lu; Yu-Hung Chen; Yi-Chen Wu; Ya-Chi Chen; Wan-Fen Li; Teng-Yi Huang; Ming-Tain Lai

Year: 2025

Venue: Molecular Cancer Therapeutics

DOI: https://doi.org/10.1158/1535-7163.mct-24-1176

Paper Design and Evaluation of Phosphonamidate-Linked Exatecan Constructs for Highly Loaded, Stable, and Efficacious Antibody–Drug Conjugates

Saskia Schmitt; Paul Machui; I. Mai et al. · 2023 · Molecular Cancer Therapeutics · DOI

Full title: Design and Evaluation of Phosphonamidate-Linked Exatecan Constructs for Highly Loaded, Stable, and Efficacious Antibody–Drug Conjugates

Authors: Saskia Schmitt; Paul Machui; I. Mai; Sarah Herterich; Swetlana Wunder; Philipp Cyprys; M. Gerlach; P. Ochtrop; Christian P. R. Hackenberger; Dominik Schumacher; Jonas Helma; Annette M Vogl; Marc‐André Kasper

Year: 2023

Venue: Molecular Cancer Therapeutics

DOI: https://doi.org/10.1158/1535-7163.mct-23-0359

Paper Site-specific Dolasynthen antibody-drug conjugates exhibit consistent pharmacokinetic profiles across a wide range of drug to antibody ratios.

S. Clardy; Alex Uttard; Bingfan Du et al. · 2023 · Molecular Cancer Therapeutics · DOI

Full title: Site-specific Dolasynthen antibody-drug conjugates exhibit consistent pharmacokinetic profiles across a wide range of drug to antibody ratios.

Authors: S. Clardy; Alex Uttard; Bingfan Du; Kalli C. Catcott; Kelly Lancaster; Elizabeth Ditty; J. Sadowsky; J. Zurita; Naniye Malli; Liuliang Qin; Stephen P Bradley; Kenneth Avocetien; Tyler Carter; Dokyong Kim; Mark Nazzaro; Ling Xu; Thomas H. Pillow; Neelie T Zacharias; Gail D Lewis; Rebecca K Rowntree; Radha Iyengar; David H Lee; M. Damelin; D. Toader; T. Lowinger

Year: 2023

Venue: Molecular Cancer Therapeutics

DOI: https://doi.org/10.1158/1535-7163.mct-23-0262

Paper TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile

Annette M Vogl; Saskia Schmitt; I. Mai et al. · 2025 · Molecular Cancer Therapeutics · DOI

Full title: TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile

Authors: Annette M Vogl; Saskia Schmitt; I. Mai; Paul Machui; Sarah Herterich; Natascia Leonardi; Philipp Cyprys; Danila Hauswald; Philipp Ochtrop; Izabela Kozlowska; Annabel Kitowski; M. Gerlach; Florian Waldmann; Olivier Marcq; Pamela A Trail; Dominik Schumacher; Günter R Fingerle-Rowson; Björn Hock; Marc‐André Kasper; Jonas Helma

Year: 2025

Venue: Molecular Cancer Therapeutics

DOI: https://doi.org/10.1158/1535-7163.mct-25-0254

Paper Development and Characterization of a Lysosome-Targeting SLC3A2/PD-L1 Bispecific Antibody-Drug Conjugate for Enhanced Anti-Tumor Efficacy in Solid Tumors.

Zeng Wang; Meijun Zheng; Mengyao Li et al. · 2024 · Molecular Cancer Therapeutics · DOI

Full title: Development and Characterization of a Lysosome-Targeting SLC3A2/PD-L1 Bispecific Antibody-Drug Conjugate for Enhanced Anti-Tumor Efficacy in Solid Tumors.

Authors: Zeng Wang; Meijun Zheng; Mengyao Li; Huaqing Lu; Nanxi Liu; Yongdong Chen; Nian Yang; Wanqin Zeng; Yijun Dong; Jia Li; Zhixiong Zhu; Chen Yang; Zongliang Zhang; Qizhong Lu; Hexian Li; Liangxue Zhou; Hui Yang; Aiping Tong

Year: 2024

Venue: Molecular Cancer Therapeutics

DOI: https://doi.org/10.1158/1535-7163.mct-24-0319

Paper Broadening the Therapeutic Window of ADCs Using Site-Specific Bioconjugation Showcased by an MMAE-Containing Peptide Linker in a CD79b-Targeting ADC.

Probst, Philipp; Attinger-Toller, Isabella; Bertrand, Romain et al. · 2025 · Molecular cancer therapeutics · DOI

Full title: Broadening the Therapeutic Window of ADCs Using Site-Specific Bioconjugation Showcased by an MMAE-Containing Peptide Linker in a CD79b-Targeting ADC.

Authors: Probst, Philipp; Attinger-Toller, Isabella; Bertrand, Romain; Stark, Ramona; Santimaria, Roger; Schlereth, Bernd; Grabulovski, Dragan; Spycher, Philipp René

Year: 2025

Venue: Molecular cancer therapeutics

DOI: https://doi.org/10.1158/1535-7163.MCT-24-0983

Paper Preclinical Characterization of ARX517, a Site-Specific Stable PSMA-Targeted Antibody–Drug Conjugate for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Lillian K Skidmore; David Mills; Ji Young Kim et al. · 2024 · Molecular Cancer Therapeutics · DOI

Full title: Preclinical Characterization of ARX517, a Site-Specific Stable PSMA-Targeted Antibody–Drug Conjugate for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Authors: Lillian K Skidmore; David Mills; Ji Young Kim; Nick A Knudsen; Jay D Nelson; Manoj Pal; Jianing Wang; Kedar Gc; Michael J Gray; Wisam Barkho; Prathap Nagaraja Shastri; M. Ramprasad; Feng Tian; Dan O'Connor; Ying J Buechler; S. Zhang

Year: 2024

Venue: Molecular Cancer Therapeutics

DOI: https://doi.org/10.1158/1535-7163.mct-23-0927

Paper Abstract A215: Antitumor activity of an antibody-drug conjugate targeting 5T4, a putative tumor-initiating cell antigen.

J. Dijoseph; Maureen M. Dougher; B. Narayanan et al. · 2011 · DOI

Full title: Abstract A215: Antitumor activity of an antibody-drug conjugate targeting 5T4, a putative tumor-initiating cell antigen.

Authors: J. Dijoseph; Maureen M. Dougher; B. Narayanan; K. Khandke; Kimberly Marquette; R. Dushin; M. Damelin; J. Lucas; M. Leal; George Hu; Jonathon Golas; A. Maderna; F. Loganzo; Lioudmila Tchistiakova; C. J. O’Donnell; R. Abraham; H. Gerber; P. Sapra

Year: 2011

DOI: https://doi.org/10.1158/1535-7163.targ-11-a215

Paper Design and evaluation of ZD06519, a novel camptothecin payload for antibody drug conjugates.

Mark E Petersen; Michael G Brant; M. Lasalle et al. · 2024 · Molecular Cancer Therapeutics · DOI

Full title: Design and evaluation of ZD06519, a novel camptothecin payload for antibody drug conjugates.

Authors: Mark E Petersen; Michael G Brant; M. Lasalle; Samir Das; Renee Duan; Jodi Wong; Tong Ding; Kaylee J Wu; Dayananda Siddappa; Chen Fang; Wen Zhang; Alex M L Wu; Truman Hirkala-Schaefer; Graham A E Garnett; Vincent Fung; Luying Yang; Andrea Hernandez Rojas; S. Lawn; Stuart D Barnscher; Jamie R Rich; Raffaele Colombo

Year: 2024

Venue: Molecular Cancer Therapeutics

DOI: https://doi.org/10.1158/1535-7163.mct-23-0822

Paper HRA00129-C004, a Novel c-Met Antibody-Drug Conjugate (ADC), Exerts Encouraging Anti-Tumor Activities and Favorable Safety Profiles.

Yunan Tian; Jieqiong Zhang; Xing Sun et al. · 2025 · Molecular Cancer Therapeutics · DOI

Full title: HRA00129-C004, a Novel c-Met Antibody-Drug Conjugate (ADC), Exerts Encouraging Anti-Tumor Activities and Favorable Safety Profiles.

Authors: Yunan Tian; Jieqiong Zhang; Xing Sun; Changyong Yang; Cheng Liao

Year: 2025

Venue: Molecular Cancer Therapeutics

DOI: https://doi.org/10.1158/1535-7163.mct-24-0680

Paper Abstract C162: Antibody-Drug Conjugates (ADCs) with novel IGN DNA-alkylating agents display potent antigen-specific activity against hematologic and solid tumor xenograft models.

K. Whiteman; H. Johnson; Alan J. Wilhelm et al. · 2013 · DOI

Full title: Abstract C162: Antibody-Drug Conjugates (ADCs) with novel IGN DNA-alkylating agents display potent antigen-specific activity against hematologic and solid tumor xenograft models.

Authors: K. Whiteman; H. Johnson; Alan J. Wilhelm; Michael L. Miller; Wei Li; E. E. Reid; Katie E. Archer; N. Fishkin; Andre A. Dandeneau; E. K. Maloney; J. Pinkas; R. Chari

Year: 2013

DOI: https://doi.org/10.1158/1535-7163.targ-13-c162

Paper Abstract C67: Safety, efficacy, and pharmacokinetics of a new humanized anti-Trop-2 antibody-SN-38 conjugate (IMMU-132) for the treatment of diverse epithelial cancers: Phase I clinical experience.

A. Starodub; A. Ocean; M. Guarino et al. · 2013 · DOI

Full title: Abstract C67: Safety, efficacy, and pharmacokinetics of a new humanized anti-Trop-2 antibody-SN-38 conjugate (IMMU-132) for the treatment of diverse epithelial cancers: Phase I clinical experience.

Authors: A. Starodub; A. Ocean; M. Guarino; E. Chuang; Manish A. Shah; S. Tagawa; V. Picozzi; Sajev Thomas; P. Maliakal; W. Wegener; R. Sharkey; S. Govindan; D. Goldenberg

Year: 2013

DOI: https://doi.org/10.1158/1535-7163.targ-13-c67

Paper Targeted delivery of a potent STING agonist payload via an antibody drug conjugate drives robust antitumor activity in preclinical models.

David R Gruber; Elizabeth J Cummins; Weiping Zeng et al. · 2025 · Molecular Cancer Therapeutics · DOI

Full title: Targeted delivery of a potent STING agonist payload via an antibody drug conjugate drives robust antitumor activity in preclinical models.

Authors: David R Gruber; Elizabeth J Cummins; Weiping Zeng; Michelle Ulrich; Kaleb Smith; Mallory Long; Kellie Spahr; Shaylin Higgins; Katelyn Hinricher; Aditi Langalia; Kora Krumm; Devra J Olson; Bryan Grogan; Rebecca Mazahreh; Priyanka Gupta; Patrick J Burke; Alyson Smith; Peter D Senter; S. Gardai; Adam G Hill; E. Gray

Year: 2025

Venue: Molecular Cancer Therapeutics

DOI: https://doi.org/10.1158/1535-7163.mct-25-0108

Paper Abstract A107: Accelerating and Advancing Targeted Therapeutics: A One-Stop Service Platform for ADC and Next-Generation Conjugate Development

Wei Li · 2025 · Molecular Cancer Therapeutics · DOI

Full title: Abstract A107: Accelerating and Advancing Targeted Therapeutics: A One-Stop Service Platform for ADC and Next-Generation Conjugate Development

Authors: Wei Li

Year: 2025

Venue: Molecular Cancer Therapeutics

DOI: https://doi.org/10.1158/1535-7163.targ-25-a107

Paper Abstract A145: DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a potent anti-tumor efficacy with differentiation from T-DM1 in preclinical studies

Y. Ogitani; J. Yamaguchi; Chiaki Ishii et al. · 2015 · DOI

Full title: Abstract A145: DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a potent anti-tumor efficacy with differentiation from T-DM1 in preclinical studies

Authors: Y. Ogitani; J. Yamaguchi; Chiaki Ishii; Takehiro Hirai; R. Atsumi; K. Morita; Hayakawa Ichiro; H. Naito; T. Masuda; T. Nakada; Takahiro Jikoh

Year: 2015

DOI: https://doi.org/10.1158/1535-7163.targ-15-a145

Paper Abstract B209: The CD37-targeting ADC IMGN529 combines the potent anticancer activity of K7153A antibody with efficient maytansinoid delivery.

Katharine C. Lai; H. Erickson; Xiuxia Sun et al. · 2011 · DOI

Full title: Abstract B209: The CD37-targeting ADC IMGN529 combines the potent anticancer activity of K7153A antibody with efficient maytansinoid delivery.

Authors: Katharine C. Lai; H. Erickson; Xiuxia Sun; Peter U Park; J. Deckert; Min Li; Y. Yi; J. Pinkas; Jennifer A. Coccia; S. Nadworny

Year: 2011

DOI: https://doi.org/10.1158/1535-7163.targ-11-b209

Paper Abstract C026: DS-1062a, a novel TROP2-targeting antibody-drug conjugate with a novel DNA topoisomerase I inhibitor DXd, demonstrates potent antitumor activity in preclinical models

D. Okajima; J. Yamaguchi; Michiko Kitamura et al. · 2019 · Therapeutic Agents: Biological · DOI

Full title: Abstract C026: DS-1062a, a novel TROP2-targeting antibody-drug conjugate with a novel DNA topoisomerase I inhibitor DXd, demonstrates potent antitumor activity in preclinical models

Authors: D. Okajima; J. Yamaguchi; Michiko Kitamura; Reiko Kamei; T. Maejima; T. Shibutani; Satoru Yasuda; Tadashi Toki; Tsuyoshi Karibe; Tomomichi Fujitani; T. Nakada; R. Goto; Yutaka Noguchi; Abe Yuki; T. Agatsuma

Year: 2019

Venue: Therapeutic Agents: Biological

DOI: https://doi.org/10.1158/1535-7163.targ-19-c026

Paper - **DOI:** 10.1158/1535-7163.targ-23-ia003 - **Authors:** Raffaele Colombo - **Year:** 2023 - **Journal:** Molecular Cancer Therapeutics

Raffaele Colombo · 2023 · Molecular Cancer Therapeutics · DOI

Full title: - **DOI:** 10.1158/1535-7163.targ-23-ia003 - **Authors:** Raffaele Colombo - **Year:** 2023 - **Journal:** Molecular Cancer Therapeutics

Authors: Raffaele Colombo

Year: 2023

Venue: Molecular Cancer Therapeutics

DOI: https://doi.org/10.1158/1535-7163.targ-23-ia003

Paper Abstract C095: Antitumor activity of STRO-002, a novel anti-folate receptor-α (FRα) antibody drug conjugate (ADC), in patient-derived xenograft (PDX) models and preliminary phase I dose escalation safety outcomes in patients with ovarian carcinoma (OC)

D. Uyar; R. Schilder; R. Naumann et al. · 2019 · Tubulin-interacting Agents · DOI

Full title: Abstract C095: Antitumor activity of STRO-002, a novel anti-folate receptor-α (FRα) antibody drug conjugate (ADC), in patient-derived xenograft (PDX) models and preliminary phase I dose escalation safety outcomes in patients with ovarian carcinoma (OC)

Authors: D. Uyar; R. Schilder; R. Naumann; F. Braiteh; E. Hamilton; S. Diab; J. Moroney; R. Penson; Jennifer A. Smith; C. Abrahams; Michael Palumbo; V. Dealmeida; S. Matheny; A. Molina

Year: 2019

Venue: Tubulin-interacting Agents

DOI: https://doi.org/10.1158/1535-7163.targ-19-c095

Paper Abstract B121: CPL976, an innovative bispecific antibody targeting AXL and PD-L1 axis as a potential new anticancer therapeutic

Agnieszka Bojko-Matuszek; Damian Kołakowski; Magdalena Bojko et al. · 2023 · Molecular Cancer Therapeutics · DOI

Full title: Abstract B121: CPL976, an innovative bispecific antibody targeting AXL and PD-L1 axis as a potential new anticancer therapeutic

Authors: Agnieszka Bojko-Matuszek; Damian Kołakowski; Magdalena Bojko; Aleksandra Sowińska; Filip Mitula; Krzysztof Lacek; Delfina Popiel; Sebastian Kwiatkowski; Tomasz Kornatowski; Beata Kliszcz; Anna Jabłońska; Krzysztof Flis; Bartosz Wiernicki; Maciej Wieczorek; J. Pieczykolan; Olga Abramczyk

Year: 2023

Venue: Molecular Cancer Therapeutics

DOI: https://doi.org/10.1158/1535-7163.targ-23-b121

Paper Abstract C166: Combining an anti-Trop-2 antibody-SN-38 conjugate (sacituzumab govitecan) with microtubule inhibitors (paclitaxel and eribulin mesylate) or PARP inhibitor (olaparib) significantly improves therapeutic outcome in experimental triple-negative breast cancer (TNBC)

Thomas M Cardillo; S. Govindan; Maria B. Zalath et al. · 2015 · DOI

Full title: Abstract C166: Combining an anti-Trop-2 antibody-SN-38 conjugate (sacituzumab govitecan) with microtubule inhibitors (paclitaxel and eribulin mesylate) or PARP inhibitor (olaparib) significantly improves therapeutic outcome in experimental triple-negative breast cancer (TNBC)

Authors: Thomas M Cardillo; S. Govindan; Maria B. Zalath; R. Arrojo; R. Sharkey; D. Goldenberg

Year: 2015

DOI: https://doi.org/10.1158/1535-7163.targ-15-c166

Paper Abstract A119: ALX2004, a novel topoisomerase I inhibitor antibody-drug conjugate for the treatment of EGFR-expressing solid tumors

Janica C. Wong; Ana Monegal-Granados; Hanako Daino-Laizure et al. · 2025 · Molecular Cancer Therapeutics · DOI

Full title: Abstract A119: ALX2004, a novel topoisomerase I inhibitor antibody-drug conjugate for the treatment of EGFR-expressing solid tumors

Authors: Janica C. Wong; Ana Monegal-Granados; Hanako Daino-Laizure; Jia-Xu Li; Jessica L. Morgan; Sarah Bolton; Andrew Olson; Yin Labson; Connie Lu; Sen Xu; Venita De Almedia; Hadi Falahatpisheh; Peter Strop; Jaume Pons; Marija Vrljic

Year: 2025

Venue: Molecular Cancer Therapeutics

DOI: https://doi.org/10.1158/1535-7163.targ-25-a119

Paper Abstract A065: Differential sensitivity of normal and tumor organoids to targeted therapies

M. Madej; Cinthya Del Angel Zuvirie; Jara García Mateos et al. · 2019 · Cellular Responses to Therapy · DOI

Full title: Abstract A065: Differential sensitivity of normal and tumor organoids to targeted therapies

Authors: M. Madej; Cinthya Del Angel Zuvirie; Jara García Mateos; L. Price; L. Daszkiewicz; K. Yan; B. Herpers

Year: 2019

Venue: Cellular Responses to Therapy

DOI: https://doi.org/10.1158/1535-7163.targ-19-a065

Paper Abstract B116: Optimizing a CD71-targeting Probody drug conjugate (PDC) for activity in multiple solid tumor and lymphoma models and for tolerability in nonhuman primates

Shweta Singh; L. Serwer; N. Chauhan et al. · 2018 · DOI

Full title: Abstract B116: Optimizing a CD71-targeting Probody drug conjugate (PDC) for activity in multiple solid tumor and lymphoma models and for tolerability in nonhuman primates

Authors: Shweta Singh; L. Serwer; N. Chauhan; A. DuPage; Michael Krimm; Kenneth R. Wong; Yuanhui Huang; A. Jang; Eric Ureno; Adam Miller; Sarah Patrick; Shanti Duvur; F. G. Buchanan; Matthew Ravn; Rob Leanna; I. Badagnani; Tracy Henriques; Shouchun Liu; C. Krebber; Sridhar Viswanathan; J. Richardson; S. Morgan-Lappe; M. Kavanaugh

Year: 2018

DOI: https://doi.org/10.1158/1535-7163.targ-17-b116

Paper Abstract A137: GS24-B025, a highly differentiated CDH17- and CEA-directed bispecific antibody-drug conjugate (bsADC), for the treatment of colorectal cancer

Zeng Qi; Fu Li; Liping Shao et al. · 2025 · Molecular Cancer Therapeutics · DOI

Full title: Abstract A137: GS24-B025, a highly differentiated CDH17- and CEA-directed bispecific antibody-drug conjugate (bsADC), for the treatment of colorectal cancer

Authors: Zeng Qi; Fu Li; Liping Shao; Yuting Lu; Chong Ding; Nan Li; Huan Wang; Weiming He; Wenqiang Zhai; Fanglong Yang; Siqin Wang; Lei Jin; John L. Xu

Year: 2025

Venue: Molecular Cancer Therapeutics

DOI: https://doi.org/10.1158/1535-7163.targ-25-a137

Paper Abstract A125: Devleopment of TROP2-targeted cytotoxic peptides and drug conjugates for treatment of triple negative breast cancer

Hyeongyu Park; Uttapol Permpoon; Hyungi Kim et al. · 2025 · Molecular Cancer Therapeutics · DOI

Full title: Abstract A125: Devleopment of TROP2-targeted cytotoxic peptides and drug conjugates for treatment of triple negative breast cancer

Authors: Hyeongyu Park; Uttapol Permpoon; Hyungi Kim; Hyejin Ahn; Sang Jeon Chung; Byungheon Lee

Year: 2025

Venue: Molecular Cancer Therapeutics

DOI: https://doi.org/10.1158/1535-7163.targ-25-a125

Paper Abstract A136: Comparison of the bystander effects and killing capabilities of the HER2-targeting antibody drug conjugates T-DM1 and T-DXd

Eef F. Smits; J. Melis; Daphne J. F. Kluitmans et al. · 2025 · Molecular Cancer Therapeutics · DOI

Full title: Abstract A136: Comparison of the bystander effects and killing capabilities of the HER2-targeting antibody drug conjugates T-DM1 and T-DXd

Authors: Eef F. Smits; J. Melis; Daphne J. F. Kluitmans; J. Kooijman; Mandy W.E. Drossaert - Smeets; Guido J. R. Zaman

Year: 2025

Venue: Molecular Cancer Therapeutics

DOI: https://doi.org/10.1158/1535-7163.targ-25-a136

Paper Abstract B122: 2 for 1: Targeting tumor-associated macrophages and cancer cells with a novel MERTK-targeting antibody-drug conjugate (ADC)

Shugaku Takeda; Puichi lo; Daniella Schefer et al. · 2023 · Molecular Cancer Therapeutics · DOI

Full title: Abstract B122: 2 for 1: Targeting tumor-associated macrophages and cancer cells with a novel MERTK-targeting antibody-drug conjugate (ADC)

Authors: Shugaku Takeda; Puichi lo; Daniella Schefer; Maryam Siddiqui; Anudishi Tyagi; V. Battula; A. Maiti; Sohail Tavazoie; M. Tavazoie; D. Darst; Isabel Kurth

Year: 2023

Venue: Molecular Cancer Therapeutics

DOI: https://doi.org/10.1158/1535-7163.targ-23-b122

Paper Abstract B030: Development of a novel antibody drug conjugate (ADC) targeting Nectin-2 on the surface of breast cancers

Yueyue Wang; N. Shan; Xiaolong Zhu et al. · 2025 · Molecular Cancer Therapeutics · DOI

Full title: Abstract B030: Development of a novel antibody drug conjugate (ADC) targeting Nectin-2 on the surface of breast cancers

Authors: Yueyue Wang; N. Shan; Xiaolong Zhu; Tongqing Li; J. Dai; Hengyi Li; Florine Collin; Weiwei Wang; Tukiet Lam; H. Zhan; K. Blenman; Daryl E. Klein; L. Pusztai

Year: 2025

Venue: Molecular Cancer Therapeutics

DOI: https://doi.org/10.1158/1535-7163.targ-25-b030

Paper Abstract 4394: Development of parallel conjugation and assay methodologies to screen for antibodies with optimal properties for use as antibody-drug conjugates

R. Lyon; M. Ryan; M. Sutherland et al. · 2010 · DOI

Full title: Abstract 4394: Development of parallel conjugation and assay methodologies to screen for antibodies with optimal properties for use as antibody-drug conjugates

Authors: R. Lyon; M. Ryan; M. Sutherland; B. Meyer; Changpu Yu; Heather Kostner; J. Miyamoto; Dennis R. Benjamin

Year: 2010

DOI: https://doi.org/10.1158/1538-7445.am10-4394

Paper Abstract IA05: Computational pathology in ADC drug development

Mark Gustavson · 2025 · Molecular Cancer Therapeutics · DOI

Full title: Abstract IA05: Computational pathology in ADC drug development

Authors: Mark Gustavson

Year: 2025

Venue: Molecular Cancer Therapeutics

DOI: https://doi.org/10.1158/1535-7163.targ-25-ia05

Paper Abstract A124: CBB-120: A TROP2-targeted dual-payload ADC combining Top1i and ATRi mechanisms demonstrates superior efficacy in preclinical models and improved safety in non-human primates

Yasuaki Anami; V. Balasubramaniyan; Roman A. Lara et al. · 2025 · Molecular Cancer Therapeutics · DOI

Full title: Abstract A124: CBB-120: A TROP2-targeted dual-payload ADC combining Top1i and ATRi mechanisms demonstrates superior efficacy in preclinical models and improved safety in non-human primates

Authors: Yasuaki Anami; V. Balasubramaniyan; Roman A. Lara; Michael J. Torres; Daniel S. Pereira

Year: 2025

Venue: Molecular Cancer Therapeutics

DOI: https://doi.org/10.1158/1535-7163.targ-25-a124

Paper Abstract 4630: Integrin αVα6 is expressed on multiple solid tumors and is a potential therapeutic target for auristatin-based antibody-drug conjugates

M. Ryan; Heather Kostner; E. Meyer et al. · 2012 · DOI

Full title: Abstract 4630: Integrin αVα6 is expressed on multiple solid tumors and is a potential therapeutic target for auristatin-based antibody-drug conjugates

Authors: M. Ryan; Heather Kostner; E. Meyer; D. Sussman; Lindsay Torrey; Martha E. Anderson; R. Lyon; David J. Meyer; M. Jonas; Heather A. Van Epps; Dennis R. Benjamin

Year: 2012

DOI: https://doi.org/10.1158/1538-7445.am2012-4630

Paper Abstract 1683: High throughput membrane proteomics for the discovery of oncology targets ideally suited for the development of antibody drug conjugates (ADCs)

J. Terrett; L. Bozhenok; B. Belanger et al. · 2011 · DOI

Full title: Abstract 1683: High throughput membrane proteomics for the discovery of oncology targets ideally suited for the development of antibody drug conjugates (ADCs)

Authors: J. Terrett; L. Bozhenok; B. Belanger; Iñigo Montes; D. Aud; J. Ackroyd; A. Anderson; M. Trang; M. Barnes; Harry Lamble; Xiaohong Yu; C. Rohlff

Year: 2011

DOI: https://doi.org/10.1158/1538-7445.am2011-1683

Paper Abstract 2530: Long-term tumor regression induced by a novel antibody drug conjugate that targets 5T4, an oncofetal antigen expressed on tumor-initiating cells

P. Sapra; J. Dijoseph; M. Damelin et al. · 2012 · DOI

Full title: Abstract 2530: Long-term tumor regression induced by a novel antibody drug conjugate that targets 5T4, an oncofetal antigen expressed on tumor-initiating cells

Authors: P. Sapra; J. Dijoseph; M. Damelin; Maureen M. Dougher; B. Narayanan; K. Khandke; J. Lucas; Jonathon Golas; Lioudmila Tchistiakova; M. Leal; George Hu; A. Maderna; Kimberly Marquette; F. Loganzo; R. Dushin; C. J. O’Donnell; R. Abraham; H. Gerber

Year: 2012

DOI: https://doi.org/10.1158/1538-7445.am2012-2530

Paper Abstract 1754: Identification of BAY 94-9343, a mesothelin antibody-drug conjugate (ADC): Characterization and anti-tumor activity in mesothelin-positive preclinical tumor models

S. Golfier; A. Kahnert; I. Heisler et al. · 2011 · DOI

Full title: Abstract 1754: Identification of BAY 94-9343, a mesothelin antibody-drug conjugate (ADC): Characterization and anti-tumor activity in mesothelin-positive preclinical tumor models

Authors: S. Golfier; A. Kahnert; I. Heisler; C. Kopitz; Kerstin Berhoerster; B. Stelte-Ludwig; Anke Mayer-Bartschmid; Sandra Bruder; Lars Linden; A. Harrenga; Christoph A Schatz; B. Kreft; B. Müller-Tiemann; K. Ziegelbauer

Year: 2011

DOI: https://doi.org/10.1158/1538-7445.am2011-1754

Paper Abstract B060: Neratinib in combination with antibody–drug conjugates for patients with metastatic cancer

R. Bose; Haeseong Park; E. Dumbrava et al. · 2025 · Molecular Cancer Therapeutics · DOI

Full title: Abstract B060: Neratinib in combination with antibody–drug conjugates for patients with metastatic cancer

Authors: R. Bose; Haeseong Park; E. Dumbrava; Rachel Freedman; Jame Abraham; A. Davis

Year: 2025

Venue: Molecular Cancer Therapeutics

DOI: https://doi.org/10.1158/1535-7163.targ-25-b060

Paper Abstract 4397: Development of antibody-drug conjugate technology based on novel linkers & DNA alkylating duocarmycin derivatives

V. D. Groot; P. Beusker; J. Joosten et al. · 2010 · DOI

Full title: Abstract 4397: Development of antibody-drug conjugate technology based on novel linkers & DNA alkylating duocarmycin derivatives

Authors: V. D. Groot; P. Beusker; J. Joosten; H. Spijker; Ruud G. E. Coumans; W. Menge; R. Elgersma

Year: 2010

DOI: https://doi.org/10.1158/1538-7445.am10-4397

Paper Abstract 2832: Development of AGS-22M6E, a novel antibody drug conjugate (ADC) targeting Nectin-4 for the treatment of solid tumors

Daulet Satpayev; M. Torgov; Peng Yang et al. · 2011 · DOI

Full title: Abstract 2832: Development of AGS-22M6E, a novel antibody drug conjugate (ADC) targeting Nectin-4 for the treatment of solid tumors

Authors: Daulet Satpayev; M. Torgov; Peng Yang; K. Morrison; Y. Shostak; A. Raitano; Wendy Liu; Dawn Ratay Lortie; Z. An; L. Capo; Monica Leavitt; Myra Perez; Alla Verlinsky; Kenna Shirasuna; Héctor Aviña; Claudia I. Guevara; K. Morrison; P. Challita-Eid; X. Jia; J. Gudas; D. Stover

Year: 2011

DOI: https://doi.org/10.1158/1538-7445.am2011-2832

Paper Abstract C004: ADC screening platform, a useful platform for ADC drug evaluation

Jinying B. Ning; Feng Hao; Thomas B. Strong · 2025 · Molecular Cancer Therapeutics · DOI

Full title: Abstract C004: ADC screening platform, a useful platform for ADC drug evaluation

Authors: Jinying B. Ning; Feng Hao; Thomas B. Strong

Year: 2025

Venue: Molecular Cancer Therapeutics

DOI: https://doi.org/10.1158/1535-7163.targ-25-c004

Paper Abstract 2665: Transforming Notch ligands into tumor-antigen targets: A Probody-Drug Conjugate (PDC) targeting Jagged 1 and Jagged 2

J. Sagert; J. West; Chihunt Wong et al. · 2014 · DOI

Full title: Abstract 2665: Transforming Notch ligands into tumor-antigen targets: A Probody-Drug Conjugate (PDC) targeting Jagged 1 and Jagged 2

Authors: J. Sagert; J. West; Chihunt Wong; Luc R Desnoyers; O. Vasiljeva; J. Richardson; K. Polu; H. Lowman

Year: 2014

DOI: https://doi.org/10.1158/1538-7445.am2014-2665

Paper Abstract 2486: Site-specific antibody-drug conjugation through an engineered glycotransferase and a chemically reactive sugar

Zhongyu Zhu; R. Boopathy; Jinyu Li et al. · 2015 · DOI

Full title: Abstract 2486: Site-specific antibody-drug conjugation through an engineered glycotransferase and a chemically reactive sugar

Authors: Zhongyu Zhu; R. Boopathy; Jinyu Li; P. Prabakaran; S. Colantonio; Yang Feng; Yanping Wang; M. Dyba; D. Dimitrov

Year: 2015

DOI: https://doi.org/10.1158/1538-7445.am2015-2486

Paper Abstract 4837: Extracellular proteolytic cleavage of peptide-linked antibody-drug conjugates promotes bystander killing of cancer cells

M. Lam; J. Lucas; A. Maderna et al. · 2014 · DOI

Full title: Abstract 4837: Extracellular proteolytic cleavage of peptide-linked antibody-drug conjugates promotes bystander killing of cancer cells

Authors: M. Lam; J. Lucas; A. Maderna; H. S. Wald; Megan L. Wojciechowicz; R. Dushin; B. Peano; F. Wang; Jeremy S. Myers; X. Tan; S. Musto; M. Charati; H. Gerber; F. Loganzo

Year: 2014

DOI: https://doi.org/10.1158/1538-7445.am2014-4837

Paper Abstract 667: IMGN853, a folate receptor (FR) α-targeting antibody-drug conjugate (ADC), is highly effective against xenograft models with clinically relevant levels of receptor expression

O. Ab; L. Bartle; Xiuxia Sun et al. · 2014 · DOI

Full title: Abstract 667: IMGN853, a folate receptor (FR) α-targeting antibody-drug conjugate (ADC), is highly effective against xenograft models with clinically relevant levels of receptor expression

Authors: O. Ab; L. Bartle; Xiuxia Sun; Rui Wu; H. Johnson; K. Whiteman; A. Labelle; V. Goldmacher

Year: 2014

DOI: https://doi.org/10.1158/1538-7445.am2014-667

Paper Abstract 664: Amanitin-based antibody-drug conjugates targeting the prostate-specific membrane antigen

Torsten Hechler; Michael Kulke; C. Mueller et al. · 2014 · DOI

Full title: Abstract 664: Amanitin-based antibody-drug conjugates targeting the prostate-specific membrane antigen

Authors: Torsten Hechler; Michael Kulke; C. Mueller; A. Pahl; J. Anderl

Year: 2014

DOI: https://doi.org/10.1158/1538-7445.am2014-664

Paper Abstract LB-269: Anti-RON antibody-drug maytansinoid conjugates (Anti-RON ADC) as potential biotherapeutics for targeted colorectal cancer therapy

Ming-Hai Wang; Liang Feng; H. Yao et al. · 2014 · DOI

Full title: Abstract LB-269: Anti-RON antibody-drug maytansinoid conjugates (Anti-RON ADC) as potential biotherapeutics for targeted colorectal cancer therapy

Authors: Ming-Hai Wang; Liang Feng; H. Yao; Wei Wang; Sharad K Sharma; Ruiwen Zhang

Year: 2014

DOI: https://doi.org/10.1158/1538-7445.am2014-lb-269

Paper Abstract 5425: An anti-Ephrin-A4 calicheamicin conjugate effectively targets triple-negative breast and ovarian tumor-initiating cells to result in sustained tumor regression

M. Damelin; A. Bankovich; Albert Park et al. · 2015 · DOI

Full title: Abstract 5425: An anti-Ephrin-A4 calicheamicin conjugate effectively targets triple-negative breast and ovarian tumor-initiating cells to result in sustained tumor regression

Authors: M. Damelin; A. Bankovich; Albert Park; Jorge L. Aguilar; Wade C. Anderson; Marianne T Santaguida; Sarah Fong; M. Aujay; K. Khandke; V. Pulito; Elana Ernstoff; P. Escarpe; J. Bernstein; Marybeth Pysz; Wenyan Zhong; E. Upeslacis; J. Lucas; Justin Lucas; T. Nichols; Kathryn Loving; O. Foord; J. Hampl; R. Stull; F. Barletta; Hadi Falahatpisheh; P. Sapra; H. Gerber; S. Dylla

Year: 2015

DOI: https://doi.org/10.1158/1538-7445.am2015-5425

Paper Abstract 5337: Anin silicoplatform for characterizing ADC bystander effects

Jackson K. Burton; S. Teng; C. Zopf et al. · 2015 · DOI

Full title: Abstract 5337: Anin silicoplatform for characterizing ADC bystander effects

Authors: Jackson K. Burton; S. Teng; C. Zopf; R. Nolan; A. Chakravarty

Year: 2015

DOI: https://doi.org/10.1158/1538-7445.am2015-5337

Paper Abstract 661: Proteomics and selecting the right combination of target and toxin for antibody-drug-conjugate (ADC) development

J. Terrett; R. Dusek; D. Aud et al. · 2014 · DOI

Full title: Abstract 661: Proteomics and selecting the right combination of target and toxin for antibody-drug-conjugate (ADC) development

Authors: J. Terrett; R. Dusek; D. Aud; Rahel Awdew; S. Swaminathan; San Lin Lou; M. Trang; Arnima Bisht; M. Do; J. Ackroyd; R. Boyd; L. Hudson; P. H. Pham; Nickolas Attanasio; Ami Antani; C. Lynch; C. Rohlff

Year: 2014

DOI: https://doi.org/10.1158/1538-7445.am2014-661

Paper Abstract 5819: An anti-TROP2-CPT113 ADC, exhibits potent targeted antitumor activity and favorable pharmacokinetic properties

Huihui Guo; Xiangfei Kong; Yong Du et al. · 2024 · Cancer Research · DOI

Full title: Abstract 5819: An anti-TROP2-CPT113 ADC, exhibits potent targeted antitumor activity and favorable pharmacokinetic properties

Authors: Huihui Guo; Xiangfei Kong; Yong Du; Zhicang Ye; Yongxiang Chen; Zhixiang Guo; Lingli Zhang; Lu Bai; Junxiang Jia; Yunxia Zheng; Wei Zheng; Jun Zheng; Wenjun Li; Yuanyuan Huang; Zhongliang Fan; Mengmeng Liu; Binbin Chen; Meng Dai; Juan Wang; Miaomiao Chen; Qingliang Yang; R. Zhao

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-5819

Paper Abstract 3147: DXC025, a novel anti-MUC1/EGFR bispecific antibody-tubulysin conjugate with a function linker, exhibits potent anti-tumor efficacy

Xingyan Jiang; Junxiang Jia; Huihui Guo et al. · 2024 · Cancer Research · DOI

Full title: Abstract 3147: DXC025, a novel anti-MUC1/EGFR bispecific antibody-tubulysin conjugate with a function linker, exhibits potent anti-tumor efficacy

Authors: Xingyan Jiang; Junxiang Jia; Huihui Guo; Xiangfei Kong; Yongfang Xu; Sishi Ye; Yong Du; Zhicang Ye; Qikuang Cen; Lingli Zhang; Yongxiang Chen; Gaituo Chen; Lu Bai; Yunxia Zheng; Wei Zheng; Jun Zheng; Juan Wang; Wenjun Li; Yuanyuan Huang; Linyao Zhao; Yifang Xu; Mengmeng Liu; Binbin Chen; Meng Dai; Miaomiao Chen; Zhixiang Guo; Qingliang Yang; R. Zhao

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-3147

Paper Abstract 5805: A novel platform of diversified payloads to drive ADC innovation

Paolo Orsini; Matteo Salsa; Simona Rizzi et al. · 2024 · Cancer Research · DOI

Full title: Abstract 5805: A novel platform of diversified payloads to drive ADC innovation

Authors: Paolo Orsini; Matteo Salsa; Simona Rizzi; U. Cucchi; Daniela Faiardi; Alessia Burocchi; A. Ciavolella; R. Lupi; F. Gasparri; B. Valsasina

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-5805

Paper Abstract 7179: OBI-992, a novel TROP2 targeting antibody drug conjugate demonstrates superior in vivo PK/PD properties and a favorable safety profile

Chi-Sheng Shia; Shih-Ni Wen; R. Hsu et al. · 2024 · Cancer Research · DOI

Full title: Abstract 7179: OBI-992, a novel TROP2 targeting antibody drug conjugate demonstrates superior in vivo PK/PD properties and a favorable safety profile

Authors: Chi-Sheng Shia; Shih-Ni Wen; R. Hsu; Jyy-Shiuan Tu; Hui-Wen Chang; Wan-Fen Li; Ming-Tain Lai

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-7179

Paper Abstract 5733: Development of a topoisomerase 1 inhibitor platform technology for efficacious and well tolerated ADCs

Ryan Lyski; Lauren Bou; J. Sigurjonsson et al. · 2024 · Cancer Research · DOI

Full title: Abstract 5733: Development of a topoisomerase 1 inhibitor platform technology for efficacious and well tolerated ADCs

Authors: Ryan Lyski; Lauren Bou; J. Sigurjonsson; David J. Meyer; Calvin Neace; David Ortiz; Katie M Snead; Kaleb Smith; Steven Jin; Nicole Stevens; Julia H Cochran; Kaveh Alizadeh; Narayana Yeddula; Erica E McKinney; Adam Peterson; Lindsay Dotloe; Jessica Simmons; Chris Carosino; Kim K. Emmerton; Nancy Everds; S. Jeffrey; P. Senter

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-5733

Paper Abstract 5814: EPriL macrocycles as a platform for the rapid generation of effective kinase degrader antibody conjugates (DACs)

J. C. Uitdehaag; Jos e Man; Michelle Muller et al. · 2024 · Cancer Research · DOI

Full title: Abstract 5814: EPriL macrocycles as a platform for the rapid generation of effective kinase degrader antibody conjugates (DACs)

Authors: J. C. Uitdehaag; Jos e Man; Michelle Muller; Freek an Cauter; Sander an Gemert; Milan J. Hoffmann; Yvonne G. an Mil; W. R. Mulder; M. Prinsen; J. G. Sterrenburg; D. Vu; Joeri e Wit; E. Ensing; R. Buijsman

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-5814

Paper Abstract 731: pHLIP targeted intracellular delivery of calicheamicin

Michael Dupont; Craig Klumpp; Marissa Iraca et al. · 2024 · Cancer Research · DOI

Full title: Abstract 731: pHLIP targeted intracellular delivery of calicheamicin

Authors: Michael Dupont; Craig Klumpp; Marissa Iraca; Dana Allababidi; Hannah Visca; Donald Engelman; Oleg Andreev; A. Moshnikova; Y. Reshetnyak

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-731

Paper Abstract 4689: 4HF CancerDataMiner platform accelerates target discovery and evaluation

Heinz-Herbert Fiebig; Anne-Lise Peille; Mirko Schmitz et al. · 2024 · Cancer Research · DOI

Full title: Abstract 4689: 4HF CancerDataMiner platform accelerates target discovery and evaluation

Authors: Heinz-Herbert Fiebig; Anne-Lise Peille; Mirko Schmitz; V. Vuaroqueaux; Thomas Metz

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-4689

Paper Abstract 6344: Engineering of ICAM-1 refractory antibodies for the development of therapeutic antibodies and antibody drug conjugates (ADCs) in ICAM-1 over-expressing cancers

Brad Kline; L. Grasso; Nicolas Nicolaides · 2024 · Cancer Research · DOI

Full title: Abstract 6344: Engineering of ICAM-1 refractory antibodies for the development of therapeutic antibodies and antibody drug conjugates (ADCs) in ICAM-1 over-expressing cancers

Authors: Brad Kline; L. Grasso; Nicolas Nicolaides

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-6344

Paper Abstract 5083: Discovery of an asymmetric IgG-like bispecific ADC targeting EGFR/HER3

Liandi Chen; Shaogang Peng; Chao Wang et al. · 2024 · Cancer Research · DOI

Full title: Abstract 5083: Discovery of an asymmetric IgG-like bispecific ADC targeting EGFR/HER3

Authors: Liandi Chen; Shaogang Peng; Chao Wang; Xiaoniu Miao; Yao Yan; Jun Xing; Weifeng Huang; Andy Tsun; Yingda Xu; Xiaolin Liu; Yi-Long Luo

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-5083

Paper Abstract 718: CCR8 antibody drug conjugates: Targeting regulatory T cells for tumor sensitization

Lewis J. Stafford; Hayley Roth; Sarah Campbell et al. · 2024 · Cancer Research · DOI

Full title: Abstract 718: CCR8 antibody drug conjugates: Targeting regulatory T cells for tumor sensitization

Authors: Lewis J. Stafford; Hayley Roth; Sarah Campbell; Samantha Brady; Valerie Fiers; Feifan Yu; Andrew Tsourkas; Riley Payne; M. Pitts; Kyle Guldner; Tim Phillips; B. Tyrell; Colleen Ulke; Allison Snyder; Marianne Assogba; Holden Ohl; Ileine Sanchez; B. Doranz; Joseph B. Rucker; Ross Chambers

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-718

Paper Abstract 7215: Nectin-4 targeted therapy with MMAE protodrug results in anti-tumor efficacy mediated by click chemistry

G. Coricor; J. McFarland; S. Srinivasan et al. · 2024 · Cancer Research · DOI

Full title: Abstract 7215: Nectin-4 targeted therapy with MMAE protodrug results in anti-tumor efficacy mediated by click chemistry

Authors: G. Coricor; J. McFarland; S. Srinivasan; S. Wagner; N. Yee; Tri-Hung Nguyen; J. M. Mejía Oneto

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-7215

Paper Abstract CT077: An open-label phase 1 study to investigate SGN-CEACAM5C in adults with advanced solid tumors (SGNCEA5C-001, Trial in Progress)

Funda Meric-Bernstam; Cesar A Perez; N. Lakhani et al. · 2024 · Cancer Research · DOI

Full title: Abstract CT077: An open-label phase 1 study to investigate SGN-CEACAM5C in adults with advanced solid tumors (SGNCEA5C-001, Trial in Progress)

Authors: Funda Meric-Bernstam; Cesar A Perez; N. Lakhani; Meredith S. Pelster; J. Call; Suzanne McGoldrick; Tianhua Wang; Brigitte Demers; A. Patnaik

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-ct077

Paper Abstract 6734: Preclinical impact of pretreatment with CRS mitigation agents on pharmacodynamic response to TAK-500, a systemically delivered CCR2-targeted STING agonist iADC

Emily Rosentrater; M. Ganno; Tiquella Hatten et al. · 2024 · Cancer Research · DOI

Full title: Abstract 6734: Preclinical impact of pretreatment with CRS mitigation agents on pharmacodynamic response to TAK-500, a systemically delivered CCR2-targeted STING agonist iADC

Authors: Emily Rosentrater; M. Ganno; Tiquella Hatten; Henry Mack; A. Bollampalli; Dong Mei Zhang; Alexander Parent; Jeffrey Raizer; Richard C Gregory; N. Lineberry; Vicky A. Appleman

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-6734

Paper - **DOI:** 10.1158/1538-7445.am2024-lb127 - **Authors:** Yifu Zhang, Chengzhang Shang, Chaoshe Guo, Yi Yang - **Year:** 2024 - **Journal:** Cancer Research

Yifu Zhang; Chengzhang Shang; Chaoshe Guo et al. · 2024 · Cancer Research · DOI

Full title: - **DOI:** 10.1158/1538-7445.am2024-lb127 - **Authors:** Yifu Zhang, Chengzhang Shang, Chaoshe Guo, Yi Yang - **Year:** 2024 - **Journal:** Cancer Research

Authors: Yifu Zhang; Chengzhang Shang; Chaoshe Guo; Yi Yang

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-lb127

Paper Abstract 7183: Liver toxicity of amanitin-based antibody drug conjugates (ATACs) is caused by unspecific uptake of the ATAC into liver cells

Christian Orlik; K. Decker; Marija Vranic et al. · 2024 · Cancer Research · DOI

Full title: Abstract 7183: Liver toxicity of amanitin-based antibody drug conjugates (ATACs) is caused by unspecific uptake of the ATAC into liver cells

Authors: Christian Orlik; K. Decker; Marija Vranic; Marisa Schmitt; Andreas Pahl; Michael Kulke; Torsten Hechler

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-7183

Paper Abstract LB058: N-glycan deglycosylation ameliorates anti-HER2 antibody drug conjugate-induced interstitial pneumonia in preclinical models

Yuxuan Yang; Le-Tao Ma; Peng Guo · 2024 · Cancer Research · DOI

Full title: Abstract LB058: N-glycan deglycosylation ameliorates anti-HER2 antibody drug conjugate-induced interstitial pneumonia in preclinical models

Authors: Yuxuan Yang; Le-Tao Ma; Peng Guo

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-lb058

Paper Abstract 6352: Preclinical discovery of ARX622: A site-specific, TLR7 agonist, HER2-targeted immune-stimulatory antibody drug conjugate for treatment of multiple solid tumor types

David Mills; Ji Young Kim; Erica Wood et al. · 2024 · Cancer Research · DOI

Full title: Abstract 6352: Preclinical discovery of ARX622: A site-specific, TLR7 agonist, HER2-targeted immune-stimulatory antibody drug conjugate for treatment of multiple solid tumor types

Authors: David Mills; Ji Young Kim; Erica Wood; K. Tatsukawa; Nick A Knudsen; Jay D Nelson; Lillian K Skidmore; Kedar Gc; Hon Tran; Manoj Pal; H. Hashemi; Ying J Buechler; S. Zhang; Dan O'Connor

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-6352

Paper Abstract CT084: A phase 1 study of LY4101174 (ETx-22), an antibody-drug conjugate targeting nectin-4, in patients with advanced or metastatic urothelial cancer and other solid tumors (trial in progress)

J. Rosenberg; R. Sabatier; Armelle Viceneux et al. · 2024 · Cancer Research · DOI

Full title: Abstract CT084: A phase 1 study of LY4101174 (ETx-22), an antibody-drug conjugate targeting nectin-4, in patients with advanced or metastatic urothelial cancer and other solid tumors (trial in progress)

Authors: J. Rosenberg; R. Sabatier; Armelle Viceneux; T. D. M. Rouge; S. Champiat; L. Lebellec; P. Barthélémy; Guru P Sonpavde; Xin Gao; Scot A. Niglio; Tian Zhang; C. Gedye; M. Galsky; Matthew I. Milowsky; M. Reimers; A. Weickhardt; E. Grande; D. Castellano; M. Bilen; A. Patnaik; R. Zerbib; M. Balbas; Xiaojian Xu; Kaitlyn Aptaker; A. Balar; A. Awada

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-ct084

Paper Abstract 1554: Harnessing the Beacon® optofluidic platform for streamlined discovery of internalizing antibodies

Brittany Benlian; Leqian Liu; Alexander Mastroianni et al. · 2025 · Cancer Research · DOI

Full title: Abstract 1554: Harnessing the Beacon® optofluidic platform for streamlined discovery of internalizing antibodies

Authors: Brittany Benlian; Leqian Liu; Alexander Mastroianni; Minha Park; Vincent Pai; Alireza Salmanzadeh

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-1554

Paper Abstract LB448: VBC103: An innovative Trop2/Nectin4 targeted bispecific antibody drug conjugate (ADC) in bladder urothelial carcinoma (UC), triple-negative breast cancer (TNBC) and beyond

Wei Wang; Jing Li; Lingyu Guan et al. · 2024 · Cancer Research · DOI

Full title: Abstract LB448: VBC103: An innovative Trop2/Nectin4 targeted bispecific antibody drug conjugate (ADC) in bladder urothelial carcinoma (UC), triple-negative breast cancer (TNBC) and beyond

Authors: Wei Wang; Jing Li; Lingyu Guan; Man Xu; Qun Yin

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-lb448

Paper Abstract 1565: Design and development of biparatopic antibody-drug conjugates against protein tyrosine kinase 7

Luying Yang; Vincent Fung; Alex M L Wu et al. · 2025 · Cancer Research · DOI

Full title: Abstract 1565: Design and development of biparatopic antibody-drug conjugates against protein tyrosine kinase 7

Authors: Luying Yang; Vincent Fung; Alex M L Wu; Dunja Urosev; Saki Konomura; Tik Nga Tong; Katina Mak; Elizabeth M. Porter; Diego A. Alonzo; Catrina Kim; Janice P. Tsui; Linglan Fu; L. Degefie; Kaylee J Wu; Matthew Bonderud; Jamie R Rich; Stuart D Barnscher

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-1565

Paper Abstract LB025: CKD-703, a novel antibody-drug conjugate targeting cMET with an enhanced therapeutic index in solid tumors

Kwanwoo Lee; Sue-Youn Kim; Hye-Jin Hong et al. · 2024 · Cancer Research · DOI

Full title: Abstract LB025: CKD-703, a novel antibody-drug conjugate targeting cMET with an enhanced therapeutic index in solid tumors

Authors: Kwanwoo Lee; Sue-Youn Kim; Hye-Jin Hong; Eunjeong Park; Jungok Park; Seong-Ho Hong; Daekwon Bae; Nina Ha; Sohn-Ji Yeon; Inchang Hwang; Semi Kim; Yoonseok Lee; Ju-Hee Lee

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-lb025

Paper Abstract 743: Using a novel NextGen linker system to generate a conditionally active biologic (CAB) anti-nectin4-ADC demonstrates improved efficacy in pancreatic PDX cancer models and improved tolerability and toxicity profile in non-human primates

Jing Wang; Jian Chen; G. Frey et al. · 2024 · Cancer Research · DOI

Full title: Abstract 743: Using a novel NextGen linker system to generate a conditionally active biologic (CAB) anti-nectin4-ADC demonstrates improved efficacy in pancreatic PDX cancer models and improved tolerability and toxicity profile in non-human primates

Authors: Jing Wang; Jian Chen; G. Frey; Haizhen Liu; Charles Xing; Kathryn Woodard; H. Chang; William J Boyle; Jay M Short

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-743

Paper Abstract 1159: Preclinical characterization of a novel STEAP1 antibody-drug conjugate ADRX-0405 for the treatment of mCRPC

Maria Shahmoradgoli; Andrew M. Hau; Oscar Betancourt et al. · 2025 · Cancer Research · DOI

Full title: Abstract 1159: Preclinical characterization of a novel STEAP1 antibody-drug conjugate ADRX-0405 for the treatment of mCRPC

Authors: Maria Shahmoradgoli; Andrew M. Hau; Oscar Betancourt; Felipe Acosta; Sam Janssen; Paul Datta; Anna Y. Wang; Peter P. Challita; Kris Zhang; Mario M. Kuo; Albert Goldson; Erin Nye; Alexis Mahloch; Maojun Guo; Alexander Chu-Kung; Dong Jun Lee; Hui Li; Sabine Rottmann; P. Challita-Eid

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-1159

Paper Abstract CT179: Safety and efficacy of JSKN003 in patients with advanced/metastatic solid tumors: A first-in-human, dose-escalation, multicenter, open-label, phase I study

Claire Beecroft; Bo Gao; John J. Park et al. · 2024 · Cancer Research · DOI

Full title: Abstract CT179: Safety and efficacy of JSKN003 in patients with advanced/metastatic solid tumors: A first-in-human, dose-escalation, multicenter, open-label, phase I study

Authors: Claire Beecroft; Bo Gao; John J. Park; K. Wilkinson; Karl Zhang; Xiangyun Yan; Yuan Lv

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-ct179

Paper Abstract 1230: High throughput quantitative molecular characterization of cytotoxic antibody-drug conjugates in spheroid models for improved functional characterization, screening and candidate selection

Meghan F Hogan; Andrea Hernández Rojas; A. Sagoe-Wagner et al. · 2025 · Cancer Research · DOI

Full title: Abstract 1230: High throughput quantitative molecular characterization of cytotoxic antibody-drug conjugates in spheroid models for improved functional characterization, screening and candidate selection

Authors: Meghan F Hogan; Andrea Hernández Rojas; A. Sagoe-Wagner; Jodi Wong; Sarah Church; Brigitte Lovell; Sergio Hernandez; L. Chandramohan; A. Juncker-Jensen; Kirsteen Maclean

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-1230

Paper Abstract CT174: A phase 1 study of JBH492, an anti C-C chemokine receptor 7 antibody-drug conjugate (anti-CCR7 ADC), assessing safety and efficacy in lymphoid malignancies

P. Abrisqueta; Reinhard Marks; I. Avivi et al. · 2024 · Cancer Research · DOI

Full title: Abstract CT174: A phase 1 study of JBH492, an anti C-C chemokine receptor 7 antibody-drug conjugate (anti-CCR7 ADC), assessing safety and efficacy in lymphoid malignancies

Authors: P. Abrisqueta; Reinhard Marks; I. Avivi; M. Wermke; Francesca Lim; Tae Min Kim; Alba Cabirta Touzón; Kristiina Karihtala; S. Makita; Lillian Werner; Chiaki Tanaka; Anhthu Dang; A. Chaudhury; Seth Rice; Rowshan Chowdhury; Deborah A. Knee; Belén Gomezcarrillo; Elissa Furutani; Koji Izutsu; S. Leppä

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-ct174

Paper Abstract 1567: GLR1059, next-generation nectin-4-targeted ADC with a novel mechanism-of-action payload, demonstrated significantly potent anti-tumor efficacy and reduced toxicity in preclinical evaluation

Jiao Jiao; Yingjie Sun; Jiaxing Wang et al. · 2025 · Cancer Research · DOI

Full title: Abstract 1567: GLR1059, next-generation nectin-4-targeted ADC with a novel mechanism-of-action payload, demonstrated significantly potent anti-tumor efficacy and reduced toxicity in preclinical evaluation

Authors: Jiao Jiao; Yingjie Sun; Jiaxing Wang; Liming Che; Menghan Cui; Wenjie Shao; Hairui Yuan; Yan Huang; Nannan Zhai; Yuling Tang; Xiaomei Zheng; Siyao Li

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-1567

Paper Abstract 1578: Preclinical evaluation of BLB-101, a topoisomerase-inhibitor-based anti-CLDN6/9 antibody-drug conjugate featuring a proprietary hydrophilic linker

Suk Lee; Alice Juang; Aastha Jain et al. · 2025 · Cancer Research · DOI

Full title: Abstract 1578: Preclinical evaluation of BLB-101, a topoisomerase-inhibitor-based anti-CLDN6/9 antibody-drug conjugate featuring a proprietary hydrophilic linker

Authors: Suk Lee; Alice Juang; Aastha Jain; Jun Liu; Wen Zhang; Zuoan Yi; Darren Buchwald; Alice Chen

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-1578

Paper Abstract 1158: Preclinical characterization of AZD0516, a novel STEAP2 antibody-drug conjugate (ADC) for the treatment of prostate cancer

Darlene Monlish; Vanessa M. Muniz-Medina; Mel Ehudin et al. · 2025 · Cancer Research · DOI

Full title: Abstract 1158: Preclinical characterization of AZD0516, a novel STEAP2 antibody-drug conjugate (ADC) for the treatment of prostate cancer

Authors: Darlene Monlish; Vanessa M. Muniz-Medina; Mel Ehudin; Dewald van Dyk; Claire Myers; Rachel Lawrence; Liang Zhang; Linda Irons; C. Stavraka; W. Qureshi; Ruoyan Chen; Asurayya Worrede; Nicolas Giraldo; Miljenka Vuko; Melody Handali; Ali Saleh; B. Vijayakrishnan; Maximillian Lee; Jeong Min Han; Crystal Cheung; Ariel Endlich-Frazier; Amber Lee; Mark Hutchinson; Andrew Dippel; Gilad Kaplan; Keith Rickert; Shraddha Kale; Ryan Fleming; Clare Hoover; Benedicte Recolin; Jan Zaucha; Sreedevi Kesavan; John H Meekin; Aida Mariani; Christian Eisen; John Bullen; E. Gangl; Jay Harper; A. Maderna; E. Rosfjord; F. Comer; Elaine Hurt; Neil Gibson; P. Sapra

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-1158

Paper Abstract 1164: SOT106, a novel best-in-class antibody-drug conjugate targeting LRRC15, to treat sarcomas and other advanced solid cancers

M. Fojtu; Iva Valentová; Eliška Kohelová et al. · 2025 · Cancer Research · DOI

Full title: Abstract 1164: SOT106, a novel best-in-class antibody-drug conjugate targeting LRRC15, to treat sarcomas and other advanced solid cancers

Authors: M. Fojtu; Iva Valentová; Eliška Kohelová; Tomáš Zimmermann; Šárka Stehlíková; I. Adkins; Nataliia Kalynovska; L. P. Jelínková; Filip Jabůrek; Ann Ranger; U. Moebius; M. Steegmaier; A. Jensen-Smith; R. Spisek

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-1164

Paper Abstract 1716: Acquired cell adhesion molecule 1 (CADM1) ADC resistance model for optimizing payload efficacy and toxicity in osteosarcoma preclinical testing

Zhong-Fa Zhang; Wendong Zhang; Xin Zhou et al. · 2025 · Cancer Research · DOI

Full title: Abstract 1716: Acquired cell adhesion molecule 1 (CADM1) ADC resistance model for optimizing payload efficacy and toxicity in osteosarcoma preclinical testing

Authors: Zhong-Fa Zhang; Wendong Zhang; Xin Zhou; Caterina Longo; Yifei Wang; Dongxue Mao; Yanhua Yi; Zhaohui Xu; Zhao Li; Simon Olivares; Sylvester Jusu; Harjeet Singh; Michael E. Roth; J. Gill; B. Al-Lazikani; R. Gorlick

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-1716

Paper Abstract 1587: A novel dual-payload HER3-directed antibody-drug conjugate, shows potent antitumor efficacy in HER3-low in vivo tumor models

Yonghao Zhao; Pengfei Ren; Menglong Guan et al. · 2025 · Cancer Research · DOI

Full title: Abstract 1587: A novel dual-payload HER3-directed antibody-drug conjugate, shows potent antitumor efficacy in HER3-low in vivo tumor models

Authors: Yonghao Zhao; Pengfei Ren; Menglong Guan; Jiao Tang; Lu Qi; Xinzou Fan; Shijun Yin; Gang Lei; Xiao Ke

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-1587

Paper Abstract 1799: Harnessing the GlycOBI® enabling technologies: next-generation site-specific glycan ADCs with versatile DAR to enhance therapeutic index

Teng-Yi Huang; Ka-Shu Fung; Yu-Chao Huang et al. · 2025 · Cancer Research · DOI

Full title: Abstract 1799: Harnessing the GlycOBI® enabling technologies: next-generation site-specific glycan ADCs with versatile DAR to enhance therapeutic index

Authors: Teng-Yi Huang; Ka-Shu Fung; Yu-Chao Huang; Chi-Sheng Shia; Chi-Huan Lu; Nan-Hsuan Wang; Ya-Chi Chen; Ming-Tain Lai

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-1799

Paper Abstract 1576: RenBiologics- a fully human antibody library generated by RenMice facilitates the development of antibody drugs

Ting Yi; Jun Du; Yue Zhang et al. · 2025 · Cancer Research · DOI

Full title: Abstract 1576: RenBiologics- a fully human antibody library generated by RenMice facilitates the development of antibody drugs

Authors: Ting Yi; Jun Du; Yue Zhang; Yuting Hu; Shujin Zhang; Xin Ji; Yi Yang

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-1576

Paper Abstract 1761: SYNB011128: A novel bispecific peptide-drug-conjugate targeting EGFR and CAIX

Caihong Zhou; Michael Poss; Cheng Lu et al. · 2025 · Cancer Research · DOI

Full title: Abstract 1761: SYNB011128: A novel bispecific peptide-drug-conjugate targeting EGFR and CAIX

Authors: Caihong Zhou; Michael Poss; Cheng Lu; Ruochi Zhang; Yu Wang; Yuanpeng Xiong; Xin Gao; Xiao Zhang; Yan Degenhardt

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-1761

Paper Abstract 1579: PA289, a prodrug linker-payload with a novel mechanism of action for the development of antibody drug conjugates

J. Mysliwy; J. Deckert; A. Lodge et al. · 2025 · Cancer Research · DOI

Full title: Abstract 1579: PA289, a prodrug linker-payload with a novel mechanism of action for the development of antibody drug conjugates

Authors: J. Mysliwy; J. Deckert; A. Lodge; J. Thirlway; James Stephenson; Patrick Higgs; Daniel J. Williamson; Robert J Lutz

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-1579

Paper Abstract 1805: Dual-payload TME-activated ADC platform

Cheng Liu; Yuan Liu; Rui Zhang · 2025 · Cancer Research · DOI

Full title: Abstract 1805: Dual-payload TME-activated ADC platform

Authors: Cheng Liu; Yuan Liu; Rui Zhang

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-1805

Paper Abstract 1585: KH815, a novel dual-payload TROP2-directed antibody-drug conjugate, shows potent antitumor efficacy in pre-clinical tumor model

Yonghao Zhao; Pengfei Ren; Menglong Guan et al. · 2025 · Cancer Research · DOI

Full title: Abstract 1585: KH815, a novel dual-payload TROP2-directed antibody-drug conjugate, shows potent antitumor efficacy in pre-clinical tumor model

Authors: Yonghao Zhao; Pengfei Ren; Menglong Guan; Jiao Tang; Lu Qi; Xinzou Fan; Shijun Yin; Gang Lei; Xiao Ke

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-1585

Paper Abstract 1798: K-679: A novel, ultra-high-DAR antibody drug-loaded unimicelle conjugate (ADUC) enabling more effective treatment in EGFR-expressing solid tumors compared to general ADCs

Hideo Yoshida; Kenichi Suzuki; Kahori Hosono et al. · 2025 · Cancer Research · DOI

Full title: Abstract 1798: K-679: A novel, ultra-high-DAR antibody drug-loaded unimicelle conjugate (ADUC) enabling more effective treatment in EGFR-expressing solid tumors compared to general ADCs

Authors: Hideo Yoshida; Kenichi Suzuki; Kahori Hosono; Nobuhiro Fujimaki; Masaki Tamiya; Madoka Shiraishi; Hideyuki Higashi; Masato Mori

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-1798

Paper Abstract 1804: An innovative dual-payload ADC combining topoisomerase 1 inhibitor and a tubulin inhibitor efficiently overcomes drug resistance

Ailin Shan; Chun Deng; Peng Zou et al. · 2025 · Cancer Research · DOI

Full title: Abstract 1804: An innovative dual-payload ADC combining topoisomerase 1 inhibitor and a tubulin inhibitor efficiently overcomes drug resistance

Authors: Ailin Shan; Chun Deng; Peng Zou; Shuai Song; Jiaqiang Cai; Tongtong Xue

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-1804

Paper Abstract 2693: BA3361, a tumor selective, conditionally active biologic (CAB) anti-nectin4-ADC with a novel NextGen linker system enhances therapeutic efficacy in pancreatic cancer

Jing Wang; Jian Chen; G. Frey et al. · 2025 · Cancer Research · DOI

Full title: Abstract 2693: BA3361, a tumor selective, conditionally active biologic (CAB) anti-nectin4-ADC with a novel NextGen linker system enhances therapeutic efficacy in pancreatic cancer

Authors: Jing Wang; Jian Chen; G. Frey; Haizhen Liu; Cathy Y. Chang; William J Boyle; Jay M Short

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-2693

Paper Abstract 2120: A novel engineered IL-21-based immunocytokine as a therapeutic approach for tumor targeting in renal cancer

Anna Rastorgueva; Nicholas A. Maskalenko; I. Fedorov et al. · 2025 · Cancer Research · DOI

Full title: Abstract 2120: A novel engineered IL-21-based immunocytokine as a therapeutic approach for tumor targeting in renal cancer

Authors: Anna Rastorgueva; Nicholas A. Maskalenko; I. Fedorov; Ekaterina Davydova; Ashot Nazaretian; Kerry S Campbell; P. Makhov

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-2120

Paper Abstract 1793: Pre-targeting with in vivo click chemistry enables preferential drug exposure in tumors versus normal tissues

T. Biechele; M. Alečković; S. Wagner et al. · 2025 · Cancer Research · DOI

Full title: Abstract 1793: Pre-targeting with in vivo click chemistry enables preferential drug exposure in tumors versus normal tissues

Authors: T. Biechele; M. Alečković; S. Wagner; G. Coricor; S. Srinivasan; Tri-Hung Nguyen; J. McFarland; N.A. Yee; M. Zakharian; J. Oneto

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-1793

Paper Abstract 1790: Enhancing ADC efficacy through Fc-binding peptide engineered with ECM binding moiety: A versatile platform targeting various tumors and other malignancies

Dae Young Kim; Yujin Park; Dahye Sim et al. · 2025 · Cancer Research · DOI

Full title: Abstract 1790: Enhancing ADC efficacy through Fc-binding peptide engineered with ECM binding moiety: A versatile platform targeting various tumors and other malignancies

Authors: Dae Young Kim; Yujin Park; Dahye Sim; Hana Kang; Sung Min Kim; Yejin Bang; Hee Young Kang; Hoil Choi

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-1790

Paper - **DOI:** 10.1158/1538-7445.am2025-1786 - **Authors:** Ju-hyung Kang, Daekyun Lee, Seo-young Kwak, Jieon Lee - **Year:** 2025 - **Journal:** Cancer Research

Ju-hyung Kang; Daekyun Lee; Seo-young Kwak et al. · 2025 · Cancer Research · DOI

Full title: - **DOI:** 10.1158/1538-7445.am2025-1786 - **Authors:** Ju-hyung Kang, Daekyun Lee, Seo-young Kwak, Jieon Lee - **Year:** 2025 - **Journal:** Cancer Research

Authors: Ju-hyung Kang; Daekyun Lee; Seo-young Kwak; Jieon Lee

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-1786

Paper Abstract 1841: NanoGhost - A drug targeting system for treatment of solid tumors

H. Tsubery; Ziv Azoulay; Shir Weber et al. · 2025 · Cancer Research · DOI

Full title: Abstract 1841: NanoGhost - A drug targeting system for treatment of solid tumors

Authors: H. Tsubery; Ziv Azoulay; Shir Weber; Michal Lulu; Limor Matzrafi; Yonatan Malca; M. Machluf; Osnat Bohana-Kashtan

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-1841

Paper - **DOI:** 10.1158/1538-7445.am2025-2875 - **Authors:** Elin Jaensson Gyllenback, C. Millrud, Olga Ab, D. Liberg - **Year:** 2025 - **Journal:** Cancer Research

Elin Jaensson Gyllenback; C. Millrud; Olga Ab et al. · 2025 · Cancer Research · DOI

Full title: - **DOI:** 10.1158/1538-7445.am2025-2875 - **Authors:** Elin Jaensson Gyllenback, C. Millrud, Olga Ab, D. Liberg - **Year:** 2025 - **Journal:** Cancer Research

Authors: Elin Jaensson Gyllenback; C. Millrud; Olga Ab; D. Liberg

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-2875

Paper Abstract 2888: DB-1418, a bispecific antibody-drug conjugate (ADC) targeting EGFR and HER3, demonstrates superior and broad antitumor efficacy and favorable safety in preclinical models

Yun-long Zhou; Jun Yao; Rong Shi et al. · 2025 · Cancer Research · DOI

Full title: Abstract 2888: DB-1418, a bispecific antibody-drug conjugate (ADC) targeting EGFR and HER3, demonstrates superior and broad antitumor efficacy and favorable safety in preclinical models

Authors: Yun-long Zhou; Jun Yao; Rong Shi; Yang Qiu; Haiqing Hua

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-2888

Paper Abstract 2877: MRG007, a cadherin 17-targeted, glycan-linked, exatecan-based antibody-drug conjugate, demonstrated potent anti-tumor activity and a good safety profile in preclinical studies

Peng Zeng; Qi Wu; Yongjun An et al. · 2025 · Cancer Research · DOI

Full title: Abstract 2877: MRG007, a cadherin 17-targeted, glycan-linked, exatecan-based antibody-drug conjugate, demonstrated potent anti-tumor activity and a good safety profile in preclinical studies

Authors: Peng Zeng; Qi Wu; Yongjun An; Yili Feng; Yanchun Wang; Shoujia Liu; Deliang Li; Feifei Cui; Lei Fang

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-2877

Paper Abstract 2876: BR116: An antibody drug conjugate targeting CDH17 for gastrointestinal cancer therapy

Xiaobei Zhao; Jie Zhu; Zhen-Hua Wu et al. · 2025 · Cancer Research · DOI

Full title: Abstract 2876: BR116: An antibody drug conjugate targeting CDH17 for gastrointestinal cancer therapy

Authors: Xiaobei Zhao; Jie Zhu; Zhen-Hua Wu; Yiqun Li; Cindy Wu; Lei Nie; Haibin Wang; Gang Chen

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-2876

Paper Abstract 2870: Enhancing Topo1i ADC efficacy: development of homogeneous dual-payload ADCs combining Topo1i with microtubule inhibitors or PARP inhibitors

Gang Yin; Daniel Calarese; A. Yam et al. · 2025 · Cancer Research · DOI

Full title: Abstract 2870: Enhancing Topo1i ADC efficacy: development of homogeneous dual-payload ADCs combining Topo1i with microtubule inhibitors or PARP inhibitors

Authors: Gang Yin; Daniel Calarese; A. Yam; Werner Rubas; Krishna Bajjuri; Xiaofan Li; Helena Kiefei; Miao Wen; Guifen Xu; Abigail Yu; Hans-Peter Gerber

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-2870

Paper Abstract 2872: DXC018: A novel HER2 dual-payload bispecific ADC with promising potential for gastrointestinal cancers and other solid tumors

Huihui Guo; Yong Du; Yuanyuan Huang et al. · 2025 · Cancer Research · DOI

Full title: Abstract 2872: DXC018: A novel HER2 dual-payload bispecific ADC with promising potential for gastrointestinal cancers and other solid tumors

Authors: Huihui Guo; Yong Du; Yuanyuan Huang; Juan Wang; Qingliang Yang; Junxiang Jia; Jun Zheng; Hangbo Ye; Fang Du; Meng Dai; Hui Xia; Xiaoxiao Chen; Xingyan Jiang; Ziyu Zhao; Wei Liu; R. Zhao

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-2872

Paper Abstract 2955: Preclinical development of TJ101, a potent bispecific ADC targeting EGFR and B7-H3 for the treatment of solid cancers

Li Qi; Shugaku Takeda; Yangxin Zhang et al. · 2025 · Cancer Research · DOI

Full title: Abstract 2955: Preclinical development of TJ101, a potent bispecific ADC targeting EGFR and B7-H3 for the treatment of solid cancers

Authors: Li Qi; Shugaku Takeda; Yangxin Zhang; Mao Huang; Dongdong Zhou; Yanli Mao; Zhaoyuan Chen; Siyi Hu

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-2955

Paper Abstract 2874: ZW327, a novel Ly6E-targeting antibody-drug conjugate bearing a topoisomerase 1 inhibitor payload

Dunja Urosev; Saki Konomura; Michael Lee et al. · 2025 · Cancer Research · DOI

Full title: Abstract 2874: ZW327, a novel Ly6E-targeting antibody-drug conjugate bearing a topoisomerase 1 inhibitor payload

Authors: Dunja Urosev; Saki Konomura; Michael Lee; Germanna Righetto; Elizabeth M. Porter; Katina Mak; Ambroise Wu; Amos Chua; Linglan Fu; Diego A. Alonzo; Spencer Boisjoli; Edward Lau; Janice P. Tsui; Vidhi Khanna; Alex M L Wu; Devika Sim; Mark E Petersen; Jamie R Rich; Stuart D Barnscher

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-2874

Paper Abstract 2869: DXC014, a novel bispecific ADC targeting B7-H3 and PSMA, demonstrates favorable antitumor efficacy and safety profiles in preclinical evaluations

Huihui Guo; Zhicang Ye; Yuanyuan Huang et al. · 2025 · Cancer Research · DOI

Full title: Abstract 2869: DXC014, a novel bispecific ADC targeting B7-H3 and PSMA, demonstrates favorable antitumor efficacy and safety profiles in preclinical evaluations

Authors: Huihui Guo; Zhicang Ye; Yuanyuan Huang; Weibin Li; Qingliang Yang; Hangbo Ye; Junxiang Jia; Jun Zheng; Yongxiang Chen; Xiafen Wu; Yunxia Zheng; Binbin Chen; Meng Dai; Naiyan Yang; Gaituo Chen; Li Chen Chen; Xiaolei Liu; Junpeng Wang; Yi Luo; Xiaoqiang Xie; Xia Zhou; Lu Bai; Miaomiao Chen; Wenjun Li; Xiang Cai; Wei Liu; R. Zhao

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-2869

Paper Abstract 2940: Preclinical development of a next generation antibody drug conjugate (ADC) targeting CDH17 for treatment of solid tumors

Wei Lian; Qing Zong; Chun Deng et al. · 2025 · Cancer Research · DOI

Full title: Abstract 2940: Preclinical development of a next generation antibody drug conjugate (ADC) targeting CDH17 for treatment of solid tumors

Authors: Wei Lian; Qing Zong; Chun Deng; Peng Zou; Liang Xiao; Tongtong Xue; Jiaqiang Cai

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-2940

Paper Abstract 2934: Novel hydrophilic CDH17-targeting antibody-drug conjugate exhibits anti-tumor efficacy in preclinical xenograft models

Yang Ye; Yurong Qin; Xingxing Fang et al. · 2025 · Cancer Research · DOI

Full title: Abstract 2934: Novel hydrophilic CDH17-targeting antibody-drug conjugate exhibits anti-tumor efficacy in preclinical xenograft models

Authors: Yang Ye; Yurong Qin; Xingxing Fang; Xiaoya Liu; Wanting Wang; Tingting Li; Chengze Ni; Chao Chu; Mi Ye; Guojin Wu; Jianming Sun; Yue Zhao; Xiao Huang; Jordan Zhu; S. Lai; X. Kang; H. Ling

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-2934

Paper Abstract 2954: CS5007: A novel EGFR and HER3 dual-targeted antibody-drug conjugate (ADC) with potent antitumor activity in preclinical studies

Chuan Wang; Yamin Wang; Ning Zhang et al. · 2025 · Cancer Research · DOI

Full title: Abstract 2954: CS5007: A novel EGFR and HER3 dual-targeted antibody-drug conjugate (ADC) with potent antitumor activity in preclinical studies

Authors: Chuan Wang; Yamin Wang; Ning Zhang; Xinling Zhang; Yongwang Li; Yuxin Qian; Yongli Yang; Mengyao Zhu; Xuelian Liu; Yaxin Chen; Fei Ma; Yi Sun; Jianxin Yang

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-2954

Paper Abstract 3104: The mechanism of action of ADCs are dependent on Rab GTPases

Astrid Medhus; Kay Oliver Schink; A. Longva et al. · 2025 · Cancer Research · DOI

Full title: Abstract 3104: The mechanism of action of ADCs are dependent on Rab GTPases

Authors: Astrid Medhus; Kay Oliver Schink; A. Longva; O. Engebraaten; Kristian Berg; Anette Weyergang

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-3104

Paper Abstract 2878: Preclinical characterization of GLR1061, a B7H3-targeted ADC with a novel DNA topoisomerase I inhibitor, demonstrated superior bystander effect to overcome tumor heterogeneity

Jiao Jiao; Yingjie Sun; Jiaxing Wang et al. · 2025 · Cancer Research · DOI

Full title: Abstract 2878: Preclinical characterization of GLR1061, a B7H3-targeted ADC with a novel DNA topoisomerase I inhibitor, demonstrated superior bystander effect to overcome tumor heterogeneity

Authors: Jiao Jiao; Yingjie Sun; Jiaxing Wang; Menghan Cui; Siyao Li; Wenjie Shao; Hairui Yuan; Haitong Sheng

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-2878

Paper Abstract 3307: Utilizing endocytosis as a predictive biomarker for ADCs

Anette Weyergang; Astrid Medhus; Kay Oliver Schink et al. · 2025 · Cancer Research · DOI

Full title: Abstract 3307: Utilizing endocytosis as a predictive biomarker for ADCs

Authors: Anette Weyergang; Astrid Medhus; Kay Oliver Schink; Kristian Berg; O. Engebraaten

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-3307

Paper Abstract 2959: PF-08046031: A promising first-in-class antibody-drug conjugate for targeting novel tumor antigen in melanoma

Raj Giraddi; Steven Jin; Devra Olson et al. · 2025 · Cancer Research · DOI

Full title: Abstract 2959: PF-08046031: A promising first-in-class antibody-drug conjugate for targeting novel tumor antigen in melanoma

Authors: Raj Giraddi; Steven Jin; Devra Olson; Iliyana Mikell; Eliana Moskovitz; Rebecca Mazahreh; S. Sandall

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-2959

Paper - **DOI:** 10.1158/1538-7445.am2025-2884 - **Authors:** Mengyao Xu, Bo R. Rueda, David R. Spriggs, Yeku Oladapo - **Year:** 2025 - **Journal:** Cancer Research

Mengyao Xu; Bo R. Rueda; David R. Spriggs et al. · 2025 · Cancer Research · DOI

Full title: - **DOI:** 10.1158/1538-7445.am2025-2884 - **Authors:** Mengyao Xu, Bo R. Rueda, David R. Spriggs, Yeku Oladapo - **Year:** 2025 - **Journal:** Cancer Research

Authors: Mengyao Xu; Bo R. Rueda; David R. Spriggs; Yeku Oladapo

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-2884

Paper Abstract 2160: Trastuzumab deruxtecan induces immunogenic cell death, immune cell activation and -migration in viable human breast cancer slices

Nina Schulte; Misa Ikuta; Anne Mertes et al. · 2025 · Cancer Research · DOI

Full title: Abstract 2160: Trastuzumab deruxtecan induces immunogenic cell death, immune cell activation and -migration in viable human breast cancer slices

Authors: Nina Schulte; Misa Ikuta; Anne Mertes; Ivan Kanchev; Tsuneo Deguchi; Gernot Polier

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-2160

Paper Abstract 2882: Development and preclinical characterization of HER2×Trop-2 bispecific antibody-drug conjugates (bsADCs) with auristatin microtubule inhibitors

Daniel He; Greg Liang; Haixia Chen et al. · 2025 · Cancer Research · DOI

Full title: Abstract 2882: Development and preclinical characterization of HER2×Trop-2 bispecific antibody-drug conjugates (bsADCs) with auristatin microtubule inhibitors

Authors: Daniel He; Greg Liang; Haixia Chen; Mingqi Shao; Songyan Huang; Qiong Wang; Yinfei Yin; Qikuan Chen

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-2882

Paper Abstract 2966: The anti-tumor activity of a novel anti-Her2 and anti-c-Met bispecific antibody-drug conjugate

Hongyan Zhong; D. Li; Daniel Guo et al. · 2025 · Cancer Research · DOI

Full title: Abstract 2966: The anti-tumor activity of a novel anti-Her2 and anti-c-Met bispecific antibody-drug conjugate

Authors: Hongyan Zhong; D. Li; Daniel Guo; Phuong Nguyen; Ming Yang

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-2966

Paper Abstract 3132: Innovative development of IMB-201, an anti-HLA-G antibody-drug conjugate (ADC), for enhanced tumor immunotherapy

Hyeonju Kang; Inyoung Lee; Joseph Kim et al. · 2025 · Cancer Research · DOI

Full title: Abstract 3132: Innovative development of IMB-201, an anti-HLA-G antibody-drug conjugate (ADC), for enhanced tumor immunotherapy

Authors: Hyeonju Kang; Inyoung Lee; Joseph Kim; Yoojin Kim; Sung-Lyoung Kang; Yongjun Kang; H. Lee; Chun-Nan Lee; Chihye Park; Gyongsik Ha

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-3132

Paper - **DOI:** 10.1158/1538-7445.am2025-337 - **Authors:** Floris van Delft, Lianne Lelieveldt, Jasper van de Sande, Anette Sommer - **Year:** 2025 - **Journal:** Cancer Research

Floris van Delft; Lianne Lelieveldt; Jasper van de Sande et al. · 2025 · Cancer Research · DOI

Full title: - **DOI:** 10.1158/1538-7445.am2025-337 - **Authors:** Floris van Delft, Lianne Lelieveldt, Jasper van de Sande, Anette Sommer - **Year:** 2025 - **Journal:** Cancer Research

Authors: Floris van Delft; Lianne Lelieveldt; Jasper van de Sande; Anette Sommer

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-337

Paper Abstract 314: Improved tumor penetration and cytotoxic payload release with TD001, a novel PSMA-targeting ADC with optimized linker-payload composition, in PSMA-expressing CRPC CDX castrated mouse models

Daniela Impellizzieri; Elisa Storelli; Atik Balla et al. · 2025 · Cancer Research · DOI

Full title: Abstract 314: Improved tumor penetration and cytotoxic payload release with TD001, a novel PSMA-targeting ADC with optimized linker-payload composition, in PSMA-expressing CRPC CDX castrated mouse models

Authors: Daniela Impellizzieri; Elisa Storelli; Atik Balla; Simone Mosole; Cristina Dongilli; Federico Jauk; R. Frapolli; L. Morosi; M. D'Incalci; Jemila Houacine; Morris Rosenberg; Bérangère Deleglise; Esteban Cvitkovic; Carlo V. Catapano

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-314

Paper Abstract 2965: SCR-A006, an innovative and potential best-in-class EGFR/cMet bispecific antibody-drug conjugate

Yayuan Fu; Chaochao Cen; Lei Jiang et al. · 2025 · Cancer Research · DOI

Full title: Abstract 2965: SCR-A006, an innovative and potential best-in-class EGFR/cMet bispecific antibody-drug conjugate

Authors: Yayuan Fu; Chaochao Cen; Lei Jiang; Xiaohua Yan; Chuanchuan Lu; Qian Wang; Ye Hong; Renhong Tang

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-2965

Paper Abstract 3122: A novel solid tumor-tissue-penetrating platform technology: Overcoming tumor microenvironment barriers for an effective targeted delivery of therapeutic agents into solid tumors

Serry Koh; Ji-young Lee; Young Pil Jung et al. · 2025 · Cancer Research · DOI

Full title: Abstract 3122: A novel solid tumor-tissue-penetrating platform technology: Overcoming tumor microenvironment barriers for an effective targeted delivery of therapeutic agents into solid tumors

Authors: Serry Koh; Ji-young Lee; Young Pil Jung; Won-seok Choi; Min Gyu Soung

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-3122

Paper Abstract 311: Long-term tumor growth inhibition and extended survival with TD001, a novel optimized PSMA-targeting ADC, in PSMA-expressing CRPC CDX castrated mouse models

Daniela Impellizzieri; Elisa Storelli; Atik Balla et al. · 2025 · Cancer Research · DOI

Full title: Abstract 311: Long-term tumor growth inhibition and extended survival with TD001, a novel optimized PSMA-targeting ADC, in PSMA-expressing CRPC CDX castrated mouse models

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-311

Paper Abstract 351: Preclinical development of MHB009C: A novel anti-B7-H4 ADC with a potent topoisomerase I inhibitor

Liyuan Zhu; Bo Liu; Yile Chen et al. · 2025 · Cancer Research · DOI

Full title: Abstract 351: Preclinical development of MHB009C: A novel anti-B7-H4 ADC with a potent topoisomerase I inhibitor

Authors: Liyuan Zhu; Bo Liu; Yile Chen; Xiang Meng; Ao Li; Li Liu; Zhili Yao; Yan Wang; Xialian Weng; Xuefeng Zhu; Yang Liu; Shiyu Zhou; Junwei Shi; Guoqing Cao

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-351

Paper Abstract 3140: Preclinical development of YL242, a non-internalized antibody-drug conjugate (ADC) targeting soluble VEGF for treatment of solid tumors

Tongtong Xue; Wei Lian; Qing Zong et al. · 2025 · Cancer Research · DOI

Full title: Abstract 3140: Preclinical development of YL242, a non-internalized antibody-drug conjugate (ADC) targeting soluble VEGF for treatment of solid tumors

Authors: Tongtong Xue; Wei Lian; Qing Zong; Chun Deng; Qigang Liu; Peng Zou; Jiaqiang Cai

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-3140

Paper Abstract 352: Preclinical development of MHB042C: A next-generation anti-c-Met ADC conjugating VHH-Fc fusion protein with a novel topoisomerase I inhibitor

Bo Liu; Liyuan Zhu; Yile Chen et al. · 2025 · Cancer Research · DOI

Full title: Abstract 352: Preclinical development of MHB042C: A next-generation anti-c-Met ADC conjugating VHH-Fc fusion protein with a novel topoisomerase I inhibitor

Authors: Bo Liu; Liyuan Zhu; Yile Chen; Xiang Meng; Ao Li; Li Liu; Zhili Yao; Yan Wang; Xialian Weng; Xuefeng Zhu; Yang Liu; Shiyu Zhou; Junwei Shi; Guoqing Cao

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-352

Paper Abstract 315: Dose-response and tumor size at time of treatment with TD001, a novel ADC against PSMA, drive potent tumor growth inhibition in a CRPC CDX castrated mouse model

R. Frapolli; E. Bello; M. Meroni et al. · 2025 · Cancer Research · DOI

Full title: Abstract 315: Dose-response and tumor size at time of treatment with TD001, a novel ADC against PSMA, drive potent tumor growth inhibition in a CRPC CDX castrated mouse model

Authors: R. Frapolli; E. Bello; M. Meroni; Daniela Impellizzieri; Elisa Storelli; Carlo V. Catapano; L. Morosi; M. D'Incalci; Jemila Houacine; Esteban Cvitkovic

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-315

Paper Abstract 344: IBI3014, a TROP2xPD-L1 bi-specific ADC integrating ADC killing with checkpoint blockade within one molecule, exhibits promising efficacy and safety in preclinical models

Xiguang Zhang; Yanping Jin; Jinchang Lu et al. · 2025 · Cancer Research · DOI

Full title: Abstract 344: IBI3014, a TROP2xPD-L1 bi-specific ADC integrating ADC killing with checkpoint blockade within one molecule, exhibits promising efficacy and safety in preclinical models

Authors: Xiguang Zhang; Yanping Jin; Jinchang Lu; Ninghuan Li; Zhihai Wu; Ming Wu; Yan Bian; Fenggen Fu; Weiwei Wu; Shuaixiang Zhou; Huizhong Xiong

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-344

Paper Abstract 4356: OBI-902, a novel TROP2 targeted antibody-drug conjugate via GlycOBI® platform, has favorable pharmacokinetics and sustained antitumor activities in challenging solid tumors

R. Hsu; Chi-Huan Lu; Chi-Sheng Shia et al. · 2025 · Cancer Research · DOI

Full title: Abstract 4356: OBI-902, a novel TROP2 targeted antibody-drug conjugate via GlycOBI® platform, has favorable pharmacokinetics and sustained antitumor activities in challenging solid tumors

Authors: R. Hsu; Chi-Huan Lu; Chi-Sheng Shia; Hsin-Shan Wu; Lu-Tzu Chen; Jhih-Jie Yang; Jyy-Shiuan Tu; Hui-Wen Chang; Shih-Ni Wen; Ming-Tain Lai; Ya-Chi Chen

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-4356

Paper Abstract 4328: Preclinical development of SCR-A008: A CDH17-targeted ADC for gastrointestinal cancer

Guangcun Cheng; Hui Zheng; Zhiyong Yu et al. · 2025 · Cancer Research · DOI

Full title: Abstract 4328: Preclinical development of SCR-A008: A CDH17-targeted ADC for gastrointestinal cancer

Authors: Guangcun Cheng; Hui Zheng; Zhiyong Yu; Chunlei Xia; Huipeng Guo; Xiyuan Wang; Yayuan Fu; Renhong Tang

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-4328

Paper Abstract 4256: HY0001a: A novel antibody-drug conjugate (ADC) targeting CUB domain containing protein 1 (CDCP1)

Wenjun Yan; Yang Zhang; Mengyun Zhang et al. · 2025 · Cancer Research · DOI

Full title: Abstract 4256: HY0001a: A novel antibody-drug conjugate (ADC) targeting CUB domain containing protein 1 (CDCP1)

Authors: Wenjun Yan; Yang Zhang; Mengyun Zhang; Bo An; Yujing Zhang; Qing Xiong; Guifeng Chen; Ao Fu; Dan Sun; Xiaoqiang Cai; Huaqin Chen; Mingxia Geng; Haibo Wang; Chengwei Yan; Yike Yuan; Tao Wei

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-4256

Paper Abstract 4780: Engineered ICAM-1 refractory trastuzumab improves its therapeutic activity against HER2-positive cancers in native and antibody-drug conjugate (ADC) format

J. Kline; L. Grasso; N. Nicolaides · 2025 · Cancer Research · DOI

Full title: Abstract 4780: Engineered ICAM-1 refractory trastuzumab improves its therapeutic activity against HER2-positive cancers in native and antibody-drug conjugate (ADC) format

Authors: J. Kline; L. Grasso; N. Nicolaides

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-4780

Paper Abstract 353: Preclinical development of MHB048C: A novel anti-PSMA ADC with a potent topoisomerase I inhibitor

Yile Chen; Ao Li; Bo Liu et al. · 2025 · Cancer Research · DOI

Full title: Abstract 353: Preclinical development of MHB048C: A novel anti-PSMA ADC with a potent topoisomerase I inhibitor

Authors: Yile Chen; Ao Li; Bo Liu; Liyuan Zhu; Xiang Meng; Zhili Yao; Yan Wang; Xialian Weng; Xuefeng Zhu; Shiyu Zhou; Junwei Shi; Guoqing Cao

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-353

Paper Abstract 341: VBC108: a first-in-class CDH17/CLDN18.2 targeted bispecific antibody drug conjugate (ADC) to overcome tumor heterogeneity of gastrointestinal cancers (GC, PADC, CRC, etc.)

Wei Wang; Lingyu Guan; Man Xu et al. · 2025 · Cancer Research · DOI

Full title: Abstract 341: VBC108: a first-in-class CDH17/CLDN18.2 targeted bispecific antibody drug conjugate (ADC) to overcome tumor heterogeneity of gastrointestinal cancers (GC, PADC, CRC, etc.)

Authors: Wei Wang; Lingyu Guan; Man Xu; Qun Yin; Chen Dong; Jing Li

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-341

Paper Abstract 4270: Targeting CNTN4 with exatecan-based antibody-drug conjugate for the treatment of solid tumors

M. Cha; Mira Kim; Seungmin Byun et al. · 2025 · Cancer Research · DOI

Full title: Abstract 4270: Targeting CNTN4 with exatecan-based antibody-drug conjugate for the treatment of solid tumors

Authors: M. Cha; Mira Kim; Seungmin Byun; Y. Ha; Kitae Park; Bu-Nam Jeon; Hyunuk Kim; Hyunkyung Yu; Hyunjin Yoo; Soojung Moon; Gyeong-Jin Cheon; Boeun Ju; H. Park

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-4270

Paper Abstract 5451: JSKN021, an innovative site-specific dual-payload bispecific antibody drug conjugate targeting EGFR and HER3 exhibits potent preclinical activities

Ting Xu; Fan Li; Zhilong Lai et al. · 2025 · Cancer Research · DOI

Full title: Abstract 5451: JSKN021, an innovative site-specific dual-payload bispecific antibody drug conjugate targeting EGFR and HER3 exhibits potent preclinical activities

Authors: Ting Xu; Fan Li; Zhilong Lai; Rupeng Qu

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-5451

Paper Abstract 4255: Membrane interactomics (MInt) platform identifies EGFR and CDCP1 as effective co-targets for bispecific antibody drug conjugate IDP-001

Clare Malone; Anna de Regt; Chris May et al. · 2025 · Cancer Research · DOI

Full title: Abstract 4255: Membrane interactomics (MInt) platform identifies EGFR and CDCP1 as effective co-targets for bispecific antibody drug conjugate IDP-001

Authors: Clare Malone; Anna de Regt; Chris May; Lydia Vignale; Kendall Johnson; Cody Scandore; Kalee Hansen; Sohpia Romero; Hayley Ma; B. Woodruff; Ben Setter; Hengyu Xu; Carol L. Farr; Noah Dephoure; Heath Klock; Ertan Eryilmaz; Rob Oslund; Niyi Fadeyi; Pamela Holland; Scott Lesley

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-4255

Paper Abstract 5444: ImmuMab® mice enable efficient development of antibody therapeutics by unparalleled diversity across multiple formats

Yuan Li; Wenbao Wu; Yu Wei et al. · 2025 · Cancer Research · DOI

Full title: Abstract 5444: ImmuMab® mice enable efficient development of antibody therapeutics by unparalleled diversity across multiple formats

Authors: Yuan Li; Wenbao Wu; Yu Wei; Yingjun Zhao; Yu Zhang; Jiwei Zhang

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-5444

Paper - **DOI:** 10.1158/1538-7445.am2025-469 - **Authors:** Seung-hwan Jeong, Seokbong Hong, H. Yuk, Cheol Kwak - **Year:** 2025 - **Journal:** Cancer Research

Seung-hwan Jeong; Seokbong Hong; H. Yuk et al. · 2025 · Cancer Research · DOI

Full title: - **DOI:** 10.1158/1538-7445.am2025-469 - **Authors:** Seung-hwan Jeong, Seokbong Hong, H. Yuk, Cheol Kwak - **Year:** 2025 - **Journal:** Cancer Research

Authors: Seung-hwan Jeong; Seokbong Hong; H. Yuk; Cheol Kwak

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-469

Paper Abstract 5468: A novel kinase degrader antibody conjugate for the treatment of mCRPC

J. C. Uitdehaag; J. de Man; F. van Cauter et al. · 2025 · Cancer Research · DOI

Full title: Abstract 5468: A novel kinase degrader antibody conjugate for the treatment of mCRPC

Authors: J. C. Uitdehaag; J. de Man; F. van Cauter; Sander van Gemert; Y. V. van Mil; Milan J. Hoffmann; Daphne Montizaan; W. R. Mulder; Michelle Muller; M. Prinsen; J. G. Sterrenburg; D. Vu; Joeri de Wit; E. Ensing; R. Buijsman

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-5468

Paper Abstract 4778: ADCE-T02: A first-in-class topoisomerase-1 inhibitor based antibody drug conjugate against tissue factor demonstrates excellent preclinical efficacy and tolerability

Thomas T Poulsen; Yue Zhang; Jianjian Zhang et al. · 2025 · Cancer Research · DOI

Full title: Abstract 4778: ADCE-T02: A first-in-class topoisomerase-1 inhibitor based antibody drug conjugate against tissue factor demonstrates excellent preclinical efficacy and tolerability

Authors: Thomas T Poulsen; Yue Zhang; Jianjian Zhang; Huiyan Shi; Shu-Hui Liu; Xun Meng; Mette Gillberg; Dominik Mumberg

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-4778

Paper Abstract 5447: Development and preclinical evaluation of JK06, a biparatopic ADC against 5T4

Jonathan P. McNally; Binyam Z Bezabeh; Jijun Dong et al. · 2025 · Cancer Research · DOI

Full title: Abstract 5447: Development and preclinical evaluation of JK06, a biparatopic ADC against 5T4

Authors: Jonathan P. McNally; Binyam Z Bezabeh; Jijun Dong; Samuel Murphy

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-5447

Paper Abstract 4337: SYS6051, a next-generation tissue factor-targeted antibody-drug conjugates for the treatment of TF-expressing malignancies

Xiaojuan Wu; Mingyue Shen; Mo Dan et al. · 2025 · Cancer Research · DOI

Full title: Abstract 4337: SYS6051, a next-generation tissue factor-targeted antibody-drug conjugates for the treatment of TF-expressing malignancies

Authors: Xiaojuan Wu; Mingyue Shen; Mo Dan; Xiwu Hui; Bing Yao; Yanling Li; Wei Yang; Hanqian Xu; Can Yuan; Yufei Sun; Bin Kang; Yang Zhang; Linlin Xiao

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-4337

Paper Abstract 4751: CS5005: A novel SSTR2-targeted antibody-drug conjugate (ADC) with robust antitumor activity in preclinical studies

Chuan Wang; Xinling Zhang; Ning Zhang et al. · 2025 · Cancer Research · DOI

Full title: Abstract 4751: CS5005: A novel SSTR2-targeted antibody-drug conjugate (ADC) with robust antitumor activity in preclinical studies

Authors: Chuan Wang; Xinling Zhang; Ning Zhang; Yamin Wang; Yongwang Li; Xuelian Liu; Mengyao Zhu; Yuxin Qian; Yongli Yang; Jingyu Sun; Xueqin Dai; Fei Ma; Yi Sun; Jianxin Yang

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-4751

Paper Abstract 4783: Development and characterization of an antibody-drug conjugate (ADC) utilizing PB-223, a novel monoclonal antibody (mAb) specifically targeting core 2 O-glycans on human carcinomas

Kwong Y. Tsang; Massimo Fantini; A. Zaki et al. · 2025 · Cancer Research · DOI

Full title: Abstract 4783: Development and characterization of an antibody-drug conjugate (ADC) utilizing PB-223, a novel monoclonal antibody (mAb) specifically targeting core 2 O-glycans on human carcinomas

Authors: Kwong Y. Tsang; Massimo Fantini; A. Zaki; Sharon A Mavroukakis; Philip M. Arlen

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-4783

Paper Abstract 5463: AMB304: A next generation ADC with topo I inhibitor, demonstrating robust preclinical efficacy against target overexpression tumors and high tolerability in non-human primate (NHP)

Do-Hyun Nam; Yeongmun Kim; Byeongkwi Min et al. · 2025 · Cancer Research · DOI

Full title: Abstract 5463: AMB304: A next generation ADC with topo I inhibitor, demonstrating robust preclinical efficacy against target overexpression tumors and high tolerability in non-human primate (NHP)

Authors: Do-Hyun Nam; Yeongmun Kim; Byeongkwi Min; Wonsik Jung; Eunsuk Choi; J. Shin; N. Her

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-5463

Paper Abstract 5467: Therapeutic potential of antibody-drug conjugate with PARP1 selective inhibitor as a payload: A promising therapeutic approach for potent antitumor efficacy with reduced toxicity

Jina Koo; Jeong Eun Kim; Hyeon Woong Park et al. · 2025 · Cancer Research · DOI

Full title: Abstract 5467: Therapeutic potential of antibody-drug conjugate with PARP1 selective inhibitor as a payload: A promising therapeutic approach for potent antitumor efficacy with reduced toxicity

Authors: Jina Koo; Jeong Eun Kim; Hyeon Woong Park; Won Sik Lee; Myongjae Lee

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-5467

Paper Abstract 5469: Preclinical safety and efficacy of SOT109, an antibody-drug conjugate targeting cadherin 17 (CDH17) for the treatment of colorectal and other gastrointestinal tract tumors

Nataliia Kalynovska; Diana Hudecz; M. Hrdinka et al. · 2025 · Cancer Research · DOI

Full title: Abstract 5469: Preclinical safety and efficacy of SOT109, an antibody-drug conjugate targeting cadherin 17 (CDH17) for the treatment of colorectal and other gastrointestinal tract tumors

Authors: Nataliia Kalynovska; Diana Hudecz; M. Hrdinka; Ilona Prochazkova; Eliška Kohelová; L. P. Jelínková; Filip Jabůrek; Tomáš Zimmermann; Lukas Fojtik; I. Adkins; Šárka Stehlíková; A. Jensen-Smith; R. Spisek; M. Steegmaier

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-5469

Paper Abstract 5453: E-M ADC, a promising EGFR-MUC1 bispecific antibody drug conjugate, with superior anti-tumor effect in a wide range of tumors

Ziheng Liu; Le Sun; Bing Hu et al. · 2025 · Cancer Research · DOI

Full title: Abstract 5453: E-M ADC, a promising EGFR-MUC1 bispecific antibody drug conjugate, with superior anti-tumor effect in a wide range of tumors

Authors: Ziheng Liu; Le Sun; Bing Hu; Lingfeng You; Xinyu Gao; Jin Shao; Shimeng Liu; Beibei Fu; Ying Li; Manting Zhang; Dandan Xiong; Yan Liu; Guangbao Qiu; Ziwei Ren; Zhendong Xue; Yuchang Mao; Huaixin Dang; Ting Zhang; Xin Ye; Shuyu Cai; Jun Feng; Min Hu; Feng He

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-5453

Paper Abstract 639: Site specific conjugation of ARX-788, an antibody drug conjugate (ADC) targeting HER2, generates a potent and stable targeted therapeutic for multiple cancers

R. Humphreys; Jessica Kirtely; Amha Hewit et al. · 2015 · DOI

Full title: Abstract 639: Site specific conjugation of ARX-788, an antibody drug conjugate (ADC) targeting HER2, generates a potent and stable targeted therapeutic for multiple cancers

Authors: R. Humphreys; Jessica Kirtely; Amha Hewit; S. Biroc; Nick A Knudsen; Lillian K Skidmore; A. Wahl

Year: 2015

DOI: https://doi.org/10.1158/1538-7445.am2015-639

Paper Abstract 3601: Antibody-drug conjugates (ADCs) with tubulysin and PBD warheads, maintain potent in vitro cytotoxicity against multidrug-resistant tumor cells expressing P-glycoprotein (P-gp)

S. Mao; R. Fleming; Binyam Z Bezabeh et al. · 2015 · DOI

Full title: Abstract 3601: Antibody-drug conjugates (ADCs) with tubulysin and PBD warheads, maintain potent in vitro cytotoxicity against multidrug-resistant tumor cells expressing P-glycoprotein (P-gp)

Authors: S. Mao; R. Fleming; Binyam Z Bezabeh; N. Dimasi; D. Toader; Thais Cailleau; P. Howard; Changshou Gao; Bob Hollingsworth; A. Kamal; Jay Harper

Year: 2015

DOI: https://doi.org/10.1158/1538-7445.am2015-3601

Paper Abstract CT236: Advanced solid cancer therapy with a novel antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): key preclinical and clinical results

A. Starodub; A. Ocean; A. Bardia et al. · 2015 · DOI

Full title: Abstract CT236: Advanced solid cancer therapy with a novel antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): key preclinical and clinical results

Authors: A. Starodub; A. Ocean; A. Bardia; M. Guarino; W. Messersmith; J. Berlin; V. Picozzi; Sajev Thomas; G. Masters; L. Vahdat; I. Mayer; R. Moroose; J. Diamond; S. Tagawa; M. Shah; F. Wilhelm; W. Wegener; P. Maliakal; R. Sharkey; D. Goldenberg

Year: 2015

DOI: https://doi.org/10.1158/1538-7445.am2015-ct236

Paper Abstract 3836: Novel conditionally active biologic anti-Axl antibody-drug conjugate demonstrates anti-tumor efficacy and improved safety profile

Cathy Y. Chang; G. Frey; W. J. Boyle et al. · 2016 · DOI

Full title: Abstract 3836: Novel conditionally active biologic anti-Axl antibody-drug conjugate demonstrates anti-tumor efficacy and improved safety profile

Authors: Cathy Y. Chang; G. Frey; W. J. Boyle; L. Sharp; J. Short

Year: 2016

DOI: https://doi.org/10.1158/1538-7445.am2016-3836

Paper Abstract 645: Stability and efficacy comparison of site-specific and lysine-linked maytansinoid antibody-drug conjugates

Nicholas C. Yoder; Chen Bai; D. Tavares et al. · 2015 · DOI

Full title: Abstract 645: Stability and efficacy comparison of site-specific and lysine-linked maytansinoid antibody-drug conjugates

Authors: Nicholas C. Yoder; Chen Bai; D. Tavares; Wayne C. Widdison; O. Ab; K. Whiteman; Alan J. Wilhelm; E. K. Maloney; H. Erickson; T. Keating

Year: 2015

DOI: https://doi.org/10.1158/1538-7445.am2015-645

Paper - **DOI:** 10.1158/1538-7445.am2017-1820 - **Authors:** J. Teo, H. Tan, R. Huang, A. Choo - **Year:** 2017 - **Journal:** N/A

J. Teo; H. Tan; R. Huang et al. · 2017 · DOI

Full title: - **DOI:** 10.1158/1538-7445.am2017-1820 - **Authors:** J. Teo, H. Tan, R. Huang, A. Choo - **Year:** 2017 - **Journal:** N/A

Authors: J. Teo; H. Tan; R. Huang; A. Choo

Year: 2017

DOI: https://doi.org/10.1158/1538-7445.am2017-1820

Paper Abstract 2975: Development of a probody drug conjugate (PDC) targeting CD71 for the treatment of solid tumors and lymphomas

Shweta Singh; A. DuPage; A. Y. Weaver et al. · 2016 · DOI

Full title: Abstract 2975: Development of a probody drug conjugate (PDC) targeting CD71 for the treatment of solid tumors and lymphomas

Authors: Shweta Singh; A. DuPage; A. Y. Weaver; J. Sagert; Clayton White; Michael Krimm; Yuanhui Huang; L. Diep; K. Tipton; Shouchun Liu; J. Richardson; W. Kavanaugh; J. Terrett; Luc R Desnoyers

Year: 2016

DOI: https://doi.org/10.1158/1538-7445.am2016-2975

Paper Abstract 36: Novel anti-Sialyl-Tn monoclonal antibodies and antibody-drug conjugates (ADCs) demonstrate tumor specificityin vitroandin vivoantitumor efficacy

Jillian Prendergast; D. Eavarone; P. Rao et al. · 2017 · DOI

Full title: Abstract 36: Novel anti-Sialyl-Tn monoclonal antibodies and antibody-drug conjugates (ADCs) demonstrate tumor specificityin vitroandin vivoantitumor efficacy

Authors: Jillian Prendergast; D. Eavarone; P. Rao; A. Curtis; L. Shopland; Todd A. Hoffert; J. Stein; Jeff Behrens; D. Dransfield

Year: 2017

DOI: https://doi.org/10.1158/1538-7445.am2017-36

Paper Abstract 3095: The development of CPI as a novel, next-generation DNA-targeting payload for ADCs

Jennifer Kahler; Maureen M. Dougher; Jane Xu et al. · 2017 · DOI

Full title: Abstract 3095: The development of CPI as a novel, next-generation DNA-targeting payload for ADCs

Authors: Jennifer Kahler; Maureen M. Dougher; Jane Xu; M. Doroski; A. Maderna; R. Dushin; S. Thibault; M. Leal; M. Katragadda; C. J. O’Donnell; M. Sung; P. Sapra

Year: 2017

DOI: https://doi.org/10.1158/1538-7445.am2017-3095

Paper Abstract LB-222: Optimization and preclinical characterization of highly potent and stable anti-CD70 ADCs for the potential treatment of CD70 positive cancers

Lillian K Skidmore; Kari Cox; J. Kirtley et al. · 2016 · DOI

Full title: Abstract LB-222: Optimization and preclinical characterization of highly potent and stable anti-CD70 ADCs for the potential treatment of CD70 positive cancers

Authors: Lillian K Skidmore; Kari Cox; J. Kirtley; Tiep Le; Juhi Firdos; Anthony Manibusan; Shiao-Yan Fang; Andrew H. Beck; S. Bhowmik; Nick A Knudsen; Jianing Wang; Yingchaun Sun; Armando Ayala; Alyssa Powell; A. Wahl; Feng Tian; R. Humphreys

Year: 2016

DOI: https://doi.org/10.1158/1538-7445.am2016-lb-222

Paper Abstract 3111A: ADCT-401/MEDI3726, a novel pyrrolobenzodiazepine (PBD)-based antibody-drug conjugate (ADC) targeting PSMA-expressing prostate cancers

F. Zammarchi; S. Chivers; K. Havenith et al. · 2017 · DOI

Full title: Abstract 3111A: ADCT-401/MEDI3726, a novel pyrrolobenzodiazepine (PBD)-based antibody-drug conjugate (ADC) targeting PSMA-expressing prostate cancers

Authors: F. Zammarchi; S. Chivers; K. Havenith; David G. Williams; Lauren Adams; Maria Mellinas-Gomez; Simon Corbett; P. Tyrer; François D'Hooge; S. Cho; N. Dimasi; M. Hinrichs; P. Howard; J. Hartley; P. V. Berkel

Year: 2017

DOI: https://doi.org/10.1158/1538-7445.am2017-3111a

Paper Abstract 38: Target validation, antibody discovery and preclinical data supporting ADAM9 as an antibody-drug conjugate therapeutic target for solid tumors

Juniper A Scribner; B. Barat; S. Hicks et al. · 2017 · DOI

Full title: Abstract 38: Target validation, antibody discovery and preclinical data supporting ADAM9 as an antibody-drug conjugate therapeutic target for solid tumors

Authors: Juniper A Scribner; B. Barat; S. Hicks; Nicholas C. Yoder; T. Son; L. Widjaja; G. Diedrich; S. Gorlatov; J. Hooley; Ann N. Easton; Peter Lung; A. Costa; Francine Z Chen; M. Chiechi; Pam Li; M. Licea; T. Hotaling; Michael Spliedt; V. Ciccarone; Nadia Gantt; J. Tamura; Megan E Fuller; M. McShea; S. Koenig; S. Johnson; P. Moore; E. Bonvini; D. Loo

Year: 2017

DOI: https://doi.org/10.1158/1538-7445.am2017-38

Paper Abstract 3734: Pharmacokinetics of sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC) targeting Trop-2, in patients with diverse advanced solid tumors

R. Sharkey; A. Ocean; A. Starodub et al. · 2017 · DOI

Full title: Abstract 3734: Pharmacokinetics of sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC) targeting Trop-2, in patients with diverse advanced solid tumors

Authors: R. Sharkey; A. Ocean; A. Starodub; A. Bardia; M. Guarino; W. Messersmith; J. Berlin; V. Picozzi; R. Moroose; W. Wegener; P. Maliakal; S. Govindan; D. Goldenberg

Year: 2017

DOI: https://doi.org/10.1158/1538-7445.am2017-3734

Paper Abstract 67: Characterization and preclinical development of STRO-001, a novel CD74-targeting antibody-drug conjugate (ADC) for the treatment of B-cell malignancies

C. Abrahams; Xiaofan Li; V. Dealmeida et al. · 2017 · DOI

Full title: Abstract 67: Characterization and preclinical development of STRO-001, a novel CD74-targeting antibody-drug conjugate (ADC) for the treatment of B-cell malignancies

Authors: C. Abrahams; Xiaofan Li; V. Dealmeida; M. Embry; Abigail S. Yu; Stellanie Krim; H. Hoffmann; J. Zawada; Maureen Fitch Bruhns; S. Matheny; S. Bussell; T. Kline; A. Yam; R. Stafford; T. Hallam; M. Lupher; A. Molina

Year: 2017

DOI: https://doi.org/10.1158/1538-7445.am2017-67

Paper Abstract 1782: Discovery and activity of STRO-002, a novel ADC targeting folate receptor alpha for ovarian and endometrial cancer

Xiaofan Li; C. Abrahams; Sihong Zhou et al. · 2018 · Immunology · DOI

Full title: Abstract 1782: Discovery and activity of STRO-002, a novel ADC targeting folate receptor alpha for ovarian and endometrial cancer

Authors: Xiaofan Li; C. Abrahams; Sihong Zhou; Stellanie Krimm; R. Henningsen; Heather T Stephenson; J. Hanson; Mary Rose Masikat; Krishna Bajjuri; Tyler H Heibeck; Cuong Tran; Gang Yin; J. Zawada; G. Sarma; Joy J. Chen; Maureen Fitch Bruhns; W. Solis; Alexander R. Steiner; Adam Galan; T. Kline; R. Stafford; A. Yam; V. D. Almeida; M. Lupher; T. Hallam

Year: 2018

Venue: Immunology

DOI: https://doi.org/10.1158/1538-7445.am2018-1782

Paper Abstract 751: A controlled affinity-guided ADC-linker (MAGNET) technology

Nimish Gupta; Goutam Biswas; Aniruddha Sengupta et al. · 2018 · Experimental and Molecular Therapeutics · DOI

Full title: Abstract 751: A controlled affinity-guided ADC-linker (MAGNET) technology

Authors: Nimish Gupta; Goutam Biswas; Aniruddha Sengupta; Monideepa Roy; Sudip Roy; Shiladitya Sengupta

Year: 2018

Venue: Experimental and Molecular Therapeutics

DOI: https://doi.org/10.1158/1538-7445.am2018-751

Paper Abstract 51: Characterization of the mechanism of action, pharmacodynamics and preclinical safety of ADCT-402, a pyrrolobenzodiazepine (PBD) dimer-containing antibody-drug conjugate (ADC) targeting CD19-expressing hematological malignancies

F. Zammarchi; Simon Corbett; K. Havenith et al. · 2017 · DOI

Full title: Abstract 51: Characterization of the mechanism of action, pharmacodynamics and preclinical safety of ADCT-402, a pyrrolobenzodiazepine (PBD) dimer-containing antibody-drug conjugate (ADC) targeting CD19-expressing hematological malignancies

Authors: F. Zammarchi; Simon Corbett; K. Havenith; N. Janghra; K. Kiakos; T. Marafioti; David G. Williams; S. Chivers; P. Howard; J. Hartley; P. V. Berkel

Year: 2017

DOI: https://doi.org/10.1158/1538-7445.am2017-51

Paper Abstract 3912: Towards development of next-generation biparatopic ADCs using a novel linker-toxin with expanded therapeutic window

Rupert H. Davies; Stuart D Barnscher; P. Chan et al. · 2018 · Experimental and Molecular Therapeutics · DOI

Full title: Abstract 3912: Towards development of next-generation biparatopic ADCs using a novel linker-toxin with expanded therapeutic window

Authors: Rupert H. Davies; Stuart D Barnscher; P. Chan; Laurence Madera; J. Rich; M. Vallejo; G. Wickman; Kevin Yin; Vincent Fung; Kevin J. Hamblett; P. Kaminker; J. Babcook

Year: 2018

Venue: Experimental and Molecular Therapeutics

DOI: https://doi.org/10.1158/1538-7445.am2018-3912

Paper - **DOI:** 10.1158/1538-7445.am2018-745 - **Authors:** Sreedhar Reddy Suthe, H. Yao, P. Trippier, Ming-Hai Wang - **Year:** 2018 - **Journal:** Experimental and Molecular Therapeutics

Sreedhar Reddy Suthe; H. Yao; P. Trippier et al. · 2018 · Experimental and Molecular Therapeutics · DOI

Full title: - **DOI:** 10.1158/1538-7445.am2018-745 - **Authors:** Sreedhar Reddy Suthe, H. Yao, P. Trippier, Ming-Hai Wang - **Year:** 2018 - **Journal:** Experimental and Molecular Therapeutics

Authors: Sreedhar Reddy Suthe; H. Yao; P. Trippier; Ming-Hai Wang

Year: 2018

Venue: Experimental and Molecular Therapeutics

DOI: https://doi.org/10.1158/1538-7445.am2018-745

Paper - **DOI:** 10.1158/1538-7445.am2018-2780 - **Authors:** L. Cheung, K. Mohamedali, W. Hittelman, M. Rosenblum - **Year:** 2018 - **Journal:** Immunology

L. Cheung; K. Mohamedali; W. Hittelman et al. · 2018 · Immunology · DOI

Full title: - **DOI:** 10.1158/1538-7445.am2018-2780 - **Authors:** L. Cheung, K. Mohamedali, W. Hittelman, M. Rosenblum - **Year:** 2018 - **Journal:** Immunology

Authors: L. Cheung; K. Mohamedali; W. Hittelman; M. Rosenblum

Year: 2018

Venue: Immunology

DOI: https://doi.org/10.1158/1538-7445.am2018-2780

Paper Abstract 3717: α3β1-Integrin targeted DM1 micellar prodrug for targeted therapy against ovarian cancer

Xiaocen Li; W. Xiao; Yayu Wang et al. · 2018 · Cancer Chemistry · DOI

Full title: Abstract 3717: α3β1-Integrin targeted DM1 micellar prodrug for targeted therapy against ovarian cancer

Authors: Xiaocen Li; W. Xiao; Yayu Wang; Xiao Jia Chen; Ruiwu Liu; K. Lam

Year: 2018

Venue: Cancer Chemistry

DOI: https://doi.org/10.1158/1538-7445.am2018-3717

Paper Abstract 737: Antibody drug conjugates with anthracycline payload induce tumor-selective antitumor immunity and exhibit a favorable safety profile in cynomolgus monkey toxicology studies

U. Grawunder · 2018 · Experimental and Molecular Therapeutics · DOI

Full title: Abstract 737: Antibody drug conjugates with anthracycline payload induce tumor-selective antitumor immunity and exhibit a favorable safety profile in cynomolgus monkey toxicology studies

Authors: U. Grawunder

Year: 2018

Venue: Experimental and Molecular Therapeutics

DOI: https://doi.org/10.1158/1538-7445.am2018-737

Paper Abstract 757: Novel warheads for targeted therapies of cancer: The concept and design of oxime-ether-based pro-PBDs

I. Vlahov; Albert E. Felten; N. Zou et al. · 2018 · Experimental and Molecular Therapeutics · DOI

Full title: Abstract 757: Novel warheads for targeted therapies of cancer: The concept and design of oxime-ether-based pro-PBDs

Authors: I. Vlahov; Albert E. Felten; N. Zou; Kevin K. W. Wang; H. Santhapuram; Paul J. Kleindl; Spencer J. Hahn; Jeremy F. Vaughn; C. Leamon

Year: 2018

Venue: Experimental and Molecular Therapeutics

DOI: https://doi.org/10.1158/1538-7445.am2018-757

Paper Abstract 820: Preclinical development of MGC018, a duocarmycin-based antibody-drug conjugate targeting B7-H3 for solid cancer

Juniper A Scribner; Jennifer G Brown; T. Son et al. · 2017 · Experimental and Molecular Therapeutics · DOI

Full title: Abstract 820: Preclinical development of MGC018, a duocarmycin-based antibody-drug conjugate targeting B7-H3 for solid cancer

Authors: Juniper A Scribner; Jennifer G Brown; T. Son; M. Chiechi; Pam Li; Sharad K Sharma; Hua Li; Anushka De Costa; Y. Li; Yan Chen; Ann N. Easton; Nicholas C. Yee-Toy; Francine Z Chen; S. Gorlatov; B. Barat; Ling Huang; Christina Wolff; J. Hooley; T. Hotaling; Timur Gaynutdinov; V. Ciccarone; J. Tamura; S. Koenig; P. Moore; E. Bonvini; D. Loo

Year: 2017

Venue: Experimental and Molecular Therapeutics

DOI: https://doi.org/10.1158/1538-7445.am2018-820

Paper Abstract 750: Modular coiled-coil masking domains for tumor-specific antibody activation

Vivian H. Trang; Xinqun Zhang; M. M. Dominguez et al. · 2018 · Experimental and Molecular Therapeutics · DOI

Full title: Abstract 750: Modular coiled-coil masking domains for tumor-specific antibody activation

Authors: Vivian H. Trang; Xinqun Zhang; M. M. Dominguez; Weiping Zeng; Julia H Cochran; I. Stone; P. Senter; Matthew R. Levengood

Year: 2018

Venue: Experimental and Molecular Therapeutics

DOI: https://doi.org/10.1158/1538-7445.am2018-750

Paper Abstract 734: Thienoindoles: New highly promising agents for antibody-drug conjugates generation

M. Caruso; F. Gasparri; B. Valsasina et al. · 2018 · Experimental and Molecular Therapeutics · DOI

Full title: Abstract 734: Thienoindoles: New highly promising agents for antibody-drug conjugates generation

Authors: M. Caruso; F. Gasparri; B. Valsasina; C. Albanese; I. Beria; Ilaria Candiani; M. Ciomei; N. Colombo; Sabrina Cribioli; U. Cucchi; E. Felder; Ivan Fraietta; A. Galvani; A. Isacchi; A. Marsiglio; P. Orsini; R. Perego; S. Rizzi; A. Tomasi; S. Troiani; C. Visco; D. Donati

Year: 2018

Venue: Experimental and Molecular Therapeutics

DOI: https://doi.org/10.1158/1538-7445.am2018-734

Paper Abstract 2900: Evaluation of endoglin/CD105 as a tumor vasculature target with antibody drug conjugates

Rui Wu; C. Gavrilescu; Yimao Liu et al. · 2018 · Experimental and Molecular Therapeutics · DOI

Full title: Abstract 2900: Evaluation of endoglin/CD105 as a tumor vasculature target with antibody drug conjugates

Authors: Rui Wu; C. Gavrilescu; Yimao Liu; V. C. Santos; Katharine C. Lai; Luke Harris; Prerak Shah; Kerry Donahue; R. Chari; Richard Gregory; T. Chittenden; Cynthia J. Guidi; T. Keating

Year: 2018

Venue: Experimental and Molecular Therapeutics

DOI: https://doi.org/10.1158/1538-7445.am2018-2900

Paper Abstract 234: Pre-clinical characterization of 3A4-PL1601, a novel pyrrolobenzodiazepine (PBD) dimer-based antibody-drug conjugate (ADC) directed against KAAG1-expressing malignancies

F. Zammarchi; F. Bertelli; K. Havenith et al. · 2019 · Experimental and Molecular Therapeutics · DOI

Full title: Abstract 234: Pre-clinical characterization of 3A4-PL1601, a novel pyrrolobenzodiazepine (PBD) dimer-based antibody-drug conjugate (ADC) directed against KAAG1-expressing malignancies

Authors: F. Zammarchi; F. Bertelli; K. Havenith; I. Kirby; S. Chivers; P. V. Berkel

Year: 2019

Venue: Experimental and Molecular Therapeutics

DOI: https://doi.org/10.1158/1538-7445.am2019-234

Paper Abstract 755: Synthesis and evaluation of sugar alcohol based molecules for drug conjugation and delivery

Yumei Huang; Shuyan Chen; Binjie Sun et al. · 2018 · Experimental and Molecular Therapeutics · DOI

Full title: Abstract 755: Synthesis and evaluation of sugar alcohol based molecules for drug conjugation and delivery

Authors: Yumei Huang; Shuyan Chen; Binjie Sun; Amanda K K Griffin; N. Sweet; Mingqian Feng; Mitchell Ho

Year: 2018

Venue: Experimental and Molecular Therapeutics

DOI: https://doi.org/10.1158/1538-7445.am2018-755

Paper Abstract 935: Generation and preclinical characterization of CD123-CPI antibody-drug conjugate (ADC)

Yoon-Chi Han; Fan Jiang; Nicole Piché-Nicholas et al. · 2018 · Cancer Chemistry · DOI

Full title: Abstract 935: Generation and preclinical characterization of CD123-CPI antibody-drug conjugate (ADC)

Authors: Yoon-Chi Han; Fan Jiang; Nicole Piché-Nicholas; M. Katragadda; Nadira Prashad; M. Charati; Wendy Hu; M. Leal; N. Tumey; A. Maderna; R. Dushin; Kenny Sung Kyoo Kim; LuAnna Lemon; M. Damelin; H. Gerber; Lioudmila Tchistiakova; Frank Loganza; C. J. O’Donnell; P. Sapra

Year: 2018

Venue: Cancer Chemistry

DOI: https://doi.org/10.1158/1538-7445.am2018-935

Paper Abstract 231: Optimizing lysosomal activation of antibody-drug conjugates (ADCs) by incorporation of novel cleavable dipeptide linkers

Paulin L. Salomon; Luke Harris; E. E. Reid et al. · 2019 · Experimental and Molecular Therapeutics · DOI

Full title: Abstract 231: Optimizing lysosomal activation of antibody-drug conjugates (ADCs) by incorporation of novel cleavable dipeptide linkers

Authors: Paulin L. Salomon; Luke Harris; E. E. Reid; E. K. Maloney; Alan J. Wilhelm; Michael L. Miller; R. Chari; T. Keating; Rajeeva Singh

Year: 2019

Venue: Experimental and Molecular Therapeutics

DOI: https://doi.org/10.1158/1538-7445.am2019-231

Paper Abstract 1533: IMGC936, a first-in-class ADAM9-targeting antibody-drug conjugate, demonstrates promising anti-tumor activity

S. Hicks; D. Loo; K. Sinkevicius et al. · 2019 · Immunology · DOI

Full title: Abstract 1533: IMGC936, a first-in-class ADAM9-targeting antibody-drug conjugate, demonstrates promising anti-tumor activity

Authors: S. Hicks; D. Loo; K. Sinkevicius; Juniper A Scribner; B. Barat; Nicholas C. Yoder; C. Espelin; M. Themeles; Francine Z Chen; J. Lucas; Jennifer R. Brown; Bahar Matin; Megan E Fuller; Jenny Lee; Paulin L. Salomon; Juliet A. Costoplus; Sadiqa Yancey; G. Diedrich; S. Gorlatov; T. Son; M. Chiechi; Pam Li; Michael Spliedt; V. Ciccarone; J. Hooley; Nadia Gantt; J. Tamura; Kerry Donahue; P. Moore; S. Johnson; T. Chittenden; Richard Gregory; E. Bonvini

Year: 2019

Venue: Immunology

DOI: https://doi.org/10.1158/1538-7445.am2019-1533

Paper Abstract LB-275: U3-1402, a novel HER3-targeting antibody-drug conjugate, exhibits its antitumor activity through increased payload intracellular delivery via highly efficient drug internalization

K. Koyama; Hashimoto Yuuri; Y. Kamai et al. · 2019 · Experimental and Molecular Therapeutics · DOI

Full title: Abstract LB-275: U3-1402, a novel HER3-targeting antibody-drug conjugate, exhibits its antitumor activity through increased payload intracellular delivery via highly efficient drug internalization

Authors: K. Koyama; Hashimoto Yuuri; Y. Kamai; Y. Shiose; Manabu Abe; Y. Kaneda; N. Maeda; Kenji Hirotani; Y. Ogitani; Tsuyoshi Karibe; T. Kagari; K. Wakita; Suguru Ueno; T. Agatsuma; M. Murakami

Year: 2019

Venue: Experimental and Molecular Therapeutics

DOI: https://doi.org/10.1158/1538-7445.am2019-lb-275

Paper Abstract 225: TR1801-ADC, an optimized anti cMet PBD ADC with high efficacy in solid tumors of the GI tract and head & neck cancer

Marco Gymnopoulos; O. Betancourt; V. Blot et al. · 2019 · Experimental and Molecular Therapeutics · DOI

Full title: Abstract 225: TR1801-ADC, an optimized anti cMet PBD ADC with high efficacy in solid tumors of the GI tract and head & neck cancer

Authors: Marco Gymnopoulos; O. Betancourt; V. Blot; R. Fujita; Diana Ly; S. Nguyen; J. Snedden; J. Villicana; J. Wojciak; Eley Wong; Neki Patel; François D'Hooge; B. Vijayakrishnan; Conor S Barry; J. Hartley; P. Howard; R. Newman; Julia Coronella

Year: 2019

Venue: Experimental and Molecular Therapeutics

DOI: https://doi.org/10.1158/1538-7445.am2019-225

Paper Abstract CT053: BAT8001, a potent anti-HER2 antibody drug conjugate with a novel uncleavable linker to reduce toxicity for patients with HER2-positive tumor

Shusen Wang; Fei Xu; R. Hong et al. · 2019 · Clinical Trials · DOI

Full title: Abstract CT053: BAT8001, a potent anti-HER2 antibody drug conjugate with a novel uncleavable linker to reduce toxicity for patients with HER2-positive tumor

Authors: Shusen Wang; Fei Xu; R. Hong; W. Xia; Jin-Chen Yu; Weijia Tang; Jin Wei; Shu‐Lin Song; Zhaohe Wang; Li Zhang; Shengfeng Li

Year: 2019

Venue: Clinical Trials

DOI: https://doi.org/10.1158/1538-7445.am2019-ct053

Paper Abstract 2901: Gastric cancer antibody fragment drug-conjugates (FDCs): From concept to clinical development

M. Deonarain; G. Yahioglu; I. Stamati et al. · 2020 · Experimental and Molecular Therapeutics · DOI

Full title: Abstract 2901: Gastric cancer antibody fragment drug-conjugates (FDCs): From concept to clinical development

Authors: M. Deonarain; G. Yahioglu; I. Stamati; B. Edwards; S. Diez-Posada; A. Pomowski; I. Perez-Castro; Benjamin J Stenton; Laura Bouché; Ashleigh Stewart; Malcolm Ngiam; Quinn Xue

Year: 2020

Venue: Experimental and Molecular Therapeutics

DOI: https://doi.org/10.1158/1538-7445.am2020-2901

Paper Abstract LB-106: Overcoming limitations of current Antibody-Drug Conjugates (ADCs) by a novel linker technology

P. Spycher; Julia C. Frei; Jöri E. Wehrmüller et al. · 2019 · Experimental and Molecular Therapeutics · DOI

Full title: Abstract LB-106: Overcoming limitations of current Antibody-Drug Conjugates (ADCs) by a novel linker technology

Authors: P. Spycher; Julia C. Frei; Jöri E. Wehrmüller; Isabella Attinger-Toller; D. Grabulovski; Torsten Hechler; Michael Kulke; A. Pahl; M. Béhé; R. Schibli

Year: 2019

Venue: Experimental and Molecular Therapeutics

DOI: https://doi.org/10.1158/1538-7445.am2019-lb-106

Paper Abstract 4815: Novel Globo H targeting antibody-drug conjugate with binding specificity and anti-tumor efficacy in multiple cancer types

Ming-Chen Yang; Yu-Jung Chen; Chi-Sheng Shia et al. · 2019 · Experimental and Molecular Therapeutics · DOI

Full title: Abstract 4815: Novel Globo H targeting antibody-drug conjugate with binding specificity and anti-tumor efficacy in multiple cancer types

Authors: Ming-Chen Yang; Yu-Jung Chen; Chi-Sheng Shia; Hui-Wen Chang; Wan-Fen Li; C. Yu; I. Chen

Year: 2019

Venue: Experimental and Molecular Therapeutics

DOI: https://doi.org/10.1158/1538-7445.am2019-4815

Paper Abstract LB-264: Autophagy modulates intracellular dynamics of [fam-] trastuzumab deruxtecan (DS-8201a), a novel HER2 antibody-drug conjugate (HER2-ADC)

Manabu Abe; Motoko Nagata; K. Koyama et al. · 2019 · Experimental and Molecular Therapeutics · DOI

Full title: Abstract LB-264: Autophagy modulates intracellular dynamics of [fam-] trastuzumab deruxtecan (DS-8201a), a novel HER2 antibody-drug conjugate (HER2-ADC)

Authors: Manabu Abe; Motoko Nagata; K. Koyama; Satoru Yasuda; Tsuyoshi Hirata; Y. Kuwahara; K. Inaki; N. Kasanuki; Megumi Minami; K. Hagihara; K. Wakita; E. Slosberg; M. Murakami

Year: 2019

Venue: Experimental and Molecular Therapeutics

DOI: https://doi.org/10.1158/1538-7445.am2019-lb-264

Paper Abstract 2890: IMGN151 - A next generation folate receptor alpha targeting antibody drug conjugate active against tumors with low, medium and high receptor expression

O. Ab; L. Bartle; Leanne Lanieri et al. · 2020 · Experimental and Molecular Therapeutics · DOI

Full title: Abstract 2890: IMGN151 - A next generation folate receptor alpha targeting antibody drug conjugate active against tumors with low, medium and high receptor expression

Authors: O. Ab; L. Bartle; Leanne Lanieri; Jose F. Ponte; Qifeng Qiu; S. Sikka; Juliet A. Costoplus; Wayne Deats; Nicholas C. Yoder; Wayne C. Widdison; Katherine H. Mucciarone; Kate Selvitelli; Ying Chen; Neeraj Kohli; T. Chittenden; Richard Gregory; Y. Setiady; E. Westin

Year: 2020

Venue: Experimental and Molecular Therapeutics

DOI: https://doi.org/10.1158/1538-7445.am2020-2890

Paper Abstract 2889: SGN-CD30C, a new CD30-directed camptothecin antibody-drug conjugate (ADC), shows strong anti-tumor activity and superior tolerability in preclinical studies

M. Ryan; Ryan Lyski; Lauren Bou et al. · 2020 · Experimental and Molecular Therapeutics · DOI

Full title: Abstract 2889: SGN-CD30C, a new CD30-directed camptothecin antibody-drug conjugate (ADC), shows strong anti-tumor activity and superior tolerability in preclinical studies

Authors: M. Ryan; Ryan Lyski; Lauren Bou; David W Meyer; Steven Jin; J. Simmons; Dennis R. Benjamin; P. Senter; S. Jeffrey

Year: 2020

Venue: Experimental and Molecular Therapeutics

DOI: https://doi.org/10.1158/1538-7445.am2020-2889

Paper Abstract 983: Antibody-drug conjugates of NAMPT inhibitors: Discovery, optimization, and preclinical characterization

C. Neumann; K. Olivas; K. Wang et al. · 2019 · Cancer Chemistry · DOI

Full title: Abstract 983: Antibody-drug conjugates of NAMPT inhibitors: Discovery, optimization, and preclinical characterization

Authors: C. Neumann; K. Olivas; K. Wang; A. Waight; David W Meyer; Luke V. Loftus; Margo Zaval; Martha E. Anderson; Steven Jin; Julia H Cochran; J. Simmons; Paul G Pittman; Fu Li; Michelle Ulrich; Abbie Wong; Weiping Zeng; R. Lyon; P. Senter

Year: 2019

Venue: Cancer Chemistry

DOI: https://doi.org/10.1158/1538-7445.am2019-983

Paper Abstract 4054: Development of a new site-specific sulfomaleimide rebridging platform for the generation of homogeneous, stable, potent and safe antibody drug conjugates

J. Haeuw; Frédéric Marion; C. Dreyfus et al. · 2020 · Experimental and Molecular Therapeutics · DOI

Full title: Abstract 4054: Development of a new site-specific sulfomaleimide rebridging platform for the generation of homogeneous, stable, potent and safe antibody drug conjugates

Authors: J. Haeuw; Frédéric Marion; C. Dreyfus; B. Akla; L. Zanna; Marie-Claire Janin; Charlotte Beau-Larvor; M. Millet; M. Farrié; Alain Batton; C. Thuilliez; A. Beck; S. Cianférani; T. Clerc; Philippe Maillos; N. Corvaia

Year: 2020

Venue: Experimental and Molecular Therapeutics

DOI: https://doi.org/10.1158/1538-7445.am2020-4054

Paper Abstract 4821: Development of a potent Trop-2 antibody-drug conjugate, BAT8003, for the treatment of Trop-2 positive gastric tumors

Weijia Tang; Xingxing Mei; Z. Ou et al. · 2019 · Experimental and Molecular Therapeutics · DOI

Full title: Abstract 4821: Development of a potent Trop-2 antibody-drug conjugate, BAT8003, for the treatment of Trop-2 positive gastric tumors

Authors: Weijia Tang; Xingxing Mei; Z. Ou; J. Gan; Shengfeng Li; Jin-Chen Yu

Year: 2019

Venue: Experimental and Molecular Therapeutics

DOI: https://doi.org/10.1158/1538-7445.am2019-4821

Paper Abstract 921: Combination of antibody-targeted amanitin conjugates (ATAC) with immune checkpoint inhibitors shows synergistic therapeutic effectin vitroandin vivo

K. Decker; Irina Dranova; Christian Orlik et al. · 2021 · Experimental and Molecular Therapeutics · DOI

Full title: Abstract 921: Combination of antibody-targeted amanitin conjugates (ATAC) with immune checkpoint inhibitors shows synergistic therapeutic effectin vitroandin vivo

Authors: K. Decker; Irina Dranova; Christian Orlik; A. Pálfi; C. Mueller; Ram K. Singh; R. Orlowski; Torsten Hechler; A. Pahl; Michael Kulke

Year: 2021

Venue: Experimental and Molecular Therapeutics

DOI: https://doi.org/10.1158/1538-7445.am2021-921

Paper Abstract 5663: Affinity tuned XmAb®2+1 PSMA x CD3 bispecific antibodies demonstrate selective activity in prostate cancer models

Alex Nisthal; M. Dragovich; E. Pong et al. · 2020 · Immunology · DOI

Full title: Abstract 5663: Affinity tuned XmAb®2+1 PSMA x CD3 bispecific antibodies demonstrate selective activity in prostate cancer models

Authors: Alex Nisthal; M. Dragovich; E. Pong; Veronica G Zeng; Michael Hedvat; Christine Bonzon; K. Avery; R. Rashid; Connie Ardila; U. Muchhal; Gregory L Moore; S. Chu; J. Desjarlais

Year: 2020

Venue: Immunology

DOI: https://doi.org/10.1158/1538-7445.am2020-5663

Paper Abstract LB-227: Preclinical development and characterization of STI-6129, an anti-CD38 antibody-drug conjugate, as a new therapeutic agent for multiple myeloma

Lingna Li; A. Hau; Wenyong Tong et al. · 2020 · Bioinformatics, Convergence Science, and Systems Biology · DOI

Full title: Abstract LB-227: Preclinical development and characterization of STI-6129, an anti-CD38 antibody-drug conjugate, as a new therapeutic agent for multiple myeloma

Authors: Lingna Li; A. Hau; Wenyong Tong; M. Lau; Tong Zhu; Katherine Fells; A. Wei; Xiaoqing Li; D. Deng; Yingqing Sun; Ernest W Kovacs; Alisher Khasanov; Zheng Yan; Panyun Zhu; Heyue Zhou; Henry Ji; Hui Li; Hong Zhang

Year: 2020

Venue: Bioinformatics, Convergence Science, and Systems Biology

DOI: https://doi.org/10.1158/1538-7445.am2020-lb-227

Paper Abstract 3374: Development of novel and improved monoclonal antiMUC16 antibodies for the targeted therapy of ovarian cancer

Ian Laster; O. Yeku; D. Spriggs · 2020 · DOI

Full title: Abstract 3374: Development of novel and improved monoclonal antiMUC16 antibodies for the targeted therapy of ovarian cancer

Authors: Ian Laster; O. Yeku; D. Spriggs

Year: 2020

DOI: https://doi.org/10.1158/1538-7445.am2020-3374

Paper Abstract 1405: Novel ADC platform delivers promising in vivo activity and safety

Haidong Liu; Wenke Qi; Lei Wang et al. · 2022 · Cancer Research · DOI

Full title: Abstract 1405: Novel ADC platform delivers promising in vivo activity and safety

Authors: Haidong Liu; Wenke Qi; Lei Wang; Guobao Wang; Xinyue Chen; J. Gavrilyuk; Tae Han; Baiteng Zhao; Xiao-Juan Shang

Year: 2022

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2022-1405

Paper Abstract 925: Introduction to the preclinical profile of SYD1875, a novel site-specifically conjugated duocarmycin-based 5T4-targeting antibody-drug conjugate

P. Groothuis; D. Jacobs; Kim Berentsen et al. · 2021 · Experimental and Molecular Therapeutics · DOI

Full title: Abstract 925: Introduction to the preclinical profile of SYD1875, a novel site-specifically conjugated duocarmycin-based 5T4-targeting antibody-drug conjugate

Authors: P. Groothuis; D. Jacobs; Kim Berentsen; Monique van der Vleuten; Ruud G. E. Coumans; R. Elgersma; Marion Blomenrohr; Diels van den Dobbelsteen; P. Beusker; R. Ubink; M. Lee; Wim H A Dokter

Year: 2021

Venue: Experimental and Molecular Therapeutics

DOI: https://doi.org/10.1158/1538-7445.am2021-925

Paper Abstract LB-063: Phospholipid drug conjugates show specificity for a broad range of tumor cells and provides a novel approach for targeted or precision therapy

J. Longcor; M. Banach; R. Hoover · 2018 · Cancer Chemistry · DOI

Full title: Abstract LB-063: Phospholipid drug conjugates show specificity for a broad range of tumor cells and provides a novel approach for targeted or precision therapy

Authors: J. Longcor; M. Banach; R. Hoover

Year: 2018

Venue: Cancer Chemistry

DOI: https://doi.org/10.1158/1538-7445.am2018-lb-063

Paper Abstract 909: Antibody fragment drug-conjugates (FDCs)-application of ANT-043 and ANT-045 in solid tumors

M. Deonarain; G. Yahioglu; I. Stamati et al. · 2021 · Experimental and Molecular Therapeutics · DOI

Full title: Abstract 909: Antibody fragment drug-conjugates (FDCs)-application of ANT-043 and ANT-045 in solid tumors

Authors: M. Deonarain; G. Yahioglu; I. Stamati; B. Edwards; S. Diez-Posada; A. Pomowski; Ashleigh Stewart; I. Perez-Castro; Laura Bouché; Triin Jurgenson; M. Maciuszek; Sam Ness; Malcolm Ngiam; Quinn Xue

Year: 2021

Venue: Experimental and Molecular Therapeutics

DOI: https://doi.org/10.1158/1538-7445.am2021-909

Paper Abstract 3038: Evaluation of ROR1-targeted antibody-drug conjugates against ROR1-expressing pediatric preclinical models - a report from the pediatric preclinical testing consortium (PPTC)

R. Lock; K. Evans; Narimanne El-Zein et al. · 2021 · Tumor Biology · DOI

Full title: Abstract 3038: Evaluation of ROR1-targeted antibody-drug conjugates against ROR1-expressing pediatric preclinical models - a report from the pediatric preclinical testing consortium (PPTC)

Authors: R. Lock; K. Evans; Narimanne El-Zein; B. Lannutti; Katti A. Jessen; E. Earley; S. Erickson; Malcolm A. Smith; R. Kurmasheva; P. Houghton

Year: 2021

Venue: Tumor Biology

DOI: https://doi.org/10.1158/1538-7445.am2021-3038

Paper Abstract 1873: GlycoConnect™ ADCs based on topoisomerase 1 inhibitor exatecan (SYNtecan E™) show excellent in vivo efficacy and tolerability

F. L. Delft · 2021 · Immunology · DOI

Full title: Abstract 1873: GlycoConnect™ ADCs based on topoisomerase 1 inhibitor exatecan (SYNtecan E™) show excellent in vivo efficacy and tolerability

Authors: F. L. Delft

Year: 2021

Venue: Immunology

DOI: https://doi.org/10.1158/1538-7445.am2021-1873

Paper Abstract 1760: The antibody-drug conjugate GENA-111 conjugated to auristatin F shows therapeutic potency in BCAM positive epithelial cancer

Hyunkyung Yu; N. Bellocq; Y. Ha et al. · 2022 · Cancer Research · DOI

Full title: Abstract 1760: The antibody-drug conjugate GENA-111 conjugated to auristatin F shows therapeutic potency in BCAM positive epithelial cancer

Authors: Hyunkyung Yu; N. Bellocq; Y. Ha; Hyunuk Kim; Y. Kim; Bu-Nam Jeon; Léo B Marx; Mathilde Pantin; Hyunjin Yoo; Seung-Whan Byun; Joo-Yeon Chung; M. Cha; P. Garrouste; F. Lévy

Year: 2022

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2022-1760

Paper Abstract 1763: Gastric cancer antibody fragment drug-conjugates (FDCs): Succeeding in solid tumors where ADCs fail

Mahendra P Deonarain; G. Yahioglu; I. Stamati et al. · 2022 · Cancer Research · DOI

Full title: Abstract 1763: Gastric cancer antibody fragment drug-conjugates (FDCs): Succeeding in solid tumors where ADCs fail

Authors: Mahendra P Deonarain; G. Yahioglu; I. Stamati; Bryan Edwards; S. Diez-Posada; I. Perez-Castro; A. Pomowski; L. Bouché; Ashleigh Stewart; Monika Maciuszek; Sam Ness; Malcolm Ngiam; Quinn Xue

Year: 2022

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2022-1763

Paper Abstract 1764: Development of an alphalex™-auristatin low pH targeting conjugate for the treatment of solid tumors

S. Gayle; R. Aiello; J. Bechtold et al. · 2022 · Cancer Research · DOI

Full title: Abstract 1764: Development of an alphalex™-auristatin low pH targeting conjugate for the treatment of solid tumors

Authors: S. Gayle; R. Aiello; J. Bechtold; P. Bourassa; Johanna Csengery; Connor J. Hagen; K. Howard; Kelli Jones; L. Lopresti-Morrow; Robert E. Maguire; T. Paradis; T. Pasqualini; Joseph A. Tweed; L. Tylaska; Qing Zhang; V. Paralkar

Year: 2022

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2022-1764

Paper Abstract 1753: IKS014, a HER2-targeting antibody drug conjugate incorporating novel bioconjugation and tumor-selective linker technology with improved in vivo efficacy and tolerability

J. Deckert; J. Thirlway; Yun-Hee Park et al. · 2022 · Cancer Research · DOI

Full title: Abstract 1753: IKS014, a HER2-targeting antibody drug conjugate incorporating novel bioconjugation and tumor-selective linker technology with improved in vivo efficacy and tolerability

Authors: J. Deckert; J. Thirlway; Yun-Hee Park; Ho Young Song; Chul-woong Chung; Xuesong Wang; Zhenshan Zhang; R. Lutz

Year: 2022

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2022-1753

Paper Abstract 1759: PRO1160, a novel CD70-directed antibody-drug conjugate, demonstrates robust anti-tumor activity in mouse models of renal cell carcinoma and non-Hodgkin lymphoma

Lei Wang; Haidong Liu; Xiao-Juan Shang et al. · 2022 · Cancer Research · DOI

Full title: Abstract 1759: PRO1160, a novel CD70-directed antibody-drug conjugate, demonstrates robust anti-tumor activity in mouse models of renal cell carcinoma and non-Hodgkin lymphoma

Authors: Lei Wang; Haidong Liu; Xiao-Juan Shang; Tae Han; Baiteng Zhao

Year: 2022

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2022-1759

Paper Abstract 1762: A novel antibody drug conjugate linker enabling production of ADCs with high drug to antibody ratios and fast payload release for improved efficacy

N. Luong; N. Bellocq; Léo B Marx et al. · 2022 · Cancer Research · DOI

Full title: Abstract 1762: A novel antibody drug conjugate linker enabling production of ADCs with high drug to antibody ratios and fast payload release for improved efficacy

Authors: N. Luong; N. Bellocq; Léo B Marx; Mathilde Pantin; Benjamin Tchumi; Marie-Claude Roubaudi-Fraschini; Camille Riff; M. Mutter; A. Attinger

Year: 2022

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2022-1762

Paper Abstract 2638: Sacituzumab Govitecan, combination with PARP inhibitor, Talazoparib, in metastatic triple-negative breast cancer (TNBC): Translational investigation

A. Bardia; James T Coates; Laura M. Spring et al. · 2022 · Cancer Research · DOI

Full title: Abstract 2638: Sacituzumab Govitecan, combination with PARP inhibitor, Talazoparib, in metastatic triple-negative breast cancer (TNBC): Translational investigation

Authors: A. Bardia; James T Coates; Laura M. Spring; Sheng Sun; D. Juric; Nayana Thimmiah; A. Niemierko; P.K. Ryan; A. Partridge; J. Peppercorn; H. Parsons; Seth A. Wander; Kelsey Pierce; V. Attaya; D. Fitzgerald; Brenda Lormil; M. Shellock; A. Nagayama; V. Bossuyt; B. Moy; S. Tolaney; L. Ellisen

Year: 2022

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2022-2638

Paper - **DOI:** 10.1158/1538-7445.am2022-2886 - **Authors:** Maria Klimovich, L. Zekri, G. Jung, H. Salih - **Year:** 2022 - **Journal:** Cancer Research

Maria Klimovich; L. Zekri; G. Jung et al. · 2022 · Cancer Research · DOI

Full title: - **DOI:** 10.1158/1538-7445.am2022-2886 - **Authors:** Maria Klimovich, L. Zekri, G. Jung, H. Salih - **Year:** 2022 - **Journal:** Cancer Research

Authors: Maria Klimovich; L. Zekri; G. Jung; H. Salih

Year: 2022

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2022-2886

Paper Abstract 5616: Tumor-targeted immune activation via a site-specific TLR7-agonist antibody-drug conjugate

Mingchao Kang; S. Moon; Ji Young Kim et al. · 2022 · Cancer Research · DOI

Full title: Abstract 5616: Tumor-targeted immune activation via a site-specific TLR7-agonist antibody-drug conjugate

Authors: Mingchao Kang; S. Moon; Ji Young Kim; Andrew Beck; Molly E Allen; Jay D Nelson; K. Tatsukawa; Hon Tran; Manoj Pal; Michael J Gray; Nick A Knudsen; Lillian K Skidmore; David Mills; Yingchun Lu; Y. Buechler; S. Sakamuri; S. Zhang; Feng Tian

Year: 2022

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2022-5616

Paper Abstract 1765: Discovery and first disclosure of AZD8205, a B7-H4-targeted antibody-drug conjugate utilizing a novel topoisomerase I linker-warhead

Krista Kinneer; Niall J Dickinson; Luke A Masterson et al. · 2022 · Cancer Research · DOI

Full title: Abstract 1765: Discovery and first disclosure of AZD8205, a B7-H4-targeted antibody-drug conjugate utilizing a novel topoisomerase I linker-warhead

Authors: Krista Kinneer; Niall J Dickinson; Luke A Masterson; Thais Cailleau; I. Hutchinson; B. Vijayakrishnan; N. Dimasi; R. Christie; Mary McFarlane; K. Ball; A. Lewis; Sofia Koch; L. Brown; Yue Huang; A. Rosenbaum; Jiaqi Yuan; S. Mou; N. Monks; Jon Chesebrough; R. Tammali; J. Anderton; Darrin Sabol; F. Tosto; P. Wortmann; Z. Cooper; Pauline Ryan; John D. Hood; C. Teruel; Carlos Traynor; A. Pike; M. Davies; Elisabetta Leo; Kimberly M. Cook; N. Luheshi; P. Howard; P. Sapra

Year: 2022

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2022-1765

Paper Abstract 328: LCB84, a TROP2-targeted ADC, for treatment of solid tumors that express TROP-2 using the hu2G10 tumor-selective anti-TROP2 monoclonal antibody, a proprietary site-directed conjugation technology and plasma-stable tumor-selective linker chemistry

Hyejung Kim; E. Guerra; Eun-Hae Baek et al. · 2022 · Cancer Research · DOI

Full title: Abstract 328: LCB84, a TROP2-targeted ADC, for treatment of solid tumors that express TROP-2 using the hu2G10 tumor-selective anti-TROP2 monoclonal antibody, a proprietary site-directed conjugation technology and plasma-stable tumor-selective linker chemistry

Authors: Hyejung Kim; E. Guerra; Eun-Hae Baek; Yeojin Jeong; Hyogeun You; Byeongjun Yu; Taeik Jang; Alberti Saverio; Chul-Woong Chung; Changsik Park

Year: 2022

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2022-328

Paper Abstract 1766: SGN-ALPV a novel, investigational vedotin ADC demonstrates highly effective targeting of oncofetal phosphatases ALPP and ALPPL2 in preclinical models

Sara Anderson; N. Hansen; Robert Lawrence et al. · 2022 · Cancer Research · DOI

Full title: Abstract 1766: SGN-ALPV a novel, investigational vedotin ADC demonstrates highly effective targeting of oncofetal phosphatases ALPP and ALPPL2 in preclinical models

Authors: Sara Anderson; N. Hansen; Robert Lawrence; A. Chande; David Ortiz; C. Carosino; E. Trueblood; Nicole C. Stevens; K. Klussman; A. Epp; Bill Arthur; S. Gardai; Héctor Rincón

Year: 2022

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2022-1766

Paper Abstract 2114: Tumor cell-targeted STING-agonist antibody-drug conjugates achieve potent anti-tumor activity by delivering STING agonist specifically to tumor cells andFcγRI-expressing subset of myeloid cells

N. Cetinbas; Kalli C. Catcott; Travis Monnell et al. · 2022 · Cancer Research · DOI

Full title: Abstract 2114: Tumor cell-targeted STING-agonist antibody-drug conjugates achieve potent anti-tumor activity by delivering STING agonist specifically to tumor cells andFcγRI-expressing subset of myeloid cells

Authors: N. Cetinbas; Kalli C. Catcott; Travis Monnell; Jahna Soomer-James; Keith W Bentley; S. Clardy; Bingfan Du; E. Kelleher; Marina Protopopova; Cheri A Stevenson; Joshua D Thomas; Alex Uttard; D. Toader; Jeremy R. Duvall; R. Bukhalid; M. Damelin; T. Lowinger

Year: 2022

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2022-2114

Paper Abstract 4256: YH012, a novel bispecific anti-HER2 and TROP2 antibody-drug conjugate, exhibits potent antitumor efficacy

Chengzhang Shang; Liu Yang; Jiyong Zhang et al. · 2022 · Cancer Research · DOI

Full title: Abstract 4256: YH012, a novel bispecific anti-HER2 and TROP2 antibody-drug conjugate, exhibits potent antitumor efficacy

Authors: Chengzhang Shang; Liu Yang; Jiyong Zhang; Yanfei Han; Zhuolin Li; Z. Han; Jun Li; Ying Meng; G. An; Hao Yang; W. An; Lei Chen; John C. Charpentier

Year: 2022

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2022-4256

Paper - **DOI:** 10.1158/1538-7445.am2022-6227 - **Authors:** Jin-Ock Kim, Hanjun Ko, Jae-Won Kim, Sang Gyu Park - **Year:** 2022 - **Journal:** Cancer Research

Jin-Ock Kim; Hanjun Ko; Jae-Won Kim et al. · 2022 · Cancer Research · DOI

Full title: - **DOI:** 10.1158/1538-7445.am2022-6227 - **Authors:** Jin-Ock Kim, Hanjun Ko, Jae-Won Kim, Sang Gyu Park - **Year:** 2022 - **Journal:** Cancer Research

Authors: Jin-Ock Kim; Hanjun Ko; Jae-Won Kim; Sang Gyu Park

Year: 2022

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2022-6227

Paper Abstract 326: Engineered toxin bodies (ETBs) targeting Trop2

G. Cornelison; Adam Bartoš; Brigitte Brieschke et al. · 2022 · Cancer Research · DOI

Full title: Abstract 326: Engineered toxin bodies (ETBs) targeting Trop2

Authors: G. Cornelison; Adam Bartoš; Brigitte Brieschke; Jessica Momb; Ileana Pedraza; Elizabeth M. Kapeel; Rebecca Martin; Channing C. Pletka; A. González; Joseph D. Dekker; Jay Zhao; J. Majercak; G. Robinson

Year: 2022

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2022-326

Paper Abstract 5284: M1231 is a bispecific anti-MUC1xEGFR antibody-drug conjugate designed to treat solid tumors with MUC1 and EGFR co-expression

C. Knuehl; L. Toleikis; J. Dotterweich et al. · 2022 · Cancer Research · DOI

Full title: Abstract 5284: M1231 is a bispecific anti-MUC1xEGFR antibody-drug conjugate designed to treat solid tumors with MUC1 and EGFR co-expression

Authors: C. Knuehl; L. Toleikis; J. Dotterweich; Jianguo Ma; Seema Kumar; Edith Ross; C. Wilm; Martin Schmitt; H. Grote; C. Amendt

Year: 2022

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2022-5284

Paper Abstract 5566: Evaluation of the efficacy of ADC in vitro and in vivo

Jun Huang; Xiaohe Shi; Q. Gu et al. · 2022 · Cancer Research · DOI

Full title: Abstract 5566: Evaluation of the efficacy of ADC in vitro and in vivo

Authors: Jun Huang; Xiaohe Shi; Q. Gu; Q. Ji

Year: 2022

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2022-5566

Paper Abstract 6020: Preclinical activity of LM-305 targeting G-protein-coupled receptor class 5 member D (GPRC5D) antibody drug conjugate for the treatment of multiple myeloma

Wentao Huang; Jie Luo; Yifan Li et al. · 2022 · Cancer Research · DOI

Full title: Abstract 6020: Preclinical activity of LM-305 targeting G-protein-coupled receptor class 5 member D (GPRC5D) antibody drug conjugate for the treatment of multiple myeloma

Authors: Wentao Huang; Jie Luo; Yifan Li; Da Fei; X. Qin; Runsheng Li

Year: 2022

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2022-6020

Paper Abstract 452: Development and implementation of image analysis-based Quantitative Continuous Score (QCS) for B7-H4 IHC to understand AZD8205 pharmacodynamics

P. Wortmann; T. Tan; S. Haneder et al. · 2022 · Cancer Research · DOI

Full title: Abstract 452: Development and implementation of image analysis-based Quantitative Continuous Score (QCS) for B7-H4 IHC to understand AZD8205 pharmacodynamics

Authors: P. Wortmann; T. Tan; S. Haneder; A. Storti; A. Kapil; Jon Chesebrough; D. Sutton; M. Sulikowski; A. Lewis; Sofia Koch; Steve M M Sweet; Zifeng Song; David C. Chain; Yeoun Jin Kim; N. Luheshi; Krista Kinneer; Z. Cooper; M. Rebelatto; G. Schmidt; H. Sade; J. Barrett

Year: 2022

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2022-452

Paper - **DOI:** 10.1158/1538-7445.am2023-1548 - **Authors:** G. Kaushik, Bandana A. Vishwakarma, Marina Bell, K. Komurov - **Year:** 2023 - **Journal:** Cancer Research

G. Kaushik; Bandana A. Vishwakarma; Marina Bell et al. · 2023 · Cancer Research · DOI

Full title: - **DOI:** 10.1158/1538-7445.am2023-1548 - **Authors:** G. Kaushik, Bandana A. Vishwakarma, Marina Bell, K. Komurov - **Year:** 2023 - **Journal:** Cancer Research

Authors: G. Kaushik; Bandana A. Vishwakarma; Marina Bell; K. Komurov

Year: 2023

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2023-1548

Paper Abstract CT211: A phase 1 dose-escalation and dose-expansion study to evaluate the safety, pharmacokinetics, and anti- tumor activity of ARX517 in subjects with advanced solid tumors resistant or refractory to standard therapies (APEX-01 trial, NCT04662580)

R. Pachynski; L. Nordquist; M. Schweizer et al. · 2022 · Cancer Research · DOI

Full title: Abstract CT211: A phase 1 dose-escalation and dose-expansion study to evaluate the safety, pharmacokinetics, and anti- tumor activity of ARX517 in subjects with advanced solid tumors resistant or refractory to standard therapies (APEX-01 trial, NCT04662580)

Authors: R. Pachynski; L. Nordquist; M. Schweizer; John Paul Shen; N. Adra; M. Bilen; Z. Reichert; R. Aggarwal; B. Siddiqui; Ma Li; Dong Xu; Richard A. Huhn; D. L'Heureux; Jinchun Yan; Y. Buechler; S. Yao; John Simitzi; W. Shi; Shenmin Zhang; S. Tagawa

Year: 2022

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2022-ct211

Paper - **DOI:** 10.1158/1538-7445.am2022-5553 - **Authors:** Liang Du, T. Wan, Yi Jin, Ji-jun Yuan - **Year:** 2022 - **Journal:** Cancer Research

Liang Du; T. Wan; Yi Jin et al. · 2022 · Cancer Research · DOI

Full title: - **DOI:** 10.1158/1538-7445.am2022-5553 - **Authors:** Liang Du, T. Wan, Yi Jin, Ji-jun Yuan - **Year:** 2022 - **Journal:** Cancer Research

Authors: Liang Du; T. Wan; Yi Jin; Ji-jun Yuan

Year: 2022

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2022-5553

Paper Abstract 6334: In vivo efficacy and toxicity of a reduced potency DNA guanine mono-alkylating ADC payload suitable for the treatment of solid tumors

P. Jackson; Paolo Andriollo; N. Veillard et al. · 2022 · Cancer Research · DOI

Full title: Abstract 6334: In vivo efficacy and toxicity of a reduced potency DNA guanine mono-alkylating ADC payload suitable for the treatment of solid tumors

Authors: P. Jackson; Paolo Andriollo; N. Veillard; George Procopiou; D. Thurston

Year: 2022

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2022-6334

Paper Abstract 1538: Revisiting the dogma of antibody drug conjugates (ADCs): Emerging data challenge the benefit of linker stability and the primacy of payload delivery

R. Colombo; Stuart D Barnscher; J. Rich · 2023 · Cancer Research · DOI

Full title: Abstract 1538: Revisiting the dogma of antibody drug conjugates (ADCs): Emerging data challenge the benefit of linker stability and the primacy of payload delivery

Authors: R. Colombo; Stuart D Barnscher; J. Rich

Year: 2023

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2023-1538

Paper Abstract LB021: TJ102: A promising bispecific dual-payload ADC targeting CDH6 and folate receptor alpha (FRα) for the treatment of ovarian and kidney cancers

Yangxin Zhang; Shugaku Takeda; Li Qi et al. · 2025 · Cancer Research · DOI

Full title: Abstract LB021: TJ102: A promising bispecific dual-payload ADC targeting CDH6 and folate receptor alpha (FRα) for the treatment of ovarian and kidney cancers

Authors: Yangxin Zhang; Shugaku Takeda; Li Qi; Mao Huang; Lianjun Zhang; Wenchao Liu; Yanli Mao; Zhaoyuan Chen; Siyi Hu

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-lb021

Paper Antibody-maytansinoid conjugates are potent anti-cancer agents that are activated in the lysosome and arrest cancer cells in G 2 /M phase of the cell cycle in tissue culture and in xenograft tumor models

Peter U Park; Anna Skaletskaya; L. Hylander et al. · 2006

Full title: Antibody-maytansinoid conjugates are potent anti-cancer agents that are activated in the lysosome and arrest cancer cells in G 2 /M phase of the cell cycle in tissue culture and in xenograft tumor models

Authors: Peter U Park; Anna Skaletskaya; L. Hylander; K. Connors; M. Mayo; T. Chittenden; V. Goldmacher

Year: 2006

Paper Antibody-drug conjugates targeted to CD 79 for the treatment of non-Hodgkin ’ s lymphoma Antibody drug conjugates targeted to CD 79

A. Polson; Shang‐Fan Yu; Kristi Elkins et al. · 2007

Full title: Antibody-drug conjugates targeted to CD 79 for the treatment of non-Hodgkin ’ s lymphoma Antibody drug conjugates targeted to CD 79

Authors: A. Polson; Shang‐Fan Yu; Kristi Elkins; B. Zheng; Suzanna Clark; G. Ingle; Dionysos Slaga; L. Giere; C. Du; Christine Tan; J. Hongo; Alvin Gogineni; M. J. Cole; R. Vandlen; J. Stephan; Judy C. Young; Wesley S. Chang; S. Scales; S. Ross; D. Eaton; A. Ebens

Year: 2007

Paper 0595 TITLE : Prostate-Specific Membrane Antigen ( PSMA ) Targeted Bio-orthogonal Therapy for Metastatic Prostate Cancer

Principal Investigator; D. Artemov · 2018

Full title: 0595 TITLE : Prostate-Specific Membrane Antigen ( PSMA ) Targeted Bio-orthogonal Therapy for Metastatic Prostate Cancer

Authors: Principal Investigator; D. Artemov

Year: 2018

Paper CD70 is expressed on renal cell carcinoma and is a potential target for tumor cell elimination by antibody-drug conjugates

C. Law; K. Gordon; A. Yamane et al. · 2004

Full title: CD70 is expressed on renal cell carcinoma and is a potential target for tumor cell elimination by antibody-drug conjugates

Authors: C. Law; K. Gordon; A. Yamane; Melissa C. Thompson; J. Petroziello; Michelle A. Herring; M. Ryan; Damon L. Meyer; S. Doronina; Kevin J. Hamblett; J. A. Francisco; P. Senter; A. Wahl

Year: 2004

Paper Clinical Cancer esearch cer Therapy : Preclinical ineered Thio-Trastuzumab-DM 1 Conjugate with an roved Therapeutic Index to Target Human Epidermal R wth Factor Receptor 2 – Positive Breast Cancer

Jagath R Junutula; Kelly M. Flagella; R. Graham et al. · 2010

Full title: Clinical Cancer esearch cer Therapy : Preclinical ineered Thio-Trastuzumab-DM 1 Conjugate with an roved Therapeutic Index to Target Human Epidermal R wth Factor Receptor 2 – Positive Breast Cancer

Authors: Jagath R Junutula; Kelly M. Flagella; R. Graham; Kathryn L. Parsons; E. Ha; H. Raab; S. Bhakta; T. Nguyen; D. Dugger; Guangmin Li; Elaine Mai; Gail D Lewis Phillips; Hajime Hiraragi; R. Fuji; J. Tibbitts; R. Vandlen; S. Spencer; R. Scheller; P. Polakis; M. Sliwkowski

Year: 2010

Paper Development of antibody fragment auristatin drug conjugates for cancer therapy

C. McDonagh; Lori Westendorf; Melissa C. Thompson et al. · 2006

Full title: Development of antibody fragment auristatin drug conjugates for cancer therapy

Authors: C. McDonagh; Lori Westendorf; Melissa C. Thompson; Kristine M Kim; S. Alley; I. Stone; P. Carter

Year: 2006

Paper Efficient payload delivery by a bispecific antibody targeting HER2 and CD63

de Goeij; T. Vink; Hendrik H. ten Napel et al. · 2016

Full title: Efficient payload delivery by a bispecific antibody targeting HER2 and CD63

Authors: de Goeij; T. Vink; Hendrik H. ten Napel; E. Breij; D. Satijn; R. Wubbolts; David Miao; P. Parren

Year: 2016

Paper Glypican-3 as a novel target for an antibody-drug conjugate

A. Nesterova; P. Carter; Leia M. Smith · 2007

Full title: Glypican-3 as a novel target for an antibody-drug conjugate

Authors: A. Nesterova; P. Carter; Leia M. Smith

Year: 2007

Paper In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate.

R. Sanderson; Michelle A Hering; Stephanie F James et al. · 2005 · Clinical Cancer Research

Full title: In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate.

Authors: R. Sanderson; Michelle A Hering; Stephanie F James; Michael M C Sun; S. Doronina; A. Siadak; P. Senter; A. Wahl

Year: 2005

Venue: Clinical Cancer Research

Paper Impact of Endocytosis Mechanisms for the Receptors Targeted by the Currently Approved ADCs—A Necessity for Future ADC Research and Development

Manar Hammood; A. Craig; Jeffrey V. Leyton · 2021

Full title: Impact of Endocytosis Mechanisms for the Receptors Targeted by the Currently Approved ADCs—A Necessity for Future ADC Research and Development

Authors: Manar Hammood; A. Craig; Jeffrey V. Leyton

Year: 2021

Paper Large Molecule Therapeutics Discovery & Preclinical Development Long-term Tumor Regression Induced by an Antibody – Drug Conjugate That Targets 5 T 4 , anOncofetal AntigenExpressed on Tumor-Initiating Cells

P. Sapra; M. Damelin; J. Dijoseph et al. · 2013

Full title: Large Molecule Therapeutics Discovery & Preclinical Development Long-term Tumor Regression Induced by an Antibody – Drug Conjugate That Targets 5 T 4 , anOncofetal AntigenExpressed on Tumor-Initiating Cells

Authors: P. Sapra; M. Damelin; J. Dijoseph; Kimberly Marquette; K. Geles; Jonathon Golas; MaureenDougher; BithaNarayanan; AndreasGiannakou; K. Khandke; R. Dushin; Elana Ernstoff; J. Lucas; M. Leal; George Hu; C. J. O’Donnell; Lioudmila Tchistiakova; R. Abraham; H. Gerber

Year: 2013

Paper Mechanisms contributing to ado-trastuzumab emtansine ( TDM 1 )-induced toxicities : a gateway to better understanding ADC-associated toxicities

Yukinori Endo; N. Mohan; Milos Dokmanovic et al. · 2021

Full title: Mechanisms contributing to ado-trastuzumab emtansine ( TDM 1 )-induced toxicities : a gateway to better understanding ADC-associated toxicities

Authors: Yukinori Endo; N. Mohan; Milos Dokmanovic; W. J. Wu

Year: 2021

Paper INCORPORATING GLUTAMIC ACID-VALINE-CITRULLINE LINKER IN TRIFUNCTIONAL MOLECULES TARGETING PSMA ENSURES ENHANCED STABILITY, SAFETY, AND EFFICACY IN MOUSE MODEL OF PROSTATE CANCER

T. Amin · 2022

Full title: INCORPORATING GLUTAMIC ACID-VALINE-CITRULLINE LINKER IN TRIFUNCTIONAL MOLECULES TARGETING PSMA ENSURES ENHANCED STABILITY, SAFETY, AND EFFICACY IN MOUSE MODEL OF PROSTATE CANCER

Authors: T. Amin

Year: 2022

Paper Identification and targeting of internalizing breast tumor receptors for immunotherapy

Yu Zhou; Helen J. Huang; L. McDonald et al. · 2005

Full title: Identification and targeting of internalizing breast tumor receptors for immunotherapy

Authors: Yu Zhou; Helen J. Huang; L. McDonald; Hao Zou; J. Marks

Year: 2005

Paper is not an appropriate payload of antibody-drug conjugates as rapid inactivation by lysosomal enzymes

Josefa dela Cruz-Chuh; P. Dragovich; Thomas H. Pillow et al. · 2019

Full title: is not an appropriate payload of antibody-drug conjugates as rapid inactivation by lysosomal enzymes

Authors: Josefa dela Cruz-Chuh; P. Dragovich; Thomas H. Pillow; Donglu Zhang

Year: 2019

Paper BGB-C354, a novel B7H3 ADC with high DAR stability and strong bystander effect, demonstrates robust antitumor activity in preclinical models

Full title: BGB-C354, a novel B7H3 ADC with high DAR stability and strong bystander effect, demonstrates robust antitumor activity in preclinical models

Paper Pharmacologically enhanced expression of the melanoma-associated target, GPNMB, increases the sensitivity of melanoma cells to the CR011-vcMMAE antibody-drug conjugate

M. Jeffers; Xiaozhong Qian; Evan Mills et al. · 2007

Full title: Pharmacologically enhanced expression of the melanoma-associated target, GPNMB, increases the sensitivity of melanoma cells to the CR011-vcMMAE antibody-drug conjugate

Authors: M. Jeffers; Xiaozhong Qian; Evan Mills; M. Torgov; W. Larochelle

Year: 2007

Paper Potent AntitumorActivity of an Auristatin-Conjugated , Fully Human Monoclonal Antibody to Prostate-SpecificMembrane Antigen

DangsheMa; C. Hopf; A. Malewicz et al. · 2006

Full title: Potent AntitumorActivity of an Auristatin-Conjugated , Fully Human Monoclonal Antibody to Prostate-SpecificMembrane Antigen

Authors: DangsheMa; C. Hopf; A. Malewicz; G. Donovan; P. Senter; W. Goeckeler; P. Maddon; W. Olson

Year: 2006

Paper Targeting prostate-specific membrane antigen for personalized therapies in prostate cancer: morphologic and molecular backgrounds and future promises.

M. Santoni; M. Scarpelli; R. Mazzucchelli et al. · 2014 · Journal of Biological Regulators and Homeostatic Agents

Full title: Targeting prostate-specific membrane antigen for personalized therapies in prostate cancer: morphologic and molecular backgrounds and future promises.

Authors: M. Santoni; M. Scarpelli; R. Mazzucchelli; A. López-Beltran; Liang Cheng; S. Cascinu; R. Montironi

Year: 2014

Venue: Journal of Biological Regulators and Homeostatic Agents

Paper Targeted antitumor activity of anti-Sp17 mAb-doxorubicin conjugates for ovarian cancer in vitro and in vivo

Shi Li-ning · 2012

Full title: Targeted antitumor activity of anti-Sp17 mAb-doxorubicin conjugates for ovarian cancer in vitro and in vivo

Authors: Shi Li-ning

Year: 2012

Paper Targeting CD 19 in B-cell lymphoma : emerging role of SAR 3419

A. Raufi; A. Ebrahim; A. Al-Katib · 2013

Full title: Targeting CD 19 in B-cell lymphoma : emerging role of SAR 3419

Authors: A. Raufi; A. Ebrahim; A. Al-Katib

Year: 2013

Paper Trastuzumab-Auristatin immunoconjugates inhibit growth and induce apoptosis in human breast cancer cells in vitro

Guangmin Li; P. Senter; G. Phillips · 2005

Full title: Trastuzumab-Auristatin immunoconjugates inhibit growth and induce apoptosis in human breast cancer cells in vitro

Authors: Guangmin Li; P. Senter; G. Phillips

Year: 2005

Paper Scaling Amatoxin Synthesis with an Improved Route to (2S,3R,4R)-Dihydroxyisoleucine Exemplified by a Toxic, Clickable α-Amanitin Analogue.

Chido M. Hambira; Kaveh Matinkhoo; Alla Pryyma et al. · 2021 · Journal of Organic Chemistry · DOI

Full title: Scaling Amatoxin Synthesis with an Improved Route to (2S,3R,4R)-Dihydroxyisoleucine Exemplified by a Toxic, Clickable α-Amanitin Analogue.

Authors: Chido M. Hambira; Kaveh Matinkhoo; Alla Pryyma; B. Patrick; D. Perrin

Year: 2021

Venue: Journal of Organic Chemistry

DOI: https://doi.org/10.1021/acs.joc.0c03022

Paper Advances in antibody-drug conjugates for endometrial cancer.

Pan Tu; Gaofeng Li; Wen Zou et al. · 2025 · Molecular Cancer Therapeutics · DOI

Full title: Advances in antibody-drug conjugates for endometrial cancer.

Authors: Pan Tu; Gaofeng Li; Wen Zou; Chao Xu; Jingjing Wang

Year: 2025

Venue: Molecular Cancer Therapeutics

DOI: https://doi.org/10.1158/1535-7163.mct-24-0763

Paper Abstract CT160: A Phase I, open-label, safety, pharmacokinetic, and preliminary efficacy study of STRO-002, an anti-folate receptor alpha (FolRα) antibody drug conjugate (ADC), in patients with advanced epithelial ovarian cancer (including fallopian tube or primary peritoneal cancers) and endometria

R. Naumann; D. Uyar; R. Schilder et al. · 2019 · Clinical Trials · DOI

Full title: Abstract CT160: A Phase I, open-label, safety, pharmacokinetic, and preliminary efficacy study of STRO-002, an anti-folate receptor alpha (FolRα) antibody drug conjugate (ADC), in patients with advanced epithelial ovarian cancer (including fallopian tube or primary peritoneal cancers) and endometria

Authors: R. Naumann; D. Uyar; R. Schilder; Michael Palumbo; V. Dealmeida; S. Matheny; A. Molina

Year: 2019

Venue: Clinical Trials

DOI: https://doi.org/10.1158/1538-7445.am2019-ct160

Thesis Novel Strategies to Improve the Efficacy and Safety of Antibody Drug Conjugates for HER2-Positive Breast Cancer

Duro Sánchez, Santiago · 2025 · Universitat Autònoma de Barcelona (TDX) · DOI

Full title: Novel Strategies to Improve the Efficacy and Safety of Antibody Drug Conjugates for HER2-Positive Breast Cancer

Authors: Duro Sánchez, Santiago

Year: 2025

Venue: Universitat Autònoma de Barcelona (TDX)

DOI: http://hdl.handle.net/10803/694456

Thesis Functional native disulfide bridging enables delivery of a potent, stable and targeted antibody-drug conjugate (ADC)

Nunes, JPM; Morais, M; Vassileva, V et al. · 2017 · Imperial College London · DOI

Full title: Functional native disulfide bridging enables delivery of a potent, stable and targeted antibody-drug conjugate (ADC)

Authors: Nunes, JPM; Morais, M; Vassileva, V; Robinson, E; Rajkumar, VS; Smith, MEB; Pedley, RB; Caddick, S; Baker, JR; Chudasama, V

Year: 2017

Venue: Imperial College London

DOI: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000356453200007&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Thesis Aptamer-Drug Conjugates of Active Metabolites of Nucleoside Analogs and Cytotoxic Agents Inhibit Pancreatic Tumor Cell Growth

Yoon, S; Huang, K-W; Reebye, V et al. · 2017 · Imperial College London · DOI

Full title: Aptamer-Drug Conjugates of Active Metabolites of Nucleoside Analogs and Cytotoxic Agents Inhibit Pancreatic Tumor Cell Growth

Authors: Yoon, S; Huang, K-W; Reebye, V; Spalding, D; Przytycka, TM; Wang, Y; Swiderski, P; Li, L; Armstrong, B; Reccia, I; Zacharoulis, D; Dimas, K; Kusano, T; Shively, J; Habib, N; Rossi, JJ

Year: 2017

Venue: Imperial College London

DOI: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000397092100007&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Thesis Small-format drug conjugates: a viable alternative to ADCs for solid tumours?

Deonarain, Mahendra P; Yahioglu, Gokhan; Stamati, Ioanna et al. · 2018 · Imperial College London · DOI

Full title: Small-format drug conjugates: a viable alternative to ADCs for solid tumours?

Authors: Deonarain, Mahendra P; Yahioglu, Gokhan; Stamati, Ioanna; Pomowski, Anja; Clarke, James; Edwards, Bryan M; Diez-Posada, Soraya; Stewart, Ashleigh C

Year: 2018

Venue: Imperial College London

DOI: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000436112400001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Thesis Pyridazinediones deliver potent, stable, targeted and efficacious antibody-drug conjugates (ADCs) with a controlled loading of 4 drugs per antibody

Robinson, E; Nunes, JPM; Vassileva, V et al. · 2017 · Imperial College London · DOI

Full title: Pyridazinediones deliver potent, stable, targeted and efficacious antibody-drug conjugates (ADCs) with a controlled loading of 4 drugs per antibody

Authors: Robinson, E; Nunes, JPM; Vassileva, V; Maruani, A; Nogueira, JCF; Smith, MEB; Pedley, RB; Caddick, S; Baker, JR; Chudasama, V

Year: 2017

Venue: Imperial College London

DOI: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000393759900041&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Thesis Targeted Photodynamic Therapy of cancer using photoimmunoconjugates based on pyropheophorbide a derivatives

Stamati, Ioanna; Stamati, Ioanna · 2011 · Imperial College London · DOI

Full title: Targeted Photodynamic Therapy of cancer using photoimmunoconjugates based on pyropheophorbide a derivatives

Authors: Stamati, Ioanna; Stamati, Ioanna

Year: 2011

Venue: Imperial College London

DOI: http://hdl.handle.net/10044/1/6340

Thesis Using antibody directed phototherapy to target oesophageal adenocarcinoma with heterogeneous HER2 expression

Pye, Hayley; Butt, Mohammed Adil; Funnell, Laura et al. · 2018 · Imperial College London · DOI

Full title: Using antibody directed phototherapy to target oesophageal adenocarcinoma with heterogeneous HER2 expression

Authors: Pye, Hayley; Butt, Mohammed Adil; Funnell, Laura; Reinert, Halla W; Puccio, Ignazio; Rehman Khan, Saif U; Saouros, Savvas; Marklew, Jared S; Stamati, Ioanna; Qurashi, Maryam; Haidry, Rehan; Sehgal, Vinay; Oukrif, Dahmane; Gandy, Michael; Whitaker, Hayley C; Rodriguez-Justo, Manuel; Novelli, Marco; Hamoudi, Rifat; Yahioglu, Gokhan; Deonarain, Mahendra P; Lovat, Laurence B

Year: 2018

Venue: Imperial College London

DOI: https://www.ncbi.nlm.nih.gov/pubmed/29796164

Thesis Engineered collagen-binding serum albumin as a drug conjugate carrier for cancer therapy

Sasaki, Koichi; Ishihara, Jun; Ishihara, Ako et al. · 2020 · Imperial College London · DOI

Full title: Engineered collagen-binding serum albumin as a drug conjugate carrier for cancer therapy

Authors: Sasaki, Koichi; Ishihara, Jun; Ishihara, Ako; Miura, Risako; Mansurov, Aslan; Fukunaga, Kazuto; Hubbell, Jeffrey A

Year: 2020

Venue: Imperial College London

DOI: https://advances.sciencemag.org/content/5/8/eaaw6081

Thesis Frizzled-7-targeted delivery of zinc oxide nanoparticles to drug-resistant breast cancer cells

Ruenraroengsak, Pakatip; Kiryushko, Darya; Theodorou, Ioannis G et al. · 2019 · Imperial College London · DOI

Full title: Frizzled-7-targeted delivery of zinc oxide nanoparticles to drug-resistant breast cancer cells

Authors: Ruenraroengsak, Pakatip; Kiryushko, Darya; Theodorou, Ioannis G; Klosowski, Michał M; Taylor, Erik R; Niriella, Thisa; Palmieri, Carlo; Yagüe, Ernesto; Ryan, Mary P; Coombes, R Charles; Xie, Fang; Porter, Alexandra E

Year: 2019

Venue: Imperial College London

DOI: https://www.ncbi.nlm.nih.gov/pubmed/31157349

Thesis Antibody–PROTAC conjugates enable HER2-dependent targeted protein degradation of BRD4

Maneiro, Marı́a; Forte, Nafsika; Shchepinova, Maria M et al. · 2020 · Imperial College London · DOI

Full title: Antibody–PROTAC conjugates enable HER2-dependent targeted protein degradation of BRD4

Authors: Maneiro, Marı́a; Forte, Nafsika; Shchepinova, Maria M; Kounde, Cyrille S; Chudasama, Vijay; Baker, James Richard; Tate, Edward W

Year: 2020

Venue: Imperial College London

DOI: https://pubs.acs.org/doi/10.1021/acschembio.0c00285

Thesis Gallium-68 radiolabelling and preclinical evaluation of the novel single chain fragment variable (scFv) TCT1067

Fu, Ruisi · 2022 · Imperial College London · DOI

Full title: Gallium-68 radiolabelling and preclinical evaluation of the novel single chain fragment variable (scFv) TCT1067

Authors: Fu, Ruisi

Year: 2022

Venue: Imperial College London

DOI: http://hdl.handle.net/10044/1/97172

Thesis Development of Antibody-Directed Therapies: Quo Vadis?

Rodrigues, Tiago; Bernardes, Gonçalo JL · 2018 · University of Cambridge · DOI

Full title: Development of Antibody-Directed Therapies: Quo Vadis?

Authors: Rodrigues, Tiago; Bernardes, Gonçalo JL

Year: 2018

Venue: University of Cambridge

DOI: https://www.repository.cam.ac.uk/handle/1810/273730

Thesis Sulfatase-cleavable linkers for antibody-drug conjugates.

Bargh, Jonathan D; Walsh, Stephen J; Isidro-Llobet, Albert et al. · 2020 · University of Cambridge · DOI

Full title: Sulfatase-cleavable linkers for antibody-drug conjugates.

Authors: Bargh, Jonathan D; Walsh, Stephen J; Isidro-Llobet, Albert; Omarjee, Soleilmane; Carroll, Jason S; Spring, David R

Year: 2020

Venue: University of Cambridge

DOI: https://www.repository.cam.ac.uk/handle/1810/301771

Thesis Toward aplyronine payloads for antibody-drug conjugates: total synthesis of aplyronines A and D.

AnŽiček, Nika; Williams, Simon; Housden, Michael P et al. · 2018 · University of Cambridge · DOI

Full title: Toward aplyronine payloads for antibody-drug conjugates: total synthesis of aplyronines A and D.

Authors: AnŽiček, Nika; Williams, Simon; Housden, Michael P; Paterson, Ian

Year: 2018

Venue: University of Cambridge

DOI: https://www.repository.cam.ac.uk/handle/1810/274556

Thesis Rapid and robust cysteine bioconjugation with vinylheteroarenes.

Seki, Hikaru; Walsh, Stephen J; Bargh, Jonathan D et al. · 2021 · University of Cambridge · DOI

Full title: Rapid and robust cysteine bioconjugation with vinylheteroarenes.

Authors: Seki, Hikaru; Walsh, Stephen J; Bargh, Jonathan D; Parker, Jeremy S; Carroll, Jason; Spring, David R

Year: 2021

Venue: University of Cambridge

DOI: https://www.repository.cam.ac.uk/handle/1810/326977

Thesis Evaluation of ¹¹¹In-Labelled Exendin-4 Derivatives Containing Different Meprin β-Specific Cleavable Linkers

Jodal, Andreas; Pape, Fabienne; Becker-Pauly, Christoph et al. · 2015 · ETH Zurich (Swiss Federal Institute of Technology in Zurich) · DOI

Full title: Evaluation of ¹¹¹In-Labelled Exendin-4 Derivatives Containing Different Meprin β-Specific Cleavable Linkers

Authors: Jodal, Andreas; Pape, Fabienne; Becker-Pauly, Christoph; Maas, Ole; Schibli, Roger; Behe, Martin

Year: 2015

Venue: ETH Zurich (Swiss Federal Institute of Technology in Zurich)

DOI: http://hdl.handle.net/20.500.11850/100413

Thesis Designed Bond Cleavage Reactions for Next-Generation Therapeutics

Vickraman Nair Bindu, Unnikrishnan · 2025 · University of Cambridge · DOI

Full title: Designed Bond Cleavage Reactions for Next-Generation Therapeutics

Authors: Vickraman Nair Bindu, Unnikrishnan

Year: 2025

Venue: University of Cambridge

DOI: https://www.repository.cam.ac.uk/handle/1810/382404

Thesis Development of a new class of PSMA radioligands comprising ibuprofen as an albumin-binding entity

Deberle, Luisa M.; Benešová, Martina; Umbricht, Christoph A. et al. · 2020 · ETH Zurich (Swiss Federal Institute of Technology in Zurich) · DOI

Full title: Development of a new class of PSMA radioligands comprising ibuprofen as an albumin-binding entity

Authors: Deberle, Luisa M.; Benešová, Martina; Umbricht, Christoph A.; Borgna, Francesca; Buchler, Manuel; Zhernosekov, Konstantin; Schibli, Roger; Müller, Cristina

Year: 2020

Venue: ETH Zurich (Swiss Federal Institute of Technology in Zurich)

DOI: http://hdl.handle.net/20.500.11850/387503

Thesis Ex vivo mass spectrometry-based biodistribution analysis of an antibody-Resiquimod conjugate bearing a protease-cleavable and acid-labile linker

Lopez, Lydia Bisbal; Ravazza, Domenico; Bocci, Matilde et al. · 2023 · ETH Zurich (Swiss Federal Institute of Technology in Zurich) · DOI

Full title: Ex vivo mass spectrometry-based biodistribution analysis of an antibody-Resiquimod conjugate bearing a protease-cleavable and acid-labile linker

Authors: Lopez, Lydia Bisbal; Ravazza, Domenico; Bocci, Matilde; Zana, Aureliano; Principi, Lucrezia; Dakhel Plaza, Sheila; Galbiati, Andrea; Gilardoni, Ettore; id_orcid0000-0002-2010-2667; Scheuermann, Jörg; id_orcid0000-0002-2010-2667; Neri, Dario; id_orcid0000-0002-2010-2667; Pignataro, Luca; Gennari, Cesare; Cazzamalli, Samuele; Dal Corso, Alberto

Year: 2023

Venue: ETH Zurich (Swiss Federal Institute of Technology in Zurich)

DOI: http://hdl.handle.net/20.500.11850/657530

Thesis A novel anti-HER2 anthracycline-based antibody-drug conjugate induces adaptive anti-tumor immunity and potentiates PD-1 blockade in breast cancer

D'Amico, Lucia; Menzel, Ulrike; Prummer, Michael et al. · 2019 · ETH Zurich (Swiss Federal Institute of Technology in Zurich) · DOI

Full title: A novel anti-HER2 anthracycline-based antibody-drug conjugate induces adaptive anti-tumor immunity and potentiates PD-1 blockade in breast cancer

Authors: D'Amico, Lucia; Menzel, Ulrike; Prummer, Michael; id_orcid0000-0001-9896-3929; Müller, Philipp; Buchi, Mélanie; Kashyap, Abhishek; Haessler, Ulrike; Yermanos, Alexander; Gébleux, Rémy; Briendl, Manfred; Hell, Tamara; Wolter, Fabian I.; Beerli, Roger R.; Truxova, Iva; Radek, Špíšek; Vlajnic, Tatjana; Grawunder, Ulf; Reddy, Sai; Zippelius, Alfred

Year: 2019

Venue: ETH Zurich (Swiss Federal Institute of Technology in Zurich)

DOI: http://hdl.handle.net/20.500.11850/322301

Thesis In Vivo Antitumor Activity of a Novel Acetazolamide-Cryptophycin Conjugate for the Treatment of Renal Cell Carcinomas

Cazzamalli, Samuele; Figueras, Eduard; Pethő, Lilla et al. · 2018 · ETH Zurich (Swiss Federal Institute of Technology in Zurich) · DOI

Full title: In Vivo Antitumor Activity of a Novel Acetazolamide-Cryptophycin Conjugate for the Treatment of Renal Cell Carcinomas

Authors: Cazzamalli, Samuele; Figueras, Eduard; Pethő, Lilla; Borbély, Adina; Steinkühler, Christian; Neri, Dario; id_orcid0000-0001-5234-7370; Sewald, Norbert

Year: 2018

Venue: ETH Zurich (Swiss Federal Institute of Technology in Zurich)

DOI: http://hdl.handle.net/20.500.11850/304161

Thesis Antibody conjugates: from heterogeneous populations to defined reagents

Dennler, Patrick; Fischer, Eliane; Schibli, Roger · 2015 · ETH Zurich (Swiss Federal Institute of Technology in Zurich) · DOI

Full title: Antibody conjugates: from heterogeneous populations to defined reagents

Authors: Dennler, Patrick; Fischer, Eliane; Schibli, Roger

Year: 2015

Venue: ETH Zurich (Swiss Federal Institute of Technology in Zurich)

DOI: http://hdl.handle.net/20.500.11850/357346

Thesis A Chemical Proteomics Approach for the Identification of Accessible Antigens Expressed in Human Kidney Cancer

Castronovo, Vincent; Waltregny, David; Kischel, Philippe et al. · 2006 · ETH Zurich (Swiss Federal Institute of Technology in Zurich) · DOI

Full title: A Chemical Proteomics Approach for the Identification of Accessible Antigens Expressed in Human Kidney Cancer

Authors: Castronovo, Vincent; Waltregny, David; Kischel, Philippe; Roesli, Christoph; Elia, Giuliano; id_orcid0000-0001-8216-9560; Rybak, Jascha-N.; Neri, Dario; id_orcid0000-0001-8216-9560

Year: 2006

Venue: ETH Zurich (Swiss Federal Institute of Technology in Zurich)

DOI: http://hdl.handle.net/20.500.11850/35615

Thesis Peptide-Directed Attachment of Hydroxylamines to Specific Lysines of IgG Antibodies for Bioconjugations with Acylboronates

Tanriver, Matthias; Müller, Marco; Richards, Daniel et al. · 2023 · ETH Zurich (Swiss Federal Institute of Technology in Zurich) · DOI

Full title: Peptide-Directed Attachment of Hydroxylamines to Specific Lysines of IgG Antibodies for Bioconjugations with Acylboronates

Authors: Tanriver, Matthias; Müller, Marco; Richards, Daniel; Majima, Sohei; deMello, Andrew J.; Bode, Jeffrey

Year: 2023

Venue: ETH Zurich (Swiss Federal Institute of Technology in Zurich)

DOI: http://hdl.handle.net/20.500.11850/651954

Thesis A fully human anti-IL-7Rα antibody promotes antitumor activity against T-cell acute lymphoblastic leukemia

Akkapeddi, Padma; Fragoso, Rita; Hixon, Julie A. et al. · 2019 · ETH Zurich (Swiss Federal Institute of Technology in Zurich) · DOI

Full title: A fully human anti-IL-7Rα antibody promotes antitumor activity against T-cell acute lymphoblastic leukemia

Authors: Akkapeddi, Padma; Fragoso, Rita; Hixon, Julie A.; Ramalho, Ana S.; Oliveira, Mariana L.; Carvalho, Tânia; Gloger, Andreas; Matasci, Mattia; Corzana, Francisco; Durum, Scott K.; Neri, Dario; id_orcid0000-0001-5234-7370; Bernardes, Gonçalo J.L.; Barata, João T.

Year: 2019

Venue: ETH Zurich (Swiss Federal Institute of Technology in Zurich)

DOI: http://hdl.handle.net/20.500.11850/364042

Thesis Anti-Extra Domain B Splice Variant of Fibronectin Antibody-Drug Conjugate Eliminates Tumors with Enhanced Efficacy When Combined with Checkpoint Blockade

Hooper, Andrea T.; Marquette, Kimberly; Chang, Chao-Pei Betty et al. · 2022 · ETH Zurich (Swiss Federal Institute of Technology in Zurich) · DOI

Full title: Anti-Extra Domain B Splice Variant of Fibronectin Antibody-Drug Conjugate Eliminates Tumors with Enhanced Efficacy When Combined with Checkpoint Blockade

Authors: Hooper, Andrea T.; Marquette, Kimberly; Chang, Chao-Pei Betty; Golas, Jonathon; Jain, Sadhana; Lam, My-Hanh; Guffroy, Magali; Leal, Mauricio; Falahatpisheh, Hadi; Mathur, Divya; Chen, Ting; Kelleher, Kerry; Khandke, Kiran; Muszynska, Elwira; Loganzo, Frank; Rosfjord, Edward; Lucas, Judy; Kan, Zhengyan; Subramanyam, Chakrapani; O'Donnell, Christopher; Neri, Dario; id_orcid0000-0001-5234-7370; Gerber, Hans-Peter; May, Chad; Sapra, Puja

Year: 2022

Venue: ETH Zurich (Swiss Federal Institute of Technology in Zurich)

DOI: http://hdl.handle.net/20.500.11850/570266

Thesis Tumor-Homing Antibody-Cytokine Fusions for Cancer Therapy

Prodi, Eleonora; Neri, Dario; id_orcid0000-0001-5234-7370 et al. · 2024 · ETH Zurich (Swiss Federal Institute of Technology in Zurich) · DOI

Full title: Tumor-Homing Antibody-Cytokine Fusions for Cancer Therapy

Authors: Prodi, Eleonora; Neri, Dario; id_orcid0000-0001-5234-7370; De Luca, Roberto

Year: 2024

Venue: ETH Zurich (Swiss Federal Institute of Technology in Zurich)

DOI: http://hdl.handle.net/20.500.11850/692618

Thesis Dual MVK cleavable linkers effectively reduce renal retention of 111 In-fibronectin-binding peptides

Valpreda, Giulia; Trachsel, Belinda; id_orcid0000-0002-5177-4167 et al. · 2022 · ETH Zurich (Swiss Federal Institute of Technology in Zurich) · DOI

Full title: Dual MVK cleavable linkers effectively reduce renal retention of 111 In-fibronectin-binding peptides

Authors: Valpreda, Giulia; Trachsel, Belinda; id_orcid0000-0002-5177-4167; Vogel, Viola; Schibli, Roger; Mu, Linjing; id_orcid0000-0002-5177-4167; Behe, Martin

Year: 2022

Venue: ETH Zurich (Swiss Federal Institute of Technology in Zurich)

DOI: http://hdl.handle.net/20.500.11850/574167

Thesis Generation and in vivo characterization of a novel high-affinity human antibody targeting carcinoembryonic antigen

Plüss, Louis; Peissert, Frederik; Elsayed, Abdullah et al. · 2023 · ETH Zurich (Swiss Federal Institute of Technology in Zurich) · DOI

Full title: Generation and in vivo characterization of a novel high-affinity human antibody targeting carcinoembryonic antigen

Authors: Plüss, Louis; Peissert, Frederik; Elsayed, Abdullah; Rotta, Giulia; Römer, Jonas; Dakhel Plaza, Sheila; Villa, Alessandra; Puca, Emanuele; De Luca, Roberto; Oxenius, Annette; id_orcid0000-0002-2079-2354; Neri, Dario; id_orcid0000-0002-2079-2354

Year: 2023

Venue: ETH Zurich (Swiss Federal Institute of Technology in Zurich)

DOI: http://hdl.handle.net/20.500.11850/615067

Thesis Enhanced therapeutic activity of non-internalizing small-molecule-drug conjugates targeting carbonic anhydrase IX in combination with targeted interleukin-2

Cazzamalli, Samuele; https://orcid.org/0000-0003-0510-5664; Ziffels, Barbara et al. · 2018 · Vetsuisse Faculty Bern and Zurich · DOI

Full title: Enhanced therapeutic activity of non-internalizing small-molecule-drug conjugates targeting carbonic anhydrase IX in combination with targeted interleukin-2

Authors: Cazzamalli, Samuele; https://orcid.org/0000-0003-0510-5664; Ziffels, Barbara; Widmayer, Fontaine; Murer, Patrizia; Pellegrini, Giovanni; Pretto, Francesca; Wulhfard, Sarah; Neri, Dario

Year: 2018

Venue: Vetsuisse Faculty Bern and Zurich

DOI: oai:www.zora.uzh.ch:20.500.14742/153465

Thesis Site-Specific Modification of Native IgGs with Flexible Drug-Load

Wehrmüller, Jöri E.; Frei, Julia C.; Hechler, Torsten et al. · 2024 · ETH Zurich (Swiss Federal Institute of Technology in Zurich) · DOI

Full title: Site-Specific Modification of Native IgGs with Flexible Drug-Load

Authors: Wehrmüller, Jöri E.; Frei, Julia C.; Hechler, Torsten; Kulke, Michael; Pahl, Andreas; Béhé, Martin; Schibli, Roger; Spycher, Philipp R.

Year: 2024

Venue: ETH Zurich (Swiss Federal Institute of Technology in Zurich)

DOI: http://hdl.handle.net/20.500.11850/706683

Thesis DOTA-Functionalized Polylysine: A High Number of DOTA Chelates Positively Influences the Biodistribution of Enzymatic Conjugated Anti-Tumor Antibody chCE7agl

Grünberg, Jürgen; Jeger, Simone; Sarko, Dikran et al. · 2013 · ETH Zurich (Swiss Federal Institute of Technology in Zurich) · DOI

Full title: DOTA-Functionalized Polylysine: A High Number of DOTA Chelates Positively Influences the Biodistribution of Enzymatic Conjugated Anti-Tumor Antibody chCE7agl

Authors: Grünberg, Jürgen; Jeger, Simone; Sarko, Dikran; Dennler, Patrick; Zimmermann, Kurt; Mier, Walter; Schibli, Roger

Year: 2013

Venue: ETH Zurich (Swiss Federal Institute of Technology in Zurich)

DOI: http://hdl.handle.net/20.500.11850/78705

Thesis Engineering an anti-HER2 biparatopic antibody with a multimodal mechanism of action

Kast, Florian; https://orcid.org/0000-0001-5586-8382; Schwill, Martin et al. · 2021 · Vetsuisse Faculty Bern and Zurich · DOI

Full title: Engineering an anti-HER2 biparatopic antibody with a multimodal mechanism of action

Authors: Kast, Florian; https://orcid.org/0000-0001-5586-8382; Schwill, Martin; https://orcid.org/0000-0002-2798-5490; Stüber, Jakob C; https://orcid.org/0000-0002-3406-0664; Pfundstein, Svende; Nagy-Davidescu, Gabriela; Rodríguez, Josep M Monné; Seehusen, Frauke; Richter, Christian P; Honegger, Annemarie; https://orcid.org/0000-0002-3378-3967; Hartmann, Karen Patricia; Weber, Thomas G; Kroener, Felix; Ernst, Patrick; https://orcid.org/0000-0001-6037-1856; Piehler, Jacob; Plückthun, Andreas; https://orcid.org/0000-0003-4191-5306

Year: 2021

Venue: Vetsuisse Faculty Bern and Zurich

DOI: oai:www.zora.uzh.ch:20.500.14742/188862

Thesis A novel strategy to generate immunocytokines with activity-on-demand using small molecule inhibitors

Rotta, Giulia; https://orcid.org/0000-0001-6897-9225; Gilardoni, Ettore et al. · 2024 · Vetsuisse Faculty Bern and Zurich · DOI

Full title: A novel strategy to generate immunocytokines with activity-on-demand using small molecule inhibitors

Authors: Rotta, Giulia; https://orcid.org/0000-0001-6897-9225; Gilardoni, Ettore; https://orcid.org/0000-0002-2010-2667; Ravazza, Domenico; Mock, Jacqueline; https://orcid.org/0000-0002-4618-1113; Seehusen, Frauke; https://orcid.org/0000-0001-6701-7868; Elsayed, Abdullah; https://orcid.org/0000-0001-7080-0853; Puca, Emanuele; https://orcid.org/0000-0002-2869-3203; De Luca, Roberto; Pellegrino, Christian; https://orcid.org/0000-0001-7898-9988; Look, Thomas; https://orcid.org/0000-0001-5410-6220; Weiss, Tobias; https://orcid.org/0000-0002-5533-9429; Manz, Markus G; https://orcid.org/0000-0002-4676-7931; Halin, Cornelia; https://orcid.org/0000-0002-7899-2850; Neri, Dario; https://orcid.org/0000-0001-5234-7370; Dakhel Plaza, Sheila; https://orcid.org/0000-0003-2546-6053

Year: 2024

Venue: Vetsuisse Faculty Bern and Zurich

DOI: oai:www.zora.uzh.ch:20.500.14742/222783

Thesis Immunotherapy with immunocytokines and PD-1 blockade enhances the anticancer activity of small molecule-drug conjugates targeting carbonic anhydrase IX

Millul, Jacopo; https://orcid.org/0000-0003-4288-1283; Krudewig, Christiane et al. · 2021 · Vetsuisse Faculty Bern and Zurich · DOI

Full title: Immunotherapy with immunocytokines and PD-1 blockade enhances the anticancer activity of small molecule-drug conjugates targeting carbonic anhydrase IX

Authors: Millul, Jacopo; https://orcid.org/0000-0003-4288-1283; Krudewig, Christiane; Zana, Aureliano; Plaza, Sheila Dakhel; Puca, Emanuele; Villa, Alessandra; Neri, Dario; https://orcid.org/0000-0001-5234-7370; Cazzamalli, Samuele; https://orcid.org/0000-0003-0510-5664

Year: 2021

Venue: Vetsuisse Faculty Bern and Zurich

DOI: oai:www.zora.uzh.ch:20.500.14742/177931

Thesis Development of Novel Antibody-Based Immunotherapies Targeting Human Chondroitin Sulfate Proteoglycan 4

Yu, Xin · 2018 · Duke University · DOI

Full title: Development of Novel Antibody-Based Immunotherapies Targeting Human Chondroitin Sulfate Proteoglycan 4

Authors: Yu, Xin

Year: 2018

Venue: Duke University

DOI: https://hdl.handle.net/10161/16796

Thesis Novel Approaches for Tumor Targeting via Artificial Antigen Delivery

Yurkevicz, Annali · 2024 · Yale University · DOI

Full title: Novel Approaches for Tumor Targeting via Artificial Antigen Delivery

Authors: Yurkevicz, Annali

Year: 2024

Venue: Yale University

DOI: https://elischolar.library.yale.edu/gsas_dissertations/1409

Thesis RNA Aptamers that Internalize into Cancer Cells for Drug Delivery

Song, Xirui · 2023 · Duke University · DOI

Full title: RNA Aptamers that Internalize into Cancer Cells for Drug Delivery

Authors: Song, Xirui

Year: 2023

Venue: Duke University

DOI: https://hdl.handle.net/10161/29152

Thesis Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade

Müller, Philipp; Kreuzaler, Matthias; Khan, Tarik et al. · 2025 · University of Basel - edoc Repository · DOI

Full title: Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade

Authors: Müller, Philipp; Kreuzaler, Matthias; Khan, Tarik; Thommen, Daniela S; Martin, Kea; Glatz, Katharina; Savic, Spasenija; Harbeck, Nadia; Nitz, Ulrike; Gluz, Oleg; von Bergwelt-Baildon, Michael; Kreipe, Hans; Reddy, Sai; Christgen, Matthias; Zippelius, Alfred

Year: 2025

Venue: University of Basel - edoc Repository

DOI: https://hdl.handle.net/20.500.14716/33196

Thesis Optimising targeted antibodies for the treatment of metastatic solid tumours

Herbertson, Rebecca A. · 2009 · University of Nottingham · DOI

Full title: Optimising targeted antibodies for the treatment of metastatic solid tumours

Authors: Herbertson, Rebecca A.

Year: 2009

Venue: University of Nottingham

DOI: https://eprints.nottingham.ac.uk/10844/1/20090702_R_Herbertson_MD_thesis.pdf

Thesis Exploring bioorthogonal approaches to activate PROTACs

Croke, Stephen · 2024 · The University of Edinburgh · DOI

Full title: Exploring bioorthogonal approaches to activate PROTACs

Authors: Croke, Stephen

Year: 2024

Venue: The University of Edinburgh

DOI: https://hdl.handle.net/1842/42000

Thesis Chlorotoxin as a Drug Delivery System to treat Glioblastoma

Fawzy, Ahmed Faadil · 2021 · University of Nottingham · DOI

Full title: Chlorotoxin as a Drug Delivery System to treat Glioblastoma

Authors: Fawzy, Ahmed Faadil

Year: 2021

Venue: University of Nottingham

DOI: https://eprints.nottingham.ac.uk/65822/1/Faadil%20Fawzy%2C%20Ahmed%20%5B14283092%5D%20-%20PhD%20Chemistry.pdf

Thesis Development and Encapsulation of Affibody-Apoferritin Biologics for the Targeted Treatment of Breast Cancer

Holden, Isobel R · 2025 · University of Nottingham · DOI

Full title: Development and Encapsulation of Affibody-Apoferritin Biologics for the Targeted Treatment of Breast Cancer

Authors: Holden, Isobel R

Year: 2025

Venue: University of Nottingham

DOI: https://eprints.nottingham.ac.uk/78748/1/Isobel_Holden_PHDThesis_Apr%202024_final.pdf

Thesis Rational design of pyrrolobenzodiazepine derivatives

Kaliszczak, Maciej · 2011 · The University of Edinburgh · DOI

Full title: Rational design of pyrrolobenzodiazepine derivatives

Authors: Kaliszczak, Maciej

Year: 2011

Venue: The University of Edinburgh

DOI: http://hdl.handle.net/1842/4923

Thesis Novel and emerging targeted-based cancer therapy agents and methods.

Mohammad Hojjat-Farsangi (400459) · 2015 · Karolinska Institutet · DOI

Full title: Novel and emerging targeted-based cancer therapy agents and methods.

Authors: Mohammad Hojjat-Farsangi (400459)

Year: 2015

Venue: Karolinska Institutet

DOI: oai:figshare.com:article/27332139

Thesis Experimental models for antibody-drug conjugates in HER2-positive breast and gastric cancer with special reference to drug-tolerant persisting polyploid giant cancer cells

Yazdi, Narjes · 2025 · University of Helsinki (HELDA) · DOI

Full title: Experimental models for antibody-drug conjugates in HER2-positive breast and gastric cancer with special reference to drug-tolerant persisting polyploid giant cancer cells

Authors: Yazdi, Narjes

Year: 2025

Venue: University of Helsinki (HELDA)

DOI: http://hdl.handle.net/10138/625218

Thesis Antibody-drug conjugates in experimental models of HER2-positive breast cancer and gastric cancer with special reference to drug resistance

Pourjamal, Negar · 2025 · University of Helsinki (HELDA) · DOI

Full title: Antibody-drug conjugates in experimental models of HER2-positive breast cancer and gastric cancer with special reference to drug resistance

Authors: Pourjamal, Negar

Year: 2025

Venue: University of Helsinki (HELDA)

DOI: http://hdl.handle.net/10138/603220

Thesis Template directed synthesis of antibody Fc conjugates with concomitant ligand release

Postupalenko, Viktoriia; Marx, Leo; Viertl, David et al. · 2022 · École polytechnique fédérale de Lausanne (EPFL) · DOI

Full title: Template directed synthesis of antibody Fc conjugates with concomitant ligand release

Authors: Postupalenko, Viktoriia; Marx, Leo; Viertl, David; Gsponer, Nadege; Gasilova, Natalia; Denoel, Thibaut; Schaefer, Niklaus; Prior, John O.; Hagens, Gerrit; Levy, Frederic; Garrouste, Patrick; Segura, Jean-Manuel; Nyanguile, Origene

Year: 2022

Venue: École polytechnique fédérale de Lausanne (EPFL)

DOI: https://infoscience.epfl.ch/handle/20.500.14299/186729

Thesis Site-selective template-directed synthesis of antibody Fc conjugates with concomitant ligand release

Postupalenko, Viktoriia; Marx, Leo; Pantin, Mathilde et al. · 2024 · École polytechnique fédérale de Lausanne (EPFL) · DOI

Full title: Site-selective template-directed synthesis of antibody Fc conjugates with concomitant ligand release

Authors: Postupalenko, Viktoriia; Marx, Leo; Pantin, Mathilde; Viertl, David; Gsponer, Nadege; Giudice, Gaelle; Gasilova, Natalia; Schottelius, Margret; Levy, Frederic; Garrouste, Patrick; Segura, Jean-Manuel; Nyanguile, Origene

Year: 2024

Venue: École polytechnique fédérale de Lausanne (EPFL)

DOI: https://infoscience.epfl.ch/handle/20.500.14299/204781

Thesis PSMA-Targeted Small Molecule–Drug Conjugates Based on a Postprolyl Peptidase–Cleavable Linker for the Treatment of Prostate Cancer

Georgiev, Tony; Puglioli, Sara; Principi, Lucrezia et al. · 2025 · École polytechnique fédérale de Lausanne (EPFL) · DOI

Full title: PSMA-Targeted Small Molecule–Drug Conjugates Based on a Postprolyl Peptidase–Cleavable Linker for the Treatment of Prostate Cancer

Authors: Georgiev, Tony; Puglioli, Sara; Principi, Lucrezia; Gilardoni, Ettore; Pellegrino, Christian; Bassi, Gabriele; Galbiati, Andrea; Neri, Dario; Cazzamalli, Samuele

Year: 2025

Venue: École polytechnique fédérale de Lausanne (EPFL)

DOI: https://infoscience.epfl.ch/handle/20.500.14299/250676

Thesis Hybrid Polymer Therapeutics Incorporating Bioresponsive, Coiled Coil Peptide Linkers

Apostolovic, Bojana; Deacon, Samuel P. E.; Duncan, Ruth et al. · 2010 · École polytechnique fédérale de Lausanne (EPFL) · DOI

Full title: Hybrid Polymer Therapeutics Incorporating Bioresponsive, Coiled Coil Peptide Linkers

Authors: Apostolovic, Bojana; Deacon, Samuel P. E.; Duncan, Ruth; Klok, Harm-Anton

Year: 2010

Venue: École polytechnique fédérale de Lausanne (EPFL)

DOI: https://infoscience.epfl.ch/handle/20.500.14299/55256

Thesis Smart chemistry for traceless release of anticancer therapeutics

Prange, Celine Jasmin; Hu, Xile; Tang, Li · 2024 · École polytechnique fédérale de Lausanne (EPFL) · DOI

Full title: Smart chemistry for traceless release of anticancer therapeutics

Authors: Prange, Celine Jasmin; Hu, Xile; Tang, Li

Year: 2024

Venue: École polytechnique fédérale de Lausanne (EPFL)

DOI: https://infoscience.epfl.ch/handle/20.500.14299/204926

Thesis Engineering a thermostable human prolyl endopeptidase for antibody-directed enzyme prodrug therapy

Heinis, Christian; Alessi, Patrizia; Neri, Dario · 2008 · École polytechnique fédérale de Lausanne (EPFL) · DOI

Full title: Engineering a thermostable human prolyl endopeptidase for antibody-directed enzyme prodrug therapy

Authors: Heinis, Christian; Alessi, Patrizia; Neri, Dario

Year: 2008

Venue: École polytechnique fédérale de Lausanne (EPFL)

DOI: https://infoscience.epfl.ch/handle/20.500.14299/31198

Thesis Development of multivalent FAP-targeted Small Molecule-Drug Conjugates with tailored MMAE release kinetics

Bocci, Matilde; Principi, Lucrezia; Neri, Dario et al. · 2025 · École polytechnique fédérale de Lausanne (EPFL) · DOI

Full title: Development of multivalent FAP-targeted Small Molecule-Drug Conjugates with tailored MMAE release kinetics

Authors: Bocci, Matilde; Principi, Lucrezia; Neri, Dario; Cazzamalli, Samuele; Gilardoni, Ettore; Galbiati, Andrea

Year: 2025

Venue: École polytechnique fédérale de Lausanne (EPFL)

DOI: https://infoscience.epfl.ch/handle/20.500.14299/251908

Thesis Antibody-peptide conjugates deliver covalent inhibitors blocking oncogenic cathepsins

Petruzzella, Aaron Simone; Bruand, Marine; Santamaria-Martinez, Albert et al. · 2024 · École polytechnique fédérale de Lausanne (EPFL) · DOI

Full title: Antibody-peptide conjugates deliver covalent inhibitors blocking oncogenic cathepsins

Authors: Petruzzella, Aaron Simone; Bruand, Marine; Santamaria-Martinez, Albert; Katanayeva, Natalya; Reymond, Luc; Wehrle, Sarah; Georgeon, Sandrine; Inel, Damla; van Dalen, Floris J.; Viertl, David; Lau, Kelvin; Pojer, Florence; Schottelius, Margret; Zoete, Vincent; Verdoes, Martijn; Arber, Caroline; Correia, Bruno E.; Oricchio, Elisa

Year: 2024

Venue: École polytechnique fédérale de Lausanne (EPFL)

DOI: https://infoscience.epfl.ch/handle/20.500.14299/208675

Thesis Drug-to-Antibody Ratio Estimation via Proteoform Peak Integration in the Analysis of Antibody-Oligonucleotide Conjugates with Orbitrap Fourier Transform Mass Spectrometry

Nagornov, Konstantin O.; Gasilova, Natalia; Kozhinov, Anton N. et al. · 2021 · École polytechnique fédérale de Lausanne (EPFL) · DOI

Full title: Drug-to-Antibody Ratio Estimation via Proteoform Peak Integration in the Analysis of Antibody-Oligonucleotide Conjugates with Orbitrap Fourier Transform Mass Spectrometry

Authors: Nagornov, Konstantin O.; Gasilova, Natalia; Kozhinov, Anton N.; Virta, Pasi; Holm, Patrik; Menin, Laure; Nesatyy, Victor J.; Tsybin, Yury O.

Year: 2021

Venue: École polytechnique fédérale de Lausanne (EPFL)

DOI: https://infoscience.epfl.ch/handle/20.500.14299/182479

Thesis Hybrid Polymer Therapeutics Incorporating Bioresponsive, Coiled Coil Peptide Linkers

Apostolovic, Bojana · 2010 · École polytechnique fédérale de Lausanne (EPFL) · DOI

Full title: Hybrid Polymer Therapeutics Incorporating Bioresponsive, Coiled Coil Peptide Linkers

Authors: Apostolovic, Bojana

Year: 2010

Venue: École polytechnique fédérale de Lausanne (EPFL)

DOI: https://infoscience.epfl.ch/handle/20.500.14299/50450

Thesis Antibody-peptide conjugates for targeted inhibition of cysteine proteases

Oricchio, Elisa · 2024 · École polytechnique fédérale de Lausanne (EPFL) · DOI

Full title: Antibody-peptide conjugates for targeted inhibition of cysteine proteases

Authors: Oricchio, Elisa

Year: 2024

Venue: École polytechnique fédérale de Lausanne (EPFL)

DOI: https://infoscience.epfl.ch/handle/20.500.14299/208994

Thesis Chemical macrocyclization of peptides fused to antibody Fc fragments

Angelini, Alessandro; Diderich, Philippe; Morales-Sanfrutos, Julia et al. · 2012 · École polytechnique fédérale de Lausanne (EPFL) · DOI

Full title: Chemical macrocyclization of peptides fused to antibody Fc fragments

Authors: Angelini, Alessandro; Diderich, Philippe; Morales-Sanfrutos, Julia; Thurnheer, Sarah; Hacker, David; Menin, Laure; Heinis, Christian

Year: 2012

Venue: École polytechnique fédérale de Lausanne (EPFL)

DOI: https://infoscience.epfl.ch/handle/20.500.14299/85135

Thesis Phage selection of bicyclic peptides binding Her2

Diderich, Philippe; Heinis, Christian · 2014 · École polytechnique fédérale de Lausanne (EPFL) · DOI

Full title: Phage selection of bicyclic peptides binding Her2

Authors: Diderich, Philippe; Heinis, Christian

Year: 2014

Venue: École polytechnique fédérale de Lausanne (EPFL)

DOI: https://infoscience.epfl.ch/handle/20.500.14299/108651

Thesis APPLYING PROTEIN ENGINEERING TO INVESTIGATE IMMUNE BIOLOGY AND ENABLE FACILE MANUFACTURING OF ANTIBODY-DRUG CONJUGATES

Bernstein, Zachary Jacob · 2025 · Johns Hopkins University · DOI

Full title: APPLYING PROTEIN ENGINEERING TO INVESTIGATE IMMUNE BIOLOGY AND ENABLE FACILE MANUFACTURING OF ANTIBODY-DRUG CONJUGATES

Authors: Bernstein, Zachary Jacob

Year: 2025

Venue: Johns Hopkins University

DOI: https://jscholarship.library.jhu.edu/handle/1774.2/70618

Thesis IMMUNOTHERAPY FOR T CELL MALIGNANCIES

Ge, Jiaxin · 2025 · Johns Hopkins University · DOI

Full title: IMMUNOTHERAPY FOR T CELL MALIGNANCIES

Authors: Ge, Jiaxin

Year: 2025

Venue: Johns Hopkins University

DOI: https://jscholarship.library.jhu.edu/handle/1774.2/70602

Thesis Targeting of cancer cells using click-functionalized polymer capsules

Kamphuis, MMJ; Johnston, APR; Such, GK et al. · 2017 · University of Melbourne · DOI

Full title: Targeting of cancer cells using click-functionalized polymer capsules

Authors: Kamphuis, MMJ; Johnston, APR; Such, GK; Dam, HH; Evans, RA; Scott, AM; Nice, EC; Heath, JK; Caruso, F

Year: 2017

Venue: University of Melbourne

DOI: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000284202200016&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=d4d813f4571fa7d6246bdc0dfeca3a1c

Thesis Antibody-drug conjugates for cancer therapy

Parslow, AC; Parakh, S; Lee, FT et al. · 2022 · University of Melbourne · DOI

Full title: Antibody-drug conjugates for cancer therapy

Authors: Parslow, AC; Parakh, S; Lee, FT; Gan, HK; Scott, AM

Year: 2022

Venue: University of Melbourne

DOI: https://hdl.handle.net/11343/303951

Thesis Frizzled-7-targeted delivery of zinc oxide nanoparticles to drug-resistant breast cancer cells

Ruenraroengsak, Pakatip; Kiryushko, Darya; Theodorou, Ioannis G et al. · 2019 · University of Liverpool · DOI

Full title: Frizzled-7-targeted delivery of zinc oxide nanoparticles to drug-resistant breast cancer cells

Authors: Ruenraroengsak, Pakatip; Kiryushko, Darya; Theodorou, Ioannis G; Klosowski, Michal M; Taylor, Erik R; Niriella, Thisa; Palmieri, Carlo; Yague, Ernesto; Ryan, Mary P; Coombes, R Charles; Xie, Fang; Porter, Alexandra E

Year: 2019

Venue: University of Liverpool

DOI: oai:livrepository.liverpool.ac.uk:3075758

Thesis Tyrosine-based bioconjugations : strain-promoted cycloadditions for site-specific generation of protein conjugates

Bruins, Jorick J. · 2020 · Wageningen University & Research · DOI

Full title: Tyrosine-based bioconjugations : strain-promoted cycloadditions for site-specific generation of protein conjugates

Authors: Bruins, Jorick J.

Year: 2020

Venue: Wageningen University & Research

DOI: https://research.wur.nl/en/publications/tyrosine-based-bioconjugations-strain-promoted-cycloadditions-for

Thesis Tumor Uptake of Anti-CD20 Fabs Depends on Tumor Perfusion.

Mendler, Claudia Theresa; Feuchtinger, Annette; Heid, Irina et al. · 2016 · Technical University of Munich (TUM) · DOI

Full title: Tumor Uptake of Anti-CD20 Fabs Depends on Tumor Perfusion.

Authors: Mendler, Claudia Theresa;Feuchtinger, Annette;Heid, Irina;Aichler, Michaela;D'Alessandria, Calogero;Pirsig, Sabine;Blechert, Birgit;Wester, Hans-Jürgen;Braren, Rickmer;Walch, Axel;Skerra, Arne;Schwaiger, Markus

Year: 2016

Venue: Technical University of Munich (TUM)

DOI: https://mediatum.ub.tum.de/1361825

Thesis Molecular precision chemotherapy: overcoming resistance to targeted therapies?

Burdach, Stefan · 2014 · Technical University of Munich (TUM) · DOI

Full title: Molecular precision chemotherapy: overcoming resistance to targeted therapies?

Authors: Burdach, Stefan

Year: 2014

Venue: Technical University of Munich (TUM)

DOI: https://mediatum.ub.tum.de/1256100

Thesis Preparation and preclinical assessment of folate-conjugated, radiolabelled antibodies

Henriksen, G; Bruland, OS; Larsen, RH · 2005 · Technical University of Munich (TUM) · DOI

Full title: Preparation and preclinical assessment of folate-conjugated, radiolabelled antibodies

Authors: Henriksen, G;Bruland, OS;Larsen, RH

Year: 2005

Venue: Technical University of Munich (TUM)

DOI: https://mediatum.ub.tum.de/1333232

Thesis Targeted Delivery of Proteasome Inhibitors to Somatostatin-Receptor-Expressing Cancer Cells by Octreotide Conjugation.

Beck, Philipp; Cui, Haissi; Hegemann, Julian D et al. · 2015 · Technical University of Munich (TUM) · DOI

Full title: Targeted Delivery of Proteasome Inhibitors to Somatostatin-Receptor-Expressing Cancer Cells by Octreotide Conjugation.

Authors: Beck, Philipp;Cui, Haissi;Hegemann, Julian D;Marahiel, Mohammed A;Krüger, Achim;Groll, Michael

Year: 2015

Venue: Technical University of Munich (TUM)

DOI: https://mediatum.ub.tum.de/1321589

Thesis Targeted Delivery of Proteasome Inhibitors to Somatostatin-Receptor-Expressing Cancer Cells by Octreotide Conjugation

Beck, Philipp; Cui, Haissi; Hegemann, Julian D. et al. · 2015 · Technical University of Munich (TUM) · DOI

Full title: Targeted Delivery of Proteasome Inhibitors to Somatostatin-Receptor-Expressing Cancer Cells by Octreotide Conjugation

Authors: Beck, Philipp;Cui, Haissi;Hegemann, Julian D.;Marahiel, Mohammed A.;Krüger, Achim;Groll, Michael

Year: 2015

Venue: Technical University of Munich (TUM)

DOI: https://mediatum.ub.tum.de/1295552

Thesis Matrix metalloproteinase-9 (MMP-9) as an activator of nanosystems for targeted drug delivery in pancreatic cancer.

Grünwald, Barbara; Vandooren, Jennifer; Locatelli, Erica et al. · 2016 · Technical University of Munich (TUM) · DOI

Full title: Matrix metalloproteinase-9 (MMP-9) as an activator of nanosystems for targeted drug delivery in pancreatic cancer.

Authors: Grünwald, Barbara;Vandooren, Jennifer;Locatelli, Erica;Fiten, Pierre;Opdenakker, Ghislain;Proost, Paul;Krüger, Achim;Lellouche, Jean Paul;Israel, Liron Limor;Shenkman, Louis;Comes Franchini, Mauro

Year: 2016

Venue: Technical University of Munich (TUM)

DOI: https://mediatum.ub.tum.de/1362906

Thesis ??Zr-Labeled Versus ¹²?I-Labeled ?HER2 Fab with Optimized Plasma Half-Life for High-Contrast Tumor Imaging In Vivo.

Mendler, Claudia T; Gehring, Torben; Wester, Hans-Jürgen et al. · 2015 · Technical University of Munich (TUM) · DOI

Full title: ??Zr-Labeled Versus ¹²?I-Labeled ?HER2 Fab with Optimized Plasma Half-Life for High-Contrast Tumor Imaging In Vivo.

Authors: Mendler, Claudia T;Gehring, Torben;Wester, Hans-Jürgen;Schwaiger, Markus;Skerra, Arne

Year: 2015

Venue: Technical University of Munich (TUM)

DOI: https://mediatum.ub.tum.de/1322648

Thesis 89Zr-Immuno-PET: Toward a Noninvasive Clinical Tool to Measure Target Engagement of Therapeutic Antibodies In Vivo.

Jauw, Yvonne; o'Donoghue, Joseph; Zijlstra, Josée et al. · 2019 · Technical University of Munich (TUM) · DOI

Full title: 89Zr-Immuno-PET: Toward a Noninvasive Clinical Tool to Measure Target Engagement of Therapeutic Antibodies In Vivo.

Authors: Jauw, Yvonne;o'Donoghue, Joseph;Zijlstra, Josée;Hoekstra, Otto;Menke-van der Houven van Oordt, C Willemien;Morschhauser, Franck;Carrasquillo, Jorge;Zweegman, Sonja;Pandit-Taskar, Neeta;Lammertsma, Adriaan;van Dongen, Guus;Boellaard, Ronald;Weber, Wolfgang;Huisman, Marc

Year: 2019

Venue: Technical University of Munich (TUM)

DOI: https://mediatum.ub.tum.de/1588146

Thesis EPITOPE EDITING IN HEMATOPOIETIC CELLS ENABLES PROTECTION FROM CD45-DIRECTED IMMUNOTHERAPIES FOR THE TREATMENT OF BLOOD CANCERS AND BEYOND

Wellhausen, Nils · 2024 · University of Pennsylvania · DOI

Full title: EPITOPE EDITING IN HEMATOPOIETIC CELLS ENABLES PROTECTION FROM CD45-DIRECTED IMMUNOTHERAPIES FOR THE TREATMENT OF BLOOD CANCERS AND BEYOND

Authors: Wellhausen, Nils

Year: 2024

Venue: University of Pennsylvania

DOI: https://repository.upenn.edu/handle/20.500.14332/60081

Thesis The organometallic ferrocene exhibits amplified anti-tumor activity by targeted delivery via highly selective ligands to αvβ3, αvβ6, or α5β1 integrins.

Ludwig, Beatrice Stefanie; Tomassi, Stefano; Di Maro, Salvatore et al. · 2021 · Technical University of Munich (TUM) · DOI

Full title: The organometallic ferrocene exhibits amplified anti-tumor activity by targeted delivery via highly selective ligands to αvβ3, αvβ6, or α5β1 integrins.

Authors: Ludwig, Beatrice Stefanie;Tomassi, Stefano;Di Maro, Salvatore;Di Leva, Francesco Saverio;Benge, Anke;Reichart, Florian;Nieberler, Markus;Kühn, Fritz E;Kessler, Horst;Marinelli, Luciana;Reuning, Ute;Kossatz, Susanne

Year: 2021

Venue: Technical University of Munich (TUM)

DOI: https://mediatum.ub.tum.de/1619848

Thesis Characterizing ALCAM as an oncoprotein and immunotherapeutic target in neuroblastoma

Lindsay, Jarrett · 2025 · University of Pennsylvania · DOI

Full title: Characterizing ALCAM as an oncoprotein and immunotherapeutic target in neuroblastoma

Authors: Lindsay, Jarrett

Year: 2025

Venue: University of Pennsylvania

DOI: https://repository.upenn.edu/handle/20.500.14332/60941

Thesis On the design of a bacterial cell-based prodrug enzyme system for HER2 positive breast cancer:

Kuziez, A · 2023 · University of Oxford - ORA · DOI

Full title: On the design of a bacterial cell-based prodrug enzyme system for HER2 positive breast cancer:

Authors: Kuziez, A

Year: 2023

Venue: University of Oxford - ORA

DOI: oai:ora.ox.ac.uk:uuid:3361148f-284b-4378-a24e-16f0b82c372e

Thesis Establishment of recombinant antibody technologies allowing for the generation of SNAP-tag fusion proteins

Nundalall, Trishana · 2023 · University of Cape Town · DOI

Full title: Establishment of recombinant antibody technologies allowing for the generation of SNAP-tag fusion proteins

Authors: Nundalall, Trishana

Year: 2023

Venue: University of Cape Town

DOI: http://hdl.handle.net/11427/38132

Thesis Compositions comprising enzyme cleavable linker platforms and conjugates thereof

Qvortrup, Katrine; id_orcid 0000-0003-3828-2069; Hansen, Anders Højgaard et al. · 2020 · Technical University of Denmark (DTU) · DOI

Full title: Compositions comprising enzyme cleavable linker platforms and conjugates thereof

Authors: Qvortrup, Katrine; id_orcid 0000-0003-3828-2069; Hansen, Anders Højgaard; Grier, Katja Egeskov; id_orcid 0000-0002-9854-1440; Nørskov, Amalie; id_orcid 0000-0001-5278-532X

Year: 2020

Venue: Technical University of Denmark (DTU)

DOI: https://orbit.dtu.dk/en/publications/3c2ad538-7c40-41b8-809e-a7e8186f9028

Thesis Cancer cell killing using engineered intracellular antibody fragments

Chambers, J · 2018 · University of Oxford - ORA · DOI

Full title: Cancer cell killing using engineered intracellular antibody fragments

Authors: Chambers, J

Year: 2018

Venue: University of Oxford - ORA

DOI: oai:ora.ox.ac.uk:uuid:2da702d7-3135-4dc3-ae62-2e55fad6c935

Thesis Precision Targeting of Tumor antigens by glycan Integrated Design Antibody Libraries

Gatos, Spyridon; id_orcid 0000-0002-0530-0681 · 2023 · Technical University of Denmark (DTU) · DOI

Full title: Precision Targeting of Tumor antigens by glycan Integrated Design Antibody Libraries

Authors: Gatos, Spyridon; id_orcid 0000-0002-0530-0681

Year: 2023

Venue: Technical University of Denmark (DTU)

DOI: https://orbit.dtu.dk/en/publications/084bc894-ec78-4513-b83f-e2419a06b924

Thesis Protein engineering to capture and kill cancer cells

Veggiani, G · 2015 · University of Oxford - ORA · DOI

Full title: Protein engineering to capture and kill cancer cells

Authors: Veggiani, G

Year: 2015

Venue: University of Oxford - ORA

DOI: oai:ora.ox.ac.uk:uuid:620a951d-a59b-4a33-b071-d758964e6303

Thesis Internalising radioimmunoconjugates to target KRas cancer cells for simultaneous radio-ligand therapy and radiosensitisation

Lourenço, J · 2024 · University of Oxford - ORA · DOI

Full title: Internalising radioimmunoconjugates to target KRas cancer cells for simultaneous radio-ligand therapy and radiosensitisation

Authors: Lourenço, J

Year: 2024

Venue: University of Oxford - ORA

DOI: oai:ora.ox.ac.uk:uuid:51e38f56-ddd4-4271-af13-cc8f3a999b75

Thesis A HER2 Specific Nanobody–Drug Conjugate:Site-Selective Bioconjugation and In Vitro Evaluation in Breast Cancer Models

Hansen, Anders H.; Andersen, Kasper I. H.; Xin, Li et al. · 2025 · Technical University of Denmark (DTU) · DOI

Full title: A HER2 Specific Nanobody–Drug Conjugate:Site-Selective Bioconjugation and In Vitro Evaluation in Breast Cancer Models

Authors: Hansen, Anders H.; Andersen, Kasper I. H.; Xin, Li; Krigslund, Oliver; Behrendt, Niels; Engelholm, Lars H.; Bang-Bertelsen, Claus H.; id_orcid 0000-0003-4541-2538; Schoffelen, Sanne; id_orcid 0000-0003-2664-8561; Qvortrup, Katrine; id_orcid 0000-0003-3828-2069

Year: 2025

Venue: Technical University of Denmark (DTU)

DOI: https://orbit.dtu.dk/en/publications/90bd0b68-9087-49d5-a9ee-b1eb49393b83

Thesis Advances in antibody-based strategies for targeting cancer-associated glycopeptide antigens

Meier, Edward P. W.; Laustsen, Andreas H.; id_orcid 0000-0001-6918-5574 · 2025 · Technical University of Denmark (DTU) · DOI

Full title: Advances in antibody-based strategies for targeting cancer-associated glycopeptide antigens

Authors: Meier, Edward P. W.; Laustsen, Andreas H.; id_orcid 0000-0001-6918-5574

Year: 2025

Venue: Technical University of Denmark (DTU)

DOI: https://orbit.dtu.dk/en/publications/ea628ba6-3dc2-4c10-8408-1af2b0327fc5

Thesis Advanced Bioconjugation Technologies for Site-selective Protein Modification:Antibody Drug Conjugates

Grier, Katja Egeskov; id_orcid 0000-0002-9854-1440 · 2022 · Technical University of Denmark (DTU) · DOI

Full title: Advanced Bioconjugation Technologies for Site-selective Protein Modification:Antibody Drug Conjugates

Authors: Grier, Katja Egeskov; id_orcid 0000-0002-9854-1440

Year: 2022

Venue: Technical University of Denmark (DTU)

DOI: https://orbit.dtu.dk/en/publications/c2789db1-9f2c-4338-96ed-30591bcab31e

Thesis All-in-one disulfide bridging enables the generation of antibody conjugates with modular cargo loading

Dannheim, Friederike M.; Walsh, Stephen J.; Orozco, Carolina T. et al. · 2022 · Technical University of Denmark (DTU) · DOI

Full title: All-in-one disulfide bridging enables the generation of antibody conjugates with modular cargo loading

Authors: Dannheim, Friederike M.; Walsh, Stephen J.; Orozco, Carolina T.; Hansen, Anders Højgaard; Bargh, Jonathan D.; Jackson, Sophie E.; Bond, Nicholas J.; Parker, Jeremy S.; Carroll, Jason S.; Spring, David R.

Year: 2022

Venue: Technical University of Denmark (DTU)

DOI: https://orbit.dtu.dk/en/publications/6847e749-bc33-4f8a-9ade-e4cf6a0c8bba

Thesis The collagen receptor uPARAP/Endo180 as a novel target for antibody-drug conjugate mediated treatment of mesenchymal and leukemic cancers

Nielsen, Christoffer Fagernæs; van Putten, Sander Maarten; Lund, Ida Katrine et al. · 2017 · University of Copenhagen · DOI

Full title: The collagen receptor uPARAP/Endo180 as a novel target for antibody-drug conjugate mediated treatment of mesenchymal and leukemic cancers

Authors: Nielsen, Christoffer Fagernæs; van Putten, Sander Maarten; Lund, Ida Katrine; Melander, Maria Carlsén; Nørregaard, Kirstine Sandal; Jürgensen, Henrik Jessen; Reckzeh, Kristian; Christensen, Kristine Rothaus; Ingvarsen, Signe Ziir; Gårdsvoll, Henrik; Jensen, Kamilla Ellermann; Hamerlik, Petra; Engelholm, Lars Henning; Behrendt, Niels

Year: 2017

Venue: University of Copenhagen

DOI: https://researchprofiles.ku.dk/da/publications/08f41ca8-76fb-4adc-bab9-afacc3121abb

Thesis Compositions comprising enzyme cleavable linker platforms and conjugates thereof

Qvortrup, Katrine; id_orcid 0000-0003-3828-2069; Hansen, Anders Højgaard et al. · 2020 · Technical University of Denmark (DTU) · DOI

Full title: Compositions comprising enzyme cleavable linker platforms and conjugates thereof

Authors: Qvortrup, Katrine; id_orcid 0000-0003-3828-2069; Hansen, Anders Højgaard; Grier, Katja Egeskov; id_orcid 0000-0002-9854-1440; Nørskov, Amalie; id_orcid 0000-0001-5278-532X

Year: 2020

Venue: Technical University of Denmark (DTU)

DOI: https://orbit.dtu.dk/en/publications/3c2ad538-7c40-41b8-809e-a7e8186f9028

Thesis Role of nanocarrier systems in cancer nanotherapy

Mozafari, M.R.; Pardakhty, A.; Azarmi, S. et al. · 2009 · Charles Sturt University - Research Output · DOI

Full title: Role of nanocarrier systems in cancer nanotherapy

Authors: Mozafari, M.R.; Pardakhty, A.; Azarmi, S.; Jazayeri, Jalal; Nokhodchi, A.; Omri, A.

Year: 2009

Venue: Charles Sturt University - Research Output

DOI: https://researchoutput.csu.edu.au/en/publications/5d393890-884d-46e3-bbe8-dbc8acbbe453

Thesis Targeted delivery of alcohol-containing payloads with antibody-drug conjugates

Grier, Katja E.; id_orcid 0000-0002-9854-1440; Hansen, Anders H. et al. · 2023 · Technical University of Denmark (DTU) · DOI

Full title: Targeted delivery of alcohol-containing payloads with antibody-drug conjugates

Authors: Grier, Katja E.; id_orcid 0000-0002-9854-1440; Hansen, Anders H.; Haxvig, Christina S.; Li, Xin; Krigslund, Oliver; Behrendt, Niels; Engelholm, Lars H.; Rossi, Fabio; Sousa, Bebiana C.; Harradence, Grant J.; Camper, Nicolas; Qvortrup, Katrine M.; id_orcid 0000-0003-3828-2069

Year: 2023

Venue: Technical University of Denmark (DTU)

DOI: https://orbit.dtu.dk/en/publications/608c1fa6-6d8b-4d6a-976f-95e643ba8ce5

Thesis Utilization of monoclonal antibody-targeted nanomaterials in the treatment of cancer

Julien, Daniel C; Behnke, Steven; Wang, Guankui K et al. · 2011 · Charles Sturt University - Research Output · DOI

Full title: Utilization of monoclonal antibody-targeted nanomaterials in the treatment of cancer

Authors: Julien, Daniel C; Behnke, Steven; Wang, Guankui K; Murdoch, Gordon K; Hill, Rodney A; id_orcid 0000-0001-9990-1113

Year: 2011

Venue: Charles Sturt University - Research Output

DOI: https://researchoutput.csu.edu.au/en/publications/0d654cfc-f2e8-4121-9da1-e12bb45dedda

Thesis Selective Delivery of Drugs to the CNS for Treatment of Neurological Diseases

Lillethorup, Ida Aaberg · 2024 · Technical University of Denmark (DTU) · DOI

Full title: Selective Delivery of Drugs to the CNS for Treatment of Neurological Diseases

Authors: Lillethorup, Ida Aaberg

Year: 2024

Venue: Technical University of Denmark (DTU)

DOI: https://orbit.dtu.dk/en/publications/eea0c886-a276-40b5-9202-da804d5dc5b2

Thesis Preparation of Enzyme-Activated Thapsigargin Prodrugs by Solid-Phase Synthesis

Zimmermann, Tomas; Christensen, Søren Brøgger; Franzyk, Henrik · 2018 · University of Copenhagen · DOI

Full title: Preparation of Enzyme-Activated Thapsigargin Prodrugs by Solid-Phase Synthesis

Authors: Zimmermann, Tomas; Christensen, Søren Brøgger; Franzyk, Henrik

Year: 2018

Venue: University of Copenhagen

DOI: https://researchprofiles.ku.dk/da/publications/83cf3579-3b6e-43d3-bc89-57eeeaf53fb0

Thesis A HER2 Specific Nanobody–Drug Conjugate:Site-Selective Bioconjugation and In Vitro Evaluation in Breast Cancer Models

Hansen, Anders H.; Andersen, Kasper I. H.; Xin, Li et al. · 2025 · Technical University of Denmark (DTU) · DOI

Full title: A HER2 Specific Nanobody–Drug Conjugate:Site-Selective Bioconjugation and In Vitro Evaluation in Breast Cancer Models

Year: 2025

Venue: Technical University of Denmark (DTU)

DOI: https://orbit.dtu.dk/en/publications/90bd0b68-9087-49d5-a9ee-b1eb49393b83

Thesis Targeting HER2-positive cancer using multifunctional nanoparticles

Juul, Christian Ammitzbøll · 2016 · Technical University of Denmark (DTU) · DOI

Full title: Targeting HER2-positive cancer using multifunctional nanoparticles

Authors: Juul, Christian Ammitzbøll

Year: 2016

Venue: Technical University of Denmark (DTU)

DOI: https://orbit.dtu.dk/en/publications/d2742181-afa3-49eb-972b-9372d2a14bd4

Thesis HER2-targeted, enzyme-activated liposomes show superior in vivo efficacy in an ovarian cancer model

Juul, Christian Ammitzbøll; Engel, Trine Bjørnbo; Fliedner, Frederikke Petrine et al. · 2024 · Technical University of Denmark (DTU) · DOI

Full title: HER2-targeted, enzyme-activated liposomes show superior in vivo efficacy in an ovarian cancer model

Authors: Juul, Christian Ammitzbøll; Engel, Trine Bjørnbo; Fliedner, Frederikke Petrine; Ringgaard, Lars; Eliasen, Rasmus; Melander, Fredrik; id_orcid 0000-0002-3670-6633; Bak, Martin; Kjær, Andreas; Henriksen, Jonas Rosager; id_orcid 0000-0001-9154-6639; Elema, Dennis Ringkjøbing; Hansen, Anders Elias; id_orcid 0000-0003-3526-3647; Andresen, Thomas Lars; id_orcid 0000-0002-1048-127X

Year: 2024

Venue: Technical University of Denmark (DTU)

DOI: https://orbit.dtu.dk/en/publications/aa3f79d3-9c84-433e-96ca-0d04aa34f465

Thesis All-in-one disulfide bridging enables the generation of antibody conjugates with modular cargo loading

Dannheim, Friederike M.; Walsh, Stephen J.; Orozco, Carolina T. et al. · 2022 · Technical University of Denmark (DTU) · DOI

Full title: All-in-one disulfide bridging enables the generation of antibody conjugates with modular cargo loading

Year: 2022

Venue: Technical University of Denmark (DTU)

DOI: https://orbit.dtu.dk/en/publications/6847e749-bc33-4f8a-9ade-e4cf6a0c8bba

Thesis Precision Targeting of Tumor antigens by glycan Integrated Design Antibody Libraries

Gatos, Spyridon; id_orcid 0000-0002-0530-0681 · 2023 · Technical University of Denmark (DTU) · DOI

Full title: Precision Targeting of Tumor antigens by glycan Integrated Design Antibody Libraries

Authors: Gatos, Spyridon; id_orcid 0000-0002-0530-0681

Year: 2023

Venue: Technical University of Denmark (DTU)

DOI: https://orbit.dtu.dk/en/publications/084bc894-ec78-4513-b83f-e2419a06b924

Thesis Improved Targeting of Cancers with Nanotherapeutics

Foster, Christian; Watson, Andre; Kaplinsky, Joseph John et al. · 2017 · Technical University of Denmark (DTU) · DOI

Full title: Improved Targeting of Cancers with Nanotherapeutics

Authors: Foster, Christian; Watson, Andre; Kaplinsky, Joseph John; Kamaly, Nazila; id_orcid 0000-0002-9716-5121

Year: 2017

Venue: Technical University of Denmark (DTU)

DOI: https://orbit.dtu.dk/en/publications/cdf1886c-c9b6-4d01-a6ab-820b232256a5

Thesis Selective Delivery of Drugs to the CNS for Treatment of Neurological Diseases

Lillethorup, Ida Aaberg · 2024 · Technical University of Denmark (DTU) · DOI

Full title: Selective Delivery of Drugs to the CNS for Treatment of Neurological Diseases

Authors: Lillethorup, Ida Aaberg

Year: 2024

Venue: Technical University of Denmark (DTU)

DOI: https://orbit.dtu.dk/en/publications/eea0c886-a276-40b5-9202-da804d5dc5b2

Thesis Advances in antibody-based strategies for targeting cancer-associated glycopeptide antigens

Meier, Edward P. W.; Laustsen, Andreas H.; id_orcid 0000-0001-6918-5574 · 2025 · Technical University of Denmark (DTU) · DOI

Full title: Advances in antibody-based strategies for targeting cancer-associated glycopeptide antigens

Authors: Meier, Edward P. W.; Laustsen, Andreas H.; id_orcid 0000-0001-6918-5574

Year: 2025

Venue: Technical University of Denmark (DTU)

DOI: https://orbit.dtu.dk/en/publications/ea628ba6-3dc2-4c10-8408-1af2b0327fc5

Thesis Advanced Bioconjugation Technologies for Site-selective Protein Modification:Antibody Drug Conjugates

Grier, Katja Egeskov; id_orcid 0000-0002-9854-1440 · 2022 · Technical University of Denmark (DTU) · DOI

Full title: Advanced Bioconjugation Technologies for Site-selective Protein Modification:Antibody Drug Conjugates

Authors: Grier, Katja Egeskov; id_orcid 0000-0002-9854-1440

Year: 2022

Venue: Technical University of Denmark (DTU)

DOI: https://orbit.dtu.dk/en/publications/c2789db1-9f2c-4338-96ed-30591bcab31e

Thesis Functionalization of Nanosystems in Cancer Treatment

Luiz, Marcela Tavares; Dutra, Jessyca Aparecida Paes [UNESP]; De Araújo, Jennifer Thayanne Cavalcante [UNESP] et al. · 2023 · Universidade Estadual Paulista (UNESP) · DOI

Full title: Functionalization of Nanosystems in Cancer Treatment

Authors: Luiz, Marcela Tavares; Dutra, Jessyca Aparecida Paes [UNESP]; De Araújo, Jennifer Thayanne Cavalcante [UNESP]; Di Filippo, Leonardo Delello [UNESP]; Duarte, Jonatas Lobato [UNESP]; Chorilli, Marlus [UNESP]

Year: 2023

Venue: Universidade Estadual Paulista (UNESP)

DOI: http://dx.doi.org/10.1007/978-3-031-17831-3_3

Thesis Immunoliposomes: A review on functionalization strategies and targets for drug delivery

Eloy, Josimar O. [UNESP]; Petrilli, Raquel [UNESP]; Trevizan, Lucas Noboru Fatori [UNESP] et al. · 2018 · Universidade Estadual Paulista (UNESP) · DOI

Full title: Immunoliposomes: A review on functionalization strategies and targets for drug delivery

Authors: Eloy, Josimar O. [UNESP]; Petrilli, Raquel [UNESP]; Trevizan, Lucas Noboru Fatori [UNESP]; Chorilli, Marlus [UNESP]

Year: 2018

Venue: Universidade Estadual Paulista (UNESP)

DOI: http://dx.doi.org/10.1016/j.colsurfb.2017.07.085

Thesis EGFR-targeted immunoliposomes efficiently deliver docetaxel to prostate cancer cells

Eloy, Josimar O.; Ruiz, Amalia; de Lima, Felipe Tita [UNESP] et al. · 2020 · Universidade Estadual Paulista (UNESP) · DOI

Full title: EGFR-targeted immunoliposomes efficiently deliver docetaxel to prostate cancer cells

Authors: Eloy, Josimar O.; Ruiz, Amalia; de Lima, Felipe Tita [UNESP]; Petrilli, Raquel; Raspantini, Giovanni; Nogueira, Karina Alexandre Barros; Santos, Elias; de Oliveira, Carlos Sabino; Borges, Júlio César; Marchetti, Juliana Maldonado; Al-Jamal, Wafa T.; Chorilli, Marlus [UNESP]

Year: 2020

Venue: Universidade Estadual Paulista (UNESP)

DOI: http://dx.doi.org/10.1016/j.colsurfb.2020.111185

Thesis Anti-EGFR liquid crystalline nanodispersions for docetaxel delivery: Formulation, characterization and cytotoxicity in cancer cells

Trevizan, Lucas Noboru Fatori [UNESP]; Eloy, Josimar O.; Luiz, Marcela Tavares et al. · 2021 · Universidade Estadual Paulista (UNESP) · DOI

Full title: Anti-EGFR liquid crystalline nanodispersions for docetaxel delivery: Formulation, characterization and cytotoxicity in cancer cells

Authors: Trevizan, Lucas Noboru Fatori [UNESP]; Eloy, Josimar O.; Luiz, Marcela Tavares; Petrilli, Raquel; Junior, Sergio Luiz Ramos; Borges, Julio César; Marchetti, Juliana Maldonado; Chorilli, Marlus [UNESP]

Year: 2021

Venue: Universidade Estadual Paulista (UNESP)

DOI: http://dx.doi.org/10.1016/j.colsurfa.2020.126058

Thesis Insights and therapeutic advances in pancreatic cancer: the role of electron microscopy in decoding the tumor microenvironment

Dai, Hong; Chen, Xingxuan; Yang, Jiawen et al. · 2024 · Hong Kong University of Science and Technology (HKUST) · DOI

Full title: Insights and therapeutic advances in pancreatic cancer: the role of electron microscopy in decoding the tumor microenvironment

Authors: Dai, Hong; Chen, Xingxuan; Yang, Jiawen; Wang, Yuying; Loiola, Rodrigo Azevedo; Lu, Aiping; Cheung, Kenneth C. P.

Year: 2024

Venue: Hong Kong University of Science and Technology (HKUST)

DOI: http://repository.hkust.edu.hk/ir/Record/1783.1-148941

Thesis Disrupting tumor onset and growth via selective cell tagging (SeCT) therapy

Vong, Kenward; Tahara, Tsuyoshi; Urano, Sayaka et al. · 2021 · Hong Kong University of Science and Technology (HKUST) · DOI

Full title: Disrupting tumor onset and growth via selective cell tagging (SeCT) therapy

Authors: Vong, Kenward; Tahara, Tsuyoshi; Urano, Sayaka; Nasibullin, Igor; Tsubokura, Kazuki; Nakao, Yoichi; Kurbangalieva, Almira; Onoe, Hirotaka; Watanabe, Yasuyoshi; Tanaka, Katsunori

Year: 2021

Venue: Hong Kong University of Science and Technology (HKUST)

DOI: http://repository.hkust.edu.hk/ir/Record/1783.1-112374

Thesis Oxanorbordienes and Azanorbordienes as thiol cleavable linkers

De Pascalis, Lucrezia · 2021 · Georgia Institute of Technology · DOI

Full title: Oxanorbordienes and Azanorbordienes as thiol cleavable linkers

Authors: De Pascalis, Lucrezia

Year: 2021

Venue: Georgia Institute of Technology

DOI: http://hdl.handle.net/1853/65017

Thesis Investigation of targeting mechanism of new dextran-peptide-methotrexate conjugates using biodistribution study in matrix-metalloproteinase overexpressing tumor xenograft model

Chau, Ying; Dang, Natalie M.; Tan, Frederick E. et al. · 2006 · Hong Kong University of Science and Technology (HKUST) · DOI

Full title: Investigation of targeting mechanism of new dextran-peptide-methotrexate conjugates using biodistribution study in matrix-metalloproteinase overexpressing tumor xenograft model

Authors: Chau, Ying; Dang, Natalie M.; Tan, Frederick E.; Langer, Robert Samuel M.

Year: 2006

Venue: Hong Kong University of Science and Technology (HKUST)

DOI: http://repository.hkust.edu.hk/ir/Record/1783.1-33997

Thesis Synthesis and characterization of dextran-peptide-methotrexate conjugates for tumor targeting via mediation by matrix-metalloproteinase II and matrixmetalloproteinase IX

Chau, Ying; Tan, Frederick E.; Langer, Robert Samuel M. · 2004 · Hong Kong University of Science and Technology (HKUST) · DOI

Full title: Synthesis and characterization of dextran-peptide-methotrexate conjugates for tumor targeting via mediation by matrix-metalloproteinase II and matrixmetalloproteinase IX

Authors: Chau, Ying; Tan, Frederick E.; Langer, Robert Samuel M.

Year: 2004

Venue: Hong Kong University of Science and Technology (HKUST)

DOI: http://repository.hkust.edu.hk/ir/Record/1783.1-33989

Thesis Antitumor efficacy of a novel polymer peptide drug conjugate in human tumor xenograft models

Chau, Ying; Padera, Robert F.; Dang, Natalie M. et al. · 2005 · Hong Kong University of Science and Technology (HKUST) · DOI

Full title: Antitumor efficacy of a novel polymer peptide drug conjugate in human tumor xenograft models

Authors: Chau, Ying; Padera, Robert F.; Dang, Natalie M.; Langer, Robert Samuel M.

Year: 2005

Venue: Hong Kong University of Science and Technology (HKUST)

DOI: http://repository.hkust.edu.hk/ir/Record/1783.1-33999

Thesis N-terminal α-amino group modification of antibodies using a site-selective click chemistry method

Li, De-zhi; Han, Bing-nan; Wei, Rui et al. · 2018 · Hong Kong University of Science and Technology (HKUST) · DOI

Full title: N-terminal α-amino group modification of antibodies using a site-selective click chemistry method

Authors: Li, De-zhi; Han, Bing-nan; Wei, Rui; Yao, Gui-Yang; Chen, Zhizhen; Liu, Jie; Poon, Terence C. W.; Su, Wu; Zhu, Zhongyu; Dimitrov, Dimiter S.; Zhao, Qi

Year: 2018

Venue: Hong Kong University of Science and Technology (HKUST)

DOI: http://repository.hkust.edu.hk/ir/Record/1783.1-95463

Thesis Improving the Therapeutic Potential of Tyrosine Kinase Inhibitors in the Treatment of Glioblastoma: Conjugation with Heptamethine Cyanine Dyes

Cooper, Elizabeth Alexandra · 2023 · University of Auckland · DOI

Full title: Improving the Therapeutic Potential of Tyrosine Kinase Inhibitors in the Treatment of Glioblastoma: Conjugation with Heptamethine Cyanine Dyes

Authors: Cooper, Elizabeth Alexandra

Year: 2023

Venue: University of Auckland

DOI: https://hdl.handle.net/2292/66539

Thesis Modulating prodrug selectivity for prostate cancer: Design, synthesis, and testing of a modified peptide vehicle

Tondl, Elisabeth Michelle · 2020 · University of Sydney · DOI

Full title: Modulating prodrug selectivity for prostate cancer: Design, synthesis, and testing of a modified peptide vehicle

Authors: Tondl, Elisabeth Michelle

Year: 2020

Venue: University of Sydney

DOI: https://hdl.handle.net/2123/24553

Thesis The development and evaluation of PSMA targeted therapeutic and imaging agents

Yang, Zixuan · 2024 · Imperial College London · DOI

Full title: The development and evaluation of PSMA targeted therapeutic and imaging agents

Authors: Yang, Zixuan

Year: 2024

Venue: Imperial College London

DOI: http://hdl.handle.net/10044/1/115593

Thesis Fluorescently tagged prostate-specific antigen targeting peptides as models of tumour activated prodrugs

Di Marco, Lina · 2013 · University of Sydney · DOI

Full title: Fluorescently tagged prostate-specific antigen targeting peptides as models of tumour activated prodrugs

Authors: Di Marco, Lina

Year: 2013

Venue: University of Sydney

DOI: http://hdl.handle.net/2123/11775

Thesis New Directions Towards the Development of Protein Drug Conjugates for the Treatment of Cancer

Mckertish, Candice · 2021 · University of Sydney · DOI

Full title: New Directions Towards the Development of Protein Drug Conjugates for the Treatment of Cancer

Authors: Mckertish, Candice

Year: 2021

Venue: University of Sydney

DOI: https://hdl.handle.net/2123/27521

Thesis Demibodies for highly specific detection and cell-killing

Manakas, Athina · 2019 · University of Sydney · DOI

Full title: Demibodies for highly specific detection and cell-killing

Authors: Manakas, Athina

Year: 2019

Venue: University of Sydney

DOI: https://hdl.handle.net/2123/24235

Thesis THE in vitro EVALUATION OF NEW TARGETED DRUG DELIVERY SYSTEMS FOR THE TREATMENT OF BREAST AND PROSTATE CANCER

Khazeni, Sepideh · 2021 · University of Sydney · DOI

Full title: THE in vitro EVALUATION OF NEW TARGETED DRUG DELIVERY SYSTEMS FOR THE TREATMENT OF BREAST AND PROSTATE CANCER

Authors: Khazeni, Sepideh

Year: 2021

Venue: University of Sydney

DOI: https://hdl.handle.net/2123/27294

Thesis A study of Pyropheophorbide-a based photosensitisers for photodynamic therapy

Pye, Hayley · 2015 · Imperial College London · DOI

Full title: A study of Pyropheophorbide-a based photosensitisers for photodynamic therapy

Authors: Pye, Hayley

Year: 2015

Venue: Imperial College London

DOI: http://hdl.handle.net/10044/1/24127

Thesis Antibody and Anticancer Drug Functionalised Gold Nanoparticles as Novel and Potential Immunotherapeutic Agents for Targeted Biological Treatment Against Cancers

Anisuzzman, Mohammad · 2023 · University of Sydney · DOI

Full title: Antibody and Anticancer Drug Functionalised Gold Nanoparticles as Novel and Potential Immunotherapeutic Agents for Targeted Biological Treatment Against Cancers

Authors: Anisuzzman, Mohammad

Year: 2023

Venue: University of Sydney

DOI: https://hdl.handle.net/2123/31059

Thesis Use of a next generation maleimide in combination with THIOMAB (TM) antibody technology delivers a highly stable, potent and near homogeneous THIOMAB (TM) antibody-drug conjugate (TDC)

Nunes, JPM; Vassileva, V; Robinson, E et al. · 2017 · Imperial College London · DOI

Full title: Use of a next generation maleimide in combination with THIOMAB (TM) antibody technology delivers a highly stable, potent and near homogeneous THIOMAB (TM) antibody-drug conjugate (TDC)

Authors: Nunes, JPM; Vassileva, V; Robinson, E; Morais, M; Smith, MEB; Pedley, RB; Caddick, S; Baker, JR; Chudasama, V

Year: 2017

Venue: Imperial College London

DOI: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000401525700035&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Thesis Conditional protein degradation with novel PROteolysis-TArgeting Chimeras (PROTACs)

Zhang, Qisi · 2023 · Imperial College London · DOI

Full title: Conditional protein degradation with novel PROteolysis-TArgeting Chimeras (PROTACs)

Authors: Zhang, Qisi

Year: 2023

Venue: Imperial College London

DOI: http://hdl.handle.net/10044/1/108288

Thesis Peptide‐drug conjugates: a new hope for cancer

Armstrong, Amy; Coburn, Fleur; Nsereko, Yanyamba et al. · 2025 · Imperial College London · DOI

Full title: Peptide‐drug conjugates: a new hope for cancer

Authors: Armstrong, Amy; Coburn, Fleur; Nsereko, Yanyamba; Al Musaimi, Othman

Year: 2025

Venue: Imperial College London

DOI: https://hdl.handle.net/10044/1/121893

Thesis Investigations into the Development of Epothilones as Antibody-Drug Conjugate Payloads

Imlay, Hunter David · 2020 · Columbia University · DOI

Full title: Investigations into the Development of Epothilones as Antibody-Drug Conjugate Payloads

Authors: Imlay, Hunter David

Year: 2020

Venue: Columbia University

DOI: https://doi.org/10.7916/d8-kc6b-yw36

Thesis TUMOR-TARGETED RELEASE OF IMMUNOSTIMULATORY AGENTS: SYNTHESIS AND BIOLOGICAL EVALUATION OF IMIDAZOQUINOLINE-BASED PRODRUGS AND ANTIBODY CONJUGATES

BISBAL LOPEZ, LYDIA · 2023 · Università degli Studi di Milano (AIR) · DOI

Full title: TUMOR-TARGETED RELEASE OF IMMUNOSTIMULATORY AGENTS: SYNTHESIS AND BIOLOGICAL EVALUATION OF IMIDAZOQUINOLINE-BASED PRODRUGS AND ANTIBODY CONJUGATES

Authors: BISBAL LOPEZ, LYDIA

Year: 2023

Venue: Università degli Studi di Milano (AIR)

DOI: https://hdl.handle.net/2434/1019088

Thesis Fully Synthetic Trioxacarcins for Use in Antibody-Drug Conjugates

Magno, Ethan Lindsay · 2021 · Harvard University - DASH · DOI

Full title: Fully Synthetic Trioxacarcins for Use in Antibody-Drug Conjugates

Authors: Magno, Ethan Lindsay

Year: 2021

Venue: Harvard University - DASH

DOI: https://nrs.harvard.edu/URN-3:HUL.INSTREPOS:37368243

Thesis The Clean Cut: Design, Synthesis, Assay Optimization, and Biological Evaluation of Compounds That Can Produce Double Strand Breaks in Deoxyribonucleic Acid

Brouard, Maria · 2019 · Harvard University - DASH · DOI

Full title: The Clean Cut: Design, Synthesis, Assay Optimization, and Biological Evaluation of Compounds That Can Produce Double Strand Breaks in Deoxyribonucleic Acid

Authors: Brouard, Maria

Year: 2019

Venue: Harvard University - DASH

DOI: http://nrs.harvard.edu/urn-3:HUL.InstRepos:38811523

Thesis Synthesis and characterization of polyethylene glycol-doxorubicin conjugates containing β-thiopropanamide linkers for enhanced selective cytotoxicity against breast cancer cells

Supasena, Wiwat · 2019 · Chulalongkorn University · DOI

Full title: Synthesis and characterization of polyethylene glycol-doxorubicin conjugates containing β-thiopropanamide linkers for enhanced selective cytotoxicity against breast cancer cells

Authors: Supasena, Wiwat

Year: 2019

Venue: Chulalongkorn University

DOI: https://digital.car.chula.ac.th/chulaetd/8791

Thesis Epidermal growth factor receptor-targeted antibody therapy - Mechanisms of action and modulators of therapeutic efficacy

Lammerts van Bueren, Jeroen Jilles · 2008 · Utrecht University · DOI

Full title: Epidermal growth factor receptor-targeted antibody therapy - Mechanisms of action and modulators of therapeutic efficacy

Authors: Lammerts van Bueren, Jeroen Jilles

Year: 2008

Venue: Utrecht University

DOI: https://dspace.library.uu.nl/handle/1874/26198

Thesis Nanobody-photosensitizer conjugates for targeted photodynamic therapy

Heukers, Raimond; van Bergen en Henegouwen, P; Oliveira, Sabrina · 2014 · Utrecht University · DOI

Full title: Nanobody-photosensitizer conjugates for targeted photodynamic therapy

Authors: Heukers, Raimond; van Bergen en Henegouwen, P; Oliveira, Sabrina

Year: 2014

Venue: Utrecht University

DOI: https://dspace.library.uu.nl/handle/1874/307491

Thesis Complete regression of xenograft tumors upon targeted delivery of paclitaxel via ∏ - ∏ stacking stabilized polymeric micelles

Shi, Yang; van der Meel, Roy; Theek, Benjamin et al. · 2015 · Utrecht University · DOI

Full title: Complete regression of xenograft tumors upon targeted delivery of paclitaxel via ∏ - ∏ stacking stabilized polymeric micelles

Authors: Shi, Yang; van der Meel, Roy; Theek, Benjamin; Blenke, Erik Oude; Pieters, Ebel H. E.; Fens, Marcel H. A. M.; Ehling, Josef; Schiffelers, Raymond M.; Storm, Gert; van Nostrum, Cornelus F.; Lammers, Twan; Hennink, Wim E.

Year: 2015

Venue: Utrecht University

DOI: https://dspace.library.uu.nl/handle/1874/331325

Thesis Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer

Liu, J. F.; Moore, K. N.; Birrer, M. J. et al. · 2016 · Utrecht University · DOI

Full title: Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer

Authors: Liu, J. F.; Moore, K. N.; Birrer, M. J.; Berlin, S.; Matulonis, U. A.; Infante, J. R.; Wolpin, B.; Poon, K. A.; Firestein, R.; Xu, J.; Kahn, R.; Wang, Y.; Wood, K.; Darbonne, W. C.; Lackner, M. R.; Kelley, S. K.; Lu, X.; Choi, Y. J.; Maslyar, D.; Humke, E. W.; Burris, H. A.

Year: 2016

Venue: Utrecht University

DOI: https://dspace.library.uu.nl/handle/1874/345348

Thesis EGFR targeted nanobody-photosensitizer conjugates for photodynamic therapy in a pre-clinical model of head and neck cancer

Van Driel, Pieter B A A; Boonstra, Martin C.; Slooter, Maxime D. et al. · 2016 · Utrecht University · DOI

Full title: EGFR targeted nanobody-photosensitizer conjugates for photodynamic therapy in a pre-clinical model of head and neck cancer

Authors: Van Driel, Pieter B A A; Boonstra, Martin C.; Slooter, Maxime D.; Heukers, Raimond; Stammes, Marieke A.; Snoeks, Thomas J A; De Bruijn, Henriette S.; Van Diest, Paul J.; Vahrmeijer, Alexander L.; Van Bergen En Henegouwen, Paul M P; Van De Velde, Cornelis J H; Löwik, Clemens W G M; Robinson, Dominic J.; Oliveira, Sabrina

Year: 2016

Venue: Utrecht University

DOI: https://dspace.library.uu.nl/handle/1874/340479

Thesis An Anti-EGFR IgA That Displays Improved Pharmacokinetics and Myeloid Effector Cell Engagement In Vivo

Lohse, Stefan; Meyer, Saskia; Meulenbroek, Laura A P M et al. · 2016 · Utrecht University · DOI

Full title: An Anti-EGFR IgA That Displays Improved Pharmacokinetics and Myeloid Effector Cell Engagement In Vivo

Authors: Lohse, Stefan; Meyer, Saskia; Meulenbroek, Laura A P M; Jansen, J H Marco; Nederend, Maaike; Kretschmer, Anna; Klausz, Katja; Möginger, Uwe; Derer, Stefanie; Rösner, Thies; Kellner, Christian; Schewe, Denis; Sondermann, Peter; Tiwari, Sanjay; Kolarich, Daniel; Peipp, Matthias; Leusen, Jeanette H W; Valerius, Thomas

Year: 2016

Venue: Utrecht University

DOI: https://dspace.library.uu.nl/handle/1874/342876

Thesis Pharmacometrics for treatment optimization and drug development in oncology

de Vries Schultink, Aurelia H M · 2019 · Utrecht University · DOI

Full title: Pharmacometrics for treatment optimization and drug development in oncology

Authors: de Vries Schultink, Aurelia H M

Year: 2019

Venue: Utrecht University

DOI: https://dspace.library.uu.nl/handle/1874/381733

Thesis Engineering of camelid VHHs: applications in structural studies, diagnosis and solid tumor therapeutics

Xenaki, Aikaterini-Titika · 2024 · Utrecht University · DOI

Full title: Engineering of camelid VHHs: applications in structural studies, diagnosis and solid tumor therapeutics

Authors: Xenaki, Aikaterini-Titika

Year: 2024

Venue: Utrecht University

DOI: https://dspace.library.uu.nl/handle/1874/433681

Thesis Measurement of NLG207 (formerly CRLX101) nanoparticle-bound and released camptothecin in human plasma

Schmidt, Keith T; Peer, Cody J; Huitema, Alwin D R et al. · 2020 · Utrecht University · DOI

Full title: Measurement of NLG207 (formerly CRLX101) nanoparticle-bound and released camptothecin in human plasma

Authors: Schmidt, Keith T; Peer, Cody J; Huitema, Alwin D R; Williams, Monique D; Wroblewski, Susan; Schellens, Jan H M; Madan, Ravi A; Figg, William D

Year: 2020

Venue: Utrecht University

DOI: https://dspace.library.uu.nl/handle/1874/439737

Thesis Nanobody-drug conjugates to deliver drugs into target cells

Pronk, Sebas Daniël · 2024 · Utrecht University · DOI

Full title: Nanobody-drug conjugates to deliver drugs into target cells

Authors: Pronk, Sebas Daniël

Year: 2024

Venue: Utrecht University

DOI: https://dspace.library.uu.nl/handle/1874/433951

Thesis A mechanistic compartmental model for total antibody uptake in tumors

Thurber, Greg M.; Wittrup, Karl Dane · 2022 · Massachusetts Institute of Technology (MIT) · DOI

Full title: A mechanistic compartmental model for total antibody uptake in tumors

Authors: Thurber, Greg M.; Wittrup, Karl Dane

Year: 2022

Venue: Massachusetts Institute of Technology (MIT)

DOI: https://hdl.handle.net/1721.1/134471.2

Thesis IgG-Engineered Protective Antigen for Cytosolic Delivery of Proteins into Cancer Cells

Lu, Zeyu; Truex, Nicholas L; Melo, Mariane B et al. · 2022 · Massachusetts Institute of Technology (MIT) · DOI

Full title: IgG-Engineered Protective Antigen for Cytosolic Delivery of Proteins into Cancer Cells

Authors: Lu, Zeyu; Truex, Nicholas L; Melo, Mariane B; Cheng, Yiran; Li, Na; Irvine, Darrell J; Pentelute, Bradley L

Year: 2022

Venue: Massachusetts Institute of Technology (MIT)

DOI: https://hdl.handle.net/1721.1/133532.2

Thesis Targeting of drugs and nanoparticles to tumors

Rusolahti, Erkki; Bhatia, Sangeeta N. · 2011 · Massachusetts Institute of Technology (MIT) · DOI

Full title: Targeting of drugs and nanoparticles to tumors

Authors: Rusolahti, Erkki; Bhatia, Sangeeta N.

Year: 2011

Venue: Massachusetts Institute of Technology (MIT)

DOI: http://hdl.handle.net/1721.1/60655

Patent us-10449258-b2

· 2019

Full title: us-10449258-b2

Year: 2019

Patent us-10675352-b2

· 2020

Full title: us-10675352-b2

Year: 2020

Patent us-10736903-b2

· 2020

Full title: us-10736903-b2

Year: 2020

Patent us-10799598-b2

· 2020

Full title: us-10799598-b2

Year: 2020

Patent us-10758556-b2

· 2020

Full title: us-10758556-b2

Year: 2020

Patent us-10751346-b2

· 2020

Full title: us-10751346-b2

Year: 2020

Patent us-10842882-b2

· 2020

Full title: us-10842882-b2

Year: 2020

Patent us-11013816-b2

· 2021

Full title: us-11013816-b2

Year: 2021

Patent us-10975112-b2

· 2021

Full title: us-10975112-b2

Year: 2021

Patent us-11020490-b2

· 2021

Full title: us-11020490-b2

Year: 2021

Patent us-11077204-b2

· 2021

Full title: us-11077204-b2

Year: 2021

Patent us-12121527-b2

· 2024

Full title: us-12121527-b2

Year: 2024

Patent us-2002094964-a1

· 2002

Full title: us-2002094964-a1

Year: 2002

Patent us-2005238649-a1

· 2005

Full title: us-2005238649-a1

Year: 2005

Patent us-2008226657-a1

· 2008

Full title: us-2008226657-a1

Year: 2008

Patent us-2008248053-a1

· 2008

Full title: us-2008248053-a1

Year: 2008

Patent us-2008248051-a1

· 2008

Full title: us-2008248051-a1

Year: 2008

Patent us-4952394-a

· 1990

Full title: us-4952394-a

Year: 1990

Patent us-5028697-a

· 1991

Full title: us-5028697-a

Year: 1991

Patent us-5550246-a

· 1996

Full title: us-5550246-a

Year: 1996

Patent us-7498298-b2

· 2009

Full title: us-7498298-b2

Year: 2009

Patent us-8288352-b2

· 2012

Full title: us-8288352-b2

Year: 2012

Patent us-7968586-b2

· 2011

Full title: us-7968586-b2

Year: 2011

Patent us-8470980-b2

· 2013

Full title: us-8470980-b2

Year: 2013

Patent us-8343928-b2

· 2013

Full title: us-8343928-b2

Year: 2013

Patent us-8609105-b2

· 2013

Full title: us-8609105-b2

Year: 2013

Patent us-8871720-b2

· 2014

Full title: us-8871720-b2

Year: 2014

Patent us-8367065-b2

· 2013

Full title: us-8367065-b2

Year: 2013

Patent us-8828401-b2

· 2014

Full title: us-8828401-b2

Year: 2014

Patent us-9249186-b2

· 2016

Full title: us-9249186-b2

Year: 2016

Patent us-9272052-b2

· 2016

Full title: us-9272052-b2

Year: 2016

Patent us-9138486-b2

· 2015

Full title: us-9138486-b2

Year: 2015

Patent us-9387261-b2

· 2016

Full title: us-9387261-b2

Year: 2016

Patent us-9555126-b2

· 2017

Full title: us-9555126-b2

Year: 2017

Patent us-9814784-b2

· 2017

Full title: us-9814784-b2

Year: 2017

Patent us-9549993-b2

· 2017

Full title: us-9549993-b2

Year: 2017

Patent us-9463252-b2

· 2016

Full title: us-9463252-b2

Year: 2016

Patent us-9695189-b2

· 2017

Full title: us-9695189-b2

Year: 2017

Patent us-9586996-b2

· 2017

Full title: us-9586996-b2

Year: 2017

Patent us-9364554-b2

· 2016

Full title: us-9364554-b2

Year: 2016

Patent us-2018092985-a1

· 2018

Full title: us-2018092985-a1

Year: 2018

Patent us-2017340750-a1

· 2017

Full title: us-2017340750-a1

Year: 2017

Patent us-2018127512-a1

· 2018

Full title: us-2018127512-a1

Year: 2018

Patent us-2018147294-a1

· 2018

Full title: us-2018147294-a1

Year: 2018

Patent us-2018185486-a1

· 2018

Full title: us-2018185486-a1

Year: 2018

Patent us-2018140714-a1

· 2018

Full title: us-2018140714-a1

Year: 2018

Patent us-2018154018-a1

· 2018

Full title: us-2018154018-a1

Year: 2018

Patent us-2018185509-a1

· 2018

Full title: us-2018185509-a1

Year: 2018

Patent us-2018161446-a1

· 2018

Full title: us-2018161446-a1

Year: 2018

Patent us-2019038762-a1

· 2019

Full title: us-2019038762-a1

Year: 2019

Patent us-2019381079-a1

· 2019

Full title: us-2019381079-a1

Year: 2019

Patent us-2019388546-a1

· 2019

Full title: us-2019388546-a1

Year: 2019

Patent us-2020222553-a1

· 2020

Full title: us-2020222553-a1

Year: 2020

Patent us-2008300192-a1

· 2008

Full title: us-2008300192-a1

Year: 2008

Patent us-2008305044-a1

· 2008

Full title: us-2008305044-a1

Year: 2008

Patent us-2008279868-a1

· 2008

Full title: us-2008279868-a1

Year: 2008

Patent us-2009018086-a1

· 2009

Full title: us-2009018086-a1

Year: 2009

Patent us-2008293800-a1

· 2008

Full title: us-2008293800-a1

Year: 2008

Patent us-2009111756-a1

· 2009

Full title: us-2009111756-a1

Year: 2009

Patent us-2009047296-a1

· 2009

Full title: us-2009047296-a1

Year: 2009

Patent us-2009232810-a1

· 2009

Full title: us-2009232810-a1

Year: 2009

Patent us-2010092495-a1

· 2010

Full title: us-2010092495-a1

Year: 2010

Patent us-2010233190-a1

· 2010

Full title: us-2010233190-a1

Year: 2010

Patent us-2011020343-a1

· 2011

Full title: us-2011020343-a1

Year: 2011

Patent us-2012027783-a1

· 2012

Full title: us-2012027783-a1

Year: 2012

Patent us-2012034247-a1

· 2012

Full title: us-2012034247-a1

Year: 2012

Patent us-2012003248-a1

· 2012

Full title: us-2012003248-a1

Year: 2012

Patent us-2011064752-a1

· 2011

Full title: us-2011064752-a1

Year: 2011

Patent us-2012034246-a1

· 2012

Full title: us-2012034246-a1

Year: 2012

Patent us-2012003247-a1

· 2012

Full title: us-2012003247-a1

Year: 2012

Patent us-2012027784-a1

· 2012

Full title: us-2012027784-a1

Year: 2012

Patent us-2012141509-a1

· 2012

Full title: us-2012141509-a1

Year: 2012

Patent us-2012141508-a1

· 2012

Full title: us-2012141508-a1

Year: 2012

Patent us-2012148608-a1

· 2012

Full title: us-2012148608-a1

Year: 2012

Patent us-2012141510-a1

· 2012

Full title: us-2012141510-a1

Year: 2012

Patent us-2013129753-a1

· 2013

Full title: us-2013129753-a1

Year: 2013

Patent us-2012148610-a1

· 2012

Full title: us-2012148610-a1

Year: 2012

Patent us-2013157961-a1

· 2013

Full title: us-2013157961-a1

Year: 2013

Patent us-2013123465-a1

· 2013

Full title: us-2013123465-a1

Year: 2013

Patent us-2013209496-a1

· 2013

Full title: us-2013209496-a1

Year: 2013

Patent us-2013224228-a1

· 2013

Full title: us-2013224228-a1

Year: 2013

Patent us-2014050744-a1

· 2014

Full title: us-2014050744-a1

Year: 2014

Patent us-2014050746-a1

· 2014

Full title: us-2014050746-a1

Year: 2014

Patent us-2013336994-a1

· 2013

Full title: us-2013336994-a1

Year: 2013

Patent us-2014205616-a1

· 2014

Full title: us-2014205616-a1

Year: 2014

Patent us-2014072587-a1

· 2014

Full title: us-2014072587-a1

Year: 2014

Patent us-2014220047-a1

· 2014

Full title: us-2014220047-a1

Year: 2014

Patent us-2014199300-a1

· 2014

Full title: us-2014199300-a1

Year: 2014

Patent us-2014363452-a1

· 2014

Full title: us-2014363452-a1

Year: 2014

Patent us-2014294865-a1

· 2014

Full title: us-2014294865-a1

Year: 2014

Patent us-2014286969-a1

· 2014

Full title: us-2014286969-a1

Year: 2014

Patent us-2014314794-a1

· 2014

Full title: us-2014314794-a1

Year: 2014

Patent us-2015209445-a1

· 2015

Full title: us-2015209445-a1

Year: 2015

Patent us-2015165063-a1

· 2015

Full title: us-2015165063-a1

Year: 2015

Patent us-2014363454-a1

· 2014

Full title: us-2014363454-a1

Year: 2014

Patent us-2015284416-a1

· 2015

Full title: us-2015284416-a1

Year: 2015

Patent us-2024123080-a1

· 2024

Full title: us-2024123080-a1

Year: 2024

Patent us-2024207435-a1

· 2024

Full title: us-2024207435-a1

Year: 2024

Patent us-2024197889-a1

· 2024

Full title: us-2024197889-a1

Year: 2024

Patent us-2024377413-a1

· 2024

Full title: us-2024377413-a1

Year: 2024

Patent us-2024408215-a1

· 2024

Full title: us-2024408215-a1

Year: 2024

Patent us-2025101032-a1

· 2025

Full title: us-2025101032-a1

Year: 2025

Patent us-2025152729-a1

· 2025

Full title: us-2025152729-a1

Year: 2025

Patent us-2025255981-a1

· 2025

Full title: us-2025255981-a1

Year: 2025

Patent us-2025262315-a1

· 2025

Full title: us-2025262315-a1

Year: 2025

Patent us-5112953-a

· 1992

Full title: us-5112953-a

Year: 1992

Patent us-2025295803-a1

· 2025

Full title: us-2025295803-a1

Year: 2025

Patent us-2020384122-a1

· 2020

Full title: us-2020384122-a1

Year: 2020

Patent us-2021023103-a1

· 2021

Full title: us-2021023103-a1

Year: 2021

Patent us-2021137940-a1

· 2021

Full title: us-2021137940-a1

Year: 2021

Patent us-2021260211-a1

· 2021

Full title: us-2021260211-a1

Year: 2021

Patent us-2022143194-a1

· 2022

Full title: us-2022143194-a1

Year: 2022

Patent us-2015283259-a1

· 2015

Full title: us-2015283259-a1

Year: 2015

Patent us-2016015831-a1

· 2016

Full title: us-2016015831-a1

Year: 2016

Patent us-2015283258-a1

· 2015

Full title: us-2015283258-a1

Year: 2015

Patent us-2015273077-a1

· 2015

Full title: us-2015273077-a1

Year: 2015

Patent us-2015366990-a1

· 2015

Full title: us-2015366990-a1

Year: 2015

Patent us-2015250895-a1

· 2015

Full title: us-2015250895-a1

Year: 2015

Patent us-2015250896-a1

· 2015

Full title: us-2015250896-a1

Year: 2015

Patent us-2015307551-a1

· 2015

Full title: us-2015307551-a1

Year: 2015

Patent us-2015273078-a1

· 2015

Full title: us-2015273078-a1

Year: 2015

Patent us-2015290342-a1

· 2015

Full title: us-2015290342-a1

Year: 2015

Patent us-2015314007-a1

· 2015

Full title: us-2015314007-a1

Year: 2015

Patent us-2016151515-a1

· 2016

Full title: us-2016151515-a1

Year: 2016

Patent us-2016074528-a1

· 2016

Full title: us-2016074528-a1

Year: 2016

Patent us-2016193356-a1

· 2016

Full title: us-2016193356-a1

Year: 2016

Patent us-2016220693-a1

· 2016

Full title: us-2016220693-a1

Year: 2016

Patent us-2016220687-a1

· 2016

Full title: us-2016220687-a1

Year: 2016

Patent us-2016310611-a1

· 2016

Full title: us-2016310611-a1

Year: 2016

Patent us-2016279248-a1

· 2016

Full title: us-2016279248-a1

Year: 2016

Patent us-2016346403-a1

· 2016

Full title: us-2016346403-a1

Year: 2016

Patent us-2016303247-a1

· 2016

Full title: us-2016303247-a1

Year: 2016

Patent us-2017000897-a1

· 2017

Full title: us-2017000897-a1

Year: 2017

Patent us-2016296628-a1

· 2016

Full title: us-2016296628-a1

Year: 2016

Patent us-2016367699-a1

· 2016

Full title: us-2016367699-a1

Year: 2016

Patent us-2016354485-a1

· 2016

Full title: us-2016354485-a1

Year: 2016

Patent us-2017014524-a1

· 2017

Full title: us-2017014524-a1

Year: 2017

Patent us-2017095570-a1

· 2017

Full title: us-2017095570-a1

Year: 2017

Patent us-2016367685-a1

· 2016

Full title: us-2016367685-a1

Year: 2016

Patent us-2017049908-a1

· 2017

Full title: us-2017049908-a1

Year: 2017

Patent us-2017173168-a1

· 2017

Full title: us-2017173168-a1

Year: 2017

Patent us-2017143845-a1

· 2017

Full title: us-2017143845-a1

Year: 2017

Patent us-2017196988-a1

· 2017

Full title: us-2017196988-a1

Year: 2017

Patent us-2017058051-a1

· 2017

Full title: us-2017058051-a1

Year: 2017

Patent us-2017081418-a1

· 2017

Full title: us-2017081418-a1

Year: 2017

Patent us-2017157199-a1

· 2017

Full title: us-2017157199-a1

Year: 2017

Patent us-2017202974-a1

· 2017

Full title: us-2017202974-a1

Year: 2017

Patent us-2017209593-a1

· 2017

Full title: us-2017209593-a1

Year: 2017

Patent us-2018043033-a1

· 2018

Full title: us-2018043033-a1

Year: 2018

Patent us-2018086828-a1

· 2018

Full title: us-2018086828-a1

Year: 2018

Patent us-2023173093-a1

· 2023

Full title: us-2023173093-a1

Year: 2023

Patent us-2023102207-a1

· 2023

Full title: us-2023102207-a1

Year: 2023

Patent us-2023416331-a1

· 2023

Full title: us-2023416331-a1

Year: 2023

Patent us-2024123079-a1

· 2024

Full title: us-2024123079-a1

Year: 2024

Patent us-9999680-b2

· 2018

Full title: us-9999680-b2

Year: 2018

Patent us-10000555-b2

· 2018

Full title: us-10000555-b2

Year: 2018

Patent us-10072093-b2

· 2018

Full title: us-10072093-b2

Year: 2018

Patent us-10131682-b2

· 2018

Full title: us-10131682-b2

Year: 2018

Patent us-10232051-b2

· 2019

Full title: us-10232051-b2

Year: 2019

Patent us-10328157-b2

· 2019

Full title: us-10328157-b2

Year: 2019

Patent us-10293055-b2

· 2019

Full title: us-10293055-b2

Year: 2019

2. Data Extraction

0/1333 extracted

Paper

Recent advances in bispecific antibody-drug conjugates for breast cancer therapy

Xuan Ji; Yalong Yang; Cong Ma et al. · 2026

Full title: Recent advances in bispecific antibody-drug conjugates for breast cancer therapy

Authors: Xuan Ji; Yalong Yang; Cong Ma; Wenqin Huang; Senyang Guo; Lingzi Wang; Hongmei Zheng; Xinhong Wu

DOI: https://doi.org/10.1007/s00280-025-04863-9

Paper

Evaluating post-T-DXd treatment strategies in HER2-positive metastatic breast cancer

Sophia Zelizer; Grace Gallagher; Mithat Gonen et al. · 2025

Full title: Evaluating post-T-DXd treatment strategies in HER2-positive metastatic breast cancer

Authors: Sophia Zelizer; Grace Gallagher; Mithat Gonen; Chau T. Dang; S. Modi; S. Chandarlapaty; Joshua Z. Drago

DOI: https://doi.org/10.1007/s10549-025-07853-w

Paper

Current Status: Site-Specific Antibody Drug Conjugates.

Schumacher, Dominik; Hackenberger, Christian P R; Leonhardt, Heinrich et al. · 2016

Full title: Current Status: Site-Specific Antibody Drug Conjugates.

Authors: Schumacher, Dominik; Hackenberger, Christian P R; Leonhardt, Heinrich; Helma, Jonas

DOI: https://doi.org/10.1007/s10875-016-0265-6

Paper

Antibody-Drug Conjugates.

Li Peng; Xiaoyuan Chen · 2015

Full title: Antibody-Drug Conjugates.

Authors: Li Peng; Xiaoyuan Chen

DOI: https://doi.org/10.1021/acs.bioconjchem.5b00515

Paper

An Elusive Case of Mycosis Fungoides: Case Report and Review of the Literature

V. Pallazola; G. Deib; S. Abha et al. · 2019

Full title: An Elusive Case of Mycosis Fungoides: Case Report and Review of the Literature

Authors: V. Pallazola; G. Deib; S. Abha; R. Geha; Kimiyoshi Kobayashi

DOI: https://doi.org/10.1007/s11606-019-05231-z

Paper

Mechanisms of Resistance to Antibody-Drug Conjugates

Rita Khoury; K. Saleh; N. Khalife et al. · 2023

Full title: Mechanisms of Resistance to Antibody-Drug Conjugates

Authors: Rita Khoury; K. Saleh; N. Khalife; M. Saleh; C. Chahine; Rebecca Ibrahim; A. Lecesne

DOI: https://doi.org/10.3390/ijms24119674

Paper

Antibody–Drug Conjugates for the Treatment of Renal Cancer: A Scoping Review on Current Evidence and Clinical Perspectives

S. Sganga; S. Riondino; G. M. Iannantuono et al. · 2023

Full title: Antibody–Drug Conjugates for the Treatment of Renal Cancer: A Scoping Review on Current Evidence and Clinical Perspectives

Authors: S. Sganga; S. Riondino; G. M. Iannantuono; R. Rosenfeld; M. Roselli; F. Torino

DOI: https://doi.org/10.3390/jpm13091339

Paper

State-of-the-Art Native Mass Spectrometry and Ion Mobility Methods to Monitor Homogeneous Site-Specific Antibody-Drug Conjugates Synthesis

Evolène Deslignière; Anthony Ehkirch; Bastiaan L. Duivelshof et al. · 2021

Full title: State-of-the-Art Native Mass Spectrometry and Ion Mobility Methods to Monitor Homogeneous Site-Specific Antibody-Drug Conjugates Synthesis

Authors: Evolène Deslignière; Anthony Ehkirch; Bastiaan L. Duivelshof; Hanna Toftevall; Jonathan Sjögren; D. Guillarme; V. D’Atri; A. Beck; Oscar Hernandez-Alba; S. Cianférani

DOI: https://doi.org/10.3390/ph14060498

Paper

Development of Photoremovable Linkers as a Novel Strategy to Improve the Pharmacokinetics of Drug Conjugates and Their Potential Application in Antibody-Drug Conjugates for Cancer Therapy.

Johan, Audrey Nathania; Li, Yi · 2022

Authors: Johan, Audrey Nathania; Li, Yi

DOI: https://doi.org/10.3390/ph15060655

Paper

Antibody–Drug Conjugates (ADCs) and Their Journey to Autoimmune Disease Immunotherapy

A. Justiz-Vaillant · 2025

Full title: Antibody–Drug Conjugates (ADCs) and Their Journey to Autoimmune Disease Immunotherapy

Authors: A. Justiz-Vaillant

DOI: https://doi.org/10.3390/msf2025040002

Paper

Experimental HER2-Targeted Therapy Using ADAPT6-ABD-mcDM1 in Mice Bearing SKOV3 Ovarian Cancer Xenografts: Efficacy and Selection of Companion Imaging Counterpart

J. Garousi; Tianqi Xu; Yongsheng Liu et al. · 2022

Full title: Experimental HER2-Targeted Therapy Using ADAPT6-ABD-mcDM1 in Mice Bearing SKOV3 Ovarian Cancer Xenografts: Efficacy and Selection of Companion Imaging Counterpart

Authors: J. Garousi; Tianqi Xu; Yongsheng Liu; O. Vorontsova; S. Hober; A. Orlova; V. Tolmachev; T. Gräslund; A. Vorobyeva

DOI: https://doi.org/10.3390/pharmaceutics14081612

Paper

Trastuzumab: More than a Guide in HER2-Positive Cancer Nanomedicine

Celia Nieto; Milena A. Vega; E. M. Martín del Valle · 2020

Full title: Trastuzumab: More than a Guide in HER2-Positive Cancer Nanomedicine

Authors: Celia Nieto; Milena A. Vega; E. M. Martín del Valle

DOI: https://doi.org/10.3390/nano10091674

Paper

Design, Synthesis, and Evaluation of Camptothecin-Based Antibody–Drug Conjugates with High Hydrophilicity and Structural Stability

Tingyu Xiong; Jiyu Jin; Dongliang Liu et al. · 2025

Full title: Design, Synthesis, and Evaluation of Camptothecin-Based Antibody–Drug Conjugates with High Hydrophilicity and Structural Stability

Authors: Tingyu Xiong; Jiyu Jin; Dongliang Liu; Chen Jin

DOI: https://doi.org/10.3390/molecules30071398

Paper

Pharmacokinetics and Pharmacodynamics of Antibody-Drug Conjugates Administered via Subcutaneous and Intratumoral Routes.

Chang, Hsuan-Ping; Le, Huyen Khanh; Shah, Dhaval K · 2023

Full title: Pharmacokinetics and Pharmacodynamics of Antibody-Drug Conjugates Administered via Subcutaneous and Intratumoral Routes.

Authors: Chang, Hsuan-Ping; Le, Huyen Khanh; Shah, Dhaval K

DOI: https://doi.org/10.3390/pharmaceutics15041132

Paper

Advances in Targeted Therapy of Breast Cancer with Antibody-Drug Conjugate

Md Abdus Subhan; V. Torchilin · 2023

Full title: Advances in Targeted Therapy of Breast Cancer with Antibody-Drug Conjugate

Authors: Md Abdus Subhan; V. Torchilin

DOI: https://doi.org/10.3390/pharmaceutics15041242

Paper

Linkers: An Assurance for Controlled Delivery of Antibody-Drug Conjugate.

Sheyi, Rotimi; de la Torre, Beatriz G; Albericio, Fernando · 2022

Full title: Linkers: An Assurance for Controlled Delivery of Antibody-Drug Conjugate.

Authors: Sheyi, Rotimi; de la Torre, Beatriz G; Albericio, Fernando

DOI: https://doi.org/10.3390/pharmaceutics14020396

Paper

Antibody-Drug Conjugates for Cancer Therapy: Chemistry to Clinical Implications.

Dan, Nirnoy; Setua, Saini; Kashyap, Vivek K et al. · 2018

Full title: Antibody-Drug Conjugates for Cancer Therapy: Chemistry to Clinical Implications.

Authors: Dan, Nirnoy; Setua, Saini; Kashyap, Vivek K; Khan, Sheema; Jaggi, Meena; Yallapu, Murali M; Chauhan, Subhash C

DOI: https://doi.org/10.3390/ph11020032

Paper

EV20/NMS-P945, a Novel Thienoindole Based Antibody-Drug Conjugate Targeting HER-3 for Solid Tumors

E. Capone; R. Lattanzio; F. Gasparri et al. · 2021

Full title: EV20/NMS-P945, a Novel Thienoindole Based Antibody-Drug Conjugate Targeting HER-3 for Solid Tumors

Authors: E. Capone; R. Lattanzio; F. Gasparri; P. Orsini; C. Rossi; Valentina Iacobelli; V. de Laurenzi; P. Natali; B. Valsasina; S. Iacobelli; G. Sala

DOI: https://doi.org/10.3390/pharmaceutics13040483

Paper

Understanding the Toxicity Profile of Approved ADCs

Pablo Ballestín; Alfonso López de Sá; Cristina Díaz-Tejeiro et al. · 2025

Full title: Understanding the Toxicity Profile of Approved ADCs

DOI: https://doi.org/10.3390/pharmaceutics17020258

Paper

Structural Characterization of Linker Shielding in ADC Site-Specific Conjugates.

Jaime-Garza, Maru; Waight, Andrew; Hudlikar, Manish et al. · 2025

Full title: Structural Characterization of Linker Shielding in ADC Site-Specific Conjugates.

DOI: https://doi.org/10.3390/pharmaceutics17121568

Paper

Implementation of Systematic Bioanalysis of Antibody–Drug Conjugates for Preclinical Pharmacokinetic Study of Ado-Trastuzumab Emtansine (T-DM1) in Rats

Eun-Jeong Jeon; Junfeng Han; Youjin Seo et al. · 2023

Full title: Implementation of Systematic Bioanalysis of Antibody–Drug Conjugates for Preclinical Pharmacokinetic Study of Ado-Trastuzumab Emtansine (T-DM1) in Rats

Authors: Eun-Jeong Jeon; Junfeng Han; Youjin Seo; E. Koh; Kang Han; K. Hwang; Kyung-Jin Jung

DOI: https://doi.org/10.3390/pharmaceutics15030756

Paper

Towards Aptamer-Targeted Drug Delivery to Brain Tumors: The Synthesis of Ramified Conjugates of an EGFR-Specific Aptamer with MMAE on a Cathepsin B-Cleavable Linker

V. Brylev; E. V. Ryabukhina; Ekaterina V. Nazarova et al. · 2024

Full title: Towards Aptamer-Targeted Drug Delivery to Brain Tumors: The Synthesis of Ramified Conjugates of an EGFR-Specific Aptamer with MMAE on a Cathepsin B-Cleavable Linker

DOI: https://doi.org/10.3390/pharmaceutics16111434

Paper

PK/PD of Positively Charged ADC in Mice

Hsuan-Ping Chang; Huyen Khanh Le; Shufang Liu et al. · 2025

Full title: PK/PD of Positively Charged ADC in Mice

Authors: Hsuan-Ping Chang; Huyen Khanh Le; Shufang Liu; Dhaval K. Shah

DOI: https://doi.org/10.3390/pharmaceutics17030377

Paper

CXCR4-targeted theranostics in non-Hodgkin lymphoma: Present evidence and future directions

Marcus Yoakam; Uma A. Obalapuram; Kameron Hahn et al. · 2026

Full title: CXCR4-targeted theranostics in non-Hodgkin lymphoma: Present evidence and future directions

Authors: Marcus Yoakam; Uma A. Obalapuram; Kameron Hahn; Samir Dalia

DOI: https://doi.org/10.36922/arnm025480061

Paper

Novel Anti-Trop2 Nanobodies Disrupt Receptor Dimerization and Inhibit Tumor Cell Growth

Junwen Deng; Zhongmin Geng; Linli Luan et al. · 2024

Full title: Novel Anti-Trop2 Nanobodies Disrupt Receptor Dimerization and Inhibit Tumor Cell Growth

Authors: Junwen Deng; Zhongmin Geng; Linli Luan; Dingwen Jiang; Jian Lu; Hanzhong Zhang; Bingguan Chen; Xin-long Liu; Dongming Xing

DOI: https://doi.org/10.3390/pharmaceutics16101255

Paper

Revolutionizing cancer therapy: Monoclonal antibodies in radiosensitization

Abolfazl Bemidinezhad; Yasaman Abolhassani; Mojgan Noroozi-Karimabad et al. · 2025

Full title: Revolutionizing cancer therapy: Monoclonal antibodies in radiosensitization

Authors: Abolfazl Bemidinezhad; Yasaman Abolhassani; Mojgan Noroozi-Karimabad; Arman Abroumand Gholami; Abbas Alalikhan; Ramin Roshani; Mohammad Parsa-kondelaji; Fatemeh Gheybi

DOI: https://doi.org/10.34172/bi.30996

Paper

Assessments of the In Vitro and In Vivo Linker Stability and Catabolic Fate for the Ortho Hydroxy-Protected Aryl Sulfate Linker by Immuno-Affinity Capture Liquid Chromatography Quadrupole Time-of-Flight Mass Spectrometric Assay

Byeong Ill Lee; Seo-jin Park; Yuri Park et al. · 2021

Authors: Byeong Ill Lee; Seo-jin Park; Yuri Park; Seok-Ho Shin; Jang-mi Choi; Min-jae Park; Jeong-hyeon Lim; S. Kim; Hyangsook Lee; Y. Shin

DOI: https://doi.org/10.3390/pharmaceutics13010125

Paper

Advancing antibody-drug conjugates in gynecological malignancies: myth or reality?

M. Nerone; M. D. Grande; C. Sessa et al. · 2022

Full title: Advancing antibody-drug conjugates in gynecological malignancies: myth or reality?

Authors: M. Nerone; M. D. Grande; C. Sessa; I. Colombo

DOI: https://doi.org/10.37349/etat.2022.00077

Paper

Antibody-drug conjugate therapies in multiple myeloma—what’s next on the horizon?

Monique A. Hartley-Brown; P. Richardson · 2022

Full title: Antibody-drug conjugate therapies in multiple myeloma—what’s next on the horizon?

Authors: Monique A. Hartley-Brown; P. Richardson

DOI: https://doi.org/10.37349/etat.2022.00067

Paper

Physical characteristics comparison between maytansinoid-based and auristatin-based antibody-drug conjugates

Tomohiro Fujii; C. Reiling; Colette F. Quinn et al. · 2021

Full title: Physical characteristics comparison between maytansinoid-based and auristatin-based antibody-drug conjugates

Authors: Tomohiro Fujii; C. Reiling; Colette F. Quinn; Michal Kliman; B. Mendelsohn; Yutaka Matsuda

DOI: https://doi.org/10.37349/etat.2021.00064

Paper

Precision medicine and beyond: Evolving roles of targeted therapy, immunotherapy, and artificial intelligence in oncology

Linwei Li; Anika Doppalapudi; Jennifer Escamilla et al. · 2025

Full title: Precision medicine and beyond: Evolving roles of targeted therapy, immunotherapy, and artificial intelligence in oncology

DOI: https://doi.org/10.36922/itps025140018

Paper

Comparative analysis of the efficacy and safety of antibody-drug conjugates, radionuclide-drug conjugates and their combination targeting claudin 18.2 in gastric cancer treatment

Huan Du; Xiaofei Hao; B. Lin et al. · 2025

Full title: Comparative analysis of the efficacy and safety of antibody-drug conjugates, radionuclide-drug conjugates and their combination targeting claudin 18.2 in gastric cancer treatment

Authors: Huan Du; Xiaofei Hao; B. Lin; Yu Zhang; Luo Rui; Jing Wang; Mingming Tang; Decai Wang; Yihan Zhu; Jie Li; Tang-Zhi Dai; Yuchuan Yang; Xia Yang; Xiaobo Du

DOI: https://doi.org/10.3892/or.2025.9009

Paper

Trastuzumab Emtansine: Antibody-drug Conjugate in Treatment of Human Epidermal Growth Factor Receptor-2-Positive Metastatic Breast Cancer

A. Gogia; J. Nigade; C. Desai et al. · 2018

Full title: Trastuzumab Emtansine: Antibody-drug Conjugate in Treatment of Human Epidermal Growth Factor Receptor-2-Positive Metastatic Breast Cancer

Authors: A. Gogia; J. Nigade; C. Desai; B. Govind; C. Deshmukh; Binay Swarup

DOI: https://doi.org/10.4103/ijmpo.ijmpo_53_17

Paper

Advances in adoptive cell therapies in small cell lung cancer

Eljie Isaak Bragasin; Justin Cheng; Lauren Ford et al. · 2025

Full title: Advances in adoptive cell therapies in small cell lung cancer

Authors: Eljie Isaak Bragasin; Justin Cheng; Lauren Ford; Darin Poei; Sana Ali; R. Hsu

DOI: https://doi.org/10.37349/etat.2025.1002302

Paper

Preparation and evaluation of the PD0721‑DOX antibody‑drug conjugate targeting EGFRvIII to inhibit glioblastoma

Minmin Hu; Hong Liu; Yubing Zhang et al. · 2024

Full title: Preparation and evaluation of the PD0721‑DOX antibody‑drug conjugate targeting EGFRvIII to inhibit glioblastoma

Authors: Minmin Hu; Hong Liu; Yubing Zhang; Dingyan Lu; Lin Zheng; Yonglin Wang; Shuaishuai Chen; Ting Liu

DOI: https://doi.org/10.3892/etm.2024.12542

Paper

Targeting HER2: a decade of progress in breast and gastric cancer therapy

Zahraa Alkhafaje; Attaa S. Dawood; Hiba G. Hussain et al. · 2025

Full title: Targeting HER2: a decade of progress in breast and gastric cancer therapy

DOI: https://doi.org/10.3897/pharmacia.72.e148259

Paper

Perioperative systemic therapy in muscle invasive bladder cancer: Current standard method, biomarkers and emerging strategies

Kyung Hwan Kim; H. Lee; H. Ha et al. · 2023

Full title: Perioperative systemic therapy in muscle invasive bladder cancer: Current standard method, biomarkers and emerging strategies

Authors: Kyung Hwan Kim; H. Lee; H. Ha; H. Seo

DOI: https://doi.org/10.4111/icu.20230006

Paper

Treatment of metastatic bladder cancer according to clinical considerations: a narrative review

Sung Goo Yoon; Seokho Kang · 2025

Full title: Treatment of metastatic bladder cancer according to clinical considerations: a narrative review

Authors: Sung Goo Yoon; Seokho Kang

DOI: https://doi.org/10.5124/jkma.25.0047

Paper

Exo-Cleavable Linkers: Enhancing Stability and Therapeutic Efficacy in Antibody-Drug Conjugates

Tomohiro Watanabe; Tomohiro Fujii; Yutaka Matsuda · 2024

Full title: Exo-Cleavable Linkers: Enhancing Stability and Therapeutic Efficacy in Antibody-Drug Conjugates

Authors: Tomohiro Watanabe; Tomohiro Fujii; Yutaka Matsuda

DOI: https://doi.org/10.5059/yukigoseikyokaishi.82.1117

Paper

Navigating Solid Tumor Heterogeneity: The Promise and Challenges of Antibody-Drug Conjugates

Ashley A. Duhon; Karen McLean · 2025

Full title: Navigating Solid Tumor Heterogeneity: The Promise and Challenges of Antibody-Drug Conjugates

Authors: Ashley A. Duhon; Karen McLean

DOI: https://doi.org/10.47248/chp2502040017

Paper

Targeted Therapeutics for Cancer Treatment: A Review of Kinase Inhibitors, Angiogenesis Inhibitors, and Other Molecularly targeted Agents

M. Abah; M. Oladosu; Nkwocha John Nnaemeka et al. · 2025

Full title: Targeted Therapeutics for Cancer Treatment: A Review of Kinase Inhibitors, Angiogenesis Inhibitors, and Other Molecularly targeted Agents

Authors: M. Abah; M. Oladosu; Nkwocha John Nnaemeka; Ochuele Dominic Agida

DOI: https://doi.org/10.51470/bf.2025.5.1.09

Paper

Trastuzumab-deruxtecan in breast cancer treatment: Balancing the triad of efficacy, safety and accessibility.

Victor Guan Hui Lee; J. Lim · 2025

Full title: Trastuzumab-deruxtecan in breast cancer treatment: Balancing the triad of efficacy, safety and accessibility.

Authors: Victor Guan Hui Lee; J. Lim

DOI: https://doi.org/10.47102/annals-acadmedsg.2025229

Paper

Current trends in the treatment of gastrointestinal cancer: clinical applications of precision medicine and approaches by primary care and multidisciplinary teams

M. Lee · 2025

Full title: Current trends in the treatment of gastrointestinal cancer: clinical applications of precision medicine and approaches by primary care and multidisciplinary teams

Authors: M. Lee

DOI: https://doi.org/10.5124/jkma.25.0110

Paper

Constrained Peptides in Drug Discovery and Development

D. R. Cary; Masaki Ohuchi; P. Reid et al. · 2017

Full title: Constrained Peptides in Drug Discovery and Development

Authors: D. R. Cary; Masaki Ohuchi; P. Reid; K. Masuya

DOI: https://doi.org/10.5059/yukigoseikyokaishi.75.1171

Paper

Analysis Of Research Status of Antibody-Drug Conjugate in The Treatment of Colorectal Cancer

Shaoting Luo · 2024

Full title: Analysis Of Research Status of Antibody-Drug Conjugate in The Treatment of Colorectal Cancer

Authors: Shaoting Luo

DOI: https://doi.org/10.54097/xmck6m47

Paper

Research on precision treatment of pancreatic cancer targeted by antibody-drug conjugates.

Xinyue Liu; Weishuai Liu; Chao Wu et al. · 2025

Full title: Research on precision treatment of pancreatic cancer targeted by antibody-drug conjugates.

Authors: Xinyue Liu; Weishuai Liu; Chao Wu; Yudong Yuan; Antao Chang; Jihui Hao

DOI: https://doi.org/10.5582/bst.2025.01271

Paper

Unique Toxicities of Novel Myeloma Therapies: Focus on Belantamab Mafodotin, Talquetamab, and Selinexor

Jesse Shustik · 2025

Full title: Unique Toxicities of Novel Myeloma Therapies: Focus on Belantamab Mafodotin, Talquetamab, and Selinexor

Authors: Jesse Shustik

DOI: https://doi.org/10.58931/cht.2025.4379

Paper

Linker Chemistry for Tumor Microenvironment-Responsive Payload Release in ADCs

Yuhe Wang · 2025

Full title: Linker Chemistry for Tumor Microenvironment-Responsive Payload Release in ADCs

Authors: Yuhe Wang

DOI: https://doi.org/10.54097/qq36d868

Paper

Research Progress on Antibody-Drug Conjugates Therapy for Non-Small Cell Lung Cancer (NSCLC)

Han Li · 2025

Full title: Research Progress on Antibody-Drug Conjugates Therapy for Non-Small Cell Lung Cancer (NSCLC)

Authors: Han Li

DOI: https://doi.org/10.54254/2753-8818/2025.au23397

Paper

The application and development of antibody drug conjugates in cancer therapy

Hengkang He; Enxin Li; Sifei Sheng · 2023

Full title: The application and development of antibody drug conjugates in cancer therapy

Authors: Hengkang He; Enxin Li; Sifei Sheng

DOI: https://doi.org/10.54254/2753-8818/20/20230797

Paper

Targeted Liposomal Nanomedicines: Advancing Precision Therapeutics for HER-2 Positive and Triple-Negative Breast Cancer

Ujjwal Chaudhary; A. Parashar; L. Tyagi et al. · 2025

Full title: Targeted Liposomal Nanomedicines: Advancing Precision Therapeutics for HER-2 Positive and Triple-Negative Breast Cancer

Authors: Ujjwal Chaudhary; A. Parashar; L. Tyagi; Vandana Arora Sethi

DOI: https://doi.org/10.61554/ijnrph.v3i2.2025.214

Paper

Targeted Nanoparticles: an Innovative Modality in the Treatment of Cancer

Hyung-Gyoo Kang; Bryon Upton; Ryan W. Holly et al. · 2025

Full title: Targeted Nanoparticles: an Innovative Modality in the Treatment of Cancer

Authors: Hyung-Gyoo Kang; Bryon Upton; Ryan W. Holly; Racheal Upton; Sheetal A. Mitra; Jean-Hugues Parmentier; Ann F. Mohrbacher; Yong-Mi Kim; Timothy J. Triche; Jon O. Nagy

DOI: https://doi.org/10.64898/2025.12.01.691687

Paper

Research Status And Development Trend Of Monoclonal Antibodies For Non-Small Cell Lung Cancer

Minghui Gao · 2025

Full title: Research Status And Development Trend Of Monoclonal Antibodies For Non-Small Cell Lung Cancer

Authors: Minghui Gao

DOI: https://doi.org/10.62051/hg0b7s02

Paper

Antibody-Drug Conjugates in Solid Tumors: Mechanisms, Clinical Advances, and Emerging Resistance Patterns

Hassan A. Abdou; Shadi Awny · 2026

Full title: Antibody-Drug Conjugates in Solid Tumors: Mechanisms, Clinical Advances, and Emerging Resistance Patterns

Authors: Hassan A. Abdou; Shadi Awny

DOI: https://doi.org/10.71079/aside.onc.012026464

Paper

A strategically designed homogeneous antibody-drug conjugate improves safety and therapeutic index in renal cell carcinoma.

Thurakkal, Liya; Velayutham, Krishna; Sarkar, Binayak et al. · 2026

Full title: A strategically designed homogeneous antibody-drug conjugate improves safety and therapeutic index in renal cell carcinoma.

Authors: Thurakkal, Liya; Velayutham, Krishna; Sarkar, Binayak; Kalyan, Akshaya; Sengupta, Shiladitya; Saha, Tanmoy

DOI: https://doi.org/10.64898/2026.01.12.699160

Paper

Recent Progress in Targeted Drug Delivery Systems for Cancer Treatment

Ghadah Ali Al-Oudah; Noor Thamer Mahmood; Dhelal Fouad Mohammed · 2025

Full title: Recent Progress in Targeted Drug Delivery Systems for Cancer Treatment

Authors: Ghadah Ali Al-Oudah; Noor Thamer Mahmood; Dhelal Fouad Mohammed

DOI: https://doi.org/10.57238/jbb.2025.7432.1141

Paper

Advances In The Application Of Click Chemistry In The Research Of Targeted Therapeutic Drugs

Yue Zhang · 2025

Full title: Advances In The Application Of Click Chemistry In The Research Of Targeted Therapeutic Drugs

Authors: Yue Zhang

DOI: https://doi.org/10.62051/y0yezt68

Paper

Orthogonally targeted tumor radiosensitization using cell penetrating peptide-ATM inhibitor conjugates to stimulate anti-tumor immune responses

Kanika Dhawan; Mike M Allevato; Jacqueline Lesperance et al. · 2026

Full title: Orthogonally targeted tumor radiosensitization using cell penetrating peptide-ATM inhibitor conjugates to stimulate anti-tumor immune responses

Authors: Kanika Dhawan; Mike M Allevato; Jacqueline Lesperance; M. F. Camargo; Marcus M Cheng; Mahsa Mortaja; Bamdad Zareh; Dina V. Hingorani; Stephen R. Adams; J. Gutkind; Sunil J. Advani

DOI: https://doi.org/10.64898/2026.01.09.698736

Paper

A novel anti-DR5 antibody-drug conjugate possesses a high-potential therapeutic efficacy for leukemia and solid tumors

Shuyong Zhang; Chao Zheng; Wan Zhu et al. · 2019

Full title: A novel anti-DR5 antibody-drug conjugate possesses a high-potential therapeutic efficacy for leukemia and solid tumors

Authors: Shuyong Zhang; Chao Zheng; Wan Zhu; P. Xiong; Dongdong Zhou; Changjiang Huang; D. Zheng

DOI: https://doi.org/10.7150/thno.33598

Paper

Activated platelets in the tumor microenvironment for targeting of antibody-drug conjugates to tumors and metastases

M. Yap; James D. McFadyen; James D. McFadyen et al. · 2019

Full title: Activated platelets in the tumor microenvironment for targeting of antibody-drug conjugates to tumors and metastases

DOI: https://doi.org/10.7150/thno.29146

Paper

B7-H3 in Brain Malignancies: Immunology and Immunotherapy

Xiaopeng Guo; Mengqi Chang; Yu Wang et al. · 2023

Full title: B7-H3 in Brain Malignancies: Immunology and Immunotherapy

Authors: Xiaopeng Guo; Mengqi Chang; Yu Wang; B. Xing; Wenbin Ma

DOI: https://doi.org/10.7150/ijbs.85813

Paper

Untangling Triple-Negative Breast Cancer Molecular Peculiarity and Chemo-Resistance: Trailing Towards Marker-Based Targeted Therapies

Bushra Kanwal · 2021

Full title: Untangling Triple-Negative Breast Cancer Molecular Peculiarity and Chemo-Resistance: Trailing Towards Marker-Based Targeted Therapies

Authors: Bushra Kanwal

DOI: https://doi.org/10.7759/cureus.16636

Paper

Prostate-specific Membrane Antigen Based Antibody-drug Conjugates for Metastatic Castration-resistance Prostate Cancer

M. O. Niaz; Michael M C Sun; M. Ramirez-Fort et al. · 2020

Full title: Prostate-specific Membrane Antigen Based Antibody-drug Conjugates for Metastatic Castration-resistance Prostate Cancer

Authors: M. O. Niaz; Michael M C Sun; M. Ramirez-Fort; M. Niaz

DOI: https://doi.org/10.7759/cureus.7147

Paper

Immunotherapy in hematologic malignancies: achievements, challenges and future prospects

Lu Tang; Zhongpei Huang; H. Mei et al. · 2023

Full title: Immunotherapy in hematologic malignancies: achievements, challenges and future prospects

Authors: Lu Tang; Zhongpei Huang; H. Mei; Yu Hu

DOI: https://doi.org/10.1038/s41392-023-01521-5

Paper

The evolving landscape of antibody-drug conjugates (ADCs) for treatment of prostate cancer

Claire Lin; Matthew J. Hadfield; Ariana Santopietro et al. · 2025

Full title: The evolving landscape of antibody-drug conjugates (ADCs) for treatment of prostate cancer

Authors: Claire Lin; Matthew J. Hadfield; Ariana Santopietro; G. Lagos; Liang Cheng; Wafik S. El-Deiry; Rahul Aggarwal; Anthony E Mega; E. Hyams; B. Carneiro

DOI: https://doi.org/10.1038/s41698-025-01131-0

Paper

Stereoselective design of amino acid bioconjugates: targeting strategies and physicochemical optimization

Soma Mandal; ab Rajat; Choudhary † ab et al. · 2025

Full title: Stereoselective design of amino acid bioconjugates: targeting strategies and physicochemical optimization

Authors: Soma Mandal; ab Rajat; Choudhary † ab; Badireenath Konkimalla

DOI: https://doi.org/10.1039/d5md00760g

Paper

Development of therapeutic antibodies for the treatment of diseases

Zeng Wang; Guoqing Wang; Huaqing Lu et al. · 2022

Full title: Development of therapeutic antibodies for the treatment of diseases

Authors: Zeng Wang; Guoqing Wang; Huaqing Lu; Hongjian Li; Mei Tang; A. Tong

DOI: https://doi.org/10.1186/s43556-022-00100-4

Paper

Antibody-drug conjugates in cancer therapy: current landscape, challenges, and future directions.

Chen, Bonan; Zheng, Xiaohong; Wu, Jialin et al. · 2025

Full title: Antibody-drug conjugates in cancer therapy: current landscape, challenges, and future directions.

Authors: Chen, Bonan; Zheng, Xiaohong; Wu, Jialin; Chen, Guoming; Yu, Jun; Xu, Yi; Wu, William K K; Tse, Gary M K; To, Ka Fai; Kang, Wei

DOI: https://doi.org/10.1186/s12943-025-02489-2

Paper

Oligospecific Human Antibodies with Therapeutic Potential Derived from Immunized Chickens

Jan P. Bogen · 2021

Full title: Oligospecific Human Antibodies with Therapeutic Potential Derived from Immunized Chickens

Authors: Jan P. Bogen

DOI: https://doi.org/10.26083/tuprints-00019360

Paper

Importance and Considerations of Antibody Engineering in Antibody-Drug Conjugates Development from a Clinical Pharmacologist's Perspective.

Lucas, Andrew T; Moody, Amber; Schorzman, Allison N et al. · 2021

Full title: Importance and Considerations of Antibody Engineering in Antibody-Drug Conjugates Development from a Clinical Pharmacologist's Perspective.

Authors: Lucas, Andrew T; Moody, Amber; Schorzman, Allison N; Zamboni, William C

DOI: https://doi.org/10.3390/antib10030030

Paper

Antibody-Drug Conjugates in Breast Cancer: Navigating Innovations, Overcoming Resistance, and Shaping Future Therapies.

Sabit, Hussein; Abbas, Salma; El-Safoury, Moataz T et al. · 2025

Full title: Antibody-Drug Conjugates in Breast Cancer: Navigating Innovations, Overcoming Resistance, and Shaping Future Therapies.

DOI: https://doi.org/10.3390/biomedicines13092227

Paper

Actively Targeted Nanomedicines in Breast Cancer: From Pre-Clinal Investigation to Clinic

A. Fraguas-Sánchez; Irene Lozza; A. Torres-Suárez · 2022

Full title: Actively Targeted Nanomedicines in Breast Cancer: From Pre-Clinal Investigation to Clinic

Authors: A. Fraguas-Sánchez; Irene Lozza; A. Torres-Suárez

DOI: https://doi.org/10.3390/cancers14051198

Paper

Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability.

Nguyen, Toan D; Bordeau, Brandon M; Balthasar, Joseph P · 2023

Full title: Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability.

Authors: Nguyen, Toan D; Bordeau, Brandon M; Balthasar, Joseph P

DOI: https://doi.org/10.3390/cancers15030713

Paper

The Immunotherapy of Acute Myeloid Leukemia: A Clinical Point of View

F. Mosna · 2024

Full title: The Immunotherapy of Acute Myeloid Leukemia: A Clinical Point of View

Authors: F. Mosna

DOI: https://doi.org/10.3390/cancers16132359

Paper

Single-Domain Antibodies as Antibody–Drug Conjugates: From Promise to Practice—A Systematic Review

Víctor Manuel Medina Pérez; Marta Baselga; A. J. Schuhmacher · 2024

Full title: Single-Domain Antibodies as Antibody–Drug Conjugates: From Promise to Practice—A Systematic Review

Authors: Víctor Manuel Medina Pérez; Marta Baselga; A. J. Schuhmacher

DOI: https://doi.org/10.3390/cancers16152681

Paper

How Far Have We Developed Antibody–Drug Conjugate for the Treatment of Cancer?

Yu Jun Lim; Pei Sze Clarissa Lau; Shi Xuan Low et al. · 2023

Full title: How Far Have We Developed Antibody–Drug Conjugate for the Treatment of Cancer?

Authors: Yu Jun Lim; Pei Sze Clarissa Lau; Shi Xuan Low; Shong Li Ng; Min Yee Ong; Huey Ming Pang; Z. Lee; H. Yow; S. Hamzah; Renukha Sellappans; J. Foo

DOI: https://doi.org/10.3390/ddc2020020

Paper

Antibody Drug Conjugates for Cancer Therapy

P. Polakis · 2016

Full title: Antibody Drug Conjugates for Cancer Therapy

Authors: P. Polakis

DOI: https://doi.org/10.1124/pr.114.009373

Paper

Antibody Drug Conjugates for Cancer Therapy: From Metallodrugs to Nature-Inspired Payloads

Giovanni Tonon; F. Rizzolio; F. Visentin et al. · 2024

Full title: Antibody Drug Conjugates for Cancer Therapy: From Metallodrugs to Nature-Inspired Payloads

Authors: Giovanni Tonon; F. Rizzolio; F. Visentin; T. Scattolin

DOI: https://doi.org/10.3390/ijms25168651

Paper

Functional Peptide-Based Biomaterials for Pharmaceutical Application: Sequences, Mechanisms, and Optimization Strategies

Dedong Yu; Nari Han; Hyejeong Son et al. · 2026

Full title: Functional Peptide-Based Biomaterials for Pharmaceutical Application: Sequences, Mechanisms, and Optimization Strategies

Authors: Dedong Yu; Nari Han; Hyejeong Son; Sun Jo Kim; S. Kweon

DOI: https://doi.org/10.3390/jfb17010037

Paper

Impact of Endocytosis Mechanisms for the Receptors Targeted by the Currently Approved Antibody-Drug Conjugates (ADCs)—A Necessity for Future ADC Research and Development

Manar Hammood; A. Craig; Jeffrey V. Leyton · 2021

Full title: Impact of Endocytosis Mechanisms for the Receptors Targeted by the Currently Approved Antibody-Drug Conjugates (ADCs)—A Necessity for Future ADC Research and Development

Authors: Manar Hammood; A. Craig; Jeffrey V. Leyton

DOI: https://doi.org/10.3390/ph14070674

Paper

Exploring Experimental and In Silico Approaches for Antibody–Drug Conjugates in Oncology Therapies

V. M. de Almeida; M. Soares; O. Santos-Filho · 2025

Full title: Exploring Experimental and In Silico Approaches for Antibody–Drug Conjugates in Oncology Therapies

Authors: V. M. de Almeida; M. Soares; O. Santos-Filho

DOI: https://doi.org/10.3390/ph18081198

Paper

Strategic and Chemical Advances in Antibody-Drug Conjugates.

Alradwan, Ibrahim A; Alnefaie, Meshal K; Al Fayez, Nojoud et al. · 2025

Full title: Strategic and Chemical Advances in Antibody-Drug Conjugates.

DOI: https://doi.org/10.3390/pharmaceutics17091164

Paper

Immunoconjugates as an Efficient Platform for Drug Delivery: A Resurgence of Natural Products in Targeted Antitumor Therapy

Rositsa Mihaylova; D. Momekova; Viktoria Elincheva et al. · 2024

Full title: Immunoconjugates as an Efficient Platform for Drug Delivery: A Resurgence of Natural Products in Targeted Antitumor Therapy

Authors: Rositsa Mihaylova; D. Momekova; Viktoria Elincheva; Georgi Momekov

DOI: https://doi.org/10.3390/ph17121701

Paper

A Review on the Stability Challenges of Advanced Biologic Therapeutics

Sruthi Sarvepalli; Shashank Reddy Pasika; Vartika Verma et al. · 2025

Full title: A Review on the Stability Challenges of Advanced Biologic Therapeutics

Authors: Sruthi Sarvepalli; Shashank Reddy Pasika; Vartika Verma; Anusha Thumma; Sandeep Bolla; Pavan Kumar Nukala; Arun Butreddy; Pradeep Kumar Bolla

DOI: https://doi.org/10.3390/pharmaceutics17050550

Paper

A Narrative Review of Current Advances and Future Changes Regarding Bladder Cancer Treatment

Dominik Godlewski; Sara Czech; Jakub Szpara et al. · 2025

Full title: A Narrative Review of Current Advances and Future Changes Regarding Bladder Cancer Treatment

Authors: Dominik Godlewski; Sara Czech; Jakub Szpara; D. Bartusik-Aebisher; D. Aebisher

DOI: https://doi.org/10.3390/uro5020011

Paper

Strategic Combinations of Antibody–Drug Conjugates from 2023 to 2025: From Dual Therapies to Innovative ADC-Based Regimens

Heewon Jang; Ji-Eun Chang · 2025

Full title: Strategic Combinations of Antibody–Drug Conjugates from 2023 to 2025: From Dual Therapies to Innovative ADC-Based Regimens

Authors: Heewon Jang; Ji-Eun Chang

DOI: https://doi.org/10.3390/pharmaceutics17121581

Paper

ASCO 2025: key highlights in endometrial cancer

I. Tsibulak · 2026

Full title: ASCO 2025: key highlights in endometrial cancer

Authors: I. Tsibulak

DOI: https://doi.org/10.1007/s12254-025-01096-7

Paper

Adverse events of antibody–drug conjugates on the ocular surface in cancer therapy

Sandra Domínguez-Llamas; M. Caro-Magdaleno; B. Mataix-Albert et al. · 2023

Full title: Adverse events of antibody–drug conjugates on the ocular surface in cancer therapy

Authors: Sandra Domínguez-Llamas; M. Caro-Magdaleno; B. Mataix-Albert; Javier Avilés-Prieto; Isabel Romero-Barranca; E. Rodríguez-de-la-Rúa

DOI: https://doi.org/10.1007/s12094-023-03261-y

Paper

Recent Developments in ADC Technology: Preclinical Studies Signal Future Clinical Trends

Penelope M. Drake; David Rabuka · 2017

Full title: Recent Developments in ADC Technology: Preclinical Studies Signal Future Clinical Trends

Authors: Penelope M. Drake; David Rabuka

DOI: https://doi.org/10.1007/s40259-017-0254-1

Paper

Antibody–drug conjugates for breast cancer: a bibliometric study and clinical trial analysis

Mengjie Xing; Zhiyi Li; Yuwan Cui et al. · 2024

Full title: Antibody–drug conjugates for breast cancer: a bibliometric study and clinical trial analysis

Authors: Mengjie Xing; Zhiyi Li; Yuwan Cui; Minghua He; Yang Xing; Lei Yang; Ziling Liu; Linzhi Luo; Hong Wang; Rui Guo

DOI: https://doi.org/10.1007/s12672-024-01192-w

Paper

Subcutaneous Administration of Antibody-drug Conjugates

Aiman A Yaseen; Mohammad Asikur Rahman; L. N. Tumey · 2026

Full title: Subcutaneous Administration of Antibody-drug Conjugates

Authors: Aiman A Yaseen; Mohammad Asikur Rahman; L. N. Tumey

DOI: https://doi.org/10.1007/s40495-026-00442-5

Paper

Antibody–drug conjugates treatment of small cell lung cancer: advances in clinical research

Y. Meng; Xuerui Wang; Jie Yang et al. · 2024

Full title: Antibody–drug conjugates treatment of small cell lung cancer: advances in clinical research

Authors: Y. Meng; Xuerui Wang; Jie Yang; Meiying Zhu; Minghui Yu; Long-Yan Li; Yangyueying Liang; F. Kong

DOI: https://doi.org/10.1007/s12672-024-01171-1

Paper

Development of FAP-targeted theranostics discovered by next-generation sequencing-augmented mining of a novel immunized VNAR library

Gihan S. Gunaratne; Joseph P. Gallant; Kendahl L. Ott et al. · 2025

Full title: Development of FAP-targeted theranostics discovered by next-generation sequencing-augmented mining of a novel immunized VNAR library

DOI: https://doi.org/10.1101/2025.01.13.632555

Paper

Dual Site-Specific Chemoenzymatic Antibody Fragment Conjugation Using CRISPR-Based Hybridoma Engineering

Camille M. Le Gall; Johan M. S. van der Schoot; Iván Ramos-Tomillero et al. · 2020

Full title: Dual Site-Specific Chemoenzymatic Antibody Fragment Conjugation Using CRISPR-Based Hybridoma Engineering

DOI: https://doi.org/10.1101/2020.12.08.415182

Paper

NECTIN-4 PET FOR OPTIMIZING ENFORTUMAB VEDOTIN DOSE-RESPONSE IN UROTHELIAL CARCINOMA

Akhilesh Mishra; A. K. Sharma; Kuldeep Gupta et al. · 2024

Full title: NECTIN-4 PET FOR OPTIMIZING ENFORTUMAB VEDOTIN DOSE-RESPONSE IN UROTHELIAL CARCINOMA

Authors: Akhilesh Mishra; A. K. Sharma; Kuldeep Gupta; Dhanush R. Banka; Burles A Johnson; Jeannie Hoffman-Censits; Peng Huang; D. McConkey; S. Nimmagadda

DOI: https://doi.org/10.1101/2024.12.25.630315

Paper

An antibody-drug conjugate targeting GPR56 demonstrates efficacy in preclinical models of colorectal cancer

J. Jacob; Liezl E. Francisco; Treena Chatterjee et al. · 2022

Full title: An antibody-drug conjugate targeting GPR56 demonstrates efficacy in preclinical models of colorectal cancer

Authors: J. Jacob; Liezl E. Francisco; Treena Chatterjee; Zhengdong Liang; Shraddha Subramanian; Qingyun J. Liu; Julie Rowe; Kendra S. Carmon

DOI: https://doi.org/10.1101/2022.08.11.503187

Paper

In Vivo Biorthogonal Antibody Click for Dual Targeting and Augmented Efficacy in Cancer Treatment

S. S. Panikar; Na-Keysha Berry; Shayla Shmuel et al. · 2023

Full title: In Vivo Biorthogonal Antibody Click for Dual Targeting and Augmented Efficacy in Cancer Treatment

Authors: S. S. Panikar; Na-Keysha Berry; Shayla Shmuel; Nai Keltee; Patrícia M R Pereira

DOI: https://doi.org/10.1101/2023.09.05.556426

Paper

Engineering antibody–drug conjugates targeting an adhesion GPCR, CD97

T. Hattori; Michelle Wang; Alexis D Corrado et al. · 2025

Full title: Engineering antibody–drug conjugates targeting an adhesion GPCR, CD97

DOI: https://doi.org/10.1101/2025.08.24.671942

Paper

Epitope Expression Persists in Circulating Tumor Cells as Breast Cancers Acquire Resistance to Antibody Drug Conjugates

Avanish Mishra; R. Abelman; Quinn Cunneely et al. · 2025

Full title: Epitope Expression Persists in Circulating Tumor Cells as Breast Cancers Acquire Resistance to Antibody Drug Conjugates

DOI: https://doi.org/10.1101/2025.04.02.646822

Paper

Tandem-Cleavage Linkers Improve the In Vivo Stability and Tolerability of Antibody-Drug Conjugates.

Chuprakov, Stepan; Ogunkoya, Ayodele O; Barfield, Robyn M et al. · 2021

Full title: Tandem-Cleavage Linkers Improve the In Vivo Stability and Tolerability of Antibody-Drug Conjugates.

Authors: Chuprakov, Stepan; Ogunkoya, Ayodele O; Barfield, Robyn M; Bauzon, Maxine; Hickle, Colin; Kim, Yun Cheol; Yeo, Dominick; Zhang, Fangjiu; Rabuka, David; Drake, Penelope M

DOI: https://doi.org/10.1021/acs.bioconjchem.1c00029

Paper

Low-density lipoprotein receptor-targeting chimeras for membrane protein degradation and enhanced drug delivery

Fangzhu Zhao; Yan Wu; K. Schaefer et al. · 2025

Full title: Low-density lipoprotein receptor-targeting chimeras for membrane protein degradation and enhanced drug delivery

Authors: Fangzhu Zhao; Yan Wu; K. Schaefer; Yun Zhang; Kun Miao; Zi Yao; Snehal D Ganjave; Kaan Kumru; Trenton M. Peters-Clarke; Alex Inague; James A. Olzmann; K. Leung; James A. Wells

DOI: https://doi.org/10.1101/2025.06.06.658366

Paper

CD20 expression regulates CD37 levels in B-cell lymphoma – implications for immunotherapies

M. Bobrowicz; Aleksandra Kusowska; Marta Krawczyk et al. · 2023

Full title: CD20 expression regulates CD37 levels in B-cell lymphoma – implications for immunotherapies

DOI: https://doi.org/10.1101/2023.12.06.570441

Paper

TUB-010, a novel anti-CD30 antibody-drug conjugate based on Tub-tag technology, widens the therapeutic window by reducing toxicity while maintaining high efficacy

M. Gerlach; Saskia Schmitt; Philipp Cyprys et al. · 2025

Full title: TUB-010, a novel anti-CD30 antibody-drug conjugate based on Tub-tag technology, widens the therapeutic window by reducing toxicity while maintaining high efficacy

DOI: https://doi.org/10.1101/2025.01.15.633119

Paper

Biodistribution-Driven Discovery Identifies a Glycosidase-Cleavable Linker to Reprogram Radiotheranostics.

Lee, Woonghee; Doda, Sai Reddy; Baidoo, Kwamena E et al. · 2025

Full title: Biodistribution-Driven Discovery Identifies a Glycosidase-Cleavable Linker to Reprogram Radiotheranostics.

DOI: https://doi.org/10.1101/2025.09.11.675134

Paper

Systematic identification of regulators of antibody-drug conjugate toxicity using CRISPR-Cas9 screens

C. K. Tsui; Robyn M. Barfield; Curt R. Fischer et al. · 2019

Full title: Systematic identification of regulators of antibody-drug conjugate toxicity using CRISPR-Cas9 screens

Authors: C. K. Tsui; Robyn M. Barfield; Curt R. Fischer; D. Morgens; Amy Li; Benjamin A. H. Smith; Carolyn R. Bertozzi; Carolyn R. Bertozzi; David Rabuka; M. Bassik

DOI: https://doi.org/10.1101/557454

Paper

FOLR1-targeted Actinium-225-based Alpha-particle Therapy Eliminates Ovarian Cancer

Neetu Singh; Esther Need; Ayden Berndt et al. · 2025

Full title: FOLR1-targeted Actinium-225-based Alpha-particle Therapy Eliminates Ovarian Cancer

DOI: https://doi.org/10.1101/2025.10.27.684721

Paper

Co-administered antibody improves penetration of antibody–dye conjugate into human cancers with implications for antibody–drug conjugates

G. Lu; N. Nishio; N. S. van den Berg et al. · 2020

Full title: Co-administered antibody improves penetration of antibody–dye conjugate into human cancers with implications for antibody–drug conjugates

Authors: G. Lu; N. Nishio; N. S. van den Berg; B. Martin; Shayan Fakurnejad; S. van Keulen; A. Colevas; Greg M. Thurber; E. Rosenthal

DOI: https://doi.org/10.1038/s41467-020-19498-y

Paper

Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd)

Li-Chung Tsao; John S Wang; Xingru Ma et al. · 2025

Full title: Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd)

DOI: https://doi.org/10.1038/s41467-025-58266-8

Paper

Glutamic acid–valine–citrulline linkers ensure stability and efficacy of antibody–drug conjugates in mice

Y. Anami; Chisato M. Yamazaki; Wei Xiong et al. · 2018

Full title: Glutamic acid–valine–citrulline linkers ensure stability and efficacy of antibody–drug conjugates in mice

Authors: Y. Anami; Chisato M. Yamazaki; Wei Xiong; X. Gui; Ningyan Zhang; Z. An; K. Tsuchikama

DOI: https://doi.org/10.1038/s41467-018-04982-3

Paper

Construction of paclitaxel-based antibody–drug conjugates with a PEGylated linker to achieve superior therapeutic index

T. Shao; Tianzhi Chen; Yuning Chen et al. · 2020

Full title: Construction of paclitaxel-based antibody–drug conjugates with a PEGylated linker to achieve superior therapeutic index

Authors: T. Shao; Tianzhi Chen; Yuning Chen; Xiaoyue Liu; Yi-Li Chen; Qi Wang; Tong Zhu; Maojun Guo; Hui Li; D. Ju; Chunhe Wang

DOI: https://doi.org/10.1038/s41392-020-00247-y

Paper

The multifaceted roles of GSDME-mediated pyroptosis in cancer: therapeutic strategies and persisting obstacles

Yixiang Hu; Ya Liu; Lijuan Zong et al. · 2023

Full title: The multifaceted roles of GSDME-mediated pyroptosis in cancer: therapeutic strategies and persisting obstacles

Authors: Yixiang Hu; Ya Liu; Lijuan Zong; Wenyou Zhang; Renzhu Liu; Qichang Xing; Zheng Liu; Qingzi Yan; Wencan Li; Haibo Lei; Xiang Liu

DOI: https://doi.org/10.1038/s41419-023-06382-y

Paper

Subtyping-based platform guides precision medicine for heavily pretreated metastatic triple-negative breast cancer: The FUTURE phase II umbrella clinical trial

Y. Liu; Xiuzhi Zhu; Yi Xiao et al. · 2023

Full title: Subtyping-based platform guides precision medicine for heavily pretreated metastatic triple-negative breast cancer: The FUTURE phase II umbrella clinical trial

DOI: https://doi.org/10.1038/s41422-023-00795-2

Paper

Exploring the therapeutic use and outcome of antibody-drug conjugates in ovarian cancer treatment

Revu V L Narayana; Romi Gupta · 2025

Full title: Exploring the therapeutic use and outcome of antibody-drug conjugates in ovarian cancer treatment

Authors: Revu V L Narayana; Romi Gupta

DOI: https://doi.org/10.1038/s41388-025-03448-3

Paper

Delivery of a BET protein degrader via a CEACAM6-targeted antibody–drug conjugate inhibits tumour growth in pancreatic cancer models

Youya Nakazawa; Masayuki Miyano; Shuntaro Tsukamoto et al. · 2024

Full title: Delivery of a BET protein degrader via a CEACAM6-targeted antibody–drug conjugate inhibits tumour growth in pancreatic cancer models

DOI: https://doi.org/10.1038/s41467-024-46167-1

Paper

Identification of a hotspot on PD-L1 for pH-dependent binding by monoclonal antibodies for tumor therapy

Hongchuan Liu; Xiaoshan Bi; Yuehua Zhou et al. · 2020

Full title: Identification of a hotspot on PD-L1 for pH-dependent binding by monoclonal antibodies for tumor therapy

Authors: Hongchuan Liu; Xiaoshan Bi; Yuehua Zhou; R. Shi; S. Yao; J. Qi; H. Feng; Meiqing Feng; Jinghua Yan; Shuguang Tan

DOI: https://doi.org/10.1038/s41392-020-00254-z

Paper

Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance — Source link

Chisato M. Yamazaki; A. Yamaguchi; Y. Anami et al. · 2020

Full title: Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance — Source link

Authors: Chisato M. Yamazaki; A. Yamaguchi; Y. Anami; Wei Xiong; Y. Otani; 6. Jangsoon; Lee; N. Ueno; Ningyan Zhang; Z. An; K. Tsuchikama

DOI: https://doi.org/10.1038/s41467-021-23793-7

Paper

Site-specific ligase-dependent conjugation with ring-opening linker improves safety and stability of HER2-targeting ADCs

Lei Huang; Gang Qin; C. Gong et al. · 2025

Full title: Site-specific ligase-dependent conjugation with ring-opening linker improves safety and stability of HER2-targeting ADCs

DOI: https://doi.org/10.1038/s41467-025-64675-6

Paper

Novel treatment approaches utilizing antibody-drug conjugates in breast cancer

A. Davis; Jennifer Hesse; Patrícia M R Pereira et al. · 2025

Full title: Novel treatment approaches utilizing antibody-drug conjugates in breast cancer

Authors: A. Davis; Jennifer Hesse; Patrícia M R Pereira; Cynthia X. Ma

DOI: https://doi.org/10.1038/s41523-025-00743-w

Paper

Treatment strategies for breast cancer brain metastases

C. Bailleux; Lauriane Eberst; T. Bachelot · 2020

Full title: Treatment strategies for breast cancer brain metastases

Authors: C. Bailleux; Lauriane Eberst; T. Bachelot

DOI: https://doi.org/10.1038/s41416-020-01175-y

Paper

Expanding the payload scope in antibody-drug conjugates by delivery of hydroxy-containing drugs through self-immolative phosphoramidates

Philipp Ochtrop; Anil P. Jagtap; Jan G. Felber et al. · 2026

Full title: Expanding the payload scope in antibody-drug conjugates by delivery of hydroxy-containing drugs through self-immolative phosphoramidates

DOI: https://doi.org/10.1038/s41467-026-68605-y

Paper

Tumor cell-directed STING agonist antibody-drug conjugates induce type III interferons and anti-tumor innate immune responses

Naniye Malli Cetinbas; Travis Monnell; Jahna Soomer-James et al. · 2024

Full title: Tumor cell-directed STING agonist antibody-drug conjugates induce type III interferons and anti-tumor innate immune responses

DOI: https://doi.org/10.1038/s41467-024-49932-4

Paper

Precemtabart tocentecan, an anti-CEACAM5 antibody–drug conjugate, in metastatic colorectal cancer: a phase 1 trial

S. Kopetz; Valentina Boni; Ken Kato et al. · 2025

Full title: Precemtabart tocentecan, an anti-CEACAM5 antibody–drug conjugate, in metastatic colorectal cancer: a phase 1 trial

Authors: S. Kopetz; Valentina Boni; Ken Kato; K. Raghav; M. Vieito; A. Pallis; C. Habermehl; Abdul Siddiqui; Perrine Courlet; W. Sloot; Sabine Raab-Westphal; Felix Hart; I. Rodriguez-Rivera

DOI: https://doi.org/10.1038/s41591-025-03843-z

Paper

CLDN18.2–targeting antibody–drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: a phase 1 trial

Jia Liu; Jianwei Yang; Yuping Sun et al. · 2025

Full title: CLDN18.2–targeting antibody–drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: a phase 1 trial

DOI: https://doi.org/10.1038/s41591-025-03783-8

Paper

Emerging systemic therapy options beyond CDK4/6 inhibitors for hormone receptor-positive HER2-negative advanced breast cancer.

Ma, Jun; Chan, Jack Junjie; Toh, Ching Han et al. · 2023

Full title: Emerging systemic therapy options beyond CDK4/6 inhibitors for hormone receptor-positive HER2-negative advanced breast cancer.

Authors: Ma, Jun; Chan, Jack Junjie; Toh, Ching Han; Yap, Yoon-Sim

DOI: https://doi.org/10.1038/s41523-023-00578-3

Paper

RF1 attenuation enables efficient non-natural amino acid incorporation for production of homogeneous antibody drug conjugates

Gang Yin; Heather T Stephenson; Junhao Yang et al. · 2017

Full title: RF1 attenuation enables efficient non-natural amino acid incorporation for production of homogeneous antibody drug conjugates

DOI: https://doi.org/10.1038/s41598-017-03192-z

Paper

Antibody–drug conjugates in breast cancer: mechanisms of resistance and future therapeutic perspectives

Irene Valle; T. Grinda; Lorenzo Antonuzzo et al. · 2025

Full title: Antibody–drug conjugates in breast cancer: mechanisms of resistance and future therapeutic perspectives

Authors: Irene Valle; T. Grinda; Lorenzo Antonuzzo; B. Pistilli

DOI: https://doi.org/10.1038/s41523-025-00829-5

Paper

Conservation of oncofetal antigens on human embryonic stem cells enables discovery of monoclonal antibodies against cancer

H. Tan; C. Yong; B. Tan et al. · 2018

Full title: Conservation of oncofetal antigens on human embryonic stem cells enables discovery of monoclonal antibodies against cancer

Authors: H. Tan; C. Yong; B. Tan; Wey Jia Fong; J. Padmanabhan; A. Chin; Vanessa M. Y. Ding; Ally Lau; Lu Zheng; X. Bi; Yuansheng Yang; A. Choo

DOI: https://doi.org/10.1038/s41598-018-30070-z

Paper

Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic Cancer

Guoyun Zhu; D. Foletti; Xiaohui Liu et al. · 2019

Full title: Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic Cancer

DOI: https://doi.org/10.1038/s41598-019-44874-0

Paper

Internalization of CD239 highly expressed in breast cancer cells: a potential antigen for antibody-drug conjugates

Y. Kikkawa; Yurie Enomoto-Okawa; Aiko Fujiyama et al. · 2018

Full title: Internalization of CD239 highly expressed in breast cancer cells: a potential antigen for antibody-drug conjugates

Authors: Y. Kikkawa; Yurie Enomoto-Okawa; Aiko Fujiyama; Takeshi Fukuhara; Nozomi Harashima; Yumika Sugawara; Y. Negishi; Fumihiko Katagiri; K. Hozumi; M. Nomizu; Yuji Ito

DOI: https://doi.org/10.1038/s41598-018-24961-4

Paper

Novel method for screening functional antibody with comprehensive analysis of its immunoliposome

S. Hamamichi; Takeshi Fukuhara; I. Umeda et al. · 2021

Full title: Novel method for screening functional antibody with comprehensive analysis of its immunoliposome

Authors: S. Hamamichi; Takeshi Fukuhara; I. Umeda; H. Fujii; N. Hattori

DOI: https://doi.org/10.1038/s41598-021-84043-w

Paper

Placenta-specific1 (PLAC1) is a potential target for antibody-drug conjugate-based prostate cancer immunotherapy

Mohammad Reza Nejadmoghaddam; A. Zarnani; R. Ghahremanzadeh et al. · 2017

Full title: Placenta-specific1 (PLAC1) is a potential target for antibody-drug conjugate-based prostate cancer immunotherapy

Authors: Mohammad Reza Nejadmoghaddam; A. Zarnani; R. Ghahremanzadeh; R. Ghods; Jafar Mahmoudian; M. Yousefi; M. Nazari; M. Ghahremani; M. Abolhasani; A. Anissian; M. Mahmoudi; R. Dinarvand

DOI: https://doi.org/10.1038/s41598-017-13682-9

Paper

On the use of DNA as a linker in antibody-drug conjugates: synthesis, stability and in vitro potency

I. Dovgan; Anthony Ehkirch; Victor Lehot et al. · 2020

Full title: On the use of DNA as a linker in antibody-drug conjugates: synthesis, stability and in vitro potency

Authors: I. Dovgan; Anthony Ehkirch; Victor Lehot; I. Kuhn; Oleksandr Koniev; S. Kolodych; Alexandre Hentz; M. Ripoll; S. Ursuegui; M. Nothisen; S. Cianférani; A. Wagner

DOI: https://doi.org/10.1038/s41598-020-64518-y

Paper

Preclinical evaluation of a novel antibody–drug conjugate OBI-992 for Cancer therapy

Ting-Yu Chang; Chun-Jung Lin; Shih-Ni Wen et al. · 2025

Full title: Preclinical evaluation of a novel antibody–drug conjugate OBI-992 for Cancer therapy

DOI: https://doi.org/10.1038/s41598-025-92697-z

Paper

Rapid conjugation of antibodies to toxins to select candidates for the development of anticancer Antibody-Drug Conjugates (ADCs)

Ricarda M Hoffmann; S. Mele; A. Cheung et al. · 2020

Full title: Rapid conjugation of antibodies to toxins to select candidates for the development of anticancer Antibody-Drug Conjugates (ADCs)

DOI: https://doi.org/10.1038/s41598-020-65860-x

Paper

Immune-checkpoint targeting drug conjugates: a novel class of promising therapeutic agents for cancer treatment

S. Marchesi; Arianna Marinello; Paolo Ambrosini et al. · 2025

Full title: Immune-checkpoint targeting drug conjugates: a novel class of promising therapeutic agents for cancer treatment

Authors: S. Marchesi; Arianna Marinello; Paolo Ambrosini; Chiara Cavalli; G. Lo Russo; M. Occhipinti

DOI: https://doi.org/10.1038/s41698-025-01011-7

Paper

Linker-GPT: design of Antibody-drug conjugates linkers with molecular generators and reinforcement learning

An Su; Yanlin Luo; Chengwei Zhang et al. · 2025

Full title: Linker-GPT: design of Antibody-drug conjugates linkers with molecular generators and reinforcement learning

Authors: An Su; Yanlin Luo; Chengwei Zhang; Hongliang Duan

DOI: https://doi.org/10.1038/s41598-025-05555-3

Paper

Antibody–drug nanoparticle induces synergistic treatment efficacies in HER2 positive breast cancer cells

Muhammad Raisul Abedin; Kaitlyne Powers; Rachel Aiardo et al. · 2021

Full title: Antibody–drug nanoparticle induces synergistic treatment efficacies in HER2 positive breast cancer cells

Authors: Muhammad Raisul Abedin; Kaitlyne Powers; Rachel Aiardo; Dibbya Barua; Sutapa Barua

DOI: https://doi.org/10.1038/s41598-021-86762-6

Paper

Ortho-functionalized pyridinyl-tetrazines break the inverse correlation between click reactivity and cleavage yields in click-to-release chemistry

Ron M. Versteegen; R. Rossin; I. Filot et al. · 2024

Full title: Ortho-functionalized pyridinyl-tetrazines break the inverse correlation between click reactivity and cleavage yields in click-to-release chemistry

Authors: Ron M. Versteegen; R. Rossin; I. Filot; F. Hoeben; Arthur H. A. M. van Onzen; Henk M. Janssen; M. S. Robillard

DOI: https://doi.org/10.1038/s42004-024-01392-z

Paper

Antibody-drug conjugates in lung cancer: dawn of a new era?

N. Coleman; T. Yap; J. Heymach et al. · 2023

Full title: Antibody-drug conjugates in lung cancer: dawn of a new era?

Authors: N. Coleman; T. Yap; J. Heymach; F. Meric-Bernstam; X. Le

DOI: https://doi.org/10.1038/s41698-022-00338-9

Paper

Leveraging artificial intelligence in antibody-drug conjugate development: from target identification to clinical translation in oncology

Ye Lu; Weijun Huang; Yuxuan Li et al. · 2025

Full title: Leveraging artificial intelligence in antibody-drug conjugate development: from target identification to clinical translation in oncology

Authors: Ye Lu; Weijun Huang; Yuxuan Li; Yanzhi Xu; Qing Wei; Chulin Sha; Peng Guo

DOI: https://doi.org/10.1038/s41698-025-01159-2

Paper

Through every lens: assessing the impact of chemical modifications on antibody-conjugates using in vivo imaging

V. V. S. R. Edupuganti; Freddy E. Escorcia; M. Schnermann · 2025

Full title: Through every lens: assessing the impact of chemical modifications on antibody-conjugates using in vivo imaging

Authors: V. V. S. R. Edupuganti; Freddy E. Escorcia; M. Schnermann

DOI: https://doi.org/10.1038/s44303-025-00109-8

Paper

A new TROP2-targeting antibody-drug conjugate shows potent antitumor efficacy in breast and lung cancers

Dan-dan Zhou; Xiao-Tian Zhai; Lan-Wen Zhang et al. · 2024

Full title: A new TROP2-targeting antibody-drug conjugate shows potent antitumor efficacy in breast and lung cancers

Authors: Dan-dan Zhou; Xiao-Tian Zhai; Lan-Wen Zhang; Zi-hui Xie; Ying Wang; Yong-su Zhen; Rui-juan Gao; Qing-Fang Miao

DOI: https://doi.org/10.1038/s41698-024-00584-z

Paper

Development of potent antibody drug conjugates against ICAM1+ cancer cells in preclinical models of cholangiocarcinoma

B. Zhu; Xinyan Wang; T. Shimura et al. · 2023

Full title: Development of potent antibody drug conjugates against ICAM1+ cancer cells in preclinical models of cholangiocarcinoma

Authors: B. Zhu; Xinyan Wang; T. Shimura; Andrew C Huang; Nana Kong; Yujie Dai; Jianmin Fang; Peng Guo; Jieer Ying

DOI: https://doi.org/10.1038/s41698-023-00447-z

Paper

- **DOI:** 10.1038/srep30835 - **Authors:** I. Dovgan, S. Kolodych, Oleksandr Koniev, A. Wagner - **Year:** 2016 - **Journal:** Scientific Reports

I. Dovgan; S. Kolodych; Oleksandr Koniev et al. · 2016

Full title: - **DOI:** 10.1038/srep30835 - **Authors:** I. Dovgan, S. Kolodych, Oleksandr Koniev, A. Wagner - **Year:** 2016 - **Journal:** Scientific Reports

Authors: I. Dovgan; S. Kolodych; Oleksandr Koniev; A. Wagner

DOI: https://doi.org/10.1038/srep30835

Paper

The characterization of variable new antigen receptors targeting FAP isolated from a novel immunized library

Gihan S. Gunaratne; Joseph P. Gallant; Kendahl L. Ott et al. · 2025

Full title: The characterization of variable new antigen receptors targeting FAP isolated from a novel immunized library

DOI: https://doi.org/10.1038/s42003-025-08610-x

Paper

Development of a facile antibody–drug conjugate platform for increased stability and homogeneity† †Electronic supplementary information (ESI) available: Synthetic schemes and characterization data, experimental procedures, Fig. S1 and S2. See DOI: 10.1039/c6sc05149a Click here for additional data fi

Nimish Gupta; Johny Kancharla; Shelly Kaushik et al. · 2016

DOI: https://doi.org/10.1039/c6sc05149a

Paper

Towards a glutathione-cleavable azobenzene linker for antibody-drug conjugates.

M. Kapun; Roshan Patel; Mahri Park et al. · 2025

Full title: Towards a glutathione-cleavable azobenzene linker for antibody-drug conjugates.

Authors: M. Kapun; Roshan Patel; Mahri Park; F. J. Pérez‐Areales; Kristina Kostadinova; Thomas Wharton; Jason S. Carroll; David R. Spring

DOI: https://doi.org/10.1039/d5cc05824d

Paper

Diazido macrocyclic sulfates as a platform for the synthesis of sequence-defined polymers for antibody drug conjugates

N. L. Forsythe; Mikayla F. Tan; H. Maynard · 2022

Full title: Diazido macrocyclic sulfates as a platform for the synthesis of sequence-defined polymers for antibody drug conjugates

Authors: N. L. Forsythe; Mikayla F. Tan; H. Maynard

DOI: https://doi.org/10.1039/d1sc06242e

Paper

Rapid and robust cysteine bioconjugation with vinylheteroarenes

H. Seki; Stephen J. Walsh; Jonathan D Bargh et al. · 2021

Full title: Rapid and robust cysteine bioconjugation with vinylheteroarenes

Authors: H. Seki; Stephen J. Walsh; Jonathan D Bargh; J. Parker; J. Carroll; D. Spring

DOI: https://doi.org/10.1039/d1sc02722k

Paper

All-in-one disulfide bridging enables the generation of antibody conjugates with modular cargo loading

Friederike M Dannheim; Stephen J. Walsh; Carolina T Orozco et al. · 2022

Full title: All-in-one disulfide bridging enables the generation of antibody conjugates with modular cargo loading

Authors: Friederike M Dannheim; Stephen J. Walsh; Carolina T Orozco; A. Hansen; Jonathan D Bargh; S. Jackson; N. Bond; J. Parker; J. Carroll; D. Spring

DOI: https://doi.org/10.1039/d2sc02198f

Paper

Compact hydrophilic electrophiles enable highly efficacious high DAR ADCs with excellent in vivo PK profile

P. Ochtrop; Jahaziel Jahzerah; Paul Machui et al. · 2023

Full title: Compact hydrophilic electrophiles enable highly efficacious high DAR ADCs with excellent in vivo PK profile

Authors: P. Ochtrop; Jahaziel Jahzerah; Paul Machui; I. Mai; D. Schumacher; J. Helma; Marc‐André Kasper; C. Hackenberger

DOI: https://doi.org/10.1039/d2sc05678j

Paper

Sulfatase-cleavable linkers for antibody-drug conjugates†

Jonathan D Bargh; Stephen J. Walsh; Albert Isidro-Llobet et al. · 2020

Full title: Sulfatase-cleavable linkers for antibody-drug conjugates†

Authors: Jonathan D Bargh; Stephen J. Walsh; Albert Isidro-Llobet; Soleilmane Omarjee; J. Carroll; D. Spring

DOI: https://doi.org/10.1039/c9sc06410a

Paper

Technical, preclinical, and clinical developments of Fc-glycan-specific antibody-drug conjugates.

Yang, Qiang; Liu, Yunpeng · 2025

Full title: Technical, preclinical, and clinical developments of Fc-glycan-specific antibody-drug conjugates.

Authors: Yang, Qiang; Liu, Yunpeng

DOI: https://doi.org/10.1039/d4md00637b

Paper

Steric and stereoscopic disulfide construction for cross-linkage via N-dithiophthalimides†‡

Wen-Chao Gao; Jun Tian; Y. Shang et al. · 2020

Full title: Steric and stereoscopic disulfide construction for cross-linkage via N-dithiophthalimides†‡

Authors: Wen-Chao Gao; Jun Tian; Y. Shang; Xuefeng Jiang

DOI: https://doi.org/10.1039/d0sc01060j

Paper

A biparatopic HER2-targeting ADC constructed via site-specific glycan conjugation exhibits superior stability, safety, and efficacy

Q. Xue; Jianjian Peng; Wenying Dai et al. · 2025

Full title: A biparatopic HER2-targeting ADC constructed via site-specific glycan conjugation exhibits superior stability, safety, and efficacy

Authors: Q. Xue; Jianjian Peng; Wenying Dai; Qingsong Wu; Jinbiao Jiao; Yudi Hu; W. Sha; Yang Yang; Wenhao Yu; Siyang Liu; Ting Xu; Jie P. Li

DOI: https://doi.org/10.1039/d5cb00096c

Paper

Generating a Bispecific Antibody Drug Conjugate Targeting PRLR and HER2 with Improving the Internalization

Huifang Zong; Baohong Zhang; Jianjia Zhu · 2022

Full title: Generating a Bispecific Antibody Drug Conjugate Targeting PRLR and HER2 with Improving the Internalization

Authors: Huifang Zong; Baohong Zhang; Jianjia Zhu

DOI: https://doi.org/10.1055/s-0042-1749334

Paper

Functional native disulfide bridging enables delivery of a potent, stable and targeted antibody-drug conjugate (ADC).

João P. M. Nunes; M. Morais; V. Vassileva et al. · 2015

Full title: Functional native disulfide bridging enables delivery of a potent, stable and targeted antibody-drug conjugate (ADC).

Authors: João P. M. Nunes; M. Morais; V. Vassileva; E. Robinson; V. Rajkumar; Mark E. B. Smith; R. Pedley; S. Caddick; J. R. Baker; V. Chudasama

DOI: https://doi.org/10.1039/c5cc03557k

Paper

A novel antibody–drug conjugate targeting SAIL for the treatment of hematologic malignancies

S. Kim; Jan-Willem Theunissen; J. Balibalos et al. · 2015

Full title: A novel antibody–drug conjugate targeting SAIL for the treatment of hematologic malignancies

DOI: https://doi.org/10.1038/bcj.2015.39

Paper

From prodrug to pro-prodrug: hypoxia-sensitive antibody–drug conjugates

Yanming Wang; Dian Xiao; Jiaguo Li et al. · 2022

Full title: From prodrug to pro-prodrug: hypoxia-sensitive antibody–drug conjugates

Authors: Yanming Wang; Dian Xiao; Jiaguo Li; Shiyong Fan; Fei Xie; Wu Zhong; Xinbo Zhou; Song Li

DOI: https://doi.org/10.1038/s41392-021-00833-8

Paper

Quantitative systems pharmacology modeling of HER2-positive metastatic breast cancer for translational efficacy evaluation and combination assessment across therapeutic modalities

Ya-ting Zhou; Jia-Hui Chu; Shu-han Zhao et al. · 2024

Full title: Quantitative systems pharmacology modeling of HER2-positive metastatic breast cancer for translational efficacy evaluation and combination assessment across therapeutic modalities

Authors: Ya-ting Zhou; Jia-Hui Chu; Shu-han Zhao; Geli Li; Zi-yi Fu; Sujie Zhang; Xue-Hu Gao; Wen Ma; Kai Shen; Yuan Gao; Wei Li; Yongmei Yin; Chen Zhao

DOI: https://doi.org/10.1038/s41401-024-01232-9

Paper

Milatuzumab-Doxorubicin Antibody-Drug Conjugate IMMU-110

· 2020

Full title: Milatuzumab-Doxorubicin Antibody-Drug Conjugate IMMU-110

DOI: https://doi.org/10.32388/szq78x

Paper

Naked antibodies and antibody-drug conjugates: targeted therapy for childhood acute lymphoblastic leukemia

Erica Brivio; Francisco Bautista; C. Zwaan · 2024

Full title: Naked antibodies and antibody-drug conjugates: targeted therapy for childhood acute lymphoblastic leukemia

Authors: Erica Brivio; Francisco Bautista; C. Zwaan

DOI: https://doi.org/10.3324/haematol.2023.283815

Paper

Anti-LAMP1 Antibody-drug Conjugate SAR428926

· 2020

Full title: Anti-LAMP1 Antibody-drug Conjugate SAR428926

DOI: https://doi.org/10.32388/qrdzap

Paper

Antibody-drug Conjugate ABBV-155

· 2020

Full title: Antibody-drug Conjugate ABBV-155

DOI: https://doi.org/10.32388/hvqe5n

Paper

Antibody-Drug Conjugate DFRF4539A

· 2020

Full title: Antibody-Drug Conjugate DFRF4539A

DOI: https://doi.org/10.32388/yr3mn4

Paper

Soluble B-cell maturation antigen in lacrimal fluid as a potential biomarker and mediator of keratopathy in multiple myeloma

U. Munawar; J. Theuersbacher; M. Steinhardt et al. · 2024

Full title: Soluble B-cell maturation antigen in lacrimal fluid as a potential biomarker and mediator of keratopathy in multiple myeloma

DOI: https://doi.org/10.3324/haematol.2024.285205

Paper

Antibody-drug Conjugate SC-003

· 2020

Full title: Antibody-drug Conjugate SC-003

DOI: https://doi.org/10.32388/zyby9z

Paper

Discovery research and translation science of trastuzumab deruxtecan, from non-clinical study to clinical trial

T. Nakada · 2021

Full title: Discovery research and translation science of trastuzumab deruxtecan, from non-clinical study to clinical trial

Authors: T. Nakada

DOI: https://doi.org/10.33611/trs.2021-010

Paper

The Role of Immunotherapy in Non-transplant Eligible Multiple Myeloma

A. Bobin; Hélène Gardeney; Florence Sabirou et al. · 2020

Full title: The Role of Immunotherapy in Non-transplant Eligible Multiple Myeloma

Authors: A. Bobin; Hélène Gardeney; Florence Sabirou; Cécile Gruchet; A. Lévy; Laly Nsiala; Laura Cailly; C. Tomowiak; J. Torregrosa; S. Guidez; X. Leleu

DOI: https://doi.org/10.3389/fonc.2020.00676

Paper

Conditional activation of an anti-IgM antibody-drug conjugate for precise B cell lymphoma targeting

K. Schoenfeld; Julia Harwardt; Jan Habermann et al. · 2023

Full title: Conditional activation of an anti-IgM antibody-drug conjugate for precise B cell lymphoma targeting

Authors: K. Schoenfeld; Julia Harwardt; Jan Habermann; Adrian Elter; H. Kolmar

DOI: https://doi.org/10.3389/fimmu.2023.1258700

Paper

Anti-lipolysis-stimulated lipoprotein receptor antibody-drug conjugate to treat triple-negative breast cancer

Zhuoxin Zhou; Davis Ballard; Tanvi Varadkar et al. · 2025

Full title: Anti-lipolysis-stimulated lipoprotein receptor antibody-drug conjugate to treat triple-negative breast cancer

Authors: Zhuoxin Zhou; Davis Ballard; Tanvi Varadkar; Jiashuai Zhang; Zhantao Du; Ashley George; Aaron Krabacher; Rachel Yengo; Lufang Zhou; X. Liu

DOI: https://doi.org/10.3389/fonc.2025.1663743

Paper

Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy

B. Nazha; C. Inal; T. Owonikoko · 2020

Full title: Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy

Authors: B. Nazha; C. Inal; T. Owonikoko

DOI: https://doi.org/10.3389/fonc.2020.01000

Paper

Antibody-drug conjugates: the paradigm shifts in the targeted cancer therapy.

Aggarwal, Devesh; Yang, Jie; Salam, Md Abdus et al. · 2023

Full title: Antibody-drug conjugates: the paradigm shifts in the targeted cancer therapy.

Authors: Aggarwal, Devesh; Yang, Jie; Salam, Md Abdus; Sengupta, Sagnik; Al-Amin, Md Yusuf; Mustafa, Saad; Khan, Mohammad Aasif; Huang, Xun; Pawar, Jogendra Singh

DOI: https://doi.org/10.3389/fimmu.2023.1203073

Paper

Novel Antibody Drug Conjugates Targeting Tumor-Associated Receptor Tyrosine Kinase ROR2 by Functional Screening of Fully Human Antibody Libraries Using Transpo-mAb Display on Progenitor B Cells

I. Hellmann; L. Waldmeier; Marie-Christine Bannwarth-Escher et al. · 2018

Authors: I. Hellmann; L. Waldmeier; Marie-Christine Bannwarth-Escher; Kseniya Maslova; Fabian I. Wolter; U. Grawunder; R. Beerli

DOI: https://doi.org/10.3389/fimmu.2018.02490

Paper

Antibody-drug conjugates as game changers in bladder cancer: current progress and future directions

Fei Zhang; Sheng Li · 2025

Full title: Antibody-drug conjugates as game changers in bladder cancer: current progress and future directions

Authors: Fei Zhang; Sheng Li

DOI: https://doi.org/10.3389/fimmu.2025.1591191

Paper

A Unique Human Immunoglobulin Heavy Chain Variable Domain-Only CD33 CAR for the Treatment of Acute Myeloid Leukemia

D. Schneider; Y. Xiong; Peirong Hu et al. · 2018

Full title: A Unique Human Immunoglobulin Heavy Chain Variable Domain-Only CD33 CAR for the Treatment of Acute Myeloid Leukemia

Authors: D. Schneider; Y. Xiong; Peirong Hu; Darong Wu; Wei-zao Chen; T. Ying; Zhongyu Zhu; D. Dimitrov; B. Dropulić; R. Orentas

DOI: https://doi.org/10.3389/fonc.2018.00539

Paper

Lysosomal P-gp-MDR1 Confers Drug Resistance of Brentuximab Vedotin and Its Cytotoxic Payload Monomethyl Auristatin E in Tumor Cells

Liu-Kreyche Peggy; Hong Shen; A. Marino et al. · 2019

Full title: Lysosomal P-gp-MDR1 Confers Drug Resistance of Brentuximab Vedotin and Its Cytotoxic Payload Monomethyl Auristatin E in Tumor Cells

Authors: Liu-Kreyche Peggy; Hong Shen; A. Marino; R. Iyer; W. Humphreys; Yurong Lai

DOI: https://doi.org/10.3389/fphar.2019.00749

Paper

Brentuximab vedotin use in pediatric anaplastic large cell lymphoma

J. Agrusa; Emily R. Egress; E. Lowe · 2023

Full title: Brentuximab vedotin use in pediatric anaplastic large cell lymphoma

Authors: J. Agrusa; Emily R. Egress; E. Lowe

DOI: https://doi.org/10.3389/fimmu.2023.1203471

Paper

Antibody-drug conjugates targeting HER2 for the treatment of urothelial carcinoma: potential therapies for HER2-positive urothelial carcinoma

Chia-Hsien Shih; Yu-Hua Lin; Hao-Lun Luo et al. · 2024

Full title: Antibody-drug conjugates targeting HER2 for the treatment of urothelial carcinoma: potential therapies for HER2-positive urothelial carcinoma

Authors: Chia-Hsien Shih; Yu-Hua Lin; Hao-Lun Luo; Wen-Wei Sung

DOI: https://doi.org/10.3389/fphar.2024.1326296

Paper

The potential of antibody-drug conjugates in immunotherapy for non-small cell lung cancer: current progress and future

Hongyu Lin; Xinyu Ma; Xinhai Zhu et al. · 2025

Full title: The potential of antibody-drug conjugates in immunotherapy for non-small cell lung cancer: current progress and future

Authors: Hongyu Lin; Xinyu Ma; Xinhai Zhu; Linru Zhong

DOI: https://doi.org/10.3389/fonc.2025.1630056

Paper

Insights and therapeutic advances in pancreatic cancer: the role of electron microscopy in decoding the tumor microenvironment

Hong Dai; Xingxuan Chen; Jiawen Yang et al. · 2024

Full title: Insights and therapeutic advances in pancreatic cancer: the role of electron microscopy in decoding the tumor microenvironment

Authors: Hong Dai; Xingxuan Chen; Jiawen Yang; Yuying Wang; R. Loiola; Aiping Lu; K. Cheung

DOI: https://doi.org/10.3389/fcell.2024.1460544

Paper

Preclinical profiles of SKB264, a novel anti-TROP2 antibody conjugated to topoisomerase inhibitor, demonstrated promising antitumor efficacy compared to IMMU-132

Yezhe Cheng; Xiaoxi Yuan; Qiang Tian et al. · 2022

Full title: Preclinical profiles of SKB264, a novel anti-TROP2 antibody conjugated to topoisomerase inhibitor, demonstrated promising antitumor efficacy compared to IMMU-132

Authors: Yezhe Cheng; Xiaoxi Yuan; Qiang Tian; Xiuying Huang; Yang Chen; Yuzhi Pu; Huaicheng Long; Mingyu Xu; Yafei Ji; Jia Xie; Yuping Tan; Xi Zhao; Hongmei Song

DOI: https://doi.org/10.3389/fonc.2022.951589

Paper

Antibody-drug conjugate: a newly developed biological missile for tumor treatment.

Tang, Zhuoran; Xie, Yanchun; Zeng, Yanping · 2025

Full title: Antibody-drug conjugate: a newly developed biological missile for tumor treatment.

Authors: Tang, Zhuoran; Xie, Yanchun; Zeng, Yanping

DOI: https://doi.org/10.3389/fonc.2025.1688057

Paper

The development and evaluation of a tublysine-based antibody-drug conjugate with enhanced tumor therapeutic efficacy

Huihui Guo; Hongsheng Xie; Yuanyuan Huang et al. · 2025

Full title: The development and evaluation of a tublysine-based antibody-drug conjugate with enhanced tumor therapeutic efficacy

DOI: https://doi.org/10.3389/fphar.2025.1532104

Paper

Elucidating Novel Targets for Ovarian Cancer Antibody–Drug Conjugate Development: Integrating In Silico Prediction and Surface Plasmon Resonance to Identify Targets with Enhanced Antibody Internalization Capacity

E. Onyido; David James; Jezabel Garcia-Parra et al. · 2023

Authors: E. Onyido; David James; Jezabel Garcia-Parra; John Sinfield; Anna Moberg; Zoe Coombes; Jenny Worthington; Nicole Williams; Lewis W. Francis; R. S. Conlan; D. Gonzalez

DOI: https://doi.org/10.3390/antib12040065

Paper

Linker Design Impacts Antibody-Drug Conjugate Pharmacokinetics and Efficacy via Modulating the Stability and Payload Release Efficiency

Dian Su; Donglu Zhang · 2021

Full title: Linker Design Impacts Antibody-Drug Conjugate Pharmacokinetics and Efficacy via Modulating the Stability and Payload Release Efficiency

Authors: Dian Su; Donglu Zhang

DOI: https://doi.org/10.3389/fphar.2021.687926

Paper

Hydrophilic Auristatin Glycoside Payload Enables Improved Antibody-Drug Conjugate Efficacy and Biocompatibility

T. Satomaa; Henna Pynnönen; A. Vilkman et al. · 2018

Full title: Hydrophilic Auristatin Glycoside Payload Enables Improved Antibody-Drug Conjugate Efficacy and Biocompatibility

Authors: T. Satomaa; Henna Pynnönen; A. Vilkman; Titta Kotiranta; Virve Pitkänen; A. Heiskanen; B. Herpers; L. Price; J. Helin; J. Saarinen

DOI: https://doi.org/10.3390/antib7020015

Paper

Factors Affecting the Pharmacology of Antibody–Drug Conjugates

A. Lucas; Lauren S. L. Price; Allison N. Schorzman et al. · 2018

Full title: Factors Affecting the Pharmacology of Antibody–Drug Conjugates

Authors: A. Lucas; Lauren S. L. Price; Allison N. Schorzman; Mallory Storrie; J. Piscitelli; Juan Razo; W. Zamboni

DOI: https://doi.org/10.3390/antib7010010

Paper

Updates on Antibody Drug Conjugates and Bispecific T-Cell Engagers in SCLC

Kinsley Wang; Kyle Taing; R. Hsu · 2026

Full title: Updates on Antibody Drug Conjugates and Bispecific T-Cell Engagers in SCLC

Authors: Kinsley Wang; Kyle Taing; R. Hsu

DOI: https://doi.org/10.3390/antib15010004

Paper

A Purification Strategy Utilizing Hydrophobic Interaction Chromatography to Obtain Homogeneous Species from a Site-Specific Antibody Drug Conjugate Produced by AJICAP™ First Generation.

Matsuda, Yutaka; Leung, Monica; Okuzumi, Tatsuya et al. · 2020

Full title: A Purification Strategy Utilizing Hydrophobic Interaction Chromatography to Obtain Homogeneous Species from a Site-Specific Antibody Drug Conjugate Produced by AJICAP™ First Generation.

Authors: Matsuda, Yutaka; Leung, Monica; Okuzumi, Tatsuya; Mendelsohn, Brian

DOI: https://doi.org/10.3390/antib9020016

Paper

A RAGE-Targeted Antibody-Drug Conjugate: Surface Plasmon Resonance as a Platform for Accelerating Effective ADC Design and Development

Gareth D Healey; Å. Frostell; T. Fagge et al. · 2019

Full title: A RAGE-Targeted Antibody-Drug Conjugate: Surface Plasmon Resonance as a Platform for Accelerating Effective ADC Design and Development

Authors: Gareth D Healey; Å. Frostell; T. Fagge; D. Gonzalez; R. S. Conlan

DOI: https://doi.org/10.3390/antib8010007

Paper

Navigating hepatotoxicity of antibody-drug conjugates: from mechanistic insights to clinical and postmarketing evidence

Yinuo Dong; Yang Zhi; Xiaoyun Li et al. · 2025

Full title: Navigating hepatotoxicity of antibody-drug conjugates: from mechanistic insights to clinical and postmarketing evidence

Authors: Yinuo Dong; Yang Zhi; Xiaoyun Li; Mingyang Ma; Minyan Ye; Sha Huang; Jieting Tang; Wei Zhong; X. Lei; Yimin Mao

DOI: https://doi.org/10.3389/fphar.2025.1694436

Paper

Evaluation of Two Chemoenzymatic Glycan Remodeling Approaches to Generate Site-Specific Antibody–Drug Conjugates

Qiang Yang; He Chen; Chong Ou et al. · 2023

Full title: Evaluation of Two Chemoenzymatic Glycan Remodeling Approaches to Generate Site-Specific Antibody–Drug Conjugates

Authors: Qiang Yang; He Chen; Chong Ou; Zhihao Zheng; Xiao Zhang; Yunpeng Liu; Guanghui Zong; Lai-Xi Wang

DOI: https://doi.org/10.3390/antib12040071

Paper

A Polar Sulfamide Spacer Significantly Enhances the Manufacturability, Stability, and Therapeutic Index of Antibody-Drug Conjugates.

Verkade, Jorge M M; Wijdeven, Marloes A; Van Geel, Remon et al. · 2018

Full title: A Polar Sulfamide Spacer Significantly Enhances the Manufacturability, Stability, and Therapeutic Index of Antibody-Drug Conjugates.

Authors: Verkade, Jorge M M; Wijdeven, Marloes A; Van Geel, Remon; Janssen, Brian M G; Van Berkel, Sander S; Van Delft, Floris L

DOI: https://doi.org/10.3390/antib7010012

Paper

Peptide–Drug Conjugates as Next-Generation Therapeutics: Exploring the Potential and Clinical Progress

Krishna Jadhav; Ashwin Abhang; Eknath Kole et al. · 2025

Full title: Peptide–Drug Conjugates as Next-Generation Therapeutics: Exploring the Potential and Clinical Progress

Authors: Krishna Jadhav; Ashwin Abhang; Eknath Kole; Dipak Gadade; Apurva Dusane; Aditya Iyer; Ankur Sharma; S. Rout; A. Gholap; Jitendra B. Naik; R. Verma; Satish Rojekar

DOI: https://doi.org/10.3390/bioengineering12050481

Paper

Quantification for Antibody-Conjugated Drug in Trastuzumab Emtansine and Application to In Vitro Linker Stability and In Vivo Pharmacokinetic Study in Rat Using an Immuno-Affinity Capture Liquid Chromatography-Mass Spectrometric Method

Seo-jin Park; Byeong Ill Lee; Min-Ho Park et al. · 2021

Authors: Seo-jin Park; Byeong Ill Lee; Min-Ho Park; Jang-mi Choi; Yuri Park; Min-jae Park; Jeong-hyeon Lim; Ji-Young Lee; Sangsoo Hwang; Jeongmin Lee; Young G. Shin

DOI: https://doi.org/10.3390/app11209437

Paper

Multiplex LC-MS/MS Assays for Clinical Bioanalysis of MEDI4276, an Antibody-Drug Conjugate of Tubulysin Analogue Attached via Cleavable Linker to a Biparatopic Humanized Antibody against HER-2

Morse Faria; Marlking Peay; B. Lam et al. · 2019

Authors: Morse Faria; Marlking Peay; B. Lam; Eric Ma; Moucun Yuan; Michael P Waldron; W. Mylott; M. Liang; A. Rosenbaum

DOI: https://doi.org/10.3390/antib8010011

Paper

Antibody Drug Conjugates as Cancer Therapeutics

P. Trail · 2013

Full title: Antibody Drug Conjugates as Cancer Therapeutics

Authors: P. Trail

DOI: https://doi.org/10.3390/antib2010113

Paper

Pyrrolobenzodiazepine Antibody-Drug Conjugates Designed for Stable Thiol Conjugation

R. Christie; A. Tiberghien; Qun Du et al. · 2017

Full title: Pyrrolobenzodiazepine Antibody-Drug Conjugates Designed for Stable Thiol Conjugation

Authors: R. Christie; A. Tiberghien; Qun Du; Binyam Z Bezabeh; R. Fleming; Amanda Shannon; S. Mao; S. Breen; Jing Zhang; Haihong Zhong; Jay Harper; Herren Wu; P. Howard; Changshou Gao

DOI: https://doi.org/10.3390/antib6040020

Paper

Immunoconjugates for Osteosarcoma Therapy: Preclinical Experiences and Future Perspectives

D. Mercatelli; M. Bortolotti; A. Bazzocchi et al. · 2018

Full title: Immunoconjugates for Osteosarcoma Therapy: Preclinical Experiences and Future Perspectives

Authors: D. Mercatelli; M. Bortolotti; A. Bazzocchi; A. Bolognesi; L. Polito

DOI: https://doi.org/10.3390/biomedicines6010019

Paper

Advances and Limitations of Antibody Drug Conjugates for Cancer

Candice Maria Mckertish; Veysel Kayser · 2021

Full title: Advances and Limitations of Antibody Drug Conjugates for Cancer

Authors: Candice Maria Mckertish; Veysel Kayser

DOI: https://doi.org/10.3390/biomedicines9080872

Paper

Updates in the Development of ImmunoRNases for the Selective Killing of Tumor Cells

S. Jordaan; O. Akinrinmade; T. Nachreiner et al. · 2018

Full title: Updates in the Development of ImmunoRNases for the Selective Killing of Tumor Cells

Authors: S. Jordaan; O. Akinrinmade; T. Nachreiner; Christian Cremer; K. Naran; S. Chetty; S. Barth

DOI: https://doi.org/10.3390/biomedicines6010028

Paper

Antibody-Drug Conjugates for the Treatment of Breast Cancer.

Corti, Chiara; Giugliano, Federica; Nicolò, Eleonora et al. · 2021

Full title: Antibody-Drug Conjugates for the Treatment of Breast Cancer.

Authors: Corti, Chiara; Giugliano, Federica; Nicolò, Eleonora; Ascione, Liliana; Curigliano, Giuseppe

DOI: https://doi.org/10.3390/cancers13122898

Paper

Novel Silyl Ether-Based Acid-Cleavable Antibody-MMAE Conjugates with Appropriate Stability and Efficacy

Yanming Wang; Shiyong Fan; Dian Xiao et al. · 2019

Full title: Novel Silyl Ether-Based Acid-Cleavable Antibody-MMAE Conjugates with Appropriate Stability and Efficacy

Authors: Yanming Wang; Shiyong Fan; Dian Xiao; Fei Xie; Wei Li; Wu Zhong; Xinbo Zhou

DOI: https://doi.org/10.3390/cancers11070957

Paper

Rapid Evaluation of Antibody Fragment Endocytosis for Antibody Fragment–Drug Conjugates

Eunhee Kim; Jieun K. Jeong; Junghyeon Lee et al. · 2020

Full title: Rapid Evaluation of Antibody Fragment Endocytosis for Antibody Fragment–Drug Conjugates

Authors: Eunhee Kim; Jieun K. Jeong; Junghyeon Lee; H. Jung; Minho Kim; Yi Zhao; E. Yi; Kristine M Kim

DOI: https://doi.org/10.3390/biom10060955

Paper

Unlocking New Horizons: Antibody–Drug Conjugates in Small Cell Lung Cancer

Jiayu Liu; Yan Cui; Dongying Liao et al. · 2025

Full title: Unlocking New Horizons: Antibody–Drug Conjugates in Small Cell Lung Cancer

Authors: Jiayu Liu; Yan Cui; Dongying Liao; Mingwei Sima; Moxuan Han; Wanhao Li; Yan Bi; Donghui Yue

DOI: https://doi.org/10.3390/biology14121677

Paper

Acquired Resistance to Antibody-Drug Conjugates

D. Collins; B. Bossenmaier; Gwendlyn Kollmorgen et al. · 2019

Full title: Acquired Resistance to Antibody-Drug Conjugates

Authors: D. Collins; B. Bossenmaier; Gwendlyn Kollmorgen; G. Niederfellner

DOI: https://doi.org/10.3390/cancers11030394

Paper

Lysosomal-Cleavable Peptide Linkers in Antibody–Drug Conjugates

S. Balamkundu; Chuan-Fa Liu · 2023

Full title: Lysosomal-Cleavable Peptide Linkers in Antibody–Drug Conjugates

Authors: S. Balamkundu; Chuan-Fa Liu

DOI: https://doi.org/10.3390/biomedicines11113080

Paper

Antibody-Drug Conjugates: A Promising Novel Therapy for the Treatment of Ovarian Cancer

A. Manzano; A. Ocaña · 2020

Full title: Antibody-Drug Conjugates: A Promising Novel Therapy for the Treatment of Ovarian Cancer

Authors: A. Manzano; A. Ocaña

DOI: https://doi.org/10.3390/cancers12082223

Paper

The Landscape of Nucleic-Acid-Based Aptamers for Treatment of Hematologic Malignancies: Challenges and Future Directions

Siwan Wang; Xing Yan; Chang Yang et al. · 2022

Full title: The Landscape of Nucleic-Acid-Based Aptamers for Treatment of Hematologic Malignancies: Challenges and Future Directions

Authors: Siwan Wang; Xing Yan; Chang Yang; Hua Naranmandura

DOI: https://doi.org/10.3390/bioengineering9110635

Paper

Antibody-Drug Conjugate Using Ionized Cys-Linker-MMAE as the Potent Payload Shows Optimal Therapeutic Safety

Yanming Wang; Lianqi Liu; Shiyong Fan et al. · 2020

Full title: Antibody-Drug Conjugate Using Ionized Cys-Linker-MMAE as the Potent Payload Shows Optimal Therapeutic Safety

Authors: Yanming Wang; Lianqi Liu; Shiyong Fan; Dian Xiao; Fei Xie; Wei Li; Wu Zhong; Xinbo Zhou

DOI: https://doi.org/10.3390/cancers12030744

Paper

Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma: Results of the Compassionate Use or the Expanded Access Program in Spain

J. de la Rubia; R. Alonso; María Esther Clavero et al. · 2023

Full title: Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma: Results of the Compassionate Use or the Expanded Access Program in Spain

DOI: https://doi.org/10.3390/cancers15112964

Paper

Antibody–Drug Conjugates: The Dynamic Evolution from Conventional to Next-Generation Constructs

Virginia Metrangolo; L. Engelholm · 2024

Full title: Antibody–Drug Conjugates: The Dynamic Evolution from Conventional to Next-Generation Constructs

Authors: Virginia Metrangolo; L. Engelholm

DOI: https://doi.org/10.3390/cancers16020447

Paper

EGFR-Targeted Antibody-Drug Conjugate to Different Aminobisphosphonates: Direct and Indirect Antitumor Effects on Colorectal Carcinoma Cells.

Pisheh, Leila; Matis, Serena; Taglieri, Martina et al. · 2024

Full title: EGFR-Targeted Antibody-Drug Conjugate to Different Aminobisphosphonates: Direct and Indirect Antitumor Effects on Colorectal Carcinoma Cells.

Authors: Pisheh, Leila; Matis, Serena; Taglieri, Martina; Di Gregorio, Linda; Benelli, Roberto; Poggi, Alessandro

DOI: https://doi.org/10.3390/cancers16071256

Paper

Unlocking New Horizons in Small-Cell Lung Cancer Treatment: The Onset of Antibody-Drug Conjugates.

Belluomini, Lorenzo; Sposito, Marco; Avancini, Alice et al. · 2023

Full title: Unlocking New Horizons in Small-Cell Lung Cancer Treatment: The Onset of Antibody-Drug Conjugates.

Authors: Belluomini, Lorenzo; Sposito, Marco; Avancini, Alice; Insolda, Jessica; Milella, Michele; Rossi, Antonio; Pilotto, Sara

DOI: https://doi.org/10.3390/cancers15225368

Paper

Camptothein-Based Anti-Cancer Therapies and Strategies to Improve Their Therapeutic Index.

Gong, Jue; Zhang, Wenqiu; Balthasar, Joseph P · 2025

Full title: Camptothein-Based Anti-Cancer Therapies and Strategies to Improve Their Therapeutic Index.

Authors: Gong, Jue; Zhang, Wenqiu; Balthasar, Joseph P

DOI: https://doi.org/10.3390/cancers17061032

Paper

Precision Medicine to Treat Urothelial Carcinoma—The Way Forward

Carvy Floyd Luceno; Won Jin Jeon; Ravand Samaeekia et al. · 2023

Full title: Precision Medicine to Treat Urothelial Carcinoma—The Way Forward

Authors: Carvy Floyd Luceno; Won Jin Jeon; Ravand Samaeekia; John Shin; G. Sonpavde

DOI: https://doi.org/10.3390/cancers15113024

Paper

Next-Generation HER2-Targeted Antibody–Drug Conjugates in Breast Cancer

B. Zimmerman; F. Esteva · 2024

Full title: Next-Generation HER2-Targeted Antibody–Drug Conjugates in Breast Cancer

Authors: B. Zimmerman; F. Esteva

DOI: https://doi.org/10.3390/cancers16040800

Paper

Opportunities and Challenges in Antibody–Drug Conjugates for Cancer Therapy: A New Era for Cancer Treatment

Idil Buyukgolcigezli; A. Tenekeci; İ. H. Şahin · 2025

Full title: Opportunities and Challenges in Antibody–Drug Conjugates for Cancer Therapy: A New Era for Cancer Treatment

Authors: Idil Buyukgolcigezli; A. Tenekeci; İ. H. Şahin

DOI: https://doi.org/10.3390/cancers17060958

Paper

'Targeting' Improved Outcomes with Antibody-Drug Conjugates in Non-Small Cell Lung Cancer-An Updated Review.

Verma, Saurav; Breadner, Daniel; Raphael, Jacques · 2023

Full title: 'Targeting' Improved Outcomes with Antibody-Drug Conjugates in Non-Small Cell Lung Cancer-An Updated Review.

Authors: Verma, Saurav; Breadner, Daniel; Raphael, Jacques

DOI: https://doi.org/10.3390/curroncol30040330

Paper

Systemic Therapy for HER2-Positive Metastatic Breast Cancer: Current and Future Trends

Kreina Sharela Vega Cano; David Humberto Marmolejo Castañeda; S. Escrivá-de-Romaní et al. · 2022

Full title: Systemic Therapy for HER2-Positive Metastatic Breast Cancer: Current and Future Trends

Authors: Kreina Sharela Vega Cano; David Humberto Marmolejo Castañeda; S. Escrivá-de-Romaní; C. Saura

DOI: https://doi.org/10.3390/cancers15010051

Paper

Therapeutic Antibodies in Hematology: Advances in Malignant and Non-Malignant Disorders

Hiroshi Yasui; M. Idogawa; Tadao Ishida et al. · 2025

Full title: Therapeutic Antibodies in Hematology: Advances in Malignant and Non-Malignant Disorders

Authors: Hiroshi Yasui; M. Idogawa; Tadao Ishida; Kohzoh Imai

DOI: https://doi.org/10.3390/cells15010046

Paper

Anti-GD3 Antibody-drug Conjugate PF-06688992

· 2020

Full title: Anti-GD3 Antibody-drug Conjugate PF-06688992

DOI: https://doi.org/10.32388/j0hps1

Paper

Antibody-Drug Conjugates in Urothelial Cancer: From Scientific Rationale to Clinical Development

W. Kwon; Seo-Yeon Lee; Tae Jeong et al. · 2024

Full title: Antibody-Drug Conjugates in Urothelial Cancer: From Scientific Rationale to Clinical Development

Authors: W. Kwon; Seo-Yeon Lee; Tae Jeong; Hyeon Kim; Min-Kyung Lee

DOI: https://doi.org/10.3390/cancers16132420

Paper

Antibody–Drug Conjugates: A Start of a New Era in Gynecological Cancers

Samir Fasih; Stephen Welch; A. E. Lohmann · 2024

Full title: Antibody–Drug Conjugates: A Start of a New Era in Gynecological Cancers

Authors: Samir Fasih; Stephen Welch; A. E. Lohmann

DOI: https://doi.org/10.3390/curroncol31110522

Paper

HER2 in Non-Small Cell Lung Cancer: A Review of Emerging Therapies

N. Uy; C. Merkhofer; C. Baik · 2022

Full title: HER2 in Non-Small Cell Lung Cancer: A Review of Emerging Therapies

Authors: N. Uy; C. Merkhofer; C. Baik

DOI: https://doi.org/10.3390/cancers14174155

Paper

PEG Linker Improves Antitumor Efficacy and Safety of Affibody-Based Drug Conjugates

Qiyu Li; Wenjing Li; Keyuan Xu et al. · 2021

Full title: PEG Linker Improves Antitumor Efficacy and Safety of Affibody-Based Drug Conjugates

Authors: Qiyu Li; Wenjing Li; Keyuan Xu; Yutong Xing; Haobo Shi; Zhe Jing; Shuang Li; Zhangyong Hong

DOI: https://doi.org/10.3390/ijms22041540

Paper

Novel Systemic Treatment Modalities Including Immunotherapy and Molecular Targeted Therapy for Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma

Soma Ghosh; P. Shah; F. Johnson · 2022

Full title: Novel Systemic Treatment Modalities Including Immunotherapy and Molecular Targeted Therapy for Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma

Authors: Soma Ghosh; P. Shah; F. Johnson

DOI: https://doi.org/10.3390/ijms23147889

Paper

Development and Properties of Valine-Alanine based Antibody-Drug Conjugates with Monomethyl Auristatin E as the Potent Payload

Yanming Wang; Shiyong Fan; Wu Zhong et al. · 2017

Full title: Development and Properties of Valine-Alanine based Antibody-Drug Conjugates with Monomethyl Auristatin E as the Potent Payload

Authors: Yanming Wang; Shiyong Fan; Wu Zhong; Xinbo Zhou; Song Li

DOI: https://doi.org/10.3390/ijms18091860

Paper

A Versatile Chemo-Enzymatic Conjugation Approach Yields Homogeneous and Highly Potent Antibody-Drug Conjugates

Ying Xu; Shijie Jin; Wenbin Zhao et al. · 2017

Full title: A Versatile Chemo-Enzymatic Conjugation Approach Yields Homogeneous and Highly Potent Antibody-Drug Conjugates

Authors: Ying Xu; Shijie Jin; Wenbin Zhao; Wenhui Liu; Ding Ding; Jie Zhou; Shuqing Chen

DOI: https://doi.org/10.3390/ijms18112284

Paper

Peptide Drug Conjugates and Their Role in Cancer Therapy

Ethan Heh; J. Allen; Fabiola Ramirez et al. · 2023

Full title: Peptide Drug Conjugates and Their Role in Cancer Therapy

Authors: Ethan Heh; J. Allen; Fabiola Ramirez; Daniel Lovasz; Lorena Fernandez; Tanis Hogg; Hannah R. Riva; Nathan Holland; Jessica Chacon

DOI: https://doi.org/10.3390/ijms24010829

Paper

Theranostic Small-Molecule Prodrug Conjugates for Targeted Delivery and Controlled Release of Toll-like Receptor 7 Agonists

Sashi Debnath; G. Hao; B. Guan et al. · 2022

Full title: Theranostic Small-Molecule Prodrug Conjugates for Targeted Delivery and Controlled Release of Toll-like Receptor 7 Agonists

Authors: Sashi Debnath; G. Hao; B. Guan; Pawan Thapa; Justin Hao; H. Hammers; Xiankai Sun

DOI: https://doi.org/10.3390/ijms23137160

Paper

Understanding the Preclinical Efficacy of Antibody–Drug Conjugates

Cristina Díaz-Tejeiro; Alfonso López de Sá; Elisa Poyatos-Racionero et al. · 2024

Full title: Understanding the Preclinical Efficacy of Antibody–Drug Conjugates

DOI: https://doi.org/10.3390/ijms252312875

Paper

Linkers Having a Crucial Role in Antibody–Drug Conjugates

Jun Lu; Feng Jiang; Aiping Lu et al. · 2016

Full title: Linkers Having a Crucial Role in Antibody–Drug Conjugates

Authors: Jun Lu; Feng Jiang; Aiping Lu; Ge Zhang

DOI: https://doi.org/10.3390/ijms17040561

Paper

A Newly Developed Anti-L1CAM Monoclonal Antibody Targets Small Cell Lung Carcinoma Cells

Miki Yamaguchi; S. Hirai; M. Idogawa et al. · 2024

Full title: A Newly Developed Anti-L1CAM Monoclonal Antibody Targets Small Cell Lung Carcinoma Cells

Authors: Miki Yamaguchi; S. Hirai; M. Idogawa; Toshiyuki Sumi; Hiroaki Uchida; Yuji Sakuma

DOI: https://doi.org/10.3390/ijms25168748

Paper

Advances and Challenges in Structural Studies of Bioactive Peptide-Anthracycline Conjugates: A Mass Spectrometric Insight

Eszter Fehérvári; Katalin Uray; Gitta Schlosser · 2025

Full title: Advances and Challenges in Structural Studies of Bioactive Peptide-Anthracycline Conjugates: A Mass Spectrometric Insight

Authors: Eszter Fehérvári; Katalin Uray; Gitta Schlosser

DOI: https://doi.org/10.3390/ijms26104896

Paper

Theranostics for Triple-Negative Breast Cancer

Hyeryeon Choi; Kwang-Hyeok Kim · 2023

Full title: Theranostics for Triple-Negative Breast Cancer

Authors: Hyeryeon Choi; Kwang-Hyeok Kim

DOI: https://doi.org/10.3390/diagnostics13020272

Paper

New Senolysis Approach via Antibody–Drug Conjugate Targeting of the Senescent Cell Marker Apolipoprotein D for Skin Rejuvenation

Kento Takaya; T. Asou; Kazuo Kishi · 2023

Full title: New Senolysis Approach via Antibody–Drug Conjugate Targeting of the Senescent Cell Marker Apolipoprotein D for Skin Rejuvenation

Authors: Kento Takaya; T. Asou; Kazuo Kishi

DOI: https://doi.org/10.3390/ijms24065857

Paper

Toxicity Profiles of Antibody-Drug Conjugates: Synthesis and Graphical Insights to Optimize Patient-Centered Treatment Strategies for HER2-Negative Metastatic Breast Cancer.

Collineau, Bérénice; Gonçalves, Anthony; Domon, Marie et al. · 2025

Full title: Toxicity Profiles of Antibody-Drug Conjugates: Synthesis and Graphical Insights to Optimize Patient-Centered Treatment Strategies for HER2-Negative Metastatic Breast Cancer.

Authors: Collineau, Bérénice; Gonçalves, Anthony; Domon, Marie; Bruyat, Damien; Bertucci, François; de Nonneville, Alexandre

DOI: https://doi.org/10.3390/cancers17142307

Paper

CD74-Targeting Antibody–Drug Conjugate Enhances Immunosuppression of Glucocorticoid in Systemic Lupus Erythematosus

Qizhen Du; Shengtao Yao; Yuying Huang et al. · 2025

Full title: CD74-Targeting Antibody–Drug Conjugate Enhances Immunosuppression of Glucocorticoid in Systemic Lupus Erythematosus

DOI: https://doi.org/10.3390/ijms262311761

Paper

Antibody-Drug Conjugates and Targeted Treatment Strategies for Hepatocellular Carcinoma: A Drug-Delivery Perspective

D. Dahlgren; H. Lennernäs · 2020

Full title: Antibody-Drug Conjugates and Targeted Treatment Strategies for Hepatocellular Carcinoma: A Drug-Delivery Perspective

Authors: D. Dahlgren; H. Lennernäs

DOI: https://doi.org/10.3390/molecules25122861

Paper

Generation and Characterization of SORT1-Targeted Antibody–Drug Conjugate for the Treatment of SORT1-Positive Breast Tumor

Weiliang Zhuang; Wei Zhang; Liping Xie et al. · 2023

Full title: Generation and Characterization of SORT1-Targeted Antibody–Drug Conjugate for the Treatment of SORT1-Positive Breast Tumor

Authors: Weiliang Zhuang; Wei Zhang; Liping Xie; Lei Wang; Yuan Li; Ziyu Wang; Ao Zhang; Haitao Qiu; Jun Feng; Baohong Zhang; Youjia Hu

DOI: https://doi.org/10.3390/ijms242417631

Paper

Leveraging Synergy: A Review of the Therapeutic Potential of SN-38 and Immune Checkpoint Blockade in Breast and Prostate Cancer Treatment

Tayo A. Adekiya; Simeon K. Adesina · 2025

Full title: Leveraging Synergy: A Review of the Therapeutic Potential of SN-38 and Immune Checkpoint Blockade in Breast and Prostate Cancer Treatment

Authors: Tayo A. Adekiya; Simeon K. Adesina

DOI: https://doi.org/10.3390/jpm15110512

Paper

Unlocking the Complexity of Antibody-Drug Conjugates: A Cutting-Edge LC-HRMS Approach to Refine Drug-to-Antibody Ratio Measurements with Highly Reactive Payloads

Andrea Di Ianni; Kyra J. Cowan; Federico Riccardi Sirtori et al. · 2025

Full title: Unlocking the Complexity of Antibody-Drug Conjugates: A Cutting-Edge LC-HRMS Approach to Refine Drug-to-Antibody Ratio Measurements with Highly Reactive Payloads

Authors: Andrea Di Ianni; Kyra J. Cowan; Federico Riccardi Sirtori; Luca Barbero

DOI: https://doi.org/10.3390/ijms26073080

Paper

Antibody–Drug Conjugates Powered by Deruxtecan: Innovations and Challenges in Oncology

J. Jang; Donghwan Kim; Na Kyeong Lee et al. · 2025

Full title: Antibody–Drug Conjugates Powered by Deruxtecan: Innovations and Challenges in Oncology

Authors: J. Jang; Donghwan Kim; Na Kyeong Lee; Eunok Im; Nam Deuk Kim

DOI: https://doi.org/10.3390/ijms26136523

Paper

Quantification of an Antibody-Conjugated Drug in Fat Plasma by an Affinity Capture LC-MS/MS Method for a Novel Prenyl Transferase-Mediated Site-Specific Antibody–Drug Conjugate

Byeong Ill Lee; Min-Ho Park; Jin-Ju Byeon et al. · 2020

Full title: Quantification of an Antibody-Conjugated Drug in Fat Plasma by an Affinity Capture LC-MS/MS Method for a Novel Prenyl Transferase-Mediated Site-Specific Antibody–Drug Conjugate

Authors: Byeong Ill Lee; Min-Ho Park; Jin-Ju Byeon; Seok-Ho Shin; Jang-mi Choi; Yuri Park; Yun-Hee Park; Jeiwook Chae; Young G. Shin

DOI: https://doi.org/10.3390/molecules25071515

Paper

Cyanobacterial Peptides in Anticancer Therapy: A Comprehensive Review of Mechanisms, Clinical Advances, and Biotechnological Innovation.

Lee, Heayyean; Nihan, Khuld; Kwon, Yale Ryan · 2025

Full title: Cyanobacterial Peptides in Anticancer Therapy: A Comprehensive Review of Mechanisms, Clinical Advances, and Biotechnological Innovation.

Authors: Lee, Heayyean; Nihan, Khuld; Kwon, Yale Ryan

DOI: https://doi.org/10.3390/md23060233

Paper

Peptide-Drug Conjugates: A New Hope for Cancer Management

Vivek P. Chavda; Hetvi K. Solanki; Majid Davidson et al. · 2022

Full title: Peptide-Drug Conjugates: A New Hope for Cancer Management

Authors: Vivek P. Chavda; Hetvi K. Solanki; Majid Davidson; V. Apostolopoulos; J. Bojarska

DOI: https://doi.org/10.3390/molecules27217232

Paper

Antibody–Drug Conjugates in Hematological Malignancies: Current Landscape and Future Perspectives

M. C. Montalbano; Matilde Micillo; Silvia Deaglio et al. · 2026

Full title: Antibody–Drug Conjugates in Hematological Malignancies: Current Landscape and Future Perspectives

Authors: M. C. Montalbano; Matilde Micillo; Silvia Deaglio; T. Vaisitti

DOI: https://doi.org/10.3390/ijms27021025

Paper

Melanotransferrin as a Potential Target for the Selective Killing of Melanoma and Triple-Negative Breast Cancer Cells In Vitro Using Novel SNAP-Tag-Based Antibody–AURIF Conjugate

Suzanne Hippolite Magagoum; G. Siwe; F. A. Biteghe et al. · 2025

Full title: Melanotransferrin as a Potential Target for the Selective Killing of Melanoma and Triple-Negative Breast Cancer Cells In Vitro Using Novel SNAP-Tag-Based Antibody–AURIF Conjugate

Authors: Suzanne Hippolite Magagoum; G. Siwe; F. A. Biteghe; A. M. Huysamen; Dirk Lang; Roger Hunter; Stefan Barth

DOI: https://doi.org/10.3390/onco6010001

Paper

Antibody–Drug Conjugates—A Tutorial Review

Stephanie Baah; Mark Laws; K. Rahman · 2021

Full title: Antibody–Drug Conjugates—A Tutorial Review

Authors: Stephanie Baah; Mark Laws; K. Rahman

DOI: https://doi.org/10.3390/molecules26102943

Paper

IL1RAP is an immunotherapeutic target for normal karyotype triple-mutated acute myeloid leukemia

Arnaud Métois; Marie-Ève Bordeleau; L. Théret et al. · 2025

Full title: IL1RAP is an immunotherapeutic target for normal karyotype triple-mutated acute myeloid leukemia

DOI: https://doi.org/10.1186/s40364-025-00769-z

Paper

Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions.

Ferraro, Emanuela; Drago, Joshua Z; Modi, Shanu · 2021

Full title: Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions.

Authors: Ferraro, Emanuela; Drago, Joshua Z; Modi, Shanu

DOI: https://doi.org/10.1186/s13058-021-01459-y

Paper

Antibody Drug Conjugates: Application of Quantitative Pharmacology in Modality Design and Target Selection.

Sadekar, S; Figueroa, I; Tabrizi, M · 2015

Full title: Antibody Drug Conjugates: Application of Quantitative Pharmacology in Modality Design and Target Selection.

Authors: Sadekar, S; Figueroa, I; Tabrizi, M

DOI: https://doi.org/10.1208/s12248-015-9766-0

Paper

[Novel Chemical Linkers for Next-generation Antibody-drug Conjugates(ADCs)].

K. Tsuchikama · 2019

Full title: [Novel Chemical Linkers for Next-generation Antibody-drug Conjugates(ADCs)].

Authors: K. Tsuchikama

DOI: https://doi.org/10.1248/yakushi.18-00169-3

Paper

Joint Disposition Properties and Comprehensive Pharmacokinetic Characterization of Antibody-Drug Conjugates.

Liao, Kai H; Williams, Jason H; Palani, Santhosh et al. · 2022

Full title: Joint Disposition Properties and Comprehensive Pharmacokinetic Characterization of Antibody-Drug Conjugates.

Authors: Liao, Kai H; Williams, Jason H; Palani, Santhosh; Yin, Donghua; Meng, Xu

DOI: https://doi.org/10.1208/s12248-022-00717-x

Paper

Therapeutic Potential and Challenges of Targeting Receptor Tyrosine Kinase ROR1 with Monoclonal Antibodies in B-Cell Malignancies

Jiahui Yang; S. Baskar; K. Kwong et al. · 2011

Full title: Therapeutic Potential and Challenges of Targeting Receptor Tyrosine Kinase ROR1 with Monoclonal Antibodies in B-Cell Malignancies

Authors: Jiahui Yang; S. Baskar; K. Kwong; Michael G. Kennedy; A. Wiestner; C. Rader

DOI: https://doi.org/10.1371/journal.pone.0021018

Paper

Dasatinib Pharmacokinetics and Advanced Nanocarrier Strategies: from Systemic Limitations to Targeted Success

Mahesha Keerikkadu; Pragathi Devanand Bangera; Vamshi Krishna Tippavajhala et al. · 2025

Full title: Dasatinib Pharmacokinetics and Advanced Nanocarrier Strategies: from Systemic Limitations to Targeted Success

Authors: Mahesha Keerikkadu; Pragathi Devanand Bangera; Vamshi Krishna Tippavajhala; Mahalaxmi Rathnanand

DOI: https://doi.org/10.1208/s12249-025-03130-7

Paper

Site-Dependent Degradation of a Non-Cleavable Auristatin-Based Linker-Payload in Rodent Plasma and Its Effect on ADC Efficacy.

Dorywalska, Magdalena; Strop, Pavel; Melton-Witt, Jody A et al. · 2015

Full title: Site-Dependent Degradation of a Non-Cleavable Auristatin-Based Linker-Payload in Rodent Plasma and Its Effect on ADC Efficacy.

DOI: https://doi.org/10.1371/journal.pone.0132282

Paper

A monomethyl auristatin E-conjugated antibody to guanylyl cyclase C is cytotoxic to target-expressing cells in vitro and in vivo

M. Gallery; Julie Zhang; D. Bradley et al. · 2018

Full title: A monomethyl auristatin E-conjugated antibody to guanylyl cyclase C is cytotoxic to target-expressing cells in vitro and in vivo

DOI: https://doi.org/10.1371/journal.pone.0191046

Paper

NAV-001, a high-efficacy antibody-drug conjugate targeting mesothelin with improved delivery of a potent payload by counteracting MUC16/CA125 inhibitory effects

N. Nicolaides; J. Kline; L. Grasso · 2023

Full title: NAV-001, a high-efficacy antibody-drug conjugate targeting mesothelin with improved delivery of a potent payload by counteracting MUC16/CA125 inhibitory effects

Authors: N. Nicolaides; J. Kline; L. Grasso

DOI: https://doi.org/10.1371/journal.pone.0285161

Paper

Bioprocess development of antibody-drug conjugate production for cancer treatment

Jianfa Ou; Yingnan Si; K. Goh et al. · 2018

Full title: Bioprocess development of antibody-drug conjugate production for cancer treatment

Authors: Jianfa Ou; Yingnan Si; K. Goh; Norio Yasui; Yichen Guo; Jiajia Song; Lizhong Wang; R. Jaskula-Sztul; Jinda Fan; Lufang Zhou; Runhua Liu; X. Liu

DOI: https://doi.org/10.1371/journal.pone.0206246

Paper

In Vitro and In Vivo Evaluation of Cysteine and Site Specific Conjugated Herceptin Antibody-Drug Conjugates

D. Jackson; J. Atkinson; Claudia I. Guevara et al. · 2014

Full title: In Vitro and In Vivo Evaluation of Cysteine and Site Specific Conjugated Herceptin Antibody-Drug Conjugates

DOI: https://doi.org/10.1371/journal.pone.0083865

Paper

Quantitative Assessment of Antibody Internalization with Novel Monoclonal Antibodies against Alexa Fluorophores

Sindy Liao-Chan; B. Daine-Matsuoka; N. Heald et al. · 2015

Full title: Quantitative Assessment of Antibody Internalization with Novel Monoclonal Antibodies against Alexa Fluorophores

Authors: Sindy Liao-Chan; B. Daine-Matsuoka; N. Heald; T. Wong; Tracey Lin; Allen G Cai; Michelle Lai; J. A. D'alessio; Jan-Willem Theunissen

DOI: https://doi.org/10.1371/journal.pone.0124708

Paper

The Latest Research and Development into the Antibody-Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy.

Nakada, Takashi; Sugihara, Kiyoshi; Jikoh, Takahiro et al. · 2019

Full title: The Latest Research and Development into the Antibody-Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy.

Authors: Nakada, Takashi; Sugihara, Kiyoshi; Jikoh, Takahiro; Abe, Yuki; Agatsuma, Toshinori

DOI: https://doi.org/10.1248/cpb.c18-00744

Paper

Development and Evaluation of a Fluorescent Antibody-Drug Conjugate for Molecular Imaging and Targeted Therapy of Pancreatic Cancer

Steve Knutson; Erum K Raja; Ryan D. Bomgarden et al. · 2016

Full title: Development and Evaluation of a Fluorescent Antibody-Drug Conjugate for Molecular Imaging and Targeted Therapy of Pancreatic Cancer

Authors: Steve Knutson; Erum K Raja; Ryan D. Bomgarden; M. Nlend; Aoshuang Chen; R. Kalyanasundaram; S. Desai

DOI: https://doi.org/10.1371/journal.pone.0157762

Paper

SHR-A1811, a novel anti-HER2 antibody–drug conjugate with optimal drug-to-antibody ratio, efficient tumor killing potency, and favorable safety profiles

Ting Zhang; Jianyan Xu; Junzhao Yin et al. · 2025

Full title: SHR-A1811, a novel anti-HER2 antibody–drug conjugate with optimal drug-to-antibody ratio, efficient tumor killing potency, and favorable safety profiles

DOI: https://doi.org/10.1371/journal.pone.0326691

Paper

Tumor antigen glycosaminoglycan modification regulates antibody-drug conjugate delivery and cytotoxicity

H. Christianson; J. Menard; Vineesh Indira Chandran et al. · 2017

Full title: Tumor antigen glycosaminoglycan modification regulates antibody-drug conjugate delivery and cytotoxicity

Authors: H. Christianson; J. Menard; Vineesh Indira Chandran; E. Bourseau-Guilmain; D. Shevela; Jon Lidfeldt; A. Månsson; S. Pastoreková; J. Messinger; M. Belting

DOI: https://doi.org/10.18632/oncotarget.16921

Paper

Engineering a high-affinity humanized anti-CD24 antibody to target hepatocellular carcinoma by a novel CDR grafting design

Fumou Sun; Tong Wang; Jiahao Jiang et al. · 2017

Full title: Engineering a high-affinity humanized anti-CD24 antibody to target hepatocellular carcinoma by a novel CDR grafting design

Authors: Fumou Sun; Tong Wang; Jiahao Jiang; Yang Wang; Zhaoxiong Ma; Zhaoting Li; Yue Han; Mingzhu Pan; Jialing Cai; Min Wang; Juan Zhang

DOI: https://doi.org/10.18632/oncotarget.17228

Paper

Functional relevance of in vivo half antibody exchange of an IgG4 therapeutic antibody-drug conjugate

P. Herbener; K. Schönfeld; M. König et al. · 2018

Full title: Functional relevance of in vivo half antibody exchange of an IgG4 therapeutic antibody-drug conjugate

Authors: P. Herbener; K. Schönfeld; M. König; M. Germer; Jude M. Przyborski; Katrin Bernöster; J. Schüttrumpf

DOI: https://doi.org/10.1371/journal.pone.0195823

Paper

Reducing target binding affinity improves the therapeutic index of anti-MET antibody-drug conjugate in tumor bearing animals.

Datta-Mannan, Amita; Choi, Hiuwan; Jin, Zhaoyan et al. · 2024

Full title: Reducing target binding affinity improves the therapeutic index of anti-MET antibody-drug conjugate in tumor bearing animals.

Authors: Datta-Mannan, Amita; Choi, Hiuwan; Jin, Zhaoyan; Liu, Ling; Lu, Jirong; Stokell, David J; Murphy, Anthony T; Dunn, Kenneth W; Martinez, Michelle M; Feng, Yiqing

DOI: https://doi.org/10.1371/journal.pone.0293703

Paper

Antibody-drug conjugates in breast cancer: overcoming resistance and boosting immune response

Hannah L Chang; Blake Schwettmann; Heather L. McArthur et al. · 2023

Full title: Antibody-drug conjugates in breast cancer: overcoming resistance and boosting immune response

Authors: Hannah L Chang; Blake Schwettmann; Heather L. McArthur; Isaac S. Chan

DOI: https://doi.org/10.1172/jci172156

Paper

First-generation and preclinical evaluation of an EphA5-targeted antibody-drug conjugate in solid tumors

F. Staquicini; F. Tang; Vanessa de Oliveira et al. · 2025

Full title: First-generation and preclinical evaluation of an EphA5-targeted antibody-drug conjugate in solid tumors

DOI: https://doi.org/10.1172/jci188492

Paper

Targeting CD46 for both adenocarcinoma and neuroendocrine prostate cancer.

Yang Su; Yue Liu; Christopher Behrens et al. · 2018

Full title: Targeting CD46 for both adenocarcinoma and neuroendocrine prostate cancer.

DOI: https://doi.org/10.1172/jci.insight.121497

Paper

Engineered scPDL1-DM1 drug conjugate with improved in vitro analysis to target PD-L1 positive cancer cells and intracellular trafficking studies in cancer therapy

M. Kalim; Shenghao Wang; Keying Liang et al. · 2020

Full title: Engineered scPDL1-DM1 drug conjugate with improved in vitro analysis to target PD-L1 positive cancer cells and intracellular trafficking studies in cancer therapy

Authors: M. Kalim; Shenghao Wang; Keying Liang; Muhammad Saleem Iqbal Khan; Jinbiao Zhan

DOI: https://doi.org/10.1590/1678-4685-gmb-2018-0391

Paper

Tissue biodistribution and tumor targeting of near-infrared labelled anti-CD38 antibody-drug conjugate in preclinical multiple myeloma

Nicholas Cho; Sooah Ko; M. Shokeen · 2021

Full title: Tissue biodistribution and tumor targeting of near-infrared labelled anti-CD38 antibody-drug conjugate in preclinical multiple myeloma

Authors: Nicholas Cho; Sooah Ko; M. Shokeen

DOI: https://doi.org/10.18632/oncotarget.28074

Paper

Targeting CD74 in multiple myeloma with the novel, site-specific antibody-drug conjugate STRO-001

C. Abrahams; Xiaofan Li; M. Embry et al. · 2018

Full title: Targeting CD74 in multiple myeloma with the novel, site-specific antibody-drug conjugate STRO-001

DOI: https://doi.org/10.18632/oncotarget.26491

Paper

Evaluation of a novel human IgG1 anti-claudin3 antibody that specifically recognizes its aberrantly localized antigen in ovarian cancer cells and that is suitable for selective drug delivery

C. Romani; E. Cocco; E. Bignotti et al. · 2015

DOI: https://doi.org/10.18632/oncotarget.5315

Paper

Evaluation of SAS1B as a target for antibody-drug conjugate therapy in the treatment of pancreatic cancer

Kiley A. Knapp; Eusebio S. Pires; S. Adair et al. · 2018

Full title: Evaluation of SAS1B as a target for antibody-drug conjugate therapy in the treatment of pancreatic cancer

Authors: Kiley A. Knapp; Eusebio S. Pires; S. Adair; A. Mandal; A. Mills; W. Olson; C. Slingluff; J. Parsons; T. Bauer; T. Bullock; J. Herr

DOI: https://doi.org/10.18632/oncotarget.23944

Paper

Preclinical evaluation of a GFRA1 targeted antibody-drug conjugate in breast cancer

E. Bosco; R. Christie; R. Carrasco et al. · 2018

Full title: Preclinical evaluation of a GFRA1 targeted antibody-drug conjugate in breast cancer

DOI: https://doi.org/10.18632/oncotarget.25160

Paper

Evaluation of Factors Influencing Antibody Reduction for Development of Antibody Drug Conjugates.

Abdollahpour-Alitappeh, Meghdad; Lotfinia, Majid; Razavi-Vakhshourpour, Sepand et al. · 2017

Full title: Evaluation of Factors Influencing Antibody Reduction for Development of Antibody Drug Conjugates.

DOI: https://doi.org/10.18869/acadpub.ibj.21.4.270

Paper

Targeted human cytolytic fusion proteins at the cutting edge: harnessing the apoptosis-inducing properties of human enzymes for the selective elimination of tumor cells

Neelakshi Mungra; S. Jordaan; Precious Hlongwane et al. · 2019

Full title: Targeted human cytolytic fusion proteins at the cutting edge: harnessing the apoptosis-inducing properties of human enzymes for the selective elimination of tumor cells

Authors: Neelakshi Mungra; S. Jordaan; Precious Hlongwane; K. Naran; S. Chetty; S. Barth

DOI: https://doi.org/10.18632/oncotarget.26618

Paper

Mechanisms of resistance to antibody-drug conjugates in cancer therapy: molecular basis and therapeutic strategies

Yue Hao; Zhengbo Song · 2025

Full title: Mechanisms of resistance to antibody-drug conjugates in cancer therapy: molecular basis and therapeutic strategies

Authors: Yue Hao; Zhengbo Song

DOI: https://doi.org/10.20517/cdr.2025.148

Paper

Assessment of near-infrared fluorophores to study the biodistribution and tumor targeting of an IL13 receptor α2 antibody by fluorescence molecular tomography

Parul Gupta; J. Wentland; M. Leal et al. · 2017

Full title: Assessment of near-infrared fluorophores to study the biodistribution and tumor targeting of an IL13 receptor α2 antibody by fluorescence molecular tomography

Authors: Parul Gupta; J. Wentland; M. Leal; D. Ma; Rachel Roach; Antonio Esparza; Lindsay King; M. Spilker; C. Bagi; C. Winkelmann; A. Giddabasappa

DOI: https://doi.org/10.18632/oncotarget.19569

Paper

Biodistribution and efficacy of an anti-TENB2 antibody-drug conjugate in a patient-derived model of prostate cancer

C. Boswell; D. B. Yadav; E. E. Mundo et al. · 2019

Full title: Biodistribution and efficacy of an anti-TENB2 antibody-drug conjugate in a patient-derived model of prostate cancer

Authors: C. Boswell; D. B. Yadav; E. E. Mundo; Shang‐Fan Yu; J. Lacap; Aimee Fourie-O'Donohue; K. Kozak; G. Ferl; Crystal Zhang; Jason Ho; S. Ulufatu; L. Khawli; L. Khawli; Kedan Lin

DOI: https://doi.org/10.18632/oncotarget.27263

Paper

Multimodal, PSMA-Targeted, PAMAM Dendrimer-Drug Conjugates for Treatment of Prostate Cancer: Preclinical Evaluation

Wojciech G Lesniak; Srikanth Boinapally; Gabriela Lofland et al. · 2024

Full title: Multimodal, PSMA-Targeted, PAMAM Dendrimer-Drug Conjugates for Treatment of Prostate Cancer: Preclinical Evaluation

Authors: Wojciech G Lesniak; Srikanth Boinapally; Gabriela Lofland; Zirui Jiang; C. Foss; Babak Behman Azad; Anna Jablonska; Mauro Garcia; Maria Brzezinski; Martin G. Pomper

DOI: https://doi.org/10.2147/ijn.s454128

Paper

Targeted therapy for Hodgkin lymphoma and systemic anaplastic large cell lymphoma: focus on brentuximab vedotin

Xueyan Chen; L. Soma; J. Fromm · 2013

Full title: Targeted therapy for Hodgkin lymphoma and systemic anaplastic large cell lymphoma: focus on brentuximab vedotin

Authors: Xueyan Chen; L. Soma; J. Fromm

DOI: https://doi.org/10.2147/ott.s39107

Paper

Antibody-drug conjugates in breast cancer treatment: resistance mechanisms and the role of therapeutic sequencing

Émilie Audrey Larose; Xinying Hua; Silin Yu et al. · 2025

Full title: Antibody-drug conjugates in breast cancer treatment: resistance mechanisms and the role of therapeutic sequencing

Authors: Émilie Audrey Larose; Xinying Hua; Silin Yu; Amritha Thulaseedharan Pillai; Zongbi Yi; Haijun Yu

DOI: https://doi.org/10.20517/cdr.2024.180

Paper

Serum HER2 Level Predicts Therapeutic Efficacy and Prognosis in Advanced Breast Cancer Patients [Letter]

Febie Syahruddin; Prihantono; Mirna Muis · 2024

Full title: Serum HER2 Level Predicts Therapeutic Efficacy and Prognosis in Advanced Breast Cancer Patients [Letter]

Authors: Febie Syahruddin; Prihantono; Mirna Muis

DOI: https://doi.org/10.2147/bctt.s472589

Paper

Belantamab Mafodotin for the Treatment of Multiple Myeloma: An Overview of the Clinical Efficacy and Safety

M. Offidani; L. Corvatta; S. Morè et al. · 2021

Full title: Belantamab Mafodotin for the Treatment of Multiple Myeloma: An Overview of the Clinical Efficacy and Safety

Authors: M. Offidani; L. Corvatta; S. Morè; A. Olivieri

DOI: https://doi.org/10.2147/dddt.s267404

Paper

An Innovative Site-Specific Anti-HER2 Antibody-Drug Conjugate with High Homogeneity and Improved Therapeutic Index

Xiwu Hui; Can Yuan; Weirong Cao et al. · 2022

Full title: An Innovative Site-Specific Anti-HER2 Antibody-Drug Conjugate with High Homogeneity and Improved Therapeutic Index

Authors: Xiwu Hui; Can Yuan; Weirong Cao; Wenli Ge; Di Zhang; Mo Dan; Qian Zhao; Boning Liu; Bing Yao

DOI: https://doi.org/10.2147/ott.s357326

Paper

Targeting CD 19 in B-cell lymphoma : emerging role of SAR 3419

A. Raufi; A. Ebrahim; A. Al-Katib · 2013

Full title: Targeting CD 19 in B-cell lymphoma : emerging role of SAR 3419

Authors: A. Raufi; A. Ebrahim; A. Al-Katib

DOI: https://doi.org/10.2147/cmar.s45957

Paper

Current Protein Conjugation Strategies and Pioneering Anti-Cancer Applications.

Mckertish, Candice Maria; Kayser, Veysel · 2023

Full title: Current Protein Conjugation Strategies and Pioneering Anti-Cancer Applications.

Authors: Mckertish, Candice Maria; Kayser, Veysel

DOI: https://doi.org/10.24976/Discov.Med.202335178.67

Paper

Antibody-drug conjugate review in breast cancer: A targeted approach

Veenoo Agarwal; Manoj Umeshchandra Mahajan; Randeep Singh · 2024

Full title: Antibody-drug conjugate review in breast cancer: A targeted approach

Authors: Veenoo Agarwal; Manoj Umeshchandra Mahajan; Randeep Singh

DOI: https://doi.org/10.25259/ijmio_30_2024

Paper

Anti-ROR1 ADC VLS-101

· 2020

Full title: Anti-ROR1 ADC VLS-101

DOI: https://doi.org/10.32388/5pw8s1

Paper

Anti-CD37 Antibody-Drug Conjugate IMGN529

· 2020

Full title: Anti-CD37 Antibody-Drug Conjugate IMGN529

DOI: https://doi.org/10.32388/3f9y5f

Paper

Preparation and evaluation of injectable dosage form for Pemetrexed-monoclonal antibody conjugate

Faten Q. Ibraheem; Nidhal K. Maraie; Basma Talib Al-Sudani · 2025

Full title: Preparation and evaluation of injectable dosage form for Pemetrexed-monoclonal antibody conjugate

Authors: Faten Q. Ibraheem; Nidhal K. Maraie; Basma Talib Al-Sudani

DOI: https://doi.org/10.31351/vol34iss3pp100-110

Paper

Anti-c-Met Antibody-drug Conjugate HTI-1066

· 2020

Full title: Anti-c-Met Antibody-drug Conjugate HTI-1066

DOI: https://doi.org/10.32388/2onqv7

Paper

Anti-B7H3 Antibody-drug Conjugate MGC018

· 2020

Full title: Anti-B7H3 Antibody-drug Conjugate MGC018

DOI: https://doi.org/10.32388/0dmqn6

Paper

Anti-mesothelin Antibody-drug Conjugate BMS-986148

· 2020

Full title: Anti-mesothelin Antibody-drug Conjugate BMS-986148

DOI: https://doi.org/10.32388/5lejez

Paper

Polatuzumab Vedotin

Polatuzumab Vedotin · 2020

Full title: Polatuzumab Vedotin

Authors: Polatuzumab Vedotin

DOI: https://doi.org/10.32388/0mx9q1

Paper

Anti-HER2 ADC DS-8201a

· 2020

Full title: Anti-HER2 ADC DS-8201a

DOI: https://doi.org/10.32388/1c11sc

Paper

Anti-Ly6E Antibody-Drug Conjugate RG 7841

· 2020

Full title: Anti-Ly6E Antibody-Drug Conjugate RG 7841

DOI: https://doi.org/10.32388/956a5x

Paper

Antibody-drug Conjugate SC-006

· 2020

Full title: Antibody-drug Conjugate SC-006

DOI: https://doi.org/10.32388/1iio6o

Paper

Anti-c-Met Antibody-drug Conjugate TR1801

· 2020

Full title: Anti-c-Met Antibody-drug Conjugate TR1801

DOI: https://doi.org/10.32388/atw92w

Paper

Antibody-drug Conjugate MEDI7247

· 2020

Full title: Antibody-drug Conjugate MEDI7247

DOI: https://doi.org/10.32388/8akbp0

Paper

Telisotuzumab Vedotin

Telisotuzumab Vedotin · 2020

Full title: Telisotuzumab Vedotin

Authors: Telisotuzumab Vedotin

DOI: https://doi.org/10.32388/f1gne4

Paper

Antibody-drug Conjugate ABBV-085

· 2020

Full title: Antibody-drug Conjugate ABBV-085

DOI: https://doi.org/10.32388/bs5fak

Paper

Anti-HER2 Antibody-drug Conjugate ARX788

· 2020

Full title: Anti-HER2 Antibody-drug Conjugate ARX788

DOI: https://doi.org/10.32388/h0ytu2

Paper

Anti-mesothelin/MMAE Antibody-Drug Conjugate DMOT4039A

· 2020

Full title: Anti-mesothelin/MMAE Antibody-Drug Conjugate DMOT4039A

DOI: https://doi.org/10.32388/8v5j4d

Paper

Anti-FLT3 Antibody-drug Conjugate AGS62P1

· 2020

Full title: Anti-FLT3 Antibody-drug Conjugate AGS62P1

DOI: https://doi.org/10.32388/ae2wyi

Paper

Anti-CD123 ADC IMGN632

· 2020

Full title: Anti-CD123 ADC IMGN632

DOI: https://doi.org/10.32388/gzfaib

Paper

Anti-BCMA/PBD ADC MEDI2228

· 2020

Full title: Anti-BCMA/PBD ADC MEDI2228

DOI: https://doi.org/10.32388/cd2qq3

Paper

Loncastuximab Tesirine

Loncastuximab Tesirine · 2020

Full title: Loncastuximab Tesirine

Authors: Loncastuximab Tesirine

DOI: https://doi.org/10.32388/hg0n0d

Paper

Antibody-drug Conjugate ABBV-176

· 2020

Full title: Antibody-drug Conjugate ABBV-176

DOI: https://doi.org/10.32388/e1xwyq

Paper

Anti-CD33 Antibody-drug Conjugate IMGN779

· 2020

Full title: Anti-CD33 Antibody-drug Conjugate IMGN779

DOI: https://doi.org/10.32388/c3jmqs

Paper

Vandortuzumab Vedotin

Vandortuzumab Vedotin · 2020

Full title: Vandortuzumab Vedotin

Authors: Vandortuzumab Vedotin

DOI: https://doi.org/10.32388/ee1zh1

Paper

Anti-CD37 MMAE Antibody-drug Conjugate AGS67E

· 2020

Full title: Anti-CD37 MMAE Antibody-drug Conjugate AGS67E

DOI: https://doi.org/10.32388/6np2fw

Paper

Anti-HER2-vc0101 ADC PF-06804103

· 2020

Full title: Anti-HER2-vc0101 ADC PF-06804103

DOI: https://doi.org/10.32388/b4zjry

Paper

Anti-HER2 Bispecific Antibody-drug Conjugate ZW49

· 2020

Full title: Anti-HER2 Bispecific Antibody-drug Conjugate ZW49

DOI: https://doi.org/10.32388/i3iq0u

Paper

Antibody-drug Conjugate SC-004

· 2020

Full title: Antibody-drug Conjugate SC-004

DOI: https://doi.org/10.32388/mq5o2b

Paper

Lifastuzumab Vedotin

Lifastuzumab Vedotin · 2020

Full title: Lifastuzumab Vedotin

Authors: Lifastuzumab Vedotin

DOI: https://doi.org/10.32388/imseaj

Paper

Anti-BCMA Antibody-drug Conjugate AMG 224

· 2020

Full title: Anti-BCMA Antibody-drug Conjugate AMG 224

DOI: https://doi.org/10.32388/op46i6

Paper

Antibody-drug Conjugate SC-005

· 2020

Full title: Antibody-drug Conjugate SC-005

DOI: https://doi.org/10.32388/qc1fxk

Paper

Anti-HER2 Antibody-drug Conjugate RC48

· 2020

Full title: Anti-HER2 Antibody-drug Conjugate RC48

DOI: https://doi.org/10.32388/uss50u

Paper

Anti-PTK7/Auristatin-0101 Antibody-drug Conjugate PF-06647020

· 2020

Full title: Anti-PTK7/Auristatin-0101 Antibody-drug Conjugate PF-06647020

DOI: https://doi.org/10.32388/wn41c5

Paper

Anti-HER2 Antibody-drug Conjugate A166

· 2020

Full title: Anti-HER2 Antibody-drug Conjugate A166

DOI: https://doi.org/10.32388/jqjnth

Paper

Antibody-drug Conjugate ADC XMT-1536

· 2020

Full title: Antibody-drug Conjugate ADC XMT-1536

DOI: https://doi.org/10.32388/qcbnb8

Paper

Anti-CD123-Pyrrolobenzodiazepine Dimer Antibody Drug Conjugate SGN-CD123A

· 2020

Full title: Anti-CD123-Pyrrolobenzodiazepine Dimer Antibody Drug Conjugate SGN-CD123A

DOI: https://doi.org/10.32388/j6ii5b

Paper

Anti-CD71/vcMMAE Probody-drug Conjugate CX-2029

· 2020

Full title: Anti-CD71/vcMMAE Probody-drug Conjugate CX-2029

DOI: https://doi.org/10.32388/r6csm6

Paper

Anti-BCMA Antibody-drug Conjugate GSK2857916

· 2020

Full title: Anti-BCMA Antibody-drug Conjugate GSK2857916

DOI: https://doi.org/10.32388/ses2rp

Paper

Anti-CD19 Antibody-drug Conjugate SGN-CD19B

· 2020

Full title: Anti-CD19 Antibody-drug Conjugate SGN-CD19B

DOI: https://doi.org/10.32388/r3y88p

Paper

Sacituzumab Govitecan

Sacituzumab Govitecan · 2020

Full title: Sacituzumab Govitecan

Authors: Sacituzumab Govitecan

DOI: https://doi.org/10.32388/u85je1

Paper

Emerging trends in synthesis, characterization, and mechanism of action of antibody-drug and antibody-nanoparticle conjugates.

Dixit, Tanu; Aswini, Annamraju; Nikam, Harshal et al. · 2025

Full title: Emerging trends in synthesis, characterization, and mechanism of action of antibody-drug and antibody-nanoparticle conjugates.

Authors: Dixit, Tanu; Aswini, Annamraju; Nikam, Harshal; Vaidya, Anuradha; Ravindran, Selvan

DOI: https://doi.org/10.1186/s11671-025-04303-w

Paper

ITC-6102RO, a novel B7-H3 antibody-drug conjugate, exhibits potent therapeutic effects against B7-H3 expressing solid tumors

S. Shin; E. Ju; J. Park et al. · 2023

Full title: ITC-6102RO, a novel B7-H3 antibody-drug conjugate, exhibits potent therapeutic effects against B7-H3 expressing solid tumors

DOI: https://doi.org/10.1186/s12935-023-02991-x

Paper

Developing an antibody drug encapsulation nanoagent targeting HER2 for cancer treatment

Linrong Li; Ru Yao; Yan Liu et al. · 2026

Full title: Developing an antibody drug encapsulation nanoagent targeting HER2 for cancer treatment

Authors: Linrong Li; Ru Yao; Yan Liu; Nelyda Gonzalez Almeyda; Qiang Sun; Faqing Huang; Leslie Wang; Kinsley Wang; James Turkson; L. Medina-Kauwe; Armando E Giuliano; Changjun Yu; Xiaojiang Cui

DOI: https://doi.org/10.1186/s12967-025-07450-x

Paper

The cytotoxic conjugate of highly internalizing tetravalent antibody for targeting FGFR1-overproducing cancer cells

Marta Poźniak; Natalia Porębska; M. Krzyścik et al. · 2021

Full title: The cytotoxic conjugate of highly internalizing tetravalent antibody for targeting FGFR1-overproducing cancer cells

Authors: Marta Poźniak; Natalia Porębska; M. Krzyścik; Aleksandra Sokołowska-Wędzina; K. Jastrzębski; Martyna Sochacka; Jakub Szymczyk; M. Zakrzewska; J. Otlewski; Łukasz Opaliński

DOI: https://doi.org/10.1186/s10020-021-00306-2

Paper

CD13 as a new tumor target for antibody-drug conjugates: validation with the conjugate MI130110

J. Domı́nguez; G. Perez-Chacon; M. Guillén et al. · 2020

Full title: CD13 as a new tumor target for antibody-drug conjugates: validation with the conjugate MI130110

DOI: https://doi.org/10.1186/s13045-020-00865-7

Paper

TROP2-directed nanobody-drug conjugate elicited potent antitumor effect in pancreatic cancer

Cailing Xu; Min Zhu; Qian Wang et al. · 2023

Full title: TROP2-directed nanobody-drug conjugate elicited potent antitumor effect in pancreatic cancer

Authors: Cailing Xu; Min Zhu; Qian Wang; Jiajun Cui; Yuping Huang; Xiting Huang; Jing Huang; J. Gai; Guanghui Li; P. Qiao; Xian Zeng; Dianwen Ju; Y. Wan; Xuyao Zhang

DOI: https://doi.org/10.1186/s12951-023-02183-9

Paper

Decoding of the surfaceome and endocytome in primary glioblastoma cells identifies potential target antigens in the hypoxic tumor niche

K. G. de Oliveira; A. Bång-Rudenstam; Sarah Beyer et al. · 2024

Full title: Decoding of the surfaceome and endocytome in primary glioblastoma cells identifies potential target antigens in the hypoxic tumor niche

DOI: https://doi.org/10.1186/s40478-024-01740-z

Paper

Treatment-related adverse events of antibody drug-conjugates in clinical trials.

Tan, Harold Nathan; Morcillo, Marta Ascanio; Lopez, Juanita et al. · 2025

Full title: Treatment-related adverse events of antibody drug-conjugates in clinical trials.

Authors: Tan, Harold Nathan; Morcillo, Marta Ascanio; Lopez, Juanita; Minchom, Anna; Sharp, Adam; Paschalis, Alec; Silva-Fortes, Georgina; Raobaikady, Bindu; Banerji, Udai

DOI: https://doi.org/10.1186/s13045-025-01720-3

Paper

CD46 targeted 212Pb alpha particle radioimmunotherapy for prostate cancer treatment

Jun Li; Tao Huang; Jun Hua et al. · 2023

Full title: CD46 targeted 212Pb alpha particle radioimmunotherapy for prostate cancer treatment

DOI: https://doi.org/10.1186/s13046-023-02636-x

Paper

Learn from antibody–drug conjugates: consideration in the future construction of peptide-drug conjugates for cancer therapy

Mo Wu; Wei Huang; Nan Yang et al. · 2022

Full title: Learn from antibody–drug conjugates: consideration in the future construction of peptide-drug conjugates for cancer therapy

Authors: Mo Wu; Wei Huang; Nan Yang; Yanyong Liu

DOI: https://doi.org/10.1186/s40164-022-00347-1

Paper

Clinical trial update on bispecific antibodies, antibody-drug conjugates, and antibody-containing regimens for acute lymphoblastic leukemia

Delong Liu; Juanjuan Zhao; Yongping Song et al. · 2019

Full title: Clinical trial update on bispecific antibodies, antibody-drug conjugates, and antibody-containing regimens for acute lymphoblastic leukemia

Authors: Delong Liu; Juanjuan Zhao; Yongping Song; Xiao-feng Luo; Ting Yang

DOI: https://doi.org/10.1186/s13045-019-0703-z

Paper

DLL3: an emerging target in small cell lung cancer

D. Owen; M. Giffin; J. Bailis et al. · 2019

Full title: DLL3: an emerging target in small cell lung cancer

Authors: D. Owen; M. Giffin; J. Bailis; M. Smit; D. Carbone; K. He

DOI: https://doi.org/10.1186/s13045-019-0745-2

Paper

A novel anti-CD22 scFv–apoptin fusion protein induces apoptosis in malignant B-cells

S. Agha Amiri; S. Shahhosseini; N. Zarei et al. · 2017

Full title: A novel anti-CD22 scFv–apoptin fusion protein induces apoptosis in malignant B-cells

Authors: S. Agha Amiri; S. Shahhosseini; N. Zarei; Dorsa Khorasanizadeh; Elahe Aminollahi; Faegheh Rezaie; M. Zargari; M. Azizi; V. Khalaj

DOI: https://doi.org/10.1186/s13568-017-0410-5

Paper

A bifunctional molecule-based strategy for the development of theranostic antibody-drug conjugate

Dian Xiao; Lei Zhao; Fei Xie et al. · 2021

Full title: A bifunctional molecule-based strategy for the development of theranostic antibody-drug conjugate

Authors: Dian Xiao; Lei Zhao; Fei Xie; Shiyong Fan; Lianqi Liu; Wei Li; Ruiyuan Cao; Song Li; Wu Zhong; Xinbo Zhou

DOI: https://doi.org/10.7150/thno.51232

Paper

Safety and Efficacy of Anti-B-cell Maturation Antigen (Anti-BCMA) Bispecific Antibodies for Relapsed/Refractory Multiple Myeloma: A Systematic Review of Clinical Trials

Asad Ali Khan; Mansoor Rahman; Inshal Jawed et al. · 2025

Full title: Safety and Efficacy of Anti-B-cell Maturation Antigen (Anti-BCMA) Bispecific Antibodies for Relapsed/Refractory Multiple Myeloma: A Systematic Review of Clinical Trials

Authors: Asad Ali Khan; Mansoor Rahman; Inshal Jawed; Muhammad Sajjad; Muhammad Musa Khan

DOI: https://doi.org/10.7759/cureus.98368

Paper

Optimal design, anti-tumour efficacy and tolerability of anti-CXCR4 antibody drug conjugates.

Costa, Maria José; Kudaravalli, Jyothirmayee; Ma, Jing-Tyan et al. · 2019

Full title: Optimal design, anti-tumour efficacy and tolerability of anti-CXCR4 antibody drug conjugates.

DOI: https://doi.org/10.1038/s41598-019-38745-x

Paper

Targeting the ITGA3B1 Complex with A Novel Antibody-Drug Conjugate for Metastatic Bladder Cancer

H. Jung; Junghyeon Lee; Eunhee G Kim et al. · 2025

Full title: Targeting the ITGA3B1 Complex with A Novel Antibody-Drug Conjugate for Metastatic Bladder Cancer

Authors: H. Jung; Junghyeon Lee; Eunhee G Kim; Jinsung Ahn; Michael C. Haffner; Peter S. Nelson; Kwang Pyo Kim; John K. Lee; Eugene C. Yi; Kristine M. Kim

DOI: https://doi.org/10.1101/2025.04.06.647354

Paper

Customized Protein Nanoreactors for Affibody-Directed Activation of 5-Fluorcytosin in HER2-Positive Cells

Mariia Zmyslia; Martin Holzer; C. Jessen-Trefzer · 2025

Full title: Customized Protein Nanoreactors for Affibody-Directed Activation of 5-Fluorcytosin in HER2-Positive Cells

Authors: Mariia Zmyslia; Martin Holzer; C. Jessen-Trefzer

DOI: https://doi.org/10.1101/2025.09.11.675605

Paper

Targeting the human MUC1-C oncoprotein with an antibody-drug conjugate.

G. Panchamoorthy; Caining Jin; D. Raina et al. · 2018

Full title: Targeting the human MUC1-C oncoprotein with an antibody-drug conjugate.

DOI: https://doi.org/10.1172/jci.insight.99880

Paper

Improving the Therapeutic Selectivity of Trastuzumab Deruxtecan Using 8C2 Fab Fragments.

Gong, Jue; Bordeau, Brandon M; Balthasar, Joseph P · 2025

Full title: Improving the Therapeutic Selectivity of Trastuzumab Deruxtecan Using 8C2 Fab Fragments.

Authors: Gong, Jue; Bordeau, Brandon M; Balthasar, Joseph P

DOI: https://doi.org/10.1208/s12248-025-01087-w

Thesis

Exploring novel peptide-based natural products as a payload for the generation of antibody and peptide-assisted targeted cancer therapy

Kavianinia, Iman · 2024

Full title: Exploring novel peptide-based natural products as a payload for the generation of antibody and peptide-assisted targeted cancer therapy

Authors: Kavianinia, Iman

DOI: https://eps2024.com/wp-content/uploads/2024/08/EPS_PROGRAMME-18.pdf

Thesis

SYNTHESIS OF PEPTIDOMIMETIC LIGANDS TARGETING CELL-SURFACE RECEPTORS INVOLVED IN TUMOR ANGIOGENESIS

S. Zanella · 2017

Full title: SYNTHESIS OF PEPTIDOMIMETIC LIGANDS TARGETING CELL-SURFACE RECEPTORS INVOLVED IN TUMOR ANGIOGENESIS

Authors: S. Zanella

DOI: http://hdl.handle.net/2434/473075

Thesis

SYNTHESIS AND BIOLOGICAL EVALUATION OF POTENT INTEGRIN LIGANDS CONTAINING A DIKETOPIPERAZINE SCAFFOLD, AND OF THEIR CONJUGATES WITH CYTOTOXIC AGENTS

R. Colombo · 2013

Full title: SYNTHESIS AND BIOLOGICAL EVALUATION OF POTENT INTEGRIN LIGANDS CONTAINING A DIKETOPIPERAZINE SCAFFOLD, AND OF THEIR CONJUGATES WITH CYTOTOXIC AGENTS

Authors: R. Colombo

DOI: http://hdl.handle.net/2434/214953

Thesis

TARGETED DNA DAMAGE BOOST WITH LONCASTUXIMAB TESIRINE IN COMBINATION WITH PARP INHIBITORS IN DIFFUSE LARGE B-CELL LYMPHOMA

FUSANI, STEFANIA · 2023

Full title: TARGETED DNA DAMAGE BOOST WITH LONCASTUXIMAB TESIRINE IN COMBINATION WITH PARP INHIBITORS IN DIFFUSE LARGE B-CELL LYMPHOMA

Authors: FUSANI, STEFANIA

DOI: https://hdl.handle.net/2434/1015888

Thesis

TUMOR TARGETING VIA INTEGRIN LIGANDS: SYNTHESIS AND BIOLOGICAL EVALUATION OF RGD PEPTIDOMIMETIC-DRUG CONJUGATES

A. DAL CORSO · 2015

Full title: TUMOR TARGETING VIA INTEGRIN LIGANDS: SYNTHESIS AND BIOLOGICAL EVALUATION OF RGD PEPTIDOMIMETIC-DRUG CONJUGATES

Authors: A. DAL CORSO

DOI: http://hdl.handle.net/2434/331100

Thesis

HOOKING TRAIL-R2 TO ¿EDUCATE¿ IMMUNE SYSTEM TO RECOGNIZE CANCER CELLS

A. Satta · 2015

Full title: HOOKING TRAIL-R2 TO ¿EDUCATE¿ IMMUNE SYSTEM TO RECOGNIZE CANCER CELLS

Authors: A. Satta

DOI: http://hdl.handle.net/2434/333177

Thesis

SYNTHESIS AND BIOLOGICAL EVALUATION OF POTENT INTEGRIN LIGANDS CONTAINING A DIKETOPIPERAZINE SCAFFOLD, AND OF THEIR DUAL-ACTION CONJUGATES

M. Mingozzi · 2014

Full title: SYNTHESIS AND BIOLOGICAL EVALUATION OF POTENT INTEGRIN LIGANDS CONTAINING A DIKETOPIPERAZINE SCAFFOLD, AND OF THEIR DUAL-ACTION CONJUGATES

Authors: M. Mingozzi

DOI: http://hdl.handle.net/2434/229387

Thesis

DEVELOPMENT OF NOVEL STRATEGIES TO ENHANCE THE AFFINITY OF CYCLIC PEPTIDE LIGANDS FOR INTEGRIN RECEPTORS

SACCO, GIOVANNI · 2022

Full title: DEVELOPMENT OF NOVEL STRATEGIES TO ENHANCE THE AFFINITY OF CYCLIC PEPTIDE LIGANDS FOR INTEGRIN RECEPTORS

Authors: SACCO, GIOVANNI

DOI: http://hdl.handle.net/2434/919134

Thesis

SYNTHESIS OF INTEGRIN-TARGETING PRO-DRUGS FOR THE SELECTIVE RELEASE OF ANTI-TUMOR AGENTS

LOPEZ RIVAS, PAULA · 2018

Full title: SYNTHESIS OF INTEGRIN-TARGETING PRO-DRUGS FOR THE SELECTIVE RELEASE OF ANTI-TUMOR AGENTS

Authors: LOPEZ RIVAS, PAULA

DOI: http://hdl.handle.net/2434/584099

Thesis

SYNTHESIS OF RGD PEPTIDOMIMETIC-DRUG CONJUGATES FOR THE TUMOR-TARGETED DELIVERY OF CYTOTOXIC AGENTS

RAPOSO MOREIRA DIAS, ANDRE FILIPE · 2018

Full title: SYNTHESIS OF RGD PEPTIDOMIMETIC-DRUG CONJUGATES FOR THE TUMOR-TARGETED DELIVERY OF CYTOTOXIC AGENTS

Authors: RAPOSO MOREIRA DIAS, ANDRE FILIPE

DOI: http://hdl.handle.net/2434/583313

Thesis

Development of inhibitors of the prostate specific membrane antigen (PSMA) for imaging and endoradiotherapy

Dos Santos, José Carlos · 2024

Full title: Development of inhibitors of the prostate specific membrane antigen (PSMA) for imaging and endoradiotherapy

Authors: Dos Santos, José Carlos

Thesis

SYNTHESIS OF NEW RGD PEPTIDOMIMETIC-DRUG CONJUGATES TARGETING ΑVΒ3 INTEGRIN

PINA, ARIANNA · 2019

Full title: SYNTHESIS OF NEW RGD PEPTIDOMIMETIC-DRUG CONJUGATES TARGETING ΑVΒ3 INTEGRIN

Authors: PINA, ARIANNA

DOI: http://hdl.handle.net/2434/606167

Thesis

Chemically self-assembled antibody nanorings: a multifaceted approach to anti-cancer therapeutics using techniques including drug delivery, bispecific targeting, and T cell surface modification.

Gabrielse, Kari A. · 2013

Authors: Gabrielse, Kari A.

DOI: http://purl.umn.edu/158163

Thesis

IDENTIFICATION AND CHARACTERIZATION OF MONOCLONAL ANTIBODY 14C5 - A potential agent for radioimmunodetection and -therapy

Burvenich, Ingrid · 2007

Full title: IDENTIFICATION AND CHARACTERIZATION OF MONOCLONAL ANTIBODY 14C5 - A potential agent for radioimmunodetection and -therapy

Authors: Burvenich, Ingrid

DOI: https://biblio.ugent.be/publication/470887

Thesis

Intracellular Delivery of Cancer-Targeting Antibody-Drug Conjugates

Berguig, Geoffrey Yehuda · 2013

Full title: Intracellular Delivery of Cancer-Targeting Antibody-Drug Conjugates

Authors: Berguig, Geoffrey Yehuda

DOI: http://hdl.handle.net/1773/24174

Thesis

Development and characterization of CD133 positive cancer stem cell targeted toxins for use in carcinoma therapy

Waldron, Nate N. · 2013

Full title: Development and characterization of CD133 positive cancer stem cell targeted toxins for use in carcinoma therapy

Authors: Waldron, Nate N.

DOI: http://purl.umn.edu/154974

Thesis

Development of Novel Reagents for the Selective Enrichment of Vascular Accessible Proteins and the Identification of Disease-Specific Biomarkers

Hanke, Sabrina Annette · 2015

Full title: Development of Novel Reagents for the Selective Enrichment of Vascular Accessible Proteins and the Identification of Disease-Specific Biomarkers

Authors: Hanke, Sabrina Annette

DOI: https://archiv.ub.uni-heidelberg.de/volltextserver/19620/1/Doktorarbeit_Hanke.pdf

Thesis

Design, Synthesis, and Application of a Rapidly Diversifiable Trioxacarcin Pharmacophore in Antibody-Drug Conjugates

Anesini, Jason E · 2023

Full title: Design, Synthesis, and Application of a Rapidly Diversifiable Trioxacarcin Pharmacophore in Antibody-Drug Conjugates

Authors: Anesini, Jason E

DOI: https://nrs.harvard.edu/URN-3:HUL.INSTREPOS:37375457

Thesis

Site-specific labeling of affinity molecules for in vitro and in vivo studies

Perols, Anna · 2014

Full title: Site-specific labeling of affinity molecules for in vitro and in vivo studies

Authors: Perols, Anna

DOI: http://urn.kb.se/resolve?urn=urn:nbn:se:kth:diva-152349

Thesis

Tumor targeted delivery of cytotoxic payloads using affibody molecules and ABD-derived affinity proteins

Liu, Hao · 2018

Full title: Tumor targeted delivery of cytotoxic payloads using affibody molecules and ABD-derived affinity proteins

Authors: Liu, Hao

DOI: http://urn.kb.se/resolve?urn=urn:nbn:se:kth:diva-228015

Thesis

Affibody-mediated targeting of HER-family receptors for cancer imaging and therapy

Dahlsson Leitao, Charles · 2022

Full title: Affibody-mediated targeting of HER-family receptors for cancer imaging and therapy

Authors: Dahlsson Leitao, Charles

DOI: http://urn.kb.se/resolve?urn=urn:nbn:se:kth:diva-309574

Thesis

PNA and affinity protein tools for selective tumor targeting of radiopharmaceuticals

Tano, Hanna · 2022

Full title: PNA and affinity protein tools for selective tumor targeting of radiopharmaceuticals

Authors: Tano, Hanna

DOI: http://urn.kb.se/resolve?urn=urn:nbn:se:kth:diva-317137

Thesis

Targeting HER2-expressing tumors with potent drug conjugates and fusion toxins based on scaffold proteins

Ding, Haozhong · 2022

Full title: Targeting HER2-expressing tumors with potent drug conjugates and fusion toxins based on scaffold proteins

Authors: Ding, Haozhong

DOI: http://urn.kb.se/resolve?urn=urn:nbn:se:kth:diva-316518

Thesis

Development and evaluation of analytical techniques for antibodies and antibody-drug conjugates : From verification of conjugation to stability testing

Källsten, Malin · 2020

Full title: Development and evaluation of analytical techniques for antibodies and antibody-drug conjugates : From verification of conjugation to stability testing

Authors: Källsten, Malin

DOI: http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-403473

Thesis

Preclinical Development of New Alkylating Oligopeptides for Cancer Therapy

Gullbo, Joachim · 2003

Full title: Preclinical Development of New Alkylating Oligopeptides for Cancer Therapy

Authors: Gullbo, Joachim

DOI: http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-3785

Thesis

Investigations of chemical and enzymatic functionalization of affinity proteins

Myrhammar, Anders · 2020

Full title: Investigations of chemical and enzymatic functionalization of affinity proteins

Authors: Myrhammar, Anders

DOI: http://urn.kb.se/resolve?urn=urn:nbn:se:kth:diva-279052

Thesis

Pharmacometric Models for Antibody Drug Conjugates and Taxanes in HER2+ and HER2- Breast Cancer

Bender, Brendan · 2016

Full title: Pharmacometric Models for Antibody Drug Conjugates and Taxanes in HER2+ and HER2- Breast Cancer

Authors: Bender, Brendan

DOI: http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-292617

Thesis

Engineering of alternative scaffold derived drug conjugates and fusion-toxins for targeted cancer therapy

Yin, Wen · 2022

Full title: Engineering of alternative scaffold derived drug conjugates and fusion-toxins for targeted cancer therapy

Authors: Yin, Wen

DOI: http://urn.kb.se/resolve?urn=urn:nbn:se:kth:diva-308526

Thesis

A Chemical Approach Toward the Therapeutic Optimization of Cytotoxic Bioconjugates

Hartmann, Rafael · 2021

Full title: A Chemical Approach Toward the Therapeutic Optimization of Cytotoxic Bioconjugates

Authors: Hartmann, Rafael

DOI: http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-451298

Thesis

Bioconjugation of antibodies and affinity proteins for the development of novel diagnostic and therapeutic tools

Nagy, Abel · 2024

Full title: Bioconjugation of antibodies and affinity proteins for the development of novel diagnostic and therapeutic tools

Authors: Nagy, Abel

DOI: http://urn.kb.se/resolve?urn=urn:nbn:se:kth:diva-351396

Thesis

Targeting Human Epidermal Growth Factor Receptors with Drug Conjugates Based on Affibody Molecules

Zhang, Jie · 2023

Full title: Targeting Human Epidermal Growth Factor Receptors with Drug Conjugates Based on Affibody Molecules

Authors: Zhang, Jie

DOI: http://urn.kb.se/resolve?urn=urn:nbn:se:kth:diva-334736

Thesis

Mechanism-based pharmacometric models to improve the development and use of anticancer therapies

Ibrahim, Eman I. K. · 2025

Full title: Mechanism-based pharmacometric models to improve the development and use of anticancer therapies

Authors: Ibrahim, Eman I. K.

DOI: http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-565557

Thesis

Scaffold Protein-based Theranostics of HER2-overexpressing Ovarian Cancer: Imaging-guided Therapy

Xu, Tianqi · 2024

Full title: Scaffold Protein-based Theranostics of HER2-overexpressing Ovarian Cancer: Imaging-guided Therapy

Authors: Xu, Tianqi

DOI: http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-539484

Thesis

Next generation CD40 targeting immunotherapy : Development of antibody-based personalized cancer treatment

Laurén, Ida · 2025

Full title: Next generation CD40 targeting immunotherapy : Development of antibody-based personalized cancer treatment

Authors: Laurén, Ida

DOI: http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-554023

Thesis

Clustering-Induced, Clathrin-Mediated Endocytosis (CIC-ME) for Cancer Therapy

Heukers, R. · 2014

Full title: Clustering-Induced, Clathrin-Mediated Endocytosis (CIC-ME) for Cancer Therapy

Authors: Heukers, R.

DOI: https://dspace.library.uu.nl/handle/1874/287846

Thesis

Functionalized nanobodies for cancer therapy

van Vught, R.W.M. · 2014

Full title: Functionalized nanobodies for cancer therapy

Authors: van Vught, R.W.M.

DOI: https://dspace.library.uu.nl/handle/1874/307928

Thesis

Stimuli-responsive biodegradable polymeric micelles for targeted cancer therapy

Talelli, M.A. · 2011

Full title: Stimuli-responsive biodegradable polymeric micelles for targeted cancer therapy

Authors: Talelli, M.A.

DOI: https://dspace.library.uu.nl/handle/1874/209205

Thesis

Development of HER2-targeted nanobodies for molecular optical imaging and therapy of breast cancer

Kijanka, M.M. · 2014

Full title: Development of HER2-targeted nanobodies for molecular optical imaging and therapy of breast cancer

Authors: Kijanka, M.M.

DOI: https://dspace.library.uu.nl/handle/1874/298483

Thesis

Pharmaceutical development and clinical application of radiolabeled rituximab

Tran, T.H.L. · 2009

Full title: Pharmaceutical development and clinical application of radiolabeled rituximab

Authors: Tran, T.H.L.

DOI: https://dspace.library.uu.nl/handle/1874/36948

Thesis

What NIR photodynamic activation offers molecular targeted nanomedicines: Perspectives into the conundrum of tumor specificity and selectivity

Bhandari, Chanda; Guirguis, Mina; Savan, N Anna et al. · 2021

Full title: What NIR photodynamic activation offers molecular targeted nanomedicines: Perspectives into the conundrum of tumor specificity and selectivity

Authors: Bhandari, Chanda; Guirguis, Mina; Savan, N Anna; Shrivastava, Navadeep; Oliveira, Sabrina; Hasan, Tayyaba; Obaid, Girgis

DOI: https://dspace.library.uu.nl/handle/1874/411946

Thesis

Drug conjugates and polymeric micelles for targeted delivery of kinase inhibitors

SHI, HAILI · 2019

Full title: Drug conjugates and polymeric micelles for targeted delivery of kinase inhibitors

Authors: SHI, HAILI

DOI: https://dspace.library.uu.nl/handle/1874/386194

Thesis

Innovative cleavable and bioorthogonal conjugation chemistries for application in core-crosslinked polymeric micelles and bioconjugates

Timmers, Mattijs · 2023

Full title: Innovative cleavable and bioorthogonal conjugation chemistries for application in core-crosslinked polymeric micelles and bioconjugates

Authors: Timmers, Mattijs

DOI: https://dspace.library.uu.nl/handle/1874/433434

Thesis

Quantitative analysis of cellular processing of Antibody-Drug Conjugates

Maass, Katie F · 2016

Full title: Quantitative analysis of cellular processing of Antibody-Drug Conjugates

Authors: Maass, Katie F

DOI: http://hdl.handle.net/1721.1/103185

Thesis

Layer-by-Layer Nanoparticles for Targeted Delivery and Treatment of Ovarian Cancer

Kong, Stephanie Mabel · 2022

Full title: Layer-by-Layer Nanoparticles for Targeted Delivery and Treatment of Ovarian Cancer

Authors: Kong, Stephanie Mabel

DOI: https://hdl.handle.net/1721.1/139996

Thesis

Engineering kinetics of immunotherapies and vaccines

Bhagchandani, Sachin Haresh · 2024

Full title: Engineering kinetics of immunotherapies and vaccines

Authors: Bhagchandani, Sachin Haresh

DOI: https://hdl.handle.net/1721.1/154366

Thesis

Design and Synthesis of Stimuli-Responsive Polymers with Programmable Cleavability

Zafar, Hadiqa · 2024

Full title: Design and Synthesis of Stimuli-Responsive Polymers with Programmable Cleavability

Authors: Zafar, Hadiqa

DOI: https://hdl.handle.net/1721.1/157070

Thesis

Novel genotoxins that target estrogen receptor- and androgen receptor- positive cancers : identification of DNA adducts, pharmacokinetics, and mechanism

Hillier, Shawn M. (Shawn Matthew) · 2006

Full title: Novel genotoxins that target estrogen receptor- and androgen receptor- positive cancers : identification of DNA adducts, pharmacokinetics, and mechanism

Authors: Hillier, Shawn M. (Shawn Matthew)

DOI: http://hdl.handle.net/1721.1/32480

Thesis

Antibody engineering for cancer therapy

Yeung, Yik Andy · 2006

Full title: Antibody engineering for cancer therapy

Authors: Yeung, Yik Andy

DOI: http://hdl.handle.net/1721.1/32325

Thesis

Rational Approaches to Improving Selectivity in Drug Design

Huggins, David J.; Sherman, Woody; Tidor, Bruce · 2012

Full title: Rational Approaches to Improving Selectivity in Drug Design

Authors: Huggins, David J.; Sherman, Woody; Tidor, Bruce

DOI: http://hdl.handle.net/1721.1/73545

Thesis

Improved mehtods and reagents for pretargeted radioimmunotherapy of cancer

Zajic, Stefan C · 2007

Full title: Improved mehtods and reagents for pretargeted radioimmunotherapy of cancer

Authors: Zajic, Stefan C

DOI: http://hdl.handle.net/1721.1/38971

Thesis

The generation and characterisation of anti-glycan monoclonal antibodies

Chua, Jia Xin · 2017

Full title: The generation and characterisation of anti-glycan monoclonal antibodies

Authors: Chua, Jia Xin

DOI: https://eprints.nottingham.ac.uk/34932/1/chua%20PHD%20thesis%20%2812.7.16%29.pdf

Thesis

Selective targeting of WNT receptor FZD7 in human pluripotent stem cells and ovarian cancer

Do, Myan · 2021

Full title: Selective targeting of WNT receptor FZD7 in human pluripotent stem cells and ovarian cancer

Authors: Do, Myan

DOI: https://escholarship.org/uc/item/43h0n4x3

Thesis

Preclinical activity of the antibody-drug conjugate denintuzumab mafodotin (SGN-CD19A) against pediatric acute lymphoblastic leukemia xenografts

Jones, L; McCalmont, H; Evans, K et al. · 2019

Full title: Preclinical activity of the antibody-drug conjugate denintuzumab mafodotin (SGN-CD19A) against pediatric acute lymphoblastic leukemia xenografts

Authors: Jones, L; McCalmont, H; Evans, K; Mayoh, C ; https://orcid.org/0000-0002-6398-3046; Kurmasheva, RT; Billups, CA; Houghton, PJ; Smith, MA; Lock, RB ; https://orcid.org/0000-0002-3436-9071

DOI: http://hdl.handle.net/1959.4/unsworks_57907

Thesis

Site-Selective Modification of Proteins with Oxetanes

Boutureira, O; Martínez-Sáez, N; Brindle, KM et al. · 2017

Full title: Site-Selective Modification of Proteins with Oxetanes

Authors: Boutureira, O; Martínez-Sáez, N; Brindle, KM; Neves, AA; Corzana, F; Lopes Bernardes, GJ

DOI: https://www.repository.cam.ac.uk/handle/1810/264048

Thesis

The CD123 antibody–drug conjugate pivekimab sunirine exerts profound activity in preclinical models of pediatric acute lymphoblastic leukemia

Watts, B; Smith, CM; Evans, K et al. · 2025

Full title: The CD123 antibody–drug conjugate pivekimab sunirine exerts profound activity in preclinical models of pediatric acute lymphoblastic leukemia

DOI: http://hdl.handle.net/1959.4/103944

Thesis

Synthesis and Biological Evaluation of Homogeneous Thiol-Linked NHC*-Au-Albumin and -Trastuzumab Bioconjugates.

Matos, Maria J; Labão-Almeida, Carlos; Sayers, Claire et al. · 2018

Full title: Synthesis and Biological Evaluation of Homogeneous Thiol-Linked NHC*-Au-Albumin and -Trastuzumab Bioconjugates.

Authors: Matos, Maria J; Labão-Almeida, Carlos; Sayers, Claire; Dada, Oyinlola; Tacke, Matthias; Bernardes, Gonçalo JL

DOI: https://www.repository.cam.ac.uk/handle/1810/279328

Thesis

A general approach for the site-selective modification of native proteins, enabling the generation of stable and functional antibody-drug conjugates.

Walsh, Stephen J; Omarjee, Soleilmane; Galloway, Warren RJD et al. · 2018

Full title: A general approach for the site-selective modification of native proteins, enabling the generation of stable and functional antibody-drug conjugates.

Authors: Walsh, Stephen J; Omarjee, Soleilmane; Galloway, Warren RJD; Kwan, Terence T-L; Sore, Hannah F; Parker, Jeremy S; Hyvönen, Marko; Carroll, Jason S; Spring, David R

DOI: https://www.repository.cam.ac.uk/handle/1810/287080

Thesis

A fully human anti-IL-7Rα antibody promotes antitumor activity against T-cell acute lymphoblastic leukemia.

Akkapeddi, Padma; Fragoso, Rita; Hixon, Julie A et al. · 2019

Full title: A fully human anti-IL-7Rα antibody promotes antitumor activity against T-cell acute lymphoblastic leukemia.

DOI: https://www.repository.cam.ac.uk/handle/1810/290686

Thesis

Single Mutation on Trastuzumab Modulates the Stability of Antibody-Drug Conjugates Built Using Acetal-Based Linkers and Thiol-Maleimide Chemistry.

Ferhati, Xhenti; Jiménez-Moreno, Ester; Hoyt, Emily A et al. · 2022

Full title: Single Mutation on Trastuzumab Modulates the Stability of Antibody-Drug Conjugates Built Using Acetal-Based Linkers and Thiol-Maleimide Chemistry.

DOI: https://www.repository.cam.ac.uk/handle/1810/334784

Thesis

Sulfatase-cleavable linkers for antibody-drug conjugates.

Bargh, Jonathan D; Walsh, Stephen J; Isidro-Llobet, Albert et al. · 2021

Full title: Sulfatase-cleavable linkers for antibody-drug conjugates.

Authors: Bargh, Jonathan D; Walsh, Stephen J; Isidro-Llobet, Albert; Omarjee, Soleilmane; Carroll, Jason S; Spring, David R

DOI: https://www.repository.cam.ac.uk/handle/1810/325434

Thesis

In Vivo Pretargeting Based on Cysteine-Selective Antibody Modification with IEDDA Bioorthogonal Handles for Click Chemistry.

Ferreira, Vera FC; Oliveira, Bruno L; D'Onofrio, Alice et al. · 2020

Full title: In Vivo Pretargeting Based on Cysteine-Selective Antibody Modification with IEDDA Bioorthogonal Handles for Click Chemistry.

Authors: Ferreira, Vera FC; Oliveira, Bruno L; D'Onofrio, Alice; Farinha, Carlos M; Gano, Lurdes; Paulo, António; Bernardes, Gonçalo JL; Mendes, Filipa

DOI: https://www.repository.cam.ac.uk/handle/1810/314771

Thesis

Controlled masking and targeted release of redox-cycling ortho-quinones via a C-C bond-cleaving 1,6-elimination.

Dunsmore, Lavinia; Navo, Claudio D; Becher, Julie et al. · 2022

Full title: Controlled masking and targeted release of redox-cycling ortho-quinones via a C-C bond-cleaving 1,6-elimination.

DOI: https://www.repository.cam.ac.uk/handle/1810/339672

Thesis

All-in-one disulfide bridging enables the generation of antibody conjugates with modular cargo loading.

Dannheim, Friederike M; Walsh, Stephen J; Orozco, Carolina T et al. · 2022

Full title: All-in-one disulfide bridging enables the generation of antibody conjugates with modular cargo loading.

DOI: https://www.repository.cam.ac.uk/handle/1810/341118

Thesis

Mechanistic insights into the rational design of masked antibodies.

Orozco, Carolina T; Bersellini, Manuela; Irving, Lorraine M et al. · 2022

Full title: Mechanistic insights into the rational design of masked antibodies.

DOI: https://www.repository.cam.ac.uk/handle/1810/339932

Thesis

Peroxide-cleavable linkers for antibody–drug conjugates †

Ashman, Nicola; Bargh, Jonathan D.; Walsh, Stephen J. et al. · 2023

Full title: Peroxide-cleavable linkers for antibody–drug conjugates †

Authors: Ashman, Nicola; Bargh, Jonathan D.; Walsh, Stephen J.; Greenwood, Ryan D.; Tiberghien, Arnaud; Carroll, Jason S.; Spring, David R.; resid: K-2283-2016

DOI: https://www.repository.cam.ac.uk/handle/1810/345781

Thesis

Rapid and robust cysteine bioconjugation with vinylheteroarenes.

Seki, Hikaru; Walsh, Stephen J; Bargh, Jonathan D et al. · 2021

Full title: Rapid and robust cysteine bioconjugation with vinylheteroarenes.

Authors: Seki, Hikaru; Walsh, Stephen J; Bargh, Jonathan D; Parker, Jeremy S; Carroll, Jason; Spring, David R

DOI: https://www.repository.cam.ac.uk/handle/1810/327136

Thesis

Cathepsin B Processing Is Required for the In Vivo Efficacy of Albumin-Drug Conjugates.

Bernardim, Barbara; Conde, João; Hakala, Tuuli et al. · 2024

Full title: Cathepsin B Processing Is Required for the In Vivo Efficacy of Albumin-Drug Conjugates.

Authors: Bernardim, Barbara; Conde, João; Hakala, Tuuli; Becher, Julie B; Canzano, Mary; Vasco, Aldrin V; Knowles, Tuomas PJ; Cameron, Jason; Bernardes, Gonçalo JL

DOI: https://www.repository.cam.ac.uk/handle/1810/364915

Thesis

Is HER2-Low a New Clinical Entity or Merely a Biomarker for an Antibody Drug Conjugate?

Ko, Heidi; Previs, Rebecca A; Strickland, Kyle C et al. · 2024

Full title: Is HER2-Low a New Clinical Entity or Merely a Biomarker for an Antibody Drug Conjugate?

Authors: Ko, Heidi; Previs, Rebecca A; Strickland, Kyle C; Klein, Jonathan; Caveney, Brian; Chiruzzi, Chiara; Eisenberg, Marcia; Severson, Eric A; Ramkissoon, Shakti; Saini, Kamal S

DOI: https://www.repository.cam.ac.uk/handle/1810/364928

Thesis

Expeditious Total Synthesis of Hemiasterlin through a Convergent Multicomponent Strategy and Its Use in Targeted Cancer Therapeutics

Charoenpattarapreeda, Jiraborrirak; Walsh, Stephen J; Carroll, Jason S et al. · 2020

Full title: Expeditious Total Synthesis of Hemiasterlin through a Convergent Multicomponent Strategy and Its Use in Targeted Cancer Therapeutics

Authors: Charoenpattarapreeda, Jiraborrirak; Walsh, Stephen J; Carroll, Jason S; Spring, David R

DOI: https://www.repository.cam.ac.uk/handle/1810/313569

Thesis

Tuneable thiol exchange linkers for traceless drug release applications in prodrugs and ADCs †

Walther, Raoul; Park, Mahri; Ashman, Nicola et al. · 2024

Full title: Tuneable thiol exchange linkers for traceless drug release applications in prodrugs and ADCs †

Authors: Walther, Raoul; Park, Mahri; Ashman, Nicola; Welch, Martin; Carroll, Jason S.; resid: K-2283-2016

DOI: https://www.repository.cam.ac.uk/handle/1810/369847

Thesis

A Platform for SpyCatcher Conjugation to Native Antibodies

Krajčovičová, Soňa; Wharton, Thomas; Driscoll, Claudia L et al. · 2025

Full title: A Platform for SpyCatcher Conjugation to Native Antibodies

Authors: Krajčovičová, Soňa; Wharton, Thomas; Driscoll, Claudia L; King, Thomas A; Howarth, Mark R; Spring, David R

DOI: https://www.repository.cam.ac.uk/handle/1810/384028

Thesis

Divinylpyrimidine reagents generate antibody-drug conjugates with excellent in vivo efficacy and tolerability.

Walsh, Stephen J; Omarjee, Soleilmane; Dannheim, Friederike M et al. · 2023

Full title: Divinylpyrimidine reagents generate antibody-drug conjugates with excellent in vivo efficacy and tolerability.

DOI: https://www.repository.cam.ac.uk/handle/1810/350669

Thesis

Advances in the Release of Amide-Containing Molecules.

Wharton, Thomas; Spring, David R · 2025

Full title: Advances in the Release of Amide-Containing Molecules.

Authors: Wharton, Thomas; Spring, David R

DOI: https://www.repository.cam.ac.uk/handle/1810/379353

Thesis

Disulfide re-bridging reagents for single-payload antibody-drug conjugates.

King, Thomas A; Walsh, Stephen J; Kapun, Mia et al. · 2023

Full title: Disulfide re-bridging reagents for single-payload antibody-drug conjugates.

Authors: King, Thomas A; Walsh, Stephen J; Kapun, Mia; Wharton, Thomas; Krajcovicova, Sona; Glossop, Melanie S; Spring, David R

DOI: https://www.repository.cam.ac.uk/handle/1810/355297

Thesis

[2.2.1]Heterobicyclic Bromovinyl Sulfones for Thiol-Triggered Strategies in Linker Chemistry: Aza- vs Oxa-Norbornadienic Systems.

Carranza, Marina; Carmona, Ana T; Maya, Celia et al. · 2025

Full title: [2.2.1]Heterobicyclic Bromovinyl Sulfones for Thiol-Triggered Strategies in Linker Chemistry: Aza- vs Oxa-Norbornadienic Systems.

Authors: Carranza, Marina; Carmona, Ana T; Maya, Celia; Gil de Montes, Enrique; Vasco, Aldrin V; Bernardes, Gonçalo JL; Moreno-Vargas, Antonio J

DOI: https://www.repository.cam.ac.uk/handle/1810/390595

Thesis

Insights from the bottom-up development of LGR5-targeting immunotherapeutics.

Mueller, Nico; de la Roche, Marc Andrew; de la Roche, Maike · 2025

Full title: Insights from the bottom-up development of LGR5-targeting immunotherapeutics.

Authors: Mueller, Nico; de la Roche, Marc Andrew; de la Roche, Maike

DOI: https://www.repository.cam.ac.uk/handle/1810/381716

Thesis

Recent advances and perspectives in cancer drug design

Andricopulo, Adriano Defini · 2018

Full title: Recent advances and perspectives in cancer drug design

Authors: Andricopulo, Adriano Defini

DOI: https://doi.org/10.1590/0001-3765201820170823

Thesis

Bridging Metals and Peptides: Introducing selectivity to transition metal complexes towards targeted cancer therapy

Truong, Dianna · 2021

Full title: Bridging Metals and Peptides: Introducing selectivity to transition metal complexes towards targeted cancer therapy

Authors: Truong, Dianna

DOI: https://hdl.handle.net/2292/57835

Thesis

Conjugation Strategies of the Anticancer Ruthenium Complex Plecstatin-1 to Tumour-targeting Peptides using Cleavable and Non-cleavable Linkers

Kumar, Saawan · 2024

Full title: Conjugation Strategies of the Anticancer Ruthenium Complex Plecstatin-1 to Tumour-targeting Peptides using Cleavable and Non-cleavable Linkers

Authors: Kumar, Saawan

DOI: https://hdl.handle.net/2292/67465

Thesis

Novel approaches for targeting the FGFR pathway in cancer to improve the therapeutic index

Ortega, Raquel · 2025

Full title: Novel approaches for targeting the FGFR pathway in cancer to improve the therapeutic index

Authors: Ortega, Raquel

DOI: https://hdl.handle.net/2292/73558

Thesis

Novel Cleavable Linkers for Antibody-Drug Conjugate Targeted Cancer Therapy

Tong, Juliana T.W. · 2024

Full title: Novel Cleavable Linkers for Antibody-Drug Conjugate Targeted Cancer Therapy

Authors: Tong, Juliana T.W.

DOI: https://hdl.handle.net/2292/67548

Thesis

Evaluation of nitroCBI prodrugs in models of pancreatic cancer and development of novel nitroCBI based ADCs

van Leeuwen, Wouter Franciscus · 2021

Full title: Evaluation of nitroCBI prodrugs in models of pancreatic cancer and development of novel nitroCBI based ADCs

Authors: van Leeuwen, Wouter Franciscus

DOI: https://hdl.handle.net/2292/56696

Thesis

Exploiting Tumor-intrinsic Cues to Engineer Interleukin-12 for Cancer Immunotherapy

Mansurov, Aslan · 2021

Full title: Exploiting Tumor-intrinsic Cues to Engineer Interleukin-12 for Cancer Immunotherapy

Authors: Mansurov, Aslan

DOI: https://knowledge.uchicago.edu/record/3480/files/Mansurov_uchicago_0330D_16002.pdf

Thesis

Development of acid-cleavable polymeric nano/microparticles for the delivery of therapeutics

Chan, Yannie Ka Yan · 2007

Full title: Development of acid-cleavable polymeric nano/microparticles for the delivery of therapeutics

Authors: Chan, Yannie Ka Yan

DOI: http://hdl.handle.net/1959.4/40442

Thesis

Multivalent Polymer-peptide Therapeutics by Combinatorial Design

Li, Zihao; https://orcid.org/0000-0002-1723-5047 · 2022

Full title: Multivalent Polymer-peptide Therapeutics by Combinatorial Design

Authors: Li, Zihao ; https://orcid.org/0000-0002-1723-5047

DOI: http://hdl.handle.net/1959.4/100471

Thesis

Design of antibody-polymer conjugates for immunotherapy: the influence of polymer structure on the antibody's activity.

Melodia, Daniele · 2022

Full title: Design of antibody-polymer conjugates for immunotherapy: the influence of polymer structure on the antibody's activity.

Authors: Melodia, Daniele

DOI: http://hdl.handle.net/1959.4/100630

Thesis

Modular nanoparticle drug delivery systems for treating multiple types of cancer

Chang, David · 2020

Full title: Modular nanoparticle drug delivery systems for treating multiple types of cancer

Authors: Chang, David

DOI: http://hdl.handle.net/1959.4/69713

Thesis

Cell-targeting peptides for selective drug delivery to tumour cells

Tjandra, Kristel · 2018

Full title: Cell-targeting peptides for selective drug delivery to tumour cells

Authors: Tjandra, Kristel

DOI: http://hdl.handle.net/1959.4/61937

Thesis

The Development of Divinyl-Heteroaryl Linkers for the Synthesis of Stable and Functional Antibody-Drug Conjugates

Walsh, Stephen · 2019

Full title: The Development of Divinyl-Heteroaryl Linkers for the Synthesis of Stable and Functional Antibody-Drug Conjugates

Authors: Walsh, Stephen

DOI: https://www.repository.cam.ac.uk/handle/1810/297916

Thesis

The Potential of Cellulose Nanocrystals in the Detection and Treatment of Cancer

Colacino, Katelyn · 2015

Full title: The Potential of Cellulose Nanocrystals in the Detection and Treatment of Cancer

Authors: Colacino, Katelyn

DOI: http://hdl.handle.net/10919/51212

Thesis

Metal Mediated Mechanisms of Drug Release

Stenton, Benjamin James · 2018

Full title: Metal Mediated Mechanisms of Drug Release

Authors: Stenton, Benjamin James

DOI: https://www.repository.cam.ac.uk/handle/1810/284402

Thesis

Designed analogues of the aplyronines for use in antibody-drug conjugates

Porter, Rachel Jayne · 2019

Full title: Designed analogues of the aplyronines for use in antibody-drug conjugates

Authors: Porter, Rachel Jayne

DOI: https://www.repository.cam.ac.uk/handle/1810/298168

Thesis

Exploration of novel linker scaffolds enabling the simultaneous rebridging of disulfide bonds for the synthesis of antibody-drug conjugates

King, Thomas · 2023

Full title: Exploration of novel linker scaffolds enabling the simultaneous rebridging of disulfide bonds for the synthesis of antibody-drug conjugates

Authors: King, Thomas

DOI: https://www.repository.cam.ac.uk/handle/1810/355950

Thesis

One-Carbon Bridge Stapling for use in Peptide-Drug Conjugates

Cooper, Bethany · 2022

Full title: One-Carbon Bridge Stapling for use in Peptide-Drug Conjugates

Authors: Cooper, Bethany

DOI: https://www.repository.cam.ac.uk/handle/1810/343871

Thesis

The Development of a Tumour-Responsive Format for Antibody Conjugates

Counsell, Andrew · 2024

Full title: The Development of a Tumour-Responsive Format for Antibody Conjugates

Authors: Counsell, Andrew

DOI: https://www.repository.cam.ac.uk/handle/1810/362896

Thesis

Single-Payload Bioconjugation to Native Antibodies And A General Method for the Self-Immolative Release of Amide-Containing Molecules

Wharton, Thomas · 2025

Full title: Single-Payload Bioconjugation to Native Antibodies And A General Method for the Self-Immolative Release of Amide-Containing Molecules

Authors: Wharton, Thomas

DOI: https://www.repository.cam.ac.uk/handle/1810/378310

Thesis

T cell-redirecting therapies in hematological malignancies: Current developments and novel strategies for improved targeting.

Anderson, Georgina SF; Chapman, Michael A · 2025

Full title: T cell-redirecting therapies in hematological malignancies: Current developments and novel strategies for improved targeting.

Authors: Anderson, Georgina SF; Chapman, Michael A

DOI: https://www.repository.cam.ac.uk/handle/1810/378647

Thesis

Engineering all-in-one protein-based nanoparticles for targeted cancer therapies

Sánchez García, Laura · 2019

Full title: Engineering all-in-one protein-based nanoparticles for targeted cancer therapies

Authors: Sánchez García, Laura

DOI: http://hdl.handle.net/10803/667195

Thesis

Development of antibody-based antitumor therapies based on Trastuzumab: antibody-drug conjugates, immunocytokines and fragment conjugates

Miret Minard, Joan · 2020

Full title: Development of antibody-based antitumor therapies based on Trastuzumab: antibody-drug conjugates, immunocytokines and fragment conjugates

Authors: Miret Minard, Joan

DOI: http://hdl.handle.net/10803/669342

Thesis

Exploring the Dysregulation of Iron Metabolism in Cancer: Leveraging Fenton Chemistry for Selective Drug Delivery

Spangler, Benjamin · 2015

Full title: Exploring the Dysregulation of Iron Metabolism in Cancer: Leveraging Fenton Chemistry for Selective Drug Delivery

Authors: Spangler, Benjamin

DOI: https://escholarship.org/uc/item/0tr3v78n

Thesis

Passerini multicomponent reaction: a versatile synthesis of nanomedicines for triple negative breast cancer treatment

Travanut, Alessandra · 2021

Full title: Passerini multicomponent reaction: a versatile synthesis of nanomedicines for triple negative breast cancer treatment

Authors: Travanut, Alessandra

DOI: https://eprints.nottingham.ac.uk/64610/1/AT%20Corrected%20Thesis%20Feb%2021.pdf

Thesis

Development of novel bispecific antibody modalities for targeted degradation and anti-viral therapeutic applications

Pance, Katarina · 2021

Full title: Development of novel bispecific antibody modalities for targeted degradation and anti-viral therapeutic applications

Authors: Pance, Katarina

DOI: https://escholarship.org/uc/item/2130p0m7

Thesis

DNA Programmed Assembly of Proteins: Applications in Antibody Engineering and Epidermal Growth Factor Receptor Signaling

Liang, Samantha Isabel · 2016

Full title: DNA Programmed Assembly of Proteins: Applications in Antibody Engineering and Epidermal Growth Factor Receptor Signaling

Authors: Liang, Samantha Isabel

DOI: https://escholarship.org/uc/item/3w5002f1

Thesis

Developing Covalent Biologics through Genetic Code Expansion for Cancer Therapeutics

Klauser, Paul Chuang · 2023

Full title: Developing Covalent Biologics through Genetic Code Expansion for Cancer Therapeutics

Authors: Klauser, Paul Chuang

DOI: https://escholarship.org/uc/item/4h4104s0

Thesis

Utilizing bio-conjugation and protein engineering to develop enhanced cancer therapeutics, viral diagnostics, and biochemical tools

Elledge, Susanna Kuroda · 2022

Full title: Utilizing bio-conjugation and protein engineering to develop enhanced cancer therapeutics, viral diagnostics, and biochemical tools

Authors: Elledge, Susanna Kuroda

DOI: https://escholarship.org/uc/item/6f066638

Thesis

Development of novel folate receptor (FR)-targeted indenoisoquinoline drug delivery systems (DDSs) using acid sensitive N-Ethoxybenzylimidazole (NEBI) crosslinkers for anti-cancer therapy /

Cao, Yuchen Z. · 2014

Authors: Cao, Yuchen Z.

DOI: https://escholarship.org/uc/item/0vs1n74d

Thesis

Delivery of RNAi Therapeutics: Building Multifunctional RNAi Triggers for Extra-Hepatic Targeting and Endosomal Escape

Springer, Aaron David · 2019

Full title: Delivery of RNAi Therapeutics: Building Multifunctional RNAi Triggers for Extra-Hepatic Targeting and Endosomal Escape

Authors: Springer, Aaron David

DOI: https://escholarship.org/uc/item/2fr5b3tj

Thesis

Development of acid-sensitive N-ethoxybenzylimidazoles for use as linkers in drug delivery systems

Luong, Alice · 2011

Full title: Development of acid-sensitive N-ethoxybenzylimidazoles for use as linkers in drug delivery systems

Authors: Luong, Alice

DOI: https://escholarship.org/uc/item/6th9r5v5

Thesis

Expanding the Antibody Toolbox

Cotton, Adam David · 2021

Full title: Expanding the Antibody Toolbox

Authors: Cotton, Adam David

DOI: https://escholarship.org/uc/item/52s0h9h3

Thesis

Investigation of the Enhancement of Drug Synergy by Co-Delivery in Targeted Liposomes

Riviere, Kareen · 2009

Full title: Investigation of the Enhancement of Drug Synergy by Co-Delivery in Targeted Liposomes

Authors: Riviere, Kareen

DOI: https://escholarship.org/uc/item/8753p1pf

Thesis

Development of Antibody-RNA Conjugates for Targets Beyond the Liver

Medina, Carlos · 2021

Full title: Development of Antibody-RNA Conjugates for Targets Beyond the Liver

Authors: Medina, Carlos

DOI: https://escholarship.org/uc/item/6sw099fd

Thesis

Targeted Drug Delivery via Exploitation of the Tumor Microenvironment

Callmann, Cassandra Elizabeth · 2018

Full title: Targeted Drug Delivery via Exploitation of the Tumor Microenvironment

Authors: Callmann, Cassandra Elizabeth

DOI: https://escholarship.org/uc/item/8cj741hm

Thesis

Protease-Gated Programmable Fusogenic Nano-Encapsulations for Spatially Selective Targeted Delivery

Mathur, Vineet Keshav · 2025

Full title: Protease-Gated Programmable Fusogenic Nano-Encapsulations for Spatially Selective Targeted Delivery

Authors: Mathur, Vineet Keshav

DOI: https://escholarship.org/uc/item/7cs7291d

Thesis

Receptor-Mediated Targeting to Enhance Therapeutic Efficacy of Chemotherapeutic Agents

Shah, Kush · 2014

Full title: Receptor-Mediated Targeting to Enhance Therapeutic Efficacy of Chemotherapeutic Agents

Authors: Shah, Kush

DOI: http://rave.ohiolink.edu/etdc/view?acc_num=akron1390926627

Thesis

Approaches to prostate cancer imaging and therapy: the use of pharmacokinetics, metabolism and biodistribution to identify new drugs

Yang, Jun · 2005

Full title: Approaches to prostate cancer imaging and therapy: the use of pharmacokinetics, metabolism and biodistribution to identify new drugs

Authors: Yang, Jun

DOI: http://rave.ohiolink.edu/etdc/view?acc_num=osu1133362520

Thesis

Activatable cell penetrating peptides and their use in clinical contrast agent and therapeutic development

Aguilera, Todd Anthony · 2009

Full title: Activatable cell penetrating peptides and their use in clinical contrast agent and therapeutic development

Authors: Aguilera, Todd Anthony

DOI: https://escholarship.org/uc/item/9871p905

Thesis

The pharmacokinetics of adriamycin and side chain elimination and the pharmacokinetics of cytembena following oral administration /

Chow, Wing Sun · 1980

Full title: The pharmacokinetics of adriamycin and side chain elimination and the pharmacokinetics of cytembena following oral administration /

Authors: Chow, Wing Sun

DOI: http://rave.ohiolink.edu/etdc/view?acc_num=osu1487094144435427

Thesis

An integrated system for tumor detection and target drug therapy of colorectal cancers with a humanized tumor targeting antibody, HuCC49ÄCH2

Fang, Lanyan · 2007

Full title: An integrated system for tumor detection and target drug therapy of colorectal cancers with a humanized tumor targeting antibody, HuCC49ÄCH2

Authors: Fang, Lanyan

DOI: http://rave.ohiolink.edu/etdc/view?acc_num=osu1173905544

Thesis

Novel payloads for immunotoxin-based treatment of neuroblastoma

Rust, Aleksander · 2016

Full title: Novel payloads for immunotoxin-based treatment of neuroblastoma

Authors: Rust, Aleksander

DOI: https://etheses.whiterose.ac.uk/id/eprint/16990/1/Aleksander_Rust_120252613_Thesis.pdf

Thesis

Synthesis of Agents Targeting Cancer Cells While Reducing MDR Liability

El-Dakdouki, Mohammad H. · 2009

Full title: Synthesis of Agents Targeting Cancer Cells While Reducing MDR Liability

Authors: El-Dakdouki, Mohammad H.

DOI: http://rave.ohiolink.edu/etdc/view?acc_num=toledo1259679671

Thesis

Targeted delivery of anti-cancer drugs by MS2 virus-like particles

Yan, Ruiyang · 2015

Full title: Targeted delivery of anti-cancer drugs by MS2 virus-like particles

Authors: Yan, Ruiyang

DOI: https://etheses.whiterose.ac.uk/id/eprint/8989/1/PhD%20Thesis%20%20Yan%20R%202015.pdf

Thesis

Design, Synthesis and Biological Evaluation of New Molecules to Selectively Target Specific Cancers

Premnauth, Gurdat · 2020

Full title: Design, Synthesis and Biological Evaluation of New Molecules to Selectively Target Specific Cancers

Authors: Premnauth, Gurdat

DOI: http://rave.ohiolink.edu/etdc/view?acc_num=ucin1613744938434214

Thesis

Development of Doxorubicin Prodrugs for Targeted and Responsive Cancer Therapy

Jafari, Mina · 2022

Full title: Development of Doxorubicin Prodrugs for Targeted and Responsive Cancer Therapy

Authors: Jafari, Mina

DOI: http://rave.ohiolink.edu/etdc/view?acc_num=ucin1668635232339841

Thesis

The targeted delivery of G3 peptide drug conjugates in prostate cancer

Martinez Andrade, Gisela · 2023

Full title: The targeted delivery of G3 peptide drug conjugates in prostate cancer

Authors: Martinez Andrade, Gisela

DOI: https://etheses.whiterose.ac.uk/id/eprint/33963/1/Gisela%20Martinez-Andrade%20Thesis%20PhD.pdf

Thesis

Characterisation of HER2 binding Affimer drug conjugates in 2D and 3D cell culture

Roberts, Sophie Elizabeth · 2020

Full title: Characterisation of HER2 binding Affimer drug conjugates in 2D and 3D cell culture

Authors: Roberts, Sophie Elizabeth

DOI: https://etheses.whiterose.ac.uk/id/eprint/27897/1/Corrected%20Thesis.pdf

Thesis

INVESTIGATION OF LIGAND SIZE ON TARGETED PLGA NANOPARTICLES FOR HER2 BREAST CANCER: TRASTUZUMAB AND ITS ScFv ANTI-HER2 ANTIBODY

Zagzoog, Ayat H 1990- · 2018

Full title: INVESTIGATION OF LIGAND SIZE ON TARGETED PLGA NANOPARTICLES FOR HER2 BREAST CANCER: TRASTUZUMAB AND ITS ScFv ANTI-HER2 ANTIBODY

Authors: Zagzoog, Ayat H 1990-

DOI: http://hdl.handle.net/10388/8622

Thesis

Development and preclinical evaluation of theranostic agents targeting muc16/ca125 and nectin-4 expression in breast, ovarian and pancreatic cancers

Babeker, Hanan · 2023

Full title: Development and preclinical evaluation of theranostic agents targeting muc16/ca125 and nectin-4 expression in breast, ovarian and pancreatic cancers

Authors: Babeker, Hanan

DOI: https://hdl.handle.net/10388/15068

Thesis

Developing protein conjugation techniques to enhance cell delivery of therapeutic enzymes

Hart, R J · 2017

Full title: Developing protein conjugation techniques to enhance cell delivery of therapeutic enzymes

Authors: Hart, R J

DOI: https://etheses.whiterose.ac.uk/id/eprint/18996/1/Rose%20Hart%20final%20thesis.pdf

Thesis

Drug-conjugated biopolymers as osteosarcoma and rheumatoid arthritis therapeutics

Perkins, Ethan Dickson · 2020

Full title: Drug-conjugated biopolymers as osteosarcoma and rheumatoid arthritis therapeutics

Authors: Perkins, Ethan Dickson

DOI: https://etheses.whiterose.ac.uk/id/eprint/28785/1/Perkins_ED_Dentistry_PhD_2020.pdf

Thesis

Příprava anti-CD20 vazebné domény a její konjugace na polymerní nosič

Cibiková, Tereza · 2024

Full title: Příprava anti-CD20 vazebné domény a její konjugace na polymerní nosič

Authors: Cibiková, Tereza

DOI: http://hdl.handle.net/20.500.11956/190552

Thesis

Development and Evaluation of Novel Anti-HER2 Theranostics Against HER2-Positive Breast Cancer

Pougoue Ketchemen, Jessica · 2024

Full title: Development and Evaluation of Novel Anti-HER2 Theranostics Against HER2-Positive Breast Cancer

Authors: Pougoue Ketchemen, Jessica

DOI: https://hdl.handle.net/10388/16064

Thesis

Development of targeted radioimmunotherapy for osteosarcoma using a comparative oncology approach

Prabaharan, Chandra Bose · 2024

Full title: Development of targeted radioimmunotherapy for osteosarcoma using a comparative oncology approach

Authors: Prabaharan, Chandra Bose

DOI: https://hdl.handle.net/10388/15501

Thesis

Surface Functionalization of Nanocarriers with Anti-EGFR Ligands for Cancer Active Targeting

Spada, Alessandra; Gerber-Lemaire, Sandrine · 2025

Full title: Surface Functionalization of Nanocarriers with Anti-EGFR Ligands for Cancer Active Targeting

Authors: Spada, Alessandra; Gerber-Lemaire, Sandrine

DOI: https://infoscience.epfl.ch/handle/20.500.14299/247110

Thesis

Syntéza, charakterizace a studium vlastností funkčních konjugátů protilátek

Stránská, Andrea · 2024

Full title: Syntéza, charakterizace a studium vlastností funkčních konjugátů protilátek

Authors: Stránská, Andrea

DOI: http://hdl.handle.net/20.500.11956/190586

Thesis

Použití imunomodulace pro potenciaci chemoterapie polymerními cytostatiky

Chmelová, Helena · 2017

Full title: Použití imunomodulace pro potenciaci chemoterapie polymerními cytostatiky

Authors: Chmelová, Helena

DOI: http://hdl.handle.net/20.500.11956/24851

Thesis

Development of cysteine cathepsin inhibitors combined with cell type-specific delivery for the treatment of B-cell lymphoma and solid tumors

Petruzzella, Aaron Simone · 2024

Full title: Development of cysteine cathepsin inhibitors combined with cell type-specific delivery for the treatment of B-cell lymphoma and solid tumors

Authors: Petruzzella, Aaron Simone

DOI: https://infoscience.epfl.ch/handle/20.500.14299/207552

Thesis

Dendrimer-Mediated Targeted Immunotherapies for the Treatment of Glioblastoma

Liaw, Kevin · 2020

Full title: Dendrimer-Mediated Targeted Immunotherapies for the Treatment of Glioblastoma

Authors: Liaw, Kevin

DOI: http://jhir.library.jhu.edu/handle/1774.2/62520

Thesis

ALPHA-PARTICLE NANOTHERAPEUTICS AGAINST METASTATIC AND/OR CHEMORESISTANT TRIPLE NEGATIVE BREAST CANCER

Prasad, Aprameya Ganesh · 2022

Full title: ALPHA-PARTICLE NANOTHERAPEUTICS AGAINST METASTATIC AND/OR CHEMORESISTANT TRIPLE NEGATIVE BREAST CANCER

Authors: Prasad, Aprameya Ganesh

DOI: http://jhir.library.jhu.edu/handle/1774.2/67067

Thesis

Mechanistic Studies of the Transcription Inhibitor Triptolide and its Selective Targeting to Cancer Cells under Hypoxia

Datan, Emmanuel · 2020

Full title: Mechanistic Studies of the Transcription Inhibitor Triptolide and its Selective Targeting to Cancer Cells under Hypoxia

Authors: Datan, Emmanuel

DOI: http://jhir.library.jhu.edu/handle/1774.2/62440

Thesis

Computational Systems Pharmacology of Antibody-Drug Conjugates

Lam, Inez · 2025

Full title: Computational Systems Pharmacology of Antibody-Drug Conjugates

Authors: Lam, Inez

DOI: https://jscholarship.library.jhu.edu/handle/1774.2/70242

Thesis

uSPIO-based Nanocarrier for Pretargeted, PET-MR Image-Guided Delivery

Si, Ge · 2023

Full title: uSPIO-based Nanocarrier for Pretargeted, PET-MR Image-Guided Delivery

Authors: Si, Ge

DOI: http://jhir.library.jhu.edu/handle/1774.2/68934

Thesis

Antibody⇓drug conjugates for cancer therapy

Hafeez, U; Parakh, S; Gan, HK et al. · 2020

Full title: Antibody⇓drug conjugates for cancer therapy

Authors: Hafeez, U; Parakh, S; Gan, HK; Scott, AM

DOI: https://hdl.handle.net/11343/251739

Thesis

Synthese und Charakterisierung eines synthetischen Antikörpers

Brehs, Manuel · 2015

Full title: Synthese und Charakterisierung eines synthetischen Antikörpers

Authors: Brehs, Manuel

DOI: https://mediatum.ub.tum.de/1096320

Thesis

Synthesis and biological properties of cytotoxic lectin conjugates

Ma, Long · 2007

Full title: Synthesis and biological properties of cytotoxic lectin conjugates

Authors: Ma, Long

DOI: https://livrepository.liverpool.ac.uk/3186170/1/33081293.pdf

Thesis

Targeting cancer therapy: using protease cleavage sequences to develop more selective and effective cancer treatments

Basel, Matthew T. · 2012

Full title: Targeting cancer therapy: using protease cleavage sequences to develop more selective and effective cancer treatments

Authors: Basel, Matthew T.

DOI: http://hdl.handle.net/2097/14087

Thesis

Radioimmunotherapy of Metastatic Disease - Studies of Alpha- and Beta-particle-Emitting Radionuclides in a Preclinical Model

Eriksson, Sophie · 2013

Full title: Radioimmunotherapy of Metastatic Disease - Studies of Alpha- and Beta-particle-Emitting Radionuclides in a Preclinical Model

Authors: Eriksson, Sophie

DOI: https://lup.lub.lu.se/record/3732513

Thesis

Structural modifications of PSMA ligands to optimize their pharmacokinetics

Schmidt, Alexander · 2018

Full title: Structural modifications of PSMA ligands to optimize their pharmacokinetics

Authors: Schmidt, Alexander

DOI: https://mediatum.ub.tum.de/1375257

Thesis

In vitro Untersuchungen des zytotoxischen Effekts der alpha-emittierenden Nuklide 213Bi, 149Tb und 225Ac gekoppelt an monoklonale Antikörper und Bewertung der physikalischen und biologischen Eigenschaften der Nuklide und Antikörper

Miederer, Matthias · 2005

Authors: Miederer, Matthias

DOI: https://mediatum.ub.tum.de/602174

Thesis

Rational design of targeted drug delivery devices for enhancing therapeutic potential of anticancer agents through bioorthogonal reactions

Hudlikar, Manish Satish · 2025

Full title: Rational design of targeted drug delivery devices for enhancing therapeutic potential of anticancer agents through bioorthogonal reactions

Authors: Hudlikar, Manish Satish

DOI: https://openscholar.uga.edu/record/26848/files/hudlikar_manish_s_201712_phd.pdf

Thesis

Development of SNAP-tag based fusion proteins as novel auristatin F-containing immunoconjugates and photoimmunotheranostics in the detection and treatment of triple-negative breast cancer

Mungra, Neelakshi · 2022

Full title: Development of SNAP-tag based fusion proteins as novel auristatin F-containing immunoconjugates and photoimmunotheranostics in the detection and treatment of triple-negative breast cancer

Authors: Mungra, Neelakshi

DOI: http://hdl.handle.net/11427/36825

Thesis

Rational Design of Responsive Prodrug-based Nanomedicines for Antitumor Therapy

Nagel, Gregor · 2019

Full title: Rational Design of Responsive Prodrug-based Nanomedicines for Antitumor Therapy

Authors: Nagel, Gregor

DOI: https://refubium.fu-berlin.de/handle/fub188/26054

Thesis

Efficacy of dianthin-based targeted toxins in a pancreatic carcinoma xenograft model

Bhargava, Cheenu · 2017

Full title: Efficacy of dianthin-based targeted toxins in a pancreatic carcinoma xenograft model

Authors: Bhargava, Cheenu

DOI: https://refubium.fu-berlin.de/handle/fub188/1854

Thesis

Design and generation of antibody-drug conjugates using non-canonical amino acids

Rakotoarinoro, Nathanaël · 2023

Full title: Design and generation of antibody-drug conjugates using non-canonical amino acids

Authors: Rakotoarinoro, Nathanaël

DOI: https://refubium.fu-berlin.de/handle/fub188/42224

Thesis

Kombinationstherapie von Anti-Tumor-Toxinen und Reinsaponinen am Maus- Tumormodell

Mallinckrodt, Benedicta-Leonie von · 2015

Full title: Kombinationstherapie von Anti-Tumor-Toxinen und Reinsaponinen am Maus- Tumormodell

Authors: Mallinckrodt, Benedicta-Leonie von

DOI: https://refubium.fu-berlin.de/handle/fub188/13069

Thesis

Charakterisierung zielgerichteter Fusionsproteine und Etablierung eines murinen Kolonkarzinom-Modells für die Antibody-directed Enzyme Prodrug Therapy

Schellmann, Nicole · 2013

Full title: Charakterisierung zielgerichteter Fusionsproteine und Etablierung eines murinen Kolonkarzinom-Modells für die Antibody-directed Enzyme Prodrug Therapy

Authors: Schellmann, Nicole

DOI: https://refubium.fu-berlin.de/handle/fub188/6628

Thesis

Elucidating the potential of IgA antibodies for cancer immunotherapy

Hart, Felix Andreas Wolfgang · 2016

Full title: Elucidating the potential of IgA antibodies for cancer immunotherapy

Authors: Hart, Felix Andreas Wolfgang

DOI: https://refubium.fu-berlin.de/handle/fub188/401

Thesis

Development of a platform technology for enhanced endo/lysosomal escape of targeted toxins by structurally specific oleanane saponins

Gilabert-Oriol, Roger · 2014

Full title: Development of a platform technology for enhanced endo/lysosomal escape of targeted toxins by structurally specific oleanane saponins

Authors: Gilabert-Oriol, Roger

DOI: https://refubium.fu-berlin.de/handle/fub188/3421

Thesis

Mechanismen der zielgerichteten antitumoralen Wirksamkeit von Dianthin-Panitumumab-Konjugaten in Kombination mit dem glykosylierten Triterpenoid SO1861

Trautner, Alexandra · 2021

Full title: Mechanismen der zielgerichteten antitumoralen Wirksamkeit von Dianthin-Panitumumab-Konjugaten in Kombination mit dem glykosylierten Triterpenoid SO1861

Authors: Trautner, Alexandra

DOI: https://refubium.fu-berlin.de/handle/fub188/28851

Thesis

Protein Phosphatase Inhibition and Cellular Uptake of Semi-Synthetic Microcystin Derivatives - Investigation of Microcystins as Leads for Drug Development

Sallandt, Laura Louisa · 2024

Full title: Protein Phosphatase Inhibition and Cellular Uptake of Semi-Synthetic Microcystin Derivatives - Investigation of Microcystins as Leads for Drug Development

Authors: Sallandt, Laura Louisa

DOI: https://refubium.fu-berlin.de/handle/fub188/47124

Thesis

Expanding the Anti-cancer Toolbox with Glycan- and Thiol-binding Nanobodies

Goerdeler, Felix · 2022

Full title: Expanding the Anti-cancer Toolbox with Glycan- and Thiol-binding Nanobodies

Authors: Goerdeler, Felix

DOI: https://refubium.fu-berlin.de/handle/fub188/37209

Thesis

Membrane lytic peptide-based molecular therapeutic for targeted anticancer treatment

Zhong, Jieying · 2012

Full title: Membrane lytic peptide-based molecular therapeutic for targeted anticancer treatment

Authors: Zhong, Jieying

DOI: http://repository.hkust.edu.hk/ir/Record/1783.1-7637

Thesis

Investigation of bystander effects of hypoxia-activated prodrugs using three dimensional cell cultures

Hong, Cho · 2019

Full title: Investigation of bystander effects of hypoxia-activated prodrugs using three dimensional cell cultures

Authors: Hong, Cho

DOI: https://hdl.handle.net/2292/45172

Thesis

Identification of determinants of sensitivity to duocarmycin analogues: A class of potent anti-cancer drugs

Ghamri, Nour · 2021

Full title: Identification of determinants of sensitivity to duocarmycin analogues: A class of potent anti-cancer drugs

Authors: Ghamri, Nour

DOI: https://hdl.handle.net/2292/56941

Thesis

Design of BET Inhibitor Bottlebrush Prodrugs with Superior Efficacy and Devoid of Systemic Toxicities

· 2022

Full title: Design of BET Inhibitor Bottlebrush Prodrugs with Superior Efficacy and Devoid of Systemic Toxicities

DOI: https://hdl.handle.net/1721.1/141089

Thesis

De novo design of a two-step approach targeting Claudin-6 for enhanced drug delivery to solid tumors

Yan, Jiayao; Zhong, Liqing; Chen, Xiaotong et al. · 2025

Full title: De novo design of a two-step approach targeting Claudin-6 for enhanced drug delivery to solid tumors

DOI: https://hdl.handle.net/1721.1/164016

Thesis

Engineering of Targeted Nanoparticles for Cancer Therapy Using Internalizing Aptamers Isolated by Cell-Uptake Selection

Xiao, Zeyu; Levy-Nissenbaum, Etgar; Alexis, Frank et al. · 2013

Full title: Engineering of Targeted Nanoparticles for Cancer Therapy Using Internalizing Aptamers Isolated by Cell-Uptake Selection

Authors: Xiao, Zeyu; Levy-Nissenbaum, Etgar; Alexis, Frank; Luptak, Andrej; Teply, Benjamin A.; Chan, Juliana Maria; Shi, Jinjun; Digga, Elise; Cheng, Judy; Langer, Robert; Farokhzad, Omid C.

DOI: http://hdl.handle.net/1721.1/79109

Thesis

Targeting of drugs and nanoparticles to tumors

Ruoslahti, Erkki; Sailor, Michael J.; Bhatia, Sangeeta N. · 2010

Full title: Targeting of drugs and nanoparticles to tumors

Authors: Ruoslahti, Erkki; Sailor, Michael J.; Bhatia, Sangeeta N.

DOI: http://hdl.handle.net/1721.1/58699

Thesis

Targeted Stimuli-Responsive Dextran Conjugates for Doxorubicin Delivery to Hepatocytes

Zaman, Noreen T.; Tan, Fred E.; Joshi, Shilpa M. et al. · 2005

Full title: Targeted Stimuli-Responsive Dextran Conjugates for Doxorubicin Delivery to Hepatocytes

Authors: Zaman, Noreen T.; Tan, Fred E.; Joshi, Shilpa M.; Ying, Jackie Y.

DOI: http://hdl.handle.net/1721.1/30394

Thesis

A Systems Approach for Tumor Pharmacokinetics

Thurber, Greg Michael; Weissleder, Ralph · 2012

Full title: A Systems Approach for Tumor Pharmacokinetics

Authors: Thurber, Greg Michael; Weissleder, Ralph

DOI: http://hdl.handle.net/1721.1/70475

Thesis

Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy

Kolishetti, Nagesh; Dhar, Shanta; Valencia, Pedro Miguel et al. · 2013

Full title: Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy

Authors: Kolishetti, Nagesh; Dhar, Shanta; Valencia, Pedro Miguel; Lin, Lucy Q.; Karnik, Rohit; Lippard, Stephen J.; Langer, Robert; Farokhzad, Omid C.

DOI: http://hdl.handle.net/1721.1/78881

Thesis

Sortase-mediated modification of αDEC205 affords optimization of antigen presentation and immunization against a set of viral epitopes

Ploegh, Hidde; Swee, Lee Kim; Guimaraes, Carla P. et al. · 2013

Full title: Sortase-mediated modification of αDEC205 affords optimization of antigen presentation and immunization against a set of viral epitopes

Authors: Ploegh, Hidde; Swee, Lee Kim; Guimaraes, Carla P.; Sehrawat, Sharvan; Spooner, Eric; Barrasa, M. Inmaculada

DOI: http://hdl.handle.net/1721.1/79815

Thesis

Synergistic Antitumor Activity from Two-Stage Delivery of Targeted Toxins and Endosome-Disrupting Nanoparticles

Su, Xingfang; Yang, Nicole Jie Yeon; Wittrup, Karl Dane et al. · 2013

Full title: Synergistic Antitumor Activity from Two-Stage Delivery of Targeted Toxins and Endosome-Disrupting Nanoparticles

Authors: Su, Xingfang; Yang, Nicole Jie Yeon; Wittrup, Karl Dane; Irvine, Darrell J

DOI: http://hdl.handle.net/1721.1/79767

Thesis

Selective treatment and monitoring of disseminated cancer micrometastases in vivo using dual-function, activatable immunoconjugates

Spring, Bryan Q.; Abu-Yousif, Adnan O.; Palanisami, Akilan et al. · 2014

Full title: Selective treatment and monitoring of disseminated cancer micrometastases in vivo using dual-function, activatable immunoconjugates

DOI: http://hdl.handle.net/1721.1/90355

Thesis

Antigen specificity can be irrelevant to immunocytokine efficacy and biodistribution

Tzeng, Alice; Navaratna, Tejas; Kwan, Byron Hua et al. · 2015

Full title: Antigen specificity can be irrelevant to immunocytokine efficacy and biodistribution

Authors: Tzeng, Alice; Navaratna, Tejas; Kwan, Byron Hua; Opel, Cary Francis; Wittrup, Karl Dane

DOI: http://hdl.handle.net/1721.1/98398

Thesis

Combination antibody treatment down-regulates epidermal growth factor receptor by inhibiting endosomal recycling

Spangler, Jamie Berta; Neil, Jason Robert; Abramovitch, Sivan et al. · 2011

Full title: Combination antibody treatment down-regulates epidermal growth factor receptor by inhibiting endosomal recycling

Authors: Spangler, Jamie Berta; Neil, Jason Robert; Abramovitch, Sivan; Yarden, Yosef; White, Forest M.; Lauffenburger, Douglas A.; Wittrup, Karl Dane

DOI: http://hdl.handle.net/1721.1/66709

Thesis

Triepitopic Antibody Fusions Inhibit Cetuximab-Resistant BRAF and KRAS Mutant Tumors via EGFR Signal Repression

Manzari, Mandana T.; Rosalia, Elizabeth K.; Chen, Tiffany Fen-yi et al. · 2014

Full title: Triepitopic Antibody Fusions Inhibit Cetuximab-Resistant BRAF and KRAS Mutant Tumors via EGFR Signal Repression

Authors: Manzari, Mandana T.; Rosalia, Elizabeth K.; Chen, Tiffany Fen-yi; Wittrup, Karl Dane; Spangler, Jamie Berta

DOI: http://hdl.handle.net/1721.1/91646

Thesis

Sensitizing Protective Tumor Microenvironments to Antibody-Mediated Therapy

Pallasch, Christian; Leskov, Ilya B.; Vorholt, Daniela et al. · 2015

Full title: Sensitizing Protective Tumor Microenvironments to Antibody-Mediated Therapy

DOI: http://hdl.handle.net/1721.1/96265

Thesis

Effect of Small-Molecule-Binding Affinity on Tumor Uptake In Vivo: A Systematic Study Using a Pretargeted Bispecific Antibody

Rhoden, John J.; Ruiz-Yi, Benjamin; Wittrup, Karl Dane et al. · 2014

Full title: Effect of Small-Molecule-Binding Affinity on Tumor Uptake In Vivo: A Systematic Study Using a Pretargeted Bispecific Antibody

Authors: Rhoden, John J.; Ruiz-Yi, Benjamin; Wittrup, Karl Dane; Frangioni, John V.; Orcutt, Kelly Davis

DOI: http://hdl.handle.net/1721.1/91642

Thesis

Targeted Nanoparticle Drugs with Immunotherapy Against Bladder and Breast Cancer

Abou-Adas, Sara · 2024

Full title: Targeted Nanoparticle Drugs with Immunotherapy Against Bladder and Breast Cancer

Authors: Abou-Adas, Sara

DOI: https://escholarship.org/uc/item/0wc2s6q3

Thesis

Production and Analysis of Re-engineered Fusion Protein to Target Receptors on Cancer Stem Cells

Tikle, Sanika · 2022

Full title: Production and Analysis of Re-engineered Fusion Protein to Target Receptors on Cancer Stem Cells

Authors: Tikle, Sanika

DOI: https://escholarship.org/uc/item/5wb2f55v

Thesis

Evaluating the Efficacy of Combination CD46-Targeted 225Ac Radioimmunotherapy and Antibody-Drug Conjugate Therapy in Multiple Myeloma

Mayne, Ellis · 2024

Full title: Evaluating the Efficacy of Combination CD46-Targeted 225Ac Radioimmunotherapy and Antibody-Drug Conjugate Therapy in Multiple Myeloma

Authors: Mayne, Ellis

DOI: https://escholarship.org/uc/item/7vr404c8

Thesis

PSMA-1-Doxorubicin Conjugates for Targeted Therapy of Prostate Cancer

Walker, Natalie · 2019

Full title: PSMA-1-Doxorubicin Conjugates for Targeted Therapy of Prostate Cancer

Authors: Walker, Natalie

DOI: http://rave.ohiolink.edu/etdc/view?acc_num=case1554496393458066

Thesis

Exploring Composition of Peptide Loops to Enhance Biophysical Properties of Antibody Fragments for Cancer Therapeutics

Han, Jeong Min · 2020

Full title: Exploring Composition of Peptide Loops to Enhance Biophysical Properties of Antibody Fragments for Cancer Therapeutics

Authors: Han, Jeong Min

DOI: http://rave.ohiolink.edu/etdc/view?acc_num=osu1598278801134316

Thesis

Synthesis and Investigation of Clickable and Cleavable Linkers for Drug Delivery

Bogen, William C. · 2016

Full title: Synthesis and Investigation of Clickable and Cleavable Linkers for Drug Delivery

Authors: Bogen, William C.

DOI: http://rave.ohiolink.edu/etdc/view?acc_num=ucin1471347221

Thesis

Design and Characterization of Antibody-Conjugated T-Cells and Mimetic Nanovesicles for Cancer Therapy

Medina Salguero, Andres X · 2023

Full title: Design and Characterization of Antibody-Conjugated T-Cells and Mimetic Nanovesicles for Cancer Therapy

Authors: Medina Salguero, Andres X

DOI: https://hdl.handle.net/10388/15314

Thesis

Příprava a charakterizace terapeutické protilátky Farletuzumab - Thiomab E154C S378C

Mochánová, Michaela · 2023

Full title: Příprava a charakterizace terapeutické protilátky Farletuzumab - Thiomab E154C S378C

Authors: Mochánová, Michaela

DOI: http://hdl.handle.net/20.500.11956/181559

Thesis

Příprava polymerního terapeutika cílícího na CD20 pozitivní B lymfomy a NK buňky

Hejl, Maxmilián · 2023

Full title: Příprava polymerního terapeutika cílícího na CD20 pozitivní B lymfomy a NK buňky

Authors: Hejl, Maxmilián

DOI: http://hdl.handle.net/20.500.11956/185124

Thesis

Polymerní terapeutika pro imunoonkoterapii

Kashmel, Pavel · 2022

Full title: Polymerní terapeutika pro imunoonkoterapii

Authors: Kashmel, Pavel

DOI: http://hdl.handle.net/20.500.11956/175217

Thesis

Nanoléčiva pro léčbu nádorů slinivky břišní

Bulková, Alžběta · 2025

Full title: Nanoléčiva pro léčbu nádorů slinivky břišní

Authors: Bulková, Alžběta

DOI: http://hdl.handle.net/20.500.11956/204058

Thesis

Rational Design of Chemically Controlled Antibodies and Protein Therapeutics

Marchand, Anthony; Bonati, Lucia; Shui, Sailan et al. · 2023

Full title: Rational Design of Chemically Controlled Antibodies and Protein Therapeutics

Authors: Marchand, Anthony; Bonati, Lucia; Shui, Sailan; Scheller, Leo; Gainza Cirauqui, Pablo; Rosset, Stéphane; Georgeon, Sandrine; Tang, Li; Correia, Bruno

DOI: https://infoscience.epfl.ch/handle/20.500.14299/198280

Thesis

Protease-activation using anti-idiotypic masks enables tumor specificity of a folate receptor 1-T cell bispecific antibody

Geiger, Martina; Stubenrauch, Kay-Gunnar; Sam, Johannes et al. · 2020

Full title: Protease-activation using anti-idiotypic masks enables tumor specificity of a folate receptor 1-T cell bispecific antibody

DOI: https://infoscience.epfl.ch/handle/20.500.14299/171106

Thesis

Switchable immune modulator for tumor-specific activation of anticancer immunity

Zhao, Yu; Xie, Yu-Qing; Van Herck, Simon et al. · 2021

Full title: Switchable immune modulator for tumor-specific activation of anticancer immunity

Authors: Zhao, Yu; Xie, Yu-Qing; Van Herck, Simon; Nassiri, Sina; Gao, Min; Guo, Yugang; Tang, Li

DOI: https://infoscience.epfl.ch/handle/20.500.14299/181693

Thesis

IMPROVING NEXT-GENERATION THERAPEUTIC DELIVERY SYSTEMS THROUGH ALLOSTERIC EXCHANGE AND SELECTIVE GLYCOSYLATION

Rosas, Jonah · 2019

Full title: IMPROVING NEXT-GENERATION THERAPEUTIC DELIVERY SYSTEMS THROUGH ALLOSTERIC EXCHANGE AND SELECTIVE GLYCOSYLATION

Authors: Rosas, Jonah

DOI: http://jhir.library.jhu.edu/handle/1774.2/61733

Thesis

Activated platelets in the tumor microenvironment for targeting of antibody-drug conjugates to tumors and metastases

Yap, ML; McFadyen, JD; Wang, X et al. · 2020

Full title: Activated platelets in the tumor microenvironment for targeting of antibody-drug conjugates to tumors and metastases

Authors: Yap, ML; McFadyen, JD; Wang, X; Ziegler, M; Chen, YC; Willcox, A; Nowell, CJ; Scott, AM; Sloan, EK; Hogarth, MP; Pietersz, GA; Peter, K

DOI: https://hdl.handle.net/11343/253772

Thesis

Engineering anti-Lewis-Y hu3S193 antibodies with improved therapeutic ratio for radioimmunotherapy of epithelial cancers

Burvenich, IJG; Lee, FT; O’Keefe, GJ et al. · 2021

Full title: Engineering anti-Lewis-Y hu3S193 antibodies with improved therapeutic ratio for radioimmunotherapy of epithelial cancers

Authors: Burvenich, IJG; Lee, FT; O’Keefe, GJ; Makris, D; Cao, D; Gong, S; Rigopoulos, A; Allan, LC; Brechbiel, MW; Liu, Z; Ramsland, PA; Scott, AM

DOI: https://hdl.handle.net/11343/262194

Thesis

Precision medicine and targeted therapy : Turning the tables on cancer

Mortensen, Anja · 2018

Full title: Precision medicine and targeted therapy : Turning the tables on cancer

Authors: Mortensen, Anja

DOI: http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-342030

Thesis

l-Tyrosine Confers Residualizing Properties to a d-Amino Acid-Rich Residualizing Peptide for Radioiodination of Internalizing Antibodies

Lee, FT; Burvenich, IJG; Guo, N et al. · 2021

Full title: l-Tyrosine Confers Residualizing Properties to a d-Amino Acid-Rich Residualizing Peptide for Radioiodination of Internalizing Antibodies

Authors: Lee, FT; Burvenich, IJG; Guo, N; Kocovski, P; Tochon-Danguy, H; Ackermann, U; O’Keefe, GJ; Gong, S; Rigopoulos, A; Liu, Z; Gan, HK; Scott, AM

DOI: https://hdl.handle.net/11343/260406

Thesis

First clinical study of a pegylated diabody 124I-labeled PEG-AVP0458 in patients with tumor-associated glycoprotein 72 positive cancers

Scott, AM; Akhurst, T; Lee, FT et al. · 2020

Full title: First clinical study of a pegylated diabody 124I-labeled PEG-AVP0458 in patients with tumor-associated glycoprotein 72 positive cancers

DOI: https://hdl.handle.net/11343/252937

Thesis

Template-Assisted Antibody Assembly: A Versatile Approach for Engineering Functional Antibody Nanoparticles

Hu, Y; Li, J; Ju, Y et al. · 2022

Full title: Template-Assisted Antibody Assembly: A Versatile Approach for Engineering Functional Antibody Nanoparticles

Authors: Hu, Y; Li, J; Ju, Y; Houston, ZH; Fletcher, NL; De Rose, R; Fernandes, S; Hagemeyer, CE; Alt, K; Thurecht, KJ; Cortez-Jugo, C; Caruso, F

DOI: https://hdl.handle.net/11343/302043

Thesis

Harnessing Cu-64/Cu-67 for a theranostic approach to pretargeted radioimmunotherapy

Keinanen, O; Fung, K; Brennan, JM et al. · 2020

Full title: Harnessing Cu-64/Cu-67 for a theranostic approach to pretargeted radioimmunotherapy

Authors: Keinanen, O; Fung, K; Brennan, JM; Zia, N; Harris, M; van Dam, E; Biggin, C; Hedt, A; Stoner, J; Donnelly, PS; Lewis, JS; Zeglis, BM

DOI: https://hdl.handle.net/11343/252244

Thesis

Radiolabeled Antibodies for Cancer Imaging and Therapy

Parakh, S; Lee, ST; Gan, HK et al. · 2022

Full title: Radiolabeled Antibodies for Cancer Imaging and Therapy

Authors: Parakh, S; Lee, ST; Gan, HK; Scott, AM

DOI: https://hdl.handle.net/11343/307131

Thesis

Antibody-drug conjugates: beyond current approvals and potential future strategies

Menon, S; Parakh, S; Scott, AM et al. · 2022

Full title: Antibody-drug conjugates: beyond current approvals and potential future strategies

Authors: Menon, S; Parakh, S; Scott, AM; Gan, HK

DOI: https://hdl.handle.net/11343/308767

Thesis

Antibody Drug Conjugates in Glioblastoma – Is There a Future for Them?

Parakh, S; Nicolazzo, J; Scott, AM et al. · 2022

Full title: Antibody Drug Conjugates in Glioblastoma – Is There a Future for Them?

Authors: Parakh, S; Nicolazzo, J; Scott, AM; Gan, HK

DOI: https://hdl.handle.net/11343/305444

Thesis

Tumor volumes as a predictor of response to the anti-EGFR antibody drug conjugate depatuxizumab mafadotin

Gan, HK; Parakh, S; Lassman, AB et al. · 2022

Full title: Tumor volumes as a predictor of response to the anti-EGFR antibody drug conjugate depatuxizumab mafadotin

Authors: Gan, HK; Parakh, S; Lassman, AB; Seow, A; Lau, E; Lee, ST; Ameratunga, M; Perchyonok, Y; Cao, D; Burvenich, IJG; O'keefe, GJ; Rigopoulos, A; Gomez, E; Maag, D; Scott, AM

DOI: https://hdl.handle.net/11343/296955

Thesis

Bifunctional Aptamer-Doxorubicin Conjugate Crosses the Blood-Brain Barrier and Selectively Delivers Its Payload to EpCAM-Positive Tumor Cells

Macdonald, J; Denoyer, D; Henri, J et al. · 2022

Full title: Bifunctional Aptamer-Doxorubicin Conjugate Crosses the Blood-Brain Barrier and Selectively Delivers Its Payload to EpCAM-Positive Tumor Cells

Authors: Macdonald, J; Denoyer, D; Henri, J; Jamieson, A; Burvenich, IJG; Pouliot, N; Shigdar, S

DOI: https://hdl.handle.net/11343/304410

Thesis

The in vitro and in vivo anti-tumour activity of N-AcMEL-(Fab′)2 conjugates

Smyth, MJ; Pietersz, GA; McKenzie, IFC · 2021

Full title: The in vitro and in vivo anti-tumour activity of N-AcMEL-(Fab′)2 conjugates

Authors: Smyth, MJ; Pietersz, GA; McKenzie, IFC

DOI: https://hdl.handle.net/11343/269476

Thesis

Engineering of bispecific affinity proteins with high affinity for ERBB2 and adaptable binding to albumin

Nilvebrant, J; Åstrand, M; Georgieva-Kotseva, M et al. · 2021

Full title: Engineering of bispecific affinity proteins with high affinity for ERBB2 and adaptable binding to albumin

Authors: Nilvebrant, J; Åstrand, M; Georgieva-Kotseva, M; Björnmalm, M; Löfblom, J; Hober, S

DOI: https://hdl.handle.net/11343/260014

Thesis

Targeting and efficacy of novel mab806-antibody-drug conjugates in malignant mesothelioma

Chia, PL; Parakh, S; Tsao, MS et al. · 2021

Full title: Targeting and efficacy of novel mab806-antibody-drug conjugates in malignant mesothelioma

Authors: Chia, PL; Parakh, S; Tsao, MS; Pham, NA; Gan, HK; Cao, D; Burvenich, IJG; Rigopoulos, A; Reilly, EB; John, T; Scott, AM

DOI: https://hdl.handle.net/11343/271967

Thesis

Tumor targeted alpha particle therapy with an actinium-225 labelled antibody for carbonic anhydrase IX

Morgan, KA; Wichmann, CW; Osellame, LD et al. · 2024

Full title: Tumor targeted alpha particle therapy with an actinium-225 labelled antibody for carbonic anhydrase IX

Authors: Morgan, KA; Wichmann, CW; Osellame, LD; Cao, Z; Guo, N; Scott, AM; Donnelly, PS

DOI: https://hdl.handle.net/11343/350949

Thesis

HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy

Yu, HA; Goto, Y; Hayashi, H et al. · 2023

DOI: https://hdl.handle.net/11343/337233

Thesis

Preferential Antibody and Drug Conjugate Targeting of the ADAM10 Metalloprotease in Tumours

Yan, H; Vail, ME; Hii, L et al. · 2022

Full title: Preferential Antibody and Drug Conjugate Targeting of the ADAM10 Metalloprotease in Tumours

Authors: Yan, H; Vail, ME; Hii, L; Guo, N; McMurrick, PJ; Oliva, K; Wilkins, S; Saha, N; Nikolov, DB; Lee, FT; Scott, AM; Janes, PW

DOI: https://hdl.handle.net/11343/316890

Thesis

Patient-Specific Nanoparticle Targeting in Human Leukemia Blood

Ju, Y; Li, S; Tan, AEQ et al. · 2024

Full title: Patient-Specific Nanoparticle Targeting in Human Leukemia Blood

Authors: Ju, Y; Li, S; Tan, AEQ; Pilkington, EH; Brannon, PT; Plebanski, M; Cui, J; Caruso, F; Thurecht, KJ; Tam, C; Kent, SJ

DOI: https://hdl.handle.net/11343/353155

Thesis

The antibody–drug conjugate targeting ROR1, NBE-002, is active in high-grade serous ovarian cancer preclinical models

Liu, D; Vandenberg, CJ; Sini, P et al. · 2025

Full title: The antibody–drug conjugate targeting ROR1, NBE-002, is active in high-grade serous ovarian cancer preclinical models

Authors: Liu, D; Vandenberg, CJ; Sini, P; Waldmeier, L; Baumgartinger, R; Pisarsky, L; Petroczi, G; Ratnayake, G; Scott, CL; Ford, CE

DOI: https://hdl.handle.net/11343/360653

Thesis

α-Radioimmunotherapy with 213 Bi-anti-CD38 immunoconjugates is effective in a mouse model of human multiple myeloma

Teiluf, Katharina; Seidl, Christof; Blechert, Birgit et al. · 2014

Full title: α-Radioimmunotherapy with 213 Bi-anti-CD38 immunoconjugates is effective in a mouse model of human multiple myeloma

DOI: https://mediatum.ub.tum.de/1514919

Thesis

Differential internalization of hu14.18-IL2 immunocytokine by NK and tumor cell: impact on conjugation, cytotoxicity, and targeting

Reisfeld, RA; Gillies, SD; Rakhmilevich, AL et al. · 2011

Full title: Differential internalization of hu14.18-IL2 immunocytokine by NK and tumor cell: impact on conjugation, cytotoxicity, and targeting

Authors: Reisfeld, RA; Gillies, SD; Rakhmilevich, AL; Yamane, B; Hank, JA; Gubbels, JA; Patankar, MS; Buhtoiarov, TN; Gan, J; Buhtoiarov, IN; Neal, ZC; Sondel, PM

DOI: http://digital.library.wisc.edu/1793/54211

Thesis

Rabbit derived VL single-domains as promising scaffolds to generate antibody-drug conjugates

Full title: Rabbit derived VL single-domains as promising scaffolds to generate antibody-drug conjugates

DOI: https://phaidra.vetmeduni.ac.at/o:2223

Thesis

Recombinant Fusion proteins for Antibody-Directed-Enzyme-Prodrug-Therapy (ADEPT) in colon cancer

Coelho, Vânia · 2008

Full title: Recombinant Fusion proteins for Antibody-Directed-Enzyme-Prodrug-Therapy (ADEPT) in colon cancer

Authors: Coelho, Vânia

DOI: https://refubium.fu-berlin.de/handle/fub188/2880

Thesis

Pró-fármaco ativado por enzima, uma estratégia promissora na quimioterapia

Blau, Lorena [UNESP]; Menegon, Renato Farina [UNESP]; Chin, Chung Man [UNESP] · 2014

Full title: Pró-fármaco ativado por enzima, uma estratégia promissora na quimioterapia

Authors: Blau, Lorena [UNESP]; Menegon, Renato Farina [UNESP]; Chin, Chung Man [UNESP]

DOI: http://dx.doi.org/10.1590/S0100-40422006000600028

Thesis

Chagasin-based Carriers Designed for the Cancer-targeted Release of Proteases

Jai, Jyotsna · 2025

Full title: Chagasin-based Carriers Designed for the Cancer-targeted Release of Proteases

Authors: Jai, Jyotsna

DOI: http://repository.hkust.edu.hk/ir/Record/1783.1-152509

Thesis

Peptide therapeutics: unveiling the potential against cancer - a journey through 1989

Almusaimi, Othman · 2024

Full title: Peptide therapeutics: unveiling the potential against cancer - a journey through 1989

Authors: Almusaimi, Othman

DOI: https://www.mdpi.com/2072-6694/16/5/1032

Thesis

ANTIBODY-DRUG CONJUGATES FOR THE TREATMENT OF BREAST CANCER.

TARANTINO, PAOLO · 2024

Full title: ANTIBODY-DRUG CONJUGATES FOR THE TREATMENT OF BREAST CANCER.

Authors: TARANTINO, PAOLO

DOI: https://hdl.handle.net/2434/1119775

Thesis

Development of a RET activity gene signature and a RET antibody-drug conjugate

Vinoo, Saasha · 2025

Full title: Development of a RET activity gene signature and a RET antibody-drug conjugate

Authors: Vinoo, Saasha

DOI: https://hdl.handle.net/11299/275842

Thesis

A Complete Pipeline for the Discovery and Development of Haptenizing Chimeras at Scale

Dhaliwal, Rohil · 2025

Full title: A Complete Pipeline for the Discovery and Development of Haptenizing Chimeras at Scale

Authors: Dhaliwal, Rohil

DOI: https://dash.harvard.edu/handle/1/42719542

Thesis

Radiolabeled HER-2 Binding Affibody Molecules for Tumor Targeting : Preclinical Studies

Steffen, Ann-Charlott · 2006

Full title: Radiolabeled HER-2 Binding Affibody Molecules for Tumor Targeting : Preclinical Studies

Authors: Steffen, Ann-Charlott

DOI: http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-6678

Thesis

Indirect Radiohalogenation of Targeting Proteins : Labelling Chemistry and Biological Characterisation

Orlova, Anna · 2003

Full title: Indirect Radiohalogenation of Targeting Proteins : Labelling Chemistry and Biological Characterisation

Authors: Orlova, Anna

DOI: http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-3349

Thesis

Targeted Therapy of Colorectal Cancer : Preclinical Evaluation of a Radiolabelled Antibody

Almqvist, Ylva · 2008

Full title: Targeted Therapy of Colorectal Cancer : Preclinical Evaluation of a Radiolabelled Antibody

Authors: Almqvist, Ylva

DOI: http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-8657

Thesis

Antibody Mediated Radionuclide Targeting of HER-2 for Cancer Diagnostics and Therapy : Preclinical Studies

Persson, Mikael · 2006

Full title: Antibody Mediated Radionuclide Targeting of HER-2 for Cancer Diagnostics and Therapy : Preclinical Studies

Authors: Persson, Mikael

DOI: http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-6798

Thesis

Tandem Native Mass-Spectrometry on Antibody-Drug Conjugates and Submillion da Antibody-Antigen Protein Assemblies on an Orbitrap EMR Equipped with a High-Mass Quadrupole Mass Selector

Dyachenko, Andrey; Wang, Guanbo; Belov, Mike et al. · 2015

Full title: Tandem Native Mass-Spectrometry on Antibody-Drug Conjugates and Submillion da Antibody-Antigen Protein Assemblies on an Orbitrap EMR Equipped with a High-Mass Quadrupole Mass Selector

Authors: Dyachenko, Andrey; Wang, Guanbo; Belov, Mike; Makarov, Alexander; De Jong, Rob N.; Van Den Bremer, Ewald T J; Parren, Paul W H I; Heck, Albert J R

DOI: https://dspace.library.uu.nl/handle/1874/320054

Thesis

Nanobody-based cancer therapy of solid tumors

Kijanka, Marta; Dorresteijn, Bram; Oliveira, Sabrina et al. · 2015

Full title: Nanobody-based cancer therapy of solid tumors

Authors: Kijanka, Marta; Dorresteijn, Bram; Oliveira, Sabrina; van Bergen en Henegouwen, Paul M P

DOI: https://dspace.library.uu.nl/handle/1874/330269

Thesis

Lysine conjugation properties in human IgGs studied by integrating high-resolution native mass spectrometry and bottom-up proteomics

Gautier, Violette; Boumeester, Anja J.; Lössl, Philip et al. · 2015

Full title: Lysine conjugation properties in human IgGs studied by integrating high-resolution native mass spectrometry and bottom-up proteomics

Authors: Gautier, Violette; Boumeester, Anja J.; Lössl, Philip; Heck, Albert J R

DOI: https://dspace.library.uu.nl/handle/1874/320061

Thesis

High turnover of Tissue Factor enables efficient intracellular delivery of antibody-drug conjugates

de Goeij, Bart Ecg; Satijn, David; Freitag, Claudia M et al. · 2015

Full title: High turnover of Tissue Factor enables efficient intracellular delivery of antibody-drug conjugates

Authors: de Goeij, Bart Ecg; Satijn, David; Freitag, Claudia M; Wubbolts, Richard; Bleeker, Wim K; Khasanov, Alisher; Zhu, Tong; Chen, Gary; Miao, David; van Berkel, Patrick Hc; Parren, Paul W H I

DOI: https://dspace.library.uu.nl/handle/1874/330565

Thesis

EGFR targeted nanobody-photosensitizer conjugates for photodynamic therapy in a pre-clinical model of head and neck cancer

van Driel, Pieter B A A; Boonstra, Martin C; Slooter, Maxime D et al. · 2016

Full title: EGFR targeted nanobody-photosensitizer conjugates for photodynamic therapy in a pre-clinical model of head and neck cancer

DOI: https://dspace.library.uu.nl/handle/1874/343679

Thesis

Efficient payload delivery by a bispecific antibody-drug conjugate targeting HER2 and CD63

de Goeij, Bart Ecg; Vink, Tom; Ten Napel, Hendrik et al. · 2016

Full title: Efficient payload delivery by a bispecific antibody-drug conjugate targeting HER2 and CD63

Authors: de Goeij, Bart Ecg; Vink, Tom; Ten Napel, Hendrik; Breij, Esther Cw; Satijn, David; Wubbolts, Richard; Miao, David; Parren, Paul Whi

DOI: https://dspace.library.uu.nl/handle/1874/346781

Thesis

Controlled Multi-functionalization Facilitates Targeted Delivery of Nanoparticles to Cancer Cells

Hudlikar, Manish S; Li, Xiuru; Gagarinov, Ivan A et al. · 2016

Full title: Controlled Multi-functionalization Facilitates Targeted Delivery of Nanoparticles to Cancer Cells

Authors: Hudlikar, Manish S; Li, Xiuru; Gagarinov, Ivan A; Kolishetti, Nagesh; Wolfert, Margreet A; Boons, Geert-Jan

DOI: https://dspace.library.uu.nl/handle/1874/368245

Thesis

Complete regression of xenograft tumors upon targeted delivery of paclitaxel via ∏ - ∏ stacking stabilized polymeric micelles

Shi, Yang; Van Der Meel, Roy; Theek, Benjamin et al. · 2015

Full title: Complete regression of xenograft tumors upon targeted delivery of paclitaxel via ∏ - ∏ stacking stabilized polymeric micelles

DOI: https://dspace.library.uu.nl/handle/1874/314667

Thesis

Strategies to target drugs to gliomas and CNS metastases of solid tumors

Milojkovic Kerklaan, B.; van Tellingen, O.; Huitema, A. D R et al. · 2016

Full title: Strategies to target drugs to gliomas and CNS metastases of solid tumors

Authors: Milojkovic Kerklaan, B.; van Tellingen, O.; Huitema, A. D R; Beijnen, J. H.; Boogerd, W.; Schellens, J. H M; Brandsma, D.

DOI: https://dspace.library.uu.nl/handle/1874/345903

Thesis

Cancer nanomedicines: oversold or underappreciated?

van der Meel, Roy; Lammers, Twan; Hennink, Wim E. · 2017

Full title: Cancer nanomedicines: oversold or underappreciated?

Authors: van der Meel, Roy; Lammers, Twan; Hennink, Wim E.

DOI: https://dspace.library.uu.nl/handle/1874/348233

Thesis

Folate decorated polymeric micelles for targeted delivery of the kinase inhibitor dactolisib to cancer cells

Shi, Haili; van Steenbergen, Mies J.; Lou, Bo et al. · 2020

Full title: Folate decorated polymeric micelles for targeted delivery of the kinase inhibitor dactolisib to cancer cells

Authors: Shi, Haili; van Steenbergen, Mies J.; Lou, Bo; Liu, Yanna; Hennink, Wim E.; Kok, Robbert J.

DOI: https://dspace.library.uu.nl/handle/1874/408808

Thesis

Anti-GD2 Immunoliposomes for Targeted Delivery of the Survivin Inhibitor Sepantronium Bromide (YM155) to Neuroblastoma Tumor Cells

Gholizadeh, Shima; Dolman, Emmy M.; Wieriks, Rebecca et al. · 2018

Full title: Anti-GD2 Immunoliposomes for Targeted Delivery of the Survivin Inhibitor Sepantronium Bromide (YM155) to Neuroblastoma Tumor Cells

Authors: Gholizadeh, Shima; Dolman, Emmy M.; Wieriks, Rebecca; Sparidans, Rolf W.; Hennink, Wim E.; Kok, Robbert J.

DOI: https://dspace.library.uu.nl/handle/1874/369779

Thesis

Antibody or Antibody Fragments: Implications for Molecular Imaging and Targeted Therapy of Solid Tumors

Xenaki, Katerina T; Oliveira, Sabrina; van Bergen En Henegouwen, Paul M P · 2017

Full title: Antibody or Antibody Fragments: Implications for Molecular Imaging and Targeted Therapy of Solid Tumors

Authors: Xenaki, Katerina T; Oliveira, Sabrina; van Bergen En Henegouwen, Paul M P

DOI: https://dspace.library.uu.nl/handle/1874/359772

Thesis

Selective Cytotoxicity to HER2 Positive Breast Cancer Cells by Saporin-Loaded Nanobody-Targeted Polymeric Nanoparticles in Combination With Photochemical Internalization

Martinez Jothar, Lucia; Beztsinna, Nataliia; van Nostrum, Cornelus F et al. · 2019

Full title: Selective Cytotoxicity to HER2 Positive Breast Cancer Cells by Saporin-Loaded Nanobody-Targeted Polymeric Nanoparticles in Combination With Photochemical Internalization

Authors: Martinez Jothar, Lucia; Beztsinna, Nataliia; van Nostrum, Cornelus F; Hennink, Wim E; Oliveira, Sabrina

DOI: https://dspace.library.uu.nl/handle/1874/379619

Thesis

In Vitro Assessment of Binding Affinity, Selectivity, Uptake, Intracellular Degradation, and Toxicity of Nanobody-Photosensitizer Conjugates

Beltrán Hernández, Irati; De Groof, Timo W M; Heukers, Raimond et al. · 2022

Full title: In Vitro Assessment of Binding Affinity, Selectivity, Uptake, Intracellular Degradation, and Toxicity of Nanobody-Photosensitizer Conjugates

Authors: Beltrán Hernández, Irati; De Groof, Timo W M; Heukers, Raimond; Oliveira, Sabrina

DOI: https://dspace.library.uu.nl/handle/1874/422262

Thesis

Nanobody-targeted photodynamic therapy induces significant tumor regression of trastuzumab-resistant HER2-positive breast cancer, after a single treatment session

Deken, Marion M; Kijanka, Marta M; Beltrán Hernández, Irati et al. · 2020

Full title: Nanobody-targeted photodynamic therapy induces significant tumor regression of trastuzumab-resistant HER2-positive breast cancer, after a single treatment session

DOI: https://dspace.library.uu.nl/handle/1874/396707

Thesis

VHH-Photosensitizer Conjugates for Targeted Photodynamic Therapy of Met-Overexpressing Tumor Cells

Heukers, Raimond; Mashayekhi, Vida; Ramirez-Escudero, Mercedes et al. · 2019

Full title: VHH-Photosensitizer Conjugates for Targeted Photodynamic Therapy of Met-Overexpressing Tumor Cells

Authors: Heukers, Raimond; Mashayekhi, Vida; Ramirez-Escudero, Mercedes; de Haard, Hans; Verrips, Theo; van Bergen en Henegouwen, Paul.; Oliveira, Sabrina

DOI: https://dspace.library.uu.nl/handle/1874/384399

Thesis

Single Domain Antibodies as Carriers for Intracellular Drug Delivery: A Proof of Principle Study

Pronk, Sebas D.; Schooten, Erik; Heinen, Jurgen et al. · 2021

Full title: Single Domain Antibodies as Carriers for Intracellular Drug Delivery: A Proof of Principle Study

Authors: Pronk, Sebas D.; Schooten, Erik; Heinen, Jurgen; Helfrich, Esra; Oliveira, Sabrina; Henegouwen, Paul M. P. van Bergen en

DOI: https://dspace.library.uu.nl/handle/1874/412539

Thesis

A New Class of Tunable Acid-Sensitive Linkers for Native Drug Release Based on the Trityl Protecting Group

Timmers, Matt; Weterings, Jimmy; Van Geijn, Michiel et al. · 2022

Full title: A New Class of Tunable Acid-Sensitive Linkers for Native Drug Release Based on the Trityl Protecting Group

Authors: Timmers, Matt; Weterings, Jimmy; Van Geijn, Michiel; Bell, Roel; Lenting, Peter E.; Rijcken, Cristianne J.F.; Vermonden, Tina; Hennink, Wim E.; Liskamp, Rob M.J.

DOI: https://dspace.library.uu.nl/handle/1874/424173

Thesis

Homogeneous tumor targeting with a single dose of HER2-targeted albumin-binding domain-fused nanobody-drug conjugates results in long-lasting tumor remission in mice

Xenaki, Katerina T; Dorrestijn, Bram; Muns, Joey A et al. · 2021

Full title: Homogeneous tumor targeting with a single dose of HER2-targeted albumin-binding domain-fused nanobody-drug conjugates results in long-lasting tumor remission in mice

Authors: Xenaki, Katerina T; Dorrestijn, Bram; Muns, Joey A; Adamzek, Kevin; Doulkeridou, Sofia; Houthoff, HendrikJan; Oliveira, Sabrina; van Bergen En Henegouwen, Paul Mp

DOI: https://dspace.library.uu.nl/handle/1874/411979

Thesis

Repurposing the Pentameric B-Subunit of Shiga Toxin for Gb3-Targeted Immunotherapy of Colorectal Cancer by Rhamnose Conjugation

Liu, Zhicheng; Li, Xia; Lu, Zhongkai et al. · 2022

Full title: Repurposing the Pentameric B-Subunit of Shiga Toxin for Gb3-Targeted Immunotherapy of Colorectal Cancer by Rhamnose Conjugation

Authors: Liu, Zhicheng; Li, Xia; Lu, Zhongkai; Qin, Xinfang; Hong, Haofei; Zhou, Zhifang; Pieters, Roland J.; Shi, Jie; Wu, Zhimeng

DOI: https://dspace.library.uu.nl/handle/1874/426399

Thesis

Versatile Click Linker Enabling Native Peptide Release from Nanocarriers upon Redox Trigger

Hebels, Erik R.; Dietl, Stefanie; Timmers, Matt et al. · 2023

Full title: Versatile Click Linker Enabling Native Peptide Release from Nanocarriers upon Redox Trigger

Authors: Hebels, Erik R.; Dietl, Stefanie; Timmers, Matt; Hak, Jaimie; van den Dikkenberg, Antionette; Rijcken, Cristianne J.F.; Hennink, Wim E.; Liskamp, Rob M.J.; Vermonden, Tina

DOI: https://dspace.library.uu.nl/handle/1874/437857

Thesis

Penetration of Nanobody-Dextran Polymer Conjugates through Tumor Spheroids

Bitsch, Peter; Baum, Eva S.; Beltrán Hernández, Irati et al. · 2023

Full title: Penetration of Nanobody-Dextran Polymer Conjugates through Tumor Spheroids

Authors: Bitsch, Peter; Baum, Eva S.; Beltrán Hernández, Irati; Bitsch, Sebastian; Harwood, Jakob; Oliveira, Sabrina; Kolmar, Harald

DOI: https://dspace.library.uu.nl/handle/1874/434542

Thesis

The physiological interactome of TCR-like antibody therapeutics in human tissues

Marrer-Berger, Estelle; Nicastri, Annalisa; Augustin, Angelique et al. · 2024

Full title: The physiological interactome of TCR-like antibody therapeutics in human tissues

DOI: https://dspace.library.uu.nl/handle/1874/438495

Thesis

Nanobody-fotosensibilisatorconjugaten voor gerichte fotodynamische therapie

Heukers, Raimond; Van Bergen en Henegouwen, Paul M P; Oliveira, Sabrina · 2015

Full title: Nanobody-fotosensibilisatorconjugaten voor gerichte fotodynamische therapie

Authors: Heukers, Raimond; Van Bergen en Henegouwen, Paul M P; Oliveira, Sabrina

DOI: https://dspace.library.uu.nl/handle/1874/428489

Thesis

Antibody-Drug Conjugates to Treat Bacterial Biofilms via Targeting and Extracellular Drug Release

Tvilum, Anne; Johansen, Mikkel I; Glud, Laerke N et al. · 2023

Full title: Antibody-Drug Conjugates to Treat Bacterial Biofilms via Targeting and Extracellular Drug Release

DOI: https://dspace.library.uu.nl/handle/1874/450688

Thesis

The relevance of tumor target expression levels on IgA-mediated cytotoxicity in cancer immunotherapy

Chan, Chilam; Cabanes, Núria Casalé; Jansen, J H Marco et al. · 2024

Full title: The relevance of tumor target expression levels on IgA-mediated cytotoxicity in cancer immunotherapy

DOI: https://dspace.library.uu.nl/handle/1874/456522

Thesis

Population Pharmacokinetics of Inotuzumab Ozogamicin in Pediatric Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia: Results of Study ITCC-059

Wu, Jen Hao; Pennesi, Edoardo; Bautista, Francisco et al. · 2024

Full title: Population Pharmacokinetics of Inotuzumab Ozogamicin in Pediatric Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia: Results of Study ITCC-059

DOI: https://dspace.library.uu.nl/handle/1874/454801

Thesis

Fc gamma receptor is not required for in vivo processing of radio- and drug-conjugates of the dead tumor cell-targeting monoclonal antibody, APOMAB (R)

Staudacher, Alexander H; Liapis, Vasilios; Wittwer, Nicole L et al. · 2022

Full title: Fc gamma receptor is not required for in vivo processing of radio- and drug-conjugates of the dead tumor cell-targeting monoclonal antibody, APOMAB (R)

Authors: Staudacher, Alexander H; Liapis, Vasilios; Wittwer, Nicole L; Tieu, William; Lam, Hiu Chun; Leusen, Jeanette; Brown, Michael P

DOI: https://dspace.library.uu.nl/handle/1874/446334

Thesis

Practical Theoretic Guidance for the Design of Tumor-Targeting Agents

Thurber, Greg M.; Schmidt, Michael M.; Rhoden, John J. et al. · 2016

Full title: Practical Theoretic Guidance for the Design of Tumor-Targeting Agents

Authors: Thurber, Greg M.; Schmidt, Michael M.; Rhoden, John J.; Wittrup, Karl Dane

DOI: http://hdl.handle.net/1721.1/101376

Thesis

Engineering of anticancer human immunoglobulin A equipped with albumin for enhanced plasma half-life

Mester, Simone; Chan, Chilam; Lustig, Marta et al. · 2025

Full title: Engineering of anticancer human immunoglobulin A equipped with albumin for enhanced plasma half-life

DOI: https://dspace.library.uu.nl/handle/1874/460851

Thesis

Salt Effect Accelerates Site-Selective Cysteine Bioconjugation

Dai, Peng; Zhang, Chi; Welborn, Matthew Gregory et al. · 2018

Full title: Salt Effect Accelerates Site-Selective Cysteine Bioconjugation

Authors: Dai, Peng; Zhang, Chi; Welborn, Matthew Gregory; Shepherd, James J; Zhu, Tianyu; Van Voorhis, Troy; Pentelute, Bradley L.

DOI: http://hdl.handle.net/1721.1/113664

Thesis

Nanoparticle conjugates of a highly potent toxin enhance safety and circumvent platinum resistance in ovarian cancer

Lauffer, Sam; Matulonis, Ursula; Pepin, David et al. · 2018

Full title: Nanoparticle conjugates of a highly potent toxin enhance safety and circumvent platinum resistance in ovarian cancer

DOI: http://hdl.handle.net/1721.1/113634

Thesis

Development and therapeutic evaluation of 5D3(CC-MLN8237)3.2 antibody-theranostic conjugates for PSMA-positive prostate cancer therapy

Liatsou, Ioanna; Assefa, Betelhem; Liyanage, Wathsala et al. · 2024

Full title: Development and therapeutic evaluation of 5D3(CC-MLN8237)3.2 antibody-theranostic conjugates for PSMA-positive prostate cancer therapy

Authors: Liatsou, Ioanna; Assefa, Betelhem; Liyanage, Wathsala; Surasinghe, Sharmane; Nováková, Zora; Bařinka, Cyril; Gabrielson, Kathleen; Raman, Venu; Artemov, Dmitri; Hapuarachchige, Sudath

DOI: https://dspace.library.uu.nl/handle/1874/455381

Thesis

Breaking the selectivity-uptake trade-off of photoimmunoconjugates with nanoliposomal irinotecan for synergistic multi-tier cancer targeting

Liang, Barry J; Pigula, Michael; Baglo, Yan et al. · 2020

Full title: Breaking the selectivity-uptake trade-off of photoimmunoconjugates with nanoliposomal irinotecan for synergistic multi-tier cancer targeting

Authors: Liang, Barry J; Pigula, Michael; Baglo, Yan; Najafali, Daniel; Hasan, Tayyaba; Huang, Huang-Chiao

DOI: https://hdl.handle.net/1721.1/126246

Thesis

Determination of Cellular Processing Rates for a Trastuzumab-Maytansinoid Antibody-Drug Conjugate (ADC) Highlights Key Parameters for ADC Design

Kulkarni, Chethana; Betts, Alison M.; Wittrup, Karl Dane et al. · 2016

Full title: Determination of Cellular Processing Rates for a Trastuzumab-Maytansinoid Antibody-Drug Conjugate (ADC) Highlights Key Parameters for ADC Design

Authors: Kulkarni, Chethana; Betts, Alison M.; Wittrup, Karl Dane; Maass, Katie F

DOI: http://hdl.handle.net/1721.1/103801

Thesis

Enzyme-Mediated Modification of Single-Domain Antibodies for Imaging Modalities with Different Characteristics

Rashidian, Mohammad; Wang, Lu; Edens, Jerre G. et al. · 2017

Full title: Enzyme-Mediated Modification of Single-Domain Antibodies for Imaging Modalities with Different Characteristics

Authors: Rashidian, Mohammad; Wang, Lu; Edens, Jerre G.; Jacobsen, Johanne T.; Hossain, Intekhab; Wang, Qifan; Victora, Gabriel D.; Vasdev, Neil; Liang, Steven H.; Ploegh, Hidde

DOI: http://hdl.handle.net/1721.1/107992

Thesis

Antibody-Mediated Neutralization of Perfringolysin O for Intracellular Protein Delivery

Yang, Nicole Jie Yeon; Sklaviadis, Demetra; Wittrup, Karl Dane et al. · 2016

Full title: Antibody-Mediated Neutralization of Perfringolysin O for Intracellular Protein Delivery

Authors: Yang, Nicole Jie Yeon; Sklaviadis, Demetra; Wittrup, Karl Dane; Gui, Dan Yi; Vander Heiden, Matthew G.; Liu, David V.

DOI: http://hdl.handle.net/1721.1/105826

Thesis

π-Clamp-mediated cysteine conjugation

Zhang, Chi; Welborn, Matthew Gregory; Zhu, Tianyu et al. · 2017

Full title: π-Clamp-mediated cysteine conjugation

Authors: Zhang, Chi; Welborn, Matthew Gregory; Zhu, Tianyu; Yang, Nicole Jie Yeon; Santos, Michael; Van Voorhis, Troy; Pentelute, Bradley L.

DOI: http://hdl.handle.net/1721.1/109381

Thesis

Theranostic pretargeted radioimmunotherapy of colorectal cancer xenografts in mice using picomolar affinity [superscript 86]Y- or [superscipt 177]Lu-DOTA-Bn binding scFv C825/GPA33 IgG bispecific immunoconjugates

Xu, Hong; Guo, Hong-fen; Lee, Sang-gyu et al. · 2016

DOI: http://hdl.handle.net/1721.1/104432

Thesis

Comparative Analysis of Bispecific Antibody and Streptavidin-Targeted Radioimmunotherapy for B-cell Cancers

Green, Damian J.; Frayo, Shani L.; Lin, Yukang et al. · 2020

Full title: Comparative Analysis of Bispecific Antibody and Streptavidin-Targeted Radioimmunotherapy for B-cell Cancers

DOI: https://hdl.handle.net/1721.1/125642

Thesis

Site-Specific Antibody Functionalization Using Tetrazine–Styrene Cycloaddition

Mix, Kalie; Raines, Ronald T · 2020

Full title: Site-Specific Antibody Functionalization Using Tetrazine–Styrene Cycloaddition

Authors: Mix, Kalie; Raines, Ronald T

DOI: https://hdl.handle.net/1721.1/125600

Thesis

One-Step Enzymatic Modification of the Cell Surface Redirects Cellular Cytotoxicity and Parasite Tropism

Swee, Lee Kim; Lourido, Sebastian; Bell, George W et al. · 2021

Full title: One-Step Enzymatic Modification of the Cell Surface Redirects Cellular Cytotoxicity and Parasite Tropism

Authors: Swee, Lee Kim; Lourido, Sebastian; Bell, George W; Ingram, Jessica R; Ploegh, Hidde L

DOI: https://hdl.handle.net/1721.1/134576

Thesis

A Tumor-Homing Peptide Platform Enhances Drug Solubility, Improves Blood–Brain Barrier Permeability and Targets Glioblastoma

Cho, Choi-Fong; Farquhar, Charlotte E.; Fadzen, Colin M. et al. · 2022

Full title: A Tumor-Homing Peptide Platform Enhances Drug Solubility, Improves Blood–Brain Barrier Permeability and Targets Glioblastoma

Authors: Cho, Choi-Fong; Farquhar, Charlotte E.; Fadzen, Colin M.; Scott, Benjamin; Zhuang, Pei; von Spreckelsen, Niklas; Loas, Andrei; Hartrampf, Nina; Pentelute, Bradley L.; Lawler, Sean E.

DOI: https://hdl.handle.net/1721.1/142518

Thesis

A mechanistic compartmental model for total antibody uptake in tumors

Thurber, Greg M; Dane Wittrup, K · 2021

Full title: A mechanistic compartmental model for total antibody uptake in tumors

Authors: Thurber, Greg M; Dane Wittrup, K

DOI: https://hdl.handle.net/1721.1/134471

Thesis

IgG-Engineered Protective Antigen for Cytosolic Delivery of Proteins into Cancer Cells

Lu, Zeyu; Truex, Nicholas L; Melo, Mariane B et al. · 2021

Full title: IgG-Engineered Protective Antigen for Cytosolic Delivery of Proteins into Cancer Cells

Authors: Lu, Zeyu; Truex, Nicholas L; Melo, Mariane B; Cheng, Yiran; Li, Na; Irvine, Darrell J; Pentelute, Bradley L

DOI: https://hdl.handle.net/1721.1/133532

Thesis

Sensitization of tumor cells for T cell mediated eradication through targeted delivery of virus-derived immunogenic peptide epitopes

Sefrin, Julian Peter · 2017

Full title: Sensitization of tumor cells for T cell mediated eradication through targeted delivery of virus-derived immunogenic peptide epitopes

Authors: Sefrin, Julian Peter

DOI: https://archiv.ub.uni-heidelberg.de/volltextserver/22809/1/Dissertation_JulianSefrin_2017.pdf

Thesis

Synthesis and evaluation of radiolabeled peptide multimers for tumor targeting

Yim, C.B. · 2011

Full title: Synthesis and evaluation of radiolabeled peptide multimers for tumor targeting

Authors: Yim, C.B.

DOI: https://dspace.library.uu.nl/handle/1874/199335

Thesis

Targeted Cytolysins Synergistically Potentiate Cytoplasmic Delivery of Gelonin Immunotoxin

Wittrup, K. D.; Pirie, Christopher M.; Liu, David V. et al. · 2016

Full title: Targeted Cytolysins Synergistically Potentiate Cytoplasmic Delivery of Gelonin Immunotoxin

Authors: Wittrup, K. D.; Pirie, Christopher M.; Liu, David V.; Wittrup, Karl Dane

DOI: http://hdl.handle.net/1721.1/101380

Patent

us-10314921-b2

· 2019

Full title: us-10314921-b2

Patent

us-10314922-b2

· 2019

Full title: us-10314922-b2

Patent

us-10322192-b2

· 2019

Full title: us-10322192-b2

Patent

us-10442836-b2

· 2019

Full title: us-10442836-b2

Patent

us-10435432-b2

· 2019

Full title: us-10435432-b2

Patent

us-10407743-b2

· 2019

Full title: us-10407743-b2

Patent

us-10617670-b2

· 2020

Full title: us-10617670-b2

Patent

us-10494423-b2

· 2019

Full title: us-10494423-b2

Patent

us-10414826-b2

· 2019

Full title: us-10414826-b2

Patent

us-10537645-b2

· 2020

Full title: us-10537645-b2

Patent

us-10550190-b2

· 2020

Full title: us-10550190-b2

Patent

us-10618935-b2

· 2020

Full title: us-10618935-b2

Patent

us-10610602-b2

· 2020

Full title: us-10610602-b2

Patent

us-10548986-b2

· 2020

Full title: us-10548986-b2

Patent

us-10617764-b2

· 2020

Full title: us-10617764-b2

Patent

us-10639373-b2

· 2020

Full title: us-10639373-b2

Patent

us-10722591-b2

· 2020

Full title: us-10722591-b2

Patent

us-10723727-b2

· 2020

Full title: us-10723727-b2

Patent

us-10633453-b2

· 2020

Full title: us-10633453-b2

Patent

us-10729740-b2

· 2020

Full title: us-10729740-b2

Patent

us-10632196-b2

· 2020

Full title: us-10632196-b2

Patent

us-10633448-b2

· 2020

Full title: us-10633448-b2

Patent

us-10787480-b2

· 2020

Full title: us-10787480-b2

Patent

us-10780179-b2

· 2020

Full title: us-10780179-b2

Patent

us-10752673-b2

· 2020

Full title: us-10752673-b2

Patent

us-10864279-b2

· 2020

Full title: us-10864279-b2

Patent

us-10842881-b2

· 2020

Full title: us-10842881-b2

Patent

us-10960082-b2

· 2021

Full title: us-10960082-b2

Patent

us-10808039-b2

· 2020

Full title: us-10808039-b2

Patent

us-10913770-b2

· 2021

Full title: us-10913770-b2

Patent

us-10835617-b2

· 2020

Full title: us-10835617-b2

Patent

us-10836821-b2

· 2020

Full title: us-10836821-b2

Patent

us-10967068-b2

· 2021

Full title: us-10967068-b2

Patent

us-10987430-b2

· 2021

Full title: us-10987430-b2

Patent

us-10792372-b2

· 2020

Full title: us-10792372-b2

Patent

us-10994019-b2

· 2021

Full title: us-10994019-b2

Patent

us-10912841-b2

· 2021

Full title: us-10912841-b2

Patent

us-11104968-b2

· 2021

Full title: us-11104968-b2

Patent

us-10994021-b1

· 2021

Full title: us-10994021-b1

Patent

us-11135306-b2

· 2021

Full title: us-11135306-b2

Patent

us-11135308-b2

· 2021

Full title: us-11135308-b2

Patent

us-11090390-b2

· 2021

Full title: us-11090390-b2

Patent

us-11090322-b2

· 2021

Full title: us-11090322-b2

Patent

us-11028126-b2

· 2021

Full title: us-11028126-b2

Patent

us-11046759-b2

· 2021

Full title: us-11046759-b2

Patent

us-11149059-b2

· 2021

Full title: us-11149059-b2

Patent

us-11136633-b2

· 2021

Full title: us-11136633-b2

Patent

us-11135307-b2

· 2021

Full title: us-11135307-b2

Patent

us-11141490-b2

· 2021

Full title: us-11141490-b2

Patent

us-11229711-b2

· 2022

Full title: us-11229711-b2

Patent

us-11236131-b2

· 2022

Full title: us-11236131-b2

Patent

us-11167040-b2

· 2021

Full title: us-11167040-b2

Patent

us-11224663-b2

· 2022

Full title: us-11224663-b2

Patent

us-11311626-b2

· 2022

Full title: us-11311626-b2

Patent

us-11185594-b2

· 2021

Full title: us-11185594-b2

Patent

us-11193117-b2

· 2021

Full title: us-11193117-b2

Patent

us-11186642-b2

· 2021

Full title: us-11186642-b2

Patent

us-11278627-b2

· 2022

Full title: us-11278627-b2

Patent

us-11235065-b2

· 2022

Full title: us-11235065-b2

Patent

us-11325888-b2

· 2022

Full title: us-11325888-b2

Patent

us-11219693-b2

· 2022

Full title: us-11219693-b2

Patent

us-11352348-b2

· 2022

Full title: us-11352348-b2

Patent

us-11413353-b2

· 2022

Full title: us-11413353-b2

Patent

us-11458120-b2

· 2022

Full title: us-11458120-b2

Patent

us-11472875-b1

· 2022

Full title: us-11472875-b1

Patent

us-11311622-b2

· 2022

Full title: us-11311622-b2

Patent

us-11370838-b2

· 2022

Full title: us-11370838-b2

Patent

us-11242407-b2

· 2022

Full title: us-11242407-b2

Patent

us-11419944-b2

· 2022

Full title: us-11419944-b2

Patent

us-11517625-b2

· 2022

Full title: us-11517625-b2

Patent

us-11564989-b2

· 2023

Full title: us-11564989-b2

Patent

us-11478553-b2

· 2022

Full title: us-11478553-b2

Patent

us-11446292-b2

· 2022

Full title: us-11446292-b2

Patent

us-11547762-b2

· 2023

Full title: us-11547762-b2

Patent

us-11510994-b2

· 2022

Full title: us-11510994-b2

Patent

us-11602525-b2

· 2023

Full title: us-11602525-b2

Patent

us-11400157-b2

· 2022

Full title: us-11400157-b2

Patent

us-11548943-b2

· 2023

Full title: us-11548943-b2

Patent

us-11591295-b2

· 2023

Full title: us-11591295-b2

Patent

us-11596693-b2

· 2023

Full title: us-11596693-b2

Patent

us-11584800-b2

· 2023

Full title: us-11584800-b2

Patent

us-11607460-b2

· 2023

Full title: us-11607460-b2

Patent

us-11541128-b2

· 2023

Full title: us-11541128-b2

Patent

us-11613588-b2

· 2023

Full title: us-11613588-b2

Patent

us-11628225-b2

· 2023

Full title: us-11628225-b2

Patent

us-11690919-b2

· 2023

Full title: us-11690919-b2

Patent

us-11548944-b2

· 2023

Full title: us-11548944-b2

Patent

us-11446388-b2

· 2022

Full title: us-11446388-b2

Patent

us-11623965-b2

· 2023

Full title: us-11623965-b2

Patent

us-11666657-b2

· 2023

Full title: us-11666657-b2

Patent

us-11692043-b2

· 2023

Full title: us-11692043-b2

Patent

us-11662348-b2

· 2023

Full title: us-11662348-b2

Patent

us-11661457-b2

· 2023

Full title: us-11661457-b2

Patent

us-11744900-b2

· 2023

Full title: us-11744900-b2

Patent

us-11814410-b2

· 2023

Full title: us-11814410-b2

Patent

us-11696958-b2

· 2023

Full title: us-11696958-b2

Patent

us-11702473-b2

· 2023

Full title: us-11702473-b2

Patent

us-11786605-b2

· 2023

Full title: us-11786605-b2

Patent

us-11833214-b2

· 2023

Full title: us-11833214-b2

Patent

us-11753431-b2

· 2023

Full title: us-11753431-b2

Patent

us-11752215-b2

· 2023

Full title: us-11752215-b2

Patent

us-11786606-b2

· 2023

Full title: us-11786606-b2

Patent

us-11884746-b2

· 2024

Full title: us-11884746-b2

Patent

us-11857565-b2

· 2024

Full title: us-11857565-b2

Patent

us-11964025-b2

· 2024

Full title: us-11964025-b2

Patent

us-11918656-b2

· 2024

Full title: us-11918656-b2

Patent

us-11827686-b2

· 2023

Full title: us-11827686-b2

Patent

us-11951175-b2

· 2024

Full title: us-11951175-b2

Patent

us-11945807-b2

· 2024

Full title: us-11945807-b2

Patent

us-11951173-b2

· 2024

Full title: us-11951173-b2

Patent

us-12187745-b2

· 2025

Full title: us-12187745-b2

Patent

us-11987622-b2

· 2024

Full title: us-11987622-b2

Patent

us-12049505-b2

· 2024

Full title: us-12049505-b2

Patent

us-12018081-b1

· 2024

Full title: us-12018081-b1

Patent

us-12090210-b2

· 2024

Full title: us-12090210-b2

Patent

us-12036286-b2

· 2024

Full title: us-12036286-b2

Patent

us-12172986-b2

· 2024

Full title: us-12172986-b2

Patent

us-12090211-b2

· 2024

Full title: us-12090211-b2

Patent

us-12144864-b2

· 2024

Full title: us-12144864-b2

Patent

us-11980668-b2

· 2024

Full title: us-11980668-b2

Patent

us-12115227-b2

· 2024

Full title: us-12115227-b2

Patent

us-12115226-b2

· 2024

Full title: us-12115226-b2

Patent

us-12162942-b2

· 2024

Full title: us-12162942-b2

Patent

us-12195552-b2

· 2025

Full title: us-12195552-b2

Patent

us-12180552-b2

· 2024

Full title: us-12180552-b2

Patent

us-12178881-b2

· 2024

Full title: us-12178881-b2

Patent

us-12357701-b2

· 2025

Full title: us-12357701-b2

Patent

us-12280120-b2

· 2025

Full title: us-12280120-b2

Patent

us-12257340-b2

· 2025

Full title: us-12257340-b2

Patent

us-12269793-b2

· 2025

Full title: us-12269793-b2

Patent

us-12220604-b2

· 2025

Full title: us-12220604-b2

Patent

us-12187810-b2

· 2025

Full title: us-12187810-b2

Patent

us-12281174-b2

· 2025

Full title: us-12281174-b2

Patent

us-12214049-b2

· 2025

Full title: us-12214049-b2

Patent

us-12350345-b2

· 2025

Full title: us-12350345-b2

Patent

us-12268752-b2

· 2025

Full title: us-12268752-b2

Patent

us-12345711-b2

· 2025

Full title: us-12345711-b2

Patent

us-12358999-b2

· 2025

Full title: us-12358999-b2

Patent

us-12377143-b2

· 2025

Full title: us-12377143-b2

Patent

us-12428450-b2

· 2025

Full title: us-12428450-b2

Patent

us-12324841-b2

· 2025

Full title: us-12324841-b2

Patent

us-12440573-b2

· 2025

Full title: us-12440573-b2

Patent

us-12428494-b2

· 2025

Full title: us-12428494-b2

Patent

us-2003035804-a1

· 2003

Full title: us-2003035804-a1

Patent

us-12358998-b2

· 2025

Full title: us-12358998-b2

Patent

us-2003130189-a1

· 2003

Full title: us-2003130189-a1

Patent

us-12390471-b2

· 2025

Full title: us-12390471-b2

Patent

us-2004006049-a1

· 2004

Full title: us-2004006049-a1

Patent

us-12440570-b2

· 2025

Full title: us-12440570-b2

Patent

us-2003216298-a1

· 2003

Full title: us-2003216298-a1

Patent

us-2003096743-a1

· 2003

Full title: us-2003096743-a1

Patent

us-2005233948-a1

· 2005

Full title: us-2005233948-a1

Patent

us-2004192900-a1

· 2004

Full title: us-2004192900-a1

Patent

us-2003199519-a1

· 2003

Full title: us-2003199519-a1

Patent

us-2004109867-a1

· 2004

Full title: us-2004109867-a1

Patent

us-2005202561-a1

· 2005

Full title: us-2005202561-a1

Patent

us-2005069551-a1

· 2005

Full title: us-2005069551-a1

Patent

us-2005214310-a1

· 2005

Full title: us-2005214310-a1

Patent

us-2005054607-a1

· 2005

Full title: us-2005054607-a1

Patent

us-2008248052-a1

· 2008

Full title: us-2008248052-a1

Patent

us-2005255042-a1

· 2005

Full title: us-2005255042-a1

Patent

us-2005233943-a1

· 2005

Full title: us-2005233943-a1

Patent

us-2006009462-a1

· 2006

Full title: us-2006009462-a1

Patent

us-2006002942-a1

· 2006

Full title: us-2006002942-a1

Patent

us-2007135346-a1

· 2007

Full title: us-2007135346-a1

Patent

us-2004082764-a1

· 2004

Full title: us-2004082764-a1

Patent

us-2008267865-a1

· 2008

Full title: us-2008267865-a1

Patent

us-5338542-a

· 1994

Full title: us-5338542-a

Patent

us-5416064-a

· 1995

Full title: us-5416064-a

Patent

us-4880935-a

· 1989

Full title: us-4880935-a

Patent

us-5144012-a

· 1992

Full title: us-5144012-a

Patent

us-2025325690-a1

· 2025

Full title: us-2025325690-a1

Patent

us-5252713-a

· 1993

Full title: us-5252713-a

Patent

us-2025296912-a1

· 2025

Full title: us-2025296912-a1

Patent

us-5017693-a

· 1991

Full title: us-5017693-a

Patent

us-5141648-a

· 1992

Full title: us-5141648-a

Patent

us-5643573-a

· 1997

Full title: us-5643573-a

Patent

us-5306809-a

· 1994

Full title: us-5306809-a

Patent

us-5475092-a

· 1995

Full title: us-5475092-a

Patent

us-5563250-a

· 1996

Full title: us-5563250-a

Patent

us-5208020-a

· 1993

Full title: us-5208020-a

Patent

us-5665358-a

· 1997

Full title: us-5665358-a

Patent

us-5585499-a

· 1996

Full title: us-5585499-a

Patent

us-6441163-b1

· 2002

Full title: us-6441163-b1

Patent

us-5556623-a

· 1996

Full title: us-5556623-a

Patent

us-6368598-b1

· 2002

Full title: us-6368598-b1

Patent

us-5716990-a

· 1998

Full title: us-5716990-a

Patent

us-6552007-b2

· 2003

Full title: us-6552007-b2

Patent

us-7049316-b2

· 2006

Full title: us-7049316-b2

Patent

us-6756397-b2

· 2004

Full title: us-6756397-b2

Patent

us-7388026-b2

· 2008

Full title: us-7388026-b2

Patent

us-7091186-b2

· 2006

Full title: us-7091186-b2

Patent

us-7252993-b2

· 2007

Full title: us-7252993-b2

Patent

us-7135547-b2

· 2006

Full title: us-7135547-b2

Patent

us-6649587-b1

· 2003

Full title: us-6649587-b1

Patent

us-7232805-b2

· 2007

Full title: us-7232805-b2

Patent

us-7279502-b2

· 2007

Full title: us-7279502-b2

Patent

us-6759509-b1

· 2004

Full title: us-6759509-b1

Patent

us-7745394-b2

· 2010

Full title: us-7745394-b2

Patent

us-7553816-b2

· 2009

Full title: us-7553816-b2

Patent

us-7718601-b2

· 2010

Full title: us-7718601-b2

Patent

us-7655661-b2

· 2010

Full title: us-7655661-b2

Patent

us-7964567-b2

· 2011

Full title: us-7964567-b2

Patent

us-7638127-b2

· 2009

Full title: us-7638127-b2

Patent

us-7655660-b2

· 2010

Full title: us-7655660-b2

Patent

us-8313731-b2

· 2012

Full title: us-8313731-b2

Patent

us-8273787-b2

· 2012

Full title: us-8273787-b2

Patent

us-7964566-b2

· 2011

Full title: us-7964566-b2

Patent

us-7829531-b2

· 2010

Full title: us-7829531-b2

Patent

us-7906545-b2

· 2011

Full title: us-7906545-b2

Patent

us-7981400-b2

· 2011

Full title: us-7981400-b2

Patent

us-8557780-b2

· 2013

Full title: us-8557780-b2

Patent

us-8722629-b2

· 2014

Full title: us-8722629-b2

Patent

us-7994135-b2

· 2011

Full title: us-7994135-b2

Patent

us-8465724-b2

· 2013

Full title: us-8465724-b2

Patent

us-8153768-b2

· 2012

Full title: us-8153768-b2

Patent

us-8314060-b2

· 2012

Full title: us-8314060-b2

Patent

us-8703714-b2

· 2014

Full title: us-8703714-b2

Patent

us-8895702-b2

· 2014

Full title: us-8895702-b2

Patent

us-8835611-b2

· 2014

Full title: us-8835611-b2

Patent

us-8808679-b2

· 2014

Full title: us-8808679-b2

Patent

us-9242012-b2

· 2016

Full title: us-9242012-b2

Patent

us-8747857-b2

· 2014

Full title: us-8747857-b2

Patent

us-9351986-b2

· 2016

Full title: us-9351986-b2

Patent

us-9044468-b2

· 2015

Full title: us-9044468-b2

Patent

us-9408923-b2

· 2016

Full title: us-9408923-b2

Patent

us-8795673-b2

· 2014

Full title: us-8795673-b2

Patent

us-9089614-b2

· 2015

Full title: us-9089614-b2

Patent

us-9150649-b2

· 2015

Full title: us-9150649-b2

Patent

us-9375488-b2

· 2016

Full title: us-9375488-b2

Patent

us-9254339-b2

· 2016

Full title: us-9254339-b2

Patent

us-9428543-b2

· 2016

Full title: us-9428543-b2

Patent

us-9193791-b2

· 2015

Full title: us-9193791-b2

Patent

us-9522194-b2

· 2016

Full title: us-9522194-b2

Patent

us-9617326-b2

· 2017

Full title: us-9617326-b2

Patent

us-9579317-b2

· 2017

Full title: us-9579317-b2

Patent

us-9669106-b2

· 2017

Full title: us-9669106-b2

Patent

us-2018133340-a1

· 2018

Full title: us-2018133340-a1

Patent

us-2018125972-a1

· 2018

Full title: us-2018125972-a1

Patent

us-2018125988-a1

· 2018

Full title: us-2018125988-a1

Patent

us-2018085478-a1

· 2018

Full title: us-2018085478-a1

Patent

us-2018147295-a1

· 2018

Full title: us-2018147295-a1

Patent

us-2018228915-a1

· 2018

Full title: us-2018228915-a1

Patent

us-2018169262-a1

· 2018

Full title: us-2018169262-a1

Patent

us-2018193478-a1

· 2018

Full title: us-2018193478-a1

Patent

us-2018228769-a1

· 2018

Full title: us-2018228769-a1

Patent

us-2018177889-a1

· 2018

Full title: us-2018177889-a1

Patent

us-2018273581-a1

· 2018

Full title: us-2018273581-a1

Patent

us-2018243428-a1

· 2018

Full title: us-2018243428-a1

Patent

us-2018355025-a1

· 2018

Full title: us-2018355025-a1

Patent

us-2018326062-a1

· 2018

Full title: us-2018326062-a1

Patent

us-2018264131-a1

· 2018

Full title: us-2018264131-a1

Patent

us-2018296694-a1

· 2018

Full title: us-2018296694-a1

Patent

us-2018311375-a1

· 2018

Full title: us-2018311375-a1

Patent

us-2018339058-a1

· 2018

Full title: us-2018339058-a1

Patent

us-2018344864-a1

· 2018

Full title: us-2018344864-a1

Patent

us-2018362519-a1

· 2018

Full title: us-2018362519-a1

Patent

us-2019054102-a1

· 2019

Full title: us-2019054102-a1

Patent

us-2019135864-a1

· 2019

Full title: us-2019135864-a1

Patent

us-2019015519-a1

· 2019

Full title: us-2019015519-a1

Patent

us-2019030180-a1

· 2019

Full title: us-2019030180-a1

Patent

us-2019184029-a1

· 2019

Full title: us-2019184029-a1

Patent

us-2019144559-a1

· 2019

Full title: us-2019144559-a1

Patent

us-2019055321-a1

· 2019

Full title: us-2019055321-a1

Patent

us-2019134213-a1

· 2019

Full title: us-2019134213-a1

Patent

us-2019083637-a1

· 2019

Full title: us-2019083637-a1

Patent

us-2019030179-a1

· 2019

Full title: us-2019030179-a1

Patent

us-2019201544-a1

· 2019

Full title: us-2019201544-a1

Patent

us-2019248887-a1

· 2019

Full title: us-2019248887-a1

Patent

us-2019077752-a1

· 2019

Full title: us-2019077752-a1

Patent

us-2019151464-a1

· 2019

Full title: us-2019151464-a1

Patent

us-2019194315-a1

· 2019

Full title: us-2019194315-a1

Patent

us-2019262467-a1

· 2019

Full title: us-2019262467-a1

Patent

us-2019151462-a1

· 2019

Full title: us-2019151462-a1

Patent

us-2019209704-a1

· 2019

Full title: us-2019209704-a1

Patent

us-2019270828-a1

· 2019

Full title: us-2019270828-a1

Patent

us-2019241652-a9

· 2019

Full title: us-2019241652-a9

Patent

us-2019321482-a1

· 2019

Full title: us-2019321482-a1

Patent

us-2019269788-a1

· 2019

Full title: us-2019269788-a1

Patent

us-2019284283-a1

· 2019

Full title: us-2019284283-a1

Patent

us-2019262417-a1

· 2019

Full title: us-2019262417-a1

Patent

us-2019328895-a1

· 2019

Full title: us-2019328895-a1

Patent

us-2019203192-a1

· 2019

Full title: us-2019203192-a1

Patent

us-2019381183-a1

· 2019

Full title: us-2019381183-a1

Patent

us-2019365914-a1

· 2019

Full title: us-2019365914-a1

Patent

us-2019375837-a1

· 2019

Full title: us-2019375837-a1

Patent

us-2019367999-a1

· 2019

Full title: us-2019367999-a1

Patent

us-2019358202-a1

· 2019

Full title: us-2019358202-a1

Patent

us-2019368000-a1

· 2019

Full title: us-2019368000-a1

Patent

us-2019358340-a1

· 2019

Full title: us-2019358340-a1

Patent

us-2019328899-a1

· 2019

Full title: us-2019328899-a1

Patent

us-2019388555-a1

· 2019

Full title: us-2019388555-a1

Patent

us-2019388553-a1

· 2019

Full title: us-2019388553-a1

Patent

us-2019382441-a1

· 2019

Full title: us-2019382441-a1

Patent

us-2019338045-a1

· 2019

Full title: us-2019338045-a1

Patent

us-2020016276-a1

· 2020

Full title: us-2020016276-a1

Patent

us-2020054764-a1

· 2020

Full title: us-2020054764-a1

Patent

us-2020003778-a1

· 2020

Full title: us-2020003778-a1

Patent

us-2020108152-a1

· 2020

Full title: us-2020108152-a1

Patent

us-2020129639-a1

· 2020

Full title: us-2020129639-a1

Patent

us-2019381185-a1

· 2019

Full title: us-2019381185-a1

Patent

us-2020116727-a1

· 2020

Full title: us-2020116727-a1

Patent

us-2020069814-a1

· 2020

Full title: us-2020069814-a1

Patent

us-2020254111-a1

· 2020

Full title: us-2020254111-a1

Patent

us-2020255543-a1

· 2020

Full title: us-2020255543-a1

Patent

us-2020069815-a1

· 2020

Full title: us-2020069815-a1

Patent

us-2020147231-a1

· 2020

Full title: us-2020147231-a1

Patent

us-2020157240-a1

· 2020

Full title: us-2020157240-a1

Patent

us-2020270352-a1

· 2020

Full title: us-2020270352-a1

Patent

us-2020276331-a1

· 2020

Full title: us-2020276331-a1

Patent

us-2020172484-a1

· 2020

Full title: us-2020172484-a1

Patent

us-2020330604-a1

· 2020

Full title: us-2020330604-a1

Patent

us-2020338206-a1

· 2020

Full title: us-2020338206-a1

Patent

us-2020282072-a1

· 2020

Full title: us-2020282072-a1

Patent

us-2007160573-a1

· 2007

Full title: us-2007160573-a1

Patent

us-2006008475-a1

· 2006

Full title: us-2006008475-a1

Patent

us-2008260685-a1

· 2008

Full title: us-2008260685-a1

Patent

us-2007160617-a1

· 2007

Full title: us-2007160617-a1

Patent

us-2009155289-a1

· 2009

Full title: us-2009155289-a1

Patent

us-2009275664-a1

· 2009

Full title: us-2009275664-a1

Patent

us-2009105461-a1

· 2009

Full title: us-2009105461-a1

Patent

us-2010129314-a1

· 2010

Full title: us-2010129314-a1

Patent

us-2009281158-a1

· 2009

Full title: us-2009281158-a1

Patent

us-2009220529-a1

· 2009

Full title: us-2009220529-a1

Patent

us-2010168019-a1

· 2010

Full title: us-2010168019-a1

Patent

us-2010215670-a1

· 2010

Full title: us-2010215670-a1

Patent

us-2010329992-a1

· 2010

Full title: us-2010329992-a1

Patent

us-2011178279-a1

· 2011

Full title: us-2011178279-a1

Patent

us-2010022615-a1

· 2010

Full title: us-2010022615-a1

Patent

us-2011229476-a1

· 2011

Full title: us-2011229476-a1

Patent

us-2011250216-a1

· 2011

Full title: us-2011250216-a1

Patent

us-2011243914-a1

· 2011

Full title: us-2011243914-a1

Patent

us-2011008373-a1

· 2011

Full title: us-2011008373-a1

Patent

us-2011064657-a1

· 2011

Full title: us-2011064657-a1

Patent

us-2011152252-a1

· 2011

Full title: us-2011152252-a1

Patent

us-2012121615-a1

· 2012

Full title: us-2012121615-a1

Patent

us-2011160147-a1

· 2011

Full title: us-2011160147-a1

Patent

us-2012226026-a1

· 2012

Full title: us-2012226026-a1

Patent

us-2012253021-a1

· 2012

Full title: us-2012253021-a1

Patent

us-2013060010-a1

· 2013

Full title: us-2013060010-a1

Patent

us-2012213804-a1

· 2012

Full title: us-2012213804-a1

Patent

us-2014004081-a1

· 2014

Full title: us-2014004081-a1

Patent

us-2013150558-a1

· 2013

Full title: us-2013150558-a1

Patent

us-2013184435-a1

· 2013

Full title: us-2013184435-a1

Patent

us-2013309192-a1

· 2013

Full title: us-2013309192-a1

Patent

us-2014235835-a1

· 2014

Full title: us-2014235835-a1

Patent

us-2014058064-a1

· 2014

Full title: us-2014058064-a1

Patent

us-2014193437-a1

· 2014

Full title: us-2014193437-a1

Patent

us-2014309406-a1

· 2014

Full title: us-2014309406-a1

Patent

us-2015044238-a1

· 2015

Full title: us-2015044238-a1

Patent

us-2014322234-a1

· 2014

Full title: us-2014322234-a1

Patent

us-2014286968-a1

· 2014

Full title: us-2014286968-a1

Patent

us-2015064130-a1

· 2015

Full title: us-2015064130-a1

Patent

us-2015218217-a1

· 2015

Full title: us-2015218217-a1

Patent

us-2015105540-a1

· 2015

Full title: us-2015105540-a1

Patent

us-2015165067-a1

· 2015

Full title: us-2015165067-a1

Patent

us-2015079114-a1

· 2015

Full title: us-2015079114-a1

Patent

us-2015140022-a1

· 2015

Full title: us-2015140022-a1

Patent

us-2024148883-a1

· 2024

Full title: us-2024148883-a1

Patent

us-2024156976-a1

· 2024

Full title: us-2024156976-a1

Patent

us-2024131176-a1

· 2024

Full title: us-2024131176-a1

Patent

us-2024132595-a1

· 2024

Full title: us-2024132595-a1

Patent

us-2024150478-a1

· 2024

Full title: us-2024150478-a1

Patent

us-2024131180-a1

· 2024

Full title: us-2024131180-a1

Patent

us-2024182537-a1

· 2024

Full title: us-2024182537-a1

Patent

us-2024156978-a1

· 2024

Full title: us-2024156978-a1

Patent

us-2024197907-a1

· 2024

Full title: us-2024197907-a1

Patent

us-2024165251-a1

· 2024

Full title: us-2024165251-a1

Patent

us-2024216521-a1

· 2024

Full title: us-2024216521-a1

Patent

us-2024216420-a1

· 2024

Full title: us-2024216420-a1

Patent

us-2024238431-a1

· 2024

Full title: us-2024238431-a1

Patent

us-2024293569-a1

· 2024

Full title: us-2024293569-a1

Patent

us-2024207427-a1

· 2024

Full title: us-2024207427-a1

Patent

us-2024218037-a1

· 2024

Full title: us-2024218037-a1

Patent

us-2024245801-a1

· 2024

Full title: us-2024245801-a1

Patent

us-2024197900-a1

· 2024

Full title: us-2024197900-a1

Patent

us-2024269305-a1

· 2024

Full title: us-2024269305-a1

Patent

us-2024335557-a1

· 2024

Full title: us-2024335557-a1

Patent

us-2024293570-a1

· 2024

Full title: us-2024293570-a1

Patent

us-2024261424-a1

· 2024

Full title: us-2024261424-a1

Patent

us-2024238440-a1

· 2024

Full title: us-2024238440-a1

Patent

us-2024342303-a1

· 2024

Full title: us-2024342303-a1

Patent

us-2024335570-a1

· 2024

Full title: us-2024335570-a1

Patent

us-2024335552-a1

· 2024

Full title: us-2024335552-a1

Patent

us-2024327538-a1

· 2024

Full title: us-2024327538-a1

Patent

us-2024366779-a1

· 2024

Full title: us-2024366779-a1

Patent

us-2024382611-a1

· 2024

Full title: us-2024382611-a1

Patent

us-2024360108-a1

· 2024

Full title: us-2024360108-a1

Patent

us-2024342304-a1

· 2024

Full title: us-2024342304-a1

Patent

us-2024400696-a1

· 2024

Full title: us-2024400696-a1

Patent

us-2024398971-a1

· 2024

Full title: us-2024398971-a1

Patent

us-2024400614-a1

· 2024

Full title: us-2024400614-a1

Patent

us-2025018052-a1

· 2025

Full title: us-2025018052-a1

Patent

us-2024398972-a1

· 2024

Full title: us-2024398972-a1

Patent

us-2024417437-a1

· 2024

Full title: us-2024417437-a1

Patent

us-2024423973-a1

· 2024

Full title: us-2024423973-a1

Patent

us-2025018051-a1

· 2025

Full title: us-2025018051-a1

Patent

us-2025064966-a1

· 2025

Full title: us-2025064966-a1

Patent

us-2025049938-a1

· 2025

Full title: us-2025049938-a1

Patent

us-2025049937-a1

· 2025

Full title: us-2025049937-a1

Patent

us-2025064953-a1

· 2025

Full title: us-2025064953-a1

Patent

us-2025082768-a1

· 2025

Full title: us-2025082768-a1

Patent

us-2025011470-a1

· 2025

Full title: us-2025011470-a1

Patent

us-2025059296-a1

· 2025

Full title: us-2025059296-a1

Patent

us-2025064965-a1

· 2025

Full title: us-2025064965-a1

Patent

us-2025115677-a1

· 2025

Full title: us-2025115677-a1

Patent

us-2025135017-a1

· 2025

Full title: us-2025135017-a1

Patent

us-2025195680-a1

· 2025

Full title: us-2025195680-a1

Patent

us-2025090875-a9

· 2025

Full title: us-2025090875-a9

Patent

us-2025108123-a1

· 2025

Full title: us-2025108123-a1

Patent

us-2025115679-a1

· 2025

Full title: us-2025115679-a1

Patent

us-2025121075-a1

· 2025

Full title: us-2025121075-a1

Patent

us-2025145731-a1

· 2025

Full title: us-2025145731-a1

Patent

us-2025161506-a1

· 2025

Full title: us-2025161506-a1

Patent

us-2025152723-a1

· 2025

Full title: us-2025152723-a1

Patent

us-2025188172-a1

· 2025

Full title: us-2025188172-a1

Patent

us-2025179117-a1

· 2025

Full title: us-2025179117-a1

Patent

us-2025195675-a1

· 2025

Full title: us-2025195675-a1

Patent

us-2025213712-a1

· 2025

Full title: us-2025213712-a1

Patent

us-2025195683-a1

· 2025

Full title: us-2025195683-a1

Patent

us-2025222128-a1

· 2025

Full title: us-2025222128-a1

Patent

us-2025136717-a1

· 2025

Full title: us-2025136717-a1

Patent

us-2025188184-a1

· 2025

Full title: us-2025188184-a1

Patent

us-2025257146-a1

· 2025

Full title: us-2025257146-a1

Patent

us-2025262312-a1

· 2025

Full title: us-2025262312-a1

Patent

us-2025205349-a1

· 2025

Full title: us-2025205349-a1

Patent

us-2025235547-a1

· 2025

Full title: us-2025235547-a1

Patent

us-2025249111-a1

· 2025

Full title: us-2025249111-a1

Patent

us-2025223302-a1

· 2025

Full title: us-2025223302-a1

Patent

us-2025242044-a1

· 2025

Full title: us-2025242044-a1

Patent

us-2025249113-a1

· 2025

Full title: us-2025249113-a1

Patent

us-2025249112-a1

· 2025

Full title: us-2025249112-a1

Patent

us-2025262307-a1

· 2025

Full title: us-2025262307-a1

Patent

us-2025276075-a1

· 2025

Full title: us-2025276075-a1

Patent

us-2025277060-a1

· 2025

Full title: us-2025277060-a1

Patent

us-2025270314-a1

· 2025

Full title: us-2025270314-a1

Patent

us-2025276077-a1

· 2025

Full title: us-2025276077-a1

Patent

us-5094849-a

· 1992

Full title: us-5094849-a

Patent

us-2020291135-a1

· 2020

Full title: us-2020291135-a1

Patent

us-2020164077-a1

· 2020

Full title: us-2020164077-a1

Patent

us-2020353032-a1

· 2020

Full title: us-2020353032-a1

Patent

us-2020347149-a1

· 2020

Full title: us-2020347149-a1

Patent

us-2020297865-a1

· 2020

Full title: us-2020297865-a1

Patent

us-2020297859-a1

· 2020

Full title: us-2020297859-a1

Patent

us-2020377602-a1

· 2020

Full title: us-2020377602-a1

Patent

us-2020297860-a1

· 2020

Full title: us-2020297860-a1

Patent

us-2020361988-a1

· 2020

Full title: us-2020361988-a1

Patent

us-2020306243-a1

· 2020

Full title: us-2020306243-a1

Patent

us-2021030889-a1

· 2021

Full title: us-2021030889-a1

Patent

us-2021017274-a1

· 2021

Full title: us-2021017274-a1

Patent

us-2020405874-a1

· 2020

Full title: us-2020405874-a1

Patent

us-2021008099-a1

· 2021

Full title: us-2021008099-a1

Patent

us-2020407457-a1

· 2020

Full title: us-2020407457-a1

Patent

us-2021101888-a1

· 2021

Full title: us-2021101888-a1

Patent

us-2021002343-a1

· 2021

Full title: us-2021002343-a1

Patent

us-2020399365-a1

· 2020

Full title: us-2020399365-a1

Patent

us-2020392108-a1

· 2020

Full title: us-2020392108-a1

Patent

us-2021138077-a1

· 2021

Full title: us-2021138077-a1

Patent

us-2021038738-a1

· 2021

Full title: us-2021038738-a1

Patent

us-2021205464-a1

· 2021

Full title: us-2021205464-a1

Patent

us-2021177985-a1

· 2021

Full title: us-2021177985-a1

Patent

us-2021030887-a1

· 2021

Full title: us-2021030887-a1

Patent

us-2021113710-a1

· 2021

Full title: us-2021113710-a1

Patent

us-2021113707-a1

· 2021

Full title: us-2021113707-a1

Patent

us-2021023094-a1

· 2021

Full title: us-2021023094-a1

Patent

us-2021154321-a1

· 2021

Full title: us-2021154321-a1

Patent

us-2021138083-a1

· 2021

Full title: us-2021138083-a1

Patent

us-2021260208-a1

· 2021

Full title: us-2021260208-a1

Patent

us-2021139549-a1

· 2021

Full title: us-2021139549-a1

Patent

us-2021238303-a1

· 2021

Full title: us-2021238303-a1

Patent

us-2021205463-a1

· 2021

Full title: us-2021205463-a1

Patent

us-2021155583-a1

· 2021

Full title: us-2021155583-a1

Patent

us-2021220477-a1

· 2021

Full title: us-2021220477-a1

Patent

us-2021283269-a1

· 2021

Full title: us-2021283269-a1

Patent

us-2021162058-a1

· 2021

Full title: us-2021162058-a1

Patent

us-2021290775-a1

· 2021

Full title: us-2021290775-a1

Patent

us-2021252160-a1

· 2021

Full title: us-2021252160-a1

Patent

us-2021299269-a1

· 2021

Full title: us-2021299269-a1

Patent

us-2021261505-a1

· 2021

Full title: us-2021261505-a1

Patent

us-2021228728-a1

· 2021

Full title: us-2021228728-a1

Patent

us-2021299270-a1

· 2021

Full title: us-2021299270-a1

Patent

us-2021290777-a1

· 2021

Full title: us-2021290777-a1

Patent

us-2021322401-a1

· 2021

Full title: us-2021322401-a1

Patent

us-2021300972-a1

· 2021

Full title: us-2021300972-a1

Patent

us-2021330802-a1

· 2021

Full title: us-2021330802-a1

Patent

us-2021324031-a1

· 2021

Full title: us-2021324031-a1

Patent

us-2021301015-a1

· 2021

Full title: us-2021301015-a1

Patent

us-2021347886-a1

· 2021

Full title: us-2021347886-a1

Patent

us-2021346510-a1

· 2021

Full title: us-2021346510-a1

Patent

us-2021355208-a1

· 2021

Full title: us-2021355208-a1

Patent

us-2021393789-a1

· 2021

Full title: us-2021393789-a1

Patent

us-2021386867-a1

· 2021

Full title: us-2021386867-a1

Patent

us-2021388017-a1

· 2021

Full title: us-2021388017-a1

Patent

us-2021369855-a1

· 2021

Full title: us-2021369855-a1

Patent

us-2022031859-a1

· 2022

Full title: us-2022031859-a1

Patent

us-2022031858-a1

· 2022

Full title: us-2022031858-a1

Patent

us-2021388115-a1

· 2021

Full title: us-2021388115-a1

Patent

us-2021393795-a1

· 2021

Full title: us-2021393795-a1

Patent

us-2021393790-a1

· 2021

Full title: us-2021393790-a1

Patent

us-2021393792-a1

· 2021

Full title: us-2021393792-a1

Patent

us-2022040321-a1

· 2022

Full title: us-2022040321-a1

Patent

us-2022040320-a1

· 2022

Full title: us-2022040320-a1

Patent

us-2022105195-a1

· 2022

Full title: us-2022105195-a1

Patent

us-2022023433-a1

· 2022

Full title: us-2022023433-a1

Patent

us-2022088191-a1

· 2022

Full title: us-2022088191-a1

Patent

us-2022073637-a1

· 2022

Full title: us-2022073637-a1

Patent

us-2022072137-a1

· 2022

Full title: us-2022072137-a1

Patent

us-2022062436-a1

· 2022

Full title: us-2022062436-a1

Patent

us-2022096652-a1

· 2022

Full title: us-2022096652-a1

Patent

us-2022119549-a1

· 2022

Full title: us-2022119549-a1

Patent

us-2022054649-a1

· 2022

Full title: us-2022054649-a1

Patent

us-2022111067-a1

· 2022

Full title: us-2022111067-a1

Patent

us-2022105197-a1

· 2022

Full title: us-2022105197-a1

Patent

us-2022133899-a1

· 2022

Full title: us-2022133899-a1

Patent

us-2022153869-a1

· 2022

Full title: us-2022153869-a1

Patent

us-2022175950-a1

· 2022

Full title: us-2022175950-a1

Patent

us-2022118104-a1

· 2022

Full title: us-2022118104-a1

Patent

us-2022143196-a1

· 2022

Full title: us-2022143196-a1

Patent

us-2022241423-a1

· 2022

Full title: us-2022241423-a1

Patent

us-2022218837-a1

· 2022

Full title: us-2022218837-a1

Patent

us-2021346508-a1

· 2021

Full title: us-2021346508-a1

Patent

us-2022226490-a1

· 2022

Full title: us-2022226490-a1

Patent

us-2022168436-a1

· 2022

Full title: us-2022168436-a1

Patent

us-2015087810-a1

· 2015

Full title: us-2015087810-a1

Patent

us-2015359903-a1

· 2015

Full title: us-2015359903-a1

Patent

us-2015352222-a1

· 2015

Full title: us-2015352222-a1

Patent

us-2016045616-a1

· 2016

Full title: us-2016045616-a1

Patent

us-2015343083-a1

· 2015

Full title: us-2015343083-a1

Patent

us-2016015830-a1

· 2016

Full title: us-2016015830-a1

Patent

us-2015307587-a1

· 2015

Full title: us-2015307587-a1

Patent

us-2015297748-a1

· 2015

Full title: us-2015297748-a1

Patent

us-2016114052-a1

· 2016

Full title: us-2016114052-a1

Patent

us-2016129128-a1

· 2016

Full title: us-2016129128-a1

Patent

us-2016144042-a1

· 2016

Full title: us-2016144042-a1

Patent

us-2016022829-a1

· 2016

Full title: us-2016022829-a1

Patent

us-2016106856-a1

· 2016

Full title: us-2016106856-a1

Patent

us-2016015832-a1

· 2016

Full title: us-2016015832-a1

Patent

us-2016130359-a1

· 2016

Full title: us-2016130359-a1

Patent

us-2016152711-a1

· 2016

Full title: us-2016152711-a1

Patent

us-2016051695-a1

· 2016

Full title: us-2016051695-a1

Patent

us-2016263244-a1

· 2016

Full title: us-2016263244-a1

Patent

us-2016220696-a1

· 2016

Full title: us-2016220696-a1

Patent

us-2016185875-a1

· 2016

Full title: us-2016185875-a1

Patent

us-2016289324-a1

· 2016

Full title: us-2016289324-a1

Patent

us-2016297890-a1

· 2016

Full title: us-2016297890-a1

Patent

us-2017035892-a1

· 2017

Full title: us-2017035892-a1

Patent

us-2016311853-a1

· 2016

Full title: us-2016311853-a1

Patent

us-2016303252-a1

· 2016

Full title: us-2016303252-a1

Patent

us-2017035894-a1

· 2017

Full title: us-2017035894-a1

Patent

us-2017037080-a1

· 2017

Full title: us-2017037080-a1

Patent

us-2017028080-a1

· 2017

Full title: us-2017028080-a1

Patent

us-2017043032-a1

· 2017

Full title: us-2017043032-a1

Patent

us-2017080102-a1

· 2017

Full title: us-2017080102-a1

Patent

us-2017043033-a1

· 2017

Full title: us-2017043033-a1

Patent

us-2017043031-a1

· 2017

Full title: us-2017043031-a1

Patent

us-2017182181-a1

· 2017

Full title: us-2017182181-a1

Patent

us-2017080103-a1

· 2017

Full title: us-2017080103-a1

Patent

us-2017119902-a1

· 2017

Full title: us-2017119902-a1

Patent

us-2017088621-a1

· 2017

Full title: us-2017088621-a1

Patent

us-2017088614-a1

· 2017

Full title: us-2017088614-a1

Patent

us-2017218074-a1

· 2017

Full title: us-2017218074-a1

Patent

us-2017112943-a1

· 2017

Full title: us-2017112943-a1

Patent

us-2017252458-a1

· 2017

Full title: us-2017252458-a1

Patent

us-2017232023-a1

· 2017

Full title: us-2017232023-a1

Patent

us-2017204139-a1

· 2017

Full title: us-2017204139-a1

Patent

us-2017210825-a1

· 2017

Full title: us-2017210825-a1

Patent

us-2017267727-a1

· 2017

Full title: us-2017267727-a1

Patent

us-2017319709-a1

· 2017

Full title: us-2017319709-a1

Patent

us-2017281787-a1

· 2017

Full title: us-2017281787-a1

Patent

us-2018055944-a1

· 2018

Full title: us-2018055944-a1

Patent

us-2017224835-a1

· 2017

Full title: us-2017224835-a1

Patent

us-2017326233-a1

· 2017

Full title: us-2017326233-a1

Patent

us-2018078654-a1

· 2018

Full title: us-2018078654-a1

Patent

us-2018028658-a1

· 2018

Full title: us-2018028658-a1

Patent

us-2017355750-a1

· 2017

Full title: us-2017355750-a1

Patent

us-2018125994-a1

· 2018

Full title: us-2018125994-a1

Patent

us-2018117172-a1

· 2018

Full title: us-2018117172-a1

Patent

us-2018078656-a1

· 2018

Full title: us-2018078656-a1

Patent

us-2022220222-a1

· 2022

Full title: us-2022220222-a1

Patent

us-2022211861-a1

· 2022

Full title: us-2022211861-a1

Patent

us-2022233708-a1

· 2022

Full title: us-2022233708-a1

Patent

us-2022249686-a1

· 2022

Full title: us-2022249686-a1

Patent

us-2022306716-a1

· 2022

Full title: us-2022306716-a1

Patent

us-2022257766-a1

· 2022

Full title: us-2022257766-a1

Patent

us-2022249594-a1

· 2022

Full title: us-2022249594-a1

Patent

us-2022211863-a1

· 2022

Full title: us-2022211863-a1

Patent

us-2022378929-a1

· 2022

Full title: us-2022378929-a1

Patent

us-2022281852-a1

· 2022

Full title: us-2022281852-a1

Patent

us-2022249681-a1

· 2022

Full title: us-2022249681-a1

Patent

us-2022265848-a1

· 2022

Full title: us-2022265848-a1

Patent

us-2022281936-a1

· 2022

Full title: us-2022281936-a1

Patent

us-2023001001-a1

· 2023

Full title: us-2023001001-a1

Patent

us-2022387615-a1

· 2022

Full title: us-2022387615-a1

Patent

us-2022362397-a1

· 2022

Full title: us-2022362397-a1

Patent

us-2022380453-a9

· 2022

Full title: us-2022380453-a9

Patent

us-2022372141-a1

· 2022

Full title: us-2022372141-a1

Patent

us-2022324975-a1

· 2022

Full title: us-2022324975-a1

Patent

us-2022380352-a1

· 2022

Full title: us-2022380352-a1

Patent

us-2023010108-a1

· 2023

Full title: us-2023010108-a1

Patent

us-2023025327-a1

· 2023

Full title: us-2023025327-a1

Patent

us-2022411470-a1

· 2022

Full title: us-2022411470-a1

Patent

us-2023013963-a1

· 2023

Full title: us-2023013963-a1

Patent

us-2023021500-a1

· 2023

Full title: us-2023021500-a1

Patent

us-2023022596-a1

· 2023

Full title: us-2023022596-a1

Patent

us-2023021301-a9

· 2023

Full title: us-2023021301-a9

Patent

us-2022401557-a1

· 2022

Full title: us-2022401557-a1

Patent

us-2023071763-a1

· 2023

Full title: us-2023071763-a1

Patent

us-2023061858-a1

· 2023

Full title: us-2023061858-a1

Patent

us-2023027495-a1

· 2023

Full title: us-2023027495-a1

Patent

us-2023057350-a1

· 2023

Full title: us-2023057350-a1

Patent

us-2023072822-a1

· 2023

Full title: us-2023072822-a1

Patent

us-2023035308-a1

· 2023

Full title: us-2023035308-a1

Patent

us-2023066474-a1

· 2023

Full title: us-2023066474-a1

Patent

us-2023146646-a1

· 2023

Full title: us-2023146646-a1

Patent

us-2023043447-a1

· 2023

Full title: us-2023043447-a1

Patent

us-2023091653-a1

· 2023

Full title: us-2023091653-a1

Patent

us-2023084099-a1

· 2023

Full title: us-2023084099-a1

Patent

us-2023085485-a1

· 2023

Full title: us-2023085485-a1

Patent

us-2023069722-a1

· 2023

Full title: us-2023069722-a1

Patent

us-2023071019-a1

· 2023

Full title: us-2023071019-a1

Patent

us-2023081720-a1

· 2023

Full title: us-2023081720-a1

Patent

us-2023158169-a1

· 2023

Full title: us-2023158169-a1

Patent

us-2023092679-a1

· 2023

Full title: us-2023092679-a1

Patent

us-2023212113-a1

· 2023

Full title: us-2023212113-a1

Patent

us-2023218778-a1

· 2023

Full title: us-2023218778-a1

Patent

us-2023109312-a1

· 2023

Full title: us-2023109312-a1

Patent

us-2023241072-a1

· 2023

Full title: us-2023241072-a1

Patent

us-2023277679-a1

· 2023

Full title: us-2023277679-a1

Patent

us-2023212181-a1

· 2023

Full title: us-2023212181-a1

Patent

us-2023277676-a1

· 2023

Full title: us-2023277676-a1

Patent

us-2023190939-a1

· 2023

Full title: us-2023190939-a1

Patent

us-2023241243-a1

· 2023

Full title: us-2023241243-a1

Patent

us-2023111996-a1

· 2023

Full title: us-2023111996-a1

Patent

us-2023212283-a1

· 2023

Full title: us-2023212283-a1

Patent

us-2023201366-a1

· 2023

Full title: us-2023201366-a1

Patent

us-2023256114-a1

· 2023

Full title: us-2023256114-a1

Patent

us-2023233700-a1

· 2023

Full title: us-2023233700-a1

Patent

us-2023310557-a1

· 2023

Full title: us-2023310557-a1

Patent

us-2023338572-a1

· 2023

Full title: us-2023338572-a1

Patent

us-2023279151-a1

· 2023

Full title: us-2023279151-a1

Patent

us-2023270874-a1

· 2023

Full title: us-2023270874-a1

Patent

us-2023372518-a1

· 2023

Full title: us-2023372518-a1

Patent

us-2023338570-a1

· 2023

Full title: us-2023338570-a1

Patent

us-2023277682-a1

· 2023

Full title: us-2023277682-a1

Patent

us-2023310629-a1

· 2023

Full title: us-2023310629-a1

Patent

us-2023321265-a1

· 2023

Full title: us-2023321265-a1

Patent

us-2023310624-a1

· 2023

Full title: us-2023310624-a1

Patent

us-2023406877-a1

· 2023

Full title: us-2023406877-a1

Patent

us-2023381330-a1

· 2023

Full title: us-2023381330-a1

Patent

us-2023390413-a1

· 2023

Full title: us-2023390413-a1

Patent

us-2023405129-a1

· 2023

Full title: us-2023405129-a1

Patent

us-2024082409-a1

· 2024

Full title: us-2024082409-a1

Patent

us-2024000960-a1

· 2024

Full title: us-2024000960-a1

Patent

us-2023414775-a1

· 2023

Full title: us-2023414775-a1

Patent

us-2023405141-a1

· 2023

Full title: us-2023405141-a1

Patent

us-2024058468-a1

· 2024

Full title: us-2024058468-a1

Patent

us-2023398228-a1

· 2023

Full title: us-2023398228-a1

Patent

us-2024075160-a1

· 2024

Full title: us-2024075160-a1

Patent

us-2024033372-a1

· 2024

Full title: us-2024033372-a1

Patent

us-2024026030-a1

· 2024

Full title: us-2024026030-a1

Patent

us-2024148887-a1

· 2024

Full title: us-2024148887-a1

Patent

us-2024009319-a1

· 2024

Full title: us-2024009319-a1

Patent

us-2024108744-a1

· 2024

Full title: us-2024108744-a1

Patent

us-2024084022-a1

· 2024

Full title: us-2024084022-a1

Patent

us-2024091375-a1

· 2024

Full title: us-2024091375-a1

Patent

us-2024150402-a1

· 2024

Full title: us-2024150402-a1

Patent

us-2024148895-a1

· 2024

Full title: us-2024148895-a1

Patent

us-9849192-b2

· 2017

Full title: us-9849192-b2

Patent

us-9562073-b2

· 2017

Full title: us-9562073-b2

Patent

us-9738726-b2

· 2017

Full title: us-9738726-b2

Patent

us-9914748-b2

· 2018

Full title: us-9914748-b2

Patent

us-9988420-b2

· 2018

Full title: us-9988420-b2

Patent

us-9884122-b2

· 2018

Full title: us-9884122-b2

Patent

us-9872904-b2

· 2018

Full title: us-9872904-b2

Patent

us-9624309-b2

· 2017

Full title: us-9624309-b2

Patent

us-9943609-b2

· 2018

Full title: us-9943609-b2

Patent

us-9943610-b2

· 2018

Full title: us-9943610-b2

Patent

us-9982018-b2

· 2018

Full title: us-9982018-b2

Patent

us-10058613-b2

· 2018

Full title: us-10058613-b2

Patent

us-10183997-b2

· 2019

Full title: us-10183997-b2

Patent

us-10118965-b2

· 2018

Full title: us-10118965-b2

Patent

us-10226535-b2

· 2019

Full title: us-10226535-b2

Patent

us-10039845-b2

· 2018

Full title: us-10039845-b2

Patent

us-10201615-b2

· 2019

Full title: us-10201615-b2

Patent

us-10138272-b2

· 2018

Full title: us-10138272-b2

Patent

us-10227417-b2

· 2019

Full title: us-10227417-b2

Patent

us-10280229-b2

· 2019

Full title: us-10280229-b2

Patent

us-10195289-b2

· 2019

Full title: us-10195289-b2

Patent

us-10149913-b2

· 2018

Full title: us-10149913-b2

Patent

us-10265413-b2

· 2019

Full title: us-10265413-b2

Patent

us-10392421-b2

· 2019

Full title: us-10392421-b2

Patent

us-10357571-b2

· 2019

Full title: us-10357571-b2

Patent

us-10307488-b2

· 2019

Full title: us-10307488-b2

Patent

us-10287321-b2

· 2019

Full title: us-10287321-b2

Patent

us-10376597-b2

· 2019

Full title: us-10376597-b2

Patent

us-10533058-b2

· 2020

Full title: us-10533058-b2

Patent

us-10544215-b2

· 2020

Full title: us-10544215-b2

Patent

us-11008398-b2

· 2021

Full title: us-11008398-b2

Patent

us-11173213-b2

· 2021

Full title: us-11173213-b2

Patent

us-2015314008-a1

· 2015

Full title: us-2015314008-a1

Patent

us-2018147292-a1

· 2018

Full title: us-2018147292-a1

Patent

us-2021260210-a1

· 2021

Full title: us-2021260210-a1

Patent

us-2021386865-a1

· 2021

Full title: us-2021386865-a1

Patent

us-2024424129-a1

· 2024

Full title: us-2024424129-a1

3. Authors & Profiles

Run data extraction first

Find authors first. Run extraction before finding authors.

4. Email Outreach

Generate emails first. Find authors, then generate emails.

Design Principles For Antibody Drug Conjugates Adc

1. Documents

Full text available

Metadata only

2. Data Extraction

3. Authors & Profiles

4. Email Outreach

Settings

Edit Email